2021-02-15 20:25:11 | INFO | fairseq_cli.generate | Namespace(all_gather_list_size=16384, beam=5, bf16=False, bpe=None, broadcast_buffers=False, bucket_cap_mb=25, checkpoint_suffix='', cpu=False, criterion='cross_entropy', data='../../../data-bin/phrase7_0.5_EMEA/', data_buffer_size=10, dataset_impl=None, ddp_backend='c10d', decoding_format=None, device_id=0, distributed_backend='nccl', distributed_init_method=None, distributed_no_spawn=False, distributed_port=-1, distributed_rank=0, distributed_world_size=1, distributed_wrapper='DDP', diverse_beam_groups=-1, diverse_beam_strength=0.5, diversity_rate=-1.0, empty_cache_freq=0, eval_bleu=True, eval_bleu_args=None, eval_bleu_detok='space', eval_bleu_detok_args=None, eval_bleu_print_samples=False, eval_bleu_remove_bpe=None, eval_tokenized_bleu=False, fast_stat_sync=False, find_unused_parameters=False, fix_batches_to_gpus=False, force_anneal=None, fp16=True, fp16_init_scale=128, fp16_no_flatten_grads=False, fp16_scale_tolerance=0.0, fp16_scale_window=None, gen_subset='test', iter_decode_eos_penalty=0.0, iter_decode_force_max_iter=False, iter_decode_max_iter=10, iter_decode_with_beam=1, iter_decode_with_external_reranker=False, left_pad_source='True', left_pad_target='False', lenpen=1, load_alignments=False, localsgd_frequency=3, log_format=None, log_interval=100, lr_scheduler='fixed', lr_shrink=0.1, match_source_len=False, max_len_a=0, max_len_b=200, max_sentences=128, max_source_positions=1024, max_target_positions=1024, max_tokens=None, memory_efficient_bf16=False, memory_efficient_fp16=False, min_len=1, min_loss_scale=0.0001, model_overrides='{}', model_parallel_size=1, momentum=0.99, nbest=1, no_beamable_mm=False, no_early_stop=False, no_progress_bar=False, no_repeat_ngram_size=0, no_seed_provided=True, nprocs_per_node=1, num_batch_buckets=0, num_shards=1, num_workers=1, optimizer='nag', path='../checkpoints/EMEA_p_best_1/checkpoint_best.pt', prefix_size=0, print_alignment=False, print_step=False, profile=False, quantization_config_path=None, quiet=False, remove_bpe='@@ ', replace_unk=None, required_batch_size_multiple=8, results_path=None, retain_dropout=False, retain_dropout_modules=None, retain_iter_history=False, sacrebleu=False, sampling=False, sampling_topk=-1, sampling_topp=-1.0, score_reference=False, scoring='sacrebleu', seed=1, shard_id=0, skip_invalid_size_inputs_valid_test=False, slowmo_algorithm='LocalSGD', slowmo_momentum=None, source_lang=None, target_lang=None, task='translation', temperature=1.0, tensorboard_logdir='', threshold_loss_scale=None, tokenizer=None, tpu=False, truncate_source=False, unkpen=0, unnormalized=False, upsample_primary=1, user_dir=None, warmup_updates=0, weight_decay=0.0)
2021-02-15 20:25:11 | INFO | fairseq.tasks.translation | [de] dictionary: 42024 types
2021-02-15 20:25:11 | INFO | fairseq.tasks.translation | [en] dictionary: 42024 types
2021-02-15 20:25:11 | INFO | fairseq.data.data_utils | loaded 2001 examples from: ../../../data-bin/phrase7_0.5_EMEA/test.de-en.de
2021-02-15 20:25:12 | INFO | fairseq.data.data_utils | loaded 2001 examples from: ../../../data-bin/phrase7_0.5_EMEA/test.de-en.en
2021-02-15 20:25:12 | INFO | fairseq.tasks.translation | ../../../data-bin/phrase7_0.5_EMEA/ test de-en 2001 examples
2021-02-15 20:25:12 | INFO | fairseq_cli.generate | loading model(s) from ../checkpoints/EMEA_p_best_1/checkpoint_best.pt
S-533	Welchen Nutzen hat Advate in diesen Studien gezeigt ?
T-533	What benefit has Advate shown during the studies ?
H-533	-0.3651143014431	What benefit has Advate shown in these trials ?
D-533	-0.3651143014431	What benefit has Advate shown in these trials ?
P-533	-0.1226 -0.2697 -0.3195 -0.7501 -0.0956 -0.1052 -0.7561 -0.1184 -0.7515 -0.5706 -0.1569
S-1044	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-1044	- Use within three hours after reconstitution .
H-1044	-0.23897980153560638	- Use within three hours after reconstitution .
D-1044	-0.23897980153560638	- Use within three hours after reconstitution .
P-1044	-0.1475 -0.4779 -0.1664 -0.2416 -0.0850 -0.7805 -0.0807 -0.0985 -0.1492 -0.1624
S-263	Die Bedeutung dieser Beobachtung für den Menschen ist nicht bekannt .
T-263	The relevance to humans is unknown .
H-263	-0.4392046332359314	The relevance of this observation for humans is unknown .
D-263	-0.4392046332359314	The relevance of this observation for humans is unknown .
P-263	-0.1806 -1.6574 -0.0734 -0.1794 -0.3630 -0.4838 -0.0543 -0.6220 -1.1648 -0.1404 -0.4913 -0.1478 -0.1516
S-459	Die Bedeutung dieser Beobachtung für den Menschen ist nicht bekannt .
T-459	The relevance to humans is unknown .
H-459	-0.4392046332359314	The relevance of this observation for humans is unknown .
D-459	-0.4392046332359314	The relevance of this observation for humans is unknown .
P-459	-0.1806 -1.6574 -0.0734 -0.1794 -0.3630 -0.4838 -0.0543 -0.6220 -1.1648 -0.1404 -0.4913 -0.1478 -0.1516
S-868	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-868	- Use within three hours after reconstitution .
H-868	-0.23897980153560638	- Use within three hours after reconstitution .
D-868	-0.23897980153560638	- Use within three hours after reconstitution .
P-868	-0.1475 -0.4779 -0.1664 -0.2416 -0.0850 -0.7805 -0.0807 -0.0985 -0.1492 -0.1624
S-692	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-692	- Use within three hours after reconstitution .
H-692	-0.23897980153560638	- Use within three hours after reconstitution .
D-692	-0.23897980153560638	- Use within three hours after reconstitution .
P-692	-0.1475 -0.4779 -0.1664 -0.2416 -0.0850 -0.7805 -0.0807 -0.0985 -0.1492 -0.1624
S-1220	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-1220	- Use within three hours after reconstitution .
H-1220	-0.23897980153560638	- Use within three hours after reconstitution .
D-1220	-0.23897980153560638	- Use within three hours after reconstitution .
P-1220	-0.1475 -0.4779 -0.1664 -0.2416 -0.0850 -0.7805 -0.0807 -0.0985 -0.1492 -0.1624
S-1396	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-1396	- Use within three hours after reconstitution .
H-1396	-0.23897980153560638	- Use within three hours after reconstitution .
D-1396	-0.23897980153560638	- Use within three hours after reconstitution .
P-1396	-0.1475 -0.4779 -0.1664 -0.2416 -0.0850 -0.7805 -0.0807 -0.0985 -0.1492 -0.1624
S-1573	- Innerhalb von drei Stunden nach Rekonstitution verwenden .
T-1573	- Use within three hours after reconstitution .
H-1573	-0.23897980153560638	- Use within three hours after reconstitution .
D-1573	-0.23897980153560638	- Use within three hours after reconstitution .
P-1573	-0.1475 -0.4779 -0.1664 -0.2416 -0.0850 -0.7805 -0.0807 -0.0985 -0.1492 -0.1624
S-1883	Wie lautete die Empfehlung des CHMP zu diesem Zeitpunkt ?
T-1883	What was the recommendation of the CHMP at that time ?
H-1883	-0.40809211134910583	What was the CHMP recommendation at this stage ?
D-1883	-0.40809211134910583	What was the CHMP recommendation at this stage ?
P-1883	-0.2377 -0.3449 -0.1864 -0.1609 -0.0367 -0.7876 -0.1386 -0.1335 -1.4797 -0.5829 -0.6562 -0.1523
S-700	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-700	Place the vials on a flat clean surface .
H-700	-0.3673853278160095	Place the vials on a level surface .
D-700	-0.3673853278160095	Place the vials on a level surface .
P-700	-1.6040 -0.1799 -0.0917 -0.0870 -0.1445 -0.7097 -0.5114 -0.0550 -0.1370 -0.1536
S-1052	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-1052	Place the vials on a flat clean surface .
H-1052	-0.3673853278160095	Place the vials on a level surface .
D-1052	-0.3673853278160095	Place the vials on a level surface .
P-1052	-1.6040 -0.1799 -0.0917 -0.0870 -0.1445 -0.7097 -0.5114 -0.0550 -0.1370 -0.1536
S-22	Reproduction is authorised provided the source is acknowledged .
T-22	Reproduction is authorised provided the source is acknowledged .
H-22	-0.3536824584007263	Reproduction is authorised provided the source is acknowledged .
D-22	-0.3536824584007263	Reproduction is authorised provided the source is acknowledged .
P-22	-0.2906 -0.4216 -0.1303 -0.3873 -0.1445 -0.0668 -0.1432 -0.0590 -0.1112 -2.1816 -0.1542 -0.1541
S-1228	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-1228	Place the vials on a flat clean surface .
H-1228	-0.3673853278160095	Place the vials on a level surface .
D-1228	-0.3673853278160095	Place the vials on a level surface .
P-1228	-1.6040 -0.1799 -0.0917 -0.0870 -0.1445 -0.7097 -0.5114 -0.0550 -0.1370 -0.1536
S-1404	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-1404	Place the vials on a flat clean surface .
H-1404	-0.3673853278160095	Place the vials on a level surface .
D-1404	-0.3673853278160095	Place the vials on a level surface .
P-1404	-1.6040 -0.1799 -0.0917 -0.0870 -0.1445 -0.7097 -0.5114 -0.0550 -0.1370 -0.1536
S-1581	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-1581	Place the vials on a flat clean surface .
H-1581	-0.3673853278160095	Place the vials on a level surface .
D-1581	-0.3673853278160095	Place the vials on a level surface .
P-1581	-1.6040 -0.1799 -0.0917 -0.0870 -0.1445 -0.7097 -0.5114 -0.0550 -0.1370 -0.1536
S-876	Die Durchstechflaschen auf eine ebene Oberfläche stellen .
T-876	Place the vials on a flat clean surface .
H-876	-0.3673853278160095	Place the vials on a level surface .
D-876	-0.3673853278160095	Place the vials on a level surface .
P-876	-1.6040 -0.1799 -0.0917 -0.0870 -0.1445 -0.7097 -0.5114 -0.0550 -0.1370 -0.1536
S-1875	Reproduction is authorised provided the source is acknowledged .
T-1875	Reproduction is authorised provided the source is acknowledged .
H-1875	-0.3536824584007263	Reproduction is authorised provided the source is acknowledged .
D-1875	-0.3536824584007263	Reproduction is authorised provided the source is acknowledged .
P-1875	-0.2906 -0.4216 -0.1303 -0.3873 -0.1445 -0.0668 -0.1432 -0.0590 -0.1112 -2.1816 -0.1542 -0.1541
S-35	Die zweite Studie erbrachte ähnliche Ergebnisse nach einem Jahr .
T-35	Similar results were seen in the second study after a year .
H-35	-0.4674726724624634	The second study yielded similar results one year later .
D-35	-0.4674726724624634	The second study yielded similar results one year later .
P-35	-0.2119 -0.0601 -1.3818 -1.0345 -0.0557 -0.1303 -0.1777 -0.2113 -0.7767 -0.1369 -1.6180 -0.1328 -0.1496
S-693	- Nach Rekonstitution nicht mehr kühlen .
T-693	- Do not refrigerate the preparation after reconstitution .
H-693	-0.46019819378852844	- Do not allow to cool after reconstitution .
D-693	-0.46019819378852844	- Do not allow to cool after reconstitution .
P-693	-0.1685 -0.2025 -0.1445 -1.4770 -0.9639 -0.8363 -0.7522 -0.0854 -0.1292 -0.1432 -0.1595
S-1045	- Nach Rekonstitution nicht mehr kühlen .
T-1045	- Do not refrigerate the preparation after reconstitution .
H-1045	-0.46019819378852844	- Do not allow to cool after reconstitution .
D-1045	-0.46019819378852844	- Do not allow to cool after reconstitution .
P-1045	-0.1685 -0.2025 -0.1445 -1.4770 -0.9639 -0.8363 -0.7522 -0.0854 -0.1292 -0.1432 -0.1595
S-1739	Im Zweifelsfall fragen Sie Ihren Arzt .
T-1739	If you are unsure about this , ask your doctor .
H-1739	-0.5188265442848206	If in doubt , ask your doctor .
D-1739	-0.5188265442848206	If in doubt , ask your doctor .
P-1739	-1.5794 -0.1675 -0.9147 -1.2266 -0.2217 -0.1312 -0.1140 -0.1578 -0.1565
S-869	- Nach Rekonstitution nicht mehr kühlen .
T-869	- Do not refrigerate the preparation after reconstitution .
H-869	-0.46019819378852844	- Do not allow to cool after reconstitution .
D-869	-0.46019819378852844	- Do not allow to cool after reconstitution .
P-869	-0.1685 -0.2025 -0.1445 -1.4770 -0.9639 -0.8363 -0.7522 -0.0854 -0.1292 -0.1432 -0.1595
S-288	Vitamin D einmal pro Tag wurde nicht untersucht .
T-288	The equivalence of intake of 5600 IU of vitamin D3 weekly in ADROVANCE to daily dosing of vitamin D 800 IU has not been studied .
H-288	-0.23153497278690338	vitamin D supplementation once a day has not been studied .
D-288	-0.23153497278690338	vitamin D supplementation once a day has not been studied .
P-288	-0.5236 -0.0829 -0.1507 -0.4897 -0.0452 -0.1348 -0.0371 -0.1894 -0.0890 -0.1030 -0.1264 -0.1082 -1.0913 -0.1495 -0.1521
S-1855	Wofür sollte Advexin angewendet werden ?
T-1855	What was Advexin expected to be used for ?
H-1855	-0.36603373289108276	What should Advexin be used for ?
D-1855	-0.36603373289108276	What should Advexin be used for ?
P-1855	-0.1729 -1.3315 -0.5627 -0.1951 -0.1415 -0.1276 -0.0723 -0.0944 -0.8089 -0.1536
S-1397	- Nach Rekonstitution nicht mehr kühlen .
T-1397	- Do not refrigerate the preparation after reconstitution .
H-1397	-0.46019819378852844	- Do not allow to cool after reconstitution .
D-1397	-0.46019819378852844	- Do not allow to cool after reconstitution .
P-1397	-0.1685 -0.2025 -0.1445 -1.4770 -0.9639 -0.8363 -0.7522 -0.0854 -0.1292 -0.1432 -0.1595
S-1221	- Nach Rekonstitution nicht mehr kühlen .
T-1221	- Do not refrigerate the preparation after reconstitution .
H-1221	-0.46019819378852844	- Do not allow to cool after reconstitution .
D-1221	-0.46019819378852844	- Do not allow to cool after reconstitution .
P-1221	-0.1685 -0.2025 -0.1445 -1.4770 -0.9639 -0.8363 -0.7522 -0.0854 -0.1292 -0.1432 -0.1595
S-1574	- Nach Rekonstitution nicht mehr kühlen .
T-1574	- Do not refrigerate the preparation after reconstitution .
H-1574	-0.46019819378852844	- Do not allow to cool after reconstitution .
D-1574	-0.46019819378852844	- Do not allow to cool after reconstitution .
P-1574	-0.1685 -0.2025 -0.1445 -1.4770 -0.9639 -0.8363 -0.7522 -0.0854 -0.1292 -0.1432 -0.1595
S-635	Verletzung , Vergiftung und durch Eingriffe
T-635	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-635	-0.9479047060012817	injury , intoxication and
D-635	-0.9479047060012817	injury , intoxication and
P-635	-1.0453 -0.1523 -2.8597 -0.0633 -0.1436 -0.1130 -0.1737 -3.0323
S-715	Nur klare , farblose Lösungen verwenden .
T-715	Only a clear and colourless solution should be used .
H-715	-0.2861626148223877	Only use clear , colourless solutions .
D-715	-0.2861626148223877	Only use clear , colourless solutions .
P-715	-1.5634 -0.0719 -0.1012 -0.2177 -0.0798 -0.1013 -0.0918 -0.3387 -0.1373 -0.1586
S-546	Die Genehmigung wurde am 2. März 2009 verlängert .
T-546	The marketing authorisation was renewed on 2 March 2009.
H-546	-0.2921915352344513	The authorisation was renewed on 2 March 2009 .
D-546	-0.2921915352344513	The authorisation was renewed on 2 March 2009 .
P-546	-0.4274 -0.9590 -0.0546 -0.3435 -0.3974 -0.1082 -0.1545 -0.2230 -0.2520 -0.1406 -0.1539
S-1067	Nur klare , farblose Lösungen verwenden .
T-1067	Only a clear and colourless solution should be used .
H-1067	-0.2861626148223877	Only use clear , colourless solutions .
D-1067	-0.2861626148223877	Only use clear , colourless solutions .
P-1067	-1.5634 -0.0719 -0.1012 -0.2177 -0.0798 -0.1013 -0.0918 -0.3387 -0.1373 -0.1586
S-1921	In der zweiten Studie wurden ähnliche Ergebnisse beobachtet .
T-1921	Similar results were seen in the second study .
H-1921	-0.40942779183387756	Similar results were observed in the second study .
D-1921	-0.40942779183387756	Similar results were observed in the second study .
P-1921	-1.2555 -0.0924 -1.0398 -0.2910 -0.4107 -0.1508 -0.1608 -0.0732 -0.7390 -0.1385 -0.1520
S-1885	Was waren die wesentlichen Bedenken des CHMP ?
T-1885	What were the main concerns of the CHMP ?
H-1885	-0.40172532200813293	What were the main concerns of the CHMP ?
D-1885	-0.40172532200813293	What were the main concerns of the CHMP ?
P-1885	-0.1082 -0.2672 -0.2349 -0.8820 -0.4982 -0.9295 -0.4300 -0.1631 -0.0337 -0.7190 -0.1531
S-891	Nur klare , farblose Lösungen verwenden .
T-891	Only a clear and colourless solution should be used .
H-891	-0.2861626148223877	Only use clear , colourless solutions .
D-891	-0.2861626148223877	Only use clear , colourless solutions .
P-891	-1.5634 -0.0719 -0.1012 -0.2177 -0.0798 -0.1013 -0.0918 -0.3387 -0.1373 -0.1586
S-1723	- Dieses Arzneimittel wurde Ihnen verschrieben .
T-1723	- This medicine has been prescribed for you .
H-1723	-0.2862139046192169	- This medicine has been prescribed for you .
D-1723	-0.2862139046192169	- This medicine has been prescribed for you .
P-1723	-0.3543 -0.1744 -1.3770 -0.4421 -0.0622 -0.0550 -0.0837 -0.1576 -0.1267 -0.1560 -0.1595
S-1243	Nur klare , farblose Lösungen verwenden .
T-1243	Only a clear and colourless solution should be used .
H-1243	-0.2861626148223877	Only use clear , colourless solutions .
D-1243	-0.2861626148223877	Only use clear , colourless solutions .
P-1243	-1.5634 -0.0719 -0.1012 -0.2177 -0.0798 -0.1013 -0.0918 -0.3387 -0.1373 -0.1586
S-1419	Nur klare , farblose Lösungen verwenden .
T-1419	Only a clear and colourless solution should be used .
H-1419	-0.2861626148223877	Only use clear , colourless solutions .
D-1419	-0.2861626148223877	Only use clear , colourless solutions .
P-1419	-1.5634 -0.0719 -0.1012 -0.2177 -0.0798 -0.1013 -0.0918 -0.3387 -0.1373 -0.1586
S-1596	Nur klare , farblose Lösungen verwenden .
T-1596	Only a clear and colourless solution should be used .
H-1596	-0.2861626148223877	Only use clear , colourless solutions .
D-1596	-0.2861626148223877	Only use clear , colourless solutions .
P-1596	-1.5634 -0.0719 -0.1012 -0.2177 -0.0798 -0.1013 -0.0918 -0.3387 -0.1373 -0.1586
S-1724	Es darf nicht an Dritte weitergegeben werden .
T-1724	Es darf nicht an Dritte weitergegeben werden . It may harm them , even
H-1724	-0.4319029152393341	Do not disclose it to third parties .
D-1724	-0.4319029152393341	Do not disclose it to third parties .
P-1724	-1.0543 -0.1416 -1.6266 -0.1438 -0.4119 -0.1308 -0.2719 -0.2376 -0.1428 -0.1576
S-633	Gelegentlich Gelegentlich Gelegentlich
T-633	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-633	-0.12452723830938339	Uncommon Uncommon Uncommon
D-633	-0.12452723830938339	Uncommon Uncommon Uncommon
P-633	-0.1072 -0.0896 -0.0523 -0.1289 -0.0477 -0.1256 -0.3204
S-629	Erkrankungen des Gastrointestinaltrakts
T-629	5 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-629	-0.10450457036495209	Gastrointestinal disorders
D-629	-0.10450457036495209	Gastrointestinal disorders
P-629	-0.1125 -0.0985 -0.0406 -0.1074 -0.0691 -0.0795 -0.1058 -0.2226
S-1793	Arzneimittel für Kinder unzugänglich aufbewahren .
T-1793	Keep out of the reach and sight of children .
H-1793	-0.22349314391613007	Keep out of the reach and sight of children .
D-1793	-0.22349314391613007	Keep out of the reach and sight of children .
P-1793	-0.9966 -0.1530 -0.1482 -0.1408 -0.1926 -0.1143 -0.0455 -0.2978 -0.0813 -0.1348 -0.1536
S-1406	Das Transfersystem nicht aus der Verpackung
T-1406	Do not remove the device from the package .
H-1406	-0.42549359798431396	Do not take the transfer system out of the package
D-1406	-0.42549359798431396	Do not take the transfer system out of the package
P-1406	-0.6438 -0.1588 -0.3538 -0.1597 -0.1233 -0.7750 -0.3580 -0.1463 -0.1589 -1.6516 -0.1512
S-1583	Das Transfersystem nicht aus der Verpackung
T-1583	Do not remove the device from the package .
H-1583	-0.42549359798431396	Do not take the transfer system out of the package
D-1583	-0.42549359798431396	Do not take the transfer system out of the package
P-1583	-0.6438 -0.1588 -0.3538 -0.1597 -0.1233 -0.7750 -0.3580 -0.1463 -0.1589 -1.6516 -0.1512
S-1666	Vor der Anwendung Gebrauchsinformation lesen .
T-1666	Vor der Anwendung Gebrauchsinformation lesen . Single use only .
H-1666	-0.514288067817688	Read the leaflet before use .
D-1666	-0.514288067817688	Read the leaflet before use .
P-1666	-0.2679 -1.3821 -1.9517 -0.0474 -0.1005 -0.3011 -0.2852 -0.1388 -0.1540
S-1230	Das Transfersystem nicht aus der Verpackung
T-1230	Do not remove the device from the package .
H-1230	-0.42549359798431396	Do not take the transfer system out of the package
D-1230	-0.42549359798431396	Do not take the transfer system out of the package
P-1230	-0.6438 -0.1588 -0.3538 -0.1597 -0.1233 -0.7750 -0.3580 -0.1463 -0.1589 -1.6516 -0.1512
S-1054	Das Transfersystem nicht aus der Verpackung
T-1054	Do not remove the device from the package .
H-1054	-0.42549359798431396	Do not take the transfer system out of the package
D-1054	-0.42549359798431396	Do not take the transfer system out of the package
P-1054	-0.6438 -0.1588 -0.3538 -0.1597 -0.1233 -0.7750 -0.3580 -0.1463 -0.1589 -1.6516 -0.1512
S-878	Das Transfersystem nicht aus der Verpackung
T-878	Do not remove the device from the package .
H-878	-0.42549359798431396	Do not take the transfer system out of the package
D-878	-0.42549359798431396	Do not take the transfer system out of the package
P-878	-0.6438 -0.1588 -0.3538 -0.1597 -0.1233 -0.7750 -0.3580 -0.1463 -0.1589 -1.6516 -0.1512
S-1804	Diese Maßnahme hilft die Umwelt zu schützen .
T-1804	These measures will help to protect the environment .
H-1804	-0.15629646182060242	These measures will help to protect the environment .
D-1804	-0.15629646182060242	These measures will help to protect the environment .
P-1804	-0.3126 -0.1456 -0.1386 -0.1110 -0.1527 -0.1092 -0.1334 -0.1723 -0.1288 -0.1587
S-702	Das Transfersystem nicht aus der Verpackung
T-702	Do not remove the device from the package .
H-702	-0.42549359798431396	Do not take the transfer system out of the package
D-702	-0.42549359798431396	Do not take the transfer system out of the package
P-702	-0.6438 -0.1588 -0.3538 -0.1597 -0.1233 -0.7750 -0.3580 -0.1463 -0.1589 -1.6516 -0.1512
S-1715	vor der Anwendung Gebrauchsinformation lesen .
T-1715	vor der Anwendung Gebrauchsinformation lesen . Single use only .
H-1715	-0.4451398551464081	read this leaflet before use .
D-1715	-0.4451398551464081	read this leaflet before use .
P-1715	-0.0763 -2.7993 -0.1626 -0.0521 -0.1015 -0.2494 -0.2649 -0.1435 -0.1566
S-1745	Sie sollten über frühe Anzeichen einer solchen
T-1745	Sie sollten über frühe Anzeichen einer solchen These symptoms can constitute an early
H-1745	-0.3581670820713043	You should be alert to early signs of such
D-1745	-0.3581670820713043	You should be alert to early signs of such
P-1745	-0.5943 -0.1956 -0.2772 -0.1826 -0.2945 -0.1688 -0.0846 -0.1846 -1.4400 -0.1595
S-806	0,85 0,43 0,43 0,43
T-806	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-806	-0.13352443277835846	0.85 0.43 0.43 0.43
D-806	-0.13352443277835846	0.85 0.43 0.43 0.43
P-806	-0.1658 -0.1752 -0.1577 -0.0876 -0.1443 -0.0833 -0.1672 -0.0821 -0.1386
S-982	0,85 0,43 0,43 0,43
T-982	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-982	-0.13352443277835846	0.85 0.43 0.43 0.43
D-982	-0.13352443277835846	0.85 0.43 0.43 0.43
P-982	-0.1658 -0.1752 -0.1577 -0.0876 -0.1443 -0.0833 -0.1672 -0.0821 -0.1386
S-1158	0,85 0,43 0,43 0,43
T-1158	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-1158	-0.13352443277835846	0.85 0.43 0.43 0.43
D-1158	-0.13352443277835846	0.85 0.43 0.43 0.43
P-1158	-0.1658 -0.1752 -0.1577 -0.0876 -0.1443 -0.0833 -0.1672 -0.0821 -0.1386
S-1334	0,85 0,43 0,43 0,43
T-1334	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-1334	-0.13352443277835846	0.85 0.43 0.43 0.43
D-1334	-0.13352443277835846	0.85 0.43 0.43 0.43
P-1334	-0.1658 -0.1752 -0.1577 -0.0876 -0.1443 -0.0833 -0.1672 -0.0821 -0.1386
S-1511	0,85 0,43 0,43 0,43
T-1511	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-1511	-0.13352443277835846	0.85 0.43 0.43 0.43
D-1511	-0.13352443277835846	0.85 0.43 0.43 0.43
P-1511	-0.1658 -0.1752 -0.1577 -0.0876 -0.1443 -0.0833 -0.1672 -0.0821 -0.1386
S-1506	Infektionen und parasitäre Erkrankungen
T-1506	( % patients<<unk>> a Infections and infestations Blood and lymphatic system disorders
H-1506	-0.36504319310188293	infections and parasitic disorders
D-1506	-0.36504319310188293	infections and parasitic disorders
P-1506	-1.1164 -0.0594 -0.1349 -0.1029 -0.1354 -0.1780 -1.2420 -0.1035 -0.2130
S-1708	Für Kinder unzugänglich aufbewahren .
T-1708	Keep out of the reach and sight of children .
H-1708	-0.27645522356033325	The reach and sight of children .
D-1708	-0.27645522356033325	The reach and sight of children .
P-1708	-1.2862 -0.1398 -0.1215 -0.0392 -0.1494 -0.1666 -0.1450 -0.1639
S-1676	Für Kinder unzugänglich aufbewahren .
T-1676	Keep out of the reach and sight of children .
H-1676	-0.27645522356033325	The reach and sight of children .
D-1676	-0.27645522356033325	The reach and sight of children .
P-1676	-1.2862 -0.1398 -0.1215 -0.0392 -0.1494 -0.1666 -0.1450 -0.1639
S-1941	Erwachsene und Jugendliche ab 12 Jahren :
T-1941	Adults and adolescents 12 years of age and over :
H-1941	-0.550194501876831	Adults and adolescents aged 12 years and over :
D-1941	-0.550194501876831	Adults and adolescents aged 12 years and over :
P-1941	-0.2842 -2.5995 -0.1454 -0.1190 -0.0542 -0.0350 -1.6911 -0.0912 -1.2227 -0.1931 -0.3622 -0.1618 -0.1931
S-1692	Für Kinder unzugänglich aufbewahren .
T-1692	Keep out of the reach and sight of children .
H-1692	-0.27645522356033325	The reach and sight of children .
D-1692	-0.27645522356033325	The reach and sight of children .
P-1692	-1.2862 -0.1398 -0.1215 -0.0392 -0.1494 -0.1666 -0.1450 -0.1639
S-1642	Für Kinder unzugänglich aufbewahren .
T-1642	Keep out of the reach and sight of children .
H-1642	-0.27645522356033325	The reach and sight of children .
D-1642	-0.27645522356033325	The reach and sight of children .
P-1642	-1.2862 -0.1398 -0.1215 -0.0392 -0.1494 -0.1666 -0.1450 -0.1639
S-1659	Für Kinder unzugänglich aufbewahren .
T-1659	Keep out of the reach and sight of children .
H-1659	-0.27645522356033325	The reach and sight of children .
D-1659	-0.27645522356033325	The reach and sight of children .
P-1659	-1.2862 -0.1398 -0.1215 -0.0392 -0.1494 -0.1666 -0.1450 -0.1639
S-1626	Für Kinder unzugänglich aufbewahren .
T-1626	Keep out of the reach and sight of children .
H-1626	-0.27645522356033325	The reach and sight of children .
D-1626	-0.27645522356033325	The reach and sight of children .
P-1626	-1.2862 -0.1398 -0.1215 -0.0392 -0.1494 -0.1666 -0.1450 -0.1639
S-654	Pharmakotherapeutische Gruppe :
T-654	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-654	-0.2114192545413971	Pharmacotherapeutic group :
D-654	-0.2114192545413971	Pharmacotherapeutic group :
P-654	-0.7019 -0.1628 -0.0761 -0.1246 -0.1240 -0.1178 -0.2310 -0.1436 -0.2211
S-1533	Pharmakotherapeutische Gruppe :
T-1533	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-1533	-0.2114192545413971	Pharmacotherapeutic group :
D-1533	-0.2114192545413971	Pharmacotherapeutic group :
P-1533	-0.7019 -0.1628 -0.0761 -0.1246 -0.1240 -0.1178 -0.2310 -0.1436 -0.2211
S-1356	Pharmakotherapeutische Gruppe :
T-1356	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-1356	-0.2114192545413971	Pharmacotherapeutic group :
D-1356	-0.2114192545413971	Pharmacotherapeutic group :
P-1356	-0.7019 -0.1628 -0.0761 -0.1246 -0.1240 -0.1178 -0.2310 -0.1436 -0.2211
S-1180	Pharmakotherapeutische Gruppe :
T-1180	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-1180	-0.2114192545413971	Pharmacotherapeutic group :
D-1180	-0.2114192545413971	Pharmacotherapeutic group :
P-1180	-0.7019 -0.1628 -0.0761 -0.1246 -0.1240 -0.1178 -0.2310 -0.1436 -0.2211
S-1004	Pharmakotherapeutische Gruppe :
T-1004	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-1004	-0.2114192545413971	Pharmacotherapeutic group :
D-1004	-0.2114192545413971	Pharmacotherapeutic group :
P-1004	-0.7019 -0.1628 -0.0761 -0.1246 -0.1240 -0.1178 -0.2310 -0.1436 -0.2211
S-828	Pharmakotherapeutische Gruppe :
T-828	Pharmacotherapeutic group : antihaemorrhagics , blood coagulation factor VIII .
H-828	-0.2114192545413971	Pharmacotherapeutic group :
D-828	-0.2114192545413971	Pharmacotherapeutic group :
P-828	-0.7019 -0.1628 -0.0761 -0.1246 -0.1240 -0.1178 -0.2310 -0.1436 -0.2211
S-632	0,43 0,43 0,43
T-632	0.85 0.43 0.43 0.43 0.85 0.85 0.43 0.43 1.28 0.43
H-632	-0.12841443717479706	0.43 0.43 0.43
D-632	-0.12841443717479706	0.43 0.43 0.43
P-632	-0.1604 -0.1061 -0.1408 -0.0941 -0.1363 -0.0932 -0.1680
S-495	ADROVANCE
T-495	You should not take ADROVANCE if you are or think you may be pregnant , or if you are breast-feeding .
H-495	-0.12740452587604523	ADROVANCE
D-495	-0.12740452587604523	ADROVANCE
P-495	-0.0592 -0.0797 -0.1210 -0.1102 -0.1619 -0.2325
S-494	Alendronat
T-494	Alendronate belongs to a group of non-hormonal medicines called bisphosphonates .
H-494	-0.15828236937522888	alendronate
D-494	-0.15828236937522888	alendronate
P-494	-0.2634 -0.1763 -0.1178 -0.0680 -0.1659
S-1023	PK-Parameter
T-1023	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1023	-0.457385778427124	PK parameter
D-1023	-0.457385778427124	PK parameter
P-1023	-0.1973 -0.1845 -0.8610 -0.8853 -0.1588
S-476	ADROVANCE
T-476	You should not take ADROVANCE if you are or think you may be pregnant , or if you are breast-feeding .
H-476	-0.12740452587604523	ADROVANCE
D-476	-0.12740452587604523	ADROVANCE
P-476	-0.0592 -0.0797 -0.1210 -0.1102 -0.1619 -0.2325
S-493	ADROVANCE
T-493	WHAT ADROVANCE IS AND WHAT IT IS USED FOR
H-493	-0.12740452587604523	ADROVANCE
D-493	-0.12740452587604523	ADROVANCE
P-493	-0.0592 -0.0797 -0.1210 -0.1102 -0.1619 -0.2325
S-474	Alendronat
T-474	Alendronate belongs to a group of non-hormonal medicines called bisphosphonates .
H-474	-0.15828236937522888	alendronate
D-474	-0.15828236937522888	alendronate
P-474	-0.2634 -0.1763 -0.1178 -0.0680 -0.1659
S-671	PK-Parameter
T-671	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-671	-0.457385778427124	PK parameter
D-671	-0.457385778427124	PK parameter
P-671	-0.1973 -0.1845 -0.8610 -0.8853 -0.1588
S-473	ADROVANCE
T-473	WHAT ADROVANCE IS AND WHAT IT IS USED FOR
H-473	-0.12740452587604523	ADROVANCE
D-473	-0.12740452587604523	ADROVANCE
P-473	-0.0592 -0.0797 -0.1210 -0.1102 -0.1619 -0.2325
S-1199	PK-Parameter
T-1199	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1199	-0.457385778427124	PK parameter
D-1199	-0.457385778427124	PK parameter
P-1199	-0.1973 -0.1845 -0.8610 -0.8853 -0.1588
S-1375	PK-Parameter
T-1375	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1375	-0.457385778427124	PK parameter
D-1375	-0.457385778427124	PK parameter
P-1375	-0.1973 -0.1845 -0.8610 -0.8853 -0.1588
S-847	PK-Parameter
T-847	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-847	-0.457385778427124	PK parameter
D-847	-0.457385778427124	PK parameter
P-847	-0.1973 -0.1845 -0.8610 -0.8853 -0.1588
S-475	ADROVANCE
T-475	Your doctor has prescribed ADROVANCE to treat your osteoporosis and because you are at risk of vitamin D insufficiency .
H-475	-0.12740452587604523	ADROVANCE
D-475	-0.12740452587604523	ADROVANCE
P-475	-0.0592 -0.0797 -0.1210 -0.1102 -0.1619 -0.2325
S-1552	PK-Parameter
T-1552	PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1552	-0.457385778427124	PK parameter
D-1552	-0.457385778427124	PK parameter
P-1552	-0.1973 -0.1845 -0.8610 -0.8853 -0.1588
S-1931	2,5 mg / 120 mg
T-1931	2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg 2.5 mg/ 120 mg
H-1931	-0.2925519049167633	2.5 mg / 120 mg
D-1931	-0.2925519049167633	2.5 mg / 120 mg
P-1931	-1.1198 -0.0445 -0.1553 -0.0999 -0.0633 -0.2725
S-497	ADROVANCE
T-497	47 5 ) If you develop difficulty or pain upon swallowing , chest pain , or new or worsening heartburn , stop taking ADROVANCE and contact your doctor .
H-497	-0.12740452587604523	ADROVANCE
D-497	-0.12740452587604523	ADROVANCE
P-497	-0.0592 -0.0797 -0.1210 -0.1102 -0.1619 -0.2325
S-481	ADROVANCE
T-481	5 ) If you develop difficulty or pain upon swallowing , chest pain , or new or worsening heartburn , stop taking ADROVANCE and contact your doctor .
H-481	-0.12740452587604523	ADROVANCE
D-481	-0.12740452587604523	ADROVANCE
P-481	-0.0592 -0.0797 -0.1210 -0.1102 -0.1619 -0.2325
S-1510	2 1 1 1
T-1510	2 1 1 1 2 2 1 1 3 1
H-1510	-0.21797390282154083	2 1 1
D-1510	-0.21797390282154083	2 1 1
P-1510	-0.1858 -0.1582 -0.1436 -0.3842
S-981	2 1 1 1
T-981	2 1 1 1 2 2 1 1 3 1
H-981	-0.21797390282154083	2 1 1
D-981	-0.21797390282154083	2 1 1
P-981	-0.1858 -0.1582 -0.1436 -0.3842
S-805	2 1 1 1
T-805	2 1 1 1 2 2 1 1 3 1
H-805	-0.21797390282154083	2 1 1
D-805	-0.21797390282154083	2 1 1
P-805	-0.1858 -0.1582 -0.1436 -0.3842
S-1333	2 1 1 1
T-1333	2 1 1 1 2 2 1 1 3 1
H-1333	-0.21797390282154083	2 1 1
D-1333	-0.21797390282154083	2 1 1
P-1333	-0.1858 -0.1582 -0.1436 -0.3842
S-204	32 % ) .
T-204	32 % , respectively ) , through week 15.
H-204	-0.14489442110061646	32 % ) .
D-204	-0.14489442110061646	32 % ) .
P-204	-0.1236 -0.1316 -0.1441 -0.1721 -0.1530
S-484	Informieren Sie
T-484	Tell your doctor or pharmacist promptly about these or any other unusual symptoms .
H-484	-0.4218173623085022	Be sure to
D-484	-0.4218173623085022	Be sure to
P-484	-0.2139 -0.0597 -0.5107 -0.9030
S-1157	2 1 1 1
T-1157	2 1 1 1 2 2 1 1 3 1
H-1157	-0.21797390282154083	2 1 1
D-1157	-0.21797390282154083	2 1 1
P-1157	-0.1858 -0.1582 -0.1436 -0.3842
S-1935	14 Tabletten
T-1935	2 tablets 4 tablets 7 tablets 10 tablets 14 tablets 20 tablets
H-1935	-0.17515228688716888	14 tablets
D-1935	-0.17515228688716888	14 tablets
P-1935	-0.2851 -0.1072 -0.1348 -0.1735
S-500	Informieren Sie
T-500	Tell your doctor or pharmacist promptly about these or any other unusual symptoms .
H-500	-0.4218173623085022	Be sure to
D-500	-0.4218173623085022	Be sure to
P-500	-0.2139 -0.0597 -0.5107 -0.9030
S-630	Verabreichungsort
T-630	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-630	-0.47083139419555664	site
D-630	-0.47083139419555664	site
P-630	-0.7922 -0.1495
S-392	32 % ) .
T-392	32 % , respectively ) , through week 15.
H-392	-0.14489442110061646	32 % ) .
D-392	-0.14489442110061646	32 % ) .
P-392	-0.1236 -0.1316 -0.1441 -0.1721 -0.1530
S-499	Gelegentlich
T-499	Gelegentlich Very rare ( occurring in less than 1 of 10,000 patients treated ) .
H-499	-0.0922216847538948	Uncommon
D-499	-0.0922216847538948	Uncommon
P-499	-0.0736 -0.0647 -0.1384
S-498	Häufig :
T-498	The following terms are used to describe how often side effects have been reported :
H-498	-0.12886041402816772	Common :
D-498	-0.12886041402816772	Common :
P-498	-0.0799 -0.1269 -0.1363 -0.1724
S-483	Gelegentlich
T-483	Gelegentlich Very rare ( occurring in less than 1 of 10,000 patients treated ) .
H-483	-0.0922216847538948	Uncommon
D-483	-0.0922216847538948	Uncommon
P-483	-0.0736 -0.0647 -0.1384
S-631	1 1 1
T-631	2 1 1 1 2 2 1 1 3 1
H-631	-0.296791136264801	1 1
D-631	-0.296791136264801	1 1
P-631	-0.1622 -0.1416 -0.5866
S-488	Tel . :
T-488	Tel . : <<unk>> 36 1 888 53 00 hungary<<unk>> msd<<unk>> merck . com
H-488	-0.12247847765684128	Tel . :
D-488	-0.12247847765684128	Tel . :
P-488	-0.0277 -0.1670 -0.1429 -0.1523
S-504	Tel . :
T-504	Tel . : <<unk>> 36 1 888 53 00 hungary<<unk>> msd<<unk>> merck . com
H-504	-0.12247847765684128	Tel . :
D-504	-0.12247847765684128	Tel . :
P-504	-0.0277 -0.1670 -0.1429 -0.1523
S-492	Tel : +
T-492	Ireland Merck Sharp and Dohme Ireland ( Human Health ) Limited Tel : <<unk>> 353 ( 0<<unk>> 1 2998771 medinfo<<unk>> ireland<<unk>> merck . com
H-492	-0.11165422946214676	Tel : +
D-492	-0.11165422946214676	Tel : +
P-492	-0.0553 -0.1373 -0.1124 -0.1416
S-508	Tel : +
T-508	Ireland Merck Sharp and Dohme Ireland ( Human Health ) Limited Tel : <<unk>> 353 ( 0<<unk>> 1 2998771 medinfo<<unk>> ireland<<unk>> merck . com
H-508	-0.11165422946214676	Tel : +
D-508	-0.11165422946214676	Tel : +
P-508	-0.0553 -0.1373 -0.1124 -0.1416
S-482	Häufig :
T-482	The following terms are used to describe how often side effects have been reported :
H-482	-0.12886041402816772	Common :
D-482	-0.12886041402816772	Common :
P-482	-0.0799 -0.1269 -0.1363 -0.1724
S-506	Tel :
T-506	Tel . : <<unk>> 48 22 549 51 00 msdpolska<<unk>> merck . com
H-506	-0.11378005146980286	Tel :
D-506	-0.11378005146980286	Tel :
P-506	-0.0530 -0.1401 -0.1482
S-507	Tel :
T-507	Tel : <<unk>> 34 93 600 37 00 medicaldep<<unk>> ferrergrupo . com
H-507	-0.11378005146980286	Tel :
D-507	-0.11378005146980286	Tel :
P-507	-0.0530 -0.1401 -0.1482
S-490	Tel :
T-490	Tel . : <<unk>> 48 22 549 51 00 msdpolska<<unk>> merck . com
H-490	-0.11378005146980286	Tel :
D-490	-0.11378005146980286	Tel :
P-490	-0.0530 -0.1401 -0.1482
S-491	Tel :
T-491	Tel : <<unk>> 34 93 600 37 00 medicaldep<<unk>> ferrergrupo . com
H-491	-0.11378005146980286	Tel :
D-491	-0.11378005146980286	Tel :
P-491	-0.0530 -0.1401 -0.1482
S-489	Tel :
T-489	Eesti Österreich Merck Sharp <<unk>> Dohme OÜ Tel . : <<unk>> 372 613 9750 msdeesti<<unk>> merck . com
H-489	-0.11378005146980286	Tel :
D-489	-0.11378005146980286	Tel :
P-489	-0.0530 -0.1401 -0.1482
S-505	Tel :
T-505	50 Eesti Österreich Merck Sharp <<unk>> Dohme OÜ Tel . : <<unk>> 372 613 9750 msdeesti<<unk>> merck . com
H-505	-0.11378005146980286	Tel :
D-505	-0.11378005146980286	Tel :
P-505	-0.0530 -0.1401 -0.1482
S-628	0,43
T-628	Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-628	-0.4262606203556061	0.43
D-628	-0.4262606203556061	0.43
P-628	-0.3608 -0.1228 -0.7952
S-486	Die
T-486	The active substances are alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-486	-0.1719633936882019	The
D-486	-0.1719633936882019	The
P-486	-0.1905 -0.1534
S-479	(
T-479	40 3 ) Do not lie down stay fully upright ( sitting , standing or walking ) for at least 30 minutes after swallowing the tablet .
H-479	-0.15705111622810364	(
D-479	-0.15705111622810364	(
P-479	-0.1577 -0.1564
S-1952	2
T-1952	2 a history of haemorrhagic stroke or with risk factors which could increase the risk of haemorrhagic stroke .
H-1952	-0.19035933911800385	2
D-1952	-0.19035933911800385	2
P-1952	-0.1814 -0.1993
S-480	(
T-480	4 ) Do not take ADROVANCE at bedtime or before getting up for the day .
H-480	-0.15705111622810364	(
D-480	-0.15705111622810364	(
P-480	-0.1577 -0.1564
S-502	Die
T-502	The active substances are alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-502	-0.1719633936882019	The
D-502	-0.1719633936882019	The
P-502	-0.1905 -0.1534
S-501	Das
T-501	The expiry date refers to the last day of that month .
H-501	-0.20190350711345673	The
D-501	-0.20190350711345673	The
P-501	-0.2297 -0.1742
S-471	2.
T-471	ADROVANCE 70 mg/ 2800 IU tablets Alendronic acid as alendronate sodium trihydrate/ colecalciferol
H-471	-0.4881218373775482	2.
D-471	-0.4881218373775482	2.
P-471	-0.0550 -0.9212
S-472	2.
T-472	ADROVANCE 70 mg/ 2800 IU tablets Alendronic acid as alendronate sodium trihydrate/ colecalciferol
H-472	-0.4881218373775482	2.
D-472	-0.4881218373775482	2.
P-472	-0.0550 -0.9212
S-477	Sie
T-477	It is very important to follow instructions 2 ) , 3 ) , 4 ) and 5 ) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet ( oesophagus - the tube that connects your mouth with your stomach ) .
H-477	-0.4157377779483795	you
D-477	-0.4157377779483795	you
P-477	-0.3666 -0.4648
S-496	Sie
T-496	It is very important to follow instructions 2 ) , 3 ) , 4 ) and 5 ) to help the ADROVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet ( oesophagus - the tube that connects your mouth with your stomach ) .
H-496	-0.4157377779483795	you
D-496	-0.4157377779483795	you
P-496	-0.3666 -0.4648
S-478	(
T-478	2 ) After getting up for the day and before taking any food , drink , or other medicine , swallow your ADROVANCE tablet with a full glass of water only ( not mineral water ) ( not less than 200 ml or 7 fl . oz . ) . Do not take with mineral water ( still or sparkling ) . Do not take with coffee or tea . Do not take with juice or milk .
H-478	-0.15705111622810364	(
D-478	-0.15705111622810364	(
P-478	-0.1577 -0.1564
S-485	Das
T-485	The expiry date refers to the last day of that month .
H-485	-0.20190350711345673	The
D-485	-0.20190350711345673	The
P-485	-0.2297 -0.1742
S-698	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-698	Wash your hands thoroughly using soap and warm water .
H-698	-0.2723866403102875	Wash hands carefully with soap and warm water .
D-698	-0.2723866403102875	Wash hands carefully with soap and warm water .
P-698	-0.9328 -0.0789 -0.2464 -0.5811 -0.1773 -0.0859 -0.1235 -0.2331 -0.1294 -0.1373 -0.2706
S-874	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-874	Wash your hands thoroughly using soap and warm water .
H-874	-0.2723866403102875	Wash hands carefully with soap and warm water .
D-874	-0.2723866403102875	Wash hands carefully with soap and warm water .
P-874	-0.9328 -0.0789 -0.2464 -0.5811 -0.1773 -0.0859 -0.1235 -0.2331 -0.1294 -0.1373 -0.2706
S-268	Es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht .
T-268	Not all pack sizes may be marketed .
H-268	-0.1681995391845703	Not all pack sizes may be marketed .
D-268	-0.1681995391845703	Not all pack sizes may be marketed .
P-268	-0.4102 -0.1446 -0.2428 -0.0943 -0.1096 -0.1667 -0.2505 -0.0707 -0.0595 -0.1461 -0.1552
S-314	Bei den meisten Patienten gingen die Beschwerden nach dem Absetzen der Therapie zurück .
T-314	Most patients had relief of symptoms after stopping treatment .
H-314	-0.4445556402206421	In most patients , symptoms decreased after discontinuation of therapy .
D-314	-0.4445556402206421	In most patients , symptoms decreased after discontinuation of therapy .
P-314	-0.4057 -0.1441 -0.4434 -1.3464 -1.3062 -1.1826 -0.1012 -0.3475 -0.0667 -0.0294 -0.1120 -0.3662 -0.5272 -0.1374 -0.1524
S-57	Die empfohlene Dosis beträgt eine Tablette einmal wöchentlich .
T-57	The recommended dose is one tablet once a week .
H-57	-0.21354730427265167	The recommended dose is one tablet once a week .
D-57	-0.21354730427265167	The recommended dose is one tablet once a week .
P-57	-0.1469 -0.1421 -0.0810 -0.1273 -0.2338 -0.2359 -0.1224 -0.6757 -0.3918 -0.1005 -0.1566 -0.1485
S-547	Den vollständigen Wortlaut des EPAR für Advate finden Sie hier .
T-547	The full EPAR for Advate is available here .
H-547	-0.1749090999364853	The full EPAR for Advate is available here .
D-547	-0.1749090999364853	The full EPAR for Advate is available here .
P-547	-0.4865 -0.1416 -0.0559 -0.0525 -0.1199 -0.3154 -0.0781 -0.1927 -0.2208 -0.0936 -0.1878 -0.1542
S-250	Vor der Ausscheidung kommt es zu weiterer Hydroxylierung .
T-250	Further hydroxylation occurs prior to elimination .
H-250	-0.2599245309829712	Further hydroxylation occurs before excretion .
D-250	-0.2599245309829712	Further hydroxylation occurs before excretion .
P-250	-0.7607 -0.0791 -0.1198 -0.1572 -0.1014 -0.5520 -0.0757 -0.9201 -0.1536 -0.0361 -0.1193 -0.1520 -0.1520
S-446	Vor der Ausscheidung kommt es zu weiterer Hydroxylierung .
T-446	Further hydroxylation occurs prior to elimination .
H-446	-0.2599245309829712	Further hydroxylation occurs before excretion .
D-446	-0.2599245309829712	Further hydroxylation occurs before excretion .
P-446	-0.7607 -0.0791 -0.1198 -0.1572 -0.1014 -0.5520 -0.0757 -0.9201 -0.1536 -0.0361 -0.1193 -0.1520 -0.1520
S-464	Es werden möglicherweise nicht alle Packungsgrößen in den Verkehr gebracht .
T-464	Not all pack sizes may be marketed .
H-464	-0.1681995391845703	Not all pack sizes may be marketed .
D-464	-0.1681995391845703	Not all pack sizes may be marketed .
P-464	-0.4102 -0.1446 -0.2428 -0.0943 -0.1096 -0.1667 -0.2505 -0.0707 -0.0595 -0.1461 -0.1552
S-596	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-596	For instructions for reconstitution prior to administration , see section 6.6 .
H-596	-0.22544853389263153	For information on reconstitution prior to administration , see section 6.6 .
D-596	-0.22544853389263153	For information on reconstitution prior to administration , see section 6.6 .
P-596	-0.2500 -0.5705 -0.2405 -0.5253 -0.0772 -0.3945 -0.1334 -0.0842 -0.1601 -0.2209 -0.1490 -0.1184 -0.1525 -0.1543 -0.1507
S-525	Advate wird angewendet , um den fehlenden Faktor VIII zu ersetzen .
T-525	Advate is used to replace the missing factor VIII .
H-525	-0.2847195565700531	Advate is used to replace the missing factor VIII .
D-525	-0.2847195565700531	Advate is used to replace the missing factor VIII .
P-525	-0.6012 -0.1069 -0.1225 -0.1462 -0.1353 -0.9423 -0.2537 -0.6204 -0.1753 -0.1239 -0.1382 -0.1799 -0.1554
S-1050	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-1050	Wash your hands thoroughly using soap and warm water .
H-1050	-0.2723866403102875	Wash hands carefully with soap and warm water .
D-1050	-0.2723866403102875	Wash hands carefully with soap and warm water .
P-1050	-0.9328 -0.0789 -0.2464 -0.5811 -0.1773 -0.0859 -0.1235 -0.2331 -0.1294 -0.1373 -0.2706
S-1226	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-1226	Wash your hands thoroughly using soap and warm water .
H-1226	-0.2723866403102875	Wash hands carefully with soap and warm water .
D-1226	-0.2723866403102875	Wash hands carefully with soap and warm water .
P-1226	-0.9328 -0.0789 -0.2464 -0.5811 -0.1773 -0.0859 -0.1235 -0.2331 -0.1294 -0.1373 -0.2706
S-1402	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-1402	Wash your hands thoroughly using soap and warm water .
H-1402	-0.2723866403102875	Wash hands carefully with soap and warm water .
D-1402	-0.2723866403102875	Wash hands carefully with soap and warm water .
P-1402	-0.9328 -0.0789 -0.2464 -0.5811 -0.1773 -0.0859 -0.1235 -0.2331 -0.1294 -0.1373 -0.2706
S-1579	Hände sorgfältig mit Seife und warmem Wasser waschen . .
T-1579	Wash your hands thoroughly using soap and warm water .
H-1579	-0.2723866403102875	Wash hands carefully with soap and warm water .
D-1579	-0.2723866403102875	Wash hands carefully with soap and warm water .
P-1579	-0.9328 -0.0789 -0.2464 -0.5811 -0.1773 -0.0859 -0.1235 -0.2331 -0.1294 -0.1373 -0.2706
S-198	Eine Ergänzung mit Vitamin D senkt diese Risiken und ihre Konsequenzen .
T-198	Supplemental vitamin D reduces these risks and their consequences .
H-198	-0.4285678565502167	Vitamin D supplementation will reduce these risks and their consequences .
D-198	-0.4285678565502167	Vitamin D supplementation will reduce these risks and their consequences .
P-198	-2.0344 -0.0657 -0.1390 -0.0103 -0.2004 -0.1177 -1.4653 -0.5580 -0.2333 -0.1371 -0.1393 -0.3591 -0.6672 -0.1465 -0.1550
S-211	5,0 , 5,8 % ) in der Gruppe mit 10 mg täglich .
T-211	5.0 , 5.8 % ) in the 10 mg daily group .
H-211	-0.16254451870918274	5.0 , 5.8 % ) in the 10 mg daily group .
D-211	-0.16254451870918274	5.0 , 5.8 % ) in the 10 mg daily group .
P-211	-0.0951 -0.0854 -0.1774 -0.0764 -0.1070 -0.1402 -0.1281 -0.1483 -0.1397 -0.4302 -0.0517 -0.3092 -0.2554 -0.1443 -0.1498
S-386	Eine Ergänzung mit Vitamin D senkt diese Risiken und ihre Konsequenzen .
T-386	Supplemental vitamin D reduces these risks and their consequences .
H-386	-0.4285678565502167	Vitamin D supplementation will reduce these risks and their consequences .
D-386	-0.4285678565502167	Vitamin D supplementation will reduce these risks and their consequences .
P-386	-2.0344 -0.0657 -0.1390 -0.0103 -0.2004 -0.1177 -1.4653 -0.5580 -0.2333 -0.1371 -0.1393 -0.3591 -0.6672 -0.1465 -0.1550
S-407	5,0 , 5,8 % ) in der Gruppe mit 10 mg täglich .
T-407	5.0 , 5.8 % ) in the 10 mg daily group .
H-407	-0.16254451870918274	5.0 , 5.8 % ) in the 10 mg daily group .
D-407	-0.16254451870918274	5.0 , 5.8 % ) in the 10 mg daily group .
P-407	-0.0951 -0.0854 -0.1774 -0.0764 -0.1070 -0.1402 -0.1281 -0.1483 -0.1397 -0.4302 -0.0517 -0.3092 -0.2554 -0.1443 -0.1498
S-126	Bei den meisten Patienten gingen die Beschwerden nach dem Absetzen der Therapie zurück .
T-126	Most patients had relief of symptoms after stopping treatment .
H-126	-0.4445556402206421	In most patients , symptoms decreased after discontinuation of therapy .
D-126	-0.4445556402206421	In most patients , symptoms decreased after discontinuation of therapy .
P-126	-0.4057 -0.1441 -0.4434 -1.3464 -1.3062 -1.1826 -0.1012 -0.3475 -0.0667 -0.0294 -0.1120 -0.3662 -0.5272 -0.1374 -0.1524
S-1125	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-1125	The product contains traces of mouse and hamster proteins .
H-1125	-0.30202099680900574	contains traces of mouse and hamster proteins .
D-1125	-0.30202099680900574	contains traces of mouse and hamster proteins .
P-1125	-1.8211 -0.3804 -0.1013 -0.1515 -0.1407 -0.0786 -0.1845 -0.2545 -0.0966 -0.3158 -0.0582 -0.1799 -0.1633
S-773	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-773	The product contains traces of mouse and hamster proteins .
H-773	-0.30202099680900574	contains traces of mouse and hamster proteins .
D-773	-0.30202099680900574	contains traces of mouse and hamster proteins .
P-773	-1.8211 -0.3804 -0.1013 -0.1515 -0.1407 -0.0786 -0.1845 -0.2545 -0.0966 -0.3158 -0.0582 -0.1799 -0.1633
S-1301	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-1301	The product contains traces of mouse and hamster proteins .
H-1301	-0.30202099680900574	contains traces of mouse and hamster proteins .
D-1301	-0.30202099680900574	contains traces of mouse and hamster proteins .
P-1301	-1.8211 -0.3804 -0.1013 -0.1515 -0.1407 -0.0786 -0.1845 -0.2545 -0.0966 -0.3158 -0.0582 -0.1799 -0.1633
S-1477	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-1477	The product contains traces of mouse and hamster proteins .
H-1477	-0.30202099680900574	contains traces of mouse and hamster proteins .
D-1477	-0.30202099680900574	contains traces of mouse and hamster proteins .
P-1477	-1.8211 -0.3804 -0.1013 -0.1515 -0.1407 -0.0786 -0.1845 -0.2545 -0.0966 -0.3158 -0.0582 -0.1799 -0.1633
S-1614	Zusammenfassung der Merkmale des Arzneimittels , Abschnitt 4.2 ) .
T-1614	Summary of Product Characteristics , section 4.2 )
H-1614	-0.13605372607707977	Summary of Product Characteristics , Section 4.2 ) .
D-1614	-0.13605372607707977	Summary of Product Characteristics , Section 4.2 ) .
P-1614	-0.0409 -0.0756 -0.1663 -0.0140 -0.0347 -0.0545 -0.0694 -0.4004 -0.1039 -0.1583 -0.4289 -0.0570 -0.1303 -0.1480 -0.1295 -0.1499 -0.1514
S-949	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-949	The product contains traces of mouse and hamster proteins .
H-949	-0.30202099680900574	contains traces of mouse and hamster proteins .
D-949	-0.30202099680900574	contains traces of mouse and hamster proteins .
P-949	-1.8211 -0.3804 -0.1013 -0.1515 -0.1407 -0.0786 -0.1845 -0.2545 -0.0966 -0.3158 -0.0582 -0.1799 -0.1633
S-102	Daher ist eine Dosisanpassung bei älteren Menschen nicht erforderlich .
T-102	Therefore no dosage adjustment is necessary for the elderly .
H-102	-0.39910122752189636	Therefore , a dose adjustment in the elderly is not necessary .
D-102	-0.39910122752189636	Therefore , a dose adjustment in the elderly is not necessary .
P-102	-1.9828 -0.0612 -0.6449 -0.5059 -0.0987 -0.0734 -0.0754 -0.1037 -1.0935 -0.7957 -0.0308 -0.1781 -0.2761 -0.1653 -0.1492 -0.1510
S-599	Das Produkt enthält Spuren von Maus- und Hamsterproteinen .
T-599	The product contains traces of mouse and hamster proteins .
H-599	-0.30202099680900574	contains traces of mouse and hamster proteins .
D-599	-0.30202099680900574	contains traces of mouse and hamster proteins .
P-599	-1.8211 -0.3804 -0.1013 -0.1515 -0.1407 -0.0786 -0.1845 -0.2545 -0.0966 -0.3158 -0.0582 -0.1799 -0.1633
S-431	Die Proteinbindung im menschlichen Plasma beträgt ca. 78 <unk> .
T-431	Protein binding in human plasma is approximately 78 % .
H-431	-0.21307633817195892	Protein binding in human plasma is approximately 78 <unk> .
D-431	-0.21307633817195892	Protein binding in human plasma is approximately 78 <unk> .
P-431	-1.6125 -0.0392 -0.0740 -0.1217 -0.1311 -0.1907 -0.1094 -0.0833 -0.1147 -0.1234 -0.0437 -0.0689 -0.1462 -0.1735 -0.1639
S-235	Die Proteinbindung im menschlichen Plasma beträgt ca. 78 <unk> .
T-235	Protein binding in human plasma is approximately 78 % .
H-235	-0.21307633817195892	Protein binding in human plasma is approximately 78 <unk> .
D-235	-0.21307633817195892	Protein binding in human plasma is approximately 78 <unk> .
P-235	-1.6125 -0.0392 -0.0740 -0.1217 -0.1311 -0.1907 -0.1094 -0.0833 -0.1147 -0.1234 -0.0437 -0.0689 -0.1462 -0.1735 -0.1639
S-1917	Welchen Nutzen hat Aerinaze in diesen Studien gezeigt ?
T-1917	What benefit has Aerinaze shown during the studies ?
H-1917	-0.3142071068286896	What benefit has Aerinaze shown in these trials ?
D-1917	-0.3142071068286896	What benefit has Aerinaze shown in these trials ?
P-1917	-0.1178 -0.2820 -0.3425 -0.1667 -0.1290 -0.1161 -0.1374 -0.1519 -0.1110 -0.9165 -0.1578 -1.0598 -0.5554 -0.1549
S-74	Welchen Nutzen hat ADROVANCE in diesen Studien gezeigt ?
T-74	What benefit has ADROVANCE shown during the studies ?
H-74	-0.3151106536388397	What benefit has ADROVANCE shown in these studies ?
D-74	-0.3151106536388397	What benefit has ADROVANCE shown in these studies ?
P-74	-0.1501 -0.3319 -0.4829 -0.0375 -0.0776 -0.1206 -0.1244 -0.1772 -0.1878 -0.8785 -0.1569 -0.9552 -0.5715 -0.1595
S-1722	- Wenn Sie weitere Fragen haben , wenden Sie sich an Ihren Arzt .
T-1722	- If you have any further questions , ask your doctor .
H-1722	-0.48574844002723694	- If you have any further questions , contact your doctor .
D-1722	-0.48574844002723694	- If you have any further questions , contact your doctor .
P-1722	-0.8353 -0.4714 -0.1106 -0.1905 -0.3364 -1.0920 -1.3001 -0.2654 -1.1585 -0.1421 -0.1006 -0.1519 -0.1600
S-30	Der Harnsäurespiegel im Blut wurde jeden Monat bestimmt .
T-30	Blood uric acid levels were measured every month .
H-30	-0.3065852224826813	The uric acid level in the blood was measured each month .
D-30	-0.3065852224826813	The uric acid level in the blood was measured each month .
P-30	-0.5830 -0.4539 -0.0789 -0.1150 -0.8415 -0.1352 -0.2214 -0.0604 -0.2108 -0.3480 -0.8535 -0.1085 -0.1333 -0.1488
S-1315	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-1315	4.5 Interaction with other medicinal products and other forms of interaction
H-1315	-0.30550771951675415	4.5 Interactions with other medicinal products and other interactions
D-1315	-0.30550771951675415	4.5 Interactions with other medicinal products and other interactions
P-1315	-0.1285 -0.1349 -0.7540 -0.6674 -0.3067 -0.2672 -0.0554 -0.0371 -0.1231 -0.1306 -0.6018 -0.8115 -0.0665 -0.1926
S-1828	Polska Baxter Poland Sp. z o.o. ul .
T-1828	Polska Baxter Poland Sp . z o. o. ul .
H-1828	-0.21983739733695984	Polska Baxter Poland Sp. z o.o. ul .
D-1828	-0.21983739733695984	Polska Baxter Poland Sp. z o.o. ul .
P-1828	-0.0849 -0.0731 -0.2612 -0.1428 -0.1303 -0.3693 -0.0999 -0.1288 -0.2264 -0.1502 -0.3716 -0.0314 -0.9434 -0.1358 -0.1484
S-11	Sie kann mit oder unabhängig von den Mahlzeiten eingenommen werden .
T-11	It can be taken with or without food .
H-11	-0.25078028440475464	It can be taken with or without meals .
D-11	-0.25078028440475464	It can be taken with or without meals .
P-11	-0.1758 -0.4055 -0.1675 -0.1254 -0.1101 -0.1391 -0.4147 -0.6713 -0.1390 -0.1595
S-1259	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-1259	For a full list of excipients , see section 6.1 .
H-1259	-0.13270249962806702	For a full list of excipients , see section 6.1 .
D-1259	-0.13270249962806702	For a full list of excipients , see section 6.1 .
P-1259	-0.1422 -0.1432 -0.0835 -0.0662 -0.1509 -0.0674 -0.0619 -0.0988 -0.0803 -0.1389 -0.3087 -0.1786 -0.1238 -0.1530 -0.1759 -0.1500
S-1139	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-1139	4.5 Interaction with other medicinal products and other forms of interaction
H-1139	-0.30550771951675415	4.5 Interactions with other medicinal products and other interactions
D-1139	-0.30550771951675415	4.5 Interactions with other medicinal products and other interactions
P-1139	-0.1285 -0.1349 -0.7540 -0.6674 -0.3067 -0.2672 -0.0554 -0.0371 -0.1231 -0.1306 -0.6018 -0.8115 -0.0665 -0.1926
S-1726	- Wenn eine der aufgeführten Nebenwirkungen Sie erheblich beeinträchtigt oder Sie
T-1726	- If any of the side effects gets serious , or if you notice any side effects not listed in this leaflet ,
H-1726	-0.45767393708229065	- If any of the side effects gets serious or gets
D-1726	-0.45767393708229065	- If any of the side effects gets serious or gets
P-1726	-0.2133 -0.3343 -0.1311 -0.1335 -0.1757 -0.1794 -0.1114 -0.1050 -1.6813 -0.7853 -1.2179 -0.4239
S-286	Die Äquivalenz der Einnahme von 5.600 I.E.
T-286	ADROVANCE should not be taken at bedtime or before arising for the day .
H-286	-0.32781586050987244	The equivalent of taking 5,600 IU of
D-286	-0.32781586050987244	The equivalent of taking 5,600 IU of
P-286	-0.1886 -0.7947 -0.2085 -0.1572 -0.3489 -0.0697 -0.1063 -0.0769 -1.1868 -0.1405
S-1796	Im Kühlschrank lagern ( 2<unk> C-8<unk> C ) .
T-1796	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1796	-0.13116972148418427	store in a refrigerator ( 2<unk> C-8<unk> C ) .
D-1796	-0.13116972148418427	store in a refrigerator ( 2<unk> C-8<unk> C ) .
P-1796	-0.3709 -0.1575 -0.1421 -0.1375 -0.0539 -0.0696 -0.0980 -0.1266 -0.1116 -0.0763 -0.1567 -0.1472 -0.1129 -0.0658 -0.0965 -0.1460 -0.1390 -0.1530
S-1491	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-1491	4.5 Interaction with other medicinal products and other forms of interaction
H-1491	-0.30550771951675415	4.5 Interactions with other medicinal products and other interactions
D-1491	-0.30550771951675415	4.5 Interactions with other medicinal products and other interactions
P-1491	-0.1285 -0.1349 -0.7540 -0.6674 -0.3067 -0.2672 -0.0554 -0.0371 -0.1231 -0.1306 -0.6018 -0.8115 -0.0665 -0.1926
S-1435	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-1435	For a full list of excipients , see section 6.1 .
H-1435	-0.13270249962806702	For a full list of excipients , see section 6.1 .
D-1435	-0.13270249962806702	For a full list of excipients , see section 6.1 .
P-1435	-0.1422 -0.1432 -0.0835 -0.0662 -0.1509 -0.0674 -0.0619 -0.0988 -0.0803 -0.1389 -0.3087 -0.1786 -0.1238 -0.1530 -0.1759 -0.1500
S-290	Daher ist eine Dosisanpassung bei älteren Menschen nicht erforderlich .
T-290	Therefore no dosage adjustment is necessary for the elderly .
H-290	-0.39910122752189636	Therefore , a dose adjustment in the elderly is not necessary .
D-290	-0.39910122752189636	Therefore , a dose adjustment in the elderly is not necessary .
P-290	-1.9828 -0.0612 -0.6449 -0.5059 -0.0987 -0.0734 -0.0754 -0.1037 -1.0935 -0.7957 -0.0308 -0.1781 -0.2761 -0.1653 -0.1492 -0.1510
S-907	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-907	For a full list of excipients , see section 6.1 .
H-907	-0.13270249962806702	For a full list of excipients , see section 6.1 .
D-907	-0.13270249962806702	For a full list of excipients , see section 6.1 .
P-907	-0.1422 -0.1432 -0.0835 -0.0662 -0.1509 -0.0674 -0.0619 -0.0988 -0.0803 -0.1389 -0.3087 -0.1786 -0.1238 -0.1530 -0.1759 -0.1500
S-556	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-556	For a full list of excipients , see section 6.1 .
H-556	-0.13270249962806702	For a full list of excipients , see section 6.1 .
D-556	-0.13270249962806702	For a full list of excipients , see section 6.1 .
P-556	-0.1422 -0.1432 -0.0835 -0.0662 -0.1509 -0.0674 -0.0619 -0.0988 -0.0803 -0.1389 -0.3087 -0.1786 -0.1238 -0.1530 -0.1759 -0.1500
S-1083	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-1083	For a full list of excipients , see section 6.1 .
H-1083	-0.13270249962806702	For a full list of excipients , see section 6.1 .
D-1083	-0.13270249962806702	For a full list of excipients , see section 6.1 .
P-1083	-0.1422 -0.1432 -0.0835 -0.0662 -0.1509 -0.0674 -0.0619 -0.0988 -0.0803 -0.1389 -0.3087 -0.1786 -0.1238 -0.1530 -0.1759 -0.1500
S-963	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-963	4.5 Interaction with other medicinal products and other forms of interaction
H-963	-0.30550771951675415	4.5 Interactions with other medicinal products and other interactions
D-963	-0.30550771951675415	4.5 Interactions with other medicinal products and other interactions
P-963	-0.1285 -0.1349 -0.7540 -0.6674 -0.3067 -0.2672 -0.0554 -0.0371 -0.1231 -0.1306 -0.6018 -0.8115 -0.0665 -0.1926
S-787	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-787	4.5 Interaction with other medicinal products and other forms of interaction
H-787	-0.30550771951675415	4.5 Interactions with other medicinal products and other interactions
D-787	-0.30550771951675415	4.5 Interactions with other medicinal products and other interactions
P-787	-0.1285 -0.1349 -0.7540 -0.6674 -0.3067 -0.2672 -0.0554 -0.0371 -0.1231 -0.1306 -0.6018 -0.8115 -0.0665 -0.1926
S-731	Eine vollständige Liste der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-731	For a full list of excipients , see section 6.1 .
H-731	-0.13270249962806702	For a full list of excipients , see section 6.1 .
D-731	-0.13270249962806702	For a full list of excipients , see section 6.1 .
P-731	-0.1422 -0.1432 -0.0835 -0.0662 -0.1509 -0.0674 -0.0619 -0.0988 -0.0803 -0.1389 -0.3087 -0.1786 -0.1238 -0.1530 -0.1759 -0.1500
S-613	4.5 . Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-613	4.5 Interaction with other medicinal products and other forms of interaction
H-613	-0.30550771951675415	4.5 Interactions with other medicinal products and other interactions
D-613	-0.30550771951675415	4.5 Interactions with other medicinal products and other interactions
P-613	-0.1285 -0.1349 -0.7540 -0.6674 -0.3067 -0.2672 -0.0554 -0.0371 -0.1231 -0.1306 -0.6018 -0.8115 -0.0665 -0.1926
S-352	Für ADROVANCE wurden keine weiteren Nebenwirkungen festgestellt .
T-352	No additional adverse reactions have been identified for ADROVANCE .
H-352	-0.4129785895347595	No other undesirable effects have been observed for ADROVANCE .
D-352	-0.4129785895347595	No other undesirable effects have been observed for ADROVANCE .
P-352	-0.3564 -0.6933 -1.4140 -0.0682 -0.0562 -0.0967 -1.1421 -0.1293 -1.7125 -0.5179 -0.1030 -0.0863 -0.1215 -0.1014 -0.1234 -0.1457 -0.1528
S-856	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-856	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-856	-0.19382500648498535	store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-856	-0.19382500648498535	store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-856	-0.2435 -0.1606 -0.1413 -0.1449 -0.0580 -0.0686 -0.1007 -0.1278 -0.2390 -0.2579 -0.1302 -1.0289 -0.0495 -0.1092 -0.1364 -0.1456 -0.1528
S-164	Für ADROVANCE wurden keine weiteren Nebenwirkungen festgestellt .
T-164	No additional adverse reactions have been identified for ADROVANCE .
H-164	-0.4129785895347595	No other undesirable effects have been observed for ADROVANCE .
D-164	-0.4129785895347595	No other undesirable effects have been observed for ADROVANCE .
P-164	-0.3564 -0.6933 -1.4140 -0.0682 -0.0562 -0.0967 -1.1421 -0.1293 -1.7125 -0.5179 -0.1030 -0.0863 -0.1215 -0.1014 -0.1234 -0.1457 -0.1528
S-680	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-680	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-680	-0.19382500648498535	store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-680	-0.19382500648498535	store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-680	-0.2435 -0.1606 -0.1413 -0.1449 -0.0580 -0.0686 -0.1007 -0.1278 -0.2390 -0.2579 -0.1302 -1.0289 -0.0495 -0.1092 -0.1364 -0.1456 -0.1528
S-1806	Jede Pulver-Durchstechflasche enthält 250 I.E.
T-1806	Each powder vial contains 250 IU octocog alfa .
H-1806	-0.279823899269104	Each powder vial contains 250 IU of
D-1806	-0.279823899269104	Each powder vial contains 250 IU of
P-1806	-0.0427 -1.2016 -0.0657 -0.0586 -0.0859 -0.1121 -0.1149 -0.1048 -0.8697 -0.1422
S-1032	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-1032	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1032	-0.19382500648498535	store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-1032	-0.19382500648498535	store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-1032	-0.2435 -0.1606 -0.1413 -0.1449 -0.0580 -0.0686 -0.1007 -0.1278 -0.2390 -0.2579 -0.1302 -1.0289 -0.0495 -0.1092 -0.1364 -0.1456 -0.1528
S-1208	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-1208	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1208	-0.19382500648498535	store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-1208	-0.19382500648498535	store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-1208	-0.2435 -0.1606 -0.1413 -0.1449 -0.0580 -0.0686 -0.1007 -0.1278 -0.2390 -0.2579 -0.1302 -1.0289 -0.0495 -0.1092 -0.1364 -0.1456 -0.1528
S-1384	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-1384	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1384	-0.19382500648498535	store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-1384	-0.19382500648498535	store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-1384	-0.2435 -0.1606 -0.1413 -0.1449 -0.0580 -0.0686 -0.1007 -0.1278 -0.2390 -0.2579 -0.1302 -1.0289 -0.0495 -0.1092 -0.1364 -0.1456 -0.1528
S-1561	Im Kühlschrank lagern ( 2 <unk> C 8 <unk> C ) .
T-1561	Store in a refrigerator ( 2<<unk>> C 8<<unk>> C ) .
H-1561	-0.19382500648498535	store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
D-1561	-0.19382500648498535	store in a refrigerator ( 2 <unk> C 8 <unk> C ) .
P-1561	-0.2435 -0.1606 -0.1413 -0.1449 -0.0580 -0.0686 -0.1007 -0.1278 -0.2390 -0.2579 -0.1302 -1.0289 -0.0495 -0.1092 -0.1364 -0.1456 -0.1528
S-1657	Nur zur einmaligen Anwendung Vor der Anwendung Gebrauchsinformation lesen .
T-1657	Nur zur einmaligen Anwendung Vor der Anwendung Gebrauchsinformation lesen . Read the package leaflet before use .
H-1657	-0.7200721502304077	Only for single use Read this leaflet before use .
D-1657	-0.7200721502304077	Only for single use Read this leaflet before use .
P-1657	-3.0805 -0.2699 -0.4167 -0.1064 -0.0759 -3.0423 -0.2319 -0.0439 -0.0995 -0.8606 -0.8292 -0.1511 -0.1531
S-1974	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-1974	4.5 Interaction with other medicinal products and other forms of interaction
H-1974	-0.27444806694984436	4.5 Interactions with other medicinal products and other interactions
D-1974	-0.27444806694984436	4.5 Interactions with other medicinal products and other interactions
P-1974	-0.1205 -0.1330 -0.1039 -0.5983 -0.3238 -0.2938 -0.0540 -0.0386 -0.1169 -0.1304 -0.6676 -1.0257 -0.0646 -0.1713
S-331	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-331	4.5 Interaction with other medicinal products and other forms of interaction
H-331	-0.27444806694984436	4.5 Interactions with other medicinal products and other interactions
D-331	-0.27444806694984436	4.5 Interactions with other medicinal products and other interactions
P-331	-0.1205 -0.1330 -0.1039 -0.5983 -0.3238 -0.2938 -0.0540 -0.0386 -0.1169 -0.1304 -0.6676 -1.0257 -0.0646 -0.1713
S-1787	Häufige Nebenwirkungen Schwindel , Kopfschmerzen und Fieber
T-1787	Common side effects dizziness , headache and fever .
H-1787	-0.15568071603775024	Common side effects Dizziness , headache and fever
D-1787	-0.15568071603775024	Common side effects Dizziness , headache and fever
P-1787	-0.1070 -0.1257 -0.7809 -0.1188 -0.1679 -0.0721 -0.0550 -0.1558 -0.1062 -0.0438 -0.1171 -0.1563 -0.1077 -0.0702 -0.1507
S-1577	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1577	shows any sign of deterioration .
H-1577	-0.43931058049201965	its packaging is damaged or shows signs of manipulation .
D-1577	-0.43931058049201965	its packaging is damaged or shows signs of manipulation .
P-1577	-0.3497 -0.7157 -0.1405 -0.1670 -0.5960 -0.1314 -1.9583 -0.3544 -0.1431 -0.7879 -0.0620 -0.1439 -0.1612
S-1224	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1224	shows any sign of deterioration .
H-1224	-0.43931058049201965	its packaging is damaged or shows signs of manipulation .
D-1224	-0.43931058049201965	its packaging is damaged or shows signs of manipulation .
P-1224	-0.3497 -0.7157 -0.1405 -0.1670 -0.5960 -0.1314 -1.9583 -0.3544 -0.1431 -0.7879 -0.0620 -0.1439 -0.1612
S-1093	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-1093	The dose is determined using the following formula :
H-1093	-0.39695796370506287	The required dose is calculated using the following formula :
D-1093	-0.39695796370506287	The required dose is calculated using the following formula :
P-1093	-0.1969 -1.7530 -0.0698 -0.2992 -0.2226 -0.1316 -1.1935 -0.1433 -0.2541 -0.2056 -0.1383 -0.1558
S-917	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-917	The dose is determined using the following formula :
H-917	-0.39695796370506287	The required dose is calculated using the following formula :
D-917	-0.39695796370506287	The required dose is calculated using the following formula :
P-917	-0.1969 -1.7530 -0.0698 -0.2992 -0.2226 -0.1316 -1.1935 -0.1433 -0.2541 -0.2056 -0.1383 -0.1558
S-741	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-741	The dose is determined using the following formula :
H-741	-0.39695796370506287	The required dose is calculated using the following formula :
D-741	-0.39695796370506287	The required dose is calculated using the following formula :
P-741	-0.1969 -1.7530 -0.0698 -0.2992 -0.2226 -0.1316 -1.1935 -0.1433 -0.2541 -0.2056 -0.1383 -0.1558
S-1445	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-1445	The dose is determined using the following formula :
H-1445	-0.39695796370506287	The required dose is calculated using the following formula :
D-1445	-0.39695796370506287	The required dose is calculated using the following formula :
P-1445	-0.1969 -1.7530 -0.0698 -0.2992 -0.2226 -0.1316 -1.1935 -0.1433 -0.2541 -0.2056 -0.1383 -0.1558
S-1400	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1400	shows any sign of deterioration .
H-1400	-0.43931058049201965	its packaging is damaged or shows signs of manipulation .
D-1400	-0.43931058049201965	its packaging is damaged or shows signs of manipulation .
P-1400	-0.3497 -0.7157 -0.1405 -0.1670 -0.5960 -0.1314 -1.9583 -0.3544 -0.1431 -0.7879 -0.0620 -0.1439 -0.1612
S-1269	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-1269	The dose is determined using the following formula :
H-1269	-0.39695796370506287	The required dose is calculated using the following formula :
D-1269	-0.39695796370506287	The required dose is calculated using the following formula :
P-1269	-0.1969 -1.7530 -0.0698 -0.2992 -0.2226 -0.1316 -1.1935 -0.1433 -0.2541 -0.2056 -0.1383 -0.1558
S-1048	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1048	shows any sign of deterioration .
H-1048	-0.43931058049201965	its packaging is damaged or shows signs of manipulation .
D-1048	-0.43931058049201965	its packaging is damaged or shows signs of manipulation .
P-1048	-0.3497 -0.7157 -0.1405 -0.1670 -0.5960 -0.1314 -1.9583 -0.3544 -0.1431 -0.7879 -0.0620 -0.1439 -0.1612
S-872	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-872	shows any sign of deterioration .
H-872	-0.43931058049201965	its packaging is damaged or shows signs of manipulation .
D-872	-0.43931058049201965	its packaging is damaged or shows signs of manipulation .
P-872	-0.3497 -0.7157 -0.1405 -0.1670 -0.5960 -0.1314 -1.9583 -0.3544 -0.1431 -0.7879 -0.0620 -0.1439 -0.1612
S-696	seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-696	shows any sign of deterioration .
H-696	-0.43931058049201965	its packaging is damaged or shows signs of manipulation .
D-696	-0.43931058049201965	its packaging is damaged or shows signs of manipulation .
P-696	-0.3497 -0.7157 -0.1405 -0.1670 -0.5960 -0.1314 -1.9583 -0.3544 -0.1431 -0.7879 -0.0620 -0.1439 -0.1612
S-567	Die erforderliche Dosis wird mit folgender Formel berechnet :
T-567	The dose is determined using the following formula :
H-567	-0.39695796370506287	The required dose is calculated using the following formula :
D-567	-0.39695796370506287	The required dose is calculated using the following formula :
P-567	-0.1969 -1.7530 -0.0698 -0.2992 -0.2226 -0.1316 -1.1935 -0.1433 -0.2541 -0.2056 -0.1383 -0.1558
S-143	4.5 Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen
T-143	4.5 Interaction with other medicinal products and other forms of interaction
H-143	-0.27444806694984436	4.5 Interactions with other medicinal products and other interactions
D-143	-0.27444806694984436	4.5 Interactions with other medicinal products and other interactions
P-143	-0.1205 -0.1330 -0.1039 -0.5983 -0.3238 -0.2938 -0.0540 -0.0386 -0.1169 -0.1304 -0.6676 -1.0257 -0.0646 -0.1713
S-723	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-723	02 March 2004 Date of last renewal :
H-723	-0.3046305775642395	02 March 2004 Date of last renewal :
D-723	-0.3046305775642395	02 March 2004 Date of last renewal :
P-723	-0.3907 -0.3540 -0.2806 -0.2764 -0.0972 -0.1866 -0.1191 -1.0986 -0.1446 -0.1998 -0.2032
S-382	Vitamin D3 wird für eine normale Knochenbildung benötigt .
T-382	Vitamin D3 is required for normal bone formation .
H-382	-0.29930827021598816	vitamin D3 is required for normal bone formation .
D-382	-0.29930827021598816	vitamin D3 is required for normal bone formation .
P-382	-0.3205 -0.1078 -0.1344 -0.1310 -0.0998 -1.6434 -0.1724 -0.2142 -0.1638 -0.3086 -0.1388 -0.1570
S-1766	Dies ist besonders bei größeren , chirurgischen Eingriffen wichtig .
T-1766	This is particularly important if you are having major surgery .
H-1766	-0.28153300285339355	This is especially important for major surgery .
D-1766	-0.28153300285339355	This is especially important for major surgery .
P-1766	-0.1089 -0.1405 -0.4068 -0.0984 -0.4645 -0.6034 -0.3928 -0.1623 -0.1562
S-1795	Das Verfalldatum bezieht sich auf den letzten Tag des Monats .
T-1795	The expiry date refers to the last day of that month .
H-1795	-0.17339245975017548	The expiry date refers to the last day of that month .
D-1795	-0.17339245975017548	The expiry date refers to the last day of that month .
P-1795	-0.2266 -0.0140 -0.0524 -0.1529 -0.0548 -0.1092 -0.1449 -0.1435 -0.1200 -0.1125 -0.1723 -0.8705 -0.1317 -0.1427 -0.1528
S-1728	Was ist ADVATE und wofür wird es angewendet ?
T-1728	What ADVATE is and what it is used for 2.
H-1728	-0.34091493487358093	What ADVATE is and what it is used for ?
D-1728	-0.34091493487358093	What ADVATE is and what it is used for ?
P-1728	-0.0898 -0.5193 -0.1464 -0.0864 -0.1131 -0.1036 -0.1245 -0.1557 -0.1502 -0.1233 -0.1267 -0.0882 -2.7845 -0.1610
S-31	Welchen Nutzen hat Adenuric in diesen Studien gezeigt ?
T-31	What benefit has Adenuric shown during the studies ?
H-31	-0.31283581256866455	What benefit has Adenuric shown in these trials ?
D-31	-0.31283581256866455	What benefit has Adenuric shown in these trials ?
P-31	-0.1280 -0.1647 -0.5112 -0.1490 -0.2045 -0.0775 -0.1083 -0.0908 -0.7873 -0.1079 -1.0222 -0.5599 -0.1556
S-1075	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-1075	02 March 2004 Date of last renewal :
H-1075	-0.3046305775642395	02 March 2004 Date of last renewal :
D-1075	-0.3046305775642395	02 March 2004 Date of last renewal :
P-1075	-0.3907 -0.3540 -0.2806 -0.2764 -0.0972 -0.1866 -0.1191 -1.0986 -0.1446 -0.1998 -0.2032
S-899	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-899	02 March 2004 Date of last renewal :
H-899	-0.3046305775642395	02 March 2004 Date of last renewal :
D-899	-0.3046305775642395	02 March 2004 Date of last renewal :
P-899	-0.3907 -0.3540 -0.2806 -0.2764 -0.0972 -0.1866 -0.1191 -1.0986 -0.1446 -0.1998 -0.2032
S-194	Vitamin D3 wird für eine normale Knochenbildung benötigt .
T-194	Vitamin D3 is required for normal bone formation .
H-194	-0.29930827021598816	vitamin D3 is required for normal bone formation .
D-194	-0.29930827021598816	vitamin D3 is required for normal bone formation .
P-194	-0.3205 -0.1078 -0.1344 -0.1310 -0.0998 -1.6434 -0.1724 -0.2142 -0.1638 -0.3086 -0.1388 -0.1570
S-1604	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-1604	02 March 2004 Date of last renewal :
H-1604	-0.3046305775642395	02 March 2004 Date of last renewal :
D-1604	-0.3046305775642395	02 March 2004 Date of last renewal :
P-1604	-0.3907 -0.3540 -0.2806 -0.2764 -0.0972 -0.1866 -0.1191 -1.0986 -0.1446 -0.1998 -0.2032
S-1427	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-1427	02 March 2004 Date of last renewal :
H-1427	-0.3046305775642395	02 March 2004 Date of last renewal :
D-1427	-0.3046305775642395	02 March 2004 Date of last renewal :
P-1427	-0.3907 -0.3540 -0.2806 -0.2764 -0.0972 -0.1866 -0.1191 -1.0986 -0.1446 -0.1998 -0.2032
S-1251	02 . März 2004 Datum der letzten Zulassungsverlängerung :
T-1251	02 March 2004 Date of last renewal :
H-1251	-0.3046305775642395	02 March 2004 Date of last renewal :
D-1251	-0.3046305775642395	02 March 2004 Date of last renewal :
P-1251	-0.3907 -0.3540 -0.2806 -0.2764 -0.0972 -0.1866 -0.1191 -1.0986 -0.1446 -0.1998 -0.2032
S-1564	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-1564	The product may not be returned to refrigerated storage again .
H-1564	-0.48983272910118103	The product must not be refrigerated .
D-1564	-0.48983272910118103	The product must not be refrigerated .
P-1564	-2.3140 -0.3535 -0.9319 -0.1898 -0.1994 -0.7263 -0.1457 -0.0787 -0.1198 -0.1695 -0.1596
S-1387	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-1387	The product may not be returned to refrigerated storage again .
H-1387	-0.48983272910118103	The product must not be refrigerated .
D-1387	-0.48983272910118103	The product must not be refrigerated .
P-1387	-2.3140 -0.3535 -0.9319 -0.1898 -0.1994 -0.7263 -0.1457 -0.0787 -0.1198 -0.1695 -0.1596
S-1211	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-1211	The product may not be returned to refrigerated storage again .
H-1211	-0.48983272910118103	The product must not be refrigerated .
D-1211	-0.48983272910118103	The product must not be refrigerated .
P-1211	-2.3140 -0.3535 -0.9319 -0.1898 -0.1994 -0.7263 -0.1457 -0.0787 -0.1198 -0.1695 -0.1596
S-1035	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-1035	The product may not be returned to refrigerated storage again .
H-1035	-0.48983272910118103	The product must not be refrigerated .
D-1035	-0.48983272910118103	The product must not be refrigerated .
P-1035	-2.3140 -0.3535 -0.9319 -0.1898 -0.1994 -0.7263 -0.1457 -0.0787 -0.1198 -0.1695 -0.1596
S-859	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-859	The product may not be returned to refrigerated storage again .
H-859	-0.48983272910118103	The product must not be refrigerated .
D-859	-0.48983272910118103	The product must not be refrigerated .
P-859	-2.3140 -0.3535 -0.9319 -0.1898 -0.1994 -0.7263 -0.1457 -0.0787 -0.1198 -0.1695 -0.1596
S-683	Das Produkt darf nicht wieder gekühlt gelagert werden .
T-683	The product may not be returned to refrigerated storage again .
H-683	-0.48983272910118103	The product must not be refrigerated .
D-683	-0.48983272910118103	The product must not be refrigerated .
P-683	-2.3140 -0.3535 -0.9319 -0.1898 -0.1994 -0.7263 -0.1457 -0.0787 -0.1198 -0.1695 -0.1596
S-808	Erkrankungen der Haut und des Unterhautzellgewebes
T-808	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-808	-0.1683623045682907	Skin and subcutaneous tissue disorders
D-808	-0.1683623045682907	Skin and subcutaneous tissue disorders
P-808	-0.1739 -0.1306 -0.1660 -0.0926 -0.0414 -0.0909 -0.1331 -0.1306 -0.7906 -0.0169 -0.1006 -0.1530
S-1775	Fragen Sie Ihren Arzt , wenn Sie nicht ganz sicher sind .
T-1775	You should check with your doctor if you are not sure .
H-1775	-0.1821611374616623	Ask your doctor if you are not sure .
D-1775	-0.1821611374616623	Ask your doctor if you are not sure .
P-1775	-0.0609 -0.0922 -0.1379 -0.1254 -0.1005 -0.1183 -0.1613 -0.7945 -0.0961 -0.1532 -0.1635
S-62	Weitere Informationen sind der Packungsbeilage zu entnehmen .
T-62	For more information , see the Package Leaflet .
H-62	-0.189173623919487	For more information , see the Package Leaflet .
D-62	-0.189173623919487	For more information , see the Package Leaflet .
P-62	-0.3440 -0.6466 -0.0870 -0.2034 -0.3199 -0.1459 -0.0637 -0.1231 -0.0947 -0.0310 -0.0911 -0.1593 -0.1496
S-1944	Die Einnahme kann unabhängig von den Mahlzeiten erfolgen .
T-1944	The tablet may be taken with or without food .
H-1944	-0.49259594082832336	They can be taken regardless of meals .
D-1944	-0.49259594082832336	They can be taken regardless of meals .
P-1944	-2.3735 -0.8434 -0.1573 -0.1431 -0.3322 -0.1412 -0.1337 -0.1528 -0.1562
S-1899	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-1899	The medicine can only be obtained with a prescription .
H-1899	-0.39912283420562744	This medicine can only be obtained with a prescription .
D-1899	-0.39912283420562744	This medicine can only be obtained with a prescription .
P-1899	-0.8438 -1.2836 -1.1306 -0.1736 -0.1544 -0.0236 -0.1379 -0.1484 -0.0559 -0.2809 -0.1576
S-516	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-516	The medicine can only be obtained with a prescription .
H-516	-0.39912283420562744	This medicine can only be obtained with a prescription .
D-516	-0.39912283420562744	This medicine can only be obtained with a prescription .
P-516	-0.8438 -1.2836 -1.1306 -0.1736 -0.1544 -0.0236 -0.1379 -0.1484 -0.0559 -0.2809 -0.1576
S-1514	Hämatokritabfall Auffällige Laborwerte
T-1514	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-1514	-0.6137612462043762	packed cell volume Abnormal laboratory values
D-1514	-0.6137612462043762	packed cell volume Abnormal laboratory values
P-1514	-0.5457 -0.0575 -0.7346 -2.0729 -0.6570 -0.2906 -0.0813 -0.9247 -0.1596
S-634	Positiver Test auf Antikörper gegen Faktor VIII
T-634	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-634	-0.27680376172065735	Positive test for antibodies to factor VIII
D-634	-0.27680376172065735	Positive test for antibodies to factor VIII
P-634	-1.1666 -0.1940 -0.2325 -0.1581 -0.1173 -0.1218 -0.1571 -0.4716 -0.1524 -0.1167 -0.1568
S-9	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-9	The medicine can only be obtained with a prescription .
H-9	-0.39912283420562744	This medicine can only be obtained with a prescription .
D-9	-0.39912283420562744	This medicine can only be obtained with a prescription .
P-9	-0.8438 -1.2836 -1.1306 -0.1736 -0.1544 -0.0236 -0.1379 -0.1484 -0.0559 -0.2809 -0.1576
S-809	Hämatokritabfall Auffällige Laborwerte
T-809	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-809	-0.6137612462043762	packed cell volume Abnormal laboratory values
D-809	-0.6137612462043762	packed cell volume Abnormal laboratory values
P-809	-0.5457 -0.0575 -0.7346 -2.0729 -0.6570 -0.2906 -0.0813 -0.9247 -0.1596
S-1159	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-1159	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-1159	-0.1032932847738266	Uncommon Uncommon Uncommon Uncommon Uncommon
D-1159	-0.1032932847738266	Uncommon Uncommon Uncommon Uncommon Uncommon
P-1159	-0.1202 -0.0927 -0.0674 -0.1356 -0.0616 -0.1571 -0.0495 -0.1577 -0.0708 -0.0774 -0.1462
S-1161	Hämatokritabfall Auffällige Laborwerte
T-1161	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-1161	-0.6137612462043762	packed cell volume Abnormal laboratory values
D-1161	-0.6137612462043762	packed cell volume Abnormal laboratory values
P-1161	-0.5457 -0.0575 -0.7346 -2.0729 -0.6570 -0.2906 -0.0813 -0.9247 -0.1596
S-1337	Hämatokritabfall Auffällige Laborwerte
T-1337	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-1337	-0.6137612462043762	packed cell volume Abnormal laboratory values
D-1337	-0.6137612462043762	packed cell volume Abnormal laboratory values
P-1337	-0.5457 -0.0575 -0.7346 -2.0729 -0.6570 -0.2906 -0.0813 -0.9247 -0.1596
S-1512	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-1512	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-1512	-0.1032932847738266	Uncommon Uncommon Uncommon Uncommon Uncommon
D-1512	-0.1032932847738266	Uncommon Uncommon Uncommon Uncommon Uncommon
P-1512	-0.1202 -0.0927 -0.0674 -0.1356 -0.0616 -0.1571 -0.0495 -0.1577 -0.0708 -0.0774 -0.1462
S-985	Hämatokritabfall Auffällige Laborwerte
T-985	Haematocrit decreased Laboratory test abnormal Injury , poisoning and Post procedural procedural complications complication
H-985	-0.6137612462043762	packed cell volume Abnormal laboratory values
D-985	-0.6137612462043762	packed cell volume Abnormal laboratory values
P-985	-0.5457 -0.0575 -0.7346 -2.0729 -0.6570 -0.2906 -0.0813 -0.9247 -0.1596
S-984	Erkrankungen der Haut und des Unterhautzellgewebes
T-984	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-984	-0.1683623045682907	Skin and subcutaneous tissue disorders
D-984	-0.1683623045682907	Skin and subcutaneous tissue disorders
P-984	-0.1739 -0.1306 -0.1660 -0.0926 -0.0414 -0.0909 -0.1331 -0.1306 -0.7906 -0.0169 -0.1006 -0.1530
S-1335	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-1335	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-1335	-0.1032932847738266	Uncommon Uncommon Uncommon Uncommon Uncommon
D-1335	-0.1032932847738266	Uncommon Uncommon Uncommon Uncommon Uncommon
P-1335	-0.1202 -0.0927 -0.0674 -0.1356 -0.0616 -0.1571 -0.0495 -0.1577 -0.0708 -0.0774 -0.1462
S-1160	Erkrankungen der Haut und des Unterhautzellgewebes
T-1160	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-1160	-0.1683623045682907	Skin and subcutaneous tissue disorders
D-1160	-0.1683623045682907	Skin and subcutaneous tissue disorders
P-1160	-0.1739 -0.1306 -0.1660 -0.0926 -0.0414 -0.0909 -0.1331 -0.1306 -0.7906 -0.0169 -0.1006 -0.1530
S-983	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-983	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-983	-0.1032932847738266	Uncommon Uncommon Uncommon Uncommon Uncommon
D-983	-0.1032932847738266	Uncommon Uncommon Uncommon Uncommon Uncommon
P-983	-0.1202 -0.0927 -0.0674 -0.1356 -0.0616 -0.1571 -0.0495 -0.1577 -0.0708 -0.0774 -0.1462
S-807	Gelegentlich Gelegentlich Gelegentlich Gelegentlich
T-807	Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Uncommon Common Uncommon
H-807	-0.1032932847738266	Uncommon Uncommon Uncommon Uncommon Uncommon
D-807	-0.1032932847738266	Uncommon Uncommon Uncommon Uncommon Uncommon
P-807	-0.1202 -0.0927 -0.0674 -0.1356 -0.0616 -0.1571 -0.0495 -0.1577 -0.0708 -0.0774 -0.1462
S-1513	Erkrankungen der Haut und des Unterhautzellgewebes
T-1513	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-1513	-0.1683623045682907	Skin and subcutaneous tissue disorders
D-1513	-0.1683623045682907	Skin and subcutaneous tissue disorders
P-1513	-0.1739 -0.1306 -0.1660 -0.0926 -0.0414 -0.0909 -0.1331 -0.1306 -0.7906 -0.0169 -0.1006 -0.1530
S-1336	Erkrankungen der Haut und des Unterhautzellgewebes
T-1336	Chest pain Chills Feeling abnormal Investigations Anti-factor VIII antibody positive
H-1336	-0.1683623045682907	Skin and subcutaneous tissue disorders
D-1336	-0.1683623045682907	Skin and subcutaneous tissue disorders
P-1336	-0.1739 -0.1306 -0.1660 -0.0926 -0.0414 -0.0909 -0.1331 -0.1306 -0.7906 -0.0169 -0.1006 -0.1530
S-56	Das Arzneimittel ist nur auf ärztliche Verschreibung erhältlich .
T-56	The medicine can only be obtained with a prescription .
H-56	-0.39912283420562744	This medicine can only be obtained with a prescription .
D-56	-0.39912283420562744	This medicine can only be obtained with a prescription .
P-56	-0.8438 -1.2836 -1.1306 -0.1736 -0.1544 -0.0236 -0.1379 -0.1484 -0.0559 -0.2809 -0.1576
S-980	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-980	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-980	-0.2693846821784973	diarrhoea Upper abdominal pain Nausea vomiting
D-980	-0.2693846821784973	diarrhoea Upper abdominal pain Nausea vomiting
P-980	-0.3471 -0.0311 -0.0566 -0.0172 -1.0324 -0.1209 -0.2005 -0.0184 -0.0714 -0.0287 -0.9867 -0.0592 -1.0191 -0.0616 -0.1010 -0.1583
S-1932	Tablette mit veränderter Wirkstofffreisetzung
T-1932	Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet Modified-release tablet
H-1932	-0.5334644913673401	altered drug release tablet
D-1932	-0.5334644913673401	altered drug release tablet
P-1932	-0.6850 -0.1379 -1.7610 -0.5012 -0.3459 -0.1023 -0.2010
S-804	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-804	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-804	-0.2693846821784973	diarrhoea Upper abdominal pain Nausea vomiting
D-804	-0.2693846821784973	diarrhoea Upper abdominal pain Nausea vomiting
P-804	-0.3471 -0.0311 -0.0566 -0.0172 -1.0324 -0.1209 -0.2005 -0.0184 -0.0714 -0.0287 -0.9867 -0.0592 -1.0191 -0.0616 -0.1010 -0.1583
S-1933	Tablette mit veränderter Wirkstofffreisetzung
T-1933	Oral use Oral use Oral use Oral use Oral use Oral use
H-1933	-0.5334644913673401	altered drug release tablet
D-1933	-0.5334644913673401	altered drug release tablet
P-1933	-0.6850 -0.1379 -1.7610 -0.5012 -0.3459 -0.1023 -0.2010
S-1156	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-1156	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-1156	-0.2693846821784973	diarrhoea Upper abdominal pain Nausea vomiting
D-1156	-0.2693846821784973	diarrhoea Upper abdominal pain Nausea vomiting
P-1156	-0.3471 -0.0311 -0.0566 -0.0172 -1.0324 -0.1209 -0.2005 -0.0184 -0.0714 -0.0287 -0.9867 -0.0592 -1.0191 -0.0616 -0.1010 -0.1583
S-1332	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-1332	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-1332	-0.2693846821784973	diarrhoea Upper abdominal pain Nausea vomiting
D-1332	-0.2693846821784973	diarrhoea Upper abdominal pain Nausea vomiting
P-1332	-0.3471 -0.0311 -0.0566 -0.0172 -1.0324 -0.1209 -0.2005 -0.0184 -0.0714 -0.0287 -0.9867 -0.0592 -1.0191 -0.0616 -0.1010 -0.1583
S-1509	Durchfall Oberbauchschmerzen Übelkeit Erbrechen
T-1509	Gastrointestinal Diarrhoea disorders Abdominal pain upper Nausea Vomiting Skin and subcutaneous Pruritus tissue disorders Rash Hyperhidrosis Dermatitis diaper General disorders and Pyrexia administration site Oedema peripheral conditions
H-1509	-0.2693846821784973	diarrhoea Upper abdominal pain Nausea vomiting
D-1509	-0.2693846821784973	diarrhoea Upper abdominal pain Nausea vomiting
P-1509	-0.3471 -0.0311 -0.0566 -0.0172 -1.0324 -0.1209 -0.2005 -0.0184 -0.0714 -0.0287 -0.9867 -0.0592 -1.0191 -0.0616 -0.1010 -0.1583
S-1930	Tablette mit veränderter Wirkstofffreisetzung
T-1930	EU/ 1/ 07/ 399/ 001 EU/ 1/ 07/ 399/ 002 EU/ 1/ 07/ 399/ 003 EU/ 1/ 07/ 399/ 004 EU/ 1/ 07/ 399/ 005 EU/ 1/ 07/ 399/ 006
H-1930	-0.5334644913673401	altered drug release tablet
D-1930	-0.5334644913673401	altered drug release tablet
P-1930	-0.6850 -0.1379 -1.7610 -0.5012 -0.3459 -0.1023 -0.2010
S-1889	Aus welchen Gründen hat das Unternehmen den Antrag zurückgenommen ?
T-1889	What were the reasons given by the company to withdraw the application ?
H-1889	-0.4792127013206482	On what grounds has the company withdrawn the application ?
D-1889	-0.4792127013206482	On what grounds has the company withdrawn the application ?
P-1889	-2.7220 -0.2538 -0.2793 -0.2182 -0.2821 -0.5637 -0.0611 -0.0859 -0.2912 -0.1763 -0.6646 -0.1523
S-615	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-615	Animal reproduction studies have not been conducted with factor VIII .
H-615	-0.42655789852142334	Reproduction studies in animals have not been performed with factor VIII .
D-615	-0.42655789852142334	Reproduction studies in animals have not been performed with factor VIII .
P-615	-2.2196 -0.1359 -0.1510 -0.1509 -0.0962 -0.4674 -0.1404 -0.3340 -1.6990 -0.2939 -0.1290 -0.1432 -0.1384 -0.1477 -0.1517
S-44	Den vollständigen Wortlaut des EPAR für Adenuric finden Sie hier .
T-44	The full EPAR for Adenuric can be found here .
H-44	-0.1547880321741104	The full EPAR for Adenuric is available here .
D-44	-0.1547880321741104	The full EPAR for Adenuric is available here .
P-44	-0.3607 -0.1735 -0.0479 -0.0594 -0.1308 -0.1505 -0.1893 -0.0686 -0.1097 -0.2270 -0.2122 -0.0836 -0.2001 -0.1538
S-748	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-748	Early haemarthrosis , muscle bleeding or oral bleeding .
H-748	-0.42495161294937134	Early joint haemorrhage , muscle haemorrhage or mouth bleeding .
D-748	-0.42495161294937134	Early joint haemorrhage , muscle haemorrhage or mouth bleeding .
P-748	-0.1878 -2.0073 -0.9108 -0.1510 -0.0295 -0.2158 -0.1462 -0.3773 -1.2240 -0.1626 -0.0131 -0.2353 -0.1718 -0.2110 -0.9786 -0.3367 -0.1377 -0.1527
S-789	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-789	Animal reproduction studies have not been conducted with factor VIII .
H-789	-0.42655789852142334	Reproduction studies in animals have not been performed with factor VIII .
D-789	-0.42655789852142334	Reproduction studies in animals have not been performed with factor VIII .
P-789	-2.2196 -0.1359 -0.1510 -0.1509 -0.0962 -0.4674 -0.1404 -0.3340 -1.6990 -0.2939 -0.1290 -0.1432 -0.1384 -0.1477 -0.1517
S-10	Die empfohlene Dosis von Adenuric beträgt 80 mg einmal täglich .
T-10	The recommended dose of Adenuric is 80 mg once a day .
H-10	-0.14217840135097504	The recommended dose of Adenuric is 80 mg once a day .
D-10	-0.14217840135097504	The recommended dose of Adenuric is 80 mg once a day .
P-10	-0.1397 -0.1841 -0.0779 -0.1366 -0.2859 -0.1895 -0.0767 -0.1136 -0.1193 -0.1367 -0.0478 -0.1423 -0.2484 -0.0781 -0.1469 -0.1513
S-1493	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-1493	Animal reproduction studies have not been conducted with factor VIII .
H-1493	-0.42655789852142334	Reproduction studies in animals have not been performed with factor VIII .
D-1493	-0.42655789852142334	Reproduction studies in animals have not been performed with factor VIII .
P-1493	-2.2196 -0.1359 -0.1510 -0.1509 -0.0962 -0.4674 -0.1404 -0.3340 -1.6990 -0.2939 -0.1290 -0.1432 -0.1384 -0.1477 -0.1517
S-1317	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-1317	Animal reproduction studies have not been conducted with factor VIII .
H-1317	-0.42655789852142334	Reproduction studies in animals have not been performed with factor VIII .
D-1317	-0.42655789852142334	Reproduction studies in animals have not been performed with factor VIII .
P-1317	-2.2196 -0.1359 -0.1510 -0.1509 -0.0962 -0.4674 -0.1404 -0.3340 -1.6990 -0.2939 -0.1290 -0.1432 -0.1384 -0.1477 -0.1517
S-1141	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-1141	Animal reproduction studies have not been conducted with factor VIII .
H-1141	-0.42655789852142334	Reproduction studies in animals have not been performed with factor VIII .
D-1141	-0.42655789852142334	Reproduction studies in animals have not been performed with factor VIII .
P-1141	-2.2196 -0.1359 -0.1510 -0.1509 -0.0962 -0.4674 -0.1404 -0.3340 -1.6990 -0.2939 -0.1290 -0.1432 -0.1384 -0.1477 -0.1517
S-965	Tierexperimentelle Reproduktionsstudien wurden mit Faktor VIII nicht durchgeführt .
T-965	Animal reproduction studies have not been conducted with factor VIII .
H-965	-0.42655789852142334	Reproduction studies in animals have not been performed with factor VIII .
D-965	-0.42655789852142334	Reproduction studies in animals have not been performed with factor VIII .
P-965	-2.2196 -0.1359 -0.1510 -0.1509 -0.0962 -0.4674 -0.1404 -0.3340 -1.6990 -0.2939 -0.1290 -0.1432 -0.1384 -0.1477 -0.1517
S-801	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-801	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-801	-0.2284041792154312	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-801	-0.2284041792154312	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-801	-0.1095 -0.1661 -0.8340 -0.0412 -0.1501 -0.1553 -1.2006 -0.0251 -0.6318 -0.0365 -0.1290 -0.0867 -0.0801 -0.1141 -0.1339 -0.1304 -0.0802 -0.0864 -0.1486
S-574	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-574	Early haemarthrosis , muscle bleeding or oral bleeding .
H-574	-0.42495161294937134	Early joint haemorrhage , muscle haemorrhage or mouth bleeding .
D-574	-0.42495161294937134	Early joint haemorrhage , muscle haemorrhage or mouth bleeding .
P-574	-0.1878 -2.0073 -0.9108 -0.1510 -0.0295 -0.2158 -0.1462 -0.3773 -1.2240 -0.1626 -0.0131 -0.2353 -0.1718 -0.2110 -0.9786 -0.3367 -0.1377 -0.1527
S-1276	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-1276	Early haemarthrosis , muscle bleeding or oral bleeding .
H-1276	-0.42495161294937134	Early joint haemorrhage , muscle haemorrhage or mouth bleeding .
D-1276	-0.42495161294937134	Early joint haemorrhage , muscle haemorrhage or mouth bleeding .
P-1276	-0.1878 -2.0073 -0.9108 -0.1510 -0.0295 -0.2158 -0.1462 -0.3773 -1.2240 -0.1626 -0.0131 -0.2353 -0.1718 -0.2110 -0.9786 -0.3367 -0.1377 -0.1527
S-1994	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-1994	4.7 Effects on ability to drive and use machines
H-1994	-0.14829754829406738	4.7 Effects on ability to drive and use machines
D-1994	-0.14829754829406738	4.7 Effects on ability to drive and use machines
P-1994	-0.1549 -0.1374 -0.0674 -0.0540 -0.1508 -0.0504 -0.2830 -0.2069 -0.1604 -0.1267 -0.2432 -0.1444
S-1610	Name und Anschrift des Herstellers , der für die Chargenfreigabe verantwortlich ist
T-1610	Name and address of the manufacturer responsible for batch release
H-1610	-0.24538497626781464	Name and address of the manufacturer responsible for batch release
D-1610	-0.24538497626781464	Name and address of the manufacturer responsible for batch release
P-1610	-1.6105 -0.1263 -0.0698 -0.1551 -0.1515 -0.2102 -0.0376 -0.1128 -0.0589 -0.0823 -0.1762 -0.1533
S-1496	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-1496	4.7 Effects on ability to drive and use machines
H-1496	-0.14829754829406738	4.7 Effects on ability to drive and use machines
D-1496	-0.14829754829406738	4.7 Effects on ability to drive and use machines
P-1496	-0.1549 -0.1374 -0.0674 -0.0540 -0.1508 -0.0504 -0.2830 -0.2069 -0.1604 -0.1267 -0.2432 -0.1444
S-1320	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-1320	4.7 Effects on ability to drive and use machines
H-1320	-0.14829754829406738	4.7 Effects on ability to drive and use machines
D-1320	-0.14829754829406738	4.7 Effects on ability to drive and use machines
P-1320	-0.1549 -0.1374 -0.0674 -0.0540 -0.1508 -0.0504 -0.2830 -0.2069 -0.1604 -0.1267 -0.2432 -0.1444
S-1144	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-1144	4.7 Effects on ability to drive and use machines
H-1144	-0.14829754829406738	4.7 Effects on ability to drive and use machines
D-1144	-0.14829754829406738	4.7 Effects on ability to drive and use machines
P-1144	-0.1549 -0.1374 -0.0674 -0.0540 -0.1508 -0.0504 -0.2830 -0.2069 -0.1604 -0.1267 -0.2432 -0.1444
S-968	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-968	4.7 Effects on ability to drive and use machines
H-968	-0.14829754829406738	4.7 Effects on ability to drive and use machines
D-968	-0.14829754829406738	4.7 Effects on ability to drive and use machines
P-968	-0.1549 -0.1374 -0.0674 -0.0540 -0.1508 -0.0504 -0.2830 -0.2069 -0.1604 -0.1267 -0.2432 -0.1444
S-792	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-792	4.7 Effects on ability to drive and use machines
H-792	-0.14829754829406738	4.7 Effects on ability to drive and use machines
D-792	-0.14829754829406738	4.7 Effects on ability to drive and use machines
P-792	-0.1549 -0.1374 -0.0674 -0.0540 -0.1508 -0.0504 -0.2830 -0.2069 -0.1604 -0.1267 -0.2432 -0.1444
S-618	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-618	4.7 Effects on ability to drive and use machines
H-618	-0.14829754829406738	4.7 Effects on ability to drive and use machines
D-618	-0.14829754829406738	4.7 Effects on ability to drive and use machines
P-618	-0.1549 -0.1374 -0.0674 -0.0540 -0.1508 -0.0504 -0.2830 -0.2069 -0.1604 -0.1267 -0.2432 -0.1444
S-924	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-924	Early haemarthrosis , muscle bleeding or oral bleeding .
H-924	-0.42495161294937134	Early joint haemorrhage , muscle haemorrhage or mouth bleeding .
D-924	-0.42495161294937134	Early joint haemorrhage , muscle haemorrhage or mouth bleeding .
P-924	-0.1878 -2.0073 -0.9108 -0.1510 -0.0295 -0.2158 -0.1462 -0.3773 -1.2240 -0.1626 -0.0131 -0.2353 -0.1718 -0.2110 -0.9786 -0.3367 -0.1377 -0.1527
S-160	4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-160	4.7 Effects on ability to drive and use machines
H-160	-0.14829754829406738	4.7 Effects on ability to drive and use machines
D-160	-0.14829754829406738	4.7 Effects on ability to drive and use machines
P-160	-0.1549 -0.1374 -0.0674 -0.0540 -0.1508 -0.0504 -0.2830 -0.2069 -0.1604 -0.1267 -0.2432 -0.1444
S-116	Viele dieser Patienten erhielten auch eine Chemotherapie und Kortikosteroide .
T-116	Many of these patients were also receiving chemotherapy and corticosteroids .
H-116	-0.15740333497524261	Many of these patients also received chemotherapy and corticosteroids .
D-116	-0.15740333497524261	Many of these patients also received chemotherapy and corticosteroids .
P-116	-0.1267 -0.1671 -0.1857 -0.0926 -0.6933 -0.1774 -0.1323 -0.0474 -0.0774 -0.1339 -0.2235 -0.1005 -0.0949 -0.1081 -0.1378 -0.0493 -0.1350 -0.1503
S-1454	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-1454	More extensive haemarthrosis , muscle bleeding or haematoma .
H-1454	-0.3405115604400635	Increased joint haemorrhage , muscle haemorrhage or haematoma .
D-1454	-0.3405115604400635	Increased joint haemorrhage , muscle haemorrhage or haematoma .
P-1454	-2.0435 -0.0424 -0.0619 -0.9862 -0.6064 -0.1358 -0.0192 -0.1918 -0.1521 -0.3710 -1.1048 -0.1219 -0.0187 -0.1535 -0.3156 -0.2546 -0.0456 -0.0559 -0.1677 -0.1506 -0.1516
S-780	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-780	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-780	-0.5075701475143433	In such cases , contact a haemophilia centre is recommended .
D-780	-0.5075701475143433	In such cases , contact a haemophilia centre is recommended .
P-780	-1.1649 -0.9114 -0.1624 -1.0645 -1.3338 -0.2712 -0.2198 -0.1055 -0.3275 -0.7655 -0.5675 -0.1521 -0.2725 -0.1443 -0.1508
S-627	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-627	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-627	-0.2284041792154312	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-627	-0.2284041792154312	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-627	-0.1095 -0.1661 -0.8340 -0.0412 -0.1501 -0.1553 -1.2006 -0.0251 -0.6318 -0.0365 -0.1290 -0.0867 -0.0801 -0.1141 -0.1339 -0.1304 -0.0802 -0.0864 -0.1486
S-606	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-606	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-606	-0.5075701475143433	In such cases , contact a haemophilia centre is recommended .
D-606	-0.5075701475143433	In such cases , contact a haemophilia centre is recommended .
P-606	-1.1649 -0.9114 -0.1624 -1.0645 -1.3338 -0.2712 -0.2198 -0.1055 -0.3275 -0.7655 -0.5675 -0.1521 -0.2725 -0.1443 -0.1508
S-447	Ein kleiner Anteil Vitamin D3 wird vor Ausscheidung glukuronidiert .
T-447	A small percentage of vitamin D3 undergoes glucuronidation prior to elimination .
H-447	-0.29567277431488037	A small fraction of vitamin D3 is glucuronised prior to excretion .
D-447	-0.29567277431488037	A small fraction of vitamin D3 is glucuronised prior to excretion .
P-447	-0.1466 -0.1050 -1.2734 -0.0705 -0.1532 -0.1590 -0.1034 -0.1294 -0.1341 -0.1184 -0.2580 -0.4749 -0.1180 -0.9002 -1.1580 -0.1294 -0.3232 -0.0209 -0.1420 -0.1403 -0.1513
S-272	Jede Tablette enthält 63 mg Lactose und 16 mg Sucrose .
T-272	Each tablet contains 63 mg lactose anhydrous and 16 mg sucrose .
H-272	-0.11425313353538513	Each tablet contains 63 mg lactose and 16 mg sucrose .
D-272	-0.11425313353538513	Each tablet contains 63 mg lactose and 16 mg sucrose .
P-272	-0.0428 -0.1130 -0.1033 -0.0610 -0.1230 -0.0618 -0.4316 -0.0365 -0.1076 -0.1305 -0.1080 -0.0657 -0.1413 -0.0731 -0.0579 -0.1321 -0.1532
S-251	Ein kleiner Anteil Vitamin D3 wird vor Ausscheidung glukuronidiert .
T-251	A small percentage of vitamin D3 undergoes glucuronidation prior to elimination .
H-251	-0.29567277431488037	A small fraction of vitamin D3 is glucuronised prior to excretion .
D-251	-0.29567277431488037	A small fraction of vitamin D3 is glucuronised prior to excretion .
P-251	-0.1466 -0.1050 -1.2734 -0.0705 -0.1532 -0.1590 -0.1034 -0.1294 -0.1341 -0.1184 -0.2580 -0.4749 -0.1180 -0.9002 -1.1580 -0.1294 -0.3232 -0.0209 -0.1420 -0.1403 -0.1513
S-85	Jede Tablette enthält 62 mg Lactose und 8 mg Sucrose .
T-85	Each tablet contains 62 mg lactose anhydrous and 8 mg sucrose .
H-85	-0.11163987964391708	Each tablet contains 62 mg lactose and 8 mg sucrose .
D-85	-0.11163987964391708	Each tablet contains 62 mg lactose and 8 mg sucrose .
P-85	-0.0481 -0.1181 -0.1021 -0.0664 -0.1467 -0.0546 -0.3574 -0.0363 -0.1059 -0.1314 -0.1157 -0.0627 -0.1339 -0.0741 -0.0589 -0.1340 -0.1516
S-304	Viele dieser Patienten erhielten auch eine Chemotherapie und Kortikosteroide .
T-304	Many of these patients were also receiving chemotherapy and corticosteroids .
H-304	-0.15740333497524261	Many of these patients also received chemotherapy and corticosteroids .
D-304	-0.15740333497524261	Many of these patients also received chemotherapy and corticosteroids .
P-304	-0.1267 -0.1671 -0.1857 -0.0926 -0.6933 -0.1774 -0.1323 -0.0474 -0.0774 -0.1339 -0.2235 -0.1005 -0.0949 -0.1081 -0.1378 -0.0493 -0.1350 -0.1503
S-1100	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-1100	Early haemarthrosis , muscle bleeding or oral bleeding .
H-1100	-0.42495161294937134	Early joint haemorrhage , muscle haemorrhage or mouth bleeding .
D-1100	-0.42495161294937134	Early joint haemorrhage , muscle haemorrhage or mouth bleeding .
P-1100	-0.1878 -2.0073 -0.9108 -0.1510 -0.0295 -0.2158 -0.1462 -0.3773 -1.2240 -0.1626 -0.0131 -0.2353 -0.1718 -0.2110 -0.9786 -0.3367 -0.1377 -0.1527
S-1452	Gelenkblutung im Frühstadium , Muskelblutungen oder Blutungen im Mund .
T-1452	Early haemarthrosis , muscle bleeding or oral bleeding .
H-1452	-0.42495161294937134	Early joint haemorrhage , muscle haemorrhage or mouth bleeding .
D-1452	-0.42495161294937134	Early joint haemorrhage , muscle haemorrhage or mouth bleeding .
P-1452	-0.1878 -2.0073 -0.9108 -0.1510 -0.0295 -0.2158 -0.1462 -0.3773 -1.2240 -0.1626 -0.0131 -0.2353 -0.1718 -0.2110 -0.9786 -0.3367 -0.1377 -0.1527
S-1278	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-1278	More extensive haemarthrosis , muscle bleeding or haematoma .
H-1278	-0.3405115604400635	Increased joint haemorrhage , muscle haemorrhage or haematoma .
D-1278	-0.3405115604400635	Increased joint haemorrhage , muscle haemorrhage or haematoma .
P-1278	-2.0435 -0.0424 -0.0619 -0.9862 -0.6064 -0.1358 -0.0192 -0.1918 -0.1521 -0.3710 -1.1048 -0.1219 -0.0187 -0.1535 -0.3156 -0.2546 -0.0456 -0.0559 -0.1677 -0.1506 -0.1516
S-1102	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-1102	More extensive haemarthrosis , muscle bleeding or haematoma .
H-1102	-0.3405115604400635	Increased joint haemorrhage , muscle haemorrhage or haematoma .
D-1102	-0.3405115604400635	Increased joint haemorrhage , muscle haemorrhage or haematoma .
P-1102	-2.0435 -0.0424 -0.0619 -0.9862 -0.6064 -0.1358 -0.0192 -0.1918 -0.1521 -0.3710 -1.1048 -0.1219 -0.0187 -0.1535 -0.3156 -0.2546 -0.0456 -0.0559 -0.1677 -0.1506 -0.1516
S-926	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-926	More extensive haemarthrosis , muscle bleeding or haematoma .
H-926	-0.3405115604400635	Increased joint haemorrhage , muscle haemorrhage or haematoma .
D-926	-0.3405115604400635	Increased joint haemorrhage , muscle haemorrhage or haematoma .
P-926	-2.0435 -0.0424 -0.0619 -0.9862 -0.6064 -0.1358 -0.0192 -0.1918 -0.1521 -0.3710 -1.1048 -0.1219 -0.0187 -0.1535 -0.3156 -0.2546 -0.0456 -0.0559 -0.1677 -0.1506 -0.1516
S-750	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-750	More extensive haemarthrosis , muscle bleeding or haematoma .
H-750	-0.3405115604400635	Increased joint haemorrhage , muscle haemorrhage or haematoma .
D-750	-0.3405115604400635	Increased joint haemorrhage , muscle haemorrhage or haematoma .
P-750	-2.0435 -0.0424 -0.0619 -0.9862 -0.6064 -0.1358 -0.0192 -0.1918 -0.1521 -0.3710 -1.1048 -0.1219 -0.0187 -0.1535 -0.3156 -0.2546 -0.0456 -0.0559 -0.1677 -0.1506 -0.1516
S-576	Ausgeprägtere Gelenkblutung , Muskelblutung oder Hämatom .
T-576	More extensive haemarthrosis , muscle bleeding or haematoma .
H-576	-0.3405115604400635	Increased joint haemorrhage , muscle haemorrhage or haematoma .
D-576	-0.3405115604400635	Increased joint haemorrhage , muscle haemorrhage or haematoma .
P-576	-2.0435 -0.0424 -0.0619 -0.9862 -0.6064 -0.1358 -0.0192 -0.1918 -0.1521 -0.3710 -1.1048 -0.1219 -0.0187 -0.1535 -0.3156 -0.2546 -0.0456 -0.0559 -0.1677 -0.1506 -0.1516
S-327	Bei diesen Patienten sind Urin und Serum-Calcium zu überwachen .
T-327	Urine and serum calcium should be monitored in these patients .
H-327	-0.25795650482177734	Urine and serum calcium should be monitored .
D-327	-0.25795650482177734	Urine and serum calcium should be monitored .
P-327	-0.4980 -0.0676 -0.1422 -0.1061 -0.1104 -0.1060 -0.0867 -0.1148 -1.3385 -0.1959 -0.2271 -0.0896 -0.3742 -0.1542
S-139	Bei diesen Patienten sind Urin und Serum-Calcium zu überwachen .
T-139	Urine and serum calcium should be monitored in these patients .
H-139	-0.25795650482177734	Urine and serum calcium should be monitored .
D-139	-0.25795650482177734	Urine and serum calcium should be monitored .
P-139	-0.4980 -0.0676 -0.1422 -0.1061 -0.1104 -0.1060 -0.0867 -0.1148 -1.3385 -0.1959 -0.2271 -0.0896 -0.3742 -0.1542
S-1818	eská republika Baxter Czech spol.s.r.o .
T-1818	eská republika Baxter Czech spol . s. r. o.
H-1818	-0.23392446339130402	eská republika Baxter Czech spol.s.r.o .
D-1818	-0.23392446339130402	eská republika Baxter Czech spol.s.r.o .
P-1818	-0.0455 -0.1488 -0.0664 -0.0322 -0.0649 -0.2452 -0.1379 -0.1394 -0.1094 -0.1173 -0.0691 -0.6348 -1.0766 -0.0807 -0.3260 -0.6283 -0.1445 -0.1438
S-549	1 Durchstechflasche + 1 Durchstechflasche + Gerät zur Rekonstitution
T-549	1 vial + 1 vial + reconstitution device
H-549	-0.32594186067581177	1 vial + 1 vial + reconstitution device
D-549	-0.32594186067581177	1 vial + 1 vial + reconstitution device
P-549	-0.1709 -0.0838 -0.1075 -0.1088 -0.1495 -0.1247 -0.1292 -0.0935 -0.2924 -0.0718 -2.4234 -0.1558
S-1566	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-1566	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-1566	-0.34450894594192505	storage conditions of the reconstituted product , see section 6.3 .
D-1566	-0.34450894594192505	storage conditions of the reconstituted product , see section 6.3 .
P-1566	-1.0601 -0.3307 -0.6749 -0.1466 -1.4527 -0.0748 -0.0725 -0.1594 -0.2084 -0.2744 -0.1567 -0.1192 -0.1165 -0.1703 -0.1504
S-329	Sonstige Bestandteile Dieses Arzneimittel enthält Lactose und Sucrose .
T-329	14 Excipients This medicinal product contains lactose and sucrose .
H-329	-0.08927428722381592	Excipients This medicinal product contains lactose and sucrose .
D-329	-0.08927428722381592	Excipients This medicinal product contains lactose and sucrose .
P-329	-0.1045 -0.2132 -0.0478 -0.0930 -0.0863 -0.0439 -0.0694 -0.0578 -0.0530 -0.0562 -0.0360 -0.0843 -0.1269 -0.0794 -0.0778 -0.0720 -0.1511 -0.1544
S-141	Sonstige Bestandteile Dieses Arzneimittel enthält Lactose und Sucrose .
T-141	4 Excipients This medicinal product contains lactose and sucrose .
H-141	-0.08927428722381592	Excipients This medicinal product contains lactose and sucrose .
D-141	-0.08927428722381592	Excipients This medicinal product contains lactose and sucrose .
P-141	-0.1045 -0.2132 -0.0478 -0.0930 -0.0863 -0.0439 -0.0694 -0.0578 -0.0530 -0.0562 -0.0360 -0.0843 -0.1269 -0.0794 -0.0778 -0.0720 -0.1511 -0.1544
S-1993	Deshalb sollte Aerinaze in der Stillzeit nicht angewendet werden .
T-1993	Therefore Aerinaze should not be used in breast-feeding women .
H-1993	-0.2582915127277374	Therefore , Aerinaze should not be used while breast-feeding .
D-1993	-0.2582915127277374	Therefore , Aerinaze should not be used while breast-feeding .
P-1993	-0.7075 -0.0744 -0.3984 -0.6984 -0.1384 -0.1168 -0.1444 -0.1263 -0.2145 -0.1475 -0.1367 -0.2701 -1.2047 -0.0931 -0.0310 -0.0496 -0.0334 -0.1675 -0.1548
S-1389	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-1389	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-1389	-0.34450894594192505	storage conditions of the reconstituted product , see section 6.3 .
D-1389	-0.34450894594192505	storage conditions of the reconstituted product , see section 6.3 .
P-1389	-1.0601 -0.3307 -0.6749 -0.1466 -1.4527 -0.0748 -0.0725 -0.1594 -0.2084 -0.2744 -0.1567 -0.1192 -0.1165 -0.1703 -0.1504
S-1213	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-1213	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-1213	-0.34450894594192505	storage conditions of the reconstituted product , see section 6.3 .
D-1213	-0.34450894594192505	storage conditions of the reconstituted product , see section 6.3 .
P-1213	-1.0601 -0.3307 -0.6749 -0.1466 -1.4527 -0.0748 -0.0725 -0.1594 -0.2084 -0.2744 -0.1567 -0.1192 -0.1165 -0.1703 -0.1504
S-1037	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-1037	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-1037	-0.34450894594192505	storage conditions of the reconstituted product , see section 6.3 .
D-1037	-0.34450894594192505	storage conditions of the reconstituted product , see section 6.3 .
P-1037	-1.0601 -0.3307 -0.6749 -0.1466 -1.4527 -0.0748 -0.0725 -0.1594 -0.2084 -0.2744 -0.1567 -0.1192 -0.1165 -0.1703 -0.1504
S-861	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-861	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-861	-0.34450894594192505	storage conditions of the reconstituted product , see section 6.3 .
D-861	-0.34450894594192505	storage conditions of the reconstituted product , see section 6.3 .
P-861	-1.0601 -0.3307 -0.6749 -0.1466 -1.4527 -0.0748 -0.0725 -0.1594 -0.2084 -0.2744 -0.1567 -0.1192 -0.1165 -0.1703 -0.1504
S-1848	ADVATE darf nicht mit anderen Arzneimitteln oder Lösungen gemischt werden .
T-1848	ADVATE must not be mixed with other medicinal products or solvents .
H-1848	-0.32335585355758667	ADVATE must not be mixed with other medicinal products or solutions .
D-1848	-0.32335585355758667	ADVATE must not be mixed with other medicinal products or solutions .
P-1848	-0.5583 -0.1470 -0.0815 -0.1052 -0.7569 -0.1635 -0.1314 -0.6642 -0.1651 -0.3995 -0.1905 -0.0521 -0.1267 -0.1193 -1.5354 -0.1448 -0.1556
S-328	Patienten mit einer Malabsorption nehmen möglicherweise nicht ausreichend Vitamin D3 auf .
T-328	Patients with malabsorption may not adequately absorb vitamin D3 .
H-328	-0.4345521330833435	Malabsorbed patients may not be receiving sufficient vitamin D3 .
D-328	-0.4345521330833435	Malabsorbed patients may not be receiving sufficient vitamin D3 .
P-328	-0.2743 -0.1200 -0.4514 -0.0617 -0.1735 -0.1671 -1.1958 -1.5033 -1.4367 -0.4461 -0.0908 -0.1402 -0.1335 -0.1688 -0.1552
S-172	Nach Markteinführung wurden folgende Reaktionen berichtet ( Häufigkeit nicht bekannt ) :
T-172	During post-marketing experience the following reactions have been reported ( frequency not known ) :
H-172	-0.2895444929599762	The following reactions have been reported ( frequency unknown ) :
D-172	-0.2895444929599762	The following reactions have been reported ( frequency unknown ) :
P-172	-1.3504 -0.1696 -0.1994 -0.0500 -0.3989 -0.1255 -0.1025 -0.2088 -0.2547 -0.0668 -0.7015 -0.1484 -0.1245 -0.1528
S-360	Nach Markteinführung wurden folgende Reaktionen berichtet ( Häufigkeit nicht bekannt ) :
T-360	During post-marketing experience the following reactions have been reported ( frequency not known ) :
H-360	-0.2895444929599762	The following reactions have been reported ( frequency unknown ) :
D-360	-0.2895444929599762	The following reactions have been reported ( frequency unknown ) :
P-360	-1.3504 -0.1696 -0.1994 -0.0500 -0.3989 -0.1255 -0.1025 -0.2088 -0.2547 -0.0668 -0.7015 -0.1484 -0.1245 -0.1528
S-592	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-592	Method of administration ADVATE should be administered via the intravenous route .
H-592	-0.1812238097190857	method of administration ADVATE should be administered intravenously .
D-592	-0.1812238097190857	method of administration ADVATE should be administered intravenously .
P-592	-0.3194 -0.1347 -0.1021 -0.0898 -0.1483 -0.0821 -0.0955 -1.0051 -0.1558 -0.1992 -0.0850 -0.1191 -0.0865 -0.0799 -0.0923 -0.1335 -0.1525
S-766	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-766	Method of administration ADVATE should be administered via the intravenous route .
H-766	-0.1812238097190857	method of administration ADVATE should be administered intravenously .
D-766	-0.1812238097190857	method of administration ADVATE should be administered intravenously .
P-766	-0.3194 -0.1347 -0.1021 -0.0898 -0.1483 -0.0821 -0.0955 -1.0051 -0.1558 -0.1992 -0.0850 -0.1191 -0.0865 -0.0799 -0.0923 -0.1335 -0.1525
S-942	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-942	Method of administration ADVATE should be administered via the intravenous route .
H-942	-0.1812238097190857	method of administration ADVATE should be administered intravenously .
D-942	-0.1812238097190857	method of administration ADVATE should be administered intravenously .
P-942	-0.3194 -0.1347 -0.1021 -0.0898 -0.1483 -0.0821 -0.0955 -1.0051 -0.1558 -0.1992 -0.0850 -0.1191 -0.0865 -0.0799 -0.0923 -0.1335 -0.1525
S-1118	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-1118	Method of administration ADVATE should be administered via the intravenous route .
H-1118	-0.1812238097190857	method of administration ADVATE should be administered intravenously .
D-1118	-0.1812238097190857	method of administration ADVATE should be administered intravenously .
P-1118	-0.3194 -0.1347 -0.1021 -0.0898 -0.1483 -0.0821 -0.0955 -1.0051 -0.1558 -0.1992 -0.0850 -0.1191 -0.0865 -0.0799 -0.0923 -0.1335 -0.1525
S-1294	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-1294	Method of administration ADVATE should be administered via the intravenous route .
H-1294	-0.1812238097190857	method of administration ADVATE should be administered intravenously .
D-1294	-0.1812238097190857	method of administration ADVATE should be administered intravenously .
P-1294	-0.3194 -0.1347 -0.1021 -0.0898 -0.1483 -0.0821 -0.0955 -1.0051 -0.1558 -0.1992 -0.0850 -0.1191 -0.0865 -0.0799 -0.0923 -0.1335 -0.1525
S-1470	Art der Anwendung ADVATE soll intravenös verabreicht werden .
T-1470	Method of administration ADVATE should be administered via the intravenous route .
H-1470	-0.1812238097190857	method of administration ADVATE should be administered intravenously .
D-1470	-0.1812238097190857	method of administration ADVATE should be administered intravenously .
P-1470	-0.3194 -0.1347 -0.1021 -0.0898 -0.1483 -0.0821 -0.0955 -1.0051 -0.1558 -0.1992 -0.0850 -0.1191 -0.0865 -0.0799 -0.0923 -0.1335 -0.1525
S-45	Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-45	EU/ 1/ 08/ 447/ 001 EU/ 1/ 08/ 447/ 002 EU/ 1/ 08/ 447/ 003 EU/ 1/ 08/ 447/ 004
H-45	-0.1839589774608612	blister ( Aclar/ PVC/ aluminium )
D-45	-0.1839589774608612	blister ( Aclar/ PVC/ aluminium )
P-45	-0.5368 -0.1767 -0.1696 -0.2698 -0.2539 -0.1275 -0.1542 -0.1179 -0.1301 -0.1172 -0.1442 -0.1625 -0.0849 -0.1362 -0.1779
S-685	Lagerungsbedingungen des rekonstiutierten Produktes siehe Abschnitt 6.3 .
T-685	For storage conditions of the reconstituted medicinal product , see section 6.3 .
H-685	-0.34450894594192505	storage conditions of the reconstituted product , see section 6.3 .
D-685	-0.34450894594192505	storage conditions of the reconstituted product , see section 6.3 .
P-685	-1.0601 -0.3307 -0.6749 -0.1466 -1.4527 -0.0748 -0.0725 -0.1594 -0.2084 -0.2744 -0.1567 -0.1192 -0.1165 -0.1703 -0.1504
S-60	Die Tablette darf nicht gekaut werden und nicht im Mund zergehen .
T-60	The tablet should not be chewed or allowed to dissolve in the mouth .
H-60	-0.5117563605308533	Do not chew or swallow the tablet .
D-60	-0.5117563605308533	Do not chew or swallow the tablet .
P-60	-0.5858 -0.1424 -0.0785 -0.1203 -0.5014 -3.3578 -0.0446 -0.8368 -0.0314 -0.1110 -0.1662 -0.1648
S-140	Patienten mit einer Malabsorption nehmen möglicherweise nicht ausreichend Vitamin D3 auf .
T-140	Patients with malabsorption may not adequately absorb vitamin D3 .
H-140	-0.4345521330833435	Malabsorbed patients may not be receiving sufficient vitamin D3 .
D-140	-0.4345521330833435	Malabsorbed patients may not be receiving sufficient vitamin D3 .
P-140	-0.2743 -0.1200 -0.4514 -0.0617 -0.1735 -0.1671 -1.1958 -1.5033 -1.4367 -0.4461 -0.0908 -0.1402 -0.1335 -0.1688 -0.1552
S-1801	Das Arzneimittel unmittelbar nach dem vollständigen Lösen des Pulvers verbrauchen .
T-1801	Use the product immediately once the powder is completely dissolved .
H-1801	-0.5697907209396362	Always consume the product immediately after dissolving the powder .
D-1801	-0.5697907209396362	Always consume the product immediately after dissolving the powder .
P-1801	-1.5845 -0.2047 -0.6072 -0.2025 -0.7905 -0.3944 -0.1387 -0.4343 -1.4198 -0.6139 -0.1631 -1.6047 -0.0850 -0.1455 -0.1581
S-1608	Name und Anschrift des Herstellers des Wirkstoffs biologischen Ursprungs
T-1608	Name and address of the manufacturer of the biological active substance
H-1608	-0.32685965299606323	Name and address of the manufacturer of the biological origin
D-1608	-0.32685965299606323	Name and address of the manufacturer of the biological origin
P-1608	-0.6669 -0.1256 -0.0973 -0.1584 -0.4715 -0.2857 -0.1493 -0.1509 -1.0273 -0.1620 -0.5522 -0.1039 -0.2982
S-152	Eine zusätzliche Ergänzung mit Vitamin D sollte individuell erwogen werden .
T-152	Additional vitamin D supplements may be considered on an individual basis .
H-152	-0.3522298336029053	Additional vitamin D supplementation should be considered on an individual basis .
D-152	-0.3522298336029053	Additional vitamin D supplementation should be considered on an individual basis .
P-152	-2.2389 -1.1028 -0.0794 -0.1316 -0.0782 -0.1259 -0.1132 -0.1353 -0.1451 -0.1234 -0.2584 -0.6162 -0.0462 -0.1516 -0.1380 -0.1514
S-1768	99 Inhibitoren liegen . Dies wird von Ihrem Arzt abgeklärt werden .
T-1768	This will be checked by your doctor .
H-1768	-0.42945629358291626	99 inhibitors and this will be determined by your doctor .
D-1768	-0.42945629358291626	99 inhibitors and this will be determined by your doctor .
P-1768	-0.4329 -0.1222 -0.0232 -0.0489 -0.1259 -0.9363 -1.6338 -0.5207 -0.2089 -1.7153 -0.1412 -0.1305 -0.0945 -0.1533 -0.1545
S-1858	Li-Fraumeni-Krebs kann in vielen Teilen des Körpers auftreten .
T-1858	People who have this mutation are more likely to develop cancer .
H-1858	-0.2949650287628174	Li-Fraumeni cancer can occur in many parts of the body .
D-1858	-0.2949650287628174	Li-Fraumeni cancer can occur in many parts of the body .
P-1858	-0.9898 -0.3801 -0.3557 -0.0381 -0.2284 -0.9920 -0.1725 -0.2806 -0.1433 -0.2424 -0.2208 -0.1415 -0.1422 -0.0886 -0.1486 -0.1549
S-340	Eine zusätzliche Ergänzung mit Vitamin D sollte individuell erwogen werden .
T-340	Additional vitamin D supplements may be considered on an individual basis .
H-340	-0.3522298336029053	Additional vitamin D supplementation should be considered on an individual basis .
D-340	-0.3522298336029053	Additional vitamin D supplementation should be considered on an individual basis .
P-340	-2.2389 -1.1028 -0.0794 -0.1316 -0.0782 -0.1259 -0.1132 -0.1353 -0.1451 -0.1234 -0.2584 -0.6162 -0.0462 -0.1516 -0.1380 -0.1514
S-146	Andere klinisch relevante Wechselwirkungen mit Arzneimitteln sind nicht zu erwarten .
T-146	No other clinically significant interactions with medicinal products are anticipated .
H-146	-0.24344903230667114	No other clinically relevant interactions with medicinal products are expected .
D-146	-0.24344903230667114	No other clinically relevant interactions with medicinal products are expected .
P-146	-1.2372 -0.0936 -0.0639 -0.0912 -0.3090 -0.2107 -0.1212 -0.1444 -0.1610 -0.0889 -0.1456 -0.1704 -0.4782 -0.1853 -0.1512
S-1725	Es kann anderen Menschen schaden , auch wenn diese die gleichen Beschwerden haben wie Sie .
T-1725	if their symptoms are the same as yours .
H-1725	-0.45602038502693176	It can harm other people , even if they have the same symptoms as you .
D-1725	-0.45602038502693176	It can harm other people , even if they have the same symptoms as you .
P-1725	-0.1894 -1.0542 -1.2350 -0.3298 -0.1816 -0.5536 -0.1610 -0.3892 -0.1353 -0.4700 -0.1517 -0.2662 -1.8502 -0.1853 -0.2004 -0.2401 -0.1593
S-412	Die BMD des Gesamtskeletts stieg ebenfalls signifikant an .
T-412	Total body BMD also increased significantly .
H-412	-0.44511133432388306	The BMD of the entire skeleton also increased significantly .
D-412	-0.44511133432388306	The BMD of the entire skeleton also increased significantly .
P-412	-1.0682 -1.0112 -0.1335 -0.2118 -0.1486 -1.1788 -0.6425 -1.0513 -0.0576 -0.1633 -0.1678 -0.1225 -0.1251 -0.1495
S-216	Die BMD des Gesamtskeletts stieg ebenfalls signifikant an .
T-216	Total body BMD also increased significantly .
H-216	-0.44511133432388306	The BMD of the entire skeleton also increased significantly .
D-216	-0.44511133432388306	The BMD of the entire skeleton also increased significantly .
P-216	-1.0682 -1.0112 -0.1335 -0.2118 -0.1486 -1.1788 -0.6425 -1.0513 -0.0576 -0.1633 -0.1678 -0.1225 -0.1251 -0.1495
S-334	Andere klinisch relevante Wechselwirkungen mit Arzneimitteln sind nicht zu erwarten .
T-334	No other clinically significant interactions with medicinal products are anticipated .
H-334	-0.24344903230667114	No other clinically relevant interactions with medicinal products are expected .
D-334	-0.24344903230667114	No other clinically relevant interactions with medicinal products are expected .
P-334	-1.2372 -0.0936 -0.0639 -0.0912 -0.3090 -0.2107 -0.1212 -0.1444 -0.1610 -0.0889 -0.1456 -0.1704 -0.4782 -0.1853 -0.1512
S-1869	Welche Unterlagen hat das Unternehmen dem CHMP zur Stützung seines Antrags vorgelegt ?
T-1869	What documentation did the company present to support its application to the CHMP ?
H-1869	-0.4728690981864929	What documents has the company presented to the CHMP in support of its application ?
D-1869	-0.4728690981864929	What documents has the company presented to the CHMP in support of its application ?
P-1869	-0.1310 -1.1223 -0.6215 -0.5238 -0.4072 -1.4089 -0.1524 -1.3435 -0.1974 -0.0395 -0.1589 -0.2059 -0.1534 -0.1479 -0.5728 -0.7029 -0.1495
S-1043	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-1043	For administration the use of a luer-lock syringe is required .
H-1043	-0.4095633625984192	A Luer-Lock syringe is required for administration .
D-1043	-0.4095633625984192	A Luer-Lock syringe is required for administration .
P-1043	-1.0694 -0.1531 -0.2016 -0.5058 -1.2868 -0.7066 -0.1377 -0.0232 -0.0129 -0.0933 -0.7148 -0.7838 -0.1600 -0.1437 -0.1507
S-1395	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-1395	For administration the use of a luer-lock syringe is required .
H-1395	-0.4095633625984192	A Luer-Lock syringe is required for administration .
D-1395	-0.4095633625984192	A Luer-Lock syringe is required for administration .
P-1395	-1.0694 -0.1531 -0.2016 -0.5058 -1.2868 -0.7066 -0.1377 -0.0232 -0.0129 -0.0933 -0.7148 -0.7838 -0.1600 -0.1437 -0.1507
S-1572	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-1572	For administration the use of a luer-lock syringe is required .
H-1572	-0.4095633625984192	A Luer-Lock syringe is required for administration .
D-1572	-0.4095633625984192	A Luer-Lock syringe is required for administration .
P-1572	-1.0694 -0.1531 -0.2016 -0.5058 -1.2868 -0.7066 -0.1377 -0.0232 -0.0129 -0.0933 -0.7148 -0.7838 -0.1600 -0.1437 -0.1507
S-86	Die vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-86	For a full list of excipients , see section 6.1 .
H-86	-0.12951351702213287	For a full list of excipients , see section 6.1 .
D-86	-0.12951351702213287	For a full list of excipients , see section 6.1 .
P-86	-0.0974 -0.1303 -0.0715 -0.1229 -0.1533 -0.0430 -0.0518 -0.1011 -0.0847 -0.1406 -0.3008 -0.1879 -0.1248 -0.1505 -0.1622 -0.1495
S-1219	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-1219	For administration the use of a luer-lock syringe is required .
H-1219	-0.4095633625984192	A Luer-Lock syringe is required for administration .
D-1219	-0.4095633625984192	A Luer-Lock syringe is required for administration .
P-1219	-1.0694 -0.1531 -0.2016 -0.5058 -1.2868 -0.7066 -0.1377 -0.0232 -0.0129 -0.0933 -0.7148 -0.7838 -0.1600 -0.1437 -0.1507
S-1738	- wenn Sie allergisch gegen Maus- oder Hamsterprotein sind .
T-1738	- if you are allergic to mouse or hamster proteins
H-1738	-0.15426871180534363	- if you are allergic to mouse or hamster protein .
D-1738	-0.15426871180534363	- if you are allergic to mouse or hamster protein .
P-1738	-0.3618 -0.1163 -0.1159 -0.1486 -0.0311 -0.0443 -0.1558 -0.2525 -0.1028 -0.1436 -0.2495 -0.0937 -0.1866 -0.1560 -0.1557
S-867	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-867	For administration the use of a luer-lock syringe is required .
H-867	-0.4095633625984192	A Luer-Lock syringe is required for administration .
D-867	-0.4095633625984192	A Luer-Lock syringe is required for administration .
P-867	-1.0694 -0.1531 -0.2016 -0.5058 -1.2868 -0.7066 -0.1377 -0.0232 -0.0129 -0.0933 -0.7148 -0.7838 -0.1600 -0.1437 -0.1507
S-1938	Die vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-1938	For a full list of excipients , see section 6.1 .
H-1938	-0.12951351702213287	For a full list of excipients , see section 6.1 .
D-1938	-0.12951351702213287	For a full list of excipients , see section 6.1 .
P-1938	-0.0974 -0.1303 -0.0715 -0.1229 -0.1533 -0.0430 -0.0518 -0.1011 -0.0847 -0.1406 -0.3008 -0.1879 -0.1248 -0.1505 -0.1622 -0.1495
S-273	Die vollständige Auflistung der sonstigen Bestandteile siehe Abschnitt 6.1 .
T-273	For a full list of excipients , see section 6.1 .
H-273	-0.12951351702213287	For a full list of excipients , see section 6.1 .
D-273	-0.12951351702213287	For a full list of excipients , see section 6.1 .
P-273	-0.0974 -0.1303 -0.0715 -0.1229 -0.1533 -0.0430 -0.0518 -0.1011 -0.0847 -0.1406 -0.3008 -0.1879 -0.1248 -0.1505 -0.1622 -0.1495
S-691	Zur Verabreichung ist eine Luer-Lock-Spritze erforderlich .
T-691	For administration the use of a luer-lock syringe is required .
H-691	-0.4095633625984192	A Luer-Lock syringe is required for administration .
D-691	-0.4095633625984192	A Luer-Lock syringe is required for administration .
P-691	-1.0694 -0.1531 -0.2016 -0.5058 -1.2868 -0.7066 -0.1377 -0.0232 -0.0129 -0.0933 -0.7148 -0.7838 -0.1600 -0.1437 -0.1507
S-1802	Arzneimittel dürfen nicht im Abwasser oder Haushaltsabfall entsorgt werden .
T-1802	Medicines should not be disposed of via waste water or household waste .
H-1802	-0.23658709228038788	Medicines should not be disposed of via wastewater or household waste .
D-1802	-0.23658709228038788	Medicines should not be disposed of via wastewater or household waste .
P-1802	-0.7477 -0.5261 -0.3513 -0.1754 -0.1661 -0.0016 -0.0268 -0.1649 -0.1886 -0.4024 -0.0214 -0.1196 -0.1368 -0.5369 -0.1720 -0.1357 -0.1486
S-1416	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-1416	The product dissolves rapidly ( usually in less than 1 minute ) .
H-1416	-0.2682076394557953	The product dissolves rapidly ( usually in less than 1 minute ) .
D-1416	-0.2682076394557953	The product dissolves rapidly ( usually in less than 1 minute ) .
P-1416	-0.4464 -0.0802 -0.6216 -0.2191 -0.1335 -1.1412 -0.1532 -0.1344 -0.2580 -0.1955 -0.1390 -0.1774 -0.1506 -0.1468 -0.1422 -0.1523
S-1593	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-1593	The product dissolves rapidly ( usually in less than 1 minute ) .
H-1593	-0.2682076394557953	The product dissolves rapidly ( usually in less than 1 minute ) .
D-1593	-0.2682076394557953	The product dissolves rapidly ( usually in less than 1 minute ) .
P-1593	-0.4464 -0.0802 -0.6216 -0.2191 -0.1335 -1.1412 -0.1532 -0.1344 -0.2580 -0.1955 -0.1390 -0.1774 -0.1506 -0.1468 -0.1422 -0.1523
S-706	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-706	Do not remove the blue cap from the BAXJECT II device .
H-706	-0.26581862568855286	Do not remove the blue cap from the BAXJECT II .
D-706	-0.26581862568855286	Do not remove the blue cap from the BAXJECT II .
P-706	-0.1102 -0.1436 -0.1782 -0.1775 -0.2115 -1.1173 -0.1417 -0.4720 -0.4564 -0.2010 -0.3503 -0.0953 -0.1077 -0.1214 -0.2085 -0.1604
S-1817	H-1123 Budapest Tel . : <unk> 361 202 19 80
T-1817	H-1123 Budapest Tel . : <<unk>> 361 202 19 80
H-1817	-0.13470515608787537	H-1123 Budapest Tel . : <unk> 361 202 19 80
D-1817	-0.13470515608787537	H-1123 Budapest Tel . : <unk> 361 202 19 80
P-1817	-0.1175 -0.1228 -0.1224 -0.0927 -0.3407 -0.0510 -0.1465 -0.1352 -0.0367 -0.1325 -0.0683 -0.2107 -0.1427 -0.1560 -0.1234 -0.1564
S-1846	Beim Auflösen und bei der Anwendung sind aseptische Techniken erforderlich .
T-1846	Aseptic technique is required during preparation of the solution and administration .
H-1846	-0.6726861596107483	Dissolution and administration require aseptic techniques .
D-1846	-0.6726861596107483	Dissolution and administration require aseptic techniques .
P-1846	-2.7948 -1.4353 -0.1256 -0.4514 -1.3838 -0.2174 -0.0816 -0.1012 -0.5074 -0.1463 -0.1548
S-882	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-882	Do not remove the blue cap from the BAXJECT II device .
H-882	-0.26581862568855286	Do not remove the blue cap from the BAXJECT II .
D-882	-0.26581862568855286	Do not remove the blue cap from the BAXJECT II .
P-882	-0.1102 -0.1436 -0.1782 -0.1775 -0.2115 -1.1173 -0.1417 -0.4720 -0.4564 -0.2010 -0.3503 -0.0953 -0.1077 -0.1214 -0.2085 -0.1604
S-1058	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-1058	Do not remove the blue cap from the BAXJECT II device .
H-1058	-0.26581862568855286	Do not remove the blue cap from the BAXJECT II .
D-1058	-0.26581862568855286	Do not remove the blue cap from the BAXJECT II .
P-1058	-0.1102 -0.1436 -0.1782 -0.1775 -0.2115 -1.1173 -0.1417 -0.4720 -0.4564 -0.2010 -0.3503 -0.0953 -0.1077 -0.1214 -0.2085 -0.1604
S-1240	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-1240	The product dissolves rapidly ( usually in less than 1 minute ) .
H-1240	-0.2682076394557953	The product dissolves rapidly ( usually in less than 1 minute ) .
D-1240	-0.2682076394557953	The product dissolves rapidly ( usually in less than 1 minute ) .
P-1240	-0.4464 -0.0802 -0.6216 -0.2191 -0.1335 -1.1412 -0.1532 -0.1344 -0.2580 -0.1955 -0.1390 -0.1774 -0.1506 -0.1468 -0.1422 -0.1523
S-1410	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-1410	Do not remove the blue cap from the BAXJECT II device .
H-1410	-0.26581862568855286	Do not remove the blue cap from the BAXJECT II .
D-1410	-0.26581862568855286	Do not remove the blue cap from the BAXJECT II .
P-1410	-0.1102 -0.1436 -0.1782 -0.1775 -0.2115 -1.1173 -0.1417 -0.4720 -0.4564 -0.2010 -0.3503 -0.0953 -0.1077 -0.1214 -0.2085 -0.1604
S-1064	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-1064	The product dissolves rapidly ( usually in less than 1 minute ) .
H-1064	-0.2682076394557953	The product dissolves rapidly ( usually in less than 1 minute ) .
D-1064	-0.2682076394557953	The product dissolves rapidly ( usually in less than 1 minute ) .
P-1064	-0.4464 -0.0802 -0.6216 -0.2191 -0.1335 -1.1412 -0.1532 -0.1344 -0.2580 -0.1955 -0.1390 -0.1774 -0.1506 -0.1468 -0.1422 -0.1523
S-888	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-888	The product dissolves rapidly ( usually in less than 1 minute ) .
H-888	-0.2682076394557953	The product dissolves rapidly ( usually in less than 1 minute ) .
D-888	-0.2682076394557953	The product dissolves rapidly ( usually in less than 1 minute ) .
P-888	-0.4464 -0.0802 -0.6216 -0.2191 -0.1335 -1.1412 -0.1532 -0.1344 -0.2580 -0.1955 -0.1390 -0.1774 -0.1506 -0.1468 -0.1422 -0.1523
S-712	Das Produkt löst sich rasch ( üblicherweise in weniger als 1 Minute ) .
T-712	The product dissolves rapidly ( usually in less than 1 minute ) .
H-712	-0.2682076394557953	The product dissolves rapidly ( usually in less than 1 minute ) .
D-712	-0.2682076394557953	The product dissolves rapidly ( usually in less than 1 minute ) .
P-712	-0.4464 -0.0802 -0.6216 -0.2191 -0.1335 -1.1412 -0.1532 -0.1344 -0.2580 -0.1955 -0.1390 -0.1774 -0.1506 -0.1468 -0.1422 -0.1523
S-515	Advate ist sowohl zur kurz- als auch zur langfristigen Anwendung angezeigt .
T-515	Advate is intended for either short-term or long-term use .
H-515	-0.39522823691368103	Advate is indicated for both short- and long-term use .
D-515	-0.39522823691368103	Advate is indicated for both short- and long-term use .
P-515	-1.0872 -0.1033 -0.1540 -0.0450 -0.1415 -0.7060 -0.0506 -0.2068 -0.1543 -2.0084 -0.7659 -0.0872 -0.1276 -0.1347 -0.1560
S-1613	Arzneimittel auf eingeschränkte ärztliche Verschreibung ( siehe Anhang I :
T-1613	Medicinal product subject to restricted medical prescription ( See Annex I :
H-1613	-0.5194698572158813	Limited prescription ( see Annex I :
D-1613	-0.5194698572158813	Limited prescription ( see Annex I :
P-1613	-1.9492 -0.4198 -0.5897 -0.6885 -0.1941 -0.1307 -0.2262 -0.2832 -0.1937
S-1474	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-1474	For instructions for reconstitution prior to administration , see section 6.6 .
H-1474	-0.22540441155433655	For information on reconstitution prior to administration , see section 6.6 .
D-1474	-0.22540441155433655	For information on reconstitution prior to administration , see section 6.6 .
P-1474	-0.2499 -0.5696 -0.2423 -0.5257 -0.0778 -0.3919 -0.1345 -0.0848 -0.1600 -0.2217 -0.1480 -0.1184 -0.1515 -0.1545 -0.1505
S-1298	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-1298	For instructions for reconstitution prior to administration , see section 6.6 .
H-1298	-0.22540441155433655	For information on reconstitution prior to administration , see section 6.6 .
D-1298	-0.22540441155433655	For information on reconstitution prior to administration , see section 6.6 .
P-1298	-0.2499 -0.5696 -0.2423 -0.5257 -0.0778 -0.3919 -0.1345 -0.0848 -0.1600 -0.2217 -0.1480 -0.1184 -0.1515 -0.1545 -0.1505
S-1122	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-1122	For instructions for reconstitution prior to administration , see section 6.6 .
H-1122	-0.22540441155433655	For information on reconstitution prior to administration , see section 6.6 .
D-1122	-0.22540441155433655	For information on reconstitution prior to administration , see section 6.6 .
P-1122	-0.2499 -0.5696 -0.2423 -0.5257 -0.0778 -0.3919 -0.1345 -0.0848 -0.1600 -0.2217 -0.1480 -0.1184 -0.1515 -0.1545 -0.1505
S-923	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-923	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-923	-0.2666599452495575	frequency of dosage ( hours ) / duration of treatment ( days )
D-923	-0.2666599452495575	frequency of dosage ( hours ) / duration of treatment ( days )
P-923	-1.4130 -0.0826 -0.3969 -0.1980 -0.0694 -0.0911 -0.1354 -0.0960 -0.1346 -0.1509 -1.0082 -0.1185 -0.1648 -0.2015 -0.1325 -0.1301 -0.1293 -0.1472
S-1234	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-1234	Do not remove the blue cap from the BAXJECT II device .
H-1234	-0.26581862568855286	Do not remove the blue cap from the BAXJECT II .
D-1234	-0.26581862568855286	Do not remove the blue cap from the BAXJECT II .
P-1234	-0.1102 -0.1436 -0.1782 -0.1775 -0.2115 -1.1173 -0.1417 -0.4720 -0.4564 -0.2010 -0.3503 -0.0953 -0.1077 -0.1214 -0.2085 -0.1604
S-946	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-946	For instructions for reconstitution prior to administration , see section 6.6 .
H-946	-0.22540441155433655	For information on reconstitution prior to administration , see section 6.6 .
D-946	-0.22540441155433655	For information on reconstitution prior to administration , see section 6.6 .
P-946	-0.2499 -0.5696 -0.2423 -0.5257 -0.0778 -0.3919 -0.1345 -0.0848 -0.1600 -0.2217 -0.1480 -0.1184 -0.1515 -0.1545 -0.1505
S-1099	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-1099	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-1099	-0.2666599452495575	frequency of dosage ( hours ) / duration of treatment ( days )
D-1099	-0.2666599452495575	frequency of dosage ( hours ) / duration of treatment ( days )
P-1099	-1.4130 -0.0826 -0.3969 -0.1980 -0.0694 -0.0911 -0.1354 -0.0960 -0.1346 -0.1509 -1.0082 -0.1185 -0.1648 -0.2015 -0.1325 -0.1301 -0.1293 -0.1472
S-573	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-573	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-573	-0.2666599452495575	frequency of dosage ( hours ) / duration of treatment ( days )
D-573	-0.2666599452495575	frequency of dosage ( hours ) / duration of treatment ( days )
P-573	-1.4130 -0.0826 -0.3969 -0.1980 -0.0694 -0.0911 -0.1354 -0.0960 -0.1346 -0.1509 -1.0082 -0.1185 -0.1648 -0.2015 -0.1325 -0.1301 -0.1293 -0.1472
S-1934	Blister ( PCTFE<unk> PVC<unk> Alu )
T-1934	Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu ) Blister ( PCTFE/ PVC/ Alu )
H-1934	-0.23366646468639374	blister ( PCTFE/ PVC/ Alu )
D-1934	-0.23366646468639374	blister ( PCTFE/ PVC/ Alu )
P-1934	-0.5198 -0.3166 -0.1548 -0.2018 -0.1190 -0.1211 -0.1179 -0.1664 -0.1271 -0.1317 -0.1169 -0.1371 -1.0556 -0.1218 -0.1345 -0.1965
S-1951	Aerinaze ist ebenfalls kontraindiziert bei Patienten mit :
T-1951	Aerinaze is also contraindicated in patients with : narrow-angle glaucoma , urinary retention , cardiovascular diseases such as ischaemic heart disease , tachyarrhythmia and severe hypertension , hyperthyroidism ,
H-1951	-0.22679343819618225	Aerinaze is also contraindicated for patients with :
D-1951	-0.22679343819618225	Aerinaze is also contraindicated for patients with :
P-1951	-0.2021 -0.1245 -0.1233 -0.1527 -0.1283 -0.1679 -0.0885 -0.1717 -0.0312 -0.1697 -0.3595 -0.7355 -0.5685 -0.1517
S-1904	Aerinaze enthält zwei arzneilich wirksame Bestandteile :
T-1904	Aerinaze contains two active substances : desloratadine , an antihistamine , and pseudoephedrine , which is a nasal decongestant .
H-1904	-0.15785518288612366	Aerinaze contains two active ingredients :
D-1904	-0.15785518288612366	Aerinaze contains two active ingredients :
P-1904	-0.1567 -0.1354 -0.1212 -0.1538 -0.1346 -0.1930 -0.2388 -0.0575 -0.2529 -0.1325 -0.1599
S-1773	Am Ende der Packungsbeilage finden Sie genaue Informationen zur Selbstbehandlung .
T-1773	Detailed instructions for self-administration are given at the end of this package leaflet .
H-1773	-0.5025761723518372	See the Package Leaflet for detailed information on self treatment .
D-1773	-0.5025761723518372	See the Package Leaflet for detailed information on self treatment .
P-1773	-2.1761 -0.1778 -0.2052 -0.1374 -0.2477 -0.0146 -0.0771 -0.1191 -1.1433 -0.4200 -0.2252 -0.5280 -1.7811 -0.1332 -0.1529
S-1758	Normalerweise wird die Ersatztherapie mit ADVATE lebenslang durchgeführt .
T-1758	Usually , the replacement therapy with ADVATE is a life-long treatment .
H-1758	-0.45718926191329956	Replacement therapy with ADVATE is usually lifelong .
D-1758	-0.45718926191329956	Replacement therapy with ADVATE is usually lifelong .
P-1758	-4.0028 -0.1776 -0.1295 -0.0770 -0.2071 -0.0847 -0.1420 -0.0901 -0.1012 -0.1731 -0.2032 -1.0987 -0.0746 -0.1422 -0.1544
S-1451	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-1451	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-1451	-0.2666599452495575	frequency of dosage ( hours ) / duration of treatment ( days )
D-1451	-0.2666599452495575	frequency of dosage ( hours ) / duration of treatment ( days )
P-1451	-1.4130 -0.0826 -0.3969 -0.1980 -0.0694 -0.0911 -0.1354 -0.0960 -0.1346 -0.1509 -1.0082 -0.1185 -0.1648 -0.2015 -0.1325 -0.1301 -0.1293 -0.1472
S-1275	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-1275	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-1275	-0.2666599452495575	frequency of dosage ( hours ) / duration of treatment ( days )
D-1275	-0.2666599452495575	frequency of dosage ( hours ) / duration of treatment ( days )
P-1275	-1.4130 -0.0826 -0.3969 -0.1980 -0.0694 -0.0911 -0.1354 -0.0960 -0.1346 -0.1509 -1.0082 -0.1185 -0.1648 -0.2015 -0.1325 -0.1301 -0.1293 -0.1472
S-1587	Die blaue Schutzkappe nicht vom BAXJECT II entfernen .
T-1587	Do not remove the blue cap from the BAXJECT II device .
H-1587	-0.26581862568855286	Do not remove the blue cap from the BAXJECT II .
D-1587	-0.26581862568855286	Do not remove the blue cap from the BAXJECT II .
P-1587	-0.1102 -0.1436 -0.1782 -0.1775 -0.2115 -1.1173 -0.1417 -0.4720 -0.4564 -0.2010 -0.3503 -0.0953 -0.1077 -0.1214 -0.2085 -0.1604
S-747	Häufigkeit der Dosierung ( Stunden ) / Behandlungsdauer ( Tage )
T-747	Frequency of doses ( hours<<unk>> / duration of therapy ( days )
H-747	-0.2666599452495575	frequency of dosage ( hours ) / duration of treatment ( days )
D-747	-0.2666599452495575	frequency of dosage ( hours ) / duration of treatment ( days )
P-747	-1.4130 -0.0826 -0.3969 -0.1980 -0.0694 -0.0911 -0.1354 -0.0960 -0.1346 -0.1509 -1.0082 -0.1185 -0.1648 -0.2015 -0.1325 -0.1301 -0.1293 -0.1472
S-1983	Die Wechselwirkung zwischen Aerinaze und Alkohol wurde nicht untersucht .
T-1983	The interaction with Aerinaze and alcohol has not been studied .
H-1983	-0.25915881991386414	The interaction between Aerinaze and alcohol has not been investigated .
D-1983	-0.25915881991386414	The interaction between Aerinaze and alcohol has not been investigated .
P-1983	-0.4481 -0.4674 -0.0712 -0.4304 -0.2261 -0.1190 -0.1147 -0.1501 -0.1119 -0.1405 -0.1711 -0.2997 -0.1323 -0.1091 -1.1181 -0.1423 -0.1538
S-1800	Im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1800	Keep the vial in the outer carton in order to protect from light .
H-1800	-0.23604117333889008	Store in the outer carton to protect from light .
D-1800	-0.23604117333889008	Store in the outer carton to protect from light .
P-1800	-0.3546 -0.1809 -0.6144 -0.0004 -0.0872 -0.5382 -0.0386 -0.4970 -0.1463 -0.1401 -0.1371 -0.1480 -0.1858
S-1575	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-1575	- Dispose any unused product or waste material in accordance with local requirements .
H-1575	-0.1460590958595276	- Any unused product or waste material should be disposed
D-1575	-0.1460590958595276	- Any unused product or waste material should be disposed
P-1575	-0.2159 -0.0722 -0.1089 -0.1121 -0.1117 -0.1147 -0.1308 -0.1469 -0.0859 -0.1798 -0.0018 -0.0326 -0.5854
S-1398	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-1398	- Dispose any unused product or waste material in accordance with local requirements .
H-1398	-0.1460590958595276	- Any unused product or waste material should be disposed
D-1398	-0.1460590958595276	- Any unused product or waste material should be disposed
P-1398	-0.2159 -0.0722 -0.1089 -0.1121 -0.1117 -0.1147 -0.1308 -0.1469 -0.0859 -0.1798 -0.0018 -0.0326 -0.5854
S-1222	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-1222	- Dispose any unused product or waste material in accordance with local requirements .
H-1222	-0.1460590958595276	- Any unused product or waste material should be disposed
D-1222	-0.1460590958595276	- Any unused product or waste material should be disposed
P-1222	-0.2159 -0.0722 -0.1089 -0.1121 -0.1117 -0.1147 -0.1308 -0.1469 -0.0859 -0.1798 -0.0018 -0.0326 -0.5854
S-1046	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-1046	- Dispose any unused product or waste material in accordance with local requirements .
H-1046	-0.1460590958595276	- Any unused product or waste material should be disposed
D-1046	-0.1460590958595276	- Any unused product or waste material should be disposed
P-1046	-0.2159 -0.0722 -0.1089 -0.1121 -0.1117 -0.1147 -0.1308 -0.1469 -0.0859 -0.1798 -0.0018 -0.0326 -0.5854
S-870	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-870	- Dispose any unused product or waste material in accordance with local requirements .
H-870	-0.1460590958595276	- Any unused product or waste material should be disposed
D-870	-0.1460590958595276	- Any unused product or waste material should be disposed
P-870	-0.2159 -0.0722 -0.1089 -0.1121 -0.1117 -0.1147 -0.1308 -0.1469 -0.0859 -0.1798 -0.0018 -0.0326 -0.5854
S-694	- Nicht verwendetes Arzneimittel oder Abfallmaterial ist entsprechend den nationalen
T-694	- Dispose any unused product or waste material in accordance with local requirements .
H-694	-0.1460590958595276	- Any unused product or waste material should be disposed
D-694	-0.1460590958595276	- Any unused product or waste material should be disposed
P-694	-0.2159 -0.0722 -0.1089 -0.1121 -0.1117 -0.1147 -0.1308 -0.1469 -0.0859 -0.1798 -0.0018 -0.0326 -0.5854
S-770	Angaben zur Rekonstitution vor der Verabreichung siehe Abschnitt 6.6 .
T-770	For instructions for reconstitution prior to administration , see section 6.6 .
H-770	-0.22540441155433655	For information on reconstitution prior to administration , see section 6.6 .
D-770	-0.22540441155433655	For information on reconstitution prior to administration , see section 6.6 .
P-770	-0.2499 -0.5696 -0.2423 -0.5257 -0.0778 -0.3919 -0.1345 -0.0848 -0.1600 -0.2217 -0.1480 -0.1184 -0.1515 -0.1545 -0.1505
S-1138	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-1138	To be taken into consideration by patients on a controlled sodium diet .
H-1138	-0.48052090406417847	This must be considered for patients on a sodium controlled diet .
D-1138	-0.48052090406417847	This must be considered for patients on a sodium controlled diet .
P-1138	-0.1835 -1.9749 -0.1561 -0.8955 -0.8291 -0.4373 -0.2763 -0.1672 -0.0426 -1.0536 -0.3614 -0.0576 -0.1383 -0.1539
S-786	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-786	To be taken into consideration by patients on a controlled sodium diet .
H-786	-0.48052090406417847	This must be considered for patients on a sodium controlled diet .
D-786	-0.48052090406417847	This must be considered for patients on a sodium controlled diet .
P-786	-0.1835 -1.9749 -0.1561 -0.8955 -0.8291 -0.4373 -0.2763 -0.1672 -0.0426 -1.0536 -0.3614 -0.0576 -0.1383 -0.1539
S-179	Spezifische Erfahrungen zur Behandlung einer Überdosis mit Alendronat liegen nicht vor .
T-179	No specific information is available on the treatment of overdose with alendronate .
H-179	-0.3239555358886719	No specific experience exists to treat overdose with alendronate .
D-179	-0.3239555358886719	No specific experience exists to treat overdose with alendronate .
P-179	-1.2561 -0.1609 -0.3006 -0.7402 -0.3987 -0.1655 -0.8669 -0.0451 -0.1412 -0.1231 -0.1505 -0.1226 -0.0857 -0.1493 -0.1530
S-90	Die empfohlene Dosierung beträgt eine ADROVANCE Tablette einmal wöchentlich .
T-90	The recommended dosage is one ADROVANCE tablet once weekly .
H-90	-0.1972656399011612	The recommended dose is one ADROVANCE tablet once a week .
D-90	-0.1972656399011612	The recommended dose is one ADROVANCE tablet once a week .
P-90	-0.1441 -0.1220 -0.3498 -0.1234 -0.2080 -0.1146 -0.0776 -0.1224 -0.1058 -0.1498 -0.1249 -0.1482 -0.7122 -0.4588 -0.0973 -0.1447 -0.1500
S-1850	Fragen und Antworten zur Rücknahme des Antrags auf Genehmigung für das Inverkehrbringen von Advexin
T-1850	Questions and answers on the withdrawal of the marketing application for Advexin
H-1850	-0.37109968066215515	Questions and Answers on the withdrawal of the marketing authorisation application for Advexin
D-1850	-0.37109968066215515	Questions and Answers on the withdrawal of the marketing authorisation application for Advexin
P-1850	-1.8436 -0.1388 -0.1640 -0.3065 -0.1327 -0.1596 -0.5262 -0.2934 -0.1468 -0.3501 -1.7771 -0.0368 -0.0702 -0.1570 -0.1269 -0.3688 -0.1721 -0.1342 -0.1462
S-863	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-863	19 6.6 Special precautions for disposal and other handling
H-863	-0.31670308113098145	6.6 Special precautions for disposal and handling
D-863	-0.31670308113098145	6.6 Special precautions for disposal and handling
P-863	-0.5576 -0.1345 -0.1144 -0.1717 -0.0808 -0.1153 -0.1093 -0.0124 -0.1246 -0.1278 -2.0552 -0.1970
S-1314	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-1314	To be taken into consideration by patients on a controlled sodium diet .
H-1314	-0.48052090406417847	This must be considered for patients on a sodium controlled diet .
D-1314	-0.48052090406417847	This must be considered for patients on a sodium controlled diet .
P-1314	-0.1835 -1.9749 -0.1561 -0.8955 -0.8291 -0.4373 -0.2763 -0.1672 -0.0426 -1.0536 -0.3614 -0.0576 -0.1383 -0.1539
S-367	Spezifische Erfahrungen zur Behandlung einer Überdosis mit Alendronat liegen nicht vor .
T-367	No specific information is available on the treatment of overdose with alendronate .
H-367	-0.3239555358886719	No specific experience exists to treat overdose with alendronate .
D-367	-0.3239555358886719	No specific experience exists to treat overdose with alendronate .
P-367	-1.2561 -0.1609 -0.3006 -0.7402 -0.3987 -0.1655 -0.8669 -0.0451 -0.1412 -0.1231 -0.1505 -0.1226 -0.0857 -0.1493 -0.1530
S-962	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-962	To be taken into consideration by patients on a controlled sodium diet .
H-962	-0.48052090406417847	This must be considered for patients on a sodium controlled diet .
D-962	-0.48052090406417847	This must be considered for patients on a sodium controlled diet .
P-962	-0.1835 -1.9749 -0.1561 -0.8955 -0.8291 -0.4373 -0.2763 -0.1672 -0.0426 -1.0536 -0.3614 -0.0576 -0.1383 -0.1539
S-684	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-684	Keep the vial in the outer carton in order to protect from light .
H-684	-0.2074912190437317	Keep the vial in the outer carton to protect from light .
D-684	-0.2074912190437317	Keep the vial in the outer carton to protect from light .
P-684	-0.3366 -0.1707 -0.1751 -0.0988 -0.1420 -0.3239 -0.0007 -0.0743 -0.6530 -0.0774 -0.5067 -0.1549 -0.1339 -0.1534 -0.1486 -0.1698
S-612	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-612	To be taken into consideration by patients on a controlled sodium diet .
H-612	-0.48052090406417847	This must be considered for patients on a sodium controlled diet .
D-612	-0.48052090406417847	This must be considered for patients on a sodium controlled diet .
P-612	-0.1835 -1.9749 -0.1561 -0.8955 -0.8291 -0.4373 -0.2763 -0.1672 -0.0426 -1.0536 -0.3614 -0.0576 -0.1383 -0.1539
S-1215	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-1215	39 6.6 Special precautions for disposal and other handling
H-1215	-0.31670308113098145	6.6 Special precautions for disposal and handling
D-1215	-0.31670308113098145	6.6 Special precautions for disposal and handling
P-1215	-0.5576 -0.1345 -0.1144 -0.1717 -0.0808 -0.1153 -0.1093 -0.0124 -0.1246 -0.1278 -2.0552 -0.1970
S-1039	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-1039	29 6.6 Special precautions for disposal and other handling
H-1039	-0.31670308113098145	6.6 Special precautions for disposal and handling
D-1039	-0.31670308113098145	6.6 Special precautions for disposal and handling
P-1039	-0.5576 -0.1345 -0.1144 -0.1717 -0.0808 -0.1153 -0.1093 -0.0124 -0.1246 -0.1278 -2.0552 -0.1970
S-158	5 Es ist nicht bekannt , ob Alendronat in die Muttermilch übergeht .
T-158	It is not known whether alendronate is excreted into human breast milk .
H-158	-0.2896134555339813	Alendronate is not known to be released into human milk .
D-158	-0.2896134555339813	Alendronate is not known to be released into human milk .
P-158	-0.1509 -0.1627 -0.0964 -0.0425 -0.2234 -0.2127 -0.1382 -0.1434 -0.4426 -1.7765 -0.3304 -0.1954 -0.1317 -0.1455 -0.1518
S-1568	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-1568	6.6 Special precautions for disposal and other handling
H-1568	-0.31670308113098145	6.6 Special precautions for disposal and handling
D-1568	-0.31670308113098145	6.6 Special precautions for disposal and handling
P-1568	-0.5576 -0.1345 -0.1144 -0.1717 -0.0808 -0.1153 -0.1093 -0.0124 -0.1246 -0.1278 -2.0552 -0.1970
S-1490	Dies muss bei Patienten , die einer natriumkontrollierten Diät unterliegen , berücksichtigt werden .
T-1490	To be taken into consideration by patients on a controlled sodium diet .
H-1490	-0.48052090406417847	This must be considered for patients on a sodium controlled diet .
D-1490	-0.48052090406417847	This must be considered for patients on a sodium controlled diet .
P-1490	-0.1835 -1.9749 -0.1561 -0.8955 -0.8291 -0.4373 -0.2763 -0.1672 -0.0426 -1.0536 -0.3614 -0.0576 -0.1383 -0.1539
S-687	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-687	6.6 Special precautions for disposal and other handling
H-687	-0.31670308113098145	6.6 Special precautions for disposal and handling
D-687	-0.31670308113098145	6.6 Special precautions for disposal and handling
P-687	-0.5576 -0.1345 -0.1144 -0.1717 -0.0808 -0.1153 -0.1093 -0.0124 -0.1246 -0.1278 -2.0552 -0.1970
S-277	Die empfohlene Dosierung beträgt eine ADROVANCE Tablette einmal wöchentlich .
T-277	The recommended dosage is one ADROVANCE tablet once weekly .
H-277	-0.1972656399011612	The recommended dose is one ADROVANCE tablet once a week .
D-277	-0.1972656399011612	The recommended dose is one ADROVANCE tablet once a week .
P-277	-0.1441 -0.1220 -0.3498 -0.1234 -0.2080 -0.1146 -0.0776 -0.1224 -0.1058 -0.1498 -0.1249 -0.1482 -0.7122 -0.4588 -0.0973 -0.1447 -0.1500
S-1486	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-1486	Rarely , inhibitors may develop after the first 100 exposure days.
H-1486	-0.22195732593536377	In rare cases , inhibitors may form after the first 100 days of exposure .
D-1486	-0.22195732593536377	In rare cases , inhibitors may form after the first 100 days of exposure .
P-1486	-0.2198 -0.1069 -0.1082 -0.2746 -0.1845 -0.0317 -0.0542 -0.1283 -0.2497 -1.6457 -0.2181 -0.1291 -0.0842 -0.0873 -0.1936 -0.1426 -0.0556 -0.1516 -0.1514
S-1310	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-1310	Rarely , inhibitors may develop after the first 100 exposure days.
H-1310	-0.22195732593536377	In rare cases , inhibitors may form after the first 100 days of exposure .
D-1310	-0.22195732593536377	In rare cases , inhibitors may form after the first 100 days of exposure .
P-1310	-0.2198 -0.1069 -0.1082 -0.2746 -0.1845 -0.0317 -0.0542 -0.1283 -0.2497 -1.6457 -0.2181 -0.1291 -0.0842 -0.0873 -0.1936 -0.1426 -0.0556 -0.1516 -0.1514
S-154	Es liegen keine geeigneten Daten zur Anwendung von ADROVANCE bei schwangeren Frauen vor .
T-154	There are no adequate data from the use of ADROVANCE in pregnant women .
H-154	-0.24568037688732147	There are no adequate data on the use of ADROVANCE in pregnant women .
D-154	-0.24568037688732147	There are no adequate data on the use of ADROVANCE in pregnant women .
P-154	-0.7034 -0.2285 -0.0784 -0.9363 -0.2857 -0.6411 -0.3165 -0.1820 -0.1473 -0.0782 -0.0801 -0.1173 -0.1133 -0.1200 -0.1411 -0.0877 -0.1144 -0.1412 -0.1554
S-3	Adenuric ist ein Arzneimittel , das den Wirkstoff Febuxostat enthält .
T-3	Adenuric is a medicine containing the active substance febuxostat .
H-3	-0.1611788421869278	Adenuric is a medicinal product containing the active substance Febuxostat .
D-3	-0.1611788421869278	Adenuric is a medicinal product containing the active substance Febuxostat .
P-3	-0.1068 -0.1665 -0.0669 -0.1181 -0.1297 -0.1537 -0.5457 -0.0696 -0.0738 -0.3474 -0.1713 -0.0915 -0.0803 -0.2864 -0.1382 -0.1146 -0.1718 -0.1070 -0.1311 -0.1533
S-1942	Die empfohlene Dosierung von Aerinaze beträgt eine Tablette zweimal täglich .
T-1942	The recommended dose of Aerinaze is one tablet twice a day .
H-1942	-0.2649553418159485	The recommended dose of Aerinaze is one tablet twice daily .
D-1942	-0.2649553418159485	The recommended dose of Aerinaze is one tablet twice daily .
P-1942	-0.1634 -0.2037 -0.1855 -0.1499 -0.1602 -0.1332 -0.1214 -0.1581 -0.1155 -0.1214 -0.2687 -0.1515 -0.1169 -1.9102 -0.2409 -0.1534 -0.1501
S-1732	Faktor VIII ist notwendig um im Blut Gerinnsel zu bilden und so Blutungen zu stoppen .
T-1732	Factor VIII is necessary for the blood to form clots and stop bleedings .
H-1732	-0.5292890071868896	Factor VIII is necessary to clot in the blood to stop bleeding .
D-1732	-0.5292890071868896	Factor VIII is necessary to clot in the blood to stop bleeding .
P-1732	-0.4601 -0.1407 -0.1321 -0.1173 -0.2574 -0.2240 -3.0825 -0.4276 -0.1926 -0.2280 -0.0489 -1.3959 -0.7040 -1.1103 -0.1565 -0.1574 -0.1627
S-1565	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1565	Keep the vial in the outer carton in order to protect from light .
H-1565	-0.2074912190437317	Keep the vial in the outer carton to protect from light .
D-1565	-0.2074912190437317	Keep the vial in the outer carton to protect from light .
P-1565	-0.3366 -0.1707 -0.1751 -0.0988 -0.1420 -0.3239 -0.0007 -0.0743 -0.6530 -0.0774 -0.5067 -0.1549 -0.1339 -0.1534 -0.1486 -0.1698
S-608	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-608	Rarely , inhibitors may develop after the first 100 exposure days.
H-608	-0.22195732593536377	In rare cases , inhibitors may form after the first 100 days of exposure .
D-608	-0.22195732593536377	In rare cases , inhibitors may form after the first 100 days of exposure .
P-608	-0.2198 -0.1069 -0.1082 -0.2746 -0.1845 -0.0317 -0.0542 -0.1283 -0.2497 -1.6457 -0.2181 -0.1291 -0.0842 -0.0873 -0.1936 -0.1426 -0.0556 -0.1516 -0.1514
S-1388	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1388	Keep the vial in the outer carton in order to protect from light .
H-1388	-0.2074912190437317	Keep the vial in the outer carton to protect from light .
D-1388	-0.2074912190437317	Keep the vial in the outer carton to protect from light .
P-1388	-0.3366 -0.1707 -0.1751 -0.0988 -0.1420 -0.3239 -0.0007 -0.0743 -0.6530 -0.0774 -0.5067 -0.1549 -0.1339 -0.1534 -0.1486 -0.1698
S-782	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-782	Rarely , inhibitors may develop after the first 100 exposure days.
H-782	-0.22195732593536377	In rare cases , inhibitors may form after the first 100 days of exposure .
D-782	-0.22195732593536377	In rare cases , inhibitors may form after the first 100 days of exposure .
P-782	-0.2198 -0.1069 -0.1082 -0.2746 -0.1845 -0.0317 -0.0542 -0.1283 -0.2497 -1.6457 -0.2181 -0.1291 -0.0842 -0.0873 -0.1936 -0.1426 -0.0556 -0.1516 -0.1514
S-1212	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1212	Keep the vial in the outer carton in order to protect from light .
H-1212	-0.2074912190437317	Keep the vial in the outer carton to protect from light .
D-1212	-0.2074912190437317	Keep the vial in the outer carton to protect from light .
P-1212	-0.3366 -0.1707 -0.1751 -0.0988 -0.1420 -0.3239 -0.0007 -0.0743 -0.6530 -0.0774 -0.5067 -0.1549 -0.1339 -0.1534 -0.1486 -0.1698
S-1134	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-1134	Rarely , inhibitors may develop after the first 100 exposure days.
H-1134	-0.22195732593536377	In rare cases , inhibitors may form after the first 100 days of exposure .
D-1134	-0.22195732593536377	In rare cases , inhibitors may form after the first 100 days of exposure .
P-1134	-0.2198 -0.1069 -0.1082 -0.2746 -0.1845 -0.0317 -0.0542 -0.1283 -0.2497 -1.6457 -0.2181 -0.1291 -0.0842 -0.0873 -0.1936 -0.1426 -0.0556 -0.1516 -0.1514
S-1036	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-1036	Keep the vial in the outer carton in order to protect from light .
H-1036	-0.2074912190437317	Keep the vial in the outer carton to protect from light .
D-1036	-0.2074912190437317	Keep the vial in the outer carton to protect from light .
P-1036	-0.3366 -0.1707 -0.1751 -0.0988 -0.1420 -0.3239 -0.0007 -0.0743 -0.6530 -0.0774 -0.5067 -0.1549 -0.1339 -0.1534 -0.1486 -0.1698
S-958	In seltenen Fällen können sich Inhibitoren nach den ersten 100 Expositionstagen bilden .
T-958	Rarely , inhibitors may develop after the first 100 exposure days.
H-958	-0.22195732593536377	In rare cases , inhibitors may form after the first 100 days of exposure .
D-958	-0.22195732593536377	In rare cases , inhibitors may form after the first 100 days of exposure .
P-958	-0.2198 -0.1069 -0.1082 -0.2746 -0.1845 -0.0317 -0.0542 -0.1283 -0.2497 -1.6457 -0.2181 -0.1291 -0.0842 -0.0873 -0.1936 -0.1426 -0.0556 -0.1516 -0.1514
S-860	Die Durchstechflasche im Umkarton aufbewahren , um den Inhalt vor Licht zu schützen .
T-860	Keep the vial in the outer carton in order to protect from light .
H-860	-0.2074912190437317	Keep the vial in the outer carton to protect from light .
D-860	-0.2074912190437317	Keep the vial in the outer carton to protect from light .
P-860	-0.3366 -0.1707 -0.1751 -0.0988 -0.1420 -0.3239 -0.0007 -0.0743 -0.6530 -0.0774 -0.5067 -0.1549 -0.1339 -0.1534 -0.1486 -0.1698
S-1391	6.6 Besondere Vorsichtsmaßnahmen für die Beseitigung und sonstige Hinweise zur Handhabung
T-1391	6.6 Special precautions for disposal and other handling
H-1391	-0.31670308113098145	6.6 Special precautions for disposal and handling
D-1391	-0.31670308113098145	6.6 Special precautions for disposal and handling
P-1391	-0.5576 -0.1345 -0.1144 -0.1717 -0.0808 -0.1153 -0.1093 -0.0124 -0.1246 -0.1278 -2.0552 -0.1970
S-346	Es ist nicht bekannt , ob Alendronat in die Muttermilch übergeht .
T-346	It is not known whether alendronate is excreted into human breast milk .
H-346	-0.321112722158432	Alendronate is not known to be released into human milk .
D-346	-0.321112722158432	Alendronate is not known to be released into human milk .
P-346	-0.3206 -0.1546 -0.0911 -0.0409 -0.2402 -0.2276 -0.1529 -0.1452 -0.5730 -1.9360 -0.3155 -0.1925 -0.1365 -0.1370 -0.1529
S-336	Unerwünschte Reaktionen , die auf diese kombinierte Anwendung zurückzuführen waren , wurden nicht beobachtet .
T-336	No adverse reactions attributable to their concomitant use were identified .
H-336	-0.5460847020149231	Adverse reactions from this combination have not been observed .
D-336	-0.5460847020149231	Adverse reactions from this combination have not been observed .
P-336	-1.1175 -0.0231 -0.0321 -0.0668 -0.8775 -0.3533 -1.6576 -2.0514 -0.1439 -0.1120 -0.3647 -0.1427 -0.1565
S-349	Es wurden keine Studien zur Verkehrstüchtigkeit oder zur Fähigkeit zum Bedienen von Maschinen durchgeführt .
T-349	No studies on the effects on the ability to drive and use machines have been performed .
H-349	-0.45551466941833496	No studies have been carried out on ability to drive or use machines .
D-349	-0.45551466941833496	No studies have been carried out on ability to drive or use machines .
P-349	-0.1662 -0.3013 -0.9037 -0.1519 -1.5025 -0.1383 -1.0880 -1.2947 -0.3072 -0.1583 -0.1312 -0.1606 -0.2314 -0.1445 -0.1528
S-1966	Ebenfalls zur Vorsicht geraten wird bei Patienten , die mit anderen Sympathomimetika behandelt werden .
T-1966	Caution should also be exercised in patients being treated with other sympathomimetics .
H-1966	-0.35942143201828003	Caution should also be exercised in patients treated with other sympathomimetics .
D-1966	-0.35942143201828003	Caution should also be exercised in patients treated with other sympathomimetics .
P-1966	-0.7118 -0.0568 -1.0357 -0.0677 -0.2043 -0.2359 -0.1033 -2.1950 -0.2462 -0.6004 -0.1450 -0.2432 -0.0371 -0.0722 -0.0705 -0.1531 -0.1383 -0.1530
S-1611	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgien
T-1611	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
H-1611	-0.19444811344146729	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgien
D-1611	-0.19444811344146729	Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgien
P-1611	-0.2289 -0.1454 -0.1334 -0.1285 -0.6526 -0.0985 -0.4024 -0.1839 -0.0934 -0.1410 -0.0990 -0.1150 -0.1074 -0.1152 -0.1266 -0.1010 -0.0857 -0.0983 -0.6679 -0.1650
S-148	Unerwünschte Reaktionen , die auf diese kombinierte Anwendung zurückzuführen waren , wurden nicht beobachtet .
T-148	No adverse reactions attributable to their concomitant use were identified .
H-148	-0.5460847020149231	Adverse reactions from this combination have not been observed .
D-148	-0.5460847020149231	Adverse reactions from this combination have not been observed .
P-148	-1.1175 -0.0231 -0.0321 -0.0668 -0.8775 -0.3533 -1.6576 -2.0514 -0.1439 -0.1120 -0.3647 -0.1427 -0.1565
S-815	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-815	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-815	-0.24315348267555237	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-815	-0.24315348267555237	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-815	-0.2130 -0.9787 -0.1155 -0.0825 -0.0412 -0.4395 -0.2464 -0.1537 -0.1117 -0.0590 -0.2898 -0.1170 -0.1108 -0.3100 -0.1500 -0.5726 -0.5212 -0.0599 -0.1413 -0.1496
S-161	Es wurden keine Studien zur Verkehrstüchtigkeit oder zur Fähigkeit zum Bedienen von Maschinen durchgeführt .
T-161	No studies on the effects on the ability to drive and use machines have been performed .
H-161	-0.45551466941833496	No studies have been carried out on ability to drive or use machines .
D-161	-0.45551466941833496	No studies have been carried out on ability to drive or use machines .
P-161	-0.1662 -0.3013 -0.9037 -0.1519 -1.5025 -0.1383 -1.0880 -1.2947 -0.3072 -0.1583 -0.1312 -0.1606 -0.2314 -0.1445 -0.1528
S-1903	Sobald die Nase wieder frei ist , können die Patienten Desloratadin allein einnehmen .
T-1903	Once the nose has cleared , patients can use desloratadine alone .
H-1903	-0.36783820390701294	Once the nose is clear , patients can take desloratadine alone .
D-1903	-0.36783820390701294	Once the nose is clear , patients can take desloratadine alone .
P-1903	-0.8560 -0.2173 -0.4219 -0.0871 -1.1241 -0.2944 -0.1243 -0.5047 -0.2255 -0.3424 -0.0655 -0.1035 -0.2763 -0.6344 -0.6851 -0.1348 -0.1559
S-1879	Zur Beurteilung eines neuen Antrags benötigt der CHMP in der Regel bis zu 210 Tage .
T-1879	The CHMP normally takes up to 210 days to evaluate a new application .
H-1879	-0.46447300910949707	It usually takes up to 210 days for the CHMP to assess a new application .
D-1879	-0.46447300910949707	It usually takes up to 210 days for the CHMP to assess a new application .
P-1879	-2.7999 -0.5348 -0.2493 -0.6746 -0.1342 -0.0389 -0.1593 -0.1990 -0.3692 -0.2017 -0.0377 -0.1440 -1.9175 -0.1700 -0.2266 -0.1877 -0.1654 -0.1507
S-307	Während der Behandlung sollten diese Patienten kieferchirurgische Eingriffe soweit möglich vermeiden .
T-307	While on treatment , these patients should avoid invasive dental procedures if possible .
H-307	-0.5214680433273315	These patients should avoid maxillofacial surgery as much as possible during treatment .
D-307	-0.5214680433273315	These patients should avoid maxillofacial surgery as much as possible during treatment .
P-307	-2.7242 -0.0870 -0.0870 -0.3843 -0.7236 -0.2937 -0.2793 -0.4051 -0.0571 -0.4302 -0.4690 -1.4213 -0.1498 -0.0905 -1.3353 -0.1636 -0.1346 -0.1508
S-119	Während der Behandlung sollten diese Patienten kieferchirurgische Eingriffe soweit möglich vermeiden .
T-119	While on treatment , these patients should avoid invasive dental procedures if possible .
H-119	-0.5214680433273315	These patients should avoid maxillofacial surgery as much as possible during treatment .
D-119	-0.5214680433273315	These patients should avoid maxillofacial surgery as much as possible during treatment .
P-119	-2.7242 -0.0870 -0.0870 -0.3843 -0.7236 -0.2937 -0.2793 -0.4051 -0.0571 -0.4302 -0.4690 -1.4213 -0.1498 -0.0905 -1.3353 -0.1636 -0.1346 -0.1508
S-376	Der unter Therapie mit Alendronat gebildete Knochen ist von normaler Qualität .
T-376	The bone formed during treatment with alendronate is of normal quality .
H-376	-0.39901238679885864	The bone produced during treatment with alendronate is of normal quality .
D-376	-0.39901238679885864	The bone produced during treatment with alendronate is of normal quality .
P-376	-0.5914 -0.1102 -2.6882 -0.7868 -0.5807 -0.1436 -0.1575 -0.1473 -0.1368 -0.0644 -0.1614 -0.1564 -0.1217 -0.2376 -0.1437 -0.1566
S-641	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-641	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-641	-0.24315348267555237	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-641	-0.24315348267555237	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-641	-0.2130 -0.9787 -0.1155 -0.0825 -0.0412 -0.4395 -0.2464 -0.1537 -0.1117 -0.0590 -0.2898 -0.1170 -0.1108 -0.3100 -0.1500 -0.5726 -0.5212 -0.0599 -0.1413 -0.1496
S-1877	Als das Unternehmen seinen Antrag zurücknahm , war in dem Antragsverfahren Tag 179 erreicht .
T-1877	The application was at day 179 when the company withdrew .
H-1877	-0.3276784420013428	When the company withdrew its application , day 179 was achieved in the application procedure .
D-1877	-0.3276784420013428	When the company withdrew its application , day 179 was achieved in the application procedure .
P-1877	-0.2925 -0.2779 -0.3938 -0.0417 -0.2128 -0.2475 -0.1600 -0.2274 -1.0259 -0.0967 -0.1485 -1.1470 -0.2200 -0.2678 -0.1552 -0.2466 -0.7809 -0.1330 -0.1504
S-1245	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-1245	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-1245	-0.5369647145271301	Turn the system upwards ( with the concentrate vial facing up ) .
D-1245	-0.5369647145271301	Turn the system upwards ( with the concentrate vial facing up ) .
P-1245	-1.0490 -0.1144 -0.2240 -0.2698 -1.1095 -1.2975 -0.1693 -0.4576 -0.1251 -0.6809 -0.0663 -0.1050 -1.5145 -1.5030 -0.1453 -0.1447 -0.1525
S-1069	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-1069	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-1069	-0.5369647145271301	Turn the system upwards ( with the concentrate vial facing up ) .
D-1069	-0.5369647145271301	Turn the system upwards ( with the concentrate vial facing up ) .
P-1069	-1.0490 -0.1144 -0.2240 -0.2698 -1.1095 -1.2975 -0.1693 -0.4576 -0.1251 -0.6809 -0.0663 -0.1050 -1.5145 -1.5030 -0.1453 -0.1447 -0.1525
S-287	Vitamin D3 einmal pro Woche in ADROVANCE und von 800 I.E.
T-287	Patients should receive supplemental calcium if intake from diet is inadequate ( see section 4.4 ) .
H-287	-0.2728848159313202	vitamin D3 once a week in ADROVANCE and 800 IU .
D-287	-0.2728848159313202	vitamin D3 once a week in ADROVANCE and 800 IU .
P-287	-1.4398 -0.1169 -0.1185 -0.1382 -0.3372 -0.2234 -0.1116 -0.1345 -0.0642 -0.0890 -0.1286 -0.1022 -0.1241 -0.1291 -0.1818 -0.1043 -0.0967 -1.3908 -0.1539
S-1851	Internationaler Freiname ( INN ) : Contusugene Ladenovec
T-1851	International non-proprietary name ( INN ) : contusugene ladenovec
H-1851	-0.40115901827812195	International Freiname ( INN ) : Contusugene Ladenovec
D-1851	-0.40115901827812195	International Freiname ( INN ) : Contusugene Ladenovec
P-1851	-0.1476 -2.5018 -0.1859 -0.2285 -0.1362 -0.0997 -0.1409 -0.1294 -0.1407 -0.1537 -0.4415 -0.1073 -1.5596 -0.6863 -0.1447 -0.1551 -0.1057 -0.1564
S-1808	Trometamol , Polysorbat 80 , Glutathion ( reduziert ) .
T-1808	trometamol , polysorbate 80 , and glutathione ( reduced ) .
H-1808	-0.13935671746730804	trometamol , polysorbate 80 , glutathione ( reduced ) .
D-1808	-0.13935671746730804	trometamol , polysorbate 80 , glutathione ( reduced ) .
P-1808	-0.2090 -0.0795 -0.1089 -0.1217 -0.1509 -0.0623 -0.0651 -0.0931 -0.0949 -0.1112 -0.1484 -0.5571 -0.0731 -0.0743 -0.1245 -0.1822 -0.1449 -0.0714 -0.1414 -0.1572 -0.1553
S-1598	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-1598	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-1598	-0.5369647145271301	Turn the system upwards ( with the concentrate vial facing up ) .
D-1598	-0.5369647145271301	Turn the system upwards ( with the concentrate vial facing up ) .
P-1598	-1.0490 -0.1144 -0.2240 -0.2698 -1.1095 -1.2975 -0.1693 -0.4576 -0.1251 -0.6809 -0.0663 -0.1050 -1.5145 -1.5030 -0.1453 -0.1447 -0.1525
S-1421	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-1421	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-1421	-0.5369647145271301	Turn the system upwards ( with the concentrate vial facing up ) .
D-1421	-0.5369647145271301	Turn the system upwards ( with the concentrate vial facing up ) .
P-1421	-1.0490 -0.1144 -0.2240 -0.2698 -1.1095 -1.2975 -0.1693 -0.4576 -0.1251 -0.6809 -0.0663 -0.1050 -1.5145 -1.5030 -0.1453 -0.1447 -0.1525
S-991	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-991	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-991	-0.24315348267555237	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-991	-0.24315348267555237	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-991	-0.2130 -0.9787 -0.1155 -0.0825 -0.0412 -0.4395 -0.2464 -0.1537 -0.1117 -0.0590 -0.2898 -0.1170 -0.1108 -0.3100 -0.1500 -0.5726 -0.5212 -0.0599 -0.1413 -0.1496
S-1167	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-1167	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-1167	-0.24315348267555237	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-1167	-0.24315348267555237	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-1167	-0.2130 -0.9787 -0.1155 -0.0825 -0.0412 -0.4395 -0.2464 -0.1537 -0.1117 -0.0590 -0.2898 -0.1170 -0.1108 -0.3100 -0.1500 -0.5726 -0.5212 -0.0599 -0.1413 -0.1496
S-893	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-893	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-893	-0.5369647145271301	Turn the system upwards ( with the concentrate vial facing up ) .
D-893	-0.5369647145271301	Turn the system upwards ( with the concentrate vial facing up ) .
P-893	-1.0490 -0.1144 -0.2240 -0.2698 -1.1095 -1.2975 -0.1693 -0.4576 -0.1251 -0.6809 -0.0663 -0.1050 -1.5145 -1.5030 -0.1453 -0.1447 -0.1525
S-717	Das System umdrehen ( mit der Konzentrat-Durchstechflasche nach oben ) .
T-717	Invert the system ( the vial with the reconstituted solution has to be on top ) .
H-717	-0.5369647145271301	Turn the system upwards ( with the concentrate vial facing up ) .
D-717	-0.5369647145271301	Turn the system upwards ( with the concentrate vial facing up ) .
P-717	-1.0490 -0.1144 -0.2240 -0.2698 -1.1095 -1.2975 -0.1693 -0.4576 -0.1251 -0.6809 -0.0663 -0.1050 -1.5145 -1.5030 -0.1453 -0.1447 -0.1525
S-1812	Pharmazeutischer Unternehmer Baxter AG Industriestrasse 67 A-1221 Wien , Österreich
T-1812	95 Marketing Authorisation Holder Baxter AG Industriestrasse 67 A-1221 Vienna
H-1812	-0.2423645257949829	Marketing Authorisation Holder Baxter AG Industriestrasse 67 A-1221 Vienna , Austria
D-1812	-0.2423645257949829	Marketing Authorisation Holder Baxter AG Industriestrasse 67 A-1221 Vienna , Austria
P-1812	-1.3348 -0.2327 -0.0804 -0.0560 -0.1102 -0.0687 -0.2419 -0.1298 -0.1531 -0.1926 -0.0627 -0.0705 -0.8578 -0.0981 -0.1246 -0.1071 -0.1025 -0.1319 -0.5157 -0.1499 -0.3612 -0.1498
S-1520	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-1520	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-1520	-0.24315348267555237	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-1520	-0.24315348267555237	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-1520	-0.2130 -0.9787 -0.1155 -0.0825 -0.0412 -0.4395 -0.2464 -0.1537 -0.1117 -0.0590 -0.2898 -0.1170 -0.1108 -0.3100 -0.1500 -0.5726 -0.5212 -0.0599 -0.1413 -0.1496
S-1343	Nachfolgende Inhibitortests an diesem Patienten nach Ausschluss aus der Studie waren negativ .
T-1343	Follow-up inhibitor tests in this patient after withdrawal from the study were negative .
H-1343	-0.24315348267555237	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
D-1343	-0.24315348267555237	Subsequent inhibitor tests in this patient after exclusion from the study were negative .
P-1343	-0.2130 -0.9787 -0.1155 -0.0825 -0.0412 -0.4395 -0.2464 -0.1537 -0.1117 -0.0590 -0.2898 -0.1170 -0.1108 -0.3100 -0.1500 -0.5726 -0.5212 -0.0599 -0.1413 -0.1496
S-188	Der unter Therapie mit Alendronat gebildete Knochen ist von normaler Qualität .
T-188	The bone formed during treatment with alendronate is of normal quality .
H-188	-0.39901238679885864	The bone produced during treatment with alendronate is of normal quality .
D-188	-0.39901238679885864	The bone produced during treatment with alendronate is of normal quality .
P-188	-0.5914 -0.1102 -2.6882 -0.7868 -0.5807 -0.1436 -0.1575 -0.1473 -0.1368 -0.0644 -0.1614 -0.1564 -0.1217 -0.2376 -0.1437 -0.1566
S-1881	Sobald das Unternehmen Antworten auf diese Fragen übermittelt hat , werden diese vom CHMP geprüft .
T-1881	Once the company has supplied responses to the questions , the CHMP reviews them and may , before giving an opinion , ask any remaining questions at day 180.
H-1881	-0.4548417031764984	Once the company has provided answers to these questions , they will be reviewed by the CHMP .
D-1881	-0.4548417031764984	Once the company has provided answers to these questions , they will be reviewed by the CHMP .
P-1881	-0.6712 -0.8764 -0.4895 -0.8674 -1.3278 -0.7082 -0.3312 -0.1962 -0.4325 -0.1836 -0.7704 -0.3710 -0.1746 -0.6569 -0.1447 -0.4026 -0.1589 -0.0319 -0.1503 -0.1516
S-1508	60 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1508	55 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1508	-0.2376716136932373	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-1508	-0.2376716136932373	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-1508	-0.1075 -0.1579 -0.9275 -0.0438 -0.1619 -0.1623 -1.2206 -0.0243 -0.6867 -0.0373 -0.1286 -0.0906 -0.0802 -0.1134 -0.1335 -0.1324 -0.0781 -0.0848 -0.1445
S-1403	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-1403	Remove caps from powder and solvent vials .
H-1403	-0.2806677222251892	Remove the protective caps from the vials with powder and solvents .
D-1403	-0.2806677222251892	Remove the protective caps from the vials with powder and solvents .
P-1403	-0.1578 -0.0753 -0.1210 -0.9092 -0.4268 -0.4824 -0.1541 -0.2794 -0.0689 -0.1254 -0.3139 -0.3910 -0.1322 -0.1129 -0.9171 -0.0972 -0.1340 -0.1535
S-1492	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-1492	54 No interaction studies have been performed with ADVATE .
H-1492	-0.4637116491794586	No interaction studies of ADVATE with other medicinal products have been conducted .
D-1492	-0.4637116491794586	No interaction studies of ADVATE with other medicinal products have been conducted .
P-1492	-0.1257 -3.0859 -0.1961 -0.7694 -0.9189 -0.1408 -0.1388 -0.0777 -0.0897 -0.1511 -0.5123 -0.0764 -0.0455 -0.0970 -0.4669 -0.1176 -1.5064 -0.1403 -0.1541
S-614	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-614	No interaction studies have been performed with ADVATE. .
H-614	-0.4637116491794586	No interaction studies of ADVATE with other medicinal products have been conducted .
D-614	-0.4637116491794586	No interaction studies of ADVATE with other medicinal products have been conducted .
P-614	-0.1257 -3.0859 -0.1961 -0.7694 -0.9189 -0.1408 -0.1388 -0.0777 -0.0897 -0.1511 -0.5123 -0.0764 -0.0455 -0.0970 -0.4669 -0.1176 -1.5064 -0.1403 -0.1541
S-1140	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-1140	34 No interaction studies have been performed with ADVATE .
H-1140	-0.4637116491794586	No interaction studies of ADVATE with other medicinal products have been conducted .
D-1140	-0.4637116491794586	No interaction studies of ADVATE with other medicinal products have been conducted .
P-1140	-0.1257 -3.0859 -0.1961 -0.7694 -0.9189 -0.1408 -0.1388 -0.0777 -0.0897 -0.1511 -0.5123 -0.0764 -0.0455 -0.0970 -0.4669 -0.1176 -1.5064 -0.1403 -0.1541
S-964	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-964	24 No interaction studies have been performed with ADVATE .
H-964	-0.4637116491794586	No interaction studies of ADVATE with other medicinal products have been conducted .
D-964	-0.4637116491794586	No interaction studies of ADVATE with other medicinal products have been conducted .
P-964	-0.1257 -3.0859 -0.1961 -0.7694 -0.9189 -0.1408 -0.1388 -0.0777 -0.0897 -0.1511 -0.5123 -0.0764 -0.0455 -0.0970 -0.4669 -0.1176 -1.5064 -0.1403 -0.1541
S-788	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-788	14 No interaction studies have been performed with ADVATE .
H-788	-0.4637116491794586	No interaction studies of ADVATE with other medicinal products have been conducted .
D-788	-0.4637116491794586	No interaction studies of ADVATE with other medicinal products have been conducted .
P-788	-0.1257 -3.0859 -0.1961 -0.7694 -0.9189 -0.1408 -0.1388 -0.0777 -0.0897 -0.1511 -0.5123 -0.0764 -0.0455 -0.0970 -0.4669 -0.1176 -1.5064 -0.1403 -0.1541
S-83	Den vollständigen Wortlaut des EPAR für ADROVANCE finden Sie hier .
T-83	The full EPAR for ADROVANCE is available here .
H-83	-0.15528859198093414	The full EPAR for ADROVANCE is available here .
D-83	-0.15528859198093414	The full EPAR for ADROVANCE is available here .
P-83	-0.4990 -0.1789 -0.0485 -0.0657 -0.1232 -0.0903 -0.0805 -0.1201 -0.1061 -0.1286 -0.2392 -0.1801 -0.0930 -0.2206 -0.1555
S-43	Der Inhaber der Genehmigung für das Inverkehrbringen ist Beaufour Ipsen Pharma .
T-43	The marketing authorisation holder is Beaufour Ipsen Pharma .
H-43	-0.1730339676141739	The holder of the marketing authorisation is Beaufour Ipsen Pharma .
D-43	-0.1730339676141739	The holder of the marketing authorisation is Beaufour Ipsen Pharma .
P-43	-0.3238 -0.3809 -0.1438 -0.1984 -0.1215 -0.1614 -0.0732 -0.1435 -0.1483 -0.2244 -0.1687 -0.2968 -0.1276 -0.0412 -0.0977 -0.1371 -0.1533
S-1316	Es wurden keine Untersuchungen zur Wechselwirkung von ADVATE mit anderen Arzneimitteln durchgeführt .
T-1316	44 No interaction studies have been performed with ADVATE .
H-1316	-0.4637116491794586	No interaction studies of ADVATE with other medicinal products have been conducted .
D-1316	-0.4637116491794586	No interaction studies of ADVATE with other medicinal products have been conducted .
P-1316	-0.1257 -3.0859 -0.1961 -0.7694 -0.9189 -0.1408 -0.1388 -0.0777 -0.0897 -0.1511 -0.5123 -0.0764 -0.0455 -0.0970 -0.4669 -0.1176 -1.5064 -0.1403 -0.1541
S-1580	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-1580	Remove caps from powder and solvent vials .
H-1580	-0.2806677222251892	Remove the protective caps from the vials with powder and solvents .
D-1580	-0.2806677222251892	Remove the protective caps from the vials with powder and solvents .
P-1580	-0.1578 -0.0753 -0.1210 -0.9092 -0.4268 -0.4824 -0.1541 -0.2794 -0.0689 -0.1254 -0.3139 -0.3910 -0.1322 -0.1129 -0.9171 -0.0972 -0.1340 -0.1535
S-1010	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-1010	Activated Factor X converts prothrombin to thrombin .
H-1010	-0.2358180731534958	Activated factor X converts prothrombin into thrombin .
D-1010	-0.2358180731534958	Activated factor X converts prothrombin into thrombin .
P-1010	-1.5241 -0.1180 -0.1264 -0.0838 -0.0991 -0.2063 -0.2474 -0.1290 -0.0300 -0.1603 -0.1220 -0.5425 -0.0402 -0.1585 -0.1187 -0.1465 -0.1561
S-1227	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-1227	Remove caps from powder and solvent vials .
H-1227	-0.2806677222251892	Remove the protective caps from the vials with powder and solvents .
D-1227	-0.2806677222251892	Remove the protective caps from the vials with powder and solvents .
P-1227	-0.1578 -0.0753 -0.1210 -0.9092 -0.4268 -0.4824 -0.1541 -0.2794 -0.0689 -0.1254 -0.3139 -0.3910 -0.1322 -0.1129 -0.9171 -0.0972 -0.1340 -0.1535
S-1051	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-1051	Remove caps from powder and solvent vials .
H-1051	-0.2806677222251892	Remove the protective caps from the vials with powder and solvents .
D-1051	-0.2806677222251892	Remove the protective caps from the vials with powder and solvents .
P-1051	-0.1578 -0.0753 -0.1210 -0.9092 -0.4268 -0.4824 -0.1541 -0.2794 -0.0689 -0.1254 -0.3139 -0.3910 -0.1322 -0.1129 -0.9171 -0.0972 -0.1340 -0.1535
S-875	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-875	Remove caps from powder and solvent vials .
H-875	-0.2806677222251892	Remove the protective caps from the vials with powder and solvents .
D-875	-0.2806677222251892	Remove the protective caps from the vials with powder and solvents .
P-875	-0.1578 -0.0753 -0.1210 -0.9092 -0.4268 -0.4824 -0.1541 -0.2794 -0.0689 -0.1254 -0.3139 -0.3910 -0.1322 -0.1129 -0.9171 -0.0972 -0.1340 -0.1535
S-699	Schutzkappen von den Durchstechflaschen mit Pulver und Lösungsmittel entfernen .
T-699	Remove caps from powder and solvent vials .
H-699	-0.2806677222251892	Remove the protective caps from the vials with powder and solvents .
D-699	-0.2806677222251892	Remove the protective caps from the vials with powder and solvents .
P-699	-0.1578 -0.0753 -0.1210 -0.9092 -0.4268 -0.4824 -0.1541 -0.2794 -0.0689 -0.1254 -0.3139 -0.3910 -0.1322 -0.1129 -0.9171 -0.0972 -0.1340 -0.1535
S-539	Falls sich Antikörper entwickeln , ist die Wirksamkeit von Advate nicht gewährleistet .
T-539	If antibodies develop , Advate will not work effectively .
H-539	-0.4614894688129425	If antibodies develop , the effectiveness of Advate is not assured .
D-539	-0.4614894688129425	If antibodies develop , the effectiveness of Advate is not assured .
P-539	-0.3476 -0.0900 -0.0662 -1.6145 -0.1530 -2.1210 -1.3420 -0.0787 -0.1372 -0.3747 -0.0841 -0.3373 -0.1852 -0.1470 -0.1483 -0.1571
S-279	Hinweise , um eine ausreichende Resorption von Alendronat zu gewährleisten :
T-279	To permit adequate absorption of alendronate :
H-279	-0.4038866460323334	other medicinal products to ensure adequate absorption of alendronate :
D-279	-0.4038866460323334	other medicinal products to ensure adequate absorption of alendronate :
P-279	-1.0097 -2.9912 -0.0661 -0.1352 -0.7230 -0.2168 -0.1477 -0.0943 -0.0759 -0.1527 -0.1857 -0.1524 -0.1242 -0.0493 -0.1687 -0.1693
S-92	Hinweise , um eine ausreichende Resorption von Alendronat zu gewährleisten :
T-92	To permit adequate absorption of alendronate :
H-92	-0.4038866460323334	other medicinal products to ensure adequate absorption of alendronate :
D-92	-0.4038866460323334	other medicinal products to ensure adequate absorption of alendronate :
P-92	-1.0097 -2.9912 -0.0661 -0.1352 -0.7230 -0.2168 -0.1477 -0.0943 -0.0759 -0.1527 -0.1857 -0.1524 -0.1242 -0.0493 -0.1687 -0.1693
S-1929	Den vollständigen Wortlaut des EPAR für Aerinaze finden Sie hier .
T-1929	The full EPAR for Aerinaze can be found here .
H-1929	-0.15741237998008728	The full EPAR for Aerinaze is available here .
D-1929	-0.15741237998008728	The full EPAR for Aerinaze is available here .
P-1929	-0.4366 -0.1564 -0.0559 -0.0560 -0.1255 -0.1731 -0.1188 -0.1209 -0.1414 -0.1285 -0.2159 -0.1864 -0.0942 -0.1970 -0.1544
S-348	16 4.7 Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen
T-348	4.7 Effects on ability to drive and use machines
H-348	-0.14830568432807922	4.7 Effects on ability to drive and use machines
D-348	-0.14830568432807922	4.7 Effects on ability to drive and use machines
P-348	-0.1226 -0.1360 -0.0838 -0.0653 -0.1610 -0.0420 -0.2940 -0.2068 -0.1588 -0.1367 -0.2297 -0.1430
S-834	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-834	Activated Factor X converts prothrombin to thrombin .
H-834	-0.2358180731534958	Activated factor X converts prothrombin into thrombin .
D-834	-0.2358180731534958	Activated factor X converts prothrombin into thrombin .
P-834	-1.5241 -0.1180 -0.1264 -0.0838 -0.0991 -0.2063 -0.2474 -0.1290 -0.0300 -0.1603 -0.1220 -0.5425 -0.0402 -0.1585 -0.1187 -0.1465 -0.1561
S-1504	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-1504	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-1504	-0.4701530933380127	The following table 2 shows the frequency of undesirable effects in clinical trials :
D-1504	-0.4701530933380127	The following table 2 shows the frequency of undesirable effects in clinical trials :
P-1504	-0.2351 -0.1645 -0.1910 -0.2215 -3.0417 -0.1559 -0.6612 -0.0825 -0.7562 -1.7592 -0.1332 -0.0786 -0.4145 -0.1385 -0.0788 -0.0794 -0.1175 -0.1535
S-1152	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-1152	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-1152	-0.4701530933380127	The following table 2 shows the frequency of undesirable effects in clinical trials :
D-1152	-0.4701530933380127	The following table 2 shows the frequency of undesirable effects in clinical trials :
P-1152	-0.2351 -0.1645 -0.1910 -0.2215 -3.0417 -0.1559 -0.6612 -0.0825 -0.7562 -1.7592 -0.1332 -0.0786 -0.4145 -0.1385 -0.0788 -0.0794 -0.1175 -0.1535
S-1331	49 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1331	45 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1331	-0.2404526025056839	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-1331	-0.2404526025056839	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-1331	-0.1409 -0.1559 -0.9432 -0.0443 -0.1630 -0.1631 -1.2634 -0.0247 -0.6481 -0.0379 -0.1296 -0.0876 -0.0810 -0.1142 -0.1342 -0.1332 -0.0766 -0.0822 -0.1455
S-1155	38 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1155	35 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1155	-0.24786515533924103	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-1155	-0.24786515533924103	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-1155	-0.1754 -0.1573 -0.9794 -0.0465 -0.1680 -0.1620 -1.2591 -0.0235 -0.7173 -0.0370 -0.1299 -0.0866 -0.0814 -0.1132 -0.1334 -0.1318 -0.0786 -0.0833 -0.1456
S-979	27 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-979	25 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-979	-0.23827852308750153	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-979	-0.23827852308750153	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-979	-0.1469 -0.1651 -0.8679 -0.0441 -0.1664 -0.1597 -1.2798 -0.0252 -0.6507 -0.0367 -0.1290 -0.0867 -0.0799 -0.1135 -0.1334 -0.1308 -0.0793 -0.0858 -0.1466
S-803	16 Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-803	15 Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-803	-0.2395097017288208	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-803	-0.2395097017288208	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-803	-0.1355 -0.1611 -0.9759 -0.0439 -0.1612 -0.1561 -1.2049 -0.0255 -0.6619 -0.0379 -0.1286 -0.0904 -0.0805 -0.1138 -0.1326 -0.1319 -0.0793 -0.0848 -0.1447
S-1840	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
T-1840	34 <<unk>> GR-163 41 . : <<unk>> 30-210-99 87 000
H-1840	-0.1690921187400818	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
D-1840	-0.1690921187400818	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
P-1840	-0.2494 -0.0631 -0.1419 -0.0941 -0.1020 -0.1377 -0.2335 -0.4703 -0.1504 -0.0432 -0.1741 -0.1446 -0.1526 -0.5222 -0.0871 -0.0393 -0.1294 -0.1203 -0.1575
S-1827	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
T-1827	34 <<unk>> GR-163 41 . : <<unk>> 30-210-99 87 000
H-1827	-0.1690921187400818	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
D-1827	-0.1690921187400818	34 <unk> GR-163 41 . : <unk> 30-210-99 87 000
P-1827	-0.2494 -0.0631 -0.1419 -0.0941 -0.1020 -0.1377 -0.2335 -0.4703 -0.1504 -0.0432 -0.1741 -0.1446 -0.1526 -0.5222 -0.0871 -0.0393 -0.1294 -0.1203 -0.1575
S-1823	4 D-85716 Unterschleißheim Tel : <unk> 49 89 31 701
T-1823	4 D-85716 Unterschleißheim Tel : <<unk>> 49 89 31 701
H-1823	-0.15150120854377747	4 D-85716 Unterschleissheim Tel : <unk> 49 89 31 701
D-1823	-0.15150120854377747	4 D-85716 Unterschleissheim Tel : <unk> 49 89 31 701
P-1823	-0.2147 -0.1304 -0.1178 -0.1268 -0.4052 -0.1306 -0.1128 -0.1737 -0.3335 -0.2370 -0.0482 -0.1386 -0.0315 -0.0685 -0.1009 -0.1071 -0.1229 -0.1240 -0.1542
S-659	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-659	Activated Factor X converts prothrombin to thrombin .
H-659	-0.2358180731534958	Activated factor X converts prothrombin into thrombin .
D-659	-0.2358180731534958	Activated factor X converts prothrombin into thrombin .
P-659	-1.5241 -0.1180 -0.1264 -0.0838 -0.0991 -0.2063 -0.2474 -0.1290 -0.0300 -0.1603 -0.1220 -0.5425 -0.0402 -0.1585 -0.1187 -0.1465 -0.1561
S-1328	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-1328	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-1328	-0.4701530933380127	The following table 2 shows the frequency of undesirable effects in clinical trials :
D-1328	-0.4701530933380127	The following table 2 shows the frequency of undesirable effects in clinical trials :
P-1328	-0.2351 -0.1645 -0.1910 -0.2215 -3.0417 -0.1559 -0.6612 -0.0825 -0.7562 -1.7592 -0.1332 -0.0786 -0.4145 -0.1385 -0.0788 -0.0794 -0.1175 -0.1535
S-1186	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-1186	Activated Factor X converts prothrombin to thrombin .
H-1186	-0.2358180731534958	Activated factor X converts prothrombin into thrombin .
D-1186	-0.2358180731534958	Activated factor X converts prothrombin into thrombin .
P-1186	-1.5241 -0.1180 -0.1264 -0.0838 -0.0991 -0.2063 -0.2474 -0.1290 -0.0300 -0.1603 -0.1220 -0.5425 -0.0402 -0.1585 -0.1187 -0.1465 -0.1561
S-976	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-976	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-976	-0.4701530933380127	The following table 2 shows the frequency of undesirable effects in clinical trials :
D-976	-0.4701530933380127	The following table 2 shows the frequency of undesirable effects in clinical trials :
P-976	-0.2351 -0.1645 -0.1910 -0.2215 -3.0417 -0.1559 -0.6612 -0.0825 -0.7562 -1.7592 -0.1332 -0.0786 -0.4145 -0.1385 -0.0788 -0.0794 -0.1175 -0.1535
S-800	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-800	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-800	-0.4701530933380127	The following table 2 shows the frequency of undesirable effects in clinical trials :
D-800	-0.4701530933380127	The following table 2 shows the frequency of undesirable effects in clinical trials :
P-800	-0.2351 -0.1645 -0.1910 -0.2215 -3.0417 -0.1559 -0.6612 -0.0825 -0.7562 -1.7592 -0.1332 -0.0786 -0.4145 -0.1385 -0.0788 -0.0794 -0.1175 -0.1535
S-626	Folgende Tabelle 2 gibt die Häufigkeit der Nebenwirkungen in klinischen Studien an :
T-626	The following table 2 provides the frequency of adverse drug reactions in clinical trials :
H-626	-0.4701530933380127	The following table 2 shows the frequency of undesirable effects in clinical trials :
D-626	-0.4701530933380127	The following table 2 shows the frequency of undesirable effects in clinical trials :
P-626	-0.2351 -0.1645 -0.1910 -0.2215 -3.0417 -0.1559 -0.6612 -0.0825 -0.7562 -1.7592 -0.1332 -0.0786 -0.4145 -0.1385 -0.0788 -0.0794 -0.1175 -0.1535
S-1780	Sollten Sie weitere Fragen zur Anwendung dieses Arzneimittels haben , wenden Sie sich an Ihren Arzt .
T-1780	If you have any further questions on the use of this product , ask your doctor .
H-1780	-0.5228093862533569	If you have any questions about the use of this product , contact your doctor .
D-1780	-0.5228093862533569	If you have any questions about the use of this product , contact your doctor .
P-1780	-0.2538 -0.1077 -0.2162 -0.5341 -1.4593 -0.2772 -2.3347 -0.2545 -0.1494 -0.0998 -1.4477 -0.1539 -1.0951 -0.1213 -0.0788 -0.1485 -0.1559
S-1784	- Atembeschwerden , pfeifendes Atmen , Engegefühl in der Brust ,
T-1784	- difficulty in breathing , wheezing , tightness in the chest ,
H-1784	-0.4965168833732605	- difficulty breathing , whistling , tightness in the chest ,
D-1784	-0.4965168833732605	- difficulty breathing , whistling , tightness in the chest ,
P-1784	-0.4937 -1.9007 -0.0492 -0.1546 -1.5674 -0.2621 -0.3443 -0.9391 -0.8322 -0.0700 -0.1412 -0.2933 -0.0472 -0.1748 -0.1779
S-1539	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-1539	Activated Factor X converts prothrombin to thrombin .
H-1539	-0.2358180731534958	Activated factor X converts prothrombin into thrombin .
D-1539	-0.2358180731534958	Activated factor X converts prothrombin into thrombin .
P-1539	-1.5241 -0.1180 -0.1264 -0.0838 -0.0991 -0.2063 -0.2474 -0.1290 -0.0300 -0.1603 -0.1220 -0.5425 -0.0402 -0.1585 -0.1187 -0.1465 -0.1561
S-1362	Der aktivierte Faktor X wandelt Prothrombin in Thrombin um .
T-1362	Activated Factor X converts prothrombin to thrombin .
H-1362	-0.2358180731534958	Activated factor X converts prothrombin into thrombin .
D-1362	-0.2358180731534958	Activated factor X converts prothrombin into thrombin .
P-1362	-1.5241 -0.1180 -0.1264 -0.0838 -0.0991 -0.2063 -0.2474 -0.1290 -0.0300 -0.1603 -0.1220 -0.5425 -0.0402 -0.1585 -0.1187 -0.1465 -0.1561
S-1778	Fahren Sie sofort mit der nächsten vorgesehenen Anwendung fort , wie von Ihrem Arzt angewiesen .
T-1778	Proceed with the next injection as scheduled immediately and continue as advised by your doctor .
H-1778	-0.5721692442893982	Continue with the next scheduled dose immediately as instructed by your doctor .
D-1778	-0.5721692442893982	Continue with the next scheduled dose immediately as instructed by your doctor .
P-1778	-1.2080 -0.1473 -1.0397 -0.1702 -0.8624 -1.0687 -1.5969 -0.8740 -0.2161 -1.2031 -0.1057 -0.1372 -0.1022 -0.1128 -0.1574 -0.1530
S-1484	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-1484	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-1484	-0.5076133608818054	In such cases , contact a haemophilia centre is recommended .
D-1484	-0.5076133608818054	In such cases , contact a haemophilia centre is recommended .
P-1484	-1.1650 -0.9116 -0.1624 -1.0636 -1.3308 -0.2731 -0.2199 -0.1053 -0.3277 -0.7655 -0.5674 -0.1533 -0.2713 -0.1453 -0.1519
S-625	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-625	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-625	-0.3484414517879486	Within the frequencies , undesirable effects are listed in descending order of severity .
D-625	-0.3484414517879486	Within the frequencies , undesirable effects are listed in descending order of severity .
P-625	-0.4120 -1.2861 -0.6597 -0.2556 -0.0973 -0.3610 -0.1794 -0.0358 -0.0662 -0.1612 -0.1281 -0.2633 -0.1601 -0.2769 -0.2553 -0.7876 -0.1711 -1.3447 -0.1270 -0.1393 -0.1495
S-1505	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1505	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1505	-0.2283911556005478	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-1505	-0.2283911556005478	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-1505	-0.1096 -0.1661 -0.8350 -0.0412 -0.1502 -0.1542 -1.1999 -0.0249 -0.6339 -0.0362 -0.1290 -0.0861 -0.0795 -0.1142 -0.1338 -0.1303 -0.0803 -0.0864 -0.1486
S-975	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-975	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-975	-0.3484414517879486	Within the frequencies , undesirable effects are listed in descending order of severity .
D-975	-0.3484414517879486	Within the frequencies , undesirable effects are listed in descending order of severity .
P-975	-0.4120 -1.2861 -0.6597 -0.2556 -0.0973 -0.3610 -0.1794 -0.0358 -0.0662 -0.1612 -0.1281 -0.2633 -0.1601 -0.2769 -0.2553 -0.7876 -0.1711 -1.3447 -0.1270 -0.1393 -0.1495
S-1329	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1329	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1329	-0.2283911556005478	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-1329	-0.2283911556005478	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-1329	-0.1096 -0.1661 -0.8350 -0.0412 -0.1502 -0.1542 -1.1999 -0.0249 -0.6339 -0.0362 -0.1290 -0.0861 -0.0795 -0.1142 -0.1338 -0.1303 -0.0803 -0.0864 -0.1486
S-1308	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-1308	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-1308	-0.5076133608818054	In such cases , contact a haemophilia centre is recommended .
D-1308	-0.5076133608818054	In such cases , contact a haemophilia centre is recommended .
P-1308	-1.1650 -0.9116 -0.1624 -1.0636 -1.3308 -0.2731 -0.2199 -0.1053 -0.3277 -0.7655 -0.5674 -0.1533 -0.2713 -0.1453 -0.1519
S-1153	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-1153	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-1153	-0.2283911556005478	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-1153	-0.2283911556005478	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-1153	-0.1096 -0.1661 -0.8350 -0.0412 -0.1502 -0.1542 -1.1999 -0.0249 -0.6339 -0.0362 -0.1290 -0.0861 -0.0795 -0.1142 -0.1338 -0.1303 -0.0803 -0.0864 -0.1486
S-1132	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-1132	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-1132	-0.5076133608818054	In such cases , contact a haemophilia centre is recommended .
D-1132	-0.5076133608818054	In such cases , contact a haemophilia centre is recommended .
P-1132	-1.1650 -0.9116 -0.1624 -1.0636 -1.3308 -0.2731 -0.2199 -0.1053 -0.3277 -0.7655 -0.5674 -0.1533 -0.2713 -0.1453 -0.1519
S-799	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-799	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-799	-0.3484414517879486	Within the frequencies , undesirable effects are listed in descending order of severity .
D-799	-0.3484414517879486	Within the frequencies , undesirable effects are listed in descending order of severity .
P-799	-0.4120 -1.2861 -0.6597 -0.2556 -0.0973 -0.3610 -0.1794 -0.0358 -0.0662 -0.1612 -0.1281 -0.2633 -0.1601 -0.2769 -0.2553 -0.7876 -0.1711 -1.3447 -0.1270 -0.1393 -0.1495
S-977	Tabelle 2 Häufigkeit der Nebenwirkungen ( ADRs ) in klinischen Studien
T-977	Table 2 Frequency of adverse drug reactions ( ADRs ) in clinical trials
H-977	-0.2283911556005478	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
D-977	-0.2283911556005478	Table 2 Frequency of adverse reactions ( ADRs ) in clinical trials
P-977	-0.1096 -0.1661 -0.8350 -0.0412 -0.1502 -0.1542 -1.1999 -0.0249 -0.6339 -0.0362 -0.1290 -0.0861 -0.0795 -0.1142 -0.1338 -0.1303 -0.0803 -0.0864 -0.1486
S-1672	300 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1672	300 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1672	-0.2225303202867508	300 IU/ ml after reconstitution Specific activity : approximately
D-1672	-0.2225303202867508	300 IU/ ml after reconstitution Specific activity : approximately
P-1672	-0.0449 -0.1259 -0.1424 -0.1418 -0.0699 -0.2694 -0.1429 -0.0688 -1.0503 -0.0398 -0.2210 -0.1592 -0.4907 -0.1485
S-1654	200 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1654	200 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1654	-0.24213683605194092	200 IU/ ml after reconstitution Specific activity : approximately
D-1654	-0.24213683605194092	200 IU/ ml after reconstitution Specific activity : approximately
P-1654	-0.4114 -0.1211 -0.1476 -0.1454 -0.0738 -0.2608 -0.1388 -0.0641 -0.9744 -0.0393 -0.2065 -0.1585 -0.5017 -0.1465
S-19	Durch die Verminderung der Harnsäureproduktion kann Adenuric die
T-19	By reducing the production of uric acid , Adenuric can reduce levels of uric acid in the blood and keep them low , stopping crystals from building up .
H-19	-0.4741911292076111	Due to a decrease in uric acid production , Adenuric
D-19	-0.4741911292076111	Due to a decrease in uric acid production , Adenuric
P-19	-3.1108 -0.1560 -0.1326 -0.4108 -0.2607 -0.3157 -0.1530 -0.0692 -0.0780 -0.0616 -0.1527 -0.6989 -0.2607 -0.1929 -0.0526 -0.1137 -1.8413
S-1704	600 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1704	600 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1704	-0.22321856021881104	600 IU/ ml after reconstitution Specific activity : approximately
D-1704	-0.22321856021881104	600 IU/ ml after reconstitution Specific activity : approximately
P-1704	-0.0849 -0.1253 -0.1399 -0.1427 -0.0719 -0.2786 -0.1440 -0.0659 -1.0129 -0.0402 -0.2131 -0.1580 -0.4995 -0.1482
S-1688	400 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1688	400 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1688	-0.22102326154708862	400 IU/ ml after reconstitution Specific activity : approximately
D-1688	-0.22102326154708862	400 IU/ ml after reconstitution Specific activity : approximately
P-1688	-0.0985 -0.1227 -0.1424 -0.1436 -0.0712 -0.2559 -0.1397 -0.0710 -1.0042 -0.0407 -0.2167 -0.1596 -0.4810 -0.1471
S-1151	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-1151	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-1151	-0.3484414517879486	Within the frequencies , undesirable effects are listed in descending order of severity .
D-1151	-0.3484414517879486	Within the frequencies , undesirable effects are listed in descending order of severity .
P-1151	-0.4120 -1.2861 -0.6597 -0.2556 -0.0973 -0.3610 -0.1794 -0.0358 -0.0662 -0.1612 -0.1281 -0.2633 -0.1601 -0.2769 -0.2553 -0.7876 -0.1711 -1.3447 -0.1270 -0.1393 -0.1495
S-1327	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-1327	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-1327	-0.3484414517879486	Within the frequencies , undesirable effects are listed in descending order of severity .
D-1327	-0.3484414517879486	Within the frequencies , undesirable effects are listed in descending order of severity .
P-1327	-0.4120 -1.2861 -0.6597 -0.2556 -0.0973 -0.3610 -0.1794 -0.0358 -0.0662 -0.1612 -0.1281 -0.2633 -0.1601 -0.2769 -0.2553 -0.7876 -0.1711 -1.3447 -0.1270 -0.1393 -0.1495
S-1638	100 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1638	100 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1638	-0.21995972096920013	100 IU/ ml after reconstitution Specific activity : approximately
D-1638	-0.21995972096920013	100 IU/ ml after reconstitution Specific activity : approximately
P-1638	-0.1337 -0.1180 -0.1411 -0.1423 -0.0684 -0.2569 -0.1332 -0.0651 -0.9568 -0.0405 -0.2085 -0.1596 -0.5078 -0.1474
S-1622	50 I.E.<unk> ml nach Rekonstitution Spezifische Aktivität : ca.
T-1622	50 I.E.<<unk>> ml nach Rekonstitution Spezifische Aktivität : ca. Specific activity : approx .
H-1622	-0.21659062802791595	50 IU/ ml after reconstitution Specific activity : approximately
D-1622	-0.21659062802791595	50 IU/ ml after reconstitution Specific activity : approximately
P-1622	-0.0884 -0.1269 -0.1352 -0.1440 -0.0707 -0.2580 -0.1350 -0.0669 -0.9660 -0.0403 -0.2105 -0.1582 -0.4857 -0.1465
S-1503	Innerhalb der Häufigkeiten sind die Nebenwirkungen nach absteigender Schwere aufgeführt .
T-1503	Within each frequency grouping , undesirable effects are presented in order of decreasing seriousness .
H-1503	-0.3484414517879486	Within the frequencies , undesirable effects are listed in descending order of severity .
D-1503	-0.3484414517879486	Within the frequencies , undesirable effects are listed in descending order of severity .
P-1503	-0.4120 -1.2861 -0.6597 -0.2556 -0.0973 -0.3610 -0.1794 -0.0358 -0.0662 -0.1612 -0.1281 -0.2633 -0.1601 -0.2769 -0.2553 -0.7876 -0.1711 -1.3447 -0.1270 -0.1393 -0.1495
S-956	In solchen Fällen wird die Kontaktaufnahme mit einem Hämophilie- Zentrum empfohlen .
T-956	In such cases , it is recommended that a specialised haemophilia centre be contacted .
H-956	-0.5076133608818054	In such cases , contact a haemophilia centre is recommended .
D-956	-0.5076133608818054	In such cases , contact a haemophilia centre is recommended .
P-956	-1.1650 -0.9116 -0.1624 -1.0636 -1.3308 -0.2731 -0.2199 -0.1053 -0.3277 -0.7655 -0.5674 -0.1533 -0.2713 -0.1453 -0.1519
S-969	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-969	ADVATE has no influence on the ability to drive and use machines .
H-969	-0.30868831276893616	ADVATE has no effect on the ability to drive and use machines .
D-969	-0.30868831276893616	ADVATE has no effect on the ability to drive and use machines .
P-969	-0.1019 -0.1539 -0.0784 -0.1036 -0.3305 -0.1350 -0.9819 -0.1729 -1.2652 -0.0516 -0.2329 -0.1630 -0.8204 -0.1455 -0.2033 -0.1464 -0.1613
S-1969	Eine fortgesetzte Anwendung kann zu einer Toleranz führen , die ein erhöhtes Risiko für eine Überdosierung bedingt .
T-1969	Continuous use can lead to tolerance resulting in an increased risk of overdosing .
H-1969	-0.4495108425617218	Continuous use may lead to a tolerance that increases the risk of overdose .
D-1969	-0.4495108425617218	Continuous use may lead to a tolerance that increases the risk of overdose .
P-1969	-0.7835 -0.6052 -0.2353 -0.1454 -0.4685 -0.1519 -1.3264 -0.0921 -0.1269 -0.6478 -2.5783 -0.1459 -0.1383 -0.1682 -0.1089 -0.0600 -0.1501 -0.1583
S-1497	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-1497	ADVATE has no influence on the ability to drive and use machines .
H-1497	-0.30868831276893616	ADVATE has no effect on the ability to drive and use machines .
D-1497	-0.30868831276893616	ADVATE has no effect on the ability to drive and use machines .
P-1497	-0.1019 -0.1539 -0.0784 -0.1036 -0.3305 -0.1350 -0.9819 -0.1729 -1.2652 -0.0516 -0.2329 -0.1630 -0.8204 -0.1455 -0.2033 -0.1464 -0.1613
S-1321	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-1321	ADVATE has no influence on the ability to drive and use machines .
H-1321	-0.30868831276893616	ADVATE has no effect on the ability to drive and use machines .
D-1321	-0.30868831276893616	ADVATE has no effect on the ability to drive and use machines .
P-1321	-0.1019 -0.1539 -0.0784 -0.1036 -0.3305 -0.1350 -0.9819 -0.1729 -1.2652 -0.0516 -0.2329 -0.1630 -0.8204 -0.1455 -0.2033 -0.1464 -0.1613
S-1145	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-1145	ADVATE has no influence on the ability to drive and use machines .
H-1145	-0.30868831276893616	ADVATE has no effect on the ability to drive and use machines .
D-1145	-0.30868831276893616	ADVATE has no effect on the ability to drive and use machines .
P-1145	-0.1019 -0.1539 -0.0784 -0.1036 -0.3305 -0.1350 -0.9819 -0.1729 -1.2652 -0.0516 -0.2329 -0.1630 -0.8204 -0.1455 -0.2033 -0.1464 -0.1613
S-125	Der Zeitpunkt des Auftretens dieser Symptome variierte von einem Tag bis zu mehreren Monaten nach Therapiebeginn .
T-125	The time to onset of symptoms varied from one day to several months after starting treatment .
H-125	-0.31776586174964905	The timing of onset of these symptoms varied from one day to several months after initiation of therapy .
D-125	-0.31776586174964905	The timing of onset of these symptoms varied from one day to several months after initiation of therapy .
P-125	-0.3796 -0.0380 -0.1646 -1.5010 -0.1308 -0.1407 -0.1364 -0.1474 -0.1082 -0.1152 -0.2491 -0.1775 -0.1183 -0.1488 -0.0738 -0.1618 -0.5663 -1.2953 -0.1548 -0.3265 -0.8866 -0.1378 -0.1502
S-793	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-793	ADVATE has no influence on the ability to drive and use machines .
H-793	-0.30868831276893616	ADVATE has no effect on the ability to drive and use machines .
D-793	-0.30868831276893616	ADVATE has no effect on the ability to drive and use machines .
P-793	-0.1019 -0.1539 -0.0784 -0.1036 -0.3305 -0.1350 -0.9819 -0.1729 -1.2652 -0.0516 -0.2329 -0.1630 -0.8204 -0.1455 -0.2033 -0.1464 -0.1613
S-619	ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen .
T-619	ADVATE has no influence on the ability to drive and use machines .
H-619	-0.30868831276893616	ADVATE has no effect on the ability to drive and use machines .
D-619	-0.30868831276893616	ADVATE has no effect on the ability to drive and use machines .
P-619	-0.1019 -0.1539 -0.0784 -0.1036 -0.3305 -0.1350 -0.9819 -0.1729 -1.2652 -0.0516 -0.2329 -0.1630 -0.8204 -0.1455 -0.2033 -0.1464 -0.1613
S-1073	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-1073	The pulse rate should be determined before and during administration of ADVATE .
H-1073	-0.4092235565185547	s pulse should be measured before and during the administration of ADVATE .
D-1073	-0.4092235565185547	s pulse should be measured before and during the administration of ADVATE .
P-1073	-2.0383 -0.5528 -0.0874 -0.1053 -0.1754 -0.1230 -1.2214 -0.1388 -0.2477 -1.7154 -0.1298 -0.1400 -0.0807 -0.1385 -0.0827 -0.0908 -0.1429 -0.1552
S-1249	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-1249	The pulse rate should be determined before and during administration of ADVATE .
H-1249	-0.4092235565185547	s pulse should be measured before and during the administration of ADVATE .
D-1249	-0.4092235565185547	s pulse should be measured before and during the administration of ADVATE .
P-1249	-2.0383 -0.5528 -0.0874 -0.1053 -0.1754 -0.1230 -1.2214 -0.1388 -0.2477 -1.7154 -0.1298 -0.1400 -0.0807 -0.1385 -0.0827 -0.0908 -0.1429 -0.1552
S-901	ADVATE 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-901	ADVATE 1000 IU powder and solvent for solution for injection .
H-901	-0.30162179470062256	ADVATE 1000 IU of powder and solvents to produce a solution for injection
D-901	-0.30162179470062256	ADVATE 1000 IU of powder and solvents to produce a solution for injection
P-901	-0.0820 -0.1407 -0.0781 -0.0995 -0.0872 -0.1082 -0.0918 -0.9360 -0.1322 -0.1404 -0.0945 -0.8403 -0.0963 -1.4876 -0.7836 -0.4920 -0.1698 -0.1199 -0.1177 -0.0849 -0.1515
S-269	Hertford Road , Hoddesdon Hertfordshire EN11 9BU Vereinigtes Königreich
T-269	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
H-269	-0.16563381254673004	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
D-269	-0.16563381254673004	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
P-269	-0.2398 -0.1291 -0.2501 -0.0572 -0.1576 -0.2165 -0.1752 -0.1213 -0.2019 -0.1930 -0.1262 -0.5551 -0.0430 -0.1247 -0.1256 -0.1163 -0.1111 -0.1210 -0.1016 -0.1463
S-1077	ADVATE 1500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-1077	ADVATE 1500 IU powder and solvent for solution for injection .
H-1077	-0.28823381662368774	ADVATE 1500 IU of powder and solvents to produce a solution for injection
D-1077	-0.28823381662368774	ADVATE 1500 IU of powder and solvents to produce a solution for injection
P-1077	-0.0679 -0.1410 -0.0795 -0.1009 -0.1876 -0.1121 -0.1005 -0.6334 -0.1285 -0.1380 -0.0930 -0.7685 -0.0954 -1.5080 -0.7487 -0.5017 -0.1730 -0.1207 -0.1173 -0.0855 -0.1518
S-725	ADVATE 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-725	ADVATE 500 IU powder and solvent for solution for injection .
H-725	-0.2635447680950165	ADVATE 500 IU of powder and solvents to produce a solution for injection
D-725	-0.2635447680950165	ADVATE 500 IU of powder and solvents to produce a solution for injection
P-725	-0.0786 -0.1395 -0.0812 -0.1018 -0.0934 -0.1080 -0.0939 -0.4340 -0.1168 -0.1385 -0.0967 -0.7713 -0.0953 -1.2784 -0.7629 -0.5021 -0.1668 -0.1194 -0.1192 -0.0840 -0.1526
S-1253	ADVATE 2000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-1253	ADVATE 2000 IU powder and solvent for solution for injection .
H-1253	-0.32334527373313904	ADVATE 2000 IU of powder and solvents to produce a solution for injection
D-1253	-0.32334527373313904	ADVATE 2000 IU of powder and solvents to produce a solution for injection
P-1253	-0.0809 -0.1413 -0.0808 -0.1064 -0.1123 -0.1205 -0.0908 -1.2491 -0.1399 -0.1387 -0.0959 -0.9141 -0.0956 -1.4867 -0.7532 -0.5412 -0.1664 -0.1216 -0.1162 -0.0867 -0.1518
S-1429	ADVATE 3000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-1429	ADVATE 3000 IU powder and solvent for solution for injection .
H-1429	-0.3013446033000946	ADVATE 3000 IU of powder and solvents to produce a solution for injection
D-1429	-0.3013446033000946	ADVATE 3000 IU of powder and solvents to produce a solution for injection
P-1429	-0.0781 -0.1409 -0.0796 -0.1020 -0.0737 -0.1099 -0.0992 -1.1741 -0.1153 -0.1378 -0.0963 -0.7208 -0.0928 -1.4096 -0.7328 -0.5170 -0.1734 -0.1199 -0.1176 -0.0851 -0.1523
S-1743	Falls Ihre Blutungen mit ADVATE nicht kontrolliert werden können , wenden Sie sich umgehend an Ihren Arzt
T-1743	If your bleeding is not controlled with ADVATE , tell your doctor immediately .
H-1743	-0.20147240161895752	If your bleeding cannot be controlled with ADVATE , contact your doctor immediately
D-1743	-0.20147240161895752	If your bleeding cannot be controlled with ADVATE , contact your doctor immediately
P-1743	-0.0896 -0.2628 -0.7620 -0.2454 -0.1530 -0.1376 -0.3812 -0.2081 -0.0928 -0.1482 -0.0850 -0.0933 -0.1371 -0.3686 -0.1198 -0.0915 -0.0920 -0.1586
S-159	Colecalciferol und einige seiner aktiven Metaboliten gehen in die Muttermilch über .
T-159	Colecalciferol and some of its active metabolites pass into breast milk .
H-159	-0.2597111761569977	Colecalciferol and some of its active metabolites are released into human milk .
D-159	-0.2597111761569977	Colecalciferol and some of its active metabolites are released into human milk .
P-159	-0.1529 -0.1119 -0.2018 -0.1228 -0.1227 -0.1733 -0.1377 -0.1550 -0.1668 -0.0775 -0.0919 -0.0932 -0.0240 -0.1002 -0.2709 -2.4959 -0.3264 -0.2314 -0.1073 -0.1397 -0.1508
S-1210	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-1210	The beginning of storage at room temperature should be recorded on the product carton .
H-1210	-0.43145355582237244	The start and end of room temperature storage should be marked on the outer carton .
D-1210	-0.43145355582237244	The start and end of room temperature storage should be marked on the outer carton .
P-1210	-0.3880 -1.1687 -0.1348 -0.2654 -0.1492 -1.6924 -0.0872 -0.2879 -0.1348 -0.1734 -2.4094 -0.1217 -0.1353 -0.0020 -0.0880 -0.6115 -0.0255 -0.1698 -0.1528
S-897	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-897	The pulse rate should be determined before and during administration of ADVATE .
H-897	-0.4092235565185547	s pulse should be measured before and during the administration of ADVATE .
D-897	-0.4092235565185547	s pulse should be measured before and during the administration of ADVATE .
P-897	-2.0383 -0.5528 -0.0874 -0.1053 -0.1754 -0.1230 -1.2214 -0.1388 -0.2477 -1.7154 -0.1298 -0.1400 -0.0807 -0.1385 -0.0827 -0.0908 -0.1429 -0.1552
S-465	Hertford Road , Hoddesdon Hertfordshire EN11 9BU Vereinigtes Königreich
T-465	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
H-465	-0.16563381254673004	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
D-465	-0.16563381254673004	Hertford Road , Hoddesdon Hertfordshire EN11 9BU United Kingdom
P-465	-0.2398 -0.1291 -0.2501 -0.0572 -0.1576 -0.2165 -0.1752 -0.1213 -0.2019 -0.1930 -0.1262 -0.5551 -0.0430 -0.1247 -0.1256 -0.1163 -0.1111 -0.1210 -0.1016 -0.1463
S-721	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-721	The pulse rate should be determined before and during administration of ADVATE .
H-721	-0.4092235565185547	s pulse should be measured before and during the administration of ADVATE .
D-721	-0.4092235565185547	s pulse should be measured before and during the administration of ADVATE .
P-721	-2.0383 -0.5528 -0.0874 -0.1053 -0.1754 -0.1230 -1.2214 -0.1388 -0.2477 -1.7154 -0.1298 -0.1400 -0.0807 -0.1385 -0.0827 -0.0908 -0.1429 -0.1552
S-550	ADVATE 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung
T-550	ADVATE 250 IU powder and solvent for solution for injection
H-550	-0.2784407138824463	ADVATE 250 IU of powder and solvents to produce a solution for injection
D-550	-0.2784407138824463	ADVATE 250 IU of powder and solvents to produce a solution for injection
P-550	-0.0643 -0.1381 -0.0799 -0.1021 -0.0892 -0.1131 -0.0887 -0.5184 -0.1201 -0.1395 -0.0946 -0.9054 -0.0961 -1.3945 -0.7595 -0.5047 -0.1694 -0.1190 -0.1176 -0.0815 -0.1516
S-682	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-682	The beginning of storage at room temperature should be recorded on the product carton .
H-682	-0.43145355582237244	The start and end of room temperature storage should be marked on the outer carton .
D-682	-0.43145355582237244	The start and end of room temperature storage should be marked on the outer carton .
P-682	-0.3880 -1.1687 -0.1348 -0.2654 -0.1492 -1.6924 -0.0872 -0.2879 -0.1348 -0.1734 -2.4094 -0.1217 -0.1353 -0.0020 -0.0880 -0.6115 -0.0255 -0.1698 -0.1528
S-1471	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-1471	In case of administration by a non health care professional appropriate training is needed .
H-1471	-0.42270076274871826	If it is not to be administered by medical staff , appropriate prior training is necessary .
D-1471	-0.42270076274871826	If it is not to be administered by medical staff , appropriate prior training is necessary .
P-1471	-0.8389 -0.2565 -0.3271 -0.2024 -0.1129 -0.1717 -0.0184 -0.0856 -0.1816 -0.6826 -0.0802 -0.2380 -0.3373 -1.8904 -0.4277 -0.7995 -1.0709 -0.1566 -0.1530
S-1783	- Hautrötung , Ausschlag , Quaddelbildung , Juckreiz am ganzen Körper ,
T-1783	- rash , hives , wheals , generalised itching ,
H-1783	-0.4612872898578644	- redness , rash , wheezing , itching all over the body ,
D-1783	-0.4612872898578644	- redness , rash , wheezing , itching all over the body ,
P-1783	-0.2173 -1.7513 -0.0701 -0.1592 -0.0622 -0.0532 -0.1466 -0.3185 -2.6217 -0.6414 -0.1398 -0.6901 -0.0584 -0.9661 -0.0912 -0.3180 -0.0591 -0.2227 -0.1775
S-1798	Bitte notieren Sie den Beginn und das Ende der Raumtemperaturlagerung auf dem Umkarton .
T-1798	Please record the beginning of storage at room temperature on the product carton .
H-1798	-0.45224660634994507	Write down the start and end of room temperature storage on the outer carton .
D-1798	-0.45224660634994507	Write down the start and end of room temperature storage on the outer carton .
P-1798	-3.0323 -0.0558 -0.2943 -0.1893 -1.3264 -0.1344 -0.2602 -0.1515 -1.3964 -0.0864 -0.3031 -0.1237 -0.1460 -0.0036 -0.0776 -0.6708 -0.0305 -0.1555 -0.1547
S-548	Pulver : Durchstechflasche ( Glas ) Lösungsmittel : Durchstechflasche ( Glas )
T-548	powder : vial ( glass ) ; solvent : vial ( glass )
H-548	-0.29674574732780457	powder : vial ( glass ) Solvent : vial ( glass )
D-548	-0.29674574732780457	powder : vial ( glass ) Solvent : vial ( glass )
P-548	-1.1263 -0.1464 -0.4059 -0.0736 -0.1432 -0.0792 -0.1330 -0.8107 -1.0326 -0.1475 -0.0836 -0.0689 -0.1275 -0.0744 -0.1347 -0.1605
S-1803	Fragen Sie Ihren Apotheker wie das Arzneimittel zu entsorgen ist , wenn Sie es nicht mehr benötigen .
T-1803	Ask your pharmacist how to dispose of medicines no longer required .
H-1803	-0.39355263113975525	Ask your pharmacist how to dispose of the medicine you no longer need .
D-1803	-0.39355263113975525	Ask your pharmacist how to dispose of the medicine you no longer need .
P-1803	-0.0782 -0.0861 -0.2271 -0.0464 -0.1107 -0.0912 -0.1638 -0.0438 -0.0557 -0.3604 -1.8192 -1.6186 -1.1396 -0.0189 -0.0899 -0.5479 -0.4197 -0.1667
S-1563	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-1563	The beginning of storage at room temperature should be recorded on the product carton .
H-1563	-0.43145355582237244	The start and end of room temperature storage should be marked on the outer carton .
D-1563	-0.43145355582237244	The start and end of room temperature storage should be marked on the outer carton .
P-1563	-0.3880 -1.1687 -0.1348 -0.2654 -0.1492 -1.6924 -0.0872 -0.2879 -0.1348 -0.1734 -2.4094 -0.1217 -0.1353 -0.0020 -0.0880 -0.6115 -0.0255 -0.1698 -0.1528
S-858	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-858	The beginning of storage at room temperature should be recorded on the product carton .
H-858	-0.43145355582237244	The start and end of room temperature storage should be marked on the outer carton .
D-858	-0.43145355582237244	The start and end of room temperature storage should be marked on the outer carton .
P-858	-0.3880 -1.1687 -0.1348 -0.2654 -0.1492 -1.6924 -0.0872 -0.2879 -0.1348 -0.1734 -2.4094 -0.1217 -0.1353 -0.0020 -0.0880 -0.6115 -0.0255 -0.1698 -0.1528
S-1034	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-1034	The beginning of storage at room temperature should be recorded on the product carton .
H-1034	-0.43145355582237244	The start and end of room temperature storage should be marked on the outer carton .
D-1034	-0.43145355582237244	The start and end of room temperature storage should be marked on the outer carton .
P-1034	-0.3880 -1.1687 -0.1348 -0.2654 -0.1492 -1.6924 -0.0872 -0.2879 -0.1348 -0.1734 -2.4094 -0.1217 -0.1353 -0.0020 -0.0880 -0.6115 -0.0255 -0.1698 -0.1528
S-1393	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1393	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1393	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-1393	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-1393	-0.7892 -0.1111 -0.0836 -1.1205 -0.1449 -0.1906 -0.1386 -0.1001 -0.1594 -0.0158 -0.1101 -0.0873 -0.1480 -0.3150 -0.9386 -0.6587 -0.1325 -0.0800 -0.1389 -0.1516
S-1386	Der Beginn und das Ende der Raumtemperaturlagerung sollten auf dem Umkarton vermerkt werden .
T-1386	The beginning of storage at room temperature should be recorded on the product carton .
H-1386	-0.43145355582237244	The start and end of room temperature storage should be marked on the outer carton .
D-1386	-0.43145355582237244	The start and end of room temperature storage should be marked on the outer carton .
P-1386	-0.3880 -1.1687 -0.1348 -0.2654 -0.1492 -1.6924 -0.0872 -0.2879 -0.1348 -0.1734 -2.4094 -0.1217 -0.1353 -0.0020 -0.0880 -0.6115 -0.0255 -0.1698 -0.1528
S-347	Colecalciferol und einige seiner aktiven Metaboliten gehen in die Muttermilch über .
T-347	Colecalciferol and some of its active metabolites pass into breast milk .
H-347	-0.2597111761569977	Colecalciferol and some of its active metabolites are released into human milk .
D-347	-0.2597111761569977	Colecalciferol and some of its active metabolites are released into human milk .
P-347	-0.1529 -0.1119 -0.2018 -0.1228 -0.1227 -0.1733 -0.1377 -0.1550 -0.1668 -0.0775 -0.0919 -0.0932 -0.0240 -0.1002 -0.2709 -2.4959 -0.3264 -0.2314 -0.1073 -0.1397 -0.1508
S-1295	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-1295	In case of administration by a non health care professional appropriate training is needed .
H-1295	-0.42270076274871826	If it is not to be administered by medical staff , appropriate prior training is necessary .
D-1295	-0.42270076274871826	If it is not to be administered by medical staff , appropriate prior training is necessary .
P-1295	-0.8389 -0.2565 -0.3271 -0.2024 -0.1129 -0.1717 -0.0184 -0.0856 -0.1816 -0.6826 -0.0802 -0.2380 -0.3373 -1.8904 -0.4277 -0.7995 -1.0709 -0.1566 -0.1530
S-1660	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1660	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1660	-0.23643188178539276	Can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1660	-0.23643188178539276	Can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1660	-1.1517 -0.2030 -0.1951 -0.1070 -0.8970 -0.0984 -0.0963 -0.1510 -0.2596 -0.1261 -0.1533 -0.2505 -0.1431 -0.1311 -0.1506 -0.1831 -0.0678 -0.1690 -0.1972 -0.1388 -0.1742 -0.1573
S-1677	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1677	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1677	-0.23643188178539276	Can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1677	-0.23643188178539276	Can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1677	-1.1517 -0.2030 -0.1951 -0.1070 -0.8970 -0.0984 -0.0963 -0.1510 -0.2596 -0.1261 -0.1533 -0.2505 -0.1431 -0.1311 -0.1506 -0.1831 -0.0678 -0.1690 -0.1972 -0.1388 -0.1742 -0.1573
S-1844	29-1 LT-09129 Vilnius Tel : <unk> 370 5 269 16 91
T-1844	29-1 LT-09129 Vilnius Tel : <<unk>> 370 5 269 16 91
H-1844	-0.14593160152435303	29-1 LT-09129 Vilnius Tel : <unk> 370 5 269 16 91
D-1844	-0.14593160152435303	29-1 LT-09129 Vilnius Tel : <unk> 370 5 269 16 91
P-1844	-0.4426 -0.2591 -0.1297 -0.1299 -0.1588 -0.1495 -0.2009 -0.0918 -0.1179 -0.3073 -0.1494 -0.1415 -0.0640 -0.1392 -0.0312 -0.0567 -0.1134 -0.0504 -0.1283 -0.1221 -0.0736 -0.1530
S-1750	Schwangerschaft und Stillzeit Informieren Sie Ihren Arzt , wenn Sie schwanger sind oder stillen .
T-1750	Pregnancy and breast-feeding Tell your doctor if you are pregnant or breast-feeding .
H-1750	-0.12831149995326996	Pregnancy and breast-feeding Tell your doctor if you are pregnant or breast-feeding .
D-1750	-0.12831149995326996	Pregnancy and breast-feeding Tell your doctor if you are pregnant or breast-feeding .
P-1750	-0.1613 -0.0361 -0.2225 -0.1215 -0.0528 -0.0244 -0.0775 -0.0234 -0.7741 -0.0779 -0.1513 -0.1287 -0.1420 -0.1296 -0.1071 -0.0698 -0.1125 -0.1143 -0.0203 -0.0552 -0.0347 -0.1637 -0.1506
S-1627	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1627	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1627	-0.23643188178539276	Can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1627	-0.23643188178539276	Can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1627	-1.1517 -0.2030 -0.1951 -0.1070 -0.8970 -0.0984 -0.0963 -0.1510 -0.2596 -0.1261 -0.1533 -0.2505 -0.1431 -0.1311 -0.1506 -0.1831 -0.0678 -0.1690 -0.1972 -0.1388 -0.1742 -0.1573
S-1643	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1643	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1643	-0.23643188178539276	Can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1643	-0.23643188178539276	Can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1643	-1.1517 -0.2030 -0.1951 -0.1070 -0.8970 -0.0984 -0.0963 -0.1510 -0.2596 -0.1261 -0.1533 -0.2505 -0.1431 -0.1311 -0.1506 -0.1831 -0.0678 -0.1690 -0.1972 -0.1388 -0.1742 -0.1573
S-1781	Wie alle Arzneimittel kann ADVATE Nebenwirkungen haben , die aber nicht bei jedem auftreten müssen .
T-1781	Like all medicines , ADVATE can cause side effects , although not everybody gets them .
H-1781	-0.2253745049238205	Like all medicinal products , ADVATE can cause side effects , but not everybody gets them .
D-1781	-0.2253745049238205	Like all medicinal products , ADVATE can cause side effects , but not everybody gets them .
P-1781	-0.2560 -0.1003 -0.1213 -0.5884 -0.0700 -0.1852 -0.1768 -0.1423 -0.0997 -0.1046 -0.2570 -0.1472 -0.0590 -0.1243 -0.6314 -0.5399 -0.2240 -0.7250 -0.0398 -0.0496 -0.1628 -0.1536
S-1742	Die Entwicklung von Inhibitoren ist eine bekannte Komplikation der Hämophilie A Behandlung .
T-1742	Development of inhibitors is a known complication in the treatment of haemophilia A.
H-1742	-0.36390918493270874	Inhibitors are a known complication of the treatment of haemophilia A .
D-1742	-0.36390918493270874	Inhibitors are a known complication of the treatment of haemophilia A .
P-1742	-0.7693 -0.0420 -0.0311 -0.1115 -1.5249 -0.1692 -0.2822 -0.1459 -0.1439 -0.2267 -1.4079 -0.4752 -0.2450 -0.4782 -0.0889 -0.1358 -0.2088 -0.1832 -0.4542 -0.1542
S-1693	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1693	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1693	-0.23643188178539276	Can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1693	-0.23643188178539276	Can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1693	-1.1517 -0.2030 -0.1951 -0.1070 -0.8970 -0.0984 -0.0963 -0.1510 -0.2596 -0.1261 -0.1533 -0.2505 -0.1431 -0.1311 -0.1506 -0.1831 -0.0678 -0.1690 -0.1972 -0.1388 -0.1742 -0.1573
S-1709	Kann einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) gelagert werden .
T-1709	Can be stored at room temperature ( up to 25<<unk>> C ) for a single period up to 2 months .
H-1709	-0.23643188178539276	Can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1709	-0.23643188178539276	Can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1709	-1.1517 -0.2030 -0.1951 -0.1070 -0.8970 -0.0984 -0.0963 -0.1510 -0.2596 -0.1261 -0.1533 -0.2505 -0.1431 -0.1311 -0.1506 -0.1831 -0.0678 -0.1690 -0.1972 -0.1388 -0.1742 -0.1573
S-1425	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-1425	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden . The pulse rate should be determined before and during administration of ADVATE .
H-1425	-0.4092235565185547	s pulse should be measured before and during the administration of ADVATE .
D-1425	-0.4092235565185547	s pulse should be measured before and during the administration of ADVATE .
P-1425	-2.0383 -0.5528 -0.0874 -0.1053 -0.1754 -0.1230 -1.2214 -0.1388 -0.2477 -1.7154 -0.1298 -0.1400 -0.0807 -0.1385 -0.0827 -0.0908 -0.1429 -0.1552
S-1602	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden .
T-1602	Der Puls des Patienten sollte vor und während der Verabreichung von ADVATE gemessen werden . The pulse rate should be determined before and during administration of ADVATE .
H-1602	-0.4092235565185547	s pulse should be measured before and during the administration of ADVATE .
D-1602	-0.4092235565185547	s pulse should be measured before and during the administration of ADVATE .
P-1602	-2.0383 -0.5528 -0.0874 -0.1053 -0.1754 -0.1230 -1.2214 -0.1388 -0.2477 -1.7154 -0.1298 -0.1400 -0.0807 -0.1385 -0.0827 -0.0908 -0.1429 -0.1552
S-1748	B. Atembeschwerden und ( Beinahe<unk> -Ohnmacht benötigen eine sofortige Notfallbehandlung .
T-1748	Severe symptoms , including difficulty in breathing and ( near ) fainting , require prompt emergency treatment .
H-1748	-0.5449113249778748	breathing and ( near faintness ) need immediate emergency treatment .
D-1748	-0.5449113249778748	breathing and ( near faintness ) need immediate emergency treatment .
P-1748	-0.6445 -0.9127 -0.4097 -0.0889 -1.2772 -0.2612 -1.8810 -0.1980 -0.8672 -0.4995 -0.1327 -0.1335 -0.1709 -0.1518
S-689	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-689	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-689	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-689	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-689	-0.7892 -0.1111 -0.0836 -1.1205 -0.1449 -0.1906 -0.1386 -0.1001 -0.1594 -0.0158 -0.1101 -0.0873 -0.1480 -0.3150 -0.9386 -0.6587 -0.1325 -0.0800 -0.1389 -0.1516
S-1810	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1810	After reconstitution , the solution is clear , colourless and free from foreign particles .
H-1810	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-1810	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-1810	-0.7892 -0.1111 -0.0836 -1.1205 -0.1449 -0.1906 -0.1386 -0.1001 -0.1594 -0.0158 -0.1101 -0.0873 -0.1480 -0.3150 -0.9386 -0.6587 -0.1325 -0.0800 -0.1389 -0.1516
S-570	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-570	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-570	-0.46996167302131653	The following table 1 indicates the dosage for haemorrhage and surgery :
D-570	-0.46996167302131653	The following table 1 indicates the dosage for haemorrhage and surgery :
P-570	-0.2431 -0.1327 -0.1789 -0.2381 -3.5521 -0.1307 -1.8262 -0.3180 -0.4899 -0.1083 -0.2860 -0.1346 -0.5134 -0.0358 -0.2723 -0.1282 -0.0622 -0.1222 -0.1567
S-1041	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1041	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1041	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-1041	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-1041	-0.7892 -0.1111 -0.0836 -1.1205 -0.1449 -0.1906 -0.1386 -0.1001 -0.1594 -0.0158 -0.1101 -0.0873 -0.1480 -0.3150 -0.9386 -0.6587 -0.1325 -0.0800 -0.1389 -0.1516
S-1217	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1217	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1217	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-1217	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-1217	-0.7892 -0.1111 -0.0836 -1.1205 -0.1449 -0.1906 -0.1386 -0.1001 -0.1594 -0.0158 -0.1101 -0.0873 -0.1480 -0.3150 -0.9386 -0.6587 -0.1325 -0.0800 -0.1389 -0.1516
S-1570	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-1570	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1570	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-1570	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-1570	-0.7892 -0.1111 -0.0836 -1.1205 -0.1449 -0.1906 -0.1386 -0.1001 -0.1594 -0.0158 -0.1101 -0.0873 -0.1480 -0.3150 -0.9386 -0.6587 -0.1325 -0.0800 -0.1389 -0.1516
S-1757	Die Einnahmehäufigkeit hängt davon ab , wie gut ADVATE bei Ihnen wirkt .
T-1757	The frequency of administration will depend on how well ADVATE is working for you .
H-1757	-0.2684575319290161	The frequency depends on how well ADVATE works for you .
D-1757	-0.2684575319290161	The frequency depends on how well ADVATE works for you .
P-1757	-0.4163 -0.1188 -0.0873 -0.8584 -0.1954 -0.0782 -0.2928 -0.0464 -0.1409 -0.0819 -0.1014 -0.5726 -0.8909 -0.1107 -0.1442 -0.1590
S-865	Nach der Rekonstitution ist die Lösung klar , farblos und frei von Fremdpartikeln .
T-865	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-865	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
D-865	-0.2807318866252899	After reconstitution , the solution is clear , colourless and free of foreign particles .
P-865	-0.7892 -0.1111 -0.0836 -1.1205 -0.1449 -0.1906 -0.1386 -0.1001 -0.1594 -0.0158 -0.1101 -0.0873 -0.1480 -0.3150 -0.9386 -0.6587 -0.1325 -0.0800 -0.1389 -0.1516
S-1448	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-1448	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-1448	-0.46996167302131653	The following table 1 indicates the dosage for haemorrhage and surgery :
D-1448	-0.46996167302131653	The following table 1 indicates the dosage for haemorrhage and surgery :
P-1448	-0.2431 -0.1327 -0.1789 -0.2381 -3.5521 -0.1307 -1.8262 -0.3180 -0.4899 -0.1083 -0.2860 -0.1346 -0.5134 -0.0358 -0.2723 -0.1282 -0.0622 -0.1222 -0.1567
S-744	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-744	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-744	-0.46996167302131653	The following table 1 indicates the dosage for haemorrhage and surgery :
D-744	-0.46996167302131653	The following table 1 indicates the dosage for haemorrhage and surgery :
P-744	-0.2431 -0.1327 -0.1789 -0.2381 -3.5521 -0.1307 -1.8262 -0.3180 -0.4899 -0.1083 -0.2860 -0.1346 -0.5134 -0.0358 -0.2723 -0.1282 -0.0622 -0.1222 -0.1567
S-920	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-920	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-920	-0.46996167302131653	The following table 1 indicates the dosage for haemorrhage and surgery :
D-920	-0.46996167302131653	The following table 1 indicates the dosage for haemorrhage and surgery :
P-920	-0.2431 -0.1327 -0.1789 -0.2381 -3.5521 -0.1307 -1.8262 -0.3180 -0.4899 -0.1083 -0.2860 -0.1346 -0.5134 -0.0358 -0.2723 -0.1282 -0.0622 -0.1222 -0.1567
S-1096	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-1096	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-1096	-0.46996167302131653	The following table 1 indicates the dosage for haemorrhage and surgery :
D-1096	-0.46996167302131653	The following table 1 indicates the dosage for haemorrhage and surgery :
P-1096	-0.2431 -0.1327 -0.1789 -0.2381 -3.5521 -0.1307 -1.8262 -0.3180 -0.4899 -0.1083 -0.2860 -0.1346 -0.5134 -0.0358 -0.2723 -0.1282 -0.0622 -0.1222 -0.1567
S-1272	Die folgende Tabelle 1 enthält Richtwerte für die Dosierung bei Blutungen und chirurgischen Eingriffen :
T-1272	The followingtable 1 can be used to guide dosing in bleeding episodes and surgery :
H-1272	-0.46996167302131653	The following table 1 indicates the dosage for haemorrhage and surgery :
D-1272	-0.46996167302131653	The following table 1 indicates the dosage for haemorrhage and surgery :
P-1272	-0.2431 -0.1327 -0.1789 -0.2381 -3.5521 -0.1307 -1.8262 -0.3180 -0.4899 -0.1083 -0.2860 -0.1346 -0.5134 -0.0358 -0.2723 -0.1282 -0.0622 -0.1222 -0.1567
S-1434	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-1434	0.45 mmol sodium ( 10 mg ) per vial .
H-1434	-0.1744958609342575	0.45 mmol Sodium chloride ( 10 mg ) per vial .
D-1434	-0.1744958609342575	0.45 mmol Sodium chloride ( 10 mg ) per vial .
P-1434	-0.3105 -0.1376 -0.1450 -0.1664 -0.1161 -1.1351 -0.0655 -0.1143 -0.1074 -0.0961 -0.0886 -0.1379 -0.1552 -0.0450 -0.1344 -0.0946 -0.0521 -0.0701 -0.1683 -0.1496
S-1119	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-1119	In case of administration by a non health care professional appropriate training is needed .
H-1119	-0.42270076274871826	If it is not to be administered by medical staff , appropriate prior training is necessary .
D-1119	-0.42270076274871826	If it is not to be administered by medical staff , appropriate prior training is necessary .
P-1119	-0.8389 -0.2565 -0.3271 -0.2024 -0.1129 -0.1717 -0.0184 -0.0856 -0.1816 -0.6826 -0.0802 -0.2380 -0.3373 -1.8904 -0.4277 -0.7995 -1.0709 -0.1566 -0.1530
S-1258	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-1258	0.45 mmol sodium ( 10 mg ) per vial .
H-1258	-0.1744958609342575	0.45 mmol Sodium chloride ( 10 mg ) per vial .
D-1258	-0.1744958609342575	0.45 mmol Sodium chloride ( 10 mg ) per vial .
P-1258	-0.3105 -0.1376 -0.1450 -0.1664 -0.1161 -1.1351 -0.0655 -0.1143 -0.1074 -0.0961 -0.0886 -0.1379 -0.1552 -0.0450 -0.1344 -0.0946 -0.0521 -0.0701 -0.1683 -0.1496
S-1710	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1710	Store in the original package in order to protect from light .
H-1710	-0.41935914754867554	Keep the container in the original package to protect from light .
D-1710	-0.41935914754867554	Keep the container in the original package to protect from light .
P-1710	-0.7638 -0.1918 -1.9892 -0.1267 -0.7948 -0.1255 -0.2363 -0.4216 -0.1413 -0.1483 -0.1359 -0.1497 -0.2269
S-14	Die Behandlung mit Adenuric darf nicht abgesetzt werden , wenn ein Gichtanfall auftritt .
T-14	Adenuric treatment should not be stopped if an attack happens .
H-14	-0.42837288975715637	Adenuric treatment should not be discontinued if an attack of gout occurs .
D-14	-0.42837288975715637	Adenuric treatment should not be discontinued if an attack of gout occurs .
P-14	-1.2053 -0.2162 -0.0797 -0.1061 -1.0492 -0.5294 -0.1731 -0.1550 -0.0849 -0.0553 -0.3241 -2.7081 -0.3484 -0.1517 -0.0928 -0.3774 -0.5229 -0.0859 -0.1516 -0.1505
S-1727	Nebenwirkungen bemerken , die nicht in dieser Gebrauchsinformation angegeben sind , informieren Sie bitte Ihren Arzt .
T-1727	please tell your doctor .
H-1727	-0.3202366232872009	if you experience undesirable effects not listed in this leaflet , please tell your doctor .
D-1727	-0.3202366232872009	if you experience undesirable effects not listed in this leaflet , please tell your doctor .
P-1727	-1.5510 -0.1599 -0.2782 -1.6460 -0.0890 -0.0526 -0.0742 -0.2267 -0.0997 -0.1361 -0.1108 -0.0457 -0.0349 -0.0513 -0.1245 -1.2213 -0.2899 -0.1371 -0.0940 -0.1511 -0.1511
S-1628	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1628	Store in the original package in order to protect from light .
H-1628	-0.41935914754867554	Keep the container in the original package to protect from light .
D-1628	-0.41935914754867554	Keep the container in the original package to protect from light .
P-1628	-0.7638 -0.1918 -1.9892 -0.1267 -0.7948 -0.1255 -0.2363 -0.4216 -0.1413 -0.1483 -0.1359 -0.1497 -0.2269
S-1644	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1644	Store in the original package in order to protect from light .
H-1644	-0.41935914754867554	Keep the container in the original package to protect from light .
D-1644	-0.41935914754867554	Keep the container in the original package to protect from light .
P-1644	-0.7638 -0.1918 -1.9892 -0.1267 -0.7948 -0.1255 -0.2363 -0.4216 -0.1413 -0.1483 -0.1359 -0.1497 -0.2269
S-1678	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1678	Store in the original package in order to protect from light .
H-1678	-0.41935914754867554	Keep the container in the original package to protect from light .
D-1678	-0.41935914754867554	Keep the container in the original package to protect from light .
P-1678	-0.7638 -0.1918 -1.9892 -0.1267 -0.7948 -0.1255 -0.2363 -0.4216 -0.1413 -0.1483 -0.1359 -0.1497 -0.2269
S-1694	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1694	Store in the original package in order to protect from light .
H-1694	-0.41935914754867554	Keep the container in the original package to protect from light .
D-1694	-0.41935914754867554	Keep the container in the original package to protect from light .
P-1694	-0.7638 -0.1918 -1.9892 -0.1267 -0.7948 -0.1255 -0.2363 -0.4216 -0.1413 -0.1483 -0.1359 -0.1497 -0.2269
S-1082	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-1082	0.45 mmol sodium ( 10 mg ) per vial .
H-1082	-0.1744958609342575	0.45 mmol Sodium chloride ( 10 mg ) per vial .
D-1082	-0.1744958609342575	0.45 mmol Sodium chloride ( 10 mg ) per vial .
P-1082	-0.3105 -0.1376 -0.1450 -0.1664 -0.1161 -1.1351 -0.0655 -0.1143 -0.1074 -0.0961 -0.0886 -0.1379 -0.1552 -0.0450 -0.1344 -0.0946 -0.0521 -0.0701 -0.1683 -0.1496
S-1661	Das Behältnis in der Originalverpackung aufbewahren , um den Inhalt vor Licht zu schützen .
T-1661	Store in the original package in order to protect from light .
H-1661	-0.41935914754867554	Keep the container in the original package to protect from light .
D-1661	-0.41935914754867554	Keep the container in the original package to protect from light .
P-1661	-0.7638 -0.1918 -1.9892 -0.1267 -0.7948 -0.1255 -0.2363 -0.4216 -0.1413 -0.1483 -0.1359 -0.1497 -0.2269
S-555	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-555	0.45 mmol sodium ( 10 mg ) per vial .
H-555	-0.1744958609342575	0.45 mmol Sodium chloride ( 10 mg ) per vial .
D-555	-0.1744958609342575	0.45 mmol Sodium chloride ( 10 mg ) per vial .
P-555	-0.3105 -0.1376 -0.1450 -0.1664 -0.1161 -1.1351 -0.0655 -0.1143 -0.1074 -0.0961 -0.0886 -0.1379 -0.1552 -0.0450 -0.1344 -0.0946 -0.0521 -0.0701 -0.1683 -0.1496
S-593	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-593	In case of administration by a non health care professional appropriate training is needed .
H-593	-0.42270076274871826	If it is not to be administered by medical staff , appropriate prior training is necessary .
D-593	-0.42270076274871826	If it is not to be administered by medical staff , appropriate prior training is necessary .
P-593	-0.8389 -0.2565 -0.3271 -0.2024 -0.1129 -0.1717 -0.0184 -0.0856 -0.1816 -0.6826 -0.0802 -0.2380 -0.3373 -1.8904 -0.4277 -0.7995 -1.0709 -0.1566 -0.1530
S-730	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-730	0.45 mmol sodium ( 10 mg ) per vial .
H-730	-0.1744958609342575	0.45 mmol Sodium chloride ( 10 mg ) per vial .
D-730	-0.1744958609342575	0.45 mmol Sodium chloride ( 10 mg ) per vial .
P-730	-0.3105 -0.1376 -0.1450 -0.1664 -0.1161 -1.1351 -0.0655 -0.1143 -0.1074 -0.0961 -0.0886 -0.1379 -0.1552 -0.0450 -0.1344 -0.0946 -0.0521 -0.0701 -0.1683 -0.1496
S-767	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-767	In case of administration by a non health care professional appropriate training is needed .
H-767	-0.42270076274871826	If it is not to be administered by medical staff , appropriate prior training is necessary .
D-767	-0.42270076274871826	If it is not to be administered by medical staff , appropriate prior training is necessary .
P-767	-0.8389 -0.2565 -0.3271 -0.2024 -0.1129 -0.1717 -0.0184 -0.0856 -0.1816 -0.6826 -0.0802 -0.2380 -0.3373 -1.8904 -0.4277 -0.7995 -1.0709 -0.1566 -0.1530
S-906	0,45 mmol Natriumchlorid ( 10 mg ) pro Durchstechflasche .
T-906	0.45 mmol sodium ( 10 mg ) per vial .
H-906	-0.1744958609342575	0.45 mmol Sodium chloride ( 10 mg ) per vial .
D-906	-0.1744958609342575	0.45 mmol Sodium chloride ( 10 mg ) per vial .
P-906	-0.3105 -0.1376 -0.1450 -0.1664 -0.1161 -1.1351 -0.0655 -0.1143 -0.1074 -0.0961 -0.0886 -0.1379 -0.1552 -0.0450 -0.1344 -0.0946 -0.0521 -0.0701 -0.1683 -0.1496
S-943	Wenn es nicht durch medizinisches Personal verabreicht werden soll , ist vorher ein entsprechendes Training erforderlich .
T-943	In case of administration by a non health care professional appropriate training is needed .
H-943	-0.42270076274871826	If it is not to be administered by medical staff , appropriate prior training is necessary .
D-943	-0.42270076274871826	If it is not to be administered by medical staff , appropriate prior training is necessary .
P-943	-0.8389 -0.2565 -0.3271 -0.2024 -0.1129 -0.1717 -0.0184 -0.0856 -0.1816 -0.6826 -0.0802 -0.2380 -0.3373 -1.8904 -0.4277 -0.7995 -1.0709 -0.1566 -0.1530
S-1207	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-1207	From a microbiological point of view , the product should be used immediately after reconstitution .
H-1207	-0.28610387444496155	From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-1207	-0.28610387444496155	From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-1207	-0.5703 -0.2350 -0.0774 -0.0774 -0.1801 -1.0492 -0.1490 -0.1568 -0.3244 -0.5476 -0.0682 -0.0782 -0.1535 -1.0126 -0.1118 -0.1209 -0.6312 -0.0999 -0.0758 -0.1378 -0.1510
S-1383	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-1383	From a microbiological point of view , the product should be used immediately after reconstitution .
H-1383	-0.28610387444496155	From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-1383	-0.28610387444496155	From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-1383	-0.5703 -0.2350 -0.0774 -0.0774 -0.1801 -1.0492 -0.1490 -0.1568 -0.3244 -0.5476 -0.0682 -0.0782 -0.1535 -1.0126 -0.1118 -0.1209 -0.6312 -0.0999 -0.0758 -0.1378 -0.1510
S-1560	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-1560	From a microbiological point of view , the product should be used immediately after reconstitution .
H-1560	-0.28610387444496155	From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-1560	-0.28610387444496155	From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-1560	-0.5703 -0.2350 -0.0774 -0.0774 -0.1801 -1.0492 -0.1490 -0.1568 -0.3244 -0.5476 -0.0682 -0.0782 -0.1535 -1.0126 -0.1118 -0.1209 -0.6312 -0.0999 -0.0758 -0.1378 -0.1510
S-855	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-855	From a microbiological point of view , the product should be used immediately after reconstitution .
H-855	-0.28610387444496155	From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-855	-0.28610387444496155	From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-855	-0.5703 -0.2350 -0.0774 -0.0774 -0.1801 -1.0492 -0.1490 -0.1568 -0.3244 -0.5476 -0.0682 -0.0782 -0.1535 -1.0126 -0.1118 -0.1209 -0.6312 -0.0999 -0.0758 -0.1378 -0.1510
S-1853	Advexin wurde am 23 . Oktober 2006 als Arzneimittel für seltene Leiden ausgewiesen .
T-1853	Advexin was designated as an orphan medicinal product on 23 October 2006.
H-1853	-0.35982057452201843	Advexin was designated an orphan medicinal product on 23 October 2006 .
D-1853	-0.35982057452201843	Advexin was designated an orphan medicinal product on 23 October 2006 .
P-1853	-0.8204 -0.1560 -0.1370 -0.1416 -1.4317 -0.1247 -0.7530 -0.6285 -0.4595 -0.3404 -0.7658 -0.0624 -0.0492 -0.1452 -0.1276 -0.1913 -0.2181 -0.1376 -0.1463
S-1977	Die gleichzeitige Anwendung von Sympathomimetika kann zu kritischen hypertonen Reaktionen führen .
T-1977	Concurrent administration with sympathomimetic medicines may result in critical hypertension reactions .
H-1977	-0.2753683924674988	Co-administration of sympathomimetics may lead to critical hypertonic reactions .
D-1977	-0.2753683924674988	Co-administration of sympathomimetics may lead to critical hypertonic reactions .
P-1977	-0.3842 -0.0469 -0.0394 -0.1674 -0.0326 -0.0786 -0.0682 -0.1301 -0.2105 -1.1304 -0.1450 -0.1952 -0.0297 -2.0474 -0.0575 -0.1264 -0.0464 -0.1422 -0.1537
S-4	Es ist als gelbe , kapselförmige Tabletten ( 80 und 120 mg ) erhältlich .
T-4	It is available as yellow , capsule- shaped tablets ( 80 and 120 mg ) .
H-4	-0.3624463379383087	It is available as yellow , capsule shaped tablets ( 80 and 120 mg ) .
D-4	-0.3624463379383087	It is available as yellow , capsule shaped tablets ( 80 and 120 mg ) .
P-4	-0.2553 -0.1294 -0.6519 -0.6489 -0.1133 -1.0944 -0.3217 -0.1402 -0.7568 -1.7753 -0.1492 -0.1760 -0.1391 -0.1557 -0.1497 -0.1019 -0.0624 -0.1402 -0.1348 -0.1527
S-598	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-598	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-598	-0.2052721232175827	As with all intravenous proteins , hypersensitivity reactions may occur .
D-598	-0.2052721232175827	As with all intravenous proteins , hypersensitivity reactions may occur .
P-598	-0.7027 -0.6085 -0.1253 -0.1360 -0.0855 -0.1138 -0.1113 -0.1356 -0.0744 -0.1556 -0.5874 -0.0988 -0.0281 -0.0541 -0.0483 -0.5110 -0.0397 -0.1321 -0.1521
S-1114	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-1114	Patients should be monitored for the development of factor VIII inhibitors .
H-1114	-0.21667498350143433	Patients should be monitored on a regular basis for the formation of factor VIII inhibitors .
D-1114	-0.21667498350143433	Patients should be monitored on a regular basis for the formation of factor VIII inhibitors .
P-1114	-0.0968 -0.0919 -0.1877 -0.1694 -0.3482 -0.0995 -0.8047 -0.1024 -0.0803 -0.1106 -0.1415 -0.4153 -0.2319 -0.1489 -1.0689 -0.1613 -0.1114 -0.1021 -0.0310 -0.0629 -0.1283 -0.1368 -0.1518
S-1031	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-1031	From a microbiological point of view , the product should be used immediately after reconstitution .
H-1031	-0.28610387444496155	From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-1031	-0.28610387444496155	From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-1031	-0.5703 -0.2350 -0.0774 -0.0774 -0.1801 -1.0492 -0.1490 -0.1568 -0.3244 -0.5476 -0.0682 -0.0782 -0.1535 -1.0126 -0.1118 -0.1209 -0.6312 -0.0999 -0.0758 -0.1378 -0.1510
S-948	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-948	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-948	-0.2052721232175827	As with all intravenous proteins , hypersensitivity reactions may occur .
D-948	-0.2052721232175827	As with all intravenous proteins , hypersensitivity reactions may occur .
P-948	-0.7027 -0.6085 -0.1253 -0.1360 -0.0855 -0.1138 -0.1113 -0.1356 -0.0744 -0.1556 -0.5874 -0.0988 -0.0281 -0.0541 -0.0483 -0.5110 -0.0397 -0.1321 -0.1521
S-679	Aus mikrobiologischer Sicht sollte das Produkt unmittelbar nach der Rekonstitution verbraucht werden .
T-679	From a microbiological point of view , the product should be used immediately after reconstitution .
H-679	-0.28610387444496155	From a microbiological point of view , the product should be consumed immediately after reconstitution .
D-679	-0.28610387444496155	From a microbiological point of view , the product should be consumed immediately after reconstitution .
P-679	-0.5703 -0.2350 -0.0774 -0.0774 -0.1801 -1.0492 -0.1490 -0.1568 -0.3244 -0.5476 -0.0682 -0.0782 -0.1535 -1.0126 -0.1118 -0.1209 -0.6312 -0.0999 -0.0758 -0.1378 -0.1510
S-1290	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-1290	Patients should be monitored for the development of factor VIII inhibitors .
H-1290	-0.21667498350143433	Patients should be monitored on a regular basis for the formation of factor VIII inhibitors .
D-1290	-0.21667498350143433	Patients should be monitored on a regular basis for the formation of factor VIII inhibitors .
P-1290	-0.0968 -0.0919 -0.1877 -0.1694 -0.3482 -0.0995 -0.8047 -0.1024 -0.0803 -0.1106 -0.1415 -0.4153 -0.2319 -0.1489 -1.0689 -0.1613 -0.1114 -0.1021 -0.0310 -0.0629 -0.1283 -0.1368 -0.1518
S-1466	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-1466	Patients should be monitored for the development of factor VIII inhibitors .
H-1466	-0.21667498350143433	Patients should be monitored on a regular basis for the formation of factor VIII inhibitors .
D-1466	-0.21667498350143433	Patients should be monitored on a regular basis for the formation of factor VIII inhibitors .
P-1466	-0.0968 -0.0919 -0.1877 -0.1694 -0.3482 -0.0995 -0.8047 -0.1024 -0.0803 -0.1106 -0.1415 -0.4153 -0.2319 -0.1489 -1.0689 -0.1613 -0.1114 -0.1021 -0.0310 -0.0629 -0.1283 -0.1368 -0.1518
S-762	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-762	Patients should be monitored for the development of factor VIII inhibitors .
H-762	-0.21667498350143433	Patients should be monitored on a regular basis for the formation of factor VIII inhibitors .
D-762	-0.21667498350143433	Patients should be monitored on a regular basis for the formation of factor VIII inhibitors .
P-762	-0.0968 -0.0919 -0.1877 -0.1694 -0.3482 -0.0995 -0.8047 -0.1024 -0.0803 -0.1106 -0.1415 -0.4153 -0.2319 -0.1489 -1.0689 -0.1613 -0.1114 -0.1021 -0.0310 -0.0629 -0.1283 -0.1368 -0.1518
S-938	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-938	Patients should be monitored for the development of factor VIII inhibitors .
H-938	-0.21667498350143433	Patients should be monitored on a regular basis for the formation of factor VIII inhibitors .
D-938	-0.21667498350143433	Patients should be monitored on a regular basis for the formation of factor VIII inhibitors .
P-938	-0.0968 -0.0919 -0.1877 -0.1694 -0.3482 -0.0995 -0.8047 -0.1024 -0.0803 -0.1106 -0.1415 -0.4153 -0.2319 -0.1489 -1.0689 -0.1613 -0.1114 -0.1021 -0.0310 -0.0629 -0.1283 -0.1368 -0.1518
S-1363	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-1363	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-1363	-0.529507040977478	This then releases fibrin from fibrinogen and clotting can occur .
D-1363	-0.529507040977478	This then releases fibrin from fibrinogen and clotting can occur .
P-1363	-0.9268 -1.3227 -0.4796 -0.0426 -0.1461 -0.2781 -0.1287 -0.2084 -0.3833 -1.0655 -0.2923 -0.2491 -2.2879 -0.4144 -0.0948 -0.5078 -0.9433 -0.1367 -0.1526
S-276	ADROVANCE vermindert das Risiko für Wirbel- und Hüftfrakturen .
T-276	ADROVANCE reduces the risk of vertebral and hip fractures .
H-276	-0.19184595346450806	ADROVANCE decreases the risk of vertebral and hip fractures .
D-276	-0.19184595346450806	ADROVANCE decreases the risk of vertebral and hip fractures .
P-276	-0.0413 -0.0785 -0.1224 -0.1027 -0.1615 -1.2730 -0.0624 -0.1450 -0.1068 -0.3495 -0.2208 -0.0572 -0.0413 -0.1468 -0.1599 -0.0707 -0.3146 -0.0779 -0.1477 -0.1570
S-89	ADROVANCE vermindert das Risiko für Wirbel- und Hüftfrakturen .
T-89	ADROVANCE reduces the risk of vertebral and hip fractures .
H-89	-0.19184595346450806	ADROVANCE decreases the risk of vertebral and hip fractures .
D-89	-0.19184595346450806	ADROVANCE decreases the risk of vertebral and hip fractures .
P-89	-0.0413 -0.0785 -0.1224 -0.1027 -0.1615 -1.2730 -0.0624 -0.1450 -0.1068 -0.3495 -0.2208 -0.0572 -0.0413 -0.1468 -0.1599 -0.0707 -0.3146 -0.0779 -0.1477 -0.1570
S-1799	Das Produkt darf nach der Lagerung bei Raumtemperatur nicht wieder gekühlt gelagert werden .
T-1799	The product may not be returned to refrigerated storage after storage at room temperature .
H-1799	-0.42717987298965454	Do not store the product refrigerated at room temperature after storage .
D-1799	-0.42717987298965454	Do not store the product refrigerated at room temperature after storage .
P-1799	-1.2471 -0.1400 -0.8364 -0.3286 -0.2210 -1.1062 -0.1166 -0.0707 -0.1208 -0.2821 -0.0977 -0.1395 -1.1696 -0.6597 -0.1422 -0.1567
S-1957	Deshalb ist bei der Anwendung des Kombinationspräparats bei Patienten über 60 Jahren Vorsicht geboten .
T-1957	Therefore the combination product should be used with caution in patients above 60 years of age .
H-1957	-0.26738953590393066	Caution should therefore be exercised when using the combination in patients over 60 years of age .
D-1957	-0.26738953590393066	Caution should therefore be exercised when using the combination in patients over 60 years of age .
P-1957	-1.5139 -0.0623 -0.1604 -0.1392 -0.1559 -0.2336 -0.0858 -0.1260 -0.4989 -0.3133 -0.3198 -0.1606 -0.1440 -0.1918 -0.2533 -0.3742 -0.2198 -0.1000 -0.1438 -0.1511
S-72	Die Patienten erhielten einmal pro Woche entweder ADROVANCE oder nur Alendronat .
T-72	Patients received either ADROVANCE or alendronate only once a week .
H-72	-0.2546652555465698	Patients received either ADROVANCE or alendronate once a week .
D-72	-0.2546652555465698	Patients received either ADROVANCE or alendronate once a week .
P-72	-1.2832 -0.0926 -1.0673 -0.0670 -0.0644 -0.0730 -0.1159 -0.1078 -0.1026 -0.2352 -0.2484 -0.1562 -0.1231 -0.0487 -0.3469 -0.3171 -0.1067 -0.1312 -0.1514
S-772	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-772	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-772	-0.2052721232175827	As with all intravenous proteins , hypersensitivity reactions may occur .
D-772	-0.2052721232175827	As with all intravenous proteins , hypersensitivity reactions may occur .
P-772	-0.7027 -0.6085 -0.1253 -0.1360 -0.0855 -0.1138 -0.1113 -0.1356 -0.0744 -0.1556 -0.5874 -0.0988 -0.0281 -0.0541 -0.0483 -0.5110 -0.0397 -0.1321 -0.1521
S-588	Die Patienten sollten regelmäßig auf die Bildung von Inhibitoren gegen Faktor VIII überwacht werden .
T-588	Patients should be monitored for the development of factor VIII inhibitors .
H-588	-0.21667498350143433	Patients should be monitored on a regular basis for the formation of factor VIII inhibitors .
D-588	-0.21667498350143433	Patients should be monitored on a regular basis for the formation of factor VIII inhibitors .
P-588	-0.0968 -0.0919 -0.1877 -0.1694 -0.3482 -0.0995 -0.8047 -0.1024 -0.0803 -0.1106 -0.1415 -0.4153 -0.2319 -0.1489 -1.0689 -0.1613 -0.1114 -0.1021 -0.0310 -0.0629 -0.1283 -0.1368 -0.1518
S-1124	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-1124	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-1124	-0.2052721232175827	As with all intravenous proteins , hypersensitivity reactions may occur .
D-1124	-0.2052721232175827	As with all intravenous proteins , hypersensitivity reactions may occur .
P-1124	-0.7027 -0.6085 -0.1253 -0.1360 -0.0855 -0.1138 -0.1113 -0.1356 -0.0744 -0.1556 -0.5874 -0.0988 -0.0281 -0.0541 -0.0483 -0.5110 -0.0397 -0.1321 -0.1521
S-881	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-881	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-881	-0.3524633049964905	Remove the package from BAXJECT II ( Fig . B ) .
D-881	-0.3524633049964905	Remove the package from BAXJECT II ( Fig . B ) .
P-881	-0.8192 -0.0523 -0.1136 -0.1865 -1.3422 -0.1422 -1.5084 -0.1850 -0.3377 -0.0857 -0.1056 -0.1164 -0.1345 -0.9846 -0.2111 -0.1593 -0.1329 -0.1294 -0.1447 -0.1580
S-1057	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-1057	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-1057	-0.3524633049964905	Remove the package from BAXJECT II ( Fig . B ) .
D-1057	-0.3524633049964905	Remove the package from BAXJECT II ( Fig . B ) .
P-1057	-0.8192 -0.0523 -0.1136 -0.1865 -1.3422 -0.1422 -1.5084 -0.1850 -0.3377 -0.0857 -0.1056 -0.1164 -0.1345 -0.9846 -0.2111 -0.1593 -0.1329 -0.1294 -0.1447 -0.1580
S-1303	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-1303	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-1303	-0.3115515410900116	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-1303	-0.3115515410900116	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-1303	-1.2362 -0.3745 -0.1055 -0.3034 -0.2498 -0.1313 -0.0726 -1.6210 -0.1447 -0.0966 -0.0381 -0.1265 -0.1425 -0.1450 -0.2096 -0.1448 -0.1542
S-1479	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-1479	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-1479	-0.3115515410900116	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-1479	-0.3115515410900116	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-1479	-1.2362 -0.3745 -0.1055 -0.3034 -0.2498 -0.1313 -0.0726 -1.6210 -0.1447 -0.0966 -0.0381 -0.1265 -0.1425 -0.1450 -0.2096 -0.1448 -0.1542
S-705	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-705	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-705	-0.3524633049964905	Remove the package from BAXJECT II ( Fig . B ) .
D-705	-0.3524633049964905	Remove the package from BAXJECT II ( Fig . B ) .
P-705	-0.8192 -0.0523 -0.1136 -0.1865 -1.3422 -0.1422 -1.5084 -0.1850 -0.3377 -0.0857 -0.1056 -0.1164 -0.1345 -0.9846 -0.2111 -0.1593 -0.1329 -0.1294 -0.1447 -0.1580
S-951	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-951	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-951	-0.3115515410900116	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-951	-0.3115515410900116	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-951	-1.2362 -0.3745 -0.1055 -0.3034 -0.2498 -0.1313 -0.0726 -1.6210 -0.1447 -0.0966 -0.0381 -0.1265 -0.1425 -0.1450 -0.2096 -0.1448 -0.1542
S-775	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-775	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-775	-0.3115515410900116	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-775	-0.3115515410900116	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-775	-1.2362 -0.3745 -0.1055 -0.3034 -0.2498 -0.1313 -0.0726 -1.6210 -0.1447 -0.0966 -0.0381 -0.1265 -0.1425 -0.1450 -0.2096 -0.1448 -0.1542
S-1233	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-1233	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-1233	-0.3524633049964905	Remove the package from BAXJECT II ( Fig . B ) .
D-1233	-0.3524633049964905	Remove the package from BAXJECT II ( Fig . B ) .
P-1233	-0.8192 -0.0523 -0.1136 -0.1865 -1.3422 -0.1422 -1.5084 -0.1850 -0.3377 -0.0857 -0.1056 -0.1164 -0.1345 -0.9846 -0.2111 -0.1593 -0.1329 -0.1294 -0.1447 -0.1580
S-1409	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-1409	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-1409	-0.3524633049964905	Remove the package from BAXJECT II ( Fig . B ) .
D-1409	-0.3524633049964905	Remove the package from BAXJECT II ( Fig . B ) .
P-1409	-0.8192 -0.0523 -0.1136 -0.1865 -1.3422 -0.1422 -1.5084 -0.1850 -0.3377 -0.0857 -0.1056 -0.1164 -0.1345 -0.9846 -0.2111 -0.1593 -0.1329 -0.1294 -0.1447 -0.1580
S-1586	Nun die Verpackung vom BAXJECT II abnehmen ( Abb . B ) .
T-1586	Grip the package at its edge and pull the package off BAXJECT II ( Fig . b ) .
H-1586	-0.3524633049964905	Remove the package from BAXJECT II ( Fig . B ) .
D-1586	-0.3524633049964905	Remove the package from BAXJECT II ( Fig . B ) .
P-1586	-0.8192 -0.0523 -0.1136 -0.1865 -1.3422 -0.1422 -1.5084 -0.1850 -0.3377 -0.0857 -0.1056 -0.1164 -0.1345 -0.9846 -0.2111 -0.1593 -0.1329 -0.1294 -0.1447 -0.1580
S-1127	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-1127	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-1127	-0.3115515410900116	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-1127	-0.3115515410900116	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-1127	-1.2362 -0.3745 -0.1055 -0.3034 -0.2498 -0.1313 -0.0726 -1.6210 -0.1447 -0.0966 -0.0381 -0.1265 -0.1425 -0.1450 -0.2096 -0.1448 -0.1542
S-1300	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-1300	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-1300	-0.2052721232175827	As with all intravenous proteins , hypersensitivity reactions may occur .
D-1300	-0.2052721232175827	As with all intravenous proteins , hypersensitivity reactions may occur .
P-1300	-0.7027 -0.6085 -0.1253 -0.1360 -0.0855 -0.1138 -0.1113 -0.1356 -0.0744 -0.1556 -0.5874 -0.0988 -0.0281 -0.0541 -0.0483 -0.5110 -0.0397 -0.1321 -0.1521
S-1011	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-1011	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-1011	-0.529507040977478	This then releases fibrin from fibrinogen and clotting can occur .
D-1011	-0.529507040977478	This then releases fibrin from fibrinogen and clotting can occur .
P-1011	-0.9268 -1.3227 -0.4796 -0.0426 -0.1461 -0.2781 -0.1287 -0.2084 -0.3833 -1.0655 -0.2923 -0.2491 -2.2879 -0.4144 -0.0948 -0.5078 -0.9433 -0.1367 -0.1526
S-1187	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-1187	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-1187	-0.529507040977478	This then releases fibrin from fibrinogen and clotting can occur .
D-1187	-0.529507040977478	This then releases fibrin from fibrinogen and clotting can occur .
P-1187	-0.9268 -1.3227 -0.4796 -0.0426 -0.1461 -0.2781 -0.1287 -0.2084 -0.3833 -1.0655 -0.2923 -0.2491 -2.2879 -0.4144 -0.0948 -0.5078 -0.9433 -0.1367 -0.1526
S-1776	Sollten Sie eine größere Menge angewendet haben , wenden Sie sich bitte schnellstmöglich an Ihren Arzt .
T-1776	If you inject more ADVATE than recommended , tell your doctor as soon as possible .
H-1776	-0.4209066927433014	If you have used more than this , contact your doctor as soon as possible .
D-1776	-0.4209066927433014	If you have used more than this , contact your doctor as soon as possible .
P-1776	-0.0950 -0.1561 -0.6634 -0.2860 -0.4684 -1.4533 -0.3347 -0.8913 -1.6730 -0.1355 -0.0939 -0.2416 -0.1202 -0.1510 -0.0958 -0.1415 -0.1547
S-660	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-660	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-660	-0.529507040977478	This then releases fibrin from fibrinogen and clotting can occur .
D-660	-0.529507040977478	This then releases fibrin from fibrinogen and clotting can occur .
P-660	-0.9268 -1.3227 -0.4796 -0.0426 -0.1461 -0.2781 -0.1287 -0.2084 -0.3833 -1.0655 -0.2923 -0.2491 -2.2879 -0.4144 -0.0948 -0.5078 -0.9433 -0.1367 -0.1526
S-835	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-835	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-835	-0.529507040977478	This then releases fibrin from fibrinogen and clotting can occur .
D-835	-0.529507040977478	This then releases fibrin from fibrinogen and clotting can occur .
P-835	-0.9268 -1.3227 -0.4796 -0.0426 -0.1461 -0.2781 -0.1287 -0.2084 -0.3833 -1.0655 -0.2923 -0.2491 -2.2879 -0.4144 -0.0948 -0.5078 -0.9433 -0.1367 -0.1526
S-1476	Wie bei allen intravenösen Proteinen können allergische Überempfindlichkeitsreaktionen auftreten .
T-1476	As with any intravenous protein product allergic type hypersensitivity reactions are possible .
H-1476	-0.2052721232175827	As with all intravenous proteins , hypersensitivity reactions may occur .
D-1476	-0.2052721232175827	As with all intravenous proteins , hypersensitivity reactions may occur .
P-1476	-0.7027 -0.6085 -0.1253 -0.1360 -0.0855 -0.1138 -0.1113 -0.1356 -0.0744 -0.1556 -0.5874 -0.0988 -0.0281 -0.0541 -0.0483 -0.5110 -0.0397 -0.1321 -0.1521
S-601	Wenn diese Symptome auftreten , sollen die Patienten die Behandlung sofort abbrechen und ihren Arzt kontaktieren .
T-601	If these symptoms occur , they should be advised to discontinue use of the product immediately and contact their physicians .
H-601	-0.3115515410900116	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
D-601	-0.3115515410900116	If these symptoms occur , patients should discontinue treatment immediately and contact their doctor .
P-601	-1.2362 -0.3745 -0.1055 -0.3034 -0.2498 -0.1313 -0.0726 -1.6210 -0.1447 -0.0966 -0.0381 -0.1265 -0.1425 -0.1450 -0.2096 -0.1448 -0.1542
S-1540	Dieses setzt dann Fibrin aus Fibrinogen frei und die Gerinnselbildung kann erfolgen .
T-1540	Thrombin then converts fibrinogen into fibrin and a clot can be formed .
H-1540	-0.529507040977478	This then releases fibrin from fibrinogen and clotting can occur .
D-1540	-0.529507040977478	This then releases fibrin from fibrinogen and clotting can occur .
P-1540	-0.9268 -1.3227 -0.4796 -0.0426 -0.1461 -0.2781 -0.1287 -0.2084 -0.3833 -1.0655 -0.2923 -0.2491 -2.2879 -0.4144 -0.0948 -0.5078 -0.9433 -0.1367 -0.1526
S-1918	Aerinaze linderte die Symptome wirksamer als die beiden Wirkstoffe jeweils allein .
T-1918	Aerinaze was more effective in reducing symptoms than either of the two active substances taken alone .
H-1918	-0.4041438400745392	Aerinaze relieved symptoms more effectively than the two agents alone .
D-1918	-0.4041438400745392	Aerinaze relieved symptoms more effectively than the two agents alone .
P-1918	-0.1727 -0.1215 -0.1201 -0.1460 -0.1396 -2.3652 -0.0846 -0.5413 -0.1169 -0.1759 -0.1061 -0.8874 -0.3079 -0.8972 -0.3906 -0.1435 -0.1540
S-1991	Desloratadin und Pseudoephedrin gehen in die Muttermilch über .
T-1991	Desloratadine and pseudoephedrine are both excreted in breast milk .
H-1991	-0.35148265957832336	Desloratadine and pseudoephedrine are released into human milk .
D-1991	-0.35148265957832336	Desloratadine and pseudoephedrine are released into human milk .
P-1991	-0.8677 -0.0480 -0.1101 -0.5838 -0.4423 -0.1323 -0.0988 -0.3866 -0.1626 -0.0618 -0.1025 -0.1194 -0.1200 -0.2625 -2.6631 -0.2801 -0.1832 -0.1161 -0.1379 -0.1507
S-342	Es liegen keine geeigneten Daten zur Anwendung von ADROVANCE bei schwangeren Frauen vor .
T-342	There are no adequate data from the use of ADROVANCE in pregnant women .
H-342	-0.24602895975112915	There are no adequate data on the use of ADROVANCE in pregnant women .
D-342	-0.24602895975112915	There are no adequate data on the use of ADROVANCE in pregnant women .
P-342	-0.7034 -0.2291 -0.0784 -0.9363 -0.2878 -0.6433 -0.3187 -0.1824 -0.1474 -0.0781 -0.0801 -0.1173 -0.1133 -0.1190 -0.1412 -0.0883 -0.1143 -0.1410 -0.1553
S-1833	78 sector 4 Bucure ti 041836-RO Tel . : <unk> 40-21-321 16 40
T-1833	78 sector 4 Bucure ti 041836-RO Tel . : <<unk>> 40-21-321 16 40
H-1833	-0.15711921453475952	78 sector 4 Bucure ti 041836-RO Tel . : <unk> 40-21-321 16 40
D-1833	-0.15711921453475952	78 sector 4 Bucure ti 041836-RO Tel . : <unk> 40-21-321 16 40
P-1833	-0.2081 -0.4016 -0.1217 -0.1889 -0.1286 -0.3730 -0.0562 -0.1279 -0.1301 -0.0845 -0.1212 -0.1991 -0.0534 -0.1443 -0.1371 -0.0418 -0.3199 -0.0779 -0.3208 -0.0792 -0.1299 -0.1098 -0.1102 -0.1126 -0.1501
S-1319	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-1319	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-1319	-0.36699700355529785	Therefore , in pregnancy and breast-feeding , factor VIII should only be used if there is a clear indication .
D-1319	-0.36699700355529785	Therefore , in pregnancy and breast-feeding , factor VIII should only be used if there is a clear indication .
P-1319	-1.1214 -0.0732 -0.3196 -1.2120 -0.1040 -0.1515 -0.1441 -0.0262 -0.0710 -0.0264 -0.9873 -0.7478 -0.1457 -0.1249 -0.1833 -0.1775 -0.1484 -0.1084 -1.2411 -0.9848 -0.2277 -0.4837 -0.2931 -0.0260 -0.2614 -0.1515
S-967	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-967	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-967	-0.36699700355529785	Therefore , in pregnancy and breast-feeding , factor VIII should only be used if there is a clear indication .
D-967	-0.36699700355529785	Therefore , in pregnancy and breast-feeding , factor VIII should only be used if there is a clear indication .
P-967	-1.1214 -0.0732 -0.3196 -1.2120 -0.1040 -0.1515 -0.1441 -0.0262 -0.0710 -0.0264 -0.9873 -0.7478 -0.1457 -0.1249 -0.1833 -0.1775 -0.1484 -0.1084 -1.2411 -0.9848 -0.2277 -0.4837 -0.2931 -0.0260 -0.2614 -0.1515
S-1003	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-1003	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-1003	-0.3739294409751892	symptoms of overdose with human recombinant blood clotting factor VIII are unknown .
D-1003	-0.3739294409751892	symptoms of overdose with human recombinant blood clotting factor VIII are unknown .
P-1003	-0.7366 -0.6275 -0.2378 -0.0557 -0.2272 -2.2370 -0.1096 -0.1015 -0.0802 -0.1399 -0.2303 -1.4681 -0.0385 -0.0894 -0.0823 -0.1298 -0.1265 -0.2009 -0.6354 -0.1482 -0.1503
S-1143	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-1143	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-1143	-0.36699700355529785	Therefore , in pregnancy and breast-feeding , factor VIII should only be used if there is a clear indication .
D-1143	-0.36699700355529785	Therefore , in pregnancy and breast-feeding , factor VIII should only be used if there is a clear indication .
P-1143	-1.1214 -0.0732 -0.3196 -1.2120 -0.1040 -0.1515 -0.1441 -0.0262 -0.0710 -0.0264 -0.9873 -0.7478 -0.1457 -0.1249 -0.1833 -0.1775 -0.1484 -0.1084 -1.2411 -0.9848 -0.2277 -0.4837 -0.2931 -0.0260 -0.2614 -0.1515
S-791	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-791	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-791	-0.36699700355529785	Therefore , in pregnancy and breast-feeding , factor VIII should only be used if there is a clear indication .
D-791	-0.36699700355529785	Therefore , in pregnancy and breast-feeding , factor VIII should only be used if there is a clear indication .
P-791	-1.1214 -0.0732 -0.3196 -1.2120 -0.1040 -0.1515 -0.1441 -0.0262 -0.0710 -0.0264 -0.9873 -0.7478 -0.1457 -0.1249 -0.1833 -0.1775 -0.1484 -0.1084 -1.2411 -0.9848 -0.2277 -0.4837 -0.2931 -0.0260 -0.2614 -0.1515
S-617	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-617	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-617	-0.36699700355529785	Therefore , in pregnancy and breast-feeding , factor VIII should only be used if there is a clear indication .
D-617	-0.36699700355529785	Therefore , in pregnancy and breast-feeding , factor VIII should only be used if there is a clear indication .
P-617	-1.1214 -0.0732 -0.3196 -1.2120 -0.1040 -0.1515 -0.1441 -0.0262 -0.0710 -0.0264 -0.9873 -0.7478 -0.1457 -0.1249 -0.1833 -0.1775 -0.1484 -0.1084 -1.2411 -0.9848 -0.2277 -0.4837 -0.2931 -0.0260 -0.2614 -0.1515
S-1355	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-1355	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-1355	-0.3739294409751892	symptoms of overdose with human recombinant blood clotting factor VIII are unknown .
D-1355	-0.3739294409751892	symptoms of overdose with human recombinant blood clotting factor VIII are unknown .
P-1355	-0.7366 -0.6275 -0.2378 -0.0557 -0.2272 -2.2370 -0.1096 -0.1015 -0.0802 -0.1399 -0.2303 -1.4681 -0.0385 -0.0894 -0.0823 -0.1298 -0.1265 -0.2009 -0.6354 -0.1482 -0.1503
S-1495	Deshalb sollte in der Schwangerschaft und Stillzeit Faktor VIII nur bei eindeutiger Indikationsstellung angewendet werden .
T-1495	Therefore , factor VIII should be used during pregnancy and lactation only if clearly indicated .
H-1495	-0.36699700355529785	Therefore , in pregnancy and breast-feeding , factor VIII should only be used if there is a clear indication .
D-1495	-0.36699700355529785	Therefore , in pregnancy and breast-feeding , factor VIII should only be used if there is a clear indication .
P-1495	-1.1214 -0.0732 -0.3196 -1.2120 -0.1040 -0.1515 -0.1441 -0.0262 -0.0710 -0.0264 -0.9873 -0.7478 -0.1457 -0.1249 -0.1833 -0.1775 -0.1484 -0.1084 -1.2411 -0.9848 -0.2277 -0.4837 -0.2931 -0.0260 -0.2614 -0.1515
S-1179	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-1179	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-1179	-0.3739294409751892	symptoms of overdose with human recombinant blood clotting factor VIII are unknown .
D-1179	-0.3739294409751892	symptoms of overdose with human recombinant blood clotting factor VIII are unknown .
P-1179	-0.7366 -0.6275 -0.2378 -0.0557 -0.2272 -2.2370 -0.1096 -0.1015 -0.0802 -0.1399 -0.2303 -1.4681 -0.0385 -0.0894 -0.0823 -0.1298 -0.1265 -0.2009 -0.6354 -0.1482 -0.1503
S-827	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-827	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-827	-0.3739294409751892	symptoms of overdose with human recombinant blood clotting factor VIII are unknown .
D-827	-0.3739294409751892	symptoms of overdose with human recombinant blood clotting factor VIII are unknown .
P-827	-0.7366 -0.6275 -0.2378 -0.0557 -0.2272 -2.2370 -0.1096 -0.1015 -0.0802 -0.1399 -0.2303 -1.4681 -0.0385 -0.0894 -0.0823 -0.1298 -0.1265 -0.2009 -0.6354 -0.1482 -0.1503
S-1532	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-1532	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-1532	-0.3739294409751892	symptoms of overdose with human recombinant blood clotting factor VIII are unknown .
D-1532	-0.3739294409751892	symptoms of overdose with human recombinant blood clotting factor VIII are unknown .
P-1532	-0.7366 -0.6275 -0.2378 -0.0557 -0.2272 -2.2370 -0.1096 -0.1015 -0.0802 -0.1399 -0.2303 -1.4681 -0.0385 -0.0894 -0.0823 -0.1298 -0.1265 -0.2009 -0.6354 -0.1482 -0.1503
S-653	Symptome durch Überdosierung mit rekombinantem Blutgerinnungsfaktor VIII vom Menschen sind nicht bekannt .
T-653	No symptoms of overdose with recombinant coagulation factor VIII have been reported .
H-653	-0.3739294409751892	symptoms of overdose with human recombinant blood clotting factor VIII are unknown .
D-653	-0.3739294409751892	symptoms of overdose with human recombinant blood clotting factor VIII are unknown .
P-653	-0.7366 -0.6275 -0.2378 -0.0557 -0.2272 -2.2370 -0.1096 -0.1015 -0.0802 -0.1399 -0.2303 -1.4681 -0.0385 -0.0894 -0.0823 -0.1298 -0.1265 -0.2009 -0.6354 -0.1482 -0.1503
S-1274	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-1274	Factor VIII level required ( % or IU/ dl )
H-1274	-0.3245452642440796	Required factor VIII- plasma level ( % or IU/ dl )
D-1274	-0.3245452642440796	Required factor VIII- plasma level ( % or IU/ dl )
P-1274	-1.3651 -0.3891 -0.1085 -0.5754 -0.2366 -0.4006 -1.5079 -0.5178 -0.1805 -0.0540 -0.0934 -0.2685 -0.1273 -0.1381 -0.1385 -0.1348 -0.1217 -0.1280 -0.0399 -0.1356 -0.1542
S-1450	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-1450	Factor VIII level required ( % or IU/ dl )
H-1450	-0.3245452642440796	Required factor VIII- plasma level ( % or IU/ dl )
D-1450	-0.3245452642440796	Required factor VIII- plasma level ( % or IU/ dl )
P-1450	-1.3651 -0.3891 -0.1085 -0.5754 -0.2366 -0.4006 -1.5079 -0.5178 -0.1805 -0.0540 -0.0934 -0.2685 -0.1273 -0.1381 -0.1385 -0.1348 -0.1217 -0.1280 -0.0399 -0.1356 -0.1542
S-746	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-746	Factor VIII level required ( % or IU/ dl )
H-746	-0.3245452642440796	Required factor VIII- plasma level ( % or IU/ dl )
D-746	-0.3245452642440796	Required factor VIII- plasma level ( % or IU/ dl )
P-746	-1.3651 -0.3891 -0.1085 -0.5754 -0.2366 -0.4006 -1.5079 -0.5178 -0.1805 -0.0540 -0.0934 -0.2685 -0.1273 -0.1381 -0.1385 -0.1348 -0.1217 -0.1280 -0.0399 -0.1356 -0.1542
S-922	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-922	Factor VIII level required ( % or IU/ dl )
H-922	-0.3245452642440796	Required factor VIII- plasma level ( % or IU/ dl )
D-922	-0.3245452642440796	Required factor VIII- plasma level ( % or IU/ dl )
P-922	-1.3651 -0.3891 -0.1085 -0.5754 -0.2366 -0.4006 -1.5079 -0.5178 -0.1805 -0.0540 -0.0934 -0.2685 -0.1273 -0.1381 -0.1385 -0.1348 -0.1217 -0.1280 -0.0399 -0.1356 -0.1542
S-1098	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-1098	Factor VIII level required ( % or IU/ dl )
H-1098	-0.3245452642440796	Required factor VIII- plasma level ( % or IU/ dl )
D-1098	-0.3245452642440796	Required factor VIII- plasma level ( % or IU/ dl )
P-1098	-1.3651 -0.3891 -0.1085 -0.5754 -0.2366 -0.4006 -1.5079 -0.5178 -0.1805 -0.0540 -0.0934 -0.2685 -0.1273 -0.1381 -0.1385 -0.1348 -0.1217 -0.1280 -0.0399 -0.1356 -0.1542
S-1648	ADVATE 500 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1648	ADVATE 500 IU powder for solution for injection Octocog alfa IV use
H-1648	-0.3191482424736023	ADVATE 500 IU of powder for preparation of a solution for injection .
D-1648	-0.3191482424736023	ADVATE 500 IU of powder for preparation of a solution for injection .
P-1648	-0.0990 -0.1412 -0.0817 -0.1040 -0.1010 -0.1057 -0.0918 -0.3975 -0.0407 -0.1956 -2.5954 -0.1528 -0.5359 -0.1370 -0.1233 -0.0943 -0.0957 -0.2393 -0.7319
S-521	Ausführliche Erläuterungen zur Berechnung der Dosierungen sind der Packungsbeilage zu entnehmen .
T-521	Full details on how to calculate the doses are included in the Package Leaflet .
H-521	-0.3270619213581085	Detailed information on the calculation of doses is available in the Package Leaflet .
D-521	-0.3270619213581085	Detailed information on the calculation of doses is available in the Package Leaflet .
P-521	-0.2703 -0.0931 -1.0939 -0.1577 -2.0544 -0.0816 -0.2391 -0.0924 -0.1493 -0.2317 -0.2822 -0.4824 -0.8747 -0.2201 -0.1262 -0.0619 -0.1197 -0.1351 -0.0348 -0.1045 -0.1417 -0.1485
S-444	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden .
T-444	Circulating vitamin D3 is bound to vitamin D-binding protein .
H-444	-0.20708447694778442	Circulating vitamin D3 is bound to vitamin D-binding protein .
D-444	-0.20708447694778442	Circulating vitamin D3 is bound to vitamin D-binding protein .
P-444	-0.3816 -0.1489 -0.0997 -0.0884 -0.1193 -0.1283 -0.1318 -0.1155 -0.1776 -0.1469 -0.4747 -0.0673 -1.1823 -0.1317 -0.0445 -0.1254 -0.0605 -0.1546 -0.1555
S-1870	Die Wirkungen von Advexin wurden zunächst in Versuchsmodellen getestet , bevor sie an Menschen untersucht wurden .
T-1870	The effects of Advexin were first tested in experimental models before being studied in humans .
H-1870	-0.37217870354652405	The effects of Advexin were first tested in experimental models before being studied in humans .
D-1870	-0.37217870354652405	The effects of Advexin were first tested in experimental models before being studied in humans .
P-1870	-0.6506 -0.2683 -0.1518 -0.6207 -0.1837 -0.1370 -0.2172 -0.8527 -0.8996 -0.1351 -1.3501 -0.0789 -0.1855 -0.5068 -0.4009 -0.2254 -0.1258 -0.1566 -0.1442 -0.1525
S-2000	Diese und andere unerwünschte Ereignisse , die in klinischen Prüfungen auftraten , sind in der nachfolgenden Tabelle aufgeführt .
T-2000	These and other undesirable effects reported during the clinical trials are listed in the following table .
H-2000	-0.23005588352680206	These and other adverse events that occurred in clinical trials are listed in the table below .
D-2000	-0.23005588352680206	These and other adverse events that occurred in clinical trials are listed in the table below .
P-2000	-0.4064 -0.1496 -0.1655 -0.0645 -0.0403 -0.0708 -1.4747 -0.1237 -0.1623 -0.1062 -0.0495 -0.2474 -0.1022 -0.1473 -0.1489 -0.5289 -0.0727 -0.1531 -0.1569
S-537	Patienten mit Hämophilie A können Antikörper ( Inhibitoren ) gegenüber Faktor VIII bilden .
T-537	Haemophilia A patients may develop antibodies ( inhibitors ) to factor VIII .
H-537	-0.27125608921051025	Patients with haemophilia A may produce antibodies ( inhibitors ) to factor VIII .
D-537	-0.27125608921051025	Patients with haemophilia A may produce antibodies ( inhibitors ) to factor VIII .
P-537	-1.2437 -0.0992 -0.1273 -0.1905 -0.0668 -0.1371 -0.1868 -0.1439 -0.1144 -1.7997 -0.0720 -0.1066 -0.1489 -0.1364 -0.0440 -0.0477 -0.1378 -0.1550 -0.2567 -0.6699 -0.1500 -0.1199 -0.2049 -0.1507
S-1729	2. Was müssen Sie vor der Anwendung von ADVATE beachten ? 3. Wie ist ADVATE anzuwenden ?
T-1729	Before you use ADVATE 3.
H-1729	-0.588245153427124	Before you start to use ADVATE , what should you take
D-1729	-0.588245153427124	Before you start to use ADVATE , what should you take
P-1729	-1.0316 -0.8971 -0.3754 -0.8630 -0.2201 -0.1016 -0.1384 -0.0815 -0.0962 -0.2017 -0.3584 -1.0392 -0.3053 -2.3783 -0.7358
S-1716	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1716	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1716	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-1716	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-1716	-0.0444 -0.1383 -0.0514 -0.0431 -0.0459 -0.0070 -0.2813 -0.0714 -0.0660 -0.0722 -0.1456 -0.1132 -0.0060 -0.1607 -0.0771 -0.0873 -0.0356 -0.1054 -0.0995 -0.0407 -0.0204 -1.4158 -0.1031 -0.1636
S-1719	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1719	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1719	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-1719	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-1719	-0.0444 -0.1383 -0.0514 -0.0431 -0.0459 -0.0070 -0.2813 -0.0714 -0.0660 -0.0722 -0.1456 -0.1132 -0.0060 -0.1607 -0.0771 -0.0873 -0.0356 -0.1054 -0.0995 -0.0407 -0.0204 -1.4158 -0.1031 -0.1636
S-1686	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1686	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1686	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-1686	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-1686	-0.0444 -0.1383 -0.0514 -0.0431 -0.0459 -0.0070 -0.2813 -0.0714 -0.0660 -0.0722 -0.1456 -0.1132 -0.0060 -0.1607 -0.0771 -0.0873 -0.0356 -0.1054 -0.0995 -0.0407 -0.0204 -1.4158 -0.1031 -0.1636
S-1699	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1699	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1699	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-1699	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-1699	-0.0444 -0.1383 -0.0514 -0.0431 -0.0459 -0.0070 -0.2813 -0.0714 -0.0660 -0.0722 -0.1456 -0.1132 -0.0060 -0.1607 -0.0771 -0.0873 -0.0356 -0.1054 -0.0995 -0.0407 -0.0204 -1.4158 -0.1031 -0.1636
S-1702	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1702	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1702	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-1702	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-1702	-0.0444 -0.1383 -0.0514 -0.0431 -0.0459 -0.0070 -0.2813 -0.0714 -0.0660 -0.0722 -0.1456 -0.1132 -0.0060 -0.1607 -0.0771 -0.0873 -0.0356 -0.1054 -0.0995 -0.0407 -0.0204 -1.4158 -0.1031 -0.1636
S-1670	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1670	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1670	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-1670	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-1670	-0.0444 -0.1383 -0.0514 -0.0431 -0.0459 -0.0070 -0.2813 -0.0714 -0.0660 -0.0722 -0.1456 -0.1132 -0.0060 -0.1607 -0.0771 -0.0873 -0.0356 -0.1054 -0.0995 -0.0407 -0.0204 -1.4158 -0.1031 -0.1636
S-1652	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1652	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1652	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-1652	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-1652	-0.0444 -0.1383 -0.0514 -0.0431 -0.0459 -0.0070 -0.2813 -0.0714 -0.0660 -0.0722 -0.1456 -0.1132 -0.0060 -0.1607 -0.0771 -0.0873 -0.0356 -0.1054 -0.0995 -0.0407 -0.0204 -1.4158 -0.1031 -0.1636
S-131	Andere mögliche Ursachen einer Osteoporose neben Östrogen-Mangel und Alter sollten in Betracht gezogen werden .
T-131	Causes of osteoporosis other than oestrogen deficiency and ageing should be considered .
H-131	-0.17540964484214783	Other possible causes of osteoporosis besides estrogen deficiency and age should be considered .
D-131	-0.17540964484214783	Other possible causes of osteoporosis besides estrogen deficiency and age should be considered .
P-131	-0.2402 -0.3534 -0.0372 -0.1557 -0.1236 -0.0730 -0.1029 -0.1351 -0.0924 -0.0824 -0.7814 -0.0975 -0.5569 -0.0621 -0.0394 -0.0526 -0.0272 -0.1403 -0.1264 -0.1945 -0.2087 -0.2879 -0.1149 -0.1478 -0.1519
S-319	Andere mögliche Ursachen einer Osteoporose neben Östrogen-Mangel und Alter sollten in Betracht gezogen werden .
T-319	Causes of osteoporosis other than oestrogen deficiency and ageing should be considered .
H-319	-0.17540964484214783	Other possible causes of osteoporosis besides estrogen deficiency and age should be considered .
D-319	-0.17540964484214783	Other possible causes of osteoporosis besides estrogen deficiency and age should be considered .
P-319	-0.2402 -0.3534 -0.0372 -0.1557 -0.1236 -0.0730 -0.1029 -0.1351 -0.0924 -0.0824 -0.7814 -0.0975 -0.5569 -0.0621 -0.0394 -0.0526 -0.0272 -0.1403 -0.1264 -0.1945 -0.2087 -0.2879 -0.1149 -0.1478 -0.1519
S-1819	Opletalova 55 CZ-110 00 Praha 1 Tel . : <unk> 420 225774111
T-1819	Opletalova 55 CZ-110 00 Praha 1 Tel . : <<unk>> 420 225774111
H-1819	-0.18117840588092804	Opletalova 55 CZ-110 00 Praha 1 Tel . : <unk> 420 225774111
D-1819	-0.18117840588092804	Opletalova 55 CZ-110 00 Praha 1 Tel . : <unk> 420 225774111
P-1819	-0.1834 -0.1186 -0.5723 -0.3213 -0.0885 -0.1288 -0.1194 -0.1458 -0.2196 -0.1346 -0.6442 -0.2777 -0.1489 -0.0584 -0.1490 -0.1369 -0.0334 -0.1626 -0.1181 -0.0989 -0.0889 -0.2215 -0.1266 -0.0826 -0.1497
S-1683	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1683	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1683	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-1683	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-1683	-0.0444 -0.1383 -0.0514 -0.0431 -0.0459 -0.0070 -0.2813 -0.0714 -0.0660 -0.0722 -0.1456 -0.1132 -0.0060 -0.1607 -0.0771 -0.0873 -0.0356 -0.1054 -0.0995 -0.0407 -0.0204 -1.4158 -0.1031 -0.1636
S-1632	ADVATE 250 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1632	ADVATE 250 IU powder for solution for injection Octocog alfa IV use
H-1632	-0.3220975697040558	ADVATE 250 IU of powder for preparation of a solution for injection .
D-1632	-0.3220975697040558	ADVATE 250 IU of powder for preparation of a solution for injection .
P-1632	-0.0922 -0.1410 -0.0811 -0.1043 -0.0919 -0.1089 -0.0894 -0.4246 -0.0414 -0.1961 -2.6309 -0.1516 -0.5553 -0.1375 -0.1231 -0.0938 -0.0932 -0.2364 -0.7272
S-1667	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1667	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1667	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-1667	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-1667	-0.0444 -0.1383 -0.0514 -0.0431 -0.0459 -0.0070 -0.2813 -0.0714 -0.0660 -0.0722 -0.1456 -0.1132 -0.0060 -0.1607 -0.0771 -0.0873 -0.0356 -0.1054 -0.0995 -0.0407 -0.0204 -1.4158 -0.1031 -0.1636
S-1959	Das Kombinationspräparat wird für die Anwendung bei Patienten mit eingeschränkter Nieren- oder Leberfunktion nicht empfohlen .
T-1959	The combination product is not recommended for use in patients with impaired renal or hepatic function .
H-1959	-0.19287778437137604	The combination preparation is not recommended for use in patients with impaired renal or hepatic impairment .
D-1959	-0.19287778437137604	The combination preparation is not recommended for use in patients with impaired renal or hepatic impairment .
P-1959	-0.7493 -0.1983 -0.6415 -0.1360 -0.1815 -0.0519 -0.1251 -0.0384 -0.1485 -0.3880 -0.1435 -0.1573 -0.3097 -0.1688 -0.1358 -0.1455 -0.2584 -0.0335 -0.0955 -0.2282 -0.0164 -0.0326 -0.1307 -0.1544 -0.1532
S-1770	Steigern Sie die Dosierung von ADVATE zur Kontrolle Ihrer Blutung nicht ohne Ihren Arzt zu befragen .
T-1770	Do not increase the total dose of ADVATE to control your bleeding without consulting your doctor .
H-1770	-0.2652905583381653	Do not increase the dosage of ADVATE to control your bleeding without asking your doctor .
D-1770	-0.2652905583381653	Do not increase the dosage of ADVATE to control your bleeding without asking your doctor .
P-1770	-0.5783 -0.1449 -0.1099 -0.1834 -0.4181 -0.0840 -0.0949 -0.1540 -0.1117 -0.1451 -0.0875 -0.0969 -0.1496 -0.3266 -0.1846 -0.6059 -0.2287 -0.1813 -1.6767 -0.1364 -0.0914 -0.1540 -0.1577
S-1682	ADVATE 1500 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1682	ADVATE 1500 IU powder for solution for injection Octocog alfa IV use
H-1682	-0.3363898694515228	ADVATE 1500 IU of powder for preparation of a solution for injection .
D-1682	-0.3363898694515228	ADVATE 1500 IU of powder for preparation of a solution for injection .
P-1682	-0.0750 -0.1431 -0.0799 -0.1029 -0.2184 -0.1105 -0.0944 -0.5205 -0.0452 -0.1790 -2.7246 -0.1526 -0.5218 -0.1386 -0.1251 -0.0935 -0.0962 -0.2391 -0.7310
S-1698	ADVATE 2000 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1698	ADVATE 2000 IU powder for solution for injection Octocog alfa IV use
H-1698	-0.35961484909057617	ADVATE 2000 IU of powder for preparation of a solution for injection .
D-1698	-0.35961484909057617	ADVATE 2000 IU of powder for preparation of a solution for injection .
P-1698	-0.0994 -0.1435 -0.0814 -0.1082 -0.1043 -0.1123 -0.0919 -1.0999 -0.0393 -0.1775 -2.6412 -0.1522 -0.5744 -0.1367 -0.1248 -0.0948 -0.0992 -0.2467 -0.7051
S-1714	ADVATE 3000 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1714	ADVATE 3000 IU powder for solution for injection Octocog alfa IV use
H-1714	-0.3387990891933441	ADVATE 3000 IU of powder for preparation of a solution for injection .
D-1714	-0.3387990891933441	ADVATE 3000 IU of powder for preparation of a solution for injection .
P-1714	-0.1136 -0.1426 -0.0811 -0.1049 -0.0774 -0.1085 -0.0965 -0.6930 -0.0417 -0.1855 -2.7259 -0.1527 -0.5289 -0.1366 -0.1246 -0.0953 -0.0965 -0.2474 -0.6845
S-1665	ADVATE 1000 I.E. Pulver zur Herstellung einer Injektionslösung . Zur i.v. Anwendung .
T-1665	ADVATE 1000 IU powder for solution for injection Octocog alfa IV use
H-1665	-0.3433806300163269	ADVATE 1000 IU of powder for preparation of a solution for injection .
D-1665	-0.3433806300163269	ADVATE 1000 IU of powder for preparation of a solution for injection .
P-1665	-0.0992 -0.1428 -0.0782 -0.1013 -0.0863 -0.1047 -0.0912 -0.8584 -0.0427 -0.1797 -2.7338 -0.1525 -0.5326 -0.1385 -0.1237 -0.0946 -0.0970 -0.2491 -0.6179
S-1649	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1649	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1649	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-1649	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-1649	-0.0444 -0.1383 -0.0514 -0.0431 -0.0459 -0.0070 -0.2813 -0.0714 -0.0660 -0.0722 -0.1456 -0.1132 -0.0060 -0.1607 -0.0771 -0.0873 -0.0356 -0.1054 -0.0995 -0.0407 -0.0204 -1.4158 -0.1031 -0.1636
S-1882	Bevor der CHMP ein Gutachten abgibt , kann er dem Unternehmen an Tag 180 etwaig verbleibende Fragen stellen .
T-1882	Following the CHMP s opinion , it usually takes around two months for the European Commission to grant a licence .
H-1882	-0.45938754081726074	Before the CHMP delivers an opinion , it may ask the company any remaining questions on Day 180 .
D-1882	-0.45938754081726074	Before the CHMP delivers an opinion , it may ask the company any remaining questions on Day 180 .
P-1882	-0.4952 -0.8308 -0.1134 -0.0390 -1.0845 -0.1202 -1.1855 -0.8899 -0.4451 -0.1135 -0.6516 -0.1390 -0.2330 -0.6349 -0.3001 -0.1111 -0.4962 -0.2349 -1.5992 -0.0491 -0.1848 -0.1555
S-1633	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1633	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1633	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-1633	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-1633	-0.0444 -0.1383 -0.0514 -0.0431 -0.0459 -0.0070 -0.2813 -0.0714 -0.0660 -0.0722 -0.1456 -0.1132 -0.0060 -0.1607 -0.0771 -0.0873 -0.0356 -0.1054 -0.0995 -0.0407 -0.0204 -1.4158 -0.1031 -0.1636
S-1636	INHALT NACH GEWICHT , VOLUMEN ODER EINHEITEN
T-1636	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
H-1636	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
D-1636	-0.1414634734392166	CONTENTS BY WEIGHT , BY VOLUME OR BY UNIT
P-1636	-0.0444 -0.1383 -0.0514 -0.0431 -0.0459 -0.0070 -0.2813 -0.0714 -0.0660 -0.0722 -0.1456 -0.1132 -0.0060 -0.1607 -0.0771 -0.0873 -0.0356 -0.1054 -0.0995 -0.0407 -0.0204 -1.4158 -0.1031 -0.1636
S-572	Erforderlicher Faktor-VIII- Plasmaspiegel ( % oder I.E.<unk> dl )
T-572	Factor VIII level required ( % or IU/ dl )
H-572	-0.3245452642440796	Required factor VIII- plasma level ( % or IU/ dl )
D-572	-0.3245452642440796	Required factor VIII- plasma level ( % or IU/ dl )
P-572	-1.3651 -0.3891 -0.1085 -0.5754 -0.2366 -0.4006 -1.5079 -0.5178 -0.1805 -0.0540 -0.0934 -0.2685 -0.1273 -0.1381 -0.1385 -0.1348 -0.1217 -0.1280 -0.0399 -0.1356 -0.1542
S-1263	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-1263	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-1263	-0.41679590940475464	Treatment must be conducted under the supervision of a physician familiar with the treatment of haemophilia .
D-1263	-0.41679590940475464	Treatment must be conducted under the supervision of a physician familiar with the treatment of haemophilia .
P-1263	-0.0613 -0.0392 -0.1119 -1.1136 -0.1464 -3.1853 -0.2579 -0.1182 -0.0786 -0.0339 -0.1574 -0.1281 -0.8482 -0.2429 -2.1850 -0.1547 -0.2048 -0.1070 -0.1371 -0.1777 -0.0685 -0.1703 -0.3951 -0.1444 -0.1523
S-1439	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-1439	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-1439	-0.41679590940475464	Treatment must be conducted under the supervision of a physician familiar with the treatment of haemophilia .
D-1439	-0.41679590940475464	Treatment must be conducted under the supervision of a physician familiar with the treatment of haemophilia .
P-1439	-0.0613 -0.0392 -0.1119 -1.1136 -0.1464 -3.1853 -0.2579 -0.1182 -0.0786 -0.0339 -0.1574 -0.1281 -0.8482 -0.2429 -2.1850 -0.1547 -0.2048 -0.1070 -0.1371 -0.1777 -0.0685 -0.1703 -0.3951 -0.1444 -0.1523
S-47	Filmtablette Zum Einnehmen Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-47	Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu ) Blister ( PVC/ Aclar/ Alu )
H-47	-0.26559728384017944	Filmtablet Oral blister ( Aclar/ PVC/ aluminium )
D-47	-0.26559728384017944	Filmtablet Oral blister ( Aclar/ PVC/ aluminium )
P-47	-0.7393 -0.0361 -0.8059 -0.7445 -0.8003 -0.1157 -0.1910 -0.1614 -0.1409 -0.2590 -0.1428 -0.1468 -0.1193 -0.1093 -0.1028 -0.1392 -0.1839 -0.0592 -0.1316 -0.1831
S-1087	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-1087	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-1087	-0.41679590940475464	Treatment must be conducted under the supervision of a physician familiar with the treatment of haemophilia .
D-1087	-0.41679590940475464	Treatment must be conducted under the supervision of a physician familiar with the treatment of haemophilia .
P-1087	-0.0613 -0.0392 -0.1119 -1.1136 -0.1464 -3.1853 -0.2579 -0.1182 -0.0786 -0.0339 -0.1574 -0.1281 -0.8482 -0.2429 -2.1850 -0.1547 -0.2048 -0.1070 -0.1371 -0.1777 -0.0685 -0.1703 -0.3951 -0.1444 -0.1523
S-911	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-911	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-911	-0.41679590940475464	Treatment must be conducted under the supervision of a physician familiar with the treatment of haemophilia .
D-911	-0.41679590940475464	Treatment must be conducted under the supervision of a physician familiar with the treatment of haemophilia .
P-911	-0.0613 -0.0392 -0.1119 -1.1136 -0.1464 -3.1853 -0.2579 -0.1182 -0.0786 -0.0339 -0.1574 -0.1281 -0.8482 -0.2429 -2.1850 -0.1547 -0.2048 -0.1070 -0.1371 -0.1777 -0.0685 -0.1703 -0.3951 -0.1444 -0.1523
S-529	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-529	The study went on to look at the number 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-529	-0.1253330409526825	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-529	-0.1253330409526825	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-529	-0.1363 -0.1161 -0.1009 -0.0724 -0.1306 -0.0628 -0.1503 -0.1071 -0.1303 -0.1262 -0.2191 -0.1304 -0.1516 -0.1184 -0.0978 -0.1121 -0.1500 -0.1210 -0.1096 -0.1504 -0.1065 -0.1221 -0.1396 -0.1464
S-560	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-560	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-560	-0.41679590940475464	Treatment must be conducted under the supervision of a physician familiar with the treatment of haemophilia .
D-560	-0.41679590940475464	Treatment must be conducted under the supervision of a physician familiar with the treatment of haemophilia .
P-560	-0.0613 -0.0392 -0.1119 -1.1136 -0.1464 -3.1853 -0.2579 -0.1182 -0.0786 -0.0339 -0.1574 -0.1281 -0.8482 -0.2429 -2.1850 -0.1547 -0.2048 -0.1070 -0.1371 -0.1777 -0.0685 -0.1703 -0.3951 -0.1444 -0.1523
S-552	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 50 I.E.<unk> ml Octocog alfa .
T-552	After reconstitution , each ml solution for injection contains approximately 50 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-552	-0.2649833559989929	After reconstitution , each ml of solution contains approximately 50 IU/ ml of Octocog alfa .
D-552	-0.2649833559989929	After reconstitution , each ml of solution contains approximately 50 IU/ ml of Octocog alfa .
P-552	-0.9643 -0.1240 -0.1157 -0.2195 -0.3662 -0.0701 -0.1525 -0.0893 -0.0713 -0.2718 -0.1377 -0.1379 -0.1344 -0.1361 -0.0869 -1.0575 -0.8344 -0.0898 -0.1503 -0.2037 -0.1062 -0.0661 -0.6251 -0.1487
S-727	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 100 I.E.<unk> ml Octocog alfa .
T-727	After reconstitution , each ml solution for injection contains approximately 100 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-727	-0.2571192979812622	After reconstitution , each ml of solution contains approximately 100 IU/ ml of Octocog alfa .
D-727	-0.2571192979812622	After reconstitution , each ml of solution contains approximately 100 IU/ ml of Octocog alfa .
P-727	-0.9365 -0.1239 -0.1162 -0.2080 -0.4133 -0.0697 -0.1527 -0.0917 -0.0721 -0.1836 -0.1241 -0.1374 -0.1325 -0.1370 -0.0871 -1.0162 -0.7847 -0.0891 -0.1507 -0.2048 -0.1053 -0.0657 -0.6204 -0.1481
S-903	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 200 I.E.<unk> ml Octocog alfa .
T-903	After reconstitution , each ml solution for injection contains approximately 200 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-903	-0.25447994470596313	After reconstitution , each ml of solution contains approximately 200 IU/ ml of Octocog alfa .
D-903	-0.25447994470596313	After reconstitution , each ml of solution contains approximately 200 IU/ ml of Octocog alfa .
P-903	-0.9303 -0.1278 -0.1155 -0.2158 -0.3859 -0.0675 -0.1520 -0.0901 -0.0726 -0.1930 -0.1180 -0.1355 -0.1337 -0.1394 -0.0878 -0.9039 -0.8309 -0.0904 -0.1505 -0.2059 -0.1053 -0.0662 -0.6418 -0.1477
S-1079	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 300 I.E.<unk> ml Octocog alfa .
T-1079	After reconstitution , each ml solution for injection contains approximately 300 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-1079	-0.24569642543792725	After reconstitution , each ml of solution contains approximately 300 IU/ ml of Octocog alfa .
D-1079	-0.24569642543792725	After reconstitution , each ml of solution contains approximately 300 IU/ ml of Octocog alfa .
P-1079	-0.9424 -0.1276 -0.1164 -0.2168 -0.3499 -0.0683 -0.1529 -0.0920 -0.0696 -0.1767 -0.0910 -0.1345 -0.1317 -0.1391 -0.0859 -0.9359 -0.8194 -0.0911 -0.1508 -0.2037 -0.1059 -0.0659 -0.4804 -0.1487
S-1255	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 400 I.E.<unk> ml Octocog alfa .
T-1255	After reconstitution , each ml solution for injection contains approximately 400 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-1255	-0.25108498334884644	After reconstitution , each ml of solution contains approximately 400 IU/ ml of Octocog alfa .
D-1255	-0.25108498334884644	After reconstitution , each ml of solution contains approximately 400 IU/ ml of Octocog alfa .
P-1255	-0.9496 -0.1284 -0.1183 -0.2165 -0.3716 -0.0673 -0.1524 -0.0914 -0.0730 -0.1900 -0.0741 -0.1316 -0.1342 -0.1377 -0.0870 -0.9235 -0.8369 -0.0900 -0.1496 -0.2051 -0.1055 -0.0648 -0.5800 -0.1476
S-1431	Nach der Rekonstitution enthält jeder ml Lösung ungefähr 600 I.E.<unk> ml Octocog alfa .
T-1431	After reconstitution , each ml solution for injection contains approximately 600 IU octocog alfa . * The potency ( International Units ) is determined using the chromogenic assay against an in-house standard that is referenced to the WHO standard .
H-1431	-0.25169092416763306	After reconstitution , each ml of solution contains approximately 600 IU/ ml of Octocog alfa .
D-1431	-0.25169092416763306	After reconstitution , each ml of solution contains approximately 600 IU/ ml of Octocog alfa .
P-1431	-0.9113 -0.1270 -0.1193 -0.2155 -0.3734 -0.0672 -0.1529 -0.0918 -0.0676 -0.1991 -0.0826 -0.1389 -0.1290 -0.1380 -0.0881 -0.9553 -0.8458 -0.0905 -0.1505 -0.2041 -0.1058 -0.0663 -0.5731 -0.1477
S-735	Die Behandlung muss unter der Überwachung eines Arztes erfolgen , der mit der Behandlung der Hämophilie vertraut ist .
T-735	Treatment should be initiated under the supervision of a physician experienced in the treatment of haemophilia .
H-735	-0.41679590940475464	Treatment must be conducted under the supervision of a physician familiar with the treatment of haemophilia .
D-735	-0.41679590940475464	Treatment must be conducted under the supervision of a physician familiar with the treatment of haemophilia .
P-735	-0.0613 -0.0392 -0.1119 -1.1136 -0.1464 -3.1853 -0.2579 -0.1182 -0.0786 -0.0339 -0.1574 -0.1281 -0.8482 -0.2429 -2.1850 -0.1547 -0.2048 -0.1070 -0.1371 -0.1777 -0.0685 -0.1703 -0.3951 -0.1444 -0.1523
S-1772	Wenn Sie selbst oder eine andere Person ADVATE verabreichen , darf dies nur nach einem entsprechenden Training geschehen .
T-1772	You or someone else might also administer ADVATE as an injection , but only after receiving adequate training .
H-1772	-0.5249991416931152	If you or someone else is administering ADVATE , this should only be done after adequate training .
D-1772	-0.5249991416931152	If you or someone else is administering ADVATE , this should only be done after adequate training .
P-1772	-0.3118 -0.2134 -0.1850 -1.8423 -0.1206 -0.8516 -1.1147 -0.3400 -0.0582 -0.1490 -0.0953 -0.0933 -0.1735 -1.3855 -1.0649 -0.3197 -0.3646 -0.8427 -0.2057 -1.4362 -0.5139 -0.2378 -0.1552
S-186	Studien zur Präklinik zeigten , dass Alendronat sich bevorzugt an den Stellen der aktiven Resorption
T-186	Preclinical studies have shown preferential localisation of alendronate to sites of active resorption .
H-186	-0.4200425446033478	Preclinical studies have shown that alendronate is preferred at sites of active absorption
D-186	-0.4200425446033478	Preclinical studies have shown that alendronate is preferred at sites of active absorption
P-186	-0.8352 -0.5879 -0.0272 -0.2529 -0.3015 -0.4064 -0.3101 -0.1180 -0.1119 -0.1569 -0.1077 -0.0544 -3.0727 -0.8557 -0.5801 -0.2977 -0.2772 -0.1014 -0.1182 -0.0779 -0.1698
S-462	In der Original-Blisterpackung aufbewahren , um den Inhalt vor Feuchtigkeit und Licht zu schützen .
T-462	Store in the original blister in order to protect from moisture and light .
H-462	-0.1779947280883789	Store in the original blister to protect from moisture and light .
D-462	-0.1779947280883789	Store in the original blister to protect from moisture and light .
P-462	-0.2169 -0.1581 -0.2340 -0.0906 -0.1888 -0.0829 -0.5740 -0.1147 -0.1295 -0.2466 -0.0686 -0.0608 -0.1577 -0.1548 -0.1625 -0.2076
S-266	In der Original-Blisterpackung aufbewahren , um den Inhalt vor Feuchtigkeit und Licht zu schützen .
T-266	Store in the original blister in order to protect from moisture and light .
H-266	-0.1779947280883789	Store in the original blister to protect from moisture and light .
D-266	-0.1779947280883789	Store in the original blister to protect from moisture and light .
P-266	-0.2169 -0.1581 -0.2340 -0.0906 -0.1888 -0.0829 -0.5740 -0.1147 -0.1295 -0.2466 -0.0686 -0.0608 -0.1577 -0.1548 -0.1625 -0.2076
S-690	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-690	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-690	-0.45182347297668457	- For reconstitution only the supplied sterilised water for injections and the
D-690	-0.45182347297668457	- For reconstitution only the supplied sterilised water for injections and the
P-690	-0.2218 -1.2539 -0.1125 -0.1288 -0.5979 -0.3267 -3.1152 -0.2590 -0.2234 -0.1305 -0.2544 -0.2091 -0.0979 -0.1333 -0.1260 -0.1384 -0.6420 -0.1621
S-536	In den zusätzlichen Studien , einschließlich der Studie mit Kindern unter sechs Jahren , wurde die Wirksamkeit von Advate bestätigt .
T-536	The additional studies confirmed Advate s effectiveness , including in children under six years of age .
H-536	-0.4065728783607483	The additional studies , including the study in children under six years of age , confirmed the efficacy of Advate .
D-536	-0.4065728783607483	The additional studies , including the study in children under six years of age , confirmed the efficacy of Advate .
P-536	-1.5739 -0.5055 -0.5067 -0.2130 -0.1132 -0.7209 -1.2879 -0.2169 -0.2426 -0.4293 -0.4819 -0.1466 -0.2765 -0.1057 -0.1533 -0.9818 -0.6711 -0.4836 -0.0505 -0.0812 -0.1397 -0.3907 -0.0919 -0.1443 -0.1558
S-535	Darüber hinaus war bei 81 % dieser Blutungsepisoden nur eine einzige Behandlung mit Advate erforderlich .
T-535	In addition , 81 % of these bleeding episodes required only a single treatment with Advate .
H-535	-0.4061114490032196	Moreover , in 81 % of these bleeding episodes , only one treatment with Advate was necessary .
D-535	-0.4061114490032196	Moreover , in 81 % of these bleeding episodes , only one treatment with Advate was necessary .
P-535	-0.9433 -0.1522 -0.5901 -0.1693 -0.1192 -0.1532 -0.2270 -1.0580 -0.3079 -0.0058 -0.6140 -0.8107 -0.6156 -0.3953 -0.6761 -0.3007 -0.0939 -0.0894 -0.9155 -0.1384 -0.1527
S-1811	Jede Packung beinhaltet des Weiteren ein Gerät zur Rekonstitution ( BAXJECTII ) .
T-1811	Each pack also contains a device for reconstitution ( BAXJECT II ) .
H-1811	-0.29364222288131714	Each carton also contains a reconstitution device ( BAXJECTII ) .
D-1811	-0.29364222288131714	Each carton also contains a reconstitution device ( BAXJECTII ) .
P-1811	-0.0462 -0.8051 -0.0599 -0.1704 -0.5307 -0.1787 -0.3143 -0.0545 -1.7557 -0.1274 -0.3236 -0.1895 -0.2908 -0.0802 -0.1334 -0.0982 -0.1323 -0.1354 -0.1527
S-1042	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-1042	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-1042	-0.45182347297668457	- For reconstitution only the supplied sterilised water for injections and the
D-1042	-0.45182347297668457	- For reconstitution only the supplied sterilised water for injections and the
P-1042	-0.2218 -1.2539 -0.1125 -0.1288 -0.5979 -0.3267 -3.1152 -0.2590 -0.2234 -0.1305 -0.2544 -0.2091 -0.0979 -0.1333 -0.1260 -0.1384 -0.6420 -0.1621
S-1218	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-1218	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-1218	-0.45182347297668457	- For reconstitution only the supplied sterilised water for injections and the
D-1218	-0.45182347297668457	- For reconstitution only the supplied sterilised water for injections and the
P-1218	-0.2218 -1.2539 -0.1125 -0.1288 -0.5979 -0.3267 -3.1152 -0.2590 -0.2234 -0.1305 -0.2544 -0.2091 -0.0979 -0.1333 -0.1260 -0.1384 -0.6420 -0.1621
S-1721	Lesen Sie die gesamte Packungsbeilage sorgfältig durch , bevor Sie mit der Anwendung dieses Arzneimittels beginnen .
T-1721	Read all of this leaflet carefully before you start using this medicine .
H-1721	-0.46298468112945557	Read all of the Package Leaflet carefully before you start to use this medicine .
D-1721	-0.46298468112945557	Read all of the Package Leaflet carefully before you start to use this medicine .
P-1721	-0.5253 -1.2056 -0.9788 -0.7071 -0.2598 -0.1399 -0.1488 -0.0210 -0.1033 -0.5018 -0.1941 -0.2479 -0.3735 -1.6585 -0.4966 -0.0946 -0.8448 -0.1408 -0.1544
S-1754	Dies muss bei Patienten , die einer natriumkontollierten Diät unterliegen , berücksichtigt werden .
T-1754	To be taken into consideration by patients on a controlled sodium diet .
H-1754	-0.756324291229248	This must be considered for patients on a sodium restricted diet .
D-1754	-0.756324291229248	This must be considered for patients on a sodium restricted diet .
P-1754	-0.2109 -1.9992 -0.1559 -1.0670 -0.9314 -0.4540 -0.2474 -0.1766 -0.1738 -0.8258 -3.9629 -0.0863 -0.1429 -0.1544
S-356	Häufig : muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen .
T-356	Musculoskeletal and connective tissue disorders :
H-356	-0.2070251852273941	Common : musculoskeletal ( bone , muscle or joint ) pain .
D-356	-0.2070251852273941	Common : musculoskeletal ( bone , muscle or joint ) pain .
P-356	-0.0650 -0.1264 -0.1520 -0.0697 -0.5547 -0.0888 -0.4262 -0.2381 -0.1223 -0.1850 -0.1550 -0.1512 -0.1517 -0.2577 -0.6116 -0.1481 -0.1092 -0.1651 -0.1556
S-168	Häufig : muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen .
T-168	Musculoskeletal and connective tissue disorders :
H-168	-0.2070251852273941	Common : musculoskeletal ( bone , muscle or joint ) pain .
D-168	-0.2070251852273941	Common : musculoskeletal ( bone , muscle or joint ) pain .
P-168	-0.0650 -0.1264 -0.1520 -0.0697 -0.5547 -0.0888 -0.4262 -0.2381 -0.1223 -0.1850 -0.1550 -0.1512 -0.1517 -0.2577 -0.6116 -0.1481 -0.1092 -0.1651 -0.1556
S-7	Wenn derartige Ablagerungen in den Gelenken entstehen und Schmerzen verursachen , spricht man von einer Gicht .
T-7	When this happens in the joints and causes pain , it is known as gout .
H-7	-0.36824482679367065	When such deposition develops in the joints and causes pain , it is called gout .
D-7	-0.36824482679367065	When such deposition develops in the joints and causes pain , it is called gout .
P-7	-0.3093 -0.9406 -1.1100 -0.7672 -1.4824 -0.1224 -0.1472 -0.1268 -0.1377 -0.0610 -0.2467 -0.3339 -0.0997 -0.1566 -0.5615 -0.1105 -0.3425 -0.0975 -0.2845 -0.1373 -0.1580
S-1911	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-1911	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-1911	-0.1253330409526825	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-1911	-0.1253330409526825	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-1911	-0.1363 -0.1161 -0.1009 -0.0724 -0.1306 -0.0628 -0.1503 -0.1071 -0.1303 -0.1262 -0.2191 -0.1304 -0.1516 -0.1184 -0.0978 -0.1121 -0.1500 -0.1210 -0.1096 -0.1504 -0.1065 -0.1221 -0.1396 -0.1464
S-866	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-866	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-866	-0.45182347297668457	- For reconstitution only the supplied sterilised water for injections and the
D-866	-0.45182347297668457	- For reconstitution only the supplied sterilised water for injections and the
P-866	-0.2218 -1.2539 -0.1125 -0.1288 -0.5979 -0.3267 -3.1152 -0.2590 -0.2234 -0.1305 -0.2544 -0.2091 -0.0979 -0.1333 -0.1260 -0.1384 -0.6420 -0.1621
S-311	Knochen- , Gelenk- und<unk> oder Muskelschmerzen wurden bei Patienten unter Bisphosphonaten berichtet .
T-311	Bone , joint , and/ or muscle pain has been reported in patients taking bisphosphonates .
H-311	-0.31534019112586975	Bone , joint and / or muscle pain have been reported in bisphosphonates patients .
D-311	-0.31534019112586975	Bone , joint and / or muscle pain have been reported in bisphosphonates patients .
P-311	-1.2723 -0.2940 -0.1619 -0.4649 -1.5520 -0.2268 -0.1005 -0.0441 -0.1013 -0.1626 -0.1478 -0.0995 -0.1898 -0.9891 -0.0266 -0.0503 -0.2096 -0.0988 -0.1253 -0.1546 -0.1503
S-123	Knochen- , Gelenk- und<unk> oder Muskelschmerzen wurden bei Patienten unter Bisphosphonaten berichtet .
T-123	Bone , joint , and/ or muscle pain has been reported in patients taking bisphosphonates .
H-123	-0.31534019112586975	Bone , joint and / or muscle pain have been reported in bisphosphonates patients .
D-123	-0.31534019112586975	Bone , joint and / or muscle pain have been reported in bisphosphonates patients .
P-123	-1.2723 -0.2940 -0.1619 -0.4649 -1.5520 -0.2268 -0.1005 -0.0441 -0.1013 -0.1626 -0.1478 -0.0995 -0.1898 -0.9891 -0.0266 -0.0503 -0.2096 -0.0988 -0.1253 -0.1546 -0.1503
S-20	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-20	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-20	-0.1253330409526825	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-20	-0.1253330409526825	7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-20	-0.1363 -0.1161 -0.1009 -0.0724 -0.1306 -0.0628 -0.1503 -0.1071 -0.1303 -0.1262 -0.2191 -0.1304 -0.1516 -0.1184 -0.0978 -0.1121 -0.1500 -0.1210 -0.1096 -0.1504 -0.1065 -0.1221 -0.1396 -0.1464
S-1972	Sportler müssen darauf hingewiesen werden , dass unter der Therapie mit Pseudoephedrin positive Dopingtests möglich sind .
T-1972	Athletes should be informed that treatment with pseudoephedrine could lead to positive doping tests .
H-1972	-0.44808685779571533	Athletes should be advised that pseudoephedrine therapy may result in positive doping tests .
D-1972	-0.44808685779571533	Athletes should be advised that pseudoephedrine therapy may result in positive doping tests .
P-1972	-0.7850 -0.1342 -0.9569 -0.1583 -1.6246 -0.1636 -0.5484 -0.6928 -0.1740 -0.0857 -0.1183 -0.1921 -0.1306 -0.0744 -0.3512 -1.5570 -0.1447 -0.6665 -0.9019 -0.0952 -0.1478 -0.1550
S-513	Advate enthält den Wirkstoff Octocog alfa ( menschlicher Gerinnungsfaktor VIII ) .
T-513	Advate contains the active substance octocog alfa ( human coagulation factor VIII ) .
H-513	-0.20342952013015747	Advate contains the active substance octocog alfa ( human coagulation factor VIII ) .
D-513	-0.20342952013015747	Advate contains the active substance octocog alfa ( human coagulation factor VIII ) .
P-513	-0.5844 -0.1061 -0.0730 -0.2183 -0.0655 -0.0641 -1.0836 -0.0898 -0.1508 -0.2544 -0.1076 -0.0663 -0.1337 -0.1378 -0.5734 -0.0602 -0.2094 -0.0416 -0.1388 -0.1094 -0.1291 -0.1325 -0.1492
S-1760	In einigen Fällen jedoch können , besonders bei jüngeren Patienten , häufigere Injektionen oder höhere Dosen erforderlich sein .
T-1760	However , in some cases , especially in younger patients , more frequent injections or higher doses may be necessary .
H-1760	-0.22184151411056519	However , in some cases , especially in younger patients , more frequent injections or higher doses may be necessary .
D-1760	-0.22184151411056519	However , in some cases , especially in younger patients , more frequent injections or higher doses may be necessary .
P-1760	-0.3765 -0.2999 -0.1269 -0.1219 -0.1813 -0.3259 -0.9752 -0.5023 -0.1037 -0.0873 -0.1509 -0.1417 -0.0914 -0.1357 -0.0428 -0.1324 -0.1641 -0.1417 -0.0971 -0.1020 -0.2148 -0.5039 -0.1531 -0.1518
S-1571	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-1571	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-1571	-0.45182347297668457	- For reconstitution only the supplied sterilised water for injections and the
D-1571	-0.45182347297668457	- For reconstitution only the supplied sterilised water for injections and the
P-1571	-0.2218 -1.2539 -0.1125 -0.1288 -0.5979 -0.3267 -3.1152 -0.2590 -0.2234 -0.1305 -0.2544 -0.2091 -0.0979 -0.1333 -0.1260 -0.1384 -0.6420 -0.1621
S-1394	- Zur Rekonstitution nur das beigepackte sterilisierte Wasser für Injektionszwecke und das
T-1394	- For reconstitution use only the sterilised water for injections and the reconstitution device
H-1394	-0.45182347297668457	- For reconstitution only the supplied sterilised water for injections and the
D-1394	-0.45182347297668457	- For reconstitution only the supplied sterilised water for injections and the
P-1394	-0.2218 -1.2539 -0.1125 -0.1288 -0.5979 -0.3267 -3.1152 -0.2590 -0.2234 -0.1305 -0.2544 -0.2091 -0.0979 -0.1333 -0.1260 -0.1384 -0.6420 -0.1621
S-449	In beiden Fällen wurde die Radioaktivität fast ausschließlich als Metaboliten der Ausgangssubstanz ausgeschieden .
T-449	In both cases , the excreted radioactivity was almost exclusively as metabolites of the parent .
H-449	-0.2642824351787567	In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
D-449	-0.2642824351787567	In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
P-449	-0.2040 -0.0802 -0.2749 -0.9180 -0.4761 -0.0892 -0.1731 -0.5812 -0.0237 -0.0908 -0.1880 -0.7880 -0.1788 -0.1843 -0.0401 -0.0877 -0.1850 -0.1363 -0.6983 -0.1337 -0.1330 -0.1498
S-409	Die zwei Behandlungsgruppen waren auch hinsichtlich der BMD-Zunahmen an anderen Skelettstellen vergleichbar .
T-409	The two treatment groups were also similar with regard to BMD increases at other skeletal sites .
H-409	-0.3244348168373108	The two treatment groups were also similar in BMD increases at other skeletal sites .
D-409	-0.3244348168373108	The two treatment groups were also similar in BMD increases at other skeletal sites .
P-409	-0.2025 -0.2183 -0.1378 -0.5242 -0.1612 -0.2054 -0.3718 -0.1807 -1.1858 -0.1601 -0.5604 -0.5021 -0.5314 -0.5729 -0.0696 -0.3108 -0.1228 -0.1845 -0.1356 -0.1509
S-253	In beiden Fällen wurde die Radioaktivität fast ausschließlich als Metaboliten der Ausgangssubstanz ausgeschieden .
T-253	In both cases , the excreted radioactivity was almost exclusively as metabolites of the parent .
H-253	-0.2642824351787567	In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
D-253	-0.2642824351787567	In both cases , radioactivity was excreted almost exclusively as metabolites of the starting substance .
P-253	-0.2040 -0.0802 -0.2749 -0.9180 -0.4761 -0.0892 -0.1731 -0.5812 -0.0237 -0.0908 -0.1880 -0.7880 -0.1788 -0.1843 -0.0401 -0.0877 -0.1850 -0.1363 -0.6983 -0.1337 -0.1330 -0.1498
S-52	Dieses Arzneimittel ist identisch mit FOSAVANCE , das bereits in der Europäischen Union zugelassen ist .
T-52	This medicine is the same as FOSAVANCE , which is already authorised in the European Union .
H-52	-0.2347213327884674	This medicinal product is identical to FOSAVANCE , which is already authorised in the European Union .
D-52	-0.2347213327884674	This medicinal product is identical to FOSAVANCE , which is already authorised in the European Union .
P-52	-0.1235 -0.5839 -0.0534 -0.0608 -0.1139 -0.5150 -0.1055 -0.1920 -0.2294 -0.0915 -0.1286 -0.1239 -0.1084 -0.1384 -0.4744 -0.2898 -0.1750 -0.9341 -0.4082 -0.1504 -0.2144 -0.1338 -0.2364 -0.2068 -0.1556 -0.1558
S-716	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-716	Connect the syringe to BAXJECT II ( Fig . d ) .
H-716	-0.38159024715423584	Connect the syringe to the BAXJECT II ( Fig.d ) .
D-716	-0.38159024715423584	Connect the syringe to the BAXJECT II ( Fig.d ) .
P-716	-1.4333 -0.0852 -0.1082 -0.1604 -0.1050 -0.0317 -0.0120 -0.1421 -0.9323 -0.2012 -0.1801 -0.3371 -0.0873 -0.1058 -0.1581 -0.4582 -2.7682 -0.5686 -0.0995 -0.1274 -0.1401 -0.1532
S-892	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-892	Connect the syringe to BAXJECT II ( Fig . d ) .
H-892	-0.38159024715423584	Connect the syringe to the BAXJECT II ( Fig.d ) .
D-892	-0.38159024715423584	Connect the syringe to the BAXJECT II ( Fig.d ) .
P-892	-1.4333 -0.0852 -0.1082 -0.1604 -0.1050 -0.0317 -0.0120 -0.1421 -0.9323 -0.2012 -0.1801 -0.3371 -0.0873 -0.1058 -0.1581 -0.4582 -2.7682 -0.5686 -0.0995 -0.1274 -0.1401 -0.1532
S-1751	Ihr Arzt wird entscheiden , ob Sie ADVATE in der Schwangerschaft und Stillzeit anwenden können .
T-1751	Your doctor will decide if ADVATE may be used during pregnancy and breast-feeding .
H-1751	-0.2088472843170166	Your doctor will decide whether you can use ADVATE in pregnancy and breast-feeding .
D-1751	-0.2088472843170166	Your doctor will decide whether you can use ADVATE in pregnancy and breast-feeding .
P-1751	-0.1629 -0.1091 -0.1614 -0.1148 -0.7991 -0.8780 -0.2507 -0.2148 -0.0563 -0.1527 -0.0971 -0.0926 -0.3735 -0.0919 -0.1592 -0.1558 -0.0271 -0.0908 -0.0242 -0.2157 -0.1580
S-1068	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-1068	Connect the syringe to BAXJECT II ( Fig . d ) .
H-1068	-0.38159024715423584	Connect the syringe to the BAXJECT II ( Fig.d ) .
D-1068	-0.38159024715423584	Connect the syringe to the BAXJECT II ( Fig.d ) .
P-1068	-1.4333 -0.0852 -0.1082 -0.1604 -0.1050 -0.0317 -0.0120 -0.1421 -0.9323 -0.2012 -0.1801 -0.3371 -0.0873 -0.1058 -0.1581 -0.4582 -2.7682 -0.5686 -0.0995 -0.1274 -0.1401 -0.1532
S-1244	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-1244	Connect the syringe to BAXJECT II ( Fig . d ) .
H-1244	-0.38159024715423584	Connect the syringe to the BAXJECT II ( Fig.d ) .
D-1244	-0.38159024715423584	Connect the syringe to the BAXJECT II ( Fig.d ) .
P-1244	-1.4333 -0.0852 -0.1082 -0.1604 -0.1050 -0.0317 -0.0120 -0.1421 -0.9323 -0.2012 -0.1801 -0.3371 -0.0873 -0.1058 -0.1581 -0.4582 -2.7682 -0.5686 -0.0995 -0.1274 -0.1401 -0.1532
S-1420	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-1420	Connect the syringe to BAXJECT II ( Fig . d ) .
H-1420	-0.38159024715423584	Connect the syringe to the BAXJECT II ( Fig.d ) .
D-1420	-0.38159024715423584	Connect the syringe to the BAXJECT II ( Fig.d ) .
P-1420	-1.4333 -0.0852 -0.1082 -0.1604 -0.1050 -0.0317 -0.0120 -0.1421 -0.9323 -0.2012 -0.1801 -0.3371 -0.0873 -0.1058 -0.1581 -0.4582 -2.7682 -0.5686 -0.0995 -0.1274 -0.1401 -0.1532
S-213	8 Behandlungsgruppen waren auch hinsichtlich der BMD-Zunahmen an anderen Skelettstellen vergleichbar .
T-213	The two treatment groups were also similar with regard to BMD increases at other skeletal sites .
H-213	-0.37940531969070435	8 treatment groups were also similar in BMD increases at other skeletal sites .
D-213	-0.37940531969070435	8 treatment groups were also similar in BMD increases at other skeletal sites .
P-213	-0.4626 -0.2509 -0.4220 -0.5300 -0.3680 -0.3716 -0.1966 -1.2616 -0.1570 -0.6446 -0.4595 -0.4570 -0.6402 -0.0692 -0.3343 -0.1234 -0.1724 -0.1376 -0.1502
S-1992	Verminderte Milchproduktion wurde von stillenden Müttern im Zusammenhang mit Pseudoephedrin berichtet .
T-1992	Decreased milk production in nursing mothers has been reported with pseudoephedrine .
H-1992	-0.41261574625968933	Decreased milk production has been reported in nursing mothers in connection with pseudoephedrine .
D-1992	-0.41261574625968933	Decreased milk production has been reported in nursing mothers in connection with pseudoephedrine .
P-1992	-1.8924 -0.0247 -0.0435 -0.0562 -0.2265 -0.2917 -0.1617 -0.0707 -1.2553 -0.5279 -0.1284 -1.2536 -1.1823 -1.1417 -0.1616 -0.1300 -0.4828 -0.1616 -0.0753 -0.1254 -0.1135 -0.1031 -0.1421 -0.1508
S-526	Es korrigiert den Faktor VIII-Mangel und ermöglicht eine vorübergehende Kontrolle der Blutungsstörung .
T-526	It corrects the factor VIII deficiency and gives temporary control of the bleeding disorder .
H-526	-0.47408413887023926	Corrects for factor VIII deficiency and allows for temporary control of the bleeding disorder .
D-526	-0.47408413887023926	Corrects for factor VIII deficiency and allows for temporary control of the bleeding disorder .
P-526	-0.6375 -0.0216 -0.2717 -0.1605 -0.7113 -0.3463 -0.4409 -1.3142 -0.0253 -0.0391 -0.1276 -0.1808 -1.5734 -0.5025 -0.7972 -0.2808 -0.1534 -0.5924 -1.9306 -0.2642 -0.2072 -0.1675 -0.1580
S-1762	Der erforderliche Faktor VIII-Spiegel hängt von der Schwere und dem Ort der Blutung ab .
T-1762	The target factor VIII levels will depend on the severity and location of the bleeding .
H-1762	-0.6265594959259033	The level required varies with the severity and site of the bleeding .
D-1762	-0.6265594959259033	The level required varies with the severity and site of the bleeding .
P-1762	-0.3732 -1.6057 -0.6456 -2.0060 -0.1317 -0.1232 -0.1393 -1.0908 -0.1055 -0.1276 -1.6567 -0.1355 -0.4633 -1.2177 -0.4830 -0.1930 -0.1537
S-1594	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-1594	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1594	-0.2692543864250183	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-1594	-0.2692543864250183	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-1594	-0.8042 -0.1146 -0.0937 -1.0668 -0.1863 -0.1823 -0.1074 -0.1466 -0.0960 -0.1565 -0.0191 -0.1100 -0.0919 -0.1504 -0.2477 -0.9410 -0.6587 -0.1137 -0.0794 -0.1387 -0.1494
S-1417	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-1417	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1417	-0.2692543864250183	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-1417	-0.2692543864250183	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-1417	-0.8042 -0.1146 -0.0937 -1.0668 -0.1863 -0.1823 -0.1074 -0.1466 -0.0960 -0.1565 -0.0191 -0.1100 -0.0919 -0.1504 -0.2477 -0.9410 -0.6587 -0.1137 -0.0794 -0.1387 -0.1494
S-1241	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-1241	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1241	-0.2692543864250183	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-1241	-0.2692543864250183	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-1241	-0.8042 -0.1146 -0.0937 -1.0668 -0.1863 -0.1823 -0.1074 -0.1466 -0.0960 -0.1565 -0.0191 -0.1100 -0.0919 -0.1504 -0.2477 -0.9410 -0.6587 -0.1137 -0.0794 -0.1387 -0.1494
S-1065	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-1065	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-1065	-0.2692543864250183	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-1065	-0.2692543864250183	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-1065	-0.8042 -0.1146 -0.0937 -1.0668 -0.1863 -0.1823 -0.1074 -0.1466 -0.0960 -0.1565 -0.0191 -0.1100 -0.0919 -0.1504 -0.2477 -0.9410 -0.6587 -0.1137 -0.0794 -0.1387 -0.1494
S-889	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-889	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-889	-0.2692543864250183	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-889	-0.2692543864250183	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-889	-0.8042 -0.1146 -0.0937 -1.0668 -0.1863 -0.1823 -0.1074 -0.1466 -0.0960 -0.1565 -0.0191 -0.1100 -0.0919 -0.1504 -0.2477 -0.9410 -0.6587 -0.1137 -0.0794 -0.1387 -0.1494
S-1960	Aerinaze darf nicht bei Kindern unter 12 Jahren angewendet werden ( siehe Abschnitt 4.2 ) .
T-1960	Aerinaze should not be used in children below the age of 12 years ( see section 4.2 ) .
H-1960	-0.2336965948343277	Do not use Aerinaze in children under 12 years of age ( see section 4.2 ) .
D-1960	-0.2336965948343277	Do not use Aerinaze in children under 12 years of age ( see section 4.2 ) .
P-1960	-1.5886 -0.1433 -0.0919 -0.1432 -0.1336 -0.1180 -0.1631 -0.1205 -0.3174 -0.1743 -0.4564 -0.1357 -0.1404 -0.2692 -0.1193 -0.1337 -0.3206 -0.1044 -0.1180 -0.1416 -0.1382 -0.1496 -0.1538
S-1597	Die Spritze an den BAXJECT II anschließen . ( Abb.d ) .
T-1597	Connect the syringe to BAXJECT II ( Fig . d ) .
H-1597	-0.38159024715423584	Connect the syringe to the BAXJECT II ( Fig.d ) .
D-1597	-0.38159024715423584	Connect the syringe to the BAXJECT II ( Fig.d ) .
P-1597	-1.4333 -0.0852 -0.1082 -0.1604 -0.1050 -0.0317 -0.0120 -0.1421 -0.9323 -0.2012 -0.1801 -0.3371 -0.0873 -0.1058 -0.1581 -0.4582 -2.7682 -0.5686 -0.0995 -0.1274 -0.1401 -0.1532
S-713	Nach der Rekonstitution sollte die Lösung klar , farblos und frei von Fremdpartikeln sein .
T-713	After reconstitution the solution should be clear , colourless and free from foreign particles .
H-713	-0.2692543864250183	After reconstitution , the solution should be clear , colourless and free of foreign particles .
D-713	-0.2692543864250183	After reconstitution , the solution should be clear , colourless and free of foreign particles .
P-713	-0.8042 -0.1146 -0.0937 -1.0668 -0.1863 -0.1823 -0.1074 -0.1466 -0.0960 -0.1565 -0.0191 -0.1100 -0.0919 -0.1504 -0.2477 -0.9410 -0.6587 -0.1137 -0.0794 -0.1387 -0.1494
S-470	Via Complutense , 140 E-28805 Alcalá de Henares Madrid , Spain
T-470	Via Complutense , 140 ES-28805 Alcalá de Henares Madrid , Spain
H-470	-0.13712969422340393	Via Complutense , 140 E-28805 Alcalá de Henares Madrid , Spain
D-470	-0.13712969422340393	Via Complutense , 140 E-28805 Alcalá de Henares Madrid , Spain
P-470	-0.1889 -0.1462 -0.3366 -0.1475 -0.0809 -0.0530 -0.1552 -0.0855 -0.1137 -0.1346 -0.0803 -0.1290 -0.0977 -0.0862 -0.1102 -0.0584 -0.1257 -0.3322 -0.1796 -0.1030 -0.1534 -0.1127 -0.1436
S-1019	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-1019	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1019	-0.1836453080177307	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery
D-1019	-0.1836453080177307	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery
P-1019	-0.0735 -0.1453 -0.2889 -0.1437 -0.1310 -0.3067 -0.1664 -0.1375 -0.0425 -0.1297 -0.1912 -0.0719 -0.1149 -0.1535 -0.1409 -0.3674 -0.1281 -0.7636 -0.1393 -0.0693 -0.1513
S-843	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-843	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-843	-0.1836453080177307	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery
D-843	-0.1836453080177307	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery
P-843	-0.0735 -0.1453 -0.2889 -0.1437 -0.1310 -0.3067 -0.1664 -0.1375 -0.0425 -0.1297 -0.1912 -0.0719 -0.1149 -0.1535 -0.1409 -0.3674 -0.1281 -0.7636 -0.1393 -0.0693 -0.1513
S-278	Angesichts des Krankheitsverlaufs bei Osteoporose ist ADROVANCE zur Langzeittherapie vorgesehen .
T-278	Due to the nature of the disease process in osteoporosis , ADROVANCE is intended for long-term use .
H-278	-0.41246384382247925	Due to the course of osteoporosis , ADROVANCE is intended for long term therapy .
D-278	-0.41246384382247925	Due to the course of osteoporosis , ADROVANCE is intended for long term therapy .
P-278	-2.5980 -0.1209 -0.1331 -0.3821 -0.2529 -0.1643 -1.1258 -0.0654 -0.0988 -0.1288 -0.0905 -0.0903 -0.3565 -0.1095 -0.0797 -0.1213 -0.1038 -0.1297 -0.4370 -1.3249 -0.5355 -0.8248 -1.0907 -0.0649 -0.1414 -0.1535
S-91	Angesichts des Krankheitsverlaufs bei Osteoporose ist ADROVANCE zur Langzeittherapie vorgesehen .
T-91	Due to the nature of the disease process in osteoporosis , ADROVANCE is intended for long-term use .
H-91	-0.41246384382247925	Due to the course of osteoporosis , ADROVANCE is intended for long term therapy .
D-91	-0.41246384382247925	Due to the course of osteoporosis , ADROVANCE is intended for long term therapy .
P-91	-2.5980 -0.1209 -0.1331 -0.3821 -0.2529 -0.1643 -1.1258 -0.0654 -0.0988 -0.1288 -0.0905 -0.0903 -0.3565 -0.1095 -0.0797 -0.1213 -0.1038 -0.1297 -0.4370 -1.3249 -0.5355 -0.8248 -1.0907 -0.0649 -0.1414 -0.1535
S-300	Es ist sehr wichtig , dass alle Dosierungsanweisungen an den Patienten weitergegeben werden und vom Patienten verstanden
T-300	It is very important that the full dosing instructions are provided to , and are understood by the patient ( see section 4.2 ) .
H-300	-0.26109716296195984	It is very important that all dosage instructions are relayed to the patient and understood by the patient
D-300	-0.26109716296195984	It is very important that all dosage instructions are relayed to the patient and understood by the patient
P-300	-0.1740 -0.1314 -0.4750 -0.0863 -0.2324 -0.1886 -0.5303 -0.6547 -0.0833 -0.5153 -0.1161 -0.6697 -0.3183 -0.1402 -0.1662 -0.0576 -0.1331 -0.4750 -0.2091 -0.1479 -0.0813 -0.1581
S-1548	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-1548	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1548	-0.1836453080177307	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery
D-1548	-0.1836453080177307	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery
P-1548	-0.0735 -0.1453 -0.2889 -0.1437 -0.1310 -0.3067 -0.1664 -0.1375 -0.0425 -0.1297 -0.1912 -0.0719 -0.1149 -0.1535 -0.1409 -0.3674 -0.1281 -0.7636 -0.1393 -0.0693 -0.1513
S-1371	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-1371	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1371	-0.1836453080177307	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery
D-1371	-0.1836453080177307	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery
P-1371	-0.0735 -0.1453 -0.2889 -0.1437 -0.1310 -0.3067 -0.1664 -0.1375 -0.0425 -0.1297 -0.1912 -0.0719 -0.1149 -0.1535 -0.1409 -0.3674 -0.1281 -0.7636 -0.1393 -0.0693 -0.1513
S-1195	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery
T-1195	AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-1195	-0.1836453080177307	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery
D-1195	-0.1836453080177307	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery
P-1195	-0.0735 -0.1453 -0.2889 -0.1437 -0.1310 -0.3067 -0.1664 -0.1375 -0.0425 -0.1297 -0.1912 -0.0719 -0.1149 -0.1535 -0.1409 -0.3674 -0.1281 -0.7636 -0.1393 -0.0693 -0.1513
S-1822	Kobaltweg 49 NL-3542 CE Utrecht Tel : <unk> 31 30 2488911
T-1822	Kobaltweg 49 NL-3542 CE Utrecht Tel : <<unk>> 31 30 2488911
H-1822	-0.16069011390209198	Cobaltweg 49 NL-3542 CE Utrecht Tel : <unk> 31 30 2488911
D-1822	-0.16069011390209198	Cobaltweg 49 NL-3542 CE Utrecht Tel : <unk> 31 30 2488911
P-1822	-1.0495 -0.1559 -0.0440 -0.0776 -0.1220 -0.1652 -0.1094 -0.1852 -0.0692 -0.0582 -0.0925 -0.0649 -0.1397 -0.0577 -0.1376 -0.0255 -0.0999 -0.1547 -0.1166 -0.3877 -0.1173 -0.1150 -0.1505
S-1838	Viale Tiziano , 25 I-00196 Roma Tel : <unk> 39 06 324911
T-1838	Viale Tiziano , 25 I-00196 Roma Tel : <<unk>> 39 06 324911
H-1838	-0.1468680500984192	Viale Tiziano , 25 I-00196 Roma Tel : <unk> 39 06 324911
D-1838	-0.1468680500984192	Viale Tiziano , 25 I-00196 Roma Tel : <unk> 39 06 324911
P-1838	-0.2301 -0.0734 -0.2342 -0.0472 -0.2350 -0.1558 -0.1276 -0.1282 -0.1478 -0.0882 -0.1860 -0.1396 -0.5088 -0.0631 -0.1399 -0.0376 -0.0768 -0.1163 -0.1294 -0.1243 -0.1243 -0.1184 -0.1459
S-293	ADROVANCE wurde bei Kindern und Jugendlichen nicht untersucht und sollte daher bei ihnen nicht angewendet werden .
T-293	ADROVANCE has not been studied in children and adolescents and therefore should not be given to them .
H-293	-0.23163065314292908	ADROVANCE has not been studied in children and adolescents and should not be used in them .
D-293	-0.23163065314292908	ADROVANCE has not been studied in children and adolescents and should not be used in them .
P-293	-0.0732 -0.0728 -0.1251 -0.1097 -0.1233 -0.1186 -0.1508 -0.0820 -0.6408 -0.1361 -0.4159 -0.1866 -0.0402 -0.0566 -0.0363 -0.1493 -0.6566 -0.9581 -0.4613 -0.1879 -0.2802 -0.1798 -0.1567 -0.1614
S-105	ADROVANCE wurde bei Kindern und Jugendlichen nicht untersucht und sollte daher bei ihnen nicht angewendet werden .
T-105	ADROVANCE has not been studied in children and adolescents and therefore should not be given to them .
H-105	-0.23163065314292908	ADROVANCE has not been studied in children and adolescents and should not be used in them .
D-105	-0.23163065314292908	ADROVANCE has not been studied in children and adolescents and should not be used in them .
P-105	-0.0732 -0.0728 -0.1251 -0.1097 -0.1233 -0.1186 -0.1508 -0.0820 -0.6408 -0.1361 -0.4159 -0.1866 -0.0402 -0.0566 -0.0363 -0.1493 -0.6566 -0.9581 -0.4613 -0.1879 -0.2802 -0.1798 -0.1567 -0.1614
S-1946	Die Dauer der Anwendung ist so kurz wie möglich zu halten und sollte nach Abklingen der Symptome nicht fortgesetzt werden .
T-1946	The duration of treatment should be kept as short as possible and should not be continued after the symptoms have disappeared .
H-1946	-0.43579092621803284	The duration of administration should be as short as possible and should not be continued after symptoms subside .
D-1946	-0.43579092621803284	The duration of administration should be as short as possible and should not be continued after symptoms subside .
P-1946	-0.4976 -0.2281 -0.1275 -0.1270 -0.7865 -0.6575 -0.2072 -0.7149 -0.8636 -0.1894 -0.0922 -0.1748 -0.1669 -0.1787 -0.1521 -0.3876 -0.6529 -1.2545 -1.7817 -0.0493 -0.1443 -0.1532
S-1813	Hersteller Baxter S.A. Boulevard René Branquart 80 B-7860 Lessines , Belgien
T-1813	Manufacturer Baxter SA Boulevard René Branquart 80 B-7860 Lessines Belgium
H-1813	-0.1817871481180191	Manufacturer Baxter S.A. Boulevard René Branquart 80 B-7860 Lessines , Belgium
D-1813	-0.1817871481180191	Manufacturer Baxter S.A. Boulevard René Branquart 80 B-7860 Lessines , Belgium
P-1813	-0.1674 -0.0566 -0.0685 -0.1044 -0.3271 -0.1242 -0.1485 -0.2667 -0.1135 -0.4985 -0.0990 -0.3701 -0.1905 -0.0929 -0.1459 -0.0942 -0.1137 -0.1066 -0.1122 -0.1310 -0.0959 -0.0735 -0.1232 -0.1529 -0.8037 -0.1458
S-61	Die Patientinnen sollen außerdem zusätzlich Calcium einnehmen , falls über die Nahrung nicht genügend aufgenommen wird .
T-61	Patients should also take calcium supplements if they are not getting enough calcium from their diet .
H-61	-0.49587708711624146	Patients should also take additional calcium if insufficient food is absorbed .
D-61	-0.49587708711624146	Patients should also take additional calcium if insufficient food is absorbed .
P-61	-0.2094 -0.0952 -0.2964 -0.0959 -0.0516 -1.6347 -0.0888 -0.0830 -0.1313 -0.2492 -1.6451 -0.9845 -1.1365 -0.2278 -1.5427 -0.0663 -0.2319 -0.1557
S-1954	Die empfohlene Dosierung und die Dauer der Behandlung dürfen nicht überschritten werden ( siehe Abschnitt 4.2 ) .
T-1954	Do not exceed the recommended dosage and the duration of treatment ( see section 4.2 ) .
H-1954	-0.2979041635990143	The recommended dosage and duration of treatment must not be exceeded ( see section 4.2 ) .
D-1954	-0.2979041635990143	The recommended dosage and duration of treatment must not be exceeded ( see section 4.2 ) .
P-1954	-0.7432 -0.1432 -0.8782 -0.0558 -0.0937 -0.1215 -1.6260 -0.1197 -0.1453 -0.0948 -1.0978 -0.1418 -0.1501 -0.0782 -0.0738 -0.1403 -0.3386 -0.1196 -0.1201 -0.1413 -0.1352 -0.1413 -0.1521
S-313	Der Zeitpunkt des Auftretens dieser Symptome variierte von einem Tag bis zu mehreren Monaten nach Therapiebeginn .
T-313	The time to onset of symptoms varied from one day to several months after starting treatment .
H-313	-0.3177315890789032	The timing of onset of these symptoms varied from one day to several months after initiation of therapy .
D-313	-0.3177315890789032	The timing of onset of these symptoms varied from one day to several months after initiation of therapy .
P-313	-0.3794 -0.0382 -0.1660 -1.4991 -0.1299 -0.1407 -0.1366 -0.1474 -0.1083 -0.1151 -0.2491 -0.1761 -0.1182 -0.1490 -0.0738 -0.1620 -0.5685 -1.2871 -0.1559 -0.3254 -0.8943 -0.1379 -0.1500
S-704	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-704	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-704	-0.43224799633026123	Rotate the opening downwards and push the transparent plastic mandrel through the rubber stopper of the solvent bottle .
D-704	-0.43224799633026123	Rotate the opening downwards and push the transparent plastic mandrel through the rubber stopper of the solvent bottle .
P-704	-2.7769 -0.1033 -0.1456 -0.2506 -0.4136 -0.3196 -0.1553 -0.8780 -0.1812 -0.4982 -0.3093 -1.1880 -0.2933 -0.2253 -0.1442 -0.1001 -0.0804 -0.1567 -1.0524 -0.1422 -0.7657 -0.1774 -0.1529 -0.1417 -0.1542
S-581	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-581	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-581	-0.3371041417121887	The dose and frequency of administration should be adjusted to reflect the clinical efficacy of the product in each case .
D-581	-0.3371041417121887	The dose and frequency of administration should be adjusted to reflect the clinical efficacy of the product in each case .
P-581	-0.2435 -0.0905 -0.1399 -0.1129 -0.0766 -0.2860 -0.0733 -0.1902 -0.1383 -0.0551 -1.9639 -0.8983 -0.1996 -0.2197 -0.1654 -0.0586 -0.0986 -0.1467 -0.1395 -0.1168 -1.0439 -1.3099 -0.3637 -0.1455 -0.1513
S-1232	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-1232	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-1232	-0.43224799633026123	Rotate the opening downwards and push the transparent plastic mandrel through the rubber stopper of the solvent bottle .
D-1232	-0.43224799633026123	Rotate the opening downwards and push the transparent plastic mandrel through the rubber stopper of the solvent bottle .
P-1232	-2.7769 -0.1033 -0.1456 -0.2506 -0.4136 -0.3196 -0.1553 -0.8780 -0.1812 -0.4982 -0.3093 -1.1880 -0.2933 -0.2253 -0.1442 -0.1001 -0.0804 -0.1567 -1.0524 -0.1422 -0.7657 -0.1774 -0.1529 -0.1417 -0.1542
S-1107	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-1107	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-1107	-0.3371041417121887	The dose and frequency of administration should be adjusted to reflect the clinical efficacy of the product in each case .
D-1107	-0.3371041417121887	The dose and frequency of administration should be adjusted to reflect the clinical efficacy of the product in each case .
P-1107	-0.2435 -0.0905 -0.1399 -0.1129 -0.0766 -0.2860 -0.0733 -0.1902 -0.1383 -0.0551 -1.9639 -0.8983 -0.1996 -0.2197 -0.1654 -0.0586 -0.0986 -0.1467 -0.1395 -0.1168 -1.0439 -1.3099 -0.3637 -0.1455 -0.1513
S-1413	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-1413	Insert the white plastic spike through the ADVATE stopper .
H-1413	-0.34412384033203125	Press the white thorn of BAXJECT II through the rubber stopper of the ADVATE bottle .
D-1413	-0.34412384033203125	Press the white thorn of BAXJECT II through the rubber stopper of the ADVATE bottle .
P-1413	-2.1800 -0.1663 -0.2691 -1.4486 -0.1264 -0.3013 -0.9989 -0.1928 -0.2998 -0.0654 -0.1715 -0.1201 -0.2589 -0.1391 -0.0419 -0.1105 -0.1597 -0.6058 -0.1185 -0.1946 -0.1766 -0.1087 -0.2164 -0.1851 -0.1350 -0.1561
S-931	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-931	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-931	-0.3371041417121887	The dose and frequency of administration should be adjusted to reflect the clinical efficacy of the product in each case .
D-931	-0.3371041417121887	The dose and frequency of administration should be adjusted to reflect the clinical efficacy of the product in each case .
P-931	-0.2435 -0.0905 -0.1399 -0.1129 -0.0766 -0.2860 -0.0733 -0.1902 -0.1383 -0.0551 -1.9639 -0.8983 -0.1996 -0.2197 -0.1654 -0.0586 -0.0986 -0.1467 -0.1395 -0.1168 -1.0439 -1.3099 -0.3637 -0.1455 -0.1513
S-880	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-880	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-880	-0.43224799633026123	Rotate the opening downwards and push the transparent plastic mandrel through the rubber stopper of the solvent bottle .
D-880	-0.43224799633026123	Rotate the opening downwards and push the transparent plastic mandrel through the rubber stopper of the solvent bottle .
P-880	-2.7769 -0.1033 -0.1456 -0.2506 -0.4136 -0.3196 -0.1553 -0.8780 -0.1812 -0.4982 -0.3093 -1.1880 -0.2933 -0.2253 -0.1442 -0.1001 -0.0804 -0.1567 -1.0524 -0.1422 -0.7657 -0.1774 -0.1529 -0.1417 -0.1542
S-755	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-755	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-755	-0.3371041417121887	The dose and frequency of administration should be adjusted to reflect the clinical efficacy of the product in each case .
D-755	-0.3371041417121887	The dose and frequency of administration should be adjusted to reflect the clinical efficacy of the product in each case .
P-755	-0.2435 -0.0905 -0.1399 -0.1129 -0.0766 -0.2860 -0.0733 -0.1902 -0.1383 -0.0551 -1.9639 -0.8983 -0.1996 -0.2197 -0.1654 -0.0586 -0.0986 -0.1467 -0.1395 -0.1168 -1.0439 -1.3099 -0.3637 -0.1455 -0.1513
S-1056	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-1056	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-1056	-0.43224799633026123	Rotate the opening downwards and push the transparent plastic mandrel through the rubber stopper of the solvent bottle .
D-1056	-0.43224799633026123	Rotate the opening downwards and push the transparent plastic mandrel through the rubber stopper of the solvent bottle .
P-1056	-2.7769 -0.1033 -0.1456 -0.2506 -0.4136 -0.3196 -0.1553 -0.8780 -0.1812 -0.4982 -0.3093 -1.1880 -0.2933 -0.2253 -0.1442 -0.1001 -0.0804 -0.1567 -1.0524 -0.1422 -0.7657 -0.1774 -0.1529 -0.1417 -0.1542
S-1585	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-1585	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-1585	-0.43224799633026123	Rotate the opening downwards and push the transparent plastic mandrel through the rubber stopper of the solvent bottle .
D-1585	-0.43224799633026123	Rotate the opening downwards and push the transparent plastic mandrel through the rubber stopper of the solvent bottle .
P-1585	-2.7769 -0.1033 -0.1456 -0.2506 -0.4136 -0.3196 -0.1553 -0.8780 -0.1812 -0.4982 -0.3093 -1.1880 -0.2933 -0.2253 -0.1442 -0.1001 -0.0804 -0.1567 -1.0524 -0.1422 -0.7657 -0.1774 -0.1529 -0.1417 -0.1542
S-285	Die Patienten sollten ergänzend Calcium erhalten , sofern die Versorgung über die Nahrung nicht ausreichend ist ( siehe Abschnitt 4.4 ) .
T-285	12 Patients should not lie down for at least 30 minutes after taking ADROVANCE .
H-285	-0.419385701417923	Patients should be supplemented with calcium if dietary supplementation is insufficient ( see section 4.4 ) .
D-285	-0.419385701417923	Patients should be supplemented with calcium if dietary supplementation is insufficient ( see section 4.4 ) .
P-285	-1.6272 -0.1030 -0.1364 -0.4519 -0.5323 -0.1143 -0.1209 -0.1775 -0.0866 -0.0844 -0.1327 -0.9647 -2.7012 -0.0469 -1.2650 -0.4324 -0.1134 -0.1423 -1.0052 -0.3077 -0.1244 -0.2927 -0.1198 -0.1093 -0.1241 -0.1351 -0.1402 -0.1512
S-1590	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-1590	Insert the white plastic spike through the ADVATE stopper .
H-1590	-0.34412384033203125	Press the white thorn of BAXJECT II through the rubber stopper of the ADVATE bottle .
D-1590	-0.34412384033203125	Press the white thorn of BAXJECT II through the rubber stopper of the ADVATE bottle .
P-1590	-2.1800 -0.1663 -0.2691 -1.4486 -0.1264 -0.3013 -0.9989 -0.1928 -0.2998 -0.0654 -0.1715 -0.1201 -0.2589 -0.1391 -0.0419 -0.1105 -0.1597 -0.6058 -0.1185 -0.1946 -0.1766 -0.1087 -0.2164 -0.1851 -0.1350 -0.1561
S-1131	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-1131	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-1131	-0.33698251843452454	Patients developing factor VIII inhibitors may experience an inadequate clinical response .
D-1131	-0.33698251843452454	Patients developing factor VIII inhibitors may experience an inadequate clinical response .
P-1131	-0.7414 -0.0999 -0.3702 -0.3995 -0.1793 -0.1217 -0.1039 -0.0307 -0.0687 -0.1266 -0.0480 -0.9938 -1.1559 -0.0976 -0.8530 -0.1069 -0.5848 -0.1627 -0.1582
S-1237	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-1237	Insert the white plastic spike through the ADVATE stopper .
H-1237	-0.34412384033203125	Press the white thorn of BAXJECT II through the rubber stopper of the ADVATE bottle .
D-1237	-0.34412384033203125	Press the white thorn of BAXJECT II through the rubber stopper of the ADVATE bottle .
P-1237	-2.1800 -0.1663 -0.2691 -1.4486 -0.1264 -0.3013 -0.9989 -0.1928 -0.2998 -0.0654 -0.1715 -0.1201 -0.2589 -0.1391 -0.0419 -0.1105 -0.1597 -0.6058 -0.1185 -0.1946 -0.1766 -0.1087 -0.2164 -0.1851 -0.1350 -0.1561
S-1061	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-1061	Insert the white plastic spike through the ADVATE stopper .
H-1061	-0.34412384033203125	Press the white thorn of BAXJECT II through the rubber stopper of the ADVATE bottle .
D-1061	-0.34412384033203125	Press the white thorn of BAXJECT II through the rubber stopper of the ADVATE bottle .
P-1061	-2.1800 -0.1663 -0.2691 -1.4486 -0.1264 -0.3013 -0.9989 -0.1928 -0.2998 -0.0654 -0.1715 -0.1201 -0.2589 -0.1391 -0.0419 -0.1105 -0.1597 -0.6058 -0.1185 -0.1946 -0.1766 -0.1087 -0.2164 -0.1851 -0.1350 -0.1561
S-885	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-885	Insert the white plastic spike through the ADVATE stopper .
H-885	-0.34412384033203125	Press the white thorn of BAXJECT II through the rubber stopper of the ADVATE bottle .
D-885	-0.34412384033203125	Press the white thorn of BAXJECT II through the rubber stopper of the ADVATE bottle .
P-885	-2.1800 -0.1663 -0.2691 -1.4486 -0.1264 -0.3013 -0.9989 -0.1928 -0.2998 -0.0654 -0.1715 -0.1201 -0.2589 -0.1391 -0.0419 -0.1105 -0.1597 -0.6058 -0.1185 -0.1946 -0.1766 -0.1087 -0.2164 -0.1851 -0.1350 -0.1561
S-1283	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-1283	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-1283	-0.3371041417121887	The dose and frequency of administration should be adjusted to reflect the clinical efficacy of the product in each case .
D-1283	-0.3371041417121887	The dose and frequency of administration should be adjusted to reflect the clinical efficacy of the product in each case .
P-1283	-0.2435 -0.0905 -0.1399 -0.1129 -0.0766 -0.2860 -0.0733 -0.1902 -0.1383 -0.0551 -1.9639 -0.8983 -0.1996 -0.2197 -0.1654 -0.0586 -0.0986 -0.1467 -0.1395 -0.1168 -1.0439 -1.3099 -0.3637 -0.1455 -0.1513
S-709	Den weißen Dorn des BAXJECTs II durch den Gummistopfen der ADVATE-Flasche drücken .
T-709	Insert the white plastic spike through the ADVATE stopper .
H-709	-0.34412384033203125	Press the white thorn of BAXJECT II through the rubber stopper of the ADVATE bottle .
D-709	-0.34412384033203125	Press the white thorn of BAXJECT II through the rubber stopper of the ADVATE bottle .
P-709	-2.1800 -0.1663 -0.2691 -1.4486 -0.1264 -0.3013 -0.9989 -0.1928 -0.2998 -0.0654 -0.1715 -0.1201 -0.2589 -0.1391 -0.0419 -0.1105 -0.1597 -0.6058 -0.1185 -0.1946 -0.1766 -0.1087 -0.2164 -0.1851 -0.1350 -0.1561
S-1459	Die Dosis und Häufigkeit der Verabreichung sollen entsprechend der klinischen Wirksamkeit des Produktes im Einzelfall angepasst werden .
T-1459	The dose and frequency of administration should be adapted to the clinical response in the individual case .
H-1459	-0.3371041417121887	The dose and frequency of administration should be adjusted to reflect the clinical efficacy of the product in each case .
D-1459	-0.3371041417121887	The dose and frequency of administration should be adjusted to reflect the clinical efficacy of the product in each case .
P-1459	-0.2435 -0.0905 -0.1399 -0.1129 -0.0766 -0.2860 -0.0733 -0.1902 -0.1383 -0.0551 -1.9639 -0.8983 -0.1996 -0.2197 -0.1654 -0.0586 -0.0986 -0.1467 -0.1395 -0.1168 -1.0439 -1.3099 -0.3637 -0.1455 -0.1513
S-98	Die Patienten sollten ergänzend Calcium erhalten , sofern die Versorgung über die Nahrung nicht ausreichend ist ( siehe Abschnitt 4.4 ) .
T-98	Patients should receive supplemental calcium if intake from diet is inadequate ( see section 4.4 ) .
H-98	-0.419385701417923	Patients should be supplemented with calcium if dietary supplementation is insufficient ( see section 4.4 ) .
D-98	-0.419385701417923	Patients should be supplemented with calcium if dietary supplementation is insufficient ( see section 4.4 ) .
P-98	-1.6272 -0.1030 -0.1364 -0.4519 -0.5323 -0.1143 -0.1209 -0.1775 -0.0866 -0.0844 -0.1327 -0.9647 -2.7012 -0.0469 -1.2650 -0.4324 -0.1134 -0.1423 -1.0052 -0.3077 -0.1244 -0.2927 -0.1198 -0.1093 -0.1241 -0.1351 -0.1402 -0.1512
S-17	Der in Adenuric enthaltene Wirkstoff Feboxustat vermindert die Bildung von Harnsäure .
T-17	The active substance in Adenuric , feboxustat , reduces the formation of uric acid .
H-17	-0.2403053194284439	Feboxustat , an active substance in Adenuric , decreases the formation of uric acid .
D-17	-0.2403053194284439	Feboxustat , an active substance in Adenuric , decreases the formation of uric acid .
P-17	-0.1633 -0.1502 -0.1814 -0.2495 -0.0908 -0.9117 -0.7493 -0.1343 -0.0754 -0.7469 -0.1114 -0.1436 -0.0966 -0.1255 -0.1864 -0.6190 -0.0629 -0.2121 -0.2150 -0.1435 -0.1682 -0.0739 -0.0935 -0.1448 -0.1585
S-955	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-955	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-955	-0.33698251843452454	Patients developing factor VIII inhibitors may experience an inadequate clinical response .
D-955	-0.33698251843452454	Patients developing factor VIII inhibitors may experience an inadequate clinical response .
P-955	-0.7414 -0.0999 -0.3702 -0.3995 -0.1793 -0.1217 -0.1039 -0.0307 -0.0687 -0.1266 -0.0480 -0.9938 -1.1559 -0.0976 -0.8530 -0.1069 -0.5848 -0.1627 -0.1582
S-779	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-779	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-779	-0.33698251843452454	Patients developing factor VIII inhibitors may experience an inadequate clinical response .
D-779	-0.33698251843452454	Patients developing factor VIII inhibitors may experience an inadequate clinical response .
P-779	-0.7414 -0.0999 -0.3702 -0.3995 -0.1793 -0.1217 -0.1039 -0.0307 -0.0687 -0.1266 -0.0480 -0.9938 -1.1559 -0.0976 -0.8530 -0.1069 -0.5848 -0.1627 -0.1582
S-605	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-605	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-605	-0.33698251843452454	Patients developing factor VIII inhibitors may experience an inadequate clinical response .
D-605	-0.33698251843452454	Patients developing factor VIII inhibitors may experience an inadequate clinical response .
P-605	-0.7414 -0.0999 -0.3702 -0.3995 -0.1793 -0.1217 -0.1039 -0.0307 -0.0687 -0.1266 -0.0480 -0.9938 -1.1559 -0.0976 -0.8530 -0.1069 -0.5848 -0.1627 -0.1582
S-1856	Advexin hätte zur Behandlung von Li-Fraumeni-Krebs bei Patienten ab einem Alter von 18 Jahren angewendet werden sollen .
T-1856	Advexin was expected to be used to treat Li-Fraumeni cancer in patients from the age of 18 years .
H-1856	-0.35313743352890015	Advexin should have been used to treat Li-Fraumeni cancer in patients 18 years of age and over .
D-1856	-0.35313743352890015	Advexin should have been used to treat Li-Fraumeni cancer in patients 18 years of age and over .
P-1856	-0.8285 -0.1692 -0.1384 -0.1885 -0.1819 -0.0751 -0.1549 -0.1552 -0.1007 -1.0373 -0.4933 -0.3141 -0.0372 -0.2283 -0.5389 -0.1456 -0.2206 -2.0761 -0.1427 -0.4708 -0.0908 -0.3057 -0.4412 -0.1399 -0.1536
S-429	Das mittlere Steady-State-Volumen der Verteilung beträgt , den Knochen ausgenommen , mindestens 28 Liter beim Menschen .
T-429	The mean steady-state volume of distribution , exclusive of bone , is at least 28 litres in humans .
H-429	-0.40925726294517517	The mean steady-state volume of distribution is at least 28 litres in humans , excluding bone .
D-429	-0.40925726294517517	The mean steady-state volume of distribution is at least 28 litres in humans , excluding bone .
P-429	-0.1672 -0.2524 -0.3836 -1.6272 -0.0987 -0.2040 -0.0586 -0.0696 -0.3140 -0.4304 -1.0566 -0.3075 -0.1105 -0.0880 -0.2771 -0.5925 -0.1227 -0.3302 -0.8296 -0.3425 -1.1224 -0.1678 -0.9357 -0.1897 -0.1528
S-233	Das mittlere Steady-State-Volumen der Verteilung beträgt , den Knochen ausgenommen , mindestens 28 Liter beim Menschen .
T-233	The mean steady-state volume of distribution , exclusive of bone , is at least 28 litres in humans .
H-233	-0.40925726294517517	The mean steady-state volume of distribution is at least 28 litres in humans , excluding bone .
D-233	-0.40925726294517517	The mean steady-state volume of distribution is at least 28 litres in humans , excluding bone .
P-233	-0.1672 -0.2524 -0.3836 -1.6272 -0.0987 -0.2040 -0.0586 -0.0696 -0.3140 -0.4304 -1.0566 -0.3075 -0.1105 -0.0880 -0.2771 -0.5925 -0.1227 -0.3302 -0.8296 -0.3425 -1.1224 -0.1678 -0.9357 -0.1897 -0.1528
S-1408	Die Öffnung nach unten drehen und den durchsichtigen Plastikdorn durch den Gummistopfen der Lösungsmittelflasche drücken .
T-1408	Turn the package over and insert the clear plastic spike through the solvent stopper .
H-1408	-0.43224799633026123	Rotate the opening downwards and push the transparent plastic mandrel through the rubber stopper of the solvent bottle .
D-1408	-0.43224799633026123	Rotate the opening downwards and push the transparent plastic mandrel through the rubber stopper of the solvent bottle .
P-1408	-2.7769 -0.1033 -0.1456 -0.2506 -0.4136 -0.3196 -0.1553 -0.8780 -0.1812 -0.4982 -0.3093 -1.1880 -0.2933 -0.2253 -0.1442 -0.1001 -0.0804 -0.1567 -1.0524 -0.1422 -0.7657 -0.1774 -0.1529 -0.1417 -0.1542
S-190	Bei unzureichender Sonnenbestrahlung ist es essenziell , dass Vitamin D3 ein Bestandteil der Nahrung ist .
T-190	In the absence of adequate sunlight exposure , vitamin D3 is an essential dietary nutrient .
H-190	-0.5851353406906128	If insufficient sunlight is received , it is essential that vitamin D3 is part of the diet .
D-190	-0.5851353406906128	If insufficient sunlight is received , it is essential that vitamin D3 is part of the diet .
P-190	-1.3837 -0.7236 -0.6159 -1.9058 -0.3037 -0.1721 -1.7968 -0.2138 -0.5268 -0.1185 -0.6199 -0.1981 -0.0894 -0.1005 -0.1318 -0.1282 -0.2632 -2.3114 -0.1402 -1.2543 -0.1635 -0.1451 -0.1520
S-42	Am 21.April 2008 erteilte die Europäische Kommission eine Genehmigung für das Inverkehrbringen von Adenuric in der gesamten Europäischen Union .
T-42	The European Commission granted a marketing authorisation valid throughout the European Union for Adenuric on 21 April 2008.
H-42	-0.39640456438064575	On 21 April 2008 the European Commission authorised Adenuric to be marketed throughout the European Union .
D-42	-0.39640456438064575	On 21 April 2008 the European Commission authorised Adenuric to be marketed throughout the European Union .
P-42	-0.4702 -0.9571 -0.3078 -0.2602 -1.9533 -0.2222 -0.1989 -1.7827 -0.1380 -0.5814 -0.1895 -0.0716 -0.1083 -0.1621 -0.2534 -0.1435 -0.0645 -0.4280 -0.1376 -0.2082 -0.1915 -0.1355 -0.1518
S-432	Biotransformation Es gibt keine Hinweise darauf , dass Alendronat beim Tier oder beim Menschen metabolisiert wird .
T-432	Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
H-432	-0.2284613996744156	biotransformation There is no evidence that alendronate is metabolised in animals or humans .
D-432	-0.2284613996744156	biotransformation There is no evidence that alendronate is metabolised in animals or humans .
P-432	-0.4094 -0.0880 -0.0738 -0.1280 -0.0557 -1.0977 -0.1676 -0.1185 -0.0395 -0.2170 -0.0823 -0.1407 -0.0901 -0.0427 -0.1505 -0.1470 -0.0352 -0.0836 -0.2131 -1.4529 -0.1447 -0.2015 -0.1424 -0.1612
S-236	Biotransformation Es gibt keine Hinweise darauf , dass Alendronat beim Tier oder beim Menschen metabolisiert wird .
T-236	Biotransformation There is no evidence that alendronate is metabolised in animals or humans .
H-236	-0.2284613996744156	biotransformation There is no evidence that alendronate is metabolised in animals or humans .
D-236	-0.2284613996744156	biotransformation There is no evidence that alendronate is metabolised in animals or humans .
P-236	-0.4094 -0.0880 -0.0738 -0.1280 -0.0557 -1.0977 -0.1676 -0.1185 -0.0395 -0.2170 -0.0823 -0.1407 -0.0901 -0.0427 -0.1505 -0.1470 -0.0352 -0.0836 -0.2131 -1.4529 -0.1447 -0.2015 -0.1424 -0.1612
S-38	Die vollständige Auflistung der im Zusammenhang mit Adenuric berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-38	For the full list of all side effects reported with Adenuric , see the Package Leaflet .
H-38	-0.19929355382919312	For a full list of side effects reported with Adenuric , see the Package Leaflet .
D-38	-0.19929355382919312	For a full list of side effects reported with Adenuric , see the Package Leaflet .
P-38	-0.1831 -0.1273 -0.0692 -0.1497 -0.1665 -1.3704 -0.1519 -0.1117 -0.2589 -0.1156 -0.2042 -0.0820 -0.1180 -0.1413 -0.4594 -0.1350 -0.0966 -0.1220 -0.0538 -0.0595 -0.1021 -0.1568 -0.1486
S-1785	Schwere Nebenwirkungen einschließlich Atmenot , und ( Beinahe<unk> -Ohnmachten erfordern eine sofortige Notfallbehandlung .
T-1785	Severe symptoms , including difficulty in breathing and ( nearly ) fainting , require prompt emergency treatment .
H-1785	-0.4877167046070099	Severe adverse reactions including breathlessness , and ( near faintness ) require immediate emergency treatment .
D-1785	-0.4877167046070099	Severe adverse reactions including breathlessness , and ( near faintness ) require immediate emergency treatment .
P-1785	-0.4170 -0.1278 -1.5172 -0.0309 -0.1627 -0.0623 -0.0572 -3.4423 -0.1255 -0.0430 -0.0968 -0.1618 -0.1270 -0.2211 -0.1212 -0.9152 -0.3233 -2.2797 -0.5368 -0.2869 -0.5825 -0.1069 -0.1532 -0.1453 -0.1493
S-378	Bei unzureichender Sonnenbestrahlung ist es essenziell , dass Vitamin D3 ein Bestandteil der Nahrung ist .
T-378	In the absence of adequate sunlight exposure , vitamin D3 is an essential dietary nutrient .
H-378	-0.5851353406906128	If insufficient sunlight is received , it is essential that vitamin D3 is part of the diet .
D-378	-0.5851353406906128	If insufficient sunlight is received , it is essential that vitamin D3 is part of the diet .
P-378	-1.3837 -0.7236 -0.6159 -1.9058 -0.3037 -0.1721 -1.7968 -0.2138 -0.5268 -0.1185 -0.6199 -0.1981 -0.0894 -0.1005 -0.1318 -0.1282 -0.2632 -2.3114 -0.1402 -1.2543 -0.1635 -0.1451 -0.1520
S-406	4,8 , 5,4 % ) in der Gruppe mit 70 mg einmal wöchentlich und 5,4 % ( 95 % CI :
T-406	4.8 , 5.4 % ) in the 70 mg once-weekly group and 5.4 % ( 95 % CI :
H-406	-0.1836957186460495	4.8 , 5.4 % ) in the 70 mg weekly and 5.4 % ( 95 % CI :
D-406	-0.1836957186460495	4.8 , 5.4 % ) in the 70 mg weekly and 5.4 % ( 95 % CI :
P-406	-0.0995 -0.1029 -0.1753 -0.0832 -0.1387 -0.1371 -0.1349 -0.1820 -0.1466 -0.1946 -0.0412 -0.9833 -0.4963 -0.1333 -0.1338 -0.0939 -0.1454 -0.0729 -0.1154 -0.1181 -0.1928 -0.1454 -0.1584
S-1805	- Der arzneilich wirksame Bestandteil ist Octocog alfa ( Blutgerinnungsfaktor VIII vom Menschen ,
T-1805	- The active substance is octocog alfa ( human coagulation Factor VIII produced by recombinant
H-1805	-0.24496027827262878	- The active substance is octocog alfa ( human blood clotting factor VIII ,
D-1805	-0.24496027827262878	- The active substance is octocog alfa ( human blood clotting factor VIII ,
P-1805	-0.2064 -0.2268 -0.0520 -0.2539 -0.1754 -0.8156 -0.0959 -0.1557 -0.2737 -0.1172 -0.0666 -0.1348 -0.2613 -0.2506 -1.2287 -0.0325 -0.0830 -0.0680 -0.1325 -0.1136 -0.3622 -0.2826
S-1829	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <unk> 48 22 4883 777
T-1829	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <<unk>> 48 22 4883 777
H-1829	-0.1884298026561737	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <unk> 48 22 4883 777
D-1829	-0.1884298026561737	Kruczkowskiego 8 PL-00-380 Warszawa Tel . : <unk> 48 22 4883 777
P-1829	-0.4567 -0.2174 -0.8283 -0.0750 -0.0481 -0.1025 -0.1099 -0.1126 -0.1527 -0.1099 -0.0631 -0.3567 -0.0693 -0.1647 -0.7109 -0.2838 -0.0514 -0.1453 -0.1338 -0.0311 -0.0896 -0.0848 -0.2456 -0.0844 -0.1093 -0.0973 -0.1535
S-1733	Bei Patienten mit Hämophilie A ( angeborenem Faktor VIII-Mangel ) fehlt er oder funktioniert nicht korrekt .
T-1733	In patients with haemophilia A ( inborn factor VIII deficiency ) , it is missing or not working properly .
H-1733	-0.3801434338092804	In patients with haemophilia A ( congenital factor VIII-deficiency ) it is missing or not working properly .
D-1733	-0.3801434338092804	In patients with haemophilia A ( congenital factor VIII-deficiency ) it is missing or not working properly .
P-1733	-0.8268 -0.1430 -0.1263 -0.1154 -0.0645 -0.1741 -0.2171 -0.1385 -0.1394 -0.5348 -0.3706 -0.3478 -0.1216 -0.4039 -0.2165 -1.6098 -0.3789 -0.0667 -0.0700 -0.1200 -0.1367 -0.7928 -0.1164 -0.8642 -0.1359 -1.3308 -0.6149 -0.9223 -0.1469 -0.1575
S-210	4,8 , 5,4 % ) in der Gruppe mit 70 mg einmal wöchentlich und 5,4 % ( 95 % CI :
T-210	4.8 , 5.4 % ) in the 70 mg once-weekly group and 5.4 % ( 95 % CI :
H-210	-0.1836957186460495	4.8 , 5.4 % ) in the 70 mg weekly and 5.4 % ( 95 % CI :
D-210	-0.1836957186460495	4.8 , 5.4 % ) in the 70 mg weekly and 5.4 % ( 95 % CI :
P-210	-0.0995 -0.1029 -0.1753 -0.0832 -0.1387 -0.1371 -0.1349 -0.1820 -0.1466 -0.1946 -0.0412 -0.9833 -0.4963 -0.1333 -0.1338 -0.0939 -0.1454 -0.0729 -0.1154 -0.1181 -0.1928 -0.1454 -0.1584
S-88	Therapie der postmenopausalen Osteoporose bei Patienten mit Risiko für einen Vitamin-D-Mangel .
T-88	Treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency .
H-88	-0.15934570133686066	Treatment of post-menopausal osteoporosis in patients at risk of vitamin D deficiency .
D-88	-0.15934570133686066	Treatment of post-menopausal osteoporosis in patients at risk of vitamin D deficiency .
P-88	-0.8534 -0.0449 -0.1062 -0.1409 -0.0715 -0.2184 -0.0322 -0.0974 -0.0336 -0.1400 -0.1791 -0.0753 -0.1113 -0.1376 -0.0940 -0.0815 -0.1448 -0.2180 -0.0429 -0.0648 -0.6736 -0.2112 -0.0645 -0.1709 -0.0483 -0.0358 -0.2223 -0.1537 -0.1532
S-565	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E.
T-565	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU
H-565	-0.3344756066799164	The calculation of the required Factor VIII dose is based on the empirical finding that 1 IU
D-565	-0.3344756066799164	The calculation of the required Factor VIII dose is based on the empirical finding that 1 IU
P-565	-1.0015 -0.2247 -0.2707 -0.0920 -0.1564 -0.1772 -1.2680 -1.3440 -0.1347 -0.1189 -0.0303 -0.1254 -0.0776 -0.2117 -0.6482 -0.1155 -0.1321 -0.3195 -0.1035 -0.4525 -0.1369 -0.1397 -0.1175 -0.0884 -0.8752
S-1591	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-1591	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-1591	-0.3894348740577698	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-1591	-0.3894348740577698	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-1591	-0.5233 -0.9964 -0.2290 -0.1451 -1.6093 -0.3273 -0.1243 -0.2774 -0.1552 -0.0759 -0.2164 -0.2120 -1.0602 -0.7283 -0.1451 -0.2561 -0.1143 -0.1245 -0.3113 -0.1574
S-1414	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-1414	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-1414	-0.3894348740577698	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-1414	-0.3894348740577698	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-1414	-0.5233 -0.9964 -0.2290 -0.1451 -1.6093 -0.3273 -0.1243 -0.2774 -0.1552 -0.0759 -0.2164 -0.2120 -1.0602 -0.7283 -0.1451 -0.2561 -0.1143 -0.1245 -0.3113 -0.1574
S-1238	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-1238	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-1238	-0.3894348740577698	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-1238	-0.3894348740577698	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-1238	-0.5233 -0.9964 -0.2290 -0.1451 -1.6093 -0.3273 -0.1243 -0.2774 -0.1552 -0.0759 -0.2164 -0.2120 -1.0602 -0.7283 -0.1451 -0.2561 -0.1143 -0.1245 -0.3113 -0.1574
S-1062	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-1062	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-1062	-0.3894348740577698	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-1062	-0.3894348740577698	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-1062	-0.5233 -0.9964 -0.2290 -0.1451 -1.6093 -0.3273 -0.1243 -0.2774 -0.1552 -0.0759 -0.2164 -0.2120 -1.0602 -0.7283 -0.1451 -0.2561 -0.1143 -0.1245 -0.3113 -0.1574
S-886	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-886	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-886	-0.3894348740577698	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-886	-0.3894348740577698	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-886	-0.5233 -0.9964 -0.2290 -0.1451 -1.6093 -0.3273 -0.1243 -0.2774 -0.1552 -0.0759 -0.2164 -0.2120 -1.0602 -0.7283 -0.1451 -0.2561 -0.1143 -0.1245 -0.3113 -0.1574
S-1963	Diese Wirkungen sind bei Kindern , älteren Patienten oder im Falle einer Überdosierung wahrscheinlicher ( siehe Abschnitt 4.9 ) .
T-1963	These effects may be more likely to occur in children , elderly patients , or in cases of overdose ( see section 4.9 ) .
H-1963	-0.2707698941230774	These effects are more likely in paediatric , elderly patients or in the case of overdose ( see section 4.9 ) .
D-1963	-0.2707698941230774	These effects are more likely in paediatric , elderly patients or in the case of overdose ( see section 4.9 ) .
P-1963	-0.3807 -0.0895 -0.1518 -0.1319 -0.6681 -0.1921 -0.5970 -0.0140 -0.0132 -0.1084 -0.1895 -0.0507 -0.0781 -0.8976 -0.3934 -0.7790 -0.5838 -0.1485 -0.8240 -0.0512 -0.1495 -0.2958 -0.1168 -0.1133 -0.1405 -0.1335 -0.1400 -0.1497
S-455	Es wurden keine nicht-klinischen Studien mit der Kombination von Alendronat und Colecalciferol durchgeführt .
T-455	Non-clinical studies with the combination of alendronate and colecalciferol have not been conducted .
H-455	-0.2824591398239136	No non-clinical trials were conducted with the combination of alendronate and colecalciferol .
D-455	-0.2824591398239136	No non-clinical trials were conducted with the combination of alendronate and colecalciferol .
P-455	-0.2216 -0.2639 -0.1680 -0.0889 -0.5445 -1.9272 -0.6774 -0.2714 -0.3921 -0.2202 -0.1597 -0.2012 -0.1463 -0.1051 -0.0475 -0.1503 -0.1818 -0.1384 -0.2075 -0.1216 -0.1041 -0.1560 -0.1305 -0.1538
S-1373	52 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-1373	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-1373	-0.3862801790237427	Data from a single dose of ADVATE in 53 children under 6 years of age were used to establish this table .
D-1373	-0.3862801790237427	Data from a single dose of ADVATE in 53 children under 6 years of age were used to establish this table .
P-1373	-1.3760 -0.2487 -0.2086 -1.4073 -0.6479 -0.1899 -0.0928 -0.1379 -0.0763 -0.0858 -0.1942 -0.1288 -0.2588 -0.4004 -0.3706 -0.0903 -0.1695 -0.0900 -0.6022 -0.2631 -0.2112 -2.1983 -0.1300 -0.1726 -0.1401 -0.1522
S-1197	41 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-1197	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-1197	-0.37214142084121704	Data from a single dose of ADVATE in 53 children under 6 years of age were used to establish this table .
D-1197	-0.37214142084121704	Data from a single dose of ADVATE in 53 children under 6 years of age were used to establish this table .
P-1197	-0.9565 -0.2374 -0.2053 -1.3869 -0.6629 -0.2001 -0.0943 -0.1395 -0.0759 -0.0863 -0.2049 -0.1335 -0.2504 -0.4193 -0.3671 -0.0904 -0.1685 -0.0896 -0.7333 -0.2494 -0.2083 -2.1282 -0.1328 -0.1634 -0.1398 -0.1517
S-1984	In einer klinisch- pharmakologischen Studie wurde bei gleichzeitiger Einnahme von Desloratadin und Alkohol die
T-1984	However , in a clinical pharmacology trial desloratadine taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol .
H-1984	-0.4556794762611389	In a clinical pharmacological trial , concomitant administration of desloratadine and alcohol increased
D-1984	-0.4556794762611389	In a clinical pharmacological trial , concomitant administration of desloratadine and alcohol increased
P-1984	-0.8495 -0.2743 -0.2190 -0.0966 -1.1855 -0.7501 -0.3504 -1.2702 -0.0441 -0.0137 -0.1684 -0.7994 -0.1619 -0.3400 -0.0560 -0.1046 -0.2599 -0.6847 -0.1877 -0.1804 -1.7928 -0.2357
S-1600	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-1600	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-1600	-0.38393938541412354	Connect the perfusion cutlery to the syringe and intravenously inject the product .
D-1600	-0.38393938541412354	Connect the perfusion cutlery to the syringe and intravenously inject the product .
P-1600	-2.3053 -0.0490 -0.1056 -0.1616 -0.3129 -0.0620 -1.7762 -0.3668 -0.1622 -0.1497 -0.1370 -0.0619 -0.0370 -0.0140 -0.1224 -0.1686 -1.8535 -0.1138 -0.1150 -0.4806 -0.1942 -0.2317 -0.2988 -0.1662 -0.1525
S-1550	63 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-1550	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-1550	-0.40476951003074646	63 data from a single dose of ADVATE in 53 children under 6 years of age were used to establish this table .
D-1550	-0.40476951003074646	63 data from a single dose of ADVATE in 53 children under 6 years of age were used to establish this table .
P-1550	-0.6389 -1.1520 -0.4258 -0.2524 -1.4420 -0.6387 -0.1899 -0.0927 -0.1394 -0.0771 -0.0858 -0.1969 -0.1264 -0.2593 -0.3835 -0.3668 -0.0919 -0.1733 -0.0898 -0.8217 -0.2682 -0.2207 -2.1926 -0.1278 -0.1770 -0.1472 -0.1508
S-1423	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-1423	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-1423	-0.38393938541412354	Connect the perfusion cutlery to the syringe and intravenously inject the product .
D-1423	-0.38393938541412354	Connect the perfusion cutlery to the syringe and intravenously inject the product .
P-1423	-2.3053 -0.0490 -0.1056 -0.1616 -0.3129 -0.0620 -1.7762 -0.3668 -0.1622 -0.1497 -0.1370 -0.0619 -0.0370 -0.0140 -0.1224 -0.1686 -1.8535 -0.1138 -0.1150 -0.4806 -0.1942 -0.2317 -0.2988 -0.1662 -0.1525
S-669	8 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-669	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-669	-0.3676372170448303	Data from a single dose of ADVATE in 53 children under 6 years of age were used to establish this table .
D-669	-0.3676372170448303	Data from a single dose of ADVATE in 53 children under 6 years of age were used to establish this table .
P-669	-0.8393 -0.2607 -0.2127 -1.3135 -0.5660 -0.1973 -0.0931 -0.1405 -0.0752 -0.0859 -0.2052 -0.1398 -0.2559 -0.4104 -0.3969 -0.0927 -0.1689 -0.0890 -0.7434 -0.2394 -0.2163 -2.2197 -0.1292 -0.1748 -0.1409 -0.1520
S-1247	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-1247	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-1247	-0.38393938541412354	Connect the perfusion cutlery to the syringe and intravenously inject the product .
D-1247	-0.38393938541412354	Connect the perfusion cutlery to the syringe and intravenously inject the product .
P-1247	-2.3053 -0.0490 -0.1056 -0.1616 -0.3129 -0.0620 -1.7762 -0.3668 -0.1622 -0.1497 -0.1370 -0.0619 -0.0370 -0.0140 -0.1224 -0.1686 -1.8535 -0.1138 -0.1150 -0.4806 -0.1942 -0.2317 -0.2988 -0.1662 -0.1525
S-719	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-719	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-719	-0.38393938541412354	Connect the perfusion cutlery to the syringe and intravenously inject the product .
D-719	-0.38393938541412354	Connect the perfusion cutlery to the syringe and intravenously inject the product .
P-719	-2.3053 -0.0490 -0.1056 -0.1616 -0.3129 -0.0620 -1.7762 -0.3668 -0.1622 -0.1497 -0.1370 -0.0619 -0.0370 -0.0140 -0.1224 -0.1686 -1.8535 -0.1138 -0.1150 -0.4806 -0.1942 -0.2317 -0.2988 -0.1662 -0.1525
S-1071	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-1071	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-1071	-0.38393938541412354	Connect the perfusion cutlery to the syringe and intravenously inject the product .
D-1071	-0.38393938541412354	Connect the perfusion cutlery to the syringe and intravenously inject the product .
P-1071	-2.3053 -0.0490 -0.1056 -0.1616 -0.3129 -0.0620 -1.7762 -0.3668 -0.1622 -0.1497 -0.1370 -0.0619 -0.0370 -0.0140 -0.1224 -0.1686 -1.8535 -0.1138 -0.1150 -0.4806 -0.1942 -0.2317 -0.2988 -0.1662 -0.1525
S-1021	30 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-1021	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-1021	-0.3824618458747864	Data from a single dose of ADVATE in 53 children under 6 years of age were used to establish this table .
D-1021	-0.3824618458747864	Data from a single dose of ADVATE in 53 children under 6 years of age were used to establish this table .
P-1021	-1.1865 -0.2426 -0.2324 -1.3527 -0.5587 -0.1982 -0.0910 -0.1399 -0.0752 -0.0868 -0.1936 -0.1329 -0.2561 -0.4057 -0.3837 -0.0906 -0.1714 -0.0903 -0.8068 -0.2539 -0.2062 -2.1882 -0.1287 -0.1779 -0.1427 -0.1513
S-895	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren .
T-895	Das Perfusionsbesteck an die Spritze anschließen und das Präparat intravenös injizieren . Inject intravenously .
H-895	-0.38393938541412354	Connect the perfusion cutlery to the syringe and intravenously inject the product .
D-895	-0.38393938541412354	Connect the perfusion cutlery to the syringe and intravenously inject the product .
P-895	-2.3053 -0.0490 -0.1056 -0.1616 -0.3129 -0.0620 -1.7762 -0.3668 -0.1622 -0.1497 -0.1370 -0.0619 -0.0370 -0.0140 -0.1224 -0.1686 -1.8535 -0.1138 -0.1150 -0.4806 -0.1942 -0.2317 -0.2988 -0.1662 -0.1525
S-845	19 Daten einer Einmalapplikation von ADVATE bei 53 Kindern unter 6 Jahren wurden zur Aufstellung dieser Tabelle verwendet .
T-845	Data from single-dose administrations of ADVATE in 53 paediatric patients less than 6 years of age were used to obtain this table .
H-845	-0.39433544874191284	Data from a single dose of ADVATE in 53 children under 6 years of age were used to establish this table .
D-845	-0.39433544874191284	Data from a single dose of ADVATE in 53 children under 6 years of age were used to establish this table .
P-845	-1.3793 -0.2511 -0.2340 -1.3270 -0.6102 -0.1928 -0.0927 -0.1414 -0.0753 -0.0858 -0.1952 -0.1355 -0.2591 -0.3960 -0.4017 -0.0918 -0.1691 -0.0899 -0.8055 -0.2386 -0.2126 -2.2691 -0.1285 -0.1772 -0.1414 -0.1518
S-710	Durch das Vakuum wird das Lösungsmittel in die ADVATE-Flasche gezogen ( Abb . C ) .
T-710	The vacuum will draw the solvent into the ADVATE vial ( Fig . c ) .
H-710	-0.3894348740577698	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
D-710	-0.3894348740577698	The solvent is drawn into the ADVATE bottle ( Fig . C ) .
P-710	-0.5233 -0.9964 -0.2290 -0.1451 -1.6093 -0.3273 -0.1243 -0.2774 -0.1552 -0.0759 -0.2164 -0.2120 -1.0602 -0.7283 -0.1451 -0.2561 -0.1143 -0.1245 -0.3113 -0.1574
S-522	Der Wirkstoff in Advate , Octocog alfa , ist ein Protein des Blutgerinnungsfaktors .
T-522	The active substance in Advate , octocog alfa , is a blood coagulation factor protein .
H-522	-0.25782686471939087	The active substance in Advate , Octocog alfa , is a protein in the blood coagulation factor .
D-522	-0.25782686471939087	The active substance in Advate , Octocog alfa , is a protein in the blood coagulation factor .
P-522	-0.2398 -0.1072 -0.0908 -0.1507 -0.5028 -0.1002 -0.1535 -0.9829 -0.0817 -0.1603 -0.2253 -0.1216 -0.0701 -0.1503 -0.1083 -0.1328 -0.3632 -0.5990 -0.1884 -0.0535 -0.9889 -0.0640 -0.6749 -0.1003 -0.1433 -0.1497
S-259	Es wurden keine nicht-klinischen Studien mit der Kombination von Alendronat und Colecalciferol durchgeführt .
T-259	Non-clinical studies with the combination of alendronate and colecalciferol have not been conducted .
H-259	-0.2824591398239136	No non-clinical trials were conducted with the combination of alendronate and colecalciferol .
D-259	-0.2824591398239136	No non-clinical trials were conducted with the combination of alendronate and colecalciferol .
P-259	-0.2216 -0.2639 -0.1680 -0.0889 -0.5445 -1.9272 -0.6774 -0.2714 -0.3921 -0.2202 -0.1597 -0.2012 -0.1463 -0.1051 -0.0475 -0.1503 -0.1818 -0.1384 -0.2075 -0.1216 -0.1041 -0.1560 -0.1305 -0.1538
S-520	Die Dosierung wird darüber hinaus je nach Schweregrad der Blutung und Art des chirurgischen Eingriffes angepasst .
T-520	The dose is also adjusted depending on the severity of the haemorrhage or the type of surgery .
H-520	-0.4624534845352173	Moreover , the dosage is adjusted according to the severity of the haemorrhage and the type of surgery .
D-520	-0.4624534845352173	Moreover , the dosage is adjusted according to the severity of the haemorrhage and the type of surgery .
P-520	-0.5906 -0.1810 -1.0563 -0.2798 -0.0694 -0.0943 -0.3651 -0.1573 -1.5837 -0.1506 -0.1520 -2.5520 -0.1076 -0.1545 -0.2930 -1.6495 -0.2769 -0.0235 -0.1148 -0.1206 -0.5620 -0.4690 -0.1404 -0.0528 -0.6756 -0.1516
S-1026	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-1026	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-1026	-0.2096785604953766	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-1026	-0.2096785604953766	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-1026	-1.0088 -0.3675 -0.0636 -0.1231 -0.0668 -0.0690 -0.1591 -0.3647 -0.6463 -0.4174 -0.1082 -0.1489 -0.0742 -0.1361 -0.0736 -0.0899 -0.1461 -0.2455 -0.0845 -0.0551 -0.0825 -0.1394 -0.1524
S-239	Die Plasmakonzentrationen fielen um mehr als 95 % innerhalb von sechs Stunden nach intravenöser Gabe .
T-239	Plasma concentrations fell by more than 95 % within six hours following intravenous administration .
H-239	-0.2789406180381775	Plasma concentrations fell by more than 95 % within six hours after intravenous administration .
D-239	-0.2789406180381775	Plasma concentrations fell by more than 95 % within six hours after intravenous administration .
P-239	-1.0160 -0.0698 -0.1067 -0.0754 -0.1554 -0.0657 -1.0948 -0.1826 -0.2061 -0.1429 -0.0963 -0.1389 -0.4084 -0.1472 -0.0909 -0.4198 -1.2391 -0.0781 -0.0956 -0.1461 -0.1469 -0.1440 -0.1489
S-435	Die Plasmakonzentrationen fielen um mehr als 95 % innerhalb von sechs Stunden nach intravenöser Gabe .
T-435	Plasma concentrations fell by more than 95 % within six hours following intravenous administration .
H-435	-0.2789406180381775	Plasma concentrations fell by more than 95 % within six hours after intravenous administration .
D-435	-0.2789406180381775	Plasma concentrations fell by more than 95 % within six hours after intravenous administration .
P-435	-1.0160 -0.0698 -0.1067 -0.0754 -0.1554 -0.0657 -1.0948 -0.1826 -0.2061 -0.1429 -0.0963 -0.1389 -0.4084 -0.1472 -0.0909 -0.4198 -1.2391 -0.0781 -0.0956 -0.1461 -0.1469 -0.1440 -0.1489
S-383	Ein Vitamin-D-Mangel entsteht , wenn Sonnenbestrahlung und Aufnahme aus der Nahrung unzureichend sind .
T-383	Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate .
H-383	-0.40254202485084534	Vitamin D deficiency occurs when exposure to the sun and food intake are insufficient .
D-383	-0.40254202485084534	Vitamin D deficiency occurs when exposure to the sun and food intake are insufficient .
P-383	-0.2356 -0.0656 -0.2006 -0.0262 -0.0215 -0.2791 -1.0913 -0.0891 -0.1752 -2.6016 -0.2278 -0.2583 -0.1716 -0.1537 -1.5687 -0.2059 -0.1291 -0.1984 -0.3510 -0.5077 -0.1462 -0.1518
S-674	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-674	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-674	-0.2096785604953766	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-674	-0.2096785604953766	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-674	-1.0088 -0.3675 -0.0636 -0.1231 -0.0668 -0.0690 -0.1591 -0.3647 -0.6463 -0.4174 -0.1082 -0.1489 -0.0742 -0.1361 -0.0736 -0.0899 -0.1461 -0.2455 -0.0845 -0.0551 -0.0825 -0.1394 -0.1524
S-73	Hauptindikator der Wirksamkeit war der Prozentsatz der Patienten mit geringem Vitamin-D-Spiegel .
T-73	The main measure of effectiveness was the percentage of patients with low vitamin D levels .
H-73	-0.42645105719566345	The main measure of efficacy was the percentage of patients with low vitamin D levels .
D-73	-0.42645105719566345	The main measure of efficacy was the percentage of patients with low vitamin D levels .
P-73	-0.4833 -1.3799 -0.0728 -0.1445 -1.0616 -0.0861 -0.1025 -0.1427 -0.1513 -0.2907 -0.1600 -0.1491 -0.3799 -0.3770 -2.0762 -0.0757 -0.1372 -0.9465 -0.1624 -0.1497
S-850	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-850	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-850	-0.2096785604953766	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-850	-0.2096785604953766	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-850	-1.0088 -0.3675 -0.0636 -0.1231 -0.0668 -0.0690 -0.1591 -0.3647 -0.6463 -0.4174 -0.1082 -0.1489 -0.0742 -0.1361 -0.0736 -0.0899 -0.1461 -0.2455 -0.0845 -0.0551 -0.0825 -0.1394 -0.1524
S-1202	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-1202	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-1202	-0.2096785604953766	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-1202	-0.2096785604953766	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-1202	-1.0088 -0.3675 -0.0636 -0.1231 -0.0668 -0.0690 -0.1591 -0.3647 -0.6463 -0.4174 -0.1082 -0.1489 -0.0742 -0.1361 -0.0736 -0.0899 -0.1461 -0.2455 -0.0845 -0.0551 -0.0825 -0.1394 -0.1524
S-1378	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-1378	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-1378	-0.2096785604953766	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-1378	-0.2096785604953766	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-1378	-1.0088 -0.3675 -0.0636 -0.1231 -0.0668 -0.0690 -0.1591 -0.3647 -0.6463 -0.4174 -0.1082 -0.1489 -0.0742 -0.1361 -0.0736 -0.0899 -0.1461 -0.2455 -0.0845 -0.0551 -0.0825 -0.1394 -0.1524
S-1555	Es liegen keine pharmakokinetischen Daten über den Einsatz von ADVATE bei bisher unbehandelten Patienten vor .
T-1555	Pharmacokinetic data with ADVATE on previously untreated patients are currently not available .
H-1555	-0.2096785604953766	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
D-1555	-0.2096785604953766	There are no pharmacokinetic data on the use of ADVATE in previously untreated patients .
P-1555	-1.0088 -0.3675 -0.0636 -0.1231 -0.0668 -0.0690 -0.1591 -0.3647 -0.6463 -0.4174 -0.1082 -0.1489 -0.0742 -0.1361 -0.0736 -0.0899 -0.1461 -0.2455 -0.0845 -0.0551 -0.0825 -0.1394 -0.1524
S-195	Ein Vitamin-D-Mangel entsteht , wenn Sonnenbestrahlung und Aufnahme aus der Nahrung unzureichend sind .
T-195	Vitamin D insufficiency develops when both sunlight exposure and dietary intake are inadequate .
H-195	-0.40254202485084534	Vitamin D deficiency occurs when exposure to the sun and food intake are insufficient .
D-195	-0.40254202485084534	Vitamin D deficiency occurs when exposure to the sun and food intake are insufficient .
P-195	-0.2356 -0.0656 -0.2006 -0.0262 -0.0215 -0.2791 -1.0913 -0.0891 -0.1752 -2.6016 -0.2278 -0.2583 -0.1716 -0.1537 -1.5687 -0.2059 -0.1291 -0.1984 -0.3510 -0.5077 -0.1462 -0.1518
S-1939	Ovale Tablette mit einer blauen und einer weißen Schicht , die blaue Schicht trägt die Prägung D12 .
T-1939	Blue and white bilayer oval tablet with D12 branded to blue layer .
H-1939	-0.2778567671775818	Oval tablet with a blue and a white layer , the blue layer is engraved with D12 .
D-1939	-0.2778567671775818	Oval tablet with a blue and a white layer , the blue layer is engraved with D12 .
P-1939	-0.5205 -0.2376 -0.1185 -0.6514 -0.1874 -0.0865 -0.2114 -0.3377 -0.0837 -0.6191 -0.2986 -0.1363 -0.0777 -0.3461 -0.2421 -1.3704 -0.0491 -0.0884 -0.2032 -0.1245 -0.1046 -0.1343 -0.1614
S-1206	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-1206	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-1206	-0.3316393792629242	After reconstitution Chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-1206	-0.3316393792629242	After reconstitution Chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-1206	-0.8745 -0.1978 -0.1058 -0.7796 -0.1183 -0.1473 -0.2134 -0.3058 -0.8390 -0.6210 -0.3471 -0.1823 -1.0101 -0.1413 -0.1284 -0.1718 -0.1990 -0.0830 -0.1232 -0.2086 -0.1671
S-1030	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-1030	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-1030	-0.3316393792629242	After reconstitution Chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-1030	-0.3316393792629242	After reconstitution Chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-1030	-0.8745 -0.1978 -0.1058 -0.7796 -0.1183 -0.1473 -0.2134 -0.3058 -0.8390 -0.6210 -0.3471 -0.1823 -1.0101 -0.1413 -0.1284 -0.1718 -0.1990 -0.0830 -0.1232 -0.2086 -0.1671
S-678	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-678	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-678	-0.3316393792629242	After reconstitution Chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-678	-0.3316393792629242	After reconstitution Chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-678	-0.8745 -0.1978 -0.1058 -0.7796 -0.1183 -0.1473 -0.2134 -0.3058 -0.8390 -0.6210 -0.3471 -0.1823 -1.0101 -0.1413 -0.1284 -0.1718 -0.1990 -0.0830 -0.1232 -0.2086 -0.1671
S-1382	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-1382	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-1382	-0.3316393792629242	After reconstitution Chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-1382	-0.3316393792629242	After reconstitution Chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-1382	-0.8745 -0.1978 -0.1058 -0.7796 -0.1183 -0.1473 -0.2134 -0.3058 -0.8390 -0.6210 -0.3471 -0.1823 -1.0101 -0.1413 -0.1284 -0.1718 -0.1990 -0.0830 -0.1232 -0.2086 -0.1671
S-1559	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-1559	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-1559	-0.3316393792629242	After reconstitution Chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-1559	-0.3316393792629242	After reconstitution Chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-1559	-0.8745 -0.1978 -0.1058 -0.7796 -0.1183 -0.1473 -0.2134 -0.3058 -0.8390 -0.6210 -0.3471 -0.1823 -1.0101 -0.1413 -0.1284 -0.1718 -0.1990 -0.0830 -0.1232 -0.2086 -0.1671
S-1764	Wenn Sie den Eindruck haben , dass die Wirkung von ADVATE unzureichend ist , informieren Sie Ihren Arzt .
T-1764	If you have the impression that the effect of ADVATE is insufficient , talk to your doctor .
H-1764	-0.21146047115325928	If you have the impression that the effect of ADVATE is insufficient , inform your doctor .
D-1764	-0.21146047115325928	If you have the impression that the effect of ADVATE is insufficient , inform your doctor .
P-1764	-0.1192 -0.1529 -0.5347 -0.1677 -0.1161 -0.1263 -0.5951 -0.1351 -0.1524 -0.0878 -0.1441 -0.0800 -0.0945 -0.1252 -0.1818 -0.3718 -0.1402 -0.8920 -0.0646 -0.1546 -0.1157 -0.1536 -0.1583
S-854	Nach der Rekonstitution Die chemischen und physikalischen Daten zeigen eine Stabilität von über 3 Stunden bei 25 <unk> C .
T-854	After reconstitution Chemical and physical in-use stability has been demonstrated for 3 hours at 25<<unk>> C .
H-854	-0.3316393792629242	After reconstitution Chemical and physical data show a stability of over 3 hours at 25 <unk> C .
D-854	-0.3316393792629242	After reconstitution Chemical and physical data show a stability of over 3 hours at 25 <unk> C .
P-854	-0.8745 -0.1978 -0.1058 -0.7796 -0.1183 -0.1473 -0.2134 -0.3058 -0.8390 -0.6210 -0.3471 -0.1823 -1.0101 -0.1413 -0.1284 -0.1718 -0.1990 -0.0830 -0.1232 -0.2086 -0.1671
S-512	Advate besteht aus einem Pulver und einem Lösungsmittel , die zur Herstellung einer Injektionslösung gemischt werden .
T-512	Advate is a powder and solvent that are mixed together to make a solution for injection .
H-512	-0.2977229356765747	Advate consists of a powder and a solvent mixed to produce a solution for injection .
D-512	-0.2977229356765747	Advate consists of a powder and a solvent mixed to produce a solution for injection .
P-512	-0.4927 -0.1081 -0.0537 -0.1084 -0.1589 -0.1347 -0.0873 -0.1421 -0.3868 -0.0849 -0.3384 -2.0637 -0.1786 -0.9246 -0.2302 -0.1558 -0.1275 -0.1009 -0.0762 -0.1467 -0.1518
S-518	Advate wird durch eine Injektion in eine Vene mit einer Geschwindigkeit von bis zu 10 ml pro Minute verabreicht .
T-518	Advate is given by injection into a vein at a rate of up to 10 ml per minute .
H-518	-0.24303293228149414	Advate is administered by injection into a vein at a rate of up to 10 ml per minute .
D-518	-0.24303293228149414	Advate is administered by injection into a vein at a rate of up to 10 ml per minute .
P-518	-0.5427 -0.0992 -0.1053 -0.6668 -0.1005 -0.3022 -0.1206 -0.0653 -0.1322 -0.1314 -0.0587 -0.0902 -0.1361 -1.1212 -0.8360 -0.1693 -0.2053 -0.1285 -0.1489 -0.1025 -0.1153 -0.1664 -0.1355 -0.1528
S-1890	Das Schreiben , in dem das Unternehmen die EMEA über die Rücknahme des Antrags informiert , kann hier aufgerufen werden .
T-1890	The letter from the company notifying the EMEA of the withdrawal of the application is available here .
H-1890	-0.37081336975097656	The letter advising the EMEA on the withdrawal of the application can be found here .
D-1890	-0.37081336975097656	The letter advising the EMEA on the withdrawal of the application can be found here .
P-1890	-0.3399 -0.5923 -2.1845 -0.2272 -0.2530 -0.1654 -0.1099 -0.1059 -0.5442 -0.1854 -0.6188 -0.1657 -0.2283 -0.1759 -0.5882 -0.1786 -0.2659 -0.1302 -0.2044 -0.1528
S-1769	Möglicherweise werden Sie höhere ADVATE-Dosen oder sogar ein anderes Produkt benötigen , um die Blutungen zu kontrollieren .
T-1769	You might need a higher dose of ADVATE or even a different product to control bleedings .
H-1769	-0.3496200740337372	You may need higher doses of ADVATE , or even another product to control the bleeding .
D-1769	-0.3496200740337372	You may need higher doses of ADVATE , or even another product to control the bleeding .
P-1769	-0.4934 -0.1852 -0.4035 -0.2293 -0.2239 -0.0821 -0.1841 -0.0871 -0.1651 -0.1149 -0.1362 -0.8460 -0.1407 -0.2137 -0.6755 -0.0940 -0.8187 -0.2994 -1.1273 -0.9361 -0.2513 -0.1764 -0.1572
S-542	Die vollständige Auflistung der im Zusammenhang mit Advate berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-542	For the full list of all side effects reported with Advate , see the Package Leaflet .
H-542	-0.27503782510757446	For a full list of reported side effects with Advate , see the Package Leaflet .
D-542	-0.27503782510757446	For a full list of reported side effects with Advate , see the Package Leaflet .
P-542	-0.1798 -0.1293 -0.0827 -0.1786 -0.1589 -0.6415 -1.2503 -0.1259 -1.0338 -0.4389 -0.0812 -0.1485 -0.4479 -0.1426 -0.1208 -0.1240 -0.0447 -0.0470 -0.0959 -0.1541 -0.1492
S-639	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-639	6 The immunogenicity of ADVATE was evaluated in previously treated patients .
H-639	-0.3052123785018921	Inhibitor Development The neoantigenicity of ADVATE was evaluated in previously treated patients .
D-639	-0.3052123785018921	Inhibitor Development The neoantigenicity of ADVATE was evaluated in previously treated patients .
P-639	-0.3320 -0.0256 -0.0920 -0.1461 -0.8898 -1.4199 -0.4219 -0.1886 -0.1044 -0.0444 -0.2566 -0.1238 -0.1421 -0.0866 -0.1357 -0.0779 -0.1030 -0.8254 -1.0170 -0.1355 -0.1142 -0.7375 -0.1227 -0.0984 -0.1435 -0.1511
S-517	Die Behandlung mit Advate sollte von einem Arzt eingeleitet werden , der über Erfahrung in der Behandlung von Hämophilie verfügt .
T-517	Advate should be started by a doctor who has experience in the treatment of haemophilia .
H-517	-0.25964969396591187	Treatment with Advate should be initiated by a physician with experience in the treatment of haemophilia .
D-517	-0.25964969396591187	Treatment with Advate should be initiated by a physician with experience in the treatment of haemophilia .
P-517	-1.0048 -0.0567 -0.1080 -0.1665 -0.4367 -0.0954 -0.1587 -0.1282 -0.1472 -0.1022 -0.1600 -0.1990 -0.9294 -0.2019 -0.4519 -0.1873 -0.2730 -0.5277 -0.1834 -0.1397 -0.1613 -0.0735 -0.1700 -0.3891 -0.1449 -0.1544
S-1341	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-1341	46 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-1341	-0.3052123785018921	Inhibitor Development The neoantigenicity of ADVATE was evaluated in previously treated patients .
D-1341	-0.3052123785018921	Inhibitor Development The neoantigenicity of ADVATE was evaluated in previously treated patients .
P-1341	-0.3320 -0.0256 -0.0920 -0.1461 -0.8898 -1.4199 -0.4219 -0.1886 -0.1044 -0.0444 -0.2566 -0.1238 -0.1421 -0.0866 -0.1357 -0.0779 -0.1030 -0.8254 -1.0170 -0.1355 -0.1142 -0.7375 -0.1227 -0.0984 -0.1435 -0.1511
S-245	Verteilung Nach der Resorption geht Vitamin D3 als Bestandteil von Chylomikronen ins Blut über .
T-245	Distribution Following absorption , vitamin D3 enters the blood as part of chylomicrons .
H-245	-0.28449493646621704	Distribution After absorption , vitamin D3 is absorbed by the blood as a component of chylomicrons .
D-245	-0.28449493646621704	Distribution After absorption , vitamin D3 is absorbed by the blood as a component of chylomicrons .
P-245	-0.1080 -0.1171 -1.0823 -0.0404 -0.0973 -0.3241 -0.1319 -0.1064 -0.1322 -0.1350 -0.2990 -0.8524 -0.0449 -0.9850 -0.1227 -0.0573 -0.1396 -0.3292 -1.1341 -0.0911 -0.2710 -0.1561 -0.1395 -0.1063 -0.0993 -0.2891 -0.5502 -0.1575 -0.1515
S-1730	WAS IST ADVATE UND WOFÜR WIRD ES ANGEWENDET ?
T-1730	WHAT ADVATE IS AND WHAT IT IS USED FOR
H-1730	-0.14369097352027893	WHAT ADVATE IS AND WHAT IT IS USED FOR
D-1730	-0.14369097352027893	WHAT ADVATE IS AND WHAT IT IS USED FOR
P-1730	-0.0891 -0.0413 -0.0489 -0.1543 -0.0980 -0.1169 -0.0464 -0.0813 -0.1336 -0.0559 -0.3518 -0.0201 -0.1908 -0.0643 -0.4238 -0.0739 -0.4524
S-1998	Es wird nicht erwartet , dass Pseudoephedrinsulfat die psychomotorische Leistungsfähigkeit beeinträchtigt .
T-1998	It is not expected that pseudoephedrine sulphate impairs psychomotor performance .
H-1998	-0.30296000838279724	Pseudoephedrine sulphate is not expected to affect psychomotor function .
D-1998	-0.30296000838279724	Pseudoephedrine sulphate is not expected to affect psychomotor function .
P-1998	-0.2373 -0.2115 -0.1660 -0.3564 -0.1216 -0.1775 -0.2071 -0.0769 -0.1527 -0.0993 -0.1753 -0.1612 -0.0923 -0.1242 -1.4779 -0.8305 -0.1543 -0.1992 -0.3439 -0.9891 -0.1551 -0.1560
S-695	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-695	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-695	-0.35757607221603394	- Do not use the BAXJECT II Unit Set if its sterile barrier is breached ,
D-695	-0.35757607221603394	- Do not use the BAXJECT II Unit Set if its sterile barrier is breached ,
P-695	-0.1929 -0.0396 -0.1331 -0.1081 -0.2040 -0.1817 -0.1748 -0.3153 -0.0978 -0.0976 -0.1849 -1.5304 -0.1241 -0.9779 -0.3094 -0.1091 -0.1411 -0.0521 -0.1788 -1.2836 -1.4174 -0.1803 -0.3144 -0.2335
S-1835	elezna cesta 14 SI-1000 Ljubljana Tel . : <unk> 386 1 420 16 80
T-1835	elezna cesta 14 SI-1000 Ljubljana Tel . : <<unk>> 386 1 420 16 80
H-1835	-0.14188292622566223	elezna cesta 14 SI-1000 Ljubljana Tel . : <unk> 386 1 420 16 80
D-1835	-0.14188292622566223	elezna cesta 14 SI-1000 Ljubljana Tel . : <unk> 386 1 420 16 80
P-1835	-0.3027 -0.1001 -0.2240 -0.1547 -0.0814 -0.1386 -0.1259 -0.1737 -0.1047 -0.0677 -0.1046 -0.2636 -0.1244 -0.3806 -0.0505 -0.1435 -0.1353 -0.0370 -0.0774 -0.1320 -0.1421 -0.1264 -0.1182 -0.1170 -0.1115 -0.1514
S-1737	- wenn Sie allergisch ( überempfindlich ) gegen Octocog alfa oder einem der sonstigen Bestandteile
T-1737	- if you are allergic ( hypersensitive ) to octocog alfa or any of the other ingredients of ADVATE
H-1737	-0.16283977031707764	- if you are allergic ( hypersensitive ) to Octocog alfa or to any of the ingredients
D-1737	-0.16283977031707764	- if you are allergic ( hypersensitive ) to Octocog alfa or to any of the ingredients
P-1737	-0.1882 -0.1171 -0.1172 -0.1348 -0.0772 -0.0295 -0.1633 -0.1170 -0.0616 -0.1476 -0.1488 -0.6264 -0.0924 -0.1432 -0.2483 -0.1175 -0.0595 -0.1589 -0.2904 -0.1243 -0.1575 -0.2009 -0.2429 -0.1437
S-1576	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-1576	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1576	-0.35757607221603394	- Do not use the BAXJECT II Unit Set if its sterile barrier is breached ,
D-1576	-0.35757607221603394	- Do not use the BAXJECT II Unit Set if its sterile barrier is breached ,
P-1576	-0.1929 -0.0396 -0.1331 -0.1081 -0.2040 -0.1817 -0.1748 -0.3153 -0.0978 -0.0976 -0.1849 -1.5304 -0.1241 -0.9779 -0.3094 -0.1091 -0.1411 -0.0521 -0.1788 -1.2836 -1.4174 -0.1803 -0.3144 -0.2335
S-1399	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-1399	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1399	-0.35757607221603394	- Do not use the BAXJECT II Unit Set if its sterile barrier is breached ,
D-1399	-0.35757607221603394	- Do not use the BAXJECT II Unit Set if its sterile barrier is breached ,
P-1399	-0.1929 -0.0396 -0.1331 -0.1081 -0.2040 -0.1817 -0.1748 -0.3153 -0.0978 -0.0976 -0.1849 -1.5304 -0.1241 -0.9779 -0.3094 -0.1091 -0.1411 -0.0521 -0.1788 -1.2836 -1.4174 -0.1803 -0.3144 -0.2335
S-1223	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-1223	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1223	-0.35757607221603394	- Do not use the BAXJECT II Unit Set if its sterile barrier is breached ,
D-1223	-0.35757607221603394	- Do not use the BAXJECT II Unit Set if its sterile barrier is breached ,
P-1223	-0.1929 -0.0396 -0.1331 -0.1081 -0.2040 -0.1817 -0.1748 -0.3153 -0.0978 -0.0976 -0.1849 -1.5304 -0.1241 -0.9779 -0.3094 -0.1091 -0.1411 -0.0521 -0.1788 -1.2836 -1.4174 -0.1803 -0.3144 -0.2335
S-1047	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-1047	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1047	-0.35757607221603394	- Do not use the BAXJECT II Unit Set if its sterile barrier is breached ,
D-1047	-0.35757607221603394	- Do not use the BAXJECT II Unit Set if its sterile barrier is breached ,
P-1047	-0.1929 -0.0396 -0.1331 -0.1081 -0.2040 -0.1817 -0.1748 -0.3153 -0.0978 -0.0976 -0.1849 -1.5304 -0.1241 -0.9779 -0.3094 -0.1091 -0.1411 -0.0521 -0.1788 -1.2836 -1.4174 -0.1803 -0.3144 -0.2335
S-871	- Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen ,
T-871	- Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-871	-0.35757607221603394	- Do not use the BAXJECT II Unit Set if its sterile barrier is breached ,
D-871	-0.35757607221603394	- Do not use the BAXJECT II Unit Set if its sterile barrier is breached ,
P-871	-0.1929 -0.0396 -0.1331 -0.1081 -0.2040 -0.1817 -0.1748 -0.3153 -0.0978 -0.0976 -0.1849 -1.5304 -0.1241 -0.9779 -0.3094 -0.1091 -0.1411 -0.0521 -0.1788 -1.2836 -1.4174 -0.1803 -0.3144 -0.2335
S-15	Die Wirksamkeit und Sicherheit von Adenuric wurden bei Patienten mit schweren Nieren- oder Leberproblemen nicht untersucht .
T-15	The safety and effectiveness of Adenuric have not been studied in patients with severe kidney or liver problems .
H-15	-0.21409872174263	The efficacy and safety of Adenuric have not been evaluated in patients with severe renal or liver problems .
D-15	-0.21409872174263	The efficacy and safety of Adenuric have not been evaluated in patients with severe renal or liver problems .
P-15	-0.3881 -0.1500 -0.0497 -0.0893 -0.1375 -0.0650 -0.1474 -0.1614 -0.2011 -0.0792 -0.1140 -0.2049 -0.1078 -0.0845 -1.2659 -0.1540 -0.1372 -0.2656 -0.1981 -0.2349 -0.1429 -0.1266 -0.1416 -0.6375 -0.1976 -0.1482 -0.1507
S-1860	Der Wirkstoff in Advexin , Contusugene Ladenovec , ist ein viraler Vektor .
T-1860	The active substance in Advexin , contusugene ladenovec , is a viral vector .
H-1860	-0.2543180286884308	The active substance in Advexin , Contusugene Ladenovec , is a viral vector .
D-1860	-0.2543180286884308	The active substance in Advexin , Contusugene Ladenovec , is a viral vector .
P-1860	-0.1649 -0.1257 -0.0993 -0.1481 -1.1643 -0.1469 -0.1409 -0.1485 -0.1908 -0.3499 -0.1136 -0.1296 -1.4673 -0.1467 -0.1508 -0.1078 -0.1519 -0.1185 -0.1086 -0.4066 -0.0688 -0.1545 -0.1491 -0.1507
S-1518	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-1518	56 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-1518	-0.3052123785018921	Inhibitor Development The neoantigenicity of ADVATE was evaluated in previously treated patients .
D-1518	-0.3052123785018921	Inhibitor Development The neoantigenicity of ADVATE was evaluated in previously treated patients .
P-1518	-0.3320 -0.0256 -0.0920 -0.1461 -0.8898 -1.4199 -0.4219 -0.1886 -0.1044 -0.0444 -0.2566 -0.1238 -0.1421 -0.0866 -0.1357 -0.0779 -0.1030 -0.8254 -1.0170 -0.1355 -0.1142 -0.7375 -0.1227 -0.0984 -0.1435 -0.1511
S-1165	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-1165	36 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-1165	-0.3052123785018921	Inhibitor Development The neoantigenicity of ADVATE was evaluated in previously treated patients .
D-1165	-0.3052123785018921	Inhibitor Development The neoantigenicity of ADVATE was evaluated in previously treated patients .
P-1165	-0.3320 -0.0256 -0.0920 -0.1461 -0.8898 -1.4199 -0.4219 -0.1886 -0.1044 -0.0444 -0.2566 -0.1238 -0.1421 -0.0866 -0.1357 -0.0779 -0.1030 -0.8254 -1.0170 -0.1355 -0.1142 -0.7375 -0.1227 -0.0984 -0.1435 -0.1511
S-813	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-813	16 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-813	-0.3052123785018921	Inhibitor Development The neoantigenicity of ADVATE was evaluated in previously treated patients .
D-813	-0.3052123785018921	Inhibitor Development The neoantigenicity of ADVATE was evaluated in previously treated patients .
P-813	-0.3320 -0.0256 -0.0920 -0.1461 -0.8898 -1.4199 -0.4219 -0.1886 -0.1044 -0.0444 -0.2566 -0.1238 -0.1421 -0.0866 -0.1357 -0.0779 -0.1030 -0.8254 -1.0170 -0.1355 -0.1142 -0.7375 -0.1227 -0.0984 -0.1435 -0.1511
S-989	Inhibitorentwicklung Die Neoantigenität von ADVATE wurde an zuvor behandelten Patienten beurteilt .
T-989	26 Inhibitor Development The immunogenicity of ADVATE was evaluated in previously treated patients .
H-989	-0.3052123785018921	Inhibitor Development The neoantigenicity of ADVATE was evaluated in previously treated patients .
D-989	-0.3052123785018921	Inhibitor Development The neoantigenicity of ADVATE was evaluated in previously treated patients .
P-989	-0.3320 -0.0256 -0.0920 -0.1461 -0.8898 -1.4199 -0.4219 -0.1886 -0.1044 -0.0444 -0.2566 -0.1238 -0.1421 -0.0866 -0.1357 -0.0779 -0.1030 -0.8254 -1.0170 -0.1355 -0.1142 -0.7375 -0.1227 -0.0984 -0.1435 -0.1511
S-441	Verteilung Nach der Resorption geht Vitamin D3 als Bestandteil von Chylomikronen ins Blut über .
T-441	Distribution Following absorption , vitamin D3 enters the blood as part of chylomicrons .
H-441	-0.28449493646621704	Distribution After absorption , vitamin D3 is absorbed by the blood as a component of chylomicrons .
D-441	-0.28449493646621704	Distribution After absorption , vitamin D3 is absorbed by the blood as a component of chylomicrons .
P-441	-0.1080 -0.1171 -1.0823 -0.0404 -0.0973 -0.3241 -0.1319 -0.1064 -0.1322 -0.1350 -0.2990 -0.8524 -0.0449 -0.9850 -0.1227 -0.0573 -0.1396 -0.3292 -1.1341 -0.0911 -0.2710 -0.1561 -0.1395 -0.1063 -0.0993 -0.2891 -0.5502 -0.1575 -0.1515
S-374	Studien zur Präklinik zeigten , dass Alendronat sich bevorzugt an den Stellen der aktiven Resorption konzentriert .
T-374	Preclinical studies have shown preferential localisation of alendronate to sites of active resorption .
H-374	-0.35115325450897217	Preclinical studies have shown that alendronate preferably concentrates at sites of active absorption .
D-374	-0.35115325450897217	Preclinical studies have shown that alendronate preferably concentrates at sites of active absorption .
P-374	-0.6963 -0.7073 -0.0272 -0.2479 -0.2795 -0.4977 -0.3651 -0.1215 -0.0973 -0.1584 -0.1005 -0.0641 -2.6322 -0.3325 -0.3032 -0.1969 -0.2987 -0.5877 -0.2096 -0.0759 -0.0602 -0.0795 -0.1363 -0.1519
S-24	Die Wirkungen von Adenuric wurden zunächst in Versuchsmodellen getestet , bevor sie an Menschen untersucht wurden .
T-24	The effects of Adenuric were first tested in experimental models before being studied in humans .
H-24	-0.3743884563446045	The effects of Adenuric were first tested in experimental models before being studied in humans .
D-24	-0.3743884563446045	The effects of Adenuric were first tested in experimental models before being studied in humans .
P-24	-1.7064 -0.2972 -0.1572 -0.1620 -0.1946 -0.0733 -0.1164 -0.2278 -0.8894 -0.8326 -0.1348 -1.0480 -0.0720 -0.1947 -0.5287 -0.3701 -0.2211 -0.1281 -0.2117 -0.1439 -0.1520
S-1755	Die Behandlung mit ADVATE wird von einem in der Behandlung von Hämophilie A erfahrenen Arzt eingeleitet .
T-1755	Treatment with ADVATE will be started by a doctor who is experienced in the care of patients with haemophilia A.
H-1755	-0.3018823266029358	ADVATE treatment is initiated by a physician with experience in the treatment of haemophilia A .
D-1755	-0.3018823266029358	ADVATE treatment is initiated by a physician with experience in the treatment of haemophilia A .
P-1755	-0.8893 -0.1561 -0.0883 -0.0962 -0.8282 -0.1485 -0.0904 -0.1090 -0.1542 -0.2798 -0.5483 -0.1437 -0.8436 -0.9064 -0.2412 -0.3657 -0.1724 -0.1412 -0.2635 -0.0857 -0.1763 -0.2275 -0.1654 -0.2739 -0.1523
S-1630	74 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1630	68 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1630	-0.09230365604162216	74 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-1630	-0.09230365604162216	74 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-1630	-1.0483 -0.0983 -0.0366 -0.0186 -0.0715 -0.0609 -0.0235 -0.0517 -0.0382 -0.0363 -0.0324 -0.0465 -0.4160 -0.0226 -0.0420 -0.0189 -0.0439 -0.1932 -0.0579 -0.0232 -0.0157 -0.0172 -0.0120 -0.0551 -0.0420 -0.0725 -0.1108 -0.0910 -0.0727 -0.0778 -0.0071 -0.0238 -0.0288 -0.1314
S-1663	82 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1663	76 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1663	-0.10180728882551193	82 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-1663	-0.10180728882551193	82 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-1663	-1.3995 -0.0951 -0.0361 -0.0157 -0.0732 -0.0635 -0.0184 -0.0536 -0.0368 -0.0411 -0.0323 -0.0481 -0.4001 -0.0168 -0.0432 -0.0186 -0.0443 -0.1933 -0.0602 -0.0226 -0.0159 -0.0164 -0.0117 -0.0545 -0.0426 -0.0751 -0.1044 -0.0909 -0.0692 -0.0781 -0.0070 -0.0245 -0.0271 -0.1318
S-523	Faktor VIII ist eine der Substanzen ( Faktoren ) im Körper , die an der Blutgerinnung beteiligt sind .
T-523	In the body , factor VIII is one of the substances ( factors ) involved in blood coagulation ( clotting ) .
H-523	-0.26604968309402466	Factor VIII is one of the substances ( factors ) in the body that contributes to blood clotting .
D-523	-0.26604968309402466	Factor VIII is one of the substances ( factors ) in the body that contributes to blood clotting .
P-523	-0.4613 -0.1461 -0.1175 -0.1299 -0.1545 -0.1610 -0.1921 -0.8899 -0.1227 -0.1592 -0.1646 -0.1370 -0.2084 -0.1440 -0.0839 -0.5084 -1.6903 -0.0710 -0.1688 -0.2991 -0.2026 -0.0395 -0.1022 -0.1420 -0.1553
S-1878	Nachdem der CHMP die Antworten des Unternehmens auf die ihm gestellten Fragen geprüft hatte , waren immer noch einige Fragen ungeklärt .
T-1878	After the CHMP had assessed the responses from the company to a list of questions , there were still some unresolved issues outstanding .
H-1878	-0.8271281123161316	After the CHMP reviewed the company &apos;s replies to the questions it received , a number of issues remained unresolved .
D-1878	-0.8271281123161316	After the CHMP reviewed the company &apos;s replies to the questions it received , a number of issues remained unresolved .
P-1878	-0.9469 -1.8657 -0.0824 -0.0428 -0.7282 -0.4227 -0.5596 -1.8435 -2.1509 -0.2641 -0.1929 -0.2290 -0.6662 -2.6499 -1.0171 -0.1444 -1.7034 -0.2873 -0.1432 -2.5715 -1.3458 -0.3013 -0.2251 -0.1409 -0.1533
S-1646	78 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1646	72 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1646	-0.1271575391292572	78 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-1646	-0.1271575391292572	78 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-1646	-2.1947 -0.0910 -0.0362 -0.0178 -0.0809 -0.0671 -0.0218 -0.0455 -0.0368 -0.0380 -0.0333 -0.0466 -0.4320 -0.0224 -0.0437 -0.0189 -0.0451 -0.2143 -0.0603 -0.0238 -0.0175 -0.0178 -0.0126 -0.0533 -0.0412 -0.0716 -0.1114 -0.0844 -0.0754 -0.0769 -0.0076 -0.0246 -0.0290 -0.1296
S-351	Folgende Nebenwirkungen wurden während klinischer Studien und<unk> oder nach Markteinführung von Alendronat berichtet .
T-351	The following adverse reactions have been reported during clinical studies and/ or post-marketing use with alendronate .
H-351	-0.22532065212726593	The following adverse reactions have been reported during clinical trials and/ or post-marketing experience with alendronate .
D-351	-0.22532065212726593	The following adverse reactions have been reported during clinical trials and/ or post-marketing experience with alendronate .
P-351	-0.4560 -0.0969 -0.8919 -0.0960 -0.1967 -0.0432 -0.3521 -0.1344 -0.0757 -0.0735 -0.1503 -0.3175 -0.0295 -0.1454 -0.1611 -1.1036 -0.0809 -0.0205 -0.0205 -0.6949 -0.1566 -0.1506 -0.0737 -0.0392 -0.1473 -0.1502
S-1680	86 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1680	80 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1680	-0.13417047262191772	86 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-1680	-0.13417047262191772	86 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-1680	-2.4681 -0.1070 -0.0415 -0.0138 -0.0772 -0.0653 -0.0197 -0.0514 -0.0386 -0.0373 -0.0321 -0.0467 -0.3995 -0.0184 -0.0427 -0.0193 -0.0436 -0.1937 -0.0520 -0.0233 -0.0188 -0.0158 -0.0113 -0.0563 -0.0429 -0.0768 -0.1086 -0.0880 -0.0759 -0.0792 -0.0070 -0.0258 -0.0282 -0.1359
S-1696	90 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1696	84 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1696	-0.10107995569705963	90 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-1696	-0.10107995569705963	90 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-1696	-1.3414 -0.1189 -0.0299 -0.0147 -0.0753 -0.0646 -0.0201 -0.0457 -0.0383 -0.0361 -0.0320 -0.0446 -0.4084 -0.0187 -0.0425 -0.0187 -0.0437 -0.2014 -0.0568 -0.0249 -0.0172 -0.0164 -0.0114 -0.0573 -0.0437 -0.0759 -0.1046 -0.0874 -0.0775 -0.0767 -0.0075 -0.0246 -0.0269 -0.1329
S-1712	94 MINDESTANGABEN AUF KLEINEN BEHÄLTNISSEN
T-1712	88 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1712	-0.13791625201702118	93 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
D-1712	-0.13791625201702118	93 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
P-1712	-2.5779 -0.1100 -0.0386 -0.0181 -0.0714 -0.0657 -0.0193 -0.0519 -0.0406 -0.0374 -0.0338 -0.0468 -0.4056 -0.0192 -0.0428 -0.0192 -0.0434 -0.1999 -0.0584 -0.0243 -0.0166 -0.0161 -0.0122 -0.0540 -0.0440 -0.0716 -0.1078 -0.0890 -0.0785 -0.0759 -0.0081 -0.0240 -0.0281 -0.1388
S-248	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden .
T-248	Zirkulierendes Vitamin D3 ist an Vitamin-D-bindendes Protein gebunden . Circulating vitamin D3 is bound to vitamin D-binding protein .
H-248	-0.20699229836463928	Circulating vitamin D3 is bound to vitamin D-binding protein .
D-248	-0.20699229836463928	Circulating vitamin D3 is bound to vitamin D-binding protein .
P-248	-0.3816 -0.1489 -0.0997 -0.0884 -0.1193 -0.1283 -0.1318 -0.1155 -0.1788 -0.1469 -0.4750 -0.0673 -1.1771 -0.1327 -0.0445 -0.1255 -0.0605 -0.1546 -0.1565
S-1873	Die 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-1873	Die 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel. 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-1873	-0.15340356528759003	Die 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-1873	-0.15340356528759003	Die 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-1873	-0.9553 -0.1091 -0.1028 -0.0971 -0.0770 -0.0919 -0.0687 -0.1516 -0.0995 -0.1286 -0.1235 -0.2255 -0.1201 -0.1529 -0.1223 -0.0974 -0.1131 -0.1501 -0.1202 -0.1063 -0.1500 -0.1043 -0.0848 -0.1338 -0.1493
S-150	B. Cholestyramin , Colestipol ) können die Resorption von Vitamin D beeinträchtigen .
T-150	Colecalciferol Olestra , mineral oils , orlistat , and bile acid sequestrants ( e. g. cholestyramine , colestipol ) may impair the absorption of vitamin D.
H-150	-0.38413679599761963	cholestyramine , colestipol ) may affect the absorption of vitamin D .
D-150	-0.38413679599761963	cholestyramine , colestipol ) may affect the absorption of vitamin D .
P-150	-0.9612 -0.0574 -0.1096 -0.0829 -0.2882 -0.1971 -0.2130 -0.1475 -1.9494 -0.1376 -0.1178 -2.3483 -0.1738 -0.0346 -0.0690 -0.1412 -0.1899 -0.0818 -0.2542 -0.3548 -0.1576
S-338	B. Cholestyramin , Colestipol ) können die Resorption von Vitamin D beeinträchtigen .
T-338	Colecalciferol Olestra , mineral oils , orlistat , and bile acid sequestrants ( e. g. cholestyramine , colestipol ) may impair the absorption of vitamin D.
H-338	-0.38413679599761963	cholestyramine , colestipol ) may affect the absorption of vitamin D .
D-338	-0.38413679599761963	cholestyramine , colestipol ) may affect the absorption of vitamin D .
P-338	-0.9612 -0.0574 -0.1096 -0.0829 -0.2882 -0.1971 -0.2130 -0.1475 -1.9494 -0.1376 -0.1178 -2.3483 -0.1738 -0.0346 -0.0690 -0.1412 -0.1899 -0.0818 -0.2542 -0.3548 -0.1576
S-163	Folgende Nebenwirkungen wurden während klinischer Studien und<unk> oder nach Markteinführung von Alendronat berichtet .
T-163	The following adverse reactions have been reported during clinical studies and/ or post-marketing use with alendronate .
H-163	-0.22532065212726593	The following adverse reactions have been reported during clinical trials and/ or post-marketing experience with alendronate .
D-163	-0.22532065212726593	The following adverse reactions have been reported during clinical trials and/ or post-marketing experience with alendronate .
P-163	-0.4560 -0.0969 -0.8919 -0.0960 -0.1967 -0.0432 -0.3521 -0.1344 -0.0757 -0.0735 -0.1503 -0.3175 -0.0295 -0.1454 -0.1611 -1.1036 -0.0809 -0.0205 -0.0205 -0.6949 -0.1566 -0.1506 -0.0737 -0.0392 -0.1473 -0.1502
S-426	Die gemeinsame Einnahme von Alendronat mit Kaffee oder Orangensaft reduzierte die Bioverfügbarkeit um etwa 60 <unk> .
T-426	Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60 % .
H-426	-0.2839236557483673	Alendronate concomitantly with coffee or orange juice reduced bioavailability by approximately 60 <unk> .
D-426	-0.2839236557483673	Alendronate concomitantly with coffee or orange juice reduced bioavailability by approximately 60 <unk> .
P-426	-0.9812 -0.1719 -0.1121 -0.0550 -0.9777 -0.0257 -0.0088 -0.9152 -0.1056 -0.1658 -0.1182 -0.3736 -0.3524 -0.3056 -0.1530 -0.1104 -0.1700 -0.2949 -0.1396 -0.3590 -0.1934 -0.1572
S-1779	Wenn Sie die Anwendung von ADVATE abbrechen Brechen Sie die Anwendung von ADVATE nicht ab ohne Ihren Arzt zu befragen .
T-1779	If you stop using ADVATE Do not stop using ADVATE without consulting your doctor .
H-1779	-0.5641240477561951	If you stop using ADVATE , do not discontinue use of ADVATE without consulting your doctor .
D-1779	-0.5641240477561951	If you stop using ADVATE , do not discontinue use of ADVATE without consulting your doctor .
P-1779	-0.3956 -0.1176 -3.7368 -0.6525 -0.1119 -0.1450 -0.0839 -0.0920 -0.9129 -0.2164 -0.1450 -1.6230 -0.3160 -1.9745 -0.3302 -0.0995 -0.1394 -0.0835 -0.0949 -0.1900 -2.5209 -0.1180 -0.1356 -0.1133 -0.1493 -0.1693
S-819	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-819	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-819	-0.45859968662261963	The frequency of detection of FVIII inhibitors to date is in line with expectations and in the range observed .
D-819	-0.45859968662261963	The frequency of detection of FVIII inhibitors to date is in line with expectations and in the range observed .
P-819	-0.3003 -1.7075 -0.0722 -2.0607 -0.2007 -0.1368 -0.2006 -0.1964 -0.1513 -0.1136 -0.6398 -0.1156 -0.0248 -0.0808 -0.1190 -1.0434 -0.1062 -1.0441 -1.1785 -0.0922 -0.1142 -0.0711 -0.1181 -0.6645 -0.1538 -0.2423 -1.2102 -0.9856 -0.1550
S-1752	Verkehrstüchtigkeit und das Bedienen von Maschinen ADVATE hat keine Auswirkungen auf die Verkehrstüchtigkeit und das Bedienen von Maschinen .
T-1752	Driving and using machines ADVATE has no influence on your ability to drive or to use machines .
H-1752	-0.24804913997650146	Driving and using machines ADVATE has no effect on the ability to drive and use machines .
D-1752	-0.24804913997650146	Driving and using machines ADVATE has no effect on the ability to drive and use machines .
P-1752	-0.2939 -0.1100 -0.1210 -0.1099 -0.1294 -0.0846 -0.1413 -0.0724 -0.1025 -0.2835 -0.1502 -0.9723 -0.1816 -1.0548 -0.1108 -0.5515 -0.2470 -0.2145 -0.0974 -0.1032 -0.1544 -0.1711
S-1794	Verwenden Sie ADVATE nicht mehr nach dem Verfalldatum , das auf dem Etikett nach verwendbar bis angegeben ist . .
T-1794	Do not use ADVATE after the expiry date , which is stated on the label after EXP .
H-1794	-0.38102325797080994	Do not use ADVATE after the expiry date listed on the label until .
D-1794	-0.38102325797080994	Do not use ADVATE after the expiry date listed on the label until .
P-1794	-0.0406 -0.1633 -0.2373 -0.1035 -0.1383 -0.0822 -0.1048 -0.8122 -0.1808 -0.0179 -0.0678 -0.1589 -3.1351 -0.1261 -0.1422 -0.1369 -0.3138 -1.0683 -0.2095
S-645	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-645	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-645	-0.45859968662261963	The frequency of detection of FVIII inhibitors to date is in line with expectations and in the range observed .
D-645	-0.45859968662261963	The frequency of detection of FVIII inhibitors to date is in line with expectations and in the range observed .
P-645	-0.3003 -1.7075 -0.0722 -2.0607 -0.2007 -0.1368 -0.2006 -0.1964 -0.1513 -0.1136 -0.6398 -0.1156 -0.0248 -0.0808 -0.1190 -1.0434 -0.1062 -1.0441 -1.1785 -0.0922 -0.1142 -0.0711 -0.1181 -0.6645 -0.1538 -0.2423 -1.2102 -0.9856 -0.1550
S-230	Die gemeinsame Einnahme von Alendronat mit Kaffee oder Orangensaft reduzierte die Bioverfügbarkeit um etwa 60 <unk> .
T-230	Concomitant administration of alendronate with coffee or orange juice reduced bioavailability by approximately 60 % .
H-230	-0.2839236557483673	Alendronate concomitantly with coffee or orange juice reduced bioavailability by approximately 60 <unk> .
D-230	-0.2839236557483673	Alendronate concomitantly with coffee or orange juice reduced bioavailability by approximately 60 <unk> .
P-230	-0.9812 -0.1719 -0.1121 -0.0550 -0.9777 -0.0257 -0.0088 -0.9152 -0.1056 -0.1658 -0.1182 -0.3736 -0.3524 -0.3056 -0.1530 -0.1104 -0.1700 -0.2949 -0.1396 -0.3590 -0.1934 -0.1572
S-1347	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-1347	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-1347	-0.45859968662261963	The frequency of detection of FVIII inhibitors to date is in line with expectations and in the range observed .
D-1347	-0.45859968662261963	The frequency of detection of FVIII inhibitors to date is in line with expectations and in the range observed .
P-1347	-0.3003 -1.7075 -0.0722 -2.0607 -0.2007 -0.1368 -0.2006 -0.1964 -0.1513 -0.1136 -0.6398 -0.1156 -0.0248 -0.0808 -0.1190 -1.0434 -0.1062 -1.0441 -1.1785 -0.0922 -0.1142 -0.0711 -0.1181 -0.6645 -0.1538 -0.2423 -1.2102 -0.9856 -0.1550
S-638	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-638	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-638	-0.3799603283405304	Upon completion of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
D-638	-0.3799603283405304	Upon completion of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
P-638	-1.8571 -0.1300 -1.0606 -0.0709 -0.1501 -0.6801 -0.1616 -0.1407 -0.0794 -0.0948 -0.1676 -0.1741 -0.2113 -0.2798 -1.2119 -0.5485 -0.1094 -0.0307 -0.0799 -0.1159 -0.2271 -1.8272 -0.1305 -0.5759 -0.2344 -0.1459 -0.2108 -0.1396 -0.1429 -0.8858 -0.1341 -0.1501
S-469	Name und Anschrift des ( der ) Hersteller<unk> s ) , der ( die ) für die Chargenfreigabe verantwortlich ist ( sind )
T-469	Name and address of the manufacturer<<unk>> s ) responsible for batch release
H-469	-0.3132222294807434	Name and address of the manufacturer ( s ) responsible for batch release ( s )
D-469	-0.3132222294807434	Name and address of the manufacturer ( s ) responsible for batch release ( s )
P-469	-2.2883 -0.1323 -0.0745 -0.1776 -0.4413 -0.6992 -0.1421 -0.1232 -0.1235 -0.0732 -0.2392 -0.2212 -0.0973 -0.1564 -0.1489 -0.2003 -0.1266 -0.1729
S-1736	WAS MÜSSEN SIE VOR DER ANWENDUNG VON ADVATE BEACHTEN ?
T-1736	BEFORE YOU USE ADVATE
H-1736	-0.46062520146369934	BEFORE USE ADVATE , WHAT YOU MUST
D-1736	-0.46062520146369934	BEFORE USE ADVATE , WHAT YOU MUST
P-1736	-0.6482 -0.0064 -0.0115 -0.6271 -0.3678 -1.1801 -0.1858 -0.0958 -0.1915 -0.3564 -2.9194 -0.0223 -0.1699 -0.1394 -0.1070 -0.5663 -0.0895 -0.1219 -0.9456
S-995	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-995	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-995	-0.45859968662261963	The frequency of detection of FVIII inhibitors to date is in line with expectations and in the range observed .
D-995	-0.45859968662261963	The frequency of detection of FVIII inhibitors to date is in line with expectations and in the range observed .
P-995	-0.3003 -1.7075 -0.0722 -2.0607 -0.2007 -0.1368 -0.2006 -0.1964 -0.1513 -0.1136 -0.6398 -0.1156 -0.0248 -0.0808 -0.1190 -1.0434 -0.1062 -1.0441 -1.1785 -0.0922 -0.1142 -0.0711 -0.1181 -0.6645 -0.1538 -0.2423 -1.2102 -0.9856 -0.1550
S-169	Selten : starke muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen ( siehe Abschnitt 4.4 ) .
T-169	Metabolism and nutrition disorders :
H-169	-0.1975071132183075	Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) .
D-169	-0.1975071132183075	Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) .
P-169	-0.1580 -0.1308 -0.1393 -0.1447 -0.1067 -0.4624 -0.0956 -0.4697 -0.2501 -0.1231 -0.2065 -0.1704 -0.1516 -0.1659 -0.2641 -0.5907 -0.1550 -0.1080 -0.1299 -0.3252 -0.1220 -0.1124 -0.1246 -0.1323 -0.1421 -0.1540
S-1368	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-1368	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-1368	-0.3942144513130188	Plasma samples were evaluated in a central laboratory using a one-step clotting test .
D-1368	-0.3942144513130188	Plasma samples were evaluated in a central laboratory using a one-step clotting test .
P-1368	-1.9448 -0.0664 -0.1880 -0.4240 -0.1335 -0.3010 -0.1352 -0.1885 -0.1262 -0.2060 -0.2321 -0.0850 -0.6771 -0.1206 -1.4471 -0.4441 -1.1164 -0.6738 -0.0423 -0.0770 -0.1550 -0.1336 -0.1493
S-1016	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-1016	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-1016	-0.3942144513130188	Plasma samples were evaluated in a central laboratory using a one-step clotting test .
D-1016	-0.3942144513130188	Plasma samples were evaluated in a central laboratory using a one-step clotting test .
P-1016	-1.9448 -0.0664 -0.1880 -0.4240 -0.1335 -0.3010 -0.1352 -0.1885 -0.1262 -0.2060 -0.2321 -0.0850 -0.6771 -0.1206 -1.4471 -0.4441 -1.1164 -0.6738 -0.0423 -0.0770 -0.1550 -0.1336 -0.1493
S-53	Der Hersteller von FOSAVANCE hat zugestimmt , dass die wissenschaftlichen Daten dieses Produkts auch für ADROVANCE verwendet werden können .
T-53	The company that makes FOSAVANCE has agreed that its scientific data can be used for ADROVANCE .
H-53	-0.3105355501174927	The manufacturer of FOSAVANCE has agreed that the scientific data on this product may also be used for ADROVANCE .
D-53	-0.3105355501174927	The manufacturer of FOSAVANCE has agreed that the scientific data on this product may also be used for ADROVANCE .
P-53	-0.6025 -0.3443 -0.1721 -0.1368 -0.0800 -0.1372 -0.1168 -0.1182 -0.1357 -0.1679 -1.2199 -0.1690 -0.2647 -0.6977 -0.3724 -1.6737 -0.1142 -0.1429 -0.4776 -0.1777 -0.2168 -0.3314 -0.5039 -0.1784 -0.0755 -0.1137 -0.1197 -0.1206 -0.1689 -0.1662
S-1996	In klinischen Studien zur Beurteilung der Verkehrstüchtigkeit wurde bei Patienten , die Desloratadin erhielten , keine Beeinträchtigung festgestellt .
T-1996	In clinical trials that assessed the driving ability , no impairment occurred in patients receiving desloratadine .
H-1996	-0.42097121477127075	In clinical trials to assess ability to drive , no impairment was detected in patients receiving desloratadine .
D-1996	-0.42097121477127075	In clinical trials to assess ability to drive , no impairment was detected in patients receiving desloratadine .
P-1996	-0.8896 -0.1745 -1.2204 -0.6168 -1.4071 -0.8214 -0.1680 -0.3533 -0.1650 -0.1367 -1.7057 -0.0836 -0.0362 -0.1007 -0.2604 -0.8605 -0.1227 -0.2687 -0.4906 -0.0546 -0.4024 -0.0636 -0.0934 -0.2719 -0.3079 -0.1410 -0.1496
S-1545	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-1545	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-1545	-0.3942144513130188	Plasma samples were evaluated in a central laboratory using a one-step clotting test .
D-1545	-0.3942144513130188	Plasma samples were evaluated in a central laboratory using a one-step clotting test .
P-1545	-1.9448 -0.0664 -0.1880 -0.4240 -0.1335 -0.3010 -0.1352 -0.1885 -0.1262 -0.2060 -0.2321 -0.0850 -0.6771 -0.1206 -1.4471 -0.4441 -1.1164 -0.6738 -0.0423 -0.0770 -0.1550 -0.1336 -0.1493
S-1171	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-1171	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-1171	-0.45859968662261963	The frequency of detection of FVIII inhibitors to date is in line with expectations and in the range observed .
D-1171	-0.45859968662261963	The frequency of detection of FVIII inhibitors to date is in line with expectations and in the range observed .
P-1171	-0.3003 -1.7075 -0.0722 -2.0607 -0.2007 -0.1368 -0.2006 -0.1964 -0.1513 -0.1136 -0.6398 -0.1156 -0.0248 -0.0808 -0.1190 -1.0434 -0.1062 -1.0441 -1.1785 -0.0922 -0.1142 -0.0711 -0.1181 -0.6645 -0.1538 -0.2423 -1.2102 -0.9856 -0.1550
S-1192	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-1192	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-1192	-0.3942144513130188	Plasma samples were evaluated in a central laboratory using a one-step clotting test .
D-1192	-0.3942144513130188	Plasma samples were evaluated in a central laboratory using a one-step clotting test .
P-1192	-1.9448 -0.0664 -0.1880 -0.4240 -0.1335 -0.3010 -0.1352 -0.1885 -0.1262 -0.2060 -0.2321 -0.0850 -0.6771 -0.1206 -1.4471 -0.4441 -1.1164 -0.6738 -0.0423 -0.0770 -0.1550 -0.1336 -0.1493
S-1524	Die bisherige Häufigkeit der Erkennung von FVIII-Inhibitoren entspricht den Erwartungen und liegt im bereits beobachteten Bereich .
T-1524	The frequency of FVIII inhibitors detected so far is within the expected and previously observed range .
H-1524	-0.45859968662261963	The frequency of detection of FVIII inhibitors to date is in line with expectations and in the range observed .
D-1524	-0.45859968662261963	The frequency of detection of FVIII inhibitors to date is in line with expectations and in the range observed .
P-1524	-0.3003 -1.7075 -0.0722 -2.0607 -0.2007 -0.1368 -0.2006 -0.1964 -0.1513 -0.1136 -0.6398 -0.1156 -0.0248 -0.0808 -0.1190 -1.0434 -0.1062 -1.0441 -1.1785 -0.0922 -0.1142 -0.0711 -0.1181 -0.6645 -0.1538 -0.2423 -1.2102 -0.9856 -0.1550
S-840	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-840	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-840	-0.3942144513130188	Plasma samples were evaluated in a central laboratory using a one-step clotting test .
D-840	-0.3942144513130188	Plasma samples were evaluated in a central laboratory using a one-step clotting test .
P-840	-1.9448 -0.0664 -0.1880 -0.4240 -0.1335 -0.3010 -0.1352 -0.1885 -0.1262 -0.2060 -0.2321 -0.0850 -0.6771 -0.1206 -1.4471 -0.4441 -1.1164 -0.6738 -0.0423 -0.0770 -0.1550 -0.1336 -0.1493
S-665	Die Auswertung der Plasmaproben fand in einem Zentrallabor unter Verwendung eines Einstufen- Gerinnungstests statt .
T-665	The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay .
H-665	-0.3942144513130188	Plasma samples were evaluated in a central laboratory using a one-step clotting test .
D-665	-0.3942144513130188	Plasma samples were evaluated in a central laboratory using a one-step clotting test .
P-665	-1.9448 -0.0664 -0.1880 -0.4240 -0.1335 -0.3010 -0.1352 -0.1885 -0.1262 -0.2060 -0.2321 -0.0850 -0.6771 -0.1206 -1.4471 -0.4441 -1.1164 -0.6738 -0.0423 -0.0770 -0.1550 -0.1336 -0.1493
S-1866	Da Krebszellen beschädigte DNA enthalten , hilft das p53-Protein , die DNA wiederherzustellen oder verursacht , dass die Zellen absterben .
T-1866	Because cancer cells contain damaged DNA , the p53 protein either helps to repair the DNA or causes the cells to die .
H-1866	-0.4299609959125519	Since cancer cells contain damaged DNA , the p53 protein helps to restore DNA or causes cells to die .
D-1866	-0.4299609959125519	Since cancer cells contain damaged DNA , the p53 protein helps to restore DNA or causes cells to die .
P-1866	-1.1628 -0.2174 -0.1035 -0.0645 -0.9659 -0.0412 -0.1573 -1.0932 -0.1406 -0.1277 -0.1047 -1.7072 -0.1529 -0.8343 -0.8377 -0.2688 -0.0914 -0.7488 -0.1252 -0.2107 -0.1453 -0.1583
S-357	Selten : starke muskuloskelettale ( Knochen- , Muskel- oder Gelenk- ) Schmerzen ( siehe Abschnitt 4.4 ) .
T-357	Metabolism and nutrition disorders :
H-357	-0.1975071132183075	Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) .
D-357	-0.1975071132183075	Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) .
P-357	-0.1580 -0.1308 -0.1393 -0.1447 -0.1067 -0.4624 -0.0956 -0.4697 -0.2501 -0.1231 -0.2065 -0.1704 -0.1516 -0.1659 -0.2641 -0.5907 -0.1550 -0.1080 -0.1299 -0.3252 -0.1220 -0.1124 -0.1246 -0.1323 -0.1421 -0.1540
S-1422	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-1422	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-1422	-0.5050029158592224	Retract the reconstituted solution slowly into the syringe ( Fig . e ) .
D-1422	-0.5050029158592224	Retract the reconstituted solution slowly into the syringe ( Fig . e ) .
P-1422	-1.1522 -0.6670 -1.5797 -0.1912 -0.1770 -0.0730 -0.1191 -0.2316 -0.4226 -1.9831 -0.1359 -0.0575 -0.0464 -0.0154 -0.2190 -2.8925 -0.0775 -0.1411 -0.4987 -0.1261 -0.1503 -0.1533
S-1246	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-1246	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-1246	-0.5050029158592224	Retract the reconstituted solution slowly into the syringe ( Fig . e ) .
D-1246	-0.5050029158592224	Retract the reconstituted solution slowly into the syringe ( Fig . e ) .
P-1246	-1.1522 -0.6670 -1.5797 -0.1912 -0.1770 -0.0730 -0.1191 -0.2316 -0.4226 -1.9831 -0.1359 -0.0575 -0.0464 -0.0154 -0.2190 -2.8925 -0.0775 -0.1411 -0.4987 -0.1261 -0.1503 -0.1533
S-894	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-894	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-894	-0.5050029158592224	Retract the reconstituted solution slowly into the syringe ( Fig . e ) .
D-894	-0.5050029158592224	Retract the reconstituted solution slowly into the syringe ( Fig . e ) .
P-894	-1.1522 -0.6670 -1.5797 -0.1912 -0.1770 -0.0730 -0.1191 -0.2316 -0.4226 -1.9831 -0.1359 -0.0575 -0.0464 -0.0154 -0.2190 -2.8925 -0.0775 -0.1411 -0.4987 -0.1261 -0.1503 -0.1533
S-1424	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-1424	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml
H-1424	-0.34937360882759094	The solution should be administered slowly , at a rate convenient to the patient and not exceeding 10 ml/ minute .
D-1424	-0.34937360882759094	The solution should be administered slowly , at a rate convenient to the patient and not exceeding 10 ml/ minute .
P-1424	-0.5420 -0.2870 -0.1183 -0.1621 -0.7325 -0.0968 -0.1344 -0.7157 -0.1710 -0.1428 -0.9658 -1.2956 -0.0953 -0.3292 -0.1284 -0.0745 -0.1739 -1.4995 -0.2488 -0.1378 -0.1306 -0.2129 -0.1828 -0.1296 -0.4333 -0.1405 -0.1520
S-1599	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-1599	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-1599	-0.5050029158592224	Retract the reconstituted solution slowly into the syringe ( Fig . e ) .
D-1599	-0.5050029158592224	Retract the reconstituted solution slowly into the syringe ( Fig . e ) .
P-1599	-1.1522 -0.6670 -1.5797 -0.1912 -0.1770 -0.0730 -0.1191 -0.2316 -0.4226 -1.9831 -0.1359 -0.0575 -0.0464 -0.0154 -0.2190 -2.8925 -0.0775 -0.1411 -0.4987 -0.1261 -0.1503 -0.1533
S-1601	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-1601	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml
H-1601	-0.34937360882759094	The solution should be administered slowly , at a rate convenient to the patient and not exceeding 10 ml/ minute .
D-1601	-0.34937360882759094	The solution should be administered slowly , at a rate convenient to the patient and not exceeding 10 ml/ minute .
P-1601	-0.5420 -0.2870 -0.1183 -0.1621 -0.7325 -0.0968 -0.1344 -0.7157 -0.1710 -0.1428 -0.9658 -1.2956 -0.0953 -0.3292 -0.1284 -0.0745 -0.1739 -1.4995 -0.2488 -0.1378 -0.1306 -0.2129 -0.1828 -0.1296 -0.4333 -0.1405 -0.1520
S-1887	Der Ausschuss hatte ferner Bedenken bezüglich der Verarbeitung des Arzneimittels im Körper , der Art der Verabreichung sowie der Sicherheit des Arzneimittels .
T-1887	The Committee also had concerns over what happens to the medicine in the body , how it should be given and how safe it is .
H-1887	-0.4127771556377411	The Committee also had concerns about how the product is processed in the body , how it is administered and the safety of the product .
D-1887	-0.4127771556377411	The Committee also had concerns about how the product is processed in the body , how it is administered and the safety of the product .
P-1887	-0.2020 -0.3176 -0.1180 -0.3551 -0.9967 -0.6120 -1.2296 -0.1886 -0.9968 -0.4503 -0.8090 -0.5842 -0.1655 -0.1189 -0.1305 -0.1736 -1.3897 -0.0747 -0.1214 -0.4270 -0.0963 -0.2264 -1.0405 -0.0642 -0.1352 -0.1620 -0.4719 -0.1611 -0.1516
S-1070	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-1070	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-1070	-0.5050029158592224	Retract the reconstituted solution slowly into the syringe ( Fig . e ) .
D-1070	-0.5050029158592224	Retract the reconstituted solution slowly into the syringe ( Fig . e ) .
P-1070	-1.1522 -0.6670 -1.5797 -0.1912 -0.1770 -0.0730 -0.1191 -0.2316 -0.4226 -1.9831 -0.1359 -0.0575 -0.0464 -0.0154 -0.2190 -2.8925 -0.0775 -0.1411 -0.4987 -0.1261 -0.1503 -0.1533
S-720	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-720	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-720	-0.34937360882759094	The solution should be administered slowly , at a rate convenient to the patient and not exceeding 10 ml/ minute .
D-720	-0.34937360882759094	The solution should be administered slowly , at a rate convenient to the patient and not exceeding 10 ml/ minute .
P-720	-0.5420 -0.2870 -0.1183 -0.1621 -0.7325 -0.0968 -0.1344 -0.7157 -0.1710 -0.1428 -0.9658 -1.2956 -0.0953 -0.3292 -0.1284 -0.0745 -0.1739 -1.4995 -0.2488 -0.1378 -0.1306 -0.2129 -0.1828 -0.1296 -0.4333 -0.1405 -0.1520
S-718	Die rekonstituierte Lösung durch langsames Zurückziehen des Kolbens in die Spritze aufziehen ( Abb.e ) .
T-718	Draw the reconstituted solution into the syringe by pulling the plunger back slowly ( Fig . e ) .
H-718	-0.5050029158592224	Retract the reconstituted solution slowly into the syringe ( Fig . e ) .
D-718	-0.5050029158592224	Retract the reconstituted solution slowly into the syringe ( Fig . e ) .
P-718	-1.1522 -0.6670 -1.5797 -0.1912 -0.1770 -0.0730 -0.1191 -0.2316 -0.4226 -1.9831 -0.1359 -0.0575 -0.0464 -0.0154 -0.2190 -2.8925 -0.0775 -0.1411 -0.4987 -0.1261 -0.1503 -0.1533
S-322	Der Vitamin-D-Gehalt von ADROVANCE ist nicht zur Behandlung eines Vitamin-D-Mangels geeignet .
T-322	The content of vitamin D in ADROVANCE is not suitable for correction of vitamin D deficiency .
H-322	-0.6003698110580444	ADROVANCE vitamin D content is not indicated to treat vitamin D deficiency .
D-322	-0.6003698110580444	ADROVANCE vitamin D content is not indicated to treat vitamin D deficiency .
P-322	-0.6538 -0.0782 -0.1225 -0.1018 -0.1267 -3.8784 -0.0884 -0.1136 -2.4938 -0.5221 -0.1947 -1.5489 -1.7518 -0.2581 -0.3095 -0.0529 -0.1112 -0.0298 -0.0261 -0.4400 -0.1493 -0.1565
S-134	Der Vitamin-D-Gehalt von ADROVANCE ist nicht zur Behandlung eines Vitamin-D-Mangels geeignet .
T-134	The content of vitamin D in ADROVANCE is not suitable for correction of vitamin D deficiency .
H-134	-0.6003698110580444	ADROVANCE vitamin D content is not indicated to treat vitamin D deficiency .
D-134	-0.6003698110580444	ADROVANCE vitamin D content is not indicated to treat vitamin D deficiency .
P-134	-0.6538 -0.0782 -0.1225 -0.1018 -0.1267 -3.8784 -0.0884 -0.1136 -2.4938 -0.5221 -0.1947 -1.5489 -1.7518 -0.2581 -0.3095 -0.0529 -0.1112 -0.0298 -0.0261 -0.4400 -0.1493 -0.1565
S-55	ADROVANCE vermindert das Risiko für Wirbel<unk> säulen<unk> - und Hüftfrakturen ( Brüche ) .
T-55	ADROVANCE reduces the risk of vertebral ( spine ) and hip fractures ( breaks ) .
H-55	-0.2488471269607544	ADROVANCE decreases the risk of spinal and hip fractures ( fractures ) .
D-55	-0.2488471269607544	ADROVANCE decreases the risk of spinal and hip fractures ( fractures ) .
P-55	-0.0259 -0.0701 -0.1248 -0.1129 -0.1544 -0.9175 -0.0641 -0.1692 -0.1198 -0.4368 -0.1986 -0.6307 -0.1935 -0.0625 -0.3497 -0.0729 -0.4984 -0.7680 -0.0648 -0.1369 -0.1482 -0.1550
S-1971	Deshalb ist es im Falle eines operativen Eingriffs vorzuziehen , die Behandlung 24 Stunden vor der Einleitung der Narkose abzusetzen .
T-1971	Therefore , if surgery is scheduled , it is preferable to discontinue treatment 24 hours before anaesthesia .
H-1971	-0.4168563485145569	Therefore , in the case of surgery , it is preferable to discontinue treatment 24 hours prior to the anaesthesia .
D-1971	-0.4168563485145569	Therefore , in the case of surgery , it is preferable to discontinue treatment 24 hours prior to the anaesthesia .
P-1971	-0.7132 -0.0736 -0.2146 -0.8963 -0.4971 -1.1024 -0.1450 -0.2146 -0.5397 -1.1099 -0.1741 -0.1353 -0.1090 -0.1888 -0.2490 -0.1212 -0.2368 -0.1518 -0.1155 -0.2487 -0.1281 -1.1856 -1.6819 -0.3810 -0.5055 -0.1186 -0.2817 -0.1528
S-113	Die Patienten sollen darüber informiert werden , dass das Risiko ösophagealer Probleme erhöht sein kann , wenn sie diese Anweisungen nicht einhalten .
T-113	Patients should be informed that failure to follow these instructions may increase their risk of oesophageal problems .
H-113	-0.33339735865592957	Patients should be advised that if they do not adhere to these instructions , they may be at increased risk of oesophageal problems .
D-113	-0.33339735865592957	Patients should be advised that if they do not adhere to these instructions , they may be at increased risk of oesophageal problems .
P-113	-0.2785 -0.0867 -0.2111 -0.1506 -1.5641 -0.1440 -1.3750 -0.1064 -0.4989 -0.1834 -1.4818 -0.0990 -0.1566 -0.0764 -0.3527 -0.5641 -0.6979 -0.1421 -0.3886 -0.0132 -0.2339 -0.0725 -0.1943 -0.5596 -0.0567 -0.1333 -0.0531 -0.0573 -0.1513 -0.2574 -0.1764 -0.1520
S-1995	Es wurden keine Studien zu den Auswirkungen von Aerinaze auf die Verkehrstüchtigkeit und die Fähigkeit zum Bedienen von Maschinen durchgeführt .
T-1995	No studies on the effects on the ability to drive and use machines have been performed with Aerinaze .
H-1995	-0.34568771719932556	No studies have been carried out on the effect of Aerinaze on ability to drive and use machines .
D-1995	-0.34568771719932556	No studies have been carried out on the effect of Aerinaze on ability to drive and use machines .
P-1995	-0.1296 -0.0564 -0.3224 -0.1525 -1.1970 -0.1321 -2.3423 -0.3806 -0.6874 -0.2528 -0.2020 -0.1248 -0.1192 -0.1559 -0.1213 -0.1463 -0.2653 -0.2243 -0.2626 -0.2159 -0.1419 -0.3647 -0.1422 -0.1574
S-769	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-769	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-769	-0.37398436665534973	In the interests of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
D-769	-0.37398436665534973	In the interests of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
P-769	-0.8462 -0.1539 -0.7177 -0.1546 -0.1889 -0.2510 -0.3118 -0.1286 -0.1364 -0.1643 -2.4002 -0.5731 -0.3110 -0.1343 -0.0823 -0.1003 -0.1228 -0.1710 -0.0897 -0.2382 -2.3471 -1.1509 -0.1820 -0.2403 -0.1203 -0.0432 -0.1108 -0.1325 -0.1548 -0.1484 -0.1273 -0.1541 -0.1532
S-68	Alendronat ist ein Biphosphonat , das seit Mitte der 1990er Jahre gegen Osteoporose eingesetzt wird .
T-68	Vitamin D3 , along with other forms of vitamin D , is required for calcium absorption and normal bone formation .
H-68	-0.2684110701084137	Alendronate is a biphosphonate that has been used to treat osteoporosis since the mid 1990s .
D-68	-0.2684110701084137	Alendronate is a biphosphonate that has been used to treat osteoporosis since the mid 1990s .
P-68	-0.1278 -0.1724 -0.0823 -0.0613 -0.1384 -0.1219 -0.0741 -0.1054 -0.0694 -0.1382 -0.8699 -0.1925 -0.0796 -0.1060 -0.4270 -0.1794 -0.1276 -0.0669 -0.0961 -0.1305 -0.1081 -0.1063 -0.5394 -0.1423 -0.2489 -2.7080 -0.1436 -0.1522
S-1814	102 Falls weitere Informationen über das Arzneimittel gewünscht werden , setzen Sie sich bitte mit dem örtlichen Vertreter des Zulassungsinhabers in Verbindung .
T-1814	96 For any information about this medicine , please contact the local representative of the Marketing Authorisation Holder :
H-1814	-0.3424820005893707	If any information about this medicinal product is required , please contact the local representative of the marketing authorisation holder .
D-1814	-0.3424820005893707	If any information about this medicinal product is required , please contact the local representative of the marketing authorisation holder .
P-1814	-0.3299 -1.0435 -0.2975 -0.5048 -0.0915 -0.9509 -0.0536 -0.0397 -0.1387 -1.4600 -0.1522 -0.6983 -0.0582 -0.1421 -0.9549 -0.3175 -0.1627 -0.1264 -0.1763 -0.0396 -0.0768 -0.0742 -0.1816 -0.1487
S-896	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-896	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-896	-0.34937360882759094	The solution should be administered slowly , at a rate convenient to the patient and not exceeding 10 ml/ minute .
D-896	-0.34937360882759094	The solution should be administered slowly , at a rate convenient to the patient and not exceeding 10 ml/ minute .
P-896	-0.5420 -0.2870 -0.1183 -0.1621 -0.7325 -0.0968 -0.1344 -0.7157 -0.1710 -0.1428 -0.9658 -1.2956 -0.0953 -0.3292 -0.1284 -0.0745 -0.1739 -1.4995 -0.2488 -0.1378 -0.1306 -0.2129 -0.1828 -0.1296 -0.4333 -0.1405 -0.1520
S-1988	In Tierversuchen war weder Desloratadin noch die Kombination von Loratadin und Pseudoephedrin teratogen .
T-1988	Neither desloratadine nor the combination of loratadine and pseudoephedrine were teratogenic in animal studies .
H-1988	-0.3316628932952881	In animal studies , neither desloratadine nor the combination of loratadine and pseudoephedrine was teratogenic .
D-1988	-0.3316628932952881	In animal studies , neither desloratadine nor the combination of loratadine and pseudoephedrine was teratogenic .
P-1988	-0.2888 -0.0766 -1.6273 -0.3345 -0.6527 -0.2919 -0.0506 -0.1102 -0.7258 -0.3037 -0.0629 -0.1803 -0.0627 -0.1527 -0.1129 -0.1041 -0.8765 -0.3733 -0.1681 -0.0928 -0.5251 -0.1506 -0.0564 -0.1066 -0.1415 -0.1539 -0.7080 -0.0840 -0.0830 -0.6467 -1.5493 -0.1358 -0.1367 -0.1506
S-305	Osteonekrose des Kiefers wurde auch bei Osteoporosepatienten unter oralen Bisphosphonaten berichtet .
T-305	Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates .
H-305	-0.17543695867061615	jaw osteonecrosis has also been reported in osteoporosis patients receiving oral bisphosphonates .
D-305	-0.17543695867061615	jaw osteonecrosis has also been reported in osteoporosis patients receiving oral bisphosphonates .
P-305	-0.4308 -0.2775 -0.1224 -0.0657 -0.1255 -0.0730 -0.0444 -0.0923 -0.2299 -0.0734 -0.1413 -0.1009 -0.4323 -0.9213 -0.0540 -0.0888 -0.1459 -0.1460 -0.0866 -0.1148 -0.3456 -0.3190 -0.0988 -0.0202 -0.0761 -0.1026 -0.0695 -0.1371 -0.1519
S-1872	Der Patient erhielt über einen Zeitraum von fünf Monaten 12 Advexin-Injektionen , die in einige der Tumore gespritzt wurden .
T-1872	Der Patient erhielt über einen Zeitraum von fünf Monaten 12 Advexin-Injektionen , die in einige der Tumore gespritzt wurden . The effectiveness of the medicine was assessed by using scans to look at how the tumours responded to treatment .
H-1872	-0.3001803755760193	The patient received 12 advexin injections over five months , which were injected into some of the tumours .
D-1872	-0.3001803755760193	The patient received 12 advexin injections over five months , which were injected into some of the tumours .
P-1872	-0.5011 -0.0768 -0.7502 -0.0756 -1.0691 -0.2259 -0.1251 -0.1474 -0.0504 -0.1519 -1.0017 -0.1896 -0.4463 -1.0834 -0.1111 -0.3327 -0.1156 -0.1759 -0.1388 -0.1437 -0.1340 -0.0733 -0.0739 -0.1592 -0.1518
S-1473	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-1473	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-1473	-0.37398436665534973	In the interests of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
D-1473	-0.37398436665534973	In the interests of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
P-1473	-0.8462 -0.1539 -0.7177 -0.1546 -0.1889 -0.2510 -0.3118 -0.1286 -0.1364 -0.1643 -2.4002 -0.5731 -0.3110 -0.1343 -0.0823 -0.1003 -0.1228 -0.1710 -0.0897 -0.2382 -2.3471 -1.1509 -0.1820 -0.2403 -0.1203 -0.0432 -0.1108 -0.1325 -0.1548 -0.1484 -0.1273 -0.1541 -0.1532
S-1297	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-1297	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-1297	-0.37398436665534973	In the interests of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
D-1297	-0.37398436665534973	In the interests of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
P-1297	-0.8462 -0.1539 -0.7177 -0.1546 -0.1889 -0.2510 -0.3118 -0.1286 -0.1364 -0.1643 -2.4002 -0.5731 -0.3110 -0.1343 -0.0823 -0.1003 -0.1228 -0.1710 -0.0897 -0.2382 -2.3471 -1.1509 -0.1820 -0.2403 -0.1203 -0.0432 -0.1108 -0.1325 -0.1548 -0.1484 -0.1273 -0.1541 -0.1532
S-1121	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-1121	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-1121	-0.37398436665534973	In the interests of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
D-1121	-0.37398436665534973	In the interests of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
P-1121	-0.8462 -0.1539 -0.7177 -0.1546 -0.1889 -0.2510 -0.3118 -0.1286 -0.1364 -0.1643 -2.4002 -0.5731 -0.3110 -0.1343 -0.0823 -0.1003 -0.1228 -0.1710 -0.0897 -0.2382 -2.3471 -1.1509 -0.1820 -0.2403 -0.1203 -0.0432 -0.1108 -0.1325 -0.1548 -0.1484 -0.1273 -0.1541 -0.1532
S-945	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-945	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-945	-0.37398436665534973	In the interests of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
D-945	-0.37398436665534973	In the interests of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
P-945	-0.8462 -0.1539 -0.7177 -0.1546 -0.1889 -0.2510 -0.3118 -0.1286 -0.1364 -0.1643 -2.4002 -0.5731 -0.3110 -0.1343 -0.0823 -0.1003 -0.1228 -0.1710 -0.0897 -0.2382 -2.3471 -1.1509 -0.1820 -0.2403 -0.1203 -0.0432 -0.1108 -0.1325 -0.1548 -0.1484 -0.1273 -0.1541 -0.1532
S-595	Im Interesse der Patienten wird empfohlen , bei jeder Verabreichung von ADVATE Name und Chargennummer des Produktes zu notieren .
T-595	In the interest of patients , it is recommended that every time ADVATE is administered , the name and batch number of the product should be recorded .
H-595	-0.37398436665534973	In the interests of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
D-595	-0.37398436665534973	In the interests of patients , it is recommended that each time ADVATE is administered , note down the name and batch number of the product .
P-595	-0.8462 -0.1539 -0.7177 -0.1546 -0.1889 -0.2510 -0.3118 -0.1286 -0.1364 -0.1643 -2.4002 -0.5731 -0.3110 -0.1343 -0.0823 -0.1003 -0.1228 -0.1710 -0.0897 -0.2382 -2.3471 -1.1509 -0.1820 -0.2403 -0.1203 -0.0432 -0.1108 -0.1325 -0.1548 -0.1484 -0.1273 -0.1541 -0.1532
S-1072	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-1072	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-1072	-0.34937360882759094	The solution should be administered slowly , at a rate convenient to the patient and not exceeding 10 ml/ minute .
D-1072	-0.34937360882759094	The solution should be administered slowly , at a rate convenient to the patient and not exceeding 10 ml/ minute .
P-1072	-0.5420 -0.2870 -0.1183 -0.1621 -0.7325 -0.0968 -0.1344 -0.7157 -0.1710 -0.1428 -0.9658 -1.2956 -0.0953 -0.3292 -0.1284 -0.0745 -0.1739 -1.4995 -0.2488 -0.1378 -0.1306 -0.2129 -0.1828 -0.1296 -0.4333 -0.1405 -0.1520
S-1771	Wie ADVATE angewendet wird ADVATE wird normalerweise vom Arzt in eine Vene ( intravenös ) verabreicht .
T-1771	How ADVATE is given ADVATE is usually injected into a vein ( intravenously ) by your doctor or nurse .
H-1771	-0.26658836007118225	How ADVATE is administered ADVATE is usually administered by the doctor into a vein ( intravenously ) .
D-1771	-0.26658836007118225	How ADVATE is administered ADVATE is usually administered by the doctor into a vein ( intravenously ) .
P-1771	-1.5297 -0.0931 -0.1588 -0.0875 -0.0997 -0.1083 -0.3804 -0.0896 -0.1066 -0.1460 -0.0935 -0.1196 -0.1068 -0.3377 -0.8657 -0.0858 -0.8755 -0.1214 -0.8828 -0.5952 -0.1715 -0.0777 -0.0644 -0.1403 -0.1623 -0.0818 -0.1029 -0.1281 -0.1417 -0.1574 -0.1523
S-1248	Die Lösung sollte langsam , mit einer Geschwindigkeit die dem Patienten angenehm ist und maxinmal 10 ml<unk> Minute beträgt , verabreicht werden .
T-1248	The solution should be administered slowly , at a rate as determined by the patient s comfort level , not to exceed 10 ml per minute .
H-1248	-0.34937360882759094	The solution should be administered slowly , at a rate convenient to the patient and not exceeding 10 ml/ minute .
D-1248	-0.34937360882759094	The solution should be administered slowly , at a rate convenient to the patient and not exceeding 10 ml/ minute .
P-1248	-0.5420 -0.2870 -0.1183 -0.1621 -0.7325 -0.0968 -0.1344 -0.7157 -0.1710 -0.1428 -0.9658 -1.2956 -0.0953 -0.3292 -0.1284 -0.0745 -0.1739 -1.4995 -0.2488 -0.1378 -0.1306 -0.2129 -0.1828 -0.1296 -0.4333 -0.1405 -0.1520
S-117	Osteonekrose des Kiefers wurde auch bei Osteoporosepatienten unter oralen Bisphosphonaten berichtet .
T-117	Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphosphonates .
H-117	-0.17543695867061615	jaw osteonecrosis has also been reported in osteoporosis patients receiving oral bisphosphonates .
D-117	-0.17543695867061615	jaw osteonecrosis has also been reported in osteoporosis patients receiving oral bisphosphonates .
P-117	-0.4308 -0.2775 -0.1224 -0.0657 -0.1255 -0.0730 -0.0444 -0.0923 -0.2299 -0.0734 -0.1413 -0.1009 -0.4323 -0.9213 -0.0540 -0.0888 -0.1459 -0.1460 -0.0866 -0.1148 -0.3456 -0.3190 -0.0988 -0.0202 -0.0761 -0.1026 -0.0695 -0.1371 -0.1519
S-1913	Die Wirksamkeit von Aerinaze wurde in zwei Hauptstudien mit insgesamt 1 248 erwachsenen und jugendlichen Patienten untersucht .
T-1913	The effectiveness of Aerinaze was assessed in two main studies involving a total of 1,248 adult and adolescent patients .
H-1913	-0.35187676548957825	The efficacy of Aerinaze was evaluated in two main studies involving a total of 1,248 adult and adolescent patients .
D-1913	-0.35187676548957825	The efficacy of Aerinaze was evaluated in two main studies involving a total of 1,248 adult and adolescent patients .
P-1913	-3.2368 -0.5665 -0.0528 -0.0954 -0.1374 -0.1645 -0.1219 -0.1185 -0.1645 -0.1163 -0.2986 -1.7477 -0.1361 -0.1259 -0.1960 -0.2806 -0.4930 -0.9052 -0.2117 -0.1569 -0.1611 -0.2711 -0.1006 -0.1158 -0.0839 -0.1496 -0.1875 -0.1433 -0.3204 -0.1117 -0.1384 -0.1504
S-1895	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-1895	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-1895	-0.20536214113235474	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
D-1895	-0.20536214113235474	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
P-1895	-1.4146 -0.4303 -0.0961 -0.4374 -0.2601 -0.0462 -0.3653 -0.3180 -0.2364 -0.0349 -0.1102 -0.1487 -0.3193 -0.1912 -0.0401 -0.0507 -0.0786 -0.0872 -0.0551 -0.1528 -0.1181 -0.1213 -0.1496 -0.1301 -0.0911 -0.0392 -0.1291 -0.1503 -0.1535
S-511	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-511	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-511	-0.20536214113235474	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
D-511	-0.20536214113235474	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
P-511	-1.4146 -0.4303 -0.0961 -0.4374 -0.2601 -0.0462 -0.3653 -0.3180 -0.2364 -0.0349 -0.1102 -0.1487 -0.3193 -0.1912 -0.0401 -0.0507 -0.0786 -0.0872 -0.0551 -0.1528 -0.1181 -0.1213 -0.1496 -0.1301 -0.0911 -0.0392 -0.1291 -0.1503 -0.1535
S-50	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-50	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-50	-0.20536214113235474	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
D-50	-0.20536214113235474	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
P-50	-1.4146 -0.4303 -0.0961 -0.4374 -0.2601 -0.0462 -0.3653 -0.3180 -0.2364 -0.0349 -0.1102 -0.1487 -0.3193 -0.1912 -0.0401 -0.0507 -0.0786 -0.0872 -0.0551 -0.1528 -0.1181 -0.1213 -0.1496 -0.1301 -0.0911 -0.0392 -0.1291 -0.1503 -0.1535
S-2	Wenn Sie weitere Informationen bezüglich der Grundlage der Empfehlungen des CHMP wünschen , lesen Sie bitte die wissenschaftliche Diskussion ( ebenfalls Teil des EPAR ) .
T-2	If you want more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
H-2	-0.20536214113235474	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
D-2	-0.20536214113235474	For more information on the basis of the CHMP recommendations , read the Scientific Discussion ( also part of the EPAR ) .
P-2	-1.4146 -0.4303 -0.0961 -0.4374 -0.2601 -0.0462 -0.3653 -0.3180 -0.2364 -0.0349 -0.1102 -0.1487 -0.3193 -0.1912 -0.0401 -0.0507 -0.0786 -0.0872 -0.0551 -0.1528 -0.1181 -0.1213 -0.1496 -0.1301 -0.0911 -0.0392 -0.1291 -0.1503 -0.1535
S-1868	Advexin hätte die Krankheit heilen oder deren Fortschreiten verlangsamen sollen , indem die normale Schutzfunktion der Zellen wiederhergestellt wird .
T-1868	Advexin was expected to cure or slow down the disease by restoring the normal protective function of the cells .
H-1868	-0.512073814868927	Advexin should have cured or slowed the progression of the disease by restoring the cells &quot; normal protective function .
D-1868	-0.512073814868927	Advexin should have cured or slowed the progression of the disease by restoring the cells &quot; normal protective function .
P-1868	-0.8261 -0.1559 -0.1394 -0.3732 -0.1663 -1.6712 -0.1288 -0.2106 -0.3726 -0.0487 -0.8726 -2.8673 -0.1467 -0.1492 -0.1532 -0.2076 -0.1139 -0.1973 -0.1451 -1.1516 -1.0065 -1.3875 -0.5535 -0.1371 -0.3229 -0.1641 -0.1571
S-1411	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-1411	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-1411	-0.4253394603729248	Only use the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
D-1411	-0.4253394603729248	Only use the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
P-1411	-1.7315 -0.1859 -0.1585 -1.9808 -0.5960 -0.1232 -0.1446 -0.1145 -0.1702 -0.1279 -0.1360 -0.1209 -0.2599 -2.0347 -0.0861 -0.3581 -0.1625 -0.2143 -0.2219 -0.0512 -0.2222 -0.1566
S-1588	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-1588	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-1588	-0.4253394603729248	Only use the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
D-1588	-0.4253394603729248	Only use the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
P-1588	-1.7315 -0.1859 -0.1585 -1.9808 -0.5960 -0.1232 -0.1446 -0.1145 -0.1702 -0.1279 -0.1360 -0.1209 -0.2599 -2.0347 -0.0861 -0.3581 -0.1625 -0.2143 -0.2219 -0.0512 -0.2222 -0.1566
S-400	3,2 % in der 5.600-I.E.-Vitamin-D3-Gruppe . Der Anteil an Patientinnen mit
T-400	3.2 % in the Vitamin D3 5600 group through the 24-week extension .
H-400	-0.40438786149024963	3.2 % in the 5,600 IU vitamin D3 group , and
D-400	-0.40438786149024963	3.2 % in the 5,600 IU vitamin D3 group , and
P-400	-0.0972 -0.1497 -0.1081 -0.2510 -0.1499 -1.0694 -0.0714 -0.1065 -0.2767 -0.4977 -0.1358 -0.2539 -0.1339 -0.1838 -1.1547 -1.1170 -1.1179
S-458	In Studien verursachten hohe Dosen bei Ratten ein vermehrtes Auftreten von unvollständiger Ossifikation bei den Feten .
T-458	In studies , rats given high doses showed an increased incidence of incomplete foetal ossification .
H-458	-0.49087217450141907	In studies , high doses in rats caused an increased occurrence of incomplete fetal ossification .
D-458	-0.49087217450141907	In studies , high doses in rats caused an increased occurrence of incomplete fetal ossification .
P-458	-0.3725 -0.9216 -0.1842 -0.8857 -0.0940 -0.0580 -0.1618 -0.0589 -2.5564 -0.1535 -0.0599 -1.6365 -0.0447 -0.0735 -0.1120 -0.1555 -0.1568 -0.6523 -2.1020 -0.0955 -0.8377 -0.1154 -0.1427 -0.1497
S-1747	Treten irgendwelche dieser Symptome auf , brechen Sie die Injektion sofort ab und kontaktieren Sie Ihren Arzt . Schwere Symptome wie z.
T-1747	If any of these symptoms occur , stop the injection immediately and contact your doctor .
H-1747	-0.26874467730522156	If any of these symptoms occurs , cancel the injection immediately and contact your doctor . Severe symptoms such as
D-1747	-0.26874467730522156	If any of these symptoms occurs , cancel the injection immediately and contact your doctor . Severe symptoms such as
P-1747	-0.1719 -0.1840 -0.1376 -0.1988 -0.1091 -1.2975 -0.0982 -0.1625 -1.6760 -0.1210 -0.1393 -0.1150 -0.0893 -0.1212 -0.1666 -0.1309 -0.1046 -0.1462 -0.2575 -0.1558 -0.1144 -0.4454 -0.1562 -0.1508
S-262	In Studien verursachten hohe Dosen bei Ratten ein vermehrtes Auftreten von unvollständiger Ossifikation bei den Feten .
T-262	In studies , rats given high doses showed an increased incidence of incomplete foetal ossification .
H-262	-0.49087217450141907	In studies , high doses in rats caused an increased occurrence of incomplete fetal ossification .
D-262	-0.49087217450141907	In studies , high doses in rats caused an increased occurrence of incomplete fetal ossification .
P-262	-0.3725 -0.9216 -0.1842 -0.8857 -0.0940 -0.0580 -0.1618 -0.0589 -2.5564 -0.1535 -0.0599 -1.6365 -0.0447 -0.0735 -0.1120 -0.1555 -0.1568 -0.6523 -2.1020 -0.0955 -0.8377 -0.1154 -0.1427 -0.1497
S-1235	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-1235	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-1235	-0.4253394603729248	Only use the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
D-1235	-0.4253394603729248	Only use the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
P-1235	-1.7315 -0.1859 -0.1585 -1.9808 -0.5960 -0.1232 -0.1446 -0.1145 -0.1702 -0.1279 -0.1360 -0.1209 -0.2599 -2.0347 -0.0861 -0.3581 -0.1625 -0.2143 -0.2219 -0.0512 -0.2222 -0.1566
S-707	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-707	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-707	-0.4253394603729248	Only use the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
D-707	-0.4253394603729248	Only use the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
P-707	-1.7315 -0.1859 -0.1585 -1.9808 -0.5960 -0.1232 -0.1446 -0.1145 -0.1702 -0.1279 -0.1360 -0.1209 -0.2599 -2.0347 -0.0861 -0.3581 -0.1625 -0.2143 -0.2219 -0.0512 -0.2222 -0.1566
S-883	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-883	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-883	-0.4253394603729248	Only use the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
D-883	-0.4253394603729248	Only use the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
P-883	-1.7315 -0.1859 -0.1585 -1.9808 -0.5960 -0.1232 -0.1446 -0.1145 -0.1702 -0.1279 -0.1360 -0.1209 -0.2599 -2.0347 -0.0861 -0.3581 -0.1625 -0.2143 -0.2219 -0.0512 -0.2222 -0.1566
S-1059	Zum Auflösen nur das beigepackte Wasser für Injektionszwecke und das beigepackte Rekonstitutionsset verwenden .
T-1059	For reconstitution only the water for injections and the reconstitution device provided in the pack should be used .
H-1059	-0.4253394603729248	Only use the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
D-1059	-0.4253394603729248	Only use the enclosed water for injections and the enclosed Reconstitution Kit to dissolve .
P-1059	-1.7315 -0.1859 -0.1585 -1.9808 -0.5960 -0.1232 -0.1446 -0.1145 -0.1702 -0.1279 -0.1360 -0.1209 -0.2599 -2.0347 -0.0861 -0.3581 -0.1625 -0.2143 -0.2219 -0.0512 -0.2222 -0.1566
S-1066	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-1066	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-1066	-0.49401986598968506	If the solution and containers allow , always check for suspended particles before administration .
D-1066	-0.49401986598968506	If the solution and containers allow , always check for suspended particles before administration .
P-1066	-0.6148 -1.2787 -0.0784 -0.2095 -0.2385 -0.1359 -0.1462 -0.8884 -0.2244 -0.6713 -0.1300 -0.2144 -1.7434 -0.7963 -0.0869 -0.6486 -0.4881 -0.6406 -0.1519
S-1242	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-1242	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-1242	-0.49401986598968506	If the solution and containers allow , always check for suspended particles before administration .
D-1242	-0.49401986598968506	If the solution and containers allow , always check for suspended particles before administration .
P-1242	-0.6148 -1.2787 -0.0784 -0.2095 -0.2385 -0.1359 -0.1462 -0.8884 -0.2244 -0.6713 -0.1300 -0.2144 -1.7434 -0.7963 -0.0869 -0.6486 -0.4881 -0.6406 -0.1519
S-1418	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-1418	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-1418	-0.49401986598968506	If the solution and containers allow , always check for suspended particles before administration .
D-1418	-0.49401986598968506	If the solution and containers allow , always check for suspended particles before administration .
P-1418	-0.6148 -1.2787 -0.0784 -0.2095 -0.2385 -0.1359 -0.1462 -0.8884 -0.2244 -0.6713 -0.1300 -0.2144 -1.7434 -0.7963 -0.0869 -0.6486 -0.4881 -0.6406 -0.1519
S-714	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-714	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-714	-0.49401986598968506	If the solution and containers allow , always check for suspended particles before administration .
D-714	-0.49401986598968506	If the solution and containers allow , always check for suspended particles before administration .
P-714	-0.6148 -1.2787 -0.0784 -0.2095 -0.2385 -0.1359 -0.1462 -0.8884 -0.2244 -0.6713 -0.1300 -0.2144 -1.7434 -0.7963 -0.0869 -0.6486 -0.4881 -0.6406 -0.1519
S-1595	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-1595	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-1595	-0.49401986598968506	If the solution and containers allow , always check for suspended particles before administration .
D-1595	-0.49401986598968506	If the solution and containers allow , always check for suspended particles before administration .
P-1595	-0.6148 -1.2787 -0.0784 -0.2095 -0.2385 -0.1359 -0.1462 -0.8884 -0.2244 -0.6713 -0.1300 -0.2144 -1.7434 -0.7963 -0.0869 -0.6486 -0.4881 -0.6406 -0.1519
S-339	Antikonvulsiva , Cimetidin und Thiazide können den Abbaustoffwechsel von Vitamin D verstärken .
T-339	Anticonvulsants , cimetidine and thiazides may increase the catabolism of vitamin D.
H-339	-0.28247180581092834	Anticonvulsants , cimetidine and thiazides may increase the breakdown metabolism of vitamin D .
D-339	-0.28247180581092834	Anticonvulsants , cimetidine and thiazides may increase the breakdown metabolism of vitamin D .
P-339	-0.2849 -0.1701 -0.0122 -0.2707 -0.3124 -0.1489 -0.3198 -0.1287 -0.1633 -0.1185 -0.6055 -0.1624 -0.0423 -0.1386 -0.0624 -0.1725 -0.2959 -1.3841 -0.2028 -1.2261 -0.6298 -0.0774 -0.0771 -0.1395 -0.1268 -0.0995 -0.3866 -0.2756 -0.1571
S-1863	Das Gen , welches das Virus in Advexin trägt , ist das normale ( nicht defekte ) p53-Gen .
T-1863	The gene carried by the virus in Advexin is the normal ( non-defective ) p53 gene .
H-1863	-0.32826533913612366	The gene that carries the virus in Advexin is the normal ( not defective ) p53 gene .
D-1863	-0.32826533913612366	The gene that carries the virus in Advexin is the normal ( not defective ) p53 gene .
P-1863	-0.1708 -0.1005 -0.7626 -1.4305 -0.1603 -0.2063 -0.2079 -0.6665 -0.1912 -0.1391 -0.1168 -0.2851 -0.1126 -0.2564 -1.2390 -0.5497 -0.1505 -0.1425 -0.1217 -0.0647 -0.1694 -0.1525 -0.1536
S-890	Wenn es Lösung und Behältnisse zulassen , sind Parenteralia vor der Verabreichung immer auf Schwebeteilchen zu überprüfen .
T-890	Parenteral medicinal products should be inspected for particulate matter prior to administration , whenever solution and container permit .
H-890	-0.49401986598968506	If the solution and containers allow , always check for suspended particles before administration .
D-890	-0.49401986598968506	If the solution and containers allow , always check for suspended particles before administration .
P-890	-0.6148 -1.2787 -0.0784 -0.2095 -0.2385 -0.1359 -0.1462 -0.8884 -0.2244 -0.6713 -0.1300 -0.2144 -1.7434 -0.7963 -0.0869 -0.6486 -0.4881 -0.6406 -0.1519
S-541	Bei einigen Patienten , die mit Arzneimitteln behandelt wurden , welche Faktor VIII enthalten , wurde Überempfindlichkeit ( allergische Reaktion ) beobachtet .
T-541	Hypersensitivity ( allergic reactions ) has sometimes been seen in patients treated with factor VIII-containing products .
H-541	-0.2832094430923462	Hypersensitivity ( allergic reaction ) has been observed in some patients treated with medicinal products containing factor VIII .
D-541	-0.2832094430923462	Hypersensitivity ( allergic reaction ) has been observed in some patients treated with medicinal products containing factor VIII .
P-541	-1.9931 -0.0628 -0.0386 -0.0478 -0.1558 -0.2440 -0.0704 -0.1023 -0.1464 -0.4038 -0.2000 -0.1388 -0.1728 -0.1827 -0.1076 -0.3457 -0.1520 -0.4823 -0.7014 -0.0842 -0.2183 -0.6901 -0.1538 -0.1325 -0.1824 -0.1540
S-1923	Die vollständige Auflistung der im Zusammenhang mit Aerinaze berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-1923	For the full list of all side effects reported with Aerinaze , see the Package Leaflet .
H-1923	-0.19544538855552673	For a full list of side effects reported with Aerinaze , see the Package Leaflet .
D-1923	-0.19544538855552673	For a full list of side effects reported with Aerinaze , see the Package Leaflet .
P-1923	-0.1893 -0.1301 -0.0674 -0.1684 -0.1619 -1.2033 -0.1499 -0.0669 -0.3405 -0.1730 -0.1315 -0.1158 -0.1495 -0.1082 -0.1537 -0.4745 -0.1391 -0.1188 -0.1222 -0.0542 -0.0620 -0.1041 -0.1576 -0.1490
S-566	Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-566	2 factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-566	-0.27050843834877014	Factor VIII per kg bodyweight , factor VIII-activity in plasma is increased by 2 IU/ dl .
D-566	-0.27050843834877014	Factor VIII per kg bodyweight , factor VIII-activity in plasma is increased by 2 IU/ dl .
P-566	-1.0708 -0.1584 -0.1223 -0.1054 -0.0601 -0.3074 -0.0581 -0.4157 -0.4860 -0.3180 -0.1358 -0.9584 -0.5049 -0.1474 -0.1148 -0.1577 -0.0838 -0.0894 -1.0945 -0.1584 -0.1463 -0.1126 -0.1185 -0.1455 -0.1381 -0.0356 -0.1765 -0.1541
S-78	Die vollständige Auflistung der im Zusammenhang mit ADROVANCE berichteten Nebenwirkungen ist der Packungsbeilage zu entnehmen .
T-78	For the full list of all side effects reported with ADROVANCE , see the Package Leaflet .
H-78	-0.19563548266887665	For a full list of side effects reported with ADROVANCE , see the Package Leaflet .
D-78	-0.19563548266887665	For a full list of side effects reported with ADROVANCE , see the Package Leaflet .
P-78	-0.1762 -0.1326 -0.0710 -0.1516 -0.1587 -1.1185 -0.1649 -0.0646 -0.5999 -0.1277 -0.0959 -0.1219 -0.1042 -0.0982 -0.1509 -0.4776 -0.1373 -0.0901 -0.1226 -0.0536 -0.0584 -0.1018 -0.1659 -0.1511
S-1940	Symptomatische Behandlung der saisonalen allergischen Rhinitis mit begleitender Nasenschleimhautschwellung .
T-1940	Symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion .
H-1940	-0.23625241219997406	Treatment of seasonal allergic rhinitis with associated nasal swelling .
D-1940	-0.23625241219997406	Treatment of seasonal allergic rhinitis with associated nasal swelling .
P-1940	-0.7301 -0.0480 -0.1087 -0.1476 -0.7542 -0.1316 -0.0782 -0.0706 -0.1187 -0.0802 -0.0983 -0.0742 -0.3931 -1.2046 -0.0675 -0.0157 -0.1984 -0.1573 -0.1053 -0.2205 -0.1586
S-1381	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-1381	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-1381	-0.16239388287067413	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
D-1381	-0.16239388287067413	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
P-1381	-0.5300 -0.1354 -0.1717 -0.1501 -0.1991 -0.0722 -0.0899 -0.1540 -0.1684 -0.1599 -0.0920 -0.0446 -0.0537 -0.4900 -0.1659 -0.1414 -0.3404 -0.1670 -0.1634 -0.1743 -0.0383 -0.1382 -0.1113 -0.1181 -0.0853 -0.0934 -0.1484 -0.1506
S-1489	59 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-1489	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-1489	-0.210096538066864	After reconstitution , this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
D-1489	-0.210096538066864	After reconstitution , this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
P-1489	-2.2124 -0.1412 -0.0696 -0.5692 -0.1067 -0.0968 -0.0495 -0.0503 -0.0909 -0.1114 -0.1190 -0.1300 -0.1697 -0.1070 -0.1090 -0.0588 -0.1348 -0.1691 -0.0519 -0.1358 -0.0905 -0.0902 -0.0742 -0.1634 -0.1512
S-1313	48 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-1313	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-1313	-0.2256859689950943	48 This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
D-1313	-0.2256859689950943	48 This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
P-1313	-0.8205 -0.3813 -0.2897 -0.0656 -0.0528 -0.9706 -0.4960 -0.1186 -0.1364 -0.1729 -0.1085 -0.0942 -0.0553 -0.1375 -0.1646 -0.0539 -0.1378 -0.0904 -0.1019 -0.0718 -0.5436 -0.2056 -0.0741 -0.1497 -0.1490
S-1137	37 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-1137	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-1137	-0.21286118030548096	37 This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
D-1137	-0.21286118030548096	37 This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
P-1137	-0.7828 -0.3675 -0.2522 -0.0666 -0.0534 -0.7998 -0.4516 -0.1207 -0.1358 -0.1741 -0.1086 -0.0959 -0.0569 -0.1387 -0.1638 -0.0558 -0.1377 -0.0898 -0.1031 -0.0703 -0.5174 -0.2059 -0.0753 -0.1499 -0.1481
S-961	26 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-961	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-961	-0.21185970306396484	This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
D-961	-0.21185970306396484	This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
P-961	-1.1016 -0.1189 -0.0672 -0.0518 -0.5649 -0.6141 -0.1189 -0.1373 -0.1730 -0.1080 -0.0978 -0.0547 -0.1393 -0.1649 -0.0566 -0.1375 -0.0911 -0.1043 -0.0699 -0.5277 -0.2121 -0.0769 -0.1467 -0.1494
S-538	Ein Antikörper ist ein Protein , das vom Körper aufgrund seines natürlichen Schutzmechanismus als Reaktion auf unbekannte Stoffe gebildet wird .
T-538	An antibody is a protein produced by the body in reaction to unknown agents as part of the natural defence system of the body .
H-538	-0.369783490896225	An antibody is a protein produced by the body in response to unknown substances because of its natural protective mechanism .
D-538	-0.369783490896225	An antibody is a protein produced by the body in response to unknown substances because of its natural protective mechanism .
P-538	-0.3877 -0.1031 -0.1403 -0.1135 -0.1395 -0.0866 -1.0610 -0.1722 -0.1225 -0.1475 -0.9237 -0.4990 -0.1431 -0.6840 -0.8934 -0.1152 -1.6084 -0.1658 -0.0723 -0.1659 -0.9782 -0.1298 -0.0969 -0.1402 -0.1547
S-611	4 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-611	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-611	-0.22162361443042755	This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
D-611	-0.22162361443042755	This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
P-611	-1.3334 -0.1275 -0.0649 -0.0521 -0.6287 -0.5439 -0.1207 -0.1384 -0.1735 -0.1088 -0.0976 -0.0593 -0.1387 -0.1664 -0.0553 -0.1376 -0.0907 -0.1009 -0.0693 -0.5435 -0.1957 -0.0796 -0.1432 -0.1493
S-1281	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-1281	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-1281	-0.27124837040901184	Every 24 hours ( 12-24 hours for patients under 6 years of age ) for at least 1 day until wound healing is achieved .
D-1281	-0.27124837040901184	Every 24 hours ( 12-24 hours for patients under 6 years of age ) for at least 1 day until wound healing is achieved .
P-1281	-1.3341 -0.1582 -0.1210 -0.1506 -0.3389 -0.1196 -0.1660 -0.1437 -1.0168 -0.1943 -0.4197 -0.2057 -0.0987 -0.3607 -0.1090 -0.1375 -0.1293 -0.1580 -0.1208 -0.2344 -0.1119 -0.2528 -0.7655 -0.3002 -0.0922 -0.1522 -0.1368 -0.1775 -0.1602
S-929	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-929	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-929	-0.27124837040901184	Every 24 hours ( 12-24 hours for patients under 6 years of age ) for at least 1 day until wound healing is achieved .
D-929	-0.27124837040901184	Every 24 hours ( 12-24 hours for patients under 6 years of age ) for at least 1 day until wound healing is achieved .
P-929	-1.3341 -0.1582 -0.1210 -0.1506 -0.3389 -0.1196 -0.1660 -0.1437 -1.0168 -0.1943 -0.4197 -0.2057 -0.0987 -0.3607 -0.1090 -0.1375 -0.1293 -0.1580 -0.1208 -0.2344 -0.1119 -0.2528 -0.7655 -0.3002 -0.0922 -0.1522 -0.1368 -0.1775 -0.1602
S-371	Vitamin D3 über bis zu 5 Monate nicht mit Hypercalciurie oder Hypercalcämie assoziiert .
T-371	In a clinical study of healthy adults a 4000 IU daily dose of vitamin D3 for up to five months was not associated with hypercalciuria or hypercalcaemia .
H-371	-0.18419532477855682	vitamin D3 for up to 5 months not associated with hypercalciuria or hypercalcaemia .
D-371	-0.18419532477855682	vitamin D3 for up to 5 months not associated with hypercalciuria or hypercalcaemia .
P-371	-0.1500 -0.0944 -0.1303 -0.1436 -0.4234 -0.1317 -0.1385 -0.1782 -0.1613 -1.4944 -0.0986 -0.1601 -0.0510 -0.1300 -0.1108 -0.0489 -0.1349 -0.1168 -0.0429 -0.1283 -0.0440 -0.0511 -0.1360 -0.1494 -0.1563
S-183	Vitamin D3 über bis zu 5 Monate nicht mit Hypercalciurie oder Hypercalcämie assoziiert .
T-183	In a clinical study of healthy adults a 4000 IU daily dose of vitamin D3 for up to five months was not associated with hypercalciuria or hypercalcaemia .
H-183	-0.18419532477855682	vitamin D3 for up to 5 months not associated with hypercalciuria or hypercalcaemia .
D-183	-0.18419532477855682	vitamin D3 for up to 5 months not associated with hypercalciuria or hypercalcaemia .
P-183	-0.1500 -0.0944 -0.1303 -0.1436 -0.4234 -0.1317 -0.1385 -0.1782 -0.1613 -1.4944 -0.0986 -0.1601 -0.0510 -0.1300 -0.1108 -0.0489 -0.1349 -0.1168 -0.0429 -0.1283 -0.0440 -0.0511 -0.1360 -0.1494 -0.1563
S-1914	In beiden Studien wurde Aerinaze mit Desloratadin allein und mit Pseudoephedrin allein verglichen .
T-1914	In both studies , Aerinaze was compared with desloratadine alone and with pseudoephedrine alone .
H-1914	-0.2484627068042755	In both studies , Aerinaze was compared to desloratadine alone and to pseudoephedrine alone .
D-1914	-0.2484627068042755	In both studies , Aerinaze was compared to desloratadine alone and to pseudoephedrine alone .
P-1914	-0.4591 -0.0797 -0.4976 -0.4174 -0.2425 -0.1179 -0.1138 -0.1257 -0.1219 -0.1454 -0.1443 -0.6071 -0.6504 -0.0715 -0.1089 -0.4296 -0.8250 -0.1407 -0.1374 -0.4903 -0.1034 -0.4738 -0.1628 -0.0772 -0.1000 -0.1269 -0.1226 -0.0711 -0.1374 -0.1523
S-1836	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
T-1836	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <<unk>> 354 533 6100
H-1836	-0.3203185498714447	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
D-1836	-0.3203185498714447	Suðurlandsbraut 22 IS-108 Reykjavík Sími : <unk> 354 533 6100
P-1836	-0.1162 -0.5798 -0.0958 -1.0018 -1.2354 -3.5299 -0.1236 -0.1239 -0.1084 -0.0706 -0.0939 -0.1334 -0.1260 -0.4176 -0.1167 -0.0592 -0.1034 -0.1213 -0.0422 -0.0471 -0.1348 -0.0601 -0.1344 -0.0842 -0.1204 -0.0909 -0.1465 -0.1216 -0.1503
S-1825	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <unk> 372 6 515 100
T-1825	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <<unk>> 372 6 515 100
H-1825	-0.1316748559474945	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <unk> 372 6 515 100
D-1825	-0.1316748559474945	Eesti AS Oriola Kungla 2 EE-76505 Saue Tel . : <unk> 372 6 515 100
P-1825	-0.1114 -0.0809 -0.1302 -0.0519 -0.1574 -0.3651 -0.1337 -0.0513 -0.2533 -0.1489 -0.1104 -0.1116 -0.0925 -0.2502 -0.0994 -0.1210 -0.0705 -0.1200 -0.0728 -0.1465 -0.1333 -0.0336 -0.1282 -0.1570 -0.1348 -0.1271 -0.1679 -0.1090 -0.1486
S-1824	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <unk> 47 22 58 4800
T-1824	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <<unk>> 47 22 58 4800
H-1824	-0.14796209335327148	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <unk> 47 22 58 4800
D-1824	-0.14796209335327148	Norge Baxter AS Gjerdrumsvei 11 N-0486 Oslo Tlf : <unk> 47 22 58 4800
P-1824	-0.0783 -0.1040 -0.2337 -0.1269 -0.1405 -0.0786 -0.1301 -0.4189 -0.1271 -0.5668 -0.1292 -0.1704 -0.1200 -0.1236 -0.1132 -0.0649 -0.1249 -0.2385 -0.1476 -0.1084 -0.1058 -0.1359 -0.0390 -0.1023 -0.1150 -0.0964 -0.1182 -0.0798 -0.1528
S-1457	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-1457	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-1457	-0.27124837040901184	Every 24 hours ( 12-24 hours for patients under 6 years of age ) for at least 1 day until wound healing is achieved .
D-1457	-0.27124837040901184	Every 24 hours ( 12-24 hours for patients under 6 years of age ) for at least 1 day until wound healing is achieved .
P-1457	-1.3341 -0.1582 -0.1210 -0.1506 -0.3389 -0.1196 -0.1660 -0.1437 -1.0168 -0.1943 -0.4197 -0.2057 -0.0987 -0.3607 -0.1090 -0.1375 -0.1293 -0.1580 -0.1208 -0.2344 -0.1119 -0.2528 -0.7655 -0.3002 -0.0922 -0.1522 -0.1368 -0.1775 -0.1602
S-677	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-677	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-677	-0.16239388287067413	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
D-677	-0.16239388287067413	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
P-677	-0.5300 -0.1354 -0.1717 -0.1501 -0.1991 -0.0722 -0.0899 -0.1540 -0.1684 -0.1599 -0.0920 -0.0446 -0.0537 -0.4900 -0.1659 -0.1414 -0.3404 -0.1670 -0.1634 -0.1743 -0.0383 -0.1382 -0.1113 -0.1181 -0.0853 -0.0934 -0.1484 -0.1506
S-1105	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-1105	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-1105	-0.27124837040901184	Every 24 hours ( 12-24 hours for patients under 6 years of age ) for at least 1 day until wound healing is achieved .
D-1105	-0.27124837040901184	Every 24 hours ( 12-24 hours for patients under 6 years of age ) for at least 1 day until wound healing is achieved .
P-1105	-1.3341 -0.1582 -0.1210 -0.1506 -0.3389 -0.1196 -0.1660 -0.1437 -1.0168 -0.1943 -0.4197 -0.2057 -0.0987 -0.3607 -0.1090 -0.1375 -0.1293 -0.1580 -0.1208 -0.2344 -0.1119 -0.2528 -0.7655 -0.3002 -0.0922 -0.1522 -0.1368 -0.1775 -0.1602
S-151	Antikonvulsiva , Cimetidin und Thiazide können den Abbaustoffwechsel von Vitamin D verstärken .
T-151	Anticonvulsants , cimetidine and thiazides may increase the catabolism of vitamin D.
H-151	-0.28247180581092834	Anticonvulsants , cimetidine and thiazides may increase the breakdown metabolism of vitamin D .
D-151	-0.28247180581092834	Anticonvulsants , cimetidine and thiazides may increase the breakdown metabolism of vitamin D .
P-151	-0.2849 -0.1701 -0.0122 -0.2707 -0.3124 -0.1489 -0.3198 -0.1287 -0.1633 -0.1185 -0.6055 -0.1624 -0.0423 -0.1386 -0.0624 -0.1725 -0.2959 -1.3841 -0.2028 -1.2261 -0.6298 -0.0774 -0.0771 -0.1395 -0.1268 -0.0995 -0.3866 -0.2756 -0.1571
S-753	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-753	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-753	-0.27124837040901184	Every 24 hours ( 12-24 hours for patients under 6 years of age ) for at least 1 day until wound healing is achieved .
D-753	-0.27124837040901184	Every 24 hours ( 12-24 hours for patients under 6 years of age ) for at least 1 day until wound healing is achieved .
P-753	-1.3341 -0.1582 -0.1210 -0.1506 -0.3389 -0.1196 -0.1660 -0.1437 -1.0168 -0.1943 -0.4197 -0.2057 -0.0987 -0.3607 -0.1090 -0.1375 -0.1293 -0.1580 -0.1208 -0.2344 -0.1119 -0.2528 -0.7655 -0.3002 -0.0922 -0.1522 -0.1368 -0.1775 -0.1602
S-579	Alle 24 Stunden ( 12-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag bis die Wundheilung erreicht ist .
T-579	Every 24 hours ( 12 to 24 hours for patients under the age of 6 ) , at least 1 day , until healing is achieved .
H-579	-0.27124837040901184	Every 24 hours ( 12-24 hours for patients under 6 years of age ) for at least 1 day until wound healing is achieved .
D-579	-0.27124837040901184	Every 24 hours ( 12-24 hours for patients under 6 years of age ) for at least 1 day until wound healing is achieved .
P-579	-1.3341 -0.1582 -0.1210 -0.1506 -0.3389 -0.1196 -0.1660 -0.1437 -1.0168 -0.1943 -0.4197 -0.2057 -0.0987 -0.3607 -0.1090 -0.1375 -0.1293 -0.1580 -0.1208 -0.2344 -0.1119 -0.2528 -0.7655 -0.3002 -0.0922 -0.1522 -0.1368 -0.1775 -0.1602
S-16	Das Arzneimittel wird nicht empfohlen bei Kindern und bei Patienten , die eine Organtransplantation hatten , da es für diese Gruppen nicht untersucht wurde .
T-16	It is not recommended for use in children or in patients who have had an organ transplant because it has not been studied in these groups .
H-16	-0.3341349959373474	This medicinal product is not recommended for paediatric and organ transplant patients as it has not been studied for these groups .
D-16	-0.3341349959373474	This medicinal product is not recommended for paediatric and organ transplant patients as it has not been studied for these groups .
P-16	-0.9485 -0.8109 -0.0596 -0.0672 -0.1310 -0.1754 -0.0496 -1.1517 -0.3561 -0.0156 -0.0112 -0.1094 -0.2101 -0.8940 -0.2016 -0.2116 -0.0457 -0.5243 -0.1553 -0.1163 -0.1332 -0.0841 -0.7940 -0.9225 -0.4587 -0.4066 -0.1506 -0.1611
S-1558	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-1558	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-1558	-0.16239388287067413	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
D-1558	-0.16239388287067413	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
P-1558	-0.5300 -0.1354 -0.1717 -0.1501 -0.1991 -0.0722 -0.0899 -0.1540 -0.1684 -0.1599 -0.0920 -0.0446 -0.0537 -0.4900 -0.1659 -0.1414 -0.3404 -0.1670 -0.1634 -0.1743 -0.0383 -0.1382 -0.1113 -0.1181 -0.0853 -0.0934 -0.1484 -0.1506
S-1205	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-1205	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-1205	-0.16239388287067413	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
D-1205	-0.16239388287067413	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
P-1205	-0.5300 -0.1354 -0.1717 -0.1501 -0.1991 -0.0722 -0.0899 -0.1540 -0.1684 -0.1599 -0.0920 -0.0446 -0.0537 -0.4900 -0.1659 -0.1414 -0.3404 -0.1670 -0.1634 -0.1743 -0.0383 -0.1382 -0.1113 -0.1181 -0.0853 -0.0934 -0.1484 -0.1506
S-853	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-853	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-853	-0.16239388287067413	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
D-853	-0.16239388287067413	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
P-853	-0.5300 -0.1354 -0.1717 -0.1501 -0.1991 -0.0722 -0.0899 -0.1540 -0.1684 -0.1599 -0.0920 -0.0446 -0.0537 -0.4900 -0.1659 -0.1414 -0.3404 -0.1670 -0.1634 -0.1743 -0.0383 -0.1382 -0.1113 -0.1181 -0.0853 -0.0934 -0.1484 -0.1506
S-1029	Da keine Kompatibilitätsstudien durchgeführt wurden , darf dieses Arzneimittel nicht mit anderen Arzneimitteln oder Lösungsmitteln gemischt werden .
T-1029	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
H-1029	-0.16239388287067413	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
D-1029	-0.16239388287067413	In the absence of compatibility studies , this medicinal product must not be mixed with other medicinal products or solvents .
P-1029	-0.5300 -0.1354 -0.1717 -0.1501 -0.1991 -0.0722 -0.0899 -0.1540 -0.1684 -0.1599 -0.0920 -0.0446 -0.0537 -0.4900 -0.1659 -0.1414 -0.3404 -0.1670 -0.1634 -0.1743 -0.0383 -0.1382 -0.1113 -0.1181 -0.0853 -0.0934 -0.1484 -0.1506
S-785	15 Dieses Arzneimittel enthält nach der Rekonstitution 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-785	After reconstitution this medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-785	-0.2102622091770172	This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
D-785	-0.2102622091770172	This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial after reconstitution .
P-785	-1.0073 -0.1319 -0.0666 -0.0538 -0.6428 -0.5677 -0.1200 -0.1377 -0.1744 -0.1082 -0.1020 -0.0561 -0.1381 -0.1687 -0.0542 -0.1374 -0.0915 -0.1021 -0.0689 -0.5408 -0.2040 -0.0769 -0.1458 -0.1491
S-312	Nach Markteinführung waren diese Symptome selten schwerwiegend und<unk> oder mit Einschränkungen der Beweglichkeit verbunden ( siehe Abschnitt 4.8 ) .
T-312	In post-marketing experience , these symptoms have rarely been severe and/ or incapacitating ( see section 4.8 ) .
H-312	-0.48911169171333313	These post-marketing symptoms have rarely been severe and/ or associated with mobility restrictions ( see section 4.8 ) .
D-312	-0.48911169171333313	These post-marketing symptoms have rarely been severe and/ or associated with mobility restrictions ( see section 4.8 ) .
P-312	-2.5778 -1.0847 -0.0873 -0.0344 -0.1347 -0.7244 -0.4155 -0.0942 -0.7415 -0.1312 -0.1103 -0.1334 -1.8625 -0.1358 -1.4946 -0.2625 -0.9384 -0.1369 -0.3674 -0.0983 -0.1057 -0.1303 -0.1380 -0.1384 -0.1496
S-384	Ein Mangel steht in Verbindung mit einer negativen Calciumbilanz , Knochenverlust und einem erhöhten Risiko für Skelettfrakturen .
T-384	Insufficiency is associated with negative calcium balance , bone loss , and increased risk of skeletal fracture .
H-384	-0.28786882758140564	Deficiency is associated with negative calcium balance , bone loss and an increased risk of skeletal fracture .
D-384	-0.28786882758140564	Deficiency is associated with negative calcium balance , bone loss and an increased risk of skeletal fracture .
P-384	-0.4774 -0.0363 -0.1993 -0.8932 -0.1062 -0.1345 -0.4698 -0.0346 -0.0675 -0.1191 -0.5722 -0.1550 -0.0873 -0.1163 -0.6543 -0.8311 -0.0260 -0.1366 -1.1097 -0.0703 -0.0616 -0.2429 -0.1331 -0.6147 -0.1075 -0.1596 -0.1564
S-1937	Jede Tablette enthält 2,5 mg Desloratadin und 120 mg Pseudoephedrin ( als Sulfat ) .
T-1937	Each tablet contains 2.5 mg desloratadine and 120 mg pseudoephedrine ( as sulphate ) .
H-1937	-0.20310088992118835	Each tablet contains 2.5 mg desloratadine and 120 mg pseudoephedrine ( as sulphate ) .
D-1937	-0.20310088992118835	Each tablet contains 2.5 mg desloratadine and 120 mg pseudoephedrine ( as sulphate ) .
P-1937	-0.0414 -0.1267 -0.1037 -0.0750 -0.1121 -0.0489 -1.1964 -0.0840 -0.1076 -0.6128 -0.4913 -0.1336 -0.0581 -0.0555 -0.3074 -0.5753 -0.1475 -0.0497 -0.1322 -0.1738 -0.1496 -0.1423 -0.2146 -0.0643 -0.1569 -0.0879 -0.1408 -0.1472 -0.1534
S-196	Ein Mangel steht in Verbindung mit einer negativen Calciumbilanz , Knochenverlust und einem erhöhten Risiko für Skelettfrakturen .
T-196	Insufficiency is associated with negative calcium balance , bone loss , and increased risk of skeletal fracture .
H-196	-0.28786882758140564	Deficiency is associated with negative calcium balance , bone loss and an increased risk of skeletal fracture .
D-196	-0.28786882758140564	Deficiency is associated with negative calcium balance , bone loss and an increased risk of skeletal fracture .
P-196	-0.4774 -0.0363 -0.1993 -0.8932 -0.1062 -0.1345 -0.4698 -0.0346 -0.0675 -0.1191 -0.5722 -0.1550 -0.0873 -0.1163 -0.6543 -0.8311 -0.0260 -0.1366 -1.1097 -0.0703 -0.0616 -0.2429 -0.1331 -0.6147 -0.1075 -0.1596 -0.1564
S-124	Nach Markteinführung waren diese Symptome selten schwerwiegend und<unk> oder mit Einschränkungen der Beweglichkeit verbunden ( siehe Abschnitt 4.8 ) .
T-124	In post-marketing experience , these symptoms have rarely been severe and/ or incapacitating ( see section 4.8 ) .
H-124	-0.48911169171333313	These post-marketing symptoms have rarely been severe and/ or associated with mobility restrictions ( see section 4.8 ) .
D-124	-0.48911169171333313	These post-marketing symptoms have rarely been severe and/ or associated with mobility restrictions ( see section 4.8 ) .
P-124	-2.5778 -1.0847 -0.0873 -0.0344 -0.1347 -0.7244 -0.4155 -0.0942 -0.7415 -0.1312 -0.1103 -0.1334 -1.8625 -0.1358 -1.4946 -0.2625 -0.9384 -0.1369 -0.3674 -0.0983 -0.1057 -0.1303 -0.1380 -0.1384 -0.1496
S-6	Bei der Hyperurikämie können sich Uratkristalle bilden und in den Gelenken und Nieren ablagern .
T-6	Hyperuricaemia can lead to urate crystals forming and building up in the joints and the kidneys .
H-6	-0.3779139518737793	Hyperuricaemia may see the formation of urine crystals and deposit them in the joints and kidneys .
D-6	-0.3779139518737793	Hyperuricaemia may see the formation of urine crystals and deposit them in the joints and kidneys .
P-6	-0.1482 -0.0730 -0.0727 -0.2882 -0.0220 -0.1386 -1.1694 -2.1776 -0.3942 -0.2547 -0.1871 -1.3407 -0.7569 -0.0671 -0.0274 -0.1449 -0.2834 -1.7210 -0.0493 -0.1523 -0.2137 -0.1067 -0.0437 -0.1238 -0.2940 -0.3666 -0.0469 -0.1432 -0.1520
S-1483	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-1483	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-1483	-0.33676642179489136	Patients developing factor VIII inhibitors may experience an inadequate clinical response .
D-1483	-0.33676642179489136	Patients developing factor VIII inhibitors may experience an inadequate clinical response .
P-1483	-0.7448 -0.0999 -0.3703 -0.3956 -0.1794 -0.1226 -0.1040 -0.0307 -0.0682 -0.1266 -0.0476 -0.9954 -1.1559 -0.0975 -0.8482 -0.1062 -0.5848 -0.1629 -0.1580
S-681	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-681	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-681	-0.361423134803772	During term , the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
D-681	-0.361423134803772	During term , the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
P-681	-1.2209 -3.0056 -0.4191 -0.2071 -0.0749 -0.3169 -0.1916 -0.2592 -0.1107 -0.3342 -0.0954 -0.0954 -0.1415 -0.2760 -0.1267 -0.1924 -0.6561 -0.1768 -0.1314 -0.2048 -0.1728 -0.0886 -0.1741 -0.6548 -0.1373 -0.1452 -0.1490
S-857	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-857	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-857	-0.361423134803772	During term , the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
D-857	-0.361423134803772	During term , the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
P-857	-1.2209 -3.0056 -0.4191 -0.2071 -0.0749 -0.3169 -0.1916 -0.2592 -0.1107 -0.3342 -0.0954 -0.0954 -0.1415 -0.2760 -0.1267 -0.1924 -0.6561 -0.1768 -0.1314 -0.2048 -0.1728 -0.0886 -0.1741 -0.6548 -0.1373 -0.1452 -0.1490
S-1033	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-1033	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-1033	-0.361423134803772	During term , the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
D-1033	-0.361423134803772	During term , the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
P-1033	-1.2209 -3.0056 -0.4191 -0.2071 -0.0749 -0.3169 -0.1916 -0.2592 -0.1107 -0.3342 -0.0954 -0.0954 -0.1415 -0.2760 -0.1267 -0.1924 -0.6561 -0.1768 -0.1314 -0.2048 -0.1728 -0.0886 -0.1741 -0.6548 -0.1373 -0.1452 -0.1490
S-1209	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-1209	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-1209	-0.361423134803772	During term , the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
D-1209	-0.361423134803772	During term , the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
P-1209	-1.2209 -3.0056 -0.4191 -0.2071 -0.0749 -0.3169 -0.1916 -0.2592 -0.1107 -0.3342 -0.0954 -0.0954 -0.1415 -0.2760 -0.1267 -0.1924 -0.6561 -0.1768 -0.1314 -0.2048 -0.1728 -0.0886 -0.1741 -0.6548 -0.1373 -0.1452 -0.1490
S-1385	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-1385	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-1385	-0.361423134803772	During term , the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
D-1385	-0.361423134803772	During term , the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
P-1385	-1.2209 -3.0056 -0.4191 -0.2071 -0.0749 -0.3169 -0.1916 -0.2592 -0.1107 -0.3342 -0.0954 -0.0954 -0.1415 -0.2760 -0.1267 -0.1924 -0.6561 -0.1768 -0.1314 -0.2048 -0.1728 -0.0886 -0.1741 -0.6548 -0.1373 -0.1452 -0.1490
S-1562	Während der Laufzeit kann das Produkt einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25<unk> C ) aufbewahrt werden .
T-1562	During the shelf life , the product may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-1562	-0.361423134803772	During term , the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
D-1562	-0.361423134803772	During term , the product can be stored at room temperature ( up to 25ºC ) for a maximum of 2 months .
P-1562	-1.2209 -3.0056 -0.4191 -0.2071 -0.0749 -0.3169 -0.1916 -0.2592 -0.1107 -0.3342 -0.0954 -0.0954 -0.1415 -0.2760 -0.1267 -0.1924 -0.6561 -0.1768 -0.1314 -0.2048 -0.1728 -0.0886 -0.1741 -0.6548 -0.1373 -0.1452 -0.1490
S-1949	Überempfindlichkeit gegen den Wirkstoff , einen der sonstigen Bestandteile , adrenergen Wirkstoffen oder Loratadin .
T-1949	Hypersensitivity to the active substance , to any of the excipients , to adrenergic agents or to loratadine .
H-1949	-0.19667263329029083	Hypersensitivity to the active substance , to any of the excipients , adrenergic agents or loratadin .
D-1949	-0.19667263329029083	Hypersensitivity to the active substance , to any of the excipients , adrenergic agents or loratadin .
P-1949	-0.1144 -0.0403 -0.0556 -0.0541 -0.1543 -0.1911 -0.0972 -0.0555 -0.1943 -0.2872 -0.1028 -0.1555 -0.1614 -0.3536 -0.0420 -0.0666 -0.0797 -0.1519 -0.0923 -0.0745 -0.1368 -0.0526 -0.0845 -0.1494 -0.0832 -0.0960 -2.1173 -0.3294 -0.1752 -0.1518
S-1307	Bei Patienten , die Inhibitoren gegen Faktor VIII entwickeln , kann sich dies in einer ungenügenden klinischen Reaktion zeigen .
T-1307	In patients who develop inhibitors to factor VIII , the condition may manifest itself as an insufficient clinical response .
H-1307	-0.33676642179489136	Patients developing factor VIII inhibitors may experience an inadequate clinical response .
D-1307	-0.33676642179489136	Patients developing factor VIII inhibitors may experience an inadequate clinical response .
P-1307	-0.7448 -0.0999 -0.3703 -0.3956 -0.1794 -0.1226 -0.1040 -0.0307 -0.0682 -0.1266 -0.0476 -0.9954 -1.1559 -0.0975 -0.8482 -0.1062 -0.5848 -0.1629 -0.1580
S-742	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-742	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-742	-0.2427021712064743	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
D-742	-0.2427021712064743	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
P-742	-0.4644 -0.4205 -0.1083 -0.3460 -0.1432 -0.1139 -0.0611 -0.1323 -0.1615 -0.7955 -0.0730 -0.1368 -0.0605 -0.1359 -0.1420 -0.5557 -0.0573 -0.1028 -0.0542 -0.3643 -1.3110 -0.2517 -0.1417 -0.1750 -0.1329 -0.1582 -0.0509 -0.1450
S-568	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-568	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-568	-0.2427021712064743	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
D-568	-0.2427021712064743	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
P-568	-0.4644 -0.4205 -0.1083 -0.3460 -0.1432 -0.1139 -0.0611 -0.1323 -0.1615 -0.7955 -0.0730 -0.1368 -0.0605 -0.1359 -0.1420 -0.5557 -0.0573 -0.1028 -0.0542 -0.3643 -1.3110 -0.2517 -0.1417 -0.1750 -0.1329 -0.1582 -0.0509 -0.1450
S-644	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-644	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-644	-0.3495227098464966	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
D-644	-0.3495227098464966	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
P-644	-3.0163 -0.1858 -0.1889 -0.2728 -0.5749 -0.4533 -0.4123 -0.1188 -0.6225 -0.1409 -0.1396 -0.4839 -0.0824 -0.4455 -0.3141 -0.1350 -0.1699 -0.1229 -0.4793 -0.2648 -0.1078 -0.4651 -0.1378 -0.1270 -0.1098 -0.4818 -0.0947 -0.4896 -0.1351 -0.1226 -0.1380 -0.1516
S-1446	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-1446	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-1446	-0.2427021712064743	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
D-1446	-0.2427021712064743	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
P-1446	-0.4644 -0.4205 -0.1083 -0.3460 -0.1432 -0.1139 -0.0611 -0.1323 -0.1615 -0.7955 -0.0730 -0.1368 -0.0605 -0.1359 -0.1420 -0.5557 -0.0573 -0.1028 -0.0542 -0.3643 -1.3110 -0.2517 -0.1417 -0.1750 -0.1329 -0.1582 -0.0509 -0.1450
S-1270	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-1270	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-1270	-0.2427021712064743	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
D-1270	-0.2427021712064743	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
P-1270	-0.4644 -0.4205 -0.1083 -0.3460 -0.1432 -0.1139 -0.0611 -0.1323 -0.1615 -0.7955 -0.0730 -0.1368 -0.0605 -0.1359 -0.1420 -0.5557 -0.0573 -0.1028 -0.0542 -0.3643 -1.3110 -0.2517 -0.1417 -0.1750 -0.1329 -0.1582 -0.0509 -0.1450
S-107	Alendronat Alendronat kann lokale Irritationen der Schleimhäute des oberen Gastrointestinaltraktes verursachen .
T-107	Alendronate Alendronate can cause local irritation of the upper gastrointestinal mucosa .
H-107	-0.19872541725635529	Alendronate Alendronate may cause local irritation to the mucosae of the upper gastrointestinal tract .
D-107	-0.19872541725635529	Alendronate Alendronate may cause local irritation to the mucosae of the upper gastrointestinal tract .
P-107	-0.0746 -0.1678 -0.1150 -0.0867 -0.1024 -0.1725 -0.1081 -0.0661 -0.2110 -0.0573 -0.4485 -0.0823 -0.1428 -1.2675 -0.1764 -0.5633 -0.0494 -0.0185 -0.1542 -0.1175 -0.2751 -0.5442 -0.0975 -0.1222 -0.0863 -0.0889 -0.1877 -0.0689 -0.1504 -0.1586
S-918	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-918	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-918	-0.2427021712064743	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
D-918	-0.2427021712064743	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
P-918	-0.4644 -0.4205 -0.1083 -0.3460 -0.1432 -0.1139 -0.0611 -0.1323 -0.1615 -0.7955 -0.0730 -0.1368 -0.0605 -0.1359 -0.1420 -0.5557 -0.0573 -0.1028 -0.0542 -0.3643 -1.3110 -0.2517 -0.1417 -0.1750 -0.1329 -0.1582 -0.0509 -0.1450
S-994	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-994	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-994	-0.3495227098464966	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
D-994	-0.3495227098464966	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
P-994	-3.0163 -0.1858 -0.1889 -0.2728 -0.5749 -0.4533 -0.4123 -0.1188 -0.6225 -0.1409 -0.1396 -0.4839 -0.0824 -0.4455 -0.3141 -0.1350 -0.1699 -0.1229 -0.4793 -0.2648 -0.1078 -0.4651 -0.1378 -0.1270 -0.1098 -0.4818 -0.0947 -0.4896 -0.1351 -0.1226 -0.1380 -0.1516
S-1346	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-1346	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-1346	-0.3495227098464966	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
D-1346	-0.3495227098464966	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
P-1346	-3.0163 -0.1858 -0.1889 -0.2728 -0.5749 -0.4533 -0.4123 -0.1188 -0.6225 -0.1409 -0.1396 -0.4839 -0.0824 -0.4455 -0.3141 -0.1350 -0.1699 -0.1229 -0.4793 -0.2648 -0.1078 -0.4651 -0.1378 -0.1270 -0.1098 -0.4818 -0.0947 -0.4896 -0.1351 -0.1226 -0.1380 -0.1516
S-379	Vitamin D3 wird in der Leber zu 25-Hydroxyvitamin D3 umgewandelt und gespeichert , bis es gebraucht wird .
T-379	Vitamin D3 is converted to 25-hydroxyvitamin D3 in the liver , and stored until needed .
H-379	-0.2899828553199768	Vitamin D3 is converted by the liver to 25-hydroxyvitamin D3 and stored until it is needed .
D-379	-0.2899828553199768	Vitamin D3 is converted by the liver to 25-hydroxyvitamin D3 and stored until it is needed .
P-379	-0.9062 -0.0806 -0.1268 -0.1304 -0.1043 -1.3149 -0.4813 -0.1272 -0.0753 -1.0226 -0.2209 -0.1051 -0.0622 -0.2575 -0.0902 -0.1155 -0.1154 -0.1219 -0.1327 -0.2346 -0.4520 -0.1090 -0.1270 -0.4566 -0.1248 -0.7173 -0.1476 -0.1597
S-310	Die klinische Einschätzung durch den behandelnden Arzt ist maßgebend für die Therapieplanung bei jedem Patienten auf Basis einer individuellen Nutzen-Risiko-Bewertung .
T-310	Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/ risk assessment .
H-310	-0.4221560060977936	The clinical assessment by the attending physician is decisive for the therapy planning of each patient on the basis of an individual benefit-risk assessment .
D-310	-0.4221560060977936	The clinical assessment by the attending physician is decisive for the therapy planning of each patient on the basis of an individual benefit-risk assessment .
P-310	-0.2181 -0.3861 -0.8173 -1.3123 -0.1568 -0.6631 -0.3270 -0.2620 -0.2426 -2.8715 -0.1775 -0.3931 -1.6310 -0.2351 -0.7661 -0.1934 -0.0452 -0.3028 -0.1384 -0.0955 -0.1451 -0.2469 -0.0693 -0.1018 -0.0519 -0.2197 -0.0594 -0.2467 -0.1368 -0.1521
S-191	Vitamin D3 wird in der Leber zu 25-Hydroxyvitamin D3 umgewandelt und gespeichert , bis es gebraucht wird .
T-191	Vitamin D3 is converted to 25-hydroxyvitamin D3 in the liver , and stored until needed .
H-191	-0.2899828553199768	Vitamin D3 is converted by the liver to 25-hydroxyvitamin D3 and stored until it is needed .
D-191	-0.2899828553199768	Vitamin D3 is converted by the liver to 25-hydroxyvitamin D3 and stored until it is needed .
P-191	-0.9062 -0.0806 -0.1268 -0.1304 -0.1043 -1.3149 -0.4813 -0.1272 -0.0753 -1.0226 -0.2209 -0.1051 -0.0622 -0.2575 -0.0902 -0.1155 -0.1154 -0.1219 -0.1327 -0.2346 -0.4520 -0.1090 -0.1270 -0.4566 -0.1248 -0.7173 -0.1476 -0.1597
S-122	Die klinische Einschätzung durch den behandelnden Arzt ist maßgebend für die Therapieplanung bei jedem Patienten auf Basis einer individuellen Nutzen-Risiko-Bewertung .
T-122	Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/ risk assessment .
H-122	-0.4221560060977936	The clinical assessment by the attending physician is decisive for the therapy planning of each patient on the basis of an individual benefit-risk assessment .
D-122	-0.4221560060977936	The clinical assessment by the attending physician is decisive for the therapy planning of each patient on the basis of an individual benefit-risk assessment .
P-122	-0.2181 -0.3861 -0.8173 -1.3123 -0.1568 -0.6631 -0.3270 -0.2620 -0.2426 -2.8715 -0.1775 -0.3931 -1.6310 -0.2351 -0.7661 -0.1934 -0.0452 -0.3028 -0.1384 -0.0955 -0.1451 -0.2469 -0.0693 -0.1018 -0.0519 -0.2197 -0.0594 -0.2467 -0.1368 -0.1521
S-295	Alendronat Alendronat kann lokale Irritationen der Schleimhäute des oberen Gastrointestinaltraktes verursachen .
T-295	Alendronate Alendronate can cause local irritation of the upper gastrointestinal mucosa .
H-295	-0.19872541725635529	Alendronate Alendronate may cause local irritation to the mucosae of the upper gastrointestinal tract .
D-295	-0.19872541725635529	Alendronate Alendronate may cause local irritation to the mucosae of the upper gastrointestinal tract .
P-295	-0.0746 -0.1678 -0.1150 -0.0867 -0.1024 -0.1725 -0.1081 -0.0661 -0.2110 -0.0573 -0.4485 -0.0823 -0.1428 -1.2675 -0.1764 -0.5633 -0.0494 -0.0185 -0.1542 -0.1175 -0.2751 -0.5442 -0.0975 -0.1222 -0.0863 -0.0889 -0.1877 -0.0689 -0.1504 -0.1586
S-1094	Erforderliche Einheiten ( I.E. ) = Körpergewicht ( kg ) x gewünschter Faktor-VIII-Anstieg ( % ) x 0,5
T-1094	Required units ( IU ) = body weight ( kg ) x desired factor VIII rise ( % ) x 0.5
H-1094	-0.2427021712064743	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
D-1094	-0.2427021712064743	Required units ( IU ) = body weight ( kg ) x desired factor VIII increase ( % ) x 0.5
P-1094	-0.4644 -0.4205 -0.1083 -0.3460 -0.1432 -0.1139 -0.0611 -0.1323 -0.1615 -0.7955 -0.0730 -0.1368 -0.0605 -0.1359 -0.1420 -0.5557 -0.0573 -0.1028 -0.0542 -0.3643 -1.3110 -0.2517 -0.1417 -0.1750 -0.1329 -0.1582 -0.0509 -0.1450
S-1777	Wenn Sie die Anwendung von ADVATE vergessen haben Injizieren Sie nicht die doppelte Dosis , wenn Sie die vorherige Anwendung vergessen haben .
T-1777	If you forget to use ADVATE Do not inject a double dose to make up for a forgotten dose .
H-1777	-0.41035833954811096	If you forget to use ADVATE Do not inject the double dose if you missed the previous dose .
D-1777	-0.41035833954811096	If you forget to use ADVATE Do not inject the double dose if you missed the previous dose .
P-1777	-0.1465 -0.1168 -0.8082 -0.1231 -0.5744 -0.0865 -0.1459 -0.0844 -0.0910 -0.0903 -0.1358 -0.5275 -0.0950 -1.5461 -0.6132 -0.0520 -0.1476 -0.1313 -2.2920 -0.2956 -0.1415 -1.2789 -0.1483 -0.1770
S-818	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-818	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-818	-0.3495227098464966	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
D-818	-0.3495227098464966	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
P-818	-3.0163 -0.1858 -0.1889 -0.2728 -0.5749 -0.4533 -0.4123 -0.1188 -0.6225 -0.1409 -0.1396 -0.4839 -0.0824 -0.4455 -0.3141 -0.1350 -0.1699 -0.1229 -0.4793 -0.2648 -0.1078 -0.4651 -0.1378 -0.1270 -0.1098 -0.4818 -0.0947 -0.4896 -0.1351 -0.1226 -0.1380 -0.1516
S-921	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-921	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-921	-0.5804382562637329	Table 1 : Dosage regimen for haemorrhage events and surgery Grade of haemorrhage / type of surgery Haemorrhage
D-921	-0.5804382562637329	Table 1 : Dosage regimen for haemorrhage events and surgery Grade of haemorrhage / type of surgery Haemorrhage
P-921	-0.1512 -0.1582 -0.1465 -0.8097 -0.0743 -0.0879 -2.1287 -0.4847 -0.1566 -0.9156 -0.8705 -0.0659 -0.1734 -0.0992 -0.1456 -1.9694 -2.9145 -0.1178 -0.1465 -1.5723 -0.3035 -0.0166 -0.1188 -0.1385 -1.7889 -0.1434 -0.0641 -2.0247 -0.4590 -0.0265 -0.1476 -0.1538
S-833	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-833	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-833	-0.2462434619665146	Activated factor VIII acts as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.
D-833	-0.2462434619665146	Activated factor VIII acts as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.
P-833	-1.7546 -0.1266 -0.1289 -0.2653 -0.1483 -0.1498 -0.1105 -0.1447 -0.2292 -0.1578 -0.0500 -0.1952 -0.2433 -0.1237 -0.0741 -0.1245 -0.1190 -0.2481 -0.9591 -0.1069 -0.1255 -0.2480 -0.1484 -0.2184 -0.1208 -0.0710 -0.0803 -0.4526 -0.1446 -0.5286 -0.1191 -0.1631
S-1273	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-1273	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-1273	-0.5804382562637329	Table 1 : Dosage regimen for haemorrhage events and surgery Grade of haemorrhage / type of surgery Haemorrhage
D-1273	-0.5804382562637329	Table 1 : Dosage regimen for haemorrhage events and surgery Grade of haemorrhage / type of surgery Haemorrhage
P-1273	-0.1512 -0.1582 -0.1465 -0.8097 -0.0743 -0.0879 -2.1287 -0.4847 -0.1566 -0.9156 -0.8705 -0.0659 -0.1734 -0.0992 -0.1456 -1.9694 -2.9145 -0.1178 -0.1465 -1.5723 -0.3035 -0.0166 -0.1188 -0.1385 -1.7889 -0.1434 -0.0641 -2.0247 -0.4590 -0.0265 -0.1476 -0.1538
S-1185	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-1185	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-1185	-0.2462434619665146	Activated factor VIII acts as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.
D-1185	-0.2462434619665146	Activated factor VIII acts as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.
P-1185	-1.7546 -0.1266 -0.1289 -0.2653 -0.1483 -0.1498 -0.1105 -0.1447 -0.2292 -0.1578 -0.0500 -0.1952 -0.2433 -0.1237 -0.0741 -0.1245 -0.1190 -0.2481 -0.9591 -0.1069 -0.1255 -0.2480 -0.1484 -0.2184 -0.1208 -0.0710 -0.0803 -0.4526 -0.1446 -0.5286 -0.1191 -0.1631
S-1097	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-1097	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-1097	-0.5804382562637329	Table 1 : Dosage regimen for haemorrhage events and surgery Grade of haemorrhage / type of surgery Haemorrhage
D-1097	-0.5804382562637329	Table 1 : Dosage regimen for haemorrhage events and surgery Grade of haemorrhage / type of surgery Haemorrhage
P-1097	-0.1512 -0.1582 -0.1465 -0.8097 -0.0743 -0.0879 -2.1287 -0.4847 -0.1566 -0.9156 -0.8705 -0.0659 -0.1734 -0.0992 -0.1456 -1.9694 -2.9145 -0.1178 -0.1465 -1.5723 -0.3035 -0.0166 -0.1188 -0.1385 -1.7889 -0.1434 -0.0641 -2.0247 -0.4590 -0.0265 -0.1476 -0.1538
S-1009	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-1009	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-1009	-0.2462434619665146	Activated factor VIII acts as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.
D-1009	-0.2462434619665146	Activated factor VIII acts as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.
P-1009	-1.7546 -0.1266 -0.1289 -0.2653 -0.1483 -0.1498 -0.1105 -0.1447 -0.2292 -0.1578 -0.0500 -0.1952 -0.2433 -0.1237 -0.0741 -0.1245 -0.1190 -0.2481 -0.9591 -0.1069 -0.1255 -0.2480 -0.1484 -0.2184 -0.1208 -0.0710 -0.0803 -0.4526 -0.1446 -0.5286 -0.1191 -0.1631
S-932	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-932	Under certain circumstances ( e. g. presence of a low titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-932	-0.2802318334579468	In some circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
D-932	-0.2802318334579468	In some circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
P-932	-0.7090 -0.6887 -0.1669 -0.1683 -0.2205 -0.0956 -0.0772 -0.9151 -0.1538 -0.1996 -0.3248 -0.0877 -0.0780 -0.0788 -0.3038 -0.1869 -0.8143 -0.1383 -0.5313 -0.1523 -0.0951 -0.5482 -0.0256 -0.2494 -0.1148 -0.8290 -0.2150 -0.4334 -0.0946 -0.1525 -0.0927 -0.1552 -0.1513
S-1170	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-1170	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-1170	-0.3495227098464966	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
D-1170	-0.3495227098464966	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
P-1170	-3.0163 -0.1858 -0.1889 -0.2728 -0.5749 -0.4533 -0.4123 -0.1188 -0.6225 -0.1409 -0.1396 -0.4839 -0.0824 -0.4455 -0.3141 -0.1350 -0.1699 -0.1229 -0.4793 -0.2648 -0.1078 -0.4651 -0.1378 -0.1270 -0.1098 -0.4818 -0.0947 -0.4896 -0.1351 -0.1226 -0.1380 -0.1516
S-1523	Davon wiesen 4 einen hohen Titer ( 5 Bethesda-Einheiten ) und 1 einen niedrigen Titer ( <unk> 5 Bethesda-Einheiten ) auf .
T-1523	Of those , 4 were high-titre ( 5 BU ) and 1 was low-titre ( <<unk>> 5 BU ) .
H-1523	-0.3495227098464966	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
D-1523	-0.3495227098464966	Of these , 4 had a high titer ( 5 Bethesda units ) and 1 a low titer ( <unk> 5 Bethesda units ) .
P-1523	-3.0163 -0.1858 -0.1889 -0.2728 -0.5749 -0.4533 -0.4123 -0.1188 -0.6225 -0.1409 -0.1396 -0.4839 -0.0824 -0.4455 -0.3141 -0.1350 -0.1699 -0.1229 -0.4793 -0.2648 -0.1078 -0.4651 -0.1378 -0.1270 -0.1098 -0.4818 -0.0947 -0.4896 -0.1351 -0.1226 -0.1380 -0.1516
S-756	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-756	Under certain circumstances ( e. g. presence of a low titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-756	-0.2802318334579468	In some circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
D-756	-0.2802318334579468	In some circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
P-756	-0.7090 -0.6887 -0.1669 -0.1683 -0.2205 -0.0956 -0.0772 -0.9151 -0.1538 -0.1996 -0.3248 -0.0877 -0.0780 -0.0788 -0.3038 -0.1869 -0.8143 -0.1383 -0.5313 -0.1523 -0.0951 -0.5482 -0.0256 -0.2494 -0.1148 -0.8290 -0.2150 -0.4334 -0.0946 -0.1525 -0.0927 -0.1552 -0.1513
S-745	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-745	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-745	-0.5804382562637329	Table 1 : Dosage regimen for haemorrhage events and surgery Grade of haemorrhage / type of surgery Haemorrhage
D-745	-0.5804382562637329	Table 1 : Dosage regimen for haemorrhage events and surgery Grade of haemorrhage / type of surgery Haemorrhage
P-745	-0.1512 -0.1582 -0.1465 -0.8097 -0.0743 -0.0879 -2.1287 -0.4847 -0.1566 -0.9156 -0.8705 -0.0659 -0.1734 -0.0992 -0.1456 -1.9694 -2.9145 -0.1178 -0.1465 -1.5723 -0.3035 -0.0166 -0.1188 -0.1385 -1.7889 -0.1434 -0.0641 -2.0247 -0.4590 -0.0265 -0.1476 -0.1538
S-658	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-658	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-658	-0.2462434619665146	Activated factor VIII acts as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.
D-658	-0.2462434619665146	Activated factor VIII acts as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.
P-658	-1.7546 -0.1266 -0.1289 -0.2653 -0.1483 -0.1498 -0.1105 -0.1447 -0.2292 -0.1578 -0.0500 -0.1952 -0.2433 -0.1237 -0.0741 -0.1245 -0.1190 -0.2481 -0.9591 -0.1069 -0.1255 -0.2480 -0.1484 -0.2184 -0.1208 -0.0710 -0.0803 -0.4526 -0.1446 -0.5286 -0.1191 -0.1631
S-571	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-571	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-571	-0.5804382562637329	Table 1 : Dosage regimen for haemorrhage events and surgery Grade of haemorrhage / type of surgery Haemorrhage
D-571	-0.5804382562637329	Table 1 : Dosage regimen for haemorrhage events and surgery Grade of haemorrhage / type of surgery Haemorrhage
P-571	-0.1512 -0.1582 -0.1465 -0.8097 -0.0743 -0.0879 -2.1287 -0.4847 -0.1566 -0.9156 -0.8705 -0.0659 -0.1734 -0.0992 -0.1456 -1.9694 -2.9145 -0.1178 -0.1465 -1.5723 -0.3035 -0.0166 -0.1188 -0.1385 -1.7889 -0.1434 -0.0641 -2.0247 -0.4590 -0.0265 -0.1476 -0.1538
S-1928	Am 30 Juli 2007 erteilte die Europäische Kommission dem Unternehmen SP Europe eine Genehmigung für das Inverkehrbringen von Aerinaze in der gesamten Europäischen Union .
T-1928	The European Commission granted a marketing authorisation valid throughout the European Union for Aerinaze to SP Europe on 30 July 2007.
H-1928	-0.3051314353942871	On 30 July 2007 , the European Commission authorised SP Europe to market Aerinaze throughout the European Union .
D-1928	-0.3051314353942871	On 30 July 2007 , the European Commission authorised SP Europe to market Aerinaze throughout the European Union .
P-1928	-0.4544 -0.1990 -0.2765 -0.1584 -0.7321 -0.1433 -0.2547 -0.2023 -1.4016 -0.1201 -0.1483 -0.1315 -0.1590 -1.1218 -0.1944 -0.1180 -0.1177 -0.1843 -0.1186 -0.5365 -0.1366 -0.2187 -0.1918 -0.1512 -0.1572
S-1284	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-1284	Under certain circumstances ( e. g. presence of a low titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-1284	-0.2802318334579468	In some circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
D-1284	-0.2802318334579468	In some circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
P-1284	-0.7090 -0.6887 -0.1669 -0.1683 -0.2205 -0.0956 -0.0772 -0.9151 -0.1538 -0.1996 -0.3248 -0.0877 -0.0780 -0.0788 -0.3038 -0.1869 -0.8143 -0.1383 -0.5313 -0.1523 -0.0951 -0.5482 -0.0256 -0.2494 -0.1148 -0.8290 -0.2150 -0.4334 -0.0946 -0.1525 -0.0927 -0.1552 -0.1513
S-1111	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-1111	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-1111	-0.4018975794315338	Individual patients may vary in their response to factor VIII , may achieve different in vivo recovery and may have different half-lives .
D-1111	-0.4018975794315338	Individual patients may vary in their response to factor VIII , may achieve different in vivo recovery and may have different half-lives .
P-1111	-0.3921 -0.1392 -0.0644 -0.0845 -1.5066 -0.0806 -0.1339 -0.0962 -0.8200 -0.1585 -0.6458 -0.1543 -0.1251 -0.1513 -0.3392 -0.2270 -1.3092 -0.1844 -0.0927 -0.0686 -0.0925 -1.8230 -0.1990 -0.5103 -0.6173 -0.0719 -0.2008 -1.4776 -0.1343 -0.1568
S-941	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-941	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-941	-0.3454073667526245	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
D-941	-0.3454073667526245	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
P-941	-0.4119 -1.9620 -0.2975 -0.1390 -0.4315 -0.1334 -0.5082 -0.1024 -0.1737 -1.0669 -0.0717 -0.7737 -0.1683 -0.4307 -0.8380 -0.1772 -0.1408 -0.1677 -0.0614 -0.1668 -0.3695 -0.2454 -0.1461 -0.1002 -0.1161 -0.1247 -0.1853 -0.1613
S-765	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-765	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-765	-0.3454073667526245	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
D-765	-0.3454073667526245	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
P-765	-0.4119 -1.9620 -0.2975 -0.1390 -0.4315 -0.1334 -0.5082 -0.1024 -0.1737 -1.0669 -0.0717 -0.7737 -0.1683 -0.4307 -0.8380 -0.1772 -0.1408 -0.1677 -0.0614 -0.1668 -0.3695 -0.2454 -0.1461 -0.1002 -0.1161 -0.1247 -0.1853 -0.1613
S-1117	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-1117	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-1117	-0.3454073667526245	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
D-1117	-0.3454073667526245	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
P-1117	-0.4119 -1.9620 -0.2975 -0.1390 -0.4315 -0.1334 -0.5082 -0.1024 -0.1737 -1.0669 -0.0717 -0.7737 -0.1683 -0.4307 -0.8380 -0.1772 -0.1408 -0.1677 -0.0614 -0.1668 -0.3695 -0.2454 -0.1461 -0.1002 -0.1161 -0.1247 -0.1853 -0.1613
S-1287	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-1287	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-1287	-0.4018975794315338	Individual patients may vary in their response to factor VIII , may achieve different in vivo recovery and may have different half-lives .
D-1287	-0.4018975794315338	Individual patients may vary in their response to factor VIII , may achieve different in vivo recovery and may have different half-lives .
P-1287	-0.3921 -0.1392 -0.0644 -0.0845 -1.5066 -0.0806 -0.1339 -0.0962 -0.8200 -0.1585 -0.6458 -0.1543 -0.1251 -0.1513 -0.3392 -0.2270 -1.3092 -0.1844 -0.0927 -0.0686 -0.0925 -1.8230 -0.1990 -0.5103 -0.6173 -0.0719 -0.2008 -1.4776 -0.1343 -0.1568
S-935	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-935	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-935	-0.4018975794315338	Individual patients may vary in their response to factor VIII , may achieve different in vivo recovery and may have different half-lives .
D-935	-0.4018975794315338	Individual patients may vary in their response to factor VIII , may achieve different in vivo recovery and may have different half-lives .
P-935	-0.3921 -0.1392 -0.0644 -0.0845 -1.5066 -0.0806 -0.1339 -0.0962 -0.8200 -0.1585 -0.6458 -0.1543 -0.1251 -0.1513 -0.3392 -0.2270 -1.3092 -0.1844 -0.0927 -0.0686 -0.0925 -1.8230 -0.1990 -0.5103 -0.6173 -0.0719 -0.2008 -1.4776 -0.1343 -0.1568
S-1463	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-1463	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-1463	-0.4018975794315338	Individual patients may vary in their response to factor VIII , may achieve different in vivo recovery and may have different half-lives .
D-1463	-0.4018975794315338	Individual patients may vary in their response to factor VIII , may achieve different in vivo recovery and may have different half-lives .
P-1463	-0.3921 -0.1392 -0.0644 -0.0845 -1.5066 -0.0806 -0.1339 -0.0962 -0.8200 -0.1585 -0.6458 -0.1543 -0.1251 -0.1513 -0.3392 -0.2270 -1.3092 -0.1844 -0.0927 -0.0686 -0.0925 -1.8230 -0.1990 -0.5103 -0.6173 -0.0719 -0.2008 -1.4776 -0.1343 -0.1568
S-759	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-759	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-759	-0.4018975794315338	Individual patients may vary in their response to factor VIII , may achieve different in vivo recovery and may have different half-lives .
D-759	-0.4018975794315338	Individual patients may vary in their response to factor VIII , may achieve different in vivo recovery and may have different half-lives .
P-759	-0.3921 -0.1392 -0.0644 -0.0845 -1.5066 -0.0806 -0.1339 -0.0962 -0.8200 -0.1585 -0.6458 -0.1543 -0.1251 -0.1513 -0.3392 -0.2270 -1.3092 -0.1844 -0.0927 -0.0686 -0.0925 -1.8230 -0.1990 -0.5103 -0.6173 -0.0719 -0.2008 -1.4776 -0.1343 -0.1568
S-591	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-591	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-591	-0.3454073667526245	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
D-591	-0.3454073667526245	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
P-591	-0.4119 -1.9620 -0.2975 -0.1390 -0.4315 -0.1334 -0.5082 -0.1024 -0.1737 -1.0669 -0.0717 -0.7737 -0.1683 -0.4307 -0.8380 -0.1772 -0.1408 -0.1677 -0.0614 -0.1668 -0.3695 -0.2454 -0.1461 -0.1002 -0.1161 -0.1247 -0.1853 -0.1613
S-585	Einzelne Patienten können sich in ihrer Reaktion auf Faktor VIII unterscheiden , verschiedene in vivo Recovery erreichen und unterschiedliche Halbwertzeiten aufweisen .
T-585	Individual patients may vary in their response to factor VIII , achieving different levels of in vivo recovery and demonstrating different half-lives .
H-585	-0.4018975794315338	Individual patients may vary in their response to factor VIII , may achieve different in vivo recovery and may have different half-lives .
D-585	-0.4018975794315338	Individual patients may vary in their response to factor VIII , may achieve different in vivo recovery and may have different half-lives .
P-585	-0.3921 -0.1392 -0.0644 -0.0845 -1.5066 -0.0806 -0.1339 -0.0962 -0.8200 -0.1585 -0.6458 -0.1543 -0.1251 -0.1513 -0.3392 -0.2270 -1.3092 -0.1844 -0.0927 -0.0686 -0.0925 -1.8230 -0.1990 -0.5103 -0.6173 -0.0719 -0.2008 -1.4776 -0.1343 -0.1568
S-375	Die Aktivität der Osteoklasten wird gehemmt , Rekrutierung und Anbindung der Osteoklasten sind jedoch nicht betroffen .
T-375	Activity of osteoclasts is inhibited , but recruitment or attachment of osteoclasts is not affected .
H-375	-0.3220228850841522	The activity of the osteoclasts is inhibited , but osteoclast recruitment and attachment are not affected .
D-375	-0.3220228850841522	The activity of the osteoclasts is inhibited , but osteoclast recruitment and attachment are not affected .
P-375	-1.2951 -0.7954 -0.1404 -0.2408 -0.1537 -0.0674 -0.1734 -0.0378 -0.1141 -0.1192 -0.3367 -0.1394 -0.0880 -0.5555 -0.2356 -0.6415 -0.0808 -0.1566 -0.0057 -0.8507 -1.0543 -0.1226 -0.9577 -0.1199 -0.0842 -0.4131 -0.2998 -0.0733 -0.1547 -0.1531
S-1456	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-1456	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-1456	-0.25788429379463196	injection every 8-24 hours ( 6-12 hours for patients under 6 years of age ) until the risk to the patient is over .
D-1456	-0.25788429379463196	injection every 8-24 hours ( 6-12 hours for patients under 6 years of age ) until the risk to the patient is over .
P-1456	-0.4115 -0.1046 -0.2921 -0.5874 -0.1794 -0.1234 -0.1309 -0.1616 -0.1272 -0.1100 -0.1184 -0.1553 -0.8075 -0.2203 -0.6925 -0.2571 -0.0964 -0.2551 -0.1103 -0.1419 -0.2567 -0.1475 -0.4923 -0.2400 -0.1352 -0.0529 -0.3905 -0.5655 -0.2104 -0.1623
S-1280	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-1280	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-1280	-0.25788429379463196	injection every 8-24 hours ( 6-12 hours for patients under 6 years of age ) until the risk to the patient is over .
D-1280	-0.25788429379463196	injection every 8-24 hours ( 6-12 hours for patients under 6 years of age ) until the risk to the patient is over .
P-1280	-0.4115 -0.1046 -0.2921 -0.5874 -0.1794 -0.1234 -0.1309 -0.1616 -0.1272 -0.1100 -0.1184 -0.1553 -0.8075 -0.2203 -0.6925 -0.2571 -0.0964 -0.2551 -0.1103 -0.1419 -0.2567 -0.1475 -0.4923 -0.2400 -0.1352 -0.0529 -0.3905 -0.5655 -0.2104 -0.1623
S-1293	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-1293	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-1293	-0.3454073667526245	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
D-1293	-0.3454073667526245	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
P-1293	-0.4119 -1.9620 -0.2975 -0.1390 -0.4315 -0.1334 -0.5082 -0.1024 -0.1737 -1.0669 -0.0717 -0.7737 -0.1683 -0.4307 -0.8380 -0.1772 -0.1408 -0.1677 -0.0614 -0.1668 -0.3695 -0.2454 -0.1461 -0.1002 -0.1161 -0.1247 -0.1853 -0.1613
S-928	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-928	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-928	-0.25788429379463196	injection every 8-24 hours ( 6-12 hours for patients under 6 years of age ) until the risk to the patient is over .
D-928	-0.25788429379463196	injection every 8-24 hours ( 6-12 hours for patients under 6 years of age ) until the risk to the patient is over .
P-928	-0.4115 -0.1046 -0.2921 -0.5874 -0.1794 -0.1234 -0.1309 -0.1616 -0.1272 -0.1100 -0.1184 -0.1553 -0.8075 -0.2203 -0.6925 -0.2571 -0.0964 -0.2551 -0.1103 -0.1419 -0.2567 -0.1475 -0.4923 -0.2400 -0.1352 -0.0529 -0.3905 -0.5655 -0.2104 -0.1623
S-1469	Diese Therapien sollten nur von Ärzten durchgeführt werden , die über Erfahrung in der Behandlung von Patienten mit Hämophilie verfügen . Siehe Abschnitt 4.4 .
T-1469	The management of such patients should be directed by physicians with experience in the care of patients with haemophilia ( see section 4.4 ) .
H-1469	-0.3454073667526245	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
D-1469	-0.3454073667526245	These therapies should only be administered by physicians with experience in treating patients with haemophilia . See section 4.4 .
P-1469	-0.4119 -1.9620 -0.2975 -0.1390 -0.4315 -0.1334 -0.5082 -0.1024 -0.1737 -1.0669 -0.0717 -0.7737 -0.1683 -0.4307 -0.8380 -0.1772 -0.1408 -0.1677 -0.0614 -0.1668 -0.3695 -0.2454 -0.1461 -0.1002 -0.1161 -0.1247 -0.1853 -0.1613
S-1717	95 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-1717	89 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1717	-0.20035935938358307	95 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
D-1717	-0.20035935938358307	95 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
P-1717	-1.1739 -0.0182 -0.0967 -0.0399 -0.0401 -0.0254 -0.0537 -0.0746 -0.0556 -0.0277 -0.0244 -0.0389 -0.1765 -0.1372 -0.9336 -0.0287 -0.0368 -0.0869 -0.1249 -0.1574 -0.0949 -0.4411 -0.4370 -0.3327 -0.1237 -0.0565 -0.6213 -0.1514
S-1700	91 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-1700	85 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1700	-0.21217142045497894	91 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
D-1700	-0.21217142045497894	91 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
P-1700	-1.6084 -0.0239 -0.1272 -0.0367 -0.0543 -0.0301 -0.0530 -0.0706 -0.0694 -0.0294 -0.0246 -0.0391 -0.1738 -0.1293 -0.8360 -0.0281 -0.0367 -0.0894 -0.1134 -0.1730 -0.0978 -0.3653 -0.4375 -0.3407 -0.1252 -0.0580 -0.6227 -0.1473
S-1907	Wenn die Rezeptoren blockiert sind , kann Histamin seine Wirkung nicht entfalten , und dies führt zur Linderung der Allergiesymptome .
T-1907	Wenn die Rezeptoren blockiert sind , kann Histamin seine Wirkung nicht entfalten , und dies führt zur Linderung der Allergiesymptome . This reduces the amount of fluid released from the vessels , resulting in less swelling and less mucus production in the nose .
H-1907	-0.41209253668785095	If the receptors are blocked , histamine is unable to act and this relieves the symptoms of allergy .
D-1907	-0.41209253668785095	If the receptors are blocked , histamine is unable to act and this relieves the symptoms of allergy .
P-1907	-0.9603 -0.7162 -0.1135 -0.0666 -0.0678 -0.1828 -0.2343 -0.1590 -0.1942 -0.0385 -1.5195 -0.2069 -0.1353 -0.7875 -0.3741 -0.1314 -1.3830 -0.1586 -0.4910 -0.4101 -0.1610 -1.5185 -0.2339 -0.1644 -0.1462 -0.1597
S-503	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium<unk> info<unk> merck.com
T-503	Succursale belge/ Belgisch bijhuis Tél/ Tel : <<unk>> 32 ( 0 ) 800 38693 MSDBelgium<<unk>> info<<unk>> merck . com
H-503	-0.12889042496681213	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium/ info/ merck.com
D-503	-0.12889042496681213	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium/ info/ merck.com
P-503	-0.0979 -0.0450 -0.1284 -0.0860 -0.1370 -0.0914 -0.1328 -0.0771 -0.1251 -0.1378 -0.0406 -0.1019 -0.1358 -0.1192 -0.1297 -0.0847 -0.0680 -0.1272 -0.0893 -0.1199 -0.1249 -0.1385 -0.0388 -0.0856 -0.3560 -0.2092 -0.0961 -0.2119 -0.1871 -0.1720 -0.2779 -0.1521
S-487	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium<unk> info<unk> merck.com
T-487	Succursale belge/ Belgisch bijhuis Tél/ Tel : <<unk>> 32 ( 0 ) 800 38693 MSDBelgium<<unk>> info<<unk>> merck . com
H-487	-0.12889042496681213	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium/ info/ merck.com
D-487	-0.12889042496681213	Succursale belge Tél : <unk> 32 ( 0 ) 800 38693 MSDBelgium/ info/ merck.com
P-487	-0.0979 -0.0450 -0.1284 -0.0860 -0.1370 -0.0914 -0.1328 -0.0771 -0.1251 -0.1378 -0.0406 -0.1019 -0.1358 -0.1192 -0.1297 -0.0847 -0.0680 -0.1272 -0.0893 -0.1199 -0.1249 -0.1385 -0.0388 -0.0856 -0.3560 -0.2092 -0.0961 -0.2119 -0.1871 -0.1720 -0.2779 -0.1521
S-292	ADROVANCE wird für Patienten mit eingeschränkter Nierenfunktion mit einer GFR unter 35 ml<unk> min aufgrund mangelnder Erfahrung nicht empfohlen .
T-292	ADROVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min , due to lack of experience .
H-292	-0.23160941898822784	ADROVANCE is not recommended for renal impairment patients with GFR below 35 ml/ min due to lack of experience .
D-292	-0.23160941898822784	ADROVANCE is not recommended for renal impairment patients with GFR below 35 ml/ min due to lack of experience .
P-292	-0.0691 -0.0750 -0.1253 -0.1012 -0.1209 -0.1706 -0.1596 -0.0503 -0.2452 -1.2206 -0.1745 -0.0785 -0.0549 -0.0433 -0.1259 -0.0708 -0.1828 -0.6692 -0.2269 -0.5385 -0.0861 -0.1951 -0.1630 -0.1275 -0.2883 -0.1991 -0.1329 -1.1209 -0.1360 -0.1167 -0.1859 -0.1567
S-104	ADROVANCE wird für Patienten mit eingeschränkter Nierenfunktion mit einer GFR unter 35 ml<unk> min aufgrund mangelnder Erfahrung nicht empfohlen .
T-104	ADROVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min , due to lack of experience .
H-104	-0.23160941898822784	ADROVANCE is not recommended for renal impairment patients with GFR below 35 ml/ min due to lack of experience .
D-104	-0.23160941898822784	ADROVANCE is not recommended for renal impairment patients with GFR below 35 ml/ min due to lack of experience .
P-104	-0.0691 -0.0750 -0.1253 -0.1012 -0.1209 -0.1706 -0.1596 -0.0503 -0.2452 -1.2206 -0.1745 -0.0785 -0.0549 -0.0433 -0.1259 -0.0708 -0.1828 -0.6692 -0.2269 -0.5385 -0.0861 -0.1951 -0.1630 -0.1275 -0.2883 -0.1991 -0.1329 -1.1209 -0.1360 -0.1167 -0.1859 -0.1567
S-229	Die Bioverfügbarkeit war minimal , wenn Alendronat mit oder bis zu zwei Stunden nach einem standardisierten Frühstück angewendet wurde .
T-229	Bioavailability was negligible whether alendronate was administered with , or up to two hours after , a standardised breakfast .
H-229	-0.226436585187912	Bioavailability was minimal when alendronate was administered with or up to two hours after a standardized breakfast .
D-229	-0.226436585187912	Bioavailability was minimal when alendronate was administered with or up to two hours after a standardized breakfast .
P-229	-0.4274 -0.1022 -0.2207 -0.0456 -0.2794 -0.1418 -0.1559 -0.0876 -0.0554 -0.1189 -0.2258 -0.0867 -0.2150 -0.1619 -0.9487 -0.1347 -0.2108 -0.0827 -0.2588 -0.1892 -0.4463 -0.3219 -0.4924 -0.1587 -0.1643 -0.1545
S-425	Die Bioverfügbarkeit war minimal , wenn Alendronat mit oder bis zu zwei Stunden nach einem standardisierten Frühstück angewendet wurde .
T-425	Bioavailability was negligible whether alendronate was administered with , or up to two hours after , a standardised breakfast .
H-425	-0.226436585187912	Bioavailability was minimal when alendronate was administered with or up to two hours after a standardized breakfast .
D-425	-0.226436585187912	Bioavailability was minimal when alendronate was administered with or up to two hours after a standardized breakfast .
P-425	-0.4274 -0.1022 -0.2207 -0.0456 -0.2794 -0.1418 -0.1559 -0.0876 -0.0554 -0.1189 -0.2258 -0.0867 -0.2150 -0.1619 -0.9487 -0.1347 -0.2108 -0.0827 -0.2588 -0.1892 -0.4463 -0.3219 -0.4924 -0.1587 -0.1643 -0.1545
S-1684	87 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-1684	81 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1684	-0.19673381745815277	87 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
D-1684	-0.19673381745815277	87 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
P-1684	-1.0796 -0.0233 -0.1150 -0.0406 -0.0452 -0.0290 -0.0560 -0.0808 -0.0614 -0.0297 -0.0245 -0.0383 -0.1651 -0.1570 -0.8928 -0.0295 -0.0363 -0.0901 -0.1285 -0.1758 -0.0923 -0.4161 -0.4261 -0.3248 -0.1255 -0.0545 -0.6216 -0.1493
S-1668	83 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-1668	77 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1668	-0.2582826316356659	83 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
D-1668	-0.2582826316356659	83 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
P-1668	-2.8439 -0.0247 -0.1234 -0.0384 -0.0451 -0.0286 -0.0549 -0.0755 -0.0625 -0.0293 -0.0256 -0.0396 -0.1692 -0.1429 -0.9156 -0.0303 -0.0357 -0.0903 -0.1223 -0.1704 -0.0961 -0.3772 -0.3918 -0.3456 -0.1322 -0.0535 -0.6190 -0.1483
S-1650	79 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-1650	73 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1650	-0.1802404671907425	PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
D-1650	-0.1802404671907425	PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
P-1650	-0.4615 -0.1070 -0.0236 -0.0462 -0.0317 -0.0523 -0.0641 -0.0483 -0.0296 -0.0232 -0.0402 -0.1399 -0.1278 -1.0052 -0.0289 -0.0315 -0.1096 -0.1185 -0.1652 -0.0919 -0.3776 -0.4406 -0.3585 -0.1322 -0.0544 -0.6122 -0.1450
S-1634	75 ANGABEN AUF DER DURCHSTECHFLASCHE MIT DEM LÖSUNGSMITTEL
T-1634	69 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
H-1634	-0.22067536413669586	75 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
D-1634	-0.22067536413669586	75 PARTICULARS TO APPEAR ON THE BOTTLE WITH THE SOLUTION
P-1634	-1.6136 -0.0270 -0.0991 -0.0346 -0.0435 -0.0258 -0.0533 -0.0682 -0.0556 -0.0286 -0.0261 -0.0384 -0.1735 -0.1496 -1.0298 -0.0303 -0.0352 -0.0885 -0.1240 -0.1549 -0.0967 -0.4343 -0.4487 -0.3369 -0.1305 -0.0568 -0.6274 -0.1479
S-25	Die Wirksamkeit von Adenuric wurde in zwei Hauptstudien an insgesamt 1 834 Patienten mit Hyperurikämie und Gicht untersucht .
T-25	The effectiveness of Adenuric has been studied in two main studies involving a total of 1,834 patients with hyperuricaemia and gout .
H-25	-0.302689790725708	Adenuric s efficacy was investigated in two main studies in a total of 1,834 patients with hyperuricaemia and gout .
D-25	-0.302689790725708	Adenuric s efficacy was investigated in two main studies in a total of 1,834 patients with hyperuricaemia and gout .
P-25	-0.2114 -0.2203 -0.0784 -0.1146 -2.3056 -0.1551 -0.0471 -0.0770 -0.2021 -1.6850 -0.1282 -0.1968 -0.2533 -0.6172 -0.9600 -0.2351 -0.1490 -0.1609 -0.2371 -0.0885 -0.0992 -0.2144 -0.1371 -0.0613 -0.0533 -0.3346 -0.0227 -0.1313 -0.1198 -0.0805 -0.3210 -0.1397 -0.1510
S-1104	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-1104	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-1104	-0.25788429379463196	injection every 8-24 hours ( 6-12 hours for patients under 6 years of age ) until the risk to the patient is over .
D-1104	-0.25788429379463196	injection every 8-24 hours ( 6-12 hours for patients under 6 years of age ) until the risk to the patient is over .
P-1104	-0.4115 -0.1046 -0.2921 -0.5874 -0.1794 -0.1234 -0.1309 -0.1616 -0.1272 -0.1100 -0.1184 -0.1553 -0.8075 -0.2203 -0.6925 -0.2571 -0.0964 -0.2551 -0.1103 -0.1419 -0.2567 -0.1475 -0.4923 -0.2400 -0.1352 -0.0529 -0.3905 -0.5655 -0.2104 -0.1623
S-578	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-578	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-578	-0.25788429379463196	injection every 8-24 hours ( 6-12 hours for patients under 6 years of age ) until the risk to the patient is over .
D-578	-0.25788429379463196	injection every 8-24 hours ( 6-12 hours for patients under 6 years of age ) until the risk to the patient is over .
P-578	-0.4115 -0.1046 -0.2921 -0.5874 -0.1794 -0.1234 -0.1309 -0.1616 -0.1272 -0.1100 -0.1184 -0.1553 -0.8075 -0.2203 -0.6925 -0.2571 -0.0964 -0.2551 -0.1103 -0.1419 -0.2567 -0.1475 -0.4923 -0.2400 -0.1352 -0.0529 -0.3905 -0.5655 -0.2104 -0.1623
S-752	Injektion alle 8-24 Stunden ( 6-12 Stunden bei Patienten unter 6 Jahren ) wiederholen , bis die Gefahr für den Patienten vorüber ist .
T-752	Repeat injections every 8 to 24 hours ( 6 to 12 hours for patients under the age of 6 ) until threat is resolved .
H-752	-0.25788429379463196	injection every 8-24 hours ( 6-12 hours for patients under 6 years of age ) until the risk to the patient is over .
D-752	-0.25788429379463196	injection every 8-24 hours ( 6-12 hours for patients under 6 years of age ) until the risk to the patient is over .
P-752	-0.4115 -0.1046 -0.2921 -0.5874 -0.1794 -0.1234 -0.1309 -0.1616 -0.1272 -0.1100 -0.1184 -0.1553 -0.8075 -0.2203 -0.6925 -0.2571 -0.0964 -0.2551 -0.1103 -0.1419 -0.2567 -0.1475 -0.4923 -0.2400 -0.1352 -0.0529 -0.3905 -0.5655 -0.2104 -0.1623
S-289	In klinischen Studien gab es keinen altersabhängigen Unterschied bei dem Wirksamkeits- oder Sicherheitsprofil von Alendronat .
T-289	In clinical studies there was no age-related difference in the efficacy or safety profiles of alendronate .
H-289	-0.25680282711982727	In clinical trials , there was no age related difference in the efficacy or safety profile of alendronate .
D-289	-0.25680282711982727	In clinical trials , there was no age related difference in the efficacy or safety profile of alendronate .
P-289	-0.1548 -0.0834 -0.0711 -0.8835 -0.2211 -0.1271 -0.0977 -0.0585 -2.3359 -0.2333 -0.1603 -0.3196 -0.1297 -0.0664 -0.1059 -0.1164 -0.0868 -0.2426 -0.1485 -0.1669 -0.1540 -0.1043 -0.0570 -0.1463 -0.1491
S-952	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-952	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-952	-0.2986333668231964	In the case of anaphylactic shock , shock therapy should be based on current medical standards ( see section 4.8 ) .
D-952	-0.2986333668231964	In the case of anaphylactic shock , shock therapy should be based on current medical standards ( see section 4.8 ) .
P-952	-0.3753 -0.3953 -1.2054 -0.1457 -0.1100 -0.1011 -0.0641 -0.0825 -0.0964 -0.1107 -0.2655 -0.2073 -0.1055 -0.1899 -0.1121 -1.5580 -0.4147 -0.5482 -0.1330 -0.8796 -0.1593 -0.3301 -0.1116 -0.1094 -0.1247 -0.1352 -0.1424 -0.1486
S-1891	Welche Konsequenzen hat die Rücknahme für Patienten , die derzeit an klinischen Studien bzw. Compassionate-Use -Programmen mit Advexin teilnehmen ?
T-1891	What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Advexin ?
H-1891	-0.5439725518226624	What consequences does the withdrawal have for patients currently participating in clinical trials and / or compassionate-use programmes with Advexin ?
D-1891	-0.5439725518226624	What consequences does the withdrawal have for patients currently participating in clinical trials and / or compassionate-use programmes with Advexin ?
P-1891	-0.1821 -0.8007 -1.4179 -1.0960 -0.5085 -0.2827 -0.1247 -0.3306 -0.9010 -0.5218 -0.0902 -0.1294 -0.2701 -0.0261 -1.7991 -0.3868 -0.1154 -1.7572 -1.9380 -0.1126 -0.4653 -0.2027 -0.0943 -0.4717 -0.4503 -0.5681 -0.1934 -0.1380 -0.7930 -0.1514
S-101	In klinischen Studien gab es keinen altersabhängigen Unterschied bei dem Wirksamkeits- oder Sicherheitsprofil von Alendronat .
T-101	In clinical studies there was no age-related difference in the efficacy or safety profiles of alendronate .
H-101	-0.25680282711982727	In clinical trials , there was no age related difference in the efficacy or safety profile of alendronate .
D-101	-0.25680282711982727	In clinical trials , there was no age related difference in the efficacy or safety profile of alendronate .
P-101	-0.1548 -0.0834 -0.0711 -0.8835 -0.2211 -0.1271 -0.0977 -0.0585 -2.3359 -0.2333 -0.1603 -0.3196 -0.1297 -0.0664 -0.1059 -0.1164 -0.0868 -0.2426 -0.1485 -0.1669 -0.1540 -0.1043 -0.0570 -0.1463 -0.1491
S-545	Am 2. März 2004 erteilte die Europäische Kommission dem Unternehmen Baxter AG eine Genehmigung für das Inverkehrbringen von Advate in der gesamten Europäischen Union .
T-545	The European Commission granted a marketing authorisation valid throughout the EU for Advate to Baxter AG on 2 March 2004.
H-545	-0.356189489364624	On 2 March 2004 , the European Commission authorised Baxter AG to market Advate throughout the European Union .
D-545	-0.356189489364624	On 2 March 2004 , the European Commission authorised Baxter AG to market Advate throughout the European Union .
P-545	-0.4776 -0.3044 -0.2813 -0.3368 -0.8935 -0.1537 -0.2483 -0.1979 -1.5343 -0.1190 -0.3399 -0.1265 -0.1546 -0.3880 -0.1631 -0.8312 -0.4714 -0.0906 -0.5883 -0.1391 -0.2040 -0.1975 -0.1532 -0.1542
S-602	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-602	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-602	-0.2986333668231964	In the case of anaphylactic shock , shock therapy should be based on current medical standards ( see section 4.8 ) .
D-602	-0.2986333668231964	In the case of anaphylactic shock , shock therapy should be based on current medical standards ( see section 4.8 ) .
P-602	-0.3753 -0.3953 -1.2054 -0.1457 -0.1100 -0.1011 -0.0641 -0.0825 -0.0964 -0.1107 -0.2655 -0.2073 -0.1055 -0.1899 -0.1121 -1.5580 -0.4147 -0.5482 -0.1330 -0.8796 -0.1593 -0.3301 -0.1116 -0.1094 -0.1247 -0.1352 -0.1424 -0.1486
S-776	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-776	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-776	-0.2986333668231964	In the case of anaphylactic shock , shock therapy should be based on current medical standards ( see section 4.8 ) .
D-776	-0.2986333668231964	In the case of anaphylactic shock , shock therapy should be based on current medical standards ( see section 4.8 ) .
P-776	-0.3753 -0.3953 -1.2054 -0.1457 -0.1100 -0.1011 -0.0641 -0.0825 -0.0964 -0.1107 -0.2655 -0.2073 -0.1055 -0.1899 -0.1121 -1.5580 -0.4147 -0.5482 -0.1330 -0.8796 -0.1593 -0.3301 -0.1116 -0.1094 -0.1247 -0.1352 -0.1424 -0.1486
S-315	Bei einem Teil der Patienten traten die Symptome erneut auf , wenn die Therapie mit demselben Arzneimittel oder einem anderen Bisphosphonat wieder aufgenommen wurde .
T-315	A subset had recurrence of symptoms when rechallenged with the same medicinal product or another bisphosphonate .
H-315	-0.4525272250175476	In some of the patients , symptoms recurred when therapy with the same medicinal product or another bisphosphonate was resumed .
D-315	-0.4525272250175476	In some of the patients , symptoms recurred when therapy with the same medicinal product or another bisphosphonate was resumed .
P-315	-1.0898 -0.2641 -0.6208 -0.4197 -0.0570 -0.6977 -1.2079 -2.1300 -0.2757 -0.2708 -1.5686 -0.2649 -0.1528 -0.1778 -0.6447 -0.0574 -0.0589 -0.1347 -1.2827 -0.0894 -0.0312 -0.0432 -0.0741 -0.2422 -0.6168 -0.2542 -0.1020 -0.1418 -0.1525
S-1128	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-1128	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-1128	-0.2986333668231964	In the case of anaphylactic shock , shock therapy should be based on current medical standards ( see section 4.8 ) .
D-1128	-0.2986333668231964	In the case of anaphylactic shock , shock therapy should be based on current medical standards ( see section 4.8 ) .
P-1128	-0.3753 -0.3953 -1.2054 -0.1457 -0.1100 -0.1011 -0.0641 -0.0825 -0.0964 -0.1107 -0.2655 -0.2073 -0.1055 -0.1899 -0.1121 -1.5580 -0.4147 -0.5482 -0.1330 -0.8796 -0.1593 -0.3301 -0.1116 -0.1094 -0.1247 -0.1352 -0.1424 -0.1486
S-1304	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-1304	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-1304	-0.2986333668231964	In the case of anaphylactic shock , shock therapy should be based on current medical standards ( see section 4.8 ) .
D-1304	-0.2986333668231964	In the case of anaphylactic shock , shock therapy should be based on current medical standards ( see section 4.8 ) .
P-1304	-0.3753 -0.3953 -1.2054 -0.1457 -0.1100 -0.1011 -0.0641 -0.0825 -0.0964 -0.1107 -0.2655 -0.2073 -0.1055 -0.1899 -0.1121 -1.5580 -0.4147 -0.5482 -0.1330 -0.8796 -0.1593 -0.3301 -0.1116 -0.1094 -0.1247 -0.1352 -0.1424 -0.1486
S-1480	Im Falle eines anaphylaktischen Schocks soll eine Schocktherapie nach aktuellem medizinischen Standard durchgeführt werden ( siehe Abschnitt 4.8 ) .
T-1480	In case of anaphylactic shock , the current medical standards for shock treatment should be implemented ( see section 4.8 ) .
H-1480	-0.2986333668231964	In the case of anaphylactic shock , shock therapy should be based on current medical standards ( see section 4.8 ) .
D-1480	-0.2986333668231964	In the case of anaphylactic shock , shock therapy should be based on current medical standards ( see section 4.8 ) .
P-1480	-0.3753 -0.3953 -1.2054 -0.1457 -0.1100 -0.1011 -0.0641 -0.0825 -0.0964 -0.1107 -0.2655 -0.2073 -0.1055 -0.1899 -0.1121 -1.5580 -0.4147 -0.5482 -0.1330 -0.8796 -0.1593 -0.3301 -0.1116 -0.1094 -0.1247 -0.1352 -0.1424 -0.1486
S-1861	Dabei handelt es sich um eine Art von Virus , das genetisch so verändert wurde , dass es ein Gen in die Zellen des Körpers tragen kann .
T-1861	This is a type of virus that has been altered genetically so that it can carry a gene into the cells of the body .
H-1861	-0.43761172890663147	This is a type of virus that has been genetically modified to carry a gene into the cells of the body .
D-1861	-0.43761172890663147	This is a type of virus that has been genetically modified to carry a gene into the cells of the body .
P-1861	-1.1693 -0.1334 -0.1480 -0.0837 -0.1452 -0.3868 -0.4675 -0.2043 -0.1145 -1.0377 -0.4991 -1.6312 -0.0808 -0.2407 -0.7254 -0.6930 -0.2133 -0.4801 -1.0223 -0.3207 -0.3915 -0.2225 -0.2156 -0.1514 -0.1623
S-1982	Die Resorptionsrate von Pseudoephedrinsulfat wird durch Antazida erhöht und durch Kaolin gemindert .
T-1982	Antacids increase the rate of pseudoephedrine sulphate absorption , kaolin decreases it .
H-1982	-0.2051512449979782	The rate of absorption of pseudoephedrine sulphate is increased by antacids and decreased by kaolin .
D-1982	-0.2051512449979782	The rate of absorption of pseudoephedrine sulphate is increased by antacids and decreased by kaolin .
P-1982	-0.3640 -0.3253 -0.1474 -0.1714 -0.0961 -0.1521 -0.1971 -0.3962 -0.1556 -0.1245 -0.1375 -0.5356 -0.2561 -0.0916 -0.1513 -0.0998 -0.1329 -0.0628 -0.1602 -0.0482 -0.1325 -0.3156 -0.1524 -0.6025 -0.1158 -0.1218 -0.5431 -0.1645 -0.1165 -0.1371 -0.1524
S-127	Bei einem Teil der Patienten traten die Symptome erneut auf , wenn die Therapie mit demselben Arzneimittel oder einem anderen Bisphosphonat wieder aufgenommen wurde .
T-127	A subset had recurrence of symptoms when rechallenged with the same medicinal product or another bisphosphonate .
H-127	-0.4525272250175476	In some of the patients , symptoms recurred when therapy with the same medicinal product or another bisphosphonate was resumed .
D-127	-0.4525272250175476	In some of the patients , symptoms recurred when therapy with the same medicinal product or another bisphosphonate was resumed .
P-127	-1.0898 -0.2641 -0.6208 -0.4197 -0.0570 -0.6977 -1.2079 -2.1300 -0.2757 -0.2708 -1.5686 -0.2649 -0.1528 -0.1778 -0.6447 -0.0574 -0.0589 -0.1347 -1.2827 -0.0894 -0.0312 -0.0432 -0.0741 -0.2422 -0.6168 -0.2542 -0.1020 -0.1418 -0.1525
S-368	Bei einer Überdosis mit ADROVANCE sollten Milch oder Antazida gegeben werden , um Alendronat zu binden .
T-368	In case of overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
H-368	-0.29037871956825256	If an overdose with ADROVANCE occurs , milk or antacids should be administered to bind to alendronate .
D-368	-0.29037871956825256	If an overdose with ADROVANCE occurs , milk or antacids should be administered to bind to alendronate .
P-368	-1.1502 -1.4618 -0.0770 -0.0434 -1.2933 -0.0738 -0.0868 -0.1213 -0.1114 -0.1250 -0.1798 -0.0760 -0.1349 -0.2097 -0.1118 -0.0631 -0.1320 -0.2217 -0.0926 -0.1547 -1.0892 -0.0967 -0.2332 -0.0892 -0.0729 -1.0903 -0.1175 -0.1427 -0.1113 -0.0301 -0.1453 -0.1533
S-564	2 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-564	One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-564	-0.2548447847366333	1 IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
D-564	-0.2548447847366333	1 IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
P-564	-1.1976 -0.1125 -0.0481 -0.1544 -0.1635 -0.1731 -0.1533 -1.2421 -0.4624 -0.2447 -0.1521 -0.1097 -0.1363 -0.1704 -0.0979 -0.1756 -0.1125 -0.1559 -0.1291 -0.1660 -1.0875 -0.1138 -0.1921 -0.1168 -0.1590 -0.0987 -0.0857 -0.1382 -0.1473 -0.1489
S-1809	101 Wie ADVATE aussieht und Inhalt der Packung ADVATE liegt als weiße bis gelbliche , pulvrige Substanz vor .
T-1809	What ADVATE looks like and contents of the pack ADVATE is a white to off-white friable powder .
H-1809	-0.21289996802806854	What ADVATE looks like and contents of the pack ADVATE are available as white to yellowish , powdery substance .
D-1809	-0.21289996802806854	What ADVATE looks like and contents of the pack ADVATE are available as white to yellowish , powdery substance .
P-1809	-0.3496 -0.0898 -0.1441 -0.0873 -0.1096 -0.0921 -0.2153 -0.1335 -0.1424 -0.0868 -0.1494 -0.1372 -0.3446 -0.1909 -0.1458 -0.0751 -0.1051 -0.7967 -0.4508 -0.3495 -0.8622 -0.1494 -0.2441 -0.0851 -0.1007 -0.0279 -0.3342 -0.0863 -0.2878 -0.1626 -0.1816 -0.1502 -0.1582
S-739	13 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-739	12 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-739	-0.2659982442855835	One IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
D-739	-0.2659982442855835	One IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
P-739	-1.3802 -0.1198 -0.0537 -0.1535 -0.1612 -0.1983 -0.1501 -1.1215 -0.5175 -0.2561 -0.1381 -0.1119 -0.1368 -0.1768 -0.1012 -0.1763 -0.1136 -0.1546 -0.1231 -0.1631 -1.2651 -0.1159 -0.1904 -0.1204 -0.1615 -0.1010 -0.0854 -0.1395 -0.1443 -0.1489
S-1475	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-1475	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-1475	-0.13916099071502686	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
D-1475	-0.13916099071502686	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
P-1475	-0.1218 -0.0471 -0.0535 -0.0659 -0.1514 -0.3448 -0.0334 -0.1409 -0.1361 -0.2048 -0.1114 -0.1567 -0.1462 -0.0936 -0.0238 -0.0608 -0.0856 -0.3316 -0.1544 -0.1283 -0.0767 -0.1406 -0.3937 -0.0888 -0.1993 -0.0541 -0.1988 -0.1523
S-915	24 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-915	22 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-915	-0.2680278718471527	One IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
D-915	-0.2680278718471527	One IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
P-915	-1.4626 -0.1153 -0.0536 -0.1523 -0.1536 -0.1948 -0.1498 -1.2414 -0.4801 -0.2523 -0.1310 -0.1116 -0.1362 -0.1770 -0.1032 -0.1773 -0.1177 -0.1570 -0.1209 -0.1639 -1.1803 -0.1167 -0.1917 -0.1181 -0.1620 -0.1006 -0.0852 -0.1422 -0.1426 -0.1498
S-1091	35 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-1091	32 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-1091	-0.26760154962539673	35 One IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
D-1091	-0.26760154962539673	35 One IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
P-1091	-1.3807 -0.4730 -0.1187 -0.0525 -0.1511 -0.1571 -0.1894 -0.1500 -1.0551 -0.5058 -0.2503 -0.1462 -0.1116 -0.1357 -0.1748 -0.0991 -0.1766 -0.1198 -0.1537 -0.1225 -0.1623 -1.2091 -0.1153 -0.1909 -0.1192 -0.1600 -0.0999 -0.0833 -0.1397 -0.1442 -0.1481
S-1267	46 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-1267	42 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-1267	-0.26310452818870544	One IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
D-1267	-0.26310452818870544	One IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
P-1267	-1.3136 -0.1174 -0.0517 -0.1527 -0.1572 -0.1869 -0.1518 -1.1893 -0.4856 -0.2545 -0.1328 -0.1117 -0.1358 -0.1752 -0.0986 -0.1772 -0.1169 -0.1551 -0.1227 -0.1631 -1.2313 -0.1167 -0.1947 -0.1206 -0.1609 -0.1011 -0.0835 -0.1396 -0.1443 -0.1505
S-1443	57 Eine I.E. der Faktor VIII-Aktivität entspricht der Menge an Faktor VIII in einem ml normalem menschlichen Plasma .
T-1443	52 One IU of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma .
H-1443	-0.25550946593284607	One IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
D-1443	-0.25550946593284607	One IU of factor VIII-activity corresponds to the amount of factor VIII in a ml of normal human plasma .
P-1443	-1.1237 -0.1134 -0.0504 -0.1536 -0.1482 -0.1984 -0.1506 -1.1142 -0.5075 -0.2552 -0.1283 -0.1114 -0.1368 -0.1766 -0.1016 -0.1767 -0.1144 -0.1548 -0.1227 -0.1631 -1.2618 -0.1164 -0.1918 -0.1166 -0.1619 -0.0995 -0.0832 -0.1402 -0.1428 -0.1495
S-112	Es ist sehr wichtig , dass alle Dosierungsanweisungen an den Patienten weitergegeben werden und vom Patienten verstanden werden ( siehe Abschnitt 4.2 ) .
T-112	It is very important that the full dosing instructions are provided to , and are understood by the patient ( see section 4.2 ) .
H-112	-0.258769690990448	It is very important that all dosage instructions are relayed to the patient and understood by the patient ( see section 4.2 ) .
D-112	-0.258769690990448	It is very important that all dosage instructions are relayed to the patient and understood by the patient ( see section 4.2 ) .
P-112	-0.1773 -0.1328 -0.4964 -0.0734 -0.2045 -0.1837 -0.6562 -0.6254 -0.0818 -0.5613 -0.1347 -0.6517 -0.2966 -0.1533 -0.2153 -0.0603 -0.1405 -0.9809 -0.1786 -0.1763 -0.0776 -0.1410 -0.3064 -0.1135 -0.1144 -0.1428 -0.1341 -0.1442 -0.1497
S-180	Bei einer Überdosis mit ADROVANCE sollten Milch oder Antazida gegeben werden , um Alendronat zu binden .
T-180	In case of overdose with ADROVANCE , milk or antacids should be given to bind alendronate .
H-180	-0.29037871956825256	If an overdose with ADROVANCE occurs , milk or antacids should be administered to bind to alendronate .
D-180	-0.29037871956825256	If an overdose with ADROVANCE occurs , milk or antacids should be administered to bind to alendronate .
P-180	-1.1502 -1.4618 -0.0770 -0.0434 -1.2933 -0.0738 -0.0868 -0.1213 -0.1114 -0.1250 -0.1798 -0.0760 -0.1349 -0.2097 -0.1118 -0.0631 -0.1320 -0.2217 -0.0926 -0.1547 -1.0892 -0.0967 -0.2332 -0.0892 -0.0729 -1.0903 -0.1175 -0.1427 -0.1113 -0.0301 -0.1453 -0.1533
S-1609	Baxter BioScience Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Schweiz
T-1609	Baxter BioScience Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Switzerland
H-1609	-0.22749491035938263	Baxter BioScience Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Switzerland
D-1609	-0.22749491035938263	Baxter BioScience Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Switzerland
P-1609	-0.2566 -0.1397 -0.1279 -0.1061 -0.0597 -0.1280 -0.0842 -0.3967 -0.1565 -0.3581 -0.0766 -0.1282 -0.2701 -0.1452 -0.1523 -0.1373 -0.0751 -1.2476 -0.0808 -0.2295 -0.1303 -0.1035 -0.0904 -0.0953 -0.1129 -0.3220 -0.1227 -0.2310 -0.3203 -1.0166 -0.1511
S-1437	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-1437	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-1437	-0.2310626208782196	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-1437	-0.2310626208782196	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-1437	-0.0291 -0.0871 -0.1152 -0.1176 -0.0795 -0.0621 -0.1177 -0.0919 -0.0875 -0.1469 -1.3186 -0.2498 -0.1432 -0.2385 -0.1322 -0.1126 -0.0647 -0.1692 -0.2380 -0.1368 -0.1299 -0.8507 -0.2818 -0.3369 -0.0580 -0.3410 -1.1121 -0.3651 -0.0618 -0.0374 -0.1097 -0.1282 -0.1557 -0.1499
S-320	Eine bestehende Hypocalcämie muss ausgeglichen werden , bevor die Therapie mit ADROVANCE begonnen wird ( siehe Abschnitt 4.3 ) .
T-320	Hypocalcaemia must be corrected before initiating therapy with ADROVANCE ( see section 4.3 ) .
H-320	-0.31984663009643555	Existing hypocalcaemia must be corrected before ADROVANCE therapy is initiated ( see section 4.3 ) .
D-320	-0.31984663009643555	Existing hypocalcaemia must be corrected before ADROVANCE therapy is initiated ( see section 4.3 ) .
P-320	-1.4225 -0.1433 -0.0604 -0.0918 -0.0428 -0.0655 -0.1324 -0.7570 -0.1619 -1.1531 -0.0978 -0.2799 -1.0182 -0.0799 -0.1256 -0.0987 -0.1203 -0.1462 -1.4360 -0.5198 -0.1175 -0.1316 -0.2918 -0.1241 -0.1133 -0.1145 -0.1357 -0.1393 -0.1546
S-1164	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-1164	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-1164	-0.37935441732406616	Upon completion of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
D-1164	-0.37935441732406616	Upon completion of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
P-1164	-1.8579 -0.1300 -1.0649 -0.0709 -0.1501 -0.6732 -0.1617 -0.1408 -0.0801 -0.0948 -0.1675 -0.1742 -0.2114 -0.2809 -1.2056 -0.5473 -0.1085 -0.0309 -0.0799 -0.1158 -0.2269 -1.8262 -0.1305 -0.5724 -0.2327 -0.1448 -0.2108 -0.1408 -0.1429 -0.8806 -0.1341 -0.1501
S-1340	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-1340	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-1340	-0.37935441732406616	Upon completion of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
D-1340	-0.37935441732406616	Upon completion of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
P-1340	-1.8579 -0.1300 -1.0649 -0.0709 -0.1501 -0.6732 -0.1617 -0.1408 -0.0801 -0.0948 -0.1675 -0.1742 -0.2114 -0.2809 -1.2056 -0.5473 -0.1085 -0.0309 -0.0799 -0.1158 -0.2269 -1.8262 -0.1305 -0.5724 -0.2327 -0.1448 -0.2108 -0.1408 -0.1429 -0.8806 -0.1341 -0.1501
S-1517	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-1517	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-1517	-0.37935441732406616	Upon completion of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
D-1517	-0.37935441732406616	Upon completion of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
P-1517	-1.8579 -0.1300 -1.0649 -0.0709 -0.1501 -0.6732 -0.1617 -0.1408 -0.0801 -0.0948 -0.1675 -0.1742 -0.2114 -0.2809 -1.2056 -0.5473 -0.1085 -0.0309 -0.0799 -0.1158 -0.2269 -1.8262 -0.1305 -0.5724 -0.2327 -0.1448 -0.2108 -0.1408 -0.1429 -0.8806 -0.1341 -0.1501
S-1299	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-1299	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-1299	-0.13916099071502686	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
D-1299	-0.13916099071502686	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
P-1299	-0.1218 -0.0471 -0.0535 -0.0659 -0.1514 -0.3448 -0.0334 -0.1409 -0.1361 -0.2048 -0.1114 -0.1567 -0.1462 -0.0936 -0.0238 -0.0608 -0.0856 -0.3316 -0.1544 -0.1283 -0.0767 -0.1406 -0.3937 -0.0888 -0.1993 -0.0541 -0.1988 -0.1523
S-132	Eine bestehende Hypocalcämie muss ausgeglichen werden , bevor die Therapie mit ADROVANCE begonnen wird ( siehe Abschnitt 4.3 ) .
T-132	Hypocalcaemia must be corrected before initiating therapy with ADROVANCE ( see section 4.3 ) .
H-132	-0.31984663009643555	Existing hypocalcaemia must be corrected before ADROVANCE therapy is initiated ( see section 4.3 ) .
D-132	-0.31984663009643555	Existing hypocalcaemia must be corrected before ADROVANCE therapy is initiated ( see section 4.3 ) .
P-132	-1.4225 -0.1433 -0.0604 -0.0918 -0.0428 -0.0655 -0.1324 -0.7570 -0.1619 -1.1531 -0.0978 -0.2799 -1.0182 -0.0799 -0.1256 -0.0987 -0.1203 -0.1462 -1.4360 -0.5198 -0.1175 -0.1316 -0.2918 -0.1241 -0.1133 -0.1145 -0.1357 -0.1393 -0.1546
S-1123	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-1123	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-1123	-0.13916099071502686	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
D-1123	-0.13916099071502686	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
P-1123	-0.1218 -0.0471 -0.0535 -0.0659 -0.1514 -0.3448 -0.0334 -0.1409 -0.1361 -0.2048 -0.1114 -0.1567 -0.1462 -0.0936 -0.0238 -0.0608 -0.0856 -0.3316 -0.1544 -0.1283 -0.0767 -0.1406 -0.3937 -0.0888 -0.1993 -0.0541 -0.1988 -0.1523
S-597	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-597	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-597	-0.13916099071502686	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
D-597	-0.13916099071502686	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
P-597	-0.1218 -0.0471 -0.0535 -0.0659 -0.1514 -0.3448 -0.0334 -0.1409 -0.1361 -0.2048 -0.1114 -0.1567 -0.1462 -0.0936 -0.0238 -0.0608 -0.0856 -0.3316 -0.1544 -0.1283 -0.0767 -0.1406 -0.3937 -0.0888 -0.1993 -0.0541 -0.1988 -0.1523
S-771	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-771	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-771	-0.13916099071502686	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
D-771	-0.13916099071502686	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
P-771	-0.1218 -0.0471 -0.0535 -0.0659 -0.1514 -0.3448 -0.0334 -0.1409 -0.1361 -0.2048 -0.1114 -0.1567 -0.1462 -0.0936 -0.0238 -0.0608 -0.0856 -0.3316 -0.1544 -0.1283 -0.0767 -0.1406 -0.3937 -0.0888 -0.1993 -0.0541 -0.1988 -0.1523
S-947	Überempfindlichkeit gegen den arzneilich wirksamen Bestandteil oder einen der sonstigen Bestandteile oder gegen Maus- oder Hamsterproteinen .
T-947	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
H-947	-0.13916099071502686	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
D-947	-0.13916099071502686	Hypersensitivity to the active substance or to any of the excipients or to mouse or hamster proteins .
P-947	-0.1218 -0.0471 -0.0535 -0.0659 -0.1514 -0.3448 -0.0334 -0.1409 -0.1361 -0.2048 -0.1114 -0.1567 -0.1462 -0.0936 -0.0238 -0.0608 -0.0856 -0.3316 -0.1544 -0.1283 -0.0767 -0.1406 -0.3937 -0.0888 -0.1993 -0.0541 -0.1988 -0.1523
S-1902	Eine Behandlungsdauer von mehr als 10 Tagen wird nicht empfohlen , weil die Wirkungen des Arzneimittels auf die Verstopfung der Nase nachlassen können .
T-1902	Treatment for more than 10 days is not advisable , as the medicine s effects on nasal congestion may wear off .
H-1902	-0.43426916003227234	Duration of treatment of more than 10 days is not recommended because the effects of the medicinal product on nasal constipation may decrease .
D-1902	-0.43426916003227234	Duration of treatment of more than 10 days is not recommended because the effects of the medicinal product on nasal constipation may decrease .
P-1902	-1.5524 -0.1209 -0.1285 -0.2834 -0.5324 -0.8758 -0.1300 -0.1652 -0.1469 -0.1075 -0.1942 -0.0430 -1.0685 -0.6523 -0.3557 -0.2454 -0.2803 -1.8019 -0.1184 -0.0941 -0.1667 -1.2180 -0.0164 -0.2040 -0.5342 -0.1852 -0.0560 -0.1325 -0.1235 -2.3801 -0.1197 -0.1430 -0.1544
S-988	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-988	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-988	-0.37935441732406616	Upon completion of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
D-988	-0.37935441732406616	Upon completion of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
P-988	-1.8579 -0.1300 -1.0649 -0.0709 -0.1501 -0.6732 -0.1617 -0.1408 -0.0801 -0.0948 -0.1675 -0.1742 -0.2114 -0.2809 -1.2056 -0.5473 -0.1085 -0.0309 -0.0799 -0.1158 -0.2269 -1.8262 -0.1305 -0.5724 -0.2327 -0.1448 -0.2108 -0.1408 -0.1429 -0.8806 -0.1341 -0.1501
S-1551	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-1551	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-1551	-0.25876912474632263	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-1551	-0.25876912474632263	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-1551	-0.7382 -0.1338 -0.1145 -0.0721 -0.1622 -0.8830 -0.1490 -0.0758 -0.0866 -1.7444 -0.1061 -0.0642 -0.1183 -0.1946 -0.0649 -0.1203 -0.5574 -0.1063 -0.4126 -0.1225 -0.0828 -0.2129 -0.1053 -0.3739 -0.0808 -0.1448 -0.1846 -0.1422 -0.1504
S-1965	Bei der Anwendung bei Patienten mit stenosierenden Magengeschwüren und pyloroduodenaler Obstruktion ist Vorsicht geboten .
T-1965	Use with caution in patients with stenosing peptic ulcer , pyloroduodenal obstruction , and obstruction of the vesical cervix .
H-1965	-0.39252907037734985	Caution should be used in patients with stenosising stomach ulcers and pyloroduodenal obstruction .
D-1965	-0.39252907037734985	Caution should be used in patients with stenosising stomach ulcers and pyloroduodenal obstruction .
P-1965	-0.5909 -0.0484 -0.2370 -0.2129 -1.0086 -1.9602 -0.2790 -0.1778 -0.0224 -0.2265 -2.1261 -1.1157 -0.3035 -0.1500 -0.6804 -0.1371 -0.1485 -0.0603 -0.0542 -0.1668 -0.1051 -0.1355 -0.0664 -0.4049 -0.1740 -0.1032 -0.1435 -0.1517
S-1022	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-1022	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-1022	-0.25876912474632263	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-1022	-0.25876912474632263	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-1022	-0.7382 -0.1338 -0.1145 -0.0721 -0.1622 -0.8830 -0.1490 -0.0758 -0.0866 -1.7444 -0.1061 -0.0642 -0.1183 -0.1946 -0.0649 -0.1203 -0.5574 -0.1063 -0.4126 -0.1225 -0.0828 -0.2129 -0.1053 -0.3739 -0.0808 -0.1448 -0.1846 -0.1422 -0.1504
S-1198	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-1198	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-1198	-0.25876912474632263	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-1198	-0.25876912474632263	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-1198	-0.7382 -0.1338 -0.1145 -0.0721 -0.1622 -0.8830 -0.1490 -0.0758 -0.0866 -1.7444 -0.1061 -0.0642 -0.1183 -0.1946 -0.0649 -0.1203 -0.5574 -0.1063 -0.4126 -0.1225 -0.0828 -0.2129 -0.1053 -0.3739 -0.0808 -0.1448 -0.1846 -0.1422 -0.1504
S-1374	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-1374	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-1374	-0.25876912474632263	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-1374	-0.25876912474632263	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-1374	-0.7382 -0.1338 -0.1145 -0.0721 -0.1622 -0.8830 -0.1490 -0.0758 -0.0866 -1.7444 -0.1061 -0.0642 -0.1183 -0.1946 -0.0649 -0.1203 -0.5574 -0.1063 -0.4126 -0.1225 -0.0828 -0.2129 -0.1053 -0.3739 -0.0808 -0.1448 -0.1846 -0.1422 -0.1504
S-670	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-670	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-670	-0.25876912474632263	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-670	-0.25876912474632263	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-670	-0.7382 -0.1338 -0.1145 -0.0721 -0.1622 -0.8830 -0.1490 -0.0758 -0.0866 -1.7444 -0.1061 -0.0642 -0.1183 -0.1946 -0.0649 -0.1203 -0.5574 -0.1063 -0.4126 -0.1225 -0.0828 -0.2129 -0.1053 -0.3739 -0.0808 -0.1448 -0.1846 -0.1422 -0.1504
S-1323	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-1323	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-1323	-0.31507062911987305	A total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients during clinical trials of ADVATE .
D-1323	-0.31507062911987305	A total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients during clinical trials of ADVATE .
P-1323	-0.6504 -0.1046 -0.1459 -0.0873 -0.3580 -0.0405 -0.3205 -0.0377 -0.1383 -0.0994 -0.0783 -0.1069 -0.1350 -0.5685 -0.4869 -0.1838 -0.1524 -1.6562 -0.1506 -0.0852 -0.0601 -1.4700 -1.5732 -0.0553 -0.1053 -0.1175 -0.0397 -0.9618 -0.1194 -0.1502 -0.0871 -0.0968 -0.1392 -0.1504
S-65	Dies tritt dann ein , wenn nicht genug neues Knochengewebe nachwächst , um die natürlich abgebaute Knochensubstanz zu ersetzen .
T-65	Dies tritt dann ein , wenn nicht genug neues Knochengewebe nachwächst , um die natürlich abgebaute Knochensubstanz zu ersetzen . The active substances in ADROVANCE are alendronate and vitamin D3 .
H-65	-0.34065669775009155	This occurs when not enough new bone tissue grows to replace the naturally broken down bone .
D-65	-0.34065669775009155	This occurs when not enough new bone tissue grows to replace the naturally broken down bone .
P-65	-0.1186 -0.5805 -0.1217 -0.5004 -0.6928 -0.3910 -0.2650 -0.0852 -0.0638 -0.9529 -0.2263 -0.1423 -0.7869 -0.1986 -0.4945 -0.4515 -0.1438 -0.0741 -0.3679 -0.1553
S-170	Selten : symptomatische Hypocalcämie , meist bei Patienten mit entsprechenden prädisponierenden Faktoren ( siehe Abschnitt 4.4 ) .
T-170	Common : musculoskeletal ( bone , muscle or joint ) pain Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) Rare : symptomatic hypocalcaemia , often in association with predisposing conditions .
H-170	-0.1879429668188095	Rare : symptomatic hypocalcaemia , usually in patients with corresponding predisposing factors ( see section 4.4 ) .
D-170	-0.1879429668188095	Rare : symptomatic hypocalcaemia , usually in patients with corresponding predisposing factors ( see section 4.4 ) .
P-170	-0.1294 -0.1184 -0.1302 -0.0363 -0.0633 -0.1180 -0.0247 -0.0724 -0.0800 -0.0820 -0.1305 -0.1481 -1.4712 -0.1773 -0.1880 -0.2604 -0.1749 -0.1122 -0.2499 -0.2982 -0.2001 -0.1642 -0.1438 -0.2844 -0.1129 -0.1165 -0.1258 -0.1315 -0.1443 -0.1494
S-358	Selten : symptomatische Hypocalcämie , meist bei Patienten mit entsprechenden prädisponierenden Faktoren ( siehe Abschnitt 4.4 ) .
T-358	Common : musculoskeletal ( bone , muscle or joint ) pain Rare : severe musculoskeletal ( bone , muscle or joint ) pain ( see section 4.4 ) Rare : symptomatic hypocalcaemia , often in association with predisposing conditions .
H-358	-0.1879429668188095	Rare : symptomatic hypocalcaemia , usually in patients with corresponding predisposing factors ( see section 4.4 ) .
D-358	-0.1879429668188095	Rare : symptomatic hypocalcaemia , usually in patients with corresponding predisposing factors ( see section 4.4 ) .
P-358	-0.1294 -0.1184 -0.1302 -0.0363 -0.0633 -0.1180 -0.0247 -0.0724 -0.0800 -0.0820 -0.1305 -0.1481 -1.4712 -0.1773 -0.1880 -0.2604 -0.1749 -0.1122 -0.2499 -0.2982 -0.2001 -0.1642 -0.1438 -0.2844 -0.1129 -0.1165 -0.1258 -0.1315 -0.1443 -0.1494
S-846	Tabelle 4 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 53 Kindern mit schwerer bis mäßiger Hämophilie A
T-846	Table 4 Summary of pharmacokinetic parameters for ADVATE in 53 paediatric patients with severe to moderately severe haemophilia A
H-846	-0.25876912474632263	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
D-846	-0.25876912474632263	Table 4 Summary of ADVATE pharmacokinetic parameters in 53 children with severe to moderate haemophilia A
P-846	-0.7382 -0.1338 -0.1145 -0.0721 -0.1622 -0.8830 -0.1490 -0.0758 -0.0866 -1.7444 -0.1061 -0.0642 -0.1183 -0.1946 -0.0649 -0.1203 -0.5574 -0.1063 -0.4126 -0.1225 -0.0828 -0.2129 -0.1053 -0.3739 -0.0808 -0.1448 -0.1846 -0.1422 -0.1504
S-1821	Danmark Baxter A<unk> S Gydevang 43 DK-3450 Allerød Tlf : <unk> 45 48 16 64 00
T-1821	Danmark Baxter A/ S Gydevang 43 DK-3450 Allerød Tlf : <<unk>> 45 48 16 64 00
H-1821	-0.12883910536766052	Danmark Baxter A/ S Gydevang 43 DK-3450 Allerød Tlf : <unk> 45 48 16 64 00
D-1821	-0.12883910536766052	Danmark Baxter A/ S Gydevang 43 DK-3450 Allerød Tlf : <unk> 45 48 16 64 00
P-1821	-0.1682 -0.0679 -0.2042 -0.1241 -0.1536 -0.1206 -0.1167 -0.1342 -0.0954 -0.1634 -0.2074 -0.0993 -0.1421 -0.1337 -0.1198 -0.0518 -0.1243 -0.0545 -0.3358 -0.1134 -0.1333 -0.1166 -0.1064 -0.1351 -0.0393 -0.1092 -0.1525 -0.1386 -0.0665 -0.1144 -0.1517
S-1499	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-1499	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-1499	-0.31507062911987305	A total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients during clinical trials of ADVATE .
D-1499	-0.31507062911987305	A total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients during clinical trials of ADVATE .
P-1499	-0.6504 -0.1046 -0.1459 -0.0873 -0.3580 -0.0405 -0.3205 -0.0377 -0.1383 -0.0994 -0.0783 -0.1069 -0.1350 -0.5685 -0.4869 -0.1838 -0.1524 -1.6562 -0.1506 -0.0852 -0.0601 -1.4700 -1.5732 -0.0553 -0.1053 -0.1175 -0.0397 -0.9618 -0.1194 -0.1502 -0.0871 -0.0968 -0.1392 -0.1504
S-1085	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-1085	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-1085	-0.2310626208782196	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-1085	-0.2310626208782196	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-1085	-0.0291 -0.0871 -0.1152 -0.1176 -0.0795 -0.0621 -0.1177 -0.0919 -0.0875 -0.1469 -1.3186 -0.2498 -0.1432 -0.2385 -0.1322 -0.1126 -0.0647 -0.1692 -0.2380 -0.1368 -0.1299 -0.8507 -0.2818 -0.3369 -0.0580 -0.3410 -1.1121 -0.3651 -0.0618 -0.0374 -0.1097 -0.1282 -0.1557 -0.1499
S-1261	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-1261	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-1261	-0.2310626208782196	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-1261	-0.2310626208782196	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-1261	-0.0291 -0.0871 -0.1152 -0.1176 -0.0795 -0.0621 -0.1177 -0.0919 -0.0875 -0.1469 -1.3186 -0.2498 -0.1432 -0.2385 -0.1322 -0.1126 -0.0647 -0.1692 -0.2380 -0.1368 -0.1299 -0.8507 -0.2818 -0.3369 -0.0580 -0.3410 -1.1121 -0.3651 -0.0618 -0.0374 -0.1097 -0.1282 -0.1557 -0.1499
S-558	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-558	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-558	-0.2310626208782196	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-558	-0.2310626208782196	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-558	-0.0291 -0.0871 -0.1152 -0.1176 -0.0795 -0.0621 -0.1177 -0.0919 -0.0875 -0.1469 -1.3186 -0.2498 -0.1432 -0.2385 -0.1322 -0.1126 -0.0647 -0.1692 -0.2380 -0.1368 -0.1299 -0.8507 -0.2818 -0.3369 -0.0580 -0.3410 -1.1121 -0.3651 -0.0618 -0.0374 -0.1097 -0.1282 -0.1557 -0.1499
S-733	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-733	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-733	-0.2310626208782196	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-733	-0.2310626208782196	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-733	-0.0291 -0.0871 -0.1152 -0.1176 -0.0795 -0.0621 -0.1177 -0.0919 -0.0875 -0.1469 -1.3186 -0.2498 -0.1432 -0.2385 -0.1322 -0.1126 -0.0647 -0.1692 -0.2380 -0.1368 -0.1299 -0.8507 -0.2818 -0.3369 -0.0580 -0.3410 -1.1121 -0.3651 -0.0618 -0.0374 -0.1097 -0.1282 -0.1557 -0.1499
S-909	Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Faktor VIII- Mangel ) .
T-909	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
H-909	-0.2310626208782196	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
D-909	-0.2310626208782196	Treatment and prophylaxis of bleeding in patients with haemophilia A ( congenital factor VIII deficiency ) .
P-909	-0.0291 -0.0871 -0.1152 -0.1176 -0.0795 -0.0621 -0.1177 -0.0919 -0.0875 -0.1469 -1.3186 -0.2498 -0.1432 -0.2385 -0.1322 -0.1126 -0.0647 -0.1692 -0.2380 -0.1368 -0.1299 -0.8507 -0.2818 -0.3369 -0.0580 -0.3410 -1.1121 -0.3651 -0.0618 -0.0374 -0.1097 -0.1282 -0.1557 -0.1499
S-1837	Dúbravská cesta 2 SK-841 04 Bratislava Tel : <unk> 421 2 59418455
T-1837	Dúbravská cesta 2 SK-841 04 Bratislava Tel : <<unk>> 421 2 59418455
H-1837	-0.14019817113876343	Dúbravská cesta 2 SK-841 04 Bratislava Tel : <unk> 421 2 59418455
D-1837	-0.14019817113876343	Dúbravská cesta 2 SK-841 04 Bratislava Tel : <unk> 421 2 59418455
P-1837	-0.1244 -0.4565 -0.0748 -0.1187 -0.1129 -0.0558 -0.1353 -0.0865 -0.1374 -0.1456 -0.2787 -0.1039 -0.1201 -0.1121 -0.1011 -0.1062 -0.1226 -0.2107 -0.0708 -0.0719 -0.1398 -0.0392 -0.1587 -0.1264 -0.1384 -0.3470 -0.1333 -0.1316 -0.1363 -0.0960 -0.1535
S-1147	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-1147	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-1147	-0.31507062911987305	A total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients during clinical trials of ADVATE .
D-1147	-0.31507062911987305	A total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients during clinical trials of ADVATE .
P-1147	-0.6504 -0.1046 -0.1459 -0.0873 -0.3580 -0.0405 -0.3205 -0.0377 -0.1383 -0.0994 -0.0783 -0.1069 -0.1350 -0.5685 -0.4869 -0.1838 -0.1524 -1.6562 -0.1506 -0.0852 -0.0601 -1.4700 -1.5732 -0.0553 -0.1053 -0.1175 -0.0397 -0.9618 -0.1194 -0.1502 -0.0871 -0.0968 -0.1392 -0.1504
S-621	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-621	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-621	-0.31507062911987305	A total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients during clinical trials of ADVATE .
D-621	-0.31507062911987305	A total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients during clinical trials of ADVATE .
P-621	-0.6504 -0.1046 -0.1459 -0.0873 -0.3580 -0.0405 -0.3205 -0.0377 -0.1383 -0.0994 -0.0783 -0.1069 -0.1350 -0.5685 -0.4869 -0.1838 -0.1524 -1.6562 -0.1506 -0.0852 -0.0601 -1.4700 -1.5732 -0.0553 -0.1053 -0.1175 -0.0397 -0.9618 -0.1194 -0.1502 -0.0871 -0.0968 -0.1392 -0.1504
S-795	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-795	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-795	-0.31507062911987305	A total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients during clinical trials of ADVATE .
D-795	-0.31507062911987305	A total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients during clinical trials of ADVATE .
P-795	-0.6504 -0.1046 -0.1459 -0.0873 -0.3580 -0.0405 -0.3205 -0.0377 -0.1383 -0.0994 -0.0783 -0.1069 -0.1350 -0.5685 -0.4869 -0.1838 -0.1524 -1.6562 -0.1506 -0.0852 -0.0601 -1.4700 -1.5732 -0.0553 -0.1053 -0.1175 -0.0397 -0.9618 -0.1194 -0.1502 -0.0871 -0.0968 -0.1392 -0.1504
S-971	Während klinischer Studien mit ADVATE wurden insgesamt 56 Nebenwirkungen ( ADRs ) bei 27 von 234 einmal behandelten Patienten angezeigt .
T-971	During clinical studies with ADVATE , a total of 56 adverse drug reactions ( ADRs ) were reported in 27 of 234 unique treated patients .
H-971	-0.31507062911987305	A total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients during clinical trials of ADVATE .
D-971	-0.31507062911987305	A total of 56 adverse reactions ( ADRs ) were reported in 27 out of 234 once treated patients during clinical trials of ADVATE .
P-971	-0.6504 -0.1046 -0.1459 -0.0873 -0.3580 -0.0405 -0.3205 -0.0377 -0.1383 -0.0994 -0.0783 -0.1069 -0.1350 -0.5685 -0.4869 -0.1838 -0.1524 -1.6562 -0.1506 -0.0852 -0.0601 -1.4700 -1.5732 -0.0553 -0.1053 -0.1175 -0.0397 -0.9618 -0.1194 -0.1502 -0.0871 -0.0968 -0.1392 -0.1504
S-812	Nach Beendigung der kontinuierlichen Infusion wurden Tests auf Faktor VIII-Inhibitoren durchgeführt und waren am Ende der Studie negativ .
T-812	Factor VIII inhibitor assays performed after completion of continuous infusion and at study termination were negative .
H-812	-0.37935441732406616	Upon completion of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
D-812	-0.37935441732406616	Upon completion of the continuous infusion , tests for factor VIII inhibitors were conducted and negative at the end of the study .
P-812	-1.8579 -0.1300 -1.0649 -0.0709 -0.1501 -0.6732 -0.1617 -0.1408 -0.0801 -0.0948 -0.1675 -0.1742 -0.2114 -0.2809 -1.2056 -0.5473 -0.1085 -0.0309 -0.0799 -0.1158 -0.2269 -1.8262 -0.1305 -0.5724 -0.2327 -0.1448 -0.2108 -0.1408 -0.1429 -0.8806 -0.1341 -0.1501
S-135	Bei Patienten mit diesen Erkrankungen sollten unter der Therapie mit ADROVANCE das Serum-Calcium sowie Symptome einer Hypocalcämie überwacht werden .
T-135	In patients with these conditions , serum calcium and symptoms of hypocalcaemia should be monitored during therapy with ADROVANCE .
H-135	-0.28601324558258057	Patients with these disorders should be monitored under ADROVANCE therapy for serum calcium and symptoms of hypocalcaemia .
D-135	-0.28601324558258057	Patients with these disorders should be monitored under ADROVANCE therapy for serum calcium and symptoms of hypocalcaemia .
P-135	-0.9043 -0.0918 -0.1115 -0.1374 -1.0529 -0.1025 -0.1514 -0.2834 -0.1084 -0.1025 -1.9245 -0.3283 -0.0815 -0.1253 -0.1007 -0.1198 -0.9749 -0.5137 -0.0643 -0.1169 -0.0438 -0.0845 -0.1048 -0.4109 -0.5754 -0.1251 -0.0315 -0.0803 -0.0791 -0.0792 -0.1319 -0.1408 -0.1550
S-1436	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-1436	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-1436	-0.24543100595474243	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
D-1436	-0.24543100595474243	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
P-1436	-0.6846 -0.1074 -0.0980 -1.0956 -0.1446 -0.1829 -0.1308 -0.0994 -0.1610 -0.0150 -0.1112 -0.0923 -0.1619 -0.5688 -0.7990 -0.7297 -0.1393 -0.0845 -0.1680 -0.6643 -0.1832 -0.0754 -0.0912 -0.1651 -0.0924 -0.1133 -0.1204 -0.1115 -0.1230 -0.1403 -0.1542
S-247	Kleinere Mengen verteilen sich in Fett- und Muskelgewebe und werden dort als Vitamin D3 gespeichert , um später in den Kreislauf abgegeben zu werden .
T-247	Lesser amounts are distributed to adipose and muscle tissue and stored as vitamin D3 at
H-247	-0.4815492630004883	Smaller amounts are distributed in fat and muscle tissue where they are stored as vitamin D3 for later circulation .
D-247	-0.4815492630004883	Smaller amounts are distributed in fat and muscle tissue where they are stored as vitamin D3 for later circulation .
P-247	-1.2732 -0.1903 -0.4077 -0.3282 -1.7238 -0.1130 -0.9514 -0.7236 -0.1576 -0.0407 -0.1484 -2.0613 -0.0618 -0.1310 -0.1334 -0.1135 -0.1933 -0.1707 -0.0856 -0.1302 -0.1312 -1.1507 -0.5554 -1.6201 -0.0837 -0.1632 -0.1587
S-557	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-557	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-557	-0.24543100595474243	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
D-557	-0.24543100595474243	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
P-557	-0.6846 -0.1074 -0.0980 -1.0956 -0.1446 -0.1829 -0.1308 -0.0994 -0.1610 -0.0150 -0.1112 -0.0923 -0.1619 -0.5688 -0.7990 -0.7297 -0.1393 -0.0845 -0.1680 -0.6643 -0.1832 -0.0754 -0.0912 -0.1651 -0.0924 -0.1133 -0.1204 -0.1115 -0.1230 -0.1403 -0.1542
S-732	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-732	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-732	-0.24543100595474243	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
D-732	-0.24543100595474243	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
P-732	-0.6846 -0.1074 -0.0980 -1.0956 -0.1446 -0.1829 -0.1308 -0.0994 -0.1610 -0.0150 -0.1112 -0.0923 -0.1619 -0.5688 -0.7990 -0.7297 -0.1393 -0.0845 -0.1680 -0.6643 -0.1832 -0.0754 -0.0912 -0.1651 -0.0924 -0.1133 -0.1204 -0.1115 -0.1230 -0.1403 -0.1542
S-908	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-908	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-908	-0.24543100595474243	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
D-908	-0.24543100595474243	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
P-908	-0.6846 -0.1074 -0.0980 -1.0956 -0.1446 -0.1829 -0.1308 -0.0994 -0.1610 -0.0150 -0.1112 -0.0923 -0.1619 -0.5688 -0.7990 -0.7297 -0.1393 -0.0845 -0.1680 -0.6643 -0.1832 -0.0754 -0.0912 -0.1651 -0.0924 -0.1133 -0.1204 -0.1115 -0.1230 -0.1403 -0.1542
S-1084	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-1084	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-1084	-0.24543100595474243	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
D-1084	-0.24543100595474243	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
P-1084	-0.6846 -0.1074 -0.0980 -1.0956 -0.1446 -0.1829 -0.1308 -0.0994 -0.1610 -0.0150 -0.1112 -0.0923 -0.1619 -0.5688 -0.7990 -0.7297 -0.1393 -0.0845 -0.1680 -0.6643 -0.1832 -0.0754 -0.0912 -0.1651 -0.0924 -0.1133 -0.1204 -0.1115 -0.1230 -0.1403 -0.1542
S-1260	Nach der Rekonstitution ist die Lösung klar , farblos , frei von Fremdpartikeln und weist einen pH-Wert von 6,7 bis 7,3 auf .
T-1260	After reconstitution , the solution is clear , colourless , free from foreign particles and has a pH of 6.7 to 7.3 .
H-1260	-0.24543100595474243	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
D-1260	-0.24543100595474243	After reconstitution , the solution is clear , colourless , free of foreign particles and has a pH of 6.7 to 7.3 .
P-1260	-0.6846 -0.1074 -0.0980 -1.0956 -0.1446 -0.1829 -0.1308 -0.0994 -0.1610 -0.0150 -0.1112 -0.0923 -0.1619 -0.5688 -0.7990 -0.7297 -0.1393 -0.0845 -0.1680 -0.6643 -0.1832 -0.0754 -0.0912 -0.1651 -0.0924 -0.1133 -0.1204 -0.1115 -0.1230 -0.1403 -0.1542
S-403	Es gab keinen statistisch signifikanten Unterschied zwischen den Behandlungsgruppen beim Anteil der Patientinnen mit Hypercalciurie am Ende der 24-wöchigen Verlängerung .
T-403	The percentage of patients with hypercalciuria at the end of the 24-week extension was not statistically different between treatment groups .
H-403	-0.19793285429477692	There was no statistically significant difference between treatment groups in the proportion of patients with hypercalciuria at the end of the 24-week extension .
D-403	-0.19793285429477692	There was no statistically significant difference between treatment groups in the proportion of patients with hypercalciuria at the end of the 24-week extension .
P-403	-0.2763 -0.1217 -0.0893 -0.1672 -0.1323 -0.0741 -0.3603 -0.0557 -0.2259 -0.1236 -0.5437 -0.1899 -0.1586 -0.3218 -0.1632 -0.7474 -0.1428 -0.0406 -0.1017 -0.1230 -0.0464 -0.1567 -0.1746 -0.1394 -0.1531 -0.1423 -0.3372 -0.4932 -0.0383 -0.0840 -0.3123 -0.1443 -0.1507
S-443	Kleinere Mengen verteilen sich in Fett- und Muskelgewebe und werden dort als Vitamin D3 gespeichert , um später in den Kreislauf abgegeben zu werden .
T-443	Lesser amounts are distributed to adipose and muscle tissue and stored as vitamin D3 at these sites for later release into the circulation .
H-443	-0.4815492630004883	Smaller amounts are distributed in fat and muscle tissue where they are stored as vitamin D3 for later circulation .
D-443	-0.4815492630004883	Smaller amounts are distributed in fat and muscle tissue where they are stored as vitamin D3 for later circulation .
P-443	-1.2732 -0.1903 -0.4077 -0.3282 -1.7238 -0.1130 -0.9514 -0.7236 -0.1576 -0.0407 -0.1484 -2.0613 -0.0618 -0.1310 -0.1334 -0.1135 -0.1933 -0.1707 -0.0856 -0.1302 -0.1312 -1.1507 -0.5554 -1.6201 -0.0837 -0.1632 -0.1587
S-1905	Desloratadin , ein Antihistaminikum , und Pseudoephedrin , ein die Nasenschleimhaut abschwellendes Mittel .
T-1905	Desloratadine works by blocking the receptors on which histamine , a substance in the body that causes allergic symptoms , normally fixes itself .
H-1905	-0.21904779970645905	desloratadine , an antihistamine , and pseudoephedrine , a nasal decongestant .
D-1905	-0.21904779970645905	desloratadine , an antihistamine , and pseudoephedrine , a nasal decongestant .
P-1905	-1.4029 -0.0470 -0.1029 -0.6401 -0.3436 -0.1442 -0.1433 -0.0793 -0.0962 -0.0437 -0.1395 -0.1289 -0.1008 -0.4507 -0.1656 -0.0590 -0.1134 -0.1583 -0.1068 -0.1461 -0.2162 -0.5120 -0.0178 -0.2561 -0.0811 -0.2153 -0.2310 -0.1306 -0.1438 -0.1553
S-323	Bei Patienten mit diesen Erkrankungen sollten unter der Therapie mit ADROVANCE das Serum-Calcium sowie Symptome einer Hypocalcämie überwacht werden .
T-323	In patients with these conditions , serum calcium and symptoms of hypocalcaemia should be monitored during therapy with ADROVANCE .
H-323	-0.28601324558258057	Patients with these disorders should be monitored under ADROVANCE therapy for serum calcium and symptoms of hypocalcaemia .
D-323	-0.28601324558258057	Patients with these disorders should be monitored under ADROVANCE therapy for serum calcium and symptoms of hypocalcaemia .
P-323	-0.9043 -0.0918 -0.1115 -0.1374 -1.0529 -0.1025 -0.1514 -0.2834 -0.1084 -0.1025 -1.9245 -0.3283 -0.0815 -0.1253 -0.1007 -0.1198 -0.9749 -0.5137 -0.0643 -0.1169 -0.0438 -0.0845 -0.1048 -0.4109 -0.5754 -0.1251 -0.0315 -0.0803 -0.0791 -0.0792 -0.1319 -0.1408 -0.1550
S-1761	Behandlung von Blutungen Die Dosis von Octocog alfa wird in Abhängigkeit vom Körpergewicht und den angestrebten Faktor VIII-Spiegeln errechnet .
T-1761	Treatment of bleeding The dose of octocog alfa is calculated depending on you body weight and the factor VIII levels to be achieved .
H-1761	-0.3860001862049103	Treatment of haemorrhage Octocog alfa dose is calculated with body weight and desired factor VIII-levels in mind .
D-1761	-0.3860001862049103	Treatment of haemorrhage Octocog alfa dose is calculated with body weight and desired factor VIII-levels in mind .
P-1761	-0.0288 -0.1426 -0.0914 -0.1400 -0.9551 -0.5352 -0.0213 -0.3289 -0.2906 -0.0869 -0.1515 -0.2496 -0.1082 -0.0659 -0.0802 -0.1410 -0.2124 -0.1232 -1.4166 -1.4305 -0.0538 -1.0452 -1.7889 -0.0781 -0.7337 -0.1647 -0.2199 -0.9821 -0.5744 -0.1791 -0.2292 -0.1478 -0.1699 -0.1572
S-1254	Jede Flasche enthält nominal 2000 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-1254	Each vial contains nominally 2000 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-1254	-0.22404353320598602	Each bottle contains a nominal 2000 IU/ recombinant blood coagulation factor VIII ( rDNA ) Octocog alfa/ * .
D-1254	-0.22404353320598602	Each bottle contains a nominal 2000 IU/ recombinant blood coagulation factor VIII ( rDNA ) Octocog alfa/ * .
P-1254	-0.0681 -0.1042 -0.5621 -1.0035 -0.0695 -0.0806 -0.2117 -0.1162 -0.5666 -0.4793 -0.1473 -0.1108 -0.0855 -0.1274 -0.1149 -0.9662 -0.1169 -0.4265 -0.0473 -0.1210 -0.1129 -0.1354 -0.0994 -0.0628 -0.1363 -0.5160 -0.0863 -0.1452 -0.2105 -0.0918 -0.1687 -0.1566 -0.0719 -0.1717 -0.1506
S-726	Jede Flasche enthält nominal 500 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-726	Each vial contains nominally 500 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-726	-0.22162958979606628	Each bottle contains a nominal 500 IU/ recombinant blood coagulation factor VIII ( rDNA ) Octocog alfa/ * .
D-726	-0.22162958979606628	Each bottle contains a nominal 500 IU/ recombinant blood coagulation factor VIII ( rDNA ) Octocog alfa/ * .
P-726	-0.0465 -0.0990 -0.5026 -0.9440 -0.0998 -0.0847 -0.1859 -0.1145 -0.5401 -0.5781 -0.1573 -0.1133 -0.0883 -0.1264 -0.1089 -0.9660 -0.1148 -0.4183 -0.0463 -0.1189 -0.1143 -0.1337 -0.0994 -0.0646 -0.1355 -0.5054 -0.0861 -0.1462 -0.2107 -0.0909 -0.1644 -0.1579 -0.0725 -0.1702 -0.1514
S-902	Jede Flasche enthält nominal 1000 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-902	Each vial contains nominally 1000 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-902	-0.2173835039138794	Each bottle contains a nominal 1000 IU/ recombinant blood coagulation factor VIII ( rDNA ) Octocog alfa/ * .
D-902	-0.2173835039138794	Each bottle contains a nominal 1000 IU/ recombinant blood coagulation factor VIII ( rDNA ) Octocog alfa/ * .
P-902	-0.0636 -0.1107 -0.7065 -0.6424 -0.0647 -0.0742 -0.1729 -0.1138 -0.5463 -0.5615 -0.1543 -0.1119 -0.0882 -0.1265 -0.1118 -0.9832 -0.1155 -0.4336 -0.0462 -0.1196 -0.1130 -0.1339 -0.1000 -0.0636 -0.1358 -0.4572 -0.0861 -0.1460 -0.2120 -0.0912 -0.1683 -0.1581 -0.0728 -0.1718 -0.1514
S-1078	Jede Flasche enthält nominal 1500 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-1078	Each vial contains nominally 1500 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-1078	-0.23776830732822418	Each bottle contains a nominal 1500 IU/ recombinant blood coagulation factor VIII ( rDNA ) Octocog alfa/ * .
D-1078	-0.23776830732822418	Each bottle contains a nominal 1500 IU/ recombinant blood coagulation factor VIII ( rDNA ) Octocog alfa/ * .
P-1078	-0.0682 -0.0974 -0.6714 -0.5500 -0.0704 -0.0837 -1.0528 -0.1147 -0.5894 -0.4597 -0.1696 -0.1130 -0.0866 -0.1302 -0.1110 -1.0011 -0.1141 -0.4290 -0.0464 -0.1197 -0.1118 -0.1338 -0.1000 -0.0633 -0.1357 -0.4414 -0.0862 -0.1451 -0.2123 -0.0909 -0.1663 -0.1582 -0.0717 -0.1755 -0.1511
S-324	Aufgrund der Stimulation der Knochenmineralisation durch Alendronat können Abnahmen des Serum-Calciums und -Phosphats auftreten .
T-324	Due to the positive effects of alendronate in increasing bone mineral , decreases in serum calcium and phosphate may occur .
H-324	-0.27065759897232056	Due to bone mineralization stimulation by alendronate , decreases in serum calcium and phosphate may occur .
D-324	-0.27065759897232056	Due to bone mineralization stimulation by alendronate , decreases in serum calcium and phosphate may occur .
P-324	-0.9852 -0.0738 -0.1340 -1.0334 -0.1040 -0.1611 -1.6718 -0.0571 -0.2078 -0.5848 -0.1376 -0.1392 -0.1293 -0.0529 -0.1764 -1.1641 -0.1311 -0.1444 -0.0580 -0.1049 -0.0997 -0.0859 -0.1145 -0.1318 -0.0669 -0.0645 -0.0863 -0.1451 -0.0532 -0.1377 -0.1538
S-1430	Jede Flasche enthält nominal 3000 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-1430	Each vial contains nominally 3000 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-1430	-0.226824089884758	Each bottle contains a nominal 3000 IU/ recombinant blood coagulation factor VIII ( rDNA ) Octocog alfa/ * .
D-1430	-0.226824089884758	Each bottle contains a nominal 3000 IU/ recombinant blood coagulation factor VIII ( rDNA ) Octocog alfa/ * .
P-1430	-0.0578 -0.0990 -0.5480 -1.2687 -0.0803 -0.0867 -0.0763 -0.1144 -0.5189 -0.4809 -0.1780 -0.1120 -0.0871 -0.1270 -0.1131 -0.9856 -0.1173 -0.4208 -0.0462 -0.1197 -0.1128 -0.1342 -0.1000 -0.0635 -0.1364 -0.4917 -0.0868 -0.1464 -0.2094 -0.0922 -0.1680 -0.1600 -0.0728 -0.1754 -0.1515
S-227	In Osteoporosestudien war Alendronat wirksam , wenn es mindestens 30 Minuten vor dem ersten Essen oder Trinken des Tages eingenommen wurde .
T-227	In osteoporosis studies , alendronate was effective when administered at least 30 minutes before the first food or beverage of the day .
H-227	-0.26942968368530273	In osteoporosis studies , alendronate was effective when taken at least 30 minutes prior to the first meal or drink of the day .
D-227	-0.26942968368530273	In osteoporosis studies , alendronate was effective when taken at least 30 minutes prior to the first meal or drink of the day .
P-227	-0.4262 -0.1617 -0.0657 -0.0905 -0.1310 -0.1412 -0.0899 -0.3842 -0.5905 -0.1064 -0.1636 -0.0803 -0.0495 -0.1363 -0.1017 -1.2139 -0.6891 -0.1154 -0.1184 -0.1399 -0.1592 -1.0503 -0.1346 -0.6112 -0.1062 -0.8010 -0.1073 -0.2103 -0.1515 -0.1715 -0.0958 -0.1443 -0.1529
S-551	Jede Flasche enthält nominal 250 I.E.* rekombinanter Blutgerinnungsfaktor VIII ( rDNS ) Octocog alfa<unk> * .
T-551	Each vial contains nominally 250 IU* human coagulation factor VIII ( rDNA ) , octocog alfa<<unk>> * .
H-551	-0.21925704181194305	Each bottle contains a nominal 250 IU/ recombinant blood coagulation factor VIII ( rDNA ) Octocog alfa/ * .
D-551	-0.21925704181194305	Each bottle contains a nominal 250 IU/ recombinant blood coagulation factor VIII ( rDNA ) Octocog alfa/ * .
P-551	-0.0566 -0.1077 -0.7073 -0.5906 -0.1050 -0.0835 -0.2353 -0.1174 -0.5366 -0.5725 -0.1764 -0.1114 -0.0887 -0.1269 -0.1137 -0.9828 -0.1114 -0.4136 -0.0467 -0.1219 -0.1126 -0.1338 -0.0989 -0.0639 -0.1353 -0.4746 -0.0855 -0.1461 -0.2110 -0.0910 -0.1636 -0.1587 -0.0721 -0.1689 -0.1520
S-436	Die terminale Halbwertszeit beim Menschen wird unter Berücksichtigung der Freisetzung von Alendronat aus dem Skelett auf über zehn Jahre geschätzt .
T-436	The terminal half-life in humans is estimated to exceed ten years , reflecting release of alendronate from the skeleton .
H-436	-0.4352931082248688	The terminal half-life in humans is estimated to exceed ten years when alendronate is released from the skeleton .
D-436	-0.4352931082248688	The terminal half-life in humans is estimated to exceed ten years when alendronate is released from the skeleton .
P-436	-0.2992 -0.4134 -0.1849 -0.1561 -0.1031 -0.1445 -0.3942 -0.1605 -0.1161 -1.4779 -1.2835 -0.0769 -1.1487 -0.1027 -1.5688 -1.8169 -0.1499 -0.1469 -0.0716 -1.1089 -0.4199 -0.1292 -0.1293 -0.0867 -0.0969 -0.0985 -0.1499 -0.1533
S-187	7 konzentriert . Die Aktivität der Osteoklasten wird gehemmt , Rekrutierung und Anbindung der Osteoklasten sind jedoch nicht betroffen .
T-187	Activity of osteoclasts is inhibited , but recruitment or attachment of osteoclasts is not affected .
H-187	-0.3543938100337982	. Osteoclast activity is inhibited , but osteoclast recruitment and attachment are not affected .
D-187	-0.3543938100337982	. Osteoclast activity is inhibited , but osteoclast recruitment and attachment are not affected .
P-187	-1.2658 -0.2688 -0.0879 -0.1685 -0.0182 -1.2316 -0.1447 -0.1369 -0.2466 -0.1722 -0.0979 -0.7939 -0.3053 -0.1347 -0.0763 -0.1691 -0.0101 -0.9950 -1.0224 -0.1227 -1.0079 -0.1157 -0.0850 -0.4012 -0.4533 -0.0733 -0.1620 -0.1562
S-240	Die terminale Halbwertszeit beim Menschen wird unter Berücksichtigung der Freisetzung von Alendronat aus dem Skelett auf über zehn Jahre geschätzt .
T-240	The terminal half-life in humans is estimated to exceed ten years , reflecting release of alendronate from the skeleton .
H-240	-0.4352931082248688	The terminal half-life in humans is estimated to exceed ten years when alendronate is released from the skeleton .
D-240	-0.4352931082248688	The terminal half-life in humans is estimated to exceed ten years when alendronate is released from the skeleton .
P-240	-0.2992 -0.4134 -0.1849 -0.1561 -0.1031 -0.1445 -0.3942 -0.1605 -0.1161 -1.4779 -1.2835 -0.0769 -1.1487 -0.1027 -1.5688 -1.8169 -0.1499 -0.1469 -0.0716 -1.1089 -0.4199 -0.1292 -0.1293 -0.0867 -0.0969 -0.0985 -0.1499 -0.1533
S-1909	Dies führt dazu , dass weniger Flüssigkeit aus den Gefäßen austritt , sodass die Schwellung abnimmt und die Nase weniger Schleim absondert .
T-1909	Aerinaze tablets have two layers , one containing desloratadine , and the other containing pseudoephedrine .
H-1909	-0.45648834109306335	As a result , less fluid escapes from the vessels , which reduces swelling and allows the nose to secrete less mucus .
D-1909	-0.45648834109306335	As a result , less fluid escapes from the vessels , which reduces swelling and allows the nose to secrete less mucus .
P-1909	-1.4512 -0.1195 -0.2027 -0.1932 -0.1008 -0.7065 -0.2632 -1.8784 -0.1039 -0.1711 -0.3114 -0.2370 -0.1056 -0.2952 -2.2245 -1.3443 -0.0768 -0.2346 -0.1080 -0.1321 -2.3686 -0.1588 -0.1917 -0.1252 -0.1406 -0.1176 -0.1520 -0.1778 -0.1609 -0.1422 -0.1557
S-264	Colecalciferol In Tierstudien wurden bei weit höheren Dosen als der therapeutischen Dosis beim Menschen reproduktionstoxische Wirkungen beobachtet .
T-264	Colecalciferol At doses far higher than the human therapeutic range , reproductive toxicity has been observed in animal studies .
H-264	-0.3774448037147522	Colecalciferol Animal studies , reproductive toxicity effects have been observed at doses far higher than the therapeutic dose in humans .
D-264	-0.3774448037147522	Colecalciferol Animal studies , reproductive toxicity effects have been observed at doses far higher than the therapeutic dose in humans .
P-264	-0.1268 -0.1215 -0.1782 -0.1318 -0.1172 -0.2602 -0.4144 -0.1134 -0.1385 -1.9014 -0.0613 -1.2499 -0.1115 -0.2637 -0.1127 -0.1401 -0.4081 -0.2057 -0.1153 -0.1389 -0.7832 -0.0546 -2.3288 -0.5728 -0.1766 -0.3362 -0.2095 -0.0962 -0.1245 -0.2981 -0.8733 -0.1399 -0.1513
S-460	Colecalciferol In Tierstudien wurden bei weit höheren Dosen als der therapeutischen Dosis beim Menschen reproduktionstoxische Wirkungen beobachtet .
T-460	Colecalciferol At doses far higher than the human therapeutic range , reproductive toxicity has been observed in animal studies .
H-460	-0.3774448037147522	Colecalciferol Animal studies , reproductive toxicity effects have been observed at doses far higher than the therapeutic dose in humans .
D-460	-0.3774448037147522	Colecalciferol Animal studies , reproductive toxicity effects have been observed at doses far higher than the therapeutic dose in humans .
P-460	-0.1268 -0.1215 -0.1782 -0.1318 -0.1172 -0.2602 -0.4144 -0.1134 -0.1385 -1.9014 -0.0613 -1.2499 -0.1115 -0.2637 -0.1127 -0.1401 -0.4081 -0.2057 -0.1153 -0.1389 -0.7832 -0.0546 -2.3288 -0.5728 -0.1766 -0.3362 -0.2095 -0.0962 -0.1245 -0.2981 -0.8733 -0.1399 -0.1513
S-1744	Es besteht die geringe Möglichkeit , dass Sie eine anaphylaktische Reaktion ( eine plötzliche , schwere , allergische Reaktion ) auf ADVATE entwickeln .
T-1744	There is a rare chance that you may experience an anaphylactic reaction ( a severe , sudden allergic reaction ) to ADVATE .
H-1744	-0.2785167098045349	There is a small possibility that you may develop anaphylactic reaction ( sudden , severe , allergic reaction ) to ADVATE .
D-1744	-0.2785167098045349	There is a small possibility that you may develop anaphylactic reaction ( sudden , severe , allergic reaction ) to ADVATE .
P-1744	-0.2347 -0.1541 -0.4131 -0.8614 -0.7776 -0.3613 -0.1189 -1.1457 -1.0077 -0.3678 -0.1025 -0.0586 -0.1022 -0.0595 -0.0782 -0.1383 -0.9472 -0.1685 -0.0591 -0.1550 -0.1300 -0.0484 -0.1152 -0.1506 -0.1687 -0.0538 -0.1425 -0.0895 -0.0863 -0.1766 -0.1608
S-37	Insbesondere bei Patienten mit Herzbeschwerden in der Vorgeschichte besteht möglicherweise auch ein erhöhtes Risiko bestimmter Nebenwirkungen , die das Herz und die Blutgefäße betreffen .
T-37	There may also be an increased risk of certain side effects affecting the heart and blood vessels , particularly in patients with a history of heart problems .
H-37	-0.4954696595668793	Particularly in patients with a history of heart discomfort , there may also be an increased risk of certain undesirable effects affecting the heart and blood vessels .
D-37	-0.4954696595668793	Particularly in patients with a history of heart discomfort , there may also be an increased risk of certain undesirable effects affecting the heart and blood vessels .
P-37	-1.0649 -0.0362 -1.2671 -0.8475 -0.7067 -0.1491 -0.3268 -0.9513 -0.1481 -0.3540 -2.6720 -0.4742 -0.1953 -0.4262 -0.1494 -0.0964 -0.1491 -0.1065 -0.0360 -0.1130 -0.6110 -0.9002 -2.6872 -0.0362 -0.0658 -0.3243 -1.4051 -0.1550 -0.0397 -0.1416 -0.1270 -0.2002 -0.0867 -0.1375 -0.1541
S-153	ADROVANCE ist nur für die Anwendung bei postmenopausalen Frauen vorgesehen und ist daher weder während der Schwangerschaft noch von stillenden Frauen anzuwenden .
T-153	ADROVANCE is only intended for use in postmenopausal women and therefore it should not be used during pregnancy or in breast-feeding women .
H-153	-0.3780411183834076	ADROVANCE is for use in post-menopausal women only and therefore cannot be used during pregnancy or by nursing women .
D-153	-0.3780411183834076	ADROVANCE is for use in post-menopausal women only and therefore cannot be used during pregnancy or by nursing women .
P-153	-0.0648 -0.0681 -0.1240 -0.1156 -0.1198 -0.1699 -2.0331 -0.0525 -0.4569 -0.1051 -0.1939 -0.0423 -0.0959 -0.0264 -0.1308 -0.1366 -0.2196 -0.1647 -2.0614 -0.6272 -0.1372 -0.2446 -0.3800 -0.0535 -0.2505 -1.8418 -1.1968 -0.1356 -0.1740 -0.1405 -0.1562
S-1529	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-1529	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-1529	-0.2614087760448456	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
D-1529	-0.2614087760448456	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
P-1529	-0.9642 -0.0571 -1.3971 -0.0617 -0.1466 -0.1511 -0.1020 -0.0854 -0.0623 -0.1653 -0.1295 -1.5074 -0.1883 -0.2102 -0.0517 -0.0278 -0.1717 -0.0546 -0.2550 -0.1351 -0.2150 -0.0365 -0.2516 -0.1595 -0.1793 -0.1382 -0.1539
S-1352	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-1352	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-1352	-0.2614087760448456	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
D-1352	-0.2614087760448456	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
P-1352	-0.9642 -0.0571 -1.3971 -0.0617 -0.1466 -0.1511 -0.1020 -0.0854 -0.0623 -0.1653 -0.1295 -1.5074 -0.1883 -0.2102 -0.0517 -0.0278 -0.1717 -0.0546 -0.2550 -0.1351 -0.2150 -0.0365 -0.2516 -0.1595 -0.1793 -0.1382 -0.1539
S-1176	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-1176	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-1176	-0.2614087760448456	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
D-1176	-0.2614087760448456	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
P-1176	-0.9642 -0.0571 -1.3971 -0.0617 -0.1466 -0.1511 -0.1020 -0.0854 -0.0623 -0.1653 -0.1295 -1.5074 -0.1883 -0.2102 -0.0517 -0.0278 -0.1717 -0.0546 -0.2550 -0.1351 -0.2150 -0.0365 -0.2516 -0.1595 -0.1793 -0.1382 -0.1539
S-1000	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-1000	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-1000	-0.2614087760448456	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
D-1000	-0.2614087760448456	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
P-1000	-0.9642 -0.0571 -1.3971 -0.0617 -0.1466 -0.1511 -0.1020 -0.0854 -0.0623 -0.1653 -0.1295 -1.5074 -0.1883 -0.2102 -0.0517 -0.0278 -0.1717 -0.0546 -0.2550 -0.1351 -0.2150 -0.0365 -0.2516 -0.1595 -0.1793 -0.1382 -0.1539
S-824	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-824	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-824	-0.2614087760448456	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
D-824	-0.2614087760448456	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
P-824	-0.9642 -0.0571 -1.3971 -0.0617 -0.1466 -0.1511 -0.1020 -0.0854 -0.0623 -0.1653 -0.1295 -1.5074 -0.1883 -0.2102 -0.0517 -0.0278 -0.1717 -0.0546 -0.2550 -0.1351 -0.2150 -0.0365 -0.2516 -0.1595 -0.1793 -0.1382 -0.1539
S-650	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak der Antikörperspiegel gegen murines IgG .
T-650	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-murine IgG antibody level .
H-650	-0.2614087760448456	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
D-650	-0.2614087760448456	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to murine IgG .
P-650	-0.9642 -0.0571 -1.3971 -0.0617 -0.1466 -0.1511 -0.1020 -0.0854 -0.0623 -0.1653 -0.1295 -1.5074 -0.1883 -0.2102 -0.0517 -0.0278 -0.1717 -0.0546 -0.2550 -0.1351 -0.2150 -0.0365 -0.2516 -0.1595 -0.1793 -0.1382 -0.1539
S-1620	Der Inhaber dieser Arzneimittelzulassung wird PSURs im Abstand von 6 Monaten vorlegen , es sei denn , dass der CHMP andere Zeiträume festlegt .
T-1620	The holder of this marketing authorisation holder will submit PSURs every 6 months unless otherwise specified by the CHMP .
H-1620	-0.38331931829452515	The holder of this marketing authorisation will submit PSURs six months apart , unless otherwise specified by the CHMP .
D-1620	-0.38331931829452515	The holder of this marketing authorisation will submit PSURs six months apart , unless otherwise specified by the CHMP .
P-1620	-0.8688 -0.2144 -0.1667 -0.2395 -1.6006 -0.0103 -0.0635 -0.2753 -1.3203 -0.0646 -0.1675 -0.1461 -0.0695 -0.1382 -1.1491 -0.1787 -0.1439 -0.4624 -0.1037 -0.7650 -1.5252 -0.0577 -0.1762 -0.2748 -0.1711 -0.0380 -0.1862 -0.1557
S-1472	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-1472	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-1472	-0.29299643635749817	The rate of administration should vary with the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
D-1472	-0.29299643635749817	The rate of administration should vary with the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
P-1472	-1.0518 -0.4910 -0.2048 -0.2965 -0.1571 -1.1949 -0.0779 -0.4511 -0.2069 -0.2360 -0.6843 -0.7877 -0.1710 -0.3940 -0.0844 -0.1546 -0.1447 -0.1362 -0.1757 -0.1486 -0.1346 -0.2497 -0.0787 -0.1434 -0.1540 -0.0801 -0.0953 -0.1607 -0.1512
S-1296	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-1296	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-1296	-0.29299643635749817	The rate of administration should vary with the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
D-1296	-0.29299643635749817	The rate of administration should vary with the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
P-1296	-1.0518 -0.4910 -0.2048 -0.2965 -0.1571 -1.1949 -0.0779 -0.4511 -0.2069 -0.2360 -0.6843 -0.7877 -0.1710 -0.3940 -0.0844 -0.1546 -0.1447 -0.1362 -0.1757 -0.1486 -0.1346 -0.2497 -0.0787 -0.1434 -0.1540 -0.0801 -0.0953 -0.1607 -0.1512
S-1142	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-1142	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-1142	-0.2825169861316681	Due to the rare occurrence of haemophilia A in women , no experience exists with the use of factor VIII during pregnancy and breast-feeding .
D-1142	-0.2825169861316681	Due to the rare occurrence of haemophilia A in women , no experience exists with the use of factor VIII during pregnancy and breast-feeding .
P-1142	-0.8174 -0.0684 -0.1386 -0.3427 -0.2665 -0.3591 -0.0361 -0.0694 -0.1154 -0.1595 -0.2145 -0.0866 -0.1553 -0.2507 -0.1352 -0.1568 -0.1665 -0.1889 -0.7931 -0.1612 -1.0631 -1.8299 -0.4503 -0.3854 -0.1505 -0.5000 -0.1428 -0.1436 -0.1419 -0.0495 -0.1716 -0.2383 -0.0278 -0.1339 -0.0389 -0.1501 -0.1535
S-28	In beiden Studien wurde Allopurinol in einer Dosis von einmal täglich 300 mg angewendet ; Patienten mit Nierenproblemen erhielten nur 100 mg pro Tag .
T-28	In both studies , allopurinol was used at a dose of 300 mg once a day , except for patients with kidney problems , who took 100 mg .
H-28	-0.36566361784935	In both studies , 300 mg of allopurinol was administered once daily ; patients with renal problems received only 100 mg per day .
D-28	-0.36566361784935	In both studies , 300 mg of allopurinol was administered once daily ; patients with renal problems received only 100 mg per day .
P-28	-0.3354 -0.0731 -1.0336 -0.3278 -0.4608 -0.0597 -0.7421 -1.4186 -0.1676 -0.1294 -0.1448 -0.1228 -0.3625 -0.0859 -0.1261 -1.0268 -0.2878 -1.0380 -0.1477 -0.6478 -0.1290 -0.2547 -0.5901 -0.4640 -0.1284 -0.0353 -0.2351 -0.0965 -0.1439 -0.1544
S-944	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-944	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-944	-0.29299643635749817	The rate of administration should vary with the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
D-944	-0.29299643635749817	The rate of administration should vary with the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
P-944	-1.0518 -0.4910 -0.2048 -0.2965 -0.1571 -1.1949 -0.0779 -0.4511 -0.2069 -0.2360 -0.6843 -0.7877 -0.1710 -0.3940 -0.0844 -0.1546 -0.1447 -0.1362 -0.1757 -0.1486 -0.1346 -0.2497 -0.0787 -0.1434 -0.1540 -0.0801 -0.0953 -0.1607 -0.1512
S-341	ADROVANCE ist nur für die Anwendung bei postmenopausalen Frauen vorgesehen und ist daher weder während der Schwangerschaft noch von stillenden Frauen anzuwenden .
T-341	ADROVANCE is only intended for use in postmenopausal women and therefore it should not be used during pregnancy or in breast-feeding women .
H-341	-0.3780411183834076	ADROVANCE is for use in post-menopausal women only and therefore cannot be used during pregnancy or by nursing women .
D-341	-0.3780411183834076	ADROVANCE is for use in post-menopausal women only and therefore cannot be used during pregnancy or by nursing women .
P-341	-0.0648 -0.0681 -0.1240 -0.1156 -0.1198 -0.1699 -2.0331 -0.0525 -0.4569 -0.1051 -0.1939 -0.0423 -0.0959 -0.0264 -0.1308 -0.1366 -0.2196 -0.1647 -2.0614 -0.6272 -0.1372 -0.2446 -0.3800 -0.0535 -0.2505 -1.8418 -1.1968 -0.1356 -0.1740 -0.1405 -0.1562
S-1494	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-1494	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-1494	-0.2825169861316681	Due to the rare occurrence of haemophilia A in women , no experience exists with the use of factor VIII during pregnancy and breast-feeding .
D-1494	-0.2825169861316681	Due to the rare occurrence of haemophilia A in women , no experience exists with the use of factor VIII during pregnancy and breast-feeding .
P-1494	-0.8174 -0.0684 -0.1386 -0.3427 -0.2665 -0.3591 -0.0361 -0.0694 -0.1154 -0.1595 -0.2145 -0.0866 -0.1553 -0.2507 -0.1352 -0.1568 -0.1665 -0.1889 -0.7931 -0.1612 -1.0631 -1.8299 -0.4503 -0.3854 -0.1505 -0.5000 -0.1428 -0.1436 -0.1419 -0.0495 -0.1716 -0.2383 -0.0278 -0.1339 -0.0389 -0.1501 -0.1535
S-966	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-966	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-966	-0.2825169861316681	Due to the rare occurrence of haemophilia A in women , no experience exists with the use of factor VIII during pregnancy and breast-feeding .
D-966	-0.2825169861316681	Due to the rare occurrence of haemophilia A in women , no experience exists with the use of factor VIII during pregnancy and breast-feeding .
P-966	-0.8174 -0.0684 -0.1386 -0.3427 -0.2665 -0.3591 -0.0361 -0.0694 -0.1154 -0.1595 -0.2145 -0.0866 -0.1553 -0.2507 -0.1352 -0.1568 -0.1665 -0.1889 -0.7931 -0.1612 -1.0631 -1.8299 -0.4503 -0.3854 -0.1505 -0.5000 -0.1428 -0.1436 -0.1419 -0.0495 -0.1716 -0.2383 -0.0278 -0.1339 -0.0389 -0.1501 -0.1535
S-416	FIT 1 : eine Drei-Jahres-Studie an 2.027 Patientinnen mit mindestens einer vorbestehenden Wirbel-<unk> Kompressions-<unk> Fraktur .
T-416	FIT 1 : eine Drei-Jahres-Studie an 2.027 Patientinnen mit mindestens einer vorbestehenden Wirbel-<<unk>> Kompressions-<<unk>> Fraktur . A three-year study of 2,027 patients who had at least one baseline vertebral ( compression ) fracture .
H-416	-0.33841198682785034	FIT 1 : a three year trial involving 2,027 patients with at least one pre-existing vertebral <unk> compression <unk> fracture .
D-416	-0.33841198682785034	FIT 1 : a three year trial involving 2,027 patients with at least one pre-existing vertebral <unk> compression <unk> fracture .
P-416	-0.1834 -0.1144 -0.1816 -0.1880 -0.1284 -1.3417 -0.3621 -0.2487 -0.8112 -0.1165 -0.0563 -0.1416 -1.0105 -0.1494 -0.1152 -0.1180 -0.1142 -0.8130 -0.1718 -0.1221 -1.4696 -0.0779 -0.0216 -0.2397 -1.0509 -0.1688 -0.0617 -0.0820 -0.9693 -0.1546 -0.0622 -0.1705 -0.1506
S-220	FIT 1 : eine Drei-Jahres-Studie an 2.027 Patientinnen mit mindestens einer vorbestehenden Wirbel-<unk> Kompressions-<unk> Fraktur .
T-220	FIT 1 : eine Drei-Jahres-Studie an 2.027 Patientinnen mit mindestens einer vorbestehenden Wirbel-<<unk>> Kompressions-<<unk>> Fraktur . A three-year study of 2,027 patients who had at least one baseline vertebral ( compression ) fracture .
H-220	-0.33841198682785034	FIT 1 : a three year trial involving 2,027 patients with at least one pre-existing vertebral <unk> compression <unk> fracture .
D-220	-0.33841198682785034	FIT 1 : a three year trial involving 2,027 patients with at least one pre-existing vertebral <unk> compression <unk> fracture .
P-220	-0.1834 -0.1144 -0.1816 -0.1880 -0.1284 -1.3417 -0.3621 -0.2487 -0.8112 -0.1165 -0.0563 -0.1416 -1.0105 -0.1494 -0.1152 -0.1180 -0.1142 -0.8130 -0.1718 -0.1221 -1.4696 -0.0779 -0.0216 -0.2397 -1.0509 -0.1688 -0.0617 -0.0820 -0.9693 -0.1546 -0.0622 -0.1705 -0.1506
S-419	FIT 2 : eine Vier-Jahres-Studie an 4.432 Patientinnen mit einer niedrigen Knochenmasse , aber ohne vorbestehende Wirbelfraktur .
T-419	FIT 2 : eine Vier-Jahres-Studie an 4.432 Patientinnen mit einer niedrigen Knochenmasse , aber ohne vorbestehende Wirbelfraktur . A four-year study of 4,432 patients with low bone mass but without a baseline vertebral fracture .
H-419	-0.3569340407848358	FIT 2 : a four-year trial involving 4,432 patients with low bone mass but no pre-existing vertebral fracture .
D-419	-0.3569340407848358	FIT 2 : a four-year trial involving 4,432 patients with low bone mass but no pre-existing vertebral fracture .
P-419	-0.2014 -0.1052 -0.1657 -0.1689 -0.1300 -1.6498 -0.1257 -0.0395 -0.0840 -0.4479 -0.6370 -0.5857 -0.1273 -0.1234 -2.3988 -0.1952 -0.2777 -0.0827 -0.0444 -0.0919 -1.6464 -0.9852 -0.1553 -0.1007 -0.1291 -0.0980 -0.0443 -0.1063 -0.0627 -0.0847 -0.1756 -0.1515
S-223	FIT 2 : eine Vier-Jahres-Studie an 4.432 Patientinnen mit einer niedrigen Knochenmasse , aber ohne vorbestehende Wirbelfraktur .
T-223	FIT 2 : eine Vier-Jahres-Studie an 4.432 Patientinnen mit einer niedrigen Knochenmasse , aber ohne vorbestehende Wirbelfraktur . A four-year study of 4,432 patients with low bone mass but without a baseline vertebral fracture .
H-223	-0.3569340407848358	FIT 2 : a four-year trial involving 4,432 patients with low bone mass but no pre-existing vertebral fracture .
D-223	-0.3569340407848358	FIT 2 : a four-year trial involving 4,432 patients with low bone mass but no pre-existing vertebral fracture .
P-223	-0.2014 -0.1052 -0.1657 -0.1689 -0.1300 -1.6498 -0.1257 -0.0395 -0.0840 -0.4479 -0.6370 -0.5857 -0.1273 -0.1234 -2.3988 -0.1952 -0.2777 -0.0827 -0.0444 -0.0919 -1.6464 -0.9852 -0.1553 -0.1007 -0.1291 -0.0980 -0.0443 -0.1063 -0.0627 -0.0847 -0.1756 -0.1515
S-418	Zusätzlich wurde eine signifikante Reduktion der Inzidenz von Hüftfrakturen ( 1,1 % gegenüber 2,2 % ; Reduktion um 51 % ) festgestellt .
T-418	Zusätzlich wurde eine signifikante Reduktion der Inzidenz von Hüftfrakturen ( 1,1 % gegenüber 2,2 % ; Reduktion um 51 % ) festgestellt . 2.2 % , a reduction of 51 % ) .
H-418	-0.2808787226676941	In addition , a significant reduction in the incidence of hip fractures was observed ( 1.1 % versus 2.2 % ; reduction of 51 % ) .
D-418	-0.2808787226676941	In addition , a significant reduction in the incidence of hip fractures was observed ( 1.1 % versus 2.2 % ; reduction of 51 % ) .
P-418	-0.5343 -0.0851 -0.1706 -0.3827 -0.1348 -0.1530 -0.1932 -0.8481 -0.0525 -0.0857 -0.1564 -0.0562 -0.7847 -0.0849 -0.5250 -0.6965 -0.1372 -0.0363 -0.1096 -1.3717 -0.1491 -0.1440 -0.1249 -0.1528 -0.7522 -0.1795 -0.0596 -0.1195 -0.1370 -0.1403 -0.1496
S-222	Zusätzlich wurde eine signifikante Reduktion der Inzidenz von Hüftfrakturen ( 1,1 % gegenüber 2,2 % ; Reduktion um 51 % ) festgestellt .
T-222	Zusätzlich wurde eine signifikante Reduktion der Inzidenz von Hüftfrakturen ( 1,1 % gegenüber 2,2 % ; Reduktion um 51 % ) festgestellt . 2.2 % , a reduction of 51 % ) .
H-222	-0.2808787226676941	In addition , a significant reduction in the incidence of hip fractures was observed ( 1.1 % versus 2.2 % ; reduction of 51 % ) .
D-222	-0.2808787226676941	In addition , a significant reduction in the incidence of hip fractures was observed ( 1.1 % versus 2.2 % ; reduction of 51 % ) .
P-222	-0.5343 -0.0851 -0.1706 -0.3827 -0.1348 -0.1530 -0.1932 -0.8481 -0.0525 -0.0857 -0.1564 -0.0562 -0.7847 -0.0849 -0.5250 -0.6965 -0.1372 -0.0363 -0.1096 -1.3717 -0.1491 -0.1440 -0.1249 -0.1528 -0.7522 -0.1795 -0.0596 -0.1195 -0.1370 -0.1403 -0.1496
S-274	Rechteckartige , weiße bis gebrochen weiße Tabletten , gekennzeichnet mit dem Umriss eines Knochens auf der einen Seite und 270 auf der anderen Seite .
T-274	Modified rectangle-shaped , white to off-white tablets , marked with an outline of a bone image on one side , and <<unk>> 270 <<unk>> on the other .
H-274	-0.2011609673500061	Rectangular , white to broken white tablets marked with the outline of a bone on one side and 270 on the other .
D-274	-0.2011609673500061	Rectangular , white to broken white tablets marked with the outline of a bone on one side and 270 on the other .
P-274	-0.3012 -0.0423 -0.0720 -0.0913 -0.6852 -0.0601 -0.1309 -0.5423 -0.0711 -0.1335 -0.1203 -0.8248 -0.1606 -0.1722 -0.2884 -0.1400 -0.1644 -0.1523 -0.0895 -0.1551 -0.1343 -0.1311 -0.1435 -0.2215 -0.1664 -0.1318 -0.1184 -0.2213 -0.1681
S-1735	ADVATE wird ohne Zusatz eines menschlichen oder tierischen Proteins während des Zellkultur- Prozesses , der Reinigung und der Endformulierung hergestellt .
T-1735	ADVATE is prepared without the addition of any human- or animal-derived protein in the cell culture process , purification or final formulation .
H-1735	-0.27818426489830017	ADVATE is produced without the addition of a human or animal protein during the cell culture , purification and final formulation process .
D-1735	-0.27818426489830017	ADVATE is produced without the addition of a human or animal protein during the cell culture , purification and final formulation process .
P-1735	-0.0904 -0.1488 -0.0803 -0.1069 -0.1342 -0.5062 -0.3926 -0.7895 -0.1635 -0.1545 -1.1469 -0.1065 -0.1242 -0.0628 -0.0829 -0.1624 -0.4229 -0.3489 -0.0987 -0.4274 -0.3292 -0.0818 -0.1041 -0.3578 -0.7056 -0.0212 -0.0820 -0.8250 -0.1373 -0.1508
S-1318	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-1318	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-1318	-0.2825169861316681	Due to the rare occurrence of haemophilia A in women , no experience exists with the use of factor VIII during pregnancy and breast-feeding .
D-1318	-0.2825169861316681	Due to the rare occurrence of haemophilia A in women , no experience exists with the use of factor VIII during pregnancy and breast-feeding .
P-1318	-0.8174 -0.0684 -0.1386 -0.3427 -0.2665 -0.3591 -0.0361 -0.0694 -0.1154 -0.1595 -0.2145 -0.0866 -0.1553 -0.2507 -0.1352 -0.1568 -0.1665 -0.1889 -0.7931 -0.1612 -1.0631 -1.8299 -0.4503 -0.3854 -0.1505 -0.5000 -0.1428 -0.1436 -0.1419 -0.0495 -0.1716 -0.2383 -0.0278 -0.1339 -0.0389 -0.1501 -0.1535
S-1826	Österreich Baxter Vertriebs GmbH Landstra er Hauptstra e 99 <unk> Top 2A A-1031 Wien Tel . : <unk> 43 1 71120 0
T-1826	Österreich Baxter Vertriebs GmbH Landstra er Hauptstra e 99 / Top 2A A-1031 Wien Tel . : <<unk>> 43 1 71120 0
H-1826	-0.21672028303146362	Österreich Baxter Vertriebs GmbH Landstra er Hauptstra e 99 <unk> Top 2A A-1031 Wien Tel . : <unk> 43 1 71120 0
D-1826	-0.21672028303146362	Österreich Baxter Vertriebs GmbH Landstra er Hauptstra e 99 <unk> Top 2A A-1031 Wien Tel . : <unk> 43 1 71120 0
P-1826	-0.1625 -0.2646 -0.1203 -0.1336 -0.5103 -0.0605 -0.1350 -0.0815 -0.1877 -0.4990 -0.1187 -0.4170 -1.2071 -0.1433 -0.0496 -0.0332 -0.2944 -0.1096 -0.1206 -0.1255 -0.1653 -0.2699 -0.1197 -1.0155 -0.0365 -0.1500 -0.1370 -0.0401 -0.1039 -0.1633 -0.1088 -0.1096 -0.0791 -0.1510 -0.1613
S-790	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-790	Based on the rare occurrence of haemophilia A in women , experience regarding the use of factor VIII during pregnancy and breast- feeding is not available .
H-790	-0.2825169861316681	Due to the rare occurrence of haemophilia A in women , no experience exists with the use of factor VIII during pregnancy and breast-feeding .
D-790	-0.2825169861316681	Due to the rare occurrence of haemophilia A in women , no experience exists with the use of factor VIII during pregnancy and breast-feeding .
P-790	-0.8174 -0.0684 -0.1386 -0.3427 -0.2665 -0.3591 -0.0361 -0.0694 -0.1154 -0.1595 -0.2145 -0.0866 -0.1553 -0.2507 -0.1352 -0.1568 -0.1665 -0.1889 -0.7931 -0.1612 -1.0631 -1.8299 -0.4503 -0.3854 -0.1505 -0.5000 -0.1428 -0.1436 -0.1419 -0.0495 -0.1716 -0.2383 -0.0278 -0.1339 -0.0389 -0.1501 -0.1535
S-616	Aufgrund des seltenen Auftretens der Hämophilie A bei Frauen liegen über die Anwendung von Faktor VIII während der Schwangerschaft und Stillzeit keine Erfahrungen vor .
T-616	Based on the rare occurrence of haemophilia A in women , experience regarding the use of Factor VIII during pregnancy and breast-feeding is not available .
H-616	-0.2825169861316681	Due to the rare occurrence of haemophilia A in women , no experience exists with the use of factor VIII during pregnancy and breast-feeding .
D-616	-0.2825169861316681	Due to the rare occurrence of haemophilia A in women , no experience exists with the use of factor VIII during pregnancy and breast-feeding .
P-616	-0.8174 -0.0684 -0.1386 -0.3427 -0.2665 -0.3591 -0.0361 -0.0694 -0.1154 -0.1595 -0.2145 -0.0866 -0.1553 -0.2507 -0.1352 -0.1568 -0.1665 -0.1889 -0.7931 -0.1612 -1.0631 -1.8299 -0.4503 -0.3854 -0.1505 -0.5000 -0.1428 -0.1436 -0.1419 -0.0495 -0.1716 -0.2383 -0.0278 -0.1339 -0.0389 -0.1501 -0.1535
S-1886	Nach Ansicht des CHMP wurde nicht ausreichend nachgewiesen , dass die Injektion von Advexin in Li-Fraumeni-Tumore Vorteile für die Patienten bringt .
T-1886	The CHMP was concerned that there was not enough evidence to show that the injection of Advexin into Li-Fraumeni tumours led to benefits for patients .
H-1886	-0.555144190788269	The CHMP believes there is insufficient evidence to show that injection of Advexin into Li-Fraumeni tumours delivers benefits for patients .
D-1886	-0.555144190788269	The CHMP believes there is insufficient evidence to show that injection of Advexin into Li-Fraumeni tumours delivers benefits for patients .
P-1886	-1.5215 -0.0781 -0.0379 -2.1793 -1.4408 -0.2308 -0.2145 -0.0712 -0.2873 -1.0677 -0.5519 -0.2294 -0.7800 -0.1281 -0.1504 -1.3202 -0.1911 -0.1344 -0.1924 -1.8761 -0.3117 -0.2917 -0.0311 -0.2309 -1.7292 -0.1702 -1.2945 -0.1321 -0.3486 -0.6803 -0.1092 -0.1514 -0.1558
S-318	ADROVANCE wird für Patienten mit Niereninsuffizienz mit einer GFR unter 35 ml<unk> min nicht empfohlen ( siehe Abschnitt 4.2 ) .
T-318	ADROVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min ( see section 4.2 ) .
H-318	-0.18197640776634216	ADROVANCE is not recommended for renal failure patients with GFR below 35 ml/ min ( see section 4.2 ) .
D-318	-0.18197640776634216	ADROVANCE is not recommended for renal failure patients with GFR below 35 ml/ min ( see section 4.2 ) .
P-318	-0.0543 -0.0795 -0.1256 -0.1077 -0.1220 -0.1601 -0.1734 -0.0491 -0.2278 -0.2745 -0.1491 -0.0657 -0.0482 -0.1609 -0.9027 -0.2496 -0.4676 -0.0844 -0.1778 -0.1685 -0.1242 -0.2317 -0.1409 -0.3273 -0.1076 -0.1109 -0.1401 -0.1355 -0.1402 -0.1523
S-130	ADROVANCE wird für Patienten mit Niereninsuffizienz mit einer GFR unter 35 ml<unk> min nicht empfohlen ( siehe Abschnitt 4.2 ) .
T-130	ADROVANCE is not recommended for patients with renal impairment where GFR is less than 35ml/ min ( see section 4.2 ) .
H-130	-0.18197640776634216	ADROVANCE is not recommended for renal failure patients with GFR below 35 ml/ min ( see section 4.2 ) .
D-130	-0.18197640776634216	ADROVANCE is not recommended for renal failure patients with GFR below 35 ml/ min ( see section 4.2 ) .
P-130	-0.0543 -0.0795 -0.1256 -0.1077 -0.1220 -0.1601 -0.1734 -0.0491 -0.2278 -0.2745 -0.1491 -0.0657 -0.0482 -0.1609 -0.9027 -0.2496 -0.4676 -0.0844 -0.1778 -0.1685 -0.1242 -0.2317 -0.1409 -0.3273 -0.1076 -0.1109 -0.1401 -0.1355 -0.1402 -0.1523
S-1948	Nach Rückgang der Schwellung der Schleimhäute in den oberen Atemwegen kann die Behandlung bei Bedarf mit Desloratadin als Monotherapie fortgesetzt werden .
T-1948	After improvement of the congestive condition of the mucosae of the upper airway , treatment may be maintained with desloratadine alone , if necessary .
H-1948	-0.4136461317539215	Following decreased mucosal swelling in the upper respiratory tract , treatment with desloratadine as monotherapy may be continued as necessary .
D-1948	-0.4136461317539215	Following decreased mucosal swelling in the upper respiratory tract , treatment with desloratadine as monotherapy may be continued as necessary .
P-1948	-1.3666 -0.8763 -0.6008 -1.8211 -0.0904 -0.0568 -0.1151 -0.1220 -0.1612 -0.1147 -0.1618 -0.8517 -0.0255 -0.0611 -0.2384 -0.0918 -0.1694 -1.4756 -0.2330 -0.5892 -0.0682 -0.1022 -0.4652 -0.2586 -0.4595 -0.1861 -0.1337 -0.0433 -0.9959 -0.5317 -0.6949 -0.7994 -0.2178 -0.1472 -0.1515
S-1841	Sverige Baxter Medical AB Box 63 Torshamnsgatan 35 S-164 94 Kista Tel : <unk> 46 8 6326400
T-1841	Sverige Baxter Medical AB Box 63 Torshamnsgatan 35 S-164 94 Kista Tel : <<unk>> 46 8 6326400
H-1841	-0.13496153056621552	Sverige Baxter Medical AB Box 63 Torshamnsgatan 35 S-164 94 Kista Tel : <unk> 46 8 6326400
D-1841	-0.13496153056621552	Sverige Baxter Medical AB Box 63 Torshamnsgatan 35 S-164 94 Kista Tel : <unk> 46 8 6326400
P-1841	-0.1002 -0.0866 -0.0196 -0.2411 -0.1306 -0.1371 -0.2437 -0.0477 -0.4045 -0.0638 -0.2076 -0.0600 -0.4992 -0.1186 -0.1284 -0.1343 -0.0733 -0.1228 -0.1072 -0.1012 -0.1250 -0.2314 -0.1349 -0.0628 -0.1412 -0.0577 -0.1392 -0.0340 -0.0842 -0.1245 -0.1378 -0.1387 -0.0577 -0.0779 -0.1493
S-1120	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-1120	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-1120	-0.29299643635749817	The rate of administration should vary with the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
D-1120	-0.29299643635749817	The rate of administration should vary with the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
P-1120	-1.0518 -0.4910 -0.2048 -0.2965 -0.1571 -1.1949 -0.0779 -0.4511 -0.2069 -0.2360 -0.6843 -0.7877 -0.1710 -0.3940 -0.0844 -0.1546 -0.1447 -0.1362 -0.1757 -0.1486 -0.1346 -0.2497 -0.0787 -0.1434 -0.1540 -0.0801 -0.0953 -0.1607 -0.1512
S-594	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-594	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-594	-0.29299643635749817	The rate of administration should vary with the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
D-594	-0.29299643635749817	The rate of administration should vary with the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
P-594	-1.0518 -0.4910 -0.2048 -0.2965 -0.1571 -1.1949 -0.0779 -0.4511 -0.2069 -0.2360 -0.6843 -0.7877 -0.1710 -0.3940 -0.0844 -0.1546 -0.1447 -0.1362 -0.1757 -0.1486 -0.1346 -0.2497 -0.0787 -0.1434 -0.1540 -0.0801 -0.0953 -0.1607 -0.1512
S-768	Die Verabreichungsgeschwindigkeit soll sich nach dem Befinden des Patienten richten , wobei eine maximale Injektionsrate von 10 ml<unk> min nicht überschritten werden sollte .
T-768	The rate of administration should be determined to ensure the comfort of the patient up to a maximum of 10 ml/ min .
H-768	-0.29299643635749817	The rate of administration should vary with the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
D-768	-0.29299643635749817	The rate of administration should vary with the patient and a maximum injection rate of 10 ml/ min should not be exceeded .
P-768	-1.0518 -0.4910 -0.2048 -0.2965 -0.1571 -1.1949 -0.0779 -0.4511 -0.2069 -0.2360 -0.6843 -0.7877 -0.1710 -0.3940 -0.0844 -0.1546 -0.1447 -0.1362 -0.1757 -0.1486 -0.1346 -0.2497 -0.0787 -0.1434 -0.1540 -0.0801 -0.0953 -0.1607 -0.1512
S-350	Es liegen jedoch keine Informationen vor , die nahelegen , dass ADROVANCE die Verkehrstüchtigkeit oder die Fähigkeit zum Bedienen von Maschinen beeinträchtigt .
T-350	However , there is no information to indicate that ADROVANCE affects a patient s ability to drive or operate machines .
H-350	-0.2869533598423004	However , there is no information to suggest that ADROVANCE impairs the ability to drive or use machines .
D-350	-0.2869533598423004	However , there is no information to suggest that ADROVANCE impairs the ability to drive or use machines .
P-350	-0.1463 -0.1721 -0.7331 -0.1419 -0.1246 -0.1528 -0.2679 -0.1473 -0.1250 -0.1687 -0.0749 -0.1217 -0.1116 -0.1523 -1.2990 -0.6049 -0.8743 -0.0732 -0.5781 -0.2238 -0.1240 -0.1792 -0.2799 -0.1386 -0.1589
S-162	Es liegen jedoch keine Informationen vor , die nahelegen , dass ADROVANCE die Verkehrstüchtigkeit oder die Fähigkeit zum Bedienen von Maschinen beeinträchtigt .
T-162	However , there is no information to indicate that ADROVANCE affects a patient s ability to drive or operate machines .
H-162	-0.2869533598423004	However , there is no information to suggest that ADROVANCE impairs the ability to drive or use machines .
D-162	-0.2869533598423004	However , there is no information to suggest that ADROVANCE impairs the ability to drive or use machines .
P-162	-0.1463 -0.1721 -0.7331 -0.1419 -0.1246 -0.1528 -0.2679 -0.1473 -0.1250 -0.1687 -0.0749 -0.1217 -0.1116 -0.1523 -1.2990 -0.6049 -0.8743 -0.0732 -0.5781 -0.2238 -0.1240 -0.1792 -0.2799 -0.1386 -0.1589
S-1765	Ihr Arzt wird in regelmäßigen Abständen geeignete Labortests durchführen , um sicherzustellen , dass Sie ausreichende Faktor-VIII-Spiegel haben .
T-1765	Your doctor will perform appropriate laboratory tests to make sure that you have adequate Factor VIII levels .
H-1765	-0.38532406091690063	Your doctor will periodically perform appropriate laboratory tests to ensure that you have adequate factor VIII-levels .
D-1765	-0.38532406091690063	Your doctor will periodically perform appropriate laboratory tests to ensure that you have adequate factor VIII-levels .
P-1765	-0.1283 -0.1196 -0.1585 -0.8269 -0.0630 -0.0869 -2.4315 -0.1557 -0.1657 -0.1074 -0.1337 -0.1413 -0.1819 -1.1524 -0.1134 -0.1410 -0.1043 -0.4943 -0.4604 -0.1910 -0.9056 -0.8349 -0.2348 -0.1469 -0.1536
S-1113	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-1113	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-1113	-0.2669689953327179	In patients under 6 years of age , doses between 20 and 50 IU of factor VIII per kg bodyweight 3 times weekly is recommended .
D-1113	-0.2669689953327179	In patients under 6 years of age , doses between 20 and 50 IU of factor VIII per kg bodyweight 3 times weekly is recommended .
P-1113	-0.2900 -0.1361 -0.8655 -0.2702 -0.0941 -0.1681 -0.1013 -0.3201 -0.5997 -0.1174 -0.4698 -0.1162 -0.1671 -0.1254 -0.1064 -0.1199 -0.2055 -0.2135 -0.1536 -0.1379 -0.1460 -0.0610 -0.5930 -0.0576 -0.1565 -0.4961 -0.8485 -0.7174 -0.1167 -0.1574 -0.1480
S-761	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-761	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-761	-0.2669689953327179	In patients under 6 years of age , doses between 20 and 50 IU of factor VIII per kg bodyweight 3 times weekly is recommended .
D-761	-0.2669689953327179	In patients under 6 years of age , doses between 20 and 50 IU of factor VIII per kg bodyweight 3 times weekly is recommended .
P-761	-0.2900 -0.1361 -0.8655 -0.2702 -0.0941 -0.1681 -0.1013 -0.3201 -0.5997 -0.1174 -0.4698 -0.1162 -0.1671 -0.1254 -0.1064 -0.1199 -0.2055 -0.2135 -0.1536 -0.1379 -0.1460 -0.0610 -0.5930 -0.0576 -0.1565 -0.4961 -0.8485 -0.7174 -0.1167 -0.1574 -0.1480
S-937	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-937	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-937	-0.2669689953327179	In patients under 6 years of age , doses between 20 and 50 IU of factor VIII per kg bodyweight 3 times weekly is recommended .
D-937	-0.2669689953327179	In patients under 6 years of age , doses between 20 and 50 IU of factor VIII per kg bodyweight 3 times weekly is recommended .
P-937	-0.2900 -0.1361 -0.8655 -0.2702 -0.0941 -0.1681 -0.1013 -0.3201 -0.5997 -0.1174 -0.4698 -0.1162 -0.1671 -0.1254 -0.1064 -0.1199 -0.2055 -0.2135 -0.1536 -0.1379 -0.1460 -0.0610 -0.5930 -0.0576 -0.1565 -0.4961 -0.8485 -0.7174 -0.1167 -0.1574 -0.1480
S-587	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-587	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-587	-0.2669689953327179	In patients under 6 years of age , doses between 20 and 50 IU of factor VIII per kg bodyweight 3 times weekly is recommended .
D-587	-0.2669689953327179	In patients under 6 years of age , doses between 20 and 50 IU of factor VIII per kg bodyweight 3 times weekly is recommended .
P-587	-0.2900 -0.1361 -0.8655 -0.2702 -0.0941 -0.1681 -0.1013 -0.3201 -0.5997 -0.1174 -0.4698 -0.1162 -0.1671 -0.1254 -0.1064 -0.1199 -0.2055 -0.2135 -0.1536 -0.1379 -0.1460 -0.0610 -0.5930 -0.0576 -0.1565 -0.4961 -0.8485 -0.7174 -0.1167 -0.1574 -0.1480
S-1289	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-1289	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-1289	-0.2669689953327179	In patients under 6 years of age , doses between 20 and 50 IU of factor VIII per kg bodyweight 3 times weekly is recommended .
D-1289	-0.2669689953327179	In patients under 6 years of age , doses between 20 and 50 IU of factor VIII per kg bodyweight 3 times weekly is recommended .
P-1289	-0.2900 -0.1361 -0.8655 -0.2702 -0.0941 -0.1681 -0.1013 -0.3201 -0.5997 -0.1174 -0.4698 -0.1162 -0.1671 -0.1254 -0.1064 -0.1199 -0.2055 -0.2135 -0.1536 -0.1379 -0.1460 -0.0610 -0.5930 -0.0576 -0.1565 -0.4961 -0.8485 -0.7174 -0.1167 -0.1574 -0.1480
S-1906	Desloratadin blockiert die Rezeptoren , an denen Histamin , eine körpereigene Substanz , die allergische Symptome verursacht , normalerweise andockt .
T-1906	When the receptors are blocked , histamine cannot have its effect , and this leads to a decrease in the symptoms of allergy .
H-1906	-0.4372539818286896	Desloratadine blocks the receptors that histamine , an endogenous substance that causes allergic symptoms , usually attaches to .
D-1906	-0.4372539818286896	Desloratadine blocks the receptors that histamine , an endogenous substance that causes allergic symptoms , usually attaches to .
P-1906	-0.3444 -0.0528 -0.1010 -0.4191 -0.3932 -0.1679 -0.9602 -0.0898 -0.0836 -0.0746 -1.0964 -0.5953 -0.0287 -0.1893 -2.6937 -0.5859 -0.7500 -0.0458 -0.2785 -1.2098 -0.2148 -0.1878 -0.0653 -0.0993 -0.1894 -1.8993 -0.2102 -0.0670 -0.1315 -0.1757 -0.1547
S-1631	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1631	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1631	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-1631	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-1631	-0.0579 -0.0148 -0.0854 -0.1148 -0.0648 -0.1455 -0.0319 -0.0727 -0.0483 -0.0436 -0.1027 -0.1049 -0.0722 -0.0686 -0.0421 -0.1179 -0.2871 -0.0163 -0.0422 -0.0180 -0.0080 -0.0504 -0.1114 -0.0443 -0.0496 -0.3368 -0.0217 -0.0461 -0.0061 -0.0128 -0.0480 -0.0547 -0.1552
S-258	Daher ist bei Patienten mit eingeschränkter Nierenfunktion eine etwas erhöhte Kumulation von Alendronat im Knochen zu erwarten ( siehe Abschnitt 4.2 ) .
T-258	Therefore , somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function ( see section 4.2 ) .
H-258	-0.3632684051990509	Patients with renal impairment may therefore expect somewhat increased accumulation of alendronate in bone ( see section 4.2 ) .
D-258	-0.3632684051990509	Patients with renal impairment may therefore expect somewhat increased accumulation of alendronate in bone ( see section 4.2 ) .
P-258	-2.5894 -0.0926 -0.1326 -1.3407 -0.1633 -0.0821 -0.0156 -0.0286 -0.1206 -0.4414 -0.7231 -1.0558 -1.1270 -0.5153 -0.5793 -0.0694 -0.1611 -0.0941 -0.1654 -0.1304 -0.0403 -0.1360 -0.2719 -0.1338 -0.2830 -0.1014 -0.1100 -0.1394 -0.1336 -0.1340 -0.1500
S-1647	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1647	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1647	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-1647	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-1647	-0.0579 -0.0148 -0.0854 -0.1148 -0.0648 -0.1455 -0.0319 -0.0727 -0.0483 -0.0436 -0.1027 -0.1049 -0.0722 -0.0686 -0.0421 -0.1179 -0.2871 -0.0163 -0.0422 -0.0180 -0.0080 -0.0504 -0.1114 -0.0443 -0.0496 -0.3368 -0.0217 -0.0461 -0.0061 -0.0128 -0.0480 -0.0547 -0.1552
S-454	Daher ist bei Patienten mit eingeschränkter Nierenfunktion eine etwas erhöhte Kumulation von Alendronat im Knochen zu erwarten ( siehe Abschnitt 4.2 ) .
T-454	Therefore , somewhat greater accumulation of alendronate in bone might be expected in patients with impaired renal function ( see section 4.2 ) .
H-454	-0.3632684051990509	Patients with renal impairment may therefore expect somewhat increased accumulation of alendronate in bone ( see section 4.2 ) .
D-454	-0.3632684051990509	Patients with renal impairment may therefore expect somewhat increased accumulation of alendronate in bone ( see section 4.2 ) .
P-454	-2.5894 -0.0926 -0.1326 -1.3407 -0.1633 -0.0821 -0.0156 -0.0286 -0.1206 -0.4414 -0.7231 -1.0558 -1.1270 -0.5153 -0.5793 -0.0694 -0.1611 -0.0941 -0.1654 -0.1304 -0.0403 -0.1360 -0.2719 -0.1338 -0.2830 -0.1014 -0.1100 -0.1394 -0.1336 -0.1340 -0.1500
S-1664	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1664	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1664	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-1664	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-1664	-0.0579 -0.0148 -0.0854 -0.1148 -0.0648 -0.1455 -0.0319 -0.0727 -0.0483 -0.0436 -0.1027 -0.1049 -0.0722 -0.0686 -0.0421 -0.1179 -0.2871 -0.0163 -0.0422 -0.0180 -0.0080 -0.0504 -0.1114 -0.0443 -0.0496 -0.3368 -0.0217 -0.0461 -0.0061 -0.0128 -0.0480 -0.0547 -0.1552
S-1880	Basierend auf der Prüfung der anfänglich eingereichten Unterlagen erstellt der CHMP an Tag 120 eine Liste von Fragen , die dem Unternehmen zugesandt wird .
T-1880	Based on the review of the initial documentation , the CHMP prepares a list of questions at day 120 , which is sent to the company .
H-1880	-0.5968300700187683	Based on the review of initial submissions , on day 120 the CHMP will draw up a list of questions to be sent to the company .
D-1880	-0.5968300700187683	Based on the review of initial submissions , on day 120 the CHMP will draw up a list of questions to be sent to the company .
P-1880	-0.4362 -0.1933 -2.4126 -0.9010 -0.1566 -1.0724 -1.8878 -0.6238 -0.1957 -1.1338 -0.4358 -0.0779 -0.9321 -0.1661 -0.0329 -0.7125 -1.7443 -0.1778 -0.1289 -0.1463 -0.1525 -0.8297 -0.5408 -0.2521 -1.3684 -0.1287 -0.1549 -0.6085 -0.1488 -0.1529
S-63	Knochengewebe ist ein lebendes Gewebe , das ständig erneuert wird , indem altes Knochengewebe abgebaut und durch neues ersetzt wird .
T-63	Bone is a living tissue that is constantly renewed by a process that erodes old bone and replaces it with new bone at the same rate .
H-63	-0.4486351013183594	Bone tissue is living tissue that is continually renewed by breaking down old bone tissue and replacing it with new .
D-63	-0.4486351013183594	Bone tissue is living tissue that is continually renewed by breaking down old bone tissue and replacing it with new .
P-63	-0.2111 -0.2569 -0.6692 -0.1083 -1.7474 -0.0992 -0.2719 -0.1056 -0.8631 -0.8909 -0.3572 -0.3017 -1.2742 -0.0886 -0.7835 -0.1193 -0.8042 -0.1296 -0.5112 -0.1027 -0.1605 -0.2057 -0.5467 -0.1584
S-1864	Advexin hätte direkt in die Tumore gespritzt werden und so den Krebszellen ermöglichen sollen , das normale p53-Protein erneut zu bilden .
T-1864	Advexin was expected to be injected directly into the tumours , thus allowing the cancer cells to produce normal p53 protein again .
H-1864	-0.37066397070884705	Advexin should have been injected directly into the tumours , enabling cancer cells to reproduce the normal p53 protein .
D-1864	-0.37066397070884705	Advexin should have been injected directly into the tumours , enabling cancer cells to reproduce the normal p53 protein .
P-1864	-0.8170 -0.1771 -0.1369 -0.1458 -0.1907 -0.0781 -0.6303 -0.0808 -0.4439 -0.2378 -0.4572 -0.0513 -0.1419 -0.4009 -1.5246 -0.1318 -1.0535 -0.0994 -0.1335 -0.6342 -0.8364 -0.8322 -0.1110 -0.0993 -0.5794 -0.0537 -0.1436 -0.1563
S-18	Er wirkt durch Hemmung eines Enzyms , der so genannten Xanthinoxidase , das für die Harnsäureproduktion im Körper erforderlich ist .
T-18	It works by blocking an enzyme called xanthine oxidase , which is needed to make uric acid in the body .
H-18	-0.2200452834367752	It works by inhibiting an enzyme called xanthine oxidase , which is necessary for uric acid production in the body .
D-18	-0.2200452834367752	It works by inhibiting an enzyme called xanthine oxidase , which is necessary for uric acid production in the body .
P-18	-0.1390 -0.1382 -0.1281 -0.8669 -0.2971 -0.2781 -0.2093 -0.1504 -0.0770 -0.1453 -0.3358 -0.1944 -0.0732 -0.1706 -0.0426 -0.1939 -0.0773 -0.5748 -0.3052 -0.1028 -0.6433 -0.1760 -0.5535 -0.0699 -0.0632 -0.1489 -0.1508 -0.1315 -0.0678 -0.1627 -0.1536
S-1763	Dosis ( I.E. ) = Körpergewicht ( kg ) x erwünschter Faktor VIII-Anstieg ( % des Normalwertes ) x 0,5
T-1763	Dose ( IU ) = body weight ( kg ) x desired Factor VIII rise ( % of normal ) x 0.5
H-1763	-0.22717179358005524	dose ( IU ) = body weight ( kg ) x desired factor VIII-increase ( % of normal ) x 0.5
D-1763	-0.22717179358005524	dose ( IU ) = body weight ( kg ) x desired factor VIII-increase ( % of normal ) x 0.5
P-1763	-1.3845 -0.1356 -0.1182 -0.0746 -0.1299 -0.1348 -0.2837 -0.0835 -0.1382 -0.0639 -0.1362 -0.1496 -0.3358 -0.2900 -0.0978 -0.0723 -0.1535 -0.6964 -0.3892 -0.3263 -0.1366 -0.2012 -0.1467 -0.0616 -0.2359 -0.1864 -0.0551 -0.1432
S-1635	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1635	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1635	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-1635	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-1635	-0.0579 -0.0148 -0.0854 -0.1148 -0.0648 -0.1455 -0.0319 -0.0727 -0.0483 -0.0436 -0.1027 -0.1049 -0.0722 -0.0686 -0.0421 -0.1179 -0.2871 -0.0163 -0.0422 -0.0180 -0.0080 -0.0504 -0.1114 -0.0443 -0.0496 -0.3368 -0.0217 -0.0461 -0.0061 -0.0128 -0.0480 -0.0547 -0.1552
S-32	Adenuric war bei der Senkung des Harnsäurespiegels im Blut wirksamer als Allopurinol und Placebo .
T-32	Adenuric was more effective than allopurinol and placebo in reducing blood uric acid levels .
H-32	-0.2456093430519104	Adenuric was more effective in lowering uric acid levels in the blood than allopurinol and placebo .
D-32	-0.2456093430519104	Adenuric was more effective in lowering uric acid levels in the blood than allopurinol and placebo .
P-32	-0.1503 -0.1670 -0.0753 -0.1145 -0.8054 -0.1673 -0.2275 -2.0009 -0.3186 -0.0630 -0.3318 -0.0777 -0.1166 -0.5590 -0.1270 -0.1227 -0.0450 -0.1496 -0.2502 -0.1209 -0.1337 -0.1591 -0.1574 -0.0457 -0.1427 -0.0686 -0.1326 -0.1374 -0.1551
S-1807	- Die sonstigen Bestandteile sind Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid ,
T-1807	- The other ingredients are mannitol , sodium chloride , histidine , trehalose , calcium chloride ,
H-1807	-0.14667119085788727	- The other ingredients are mannitol , sodium chloride , histidine , trehalose , calcium chloride ,
D-1807	-0.14667119085788727	- The other ingredients are mannitol , sodium chloride , histidine , trehalose , calcium chloride ,
P-1807	-0.1995 -0.1887 -0.3042 -0.0779 -0.0979 -0.0404 -0.0830 -0.0917 -0.1463 -0.0865 -0.0601 -0.1234 -0.0990 -0.1225 -0.0910 -0.1478 -0.2070 -0.6406 -0.1839 -0.1471 -0.1137 -0.0925 -0.2833 -0.1464 -0.0999 -0.0692 -0.1410 -0.1440 -0.0869 -0.1065 -0.0935 -0.1494 -0.1755
S-1718	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1718	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1718	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-1718	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-1718	-0.0579 -0.0148 -0.0854 -0.1148 -0.0648 -0.1455 -0.0319 -0.0727 -0.0483 -0.0436 -0.1027 -0.1049 -0.0722 -0.0686 -0.0421 -0.1179 -0.2871 -0.0163 -0.0422 -0.0180 -0.0080 -0.0504 -0.1114 -0.0443 -0.0496 -0.3368 -0.0217 -0.0461 -0.0061 -0.0128 -0.0480 -0.0547 -0.1552
S-1955	Bei Patienten ab 60 Jahren ist die Wahrscheinlichkeit für das Auftreten von unerwünschten Ereignissen unter Sympathomimetika wie Pseudoephedrin höher .
T-1955	Patients of 60 years or older are more likely to experience adverse reactions to sympathomimetic medicinal products , such as pseudoephedrine .
H-1955	-0.2465190291404724	Patients over 60 years of age are more likely to experience adverse events with sympathomimetics such as pseudoephedrine .
D-1955	-0.2465190291404724	Patients over 60 years of age are more likely to experience adverse events with sympathomimetics such as pseudoephedrine .
P-1955	-0.2734 -0.0927 -1.2936 -0.2811 -0.1643 -0.1586 -0.1067 -0.2042 -0.2623 -0.1695 -0.1980 -0.4325 -0.0384 -0.0193 -0.1359 -1.5115 -0.1340 -0.0658 -0.0562 -0.1361 -0.1933 -0.1518 -0.1025 -0.5013 -0.1509 -0.0717 -0.1139 -0.1944 -0.1303 -0.1459 -0.1518
S-1834	Ireland Baxter Healthcare Ltd Unit 7 Deansgrange Industrial Estate IRL-Blackrock , Dublin Tel : <unk> 353 1 2065500
T-1834	Ireland Baxter Healthcare Ltd Unit 7 Deansgrange Industrial Estate IRL-Blackrock , Dublin Tel : <<unk>> 353 1 2065500
H-1834	-0.1395636647939682	Ireland Baxter Healthcare Ltd Unit 7 Deansgrange Industrial Estate IRL-Blackrock , Dublin Tel : <unk> 353 1 2065500
D-1834	-0.1395636647939682	Ireland Baxter Healthcare Ltd Unit 7 Deansgrange Industrial Estate IRL-Blackrock , Dublin Tel : <unk> 353 1 2065500
P-1834	-0.0490 -0.2456 -0.2145 -0.1429 -0.0573 -0.1218 -0.1392 -0.0293 -0.1311 -0.1842 -0.1437 -0.1639 -0.0799 -0.1260 -0.1016 -0.0604 -0.4152 -0.1880 -0.1307 -0.1301 -0.1938 -0.1879 -0.1546 -0.1691 -0.0506 -0.1395 -0.0394 -0.1265 -0.1021 -0.1555 -0.2537 -0.0935 -0.0775 -0.1471
S-1830	Pouet de Camilo , 2 E- 46394 Ribarroja del Turia ( Valencia ) Tel : <unk> 34 96 2722800
T-1830	Pouet de Camilo , 2 E- 46394 Ribarroja del Turia ( Valencia ) Tel : <<unk>> 34 96 2722800
H-1830	-0.1776263564825058	Pouet de Camilo , 2 E- 46394 Ribarroja del Turia ( Valencia ) Tel : <unk> 34 96 2722800
D-1830	-0.1776263564825058	Pouet de Camilo , 2 E- 46394 Ribarroja del Turia ( Valencia ) Tel : <unk> 34 96 2722800
P-1830	-0.1206 -0.0929 -0.1437 -0.1331 -0.2642 -0.1182 -0.1293 -0.1554 -0.1663 -1.1294 -0.2197 -0.1354 -0.1244 -0.2568 -0.2220 -0.2933 -0.1339 -0.0986 -0.2313 -0.1420 -0.0950 -0.1381 -0.3526 -0.1296 -0.0583 -0.1410 -0.0375 -0.1001 -0.1134 -0.0838 -0.1195 -0.0792 -0.1308 -0.1498
S-291	Bei Patienten mit einer glomerulären Filtrationsrate ( GFR ) über 35 ml<unk> min ist eine Dosisanpassung nicht erforderlich .
T-291	No dosage adjustment is necessary for patients with a glomerular filtration rate ( GFR ) greater than 35ml/ min .
H-291	-0.26761990785598755	No dose adjustment is necessary for patients with a glomerular filtration rate ( GFR ) exceeding 35 ml/ min .
D-291	-0.26761990785598755	No dose adjustment is necessary for patients with a glomerular filtration rate ( GFR ) exceeding 35 ml/ min .
P-291	-0.3434 -0.0455 -0.0654 -0.0760 -0.1195 -0.1391 -0.5570 -1.0375 -0.0737 -0.2316 -0.1661 -0.6455 -0.1155 -0.1116 -0.2748 -0.1273 -0.0889 -0.1291 -0.0756 -0.1313 -0.1604 -0.1957 -0.1380 -2.2955 -0.0879 -0.0867 -0.1872 -0.1746 -0.1316 -0.2232 -0.1767 -0.1518
S-103	Bei Patienten mit einer glomerulären Filtrationsrate ( GFR ) über 35 ml<unk> min ist eine Dosisanpassung nicht erforderlich .
T-103	No dosage adjustment is necessary for patients with a glomerular filtration rate ( GFR ) greater than 35ml/ min .
H-103	-0.26761990785598755	No dose adjustment is necessary for patients with a glomerular filtration rate ( GFR ) exceeding 35 ml/ min .
D-103	-0.26761990785598755	No dose adjustment is necessary for patients with a glomerular filtration rate ( GFR ) exceeding 35 ml/ min .
P-103	-0.3434 -0.0455 -0.0654 -0.0760 -0.1195 -0.1391 -0.5570 -1.0375 -0.0737 -0.2316 -0.1661 -0.6455 -0.1155 -0.1116 -0.2748 -0.1273 -0.0889 -0.1291 -0.0756 -0.1313 -0.1604 -0.1957 -0.1380 -2.2955 -0.0879 -0.0867 -0.1872 -0.1746 -0.1316 -0.2232 -0.1767 -0.1518
S-1968	Außerdem ist bei der Anwendung bei Patienten mit Migräne , die gleichzeitig mit gefäßverengenden Ergotalkaloiden behandelt werden , Vorsicht geboten .
T-1968	Caution should be exercised in patients suffering from migraine who are currently being treated with ergot alkaloid vasoconstrictors .
H-1968	-0.46504315733909607	Moreover , caution should be exercised in patients with migraine who are treated concomitantly with vasoconstricting ergotalkaloids .
D-1968	-0.46504315733909607	Moreover , caution should be exercised in patients with migraine who are treated concomitantly with vasoconstricting ergotalkaloids .
P-1968	-2.6192 -0.1498 -0.2874 -0.2663 -0.1591 -0.2597 -0.1028 -1.1593 -1.3150 -0.2077 -0.0878 -0.0224 -0.7708 -0.3439 -0.1508 -2.0345 -0.8779 -0.0996 -0.0191 -0.0854 -0.1555 -0.5393 -0.0476 -1.0531 -0.1642 -0.4561 -0.6357 -1.3524 -0.1488 -0.1364 -0.1345 -0.0557 -0.0853 -0.1422 -0.1512
S-1465	Bei Patienten unter 6 Jahren wird die Gabe von Dosen zwischen 20 und 50 I.E. Faktor VIII pro kg Körpergewicht 3 4 Mal wöchentlich empfohlen .
T-1465	In patients under the age of 6 , doses of 20 to 50 IU of factor VIII per kg body weight 3 to 4 times weekly are recommended .
H-1465	-0.2669689953327179	In patients under 6 years of age , doses between 20 and 50 IU of factor VIII per kg bodyweight 3 times weekly is recommended .
D-1465	-0.2669689953327179	In patients under 6 years of age , doses between 20 and 50 IU of factor VIII per kg bodyweight 3 times weekly is recommended .
P-1465	-0.2900 -0.1361 -0.8655 -0.2702 -0.0941 -0.1681 -0.1013 -0.3201 -0.5997 -0.1174 -0.4698 -0.1162 -0.1671 -0.1254 -0.1064 -0.1199 -0.2055 -0.2135 -0.1536 -0.1379 -0.1460 -0.0610 -0.5930 -0.0576 -0.1565 -0.4961 -0.8485 -0.7174 -0.1167 -0.1574 -0.1480
S-1797	Während der Laufzeit kann die Pulver-Durchstechflasche einmal für maximal 2 Monate bei Raumtemperatur ( bis zu 25 <unk> C ) aufbewahrt werden .
T-1797	During the shelf life the powder vial may be kept at room temperature ( up to 25<<unk>> C ) for a single period not exceeding 2 months .
H-1797	-0.35351449251174927	During runtime , the vial can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
D-1797	-0.35351449251174927	During runtime , the vial can be stored at room temperature ( up to 25 <unk> C ) for a maximum of 2 months .
P-1797	-0.9631 -2.1592 -0.1836 -0.5011 -0.1502 -2.2758 -0.0863 -0.2815 -0.1747 -0.4262 -0.1115 -0.3426 -0.0878 -0.1176 -0.1380 -0.2596 -0.1261 -0.1641 -0.1678 -0.1390 -0.1325 -0.1461 -0.1601 -0.0758 -0.1778 -0.2828 -0.1263 -0.1434 -0.1515
S-1651	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1651	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1651	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-1651	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-1651	-0.0579 -0.0148 -0.0854 -0.1148 -0.0648 -0.1455 -0.0319 -0.0727 -0.0483 -0.0436 -0.1027 -0.1049 -0.0722 -0.0686 -0.0421 -0.1179 -0.2871 -0.0163 -0.0422 -0.0180 -0.0080 -0.0504 -0.1114 -0.0443 -0.0496 -0.3368 -0.0217 -0.0461 -0.0061 -0.0128 -0.0480 -0.0547 -0.1552
S-1713	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1713	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1713	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-1713	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-1713	-0.0579 -0.0148 -0.0854 -0.1148 -0.0648 -0.1455 -0.0319 -0.0727 -0.0483 -0.0436 -0.1027 -0.1049 -0.0722 -0.0686 -0.0421 -0.1179 -0.2871 -0.0163 -0.0422 -0.0180 -0.0080 -0.0504 -0.1114 -0.0443 -0.0496 -0.3368 -0.0217 -0.0461 -0.0061 -0.0128 -0.0480 -0.0547 -0.1552
S-1701	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1701	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1701	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-1701	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-1701	-0.0579 -0.0148 -0.0854 -0.1148 -0.0648 -0.1455 -0.0319 -0.0727 -0.0483 -0.0436 -0.1027 -0.1049 -0.0722 -0.0686 -0.0421 -0.1179 -0.2871 -0.0163 -0.0422 -0.0180 -0.0080 -0.0504 -0.1114 -0.0443 -0.0496 -0.3368 -0.0217 -0.0461 -0.0061 -0.0128 -0.0480 -0.0547 -0.1552
S-1697	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1697	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1697	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-1697	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-1697	-0.0579 -0.0148 -0.0854 -0.1148 -0.0648 -0.1455 -0.0319 -0.0727 -0.0483 -0.0436 -0.1027 -0.1049 -0.0722 -0.0686 -0.0421 -0.1179 -0.2871 -0.0163 -0.0422 -0.0180 -0.0080 -0.0504 -0.1114 -0.0443 -0.0496 -0.3368 -0.0217 -0.0461 -0.0061 -0.0128 -0.0480 -0.0547 -0.1552
S-1685	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1685	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1685	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-1685	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-1685	-0.0579 -0.0148 -0.0854 -0.1148 -0.0648 -0.1455 -0.0319 -0.0727 -0.0483 -0.0436 -0.1027 -0.1049 -0.0722 -0.0686 -0.0421 -0.1179 -0.2871 -0.0163 -0.0422 -0.0180 -0.0080 -0.0504 -0.1114 -0.0443 -0.0496 -0.3368 -0.0217 -0.0461 -0.0061 -0.0128 -0.0480 -0.0547 -0.1552
S-1681	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1681	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1681	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-1681	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-1681	-0.0579 -0.0148 -0.0854 -0.1148 -0.0648 -0.1455 -0.0319 -0.0727 -0.0483 -0.0436 -0.1027 -0.1049 -0.0722 -0.0686 -0.0421 -0.1179 -0.2871 -0.0163 -0.0422 -0.0180 -0.0080 -0.0504 -0.1114 -0.0443 -0.0496 -0.3368 -0.0217 -0.0461 -0.0061 -0.0128 -0.0480 -0.0547 -0.1552
S-1669	BEZEICHNUNG DES ARZNEIMITTELS SOWIE ART<unk> EN ) DER ANWENDUNG
T-1669	NAME OF THE MEDICINAL PRODUCT AND ROUTE<<unk>> S ) OF ADMINISTRATION
H-1669	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
D-1669	-0.07565493881702423	NAME OF THE MEDICINAL PRODUCT AND ROUTE<unk> S ) OF ADMINISTRATION
P-1669	-0.0579 -0.0148 -0.0854 -0.1148 -0.0648 -0.1455 -0.0319 -0.0727 -0.0483 -0.0436 -0.1027 -0.1049 -0.0722 -0.0686 -0.0421 -0.1179 -0.2871 -0.0163 -0.0422 -0.0180 -0.0080 -0.0504 -0.1114 -0.0443 -0.0496 -0.3368 -0.0217 -0.0461 -0.0061 -0.0128 -0.0480 -0.0547 -0.1552
S-1108	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-1108	Under certain circumstances ( e. g. presence of a low-titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-1108	-0.2800309658050537	In some circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
D-1108	-0.2800309658050537	In some circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
P-1108	-0.7083 -0.6886 -0.1668 -0.1670 -0.2220 -0.0956 -0.0772 -0.9152 -0.1550 -0.1980 -0.3226 -0.0877 -0.0787 -0.0782 -0.3036 -0.1883 -0.8193 -0.1383 -0.5256 -0.1523 -0.0945 -0.5519 -0.0254 -0.2477 -0.1148 -0.8239 -0.2149 -0.4337 -0.0946 -0.1526 -0.0920 -0.1563 -0.1501
S-335	In klinischen Studien erhielten mehrere Patientinnen Östrogen ( intravaginal , transdermal oder oral ) gemeinsam mit Alendronat .
T-335	A number of patients in the clinical trials received oestrogen ( intravaginal , transdermal , or oral ) while taking alendronate .
H-335	-0.2335280328989029	In clinical trials , several patients were receiving estrogen ( intravaginal , transdermal or oral ) concomitantly with alendronate .
D-335	-0.2335280328989029	In clinical trials , several patients were receiving estrogen ( intravaginal , transdermal or oral ) concomitantly with alendronate .
P-335	-0.2037 -0.1044 -0.0726 -0.2174 -0.4980 -0.1328 -0.9048 -0.0392 -0.4178 -0.1324 -0.0741 -0.1407 -0.1626 -0.9490 -0.1230 -0.0911 -0.1487 -0.0369 -0.2283 -0.1981 -0.2734 -0.1061 -0.1441 -1.1570 -0.0175 -0.0112 -0.4817 -0.1270 -0.1337 -0.1476 -0.1298 -0.0479 -0.1390 -0.1487
S-582	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-582	Under certain circumstances ( e. g. presence of a low-titre inhibitor ) , doses larger than those calculated using the formula may be necessary .
H-582	-0.2800309658050537	In some circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
D-582	-0.2800309658050537	In some circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
P-582	-0.7083 -0.6886 -0.1668 -0.1670 -0.2220 -0.0956 -0.0772 -0.9152 -0.1550 -0.1980 -0.3226 -0.0877 -0.0787 -0.0782 -0.3036 -0.1883 -0.8193 -0.1383 -0.5256 -0.1523 -0.0945 -0.5519 -0.0254 -0.2477 -0.1148 -0.8239 -0.2149 -0.4337 -0.0946 -0.1526 -0.0920 -0.1563 -0.1501
S-369	Wegen des Risikos einer ösophagealen Irritation sollten keine Maßnahmen zum Erbrechen eingeleitet werden und der Patient sollte sich vollständig aufrecht halten .
T-369	Owing to the risk of oesophageal irritation , vomiting should not be induced and the patient should remain fully upright .
H-369	-0.3432529866695404	Due to the risk of oesophageal irritation , vomiting should not be initiated and the patient should remain upright .
D-369	-0.3432529866695404	Due to the risk of oesophageal irritation , vomiting should not be initiated and the patient should remain upright .
P-369	-1.9418 -0.0674 -0.1317 -0.1364 -0.1016 -0.1708 -0.4972 -0.0374 -0.1157 -0.0510 -0.0874 -0.1466 -0.0583 -0.1321 -0.2846 -1.4522 -0.0701 -0.1094 -0.1870 -0.1865 -0.1480 -1.0252 -0.1149 -0.1236 -0.1488 -0.0759 -0.1096 -1.0164 -1.7744 -0.1347 -0.1141 -0.4225 -0.1537
S-620	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-620	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-620	-0.22597359120845795	As with any intravenous protein , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
D-620	-0.22597359120845795	As with any intravenous protein , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
P-620	-0.5056 -0.4339 -0.3371 -0.4861 -0.0832 -0.0887 -0.5561 -0.1151 -0.1686 -0.3559 -0.0660 -0.4230 -0.3944 -0.0306 -0.0377 -0.0349 -0.0702 -0.6639 -0.0235 -0.1300 -0.3242 -0.1107 -0.1131 -0.1256 -0.1349 -0.1375 -0.1507
S-181	Wegen des Risikos einer ösophagealen Irritation sollten keine Maßnahmen zum Erbrechen eingeleitet werden und der Patient sollte sich vollständig aufrecht halten .
T-181	Owing to the risk of oesophageal irritation , vomiting should not be induced and the patient should remain fully upright .
H-181	-0.3432529866695404	Due to the risk of oesophageal irritation , vomiting should not be initiated and the patient should remain upright .
D-181	-0.3432529866695404	Due to the risk of oesophageal irritation , vomiting should not be initiated and the patient should remain upright .
P-181	-1.9418 -0.0674 -0.1317 -0.1364 -0.1016 -0.1708 -0.4972 -0.0374 -0.1157 -0.0510 -0.0874 -0.1466 -0.0583 -0.1321 -0.2846 -1.4522 -0.0701 -0.1094 -0.1870 -0.1865 -0.1480 -1.0252 -0.1149 -0.1236 -0.1488 -0.0759 -0.1096 -1.0164 -1.7744 -0.1347 -0.1141 -0.4225 -0.1537
S-147	In klinischen Studien erhielten mehrere Patientinnen Östrogen ( intravaginal , transdermal oder oral ) gemeinsam mit Alendronat .
T-147	A number of patients in the clinical trials received oestrogen ( intravaginal , transdermal , or oral ) while taking alendronate .
H-147	-0.2335280328989029	In clinical trials , several patients were receiving estrogen ( intravaginal , transdermal or oral ) concomitantly with alendronate .
D-147	-0.2335280328989029	In clinical trials , several patients were receiving estrogen ( intravaginal , transdermal or oral ) concomitantly with alendronate .
P-147	-0.2037 -0.1044 -0.0726 -0.2174 -0.4980 -0.1328 -0.9048 -0.0392 -0.4178 -0.1324 -0.0741 -0.1407 -0.1626 -0.9490 -0.1230 -0.0911 -0.1487 -0.0369 -0.2283 -0.1981 -0.2734 -0.1061 -0.1441 -1.1570 -0.0175 -0.0112 -0.4817 -0.1270 -0.1337 -0.1476 -0.1298 -0.0479 -0.1390 -0.1487
S-1832	103 France Baxter SAS 6 Avenue Louis PasteurF-78310 Maurepas Tél : <unk> 33 1 3461 5050
T-1832	97 France Baxter SAS 6 Avenue Louis PasteurF-78310 Maurepas Tél : <<unk>> 33 1 3461 5050
H-1832	-0.1412344127893448	103 France Baxter SAS 6 Avenue Louis PasteurF-78310 Maurepas Tél : <unk> 33 1 3461 5050
D-1832	-0.1412344127893448	103 France Baxter SAS 6 Avenue Louis PasteurF-78310 Maurepas Tél : <unk> 33 1 3461 5050
P-1832	-0.5242 -0.0873 -0.2435 -0.1340 -0.1358 -0.1178 -0.0856 -0.1285 -0.0464 -0.2150 -0.1674 -0.0928 -0.1076 -0.0964 -0.1167 -0.1134 -0.1544 -0.2578 -0.1488 -0.1372 -0.1385 -0.0661 -0.1207 -0.1399 -0.0366 -0.1148 -0.1570 -0.1453 -0.1180 -0.1362 -0.0995 -0.1276 -0.1498
S-1538	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-1538	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-1538	-0.24613764882087708	Activated factor VIII acts as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.
D-1538	-0.24613764882087708	Activated factor VIII acts as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.
P-1538	-1.7472 -0.1259 -0.1279 -0.2672 -0.1483 -0.1498 -0.1104 -0.1446 -0.2270 -0.1578 -0.0500 -0.1951 -0.2432 -0.1246 -0.0741 -0.1245 -0.1191 -0.2480 -0.9578 -0.1069 -0.1257 -0.2496 -0.1484 -0.2201 -0.1207 -0.0714 -0.0803 -0.4528 -0.1447 -0.5306 -0.1201 -0.1629
S-1460	Unter bestimmten Umständen ( z. B. Anwesenheit eines niedrigen Inhibitortiters ) können höhere Dosierungen als die mit der Formel berechneten notwendig sein .
T-1460	Under certain circumstances ( e. g. presence of a low titre inhibitor ) doses larger than those calculated using the formula may be necessary .
H-1460	-0.2800309658050537	In some circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
D-1460	-0.2800309658050537	In some circumstances ( e. g. presence of a low inhibitor titer ) higher doses than those calculated with the formula may be necessary .
P-1460	-0.7083 -0.6886 -0.1668 -0.1670 -0.2220 -0.0956 -0.0772 -0.9152 -0.1550 -0.1980 -0.3226 -0.0877 -0.0787 -0.0782 -0.3036 -0.1883 -0.8193 -0.1383 -0.5256 -0.1523 -0.0945 -0.5519 -0.0254 -0.2477 -0.1148 -0.8239 -0.2149 -0.4337 -0.0946 -0.1526 -0.0920 -0.1563 -0.1501
S-256	Es wurden keine Hinweise auf eine Sättigung der Aufnahmefähigkeit des Knochens nach Langzeitdosierung von kumulativen intravenösen Dosen bis zu
T-256	No evidence of saturation of bone uptake was found after chronic dosing with cumulative intravenous doses up to 35 mg/ kg in animals .
H-256	-0.387285053730011	No evidence of saturation of bone absorption after long term doses of cumulative intravenous doses to
D-256	-0.387285053730011	No evidence of saturation of bone absorption after long term doses of cumulative intravenous doses to
P-256	-0.4424 -0.0197 -0.7096 -2.8287 -0.0768 -0.1445 -0.1501 -0.3334 -0.5193 -0.1171 -0.9431 -1.0486 -0.3081 -0.1203 -0.2504 -0.7570 -0.1697 -0.0680 -0.1465 -0.1573 -0.0884 -0.0895 -0.1190 -0.1358 -0.0669 -0.5003 -0.1464
S-1449	Tabelle 1 : Dosierungsanleitung bei Blutungsereignissen und Operationen Grad der Blutung / Art des chirurgischen Eingriffes Blutung
T-1449	Table 1 Guide for dosing in bleeding episodes and surgery Degree of haemorrhage/ type of surgical procedure Haemorrhage
H-1449	-0.5808080434799194	Table 1 : Dosage regimen for haemorrhage events and surgery Grade of haemorrhage / type of surgery Haemorrhage
D-1449	-0.5808080434799194	Table 1 : Dosage regimen for haemorrhage events and surgery Grade of haemorrhage / type of surgery Haemorrhage
P-1449	-0.1512 -0.1582 -0.1465 -0.8091 -0.0735 -0.0886 -2.1188 -0.4836 -0.1579 -0.9148 -0.8755 -0.0659 -0.1723 -0.0993 -0.1456 -1.9727 -2.9151 -0.1187 -0.1465 -1.5718 -0.3055 -0.0166 -0.1188 -0.1385 -1.7940 -0.1433 -0.0641 -2.0331 -0.4618 -0.0266 -0.1466 -0.1514
S-794	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-794	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-794	-0.22597359120845795	As with any intravenous protein , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
D-794	-0.22597359120845795	As with any intravenous protein , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
P-794	-0.5056 -0.4339 -0.3371 -0.4861 -0.0832 -0.0887 -0.5561 -0.1151 -0.1686 -0.3559 -0.0660 -0.4230 -0.3944 -0.0306 -0.0377 -0.0349 -0.0702 -0.6639 -0.0235 -0.1300 -0.3242 -0.1107 -0.1131 -0.1256 -0.1349 -0.1375 -0.1507
S-1188	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-1188	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-1188	-0.48017334938049316	Haemophilia A is a gender inherited blood clotting disorder due to decreased Factor VIII-levels .
D-1188	-0.48017334938049316	Haemophilia A is a gender inherited blood clotting disorder due to decreased Factor VIII-levels .
P-1188	-0.3443 -0.0435 -0.1484 -0.2668 -0.1327 -0.1143 -0.1737 -1.0770 -1.5810 -0.1828 -0.1441 -0.3594 -0.0283 -0.0874 -0.1368 -1.4083 -0.1425 -1.6236 -0.0590 -1.2816 -0.5882 -0.1437 -1.2446 -0.7477 -0.5955 -0.1540 -0.1556
S-836	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-836	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-836	-0.48017334938049316	Haemophilia A is a gender inherited blood clotting disorder due to decreased Factor VIII-levels .
D-836	-0.48017334938049316	Haemophilia A is a gender inherited blood clotting disorder due to decreased Factor VIII-levels .
P-836	-0.3443 -0.0435 -0.1484 -0.2668 -0.1327 -0.1143 -0.1737 -1.0770 -1.5810 -0.1828 -0.1441 -0.3594 -0.0283 -0.0874 -0.1368 -1.4083 -0.1425 -1.6236 -0.0590 -1.2816 -0.5882 -0.1437 -1.2446 -0.7477 -0.5955 -0.1540 -0.1556
S-1789	100 Anschwellen von Füßen und Beinen , erhöhte Leberenzyme , Hämatokritabfall und Schmerzen im Oberbauch oder unteren Brustbereich
T-1789	94 itching , increased sweating , unusual taste in the mouth , hot flushes , migraines , memory impairment , chills , diarrhoea , nausea , vomiting , shortness of breath , sore throat , infection of the lymphatic vessels , whitening of skin , eye inflammation , rashes , excessive sweating , foot and leg swelling , increase in enzymes that track liver function , reduced percentage of red blood cells and pain in the upper abdomen or lower chest .
H-1789	-0.42433875799179077	foot and leg swelling , increased liver enzymes , haematocrit loss and upper or lower chest pain
D-1789	-0.42433875799179077	foot and leg swelling , increased liver enzymes , haematocrit loss and upper or lower chest pain
P-1789	-1.5936 -0.1701 -0.4021 -0.0458 -0.0901 -0.1373 -0.2816 -0.0876 -0.0419 -0.0570 -0.1348 -0.1424 -1.1106 -0.1035 -0.0585 -0.1953 -0.1293 -1.0296 -1.9946 -0.4879 -0.7764 -1.5159 -0.1033 -0.1437 -0.0555 -0.1445
S-1541	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-1541	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-1541	-0.48017334938049316	Haemophilia A is a gender inherited blood clotting disorder due to decreased Factor VIII-levels .
D-1541	-0.48017334938049316	Haemophilia A is a gender inherited blood clotting disorder due to decreased Factor VIII-levels .
P-1541	-0.3443 -0.0435 -0.1484 -0.2668 -0.1327 -0.1143 -0.1737 -1.0770 -1.5810 -0.1828 -0.1441 -0.3594 -0.0283 -0.0874 -0.1368 -1.4083 -0.1425 -1.6236 -0.0590 -1.2816 -0.5882 -0.1437 -1.2446 -0.7477 -0.5955 -0.1540 -0.1556
S-1364	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-1364	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-1364	-0.48017334938049316	Haemophilia A is a gender inherited blood clotting disorder due to decreased Factor VIII-levels .
D-1364	-0.48017334938049316	Haemophilia A is a gender inherited blood clotting disorder due to decreased Factor VIII-levels .
P-1364	-0.3443 -0.0435 -0.1484 -0.2668 -0.1327 -0.1143 -0.1737 -1.0770 -1.5810 -0.1828 -0.1441 -0.3594 -0.0283 -0.0874 -0.1368 -1.4083 -0.1425 -1.6236 -0.0590 -1.2816 -0.5882 -0.1437 -1.2446 -0.7477 -0.5955 -0.1540 -0.1556
S-970	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-970	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-970	-0.22597359120845795	As with any intravenous protein , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
D-970	-0.22597359120845795	As with any intravenous protein , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
P-970	-0.5056 -0.4339 -0.3371 -0.4861 -0.0832 -0.0887 -0.5561 -0.1151 -0.1686 -0.3559 -0.0660 -0.4230 -0.3944 -0.0306 -0.0377 -0.0349 -0.0702 -0.6639 -0.0235 -0.1300 -0.3242 -0.1107 -0.1131 -0.1256 -0.1349 -0.1375 -0.1507
S-1012	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-1012	Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII activity and results in profuse bleeding into joints , muscles or internal organs , either
H-1012	-0.48017334938049316	Haemophilia A is a gender inherited blood clotting disorder due to decreased Factor VIII-levels .
D-1012	-0.48017334938049316	Haemophilia A is a gender inherited blood clotting disorder due to decreased Factor VIII-levels .
P-1012	-0.3443 -0.0435 -0.1484 -0.2668 -0.1327 -0.1143 -0.1737 -1.0770 -1.5810 -0.1828 -0.1441 -0.3594 -0.0283 -0.0874 -0.1368 -1.4083 -0.1425 -1.6236 -0.0590 -1.2816 -0.5882 -0.1437 -1.2446 -0.7477 -0.5955 -0.1540 -0.1556
S-1146	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-1146	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-1146	-0.22597359120845795	As with any intravenous protein , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
D-1146	-0.22597359120845795	As with any intravenous protein , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
P-1146	-0.5056 -0.4339 -0.3371 -0.4861 -0.0832 -0.0887 -0.5561 -0.1151 -0.1686 -0.3559 -0.0660 -0.4230 -0.3944 -0.0306 -0.0377 -0.0349 -0.0702 -0.6639 -0.0235 -0.1300 -0.3242 -0.1107 -0.1131 -0.1256 -0.1349 -0.1375 -0.1507
S-661	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel .
T-661	Hämophilie A ist eine geschlechtsgebundene , erbliche Störung der Blutgerinnung aufgrund erniedrigter Faktor VIII-Spiegel . The plasma levels of factor VIII are
H-661	-0.48017334938049316	Haemophilia A is a gender inherited blood clotting disorder due to decreased Factor VIII-levels .
D-661	-0.48017334938049316	Haemophilia A is a gender inherited blood clotting disorder due to decreased Factor VIII-levels .
P-661	-0.3443 -0.0435 -0.1484 -0.2668 -0.1327 -0.1143 -0.1737 -1.0770 -1.5810 -0.1828 -0.1441 -0.3594 -0.0283 -0.0874 -0.1368 -1.4083 -0.1425 -1.6236 -0.0590 -1.2816 -0.5882 -0.1437 -1.2446 -0.7477 -0.5955 -0.1540 -0.1556
S-1498	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-1498	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-1498	-0.22597359120845795	As with any intravenous protein , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
D-1498	-0.22597359120845795	As with any intravenous protein , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
P-1498	-0.5056 -0.4339 -0.3371 -0.4861 -0.0832 -0.0887 -0.5561 -0.1151 -0.1686 -0.3559 -0.0660 -0.4230 -0.3944 -0.0306 -0.0377 -0.0349 -0.0702 -0.6639 -0.0235 -0.1300 -0.3242 -0.1107 -0.1131 -0.1256 -0.1349 -0.1375 -0.1507
S-1322	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) .
T-1322	Wie bei jedem intravenös zu verabreichenden Protein sind Überempfindlichkeitsreaktionen vom allergischen Typ möglich ( siehe Abschnitt 4.4 ) . ( see section 4.4 ) .
H-1322	-0.22597359120845795	As with any intravenous protein , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
D-1322	-0.22597359120845795	As with any intravenous protein , allergic type hypersensitivity reactions may occur ( see section 4.4 ) .
P-1322	-0.5056 -0.4339 -0.3371 -0.4861 -0.0832 -0.0887 -0.5561 -0.1151 -0.1686 -0.3559 -0.0660 -0.4230 -0.3944 -0.0306 -0.0377 -0.0349 -0.0702 -0.6639 -0.0235 -0.1300 -0.3242 -0.1107 -0.1131 -0.1256 -0.1349 -0.1375 -0.1507
S-1361	Der aktivierte Faktor VIII wirkt als Cofaktor für den aktivierten Faktor IX und beschleunigt die Bildung von aktiviertem Faktor X aus Faktor X.
T-1361	Activated factor VIII acts as a Cofactor for activated Factor IX , accelerating the conversion of Factor X to activated Factor X.
H-1361	-0.24613764882087708	Activated factor VIII acts as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.
D-1361	-0.24613764882087708	Activated factor VIII acts as a cofactor for activated factor IX and accelerates the formation of activated factor X from factor X.
P-1361	-1.7472 -0.1259 -0.1279 -0.2672 -0.1483 -0.1498 -0.1104 -0.1446 -0.2270 -0.1578 -0.0500 -0.1951 -0.2432 -0.1246 -0.0741 -0.1245 -0.1191 -0.2480 -0.9578 -0.1069 -0.1257 -0.2496 -0.1484 -0.2201 -0.1207 -0.0714 -0.0803 -0.4528 -0.1447 -0.5306 -0.1201 -0.1629
S-688	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-688	Advate is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-688	-0.2815020680427551	ADVATE is administered intravenously for injections after the lyophilised product has dissolved with the sterilised water provided .
D-688	-0.2815020680427551	ADVATE is administered intravenously for injections after the lyophilised product has dissolved with the sterilised water provided .
P-688	-0.5476 -0.1483 -0.0787 -0.1084 -0.1262 -0.5930 -0.0858 -0.2141 -0.0817 -0.0681 -0.0958 -0.1370 -0.0855 -0.1326 -0.5519 -0.9368 -0.7857 -0.2378 -0.1319 -0.1319 -0.1120 -0.9877 -0.3298 -0.0564 -0.0605 -0.3526 -0.1787 -0.5685 -0.1250 -0.0819 -0.2192 -0.8663 -0.2036 -0.1505
S-1040	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-1040	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-1040	-0.2815020680427551	ADVATE is administered intravenously for injections after the lyophilised product has dissolved with the sterilised water provided .
D-1040	-0.2815020680427551	ADVATE is administered intravenously for injections after the lyophilised product has dissolved with the sterilised water provided .
P-1040	-0.5476 -0.1483 -0.0787 -0.1084 -0.1262 -0.5930 -0.0858 -0.2141 -0.0817 -0.0681 -0.0958 -0.1370 -0.0855 -0.1326 -0.5519 -0.9368 -0.7857 -0.2378 -0.1319 -0.1319 -0.1120 -0.9877 -0.3298 -0.0564 -0.0605 -0.3526 -0.1787 -0.5685 -0.1250 -0.0819 -0.2192 -0.8663 -0.2036 -0.1505
S-864	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-864	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-864	-0.2815020680427551	ADVATE is administered intravenously for injections after the lyophilised product has dissolved with the sterilised water provided .
D-864	-0.2815020680427551	ADVATE is administered intravenously for injections after the lyophilised product has dissolved with the sterilised water provided .
P-864	-0.5476 -0.1483 -0.0787 -0.1084 -0.1262 -0.5930 -0.0858 -0.2141 -0.0817 -0.0681 -0.0958 -0.1370 -0.0855 -0.1326 -0.5519 -0.9368 -0.7857 -0.2378 -0.1319 -0.1319 -0.1120 -0.9877 -0.3298 -0.0564 -0.0605 -0.3526 -0.1787 -0.5685 -0.1250 -0.0819 -0.2192 -0.8663 -0.2036 -0.1505
S-27	In der zweiten Studie wurden zwei Dosierungen von Adenuric ( einmal täglich 80 und 120 mg ) ein Jahr lang an 762 Patienten jeweils mit Allopurinol verglichen .
T-27	The second study compared two doses of Adenuric ( 80 and 120 mg once a day ) with allopurinol over one year in 762 patients .
H-27	-0.2759298086166382	In the second study , two doses of Adenuric ( 80 and 120 mg once daily ) for one year were compared to allopurinol in 762 patients .
D-27	-0.2759298086166382	In the second study , two doses of Adenuric ( 80 and 120 mg once daily ) for one year were compared to allopurinol in 762 patients .
P-27	-0.8969 -0.1519 -0.0496 -0.8750 -0.2705 -0.2884 -0.1207 -0.0752 -0.1505 -0.9104 -0.1843 -0.0901 -0.1148 -0.1499 -0.6291 -0.1356 -0.0810 -0.0440 -0.4763 -0.5753 -0.4621 -0.5023 -0.2338 -0.1334 -0.6981 -0.1651 -0.2698 -0.3018 -0.1556 -0.1293 -0.1433 -0.1482 -0.0910 -0.0716 -0.0726 -0.2126 -0.1491
S-1216	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-1216	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-1216	-0.2815020680427551	ADVATE is administered intravenously for injections after the lyophilised product has dissolved with the sterilised water provided .
D-1216	-0.2815020680427551	ADVATE is administered intravenously for injections after the lyophilised product has dissolved with the sterilised water provided .
P-1216	-0.5476 -0.1483 -0.0787 -0.1084 -0.1262 -0.5930 -0.0858 -0.2141 -0.0817 -0.0681 -0.0958 -0.1370 -0.0855 -0.1326 -0.5519 -0.9368 -0.7857 -0.2378 -0.1319 -0.1319 -0.1120 -0.9877 -0.3298 -0.0564 -0.0605 -0.3526 -0.1787 -0.5685 -0.1250 -0.0819 -0.2192 -0.8663 -0.2036 -0.1505
S-519	Die Dosierung und Häufigkeit der Anwendung richten sich danach , ob Advate zur Behandlung von Blutungen oder zur Vorbeugung von Blutungen bei chirurgischen Eingriffen angewendet wird .
T-519	The dose and frequency depend on whether Advate is used to treat haemorrhage ( bleeding ) or to prevent it during surgery .
H-519	-0.33152052760124207	The dosage and frequency of administration will vary with whether Advate is used to treat haemorrhage or to prevent haemorrhage during surgery .
D-519	-0.33152052760124207	The dosage and frequency of administration will vary with whether Advate is used to treat haemorrhage or to prevent haemorrhage during surgery .
P-519	-0.6700 -0.3761 -0.1310 -0.0947 -0.1245 -0.0913 -0.0883 -0.1643 -0.6039 -0.8594 -0.9431 -0.0722 -0.4902 -0.7529 -0.6014 -0.0780 -0.1227 -0.1167 -0.1478 -0.0990 -1.0873 -0.3945 -0.0194 -0.2711 -0.1537 -0.1237 -0.1296 -1.0479 -0.3154 -0.0188 -0.2034 -0.8244 -0.0926 -0.1391 -0.1548
S-1229	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-1229	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-1229	-0.5193436741828918	Open the package contents of the BAXJECT II by peeling off the protective foil ( Fig . A ) .
D-1229	-0.5193436741828918	Open the package contents of the BAXJECT II by peeling off the protective foil ( Fig . A ) .
P-1229	-2.1615 -0.1594 -2.4430 -0.2373 -0.0828 -0.3730 -0.7268 -0.2045 -0.1832 -0.3094 -0.0599 -0.2236 -0.0992 -0.1006 -2.6544 -0.2264 -0.5747 -0.1598 -0.2525 -1.2732 -0.1169 -0.2441 -1.2500 -0.1337 -0.2222 -0.1442 -0.1272 -0.1585 -0.1588
S-1053	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-1053	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-1053	-0.5193436741828918	Open the package contents of the BAXJECT II by peeling off the protective foil ( Fig . A ) .
D-1053	-0.5193436741828918	Open the package contents of the BAXJECT II by peeling off the protective foil ( Fig . A ) .
P-1053	-2.1615 -0.1594 -2.4430 -0.2373 -0.0828 -0.3730 -0.7268 -0.2045 -0.1832 -0.3094 -0.0599 -0.2236 -0.0992 -0.1006 -2.6544 -0.2264 -0.5747 -0.1598 -0.2525 -1.2732 -0.1169 -0.2441 -1.2500 -0.1337 -0.2222 -0.1442 -0.1272 -0.1585 -0.1588
S-1292	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-1292	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-1292	-0.39917147159576416	In patients with high inhibitors , Factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
D-1292	-0.39917147159576416	In patients with high inhibitors , Factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
P-1292	-0.3881 -0.1292 -0.3038 -0.4448 -0.4200 -0.0706 -0.0322 -0.7663 -0.3059 -1.3048 -0.6435 -0.2655 -1.2718 -0.2950 -0.0863 -0.3037 -0.1557 -0.1180 -0.2304 -0.2544 -0.0718 -0.0842 -1.0302 -1.5514 -0.7667 -0.1287 -0.1529 -0.0955 -0.1475 -0.1562
S-701	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-701	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-701	-0.5193436741828918	Open the package contents of the BAXJECT II by peeling off the protective foil ( Fig . A ) .
D-701	-0.5193436741828918	Open the package contents of the BAXJECT II by peeling off the protective foil ( Fig . A ) .
P-701	-2.1615 -0.1594 -2.4430 -0.2373 -0.0828 -0.3730 -0.7268 -0.2045 -0.1832 -0.3094 -0.0599 -0.2236 -0.0992 -0.1006 -2.6544 -0.2264 -0.5747 -0.1598 -0.2525 -1.2732 -0.1169 -0.2441 -1.2500 -0.1337 -0.2222 -0.1442 -0.1272 -0.1585 -0.1588
S-590	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-590	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-590	-0.39917147159576416	In patients with high inhibitors , Factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
D-590	-0.39917147159576416	In patients with high inhibitors , Factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
P-590	-0.3881 -0.1292 -0.3038 -0.4448 -0.4200 -0.0706 -0.0322 -0.7663 -0.3059 -1.3048 -0.6435 -0.2655 -1.2718 -0.2950 -0.0863 -0.3037 -0.1557 -0.1180 -0.2304 -0.2544 -0.0718 -0.0842 -1.0302 -1.5514 -0.7667 -0.1287 -0.1529 -0.0955 -0.1475 -0.1562
S-1116	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-1116	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-1116	-0.39917147159576416	In patients with high inhibitors , Factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
D-1116	-0.39917147159576416	In patients with high inhibitors , Factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
P-1116	-0.3881 -0.1292 -0.3038 -0.4448 -0.4200 -0.0706 -0.0322 -0.7663 -0.3059 -1.3048 -0.6435 -0.2655 -1.2718 -0.2950 -0.0863 -0.3037 -0.1557 -0.1180 -0.2304 -0.2544 -0.0718 -0.0842 -1.0302 -1.5514 -0.7667 -0.1287 -0.1529 -0.0955 -0.1475 -0.1562
S-1582	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-1582	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-1582	-0.5193436741828918	Open the package contents of the BAXJECT II by peeling off the protective foil ( Fig . A ) .
D-1582	-0.5193436741828918	Open the package contents of the BAXJECT II by peeling off the protective foil ( Fig . A ) .
P-1582	-2.1615 -0.1594 -2.4430 -0.2373 -0.0828 -0.3730 -0.7268 -0.2045 -0.1832 -0.3094 -0.0599 -0.2236 -0.0992 -0.1006 -2.6544 -0.2264 -0.5747 -0.1598 -0.2525 -1.2732 -0.1169 -0.2441 -1.2500 -0.1337 -0.2222 -0.1442 -0.1272 -0.1585 -0.1588
S-940	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-940	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-940	-0.39917147159576416	In patients with high inhibitors , Factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
D-940	-0.39917147159576416	In patients with high inhibitors , Factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
P-940	-0.3881 -0.1292 -0.3038 -0.4448 -0.4200 -0.0706 -0.0322 -0.7663 -0.3059 -1.3048 -0.6435 -0.2655 -1.2718 -0.2950 -0.0863 -0.3037 -0.1557 -0.1180 -0.2304 -0.2544 -0.0718 -0.0842 -1.0302 -1.5514 -0.7667 -0.1287 -0.1529 -0.0955 -0.1475 -0.1562
S-877	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-877	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-877	-0.5193436741828918	Open the package contents of the BAXJECT II by peeling off the protective foil ( Fig . A ) .
D-877	-0.5193436741828918	Open the package contents of the BAXJECT II by peeling off the protective foil ( Fig . A ) .
P-877	-2.1615 -0.1594 -2.4430 -0.2373 -0.0828 -0.3730 -0.7268 -0.2045 -0.1832 -0.3094 -0.0599 -0.2236 -0.0992 -0.1006 -2.6544 -0.2264 -0.5747 -0.1598 -0.2525 -1.2732 -0.1169 -0.2441 -1.2500 -0.1337 -0.2222 -0.1442 -0.1272 -0.1585 -0.1588
S-764	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-764	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-764	-0.39917147159576416	In patients with high inhibitors , Factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
D-764	-0.39917147159576416	In patients with high inhibitors , Factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
P-764	-0.3881 -0.1292 -0.3038 -0.4448 -0.4200 -0.0706 -0.0322 -0.7663 -0.3059 -1.3048 -0.6435 -0.2655 -1.2718 -0.2950 -0.0863 -0.3037 -0.1557 -0.1180 -0.2304 -0.2544 -0.0718 -0.0842 -1.0302 -1.5514 -0.7667 -0.1287 -0.1529 -0.0955 -0.1475 -0.1562
S-1947	Es wird empfohlen , die Anwendungsdauer auf 10 Tage zu begrenzen , da bei Langzeitanwendung die Aktivität von Pseudoephedrin mit der Zeit abnehmen kann .
T-1947	It is advisable to limit treatment to about 10 days , as during chronic administration the activity of pseudoephedrine may diminish .
H-1947	-0.2866402268409729	It is recommended that the duration of administration is limited to 10 days , as long-term use may reduce the activity of pseudoephedrine over time .
D-1947	-0.2866402268409729	It is recommended that the duration of administration is limited to 10 days , as long-term use may reduce the activity of pseudoephedrine over time .
P-1947	-0.2732 -0.1279 -0.0980 -0.5449 -0.1953 -0.2975 -0.1242 -0.1344 -0.2915 -1.1637 -0.1771 -0.1482 -0.1518 -0.1432 -0.5941 -1.0710 -0.4627 -0.3211 -0.0598 -0.0774 -0.1117 -0.7796 -0.9236 -0.1640 -0.1495 -0.1085 -0.4014 -0.1603 -0.0811 -0.1238 -0.1271 -0.1297 -0.2181 -0.0915 -0.1370 -0.1552
S-1956	Die Sicherheit und die Wirksamkeit dieser Kombinationstherapie wurden für dieses Patientenkollektiv nicht geprüft und die Daten reichen nicht aus , um entsprechende Empfehlungen zur Dosierung auszusprechen .
T-1956	The safety and efficacy of the combination have not been established in this population , and there are insufficient data to give adequate dose recommendations .
H-1956	-0.3166218101978302	The safety and efficacy of this combination therapy have not been evaluated for this population and data are insufficient to recommend appropriate dosing regimens .
D-1956	-0.3166218101978302	The safety and efficacy of this combination therapy have not been evaluated for this population and data are insufficient to recommend appropriate dosing regimens .
P-1956	-0.1735 -0.0639 -0.1383 -0.1683 -0.0551 -0.1022 -0.1405 -0.1124 -0.1003 -0.1270 -0.2266 -0.1214 -0.1054 -0.6372 -0.1375 -0.7507 -0.4064 -0.9268 -0.4292 -0.6550 -0.3551 -0.5646 -0.1299 -0.1482 -0.9208 -0.1547 -0.1578 -1.1050 -0.6317 -0.0875 -0.1446 -0.1544
S-29	Hauptindikator für die Wirksamkeit war die Anzahl der Patienten , deren Harnsäurespiegel im Blut bei den letzten drei Messungen unter 6 mg<unk> dl lag .
T-29	The main measure of effectiveness was the number of patients whose final three blood uric acid levels were below 6 mg/ dl .
H-29	-0.3640952706336975	The main measure of efficacy was the number of patients whose uric acid levels in the blood were below 6 mg/ dl at the last three readings .
D-29	-0.3640952706336975	The main measure of efficacy was the number of patients whose uric acid levels in the blood were below 6 mg/ dl at the last three readings .
P-29	-1.0315 -0.5549 -0.0425 -0.1471 -0.9738 -0.0815 -0.1091 -0.1242 -0.1544 -0.1004 -0.1460 -0.1124 -0.4455 -1.3277 -0.0774 -0.1208 -0.2016 -0.1631 -0.7970 -0.0670 -0.2380 -0.4571 -0.1279 -0.2065 -0.1178 -0.1467 -0.0499 -1.6173 -0.1392 -0.3311 -0.1533 -1.9371 -0.1569 -0.1369 -0.1500
S-1468	Bei Patienten mit hohen Inhibitorwerten ist es möglich , dass die Faktor VIII-Therapie nicht effektiv ist , so dass andere therapeutische Maßnahmen erwogen werden müssen .
T-1468	In patients with high levels of inhibitor , factor VIII substitution therapy may not be effective and other therapeutic options should be considered .
H-1468	-0.39917147159576416	In patients with high inhibitors , Factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
D-1468	-0.39917147159576416	In patients with high inhibitors , Factor VIII therapy may not be effective and other therapeutic measures may need to be considered .
P-1468	-0.3881 -0.1292 -0.3038 -0.4448 -0.4200 -0.0706 -0.0322 -0.7663 -0.3059 -1.3048 -0.6435 -0.2655 -1.2718 -0.2950 -0.0863 -0.3037 -0.1557 -0.1180 -0.2304 -0.2544 -0.0718 -0.0842 -1.0302 -1.5514 -0.7667 -0.1287 -0.1529 -0.0955 -0.1475 -0.1562
S-301	14 werden ( siehe Abschnitt 4.2 ) . Die Patienten sollen darüber informiert werden , dass das Risiko ösophagealer Probleme erhöht sein kann , wenn sie diese Anweisungen nicht einhalten .
T-301	Patients should be informed that failure to follow these instructions may increase their risk of oesophageal problems .
H-301	-0.3760930895805359	patients should be advised that if they do not adhere to these instructions , they may be at increased risk of oesophageal problems .
D-301	-0.3760930895805359	patients should be advised that if they do not adhere to these instructions , they may be at increased risk of oesophageal problems .
P-301	-1.0101 -0.1796 -0.1364 -1.2095 -0.1478 -1.5773 -0.1124 -0.4449 -0.1833 -1.3519 -0.1042 -0.1568 -0.0803 -0.3349 -0.4760 -1.1321 -0.1412 -0.4356 -0.0098 -0.2254 -0.0672 -0.2006 -0.9110 -0.0422 -0.1386 -0.0519 -0.0588 -0.1445 -0.2341 -0.1988 -0.1615
S-1236	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-1236	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-1236	-0.4537084698677063	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
D-1236	-0.4537084698677063	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
P-1236	-2.8215 -0.1330 -0.2281 -0.2393 -1.2864 -1.1203 -0.4819 -0.1559 -0.2527 -0.2355 -0.1978 -0.3085 -0.0855 -0.1095 -0.1135 -0.1654 -0.1352 -0.2371 -0.2626 -0.0849 -0.0852 -0.2470 -0.5600 -1.1788 -0.8939 -0.1768
S-1060	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-1060	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-1060	-0.4537084698677063	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
D-1060	-0.4537084698677063	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
P-1060	-2.8215 -0.1330 -0.2281 -0.2393 -1.2864 -1.1203 -0.4819 -0.1559 -0.2527 -0.2355 -0.1978 -0.3085 -0.0855 -0.1095 -0.1135 -0.1654 -0.1352 -0.2371 -0.2626 -0.0849 -0.0852 -0.2470 -0.5600 -1.1788 -0.8939 -0.1768
S-1839	Suomi<unk> Finland Baxter Oy Valimotie 15 A FIN-00380 Helsinki Puh<unk> Tel : <unk> 358 9 8621111
T-1839	Suomi/ Finland Baxter Oy Valimotie 15 A FIN-00380 Helsinki Puh/ Tel : <<unk>> 358 9 8621111
H-1839	-0.1369415521621704	Suomi/ Finland Baxter Oy Valimotie 15 A FIN-00380 Helsinki Puh/ Tel : <unk> 358 9 8621111
D-1839	-0.1369415521621704	Suomi/ Finland Baxter Oy Valimotie 15 A FIN-00380 Helsinki Puh/ Tel : <unk> 358 9 8621111
P-1839	-0.1003 -0.0244 -0.1251 -0.1684 -0.1020 -0.2293 -0.1252 -0.1471 -0.1376 -0.1756 -0.2718 -0.1280 -0.1358 -0.1786 -0.1561 -0.1179 -0.1160 -0.1105 -0.1288 -0.1076 -0.3740 -0.1973 -0.1335 -0.1306 -0.0628 -0.1115 -0.1337 -0.0827 -0.1387 -0.0558 -0.1251 -0.0801 -0.1108 -0.1281 -0.1212 -0.1122 -0.2036 -0.1025 -0.1503
S-510	Wenn Sie weitere Informationen über Ihre Krankheit oder deren Behandlung benötigen , lesen Sie bitte die Packungsbeilage ( ebenfalls Bestandteil des EPAR ) oder wenden Sie sich an Ihren Arzt oder Apotheker .
T-510	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
H-510	-0.29543355107307434	If you need more information about your condition or treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
D-510	-0.29543355107307434	If you need more information about your condition or treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
P-510	-0.9756 -0.1241 -0.3179 -0.8116 -0.0621 -0.1505 -0.1937 -1.7910 -0.1284 -1.4732 -0.1542 -0.3103 -0.1445 -0.0558 -0.1284 -0.0777 -0.0389 -0.0952 -0.1684 -0.1907 -0.8736 -0.1468 -0.1293 -0.1079 -0.0678 -0.1309 -0.2474 -0.4786 -0.1198 -0.0906 -0.1125 -0.0429 -0.0871 -0.1567 -0.1561
S-1	Wenn Sie weitere Informationen über Ihre Krankheit oder deren Behandlung benötigen , lesen Sie bitte die Packungsbeilage ( ebenfalls Bestandteil des EPAR ) oder wenden Sie sich an Ihren Arzt oder Apotheker .
T-1	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
H-1	-0.29543355107307434	If you need more information about your condition or treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
D-1	-0.29543355107307434	If you need more information about your condition or treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
P-1	-0.9756 -0.1241 -0.3179 -0.8116 -0.0621 -0.1505 -0.1937 -1.7910 -0.1284 -1.4732 -0.1542 -0.3103 -0.1445 -0.0558 -0.1284 -0.0777 -0.0389 -0.0952 -0.1684 -0.1907 -0.8736 -0.1468 -0.1293 -0.1079 -0.0678 -0.1309 -0.2474 -0.4786 -0.1198 -0.0906 -0.1125 -0.0429 -0.0871 -0.1567 -0.1561
S-1589	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-1589	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-1589	-0.4537084698677063	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
D-1589	-0.4537084698677063	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
P-1589	-2.8215 -0.1330 -0.2281 -0.2393 -1.2864 -1.1203 -0.4819 -0.1559 -0.2527 -0.2355 -0.1978 -0.3085 -0.0855 -0.1095 -0.1135 -0.1654 -0.1352 -0.2371 -0.2626 -0.0849 -0.0852 -0.2470 -0.5600 -1.1788 -0.8939 -0.1768
S-1412	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-1412	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-1412	-0.4537084698677063	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
D-1412	-0.4537084698677063	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
P-1412	-2.8215 -0.1330 -0.2281 -0.2393 -1.2864 -1.1203 -0.4819 -0.1559 -0.2527 -0.2355 -0.1978 -0.3085 -0.0855 -0.1095 -0.1135 -0.1654 -0.1352 -0.2371 -0.2626 -0.0849 -0.0852 -0.2470 -0.5600 -1.1788 -0.8939 -0.1768
S-1871	Das Unternehmen legte Daten aus einer Studie mit einem Patienten vor , bei dem Li-Fraumeni-Krebs im Bereich des Unterbauchs , in den Knochen und im Gehirn auftrat .
T-1871	The company presented information from a study on one patient with Li-Fraumeni cancer in the lower abdomen , the bones and the brain .
H-1871	-0.45106181502342224	The company presented data from a trial in a patient who had Li-Fraumeni cancer in the abdominal region , in the bone and in the brain .
D-1871	-0.45106181502342224	The company presented data from a trial in a patient who had Li-Fraumeni cancer in the abdominal region , in the bone and in the brain .
P-1871	-0.5341 -0.1807 -0.4633 -0.2052 -0.1636 -0.1309 -0.5687 -0.4704 -0.7377 -0.0325 -0.4117 -0.6924 -1.3940 -0.3383 -0.3773 -0.0325 -0.2978 -1.6054 -0.2397 -0.3143 -1.3847 -0.0179 -0.3611 -0.5783 -0.1431 -1.5577 -0.2525 -0.6917 -0.3862 -0.2501 -0.1321 -0.1060 -0.1301 -0.1541
S-1405	Die Verpackung des BAXJECTs II öffnen , indem die Schutzfolie abgezogen wird ohne dabei den Packungsinhalt zu berühren ( Abb . A ) .
T-1405	Open the package of BAXJECT II device by peeling away the paper lid without touching the inside ( Fig . a ) .
H-1405	-0.5193436741828918	Open the package contents of the BAXJECT II by peeling off the protective foil ( Fig . A ) .
D-1405	-0.5193436741828918	Open the package contents of the BAXJECT II by peeling off the protective foil ( Fig . A ) .
P-1405	-2.1615 -0.1594 -2.4430 -0.2373 -0.0828 -0.3730 -0.7268 -0.2045 -0.1832 -0.3094 -0.0599 -0.2236 -0.0992 -0.1006 -2.6544 -0.2264 -0.5747 -0.1598 -0.2525 -1.2732 -0.1169 -0.2441 -1.2500 -0.1337 -0.2222 -0.1442 -0.1272 -0.1585 -0.1588
S-884	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-884	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-884	-0.4537084698677063	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
D-884	-0.4537084698677063	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
P-884	-2.8215 -0.1330 -0.2281 -0.2393 -1.2864 -1.1203 -0.4819 -0.1559 -0.2527 -0.2355 -0.1978 -0.3085 -0.0855 -0.1095 -0.1135 -0.1654 -0.1352 -0.2371 -0.2626 -0.0849 -0.0852 -0.2470 -0.5600 -1.1788 -0.8939 -0.1768
S-708	Das System , bestehend aus dem BAXJECT II und der Lösungsmitteldurchstechflasche , nun wenden , so dass sich die Lösungsmittelflasche oben befindet .
T-708	With BAXJECT II attached to the solvent vial , invert the system so that the solvent vial is on top of the device .
H-708	-0.4537084698677063	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
D-708	-0.4537084698677063	Turn the system , consisting of the BAXJECT II and the solvent vial , upwards .
P-708	-2.8215 -0.1330 -0.2281 -0.2393 -1.2864 -1.1203 -0.4819 -0.1559 -0.2527 -0.2355 -0.1978 -0.3085 -0.0855 -0.1095 -0.1135 -0.1654 -0.1352 -0.2371 -0.2626 -0.0849 -0.0852 -0.2470 -0.5600 -1.1788 -0.8939 -0.1768
S-1979	Dihydroergotamin , Ergotamin , Methylergometrin : Risiko für das Auftreten einer Gefäßverengung und einer Hypertonie .
T-1979	Dihydroergotamine , ergotamine , methylergometrine : risk of vasoconstriction and increase in blood pressure .
H-1979	-0.3836615979671478	Dihydroergotamine , ergotamine , methylergometrine : risk for vascular narrowing and hypertension .
D-1979	-0.3836615979671478	Dihydroergotamine , ergotamine , methylergometrine : risk for vascular narrowing and hypertension .
P-1979	-0.2857 -0.0561 -0.4389 -0.0956 -0.0917 -0.1484 -1.3886 -0.1796 -0.0984 -0.0708 -0.1418 -0.3584 -0.1704 -0.8034 -0.1551 -0.0763 -2.1219 -0.1681 -0.1348 -0.1374 -0.4584 -1.1523 -0.0198 -0.3438 -2.1943 -0.0937 -0.1278 -0.0288 -0.0394 -0.1539 -0.1600
S-120	Wenn Patienten während einer Bisphosphonattherapie eine Osteonekrose des Kiefers entwickeln , kann ein kieferchirurgischer Eingriff zu einer Verschlechterung führen .
T-120	For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy , dental surgery may exacerbate the condition .
H-120	-0.34593814611434937	If patients develop osteonecrosis of the jaw during bisphosphonate therapy , jaw surgery may lead to deterioration .
D-120	-0.34593814611434937	If patients develop osteonecrosis of the jaw during bisphosphonate therapy , jaw surgery may lead to deterioration .
P-120	-0.3953 -0.3800 -0.6407 -0.6163 -0.0647 -0.1172 -0.1259 -0.0150 -0.1008 -0.1484 -0.1314 -0.0714 -0.1409 -0.2749 -0.0899 -0.0291 -0.0411 -0.6751 -0.8128 -0.1322 -0.1471 -0.6595 -0.1833 -0.0668 -0.1670 -1.6691 -0.1510 -2.2099 -0.1466 -0.1639 -0.1568
S-308	Wenn Patienten während einer Bisphosphonattherapie eine Osteonekrose des Kiefers entwickeln , kann ein kieferchirurgischer Eingriff zu einer Verschlechterung führen .
T-308	For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy , dental surgery may exacerbate the condition .
H-308	-0.34593814611434937	If patients develop osteonecrosis of the jaw during bisphosphonate therapy , jaw surgery may lead to deterioration .
D-308	-0.34593814611434937	If patients develop osteonecrosis of the jaw during bisphosphonate therapy , jaw surgery may lead to deterioration .
P-308	-0.3953 -0.3800 -0.6407 -0.6163 -0.0647 -0.1172 -0.1259 -0.0150 -0.1008 -0.1484 -0.1314 -0.0714 -0.1409 -0.2749 -0.0899 -0.0291 -0.0411 -0.6751 -0.8128 -0.1322 -0.1471 -0.6595 -0.1833 -0.0668 -0.1670 -1.6691 -0.1510 -2.2099 -0.1466 -0.1639 -0.1568
S-1076	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-1076	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-1076	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
D-1076	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
P-1076	-0.0488 -0.0889 -0.1271 -0.6145 -0.1457 -1.7968 -0.0810 -0.0589 -0.1533 -0.1599 -0.1473 -0.1355 -0.8491 -0.5848 -0.1670 -0.1288 -0.2279 -0.0884 -0.1077 -0.1151 -0.1405 -0.5791 -0.4413 -0.4416 -0.1604 -0.3586 -0.0203 -3.1296 -0.0977 -0.1811 -0.1030 -0.1767 -0.2657 -0.1521
S-724	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-724	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-724	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
D-724	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
P-724	-0.0488 -0.0889 -0.1271 -0.6145 -0.1457 -1.7968 -0.0810 -0.0589 -0.1533 -0.1599 -0.1473 -0.1355 -0.8491 -0.5848 -0.1670 -0.1288 -0.2279 -0.0884 -0.1077 -0.1151 -0.1405 -0.5791 -0.4413 -0.4416 -0.1604 -0.3586 -0.0203 -3.1296 -0.0977 -0.1811 -0.1030 -0.1767 -0.2657 -0.1521
S-1252	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-1252	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-1252	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
D-1252	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
P-1252	-0.0488 -0.0889 -0.1271 -0.6145 -0.1457 -1.7968 -0.0810 -0.0589 -0.1533 -0.1599 -0.1473 -0.1355 -0.8491 -0.5848 -0.1670 -0.1288 -0.2279 -0.0884 -0.1077 -0.1151 -0.1405 -0.5791 -0.4413 -0.4416 -0.1604 -0.3586 -0.0203 -3.1296 -0.0977 -0.1811 -0.1030 -0.1767 -0.2657 -0.1521
S-1428	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-1428	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-1428	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
D-1428	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
P-1428	-0.0488 -0.0889 -0.1271 -0.6145 -0.1457 -1.7968 -0.0810 -0.0589 -0.1533 -0.1599 -0.1473 -0.1355 -0.8491 -0.5848 -0.1670 -0.1288 -0.2279 -0.0884 -0.1077 -0.1151 -0.1405 -0.5791 -0.4413 -0.4416 -0.1604 -0.3586 -0.0203 -3.1296 -0.0977 -0.1811 -0.1030 -0.1767 -0.2657 -0.1521
S-900	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-900	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-900	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
D-900	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
P-900	-0.0488 -0.0889 -0.1271 -0.6145 -0.1457 -1.7968 -0.0810 -0.0589 -0.1533 -0.1599 -0.1473 -0.1355 -0.8491 -0.5848 -0.1670 -0.1288 -0.2279 -0.0884 -0.1077 -0.1151 -0.1405 -0.5791 -0.4413 -0.4416 -0.1604 -0.3586 -0.0203 -3.1296 -0.0977 -0.1811 -0.1030 -0.1767 -0.2657 -0.1521
S-1845	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-1845	Detailed information on this medicine is available on the European Medicines Agency ( EMEA ) web site : http : / <<unk>> www . emea . europa . eu/
H-1845	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
D-1845	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
P-1845	-0.0488 -0.0889 -0.1271 -0.6145 -0.1457 -1.7968 -0.0810 -0.0589 -0.1533 -0.1599 -0.1473 -0.1355 -0.8491 -0.5848 -0.1670 -0.1288 -0.2279 -0.0884 -0.1077 -0.1151 -0.1405 -0.5791 -0.4413 -0.4416 -0.1604 -0.3586 -0.0203 -3.1296 -0.0977 -0.1811 -0.1030 -0.1767 -0.2657 -0.1521
S-1536	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-1536	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-1536	-0.17764349281787872	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
D-1536	-0.17764349281787872	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
P-1536	-0.0548 -0.0798 -0.1479 -0.2042 -0.1163 -0.0614 -0.1160 -0.1313 -0.1613 -0.0909 -0.0753 -0.0523 -0.0594 -1.3488 -0.3514 -0.1559 -0.3385 -0.1290 -0.0691 -0.0561 -0.0637 -0.1014 -0.4017 -0.1900 -0.3428 -0.0726 -0.0957 -0.0659 -0.1421 -0.2691 -0.1331 -0.1174 -0.1432 -0.1285 -0.1508
S-1359	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-1359	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-1359	-0.17764349281787872	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
D-1359	-0.17764349281787872	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
P-1359	-0.0548 -0.0798 -0.1479 -0.2042 -0.1163 -0.0614 -0.1160 -0.1313 -0.1613 -0.0909 -0.0753 -0.0523 -0.0594 -1.3488 -0.3514 -0.1559 -0.3385 -0.1290 -0.0691 -0.0561 -0.0637 -0.1014 -0.4017 -0.1900 -0.3428 -0.0726 -0.0957 -0.0659 -0.1421 -0.2691 -0.1331 -0.1174 -0.1432 -0.1285 -0.1508
S-1183	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-1183	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-1183	-0.17764349281787872	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
D-1183	-0.17764349281787872	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
P-1183	-0.0548 -0.0798 -0.1479 -0.2042 -0.1163 -0.0614 -0.1160 -0.1313 -0.1613 -0.0909 -0.0753 -0.0523 -0.0594 -1.3488 -0.3514 -0.1559 -0.3385 -0.1290 -0.0691 -0.0561 -0.0637 -0.1014 -0.4017 -0.1900 -0.3428 -0.0726 -0.0957 -0.0659 -0.1421 -0.2691 -0.1331 -0.1174 -0.1432 -0.1285 -0.1508
S-1007	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-1007	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-1007	-0.17764349281787872	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
D-1007	-0.17764349281787872	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
P-1007	-0.0548 -0.0798 -0.1479 -0.2042 -0.1163 -0.0614 -0.1160 -0.1313 -0.1613 -0.0909 -0.0753 -0.0523 -0.0594 -1.3488 -0.3514 -0.1559 -0.3385 -0.1290 -0.0691 -0.0561 -0.0637 -0.1014 -0.4017 -0.1900 -0.3428 -0.0726 -0.0957 -0.0659 -0.1421 -0.2691 -0.1331 -0.1174 -0.1432 -0.1285 -0.1508
S-831	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-831	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-831	-0.17764349281787872	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
D-831	-0.17764349281787872	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
P-831	-0.0548 -0.0798 -0.1479 -0.2042 -0.1163 -0.0614 -0.1160 -0.1313 -0.1613 -0.0909 -0.0753 -0.0523 -0.0594 -1.3488 -0.3514 -0.1559 -0.3385 -0.1290 -0.0691 -0.0561 -0.0637 -0.1014 -0.4017 -0.1900 -0.3428 -0.0726 -0.0957 -0.0659 -0.1421 -0.2691 -0.1331 -0.1174 -0.1432 -0.1285 -0.1508
S-656	Octocog alfa ist ein Glycoprotein , das aus 2332 Aminosäuren mit einem Molekulargewicht von ca. 280 kD besteht .
T-656	Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass of 280 kD .
H-656	-0.17764349281787872	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
D-656	-0.17764349281787872	Octocog alfa is a glycoprotein consisting of 2332 amino acids with a molecular weight of approximately 280 kD .
P-656	-0.0548 -0.0798 -0.1479 -0.2042 -0.1163 -0.0614 -0.1160 -0.1313 -0.1613 -0.0909 -0.0753 -0.0523 -0.0594 -1.3488 -0.3514 -0.1559 -0.3385 -0.1290 -0.0691 -0.0561 -0.0637 -0.1014 -0.4017 -0.1900 -0.3428 -0.0726 -0.0957 -0.0659 -0.1421 -0.2691 -0.1331 -0.1174 -0.1432 -0.1285 -0.1508
S-1605	Ausführliche Informationen zu diesem Arzneimittel sind auf der Website der Europäischen Arzneimittel-Agentur ( EMEA ) http<unk> <unk> <unk> www.emea.europa.eu / verfügbar .
T-1605	Detailed information on this product is available on the website of the European Medicines Agency ( EMEA ) http : / <<unk>> www . emea . europa . eu/
H-1605	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
D-1605	-0.3551255166530609	Detailed information on this medicinal product is available on the European Medicines Agency ( EMEA ) website http/ www.emea.europa.eu / .
P-1605	-0.0488 -0.0889 -0.1271 -0.6145 -0.1457 -1.7968 -0.0810 -0.0589 -0.1533 -0.1599 -0.1473 -0.1355 -0.8491 -0.5848 -0.1670 -0.1288 -0.2279 -0.0884 -0.1077 -0.1151 -0.1405 -0.5791 -0.4413 -0.4416 -0.1604 -0.3586 -0.0203 -3.1296 -0.0977 -0.1811 -0.1030 -0.1767 -0.2657 -0.1521
S-333	Daher müssen die Patienten nach der Einnahme von Alendronat mindestens 30 Minuten warten , bevor sie andere Arzneimittel einnehmen ( siehe Abschnitte 4.2 und 5.2 ) .
T-333	Therefore , patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product ( see sections 4.2 and 5.2 ) .
H-333	-0.2292836606502533	Therefore , patients must wait at least 30 minutes after taking alendronate before taking other medicinal products ( see sections 4.2 and 5.2 ) .
D-333	-0.2292836606502533	Therefore , patients must wait at least 30 minutes after taking alendronate before taking other medicinal products ( see sections 4.2 and 5.2 ) .
P-333	-0.9866 -0.0742 -0.2258 -0.2929 -1.2196 -0.1628 -0.1429 -0.1209 -0.1442 -0.1544 -0.2180 -0.4385 -0.1320 -0.1601 -0.1130 -0.0882 -0.2133 -0.1505 -0.6764 -0.0791 -0.0558 -0.1287 -0.1696 -0.2487 -0.0877 -0.1222 -0.1464 -0.1347 -0.1001 -0.1499 -0.1346 -0.1449 -0.1493
S-1013	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-1013	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 27 spontaneously or as a result of accidental or surgical trauma .
H-1013	-0.26509350538253784	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgery trauma .
D-1013	-0.26509350538253784	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgery trauma .
P-1013	-0.1575 -0.9234 -0.2257 -0.5775 -0.8270 -0.1822 -0.2929 -0.3522 -0.0479 -0.1574 -0.3182 -0.2541 -0.0538 -0.2715 -0.1140 -0.1313 -0.2718 -0.0903 -0.0400 -0.1144 -0.1597 -0.4510 -0.1684 -0.3958 -0.1531 -0.5118 -0.0428 -0.1360 -0.6145 -0.1453 -0.1507 -0.1509
S-359	Selten : vorübergehende Symptome einer Akute-Phase-Reaktion ( Myalgie , Unwohlsein und selten Fieber ) , üblicherweise bei Therapiebeginn .
T-359	( see section 4.4 ) Rare : transient symptoms as in an acute-phase response ( myalgia , malaise and rarely , fever ) , typically in association with initiation of treatment .
H-359	-0.23449590802192688	Rare : transient symptoms of acute phase reaction ( myalgia , discomfort and rare fever ) , usually at the outset of therapy .
D-359	-0.23449590802192688	Rare : transient symptoms of acute phase reaction ( myalgia , discomfort and rare fever ) , usually at the outset of therapy .
P-359	-0.1492 -0.1359 -0.1332 -0.0946 -0.0616 -0.1733 -0.2914 -0.1519 -0.1738 -0.1365 -0.1020 -0.1782 -0.1325 -0.2645 -0.1011 -0.0600 -0.1506 -0.6619 -0.0965 -0.2437 -0.4942 -0.1200 -0.0700 -0.1409 -0.1501 -0.1162 -0.2130 -0.1637 -0.7765 -0.0810 -0.1502 -1.6713 -0.1837 -0.1497
S-527	Octocog alfa wird nicht aus menschlichem Plasma extrahiert , sondern nach einer Methode hergestellt , die als rekombinante DNA-Technologie bezeichnet wird :
T-527	Octocog alfa is not extracted from human plasma but produced by a method known as recombinant DNA technology : it is made by a cell that has received a gene ( DNA ) , which makes it able to produce human coagulation factor VIII .
H-527	-0.2301643341779709	Octocog alfa is not extracted from human plasma , but is produced by a method known as recombinant DNA technology :
D-527	-0.2301643341779709	Octocog alfa is not extracted from human plasma , but is produced by a method known as recombinant DNA technology :
P-527	-0.0417 -0.0868 -0.1467 -0.2504 -0.1179 -0.0629 -0.1423 -0.1952 -0.3066 -0.1128 -0.1495 -0.1755 -0.0940 -0.0760 -0.1410 -0.9014 -0.0699 -0.7373 -0.4069 -0.8593 -0.1945 -0.3035 -0.6846 -0.1557 -0.1440 -0.1170 -0.0967 -0.1332 -0.0779 -0.0813 -0.1301 -0.1724
S-1542	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-1542	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 57 spontaneously or as a result of accidental or surgical trauma .
H-1542	-0.26509350538253784	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgery trauma .
D-1542	-0.26509350538253784	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgery trauma .
P-1542	-0.1575 -0.9234 -0.2257 -0.5775 -0.8270 -0.1822 -0.2929 -0.3522 -0.0479 -0.1574 -0.3182 -0.2541 -0.0538 -0.2715 -0.1140 -0.1313 -0.2718 -0.0903 -0.0400 -0.1144 -0.1597 -0.4510 -0.1684 -0.3958 -0.1531 -0.5118 -0.0428 -0.1360 -0.6145 -0.1453 -0.1507 -0.1509
S-1365	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-1365	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 47 spontaneously or as a result of accidental or surgical trauma .
H-1365	-0.26509350538253784	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgery trauma .
D-1365	-0.26509350538253784	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgery trauma .
P-1365	-0.1575 -0.9234 -0.2257 -0.5775 -0.8270 -0.1822 -0.2929 -0.3522 -0.0479 -0.1574 -0.3182 -0.2541 -0.0538 -0.2715 -0.1140 -0.1313 -0.2718 -0.0903 -0.0400 -0.1144 -0.1597 -0.4510 -0.1684 -0.3958 -0.1531 -0.5118 -0.0428 -0.1360 -0.6145 -0.1453 -0.1507 -0.1509
S-1189	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-1189	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 37 spontaneously or as a result of accidental or surgical trauma .
H-1189	-0.26509350538253784	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgery trauma .
D-1189	-0.26509350538253784	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgery trauma .
P-1189	-0.1575 -0.9234 -0.2257 -0.5775 -0.8270 -0.1822 -0.2929 -0.3522 -0.0479 -0.1574 -0.3182 -0.2541 -0.0538 -0.2715 -0.1140 -0.1313 -0.2718 -0.0903 -0.0400 -0.1144 -0.1597 -0.4510 -0.1684 -0.3958 -0.1531 -0.5118 -0.0428 -0.1360 -0.6145 -0.1453 -0.1507 -0.1509
S-95	Folgende Hinweise sind genau zu befolgen , um das Risiko für ösophageale Reizungen und damit verbundene Nebenwirkungen zu verringern ( siehe Abschnitt 4.4 ) :
T-95	The following instructions should be followed exactly in order to minimize the risk of oesophageal irritation and related adverse reactions ( see section 4.4 ) :
H-95	-0.3223296105861664	The following recommendations should be followed closely to reduce the risk of oesophageal irritation and associated side effects ( see section 4.4 ) :
D-95	-0.3223296105861664	The following recommendations should be followed closely to reduce the risk of oesophageal irritation and associated side effects ( see section 4.4 ) :
P-95	-0.4192 -0.0869 -2.6102 -0.5705 -0.1971 -0.1787 -0.2470 -0.4117 -0.2810 -0.1313 -0.1248 -0.3152 -0.6440 -0.0487 -0.0879 -0.0449 -0.0717 -0.1570 -0.0446 -0.1395 -0.1565 -0.9099 -1.1481 -0.1069 -0.1430 -0.2752 -0.1116 -0.1164 -0.1242 -0.1328 -0.1220 -0.1562
S-837	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-837	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen . 17 spontaneously or as a result of accidental or surgical trauma .
H-837	-0.26509350538253784	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgery trauma .
D-837	-0.26509350538253784	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgery trauma .
P-837	-0.1575 -0.9234 -0.2257 -0.5775 -0.8270 -0.1822 -0.2929 -0.3522 -0.0479 -0.1574 -0.3182 -0.2541 -0.0538 -0.2715 -0.1140 -0.1313 -0.2718 -0.0903 -0.0400 -0.1144 -0.1597 -0.4510 -0.1684 -0.3958 -0.1531 -0.5118 -0.0428 -0.1360 -0.6145 -0.1453 -0.1507 -0.1509
S-282	Folgende Hinweise sind genau zu befolgen , um das Risiko für ösophageale Reizungen und damit verbundene Nebenwirkungen zu verringern ( siehe Abschnitt 4.4 ) :
T-282	The following instructions should be followed exactly in order to minimize the risk of oesophageal irritation and related adverse reactions ( see section 4.4 ) :
H-282	-0.3223296105861664	The following recommendations should be followed closely to reduce the risk of oesophageal irritation and associated side effects ( see section 4.4 ) :
D-282	-0.3223296105861664	The following recommendations should be followed closely to reduce the risk of oesophageal irritation and associated side effects ( see section 4.4 ) :
P-282	-0.4192 -0.0869 -2.6102 -0.5705 -0.1971 -0.1787 -0.2470 -0.4117 -0.2810 -0.1313 -0.1248 -0.3152 -0.6440 -0.0487 -0.0879 -0.0449 -0.0717 -0.1570 -0.0446 -0.1395 -0.1565 -0.9099 -1.1481 -0.1069 -0.1430 -0.2752 -0.1116 -0.1164 -0.1242 -0.1328 -0.1220 -0.1562
S-171	Selten : vorübergehende Symptome einer Akute-Phase-Reaktion ( Myalgie , Unwohlsein und selten Fieber ) , üblicherweise bei Therapiebeginn .
T-171	( see section 4.4 ) Rare : transient symptoms as in an acute-phase response ( myalgia , malaise and rarely , fever ) , typically in association with initiation of treatment .
H-171	-0.23449590802192688	Rare : transient symptoms of acute phase reaction ( myalgia , discomfort and rare fever ) , usually at the outset of therapy .
D-171	-0.23449590802192688	Rare : transient symptoms of acute phase reaction ( myalgia , discomfort and rare fever ) , usually at the outset of therapy .
P-171	-0.1492 -0.1359 -0.1332 -0.0946 -0.0616 -0.1733 -0.2914 -0.1519 -0.1738 -0.1365 -0.1020 -0.1782 -0.1325 -0.2645 -0.1011 -0.0600 -0.1506 -0.6619 -0.0965 -0.2437 -0.4942 -0.1200 -0.0700 -0.1409 -0.1501 -0.1162 -0.2130 -0.1637 -0.7765 -0.0810 -0.1502 -1.6713 -0.1837 -0.1497
S-1986	Das für den Metabolismus von Desloratadin verantwortliche Enzym wurde noch nicht identifiziert , so dass Wechselwirkungen mit anderen Arzneimitteln nicht ganz ausgeschlossen werden können .
T-1986	The enzyme responsible for the metabolism of desloratadine has not been identified yet , and therefore , some interactions with other medicinal products can not be fully excluded .
H-1986	-0.23951029777526855	The enzyme responsible for the metabolism of desloratadine has not yet been identified and interactions with other medicinal products cannot be excluded .
D-1986	-0.23951029777526855	The enzyme responsible for the metabolism of desloratadine has not yet been identified and interactions with other medicinal products cannot be excluded .
P-1986	-0.2400 -0.0480 -0.0603 -0.0785 -0.1666 -0.1146 -0.2931 -0.0429 -0.0473 -0.0664 -0.1473 -0.9381 -0.0624 -0.1026 -0.5203 -1.2577 -0.1595 -0.1496 -0.4144 -0.1756 -0.0623 -0.4569 -0.1826 -0.2526 -0.1398 -0.3328 -0.0626 -0.0563 -0.0726 -0.0726 -0.4137 -0.4629 -0.0999 -0.4751 -0.1550
S-1843	United Kingdom Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <unk> 44 1635 206345
T-1843	United Kingdom Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <<unk>> 44 1635 206345
H-1843	-0.13811492919921875	United Kingdom Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <unk> 44 1635 206345
D-1843	-0.13811492919921875	United Kingdom Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel : <unk> 44 1635 206345
P-1843	-0.0910 -0.0570 -0.2674 -0.1881 -0.1363 -0.0544 -0.1160 -0.1273 -0.0410 -0.2003 -0.0974 -0.2702 -0.0689 -0.1534 -0.0581 -0.0690 -0.3880 -0.1556 -0.1508 -0.0264 -0.1359 -0.4339 -0.1191 -0.1127 -0.3384 -0.1475 -0.1101 -0.0786 -0.1391 -0.0367 -0.0815 -0.0774 -0.0608 -0.1723 -0.1154 -0.1263 -0.1012 -0.1450
S-1820	Malta Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel . : <unk> 44 1635 206345
T-1820	Malta Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel . : <<unk>> 44 1635 206345
H-1820	-0.13651548326015472	Malta Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel . : <unk> 44 1635 206345
D-1820	-0.13651548326015472	Malta Baxter Healthcare Ltd Wallingford Road , Compton Newbury Berkshire RG20 7QW - UK Tel . : <unk> 44 1635 206345
P-1820	-0.0442 -0.2309 -0.2037 -0.1355 -0.0484 -0.1160 -0.1315 -0.0402 -0.2095 -0.0990 -0.2581 -0.0689 -0.1536 -0.0558 -0.0694 -0.3855 -0.1495 -0.1423 -0.0259 -0.1370 -0.3899 -0.1178 -0.1141 -0.3162 -0.1503 -0.1322 -0.0444 -0.1766 -0.1358 -0.0360 -0.0798 -0.0734 -0.0585 -0.1704 -0.1145 -0.1254 -0.0991 -0.1481
S-1962	Sympathomimetische Amine können eine Stimulation des Zentralnervensystems mit Krampfanfällen oder einen Herz-Kreislauf-Kollaps mit Hypotonie verursachen .
T-1962	Central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension may be produced by sympathomimetic amines .
H-1962	-0.22238321602344513	Sympathomimetic amines may cause central nervous system stimulation with seizure or cardiovascular collapse with hypotension .
D-1962	-0.22238321602344513	Sympathomimetic amines may cause central nervous system stimulation with seizure or cardiovascular collapse with hypotension .
P-1962	-0.7552 -0.0914 -0.0764 -0.1159 -1.1785 -0.2941 -0.2991 -0.0633 -0.5068 -0.1086 -0.0937 -0.3058 -0.1504 -0.6212 -0.1740 -0.0910 -0.0980 -0.1625 -0.0599 -0.0899 -0.1126 -0.0532 -0.5021 -0.1327 -0.0872 -0.0451 -0.0714 -0.0380 -0.1375 -0.1563
S-34	Im Vergleich dazu war dies bei 22 % ( 60 von 268 ) der Patienten unter Allopurinol und bei keinem der 134 Patienten unter Placebo der Fall .
T-34	This was compared with 22 % of the patients taking allopurinol ( 60 out of 268 ) and none of the 134 patients taking placebo .
H-34	-0.30360400676727295	This compared to 22 % ( 60 out of 268 ) of patients receiving allopurinol and none of 134 receiving placebo .
D-34	-0.30360400676727295	This compared to 22 % ( 60 out of 268 ) of patients receiving allopurinol and none of 134 receiving placebo .
P-34	-0.3762 -0.8746 -0.8918 -0.0968 -0.1086 -0.1455 -0.0996 -0.4339 -0.1550 -0.0614 -0.1065 -0.1595 -0.1686 -1.7630 -0.4367 -0.4373 -0.1620 -0.1260 -0.1121 -0.2171 -0.1955 -0.1600 -0.6011 -0.1366 -0.7254 -0.0263 -0.1428 -0.0742 -0.1245 -0.1419 -0.1512
S-145	Daher müssen die Patienten nach der Einnahme von Alendronat mindestens 30 Minuten warten , bevor sie andere Arzneimittel einnehmen ( siehe Abschnitte 4.2 und 5.2 ) .
T-145	Therefore , patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product ( see sections 4.2 and 5.2 ) .
H-145	-0.2292836606502533	Therefore , patients must wait at least 30 minutes after taking alendronate before taking other medicinal products ( see sections 4.2 and 5.2 ) .
D-145	-0.2292836606502533	Therefore , patients must wait at least 30 minutes after taking alendronate before taking other medicinal products ( see sections 4.2 and 5.2 ) .
P-145	-0.9866 -0.0742 -0.2258 -0.2929 -1.2196 -0.1628 -0.1429 -0.1209 -0.1442 -0.1544 -0.2180 -0.4385 -0.1320 -0.1601 -0.1130 -0.0882 -0.2133 -0.1505 -0.6764 -0.0791 -0.0558 -0.1287 -0.1696 -0.2487 -0.0877 -0.1222 -0.1464 -0.1347 -0.1001 -0.1499 -0.1346 -0.1449 -0.1493
S-345	In Tierstudien wurde unter hohen Vitamin-D-Dosen Hypercalcämie und Reproduktionstoxizität ( siehe Abschnitt 5.3 ) nachgewiesen .
T-345	Studies in animals have shown hypercalcaemia and reproductive toxicity with high doses of vitamin D ( see section 5.3 ) .
H-345	-0.2942347824573517	Animal studies at high doses of vitamin D have shown hypercalcaemia and reproductive toxicity ( see section 5.3 ) .
D-345	-0.2942347824573517	Animal studies at high doses of vitamin D have shown hypercalcaemia and reproductive toxicity ( see section 5.3 ) .
P-345	-0.3266 -0.0956 -0.1360 -1.8268 -1.1929 -0.1158 -0.0432 -0.4037 -0.5938 -0.9674 -0.3640 -0.0733 -0.7477 -0.0909 -0.0801 -0.0173 -0.0375 -0.1329 -0.1258 -0.1420 -0.3656 -0.0799 -0.0699 -0.1187 -0.1346 -0.3373 -0.1323 -0.1060 -0.1192 -0.1311 -0.1579 -0.1498
S-1792	Informieren Sie Ihren Arzt , wenn eine der aufgeführten Nebenwirkungen Sie erheblich beeinträchtigt oder wenn Sie Nebenwirkungen bemerken , die nicht in dieser Packungsbeilage aufgeführt sind .
T-1792	If any of these side effects gets serious , or if you notice any side effects not listed in this leaflet , please tell your doctor .
H-1792	-0.3039500117301941	Be sure to tell your doctor if any of the side effects affects you significantly or if you experience side effects not listed in this Package Leaflet .
D-1792	-0.3039500117301941	Be sure to tell your doctor if any of the side effects affects you significantly or if you experience side effects not listed in this Package Leaflet .
P-1792	-0.2811 -0.1255 -0.1679 -0.1037 -0.1614 -0.0947 -0.1491 -0.1041 -0.1453 -0.5847 -0.1879 -0.1378 -2.2313 -0.1554 -0.4153 -1.2066 -0.1539 -0.1303 -0.4619 -1.3099 -0.1231 -0.1952 -0.0183 -0.1341 -0.1085 -0.1759 -0.1289 -0.1318 -0.0141 -0.0849 -0.1486 -0.1555
S-662	Dies führt , entweder spontan oder in Folge unfallbedingter oder chirurgischer Traumata , zu starken Blutungen in Gelenken , Muskeln oder inneren Organen .
T-662	2 paediatric patients ( age 0 16 years ) and adult patients ( age over 16 years )
H-662	-0.26509350538253784	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgery trauma .
D-662	-0.26509350538253784	This results in severe bleeding in joints , muscles or internal organs , either spontaneously or as a result of accidental or surgery trauma .
P-662	-0.1575 -0.9234 -0.2257 -0.5775 -0.8270 -0.1822 -0.2929 -0.3522 -0.0479 -0.1574 -0.3182 -0.2541 -0.0538 -0.2715 -0.1140 -0.1313 -0.2718 -0.0903 -0.0400 -0.1144 -0.1597 -0.4510 -0.1684 -0.3958 -0.1531 -0.5118 -0.0428 -0.1360 -0.6145 -0.1453 -0.1507 -0.1509
S-207	Hinsichtlich der Mittelwerte von Serum-Calcium , Phosphat oder Calcium im 24-Stunden-Harn gab es keine Unterschiede zwischen den Behandlungsgruppen .
T-207	There were no differences in mean serum calcium , phosphate , or 24-hour urine calcium between treatment groups .
H-207	-0.4013652503490448	There were no differences between treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24-hour urine .
D-207	-0.4013652503490448	There were no differences between treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24-hour urine .
P-207	-1.1987 -0.2692 -0.0496 -0.1256 -0.2516 -0.3022 -0.4766 -2.3563 -0.7954 -0.1412 -1.0290 -1.5867 -0.7494 -0.2256 -0.0930 -0.1286 -0.1370 -0.0835 -0.1282 -0.1506 -0.0699 -0.0532 -0.0829 -0.1684 -0.0664 -0.0924 -0.1289 -0.1467 -1.8671 -0.4143 -0.1712 -0.1166 -0.1016 -0.1411 -0.1493
S-395	Hinsichtlich der Mittelwerte von Serum-Calcium , Phosphat oder Calcium im 24-Stunden-Harn gab es keine Unterschiede zwischen den Behandlungsgruppen .
T-395	There were no differences in mean serum calcium , phosphate , or 24-hour urine calcium between treatment groups .
H-395	-0.4013652503490448	There were no differences between treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24-hour urine .
D-395	-0.4013652503490448	There were no differences between treatment groups with regard to the mean values of serum calcium , phosphate or calcium in 24-hour urine .
P-395	-1.1987 -0.2692 -0.0496 -0.1256 -0.2516 -0.3022 -0.4766 -2.3563 -0.7954 -0.1412 -1.0290 -1.5867 -0.7494 -0.2256 -0.0930 -0.1286 -0.1370 -0.0835 -0.1282 -0.1506 -0.0699 -0.0532 -0.0829 -0.1684 -0.0664 -0.0924 -0.1289 -0.1467 -1.8671 -0.4143 -0.1712 -0.1166 -0.1016 -0.1411 -0.1493
S-402	Hinsichtlich der Mittelwerte von Serum-Calcium , Phosphat oder Calcium im 24-Stunden- Harn gab es keine Unterschiede zwischen den Behandlungsgruppen .
T-402	There were no differences in mean serum calcium , phosphate , or 24-hour urine calcium between treatment groups .
H-402	-0.3816125690937042	There were no differences between treatment groups in terms of averages of serum calcium , phosphate or calcium in 24-hour urine .
D-402	-0.3816125690937042	There were no differences between treatment groups in terms of averages of serum calcium , phosphate or calcium in 24-hour urine .
P-402	-1.2397 -0.2728 -0.0497 -0.1247 -0.2533 -0.3002 -0.4733 -1.3948 -1.8657 -0.1474 -2.3432 -0.1261 -0.1859 -0.1115 -0.1245 -0.1418 -0.0821 -0.1254 -0.1514 -0.0758 -0.0516 -0.0845 -0.1891 -0.0661 -0.0926 -0.1292 -0.1653 -1.7050 -0.2514 -0.1534 -0.1045 -0.1041 -0.1373 -0.1513
S-129	Sie sollen keine zwei Tabletten am selben Tag einnehmen , sondern die Einnahme von einer Tablette pro Woche wie ursprünglich geplant am dafür vorgesehenen Wochentag weiterführen .
T-129	They should not take two tablets on the same day but should return to taking one tablet once a week , as originally scheduled on their chosen day .
H-129	-0.4445590376853943	Do not take two tablets on the same day but continue to take one tablet per week on the designated day of the week as originally planned .
D-129	-0.4445590376853943	Do not take two tablets on the same day but continue to take one tablet per week on the designated day of the week as originally planned .
P-129	-2.2579 -0.1380 -0.0654 -0.2084 -0.1604 -0.1375 -0.1995 -0.1665 -0.2044 -0.1157 -0.8969 -0.4288 -2.4042 -0.0581 -0.1507 -0.1351 -0.1236 -0.3363 -0.1400 -0.4154 -0.3942 -2.7222 -0.1192 -0.3072 -0.2233 -0.1185 -0.2918 -0.1950 -0.4680 -0.3531 -0.1348 -0.1558
S-157	In Tierstudien wurde unter hohen Vitamin-D-Dosen Hypercalcämie und Reproduktionstoxizität ( siehe Abschnitt 5.3 ) nachgewiesen .
T-157	Studies in animals have shown hypercalcaemia and reproductive toxicity with high doses of vitamin D ( see section 5.3 ) .
H-157	-0.2942347824573517	Animal studies at high doses of vitamin D have shown hypercalcaemia and reproductive toxicity ( see section 5.3 ) .
D-157	-0.2942347824573517	Animal studies at high doses of vitamin D have shown hypercalcaemia and reproductive toxicity ( see section 5.3 ) .
P-157	-0.3266 -0.0956 -0.1360 -1.8268 -1.1929 -0.1158 -0.0432 -0.4037 -0.5938 -0.9674 -0.3640 -0.0733 -0.7477 -0.0909 -0.0801 -0.0173 -0.0375 -0.1329 -0.1258 -0.1420 -0.3656 -0.0799 -0.0699 -0.1187 -0.1346 -0.3373 -0.1323 -0.1060 -0.1192 -0.1311 -0.1579 -0.1498
S-317	Sie sollen keine zwei Tabletten am selben Tag einnehmen , sondern die Einnahme von einer Tablette pro Woche wie ursprünglich geplant am dafür vorgesehenen Wochentag weiterführen .
T-317	They should not take two tablets on the same day but should return to taking one tablet once a week , as originally scheduled on their chosen day .
H-317	-0.4445590376853943	Do not take two tablets on the same day but continue to take one tablet per week on the designated day of the week as originally planned .
D-317	-0.4445590376853943	Do not take two tablets on the same day but continue to take one tablet per week on the designated day of the week as originally planned .
P-317	-2.2579 -0.1380 -0.0654 -0.2084 -0.1604 -0.1375 -0.1995 -0.1665 -0.2044 -0.1157 -0.8969 -0.4288 -2.4042 -0.0581 -0.1507 -0.1351 -0.1236 -0.3363 -0.1400 -0.4154 -0.3942 -2.7222 -0.1192 -0.3072 -0.2233 -0.1185 -0.2918 -0.1950 -0.4680 -0.3531 -0.1348 -0.1558
S-1481	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-1481	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-1481	-0.20686200261116028	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A
D-1481	-0.20686200261116028	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A
P-1481	-0.2634 -0.3325 -0.1555 -0.1866 -0.8239 -0.4060 -0.0739 -0.0999 -0.1470 -0.1224 -0.0638 -0.0431 -0.1401 -0.1522 -0.2772 -0.8151 -0.1385 -0.1263 -0.1470 -0.1237 -0.1873 -0.0884 -0.1479 -0.1568 -0.1539 -0.1625 -0.1411 -0.2097 -0.1458 -0.1393 -0.0639 -0.1537 -0.1803 -0.4887 -0.1829
S-174	Osteonekrose des Kiefers steht üblicherweise im Zusammenhang mit einer Zahnextraktion und<unk> oder einer lokalen Infektion ( einschließlich Osteomyelitis ) .
T-174	Osteonecrosis of the jaw is generally associated with tooth extraction and / or local infection ( including osteomyelitis ) .
H-174	-0.16563700139522552	jaw osteonecrosis is usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) .
D-174	-0.16563700139522552	jaw osteonecrosis is usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) .
P-174	-0.6425 -0.2296 -0.1112 -0.0659 -0.1309 -0.0862 -0.0406 -0.0745 -0.1055 -0.7701 -0.1963 -0.1562 -0.0735 -0.0422 -0.2583 -0.2132 -0.0553 -0.1397 -0.1208 -0.4625 -0.0511 -0.1613 -0.0839 -0.1098 -0.0800 -0.1150 -0.1566 -0.0741 -0.0615 -0.1325 -0.1473 -0.1524
S-777	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-777	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-777	-0.20686200261116028	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A
D-777	-0.20686200261116028	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A
P-777	-0.2634 -0.3325 -0.1555 -0.1866 -0.8239 -0.4060 -0.0739 -0.0999 -0.1470 -0.1224 -0.0638 -0.0431 -0.1401 -0.1522 -0.2772 -0.8151 -0.1385 -0.1263 -0.1470 -0.1237 -0.1873 -0.0884 -0.1479 -0.1568 -0.1539 -0.1625 -0.1411 -0.2097 -0.1458 -0.1393 -0.0639 -0.1537 -0.1803 -0.4887 -0.1829
S-362	Osteonekrose des Kiefers steht üblicherweise im Zusammenhang mit einer Zahnextraktion und<unk> oder einer lokalen Infektion ( einschließlich Osteomyelitis ) .
T-362	Osteonecrosis of the jaw is generally associated with tooth extraction and / or local infection ( including osteomyelitis ) .
H-362	-0.16563700139522552	jaw osteonecrosis is usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) .
D-362	-0.16563700139522552	jaw osteonecrosis is usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) .
P-362	-0.6425 -0.2296 -0.1112 -0.0659 -0.1309 -0.0862 -0.0406 -0.0745 -0.1055 -0.7701 -0.1963 -0.1562 -0.0735 -0.0422 -0.2583 -0.2132 -0.0553 -0.1397 -0.1208 -0.4625 -0.0511 -0.1613 -0.0839 -0.1098 -0.0800 -0.1150 -0.1566 -0.0741 -0.0615 -0.1325 -0.1473 -0.1524
S-603	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-603	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-603	-0.20686200261116028	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A
D-603	-0.20686200261116028	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A
P-603	-0.2634 -0.3325 -0.1555 -0.1866 -0.8239 -0.4060 -0.0739 -0.0999 -0.1470 -0.1224 -0.0638 -0.0431 -0.1401 -0.1522 -0.2772 -0.8151 -0.1385 -0.1263 -0.1470 -0.1237 -0.1873 -0.0884 -0.1479 -0.1568 -0.1539 -0.1625 -0.1411 -0.2097 -0.1458 -0.1393 -0.0639 -0.1537 -0.1803 -0.4887 -0.1829
S-39	Adenuric darf nicht bei Patienten angewendet werden , die möglicherweise überempfindlich ( allergisch ) gegen Feboxustat oder einen der sonstigen Bestandteile sind .
T-39	Adenuric should not be used in people who may be hypersensitive ( allergic ) to feboxustat or any of the other ingredients .
H-39	-0.20032444596290588	Adenuric must not be used in patients who may be hypersensitive ( allergic ) to Feboxustat or to any of the ingredients .
D-39	-0.20032444596290588	Adenuric must not be used in patients who may be hypersensitive ( allergic ) to Feboxustat or to any of the ingredients .
P-39	-0.1555 -0.1728 -0.0687 -0.1214 -1.1629 -0.1363 -0.1337 -0.1704 -0.2568 -0.3110 -0.1585 -0.2266 -0.1522 -0.1543 -0.0599 -0.1719 -0.0874 -0.0392 -0.1535 -0.1459 -0.7263 -0.1083 -0.1400 -0.1809 -0.1147 -0.1172 -0.1934 -0.1210 -0.1628 -0.2478 -0.1558 -0.1446 -0.1589
S-953	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-953	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-953	-0.20686200261116028	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A
D-953	-0.20686200261116028	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A
P-953	-0.2634 -0.3325 -0.1555 -0.1866 -0.8239 -0.4060 -0.0739 -0.0999 -0.1470 -0.1224 -0.0638 -0.0431 -0.1401 -0.1522 -0.2772 -0.8151 -0.1385 -0.1263 -0.1470 -0.1237 -0.1873 -0.0884 -0.1479 -0.1568 -0.1539 -0.1625 -0.1411 -0.2097 -0.1458 -0.1393 -0.0639 -0.1537 -0.1803 -0.4887 -0.1829
S-1129	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-1129	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-1129	-0.20686200261116028	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A
D-1129	-0.20686200261116028	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A
P-1129	-0.2634 -0.3325 -0.1555 -0.1866 -0.8239 -0.4060 -0.0739 -0.0999 -0.1470 -0.1224 -0.0638 -0.0431 -0.1401 -0.1522 -0.2772 -0.8151 -0.1385 -0.1263 -0.1470 -0.1237 -0.1873 -0.0884 -0.1479 -0.1568 -0.1539 -0.1625 -0.1411 -0.2097 -0.1458 -0.1393 -0.0639 -0.1537 -0.1803 -0.4887 -0.1829
S-1305	Die Bildung von neutralisierenden Antikörpern ( Inhibitoren ) gegen Faktor VIII ist eine bekannte Komplikation bei der Behandlung von Patienten mit Hämophilie A.
T-1305	The formation of neutralising antibodies ( inhibitors ) against factor VIII is a known complication in the management of individuals with haemophilia A.
H-1305	-0.20686200261116028	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A
D-1305	-0.20686200261116028	The formation of neutralizing antibodies ( inhibitors ) to factor VIII is a known complication in the treatment of patients with haemophilia A
P-1305	-0.2634 -0.3325 -0.1555 -0.1866 -0.8239 -0.4060 -0.0739 -0.0999 -0.1470 -0.1224 -0.0638 -0.0431 -0.1401 -0.1522 -0.2772 -0.8151 -0.1385 -0.1263 -0.1470 -0.1237 -0.1873 -0.0884 -0.1479 -0.1568 -0.1539 -0.1625 -0.1411 -0.2097 -0.1458 -0.1393 -0.0639 -0.1537 -0.1803 -0.4887 -0.1829
S-993	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-993	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-993	-0.24979212880134583	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) patients treated with ADVATE were inhibitors of factor VIII .
D-993	-0.24979212880134583	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) patients treated with ADVATE were inhibitors of factor VIII .
P-993	-0.1671 -0.1049 -0.0714 -0.0263 -0.0779 -0.2168 -0.2493 -0.2229 -0.0830 -0.1714 -0.1952 -0.1763 -0.4719 -0.1792 -0.1670 -0.1364 -0.0949 -0.1413 -0.1390 -1.1750 -0.1744 -0.1784 -0.0678 -0.1440 -0.0758 -0.0920 -1.1533 -0.3041 -0.0872 -0.0619 -0.1428 -0.7751 -0.2050 -0.1495 -0.1758 -1.0389 -0.1494
S-643	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-643	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-643	-0.24979212880134583	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) patients treated with ADVATE were inhibitors of factor VIII .
D-643	-0.24979212880134583	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) patients treated with ADVATE were inhibitors of factor VIII .
P-643	-0.1671 -0.1049 -0.0714 -0.0263 -0.0779 -0.2168 -0.2493 -0.2229 -0.0830 -0.1714 -0.1952 -0.1763 -0.4719 -0.1792 -0.1670 -0.1364 -0.0949 -0.1413 -0.1390 -1.1750 -0.1744 -0.1784 -0.0678 -0.1440 -0.0758 -0.0920 -1.1533 -0.3041 -0.0872 -0.0619 -0.1428 -0.7751 -0.2050 -0.1495 -0.1758 -1.0389 -0.1494
S-1169	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-1169	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-1169	-0.24979212880134583	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) patients treated with ADVATE were inhibitors of factor VIII .
D-1169	-0.24979212880134583	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) patients treated with ADVATE were inhibitors of factor VIII .
P-1169	-0.1671 -0.1049 -0.0714 -0.0263 -0.0779 -0.2168 -0.2493 -0.2229 -0.0830 -0.1714 -0.1952 -0.1763 -0.4719 -0.1792 -0.1670 -0.1364 -0.0949 -0.1413 -0.1390 -1.1750 -0.1744 -0.1784 -0.0678 -0.1440 -0.0758 -0.0920 -1.1533 -0.3041 -0.0872 -0.0619 -0.1428 -0.7751 -0.2050 -0.1495 -0.1758 -1.0389 -0.1494
S-817	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-817	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-817	-0.24979212880134583	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) patients treated with ADVATE were inhibitors of factor VIII .
D-817	-0.24979212880134583	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) patients treated with ADVATE were inhibitors of factor VIII .
P-817	-0.1671 -0.1049 -0.0714 -0.0263 -0.0779 -0.2168 -0.2493 -0.2229 -0.0830 -0.1714 -0.1952 -0.1763 -0.4719 -0.1792 -0.1670 -0.1364 -0.0949 -0.1413 -0.1390 -1.1750 -0.1744 -0.1784 -0.0678 -0.1440 -0.0758 -0.0920 -1.1533 -0.3041 -0.0872 -0.0619 -0.1428 -0.7751 -0.2050 -0.1495 -0.1758 -1.0389 -0.1494
S-405	Die Anstiege über die Ausgangswerte der BMD an der Lendenwirbelsäule betrugen nach einem Jahr im Mittel 5,1 % ( 95 % CI :
T-405	The mean increases from baseline in lumbar spine BMD at one year were 5.1 % ( 95 % CI :
H-405	-0.2535998225212097	Elevations above baseline lumbar spine BMD were 5.1 % ( 95 % CI :
D-405	-0.2535998225212097	Elevations above baseline lumbar spine BMD were 5.1 % ( 95 % CI :
P-405	-1.2253 -0.2394 -0.1790 -1.1532 -0.0140 -0.0134 -0.1042 -0.0405 -0.0366 -0.1282 -0.3288 -0.0811 -0.2092 -0.3410 -0.4601 -0.1415 -0.1202 -0.4518 -0.0864 -0.1179 -0.1125 -0.1897 -0.1477 -0.1646
S-1753	Wichtige Informationen über bestimmte sonstige Bestandteile von ADVATE Dieses Arzneimittel enthält 0,45 mmol Natrium ( 10 mg ) pro Durchstechflasche .
T-1753	Important information about some of the ingredients of ADVATE This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
H-1753	-0.1293957382440567	Important information about some of the ingredients of ADVATE This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
D-1753	-0.1293957382440567	Important information about some of the ingredients of ADVATE This medicinal product contains 0.45 mmol sodium ( 10 mg ) per vial .
P-1753	-0.1214 -0.0954 -0.1064 -0.1161 -0.1711 -0.6448 -0.1903 -0.1523 -0.0553 -0.2002 -0.0844 -0.1444 -0.0848 -0.0998 -0.0848 -0.0772 -0.0553 -0.0560 -0.0870 -0.1063 -0.1285 -0.1397 -0.1667 -0.1064 -0.1169 -0.0615 -0.1348 -0.1648 -0.0574 -0.1382 -0.0946 -0.1079 -0.0645 -0.1616 -0.1523
S-5	Adenuric wird zur Behandlung der chronischen ( langfristigen ) Hyperurikämie ( hohe Harnsäure- bzw. Uratspiegel im Blut ) angewendet .
T-5	Adenuric is used to treat chronic ( long-term ) hyperuricaemia ( high levels of uric acid or urate in the blood ) .
H-5	-0.26202625036239624	Adenuric is used to treat chronic ( long term ) hyperuricaemia ( high levels of uric acid and urine in the blood ) .
D-5	-0.26202625036239624	Adenuric is used to treat chronic ( long term ) hyperuricaemia ( high levels of uric acid and urine in the blood ) .
P-5	-0.1094 -0.1853 -0.0744 -0.1295 -0.1531 -0.0697 -0.1635 -0.0836 -0.0841 -0.1531 -0.7450 -0.9273 -0.1342 -0.1505 -0.0487 -0.2862 -0.0328 -0.1337 -0.1315 -0.5250 -0.4383 -0.2538 -0.0641 -0.0805 -0.2642 -0.4827 -0.6755 -1.0352 -0.5585 -0.1716 -0.0462 -0.2178 -0.1438 -0.1562
S-1734	ADVATE wird bei Patienten mit Hämophilie A eingesetzt zur Vorbeugung oder Behandlung von Sponatanblutungen oder Blutungen nach chirurgischen Eingriffen .
T-1734	ADVATE is used in patients with haemophilia A for prevention or treatment of spontaneous or surgery-related bleeding .
H-1734	-0.36211341619491577	ADVATE is used to prevent or treat spontaneous haemorrhage or haemorrhage following surgery in patients with haemophilia A .
D-1734	-0.36211341619491577	ADVATE is used to prevent or treat spontaneous haemorrhage or haemorrhage following surgery in patients with haemophilia A .
P-1734	-0.3751 -0.1485 -0.0808 -0.1116 -0.1514 -0.3217 -0.2987 -0.3078 -0.4042 -0.1178 -0.5776 -0.5560 -0.1205 -0.9541 -0.2501 -0.0197 -0.3235 -0.3795 -2.3565 -0.5700 -0.0131 -0.2539 -1.6184 -0.1219 -0.1716 -0.2383 -0.1269 -0.1314 -0.0642 -0.1565 -0.2015 -0.1617 -0.4745 -0.1530
S-136	4 Aufgrund der Stimulation der Knochenmineralisation durch Alendronat können Abnahmen des Serum-Calciums und -Phosphats auftreten .
T-136	Due to the positive effects of alendronate in increasing bone mineral , decreases in serum calcium and phosphate may occur .
H-136	-0.2794032692909241	Due to bone mineralization stimulation by alendronate , decreases in serum calcium and phosphate may occur .
D-136	-0.2794032692909241	Due to bone mineralization stimulation by alendronate , decreases in serum calcium and phosphate may occur .
P-136	-1.0555 -0.0845 -0.1349 -1.2040 -0.1010 -0.1654 -1.6805 -0.0480 -0.1702 -0.6334 -0.1387 -0.1402 -0.1248 -0.0538 -0.1743 -1.1779 -0.1278 -0.1428 -0.0615 -0.1035 -0.0931 -0.0868 -0.1153 -0.1323 -0.0713 -0.0629 -0.0843 -0.1447 -0.0548 -0.1387 -0.1545
S-1372	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1372	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-1372	-0.2619342803955078	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric mean
D-1372	-0.2619342803955078	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric mean
P-1372	-0.1110 -0.0997 -0.1384 -0.1482 -0.1323 -0.1394 -0.0477 -0.1244 -0.3082 -0.2634 -0.1107 -0.1364 -1.2809 -0.1205 -0.0887 -0.4629 -0.1233 -0.0706 -0.2315 -0.1381 -0.4121 -0.1224 -0.1221 -0.0657 -0.1392 -1.6364 -0.1170 -0.0669 -0.1271 -0.0793 -0.4973 -0.0535 -0.1212 -1.1694 -0.1618
S-1345	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-1345	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-1345	-0.24979212880134583	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) patients treated with ADVATE were inhibitors of factor VIII .
D-1345	-0.24979212880134583	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) patients treated with ADVATE were inhibitors of factor VIII .
P-1345	-0.1671 -0.1049 -0.0714 -0.0263 -0.0779 -0.2168 -0.2493 -0.2229 -0.0830 -0.1714 -0.1952 -0.1763 -0.4719 -0.1792 -0.1670 -0.1364 -0.0949 -0.1413 -0.1390 -1.1750 -0.1744 -0.1784 -0.0678 -0.1440 -0.0758 -0.0920 -1.1533 -0.3041 -0.0872 -0.0619 -0.1428 -0.7751 -0.2050 -0.1495 -0.1758 -1.0389 -0.1494
S-1774	Wenn Sie eine größere Menge von ADVATE angewendet haben , als Sie sollten Wenden Sie ADVATE immer genauso an , wie es Ihnen Ihr Arzt empfohlen hat .
T-1774	If you use more ADVATE than you should Always take ADVATE exactly as your doctor has told you .
H-1774	-0.309965044260025	If you have used more ADVATE than you should , always use ADVATE exactly as your doctor has recommended .
D-1774	-0.309965044260025	If you have used more ADVATE than you should , always use ADVATE exactly as your doctor has recommended .
P-1774	-0.4540 -0.1349 -0.3101 -0.9189 -0.2128 -0.3225 -0.1463 -0.0933 -0.0970 -0.1604 -0.1443 -0.1188 -0.2953 -0.7543 -1.0452 -0.2743 -0.1469 -0.0918 -0.1090 -0.6175 -0.2312 -0.1063 -0.0870 -0.2373 -0.7671 -0.2848 -0.2078
S-94	Andere Getränke ( einschließlich Mineralwasser ) , Nahrungsmittel und manche Arzneimittel können möglicherweise die Resorption von Alendronat beeinträchtigen ( siehe Abschnitt 4.5 ) .
T-94	Other beverages ( including mineral water ) , food and some medicinal products are likely to reduce the absorption of alendronate ( see section 4.5 ) .
H-94	-0.2285948246717453	Other beverages ( including mineral water ) , food and some medicinal products may affect the absorption of alendronate ( see section 4.5 ) .
D-94	-0.2285948246717453	Other beverages ( including mineral water ) , food and some medicinal products may affect the absorption of alendronate ( see section 4.5 ) .
P-94	-0.3184 -0.4353 -0.1286 -0.1749 -0.2113 -0.0682 -0.2826 -0.0909 -0.4030 -0.1359 -0.1531 -0.8096 -0.2722 -0.3184 -0.1885 -0.0603 -0.1015 -0.1398 -1.5418 -0.1335 -0.0855 -0.0734 -0.1528 -0.1828 -0.1544 -0.1271 -0.0503 -0.1335 -0.2894 -0.0994 -0.1147 -0.1402 -0.1341 -0.1443 -0.1509
S-668	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-668	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-668	-0.2619342803955078	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric mean
D-668	-0.2619342803955078	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric mean
P-668	-0.1110 -0.0997 -0.1384 -0.1482 -0.1323 -0.1394 -0.0477 -0.1244 -0.3082 -0.2634 -0.1107 -0.1364 -1.2809 -0.1205 -0.0887 -0.4629 -0.1233 -0.0706 -0.2315 -0.1381 -0.4121 -0.1224 -0.1221 -0.0657 -0.1392 -1.6364 -0.1170 -0.0669 -0.1271 -0.0793 -0.4973 -0.0535 -0.1212 -1.1694 -0.1618
S-844	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-844	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-844	-0.2619342803955078	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric mean
D-844	-0.2619342803955078	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric mean
P-844	-0.1110 -0.0997 -0.1384 -0.1482 -0.1323 -0.1394 -0.0477 -0.1244 -0.3082 -0.2634 -0.1107 -0.1364 -1.2809 -0.1205 -0.0887 -0.4629 -0.1233 -0.0706 -0.2315 -0.1381 -0.4121 -0.1224 -0.1221 -0.0657 -0.1392 -1.6364 -0.1170 -0.0669 -0.1271 -0.0793 -0.4973 -0.0535 -0.1212 -1.1694 -0.1618
S-528	Es wird von einer Zelle produziert , in die ein Gen ( DNA ) eingebracht wurde , das sie zur Bildung des menschlichen Gerinnungsfaktors VIII befähigt .
T-528	Es wird von einer Zelle produziert , in die ein Gen ( DNA ) eingebracht wurde , das sie zur Bildung des menschlichen Gerinnungsfaktors VIII befähigt . Advate is similar to another medicine approved in the European Union ( EU ) called Recombinate , but it is prepared differently so that there are no human- or animal-derived proteins in the medicine .
H-528	-0.2782531678676605	It is produced by a cell into which a gene ( DNA ) has been introduced that enables it to form human clotting factor VIII .
D-528	-0.2782531678676605	It is produced by a cell into which a gene ( DNA ) has been introduced that enables it to form human clotting factor VIII .
P-528	-0.2049 -0.1224 -0.0651 -0.1539 -0.1625 -0.0880 -0.3601 -0.2787 -0.2394 -0.1671 -0.1702 -0.0478 -0.1336 -0.1865 -0.1736 -1.4800 -0.2198 -0.2844 -0.0967 -0.1882 -0.1402 -1.4510 -0.7830 -0.7102 -0.0162 -0.0882 -0.0673 -0.1267 -0.1166 -0.1472 -0.1564
S-1549	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1549	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-1549	-0.2619342803955078	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric mean
D-1549	-0.2619342803955078	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric mean
P-1549	-0.1110 -0.0997 -0.1384 -0.1482 -0.1323 -0.1394 -0.0477 -0.1244 -0.3082 -0.2634 -0.1107 -0.1364 -1.2809 -0.1205 -0.0887 -0.4629 -0.1233 -0.0706 -0.2315 -0.1381 -0.4121 -0.1224 -0.1221 -0.0657 -0.1392 -1.6364 -0.1170 -0.0669 -0.1271 -0.0793 -0.4973 -0.0535 -0.1212 -1.1694 -0.1618
S-1196	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1196	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-1196	-0.2619342803955078	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric mean
D-1196	-0.2619342803955078	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric mean
P-1196	-0.1110 -0.0997 -0.1384 -0.1482 -0.1323 -0.1394 -0.0477 -0.1244 -0.3082 -0.2634 -0.1107 -0.1364 -1.2809 -0.1205 -0.0887 -0.4629 -0.1233 -0.0706 -0.2315 -0.1381 -0.4121 -0.1224 -0.1221 -0.0657 -0.1392 -1.6364 -0.1170 -0.0669 -0.1271 -0.0793 -0.4973 -0.0535 -0.1212 -1.1694 -0.1618
S-281	Andere Getränke ( einschließlich Mineralwasser ) , Nahrungsmittel und manche Arzneimittel können möglicherweise die Resorption von Alendronat beeinträchtigen ( siehe Abschnitt 4.5 ) .
T-281	Other beverages ( including mineral water ) , food and some medicinal products are likely to reduce the absorption of alendronate ( see section 4.5 ) .
H-281	-0.2285948246717453	Other beverages ( including mineral water ) , food and some medicinal products may affect the absorption of alendronate ( see section 4.5 ) .
D-281	-0.2285948246717453	Other beverages ( including mineral water ) , food and some medicinal products may affect the absorption of alendronate ( see section 4.5 ) .
P-281	-0.3184 -0.4353 -0.1286 -0.1749 -0.2113 -0.0682 -0.2826 -0.0909 -0.4030 -0.1359 -0.1531 -0.8096 -0.2722 -0.3184 -0.1885 -0.0603 -0.1015 -0.1398 -1.5418 -0.1335 -0.0855 -0.0734 -0.1528 -0.1828 -0.1544 -0.1271 -0.0503 -0.1335 -0.2894 -0.0994 -0.1147 -0.1402 -0.1341 -0.1443 -0.1509
S-1020	Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1020	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric mean
H-1020	-0.2619342803955078	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric mean
D-1020	-0.2619342803955078	Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRI ( h ) VSS ( dl/ kg ) * Geometric mean
P-1020	-0.1110 -0.0997 -0.1384 -0.1482 -0.1323 -0.1394 -0.0477 -0.1244 -0.3082 -0.2634 -0.1107 -0.1364 -1.2809 -0.1205 -0.0887 -0.4629 -0.1233 -0.0706 -0.2315 -0.1381 -0.4121 -0.1224 -0.1221 -0.0657 -0.1392 -1.6364 -0.1170 -0.0669 -0.1271 -0.0793 -0.4973 -0.0535 -0.1212 -1.1694 -0.1618
S-1916	Während der Studie trugen die Patienten ihre Symptome alle 12 Stunden in ein Tagebuch ein und bewerteten mit einer Standardskala , wie schwer die Symptome in den letzten 12 Stunden waren .
T-1916	The patients recorded their symptoms in a diary every 12 hours during the study , scoring on a standard symptom scale how severe the symptoms were over the previous 12-hour period .
H-1916	-0.41928166151046753	During the study , patients entered their symptoms in a diary every 12 hours and used a standard scale to assess how severe their symptoms were in the last 12 hours .
D-1916	-0.41928166151046753	During the study , patients entered their symptoms in a diary every 12 hours and used a standard scale to assess how severe their symptoms were in the last 12 hours .
P-1916	-0.3193 -0.1563 -1.0705 -0.4111 -0.0929 -2.2132 -0.1318 -0.1003 -0.2697 -0.1403 -0.4171 -0.1457 -0.2839 -0.2445 -0.1163 -0.1683 -0.4016 -0.1136 -0.3211 -0.0800 -0.1270 -1.5882 -0.1174 -0.2416 -1.0395 -0.1113 -0.7458 -1.0434 -0.1416 -1.3139 -0.1713 -0.1242 -0.1403 -0.1524
S-1522	Bei zuvor nicht behandelten Patienten einer laufenden klinischen Studie bildeten 5 von 25 ( 20 % ) mit ADVATE behandelte Patienten Inhibitoren gegen Faktor VIII.
T-1522	In previously untreated patients in an ongoing clinical study , 5 ( 20 % ) of 25 patients who received ADVATE developed inhibitors to factor VIII .
H-1522	-0.24979212880134583	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) patients treated with ADVATE were inhibitors of factor VIII .
D-1522	-0.24979212880134583	In previously untreated patients in an ongoing clinical trial , 5 out of 25 ( 20 % ) patients treated with ADVATE were inhibitors of factor VIII .
P-1522	-0.1671 -0.1049 -0.0714 -0.0263 -0.0779 -0.2168 -0.2493 -0.2229 -0.0830 -0.1714 -0.1952 -0.1763 -0.4719 -0.1792 -0.1670 -0.1364 -0.0949 -0.1413 -0.1390 -1.1750 -0.1744 -0.1784 -0.0678 -0.1440 -0.0758 -0.0920 -1.1533 -0.3041 -0.0872 -0.0619 -0.1428 -0.7751 -0.2050 -0.1495 -0.1758 -1.0389 -0.1494
S-422	Die Bioverfügbarkeit nahm entsprechend auf etwa 0,46 % und 0,39 % ab , wenn Alendronat eine oder eine halbe Stunde vor einem standardisierten Frühstück
T-422	Bioavailability was decreased similarly to an estimated 0.46 % and 0.39 % when alendronate was administered one hour or half an hour before a standardised breakfast .
H-422	-0.29743900895118713	Bioavailability decreased correspondingly to approximately 0.46 % and 0.39 % when alendronate was administered one or half an hour prior to a standardized breakfast
D-422	-0.29743900895118713	Bioavailability decreased correspondingly to approximately 0.46 % and 0.39 % when alendronate was administered one or half an hour prior to a standardized breakfast
P-422	-0.8279 -0.1044 -0.2991 -0.1653 -0.4445 -0.4192 -0.0955 -0.2384 -0.4874 -0.0894 -0.0767 -0.1253 -0.1278 -0.0665 -0.0762 -0.1157 -0.2380 -0.1539 -0.1596 -0.0977 -0.0501 -0.0645 -0.7941 -0.0904 -0.0932 -0.5923 -0.8721 -1.5040 -0.0865 -0.4313 -0.1296 -0.1712 -0.5290 -0.2728 -0.4827 -0.1921 -0.2409
S-1945	Aerinaze sollte aufgrund des Fehlens von Daten zur Unbedenklichkeit und Wirksamkeit ( siehe Abschnitt 5.1 ) nicht bei Kindern unter 12 Jahren angewendet werden .
T-1945	Aerinaze should not be used in children below the age of 12 years due to a lack of data on safety and efficacy ( see section 5.1 ) .
H-1945	-0.19079431891441345	Due to the lack of safety and efficacy data ( see section 5.1 ) , Aerinaze should not be used in children under 12 years of age .
D-1945	-0.19079431891441345	Due to the lack of safety and efficacy data ( see section 5.1 ) , Aerinaze should not be used in children under 12 years of age .
P-1945	-0.6141 -0.0678 -0.1396 -0.7785 -0.3247 -0.1580 -0.0583 -0.1370 -0.0249 -0.0768 -0.1071 -0.1594 -0.1314 -0.2895 -0.1381 -0.1081 -0.1499 -0.1352 -0.2043 -0.2090 -0.1336 -0.1180 -0.1545 -0.1366 -0.1639 -0.1510 -0.1429 -0.2206 -0.1997 -0.2145 -0.5423 -0.1730 -0.1246 -0.1738 -0.0978 -0.1461 -0.1549
S-209	Die Anstiege über die Ausgangswerte der BMD an der Lendenwirbelsäule betrugen nach einem Jahr im Mittel 5,1 % ( 95 % CI :
T-209	The mean increases from baseline in lumbar spine BMD at one year were 5.1 % ( 95 % CI :
H-209	-0.2535998225212097	Elevations above baseline lumbar spine BMD were 5.1 % ( 95 % CI :
D-209	-0.2535998225212097	Elevations above baseline lumbar spine BMD were 5.1 % ( 95 % CI :
P-209	-1.2253 -0.2394 -0.1790 -1.1532 -0.0140 -0.0134 -0.1042 -0.0405 -0.0366 -0.1282 -0.3288 -0.0811 -0.2092 -0.3410 -0.4601 -0.1415 -0.1202 -0.4518 -0.0864 -0.1179 -0.1125 -0.1897 -0.1477 -0.1646
S-1433	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-1433	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-1433	-0.27280718088150024	Prepared without the addition of a ( exogenous ) human or animal protein during the cell culture , purification and final formulation process .
D-1433	-0.27280718088150024	Prepared without the addition of a ( exogenous ) human or animal protein during the cell culture , purification and final formulation process .
P-1433	-0.6604 -0.3678 -0.1183 -0.5586 -0.1653 -0.1536 -1.3291 -0.1563 -0.1215 -0.1514 -0.0924 -0.1371 -0.1076 -0.1530 -0.0768 -0.0870 -0.1408 -0.5534 -0.2395 -0.1028 -0.3969 -0.2711 -0.0755 -0.0915 -0.3135 -0.8647 -0.0205 -0.0770 -0.5621 -0.1589 -0.1526
S-584	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-584	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma factor VIII activity assay is indispensable .
H-584	-0.4772413969039917	Especially for major surgery , close monitoring of substitution therapy by determination of factor VIII-activity in plasma is imperative .
D-584	-0.4772413969039917	Especially for major surgery , close monitoring of substitution therapy by determination of factor VIII-activity in plasma is imperative .
P-584	-1.6657 -0.2240 -1.2881 -0.3478 -0.3547 -0.3976 -1.0666 -0.5589 -0.1373 -0.3828 -0.0613 -0.0839 -0.1503 -2.0996 -0.1428 -0.1588 -0.3700 -0.1741 -1.5074 -0.3676 -0.1672 -0.1206 -0.1474 -0.0839 -0.1130 -0.1537 -1.6419 -0.4281 -0.1028 -0.1433 -0.1532
S-87	Kapselförmige , weiße bis gebrochen weiße Tabletten , gekennzeichnet mit dem Umriss eines Knochens auf der einen Seite und 710 auf der anderen Seite .
T-87	Capsule-shaped , white to off-white tablets , marked with an outline of a bone image on one side , and <<unk>> 710 <<unk>> on the other .
H-87	-0.2875330448150635	Capsule shaped , white to broken white tablets marked with the outline of a bone on one side and 710 on the other .
D-87	-0.2875330448150635	Capsule shaped , white to broken white tablets marked with the outline of a bone on one side and 710 on the other .
P-87	-0.3109 -0.1055 -0.8934 -1.4230 -0.4568 -0.0650 -0.1291 -0.5858 -0.0781 -0.1453 -0.1154 -1.4827 -0.1565 -0.1580 -0.3157 -0.1379 -0.1612 -0.1579 -0.0933 -0.1536 -0.1441 -0.1328 -0.1409 -0.1060 -0.1632 -0.1758 -0.1318 -0.1260 -0.2188 -0.1615
S-737	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-737	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-737	-0.5276194214820862	Needs Treatment The Factor VIII dose is given in International Units ( IU ) in line with the WHO standard for Factor VIII products .
D-737	-0.5276194214820862	Needs Treatment The Factor VIII dose is given in International Units ( IU ) in line with the WHO standard for Factor VIII products .
P-737	-0.7570 -1.4640 -2.8911 -0.0662 -0.0776 -0.2854 -1.0010 -0.1444 -0.1148 -0.0460 -0.1149 -1.4913 -0.1225 -0.5600 -0.0770 -0.0991 -0.1395 -0.1231 -0.0726 -0.1295 -2.0493 -0.9305 -0.1364 -0.3009 -0.6216 -0.6640 -0.3880 -0.1254 -0.6009 -0.3104 -0.1407 -1.9930 -0.1311 -0.1436 -0.1536
S-1257	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-1257	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-1257	-0.27280718088150024	Prepared without the addition of a ( exogenous ) human or animal protein during the cell culture , purification and final formulation process .
D-1257	-0.27280718088150024	Prepared without the addition of a ( exogenous ) human or animal protein during the cell culture , purification and final formulation process .
P-1257	-0.6604 -0.3678 -0.1183 -0.5586 -0.1653 -0.1536 -1.3291 -0.1563 -0.1215 -0.1514 -0.0924 -0.1371 -0.1076 -0.1530 -0.0768 -0.0870 -0.1408 -0.5534 -0.2395 -0.1028 -0.3969 -0.2711 -0.0755 -0.0915 -0.3135 -0.8647 -0.0205 -0.0770 -0.5621 -0.1589 -0.1526
S-1081	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-1081	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-1081	-0.27280718088150024	Prepared without the addition of a ( exogenous ) human or animal protein during the cell culture , purification and final formulation process .
D-1081	-0.27280718088150024	Prepared without the addition of a ( exogenous ) human or animal protein during the cell culture , purification and final formulation process .
P-1081	-0.6604 -0.3678 -0.1183 -0.5586 -0.1653 -0.1536 -1.3291 -0.1563 -0.1215 -0.1514 -0.0924 -0.1371 -0.1076 -0.1530 -0.0768 -0.0870 -0.1408 -0.5534 -0.2395 -0.1028 -0.3969 -0.2711 -0.0755 -0.0915 -0.3135 -0.8647 -0.0205 -0.0770 -0.5621 -0.1589 -0.1526
S-905	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-905	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-905	-0.27280718088150024	Prepared without the addition of a ( exogenous ) human or animal protein during the cell culture , purification and final formulation process .
D-905	-0.27280718088150024	Prepared without the addition of a ( exogenous ) human or animal protein during the cell culture , purification and final formulation process .
P-905	-0.6604 -0.3678 -0.1183 -0.5586 -0.1653 -0.1536 -1.3291 -0.1563 -0.1215 -0.1514 -0.0924 -0.1371 -0.1076 -0.1530 -0.0768 -0.0870 -0.1408 -0.5534 -0.2395 -0.1028 -0.3969 -0.2711 -0.0755 -0.0915 -0.3135 -0.8647 -0.0205 -0.0770 -0.5621 -0.1589 -0.1526
S-729	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-729	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-729	-0.27280718088150024	Prepared without the addition of a ( exogenous ) human or animal protein during the cell culture , purification and final formulation process .
D-729	-0.27280718088150024	Prepared without the addition of a ( exogenous ) human or animal protein during the cell culture , purification and final formulation process .
P-729	-0.6604 -0.3678 -0.1183 -0.5586 -0.1653 -0.1536 -1.3291 -0.1563 -0.1215 -0.1514 -0.0924 -0.1371 -0.1076 -0.1530 -0.0768 -0.0870 -0.1408 -0.5534 -0.2395 -0.1028 -0.3969 -0.2711 -0.0755 -0.0915 -0.3135 -0.8647 -0.0205 -0.0770 -0.5621 -0.1589 -0.1526
S-562	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-562	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-562	-0.5276194214820862	Needs Treatment The Factor VIII dose is given in International Units ( IU ) in line with the WHO standard for Factor VIII products .
D-562	-0.5276194214820862	Needs Treatment The Factor VIII dose is given in International Units ( IU ) in line with the WHO standard for Factor VIII products .
P-562	-0.7570 -1.4640 -2.8911 -0.0662 -0.0776 -0.2854 -1.0010 -0.1444 -0.1148 -0.0460 -0.1149 -1.4913 -0.1225 -0.5600 -0.0770 -0.0991 -0.1395 -0.1231 -0.0726 -0.1295 -2.0493 -0.9305 -0.1364 -0.3009 -0.6216 -0.6640 -0.3880 -0.1254 -0.6009 -0.3104 -0.1407 -1.9930 -0.1311 -0.1436 -0.1536
S-554	Zubereitet ohne Zusatz eines ( exogenen ) menschlichen oder tierischen Proteins während des Zellkultur-Prozesses , der Reinigung und der Endformulierung .
T-554	Prepared without the addition of any ( exogenous ) human- or animal-derived protein in the cell culture process , purification or final formulation .
H-554	-0.27280718088150024	Prepared without the addition of a ( exogenous ) human or animal protein during the cell culture , purification and final formulation process .
D-554	-0.27280718088150024	Prepared without the addition of a ( exogenous ) human or animal protein during the cell culture , purification and final formulation process .
P-554	-0.6604 -0.3678 -0.1183 -0.5586 -0.1653 -0.1536 -1.3291 -0.1563 -0.1215 -0.1514 -0.0924 -0.1371 -0.1076 -0.1530 -0.0768 -0.0870 -0.1408 -0.5534 -0.2395 -0.1028 -0.3969 -0.2711 -0.0755 -0.0915 -0.3135 -0.8647 -0.0205 -0.0770 -0.5621 -0.1589 -0.1526
S-758	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-758	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 13 factor VIII activity assay is indispensable .
H-758	-0.4772413969039917	Especially for major surgery , close monitoring of substitution therapy by determination of factor VIII-activity in plasma is imperative .
D-758	-0.4772413969039917	Especially for major surgery , close monitoring of substitution therapy by determination of factor VIII-activity in plasma is imperative .
P-758	-1.6657 -0.2240 -1.2881 -0.3478 -0.3547 -0.3976 -1.0666 -0.5589 -0.1373 -0.3828 -0.0613 -0.0839 -0.1503 -2.0996 -0.1428 -0.1588 -0.3700 -0.1741 -1.5074 -0.3676 -0.1672 -0.1206 -0.1474 -0.0839 -0.1130 -0.1537 -1.6419 -0.4281 -0.1028 -0.1433 -0.1532
S-913	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-913	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-913	-0.5276194214820862	Needs Treatment The Factor VIII dose is given in International Units ( IU ) in line with the WHO standard for Factor VIII products .
D-913	-0.5276194214820862	Needs Treatment The Factor VIII dose is given in International Units ( IU ) in line with the WHO standard for Factor VIII products .
P-913	-0.7570 -1.4640 -2.8911 -0.0662 -0.0776 -0.2854 -1.0010 -0.1444 -0.1148 -0.0460 -0.1149 -1.4913 -0.1225 -0.5600 -0.0770 -0.0991 -0.1395 -0.1231 -0.0726 -0.1295 -2.0493 -0.9305 -0.1364 -0.3009 -0.6216 -0.6640 -0.3880 -0.1254 -0.6009 -0.3104 -0.1407 -1.9930 -0.1311 -0.1436 -0.1536
S-934	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-934	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 23 factor VIII activity assay is indispensable .
H-934	-0.4772413969039917	Especially for major surgery , close monitoring of substitution therapy by determination of factor VIII-activity in plasma is imperative .
D-934	-0.4772413969039917	Especially for major surgery , close monitoring of substitution therapy by determination of factor VIII-activity in plasma is imperative .
P-934	-1.6657 -0.2240 -1.2881 -0.3478 -0.3547 -0.3976 -1.0666 -0.5589 -0.1373 -0.3828 -0.0613 -0.0839 -0.1503 -2.0996 -0.1428 -0.1588 -0.3700 -0.1741 -1.5074 -0.3676 -0.1672 -0.1206 -0.1474 -0.0839 -0.1130 -0.1537 -1.6419 -0.4281 -0.1028 -0.1433 -0.1532
S-1089	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-1089	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-1089	-0.5276194214820862	Needs Treatment The Factor VIII dose is given in International Units ( IU ) in line with the WHO standard for Factor VIII products .
D-1089	-0.5276194214820862	Needs Treatment The Factor VIII dose is given in International Units ( IU ) in line with the WHO standard for Factor VIII products .
P-1089	-0.7570 -1.4640 -2.8911 -0.0662 -0.0776 -0.2854 -1.0010 -0.1444 -0.1148 -0.0460 -0.1149 -1.4913 -0.1225 -0.5600 -0.0770 -0.0991 -0.1395 -0.1231 -0.0726 -0.1295 -2.0493 -0.9305 -0.1364 -0.3009 -0.6216 -0.6640 -0.3880 -0.1254 -0.6009 -0.3104 -0.1407 -1.9930 -0.1311 -0.1436 -0.1536
S-1110	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-1110	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 33 factor VIII activity assay is indispensable .
H-1110	-0.4772413969039917	Especially for major surgery , close monitoring of substitution therapy by determination of factor VIII-activity in plasma is imperative .
D-1110	-0.4772413969039917	Especially for major surgery , close monitoring of substitution therapy by determination of factor VIII-activity in plasma is imperative .
P-1110	-1.6657 -0.2240 -1.2881 -0.3478 -0.3547 -0.3976 -1.0666 -0.5589 -0.1373 -0.3828 -0.0613 -0.0839 -0.1503 -2.0996 -0.1428 -0.1588 -0.3700 -0.1741 -1.5074 -0.3676 -0.1672 -0.1206 -0.1474 -0.0839 -0.1130 -0.1537 -1.6419 -0.4281 -0.1028 -0.1433 -0.1532
S-1265	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-1265	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-1265	-0.5276194214820862	Needs Treatment The Factor VIII dose is given in International Units ( IU ) in line with the WHO standard for Factor VIII products .
D-1265	-0.5276194214820862	Needs Treatment The Factor VIII dose is given in International Units ( IU ) in line with the WHO standard for Factor VIII products .
P-1265	-0.7570 -1.4640 -2.8911 -0.0662 -0.0776 -0.2854 -1.0010 -0.1444 -0.1148 -0.0460 -0.1149 -1.4913 -0.1225 -0.5600 -0.0770 -0.0991 -0.1395 -0.1231 -0.0726 -0.1295 -2.0493 -0.9305 -0.1364 -0.3009 -0.6216 -0.6640 -0.3880 -0.1254 -0.6009 -0.3104 -0.1407 -1.9930 -0.1311 -0.1436 -0.1536
S-1286	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-1286	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 43 factor VIII activity assay is indispensable .
H-1286	-0.4772413969039917	Especially for major surgery , close monitoring of substitution therapy by determination of factor VIII-activity in plasma is imperative .
D-1286	-0.4772413969039917	Especially for major surgery , close monitoring of substitution therapy by determination of factor VIII-activity in plasma is imperative .
P-1286	-1.6657 -0.2240 -1.2881 -0.3478 -0.3547 -0.3976 -1.0666 -0.5589 -0.1373 -0.3828 -0.0613 -0.0839 -0.1503 -2.0996 -0.1428 -0.1588 -0.3700 -0.1741 -1.5074 -0.3676 -0.1672 -0.1206 -0.1474 -0.0839 -0.1130 -0.1537 -1.6419 -0.4281 -0.1028 -0.1433 -0.1532
S-1441	Bedarfsbehandlung Die Faktor VIII Dosis wird in Internationalen Einheiten ( I.E. ) angegeben , entsprechend dem WHO- Standard für Faktor VIII-Produkte .
T-1441	On demand treatment The dose of factor VIII ( FVIII<<unk>> is expressed in International Units ( IU ) , which are related to the WHO standard for factor VIII products .
H-1441	-0.5276194214820862	Needs Treatment The Factor VIII dose is given in International Units ( IU ) in line with the WHO standard for Factor VIII products .
D-1441	-0.5276194214820862	Needs Treatment The Factor VIII dose is given in International Units ( IU ) in line with the WHO standard for Factor VIII products .
P-1441	-0.7570 -1.4640 -2.8911 -0.0662 -0.0776 -0.2854 -1.0010 -0.1444 -0.1148 -0.0460 -0.1149 -1.4913 -0.1225 -0.5600 -0.0770 -0.0991 -0.1395 -0.1231 -0.0726 -0.1295 -2.0493 -0.9305 -0.1364 -0.3009 -0.6216 -0.6640 -0.3880 -0.1254 -0.6009 -0.3104 -0.1407 -1.9930 -0.1311 -0.1436 -0.1536
S-1462	Besonders bei größeren chirurgischen Eingriffen ist eine genaue Überwachung der Substitutionstherapie durch Bestimmung der Faktor VIII-Aktivität im Plasma unerlässlich .
T-1462	In the case of major surgical interventions in particular , precise monitoring of the substitution therapy by means of plasma 53 factor VIII activity assay is indispensable .
H-1462	-0.4772413969039917	Especially for major surgery , close monitoring of substitution therapy by determination of factor VIII-activity in plasma is imperative .
D-1462	-0.4772413969039917	Especially for major surgery , close monitoring of substitution therapy by determination of factor VIII-activity in plasma is imperative .
P-1462	-1.6657 -0.2240 -1.2881 -0.3478 -0.3547 -0.3976 -1.0666 -0.5589 -0.1373 -0.3828 -0.0613 -0.0839 -0.1503 -2.0996 -0.1428 -0.1588 -0.3700 -0.1741 -1.5074 -0.3676 -0.1672 -0.1206 -0.1474 -0.0839 -0.1130 -0.1537 -1.6419 -0.4281 -0.1028 -0.1433 -0.1532
S-1976	Reversible und irreversible MAO-Hemmer können das Risiko für das Auftreten einer Gefäßverengung und einer Hypertonie erhöhen .
T-1976	Reversible and irreversible MAO inhibitor<<unk>> s ) may cause : risk of vasoconstriction and increased blood pressure .
H-1976	-0.23523232340812683	Reversible and irreversible MAOI may increase the risk of vascular narrowing and hypertension .
D-1976	-0.23523232340812683	Reversible and irreversible MAOI may increase the risk of vascular narrowing and hypertension .
P-1976	-0.1720 -0.0549 -0.1051 -0.1483 -0.2092 -0.1346 -0.0528 -0.0946 -0.0702 -0.1456 -0.1085 -0.1332 -0.0387 -0.1435 -0.1097 -0.5503 -1.2009 -0.0289 -0.1995 -1.8297 -0.0747 -0.1308 -0.0221 -0.0379 -0.1575 -0.1628
S-1749	Bei Einnahme mit anderen Arzneimitteln Bitte informieren Sie Ihren Arzt , wenn Sie andere Arzneimittel einnehmen bzw. vor kurzem eingenommen haben , auch wenn es sich um nicht-verschreibungspflichtige Arzneimittel handelt .
T-1749	Taking other medicines Please tell your doctor if you are taking or have recently taken any other medicines , including medicines obtained without a prescription .
H-1749	-0.4547165036201477	If you are taking other medicinal products Please tell your doctor if you are taking or have recently taken other medicinal products , even if they are non-prescription .
D-1749	-0.4547165036201477	If you are taking other medicinal products Please tell your doctor if you are taking or have recently taken other medicinal products , even if they are non-prescription .
P-1749	-0.4948 -0.5019 -0.4639 -0.1962 -0.3086 -0.5261 -1.3191 -0.0648 -0.9345 -0.2388 -0.1742 -0.0941 -0.1820 -0.1492 -0.1223 -0.1579 -1.3264 -0.1561 -0.2774 -0.2011 -0.2349 -0.3330 -0.1734 -0.0737 -0.1573 -0.3883 -0.4848 -0.2852 -0.0884 -2.4110 -0.2843 -0.2207 -2.2753 -0.1606
S-284	13 Die Patienten sollen sich nach Einnahme von ADROVANCE mindestens 30 Minuten nicht hinlegen . ADROVANCE soll nicht vor dem Schlafengehen oder vor dem ersten Aufstehen des Tages eingenommen werden .
T-284	Patients should not lie down until after their first food of the day which should be at least 30 minutes after taking the tablet .
H-284	-0.28590428829193115	Patients should not lie down for at least 30 minutes after taking ADROVANCE . ADROVANCE should not be taken before bedtime or before getting up for the first time .
D-284	-0.28590428829193115	Patients should not lie down for at least 30 minutes after taking ADROVANCE . ADROVANCE should not be taken before bedtime or before getting up for the first time .
P-284	-1.3761 -0.1032 -0.1050 -0.1284 -0.1706 -0.0859 -0.1132 -0.0810 -0.1243 -0.1247 -0.1685 -0.1862 -0.1230 -0.0849 -0.0791 -0.1212 -0.1142 -0.1353 -0.1553 -0.1036 -0.0714 -0.1180 -0.1138 -0.1474 -0.1486 -0.1568 -0.1621 -0.1422 -0.4106 -1.7959 -0.1183 -0.1215 -1.2897 -1.7393 -0.1156 -0.5007 -0.1495 -0.0969 -0.1016 -0.3846 -0.1539
S-254	Die mittlere Halbwertszeit von Vitamin D3 im Serum beträgt ca. 24 Stunden nach einer oralen Dosis von ADROVANCE ( 70 mg<unk> 2.800 I.E . ) .
T-254	The mean half-life of vitamin D3 in the serum following an oral dose of ADROVANCE ( 70 mg/ 2800 IU ) is approximately 24 hours .
H-254	-0.1700240522623062	The mean half-life of vitamin D3 in the serum is approximately 24 hours after an oral dose of ADROVANCE ( 70 mg/ 2,800 IU ) .
D-254	-0.1700240522623062	The mean half-life of vitamin D3 in the serum is approximately 24 hours after an oral dose of ADROVANCE ( 70 mg/ 2,800 IU ) .
P-254	-0.2145 -0.1344 -0.4146 -0.1675 -0.1252 -0.1513 -0.3404 -0.1070 -0.1312 -0.1377 -0.1553 -0.6315 -0.0908 -0.1541 -0.1308 -0.1016 -0.1323 -0.1221 -0.2542 -0.6485 -0.0781 -0.0723 -0.1573 -0.0808 -0.0835 -0.1214 -0.1090 -0.1232 -0.1364 -0.1339 -0.1903 -0.1250 -0.1297 -0.2421 -0.1025 -0.0950 -0.0600 -0.1247 -0.1424 -0.1485
S-663	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-663	7 increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-663	-0.39007529616355896	The factor VIII-plasma levels are increased by the substitution therapy , whereby a transient correction of factor VIII-deficiency and the tendency to bleed occurs .
D-663	-0.39007529616355896	The factor VIII-plasma levels are increased by the substitution therapy , whereby a transient correction of factor VIII-deficiency and the tendency to bleed occurs .
P-663	-1.3351 -2.3559 -0.2812 -0.2215 -0.9077 -0.3164 -0.6389 -0.0587 -0.0930 -0.3394 -0.2127 -0.2330 -0.2026 -0.5395 -0.1891 -0.0653 -0.1182 -0.3671 -1.0718 -0.3319 -0.4090 -0.8104 -0.0573 -0.0994 -0.0135 -0.0984 -0.2414 -0.5125 -0.2605 -0.1269 -0.2762 -0.0904 -0.0550 -0.0373 -0.1107 -0.1321 -1.5562 -0.9362 -0.1020 -0.3752 -0.2978 -0.0865 -1.0065 -0.0766 -0.1440 -0.1523
S-1005	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-1005	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-1005	-0.30147117376327515	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
D-1005	-0.30147117376327515	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
P-1005	-0.2283 -0.5090 -0.2750 -0.1435 -0.3125 -0.1201 -1.2271 -0.5970 -0.1176 -0.1630 -0.3758 -0.3281 -0.1000 -0.1000 -0.1611 -0.2059 -0.0765 -0.0977 -0.1444 -1.2332 -0.1556 -0.1297 -0.1561 -0.7262 -0.1266 -0.1207 -0.1855 -0.2358 -0.1342 -0.2087 -1.4461 -0.0758 -0.0966 -0.2443 -0.1454 -0.1495
S-1181	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-1181	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-1181	-0.30147117376327515	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
D-1181	-0.30147117376327515	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
P-1181	-0.2283 -0.5090 -0.2750 -0.1435 -0.3125 -0.1201 -1.2271 -0.5970 -0.1176 -0.1630 -0.3758 -0.3281 -0.1000 -0.1000 -0.1611 -0.2059 -0.0765 -0.0977 -0.1444 -1.2332 -0.1556 -0.1297 -0.1561 -0.7262 -0.1266 -0.1207 -0.1855 -0.2358 -0.1342 -0.2087 -1.4461 -0.0758 -0.0966 -0.2443 -0.1454 -0.1495
S-1357	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-1357	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-1357	-0.30147117376327515	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
D-1357	-0.30147117376327515	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
P-1357	-0.2283 -0.5090 -0.2750 -0.1435 -0.3125 -0.1201 -1.2271 -0.5970 -0.1176 -0.1630 -0.3758 -0.3281 -0.1000 -0.1000 -0.1611 -0.2059 -0.0765 -0.0977 -0.1444 -1.2332 -0.1556 -0.1297 -0.1561 -0.7262 -0.1266 -0.1207 -0.1855 -0.2358 -0.1342 -0.2087 -1.4461 -0.0758 -0.0966 -0.2443 -0.1454 -0.1495
S-1534	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-1534	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-1534	-0.30147117376327515	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
D-1534	-0.30147117376327515	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
P-1534	-0.2283 -0.5090 -0.2750 -0.1435 -0.3125 -0.1201 -1.2271 -0.5970 -0.1176 -0.1630 -0.3758 -0.3281 -0.1000 -0.1000 -0.1611 -0.2059 -0.0765 -0.0977 -0.1444 -1.2332 -0.1556 -0.1297 -0.1561 -0.7262 -0.1266 -0.1207 -0.1855 -0.2358 -0.1342 -0.2087 -1.4461 -0.0758 -0.0966 -0.2443 -0.1454 -0.1495
S-1867	Bei Li-Fraumeni-Krebs , bei dem das p53-Gen defekt ist , arbeitet das p53-Protein nicht richtig , und die Krebszellen können weiter wachsen und sich teilen .
T-1867	In Li-Fraumeni cancer , where the p53 gene is defective , the p53 protein does not work properly and the cancer cells can continue to grow and divide .
H-1867	-0.33095014095306396	In Li-Fraumeni cancer , which has a defective p53 gene , the p53 protein does not function properly and cancer cells can continue to grow and divide .
D-1867	-0.33095014095306396	In Li-Fraumeni cancer , which has a defective p53 gene , the p53 protein does not function properly and cancer cells can continue to grow and divide .
P-1867	-0.1550 -0.9618 -0.3518 -0.2318 -0.0651 -0.2132 -0.6498 -0.1417 -1.3304 -0.1636 -0.7111 -0.3991 -0.6030 -0.1074 -0.1429 -0.0796 -0.1562 -0.3375 -0.1171 -0.1819 -0.1379 -0.2578 -0.1422 -0.9488 -0.2069 -0.1970 -0.9453 -0.0771 -0.4193 -0.4068 -0.1649 -0.4399 -0.1375 -0.0412 -0.1343 -0.1572
S-829	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen .
T-829	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions .
H-829	-0.30147117376327515	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
D-829	-0.30147117376327515	The factor VIII/ von Willebrand factor complex consists of two proteins ( factor VIII and von Willebrand factor ) with different physiological functions .
P-829	-0.2283 -0.5090 -0.2750 -0.1435 -0.3125 -0.1201 -1.2271 -0.5970 -0.1176 -0.1630 -0.3758 -0.3281 -0.1000 -0.1000 -0.1611 -0.2059 -0.0765 -0.0977 -0.1444 -1.2332 -0.1556 -0.1297 -0.1561 -0.7262 -0.1266 -0.1207 -0.1855 -0.2358 -0.1342 -0.2087 -1.4461 -0.0758 -0.0966 -0.2443 -0.1454 -0.1495
S-514	Advate wird zur Behandlung und Vorbeugung von Blutungen bei Patienten mit Hämophilie A ( eine durch den Mangel an Faktor VIII bedingte , angeborene Blutgerinnungsstörung ) verwendet .
T-514	Advate is used for the treatment and prevention of bleeding in patients with haemophilia A ( an inherited bleeding disorder caused by lack of factor VIII ) .
H-514	-0.32334378361701965	Advate is used to treat and prevent bleeding in patients with haemophilia A ( a congenital blood clotting disorder caused by lack of factor VIII ) .
D-514	-0.32334378361701965	Advate is used to treat and prevent bleeding in patients with haemophilia A ( a congenital blood clotting disorder caused by lack of factor VIII ) .
P-514	-0.6937 -0.1074 -0.1143 -0.0451 -0.1511 -0.1915 -0.1281 -0.1598 -0.9447 -0.2225 -0.1623 -0.2678 -0.1369 -0.1773 -0.0667 -0.1720 -0.2787 -0.1265 -0.1455 -0.3551 -0.5972 -0.2438 -0.5060 -0.1700 -1.7232 -0.0392 -0.0833 -0.1687 -0.7990 -0.1795 -1.5674 -0.1543 -0.7078 -0.1174 -0.1333 -0.1402 -0.1579 -0.1520
S-450	Die mittlere Halbwertszeit von Vitamin D3 im Serum beträgt ca. 24 Stunden nach einer oralen Dosis von ADROVANCE ( 70 mg<unk> 2.800 I.E . ) .
T-450	The mean half-life of vitamin D3 in the serum following an oral dose of ADROVANCE ( 70 mg/ 2800 IU ) is approximately 24 hours .
H-450	-0.1700240522623062	The mean half-life of vitamin D3 in the serum is approximately 24 hours after an oral dose of ADROVANCE ( 70 mg/ 2,800 IU ) .
D-450	-0.1700240522623062	The mean half-life of vitamin D3 in the serum is approximately 24 hours after an oral dose of ADROVANCE ( 70 mg/ 2,800 IU ) .
P-450	-0.2145 -0.1344 -0.4146 -0.1675 -0.1252 -0.1513 -0.3404 -0.1070 -0.1312 -0.1377 -0.1553 -0.6315 -0.0908 -0.1541 -0.1308 -0.1016 -0.1323 -0.1221 -0.2542 -0.6485 -0.0781 -0.0723 -0.1573 -0.0808 -0.0835 -0.1214 -0.1090 -0.1232 -0.1364 -0.1339 -0.1903 -0.1250 -0.1297 -0.2421 -0.1025 -0.0950 -0.0600 -0.1247 -0.1424 -0.1485
S-1791	Seltene Nebenwirkungen Seit der Einführung des Arzneimittels auf dem Markt wurde vereinzelt über schwere und potentiell lebensbedrohliche Reaktionen ( Anaphylaxie ) und andere allergische Reaktionen berichtet ( siehe oben ) .
T-1791	Rare side effects Since the medicine has been on the market , there have been rare reports of severe and potentially life-threatening reactions ( anaphylaxis ) and other allergic reactions ( see above ) .
H-1791	-0.38823482394218445	Rare adverse reactions Severe and potentially life threatening reactions ( anaphylaxis ) and other allergic reactions have been isolated since the product was marketed ( see above ) .
D-1791	-0.38823482394218445	Rare adverse reactions Severe and potentially life threatening reactions ( anaphylaxis ) and other allergic reactions have been isolated since the product was marketed ( see above ) .
P-1791	-0.1831 -0.1345 -2.3778 -0.0350 -0.1189 -0.0197 -0.1861 -0.1217 -0.1550 -0.0492 -0.1784 -1.5020 -0.1597 -0.0674 -0.1396 -0.1884 -0.0966 -0.0690 -0.1038 -0.5021 -0.1332 -0.1421 -0.1037 -0.1366 -0.0815 -0.0744 -0.0317 -0.3957 -0.1951 -2.4518 -0.8502 -0.2625 -0.7794 -1.4921 -1.5395 -0.0540 -0.1509 -0.3795 -0.2201 -0.1371 -0.1557 -0.1510
S-1958	Die Sicherheit und die Wirksamkeit von Aerinaze wurden bei Patienten mit Nieren- oder Leberfunktionsstörung nicht geprüft und die Daten reichen nicht aus , um entsprechende Empfehlungen zur Dosierung auszusprechen .
T-1958	The safety and efficacy of Aerinaze has not been established in patients with impaired renal or hepatic function , and there are insufficient data to give adequate dose recommendations .
H-1958	-0.27165213227272034	The safety and efficacy of Aerinaze have not been evaluated in patients with renal or hepatic impairment , and data are insufficient to recommend appropriate dosage .
D-1958	-0.27165213227272034	The safety and efficacy of Aerinaze have not been evaluated in patients with renal or hepatic impairment , and data are insufficient to recommend appropriate dosage .
P-1958	-0.1763 -0.0544 -0.1344 -0.2681 -0.0685 -0.1085 -0.1476 -0.1719 -0.1311 -0.1158 -0.1554 -0.1119 -0.2625 -0.1226 -0.0958 -0.6213 -0.1475 -0.1425 -0.7815 -0.1312 -0.0603 -0.1485 -0.1416 -0.1487 -0.0329 -0.0992 -0.1852 -0.0586 -0.0335 -0.1132 -1.1705 -0.1328 -0.7429 -0.4786 -0.6658 -0.1388 -0.1426 -0.8547 -0.1830 -0.1245 -1.6667 -0.1347 -0.3888 -0.1579
S-1190	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-1190	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-1190	-0.39007529616355896	The factor VIII-plasma levels are increased by the substitution therapy , whereby a transient correction of factor VIII-deficiency and the tendency to bleed occurs .
D-1190	-0.39007529616355896	The factor VIII-plasma levels are increased by the substitution therapy , whereby a transient correction of factor VIII-deficiency and the tendency to bleed occurs .
P-1190	-1.3351 -2.3559 -0.2812 -0.2215 -0.9077 -0.3164 -0.6389 -0.0587 -0.0930 -0.3394 -0.2127 -0.2330 -0.2026 -0.5395 -0.1891 -0.0653 -0.1182 -0.3671 -1.0718 -0.3319 -0.4090 -0.8104 -0.0573 -0.0994 -0.0135 -0.0984 -0.2414 -0.5125 -0.2605 -0.1269 -0.2762 -0.0904 -0.0550 -0.0373 -0.1107 -0.1321 -1.5562 -0.9362 -0.1020 -0.3752 -0.2978 -0.0865 -1.0065 -0.0766 -0.1440 -0.1523
S-1366	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-1366	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-1366	-0.39007529616355896	The factor VIII-plasma levels are increased by the substitution therapy , whereby a transient correction of factor VIII-deficiency and the tendency to bleed occurs .
D-1366	-0.39007529616355896	The factor VIII-plasma levels are increased by the substitution therapy , whereby a transient correction of factor VIII-deficiency and the tendency to bleed occurs .
P-1366	-1.3351 -2.3559 -0.2812 -0.2215 -0.9077 -0.3164 -0.6389 -0.0587 -0.0930 -0.3394 -0.2127 -0.2330 -0.2026 -0.5395 -0.1891 -0.0653 -0.1182 -0.3671 -1.0718 -0.3319 -0.4090 -0.8104 -0.0573 -0.0994 -0.0135 -0.0984 -0.2414 -0.5125 -0.2605 -0.1269 -0.2762 -0.0904 -0.0550 -0.0373 -0.1107 -0.1321 -1.5562 -0.9362 -0.1020 -0.3752 -0.2978 -0.0865 -1.0065 -0.0766 -0.1440 -0.1523
S-1543	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-1543	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-1543	-0.39007529616355896	The factor VIII-plasma levels are increased by the substitution therapy , whereby a transient correction of factor VIII-deficiency and the tendency to bleed occurs .
D-1543	-0.39007529616355896	The factor VIII-plasma levels are increased by the substitution therapy , whereby a transient correction of factor VIII-deficiency and the tendency to bleed occurs .
P-1543	-1.3351 -2.3559 -0.2812 -0.2215 -0.9077 -0.3164 -0.6389 -0.0587 -0.0930 -0.3394 -0.2127 -0.2330 -0.2026 -0.5395 -0.1891 -0.0653 -0.1182 -0.3671 -1.0718 -0.3319 -0.4090 -0.8104 -0.0573 -0.0994 -0.0135 -0.0984 -0.2414 -0.5125 -0.2605 -0.1269 -0.2762 -0.0904 -0.0550 -0.0373 -0.1107 -0.1321 -1.5562 -0.9362 -0.1020 -0.3752 -0.2978 -0.0865 -1.0065 -0.0766 -0.1440 -0.1523
S-838	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-838	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-838	-0.39007529616355896	The factor VIII-plasma levels are increased by the substitution therapy , whereby a transient correction of factor VIII-deficiency and the tendency to bleed occurs .
D-838	-0.39007529616355896	The factor VIII-plasma levels are increased by the substitution therapy , whereby a transient correction of factor VIII-deficiency and the tendency to bleed occurs .
P-838	-1.3351 -2.3559 -0.2812 -0.2215 -0.9077 -0.3164 -0.6389 -0.0587 -0.0930 -0.3394 -0.2127 -0.2330 -0.2026 -0.5395 -0.1891 -0.0653 -0.1182 -0.3671 -1.0718 -0.3319 -0.4090 -0.8104 -0.0573 -0.0994 -0.0135 -0.0984 -0.2414 -0.5125 -0.2605 -0.1269 -0.2762 -0.0904 -0.0550 -0.0373 -0.1107 -0.1321 -1.5562 -0.9362 -0.1020 -0.3752 -0.2978 -0.0865 -1.0065 -0.0766 -0.1440 -0.1523
S-1999	In klinischen Prüfungen mit 414 Erwachsenen wurden als häufigste unerwünschte Ereignisse Schlaflosigkeit ( 8,9 % ) , Mundtrockenheit ( 7,2 % ) und Kopfschmerzen ( 3,1 % ) beobachtet .
T-1999	In clinical trials involving 414 adults the most frequent of adverse events reported were insomnia ( 8.9 % ) , dry mouth ( 7.2 % ) and headache ( 3.1 % ) .
H-1999	-0.24195152521133423	In clinical trials of 414 adults , the most common adverse events observed were insomnia ( 8.9 % ) , dry mouth ( 7.2 % ) and headache ( 3.1 % ) .
D-1999	-0.24195152521133423	In clinical trials of 414 adults , the most common adverse events observed were insomnia ( 8.9 % ) , dry mouth ( 7.2 % ) and headache ( 3.1 % ) .
P-1999	-0.2924 -0.6034 -0.0840 -1.3290 -0.0949 -0.1071 -0.6111 -0.1634 -0.2927 -0.1972 -1.1744 -0.0804 -0.0293 -0.1088 -1.2698 -0.2222 -0.2022 -0.0475 -0.0242 -0.1295 -0.0850 -0.1267 -0.1363 -0.1339 -0.1440 -0.2056 -0.0549 -0.1527 -0.0981 -0.1489 -0.1343 -0.1282 -0.5959 -0.0928 -0.0392 -0.1168 -0.1491 -0.0803 -0.1452 -0.1458 -0.1328 -0.1449 -0.1492
S-1014	Die Faktor VIII-Plasmaspiegel werden durch die Substitutionstherapie erhöht , wodurch eine vorübergehende Korrektur des Faktor VIII-Mangels und der Blutungsneigung erfolgt .
T-1014	The plasma levels of factor VIII are increased by replacement therapy , thereby enabling a temporary correction of the factor VIII deficiency and correction of the bleeding tendency .
H-1014	-0.39007529616355896	The factor VIII-plasma levels are increased by the substitution therapy , whereby a transient correction of factor VIII-deficiency and the tendency to bleed occurs .
D-1014	-0.39007529616355896	The factor VIII-plasma levels are increased by the substitution therapy , whereby a transient correction of factor VIII-deficiency and the tendency to bleed occurs .
P-1014	-1.3351 -2.3559 -0.2812 -0.2215 -0.9077 -0.3164 -0.6389 -0.0587 -0.0930 -0.3394 -0.2127 -0.2330 -0.2026 -0.5395 -0.1891 -0.0653 -0.1182 -0.3671 -1.0718 -0.3319 -0.4090 -0.8104 -0.0573 -0.0994 -0.0135 -0.0984 -0.2414 -0.5125 -0.2605 -0.1269 -0.2762 -0.0904 -0.0550 -0.0373 -0.1107 -0.1321 -1.5562 -0.9362 -0.1020 -0.3752 -0.2978 -0.0865 -1.0065 -0.0766 -0.1440 -0.1523
S-1637	ADVATE 500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1637	ADVATE 500 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1637	-0.2811456024646759	ADVATE 500 IU of powder and solvent to produce a solution for injection . Octocog alfa ( human recombinant blood clotting factor VIII )
D-1637	-0.2811456024646759	ADVATE 500 IU of powder and solvent to produce a solution for injection . Octocog alfa ( human recombinant blood clotting factor VIII )
P-1637	-0.0974 -0.1398 -0.0795 -0.1006 -0.0935 -0.1077 -0.0995 -0.3290 -0.0639 -0.1337 -0.1227 -0.6178 -2.0479 -0.7487 -0.5582 -0.1558 -0.1346 -0.1025 -0.0884 -1.1028 -0.0306 -0.0834 -0.1506 -0.2232 -0.1247 -0.0611 -0.1342 -0.6423 -0.1252 -0.1147 -0.0870 -0.1382 -0.1454 -1.7966 -0.0459 -0.0761 -0.0761 -0.1318 -0.1250 -0.1340 -0.1568
S-1671	ADVATE 1500 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1671	ADVATE 1500 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1671	-0.3003890812397003	ADVATE 1500 IU of powder and solvent for injection solution . Octocog alfa ( human recombinant blood clotting factor VIII )
D-1671	-0.3003890812397003	ADVATE 1500 IU of powder and solvent for injection solution . Octocog alfa ( human recombinant blood clotting factor VIII )
P-1671	-0.0799 -0.1418 -0.0767 -0.1004 -0.2060 -0.1087 -0.1041 -0.3769 -0.0707 -0.1340 -0.1209 -0.6157 -0.5116 -2.5064 -0.0440 -0.3635 -1.3035 -0.0317 -0.0844 -0.1528 -0.2240 -0.1242 -0.0626 -0.1368 -0.6082 -0.1280 -0.1140 -0.0881 -0.1383 -0.1479 -1.7490 -0.0483 -0.0756 -0.0749 -0.1340 -0.1263 -0.1336 -0.1671
S-1653	ADVATE 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1653	ADVATE 1000 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1653	-0.30848580598831177	ADVATE 1000 IU of powder and solvent for injection solution . Octocog alfa ( human recombinant blood clotting factor VIII )
D-1653	-0.30848580598831177	ADVATE 1000 IU of powder and solvent for injection solution . Octocog alfa ( human recombinant blood clotting factor VIII )
P-1653	-0.1013 -0.1402 -0.0757 -0.0973 -0.0953 -0.1049 -0.0898 -0.6100 -0.0693 -0.1330 -0.1206 -0.6497 -0.5224 -2.6937 -0.0441 -0.3519 -1.2787 -0.0332 -0.0837 -0.1537 -0.2226 -0.1248 -0.0618 -0.1368 -0.5916 -0.1303 -0.1150 -0.0887 -0.1383 -0.1442 -1.7613 -0.0482 -0.0761 -0.0734 -0.1342 -0.1248 -0.1338 -0.1680
S-316	Die Patienten sollen angewiesen werden , dass sie beim Versäumnis der Einnahme einer Dosis ADROVANCE die Tablette am nächsten Morgen einnehmen sollen , nachdem sie ihr Versäumnis bemerkt haben .
T-316	Patients should be instructed that if they miss a dose of ADROVANCE they should take one tablet on the morning after they remember .
H-316	-0.42750316858291626	Patients should be instructed that if they fail to take a dose of ADROVANCE the next morning after noticing their failure .
D-316	-0.42750316858291626	Patients should be instructed that if they fail to take a dose of ADROVANCE the next morning after noticing their failure .
P-316	-0.1423 -0.1017 -0.1886 -0.1473 -1.7936 -0.0826 -0.2349 -0.2397 -0.1176 -1.3041 -0.1373 -0.0801 -0.1623 -0.0528 -0.1713 -0.1243 -0.0670 -0.1161 -0.0988 -0.1380 -0.3085 -1.1354 -0.5555 -0.5593 -2.0479 -0.1398 -0.2834 -1.3238 -0.8080 -0.1633
S-1621	ADVATE 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1621	ADVATE 250 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1621	-0.2786700129508972	ADVATE 250 IU of powder and solvent to produce a solution for injection . Octocog alfa ( human recombinant blood clotting factor VIII )
D-1621	-0.2786700129508972	ADVATE 250 IU of powder and solvent to produce a solution for injection . Octocog alfa ( human recombinant blood clotting factor VIII )
P-1621	-0.0824 -0.1390 -0.0789 -0.1019 -0.0828 -0.1101 -0.0931 -0.2803 -0.0652 -0.1332 -0.1209 -0.6074 -2.0960 -0.7277 -0.5721 -0.1561 -0.1343 -0.1011 -0.0855 -1.0910 -0.0303 -0.0836 -0.1508 -0.2220 -0.1239 -0.0602 -0.1347 -0.6306 -0.1255 -0.1148 -0.0868 -0.1373 -0.1472 -1.7776 -0.0454 -0.0760 -0.0780 -0.1316 -0.1226 -0.1331 -0.1544
S-1862	Bei dem Virus in Advexin handelt es sich um ein Adenovirus , das so verändert wurde , dass es keine Kopien von sich selbst herstellen und somit keine Infektionen beim Menschen auslösen kann .
T-1862	The virus in Advexin is an adenovirus that has been engineered so that it cannot make copies of itself and therefore does not cause infections in humans .
H-1862	-0.5097775459289551	The virus in Advexin is an adenovirus that has been modified in such a way that it cannot produce copies of itself and therefore does not cause infection in humans .
D-1862	-0.5097775459289551	The virus in Advexin is an adenovirus that has been modified in such a way that it cannot produce copies of itself and therefore does not cause infection in humans .
P-1862	-0.2795 -1.4168 -0.1679 -0.5427 -0.1771 -0.1390 -0.1168 -0.9137 -0.0467 -0.1537 -0.3032 -1.0935 -0.2114 -0.0884 -0.8942 -0.0831 -2.1876 -0.8076 -0.1385 -0.3441 -0.2132 -0.0931 -0.4285 -1.2514 -0.5152 -0.1532 -0.3113 -0.2881 -2.3267 -1.2429 -0.1302 -0.7450 -0.2973 -0.1306 -0.3236 -0.1476 -0.1585
S-1901	Die Dauer der Behandlung sollte so kurz wie möglich sein und beendet werden , sobald die Symptome , vor allem die Schwellung der Nasenschleimhaut ( verstopfte Nase ) , abgeklungen sind .
T-1901	Treatment should continue for as short a time as possible and should stop when symptoms , chiefly the congestion ( blocked nose ) , have disappeared .
H-1901	-0.45383796095848083	Treatment should be as short as possible and should be discontinued as soon as the symptoms , especially nasal swelling ( nasal constipation ) , resolve .
D-1901	-0.45383796095848083	Treatment should be as short as possible and should be discontinued as soon as the symptoms , especially nasal swelling ( nasal constipation ) , resolve .
P-1901	-0.5330 -0.0431 -0.1098 -0.1861 -0.1778 -0.7393 -0.6580 -0.2577 -0.0887 -0.1904 -0.9976 -0.3757 -0.6191 -0.1279 -1.0861 -0.0963 -0.1665 -1.0317 -0.1048 -1.0990 -0.9842 -0.5054 -0.0185 -0.2005 -0.0623 -0.1005 -0.1240 -0.5531 -0.0173 -0.1583 -1.0994 -1.5610 -0.0352 -0.1261 -0.1345 -0.8786 -2.0932 -0.2007 -0.1582
S-1687	ADVATE 2000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1687	ADVATE 2000 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1687	-0.30393460392951965	ADVATE 2000 IU of powder and solvent for injection solution . Octocog alfa ( human recombinant blood clotting factor VIII )
D-1687	-0.30393460392951965	ADVATE 2000 IU of powder and solvent for injection solution . Octocog alfa ( human recombinant blood clotting factor VIII )
P-1687	-0.1105 -0.1426 -0.0758 -0.1042 -0.1114 -0.1129 -0.0923 -0.6203 -0.0645 -0.1327 -0.1210 -0.5660 -0.4596 -2.5810 -0.0440 -0.3268 -1.3378 -0.0338 -0.0843 -0.1516 -0.2227 -0.1249 -0.0622 -0.1364 -0.5809 -0.1295 -0.1147 -0.0889 -0.1387 -0.1447 -1.7712 -0.0487 -0.0755 -0.0748 -0.1343 -0.1266 -0.1338 -0.1679
S-128	Die Patienten sollen angewiesen werden , dass sie beim Versäumnis der Einnahme einer Dosis ADROVANCE die Tablette am nächsten Morgen einnehmen sollen , nachdem sie ihr Versäumnis bemerkt haben .
T-128	Patients should be instructed that if they miss a dose of ADROVANCE they should take one tablet on the morning after they remember .
H-128	-0.42750316858291626	Patients should be instructed that if they fail to take a dose of ADROVANCE the next morning after noticing their failure .
D-128	-0.42750316858291626	Patients should be instructed that if they fail to take a dose of ADROVANCE the next morning after noticing their failure .
P-128	-0.1423 -0.1017 -0.1886 -0.1473 -1.7936 -0.0826 -0.2349 -0.2397 -0.1176 -1.3041 -0.1373 -0.0801 -0.1623 -0.0528 -0.1713 -0.1243 -0.0670 -0.1161 -0.0988 -0.1380 -0.3085 -1.1354 -0.5555 -0.5593 -2.0479 -0.1398 -0.2834 -1.3238 -0.8080 -0.1633
S-1746	Diese Symptome können frühe Anzeichen eines anaphylaktischen Schocks darstellen , der zusätzlich folgende Symptome einschließen kann : extremer Schwindel , Bewusstseinsverlust und extreme Atembeschwerden .
T-1746	92 symptom of an anaphylactic shock , manifestations of which may additionally include extreme dizziness , loss of consciousness , and extreme difficulty in breathing .
H-1746	-0.3486812114715576	These symptoms may include early signs of anaphylactic shock , which may also include extreme dizziness , loss of consciousness and extreme breathing difficulties .
D-1746	-0.3486812114715576	These symptoms may include early signs of anaphylactic shock , which may also include extreme dizziness , loss of consciousness and extreme breathing difficulties .
P-1746	-0.1727 -0.1101 -0.9567 -1.7849 -0.2139 -0.1789 -0.1469 -0.1311 -0.0915 -0.0668 -0.1074 -0.0922 -0.0820 -0.2917 -0.3179 -0.5406 -0.9694 -0.0947 -0.4113 -0.2268 -0.0749 -0.0478 -0.1496 -0.1085 -0.1462 -0.0351 -0.0614 -0.7493 -1.2261 -1.0063 -0.6185 -0.1412 -0.1543
S-1915	Die Hauptwirksamkeitsmaße waren die Veränderungen des Schweregrades der Heuschnupfensymptome , die von den Patienten vor Beginn der Behandlung und während der 15-tägigen Behandlung berichtet wurden .
T-1915	The main measures of effectiveness were the change in the severity of hayfever symptoms reported by the patients between before treatment started , and over the entire 15 days of treatment .
H-1915	-0.3896928131580353	The main measures of efficacy were changes in the seriousness of hayfever symptoms reported by patients prior to the initiation of treatment and during 15-day treatment .
D-1915	-0.3896928131580353	The main measures of efficacy were changes in the seriousness of hayfever symptoms reported by patients prior to the initiation of treatment and during 15-day treatment .
P-1915	-0.5712 -1.1830 -1.7897 -0.1569 -0.2702 -0.0712 -0.0685 -0.2999 -0.1477 -0.1243 -0.3514 -1.6288 -0.0625 -0.1596 -0.2699 -0.6954 -0.1700 -0.1832 -0.0963 -0.0606 -0.1545 -0.1191 -0.2879 -0.1389 -0.9944 -0.8484 -0.1181 -0.1615 -0.1428 -0.1343 -0.0537 -1.9162 -0.1762 -0.1504 -0.3763 -0.1355 -0.1501
S-100	Die Äquivalenz der Einnahme von 2.800 I.E. Vitamin D3 einmal pro Woche in ADROVANCE und von 400 I.E. Vitamin D einmal pro Tag wurde nicht untersucht .
T-100	The equivalence of intake of 2800 IU of vitamin D3 weekly in ADROVANCE to daily dosing of vitamin D 400 IU has not been studied .
H-100	-0.19167272746562958	The equivalence of taking 2,800 IU of vitamin D3 once a week in ADROVANCE and 400 IU of vitamin D once a day has not been investigated .
D-100	-0.19167272746562958	The equivalence of taking 2,800 IU of vitamin D3 once a week in ADROVANCE and 400 IU of vitamin D once a day has not been investigated .
P-100	-0.2241 -0.7550 -0.1058 -0.3260 -0.1504 -1.1543 -0.3045 -0.1033 -0.0900 -0.0944 -0.1807 -0.1780 -0.1378 -0.1297 -0.1428 -0.0693 -0.2679 -0.1243 -0.1387 -0.0741 -0.0880 -0.1232 -0.1006 -0.0921 -0.1679 -0.1296 -0.1216 -0.1043 -0.1609 -0.1376 -0.0899 -0.1261 -0.0752 -0.1468 -0.0884 -0.2095 -0.1243 -0.1280 -0.5932 -0.1454 -0.1546
S-646	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-646	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-646	-0.30863022804260254	Patients &quot; immune response to traces of contaminating proteins was analysed by assessing antibody titers to these proteins , laboratory parameters and reported adverse reactions .
D-646	-0.30863022804260254	Patients &quot; immune response to traces of contaminating proteins was analysed by assessing antibody titers to these proteins , laboratory parameters and reported adverse reactions .
P-646	-1.5188 -0.1392 -1.1107 -0.1530 -0.1711 -0.1593 -0.2571 -0.1805 -0.1559 -0.2979 -0.2924 -0.2064 -0.2207 -0.0751 -0.1741 -0.7889 -0.1167 -0.2024 -2.1916 -0.0941 -0.2453 -0.2648 -0.1140 -0.5770 -0.3602 -0.1933 -0.0998 -0.0800 -0.1490 -0.1801 -0.0570 -0.1117 -0.0546 -0.1113 -0.2027 -0.0817 -1.0293 -0.0549 -0.1744 -0.0342 -0.1310 -0.1501
S-820	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-820	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-820	-0.30863022804260254	Patients &quot; immune response to traces of contaminating proteins was analysed by assessing antibody titers to these proteins , laboratory parameters and reported adverse reactions .
D-820	-0.30863022804260254	Patients &quot; immune response to traces of contaminating proteins was analysed by assessing antibody titers to these proteins , laboratory parameters and reported adverse reactions .
P-820	-1.5188 -0.1392 -1.1107 -0.1530 -0.1711 -0.1593 -0.2571 -0.1805 -0.1559 -0.2979 -0.2924 -0.2064 -0.2207 -0.0751 -0.1741 -0.7889 -0.1167 -0.2024 -2.1916 -0.0941 -0.2453 -0.2648 -0.1140 -0.5770 -0.3602 -0.1933 -0.0998 -0.0800 -0.1490 -0.1801 -0.0570 -0.1117 -0.0546 -0.1113 -0.2027 -0.0817 -1.0293 -0.0549 -0.1744 -0.0342 -0.1310 -0.1501
S-1703	ADVATE 3000 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung . Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1703	ADVATE 3000 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1703	-0.31516286730766296	ADVATE 3000 IU of powder and solvent for injection solution . Octocog alfa ( human recombinant blood clotting factor VIII )
D-1703	-0.31516286730766296	ADVATE 3000 IU of powder and solvent for injection solution . Octocog alfa ( human recombinant blood clotting factor VIII )
P-1703	-0.1007 -0.1417 -0.0763 -0.1009 -0.0842 -0.1071 -0.1001 -0.7210 -0.0644 -0.1324 -0.1229 -0.7127 -0.5307 -2.8052 -0.0430 -0.3244 -1.2566 -0.0349 -0.0838 -0.1517 -0.2212 -0.1249 -0.0614 -0.1360 -0.5936 -0.1317 -0.1143 -0.0875 -0.1383 -0.1443 -1.7697 -0.0483 -0.0765 -0.0739 -0.1340 -0.1261 -0.1333 -0.1662
S-1172	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-1172	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-1172	-0.30863022804260254	Patients &quot; immune response to traces of contaminating proteins was analysed by assessing antibody titers to these proteins , laboratory parameters and reported adverse reactions .
D-1172	-0.30863022804260254	Patients &quot; immune response to traces of contaminating proteins was analysed by assessing antibody titers to these proteins , laboratory parameters and reported adverse reactions .
P-1172	-1.5188 -0.1392 -1.1107 -0.1530 -0.1711 -0.1593 -0.2571 -0.1805 -0.1559 -0.2979 -0.2924 -0.2064 -0.2207 -0.0751 -0.1741 -0.7889 -0.1167 -0.2024 -2.1916 -0.0941 -0.2453 -0.2648 -0.1140 -0.5770 -0.3602 -0.1933 -0.0998 -0.0800 -0.1490 -0.1801 -0.0570 -0.1117 -0.0546 -0.1113 -0.2027 -0.0817 -1.0293 -0.0549 -0.1744 -0.0342 -0.1310 -0.1501
S-1348	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-1348	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-1348	-0.30863022804260254	Patients &quot; immune response to traces of contaminating proteins was analysed by assessing antibody titers to these proteins , laboratory parameters and reported adverse reactions .
D-1348	-0.30863022804260254	Patients &quot; immune response to traces of contaminating proteins was analysed by assessing antibody titers to these proteins , laboratory parameters and reported adverse reactions .
P-1348	-1.5188 -0.1392 -1.1107 -0.1530 -0.1711 -0.1593 -0.2571 -0.1805 -0.1559 -0.2979 -0.2924 -0.2064 -0.2207 -0.0751 -0.1741 -0.7889 -0.1167 -0.2024 -2.1916 -0.0941 -0.2453 -0.2648 -0.1140 -0.5770 -0.3602 -0.1933 -0.0998 -0.0800 -0.1490 -0.1801 -0.0570 -0.1117 -0.0546 -0.1113 -0.2027 -0.0817 -1.0293 -0.0549 -0.1744 -0.0342 -0.1310 -0.1501
S-996	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-996	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-996	-0.30863022804260254	Patients &quot; immune response to traces of contaminating proteins was analysed by assessing antibody titers to these proteins , laboratory parameters and reported adverse reactions .
D-996	-0.30863022804260254	Patients &quot; immune response to traces of contaminating proteins was analysed by assessing antibody titers to these proteins , laboratory parameters and reported adverse reactions .
P-996	-1.5188 -0.1392 -1.1107 -0.1530 -0.1711 -0.1593 -0.2571 -0.1805 -0.1559 -0.2979 -0.2924 -0.2064 -0.2207 -0.0751 -0.1741 -0.7889 -0.1167 -0.2024 -2.1916 -0.0941 -0.2453 -0.2648 -0.1140 -0.5770 -0.3602 -0.1933 -0.0998 -0.0800 -0.1490 -0.1801 -0.0570 -0.1117 -0.0546 -0.1113 -0.2027 -0.0817 -1.0293 -0.0549 -0.1744 -0.0342 -0.1310 -0.1501
S-1525	Die Immunantwort der Patienten auf Spuren von kontaminierenden Proteinen wurde durch die Untersuchung der Antikörpertiter gegen diese Proteine , Laborparameter und gemeldete Nebenwirkungen analysiert .
T-1525	The patient s immune response to trace amounts of contaminating proteins was analysed by examining titres of antibodies to these proteins , laboratory parameters and reported adverse events .
H-1525	-0.30863022804260254	Patients &quot; immune response to traces of contaminating proteins was analysed by assessing antibody titers to these proteins , laboratory parameters and reported adverse reactions .
D-1525	-0.30863022804260254	Patients &quot; immune response to traces of contaminating proteins was analysed by assessing antibody titers to these proteins , laboratory parameters and reported adverse reactions .
P-1525	-1.5188 -0.1392 -1.1107 -0.1530 -0.1711 -0.1593 -0.2571 -0.1805 -0.1559 -0.2979 -0.2924 -0.2064 -0.2207 -0.0751 -0.1741 -0.7889 -0.1167 -0.2024 -2.1916 -0.0941 -0.2453 -0.2648 -0.1140 -0.5770 -0.3602 -0.1933 -0.0998 -0.0800 -0.1490 -0.1801 -0.0570 -0.1117 -0.0546 -0.1113 -0.2027 -0.0817 -1.0293 -0.0549 -0.1744 -0.0342 -0.1310 -0.1501
S-1720	ADVATE 250 I.E. Pulver und Lösungsmittel zur Herstellung einer Injektionslösung Octocog alfa ( rekombinanter Blutgerinnungsfaktor VIII vom Menschen )
T-1720	ADVATE 250 IU powder and solvent for solution for injection Octocog alfa ( recombinant human coagulation factor VIII )
H-1720	-0.2645152807235718	ADVATE 250 IU of powder and solvent for injection solution Octocog alfa ( human recombinant blood clotting factor VIII )
D-1720	-0.2645152807235718	ADVATE 250 IU of powder and solvent for injection solution Octocog alfa ( human recombinant blood clotting factor VIII )
P-1720	-0.0755 -0.1378 -0.0761 -0.1000 -0.0830 -0.1128 -0.0959 -0.3221 -0.0625 -0.1321 -0.1299 -0.7278 -0.4987 -2.0691 -0.0412 -0.1703 -0.2297 -0.0805 -0.1619 -0.2108 -0.1202 -0.0676 -0.1312 -0.8187 -0.1339 -0.1091 -0.0922 -0.1395 -0.1519 -1.7763 -0.0462 -0.0733 -0.0826 -0.1343 -0.1229 -0.1329 -0.1366
S-1360	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-1360	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-1360	-0.35360193252563477	When octocog alfa is injected into a haemophilia A patient , it binds to the endogenous von Willebrand factor in the blood stream .
D-1360	-0.35360193252563477	When octocog alfa is injected into a haemophilia A patient , it binds to the endogenous von Willebrand factor in the blood stream .
P-1360	-1.4198 -0.9303 -0.1001 -0.1662 -0.3005 -0.1247 -0.0618 -0.0974 -0.3187 -0.0419 -0.3807 -0.1699 -0.8021 -0.1095 -0.3249 -1.2438 -0.3239 -0.0686 -0.3128 -0.5414 -0.9444 -0.1433 -1.0071 -0.2147 -0.1298 -0.1260 -0.0552 -0.5532 -0.2860 -0.1376 -0.2402 -0.0978 -0.1250 -0.3853 -0.6330 -0.2108 -0.1543 -0.1543
S-1896	Aerinaze ist ein Arzneimittel , das die arzneilich wirksamen Bestandteile Desloratadin ( 2,5 mg ) und Pseudoephedrin ( 120 mg ) enthält .
T-1896	Aerinaze is a medicine containing the active substances desloratadine ( 2.5 mg ) and pseudoephedrine ( 120 mg ) .
H-1896	-0.18751433491706848	Aerinaze is a medicinal product containing the active ingredients desloratadine ( 2.5 mg ) and pseudoephedrine ( 120 mg ) .
D-1896	-0.18751433491706848	Aerinaze is a medicinal product containing the active ingredients desloratadine ( 2.5 mg ) and pseudoephedrine ( 120 mg ) .
P-1896	-0.1432 -0.1274 -0.1157 -0.1503 -0.1197 -0.1170 -0.1496 -0.6535 -0.1119 -0.0515 -0.5834 -0.1607 -0.0590 -0.2032 -0.7494 -0.0686 -0.1171 -0.3670 -0.4322 -0.1287 -0.1164 -0.0476 -0.1315 -0.1355 -0.0805 -0.5174 -0.1596 -0.0723 -0.1170 -0.1238 -0.1379 -0.1433 -0.0841 -0.0514 -0.1256 -0.1357 -0.1491
S-1537	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-1537	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-1537	-0.35360193252563477	When octocog alfa is injected into a haemophilia A patient , it binds to the endogenous von Willebrand factor in the blood stream .
D-1537	-0.35360193252563477	When octocog alfa is injected into a haemophilia A patient , it binds to the endogenous von Willebrand factor in the blood stream .
P-1537	-1.4198 -0.9303 -0.1001 -0.1662 -0.3005 -0.1247 -0.0618 -0.0974 -0.3187 -0.0419 -0.3807 -0.1699 -0.8021 -0.1095 -0.3249 -1.2438 -0.3239 -0.0686 -0.3128 -0.5414 -0.9444 -0.1433 -1.0071 -0.2147 -0.1298 -0.1260 -0.0552 -0.5532 -0.2860 -0.1376 -0.2402 -0.0978 -0.1250 -0.3853 -0.6330 -0.2108 -0.1543 -0.1543
S-343	Tierstudien mit Alendronat lassen keinen Hinweis auf direkt schädigende Wirkungen im Hinblick auf die Schwangerschaft , die embryonale<unk> fetale oder postnatale Entwicklung erkennen .
T-343	Animal studies with alendronate do not indicate direct harmful effects with respect to pregnancy , embryonal/ foetal development , or postnatal development .
H-343	-0.48174408078193665	Animal studies of alendronate show no evidence of direct adverse effects on pregnancy , embryonic or post-natal development .
D-343	-0.48174408078193665	Animal studies of alendronate show no evidence of direct adverse effects on pregnancy , embryonic or post-natal development .
P-343	-0.2879 -0.0984 -0.1087 -0.7983 -0.1218 -0.1555 -0.0907 -0.0834 -1.0339 -0.0738 -0.1011 -0.2548 -1.7753 -1.2159 -0.1599 -0.4126 -2.0843 -0.1275 -0.1515 -0.3842 -0.0626 -0.1256 -0.5697 -0.6773 -1.7051 -0.9274 -0.6741 -0.1335 -0.2409 -0.1450 -0.1533
S-1184	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-1184	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-1184	-0.35360193252563477	When octocog alfa is injected into a haemophilia A patient , it binds to the endogenous von Willebrand factor in the blood stream .
D-1184	-0.35360193252563477	When octocog alfa is injected into a haemophilia A patient , it binds to the endogenous von Willebrand factor in the blood stream .
P-1184	-1.4198 -0.9303 -0.1001 -0.1662 -0.3005 -0.1247 -0.0618 -0.0974 -0.3187 -0.0419 -0.3807 -0.1699 -0.8021 -0.1095 -0.3249 -1.2438 -0.3239 -0.0686 -0.3128 -0.5414 -0.9444 -0.1433 -1.0071 -0.2147 -0.1298 -0.1260 -0.0552 -0.5532 -0.2860 -0.1376 -0.2402 -0.0978 -0.1250 -0.3853 -0.6330 -0.2108 -0.1543 -0.1543
S-1008	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-1008	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-1008	-0.35360193252563477	When octocog alfa is injected into a haemophilia A patient , it binds to the endogenous von Willebrand factor in the blood stream .
D-1008	-0.35360193252563477	When octocog alfa is injected into a haemophilia A patient , it binds to the endogenous von Willebrand factor in the blood stream .
P-1008	-1.4198 -0.9303 -0.1001 -0.1662 -0.3005 -0.1247 -0.0618 -0.0974 -0.3187 -0.0419 -0.3807 -0.1699 -0.8021 -0.1095 -0.3249 -1.2438 -0.3239 -0.0686 -0.3128 -0.5414 -0.9444 -0.1433 -1.0071 -0.2147 -0.1298 -0.1260 -0.0552 -0.5532 -0.2860 -0.1376 -0.2402 -0.0978 -0.1250 -0.3853 -0.6330 -0.2108 -0.1543 -0.1543
S-832	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-832	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-832	-0.35360193252563477	When octocog alfa is injected into a haemophilia A patient , it binds to the endogenous von Willebrand factor in the blood stream .
D-832	-0.35360193252563477	When octocog alfa is injected into a haemophilia A patient , it binds to the endogenous von Willebrand factor in the blood stream .
P-832	-1.4198 -0.9303 -0.1001 -0.1662 -0.3005 -0.1247 -0.0618 -0.0974 -0.3187 -0.0419 -0.3807 -0.1699 -0.8021 -0.1095 -0.3249 -1.2438 -0.3239 -0.0686 -0.3128 -0.5414 -0.9444 -0.1433 -1.0071 -0.2147 -0.1298 -0.1260 -0.0552 -0.5532 -0.2860 -0.1376 -0.2402 -0.0978 -0.1250 -0.3853 -0.6330 -0.2108 -0.1543 -0.1543
S-657	Wird einem Hämophilie-A-Patienten Octocog alfa injiziert , so bindet sich dieser im Blutkreislauf an den endogenen von-Willebrand-Faktor .
T-657	When infused into a haemophilia patient , octocog alfa binds to endogenous von Willebrand Factor in the patient s circulation .
H-657	-0.35360193252563477	When octocog alfa is injected into a haemophilia A patient , it binds to the endogenous von Willebrand factor in the blood stream .
D-657	-0.35360193252563477	When octocog alfa is injected into a haemophilia A patient , it binds to the endogenous von Willebrand factor in the blood stream .
P-657	-1.4198 -0.9303 -0.1001 -0.1662 -0.3005 -0.1247 -0.0618 -0.0974 -0.3187 -0.0419 -0.3807 -0.1699 -0.8021 -0.1095 -0.3249 -1.2438 -0.3239 -0.0686 -0.3128 -0.5414 -0.9444 -0.1433 -1.0071 -0.2147 -0.1298 -0.1260 -0.0552 -0.5532 -0.2860 -0.1376 -0.2402 -0.0978 -0.1250 -0.3853 -0.6330 -0.2108 -0.1543 -0.1543
S-155	Tierstudien mit Alendronat lassen keinen Hinweis auf direkt schädigende Wirkungen im Hinblick auf die Schwangerschaft , die embryonale<unk> fetale oder postnatale Entwicklung erkennen .
T-155	Animal studies with alendronate do not indicate direct harmful effects with respect to pregnancy , embryonal/ foetal development , or postnatal development .
H-155	-0.48174408078193665	Animal studies of alendronate show no evidence of direct adverse effects on pregnancy , embryonic or post-natal development .
D-155	-0.48174408078193665	Animal studies of alendronate show no evidence of direct adverse effects on pregnancy , embryonic or post-natal development .
P-155	-0.2879 -0.0984 -0.1087 -0.7983 -0.1218 -0.1555 -0.0907 -0.0834 -1.0339 -0.0738 -0.1011 -0.2548 -1.7753 -1.2159 -0.1599 -0.4126 -2.0843 -0.1275 -0.1515 -0.3842 -0.0626 -0.1256 -0.5697 -0.6773 -1.7051 -0.9274 -0.6741 -0.1335 -0.2409 -0.1450 -0.1533
S-1892	Das Unternehmen setzte den CHMP nicht davon in Kenntnis , ob die Rücknahme Konsequenzen für Patienten hat , die derzeit an klinischen Studien oder Compassionate-Use -Programmen mit Advexin teilnehmen .
T-1892	The company did not inform the CHMP whether there were any consequences of the withdrawal for patients in clinical trials or compassionate use programmes with Advexin .
H-1892	-0.4853770434856415	The company has not notified the CHMP whether the withdrawal has consequences for patients currently participating in clinical trials or compassionate use programmes with Advexin .
D-1892	-0.4853770434856415	The company has not notified the CHMP whether the withdrawal has consequences for patients currently participating in clinical trials or compassionate use programmes with Advexin .
P-1892	-0.3379 -0.1862 -0.7091 -0.1297 -2.4941 -0.0938 -0.7394 -0.1389 -0.0427 -0.5783 -0.3370 -0.6018 -0.6302 -1.3526 -0.1302 -0.1984 -1.0361 -0.4582 -0.0931 -0.1299 -0.1292 -0.0326 -0.1234 -1.9230 -0.4850 -0.2587 -0.7853 -0.1508 -0.8486 -0.6687 -0.5424 -0.1872 -0.1362 -0.1436 -0.1561
S-1455	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-1455	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-1455	-0.3443717062473297	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for 3-4 days or more until the pain and acute impairment is resolved .
D-1455	-0.3443717062473297	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for 3-4 days or more until the pain and acute impairment is resolved .
P-1455	-0.3731 -0.1207 -0.2708 -1.4966 -0.1275 -0.1377 -0.1232 -0.1629 -0.2242 -0.1720 -0.1819 -0.1548 -0.6734 -0.1829 -0.5223 -0.2057 -0.0961 -0.2545 -0.1127 -0.1443 -0.1622 -0.2701 -0.1600 -0.1561 -0.1305 -0.1200 -0.9788 -0.4324 -1.1089 -0.0734 -0.1347 -0.1893 -0.0691 -1.9657 -0.0689 -0.0361 -0.1000 -1.1381 -0.7564 -0.1729 -0.1581
S-1279	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-1279	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-1279	-0.3443717062473297	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for 3-4 days or more until the pain and acute impairment is resolved .
D-1279	-0.3443717062473297	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for 3-4 days or more until the pain and acute impairment is resolved .
P-1279	-0.3731 -0.1207 -0.2708 -1.4966 -0.1275 -0.1377 -0.1232 -0.1629 -0.2242 -0.1720 -0.1819 -0.1548 -0.6734 -0.1829 -0.5223 -0.2057 -0.0961 -0.2545 -0.1127 -0.1443 -0.1622 -0.2701 -0.1600 -0.1561 -0.1305 -0.1200 -0.9788 -0.4324 -1.1089 -0.0734 -0.1347 -0.1893 -0.0691 -1.9657 -0.0689 -0.0361 -0.1000 -1.1381 -0.7564 -0.1729 -0.1581
S-1740	Besondere Vorsicht bei der Anwendung von ADVATE ist erforderlich Sie sollten Ihren Arzt informieren , wenn Sie kürzlich mit Faktor VIII-Produkten behandelt wurden , besonders wenn Sie Inhibitoren entwickelt haben .
T-1740	Take special care with ADVATE You should tell your doctor if you have been previously treated with Factor VIII products , especially if you developed inhibitors , since there might be a higher risk that it happens again .
H-1740	-0.3552980422973633	Special caution is required when using ADVATE You should tell your doctor if you have recently been treated with Factor VIII products , especially if you have developed inhibitors .
D-1740	-0.3552980422973633	Special caution is required when using ADVATE You should tell your doctor if you have recently been treated with Factor VIII products , especially if you have developed inhibitors .
P-1740	-0.7797 -1.6566 -0.8105 -0.8728 -0.1910 -0.1901 -0.0694 -0.1462 -0.0822 -0.0942 -0.1747 -0.1455 -0.4140 -0.1328 -0.1410 -0.1694 -0.1383 -0.2787 -1.6960 -0.0590 -0.0668 -0.1509 -0.5551 -0.4928 -0.1895 -1.7998 -0.1220 -0.1403 -0.1799 -0.1886 -0.1088 -0.1795 -0.7289 -0.1722 -0.0329 -0.0739 -0.1234 -0.1543 -0.1549
S-1900	Bei Erwachsenen und Jugendlichen ab 12 Jahren ist die empfohlene Dosis von Aerinaze zweimal täglich eine Tablette , die ganz mit einem Glas Wasser mit oder ohne Nahrung eingenommen werden soll .
T-1900	In adults and adolescents over 12 years of age , the recommended dose of Aerinaze is one tablet twice a day , taken whole with a full glass of water , with or without food .
H-1900	-0.3875288963317871	In adults and adolescents 12 years of age and over , the recommended dose of Aerinaze twice daily is a tablet to be taken entirely with a glass of water with or without food .
D-1900	-0.3875288963317871	In adults and adolescents 12 years of age and over , the recommended dose of Aerinaze twice daily is a tablet to be taken entirely with a glass of water with or without food .
P-1900	-0.4329 -1.5868 -0.1498 -0.1415 -0.0576 -0.0395 -1.6830 -0.2326 -0.7818 -0.1098 -0.3153 -0.3851 -0.2980 -0.2186 -0.3037 -0.0842 -0.1519 -0.1661 -0.1338 -0.1224 -0.1708 -0.1400 -1.0265 -0.8481 -0.1220 -0.7218 -0.1067 -0.1158 -0.2909 -0.2065 -0.2256 -3.5562 -0.1520 -0.4791 -0.0849 -0.1470 -0.1394 -0.1671 -0.1194 -0.1118 -0.0525 -0.1337 -0.1516
S-1842	Latvija BAXTER AG Latvijas fili le Dzelzavas iela 117 R ga , LV 1021 Tel . : <unk> 371 67 784 784
T-1842	Latvija BAXTER AG Latvijas fili le Dzelzavas iela 117 R ga , LV 1021 Tel . : <<unk>> 371 67 784 784
H-1842	-0.13249847292900085	Latvija BAXTER AG Latvijas fili le Dzelzavas iela 117 R ga , LV 1021 Tel . : <unk> 371 67 784 784
D-1842	-0.13249847292900085	Latvija BAXTER AG Latvijas fili le Dzelzavas iela 117 R ga , LV 1021 Tel . : <unk> 371 67 784 784
P-1842	-0.0757 -0.0948 -0.0874 -0.1364 -0.1617 -0.1170 -0.1423 -0.1712 -0.0815 -0.0941 -0.3593 -0.1386 -0.1499 -0.1156 -0.1227 -0.1194 -0.2881 -0.1406 -0.1156 -0.1493 -0.0782 -0.1328 -0.1013 -0.1147 -0.0935 -0.3791 -0.1493 -0.1203 -0.1274 -0.2675 -0.1353 -0.0429 -0.1485 -0.1348 -0.0360 -0.1271 -0.0732 -0.0783 -0.1082 -0.0594 -0.1057 -0.0706 -0.1523
S-79	Bei Patienten mit etwaiger Überempfindlichkeit ( Allergie ) gegen Alendronat , Vitamin D3 oder einen der sonstigen Bestandteile darf ADROVANCE nicht angewendet werden .
T-79	ADROVANCE should not be used in people who may be hypersensitive ( allergic ) to alendronate , vitamin D3 or any of the other ingredients .
H-79	-0.3086160123348236	In patients with possible hypersensitivity ( allergy ) to alendronate , vitamin D3 or to any of the ingredients , ADROVANCE should not be used .
D-79	-0.3086160123348236	In patients with possible hypersensitivity ( allergy ) to alendronate , vitamin D3 or to any of the ingredients , ADROVANCE should not be used .
P-79	-2.4985 -0.2603 -0.7889 -1.2042 -0.2678 -0.0673 -0.0444 -0.1477 -0.3688 -0.2477 -0.1861 -0.1426 -0.1746 -0.1405 -0.1491 -0.1362 -0.0499 -0.1543 -0.1354 -0.1055 -0.1262 -0.1263 -0.1804 -0.5077 -0.1021 -0.1570 -0.1518 -0.4536 -0.9754 -0.1857 -0.0719 -0.1184 -0.1063 -0.1190 -0.9705 -0.1587 -0.1470 -0.1006 -0.1587 -0.1574
S-577	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-577	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-577	-0.3443717062473297	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for 3-4 days or more until the pain and acute impairment is resolved .
D-577	-0.3443717062473297	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for 3-4 days or more until the pain and acute impairment is resolved .
P-577	-0.3731 -0.1207 -0.2708 -1.4966 -0.1275 -0.1377 -0.1232 -0.1629 -0.2242 -0.1720 -0.1819 -0.1548 -0.6734 -0.1829 -0.5223 -0.2057 -0.0961 -0.2545 -0.1127 -0.1443 -0.1622 -0.2701 -0.1600 -0.1561 -0.1305 -0.1200 -0.9788 -0.4324 -1.1089 -0.0734 -0.1347 -0.1893 -0.0691 -1.9657 -0.0689 -0.0361 -0.1000 -1.1381 -0.7564 -0.1729 -0.1581
S-1103	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-1103	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-1103	-0.3443717062473297	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for 3-4 days or more until the pain and acute impairment is resolved .
D-1103	-0.3443717062473297	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for 3-4 days or more until the pain and acute impairment is resolved .
P-1103	-0.3731 -0.1207 -0.2708 -1.4966 -0.1275 -0.1377 -0.1232 -0.1629 -0.2242 -0.1720 -0.1819 -0.1548 -0.6734 -0.1829 -0.5223 -0.2057 -0.0961 -0.2545 -0.1127 -0.1443 -0.1622 -0.2701 -0.1600 -0.1561 -0.1305 -0.1200 -0.9788 -0.4324 -1.1089 -0.0734 -0.1347 -0.1893 -0.0691 -1.9657 -0.0689 -0.0361 -0.1000 -1.1381 -0.7564 -0.1729 -0.1581
S-927	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-927	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-927	-0.3443717062473297	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for 3-4 days or more until the pain and acute impairment is resolved .
D-927	-0.3443717062473297	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for 3-4 days or more until the pain and acute impairment is resolved .
P-927	-0.3731 -0.1207 -0.2708 -1.4966 -0.1275 -0.1377 -0.1232 -0.1629 -0.2242 -0.1720 -0.1819 -0.1548 -0.6734 -0.1829 -0.5223 -0.2057 -0.0961 -0.2545 -0.1127 -0.1443 -0.1622 -0.2701 -0.1600 -0.1561 -0.1305 -0.1200 -0.9788 -0.4324 -1.1089 -0.0734 -0.1347 -0.1893 -0.0691 -1.9657 -0.0689 -0.0361 -0.1000 -1.1381 -0.7564 -0.1729 -0.1581
S-751	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für 3-4 Tage oder länger wiederholen , bis die Schmerzen und die akute Beeinträchtigung beseitigt sind .
T-751	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for 3 4 days or more until pain and acute disability are resolved .
H-751	-0.3443717062473297	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for 3-4 days or more until the pain and acute impairment is resolved .
D-751	-0.3443717062473297	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for 3-4 days or more until the pain and acute impairment is resolved .
P-751	-0.3731 -0.1207 -0.2708 -1.4966 -0.1275 -0.1377 -0.1232 -0.1629 -0.2242 -0.1720 -0.1819 -0.1548 -0.6734 -0.1829 -0.5223 -0.2057 -0.0961 -0.2545 -0.1127 -0.1443 -0.1622 -0.2701 -0.1600 -0.1561 -0.1305 -0.1200 -0.9788 -0.4324 -1.1089 -0.0734 -0.1347 -0.1893 -0.0691 -1.9657 -0.0689 -0.0361 -0.1000 -1.1381 -0.7564 -0.1729 -0.1581
S-1970	Bei Anwendung von leicht flüchtigen halogenierten Anästhetika während der Therapie mit indirekten Sympathomimetika kann es perioperativ zu einer akuten Hypertonie kommen .
T-1970	3 Perioperative acute hypertension can occur if volatile halogenated anaesthetics are used during treatment with indirect sympathomimetic agents .
H-1970	-0.36812904477119446	Use of volatile halogenated anaesthetics during therapy with indirect sympathomimetics may lead to perioperative acute hypertension .
D-1970	-0.36812904477119446	Use of volatile halogenated anaesthetics during therapy with indirect sympathomimetics may lead to perioperative acute hypertension .
P-1970	-3.0206 -0.1530 -1.8517 -0.0944 -0.0370 -0.1622 -0.1211 -0.1255 -0.1732 -0.2360 -0.2478 -0.0674 -0.2167 -0.8921 -0.1611 -0.1309 -0.2327 -0.0162 -0.0736 -0.0821 -0.1104 -0.2799 -1.0112 -0.1609 -0.5274 -0.9646 -0.2129 -0.0609 -0.0197 -0.0324 -0.1481 -0.1565
S-1874	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 75 23 71 29 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu
T-1874	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 75 23 71 29 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu
H-1874	-0.2793286144733429	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 75 23 71 29 E-mail : mail/ emea.europa.eu http/ www.emea
D-1874	-0.2793286144733429	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 75 23 71 29 E-mail : mail/ emea.europa.eu http/ www.emea
P-1874	-0.1453 -0.0790 -0.0824 -0.1197 -0.1360 -0.0670 -0.1116 -0.0560 -0.1144 -0.6569 -0.1374 -0.0870 -0.0708 -0.1200 -0.1306 -0.0884 -0.0918 -0.0783 -0.1243 -0.1052 -0.4551 -0.4719 -0.1474 -0.6210 -0.4650 -0.0844 -1.6048 -0.1790 -0.3814 -0.1034 -0.2953 -0.1541 -0.1209 -0.1881 -0.0236 -0.4657 -1.9718
S-66	Osteoporose tritt vor allem bei postmenopausalen Frauen ( nach der 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel.
T-66	Osteoporose tritt vor allem bei postmenopausalen Frauen ( nach der 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel. 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
H-66	-0.1891995668411255	Osteoporosis primarily occurs in post-menopausal women ( after 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
D-66	-0.1891995668411255	Osteoporosis primarily occurs in post-menopausal women ( after 7 Westferry Circus , Canary Wharf , London E14 4HB , UK Tel .
P-66	-0.7593 -0.0642 -0.0915 -0.1266 -0.0775 -0.0817 -1.6234 -0.7573 -0.0904 -0.1341 -0.1647 -0.1970 -0.0404 -0.1110 -0.0425 -0.1327 -0.1239 -0.1400 -0.3530 -0.1863 -0.0908 -0.1070 -0.0790 -0.0972 -0.0761 -0.1493 -0.1033 -0.1396 -0.1125 -0.2226 -0.1323 -0.1515 -0.1128 -0.1007 -0.1046 -0.1629 -0.1213 -0.1094 -0.1508 -0.1177 -0.1180 -0.1290 -0.1496
S-21	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 86 68 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu
T-21	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 86 68 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu
H-21	-0.27961841225624084	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 86 68 E-mail : mail/ emea.europa.eu http/ www.emea
D-21	-0.27961841225624084	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 86 68 E-mail : mail/ emea.europa.eu http/ www.emea
P-21	-0.1430 -0.0786 -0.0839 -0.1216 -0.1357 -0.0645 -0.1124 -0.0563 -0.1290 -0.6687 -0.1376 -0.0870 -0.0732 -0.1210 -0.1317 -0.0584 -0.1136 -0.0711 -0.0611 -0.1074 -0.4715 -0.4932 -0.1469 -0.6235 -0.4153 -0.0780 -1.6604 -0.1738 -0.3943 -0.1053 -0.2819 -0.1517 -0.1193 -0.1477 -0.0241 -0.4577 -2.0457
S-530	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu
T-530	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu
H-530	-0.28091761469841003	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail/ emea.europa.eu http/ www.emea
D-530	-0.28091761469841003	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail/ emea.europa.eu http/ www.emea
P-530	-0.1452 -0.0791 -0.0851 -0.1200 -0.1356 -0.0653 -0.1124 -0.0566 -0.1230 -0.6732 -0.1381 -0.0846 -0.0743 -0.1195 -0.1320 -0.0618 -0.1115 -0.0473 -0.1275 -0.1017 -0.5102 -0.4804 -0.1479 -0.6193 -0.4121 -0.0885 -1.6039 -0.1809 -0.3863 -0.1032 -0.2966 -0.1523 -0.1181 -0.1619 -0.0242 -0.4841 -2.0302
S-1731	ADVATE enthält als arzneilich wirksamen Bestandteil Octocog alfa , Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie .
T-1731	ADVATE contains the active substance octocog alfa , human coagulation factor VIII produced by recombinant DNA technology .
H-1731	-0.3000708818435669	ADVATE , as active substance , contains octocog alfa , human blood clotting factor VIII produced by recombinant DNA technology .
D-1731	-0.3000708818435669	ADVATE , as active substance , contains octocog alfa , human blood clotting factor VIII produced by recombinant DNA technology .
P-1731	-1.4102 -0.1471 -0.0776 -0.1070 -1.3658 -0.1836 -0.7952 -0.3100 -0.3432 -0.0976 -0.8993 -0.0845 -0.1589 -0.2859 -0.1152 -0.0586 -0.1514 -0.3581 -0.4574 -0.9776 -0.0301 -0.0754 -0.0606 -0.1396 -0.1219 -0.5850 -0.2814 -0.1089 -0.0977 -0.0813 -0.1277 -0.0545 -0.0622 -0.1424 -0.1495
S-99	Eine zusätzliche Ergänzung mit Vitamin D sollte individuell unter Berücksichtung der Vitamin-D-Aufnahme durch Vitaminpräparate und Nahrungsergänzungsmittel erwogen werden .
T-99	Additional supplementation with vitamin D should be considered on an individual basis taking into account any vitamin D intake from vitamins and dietary supplements .
H-99	-0.3984363377094269	Additional vitamin D supplementation should be considered on an individual basis , taking into account vitamin D uptake from vitamin supplements and supplements .
D-99	-0.3984363377094269	Additional vitamin D supplementation should be considered on an individual basis , taking into account vitamin D uptake from vitamin supplements and supplements .
P-99	-2.2015 -1.0878 -0.0876 -0.1265 -0.1125 -0.1352 -0.1114 -0.1333 -0.1458 -0.1450 -0.3399 -0.2902 -0.0428 -0.2103 -1.2965 -0.7558 -1.3530 -0.2255 -0.2762 -0.0915 -0.1162 -0.9892 -0.0346 -0.6838 -0.2131 -0.2507 -0.5458 -0.1473 -0.1315 -0.4751 -0.1069 -0.1338 -0.1520
S-1936	Blister ( PCTFE<unk> PVC<unk> Alu ) 20 Tabletten 2.5 mg Desloratadin<unk> 120 mg Pseudoephedrinsulphat 1<unk> 1
T-1936	1/ 1
H-1936	-0.19563737511634827	Blister ( PCTFE/ PVC/ Alu ) 20 tablets 2.5 mg desloratadin/ 120 mg pseudoephedrine sulphate 1/
D-1936	-0.19563737511634827	Blister ( PCTFE/ PVC/ Alu ) 20 tablets 2.5 mg desloratadin/ 120 mg pseudoephedrine sulphate 1/
P-1936	-0.2403 -0.1218 -0.1347 -0.1751 -0.1154 -0.1087 -0.1337 -0.1274 -0.1235 -0.1175 -0.1366 -0.1710 -0.3312 -0.1141 -0.1291 -0.1340 -0.1156 -0.1079 -0.0998 -0.0394 -0.8396 -0.0648 -0.1338 -0.0972 -0.4336 -0.8785 -0.0977 -0.0590 -0.0686 -0.4587 -0.1268 -0.0731 -0.1042 -0.2465 -0.2642 -0.0585 -0.3287 -0.1158 -0.1575 -0.1397 -0.4977
S-156	Alendronat , das an trächtige Ratten gegeben wurde , verursachte Dystokie , die mit einer Hypocalcämie in Zusammenhang stand ( siehe Abschnitt 5.3 ) .
T-156	Alendronate given during pregnancy in rats caused dystocia related to hypocalcaemia ( see section 5.3 ) .
H-156	-0.3047262132167816	Alendronate administered to pregnant rats caused dystokia associated with hypocalcaemia ( see section 5.3 ) .
D-156	-0.3047262132167816	Alendronate administered to pregnant rats caused dystokia associated with hypocalcaemia ( see section 5.3 ) .
P-156	-0.1226 -0.1603 -0.1030 -0.0408 -1.4094 -0.0859 -0.1814 -0.0941 -0.0894 -0.8155 -0.0521 -2.7032 -0.5783 -0.0894 -0.6664 -0.1291 -0.0398 -0.0819 -0.0355 -0.0567 -0.1339 -0.1280 -0.2605 -0.1280 -0.1039 -0.1213 -0.1298 -0.1443 -0.1525
S-344	Alendronat , das an trächtige Ratten gegeben wurde , verursachte Dystokie , die mit einer Hypocalcämie in Zusammenhang stand ( siehe Abschnitt 5.3 ) .
T-344	Alendronate given during pregnancy in rats caused dystocia related to hypocalcaemia ( see section 5.3 ) .
H-344	-0.3047262132167816	Alendronate administered to pregnant rats caused dystokia associated with hypocalcaemia ( see section 5.3 ) .
D-344	-0.3047262132167816	Alendronate administered to pregnant rats caused dystokia associated with hypocalcaemia ( see section 5.3 ) .
P-344	-0.1226 -0.1603 -0.1030 -0.0408 -1.4094 -0.0859 -0.1814 -0.0941 -0.0894 -0.8155 -0.0521 -2.7032 -0.5783 -0.0894 -0.6664 -0.1291 -0.0398 -0.0819 -0.0355 -0.0567 -0.1339 -0.1280 -0.2605 -0.1280 -0.1039 -0.1213 -0.1298 -0.1443 -0.1525
S-887	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-887	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-887	-0.4008246958255768	Be sure that ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
D-887	-0.4008246958255768	Be sure that ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
P-887	-0.9424 -0.0748 -2.0071 -0.1401 -0.1444 -0.0862 -0.1091 -0.1265 -1.8952 -0.2067 -0.0338 -0.0922 -0.5697 -0.3739 -0.3607 -0.9275 -0.4805 -0.0739 -0.0846 -0.1769 -0.2586 -0.1791 -0.1852 -1.8208 -0.1944 -0.1465 -0.7293 -0.1710 -0.6906 -0.1981 -0.3143 -0.0812 -0.1108 -0.1005 -0.1736 -0.1693
S-1063	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-1063	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-1063	-0.4008246958255768	Be sure that ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
D-1063	-0.4008246958255768	Be sure that ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
P-1063	-0.9424 -0.0748 -2.0071 -0.1401 -0.1444 -0.0862 -0.1091 -0.1265 -1.8952 -0.2067 -0.0338 -0.0922 -0.5697 -0.3739 -0.3607 -0.9275 -0.4805 -0.0739 -0.0846 -0.1769 -0.2586 -0.1791 -0.1852 -1.8208 -0.1944 -0.1465 -0.7293 -0.1710 -0.6906 -0.1981 -0.3143 -0.0812 -0.1108 -0.1005 -0.1736 -0.1693
S-1239	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-1239	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-1239	-0.4008246958255768	Be sure that ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
D-1239	-0.4008246958255768	Be sure that ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
P-1239	-0.9424 -0.0748 -2.0071 -0.1401 -0.1444 -0.0862 -0.1091 -0.1265 -1.8952 -0.2067 -0.0338 -0.0922 -0.5697 -0.3739 -0.3607 -0.9275 -0.4805 -0.0739 -0.0846 -0.1769 -0.2586 -0.1791 -0.1852 -1.8208 -0.1944 -0.1465 -0.7293 -0.1710 -0.6906 -0.1981 -0.3143 -0.0812 -0.1108 -0.1005 -0.1736 -0.1693
S-1415	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-1415	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-1415	-0.4008246958255768	Be sure that ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
D-1415	-0.4008246958255768	Be sure that ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
P-1415	-0.9424 -0.0748 -2.0071 -0.1401 -0.1444 -0.0862 -0.1091 -0.1265 -1.8952 -0.2067 -0.0338 -0.0922 -0.5697 -0.3739 -0.3607 -0.9275 -0.4805 -0.0739 -0.0846 -0.1769 -0.2586 -0.1791 -0.1852 -1.8208 -0.1944 -0.1465 -0.7293 -0.1710 -0.6906 -0.1981 -0.3143 -0.0812 -0.1108 -0.1005 -0.1736 -0.1693
S-711	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-711	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-711	-0.4008246958255768	Be sure that ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
D-711	-0.4008246958255768	Be sure that ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
P-711	-0.9424 -0.0748 -2.0071 -0.1401 -0.1444 -0.0862 -0.1091 -0.1265 -1.8952 -0.2067 -0.0338 -0.0922 -0.5697 -0.3739 -0.3607 -0.9275 -0.4805 -0.0739 -0.0846 -0.1769 -0.2586 -0.1791 -0.1852 -1.8208 -0.1944 -0.1465 -0.7293 -0.1710 -0.6906 -0.1981 -0.3143 -0.0812 -0.1108 -0.1005 -0.1736 -0.1693
S-275	Therapie der postmenopausalen Osteoporose bei Patienten mit Risiko für einen Vitamin-D-Mangel , die keine zusätzliche Vitamin-D-Supplementierung erhalten .
T-275	Treatment of postmenopausal osteoporosis in patients who are not receiving vitamin D supplementation and are at risk of vitamin D insufficiency .
H-275	-0.17833806574344635	Treatment of post-menopausal osteoporosis in patients at risk of vitamin D deficiency who are not receiving additional vitamin D supplementation .
D-275	-0.17833806574344635	Treatment of post-menopausal osteoporosis in patients at risk of vitamin D deficiency who are not receiving additional vitamin D supplementation .
P-275	-1.0007 -0.0433 -0.1058 -0.1397 -0.0576 -0.2247 -0.0311 -0.0953 -0.0329 -0.1396 -0.1781 -0.0704 -0.1088 -0.1337 -0.0949 -0.0847 -0.1489 -0.4988 -0.0439 -0.0733 -0.6768 -0.2462 -0.0665 -0.1417 -0.0430 -0.0509 -0.2711 -0.1574 -0.4158 -0.2536 -0.1020 -0.3028 -0.3803 -0.0706 -0.1337 -0.0601 -0.0438 -0.1071 -0.1518 -0.1524
S-452	Es wurden keine Hinweise auf eine Sättigung der Aufnahmefähigkeit des Knochens nach Langzeitdosierung von kumulativen intravenösen Dosen bis zu 35 mg<unk> kg bei Tieren gefunden .
T-452	No evidence of saturation of bone uptake was found after chronic dosing with cumulative intravenous doses up to 35 mg/ kg in animals .
H-452	-0.3774077892303467	No evidence of bone saturation after long term doses of cumulative intravenous doses up to 35 mg/ kg in animals .
D-452	-0.3774077892303467	No evidence of bone saturation after long term doses of cumulative intravenous doses up to 35 mg/ kg in animals .
P-452	-0.5558 -0.0231 -1.6099 -1.0319 -2.3376 -0.0713 -0.1678 -0.5277 -0.9966 -0.4407 -0.8247 -0.2537 -0.1603 -0.1300 -0.0764 -0.1531 -0.1544 -0.0969 -0.0962 -0.1174 -0.1509 -0.0669 -0.7449 -0.1287 -0.0896 -0.1570 -0.1356 -0.1293 -0.0593 -0.2017 -0.1124 -0.4951 -0.1571
S-82	Am 4. Januar2007 erteilte die Europäische Kommission dem Unternehmen Merck Sharp <unk> Dohme Ltd. eine Genehmigung für das Inverkehrbringen von ADROVANCE in der gesamten Europäischen Union .
T-82	The European Commission granted a marketing authorisation valid throughout the European Union for ADROVANCE to Merck Sharp <<unk>> Dohme Ltd. on 4 January 2007.
H-82	-0.3638775646686554	On 4 January 2007 , the European Commission authorised Merck Sharp <unk> Dohme Ltd . , to market ADROVANCE throughout the European Union .
D-82	-0.3638775646686554	On 4 January 2007 , the European Commission authorised Merck Sharp <unk> Dohme Ltd . , to market ADROVANCE throughout the European Union .
P-82	-0.5105 -1.1764 -0.5784 -0.1538 -0.9418 -0.1483 -0.2163 -0.1881 -1.7871 -0.1148 -0.3221 -0.1957 -0.2221 -0.1158 -0.1212 -0.2883 -0.1942 -0.2468 -0.8524 -0.4115 -0.3669 -0.9913 -0.1241 -0.0840 -0.1175 -0.1141 -0.1206 -0.4903 -0.1346 -0.1841 -0.2022 -0.1377 -0.1549
S-524	Patienten mit Hämophilie A leiden an einem Faktor VIII-Mangel , was Blutgerinnungsprobleme wie Blutungen in den Gelenken , Muskeln oder inneren Organen verursacht .
T-524	Patients with haemophilia A lack factor VIII , and this causes blood coagulation problems , such as bleeding in the joints , muscles or internal organs .
H-524	-0.42964762449264526	Patients with haemophilia A suffer from factor VIII deficiency , which causes blood to clot , such as bleeding in the joints , muscles or internal organs .
D-524	-0.42964762449264526	Patients with haemophilia A suffer from factor VIII deficiency , which causes blood to clot , such as bleeding in the joints , muscles or internal organs .
P-524	-2.0548 -0.0988 -0.1263 -0.1503 -0.0604 -0.1620 -0.1932 -0.1335 -0.4212 -0.1798 -0.8856 -0.7043 -0.2785 -1.2226 -0.0465 -0.0423 -0.1186 -0.2014 -0.2919 -0.3572 -0.1898 -0.6699 -1.7961 -0.1704 -1.6435 -0.3954 -0.1566 -1.0716 -0.3325 -0.3524 -1.4783 -0.1924 -0.0625 -0.1544 -0.2656 -0.2263 -0.0572 -0.2587 -0.1157 -0.1442 -0.1528
S-534	In der Hauptstudie wurde die Wirksamkeit von Advate bei der Vorbeugung von Blutungen in 86 % von 510 neuen Blutungsepisoden mit ausgezeichnet bzw. mit gut bewertet .
T-534	In the main study , the effectiveness of Advate in the prevention of bleeding was rated as excellent or good in 86 % of the 510 new bleeding episodes .
H-534	-0.43877753615379333	In the main study , Advate &apos;s efficacy in preventing haemorrhage in 86 % of 510 new bleeding episodes was either excellent or well assessed .
D-534	-0.43877753615379333	In the main study , Advate &apos;s efficacy in preventing haemorrhage in 86 % of 510 new bleeding episodes was either excellent or well assessed .
P-534	-1.5026 -0.1614 -0.1179 -0.4243 -0.2057 -0.3341 -0.0923 -2.1606 -0.9355 -0.0439 -0.0776 -0.1273 -0.0368 -1.6853 -0.5394 -0.0377 -0.3185 -0.6038 -0.1214 -0.1226 -0.1620 -0.1485 -0.1570 -0.2192 -0.6664 -0.3563 -0.0168 -0.1011 -1.7785 -0.3480 -0.1470 -0.8538 -0.8273 -0.0811 -0.1323 -0.1521
S-1592	Vergewissern Sie sich , dass ADVATE vollständig gelöst ist , da sonst nicht die gesamt rekonstituierte Lösung durch den Filter im BAXJECT II gedrückt wird .
T-1592	Be sure that ADVATE is completely dissolved , otherwise not all reconstituted solution will pass through the device filter .
H-1592	-0.4008246958255768	Be sure that ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
D-1592	-0.4008246958255768	Be sure that ADVATE is completely dissolved , otherwise the entire reconstituted solution will not be pushed through the filter in BAXJECT II .
P-1592	-0.9424 -0.0748 -2.0071 -0.1401 -0.1444 -0.0862 -0.1091 -0.1265 -1.8952 -0.2067 -0.0338 -0.0922 -0.5697 -0.3739 -0.3607 -0.9275 -0.4805 -0.0739 -0.0846 -0.1769 -0.2586 -0.1791 -0.1852 -1.8208 -0.1944 -0.1465 -0.7293 -0.1710 -0.6906 -0.1981 -0.3143 -0.0812 -0.1108 -0.1005 -0.1736 -0.1693
S-244	Die Bioverfügbarkeit von 2.800 I.E. Vitamin D3 in ADROVANCE ist der von allein eingenommenem 2.800 I.E. Vitamin D3 vergleichbar .
T-244	The bioavailability of the 2800 IU vitamin D3 in ADROVANCE is similar to 2800 IU vitamin D3 administered alone .
H-244	-0.18821434676647186	The bioavailability of 2,800 IU of vitamin D3 in ADROVANCE is similar to that of 2,800 IU of vitamin D3 taken alone .
D-244	-0.18821434676647186	The bioavailability of 2,800 IU of vitamin D3 in ADROVANCE is similar to that of 2,800 IU of vitamin D3 taken alone .
P-244	-0.2139 -0.0306 -0.1277 -0.1637 -0.2896 -0.1056 -0.0962 -0.1003 -0.1763 -0.1505 -0.1574 -0.1337 -0.1444 -0.1499 -0.0622 -0.0877 -0.1207 -0.0945 -0.0987 -0.1233 -0.5270 -0.1393 -0.2589 -0.2880 -0.1203 -0.1159 -0.1678 -0.1004 -0.1736 -0.1659 -0.1282 -0.1306 -0.1366 -1.0849 -0.5110 -0.1335 -0.1553
S-451	Charakteristika bei Patienten Präklinische Studien haben gezeigt , dass der Anteil von Alendronat , der nicht im Knochen abgelagert wird , schnell über den Urin ausgeschieden wird .
T-451	Characteristics in patients Preclinical studies show that alendronate that is not deposited in bone is rapidly excreted in the urine .
H-451	-0.37590962648391724	Characteristics in patients Preclinical studies have shown that the fraction of alendronate not deposited in the bone is rapidly excreted via the urine .
D-451	-0.37590962648391724	Characteristics in patients Preclinical studies have shown that the fraction of alendronate not deposited in the bone is rapidly excreted via the urine .
P-451	-1.3356 -0.0569 -0.0646 -0.2993 -0.1224 -1.3092 -0.6394 -0.3056 -0.3006 -0.1180 -0.1511 -0.8188 -0.1274 -0.3176 -0.1215 -0.6990 -1.6137 -0.0935 -0.1548 -0.1228 -0.1424 -0.1094 -0.0325 -0.6736 -0.4104 -0.1297 -0.1388 -0.8910 -0.1272 -0.1117 -1.5210 -0.1084 -0.0161 -0.0920 -0.9354 -0.3733 -0.0633 -0.0937 -0.1392 -0.1556
S-255	Charakteristika bei Patienten Präklinische Studien haben gezeigt , dass der Anteil von Alendronat , der nicht im Knochen abgelagert wird , schnell über den Urin ausgeschieden wird .
T-255	Characteristics in patients Preclinical studies show that alendronate that is not deposited in bone is rapidly excreted in the urine .
H-255	-0.37590962648391724	Characteristics in patients Preclinical studies have shown that the fraction of alendronate not deposited in the bone is rapidly excreted via the urine .
D-255	-0.37590962648391724	Characteristics in patients Preclinical studies have shown that the fraction of alendronate not deposited in the bone is rapidly excreted via the urine .
P-255	-1.3356 -0.0569 -0.0646 -0.2993 -0.1224 -1.3092 -0.6394 -0.3056 -0.3006 -0.1180 -0.1511 -0.8188 -0.1274 -0.3176 -0.1215 -0.6990 -1.6137 -0.0935 -0.1548 -0.1228 -0.1424 -0.1094 -0.0325 -0.6736 -0.4104 -0.1297 -0.1388 -0.8910 -0.1272 -0.1117 -1.5210 -0.1084 -0.0161 -0.0920 -0.9354 -0.3733 -0.0633 -0.0937 -0.1392 -0.1556
S-440	Die Bioverfügbarkeit von 5.600 I.E. Vitamin D3 in ADROVANCE ist der von allein eingenommenem 5.600 I.E. Vitamin D3 vergleichbar .
T-440	The bioavailability of the 5600 IU vitamin D3 in ADROVANCE is similar to 5600 IU vitamin D3 administered alone .
H-440	-0.19308464229106903	The bioavailability of 5,600 IU of vitamin D3 in ADROVANCE is similar to that of 5,600 IU of vitamin D3 taken alone .
D-440	-0.19308464229106903	The bioavailability of 5,600 IU of vitamin D3 in ADROVANCE is similar to that of 5,600 IU of vitamin D3 taken alone .
P-440	-0.2079 -0.0254 -0.1217 -0.1654 -0.4410 -0.0662 -0.0976 -0.0938 -0.1758 -0.1459 -0.1598 -0.1342 -0.1446 -0.1480 -0.0590 -0.0870 -0.1213 -0.0959 -0.0996 -0.1263 -0.5219 -0.1395 -0.2395 -0.3153 -0.3541 -0.0694 -0.1399 -0.1040 -0.1741 -0.1589 -0.1286 -0.1311 -0.1376 -1.0746 -0.4511 -0.1322 -0.1559
S-423	20 eingenommen wurde . In Osteoporosestudien war Alendronat wirksam , wenn es mindestens 30 Minuten vor dem ersten Essen oder Trinken des Tages eingenommen wurde .
T-423	In osteoporosis studies , alendronate was effective when administered at least 30 minutes before the first food or beverage of the day .
H-423	-0.28744208812713623	20 . In osteoporosis studies , alendronate was effective if taken at least 30 minutes prior to the first meal or drink of the day .
D-423	-0.28744208812713623	20 . In osteoporosis studies , alendronate was effective if taken at least 30 minutes prior to the first meal or drink of the day .
P-423	-0.5022 -0.4065 -0.1288 -0.1518 -0.0613 -0.0951 -0.1328 -0.1624 -0.0920 -0.3536 -0.6419 -0.1273 -0.1703 -0.0834 -0.0467 -0.1933 -0.1137 -0.9450 -0.9461 -0.1075 -0.1208 -0.1469 -0.1481 -1.3968 -0.1358 -0.5504 -0.1015 -0.8945 -0.1052 -0.2223 -0.1552 -0.2200 -0.0962 -0.1520 -0.1530
S-1759	Vorbeugung von Blutungen Die übliche Dosierung mit Octocog alfa beträgt 20-40 I.E.pro kg Köprergewicht , verabreicht alle 2-3 Tage .
T-1759	Prevention of bleeding The usual dose of octocog alfa is 20 to 40 IU per kg body weight , administered every 2 to 3 days.
H-1759	-0.3242895305156708	preventing bleeding The usual dose of Octocog alfa is 20 40 IU per kg bodyweight , administered every 2 3 days .
D-1759	-0.3242895305156708	preventing bleeding The usual dose of Octocog alfa is 20 40 IU per kg bodyweight , administered every 2 3 days .
P-1759	-0.6473 -1.0632 -0.2399 -0.1304 -0.1180 -0.2495 -0.2351 -0.6995 -0.0889 -0.1523 -0.2195 -0.1228 -0.0712 -0.1014 -0.1732 -0.4044 -0.1314 -0.6726 -0.1278 -0.0540 -1.1562 -0.0311 -0.8777 -0.6982 -0.0891 -0.2758 -0.7072 -0.1129 -0.1173 -0.1340 -0.1511
S-1584	65 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1584	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-1584	-0.38758254051208496	Do not use the BAXJECT II Unit Set if its sterile barrier is broken , its packaging is damaged or if it shows signs of manipulation .
D-1584	-0.38758254051208496	Do not use the BAXJECT II Unit Set if its sterile barrier is broken , its packaging is damaged or if it shows signs of manipulation .
P-1584	-0.2120 -0.1426 -0.1184 -0.1876 -0.2318 -0.1824 -0.3103 -0.0934 -0.0959 -0.2256 -1.1265 -0.1119 -1.5991 -0.1293 -0.1465 -0.1652 -0.0549 -0.1742 -0.4966 -0.7455 -0.1549 -0.1181 -0.4922 -0.2107 -0.9679 -0.3004 -0.2026 -1.5358 -0.4383 -0.9584 -0.4704 -0.1406 -1.0523 -0.0628 -0.1385 -0.1594
S-722	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-722	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-722	-0.46069103479385376	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of the injection ( see sections 4.4 and 4.8 ) .
D-722	-0.46069103479385376	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of the injection ( see sections 4.4 and 4.8 ) .
P-722	-1.3682 -0.6387 -0.2789 -0.1204 -0.8015 -0.1078 -0.2834 -0.4728 -0.3024 -0.1861 -3.3864 -0.2223 -0.4212 -0.1453 -0.1146 -0.9537 -2.0715 -0.1648 -0.2129 -0.1622 -1.3224 -0.2039 -0.1410 -0.1578 -0.2660 -0.1049 -0.1192 -0.1282 -0.1395 -0.1239 -0.1170 -0.1357 -0.1393 -0.1497
S-898	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-898	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-898	-0.46069103479385376	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of the injection ( see sections 4.4 and 4.8 ) .
D-898	-0.46069103479385376	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of the injection ( see sections 4.4 and 4.8 ) .
P-898	-1.3682 -0.6387 -0.2789 -0.1204 -0.8015 -0.1078 -0.2834 -0.4728 -0.3024 -0.1861 -3.3864 -0.2223 -0.4212 -0.1453 -0.1146 -0.9537 -2.0715 -0.1648 -0.2129 -0.1622 -1.3224 -0.2039 -0.1410 -0.1578 -0.2660 -0.1049 -0.1192 -0.1282 -0.1395 -0.1239 -0.1170 -0.1357 -0.1393 -0.1497
S-1847	Benutzen Sie zum Auflösen ausschließlich das sterilisierte Wasser für Injektionszwecke und das Rekonstitutions-Gerät , das jeder Packung ADVATE beigepackt ist .
T-1847	Use only the sterilised water for injections and the reconstitution device for preparation of the solution that are provided with each package of ADVATE .
H-1847	-0.39725935459136963	To dissolve , use only sterilised water for injections and the Reconstitution Unit supplied with each pack of ADVATE .
D-1847	-0.39725935459136963	To dissolve , use only sterilised water for injections and the Reconstitution Unit supplied with each pack of ADVATE .
P-1847	-2.0587 -0.3425 -0.0912 -0.1886 -0.4438 -0.6099 -0.5537 -0.1327 -0.1878 -0.1669 -0.1269 -0.1329 -0.1229 -0.1386 -0.1498 -1.6649 -0.1601 -0.6783 -0.1082 -1.9741 -0.1108 -0.1540 -0.5446 -0.5466 -0.1351 -0.1469 -0.1413 -0.0820 -0.0929 -0.1612 -0.1672
S-1250	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-1250	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-1250	-0.46069103479385376	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of the injection ( see sections 4.4 and 4.8 ) .
D-1250	-0.46069103479385376	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of the injection ( see sections 4.4 and 4.8 ) .
P-1250	-1.3682 -0.6387 -0.2789 -0.1204 -0.8015 -0.1078 -0.2834 -0.4728 -0.3024 -0.1861 -3.3864 -0.2223 -0.4212 -0.1453 -0.1146 -0.9537 -2.0715 -0.1648 -0.2129 -0.1622 -1.3224 -0.2039 -0.1410 -0.1578 -0.2660 -0.1049 -0.1192 -0.1282 -0.1395 -0.1239 -0.1170 -0.1357 -0.1393 -0.1497
S-1407	54 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1407	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-1407	-0.3911423683166504	Do not use the BAXJECT II Unit Set if its sterile barrier is broken , its packaging is damaged or if it shows signs of manipulation .
D-1407	-0.3911423683166504	Do not use the BAXJECT II Unit Set if its sterile barrier is broken , its packaging is damaged or if it shows signs of manipulation .
P-1407	-0.3786 -0.1409 -0.1180 -0.1916 -0.2275 -0.1830 -0.3125 -0.0940 -0.0955 -0.2483 -1.0944 -0.1123 -1.4812 -0.1304 -0.1453 -0.1638 -0.0541 -0.1776 -0.4900 -0.7778 -0.1538 -0.1139 -0.5141 -0.2113 -1.0013 -0.3014 -0.1988 -1.4772 -0.4378 -0.9593 -0.5035 -0.1410 -1.0906 -0.0620 -0.1386 -0.1596
S-1231	43 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1231	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-1231	-0.3978688716888428	Do not use the BAXJECT II Unit Set if its sterile barrier is broken , its packaging is damaged or if it shows signs of manipulation .
D-1231	-0.3978688716888428	Do not use the BAXJECT II Unit Set if its sterile barrier is broken , its packaging is damaged or if it shows signs of manipulation .
P-1231	-0.5459 -0.1403 -0.1184 -0.1916 -0.2261 -0.1835 -0.3120 -0.0926 -0.0955 -0.2631 -1.0998 -0.1127 -1.6355 -0.1305 -0.1474 -0.1630 -0.0536 -0.1787 -0.4907 -0.7603 -0.1540 -0.1131 -0.5151 -0.2105 -0.9834 -0.2935 -0.1956 -1.4581 -0.4460 -0.9189 -0.4879 -0.1410 -1.1060 -0.0612 -0.1391 -0.1583
S-1055	32 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-1055	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-1055	-0.3874047100543976	Do not use the BAXJECT II Unit Set if its sterile barrier is broken , its packaging is damaged or if it shows signs of manipulation .
D-1055	-0.3874047100543976	Do not use the BAXJECT II Unit Set if its sterile barrier is broken , its packaging is damaged or if it shows signs of manipulation .
P-1055	-0.2631 -0.1423 -0.1166 -0.1945 -0.2297 -0.1834 -0.3110 -0.0937 -0.0956 -0.2561 -1.0470 -0.1127 -1.5497 -0.1327 -0.1474 -0.1678 -0.0553 -0.1777 -0.4936 -0.7684 -0.1539 -0.1145 -0.5431 -0.2124 -0.9616 -0.3042 -0.1977 -1.4806 -0.4273 -0.9052 -0.4919 -0.1412 -1.1151 -0.0616 -0.1400 -0.1584
S-879	21 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-879	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-879	-0.4032721519470215	Do not use the BAXJECT II Unit if its sterile barrier is broken , its packaging is damaged or if it shows signs of manipulation .
D-879	-0.4032721519470215	Do not use the BAXJECT II Unit if its sterile barrier is broken , its packaging is damaged or if it shows signs of manipulation .
P-879	-0.3285 -0.1416 -0.1164 -0.1935 -0.2224 -0.1836 -0.3095 -0.0947 -0.0962 -0.2487 -1.2505 -0.1119 -1.6215 -0.1822 -0.1559 -0.0555 -0.1875 -0.5626 -0.7105 -0.1543 -0.1111 -0.5151 -0.2125 -0.8567 -0.3004 -0.2003 -1.5139 -0.5414 -0.8757 -0.4426 -0.1413 -1.1134 -0.0632 -0.1394 -0.1598
S-703	10 nehmen . Den BAXJECT II-Gerätesatz nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist .
T-703	Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or shows any sign of deterioration .
H-703	-0.3921371102333069	Do not use the BAXJECT II Unit Set if its sterile barrier is broken , its packaging is damaged or if it shows signs of manipulation .
D-703	-0.3921371102333069	Do not use the BAXJECT II Unit Set if its sterile barrier is broken , its packaging is damaged or if it shows signs of manipulation .
P-703	-0.3349 -0.1412 -0.1191 -0.1937 -0.2251 -0.1830 -0.3123 -0.0927 -0.0960 -0.2624 -1.1655 -0.1121 -1.5147 -0.1340 -0.1433 -0.1631 -0.0537 -0.1782 -0.5153 -0.7681 -0.1543 -0.1127 -0.4971 -0.2115 -1.0020 -0.2966 -0.2036 -1.5100 -0.4521 -0.9215 -0.4739 -0.1417 -1.0733 -0.0615 -0.1393 -0.1574
S-1943	Die Tablette kann mit einem Glas Wasser eingenommen werden , ist jedoch im Ganzen zu schlucken ( d. h. ohne sie zu zerbeißen , zu zerbrechen oder zu kauen ) .
T-1943	The tablet may be taken with a full glass of water but must be swallowed entirely ( without crushing , breaking or chewing it ) .
H-1943	-0.390709787607193	The tablet can be taken with a glass of water but must be swallowed whole ( i. e. without biting , breaking or chewing ) .
D-1943	-0.390709787607193	The tablet can be taken with a glass of water but must be swallowed whole ( i. e. without biting , breaking or chewing ) .
P-1943	-0.3926 -0.0722 -0.1152 -1.0956 -0.1790 -0.2444 -0.1426 -0.1616 -0.0939 -0.1493 -0.1152 -0.3535 -1.8511 -0.1960 -0.1662 -0.1476 -0.0582 -1.4007 -0.1563 -0.2747 -0.1457 -0.1299 -0.1247 -0.2198 -2.3423 -0.1706 -0.8079 -0.1804 -0.1242 -0.0697 -0.9049 -0.1544 -0.1529
S-925	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-925	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-925	-0.3831392526626587	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
D-925	-0.3831392526626587	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
P-925	-0.2984 -0.0989 -0.2717 -1.5098 -0.1378 -0.1367 -0.1194 -0.1543 -0.2121 -0.1723 -0.1809 -0.1519 -0.8136 -0.1766 -0.4849 -0.2131 -0.0967 -0.2680 -0.1146 -0.1410 -0.1604 -0.1339 -0.1158 -0.2570 -0.1157 -0.7656 -0.4299 -1.1476 -0.2304 -0.2770 -1.7111 -2.7809 -0.1867 -0.1161 -0.2693 -0.1328 -0.3809 -0.0506 -0.1526 -0.1583
S-1074	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-1074	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-1074	-0.46069103479385376	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of the injection ( see sections 4.4 and 4.8 ) .
D-1074	-0.46069103479385376	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of the injection ( see sections 4.4 and 4.8 ) .
P-1074	-1.3682 -0.6387 -0.2789 -0.1204 -0.8015 -0.1078 -0.2834 -0.4728 -0.3024 -0.1861 -3.3864 -0.2223 -0.4212 -0.1453 -0.1146 -0.9537 -2.0715 -0.1648 -0.2129 -0.1622 -1.3224 -0.2039 -0.1410 -0.1578 -0.2660 -0.1049 -0.1192 -0.1282 -0.1395 -0.1239 -0.1170 -0.1357 -0.1393 -0.1497
S-46	EU<unk> 1<unk> 08<unk> 447<unk> 002 ADENURIC 80 mg Filmtablette Zum Einnehmen Blisterpackung ( Aclar<unk> PVC<unk> Aluminium )
T-46	Adenuric Adenuric Adenuric Adenuric
H-46	-0.32973238825798035	EU/ 1/ 08/ 447/ 002 ADENURIC 80 mg Filmtablet Oral blister ( Aclar/ PVC/ aluminium )
D-46	-0.32973238825798035	EU/ 1/ 08/ 447/ 002 ADENURIC 80 mg Filmtablet Oral blister ( Aclar/ PVC/ aluminium )
P-46	-2.4514 -0.0512 -0.0582 -0.0776 -0.2917 -0.1121 -0.1149 -0.4884 -0.1125 -0.1100 -0.1553 -0.0979 -0.1213 -0.1474 -0.1842 -0.1615 -0.0383 -2.0456 -0.0277 -1.1948 -1.4889 -0.2640 -0.2163 -0.1589 -0.2832 -0.1285 -0.2762 -0.1464 -0.1407 -0.1182 -0.1014 -0.1017 -0.1278 -0.2342 -0.0389 -0.1367 -0.1960
S-1426	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-1426	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-1426	-0.46069103479385376	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of the injection ( see sections 4.4 and 4.8 ) .
D-1426	-0.46069103479385376	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of the injection ( see sections 4.4 and 4.8 ) .
P-1426	-1.3682 -0.6387 -0.2789 -0.1204 -0.8015 -0.1078 -0.2834 -0.4728 -0.3024 -0.1861 -3.3864 -0.2223 -0.4212 -0.1453 -0.1146 -0.9537 -2.0715 -0.1648 -0.2129 -0.1622 -1.3224 -0.2039 -0.1410 -0.1578 -0.2660 -0.1049 -0.1192 -0.1282 -0.1395 -0.1239 -0.1170 -0.1357 -0.1393 -0.1497
S-749	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-749	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-749	-0.3831392526626587	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
D-749	-0.3831392526626587	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
P-749	-0.2984 -0.0989 -0.2717 -1.5098 -0.1378 -0.1367 -0.1194 -0.1543 -0.2121 -0.1723 -0.1809 -0.1519 -0.8136 -0.1766 -0.4849 -0.2131 -0.0967 -0.2680 -0.1146 -0.1410 -0.1604 -0.1339 -0.1158 -0.2570 -0.1157 -0.7656 -0.4299 -1.1476 -0.2304 -0.2770 -1.7111 -2.7809 -0.1867 -0.1161 -0.2693 -0.1328 -0.3809 -0.0506 -0.1526 -0.1583
S-1028	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-1028	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-1028	-0.18774786591529846	powder mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
D-1028	-0.18774786591529846	powder mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
P-1028	-0.4230 -1.1037 -0.0982 -0.0752 -0.1222 -0.0344 -0.1158 -0.0905 -0.1361 -0.1034 -0.2757 -0.4348 -0.9567 -0.5506 -0.0584 -0.0473 -0.1463 -0.0743 -0.1159 -0.1157 -0.0851 -0.1351 -0.0937 -0.4430 -0.0860 -0.1238 -0.0911 -0.1598 -0.0466 -0.0855 -0.0791 -0.0836 -0.0241 -0.0722 -0.0681 -0.1286 -0.3019 -0.1329 -0.0830 -0.1346 -0.1863 -0.1627
S-64	Osteoporose ist eine Krankheit , bei der die Knochen allmählich dünn und brüchig werden ; es kommt zu einer erhöhten Anfälligkeit für Frakturen ( Brüche ) .
T-64	Osteoporose ist eine Krankheit , bei der die Knochen allmählich dünn und brüchig werden ; es kommt zu einer erhöhten Anfälligkeit für Frakturen ( Brüche ) . It happens when not enough new bone grows to replace the bone that is naturally broken down .
H-64	-0.38753408193588257	Osteoporosis is a disease in which bones gradually become thin and fragile ; there is an increased susceptibility to fracture ( fractures ) .
D-64	-0.38753408193588257	Osteoporosis is a disease in which bones gradually become thin and fragile ; there is an increased susceptibility to fracture ( fractures ) .
P-64	-0.2185 -0.0654 -0.1023 -0.1234 -0.1016 -0.0721 -0.1113 -0.1538 -1.1457 -0.4576 -0.2142 -0.8496 -0.5985 -0.5325 -0.2486 -0.1350 -0.7644 -0.0714 -1.9588 -1.4449 -0.1163 -0.5329 -0.0869 -1.7802 -0.5224 -0.0848 -0.1111 -0.0942 -0.2248 -0.2374 -0.0990 -0.1735 -0.3709 -0.0872 -0.1329 -0.1600 -0.1548
S-1453	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-1453	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-1453	-0.3831392526626587	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
D-1453	-0.3831392526626587	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
P-1453	-0.2984 -0.0989 -0.2717 -1.5098 -0.1378 -0.1367 -0.1194 -0.1543 -0.2121 -0.1723 -0.1809 -0.1519 -0.8136 -0.1766 -0.4849 -0.2131 -0.0967 -0.2680 -0.1146 -0.1410 -0.1604 -0.1339 -0.1158 -0.2570 -0.1157 -0.7656 -0.4299 -1.1476 -0.2304 -0.2770 -1.7111 -2.7809 -0.1867 -0.1161 -0.2693 -0.1328 -0.3809 -0.0506 -0.1526 -0.1583
S-1277	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-1277	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-1277	-0.3831392526626587	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
D-1277	-0.3831392526626587	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
P-1277	-0.2984 -0.0989 -0.2717 -1.5098 -0.1378 -0.1367 -0.1194 -0.1543 -0.2121 -0.1723 -0.1809 -0.1519 -0.8136 -0.1766 -0.4849 -0.2131 -0.0967 -0.2680 -0.1146 -0.1410 -0.1604 -0.1339 -0.1158 -0.2570 -0.1157 -0.7656 -0.4299 -1.1476 -0.2304 -0.2770 -1.7111 -2.7809 -0.1867 -0.1161 -0.2693 -0.1328 -0.3809 -0.0506 -0.1526 -0.1583
S-1101	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-1101	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-1101	-0.3831392526626587	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
D-1101	-0.3831392526626587	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
P-1101	-0.2984 -0.0989 -0.2717 -1.5098 -0.1378 -0.1367 -0.1194 -0.1543 -0.2121 -0.1723 -0.1809 -0.1519 -0.8136 -0.1766 -0.4849 -0.2131 -0.0967 -0.2680 -0.1146 -0.1410 -0.1604 -0.1339 -0.1158 -0.2570 -0.1157 -0.7656 -0.4299 -1.1476 -0.2304 -0.2770 -1.7111 -2.7809 -0.1867 -0.1161 -0.2693 -0.1328 -0.3809 -0.0506 -0.1526 -0.1583
S-575	Injektion alle 12-24 Stunden ( 8-24 Stunden bei Patienten unter 6 Jahren ) für mind. 1 Tag wiederholen , bis die Blutung angezeigt durch Schmerzen steht oder Heilung erreicht ist .
T-575	Repeat injections every 12 to 24 hours ( 8 to 24 hours for patients under the age of 6 ) for at least 1 day , until the bleeding episode , as indicated by pain , is resolved or healing is achieved .
H-575	-0.3831392526626587	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
D-575	-0.3831392526626587	injection every 12-24 hours ( 8-24 hours for patients under 6 years of age ) for at least 1 day until indicated bleeding is stopped by pain or healing is achieved .
P-575	-0.2984 -0.0989 -0.2717 -1.5098 -0.1378 -0.1367 -0.1194 -0.1543 -0.2121 -0.1723 -0.1809 -0.1519 -0.8136 -0.1766 -0.4849 -0.2131 -0.0967 -0.2680 -0.1146 -0.1410 -0.1604 -0.1339 -0.1158 -0.2570 -0.1157 -0.7656 -0.4299 -1.1476 -0.2304 -0.2770 -1.7111 -2.7809 -0.1867 -0.1161 -0.2693 -0.1328 -0.3809 -0.0506 -0.1526 -0.1583
S-1603	Eine deutliche Erhöhung der Pulsfrequenz kann durch Verlangsamen oder zeitweiliges Unterbrechen der Injektion meist sofort wieder gesenkt werden ( siehe Abschnitte 4.4 und 4.8 ) .
T-1603	Should a significant increase occur , reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly ( see sections 4.4 and 4.8 ) .
H-1603	-0.46069103479385376	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of the injection ( see sections 4.4 and 4.8 ) .
D-1603	-0.46069103479385376	A significant increase in pulse rate can usually be reduced immediately by slowing or discontinuation of the injection ( see sections 4.4 and 4.8 ) .
P-1603	-1.3682 -0.6387 -0.2789 -0.1204 -0.8015 -0.1078 -0.2834 -0.4728 -0.3024 -0.1861 -3.3864 -0.2223 -0.4212 -0.1453 -0.1146 -0.9537 -2.0715 -0.1648 -0.2129 -0.1622 -1.3224 -0.2039 -0.1410 -0.1578 -0.2660 -0.1049 -0.1192 -0.1282 -0.1395 -0.1239 -0.1170 -0.1357 -0.1393 -0.1497
S-226	Die Bioverfügbarkeit nahm entsprechend auf etwa 0,46 % und 0,39 % ab , wenn Alendronat eine oder eine halbe Stunde vor einem standardisierten Frühstück eingenommen wurde .
T-226	Bioavailability was decreased similarly to an estimated 0.46 % and 0.39 % when alendronate was administered one hour or half an hour before a standardised breakfast .
H-226	-0.33607181906700134	Bioavailability decreased correspondingly to approximately 0.46 % and 0.39 % when alendronate was taken one or half an hour prior to a standardized breakfast .
D-226	-0.33607181906700134	Bioavailability decreased correspondingly to approximately 0.46 % and 0.39 % when alendronate was taken one or half an hour prior to a standardized breakfast .
P-226	-1.3444 -0.1096 -0.3947 -0.1517 -0.4885 -0.3338 -0.0990 -0.2283 -0.5561 -0.0891 -0.0780 -0.1265 -0.1242 -0.0627 -0.0759 -0.1185 -0.4323 -0.2736 -0.1594 -0.0948 -0.0565 -0.1361 -0.8577 -0.1312 -0.7752 -0.8227 -1.1830 -0.0864 -0.9052 -0.1370 -0.1938 -0.4820 -0.3704 -0.5175 -0.1322 -0.1563 -0.1504
S-1557	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-1557	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-1557	-0.18774786591529846	powder mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
D-1557	-0.18774786591529846	powder mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
P-1557	-0.4230 -1.1037 -0.0982 -0.0752 -0.1222 -0.0344 -0.1158 -0.0905 -0.1361 -0.1034 -0.2757 -0.4348 -0.9567 -0.5506 -0.0584 -0.0473 -0.1463 -0.0743 -0.1159 -0.1157 -0.0851 -0.1351 -0.0937 -0.4430 -0.0860 -0.1238 -0.0911 -0.1598 -0.0466 -0.0855 -0.0791 -0.0836 -0.0241 -0.0722 -0.0681 -0.1286 -0.3019 -0.1329 -0.0830 -0.1346 -0.1863 -0.1627
S-1380	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-1380	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-1380	-0.18774786591529846	powder mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
D-1380	-0.18774786591529846	powder mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
P-1380	-0.4230 -1.1037 -0.0982 -0.0752 -0.1222 -0.0344 -0.1158 -0.0905 -0.1361 -0.1034 -0.2757 -0.4348 -0.9567 -0.5506 -0.0584 -0.0473 -0.1463 -0.0743 -0.1159 -0.1157 -0.0851 -0.1351 -0.0937 -0.4430 -0.0860 -0.1238 -0.0911 -0.1598 -0.0466 -0.0855 -0.0791 -0.0836 -0.0241 -0.0722 -0.0681 -0.1286 -0.3019 -0.1329 -0.0830 -0.1346 -0.1863 -0.1627
S-1204	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-1204	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-1204	-0.18774786591529846	powder mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
D-1204	-0.18774786591529846	powder mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
P-1204	-0.4230 -1.1037 -0.0982 -0.0752 -0.1222 -0.0344 -0.1158 -0.0905 -0.1361 -0.1034 -0.2757 -0.4348 -0.9567 -0.5506 -0.0584 -0.0473 -0.1463 -0.0743 -0.1159 -0.1157 -0.0851 -0.1351 -0.0937 -0.4430 -0.0860 -0.1238 -0.0911 -0.1598 -0.0466 -0.0855 -0.0791 -0.0836 -0.0241 -0.0722 -0.0681 -0.1286 -0.3019 -0.1329 -0.0830 -0.1346 -0.1863 -0.1627
S-852	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-852	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-852	-0.18774786591529846	powder mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
D-852	-0.18774786591529846	powder mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
P-852	-0.4230 -1.1037 -0.0982 -0.0752 -0.1222 -0.0344 -0.1158 -0.0905 -0.1361 -0.1034 -0.2757 -0.4348 -0.9567 -0.5506 -0.0584 -0.0473 -0.1463 -0.0743 -0.1159 -0.1157 -0.0851 -0.1351 -0.0937 -0.4430 -0.0860 -0.1238 -0.0911 -0.1598 -0.0466 -0.0855 -0.0791 -0.0836 -0.0241 -0.0722 -0.0681 -0.1286 -0.3019 -0.1329 -0.0830 -0.1346 -0.1863 -0.1627
S-676	Pulver Mannitol Natriumchlorid Histidin Trehalose Calciumchlorid Trometamol Polysorbat 80 Glutathion ( reduziert ) .
T-676	Powder Mannitol Sodium chloride Histidine Trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced )
H-676	-0.18774786591529846	powder mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
D-676	-0.18774786591529846	powder mannitol Sodium chloride Histidine trehalose Calcium chloride Trometamol Polysorbate 80 Glutathione ( reduced ) .
P-676	-0.4230 -1.1037 -0.0982 -0.0752 -0.1222 -0.0344 -0.1158 -0.0905 -0.1361 -0.1034 -0.2757 -0.4348 -0.9567 -0.5506 -0.0584 -0.0473 -0.1463 -0.0743 -0.1159 -0.1157 -0.0851 -0.1351 -0.0937 -0.4430 -0.0860 -0.1238 -0.0911 -0.1598 -0.0466 -0.0855 -0.0791 -0.0836 -0.0241 -0.0722 -0.0681 -0.1286 -0.3019 -0.1329 -0.0830 -0.1346 -0.1863 -0.1627
S-246	Vitamin D3 wird rasch verteilt , hauptsächlich in die Leber , wo es zu 25-Hydroxyvitamin D3 , der Hauptspeicherform , metabolisiert wird .
T-246	Vitamin D3 is rapidly distributed mostly to the liver where it undergoes metabolism to 25-hydroxyvitamin D3 , the major storage form .
H-246	-0.3440142571926117	Vitamin D3 is rapidly distributed , primarily to the liver , where it is metabolised into 25-hydroxyvitamin D3 , the main store .
D-246	-0.3440142571926117	Vitamin D3 is rapidly distributed , primarily to the liver , where it is metabolised into 25-hydroxyvitamin D3 , the main store .
P-246	-0.8282 -0.0893 -0.1279 -0.1335 -0.1062 -0.4642 -0.6229 -0.1385 -0.1931 -0.8471 -0.5271 -0.1263 -0.0627 -0.2046 -0.1154 -0.2509 -0.1079 -0.1704 -0.0529 -0.1212 -1.1671 -0.3165 -0.1106 -0.0525 -0.1221 -0.1045 -0.1007 -0.1309 -0.1248 -0.1293 -0.1632 -0.3941 -0.5158 -3.1763 -0.3306 -0.1552
S-442	Vitamin D3 wird rasch verteilt , hauptsächlich in die Leber , wo es zu 25-Hydroxyvitamin D3 , der Hauptspeicherform , metabolisiert wird .
T-442	Vitamin D3 is rapidly distributed mostly to the liver where it undergoes metabolism to 25-hydroxyvitamin D3 , the major storage form .
H-442	-0.3440142571926117	Vitamin D3 is rapidly distributed , primarily to the liver , where it is metabolised into 25-hydroxyvitamin D3 , the main store .
D-442	-0.3440142571926117	Vitamin D3 is rapidly distributed , primarily to the liver , where it is metabolised into 25-hydroxyvitamin D3 , the main store .
P-442	-0.8282 -0.0893 -0.1279 -0.1335 -0.1062 -0.4642 -0.6229 -0.1385 -0.1931 -0.8471 -0.5271 -0.1263 -0.0627 -0.2046 -0.1154 -0.2509 -0.1079 -0.1704 -0.0529 -0.1212 -1.1671 -0.3165 -0.1106 -0.0525 -0.1221 -0.1045 -0.1007 -0.1309 -0.1248 -0.1293 -0.1632 -0.3941 -0.5158 -3.1763 -0.3306 -0.1552
S-234	Die Plasmakonzentrationen nach Aufnahme oraler therapeutischer Dosen von Alendronat sind zu niedrig für einen analytischen Nachweis ( <unk> 5 ng<unk> ml ) .
T-234	Concentrations of alendronate in plasma following therapeutic oral doses are too low for analytical detection ( <<unk>> 5 ng/ ml ) .
H-234	-0.27720338106155396	Plasma concentrations after oral therapeutic doses of alendronate are too low for analytical detection ( <unk> 5 ng/ ml ) .
D-234	-0.27720338106155396	Plasma concentrations after oral therapeutic doses of alendronate are too low for analytical detection ( <unk> 5 ng/ ml ) .
P-234	-0.8575 -0.0893 -0.1032 -0.0529 -0.1209 -0.0588 -0.5239 -0.3557 -0.1383 -0.0990 -0.0931 -0.0597 -0.1475 -0.1603 -0.1621 -0.0952 -0.0634 -1.5303 -0.2491 -0.2415 -0.3588 -1.4244 -1.1814 -0.1996 -0.1273 -0.1306 -0.0715 -0.1105 -0.1458 -0.1162 -0.1305 -0.0684 -0.1327 -0.1494 -0.1533
S-1854	Advexin ist eine Injektionssuspension , die Contusugene Ladenovec , ein genetisch verändertes Virus enthält , welches das p53-Gen trägt .
T-1854	Advexin is a suspension for injection that contains contusugene ladenovec , a genetically modified virus which carries the p53 gene .
H-1854	-0.34019801020622253	Advexin is a suspension for injection containing Contusugenes Ladenovec , a genetically modified virus carrying the p53 gene .
D-1854	-0.34019801020622253	Advexin is a suspension for injection containing Contusugenes Ladenovec , a genetically modified virus carrying the p53 gene .
P-1854	-0.6631 -0.1628 -0.1384 -0.1199 -0.2633 -0.0777 -0.1080 -0.0954 -0.0913 -0.0770 -0.3735 -0.3735 -0.1067 -1.3605 -1.8071 -0.1501 -0.1381 -0.1081 -0.1494 -0.1252 -0.6281 -0.4038 -0.5522 -0.0768 -0.2915 -1.6271 -0.2801 -0.0966 -0.0610 -0.0974 -0.1329 -0.1498
S-430	Die Plasmakonzentrationen nach Aufnahme oraler therapeutischer Dosen von Alendronat sind zu niedrig für einen analytischen Nachweis ( <unk> 5 ng<unk> ml ) .
T-430	Concentrations of alendronate in plasma following therapeutic oral doses are too low for analytical detection ( <<unk>> 5 ng/ ml ) .
H-430	-0.27720338106155396	Plasma concentrations after oral therapeutic doses of alendronate are too low for analytical detection ( <unk> 5 ng/ ml ) .
D-430	-0.27720338106155396	Plasma concentrations after oral therapeutic doses of alendronate are too low for analytical detection ( <unk> 5 ng/ ml ) .
P-430	-0.8575 -0.0893 -0.1032 -0.0529 -0.1209 -0.0588 -0.5239 -0.3557 -0.1383 -0.0990 -0.0931 -0.0597 -0.1475 -0.1603 -0.1621 -0.0952 -0.0634 -1.5303 -0.2491 -0.2415 -0.3588 -1.4244 -1.1814 -0.1996 -0.1273 -0.1306 -0.0715 -0.1105 -0.1458 -0.1162 -0.1305 -0.0684 -0.1327 -0.1494 -0.1533
S-1569	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-1569	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-1569	-0.28168097138404846	ADVATE is administered intravenously for injections after the lyophilised product has dissolved with the sterilised water provided .
D-1569	-0.28168097138404846	ADVATE is administered intravenously for injections after the lyophilised product has dissolved with the sterilised water provided .
P-1569	-0.5452 -0.1482 -0.0786 -0.1084 -0.1261 -0.5968 -0.0851 -0.2124 -0.0824 -0.0680 -0.0951 -0.1369 -0.0854 -0.1330 -0.5520 -0.9408 -0.7780 -0.2382 -0.1320 -0.1319 -0.1129 -0.9907 -0.3298 -0.0564 -0.0605 -0.3526 -0.1788 -0.5737 -0.1250 -0.0825 -0.2192 -0.8664 -0.2035 -0.1505
S-49	Wenn Sie weitere Informationen über Ihre Krankheit oder deren Behandlung benötigen , lesen Sie bitte die Packungsbeilage ( ebenfalls Bestandteil des EPAR ) , oder wenden Sie sich an Ihren Arzt oder Apotheker .
T-49	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
H-49	-0.30028146505355835	If you need more information about your condition or treatment , read the Package Leaflet ( also part of the EPAR ) , or contact your doctor or pharmacist .
D-49	-0.30028146505355835	If you need more information about your condition or treatment , read the Package Leaflet ( also part of the EPAR ) , or contact your doctor or pharmacist .
P-49	-1.0175 -0.1242 -0.3152 -0.7748 -0.0612 -0.1486 -0.1929 -1.7712 -0.1285 -1.3823 -0.1521 -0.3434 -0.1458 -0.0556 -0.1290 -0.0755 -0.0396 -0.0945 -0.1706 -0.1833 -0.8608 -0.1458 -0.1291 -0.1075 -0.0676 -0.1311 -0.6713 -0.1156 -0.5090 -0.1175 -0.0916 -0.1135 -0.0398 -0.0882 -0.1608 -0.1554
S-1894	Wenn Sie weitere Informationen über Ihre Krankheit oder deren Behandlung benötigen , lesen Sie bitte die Packungsbeilage ( ebenfalls Bestandteil des EPAR ) , oder wenden Sie sich an Ihren Arzt oder Apotheker .
T-1894	If you need more information about your medical condition or your treatment , read the Package Leaflet ( also part of the EPAR ) or contact your doctor or pharmacist .
H-1894	-0.30028146505355835	If you need more information about your condition or treatment , read the Package Leaflet ( also part of the EPAR ) , or contact your doctor or pharmacist .
D-1894	-0.30028146505355835	If you need more information about your condition or treatment , read the Package Leaflet ( also part of the EPAR ) , or contact your doctor or pharmacist .
P-1894	-1.0175 -0.1242 -0.3152 -0.7748 -0.0612 -0.1486 -0.1929 -1.7712 -0.1285 -1.3823 -0.1521 -0.3434 -0.1458 -0.0556 -0.1290 -0.0755 -0.0396 -0.0945 -0.1706 -0.1833 -0.8608 -0.1458 -0.1291 -0.1075 -0.0676 -0.1311 -0.6713 -0.1156 -0.5090 -0.1175 -0.0916 -0.1135 -0.0398 -0.0882 -0.1608 -0.1554
S-192	Die Konversion zum aktiven calciummobilisierenden Hormon 1,25-Dihydroxyvitamin D3 ( Calcitriol ) in der Niere ist streng reguliert .
T-192	Conversion to the active calcium-mobilizing hormone 1,25-dihydroxyvitamin D3 ( calcitriol ) in the kidney is tightly regulated .
H-192	-0.24032367765903473	Renal conversion to the active calcium mobilising hormone 1,25 -dihydroxyvitamin D3 ( calcitriol ) is strictly regulated .
D-192	-0.24032367765903473	Renal conversion to the active calcium mobilising hormone 1,25 -dihydroxyvitamin D3 ( calcitriol ) is strictly regulated .
P-192	-1.2819 -0.1488 -0.1125 -0.3766 -0.2760 -0.1321 -0.0781 -0.0536 -0.0734 -0.1181 -0.2877 -0.2347 -0.0903 -0.0586 -0.0964 -0.5493 -1.0764 -0.1625 -0.0494 -0.1439 -0.0837 -0.1096 -0.1473 -0.1313 -0.1241 -0.1223 -0.1786 -0.0537 -0.1425 -0.1761 -0.1333 -0.1300 -0.4580 -0.0775 -1.2525 -0.1192 -0.1364 -0.1562
S-380	Die Konversion zum aktiven calciummobilisierenden Hormon 1,25-Dihydroxyvitamin D3 ( Calcitriol ) in der Niere ist streng reguliert .
T-380	Conversion to the active calcium-mobilizing hormone 1,25-dihydroxyvitamin D3 ( calcitriol ) in the kidney is tightly regulated .
H-380	-0.24032367765903473	Renal conversion to the active calcium mobilising hormone 1,25 -dihydroxyvitamin D3 ( calcitriol ) is strictly regulated .
D-380	-0.24032367765903473	Renal conversion to the active calcium mobilising hormone 1,25 -dihydroxyvitamin D3 ( calcitriol ) is strictly regulated .
P-380	-1.2819 -0.1488 -0.1125 -0.3766 -0.2760 -0.1321 -0.0781 -0.0536 -0.0734 -0.1181 -0.2877 -0.2347 -0.0903 -0.0586 -0.0964 -0.5493 -1.0764 -0.1625 -0.0494 -0.1439 -0.0837 -0.1096 -0.1473 -0.1313 -0.1241 -0.1223 -0.1786 -0.0537 -0.1425 -0.1761 -0.1333 -0.1300 -0.4580 -0.0775 -1.2525 -0.1192 -0.1364 -0.1562
S-1859	Normalerweise sind jedoch die Brust , das Gehirn , die Knochen oder die Weichteile ( Gewebe , das andere Strukturen im Körper verbindet , umgibt und stützt ) davon betroffen .
T-1859	Li-Fraumeni cancer can occur in many areas of the body but usually affects the breast , brain , bone or soft tissue ( tissue that connects , surrounds and supports other structures in the body ) .
H-1859	-0.33969730138778687	However , it usually affects the chest , brain , bones or soft tissues ( tissue that connects , surrounds and supports other structures in the body ) .
D-1859	-0.33969730138778687	However , it usually affects the chest , brain , bones or soft tissues ( tissue that connects , surrounds and supports other structures in the body ) .
P-1859	-0.4517 -0.1755 -1.2210 -1.0666 -0.2414 -0.1406 -0.4490 -0.1523 -0.1832 -0.1602 -1.0341 -0.2008 -0.1318 -0.3680 -0.0271 -0.1290 -0.1617 -0.1623 -0.5363 -1.5022 -0.2390 -0.1916 -0.2563 -0.2675 -0.1879 -0.4046 -0.1893 -0.5386 -0.1323 -0.1240 -0.0786 -0.1440 -0.1468 -0.1544
S-1392	ADVATE wird nach dem Auflösen des lyophilisierten Produktes mit dem mitgelieferten sterilisierten Wasser für Injektionszwecke intravenös verabreicht .
T-1392	ADVATE is to be administered intravenously after reconstitution of the lyophilized product with the provided sterilised water for injections .
H-1392	-0.28168097138404846	ADVATE is administered intravenously for injections after the lyophilised product has dissolved with the sterilised water provided .
D-1392	-0.28168097138404846	ADVATE is administered intravenously for injections after the lyophilised product has dissolved with the sterilised water provided .
P-1392	-0.5452 -0.1482 -0.0786 -0.1084 -0.1261 -0.5968 -0.0851 -0.2124 -0.0824 -0.0680 -0.0951 -0.1369 -0.0854 -0.1330 -0.5520 -0.9408 -0.7780 -0.2382 -0.1320 -0.1319 -0.1129 -0.9907 -0.3298 -0.0564 -0.0605 -0.3526 -0.1788 -0.5737 -0.1250 -0.0825 -0.2192 -0.8664 -0.2035 -0.1505
S-1756	Ihr Arzt wird Ihre Dosis ADVATE ( in internationalen Einheiten oder I.E. ) berechnen , abhängig von Ihrem körperlichen Befinden und Ihrem Körpergewicht , und ob es zur Vorbeugung oder zur Behandlung von Blutungen eingesetzt wird .
T-1756	Your doctor will calculate your dose of ADVATE ( in international units or IU ) depending on your condition and body weight , and on whether it is used for prevention or treatment of bleeding .
H-1756	-0.2835628092288971	Your doctor will calculate your dose of ADVATE ( in international units or IU ) depending on your physical condition and body weight and whether it is used to prevent or treat bleeding .
D-1756	-0.2835628092288971	Your doctor will calculate your dose of ADVATE ( in international units or IU ) depending on your physical condition and body weight and whether it is used to prevent or treat bleeding .
P-1756	-0.1975 -0.1463 -0.1789 -0.7454 -0.0922 -0.1592 -0.0585 -0.6994 -0.0649 -0.1513 -0.0929 -0.0887 -0.1377 -0.2211 -0.1414 -0.1989 -0.1252 -0.1738 -0.0781 -0.1383 -1.1912 -0.2343 -0.1611 -0.3003 -0.4042 -0.1258 -1.3285 -0.0567 -0.6947 -0.1016 -0.2064 -0.2018 -0.2861 -0.1753 -0.1468 -0.1292 -0.1215 -1.3206 -0.2115 -0.1824 -0.1564
S-372	ADROVANCE ist eine Kombinationstablette mit den beiden arzneilich wirksamen Bestandteilen Natriumalendronat 3 H2O und Colecalciferol ( Vitamin D3 ) .
T-372	ADROVANCE is a combination tablet containing the two active substances alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-372	-0.1793033331632614	ADROVANCE is a combination tablet containing the active ingredients sodium alendronate 3 H2O and colecalciferol ( vitamin D3 ) .
D-372	-0.1793033331632614	ADROVANCE is a combination tablet containing the active ingredients sodium alendronate 3 H2O and colecalciferol ( vitamin D3 ) .
P-372	-0.0800 -0.0705 -0.1230 -0.1057 -0.1312 -0.1109 -0.1300 -0.0908 -0.2130 -0.1304 -0.9707 -0.3739 -0.3676 -0.2508 -0.2633 -0.0419 -0.1673 -0.3235 -0.1725 -0.0937 -0.1994 -0.1174 -0.1098 -0.2000 -0.1470 -0.2091 -0.1619 -0.2048 -0.1118 -0.1153 -0.1487 -0.1365 -0.1469 -0.1149 -0.1158 -0.1223 -0.1353 -0.1321 -0.1534
S-184	ADROVANCE ist eine Kombinationstablette mit den beiden arzneilich wirksamen Bestandteilen Natriumalendronat 3 H2O und Colecalciferol ( Vitamin D3 ) .
T-184	ADROVANCE is a combination tablet containing the two active substances alendronate sodium trihydrate and colecalciferol ( vitamin D3 ) .
H-184	-0.1793033331632614	ADROVANCE is a combination tablet containing the active ingredients sodium alendronate 3 H2O and colecalciferol ( vitamin D3 ) .
D-184	-0.1793033331632614	ADROVANCE is a combination tablet containing the active ingredients sodium alendronate 3 H2O and colecalciferol ( vitamin D3 ) .
P-184	-0.0800 -0.0705 -0.1230 -0.1057 -0.1312 -0.1109 -0.1300 -0.0908 -0.2130 -0.1304 -0.9707 -0.3739 -0.3676 -0.2508 -0.2633 -0.0419 -0.1673 -0.3235 -0.1725 -0.0937 -0.1994 -0.1174 -0.1098 -0.2000 -0.1470 -0.2091 -0.1619 -0.2048 -0.1118 -0.1153 -0.1487 -0.1365 -0.1469 -0.1149 -0.1158 -0.1223 -0.1353 -0.1321 -0.1534
S-76	Das Unternehmen legte außerdem Daten vor , die darlegen , dass die in ADROVANCE enthaltene Alendronat-Dosis genau der Dosis entspricht , die für die Verhinderung eines Knochenverlusts benötigt wird .
T-76	The company also presented evidence that the dose of alendronate included in ADROVANCE was the same as the dose needed to prevent bone loss .
H-76	-0.35002225637435913	The company also presented data showing that the alendronate dose in ADROVANCE is exactly the dose needed to prevent bone loss .
D-76	-0.35002225637435913	The company also presented data showing that the alendronate dose in ADROVANCE is exactly the dose needed to prevent bone loss .
P-76	-0.4176 -0.2147 -0.4852 -0.8464 -0.3793 -2.4138 -0.1161 -0.5544 -0.1999 -0.1250 -0.1334 -0.1476 -0.2850 -0.0886 -0.5543 -0.0685 -0.0953 -0.1252 -0.1002 -0.1039 -0.1787 -0.4188 -0.6339 -0.1976 -1.2632 -0.1466 -0.0860 -0.0488 -0.0926 -0.1601 -0.1698
S-238	Nach intravenöser Gabe einer einzelnen Dosis von 10 mg betrug die renale Clearance von Alendronat 71 ml<unk> min und die systemische Clearance überschritt nicht 200 ml<unk> min .
T-238	Following a single 10 mg intravenous dose , the renal clearance of alendronate was 71 ml/ min , and systemic clearance did not exceed 200 ml/ min .
H-238	-0.21710620820522308	After the intravenous single dose of 10 mg , the renal clearance of alendronate was 71 ml/ min and the systemic clearance did not exceed 200 ml/ min .
D-238	-0.21710620820522308	After the intravenous single dose of 10 mg , the renal clearance of alendronate was 71 ml/ min and the systemic clearance did not exceed 200 ml/ min .
P-238	-0.9088 -0.4949 -0.5713 -0.0872 -0.0819 -0.1279 -1.4383 -0.0771 -0.1510 -0.1602 -0.0402 -0.2990 -0.4714 -0.0863 -0.1164 -0.0234 -0.1258 -0.1701 -0.1835 -0.1504 -0.0953 -0.0404 -0.1415 -0.0947 -0.1434 -0.1828 -0.1408 -0.2632 -0.1644 -1.2091 -0.0517 -0.0725 -0.0965 -0.0393 -0.1009 -0.0883 -0.1250 -0.0223 -0.0712 -0.1001 -0.1494 -0.1689 -0.1358 -0.2338 -0.1401 -0.1502
S-337	Obwohl spezifische Interaktionsstudien nicht durchgeführt wurden , wurde Alendronat in klinischen Studien gemeinsam mit einer Vielzahl von gewöhnlich verschriebenen Arzneimitteln eingenommen , ohne dass klinisch relevante Wechselwirkungen auftraten .
T-337	Although specific interaction studies were not performed , in clinical studies alendronate was used concomitantly with a wide range of commonly prescribed medicinal products without evidence of interactions of clinical relevance .
H-337	-0.3218400180339813	Although specific interaction studies were not conducted , in clinical trials alendronate was administered concomitantly with a variety of commonly prescribed medicinal products without clinically relevant interactions occurring .
D-337	-0.3218400180339813	Although specific interaction studies were not conducted , in clinical trials alendronate was administered concomitantly with a variety of commonly prescribed medicinal products without clinically relevant interactions occurring .
P-337	-0.1369 -1.5455 -0.1348 -0.2043 -0.4017 -1.3741 -0.2263 -0.8062 -0.1593 -1.0307 -0.1276 -0.0921 -0.2392 -0.1498 -0.0752 -0.0467 -0.3173 -1.7047 -0.0897 -0.0959 -0.0122 -0.0328 -0.0800 -0.1347 -0.1180 -0.6194 -0.1551 -0.6207 -0.1193 -0.0800 -0.2442 -0.0950 -0.1420 -0.3242 -0.1713 -0.0781 -0.1317 -0.1609 -0.0667 -1.1269 -0.0729 -0.1452 -0.1501
S-914	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-914	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-914	-0.24086712300777435	Factor VIII-activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Factor VIII in plasma ) .
D-914	-0.24086712300777435	Factor VIII-activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Factor VIII in plasma ) .
P-914	-0.6167 -0.3472 -0.1215 -1.3972 -0.5931 -0.1142 -0.1304 -0.1364 -0.1236 -0.1027 -0.1289 -0.4781 -1.4647 -0.2328 -0.1454 -0.1743 -0.1438 -0.0427 -0.1373 -0.6065 -0.1208 -0.0777 -0.0917 -0.0886 -0.0717 -0.1263 -0.1883 -0.1697 -0.1592 -0.0906 -0.1391 -0.0664 -0.1433 -0.1418 -0.4208 -0.3454 -0.1371 -0.3232 -0.1500 -0.1353 -0.1269 -0.1150 -0.1139 -0.1100 -0.1368 -0.1429 -0.1507
S-675	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-675	Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-675	-0.3093414008617401	Non-clinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
D-675	-0.3093414008617401	Non-clinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
P-675	-0.2399 -0.7663 -0.0376 -0.2312 -1.2478 -0.1869 -0.1810 -0.7315 -0.0787 -0.1030 -0.3239 -0.0804 -0.1198 -0.1758 -0.9466 -0.2186 -0.2105 -0.0820 -0.1103 -0.1530 -0.3711 -0.0450 -0.0679 -0.1130 -0.1000 -0.1158 -0.3036 -0.1541 -1.3077 -0.0974 -0.7103 -0.8017 -0.0840 -0.1716 -0.1587
S-149	Obwohl spezifische Interaktionsstudien nicht durchgeführt wurden , wurde Alendronat in klinischen Studien gemeinsam mit einer Vielzahl von gewöhnlich verschriebenen Arzneimitteln eingenommen , ohne dass klinisch relevante Wechselwirkungen auftraten .
T-149	Although specific interaction studies were not performed , in clinical studies alendronate was used concomitantly with a wide range of commonly prescribed medicinal products without evidence of interactions of clinical relevance .
H-149	-0.3218400180339813	Although specific interaction studies were not conducted , in clinical trials alendronate was administered concomitantly with a variety of commonly prescribed medicinal products without clinically relevant interactions occurring .
D-149	-0.3218400180339813	Although specific interaction studies were not conducted , in clinical trials alendronate was administered concomitantly with a variety of commonly prescribed medicinal products without clinically relevant interactions occurring .
P-149	-0.1369 -1.5455 -0.1348 -0.2043 -0.4017 -1.3741 -0.2263 -0.8062 -0.1593 -1.0307 -0.1276 -0.0921 -0.2392 -0.1498 -0.0752 -0.0467 -0.3173 -1.7047 -0.0897 -0.0959 -0.0122 -0.0328 -0.0800 -0.1347 -0.1180 -0.6194 -0.1551 -0.6207 -0.1193 -0.0800 -0.2442 -0.0950 -0.1420 -0.3242 -0.1713 -0.0781 -0.1317 -0.1609 -0.0667 -1.1269 -0.0729 -0.1452 -0.1501
S-1485	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-1485	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-1485	-0.305056095123291	The risk of developing inhibitors correlates with the extent of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and dependent on genetic and other factors .
D-1485	-0.305056095123291	The risk of developing inhibitors correlates with the extent of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and dependent on genetic and other factors .
P-1485	-0.1703 -0.1344 -0.2126 -0.0388 -0.1321 -0.0287 -0.0745 -0.1322 -1.1700 -0.2354 -0.0923 -0.1987 -0.2080 -1.0886 -0.1611 -0.0701 -0.1541 -0.2472 -0.1500 -0.1420 -0.3532 -0.5133 -0.1206 -1.3098 -0.1586 -0.3264 -0.0424 -0.5912 -0.1282 -0.1118 -0.1037 -0.3060 -0.1400 -0.0659 -0.2812 -2.5759 -0.2307 -0.1475 -0.1580 -0.2732 -0.0412 -0.1446 -0.1530
S-563	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-563	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-563	-0.24086712300777435	Factor VIII-activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Factor VIII in plasma ) .
D-563	-0.24086712300777435	Factor VIII-activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Factor VIII in plasma ) .
P-563	-0.6167 -0.3472 -0.1215 -1.3972 -0.5931 -0.1142 -0.1304 -0.1364 -0.1236 -0.1027 -0.1289 -0.4781 -1.4647 -0.2328 -0.1454 -0.1743 -0.1438 -0.0427 -0.1373 -0.6065 -0.1208 -0.0777 -0.0917 -0.0886 -0.0717 -0.1263 -0.1883 -0.1697 -0.1592 -0.0906 -0.1391 -0.0664 -0.1433 -0.1418 -0.4208 -0.3454 -0.1371 -0.3232 -0.1500 -0.1353 -0.1269 -0.1150 -0.1139 -0.1100 -0.1368 -0.1429 -0.1507
S-738	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-738	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-738	-0.24086712300777435	Factor VIII-activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Factor VIII in plasma ) .
D-738	-0.24086712300777435	Factor VIII-activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Factor VIII in plasma ) .
P-738	-0.6167 -0.3472 -0.1215 -1.3972 -0.5931 -0.1142 -0.1304 -0.1364 -0.1236 -0.1027 -0.1289 -0.4781 -1.4647 -0.2328 -0.1454 -0.1743 -0.1438 -0.0427 -0.1373 -0.6065 -0.1208 -0.0777 -0.0917 -0.0886 -0.0717 -0.1263 -0.1883 -0.1697 -0.1592 -0.0906 -0.1391 -0.0664 -0.1433 -0.1418 -0.4208 -0.3454 -0.1371 -0.3232 -0.1500 -0.1353 -0.1269 -0.1150 -0.1139 -0.1100 -0.1368 -0.1429 -0.1507
S-851	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-851	18 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-851	-0.3093414008617401	Non-clinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
D-851	-0.3093414008617401	Non-clinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
P-851	-0.2399 -0.7663 -0.0376 -0.2312 -1.2478 -0.1869 -0.1810 -0.7315 -0.0787 -0.1030 -0.3239 -0.0804 -0.1198 -0.1758 -0.9466 -0.2186 -0.2105 -0.0820 -0.1103 -0.1530 -0.3711 -0.0450 -0.0679 -0.1130 -0.1000 -0.1158 -0.3036 -0.1541 -1.3077 -0.0974 -0.7103 -0.8017 -0.0840 -0.1716 -0.1587
S-781	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-781	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-781	-0.305056095123291	The risk of developing inhibitors correlates with the extent of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and dependent on genetic and other factors .
D-781	-0.305056095123291	The risk of developing inhibitors correlates with the extent of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and dependent on genetic and other factors .
P-781	-0.1703 -0.1344 -0.2126 -0.0388 -0.1321 -0.0287 -0.0745 -0.1322 -1.1700 -0.2354 -0.0923 -0.1987 -0.2080 -1.0886 -0.1611 -0.0701 -0.1541 -0.2472 -0.1500 -0.1420 -0.3532 -0.5133 -0.1206 -1.3098 -0.1586 -0.3264 -0.0424 -0.5912 -0.1282 -0.1118 -0.1037 -0.3060 -0.1400 -0.0659 -0.2812 -2.5759 -0.2307 -0.1475 -0.1580 -0.2732 -0.0412 -0.1446 -0.1530
S-439	Die mittlere maximale Konzentration im Serum ( Cmax ) von Vitamin D3 betrug 12,2 ng<unk> ml und die Medianzeit bis zum Erreichen der maximalen Serumkonzentration ( Tmax ) 10,6 Stunden .
T-439	The mean maximal serum concentration ( Cmax ) of vitamin D3 was 12.2 ng/ ml and the median time to maximal serum concentration ( Tmax ) was 10.6 hours .
H-439	-0.22673608362674713	The mean maximum serum concentration ( Cmax ) of vitamin D3 was 12.2 ng/ ml and the median time to reach the peak serum concentration ( Tmax ) was 10.6 hours .
D-439	-0.22673608362674713	The mean maximum serum concentration ( Cmax ) of vitamin D3 was 12.2 ng/ ml and the median time to reach the peak serum concentration ( Tmax ) was 10.6 hours .
P-439	-0.1563 -0.1975 -0.2837 -0.9690 -0.1520 -0.2223 -0.1413 -0.2708 -0.0579 -0.1273 -0.2151 -0.1347 -0.1116 -0.1380 -0.1324 -0.1621 -0.0942 -0.1576 -0.1106 -0.1163 -0.1407 -0.0812 -0.3167 -0.1371 -0.0849 -0.0883 -0.4496 -0.6046 -0.4395 -0.7888 -1.0977 -0.2687 -0.1487 -0.1138 -0.1407 -0.1414 -0.0525 -0.1258 -0.1321 -0.1330 -0.1391 -0.1161 -0.1345 -0.1503
S-1027	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-1027	28 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-1027	-0.3093414008617401	Non-clinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
D-1027	-0.3093414008617401	Non-clinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
P-1027	-0.2399 -0.7663 -0.0376 -0.2312 -1.2478 -0.1869 -0.1810 -0.7315 -0.0787 -0.1030 -0.3239 -0.0804 -0.1198 -0.1758 -0.9466 -0.2186 -0.2105 -0.0820 -0.1103 -0.1530 -0.3711 -0.0450 -0.0679 -0.1130 -0.1000 -0.1158 -0.3036 -0.1541 -1.3077 -0.0974 -0.7103 -0.8017 -0.0840 -0.1716 -0.1587
S-1309	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-1309	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-1309	-0.305056095123291	The risk of developing inhibitors correlates with the extent of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and dependent on genetic and other factors .
D-1309	-0.305056095123291	The risk of developing inhibitors correlates with the extent of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and dependent on genetic and other factors .
P-1309	-0.1703 -0.1344 -0.2126 -0.0388 -0.1321 -0.0287 -0.0745 -0.1322 -1.1700 -0.2354 -0.0923 -0.1987 -0.2080 -1.0886 -0.1611 -0.0701 -0.1541 -0.2472 -0.1500 -0.1420 -0.3532 -0.5133 -0.1206 -1.3098 -0.1586 -0.3264 -0.0424 -0.5912 -0.1282 -0.1118 -0.1037 -0.3060 -0.1400 -0.0659 -0.2812 -2.5759 -0.2307 -0.1475 -0.1580 -0.2732 -0.0412 -0.1446 -0.1530
S-1516	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-1516	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-1516	-0.532812237739563	Clotting was maintained throughout and both factor VIII levels in plasma and the clearance rate returned to adequate levels on the 15th day post-surgery .
D-1516	-0.532812237739563	Clotting was maintained throughout and both factor VIII levels in plasma and the clearance rate returned to adequate levels on the 15th day post-surgery .
P-1516	-2.9803 -0.0473 -0.2242 -0.1680 -0.9400 -0.1659 -0.4600 -0.0953 -1.5495 -1.1053 -0.6505 -0.0636 -0.1460 -0.1978 -0.0961 -0.0830 -0.1654 -1.5895 -0.0590 -0.1218 -0.0818 -1.5749 -0.2008 -1.3785 -0.1804 -0.1397 -0.6423 -0.5995 -0.7212 -0.5230 -0.2256 -0.6433 -0.1399 -0.1562
S-218	In der Zwei-Jahres-Verlängerung dieser Studien hielten die Anstiege der BMD von Wirbelsäule und Trochanter weiterhin an ; auch die BMD des Femurhalses und des gesamten Körpers wurde aufrechterhalten .
T-218	In the two-year extension of these studies BMD at the spine and trochanter continued to increase and BMD at the femoral neck and total body were maintained .
H-218	-0.4085189700126648	Throughout the two year extension of these trials , spine and trochanter BMD increases continued and femoral neck and body BMD was maintained .
D-218	-0.4085189700126648	Throughout the two year extension of these trials , spine and trochanter BMD increases continued and femoral neck and body BMD was maintained .
P-218	-1.2251 -0.1543 -0.3405 -0.3591 -1.4673 -0.2477 -0.3833 -0.2353 -0.1186 -0.7781 -0.1779 -0.2927 -1.0119 -0.1581 -0.0476 -0.3296 -0.1951 -0.1273 -0.2155 -0.4107 -0.4979 -1.3610 -0.4760 -0.7664 -0.2499 -0.2480 -0.1447 -0.2939 -0.1310 -0.1474 -0.5869 -0.1426 -0.1600
S-987	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-987	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-987	-0.532812237739563	Clotting was maintained throughout and both factor VIII levels in plasma and the clearance rate returned to adequate levels on the 15th day post-surgery .
D-987	-0.532812237739563	Clotting was maintained throughout and both factor VIII levels in plasma and the clearance rate returned to adequate levels on the 15th day post-surgery .
P-987	-2.9803 -0.0473 -0.2242 -0.1680 -0.9400 -0.1659 -0.4600 -0.0953 -1.5495 -1.1053 -0.6505 -0.0636 -0.1460 -0.1978 -0.0961 -0.0830 -0.1654 -1.5895 -0.0590 -0.1218 -0.0818 -1.5749 -0.2008 -1.3785 -0.1804 -0.1397 -0.6423 -0.5995 -0.7212 -0.5230 -0.2256 -0.6433 -0.1399 -0.1562
S-1163	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-1163	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-1163	-0.532812237739563	Clotting was maintained throughout and both factor VIII levels in plasma and the clearance rate returned to adequate levels on the 15th day post-surgery .
D-1163	-0.532812237739563	Clotting was maintained throughout and both factor VIII levels in plasma and the clearance rate returned to adequate levels on the 15th day post-surgery .
P-1163	-2.9803 -0.0473 -0.2242 -0.1680 -0.9400 -0.1659 -0.4600 -0.0953 -1.5495 -1.1053 -0.6505 -0.0636 -0.1460 -0.1978 -0.0961 -0.0830 -0.1654 -1.5895 -0.0590 -0.1218 -0.0818 -1.5749 -0.2008 -1.3785 -0.1804 -0.1397 -0.6423 -0.5995 -0.7212 -0.5230 -0.2256 -0.6433 -0.1399 -0.1562
S-1339	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-1339	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-1339	-0.532812237739563	Clotting was maintained throughout and both factor VIII levels in plasma and the clearance rate returned to adequate levels on the 15th day post-surgery .
D-1339	-0.532812237739563	Clotting was maintained throughout and both factor VIII levels in plasma and the clearance rate returned to adequate levels on the 15th day post-surgery .
P-1339	-2.9803 -0.0473 -0.2242 -0.1680 -0.9400 -0.1659 -0.4600 -0.0953 -1.5495 -1.1053 -0.6505 -0.0636 -0.1460 -0.1978 -0.0961 -0.0830 -0.1654 -1.5895 -0.0590 -0.1218 -0.0818 -1.5749 -0.2008 -1.3785 -0.1804 -0.1397 -0.6423 -0.5995 -0.7212 -0.5230 -0.2256 -0.6433 -0.1399 -0.1562
S-1133	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-1133	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-1133	-0.305056095123291	The risk of developing inhibitors correlates with the extent of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and dependent on genetic and other factors .
D-1133	-0.305056095123291	The risk of developing inhibitors correlates with the extent of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and dependent on genetic and other factors .
P-1133	-0.1703 -0.1344 -0.2126 -0.0388 -0.1321 -0.0287 -0.0745 -0.1322 -1.1700 -0.2354 -0.0923 -0.1987 -0.2080 -1.0886 -0.1611 -0.0701 -0.1541 -0.2472 -0.1500 -0.1420 -0.3532 -0.5133 -0.1206 -1.3098 -0.1586 -0.3264 -0.0424 -0.5912 -0.1282 -0.1118 -0.1037 -0.3060 -0.1400 -0.0659 -0.2812 -2.5759 -0.2307 -0.1475 -0.1580 -0.2732 -0.0412 -0.1446 -0.1530
S-957	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-957	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-957	-0.305056095123291	The risk of developing inhibitors correlates with the extent of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and dependent on genetic and other factors .
D-957	-0.305056095123291	The risk of developing inhibitors correlates with the extent of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and dependent on genetic and other factors .
P-957	-0.1703 -0.1344 -0.2126 -0.0388 -0.1321 -0.0287 -0.0745 -0.1322 -1.1700 -0.2354 -0.0923 -0.1987 -0.2080 -1.0886 -0.1611 -0.0701 -0.1541 -0.2472 -0.1500 -0.1420 -0.3532 -0.5133 -0.1206 -1.3098 -0.1586 -0.3264 -0.0424 -0.5912 -0.1282 -0.1118 -0.1037 -0.3060 -0.1400 -0.0659 -0.2812 -2.5759 -0.2307 -0.1475 -0.1580 -0.2732 -0.0412 -0.1446 -0.1530
S-414	In der Zwei-Jahres-Verlängerung dieser Studien hielten die Anstiege der BMD von Wirbelsäule und Trochanter weiterhin an ; auch die BMD des Femurhalses und des gesamten Körpers wurde aufrechterhalten .
T-414	In the two-year extension of these studies BMD at the spine and trochanter continued to increase and BMD at the femoral neck and total body were maintained .
H-414	-0.4085189700126648	Throughout the two year extension of these trials , spine and trochanter BMD increases continued and femoral neck and body BMD was maintained .
D-414	-0.4085189700126648	Throughout the two year extension of these trials , spine and trochanter BMD increases continued and femoral neck and body BMD was maintained .
P-414	-1.2251 -0.1543 -0.3405 -0.3591 -1.4673 -0.2477 -0.3833 -0.2353 -0.1186 -0.7781 -0.1779 -0.2927 -1.0119 -0.1581 -0.0476 -0.3296 -0.1951 -0.1273 -0.2155 -0.4107 -0.4979 -1.3610 -0.4760 -0.7664 -0.2499 -0.2480 -0.1447 -0.2939 -0.1310 -0.1474 -0.5869 -0.1426 -0.1600
S-607	Das Risiko , Inhibitoren zu entwickeln , korreliert mit dem Ausmaß der Exposition gegenüber dem Faktor VIII , wobei das Risiko innerhalb der ersten 20 Expositionstage am größten ist und von genetischen und sonstigen Faktoren abhängt .
T-607	The risk of developing inhibitors is correlated to the extent of exposure to factor VIII , the risk being highest within the first 20 exposure days , and to other genetic and environmental factors .
H-607	-0.305056095123291	The risk of developing inhibitors correlates with the extent of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and dependent on genetic and other factors .
D-607	-0.305056095123291	The risk of developing inhibitors correlates with the extent of exposure to factor VIII , with the highest risk occurring within the first 20 days of exposure and dependent on genetic and other factors .
P-607	-0.1703 -0.1344 -0.2126 -0.0388 -0.1321 -0.0287 -0.0745 -0.1322 -1.1700 -0.2354 -0.0923 -0.1987 -0.2080 -1.0886 -0.1611 -0.0701 -0.1541 -0.2472 -0.1500 -0.1420 -0.3532 -0.5133 -0.1206 -1.3098 -0.1586 -0.3264 -0.0424 -0.5912 -0.1282 -0.1118 -0.1037 -0.3060 -0.1400 -0.0659 -0.2812 -2.5759 -0.2307 -0.1475 -0.1580 -0.2732 -0.0412 -0.1446 -0.1530
S-1442	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-1442	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-1442	-0.24086712300777435	Factor VIII-activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Factor VIII in plasma ) .
D-1442	-0.24086712300777435	Factor VIII-activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Factor VIII in plasma ) .
P-1442	-0.6167 -0.3472 -0.1215 -1.3972 -0.5931 -0.1142 -0.1304 -0.1364 -0.1236 -0.1027 -0.1289 -0.4781 -1.4647 -0.2328 -0.1454 -0.1743 -0.1438 -0.0427 -0.1373 -0.6065 -0.1208 -0.0777 -0.0917 -0.0886 -0.0717 -0.1263 -0.1883 -0.1697 -0.1592 -0.0906 -0.1391 -0.0664 -0.1433 -0.1418 -0.4208 -0.3454 -0.1371 -0.3232 -0.1500 -0.1353 -0.1269 -0.1150 -0.1139 -0.1100 -0.1368 -0.1429 -0.1507
S-1090	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-1090	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-1090	-0.24086712300777435	Factor VIII-activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Factor VIII in plasma ) .
D-1090	-0.24086712300777435	Factor VIII-activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Factor VIII in plasma ) .
P-1090	-0.6167 -0.3472 -0.1215 -1.3972 -0.5931 -0.1142 -0.1304 -0.1364 -0.1236 -0.1027 -0.1289 -0.4781 -1.4647 -0.2328 -0.1454 -0.1743 -0.1438 -0.0427 -0.1373 -0.6065 -0.1208 -0.0777 -0.0917 -0.0886 -0.0717 -0.1263 -0.1883 -0.1697 -0.1592 -0.0906 -0.1391 -0.0664 -0.1433 -0.1418 -0.4208 -0.3454 -0.1371 -0.3232 -0.1500 -0.1353 -0.1269 -0.1150 -0.1139 -0.1100 -0.1368 -0.1429 -0.1507
S-637	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-637	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-637	-0.532812237739563	Clotting was maintained throughout and both factor VIII levels in plasma and the clearance rate returned to adequate levels on the 15th day post-surgery .
D-637	-0.532812237739563	Clotting was maintained throughout and both factor VIII levels in plasma and the clearance rate returned to adequate levels on the 15th day post-surgery .
P-637	-2.9803 -0.0473 -0.2242 -0.1680 -0.9400 -0.1659 -0.4600 -0.0953 -1.5495 -1.1053 -0.6505 -0.0636 -0.1460 -0.1978 -0.0961 -0.0830 -0.1654 -1.5895 -0.0590 -0.1218 -0.0818 -1.5749 -0.2008 -1.3785 -0.1804 -0.1397 -0.6423 -0.5995 -0.7212 -0.5230 -0.2256 -0.6433 -0.1399 -0.1562
S-849	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-849	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-849	-0.34850454330444336	Recovery and measured half-life were approximately 20 % lower in infants ( below 6 years of age ) than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
D-849	-0.34850454330444336	Recovery and measured half-life were approximately 20 % lower in infants ( below 6 years of age ) than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
P-849	-2.3792 -0.0753 -0.0550 -0.1398 -0.1458 -0.0861 -0.0918 -0.0969 -1.0592 -0.1414 -0.1016 -0.1279 -0.3559 -0.2020 -1.6340 -0.1957 -0.2930 -1.3004 -0.4060 -0.1033 -0.6963 -0.0621 -0.1350 -0.1777 -0.3391 -0.5688 -0.2485 -1.6347 -0.6892 -0.1173 -0.3299 -0.1646 -0.5026 -0.1430 -0.1520 -0.0655 -0.1527 -0.0511 -0.1280 -0.0803 -0.2469 -0.0629 -0.1795 -0.0728 -0.0867 -0.1501 -0.1519
S-1025	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-1025	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-1025	-0.34850454330444336	Recovery and measured half-life were approximately 20 % lower in infants ( below 6 years of age ) than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
D-1025	-0.34850454330444336	Recovery and measured half-life were approximately 20 % lower in infants ( below 6 years of age ) than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
P-1025	-2.3792 -0.0753 -0.0550 -0.1398 -0.1458 -0.0861 -0.0918 -0.0969 -1.0592 -0.1414 -0.1016 -0.1279 -0.3559 -0.2020 -1.6340 -0.1957 -0.2930 -1.3004 -0.4060 -0.1033 -0.6963 -0.0621 -0.1350 -0.1777 -0.3391 -0.5688 -0.2485 -1.6347 -0.6892 -0.1173 -0.3299 -0.1646 -0.5026 -0.1430 -0.1520 -0.0655 -0.1527 -0.0511 -0.1280 -0.0803 -0.2469 -0.0629 -0.1795 -0.0728 -0.0867 -0.1501 -0.1519
S-387	Bone mineral density ) an Wirbelsäule oder Hüfte , die 2,5 Standardabweichungen unter dem Mittelwert für eine normale , junge Bevölkerung liegt , oder ungeachtet der Knochendichte als vorliegende pathologische Fraktur .
T-387	Osteoporosis is defined as bone mineral density ( BMD ) of the spine or hip 2.5 standard deviations ( SD ) below the mean value of a normal young population or as a previous fragility fracture , irrespective of BMD .
H-387	-0.3434157371520996	bone mineral density ) in the spine or hip that is 2.5 standard deviations below the mean for a normal , young population , or regardless of bone density as a pathological fracture present .
D-387	-0.3434157371520996	bone mineral density ) in the spine or hip that is 2.5 standard deviations below the mean for a normal , young population , or regardless of bone density as a pathological fracture present .
P-387	-0.1498 -0.0410 -0.0903 -0.1255 -0.1291 -0.1552 -0.2322 -1.2967 -0.2716 -0.0824 -0.1368 -0.1044 -0.7026 -0.1450 -0.0889 -0.1884 -0.0932 -0.1929 -0.6112 -0.1685 -0.2016 -0.1735 -0.6474 -0.0285 -0.9165 -0.4138 -0.0990 -0.3279 -0.1411 -0.9398 -0.1541 -0.0227 -0.1787 -0.1086 -0.1388 -2.3485 -1.3706 -0.1682 -0.1290 -0.0835 -0.7955 -0.2178 -0.1560
S-80	Es darf nicht angewendet werden bei Erkrankungen der Speiseröhre , bei Patienten mit Hypocalcämie ( geringem Kalziumspiegel ) oder bei Patienten , die nicht mindestens 30 Minuten lang aufrecht stehen oder sitzen können .
T-80	It should not be used where there are abnormalities of the oesophagus ( gullet ) , in patients who have hypocalcaemia ( low calcium levels ) , or in patients who cannot stand or sit upright for at least 30 minutes .
H-80	-0.2817460596561432	Do not use in oesophageal disorders , in patients with hypocalcaemia ( low calcium levels ) , or in patients who cannot stand or sit upright for at least 30 minutes .
D-80	-0.2817460596561432	Do not use in oesophageal disorders , in patients with hypocalcaemia ( low calcium levels ) , or in patients who cannot stand or sit upright for at least 30 minutes .
P-80	-0.9524 -0.1289 -0.0753 -0.9727 -1.1097 -0.0267 -0.1860 -0.0171 -0.0246 -0.1377 -0.1839 -0.1009 -0.1417 -0.7676 -0.5650 -0.1627 -0.0603 -0.1039 -0.1257 -0.1036 -0.1377 -0.1502 -0.1974 -0.1487 -0.0823 -0.1095 -0.4892 -0.1369 -0.5859 -0.1460 -0.1985 -0.2325 -0.2138 -0.4583 -0.5550 -0.3561 -0.2833 -1.5242 -0.2078 -0.1173 -0.1697 -0.0986 -0.1094 -0.1480 -0.1157 -0.1603 -0.1633
S-673	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-673	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-673	-0.34850454330444336	Recovery and measured half-life were approximately 20 % lower in infants ( below 6 years of age ) than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
D-673	-0.34850454330444336	Recovery and measured half-life were approximately 20 % lower in infants ( below 6 years of age ) than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
P-673	-2.3792 -0.0753 -0.0550 -0.1398 -0.1458 -0.0861 -0.0918 -0.0969 -1.0592 -0.1414 -0.1016 -0.1279 -0.3559 -0.2020 -1.6340 -0.1957 -0.2930 -1.3004 -0.4060 -0.1033 -0.6963 -0.0621 -0.1350 -0.1777 -0.3391 -0.5688 -0.2485 -1.6347 -0.6892 -0.1173 -0.3299 -0.1646 -0.5026 -0.1430 -0.1520 -0.0655 -0.1527 -0.0511 -0.1280 -0.0803 -0.2469 -0.0629 -0.1795 -0.0728 -0.0867 -0.1501 -0.1519
S-1705	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-1705	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-1705	-0.15577708184719086	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-1705	-0.15577708184719086	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-1705	-0.0351 -0.0933 -0.0705 -0.0933 -0.1516 -0.0734 -0.0900 -0.0736 -0.1466 -0.0770 -0.0477 -0.1129 -0.1007 -0.1243 -0.0917 -0.1464 -0.2130 -1.3686 -0.1751 -0.1457 -0.0964 -0.1639 -0.1613 -0.1441 -0.0954 -0.0599 -0.1367 -0.1244 -0.0863 -0.1295 -0.0850 -0.1471 -0.2180 -0.0817 -0.1214 -0.1247 -0.1441 -0.0701 -0.0781 -0.0850 -0.0971 -0.1037 -0.1439 -0.9822 -0.0618 -0.0816 -0.1283 -0.2094 -0.1553 -0.0636 -0.1401 -0.1500
S-1673	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-1673	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-1673	-0.15577708184719086	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-1673	-0.15577708184719086	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-1673	-0.0351 -0.0933 -0.0705 -0.0933 -0.1516 -0.0734 -0.0900 -0.0736 -0.1466 -0.0770 -0.0477 -0.1129 -0.1007 -0.1243 -0.0917 -0.1464 -0.2130 -1.3686 -0.1751 -0.1457 -0.0964 -0.1639 -0.1613 -0.1441 -0.0954 -0.0599 -0.1367 -0.1244 -0.0863 -0.1295 -0.0850 -0.1471 -0.2180 -0.0817 -0.1214 -0.1247 -0.1441 -0.0701 -0.0781 -0.0850 -0.0971 -0.1037 -0.1439 -0.9822 -0.0618 -0.0816 -0.1283 -0.2094 -0.1553 -0.0636 -0.1401 -0.1500
S-1201	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-1201	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-1201	-0.34850454330444336	Recovery and measured half-life were approximately 20 % lower in infants ( below 6 years of age ) than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
D-1201	-0.34850454330444336	Recovery and measured half-life were approximately 20 % lower in infants ( below 6 years of age ) than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
P-1201	-2.3792 -0.0753 -0.0550 -0.1398 -0.1458 -0.0861 -0.0918 -0.0969 -1.0592 -0.1414 -0.1016 -0.1279 -0.3559 -0.2020 -1.6340 -0.1957 -0.2930 -1.3004 -0.4060 -0.1033 -0.6963 -0.0621 -0.1350 -0.1777 -0.3391 -0.5688 -0.2485 -1.6347 -0.6892 -0.1173 -0.3299 -0.1646 -0.5026 -0.1430 -0.1520 -0.0655 -0.1527 -0.0511 -0.1280 -0.0803 -0.2469 -0.0629 -0.1795 -0.0728 -0.0867 -0.1501 -0.1519
S-1377	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-1377	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-1377	-0.34850454330444336	Recovery and measured half-life were approximately 20 % lower in infants ( below 6 years of age ) than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
D-1377	-0.34850454330444336	Recovery and measured half-life were approximately 20 % lower in infants ( below 6 years of age ) than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
P-1377	-2.3792 -0.0753 -0.0550 -0.1398 -0.1458 -0.0861 -0.0918 -0.0969 -1.0592 -0.1414 -0.1016 -0.1279 -0.3559 -0.2020 -1.6340 -0.1957 -0.2930 -1.3004 -0.4060 -0.1033 -0.6963 -0.0621 -0.1350 -0.1777 -0.3391 -0.5688 -0.2485 -1.6347 -0.6892 -0.1173 -0.3299 -0.1646 -0.5026 -0.1430 -0.1520 -0.0655 -0.1527 -0.0511 -0.1280 -0.0803 -0.2469 -0.0629 -0.1795 -0.0728 -0.0867 -0.1501 -0.1519
S-1554	Die Recovery und gemessene Halbwertszeit war bei Kleinkindern ( unterhalb von 6 Jahren ) um ca. 20 % niedriger als bei Erwachsenen , was an dem höheren Plasmavolumen pro kg Körpergewicht bei jüngeren Patienten liegen könnte .
T-1554	Adjusted recovery and terminal half-life ( t1/ 2 ) was approximately 20 % lower in young children ( less than 6 years of age ) than in adults , which may be due in part to the known higher plasma volume per kilogram body weight in younger patients .
H-1554	-0.34850454330444336	Recovery and measured half-life were approximately 20 % lower in infants ( below 6 years of age ) than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
D-1554	-0.34850454330444336	Recovery and measured half-life were approximately 20 % lower in infants ( below 6 years of age ) than in adults , which may be due to the higher plasma volume per kg bodyweight in younger patients .
P-1554	-2.3792 -0.0753 -0.0550 -0.1398 -0.1458 -0.0861 -0.0918 -0.0969 -1.0592 -0.1414 -0.1016 -0.1279 -0.3559 -0.2020 -1.6340 -0.1957 -0.2930 -1.3004 -0.4060 -0.1033 -0.6963 -0.0621 -0.1350 -0.1777 -0.3391 -0.5688 -0.2485 -1.6347 -0.6892 -0.1173 -0.3299 -0.1646 -0.5026 -0.1430 -0.1520 -0.0655 -0.1527 -0.0511 -0.1280 -0.0803 -0.2469 -0.0629 -0.1795 -0.0728 -0.0867 -0.1501 -0.1519
S-199	Bone mineral density ) an Wirbelsäule oder Hüfte , die 2,5 Standardabweichungen unter dem Mittelwert für eine normale , junge Bevölkerung liegt , oder ungeachtet der Knochendichte als vorliegende pathologische Fraktur .
T-199	Osteoporosis is defined as bone mineral density ( BMD ) of the spine or hip 2.5 standard deviations ( SD ) below the mean value of a normal young population or as a previous fragility fracture , irrespective of BMD .
H-199	-0.3434157371520996	bone mineral density ) in the spine or hip that is 2.5 standard deviations below the mean for a normal , young population , or regardless of bone density as a pathological fracture present .
D-199	-0.3434157371520996	bone mineral density ) in the spine or hip that is 2.5 standard deviations below the mean for a normal , young population , or regardless of bone density as a pathological fracture present .
P-199	-0.1498 -0.0410 -0.0903 -0.1255 -0.1291 -0.1552 -0.2322 -1.2967 -0.2716 -0.0824 -0.1368 -0.1044 -0.7026 -0.1450 -0.0889 -0.1884 -0.0932 -0.1929 -0.6112 -0.1685 -0.2016 -0.1735 -0.6474 -0.0285 -0.9165 -0.4138 -0.0990 -0.3279 -0.1411 -0.9398 -0.1541 -0.0227 -0.1787 -0.1086 -0.1388 -2.3485 -1.3706 -0.1682 -0.1290 -0.0835 -0.7955 -0.2178 -0.1560
S-1266	Die Faktor VIII-Aktivität im Plasma wird entweder als Prozentsatz ( relativ zur Aktivität normalen menschlichen Plasmas ) oder in I.E. ( relativ zum Internationalen Standard für Faktor VIII im Plasma ) angegeben .
T-1266	Factor VIII activity in plasma is expressed either as a percentage ( relative to normal human plasma ) or in IUs ( relative to the international standard for factor VIII in plasma ) .
H-1266	-0.24086712300777435	Factor VIII-activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Factor VIII in plasma ) .
D-1266	-0.24086712300777435	Factor VIII-activity in plasma is presented either as a percentage ( relative to normal human plasma activity ) or in IU ( relative to the International Standard for Factor VIII in plasma ) .
P-1266	-0.6167 -0.3472 -0.1215 -1.3972 -0.5931 -0.1142 -0.1304 -0.1364 -0.1236 -0.1027 -0.1289 -0.4781 -1.4647 -0.2328 -0.1454 -0.1743 -0.1438 -0.0427 -0.1373 -0.6065 -0.1208 -0.0777 -0.0917 -0.0886 -0.0717 -0.1263 -0.1883 -0.1697 -0.1592 -0.0906 -0.1391 -0.0664 -0.1433 -0.1418 -0.4208 -0.3454 -0.1371 -0.3232 -0.1500 -0.1353 -0.1269 -0.1150 -0.1139 -0.1100 -0.1368 -0.1429 -0.1507
S-1689	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-1689	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-1689	-0.15577708184719086	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-1689	-0.15577708184719086	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-1689	-0.0351 -0.0933 -0.0705 -0.0933 -0.1516 -0.0734 -0.0900 -0.0736 -0.1466 -0.0770 -0.0477 -0.1129 -0.1007 -0.1243 -0.0917 -0.1464 -0.2130 -1.3686 -0.1751 -0.1457 -0.0964 -0.1639 -0.1613 -0.1441 -0.0954 -0.0599 -0.1367 -0.1244 -0.0863 -0.1295 -0.0850 -0.1471 -0.2180 -0.0817 -0.1214 -0.1247 -0.1441 -0.0701 -0.0781 -0.0850 -0.0971 -0.1037 -0.1439 -0.9822 -0.0618 -0.0816 -0.1283 -0.2094 -0.1553 -0.0636 -0.1401 -0.1500
S-165	<unk> Häufig ( 1<unk> 100 , <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 , <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 , <unk> 1<unk> 1.000 ) , sehr selten ( <unk> 1<unk> 10.000 ) <unk>
T-165	<<unk>> Common ( 1/ 100 , <<unk>> 1/ 10 ) , uncommon ( 1/ 1000 , <<unk>> 1/ 100 ) , rare ( 1/ 10,000 , <<unk>> 1/ 1000 ) , very rare ( <<unk>> 1/ 10,000 ) <<unk>>
H-165	-0.2832745909690857	<unk> Common ( 1/ 100 , <unk> 1/ 10 ) , rare ( 1/ 1,000 , <unk> 1/ 100 ) , rare ( 1/ 10,000 , <unk> 1/ 1,000 ) , very rare ( <unk> 1/ 10,000 ) <unk>
D-165	-0.2832745909690857	<unk> Common ( 1/ 100 , <unk> 1/ 10 ) , rare ( 1/ 1,000 , <unk> 1/ 100 ) , rare ( 1/ 10,000 , <unk> 1/ 1,000 ) , very rare ( <unk> 1/ 10,000 ) <unk>
P-165	-0.7792 -0.1074 -0.1375 -0.1422 -0.1135 -0.2773 -0.2588 -0.1522 -0.1415 -0.0809 -0.1178 -0.2083 -0.1381 -0.1439 -2.5565 -0.1442 -0.2656 -0.1180 -1.7829 -0.1492 -0.0389 -0.1722 -0.1133 -0.2246 -0.1299 -0.1438 -0.0386 -0.1421 -0.1220 -0.1120 -0.6026 -0.1504 -0.0474 -0.8991 -0.1166 -0.4257 -0.1276 -0.1448 -0.1656 -0.0332 -0.1496 -0.1733 -0.3543 -0.1333 -0.6369 -0.1424 -0.0714 -0.1708
S-353	<unk> Häufig ( 1<unk> 100 , <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 , <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 , <unk> 1<unk> 1.000 ) , sehr selten ( <unk> 1<unk> 10.000 ) <unk>
T-353	<<unk>> Common ( 1/ 100 , <<unk>> 1/ 10 ) , uncommon ( 1/ 1000 , <<unk>> 1/ 100 ) , rare ( 1/ 10,000 , <<unk>> 1/ 1000 ) , very rare ( <<unk>> 1/ 10,000 ) <<unk>>
H-353	-0.2832745909690857	<unk> Common ( 1/ 100 , <unk> 1/ 10 ) , rare ( 1/ 1,000 , <unk> 1/ 100 ) , rare ( 1/ 10,000 , <unk> 1/ 1,000 ) , very rare ( <unk> 1/ 10,000 ) <unk>
D-353	-0.2832745909690857	<unk> Common ( 1/ 100 , <unk> 1/ 10 ) , rare ( 1/ 1,000 , <unk> 1/ 100 ) , rare ( 1/ 10,000 , <unk> 1/ 1,000 ) , very rare ( <unk> 1/ 10,000 ) <unk>
P-353	-0.7792 -0.1074 -0.1375 -0.1422 -0.1135 -0.2773 -0.2588 -0.1522 -0.1415 -0.0809 -0.1178 -0.2083 -0.1381 -0.1439 -2.5565 -0.1442 -0.2656 -0.1180 -1.7829 -0.1492 -0.0389 -0.1722 -0.1133 -0.2246 -0.1299 -0.1438 -0.0386 -0.1421 -0.1220 -0.1120 -0.6026 -0.1504 -0.0474 -0.8991 -0.1166 -0.4257 -0.1276 -0.1448 -0.1656 -0.0332 -0.1496 -0.1733 -0.3543 -0.1333 -0.6369 -0.1424 -0.0714 -0.1708
S-1379	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-1379	48 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-1379	-0.3093414008617401	Non-clinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
D-1379	-0.3093414008617401	Non-clinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
P-1379	-0.2399 -0.7663 -0.0376 -0.2312 -1.2478 -0.1869 -0.1810 -0.7315 -0.0787 -0.1030 -0.3239 -0.0804 -0.1198 -0.1758 -0.9466 -0.2186 -0.2105 -0.0820 -0.1103 -0.1530 -0.3711 -0.0450 -0.0679 -0.1130 -0.1000 -0.1158 -0.3036 -0.1541 -1.3077 -0.0974 -0.7103 -0.8017 -0.0840 -0.1716 -0.1587
S-1556	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-1556	58 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-1556	-0.3093414008617401	Non-clinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
D-1556	-0.3093414008617401	Non-clinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
P-1556	-0.2399 -0.7663 -0.0376 -0.2312 -1.2478 -0.1869 -0.1810 -0.7315 -0.0787 -0.1030 -0.3239 -0.0804 -0.1198 -0.1758 -0.9466 -0.2186 -0.2105 -0.0820 -0.1103 -0.1530 -0.3711 -0.0450 -0.0679 -0.1130 -0.1000 -0.1158 -0.3036 -0.1541 -1.3077 -0.0974 -0.7103 -0.8017 -0.0840 -0.1716 -0.1587
S-1967	Diese beinhalten : Dekongestiva Anorektika oder Psychostimulanzien vom Amphetamintyp 3 Antihypertensiva trizyklische Antidepressiva und andere Antihistaminika .
T-1967	These include : decongestants anorexogenics or amphetamine-type psychostimulants antihypertensive agents tricyclic antidepressants and other antihistamines .
H-1967	-0.3259446322917938	These include : decongestants Anorectics or psychostimulants amphetamine type 3 Antihypertensives Tricyclic antidepressants and other antihistamines .
D-1967	-0.3259446322917938	These include : decongestants Anorectics or psychostimulants amphetamine type 3 Antihypertensives Tricyclic antidepressants and other antihistamines .
P-1967	-0.7332 -0.4830 -1.0493 -0.3777 -0.1901 -0.5693 -0.3244 -0.4233 -0.1253 -0.0902 -0.2242 -0.1304 -1.3278 -0.0320 -0.0563 -0.2775 -1.2815 -0.1198 -0.0869 -0.1424 -0.1388 -0.1250 -0.5102 -0.0982 -0.1427 -1.6934 -0.4396 -0.1272 -0.1366 -0.1012 -0.0431 -0.2253 -0.2170 -0.1397 -0.1383 -0.0524 -0.0863 -0.2041 -0.3275 -0.2181 -0.1544
S-1203	Nicht klinische Daten , basierend auf den Studien zu Sicherheitspharmakologie , zu akuter , wiederholter und lokaler Toxizität und zu Genotoxizität , zeigen kein spezielles Risiko für den Menschen .
T-1203	38 Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology , acute toxicology , repeated dose toxicity , local toxicity and genotoxicity .
H-1203	-0.3093414008617401	Non-clinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
D-1203	-0.3093414008617401	Non-clinical data , based on safety pharmacology , acute , repeated and local toxicity and genotoxicity studies , show no specific human risk .
P-1203	-0.2399 -0.7663 -0.0376 -0.2312 -1.2478 -0.1869 -0.1810 -0.7315 -0.0787 -0.1030 -0.3239 -0.0804 -0.1198 -0.1758 -0.9466 -0.2186 -0.2105 -0.0820 -0.1103 -0.1530 -0.3711 -0.0450 -0.0679 -0.1130 -0.1000 -0.1158 -0.3036 -0.1541 -1.3077 -0.0974 -0.7103 -0.8017 -0.0840 -0.1716 -0.1587
S-1655	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-1655	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-1655	-0.15577708184719086	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-1655	-0.15577708184719086	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-1655	-0.0351 -0.0933 -0.0705 -0.0933 -0.1516 -0.0734 -0.0900 -0.0736 -0.1466 -0.0770 -0.0477 -0.1129 -0.1007 -0.1243 -0.0917 -0.1464 -0.2130 -1.3686 -0.1751 -0.1457 -0.0964 -0.1639 -0.1613 -0.1441 -0.0954 -0.0599 -0.1367 -0.1244 -0.0863 -0.1295 -0.0850 -0.1471 -0.2180 -0.0817 -0.1214 -0.1247 -0.1441 -0.0701 -0.0781 -0.0850 -0.0971 -0.1037 -0.1439 -0.9822 -0.0618 -0.0816 -0.1283 -0.2094 -0.1553 -0.0636 -0.1401 -0.1500
S-1925	Es darf nicht angewendet werden bei Patienten , die einen Monoaminooxidasehemmer ( wie z. B. einige Arzneimittel gegen Depressionen ) einnehmen oder die Einnahme eines solchen Arzneimittels in den letzten zwei Wochen beendet haben .
T-1925	It should not be used in people who are taking a monoamine oxidase inhibitor ( such as some medicines used to treat depression ) or who have stopped taking one of these medicines within the last two weeks .
H-1925	-0.36489343643188477	It must not be used in patients who are taking or have stopped taking a monoamine oxidase inhibitor ( such as some antidepressant medicinal products ) within the last two weeks .
D-1925	-0.36489343643188477	It must not be used in patients who are taking or have stopped taking a monoamine oxidase inhibitor ( such as some antidepressant medicinal products ) within the last two weeks .
P-1925	-0.6136 -1.0869 -0.1547 -0.1442 -0.2150 -0.5535 -0.5105 -1.4331 -1.1267 -0.2449 -0.3896 -0.2520 -0.7388 -0.1036 -0.7650 -0.0848 -0.1436 -0.0675 -0.5363 -0.0769 -0.1032 -0.1172 -0.0397 -0.0723 -0.1648 -0.1604 -0.5328 -0.1589 -0.1764 -0.1451 -0.4138 -0.2033 -0.4628 -0.7316 -0.6208 -0.0862 -0.1449 -1.3090 -0.1444 -0.4446 -0.1929 -0.0878 -0.1431 -0.1581
S-1623	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-1623	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-1623	-0.15577708184719086	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-1623	-0.15577708184719086	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-1623	-0.0351 -0.0933 -0.0705 -0.0933 -0.1516 -0.0734 -0.0900 -0.0736 -0.1466 -0.0770 -0.0477 -0.1129 -0.1007 -0.1243 -0.0917 -0.1464 -0.2130 -1.3686 -0.1751 -0.1457 -0.0964 -0.1639 -0.1613 -0.1441 -0.0954 -0.0599 -0.1367 -0.1244 -0.0863 -0.1295 -0.0850 -0.1471 -0.2180 -0.0817 -0.1214 -0.1247 -0.1441 -0.0701 -0.0781 -0.0850 -0.0971 -0.1037 -0.1439 -0.9822 -0.0618 -0.0816 -0.1283 -0.2094 -0.1553 -0.0636 -0.1401 -0.1500
S-1639	Sonstige Bestandteile : Mannitol , Natriumchlorid , Histidin , Trehalose , Calciumchlorid , Trometamol , Polysorbat 80 , Glutathion ( reduziert )
T-1639	Exipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced ) .
H-1639	-0.15577708184719086	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
D-1639	-0.15577708184719086	Excipients : mannitol , sodium chloride , histidine , trehalose , calcium chloride , trometamol , polysorbate 80 , glutathione ( reduced )
P-1639	-0.0351 -0.0933 -0.0705 -0.0933 -0.1516 -0.0734 -0.0900 -0.0736 -0.1466 -0.0770 -0.0477 -0.1129 -0.1007 -0.1243 -0.0917 -0.1464 -0.2130 -1.3686 -0.1751 -0.1457 -0.0964 -0.1639 -0.1613 -0.1441 -0.0954 -0.0599 -0.1367 -0.1244 -0.0863 -0.1295 -0.0850 -0.1471 -0.2180 -0.0817 -0.1214 -0.1247 -0.1441 -0.0701 -0.0781 -0.0850 -0.0971 -0.1037 -0.1439 -0.9822 -0.0618 -0.0816 -0.1283 -0.2094 -0.1553 -0.0636 -0.1401 -0.1500
S-811	Die Blutgerinnung wurde während der ganzen Zeit aufrechterhalten und sowohl die Faktor VIII- Spiegel im Plasma als auch die Clearance-Rate zeigten am 15. postoperativen Tag wieder ausreichende Werte .
T-811	Haemostasis was maintained at all times during this period and both plasma factor VIII levels and clearance rates returned to appropriate levels by postoperative day 15.
H-811	-0.532812237739563	Clotting was maintained throughout and both factor VIII levels in plasma and the clearance rate returned to adequate levels on the 15th day post-surgery .
D-811	-0.532812237739563	Clotting was maintained throughout and both factor VIII levels in plasma and the clearance rate returned to adequate levels on the 15th day post-surgery .
P-811	-2.9803 -0.0473 -0.2242 -0.1680 -0.9400 -0.1659 -0.4600 -0.0953 -1.5495 -1.1053 -0.6505 -0.0636 -0.1460 -0.1978 -0.0961 -0.0830 -0.1654 -1.5895 -0.0590 -0.1218 -0.0818 -1.5749 -0.2008 -1.3785 -0.1804 -0.1397 -0.6423 -0.5995 -0.7212 -0.5230 -0.2256 -0.6433 -0.1399 -0.1562
S-221	In dieser Studie reduzierte die tägliche Gabe von Alendronat das Auftreten von mindestens einer neuen Wirbelfraktur um 47 % ( Alendronat 7,9 % gegenüber Plazebo 15,0 % ) .
T-221	In this study alendronate daily reduced the incidence of 1 new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
H-221	-0.20643657445907593	In this study , daily alendronate reduced the occurrence of at least one new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
D-221	-0.20643657445907593	In this study , daily alendronate reduced the occurrence of at least one new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
P-221	-0.1459 -0.1381 -0.4524 -0.4261 -0.0919 -0.8625 -0.1842 -0.1216 -0.0880 -0.7677 -0.1451 -1.2872 -0.0383 -0.0747 -0.1107 -0.1556 -0.1290 -0.1385 -0.1908 -0.1153 -0.0887 -0.0702 -0.0459 -0.1234 -0.0904 -0.1104 -0.1560 -0.0579 -0.1321 -0.1320 -0.2980 -0.1630 -0.1095 -0.0405 -0.2309 -0.1261 -0.1081 -0.9618 -0.0952 -0.1700 -0.1011 -0.1249 -0.0738 -0.0971 -0.1191 -0.1324 -0.1391 -0.1473
S-1978	Von den folgenden Begleittherapien wird abgeraten : Bromocriptin Cabergolin Lisurid , Pergolid : Risiko für das Auftreten einer Gefäßverengung und einer Hypertonie .
T-1978	The following combinations are not recommended : bromocriptine cabergoline lisuride , pergolide : risk of vasoconstriction and increase in blood pressure .
H-1978	-0.44480040669441223	The following concomitant therapies are not recommended : bromocriptine Cabergolin Lisuride , pergolide : risk for the occurrence of vascular narrowing and hypertension .
D-1978	-0.44480040669441223	The following concomitant therapies are not recommended : bromocriptine Cabergolin Lisuride , pergolide : risk for the occurrence of vascular narrowing and hypertension .
P-1978	-0.2405 -0.1187 -0.6266 -0.0063 -0.0214 -0.1322 -1.5488 -0.3461 -0.1261 -1.3406 -1.2575 -0.1224 -0.1028 -0.1152 -0.0930 -0.0959 -1.5675 -0.1367 -1.3612 -0.2488 -3.1051 -0.1348 -0.4637 -0.1185 -0.7849 -0.1376 -0.1565 -0.2331 -0.1347 -0.2809 -0.1517 -0.0509 -0.2912 -1.8445 -0.9397 -0.0415 -0.0597 -0.1178 -0.1506 -0.4597 -0.0290 -0.1932 -1.7129 -0.0860 -0.1336 -0.0191 -0.0415 -0.1641 -0.1504
S-243	Die mittlere maximale Konzentration im Serum ( Cmax ) von Vitamin D3 betrug 5,9 ng<unk> ml und die Medianzeit bis zum Erreichen der maximalen Serumkonzentration ( Tmax ) 12 Stunden .
T-243	The mean maximal serum concentration ( Cmax ) of vitamin D3 was 5.9 ng/ ml , and the median time to maximal serum concentration ( Tmax ) was 12 hours .
H-243	-0.2258647233247757	The mean maximum serum concentration ( Cmax ) of vitamin D3 was 5.9 ng/ ml and the median time to reach the maximum serum concentration ( Tmax ) was 12 hours .
D-243	-0.2258647233247757	The mean maximum serum concentration ( Cmax ) of vitamin D3 was 5.9 ng/ ml and the median time to reach the maximum serum concentration ( Tmax ) was 12 hours .
P-243	-0.1520 -0.2103 -0.2815 -0.9423 -0.1515 -0.2183 -0.1445 -0.1951 -0.0582 -0.1280 -0.2202 -0.1385 -0.1127 -0.1379 -0.1316 -0.1596 -0.0841 -0.1225 -0.1220 -0.1229 -0.1411 -0.0820 -0.3281 -0.1343 -0.0919 -0.0890 -0.5366 -0.5367 -0.3778 -0.7136 -1.0813 -0.2992 -0.1588 -0.1338 -0.1434 -0.1423 -0.0517 -0.1265 -0.1852 -0.1186 -0.1196 -0.1370 -0.1500
S-417	In dieser Studie reduzierte die tägliche Gabe von Alendronat das Auftreten von mindestens einer neuen Wirbelfraktur um 47 % ( Alendronat 7,9 % gegenüber Plazebo 15,0 % ) .
T-417	In this study alendronate daily reduced the incidence of 1 new 18 vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
H-417	-0.20643657445907593	In this study , daily alendronate reduced the occurrence of at least one new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
D-417	-0.20643657445907593	In this study , daily alendronate reduced the occurrence of at least one new vertebral fracture by 47 % ( alendronate 7.9 % vs. placebo 15.0 % ) .
P-417	-0.1459 -0.1381 -0.4524 -0.4261 -0.0919 -0.8625 -0.1842 -0.1216 -0.0880 -0.7677 -0.1451 -1.2872 -0.0383 -0.0747 -0.1107 -0.1556 -0.1290 -0.1385 -0.1908 -0.1153 -0.0887 -0.0702 -0.0459 -0.1234 -0.0904 -0.1104 -0.1560 -0.0579 -0.1321 -0.1320 -0.2980 -0.1630 -0.1095 -0.0405 -0.2309 -0.1261 -0.1081 -0.9618 -0.0952 -0.1700 -0.1011 -0.1249 -0.0738 -0.0971 -0.1191 -0.1324 -0.1391 -0.1473
S-377	18 Colecalciferol ( Vitamin D3 ) Vitamin D3 wird in der Haut durch UV-Licht über die Umwandlung von 7-Dehydrocholesterol zu Vitamin D3 produziert .
T-377	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by conversion of 7-dehydrocholesterol to vitamin D3 by ultraviolet light .
H-377	-0.24057067930698395	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by UV light via the conversion of 7-dehydrocholesterol to vitamin D3 .
D-377	-0.24057067930698395	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by UV light via the conversion of 7-dehydrocholesterol to vitamin D3 .
P-377	-0.3615 -0.1372 -0.2288 -0.1324 -0.1117 -0.1986 -0.1425 -0.1473 -0.1213 -0.1203 -0.1253 -0.1387 -0.3045 -0.0653 -0.1294 -0.1297 -0.1191 -0.1263 -0.5319 -0.1247 -0.0654 -0.1765 -0.2673 -0.1910 -0.2212 -0.8506 -0.4654 -0.7709 -0.4383 -0.1631 -1.2085 -0.1094 -0.1475 -0.0701 -0.2865 -0.0463 -0.1768 -0.6090 -0.1698 -0.0891 -0.1333 -0.1290 -0.1432 -0.1603
S-1271	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-1271	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-1271	-0.45015642046928406	Following haemorrhagic events , the factor VIII-activity should not fall below the indicated plasma levels ( in % of the norm or IU/ dl ) during the corresponding period .
D-1271	-0.45015642046928406	Following haemorrhagic events , the factor VIII-activity should not fall below the indicated plasma levels ( in % of the norm or IU/ dl ) during the corresponding period .
P-1271	-0.7545 -0.1542 -1.0087 -0.0630 -0.5241 -0.1164 -0.1491 -0.4794 -2.7807 -0.1178 -0.3397 -0.1321 -0.6321 -0.5226 -0.3167 -0.8971 -0.1884 -0.9875 -0.0702 -1.1629 -1.1013 -0.1324 -0.0610 -0.0891 -0.3109 -0.1848 -0.7847 -0.1453 -0.1558 -0.4296 -0.9993 -0.0902 -0.1166 -1.7100 -0.1169 -0.1398 -0.0556 -0.1402 -0.9700 -0.2869 -0.1845 -0.1412 -0.1538 -0.2066 -0.1535
S-919	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-919	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-919	-0.45015642046928406	Following haemorrhagic events , the factor VIII-activity should not fall below the indicated plasma levels ( in % of the norm or IU/ dl ) during the corresponding period .
D-919	-0.45015642046928406	Following haemorrhagic events , the factor VIII-activity should not fall below the indicated plasma levels ( in % of the norm or IU/ dl ) during the corresponding period .
P-919	-0.7545 -0.1542 -1.0087 -0.0630 -0.5241 -0.1164 -0.1491 -0.4794 -2.7807 -0.1178 -0.3397 -0.1321 -0.6321 -0.5226 -0.3167 -0.8971 -0.1884 -0.9875 -0.0702 -1.1629 -1.1013 -0.1324 -0.0610 -0.0891 -0.3109 -0.1848 -0.7847 -0.1453 -0.1558 -0.4296 -0.9993 -0.0902 -0.1166 -1.7100 -0.1169 -0.1398 -0.0556 -0.1402 -0.9700 -0.2869 -0.1845 -0.1412 -0.1538 -0.2066 -0.1535
S-1447	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-1447	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-1447	-0.45015642046928406	Following haemorrhagic events , the factor VIII-activity should not fall below the indicated plasma levels ( in % of the norm or IU/ dl ) during the corresponding period .
D-1447	-0.45015642046928406	Following haemorrhagic events , the factor VIII-activity should not fall below the indicated plasma levels ( in % of the norm or IU/ dl ) during the corresponding period .
P-1447	-0.7545 -0.1542 -1.0087 -0.0630 -0.5241 -0.1164 -0.1491 -0.4794 -2.7807 -0.1178 -0.3397 -0.1321 -0.6321 -0.5226 -0.3167 -0.8971 -0.1884 -0.9875 -0.0702 -1.1629 -1.1013 -0.1324 -0.0610 -0.0891 -0.3109 -0.1848 -0.7847 -0.1453 -0.1558 -0.4296 -0.9993 -0.0902 -0.1166 -1.7100 -0.1169 -0.1398 -0.0556 -0.1402 -0.9700 -0.2869 -0.1845 -0.1412 -0.1538 -0.2066 -0.1535
S-1981	Sympathomimetika können die antihypertensive Wirkung von -Methyldopa , Mecamylamin , Reserpin , Veratrum-Alkaloiden und Guanethidin mindern .
T-1981	Sympathomimetic medicines reduce the antihypertensive effect of -methyldopa , mecamylamine , reserpine , veratrum alkaloids , and guanethidine .
H-1981	-0.30412423610687256	Sympathomimetics may reduce the antihypertensive effect of -methyldopa , mecamylamine , reserpine , veratrum alkaloids and guanethidine .
D-1981	-0.30412423610687256	Sympathomimetics may reduce the antihypertensive effect of -methyldopa , mecamylamine , reserpine , veratrum alkaloids and guanethidine .
P-1981	-1.1534 -0.0615 -0.0603 -0.1119 -0.1966 -0.4128 -0.1494 -0.1810 -0.0286 -0.1030 -0.1310 -1.6317 -0.1517 -0.0673 -0.0889 -0.2935 -1.1544 -0.3145 -0.1284 -0.1473 -0.1970 -0.0937 -0.1071 -0.3983 -0.0559 -0.1440 -0.4269 -0.2926 -0.2275 -0.1498 -0.8980 -0.0513 -2.2696 -0.1101 -0.0892 -0.0595 -0.0537 -0.1855 -0.1861 -0.1040 -0.1037 -0.1394 -0.4711 -0.1473 -0.1573
S-1095	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-1095	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-1095	-0.45015642046928406	Following haemorrhagic events , the factor VIII-activity should not fall below the indicated plasma levels ( in % of the norm or IU/ dl ) during the corresponding period .
D-1095	-0.45015642046928406	Following haemorrhagic events , the factor VIII-activity should not fall below the indicated plasma levels ( in % of the norm or IU/ dl ) during the corresponding period .
P-1095	-0.7545 -0.1542 -1.0087 -0.0630 -0.5241 -0.1164 -0.1491 -0.4794 -2.7807 -0.1178 -0.3397 -0.1321 -0.6321 -0.5226 -0.3167 -0.8971 -0.1884 -0.9875 -0.0702 -1.1629 -1.1013 -0.1324 -0.0610 -0.0891 -0.3109 -0.1848 -0.7847 -0.1453 -0.1558 -0.4296 -0.9993 -0.0902 -0.1166 -1.7100 -0.1169 -0.1398 -0.0556 -0.1402 -0.9700 -0.2869 -0.1845 -0.1412 -0.1538 -0.2066 -0.1535
S-569	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-569	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-569	-0.45015642046928406	Following haemorrhagic events , the factor VIII-activity should not fall below the indicated plasma levels ( in % of the norm or IU/ dl ) during the corresponding period .
D-569	-0.45015642046928406	Following haemorrhagic events , the factor VIII-activity should not fall below the indicated plasma levels ( in % of the norm or IU/ dl ) during the corresponding period .
P-569	-0.7545 -0.1542 -1.0087 -0.0630 -0.5241 -0.1164 -0.1491 -0.4794 -2.7807 -0.1178 -0.3397 -0.1321 -0.6321 -0.5226 -0.3167 -0.8971 -0.1884 -0.9875 -0.0702 -1.1629 -1.1013 -0.1324 -0.0610 -0.0891 -0.3109 -0.1848 -0.7847 -0.1453 -0.1558 -0.4296 -0.9993 -0.0902 -0.1166 -1.7100 -0.1169 -0.1398 -0.0556 -0.1402 -0.9700 -0.2869 -0.1845 -0.1412 -0.1538 -0.2066 -0.1535
S-743	Bei folgenden hämorrhagischen Ereignissen soll die Faktor VIII-Aktivität im entsprechenden Zeitraum nicht unter die angegebenen Plasmaspiegel ( in % der Norm oder in I.E.<unk> dl ) sinken .
T-743	In case of the following haemorrhagic events , the factor VIII activity should not fall below the given plasma activity level ( in % of normal or IU/ dl ) in the corresponding period .
H-743	-0.45015642046928406	Following haemorrhagic events , the factor VIII-activity should not fall below the indicated plasma levels ( in % of the norm or IU/ dl ) during the corresponding period .
D-743	-0.45015642046928406	Following haemorrhagic events , the factor VIII-activity should not fall below the indicated plasma levels ( in % of the norm or IU/ dl ) during the corresponding period .
P-743	-0.7545 -0.1542 -1.0087 -0.0630 -0.5241 -0.1164 -0.1491 -0.4794 -2.7807 -0.1178 -0.3397 -0.1321 -0.6321 -0.5226 -0.3167 -0.8971 -0.1884 -0.9875 -0.0702 -1.1629 -1.1013 -0.1324 -0.0610 -0.0891 -0.3109 -0.1848 -0.7847 -0.1453 -0.1558 -0.4296 -0.9993 -0.0902 -0.1166 -1.7100 -0.1169 -0.1398 -0.0556 -0.1402 -0.9700 -0.2869 -0.1845 -0.1412 -0.1538 -0.2066 -0.1535
S-219	FIT bestand aus zwei plazebokontrollierten Studien , bei denen Alendronat täglich ( 5 mg täglich über 2 Jahre und anschließend 10 mg täglich weiterhin entweder über 1 oder 2 Jahre ) eingenommen wurde :
T-219	FIT consisted of two placebo-controlled studies using alendronate daily ( 5 mg daily for two years and 10 mg daily for either one or two additional years ) :
H-219	-0.2763259708881378	FIT consisted of two placebo-controlled trials in which alendronate was taken daily ( 5 mg daily for 2 years and then 10 mg daily for either 1 or 2 years ) :
D-219	-0.2763259708881378	FIT consisted of two placebo-controlled trials in which alendronate was taken daily ( 5 mg daily for 2 years and then 10 mg daily for either 1 or 2 years ) :
P-219	-0.0734 -0.0977 -0.0746 -0.1897 -0.1616 -0.3373 -0.0525 -0.1338 -0.0740 -0.1498 -0.0770 -0.9022 -1.2208 -0.2154 -0.1829 -0.1569 -0.0922 -0.0614 -0.1638 -1.5456 -0.1489 -0.1350 -0.2227 -0.0425 -0.2196 -0.1213 -0.7482 -0.1035 -0.7832 -1.2316 -0.3567 -0.0487 -0.2655 -0.1556 -0.1147 -0.1220 -0.1712 -0.1157 -0.1082 -0.1488 -0.1265 -0.1529
S-1017	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-1017	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-1017	-0.2780005633831024	The pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or <unk> 10 years and are listed in Table 3 below .
D-1017	-0.2780005633831024	The pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or <unk> 10 years and are listed in Table 3 below .
P-1017	-0.7191 -0.0994 -0.0736 -0.0600 -0.3277 -0.2960 -0.0673 -0.1139 -0.3782 -1.8700 -0.1721 -1.5663 -0.1666 -0.1014 -0.7714 -0.2391 -0.0778 -0.1444 -0.0758 -0.0998 -0.1617 -0.0878 -0.3197 -0.1519 -0.0780 -0.0810 -0.1549 -0.2350 -0.0275 -0.1542 -0.1035 -0.3863 -0.1817 -0.2680 -0.1705 -0.5940 -0.1302 -0.1119 -0.1487 -0.1537
S-1997	Die Patienten sollten jedoch darüber aufgeklärt werden , dass es in sehr seltenen Fällen zu einer Benommenheit kommen kann , die zu einer Beeinträchtigung der Verkehrstüchtigkeit oder der Fähigkeit zum Bedienen von Maschinen führen kann .
T-1997	However , patients should be informed that very rarely some people experience drowsiness , which may affect their ability to drive or use machines .
H-1997	-0.3025345802307129	However , patients should be advised that in very rare cases light-headedness may occur , which may result in impairment of ability to drive or use machines .
D-1997	-0.3025345802307129	However , patients should be advised that in very rare cases light-headedness may occur , which may result in impairment of ability to drive or use machines .
P-1997	-0.3333 -0.2341 -0.1528 -0.1593 -0.1414 -1.3565 -0.1467 -0.4089 -0.1658 -0.0455 -0.1474 -0.5065 -0.1008 -0.0363 -0.0661 -0.0545 -0.5913 -0.0866 -1.1768 -0.4483 -0.2329 -1.9777 -0.1457 -0.2649 -0.0603 -0.0332 -0.1030 -0.1983 -0.3361 -0.1705 -0.2464 -0.1340 -0.1156 -0.2151 -0.1402 -0.1584
S-666	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-666	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-666	-0.2780005633831024	The pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or <unk> 10 years and are listed in Table 3 below .
D-666	-0.2780005633831024	The pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or <unk> 10 years and are listed in Table 3 below .
P-666	-0.7191 -0.0994 -0.0736 -0.0600 -0.3277 -0.2960 -0.0673 -0.1139 -0.3782 -1.8700 -0.1721 -1.5663 -0.1666 -0.1014 -0.7714 -0.2391 -0.0778 -0.1444 -0.0758 -0.0998 -0.1617 -0.0878 -0.3197 -0.1519 -0.0780 -0.0810 -0.1549 -0.2350 -0.0275 -0.1542 -0.1035 -0.3863 -0.1817 -0.2680 -0.1705 -0.5940 -0.1302 -0.1119 -0.1487 -0.1537
S-841	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-841	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-841	-0.2780005633831024	The pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or <unk> 10 years and are listed in Table 3 below .
D-841	-0.2780005633831024	The pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or <unk> 10 years and are listed in Table 3 below .
P-841	-0.7191 -0.0994 -0.0736 -0.0600 -0.3277 -0.2960 -0.0673 -0.1139 -0.3782 -1.8700 -0.1721 -1.5663 -0.1666 -0.1014 -0.7714 -0.2391 -0.0778 -0.1444 -0.0758 -0.0998 -0.1617 -0.0878 -0.3197 -0.1519 -0.0780 -0.0810 -0.1549 -0.2350 -0.0275 -0.1542 -0.1035 -0.3863 -0.1817 -0.2680 -0.1705 -0.5940 -0.1302 -0.1119 -0.1487 -0.1537
S-1193	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-1193	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-1193	-0.2780005633831024	The pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or <unk> 10 years and are listed in Table 3 below .
D-1193	-0.2780005633831024	The pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or <unk> 10 years and are listed in Table 3 below .
P-1193	-0.7191 -0.0994 -0.0736 -0.0600 -0.3277 -0.2960 -0.0673 -0.1139 -0.3782 -1.8700 -0.1721 -1.5663 -0.1666 -0.1014 -0.7714 -0.2391 -0.0778 -0.1444 -0.0758 -0.0998 -0.1617 -0.0878 -0.3197 -0.1519 -0.0780 -0.0810 -0.1549 -0.2350 -0.0275 -0.1542 -0.1035 -0.3863 -0.1817 -0.2680 -0.1705 -0.5940 -0.1302 -0.1119 -0.1487 -0.1537
S-1369	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-1369	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-1369	-0.2780005633831024	The pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or <unk> 10 years and are listed in Table 3 below .
D-1369	-0.2780005633831024	The pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or <unk> 10 years and are listed in Table 3 below .
P-1369	-0.7191 -0.0994 -0.0736 -0.0600 -0.3277 -0.2960 -0.0673 -0.1139 -0.3782 -1.8700 -0.1721 -1.5663 -0.1666 -0.1014 -0.7714 -0.2391 -0.0778 -0.1444 -0.0758 -0.0998 -0.1617 -0.0878 -0.3197 -0.1519 -0.0780 -0.0810 -0.1549 -0.2350 -0.0275 -0.1542 -0.1035 -0.3863 -0.1817 -0.2680 -0.1705 -0.5940 -0.1302 -0.1119 -0.1487 -0.1537
S-1546	Die pharmakokinetischen Parameter stammen aus einer Cross-Over-Studie mit ADVATE in 100 zuvor behandelten Patienten gleich oder <unk> 10 Jahre und sind in unten stehender Tabelle 3 aufgelistet .
T-1546	The pharmacokinetic parameters derived from a crossover study of ADVATE in 100 previously treated patients 10 years of age are listed in table 3 below .
H-1546	-0.2780005633831024	The pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or <unk> 10 years and are listed in Table 3 below .
D-1546	-0.2780005633831024	The pharmacokinetic parameters are from a cross-over study of ADVATE in 100 previously treated patients equal to or <unk> 10 years and are listed in Table 3 below .
P-1546	-0.7191 -0.0994 -0.0736 -0.0600 -0.3277 -0.2960 -0.0673 -0.1139 -0.3782 -1.8700 -0.1721 -1.5663 -0.1666 -0.1014 -0.7714 -0.2391 -0.0778 -0.1444 -0.0758 -0.0998 -0.1617 -0.0878 -0.3197 -0.1519 -0.0780 -0.0810 -0.1549 -0.2350 -0.0275 -0.1542 -0.1035 -0.3863 -0.1817 -0.2680 -0.1705 -0.5940 -0.1302 -0.1119 -0.1487 -0.1537
S-189	Colecalciferol ( Vitamin D3 ) Vitamin D3 wird in der Haut durch UV-Licht über die Umwandlung von 7-Dehydrocholesterol zu Vitamin D3 produziert .
T-189	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by conversion of 7-dehydrocholesterol to vitamin D3 by ultraviolet light .
H-189	-0.2393430769443512	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by UV light via the conversion of 7-dehydrocholesterol to vitamin D3 .
D-189	-0.2393430769443512	Colecalciferol ( vitamin D3 ) Vitamin D3 is produced in the skin by UV light via the conversion of 7-dehydrocholesterol to vitamin D3 .
P-189	-0.2973 -0.1257 -0.2239 -0.1227 -0.1152 -0.1953 -0.1468 -0.1469 -0.1192 -0.1202 -0.1257 -0.1390 -0.3213 -0.0671 -0.1310 -0.1303 -0.1181 -0.1206 -0.5031 -0.1252 -0.0625 -0.1722 -0.2299 -0.2002 -0.2107 -0.7741 -0.4297 -0.7701 -0.4359 -0.1602 -1.4411 -0.1067 -0.1377 -0.0831 -0.3054 -0.0443 -0.1871 -0.5664 -0.1660 -0.0912 -0.1329 -0.1288 -0.1422 -0.1580
S-610	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-610	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-610	-0.2799146771430969	All patients treated with blood clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for developmental inhibitors . See section 4.8 .
D-610	-0.2799146771430969	All patients treated with blood clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for developmental inhibitors . See section 4.8 .
P-610	-0.4313 -0.1354 -0.1641 -0.1564 -0.8173 -0.9852 -0.0236 -0.1092 -0.0621 -0.1363 -0.1122 -0.1660 -0.1852 -1.3749 -0.8311 -0.1074 -0.0516 -0.0797 -0.1454 -0.2035 -0.2094 -0.1116 -0.0813 -0.1134 -0.2730 -1.6795 -0.3716 -0.2462 -0.0315 -0.0470 -0.1122 -0.2874 -0.1190 -0.0881 -0.1179 -0.1496 -0.1615 -0.1586
S-1136	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-1136	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-1136	-0.2799146771430969	All patients treated with blood clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for developmental inhibitors . See section 4.8 .
D-1136	-0.2799146771430969	All patients treated with blood clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for developmental inhibitors . See section 4.8 .
P-1136	-0.4313 -0.1354 -0.1641 -0.1564 -0.8173 -0.9852 -0.0236 -0.1092 -0.0621 -0.1363 -0.1122 -0.1660 -0.1852 -1.3749 -0.8311 -0.1074 -0.0516 -0.0797 -0.1454 -0.2035 -0.2094 -0.1116 -0.0813 -0.1134 -0.2730 -1.6795 -0.3716 -0.2462 -0.0315 -0.0470 -0.1122 -0.2874 -0.1190 -0.0881 -0.1179 -0.1496 -0.1615 -0.1586
S-784	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-784	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-784	-0.2799146771430969	All patients treated with blood clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for developmental inhibitors . See section 4.8 .
D-784	-0.2799146771430969	All patients treated with blood clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for developmental inhibitors . See section 4.8 .
P-784	-0.4313 -0.1354 -0.1641 -0.1564 -0.8173 -0.9852 -0.0236 -0.1092 -0.0621 -0.1363 -0.1122 -0.1660 -0.1852 -1.3749 -0.8311 -0.1074 -0.0516 -0.0797 -0.1454 -0.2035 -0.2094 -0.1116 -0.0813 -0.1134 -0.2730 -1.6795 -0.3716 -0.2462 -0.0315 -0.0470 -0.1122 -0.2874 -0.1190 -0.0881 -0.1179 -0.1496 -0.1615 -0.1586
S-960	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-960	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-960	-0.2799146771430969	All patients treated with blood clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for developmental inhibitors . See section 4.8 .
D-960	-0.2799146771430969	All patients treated with blood clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for developmental inhibitors . See section 4.8 .
P-960	-0.4313 -0.1354 -0.1641 -0.1564 -0.8173 -0.9852 -0.0236 -0.1092 -0.0621 -0.1363 -0.1122 -0.1660 -0.1852 -1.3749 -0.8311 -0.1074 -0.0516 -0.0797 -0.1454 -0.2035 -0.2094 -0.1116 -0.0813 -0.1134 -0.2730 -1.6795 -0.3716 -0.2462 -0.0315 -0.0470 -0.1122 -0.2874 -0.1190 -0.0881 -0.1179 -0.1496 -0.1615 -0.1586
S-415	FIT bestand aus zwei plazebokontrollierten Studien , bei denen Alendronat täglich ( 5 mg täglich über 2 Jahre und anschließend 10 mg täglich weiterhin entweder über 1 oder 2 Jahre ) eingenommen wurde :
T-415	FIT consisted of two placebo-controlled studies using alendronate daily ( 5 mg daily for two years and 10 mg daily for either one or two additional years ) :
H-415	-0.2763259708881378	FIT consisted of two placebo-controlled trials in which alendronate was taken daily ( 5 mg daily for 2 years and then 10 mg daily for either 1 or 2 years ) :
D-415	-0.2763259708881378	FIT consisted of two placebo-controlled trials in which alendronate was taken daily ( 5 mg daily for 2 years and then 10 mg daily for either 1 or 2 years ) :
P-415	-0.0734 -0.0977 -0.0746 -0.1897 -0.1616 -0.3373 -0.0525 -0.1338 -0.0740 -0.1498 -0.0770 -0.9022 -1.2208 -0.2154 -0.1829 -0.1569 -0.0922 -0.0614 -0.1638 -1.5456 -0.1489 -0.1350 -0.2227 -0.0425 -0.2196 -0.1213 -0.7482 -0.1035 -0.7832 -1.2316 -0.3567 -0.0487 -0.2655 -0.1556 -0.1147 -0.1220 -0.1712 -0.1157 -0.1082 -0.1488 -0.1265 -0.1529
S-1312	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-1312	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-1312	-0.2799146771430969	All patients treated with blood clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for developmental inhibitors . See section 4.8 .
D-1312	-0.2799146771430969	All patients treated with blood clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for developmental inhibitors . See section 4.8 .
P-1312	-0.4313 -0.1354 -0.1641 -0.1564 -0.8173 -0.9852 -0.0236 -0.1092 -0.0621 -0.1363 -0.1122 -0.1660 -0.1852 -1.3749 -0.8311 -0.1074 -0.0516 -0.0797 -0.1454 -0.2035 -0.2094 -0.1116 -0.0813 -0.1134 -0.2730 -1.6795 -0.3716 -0.2462 -0.0315 -0.0470 -0.1122 -0.2874 -0.1190 -0.0881 -0.1179 -0.1496 -0.1615 -0.1586
S-1488	Alle Patienten , die mit Blutgerinnungsfaktor VIII behandelt wurden , sollten sorgfältig klinisch und mit geeigneten Labortests hinsichtlich der Entwicklung von Inhibitoren überwacht werden . Siehe Abschnitt 4.8 .
T-1488	Patients treated with coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests ( see section 4.8 ) .
H-1488	-0.2799146771430969	All patients treated with blood clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for developmental inhibitors . See section 4.8 .
D-1488	-0.2799146771430969	All patients treated with blood clotting factor VIII should be carefully monitored clinically and with appropriate laboratory tests for developmental inhibitors . See section 4.8 .
P-1488	-0.4313 -0.1354 -0.1641 -0.1564 -0.8173 -0.9852 -0.0236 -0.1092 -0.0621 -0.1363 -0.1122 -0.1660 -0.1852 -1.3749 -0.8311 -0.1074 -0.0516 -0.0797 -0.1454 -0.2035 -0.2094 -0.1116 -0.0813 -0.1134 -0.2730 -1.6795 -0.3716 -0.2462 -0.0315 -0.0470 -0.1122 -0.2874 -0.1190 -0.0881 -0.1179 -0.1496 -0.1615 -0.1586
S-1191	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-1191	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-1191	-0.26577720046043396	All pharmacokinetic trials of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
D-1191	-0.26577720046043396	All pharmacokinetic trials of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
P-1191	-0.2281 -0.3410 -0.0618 -0.0423 -0.4285 -1.1787 -0.2776 -0.0983 -0.1487 -0.0779 -0.0956 -0.3400 -0.8632 -0.1377 -0.1541 -0.0955 -0.1779 -0.1457 -0.1259 -0.3655 -0.2594 -0.3369 -0.1330 -0.1709 -0.2347 -0.1319 -0.1328 -0.1696 -0.0561 -0.1685 -0.2533 -0.7554 -1.2158 -0.1030 -0.2780 -0.1422 -0.1429 -0.1481 -0.1486
S-839	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-839	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-839	-0.26577720046043396	All pharmacokinetic trials of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
D-839	-0.26577720046043396	All pharmacokinetic trials of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
P-839	-0.2281 -0.3410 -0.0618 -0.0423 -0.4285 -1.1787 -0.2776 -0.0983 -0.1487 -0.0779 -0.0956 -0.3400 -0.8632 -0.1377 -0.1541 -0.0955 -0.1779 -0.1457 -0.1259 -0.3655 -0.2594 -0.3369 -0.1330 -0.1709 -0.2347 -0.1319 -0.1328 -0.1696 -0.0561 -0.1685 -0.2533 -0.7554 -1.2158 -0.1030 -0.2780 -0.1422 -0.1429 -0.1481 -0.1486
S-1367	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-1367	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-1367	-0.26577720046043396	All pharmacokinetic trials of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
D-1367	-0.26577720046043396	All pharmacokinetic trials of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
P-1367	-0.2281 -0.3410 -0.0618 -0.0423 -0.4285 -1.1787 -0.2776 -0.0983 -0.1487 -0.0779 -0.0956 -0.3400 -0.8632 -0.1377 -0.1541 -0.0955 -0.1779 -0.1457 -0.1259 -0.3655 -0.2594 -0.3369 -0.1330 -0.1709 -0.2347 -0.1319 -0.1328 -0.1696 -0.0561 -0.1685 -0.2533 -0.7554 -1.2158 -0.1030 -0.2780 -0.1422 -0.1429 -0.1481 -0.1486
S-1544	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-1544	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-1544	-0.26577720046043396	All pharmacokinetic trials of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
D-1544	-0.26577720046043396	All pharmacokinetic trials of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
P-1544	-0.2281 -0.3410 -0.0618 -0.0423 -0.4285 -1.1787 -0.2776 -0.0983 -0.1487 -0.0779 -0.0956 -0.3400 -0.8632 -0.1377 -0.1541 -0.0955 -0.1779 -0.1457 -0.1259 -0.3655 -0.2594 -0.3369 -0.1330 -0.1709 -0.2347 -0.1319 -0.1328 -0.1696 -0.0561 -0.1685 -0.2533 -0.7554 -1.2158 -0.1030 -0.2780 -0.1422 -0.1429 -0.1481 -0.1486
S-1015	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-1015	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-1015	-0.26577720046043396	All pharmacokinetic trials of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
D-1015	-0.26577720046043396	All pharmacokinetic trials of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
P-1015	-0.2281 -0.3410 -0.0618 -0.0423 -0.4285 -1.1787 -0.2776 -0.0983 -0.1487 -0.0779 -0.0956 -0.3400 -0.8632 -0.1377 -0.1541 -0.0955 -0.1779 -0.1457 -0.1259 -0.3655 -0.2594 -0.3369 -0.1330 -0.1709 -0.2347 -0.1319 -0.1328 -0.1696 -0.0561 -0.1685 -0.2533 -0.7554 -1.2158 -0.1030 -0.2780 -0.1422 -0.1429 -0.1481 -0.1486
S-1086	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-1086	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-1086	-0.39413273334503174	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not indicated for the treatment of von Willebrand Jürgen syndrome .
D-1086	-0.39413273334503174	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not indicated for the treatment of von Willebrand Jürgen syndrome .
P-1086	-0.1791 -0.1495 -0.0872 -0.1078 -0.8338 -0.1232 -1.1341 -0.1718 -0.1506 -0.1529 -0.9654 -0.1616 -0.4903 -0.7525 -0.1863 -0.1172 -0.1634 -0.1144 -0.1292 -0.1293 -0.2852 -0.2128 -1.7239 -0.2052 -0.1598 -0.1586 -0.1398 -0.5556 -0.1750 -0.1100 -0.3033 -0.5156 -0.9750 -2.4115 -0.0593 -0.1371 -0.1554
S-664	Alle Pharmakokinetikstudien mit ADVATE wurden an vorbehandelten Patienten mit schwerer oder mittelschwerer Hämophilie A ( Basiswert der Faktor VIII-Aktivität 2 % ) durchgeführt .
T-664	All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe to moderately severe haemophilia A ( baseline factor VIII 2 % ) .
H-664	-0.26577720046043396	All pharmacokinetic trials of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
D-664	-0.26577720046043396	All pharmacokinetic trials of ADVATE were conducted in previously treated patients with severe or moderate haemophilia A ( baseline factor VIII activity 2 % ) .
P-664	-0.2281 -0.3410 -0.0618 -0.0423 -0.4285 -1.1787 -0.2776 -0.0983 -0.1487 -0.0779 -0.0956 -0.3400 -0.8632 -0.1377 -0.1541 -0.0955 -0.1779 -0.1457 -0.1259 -0.3655 -0.2594 -0.3369 -0.1330 -0.1709 -0.2347 -0.1319 -0.1328 -0.1696 -0.0561 -0.1685 -0.2533 -0.7554 -1.2158 -0.1030 -0.2780 -0.1422 -0.1429 -0.1481 -0.1486
S-1438	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-1438	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-1438	-0.39413273334503174	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not indicated for the treatment of von Willebrand Jürgen syndrome .
D-1438	-0.39413273334503174	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not indicated for the treatment of von Willebrand Jürgen syndrome .
P-1438	-0.1791 -0.1495 -0.0872 -0.1078 -0.8338 -0.1232 -1.1341 -0.1718 -0.1506 -0.1529 -0.9654 -0.1616 -0.4903 -0.7525 -0.1863 -0.1172 -0.1634 -0.1144 -0.1292 -0.1293 -0.2852 -0.2128 -1.7239 -0.2052 -0.1598 -0.1586 -0.1398 -0.5556 -0.1750 -0.1100 -0.3033 -0.5156 -0.9750 -2.4115 -0.0593 -0.1371 -0.1554
S-1262	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-1262	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-1262	-0.39413273334503174	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not indicated for the treatment of von Willebrand Jürgen syndrome .
D-1262	-0.39413273334503174	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not indicated for the treatment of von Willebrand Jürgen syndrome .
P-1262	-0.1791 -0.1495 -0.0872 -0.1078 -0.8338 -0.1232 -1.1341 -0.1718 -0.1506 -0.1529 -0.9654 -0.1616 -0.4903 -0.7525 -0.1863 -0.1172 -0.1634 -0.1144 -0.1292 -0.1293 -0.2852 -0.2128 -1.7239 -0.2052 -0.1598 -0.1586 -0.1398 -0.5556 -0.1750 -0.1100 -0.3033 -0.5156 -0.9750 -2.4115 -0.0593 -0.1371 -0.1554
S-910	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-910	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-910	-0.39413273334503174	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not indicated for the treatment of von Willebrand Jürgen syndrome .
D-910	-0.39413273334503174	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not indicated for the treatment of von Willebrand Jürgen syndrome .
P-910	-0.1791 -0.1495 -0.0872 -0.1078 -0.8338 -0.1232 -1.1341 -0.1718 -0.1506 -0.1529 -0.9654 -0.1616 -0.4903 -0.7525 -0.1863 -0.1172 -0.1634 -0.1144 -0.1292 -0.1293 -0.2852 -0.2128 -1.7239 -0.2052 -0.1598 -0.1586 -0.1398 -0.5556 -0.1750 -0.1100 -0.3033 -0.5156 -0.9750 -2.4115 -0.0593 -0.1371 -0.1554
S-1149	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 7 gemeldet .
T-1149	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 7 gemeldet . 7
H-1149	-0.35393989086151123	Out of a total of 56 adverse reactions , no were observed in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults .
D-1149	-0.35393989086151123	Out of a total of 56 adverse reactions , no were observed in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults .
P-1149	-3.5793 -0.1544 -0.3473 -0.1530 -0.2725 -0.0849 -0.4636 -0.0621 -0.1541 -0.0411 -0.2963 -0.3447 -1.0948 -1.0124 -0.1506 -0.6559 -0.7790 -0.1375 -0.2668 -0.1799 -0.3382 -0.0406 -0.1340 -1.1379 -0.2278 -0.1257 -1.1485 -0.2113 -0.1442 -0.1012 -0.1382 -0.0899 -0.1211 -0.0692 -0.7785 -0.1436 -0.1227 -0.1428 -0.0962 -0.1266 -0.0775 -0.0666 -0.0462 -0.0379 -0.4560 -0.1012 -0.1376 -0.2457 -0.1229 -0.1477 -0.4917 -0.8228 -0.3369
S-175	Eine Krebsdiagnose , Chemotherapie , Strahlentherapie , Kortikosteroide und unzureichende Mundhygiene gelten ebenfalls als Risikofaktoren ( siehe Abschnitt 4.4 ) . Gelenkschwellungen .
T-175	Diagnosis of cancer , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also deemed as risk factors ( see section 4.4 ) ; joint swelling .
H-175	-0.15089809894561768	Cancer diagnosis , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also considered risk factors ( see section 4.4 ) .
D-175	-0.15089809894561768	Cancer diagnosis , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also considered risk factors ( see section 4.4 ) .
P-175	-0.0895 -0.0856 -0.1499 -0.0870 -0.0505 -0.0664 -0.1501 -0.3570 -0.0677 -0.1468 -0.1490 -0.1157 -0.0738 -0.1136 -0.1514 -0.0581 -0.1929 -0.4318 -0.1996 -0.0720 -0.2853 -0.2745 -0.2917 -0.1595 -0.0322 -0.0584 -0.1460 -0.2834 -0.1068 -0.1169 -0.1207 -0.1261 -0.1659 -0.1547
S-559	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-559	ADVATE does not contain von Willebrand factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-559	-0.39413273334503174	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not indicated for the treatment of von Willebrand Jürgen syndrome .
D-559	-0.39413273334503174	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not indicated for the treatment of von Willebrand Jürgen syndrome .
P-559	-0.1791 -0.1495 -0.0872 -0.1078 -0.8338 -0.1232 -1.1341 -0.1718 -0.1506 -0.1529 -0.9654 -0.1616 -0.4903 -0.7525 -0.1863 -0.1172 -0.1634 -0.1144 -0.1292 -0.1293 -0.2852 -0.2128 -1.7239 -0.2052 -0.1598 -0.1586 -0.1398 -0.5556 -0.1750 -0.1100 -0.3033 -0.5156 -0.9750 -2.4115 -0.0593 -0.1371 -0.1554
S-363	Eine Krebsdiagnose , Chemotherapie , Strahlentherapie , Kortikosteroide und unzureichende Mundhygiene gelten ebenfalls als Risikofaktoren ( siehe Abschnitt 4.4 ) . Gelenkschwellungen .
T-363	Diagnosis of cancer , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also deemed as risk factors ( see section 4.4 ) ; joint swelling .
H-363	-0.15089809894561768	Cancer diagnosis , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also considered risk factors ( see section 4.4 ) .
D-363	-0.15089809894561768	Cancer diagnosis , chemotherapy , radiotherapy , corticosteroids and poor oral hygiene are also considered risk factors ( see section 4.4 ) .
P-363	-0.0895 -0.0856 -0.1499 -0.0870 -0.0505 -0.0664 -0.1501 -0.3570 -0.0677 -0.1468 -0.1490 -0.1157 -0.0738 -0.1136 -0.1514 -0.0581 -0.1929 -0.4318 -0.1996 -0.0720 -0.2853 -0.2745 -0.2917 -0.1595 -0.0322 -0.0584 -0.1460 -0.2834 -0.1068 -0.1169 -0.1207 -0.1261 -0.1659 -0.1547
S-973	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 5 gemeldet .
T-973	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 5 gemeldet . 5
H-973	-0.34809377789497375	Out of a total of 56 adverse reactions , no were observed in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults 5 .
D-973	-0.34809377789497375	Out of a total of 56 adverse reactions , no were observed in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults 5 .
P-973	-3.6339 -0.1542 -0.3399 -0.1517 -0.2657 -0.0848 -0.4627 -0.0622 -0.1510 -0.0407 -0.3048 -0.3430 -1.1123 -1.0442 -0.1509 -0.6584 -0.7748 -0.1385 -0.2830 -0.1631 -0.3496 -0.0398 -0.1359 -1.1482 -0.2353 -0.1256 -1.1707 -0.2062 -0.1434 -0.1126 -0.1396 -0.0908 -0.1212 -0.0699 -0.8004 -0.1453 -0.1246 -0.1462 -0.0991 -0.1247 -0.0760 -0.0630 -0.0473 -0.0380 -0.3828 -0.1091 -0.1376 -0.2456 -0.1222 -0.1497 -0.4918 -0.7422 -0.1956 -0.1473
S-540	Die häufigsten Nebenwirkungen von Advate ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Schwindel , Kopfschmerzen , Pyrexie ( Fieber ) und die Bildung von Antikörpern gegenüber Faktor VIII.
T-540	The most common side effects with Advate ( seen in between 1 to 10 patients in 100 ) are dizziness , headache , pyrexia ( fever ) and the presence of antibodies against factor VIII .
H-540	-0.2686369717121124	The most frequent adverse reactions with Advate ( observed in 1 to 10 patients in 100 ) are dizziness , headache , pyrexia ( fever ) , and the formation of antibodies to factor VIII .
D-540	-0.2686369717121124	The most frequent adverse reactions with Advate ( observed in 1 to 10 patients in 100 ) are dizziness , headache , pyrexia ( fever ) , and the formation of antibodies to factor VIII .
P-540	-0.2073 -0.1724 -1.0969 -0.2665 -0.0397 -0.1075 -0.0385 -1.8892 -0.3309 -0.0936 -0.1451 -0.1874 -0.1444 -0.1605 -0.1307 -0.1457 -1.4761 -0.4181 -0.1685 -0.2075 -0.2020 -0.1057 -0.0560 -0.0548 -0.1438 -0.1498 -0.0458 -0.0899 -0.1437 -0.0448 -0.1327 -0.1034 -0.0492 -0.2378 -0.1552 -0.0938 -0.1381 -0.6821 -0.1320 -0.7366 -0.3079 -0.1458 -0.0469 -0.0811 -0.1557 -0.7386 -0.1645 -0.2066 -0.5117 -0.1498
S-1816	Luxembourg<unk> Luxemburg Baxter Belgium SPRL Bd. de la Plaine<unk> Pleinlaan 5 B-1050 Bruxelles<unk> Brüssel Tél<unk> Tel : <unk> 32 2 650 1711
T-1816	Luxembourg/ Luxemburg Baxter Belgium SPRL Bd . de la Plaine/ Pleinlaan 5 B-1050 Bruxelles/ Brüssel Tél/ Tel : <<unk>> 32 2 650 1711
H-1816	-0.17410580813884735	Luxembourg/ Luxemburg Baxter Belgium SPRL Bd. de la Plaine/ Pleinlaan 5 B-1050 Bruxelles/ Brüssel Tél/ Tel : <unk> 32 2 650 1711
D-1816	-0.17410580813884735	Luxembourg/ Luxemburg Baxter Belgium SPRL Bd. de la Plaine/ Pleinlaan 5 B-1050 Bruxelles/ Brüssel Tél/ Tel : <unk> 32 2 650 1711
P-1816	-0.0580 -0.0271 -0.1481 -0.1388 -0.0685 -0.2664 -0.1375 -0.1565 -0.1600 -0.0779 -0.1261 -0.1211 -0.1432 -0.0472 -0.1289 -0.1898 -0.1466 -0.0366 -0.1069 -0.3334 -0.1014 -0.1079 -0.1227 -0.1128 -0.1133 -0.1193 -0.2384 -0.1335 -0.2127 -0.1277 -0.1057 -0.1586 -0.1117 -2.0408 -0.1366 -0.0860 -0.1253 -0.1470 -0.0608 -0.1352 -0.0401 -0.1073 -0.1366 -0.4035 -0.1152 -0.1103 -0.1539
S-1618	Wie in der CHMP-Richtlinie zum Risiko-Managment-Plan für Human-Arzneimittel festgelegt , sollen diese Aktualisierungen gleichzeitig mit dem nächsten Periodic Safety Update Report ( PSUR ) eingereicht werden .
T-1618	As per the CHMP Guideline on Risk Management Systems for medicinal products for human use , the updated RMP should be submitted at the same time as the next Periodic Safety Update Report ( PSUR ) .
H-1618	-0.39545977115631104	As defined in the CHMP Risk Management Plan for Medicinal products for human use , these updates should be submitted concomitantly with the next Periodic Safety Update Report ( PSUR ) .
D-1618	-0.39545977115631104	As defined in the CHMP Risk Management Plan for Medicinal products for human use , these updates should be submitted concomitantly with the next Periodic Safety Update Report ( PSUR ) .
P-1618	-0.5290 -1.8400 -0.2191 -0.2101 -0.4690 -0.4138 -0.5718 -0.1097 -0.2929 -0.3381 -0.1312 -1.0225 -0.0519 -0.4566 -0.2735 -2.8066 -0.2337 -0.1424 -0.5106 -0.3722 -0.4700 -0.1504 -1.9049 -0.8378 -0.2515 -0.0152 -0.0828 -0.1455 -0.1328 -0.6002 -0.1289 -0.1495 -0.0365 -0.0608 -0.0842 -0.1337 -0.1287 -0.1178 -0.0588 -0.0982 -0.1294 -0.1439 -0.1489
S-1501	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 11 gemeldet .
T-1501	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 11 gemeldet . 11
H-1501	-0.3630742132663727	Out of a total of 56 adverse reactions , no were observed in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults .
D-1501	-0.3630742132663727	Out of a total of 56 adverse reactions , no were observed in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults .
P-1501	-3.6346 -0.1542 -0.3397 -0.1529 -0.2712 -0.0846 -0.4497 -0.0610 -0.1551 -0.0404 -0.2949 -0.3365 -1.2407 -1.0329 -0.1502 -0.6532 -0.7790 -0.1369 -0.2877 -0.1771 -0.4059 -0.0387 -0.1340 -1.1964 -0.2294 -0.1272 -1.1156 -0.2061 -0.1443 -0.1309 -0.1389 -0.0899 -0.1220 -0.0697 -0.7633 -0.1445 -0.1229 -0.1468 -0.0964 -0.1268 -0.0758 -0.0622 -0.0470 -0.0375 -0.3298 -0.1027 -0.1404 -0.2617 -0.1239 -0.1447 -0.5198 -1.2563 -0.1585
S-1325	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 9 gemeldet .
T-1325	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 9 gemeldet . 9
H-1325	-0.3514581620693207	Out of a total of 56 adverse reactions , no were observed in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults .
D-1325	-0.3514581620693207	Out of a total of 56 adverse reactions , no were observed in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults .
P-1325	-3.6595 -0.1543 -0.3396 -0.1517 -0.2687 -0.0855 -0.4665 -0.0620 -0.1539 -0.0407 -0.2993 -0.3414 -1.2053 -1.0243 -0.1503 -0.6597 -0.7743 -0.1375 -0.2796 -0.1693 -0.3584 -0.0397 -0.1340 -1.1179 -0.2335 -0.1265 -1.1669 -0.2062 -0.1432 -0.1056 -0.1416 -0.0913 -0.1210 -0.0695 -0.7820 -0.1444 -0.1277 -0.1457 -0.0964 -0.1253 -0.0765 -0.0648 -0.0474 -0.0373 -0.5160 -0.1013 -0.1397 -0.2639 -0.1243 -0.1461 -0.4783 -0.5063 -0.2254
S-543	Advate darf nicht bei Patienten angewendet werden , die möglicherweise überempfindlich ( allergisch ) gegen den menschlichen Gerinnungsfaktor VIII , Maus- oder Hamsterprotein oder einen der sonstigen Bestandteile sind .
T-543	Advate should not be used in people who may be hypersensitive ( allergic ) to human coagulation factor VIII , to mouse or hamster protein , or to any of the other ingredients .
H-543	-0.26308977603912354	Do not use Advate in patients who may be hypersensitive ( allergic ) to human clotting factor VIII , mouse or hamster protein or to any of the excipients .
D-543	-0.26308977603912354	Do not use Advate in patients who may be hypersensitive ( allergic ) to human clotting factor VIII , mouse or hamster protein or to any of the excipients .
P-543	-3.0734 -0.1284 -0.1105 -0.7011 -0.0960 -0.2647 -0.4057 -0.1990 -0.1726 -0.1388 -0.1411 -0.0521 -0.1723 -0.1091 -0.0398 -0.1502 -0.1528 -0.2047 -0.9297 -0.0189 -0.0942 -0.0988 -0.1374 -0.1114 -0.1523 -0.1559 -0.0731 -0.1800 -0.2333 -0.0930 -0.0296 -0.2359 -0.1800 -0.1107 -0.1619 -0.2166 -1.0608 -0.0245 -0.0448 -0.0825 -0.1479 -0.1641
S-59	Um eine Reizung der Speiseröhre zu vermeiden , darf die Patientin sich bis nach der ersten Nahrungsaufnahme des Tages , die frühestens 30 Minuten nach Einnahme der Tablette erfolgen soll , nicht hinlegen .
T-59	To avoid irritation of the oesophagus ( gullet ) , the patient should not lie down until after their first food of the day , which should be at least 30 minutes after taking the tablet .
H-59	-0.367228239774704	In order to avoid oesophageal irritation , the patient should not lie down until after the first food intake of the day , which is not until 30 minutes after taking the tablet at the earliest .
D-59	-0.367228239774704	In order to avoid oesophageal irritation , the patient should not lie down until after the first food intake of the day , which is not until 30 minutes after taking the tablet at the earliest .
P-59	-1.2180 -0.1473 -0.1609 -1.1711 -1.0822 -0.0193 -0.0990 -0.0145 -0.0098 -0.0921 -0.1138 -0.1359 -0.1569 -0.3270 -0.1458 -1.0126 -0.1518 -0.0707 -0.0868 -0.1205 -0.1304 -0.1470 -0.1289 -0.7495 -0.1603 -0.2281 -0.1491 -0.1463 -0.0941 -0.2154 -0.6767 -1.5208 -1.1392 -1.3332 -0.1105 -0.1632 -0.2693 -0.7006 -0.1291 -0.1081 -0.1512 -1.5846 -0.1357 -0.1405 -0.3043 -0.1589 -0.1485
S-797	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 3 gemeldet .
T-797	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 3 gemeldet . 3
H-797	-0.3461168706417084	Out of a total of 56 adverse reactions , no were observed in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults 3 .
D-797	-0.3461168706417084	Out of a total of 56 adverse reactions , no were observed in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults 3 .
P-797	-3.5720 -0.1544 -0.3502 -0.1528 -0.2731 -0.0852 -0.4539 -0.0625 -0.1537 -0.0404 -0.2916 -0.3461 -0.9964 -1.0420 -0.1508 -0.6537 -0.7679 -0.1370 -0.2779 -0.1701 -0.3277 -0.0407 -0.1350 -1.1423 -0.2303 -0.1312 -1.1856 -0.2110 -0.1425 -0.0973 -0.1393 -0.0922 -0.1208 -0.0708 -0.7932 -0.1452 -0.1207 -0.1471 -0.0986 -0.1235 -0.0773 -0.0619 -0.0468 -0.0382 -0.4410 -0.1028 -0.1365 -0.2499 -0.1209 -0.1581 -0.9343 -0.3004 -0.2483 -0.1472
S-623	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<unk> 32 Kleinkindern , 7 bei 4<unk> 56 Kindern , 8 bei 4<unk> 31 Jugendlichen und 25 bei 14<unk> 94 Erwachsenen 1 gemeldet .
T-623	Von den insgesamt 56 Nebenwirkungen wurden keine bei Neugeborenen beobachtet , 16 wurden bei 13<<unk>> 32 Kleinkindern , 7 bei 4<<unk>> 56 Kindern , 8 bei 4<<unk>> 31 Jugendlichen und 25 bei 14<<unk>> 94 Erwachsenen 1 gemeldet . 1
H-623	-0.3573441505432129	Out of a total of 56 adverse reactions , no were observed in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults 1 .
D-623	-0.3573441505432129	Out of a total of 56 adverse reactions , no were observed in newborns , 16 were reported in 13/ 32 infants , 7 in 4/ 56 children , 8 in 4/ 31 adolescents and 25 in 14/ 94 adults 1 .
P-623	-3.6018 -0.1543 -0.3438 -0.1542 -0.2656 -0.0849 -0.4564 -0.0621 -0.1537 -0.0409 -0.2816 -0.3500 -1.0673 -1.0089 -0.1497 -0.6498 -0.7542 -0.1384 -0.2672 -0.1650 -0.3348 -0.0389 -0.1329 -1.1337 -0.2170 -0.1307 -1.1421 -0.2137 -0.1436 -0.1057 -0.1392 -0.0915 -0.1213 -0.0709 -0.8280 -0.1447 -0.1238 -0.1483 -0.0995 -0.1235 -0.0774 -0.0615 -0.0463 -0.0377 -0.3751 -0.1043 -0.1389 -0.2444 -0.1218 -0.1525 -1.3200 -0.5362 -0.2997 -0.1473
S-1973	Aerinaze ist mindestens 48 Stunden vor der Durchführung dermatologischer Tests abzusetzen , da Antihistaminika ansonsten positive Reaktionen auf Indikatoren für Hautreaktionen verhindern bzw. in ihrem Ausmaß reduzieren können .
T-1973	The administration of Aerinaze should be discontinued at least 48 hours before skin tests since antihistamines maybe prevent or reduce other wise positive reaction to dermal reactivity index .
H-1973	-0.34275510907173157	Aerinaze should be discontinued at least 48 hours prior to dermatological tests as antihistamines may otherwise prevent or reduce the extent of positive reactions to indicators of skin reaction .
D-1973	-0.34275510907173157	Aerinaze should be discontinued at least 48 hours prior to dermatological tests as antihistamines may otherwise prevent or reduce the extent of positive reactions to indicators of skin reaction .
P-1973	-0.1343 -0.1329 -0.1157 -0.1421 -0.1283 -0.5576 -0.1230 -0.1042 -0.0432 -0.1234 -0.1227 -0.0900 -0.0924 -0.2146 -0.1265 -2.2266 -0.1757 -0.4605 -0.4036 -1.3832 -0.4095 -0.0812 -0.2282 -0.3221 -0.0881 -0.1745 -0.3730 -0.2856 -0.1700 -0.5060 -0.7828 -0.2694 -1.5889 -0.0447 -0.0564 -0.1710 -1.5882 -0.0541 -0.1270 -0.1626 -0.0946 -0.2883 -0.1627 -0.1520
S-1888	Darüber hinaus hatte das Unternehmen nicht ausreichend nachgewiesen , dass Advexin auf zuverlässige Weise hergestellt werden kann und dass es weder für die Umwelt noch für Menschen , die in engem Kontakt mit dem Patienten kommen , schädlich ist .
T-1888	In addition , the company had not supplied enough evidence to demonstrate that Advexin could be made in a reliable manner , or that it would not be harmful to the environment or to people in close contact with the patient .
H-1888	-0.3804607391357422	Moreover , the company had not sufficiently demonstrated that Advexin can be produced in a reliable manner and that it is not harmful for the environment or for people who come into close contact with the patient .
D-1888	-0.3804607391357422	Moreover , the company had not sufficiently demonstrated that Advexin can be produced in a reliable manner and that it is not harmful for the environment or for people who come into close contact with the patient .
P-1888	-0.7656 -0.1700 -0.3339 -0.2687 -0.4424 -0.1733 -1.4191 -0.0444 -0.1233 -0.5431 -0.1227 -0.4794 -0.1934 -0.1393 -0.2768 -0.1331 -1.1187 -0.8879 -0.1259 -0.6423 -0.4567 -0.1920 -0.1638 -0.1507 -0.2631 -0.4674 -0.1439 -0.0989 -1.5291 -0.3358 -0.0801 -0.2541 -0.2843 -1.3336 -0.5387 -0.2687 -0.3513 -0.4797 -0.2284 -0.1763 -0.1876 -0.0478 -0.1474 -0.1576
S-734	ADVATE enthält keine pharmakologisch wirksamen Mengen des von-Willebrand-Faktors und ist daher nicht für die Behandlung des von-Willebrand-Jürgens-Syndroms geeignet .
T-734	ADVATE does not contain von Willebrand Factor in pharmacologically effective quantities and is therefore not indicated in von Willebrand disease .
H-734	-0.39413273334503174	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not indicated for the treatment of von Willebrand Jürgen syndrome .
D-734	-0.39413273334503174	ADVATE contains no pharmacologically active amounts of the von Willebrand factor and is therefore not indicated for the treatment of von Willebrand Jürgen syndrome .
P-734	-0.1791 -0.1495 -0.0872 -0.1078 -0.8338 -0.1232 -1.1341 -0.1718 -0.1506 -0.1529 -0.9654 -0.1616 -0.4903 -0.7525 -0.1863 -0.1172 -0.1634 -0.1144 -0.1292 -0.1293 -0.2852 -0.2128 -1.7239 -0.2052 -0.1598 -0.1586 -0.1398 -0.5556 -0.1750 -0.1100 -0.3033 -0.5156 -0.9750 -2.4115 -0.0593 -0.1371 -0.1554
S-1908	Pseudoephedrin regt die Nervenenden dazu an , den chemischen Botenstoff Noradrenalin freizusetzen , der eine Konstriktion ( Verengung ) der Blutgefäße verursacht .
T-1908	In Aerinaze , the two active substances are used together , since an antihistamine alone may not provide adequate relief for patients with nasal congestion .
H-1908	-0.3797435760498047	Pseudoephedrine stimulates the nerve endings to release the chemical messenger substance noradrenaline , which causes blood vessels to contract ( narrow ) .
D-1908	-0.3797435760498047	Pseudoephedrine stimulates the nerve endings to release the chemical messenger substance noradrenaline , which causes blood vessels to contract ( narrow ) .
P-1908	-0.1690 -0.1801 -0.1356 -0.0614 -0.1653 -0.2890 -0.1014 -0.4744 -0.0980 -0.3999 -0.0206 -0.2054 -0.2176 -0.1527 -0.1760 -0.1939 -0.1204 -0.3172 -0.5164 -0.1516 -0.4259 -0.5577 -0.6314 -0.0955 -0.1315 -0.2337 -0.3439 -0.1595 -0.0813 -1.6738 -0.7743 -0.0744 -0.1267 -2.1538 -0.1765 -2.4855 -0.2533 -0.1320 -0.1532
S-70	Da Alendronat und Vitamin D3 bereits getrennt voneinander in Arzneimitteln verwendet werden , die in der Europäischen Union zugelassen sind , legte das Unternehmen Daten vor , die aus früheren Studien und der veröffentlichten Literatur stammen .
T-70	Because alendronate and vitamin D3 are already used separately in authorised medicines in the European Union , the company presented data obtained in earlier studies and from the published literature .
H-70	-0.294027179479599	Since alendronate and vitamin D3 are already used separately in medicinal products authorised in the European Union , the company presented data from previous studies and published literature .
D-70	-0.294027179479599	Since alendronate and vitamin D3 are already used separately in medicinal products authorised in the European Union , the company presented data from previous studies and published literature .
P-70	-1.4286 -0.1969 -0.1582 -0.1085 -0.0434 -0.1374 -0.1378 -0.1251 -0.1302 -0.1309 -0.1507 -1.8475 -0.2813 -0.4544 -0.0974 -0.1746 -0.2925 -0.1898 -0.0747 -0.5616 -0.1848 -0.3519 -0.1363 -0.2387 -0.2015 -0.1433 -0.1852 -0.1999 -0.9685 -0.2318 -0.5263 -0.3841 -0.3266 -0.1312 -0.0247 -0.0593 -0.1475 -0.1488 -0.1555
S-453	Obwohl keine klinischen Daten darüber vorliegen , ist dennoch damit zu rechnen , dass die renale Elimination von Alendronat wie in den Tierversuchen auch bei Patienten mit eingeschränkter Nierenfunktion reduziert sein wird .
T-453	Although no clinical information is available , it is likely that , as in animals , elimination of alendronate via the kidney will be reduced in patients with impaired renal function .
H-453	-0.3991397023200989	Although no clinical data are available , renal elimination of alendronate is expected to be reduced in patients with impaired renal function , as in animal studies .
D-453	-0.3991397023200989	Although no clinical data are available , renal elimination of alendronate is expected to be reduced in patients with impaired renal function , as in animal studies .
P-453	-0.1501 -1.2409 -0.0928 -0.2461 -0.2598 -0.1559 -0.3823 -0.5427 -0.1132 -0.0569 -0.0750 -0.1432 -0.1493 -0.1661 -0.1277 -0.0586 -1.8350 -0.7819 -0.1506 -0.2660 -0.5196 -1.4398 -1.2432 -0.1399 -0.4983 -0.1603 -0.1376 -0.1518 -0.0619 -0.3993 -0.4206 -1.0661 -0.2811 -0.5464 -0.1496 -0.1593
S-736	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-736	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-736	-0.4178730845451355	Dosage The dosage and duration of the substitution therapy depend on the seriousness of Factor VIII deficiency , on the site and extent of the haemorrhage and on the clinical condition of the patient .
D-736	-0.4178730845451355	Dosage The dosage and duration of the substitution therapy depend on the seriousness of Factor VIII deficiency , on the site and extent of the haemorrhage and on the clinical condition of the patient .
P-736	-0.5131 -0.0209 -0.0929 -1.2477 -0.4418 -0.0758 -0.0934 -0.1203 -0.3191 -0.1294 -0.1456 -0.7838 -0.4299 -0.0927 -0.1444 -1.5926 -0.2141 -0.1387 -1.0707 -0.0416 -0.1587 -1.0375 -0.8950 -0.5878 -0.6793 -0.0389 -0.0280 -0.1361 -0.1731 -1.4180 -0.1499 -1.4930 -0.1223 -0.0337 -0.1525 -0.5542 -2.1246 -0.2516 -0.0347 -0.1117 -0.2592 -0.8475 -0.1294 -0.8674 -0.2589 -0.1476 -0.1312 -0.0671 -0.1479 -0.1484
S-1461	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-1461	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-1461	-0.5365997552871704	During the course of treatment , appropriate Factor VIII plasma levels are advised in order to control the dose and frequency of injections .
D-1461	-0.5365997552871704	During the course of treatment , appropriate Factor VIII plasma levels are advised in order to control the dose and frequency of injections .
P-1461	-0.9958 -1.7578 -0.0937 -0.1824 -0.3134 -0.5927 -0.3829 -2.4110 -0.6287 -0.5787 -1.1840 -0.1618 -0.0631 -0.1078 -1.0808 -1.4217 -0.9755 -1.2530 -0.0966 -0.1653 -0.6268 -0.1322 -0.0596 -0.2659 -0.0944 -0.1021 -0.2083 -0.2082 -0.1441 -0.1952 -0.1510
S-1285	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-1285	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-1285	-0.5365997552871704	During the course of treatment , appropriate Factor VIII plasma levels are advised in order to control the dose and frequency of injections .
D-1285	-0.5365997552871704	During the course of treatment , appropriate Factor VIII plasma levels are advised in order to control the dose and frequency of injections .
P-1285	-0.9958 -1.7578 -0.0937 -0.1824 -0.3134 -0.5927 -0.3829 -2.4110 -0.6287 -0.5787 -1.1840 -0.1618 -0.0631 -0.1078 -1.0808 -1.4217 -0.9755 -1.2530 -0.0966 -0.1653 -0.6268 -0.1322 -0.0596 -0.2659 -0.0944 -0.1021 -0.2083 -0.2082 -0.1441 -0.1952 -0.1510
S-1109	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-1109	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-1109	-0.5365997552871704	During the course of treatment , appropriate Factor VIII plasma levels are advised in order to control the dose and frequency of injections .
D-1109	-0.5365997552871704	During the course of treatment , appropriate Factor VIII plasma levels are advised in order to control the dose and frequency of injections .
P-1109	-0.9958 -1.7578 -0.0937 -0.1824 -0.3134 -0.5927 -0.3829 -2.4110 -0.6287 -0.5787 -1.1840 -0.1618 -0.0631 -0.1078 -1.0808 -1.4217 -0.9755 -1.2530 -0.0966 -0.1653 -0.6268 -0.1322 -0.0596 -0.2659 -0.0944 -0.1021 -0.2083 -0.2082 -0.1441 -0.1952 -0.1510
S-933	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-933	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-933	-0.5365997552871704	During the course of treatment , appropriate Factor VIII plasma levels are advised in order to control the dose and frequency of injections .
D-933	-0.5365997552871704	During the course of treatment , appropriate Factor VIII plasma levels are advised in order to control the dose and frequency of injections .
P-933	-0.9958 -1.7578 -0.0937 -0.1824 -0.3134 -0.5927 -0.3829 -2.4110 -0.6287 -0.5787 -1.1840 -0.1618 -0.0631 -0.1078 -1.0808 -1.4217 -0.9755 -1.2530 -0.0966 -0.1653 -0.6268 -0.1322 -0.0596 -0.2659 -0.0944 -0.1021 -0.2083 -0.2082 -0.1441 -0.1952 -0.1510
S-561	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-561	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-561	-0.4178730845451355	Dosage The dosage and duration of the substitution therapy depend on the seriousness of Factor VIII deficiency , on the site and extent of the haemorrhage and on the clinical condition of the patient .
D-561	-0.4178730845451355	Dosage The dosage and duration of the substitution therapy depend on the seriousness of Factor VIII deficiency , on the site and extent of the haemorrhage and on the clinical condition of the patient .
P-561	-0.5131 -0.0209 -0.0929 -1.2477 -0.4418 -0.0758 -0.0934 -0.1203 -0.3191 -0.1294 -0.1456 -0.7838 -0.4299 -0.0927 -0.1444 -1.5926 -0.2141 -0.1387 -1.0707 -0.0416 -0.1587 -1.0375 -0.8950 -0.5878 -0.6793 -0.0389 -0.0280 -0.1361 -0.1731 -1.4180 -0.1499 -1.4930 -0.1223 -0.0337 -0.1525 -0.5542 -2.1246 -0.2516 -0.0347 -0.1117 -0.2592 -0.8475 -0.1294 -0.8674 -0.2589 -0.1476 -0.1312 -0.0671 -0.1479 -0.1484
S-757	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-757	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-757	-0.5365997552871704	During the course of treatment , appropriate Factor VIII plasma levels are advised in order to control the dose and frequency of injections .
D-757	-0.5365997552871704	During the course of treatment , appropriate Factor VIII plasma levels are advised in order to control the dose and frequency of injections .
P-757	-0.9958 -1.7578 -0.0937 -0.1824 -0.3134 -0.5927 -0.3829 -2.4110 -0.6287 -0.5787 -1.1840 -0.1618 -0.0631 -0.1078 -1.0808 -1.4217 -0.9755 -1.2530 -0.0966 -0.1653 -0.6268 -0.1322 -0.0596 -0.2659 -0.0944 -0.1021 -0.2083 -0.2082 -0.1441 -0.1952 -0.1510
S-912	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-912	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-912	-0.4178730845451355	Dosage The dosage and duration of the substitution therapy depend on the seriousness of Factor VIII deficiency , on the site and extent of the haemorrhage and on the clinical condition of the patient .
D-912	-0.4178730845451355	Dosage The dosage and duration of the substitution therapy depend on the seriousness of Factor VIII deficiency , on the site and extent of the haemorrhage and on the clinical condition of the patient .
P-912	-0.5131 -0.0209 -0.0929 -1.2477 -0.4418 -0.0758 -0.0934 -0.1203 -0.3191 -0.1294 -0.1456 -0.7838 -0.4299 -0.0927 -0.1444 -1.5926 -0.2141 -0.1387 -1.0707 -0.0416 -0.1587 -1.0375 -0.8950 -0.5878 -0.6793 -0.0389 -0.0280 -0.1361 -0.1731 -1.4180 -0.1499 -1.4930 -0.1223 -0.0337 -0.1525 -0.5542 -2.1246 -0.2516 -0.0347 -0.1117 -0.2592 -0.8475 -0.1294 -0.8674 -0.2589 -0.1476 -0.1312 -0.0671 -0.1479 -0.1484
S-1088	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-1088	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-1088	-0.4178730845451355	Dosage The dosage and duration of the substitution therapy depend on the seriousness of Factor VIII deficiency , on the site and extent of the haemorrhage and on the clinical condition of the patient .
D-1088	-0.4178730845451355	Dosage The dosage and duration of the substitution therapy depend on the seriousness of Factor VIII deficiency , on the site and extent of the haemorrhage and on the clinical condition of the patient .
P-1088	-0.5131 -0.0209 -0.0929 -1.2477 -0.4418 -0.0758 -0.0934 -0.1203 -0.3191 -0.1294 -0.1456 -0.7838 -0.4299 -0.0927 -0.1444 -1.5926 -0.2141 -0.1387 -1.0707 -0.0416 -0.1587 -1.0375 -0.8950 -0.5878 -0.6793 -0.0389 -0.0280 -0.1361 -0.1731 -1.4180 -0.1499 -1.4930 -0.1223 -0.0337 -0.1525 -0.5542 -2.1246 -0.2516 -0.0347 -0.1117 -0.2592 -0.8475 -0.1294 -0.8674 -0.2589 -0.1476 -0.1312 -0.0671 -0.1479 -0.1484
S-1264	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-1264	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-1264	-0.4178730845451355	Dosage The dosage and duration of the substitution therapy depend on the seriousness of Factor VIII deficiency , on the site and extent of the haemorrhage and on the clinical condition of the patient .
D-1264	-0.4178730845451355	Dosage The dosage and duration of the substitution therapy depend on the seriousness of Factor VIII deficiency , on the site and extent of the haemorrhage and on the clinical condition of the patient .
P-1264	-0.5131 -0.0209 -0.0929 -1.2477 -0.4418 -0.0758 -0.0934 -0.1203 -0.3191 -0.1294 -0.1456 -0.7838 -0.4299 -0.0927 -0.1444 -1.5926 -0.2141 -0.1387 -1.0707 -0.0416 -0.1587 -1.0375 -0.8950 -0.5878 -0.6793 -0.0389 -0.0280 -0.1361 -0.1731 -1.4180 -0.1499 -1.4930 -0.1223 -0.0337 -0.1525 -0.5542 -2.1246 -0.2516 -0.0347 -0.1117 -0.2592 -0.8475 -0.1294 -0.8674 -0.2589 -0.1476 -0.1312 -0.0671 -0.1479 -0.1484
S-1440	Dosierung Die Dosierung und Dauer der Substitutionstherapie richten sich nach dem Schweregrad des Faktor VIII-Mangels , nach dem Ort und dem Ausmaß der Blutung und dem klinischen Zustand des Patienten .
T-1440	Posology The posology and duration of the substitution therapy depend on the severity of the factor VIII deficiency , on the location and extent of the bleeding and on the patient s clinical condition .
H-1440	-0.4178730845451355	Dosage The dosage and duration of the substitution therapy depend on the seriousness of Factor VIII deficiency , on the site and extent of the haemorrhage and on the clinical condition of the patient .
D-1440	-0.4178730845451355	Dosage The dosage and duration of the substitution therapy depend on the seriousness of Factor VIII deficiency , on the site and extent of the haemorrhage and on the clinical condition of the patient .
P-1440	-0.5131 -0.0209 -0.0929 -1.2477 -0.4418 -0.0758 -0.0934 -0.1203 -0.3191 -0.1294 -0.1456 -0.7838 -0.4299 -0.0927 -0.1444 -1.5926 -0.2141 -0.1387 -1.0707 -0.0416 -0.1587 -1.0375 -0.8950 -0.5878 -0.6793 -0.0389 -0.0280 -0.1361 -0.1731 -1.4180 -0.1499 -1.4930 -0.1223 -0.0337 -0.1525 -0.5542 -2.1246 -0.2516 -0.0347 -0.1117 -0.2592 -0.8475 -0.1294 -0.8674 -0.2589 -0.1476 -0.1312 -0.0671 -0.1479 -0.1484
S-36	Die häufigsten Nebenwirkungen von Adenuric ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Kopfschmerzen , Durchfall , Übelkeit ( Nausea ) , Hautausschlag und abnormale Leberwerte .
T-36	The most common side effects with Adenuric ( seen in between 1 and 10 patients in 100 ) are headache , diarrhoea , nausea ( feeling sick ) , rash and abnormal liver test results .
H-36	-0.2652459144592285	The most frequent adverse reactions with Adenuric ( observed in 1 to 10 patients in 100 ) are headache , diarrhoea , nausea , rash and abnormal liver values .
D-36	-0.2652459144592285	The most frequent adverse reactions with Adenuric ( observed in 1 to 10 patients in 100 ) are headache , diarrhoea , nausea , rash and abnormal liver values .
P-36	-0.2108 -0.1638 -0.9741 -0.2240 -0.0566 -0.1249 -0.0349 -1.7135 -0.3150 -0.2099 -0.0787 -0.1128 -0.1564 -0.2060 -0.1419 -0.1534 -0.1329 -0.1480 -1.5419 -0.5986 -0.2417 -0.2174 -0.2367 -0.1710 -0.0363 -0.1211 -0.1427 -0.1172 -0.0265 -0.0693 -0.0261 -0.1470 -0.0162 -0.0462 -0.1454 -0.1630 -0.0602 -0.1660 -0.1148 -0.0845 -0.2099 -1.5149 -0.1467 -0.1519
S-1910	In Aerinaze werden zwei arzneilich wirksame Bestandteile kombiniert , weil ein Antihistaminikum allein bei Patienten mit Verstopfung der Nase häufig keine ausreichende Linderung der Symptome bewirkt .
T-1910	In Aerinaze werden zwei arzneilich wirksame Bestandteile kombiniert , weil ein Antihistaminikum allein bei Patienten mit Verstopfung der Nase häufig keine ausreichende Linderung der Symptome bewirkt . This means that patients only need to take the tablet twice a day .
H-1910	-0.38099926710128784	Aerinaze combines two active ingredients because one antihistamine alone often does not provide adequate relief from symptoms in patients with nasal constipation .
D-1910	-0.38099926710128784	Aerinaze combines two active ingredients because one antihistamine alone often does not provide adequate relief from symptoms in patients with nasal constipation .
P-1910	-1.1564 -0.1285 -0.1195 -0.1509 -0.1124 -0.1638 -0.0798 -0.1029 -0.1715 -0.2408 -0.1189 -0.2049 -1.1124 -0.0323 -0.1150 -0.0420 -0.7420 -1.5726 -0.4735 -0.2220 -0.8730 -0.8657 -1.1281 -0.9973 -0.1909 -0.1606 -0.5199 -0.2165 -0.8366 -0.0164 -0.2090 -0.3175 -0.2020 -0.0606 -0.1348 -0.1465 -0.1593
S-97	2 Die Patienten sollen sich nach Einnahme von ADROVANCE mindestens 30 Minuten nicht hinlegen . ADROVANCE soll nicht vor dem Schlafengehen oder vor dem ersten Aufstehen des Tages eingenommen werden .
T-97	2 Die Patienten sollen sich nach Einnahme von ADROVANCE mindestens 30 Minuten nicht hinlegen . ADROVANCE soll nicht vor dem Schlafengehen oder vor dem ersten Aufstehen des Tages eingenommen werden . 2 ADROVANCE should not be taken at bedtime or before arising for the day .
H-97	-0.2728535532951355	Patients should not lie down for at least 30 minutes after taking ADROVANCE . ADROVANCE should not be taken before bed or before getting up for the first time .
D-97	-0.2728535532951355	Patients should not lie down for at least 30 minutes after taking ADROVANCE . ADROVANCE should not be taken before bed or before getting up for the first time .
P-97	-1.0056 -0.0999 -0.1066 -0.1305 -0.1688 -0.0881 -0.1079 -0.0793 -0.1209 -0.1226 -0.1648 -0.1842 -0.1187 -0.0835 -0.0795 -0.1217 -0.1156 -0.1335 -0.1589 -0.0992 -0.0713 -0.1176 -0.1137 -0.1479 -0.1495 -0.1549 -0.1635 -0.1352 -0.4019 -0.8698 -0.1421 -1.4686 -2.2589 -0.1098 -0.4679 -0.1508 -0.0936 -0.1033 -0.3498 -0.1542
S-173	Osteonekrose des Kiefers wurde bei Patienten unter Bisphosphonaten berichtet ; die meisten Berichte stammen von Krebspatienten , jedoch wurde auch bei Osteoporosepatienten darüber berichtet .
T-173	Osteonekrose des Kiefers wurde bei Patienten unter Bisphosphonaten berichtet ; die meisten Berichte stammen von Krebspatienten , jedoch wurde auch bei Osteoporosepatienten darüber berichtet . The majority of the reports refer to cancer patients , but such cases have also been reported in patients treated for osteoporosis .
H-173	-0.2580130994319916	jaw osteonecrosis has been reported in bisphosphonate patients ; most reports have been from cancer patients , but osteoporosis patients have also been reported .
D-173	-0.2580130994319916	jaw osteonecrosis has been reported in bisphosphonate patients ; most reports have been from cancer patients , but osteoporosis patients have also been reported .
P-173	-0.5712 -0.2851 -0.1232 -0.0609 -0.1237 -0.0804 -0.0387 -0.0943 -0.2063 -0.1394 -0.1080 -0.2653 -0.2112 -0.0266 -0.0734 -0.2278 -1.3800 -0.1691 -0.2968 -0.0822 -0.5267 -0.2421 -0.6556 -1.0246 -0.0469 -0.1686 -0.7116 -0.2276 -0.3282 -0.0489 -0.0944 -0.1397 -0.1388 -0.0693 -0.1167 -0.2354 -0.0809 -0.2532 -0.5845 -0.1664 -0.1545
S-361	Osteonekrose des Kiefers wurde bei Patienten unter Bisphosphonaten berichtet ; die meisten Berichte stammen von Krebspatienten , jedoch wurde auch bei Osteoporosepatienten darüber berichtet .
T-361	Osteonekrose des Kiefers wurde bei Patienten unter Bisphosphonaten berichtet ; die meisten Berichte stammen von Krebspatienten , jedoch wurde auch bei Osteoporosepatienten darüber berichtet . The majority of the reports refer to cancer patients , but such cases have also been reported in patients treated for osteoporosis .
H-361	-0.2580130994319916	jaw osteonecrosis has been reported in bisphosphonate patients ; most reports have been from cancer patients , but osteoporosis patients have also been reported .
D-361	-0.2580130994319916	jaw osteonecrosis has been reported in bisphosphonate patients ; most reports have been from cancer patients , but osteoporosis patients have also been reported .
P-361	-0.5712 -0.2851 -0.1232 -0.0609 -0.1237 -0.0804 -0.0387 -0.0943 -0.2063 -0.1394 -0.1080 -0.2653 -0.2112 -0.0266 -0.0734 -0.2278 -1.3800 -0.1691 -0.2968 -0.0822 -0.5267 -0.2421 -0.6556 -1.0246 -0.0469 -0.1686 -0.7116 -0.2276 -0.3282 -0.0489 -0.0944 -0.1397 -0.1388 -0.0693 -0.1167 -0.2354 -0.0809 -0.2532 -0.5845 -0.1664 -0.1545
S-583	Während des Behandlungsverlaufes wird zur Steuerung der zu verabreichenden Dosis und der Häufigkeit der Injektionen eine angemessene Bestimmung der Faktor VIII-Plasmaspiegel angeraten .
T-583	During the course of treatment , appropriate determination of plasma factor VIII levels is advised to guide the dose to be administered and the frequency of repeated injections .
H-583	-0.5365997552871704	During the course of treatment , appropriate Factor VIII plasma levels are advised in order to control the dose and frequency of injections .
D-583	-0.5365997552871704	During the course of treatment , appropriate Factor VIII plasma levels are advised in order to control the dose and frequency of injections .
P-583	-0.9958 -1.7578 -0.0937 -0.1824 -0.3134 -0.5927 -0.3829 -2.4110 -0.6287 -0.5787 -1.1840 -0.1618 -0.0631 -0.1078 -1.0808 -1.4217 -0.9755 -1.2530 -0.0966 -0.1653 -0.6268 -0.1322 -0.0596 -0.2659 -0.0944 -0.1021 -0.2083 -0.2082 -0.1441 -0.1952 -0.1510
S-302	Während in groß angelegten klinischen Studien mit Alendronat kein erhöhtes Risiko festgestellt wurde , wurden selten ( nach Markteinführung ) Magen- und Duodenalulzera , darunter manche schwerwiegend und mit Komplikationen , berichtet ( siehe Abschnitt 4.8 ) .
T-302	13 While no increased risk was observed in extensive clinical trials with alendronate , there have been rare ( post-marketing ) reports of gastric and duodenal ulcers , some of which were severe and with complications ( see section 4.8 ) .
H-302	-0.3341876268386841	While no increased risk was detected in large scale clinical trials of alendronate , uncommon ( post-marketing ) stomach and duodenal ulcers , some severe and with complications , have been reported ( see section 4.8 ) .
D-302	-0.3341876268386841	While no increased risk was detected in large scale clinical trials of alendronate , uncommon ( post-marketing ) stomach and duodenal ulcers , some severe and with complications , have been reported ( see section 4.8 ) .
P-302	-0.7781 -0.8552 -0.0833 -0.0935 -0.7472 -0.6494 -0.1104 -0.1451 -0.1769 -2.4769 -0.0673 -0.1056 -0.2352 -0.1521 -0.1737 -0.1225 -0.0675 -0.1449 -3.0834 -0.0219 -0.4579 -0.1304 -0.1604 -0.1309 -0.2629 -0.1183 -0.3066 -0.1785 -0.3132 -0.0111 -0.0677 -0.1063 -0.1629 -0.1584 -0.1674 -1.4682 -0.3780 -0.1857 -0.2497 -0.0694 -0.1347 -0.5314 -0.1777 -0.1706 -0.0827 -0.1324 -0.3460 -0.0805 -0.1144 -0.1256 -0.1310 -0.1622 -0.1486
S-1567	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-1567	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-1567	-0.24187001585960388	Each unit consists of a vial with powder , a vial with 5 ml solvent ( both glass type I with chlorobutyl rubber stopper ) and a reconstitution device ( BAXJECT II ) .
D-1567	-0.24187001585960388	Each unit consists of a vial with powder , a vial with 5 ml solvent ( both glass type I with chlorobutyl rubber stopper ) and a reconstitution device ( BAXJECT II ) .
P-1567	-0.0433 -1.3267 -0.5994 -0.1033 -0.1658 -0.1460 -0.0823 -0.1052 -0.3904 -0.1312 -0.1459 -0.1412 -0.0665 -0.0989 -0.2618 -0.1538 -0.0849 -0.3502 -0.5740 -0.1460 -0.0402 -0.3707 -0.2303 -0.2529 -0.1993 -0.5855 -0.1039 -0.1147 -0.0903 -0.1914 -0.0592 -0.0895 -0.1233 -0.1286 -0.1888 -0.1492 -0.3847 -0.0923 -1.8305 -0.1316 -0.1967 -0.1796 -0.2731 -0.0810 -0.1162 -0.1075 -0.1315 -0.1410 -0.1514
S-862	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-862	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-862	-0.24187001585960388	Each unit consists of a vial with powder , a vial with 5 ml solvent ( both glass type I with chlorobutyl rubber stopper ) and a reconstitution device ( BAXJECT II ) .
D-862	-0.24187001585960388	Each unit consists of a vial with powder , a vial with 5 ml solvent ( both glass type I with chlorobutyl rubber stopper ) and a reconstitution device ( BAXJECT II ) .
P-862	-0.0433 -1.3267 -0.5994 -0.1033 -0.1658 -0.1460 -0.0823 -0.1052 -0.3904 -0.1312 -0.1459 -0.1412 -0.0665 -0.0989 -0.2618 -0.1538 -0.0849 -0.3502 -0.5740 -0.1460 -0.0402 -0.3707 -0.2303 -0.2529 -0.1993 -0.5855 -0.1039 -0.1147 -0.0903 -0.1914 -0.0592 -0.0895 -0.1233 -0.1286 -0.1888 -0.1492 -0.3847 -0.0923 -1.8305 -0.1316 -0.1967 -0.1796 -0.2731 -0.0810 -0.1162 -0.1075 -0.1315 -0.1410 -0.1514
S-1038	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-1038	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-1038	-0.24187001585960388	Each unit consists of a vial with powder , a vial with 5 ml solvent ( both glass type I with chlorobutyl rubber stopper ) and a reconstitution device ( BAXJECT II ) .
D-1038	-0.24187001585960388	Each unit consists of a vial with powder , a vial with 5 ml solvent ( both glass type I with chlorobutyl rubber stopper ) and a reconstitution device ( BAXJECT II ) .
P-1038	-0.0433 -1.3267 -0.5994 -0.1033 -0.1658 -0.1460 -0.0823 -0.1052 -0.3904 -0.1312 -0.1459 -0.1412 -0.0665 -0.0989 -0.2618 -0.1538 -0.0849 -0.3502 -0.5740 -0.1460 -0.0402 -0.3707 -0.2303 -0.2529 -0.1993 -0.5855 -0.1039 -0.1147 -0.0903 -0.1914 -0.0592 -0.0895 -0.1233 -0.1286 -0.1888 -0.1492 -0.3847 -0.0923 -1.8305 -0.1316 -0.1967 -0.1796 -0.2731 -0.0810 -0.1162 -0.1075 -0.1315 -0.1410 -0.1514
S-1214	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-1214	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-1214	-0.24187001585960388	Each unit consists of a vial with powder , a vial with 5 ml solvent ( both glass type I with chlorobutyl rubber stopper ) and a reconstitution device ( BAXJECT II ) .
D-1214	-0.24187001585960388	Each unit consists of a vial with powder , a vial with 5 ml solvent ( both glass type I with chlorobutyl rubber stopper ) and a reconstitution device ( BAXJECT II ) .
P-1214	-0.0433 -1.3267 -0.5994 -0.1033 -0.1658 -0.1460 -0.0823 -0.1052 -0.3904 -0.1312 -0.1459 -0.1412 -0.0665 -0.0989 -0.2618 -0.1538 -0.0849 -0.3502 -0.5740 -0.1460 -0.0402 -0.3707 -0.2303 -0.2529 -0.1993 -0.5855 -0.1039 -0.1147 -0.0903 -0.1914 -0.0592 -0.0895 -0.1233 -0.1286 -0.1888 -0.1492 -0.3847 -0.0923 -1.8305 -0.1316 -0.1967 -0.1796 -0.2731 -0.0810 -0.1162 -0.1075 -0.1315 -0.1410 -0.1514
S-686	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-686	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-686	-0.24187001585960388	Each unit consists of a vial with powder , a vial with 5 ml solvent ( both glass type I with chlorobutyl rubber stopper ) and a reconstitution device ( BAXJECT II ) .
D-686	-0.24187001585960388	Each unit consists of a vial with powder , a vial with 5 ml solvent ( both glass type I with chlorobutyl rubber stopper ) and a reconstitution device ( BAXJECT II ) .
P-686	-0.0433 -1.3267 -0.5994 -0.1033 -0.1658 -0.1460 -0.0823 -0.1052 -0.3904 -0.1312 -0.1459 -0.1412 -0.0665 -0.0989 -0.2618 -0.1538 -0.0849 -0.3502 -0.5740 -0.1460 -0.0402 -0.3707 -0.2303 -0.2529 -0.1993 -0.5855 -0.1039 -0.1147 -0.0903 -0.1914 -0.0592 -0.0895 -0.1233 -0.1286 -0.1888 -0.1492 -0.3847 -0.0923 -1.8305 -0.1316 -0.1967 -0.1796 -0.2731 -0.0810 -0.1162 -0.1075 -0.1315 -0.1410 -0.1514
S-1390	Jede Einzelpackung besteht aus einer Durchstechflasche mit Pulver , einer Durchstechflasche mit 5 ml Lösungsmittel ( beide Glas Typ I mit Chlorobutyl-Gummistopfen ) und einem Gerät zur Rekonstitution ( BAXJECT II ) .
T-1390	Each pack contains a powder vial , a vial containing 5 ml solvent ( both type I glass closed with chlorobutyl rubber stoppers ) and a device for reconstitution ( BAXJECT II ) .
H-1390	-0.24187001585960388	Each unit consists of a vial with powder , a vial with 5 ml solvent ( both glass type I with chlorobutyl rubber stopper ) and a reconstitution device ( BAXJECT II ) .
D-1390	-0.24187001585960388	Each unit consists of a vial with powder , a vial with 5 ml solvent ( both glass type I with chlorobutyl rubber stopper ) and a reconstitution device ( BAXJECT II ) .
P-1390	-0.0433 -1.3267 -0.5994 -0.1033 -0.1658 -0.1460 -0.0823 -0.1052 -0.3904 -0.1312 -0.1459 -0.1412 -0.0665 -0.0989 -0.2618 -0.1538 -0.0849 -0.3502 -0.5740 -0.1460 -0.0402 -0.3707 -0.2303 -0.2529 -0.1993 -0.5855 -0.1039 -0.1147 -0.0903 -0.1914 -0.0592 -0.0895 -0.1233 -0.1286 -0.1888 -0.1492 -0.3847 -0.0923 -1.8305 -0.1316 -0.1967 -0.1796 -0.2731 -0.0810 -0.1162 -0.1075 -0.1315 -0.1410 -0.1514
S-232	9 Verteilung Studien an Ratten haben ergeben , dass Alendronat sich nach intravenöser Gabe von 1 mg<unk> kg vorübergehend in Weichteilgeweben verteilt , sich aber dann rasch in den Knochen umverteilt oder mit dem Urin ausgeschieden wird .
T-232	Distribution Studies in rats show that alendronate transiently distributes to soft tissues following 1 mg/ kg intravenous administration but is then rapidly redistributed to bone or excreted in the urine .
H-232	-0.3148519694805145	Distribution Studies in rats have shown that alendronate temporarily distributes to soft tissue after intravenous administration of 1 mg/ kg , but is then rapidly redistributed to bone or excreted in the urine .
D-232	-0.3148519694805145	Distribution Studies in rats have shown that alendronate temporarily distributes to soft tissue after intravenous administration of 1 mg/ kg , but is then rapidly redistributed to bone or excreted in the urine .
P-232	-0.0033 -0.0934 -0.3602 -0.1284 -0.0786 -0.1898 -0.8130 -0.1188 -0.1480 -0.1618 -0.0780 -0.0560 -0.9501 -2.0009 -0.1135 -1.4194 -0.3071 -0.2371 -0.4142 -1.0698 -0.0930 -0.0928 -0.1248 -0.0927 -0.1578 -0.1468 -0.2181 -0.1259 -0.1358 -0.0600 -0.6545 -0.2406 -0.9507 -0.5823 -0.5326 -0.2969 -0.0807 -0.1115 -0.3919 -0.3142 -0.1241 -0.1093 -0.0424 -0.0793 -0.6336 -0.1554 -0.0688 -0.0880 -0.1438 -0.1530
S-1975	Im Rahmen von klinischen Prüfungen mit Desloratadin , bei denen Erythromycin oder Ketoconazol zusätzlich verabreicht wurden , wurden jedoch keine klinisch relevanten Wechselwirkungen oder Veränderungen der Plasmakonzentration von Desloratadin beobachtet .
T-1975	However , no clinically relevant interactions or changes in desloratadine plasma concentrations were observed in clinical trials with desloratadine in which erythromycin or ketoconazole were co-administered .
H-1975	-0.36288270354270935	However , no clinically relevant interactions or changes in plasma concentration of desloratadine were observed in clinical trials with desloratadine for which erythromycin or ketoconazole were added .
D-1975	-0.36288270354270935	However , no clinically relevant interactions or changes in plasma concentration of desloratadine were observed in clinical trials with desloratadine for which erythromycin or ketoconazole were added .
P-1975	-0.1037 -0.1504 -1.3265 -0.0260 -0.0732 -0.3981 -0.1906 -0.0633 -0.1383 -0.2070 -0.1508 -0.1567 -0.0705 -0.1142 -0.2921 -0.2113 -0.7534 -0.0633 -0.1064 -0.5522 -0.9580 -0.3970 -0.4852 -0.6728 -0.1739 -0.0259 -1.6119 -1.1007 -0.0870 -0.1190 -0.4788 -0.5459 -2.7686 -0.9386 -0.3618 -0.1217 -0.0656 -0.1930 -0.1286 -0.1332 -0.1221 -0.0208 -0.1198 -0.1044 -0.0893 -0.0310 -0.3389 -0.4972 -0.1520 -0.1534
S-114	Während in groß angelegten klinischen Studien mit Alendronat kein erhöhtes Risiko festgestellt wurde , wurden selten ( nach Markteinführung ) Magen- und Duodenalulzera , darunter manche schwerwiegend und mit Komplikationen , berichtet ( siehe Abschnitt 4.8 ) .
T-114	3 While no increased risk was observed in extensive clinical trials with alendronate , there have been rare ( post-marketing ) reports of gastric and duodenal ulcers , some of which were severe and with complications ( see section 4.8 ) .
H-114	-0.3341876268386841	While no increased risk was detected in large scale clinical trials of alendronate , uncommon ( post-marketing ) stomach and duodenal ulcers , some severe and with complications , have been reported ( see section 4.8 ) .
D-114	-0.3341876268386841	While no increased risk was detected in large scale clinical trials of alendronate , uncommon ( post-marketing ) stomach and duodenal ulcers , some severe and with complications , have been reported ( see section 4.8 ) .
P-114	-0.7781 -0.8552 -0.0833 -0.0935 -0.7472 -0.6494 -0.1104 -0.1451 -0.1769 -2.4769 -0.0673 -0.1056 -0.2352 -0.1521 -0.1737 -0.1225 -0.0675 -0.1449 -3.0834 -0.0219 -0.4579 -0.1304 -0.1604 -0.1309 -0.2629 -0.1183 -0.3066 -0.1785 -0.3132 -0.0111 -0.0677 -0.1063 -0.1629 -0.1584 -0.1674 -1.4682 -0.3780 -0.1857 -0.2497 -0.0694 -0.1347 -0.5314 -0.1777 -0.1706 -0.0827 -0.1324 -0.3460 -0.0805 -0.1144 -0.1256 -0.1310 -0.1622 -0.1486
S-1897	Es ist als blau-weiße Tabletten mit veränderter Wirkstofffreisetzung erhältlich . Veränderte Wirkstofffreisetzung bedeutet , dass die Tabletten so zusammengesetzt sind , dass einer der wirksamen Bestandteile sofort und der andere langsam über einige Stunden hinweg freigesetzt wird .
T-1897	It is available as blue and white modified-release tablets . Modified-release means that the tablets have been made to allow one of the active substances to be released immediately and the other one released over a few hours .
H-1897	-0.362927109003067	It is available as blue and white altered drug release tablets . Altered drug release means that the tablets are designed to release one of the active ingredients immediately and the other slowly over a few hours .
D-1897	-0.362927109003067	It is available as blue and white altered drug release tablets . Altered drug release means that the tablets are designed to release one of the active ingredients immediately and the other slowly over a few hours .
P-1897	-0.3316 -0.1157 -0.3433 -0.2843 -0.4026 -0.2277 -0.0826 -1.0489 -0.0893 -1.0579 -0.6592 -0.2842 -0.1699 -0.1771 -1.0986 -0.0742 -0.3530 -0.1572 -0.1769 -0.3095 -0.4236 -0.0941 -0.1255 -0.1618 -2.4033 -0.3324 -0.5578 -0.1663 -0.3609 -0.1789 -0.3771 -0.0955 -0.2029 -0.1460 -0.3659 -0.1397 -0.1411 -0.6663 -0.1517 -0.6382 -0.1187 -0.1535 -0.1610
S-428	Verteilung Studien an Ratten haben ergeben , dass Alendronat sich nach intravenöser Gabe von 1 mg<unk> kg vorübergehend in Weichteilgeweben verteilt , sich aber dann rasch in den Knochen umverteilt oder mit dem Urin ausgeschieden wird .
T-428	Distribution Studies in rats show that alendronate transiently distributes to soft tissues following 1 mg/ kg intravenous administration but is then rapidly redistributed to bone or excreted in the urine .
H-428	-0.3244401812553406	Distribution Studies in rats have shown that alendronate temporarily distributes to soft tissue after intravenous administration of 1 mg/ kg , but is then rapidly redistributed to bone or excreted in the urine .
D-428	-0.3244401812553406	Distribution Studies in rats have shown that alendronate temporarily distributes to soft tissue after intravenous administration of 1 mg/ kg , but is then rapidly redistributed to bone or excreted in the urine .
P-428	-0.0060 -0.1040 -0.8268 -0.1259 -0.0711 -0.1899 -0.8137 -0.1188 -0.1694 -0.1697 -0.0747 -0.0552 -0.9151 -2.0215 -0.1159 -1.4105 -0.2975 -0.2430 -0.4229 -0.9813 -0.0935 -0.0949 -0.1245 -0.0972 -0.1573 -0.1463 -0.2158 -0.1237 -0.1358 -0.0620 -0.6171 -0.2255 -1.0781 -0.5655 -0.5497 -0.2865 -0.0670 -0.1090 -0.4188 -0.3423 -0.1249 -0.1043 -0.0411 -0.0789 -0.6150 -0.1577 -0.0684 -0.0905 -0.1448 -0.1526
S-12	Adenuric senkt den Harnsäurespiegel im Blut üblicherweise innerhalb von zwei Wochen . Wenn der Harnsäurespiegel nach zwei bis vier Wochen immer noch über 6 mg pro Deziliter liegt , kann die Dosis auf einmal täglich 120 mg erhöht werden .
T-12	Adenuric usually reduces blood uric acid levels within two weeks , but the dose can be increased to 120 mg once a day if blood uric acid levels remain above 6 mg per decilitre after two to four weeks .
H-12	-0.2949939966201782	Adenuric usually lowers uric acid levels in the blood within two weeks . If uric acid levels remain above 6 mg per deciliter after two to four weeks , the dose may be increased to 120 mg once a day .
D-12	-0.2949939966201782	Adenuric usually lowers uric acid levels in the blood within two weeks . If uric acid levels remain above 6 mg per deciliter after two to four weeks , the dose may be increased to 120 mg once a day .
P-12	-0.1384 -0.1648 -0.0586 -0.1197 -0.6507 -1.1673 -0.2342 -0.8018 -0.0811 -0.2110 -0.3725 -0.1331 -0.1652 -0.0447 -0.2306 -0.2382 -0.1053 -0.1543 -0.1587 -1.7040 -0.0713 -0.1772 -0.3294 -0.7273 -0.4972 -0.1507 -0.0403 -0.1048 -0.1696 -0.1336 -0.3493 -0.5896 -0.2120 -0.1317 -0.0670 -0.0775 -0.2005 -0.2372 -0.0662 -0.7614 -0.5215 -0.0435 -0.1665 -0.0612 -0.0559 -0.2590 -1.2493 -0.0756 -0.1362 -0.1532
S-1950	Da Aerinaze Pseudoephedrin enthält , ist das Arzneimittel ebenfalls kontraindiziert bei Patienten , die mit einem Monoaminoxidase ( MAO<unk> -Hemmer behandelt werden bzw. innerhalb der 2 Wochen nach Beendigung einer solchen Therapie .
T-1950	As Aerinaze contains pseudoephedrine , it is also contraindicated in patients who are receiving monoamine oxidase ( MAO ) inhibitor therapy or during the 2 weeks following the stopping of such treatment .
H-1950	-0.3462539315223694	Since Aerinaze contains pseudoephedrine , it is also contraindicated for patients treated with a monoamine oxidase ( MAO/ inhibitor ) and within the 2 weeks after discontinuation of such therapy .
D-1950	-0.3462539315223694	Since Aerinaze contains pseudoephedrine , it is also contraindicated for patients treated with a monoamine oxidase ( MAO/ inhibitor ) and within the 2 weeks after discontinuation of such therapy .
P-1950	-1.8586 -0.1281 -0.1279 -0.1124 -0.1550 -0.1151 -0.0630 -0.1176 -0.2394 -0.1650 -0.0573 -0.1120 -0.1646 -0.1058 -0.2163 -0.4453 -0.1313 -0.0847 -0.3411 -0.0888 -0.1792 -0.4087 -0.9025 -0.1387 -1.5487 -0.0646 -0.1537 -0.0202 -0.0283 -0.1846 -0.0633 -0.1810 -0.0647 -0.0503 -0.7425 -0.3564 -0.0318 -0.0968 -0.2577 -0.3982 -0.5275 -0.4801 -0.8239 -0.9704 -0.1890 -1.1591 -2.5434 -0.0318 -0.1241 -0.4536 -0.1485 -0.2524 -0.1389 -0.1539
S-93	ADROVANCE ist nur mit Wasser ( nicht mit Mineralwasser ) mindestens 30 Minuten vor dem ersten Essen , Getränk oder Einnehmen von Arzneimitteln ( einschließlich Antazida , Calcium- und Vitaminergänzungsmitteln ) für den Tag einzunehmen .
T-93	ADROVANCE must be taken with water only ( not mineral water ) at least 30 minutes before the first food , beverage , or medicinal product ( including antacids , calcium supplements and vitamins ) of the day .
H-93	-0.2937338650226593	ADROVANCE should only be taken with water ( not mineral water ) at least 30 minutes before your first meal , drink or intake of medicinal products ( including antacids , calcium and vitamin supplements ) for the day .
D-93	-0.2937338650226593	ADROVANCE should only be taken with water ( not mineral water ) at least 30 minutes before your first meal , drink or intake of medicinal products ( including antacids , calcium and vitamin supplements ) for the day .
P-93	-0.0714 -0.0706 -0.1242 -0.1056 -0.1158 -2.0148 -1.1758 -0.1588 -0.3828 -0.1533 -0.2528 -0.1580 -0.1766 -0.1738 -0.0728 -0.0929 -0.1459 -0.2628 -0.1189 -0.1434 -0.1391 -0.7333 -0.7069 -0.1038 -0.6694 -0.1629 -0.2295 -0.1255 -2.2490 -0.8572 -0.1631 -0.5829 -0.1631 -0.1041 -0.1922 -0.0987 -0.0484 -0.0811 -0.2056 -0.1504 -0.0968 -0.0672 -0.1428 -0.1551 -0.0917 -0.3286 -0.0330 -0.1424 -0.1385 -0.3260 -0.1645 -0.1215 -0.1642 -0.1520
S-280	ADROVANCE ist nur mit Wasser ( nicht mit Mineralwasser ) mindestens 30 Minuten vor dem ersten Essen , Getränk oder Einnehmen von Arzneimitteln ( einschließlich Antazida , Calcium- und Vitaminergänzungsmitteln ) für den Tag einzunehmen .
T-280	ADROVANCE must be taken with water only ( not mineral water ) at least 30 minutes before the first food , beverage , or medicinal product ( including antacids , calcium supplements and vitamins ) of the day .
H-280	-0.2937338650226593	ADROVANCE should only be taken with water ( not mineral water ) at least 30 minutes before your first meal , drink or intake of medicinal products ( including antacids , calcium and vitamin supplements ) for the day .
D-280	-0.2937338650226593	ADROVANCE should only be taken with water ( not mineral water ) at least 30 minutes before your first meal , drink or intake of medicinal products ( including antacids , calcium and vitamin supplements ) for the day .
P-280	-0.0714 -0.0706 -0.1242 -0.1056 -0.1158 -2.0148 -1.1758 -0.1588 -0.3828 -0.1533 -0.2528 -0.1580 -0.1766 -0.1738 -0.0728 -0.0929 -0.1459 -0.2628 -0.1189 -0.1434 -0.1391 -0.7333 -0.7069 -0.1038 -0.6694 -0.1629 -0.2295 -0.1255 -2.2490 -0.8572 -0.1631 -0.5829 -0.1631 -0.1041 -0.1922 -0.0987 -0.0484 -0.0811 -0.2056 -0.1504 -0.0968 -0.0672 -0.1428 -0.1551 -0.0917 -0.3286 -0.0330 -0.1424 -0.1385 -0.3260 -0.1645 -0.1215 -0.1642 -0.1520
S-332	Alendronat Nahrungsmittel und Getränke ( einschließlich Mineralwasser ) , Calcium-Ergänzungsmittel , Antazida und einige orale Arzneimittel können die Resorption von Alendronat beeinträchtigen , wenn sie zur gleichen Zeit eingenommen werden .
T-332	Alendronate If taken at the same time , it is likely that food and beverages ( including mineral water ) , calcium supplements , antacids , and some oral medicinal products will interfere with absorption of alendronate .
H-332	-0.2718432545661926	Alendronate Food and drink ( including mineral water ) , calcium supplements , antacids and some oral medicinal products may affect the absorption of alendronate if taken at the same time .
D-332	-0.2718432545661926	Alendronate Food and drink ( including mineral water ) , calcium supplements , antacids and some oral medicinal products may affect the absorption of alendronate if taken at the same time .
P-332	-0.0903 -0.1800 -0.1437 -0.0743 -1.4407 -0.1364 -0.4644 -0.1641 -0.0582 -0.2712 -0.0896 -0.2476 -0.1349 -0.1470 -0.1121 -0.0667 -0.1290 -0.0533 -0.1202 -0.1489 -0.0648 -0.1279 -0.2183 -0.1487 -0.2862 -0.2214 -0.7239 -0.6917 -0.1317 -0.7970 -1.7072 -0.1394 -0.0703 -0.0701 -0.1507 -0.2442 -0.1667 -0.1189 -0.0592 -0.9156 -0.3247 -0.2872 -0.1423 -0.2063 -0.1664 -0.1668 -0.1565
S-397	Vitamin D3 ( der Menge von Vitamin D3 in der höheren Dosis von ADROVANCE ) einmal wöchentlich entspricht , wurde in einer 24-wöchigen Verlängerungsstudie mit 619 postmenopausalen Frauen mit Osteoporose gezeigt .
T-397	Patients in the Vitamin D3 2800 group received ADROVANCE ( 70 mg/ 2800 IU ) ( n<<unk>> 299 ) and patients in the Vitamin D3 5600 group received ADROVANCE ( 70 mg/ 2800 IU ) plus an additional 2800 IU vitamin D3 ( n<<unk>> 309 ) once a week ; additional vitamin D supplements were allowed .
H-397	-0.24513031542301178	vitamin D3 ( the amount of vitamin D3 in the higher dose of ADROVANCE ) given weekly has been demonstrated in a 24-week extension trial in 619 post-menopausal women with osteoporosis .
D-397	-0.24513031542301178	vitamin D3 ( the amount of vitamin D3 in the higher dose of ADROVANCE ) given weekly has been demonstrated in a 24-week extension trial in 619 post-menopausal women with osteoporosis .
P-397	-0.1610 -0.0786 -0.1239 -0.1347 -0.1456 -1.0949 -0.2013 -0.1662 -0.2322 -0.0954 -0.1358 -0.1326 -0.7437 -0.1757 -0.1791 -0.0733 -0.1443 -0.0626 -0.0940 -0.1178 -0.1083 -0.1236 -0.1450 -0.2394 -0.3299 -1.7259 -0.1457 -1.0029 -0.1404 -0.1308 -0.8979 -0.0416 -0.0893 -0.3505 -1.1089 -0.1688 -0.1334 -0.1067 -0.1360 -0.2820 -0.0575 -0.1104 -0.0407 -0.1324 -0.1074 -0.1356 -0.1470 -0.0710 -0.1133 -0.1289 -0.1049 -0.0868 -0.1472 -0.1542
S-144	Alendronat Nahrungsmittel und Getränke ( einschließlich Mineralwasser ) , Calcium-Ergänzungsmittel , Antazida und einige orale Arzneimittel können die Resorption von Alendronat beeinträchtigen , wenn sie zur gleichen Zeit eingenommen werden .
T-144	Alendronate If taken at the same time , it is likely that food and beverages ( including mineral water ) , calcium supplements , antacids , and some oral medicinal products will interfere with absorption of alendronate .
H-144	-0.2718432545661926	Alendronate Food and drink ( including mineral water ) , calcium supplements , antacids and some oral medicinal products may affect the absorption of alendronate if taken at the same time .
D-144	-0.2718432545661926	Alendronate Food and drink ( including mineral water ) , calcium supplements , antacids and some oral medicinal products may affect the absorption of alendronate if taken at the same time .
P-144	-0.0903 -0.1800 -0.1437 -0.0743 -1.4407 -0.1364 -0.4644 -0.1641 -0.0582 -0.2712 -0.0896 -0.2476 -0.1349 -0.1470 -0.1121 -0.0667 -0.1290 -0.0533 -0.1202 -0.1489 -0.0648 -0.1279 -0.2183 -0.1487 -0.2862 -0.2214 -0.7239 -0.6917 -0.1317 -0.7970 -1.7072 -0.1394 -0.0703 -0.0701 -0.1507 -0.2442 -0.1667 -0.1189 -0.0592 -0.9156 -0.3247 -0.2872 -0.1423 -0.2063 -0.1664 -0.1668 -0.1565
S-111	3 Das Risiko schwerer ösophagealer Nebenwirkungen scheint bei Patienten erhöht zu sein , die das Arzneimittel nicht korrekt einnehmen und<unk> oder es nach dem Auftreten von Symptomen , die auf eine ösophageale Irritation hinweisen , weiter einnehmen .
T-111	The risk of severe oesophageal adverse reactions appears to be greater in patients who fail to take alendronate properly and/ or who continue to take alendronate after developing symptoms suggestive of oesophageal irritation .
H-111	-0.36184749007225037	The risk of severe oesophageal adverse reactions appears to be increased in patients who do not take the medicine<unk> or continue to take it after the onset of symptoms indicating oesophageal irritation .
D-111	-0.36184749007225037	The risk of severe oesophageal adverse reactions appears to be increased in patients who do not take the medicine<unk> or continue to take it after the onset of symptoms indicating oesophageal irritation .
P-111	-0.7190 -0.1071 -0.2335 -0.4309 -0.3997 -0.0679 -0.1823 -0.0606 -0.0998 -0.1645 -1.1410 -0.0658 -0.5547 -0.0570 -0.5536 -0.1844 -0.1913 -0.2561 -0.6141 -0.2038 -0.2531 -0.9204 -0.1801 -0.0977 -0.3634 -0.0821 -0.9615 -1.5104 -0.6320 -0.1983 -0.5839 -0.0946 -0.4401 -0.2078 -0.4761 -1.1980 -0.0302 -0.1448 -0.1528 -1.8696 -0.1149 -0.6444 -0.0867 -0.1480 -0.0544 -0.1004 -0.1431 -0.0414 -0.1374 -0.1478 -0.1516
S-58	Die Patientin muss die Tablette mit einem vollen Glas Wasser ( kein Mineralwasser ) mindestens 30 Minuten vor dem Essen , Trinken oder Einnehmen anderer Arzneimittel ( einschließlich Antazida , Calcium- und Vitaminergänzungsmittel ) einnehmen .
T-58	The patient must take the tablet with a full glass of water ( not mineral water ) , at least 30 minutes before any food , drink , or other medicines ( including antacids , calcium supplements and vitamins ) .
H-58	-0.17994634807109833	The patient must take the tablet with a full glass of water ( not mineral water ) at least 30 minutes before eating , drinking or taking other medicinal products ( including antacids , calcium and vitamin supplements ) .
D-58	-0.17994634807109833	The patient must take the tablet with a full glass of water ( not mineral water ) at least 30 minutes before eating , drinking or taking other medicinal products ( including antacids , calcium and vitamin supplements ) .
P-58	-0.6591 -0.3427 -0.6905 -0.0417 -0.1705 -0.0999 -0.1172 -0.1687 -0.1552 -0.0785 -0.0552 -0.1540 -0.1404 -0.1452 -0.6531 -0.1100 -0.0828 -0.0926 -0.1388 -0.1274 -0.1150 -0.1401 -0.1788 -0.2796 -0.3374 -0.1596 -0.4351 -0.1404 -0.1314 -0.1802 -0.1871 -0.0638 -0.0909 -0.2294 -0.1234 -0.0462 -0.0951 -0.2793 -0.1510 -0.0957 -0.0683 -0.1336 -0.1518 -0.0804 -0.2441 -0.0422 -0.1296 -0.1432 -0.1735 -0.1476
S-1852	Am 17 . Dezember 2008 teilte Gendux Molecular Limited dem Ausschuss für Humanarzneimittel ( CHMP ) offiziell mit , dass das Unternehmen seinen Antrag auf Genehmigung für das Inverkehrbringen von Advexin zur Behandlung von Li-Fraumeni-Krebs zurücknimmt .
T-1852	On 17 December 2008 , Gendux Molecular Limited officially notified the Committee for Medicinal Products for Human Use ( CHMP ) that it wishes to withdraw its application for a marketing authorisation for Advexin for the treatment of Li-Fraumeni cancer .
H-1852	-0.3129546046257019	On 17 December 2008 , Gendux Molecular Limited formally notified the Committee for Medicinal products for Human Use ( CHMP ) that it was withdrawing its application for marketing authorisation for Advexin to treat Li-Fraumeni cancer .
D-1852	-0.3129546046257019	On 17 December 2008 , Gendux Molecular Limited formally notified the Committee for Medicinal products for Human Use ( CHMP ) that it was withdrawing its application for marketing authorisation for Advexin to treat Li-Fraumeni cancer .
P-1852	-0.4328 -0.6135 -0.1931 -0.2330 -0.3104 -0.1599 -0.1009 -0.1238 -0.1950 -0.0754 -0.0968 -0.0705 -1.1896 -1.6347 -0.0866 -0.1667 -0.1157 -0.1759 -0.0819 -0.0740 -0.7062 -0.1456 -0.7760 -0.1846 -0.1273 -0.0962 -0.0579 -0.1301 -0.1461 -0.7163 -1.1787 -0.1020 -0.2356 -0.0607 -0.4608 -0.1846 -0.5604 -0.1110 -0.0463 -0.2054 -0.4270 -0.1730 -0.1314 -1.0279 -0.2043 -0.6214 -0.3373 -0.4320 -0.0477 -0.3022 -0.2252 -0.1456 -0.1495
S-448	Ausscheidung Bei Gabe von radioaktiv markiertem Vitamin D3 an gesunde Probanden betrug die mittlere Ausscheidung der Radioaktivität im Urin nach 48 Stunden 2,4 % , in den Fäzes nach 4 Tagen 4,9 <unk> .
T-448	Elimination When radioactive vitamin D3 was administered to healthy subjects , the mean urinary excretion of radioactivity after 48 hours was 2.4 % , and the mean faecal excretion of radioactivity after 4 days was 4.9 % .
H-448	-0.3479540944099426	Excretion When radiolabelled vitamin D3 was administered to healthy subjects , the mean excretion of radioactivity in the urine at 48 hours was 2.4 % , in the faeces at four days 4.9 <unk> .
D-448	-0.3479540944099426	Excretion When radiolabelled vitamin D3 was administered to healthy subjects , the mean excretion of radioactivity in the urine at 48 hours was 2.4 % , in the faeces at four days 4.9 <unk> .
P-448	-0.8632 -0.0721 -0.1788 -2.5587 -1.7282 -0.0108 -0.0227 -0.0649 -0.1969 -0.0960 -0.1302 -0.1408 -0.1573 -0.7380 -0.0922 -0.1720 -0.0787 -0.0547 -0.1765 -0.2267 -0.0708 -1.3374 -0.0205 -0.1532 -0.2569 -1.0179 -0.0980 -0.1568 -0.2185 -0.0596 -0.0792 -1.8667 -0.1524 -0.1189 -0.2950 -0.1211 -0.1134 -0.0952 -0.1544 -0.2377 -0.5214 -0.1312 -0.0204 -0.1276 -0.6881 -1.4935 -0.1191 -0.1217 -0.1206 -0.0579 -0.1529 -0.1562
S-299	Das Risiko schwerer ösophagealer Nebenwirkungen scheint bei Patienten erhöht zu sein , die das Arzneimittel nicht korrekt einnehmen und<unk> oder es nach dem Auftreten von Symptomen , die auf eine ösophageale Irritation hinweisen , weiter einnehmen .
T-299	The risk of severe oesophageal adverse reactions appears to be greater in patients who fail to take alendronate properly and/ or who continue to take alendronate after developing symptoms suggestive of oesophageal irritation .
H-299	-0.3602895438671112	The risk of severe oesophageal adverse reactions appears to be increased in patients who do not take the medicine<unk> or continue to take it after the onset of symptoms indicating oesophageal irritation .
D-299	-0.3602895438671112	The risk of severe oesophageal adverse reactions appears to be increased in patients who do not take the medicine<unk> or continue to take it after the onset of symptoms indicating oesophageal irritation .
P-299	-0.4859 -0.1090 -0.2687 -0.4222 -0.4723 -0.0600 -0.1793 -0.0600 -0.0979 -0.1706 -1.1658 -0.0709 -0.5384 -0.0574 -0.5630 -0.1833 -0.1823 -0.2602 -0.7787 -0.2053 -0.2538 -0.8608 -0.1828 -0.0968 -0.3739 -0.1275 -0.6756 -1.4330 -0.9330 -0.1989 -0.5896 -0.1023 -0.3739 -0.2090 -0.5570 -1.2220 -0.0298 -0.1448 -0.1342 -1.8183 -0.1199 -0.6044 -0.0859 -0.1372 -0.0534 -0.1020 -0.1456 -0.0442 -0.1361 -0.1458 -0.1521
S-252	Ausscheidung Bei Gabe von radioaktiv markiertem Vitamin D3 an gesunde Probanden betrug die mittlere Ausscheidung der Radioaktivität im Urin nach 48 Stunden 2,4 % , in den Fäzes nach 4 Tagen 4,9 <unk> .
T-252	Elimination When radioactive vitamin D3 was administered to healthy subjects , the mean urinary excretion of radioactivity after 48 hours was 2.4 % , and the mean faecal excretion of radioactivity after 4 days was 4.9 % .
H-252	-0.3479540944099426	Excretion When radiolabelled vitamin D3 was administered to healthy subjects , the mean excretion of radioactivity in the urine at 48 hours was 2.4 % , in the faeces at four days 4.9 <unk> .
D-252	-0.3479540944099426	Excretion When radiolabelled vitamin D3 was administered to healthy subjects , the mean excretion of radioactivity in the urine at 48 hours was 2.4 % , in the faeces at four days 4.9 <unk> .
P-252	-0.8632 -0.0721 -0.1788 -2.5587 -1.7282 -0.0108 -0.0227 -0.0649 -0.1969 -0.0960 -0.1302 -0.1408 -0.1573 -0.7380 -0.0922 -0.1720 -0.0787 -0.0547 -0.1765 -0.2267 -0.0708 -1.3374 -0.0205 -0.1532 -0.2569 -1.0179 -0.0980 -0.1568 -0.2185 -0.0596 -0.0792 -1.8667 -0.1524 -0.1189 -0.2950 -0.1211 -0.1134 -0.0952 -0.1544 -0.2377 -0.5214 -0.1312 -0.0204 -0.1276 -0.6881 -1.4935 -0.1191 -0.1217 -0.1206 -0.0579 -0.1529 -0.1562
S-1989	Die Unbedenklichkeit der Anwendung von Aerinaze während der Schwangerschaft ist nicht gesichert , Erfahrungen aus einer großen Anzahl von betroffenen Schwangerschaften ergaben jedoch keine Erhöhung der Frequenz von Missbildungen im Vergleich zur Häufigkeit bei der Normalbevölkerung .
T-1989	The safe use of Aerinaze during pregnancy has not been established ; however experience from a large number of exposed pregnancies in humans does not reveal any increase in the frequency of malformations as compared to the incidence in the general population .
H-1989	-0.3713228702545166	The safety of use of Aerinaze during pregnancy has not been established , but experience in a large number of affected pregnancies has not revealed an increase in the frequency of malformations compared to the incidence in the normal population .
D-1989	-0.3713228702545166	The safety of use of Aerinaze during pregnancy has not been established , but experience in a large number of affected pregnancies has not revealed an increase in the frequency of malformations compared to the incidence in the normal population .
P-1989	-0.4150 -0.0391 -0.1473 -2.0003 -0.1522 -0.1663 -0.1207 -0.1138 -0.1823 -0.1411 -0.2024 -0.0989 -1.0602 -0.1470 -0.1386 -0.5493 -0.3555 -0.2279 -0.1126 -1.4431 -0.1523 -0.4149 -0.1183 -0.1610 -0.7166 -0.9268 -0.0788 -0.0714 -0.3032 -0.5349 -1.4692 -0.2735 -0.4953 -0.1301 -0.1810 -0.4199 -0.0699 -0.1568 -0.1678 -0.0463 -0.0947 -0.5722 -0.2812 -0.4908 -1.6921 -0.0936 -0.2516 -0.1547 -0.5941 -0.0857 -0.1430 -0.1536
S-373	Alendronat Natriumalendronat 3 H2O ist ein Bisphosphonat , das die durch Osteoklasten vermittelte Knochenresorption hemmt , ohne eine direkte Wirkung auf die Knochenbildung auszuüben .
T-373	Alendronate Alendronate sodium is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation .
H-373	-0.2354714423418045	Alendronate Sodium alendronate 3 H2O is a bisphosphonate that inhibits bone resorption mediated by osteoclasts without exerting a direct effect on bone formation .
D-373	-0.2354714423418045	Alendronate Sodium alendronate 3 H2O is a bisphosphonate that inhibits bone resorption mediated by osteoclasts without exerting a direct effect on bone formation .
P-373	-0.4888 -0.1644 -0.1292 -0.0521 -0.1153 -0.0485 -0.1441 -0.1469 -0.1024 -0.0890 -0.3147 -0.1173 -0.1012 -0.2106 -0.1364 -0.1241 -0.1194 -0.0256 -0.0398 -0.1234 -0.1331 -0.4041 -0.2897 -0.4011 -2.2284 -0.3083 -0.1735 -0.0574 -0.6092 -0.0988 -0.1412 -0.2228 -0.0499 -0.1355 -0.0367 -0.1080 -0.2240 -0.5925 -0.1277 -0.2191 -0.1185 -0.8705 -0.1872 -0.1577 -0.0847 -0.1323 -0.1618
S-185	Alendronat Natriumalendronat 3 H2O ist ein Bisphosphonat , das die durch Osteoklasten vermittelte Knochenresorption hemmt , ohne eine direkte Wirkung auf die Knochenbildung auszuüben .
T-185	Alendronate Alendronate sodium is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation .
H-185	-0.2354714423418045	Alendronate Sodium alendronate 3 H2O is a bisphosphonate that inhibits bone resorption mediated by osteoclasts without exerting a direct effect on bone formation .
D-185	-0.2354714423418045	Alendronate Sodium alendronate 3 H2O is a bisphosphonate that inhibits bone resorption mediated by osteoclasts without exerting a direct effect on bone formation .
P-185	-0.4888 -0.1644 -0.1292 -0.0521 -0.1153 -0.0485 -0.1441 -0.1469 -0.1024 -0.0890 -0.3147 -0.1173 -0.1012 -0.2106 -0.1364 -0.1241 -0.1194 -0.0256 -0.0398 -0.1234 -0.1331 -0.4041 -0.2897 -0.4011 -2.2284 -0.3083 -0.1735 -0.0574 -0.6092 -0.0988 -0.1412 -0.2228 -0.0499 -0.1355 -0.0367 -0.1080 -0.2240 -0.5925 -0.1277 -0.2191 -0.1185 -0.8705 -0.1872 -0.1577 -0.0847 -0.1323 -0.1618
S-1690	1 Durchstechflasche mit ADVATE 2000 I.E. Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Mediziprodukt
T-1690	1 vial with 2000 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-1690	-0.1948460191488266	1 vial of ADVATE 2000 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II product
D-1690	-0.1948460191488266	1 vial of ADVATE 2000 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II product
P-1690	-0.1273 -0.0675 -0.0922 -0.5046 -0.1124 -0.1515 -0.0852 -0.1038 -0.1065 -0.0934 -0.0981 -0.3077 -0.0798 -0.1541 -0.2109 -0.1188 -0.0803 -0.1394 -0.1320 -0.0737 -0.0745 -0.2047 -0.1768 -0.0908 -0.3668 -0.1259 -0.1088 -0.1477 -0.1149 -0.1324 -0.1749 -0.1417 -0.1341 -0.4572 -0.1664 -0.2931 -0.0886 -0.1059 -0.4265 -1.4627 -0.1551
S-1706	1 Durchstechflasche mit ADVATE 3000 I.E.Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt .
T-1706	1 vial with 3000 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-1706	-0.1653124988079071	1 vial of ADVATE 3000 IUOctocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product .
D-1706	-0.1653124988079071	1 vial of ADVATE 3000 IUOctocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product .
P-1706	-0.1286 -0.0571 -0.0994 -0.4542 -0.1058 -0.1483 -0.0863 -0.1031 -0.0724 -0.0953 -0.3281 -0.0835 -0.0843 -0.1937 -0.2310 -0.1096 -0.0798 -0.1402 -0.1293 -0.0761 -0.0854 -0.2095 -0.1734 -0.0909 -0.4353 -0.1256 -0.1060 -0.1425 -0.1134 -0.1372 -0.1785 -0.1400 -0.1342 -0.4709 -0.1716 -0.2900 -0.0886 -0.1061 -0.2186 -0.1781 -0.3928 -0.1593 -0.1541
S-257	10 35 mg<unk> kg bei Tieren gefunden . Obwohl keine klinischen Daten darüber vorliegen , ist dennoch damit zu rechnen , dass die renale Elimination von Alendronat wie in den Tierversuchen auch bei Patienten mit eingeschränkter Nierenfunktion reduziert sein wird .
T-257	Although no clinical information is available , it is likely that , as in animals , elimination of alendronate via the kidney will be reduced in patients with impaired renal function .
H-257	-0.33995455503463745	10 35 mg/ kg in animals . Although no clinical data are available , renal elimination of alendronate is expected to be reduced , as in animal studies , even in patients with impaired renal function .
D-257	-0.33995455503463745	10 35 mg/ kg in animals . Although no clinical data are available , renal elimination of alendronate is expected to be reduced , as in animal studies , even in patients with impaired renal function .
P-257	-0.2344 -0.0943 -0.1403 -0.1174 -0.1346 -0.0642 -0.9671 -0.1257 -0.4031 -0.2464 -1.3009 -0.0934 -0.1697 -0.3982 -0.1382 -0.6419 -0.9941 -0.1172 -0.0359 -0.0735 -0.1462 -0.1573 -0.1780 -0.1079 -0.0464 -1.1271 -0.6502 -0.1460 -0.2320 -0.3219 -0.9702 -0.6217 -0.4465 -0.1521 -0.4697 -0.1665 -0.9289 -0.2563 -1.0022 -0.1379 -0.3055 -0.1442 -0.1070 -0.1538 -0.1719 -0.1814 -0.1584
S-1640	1 Durchstechflasche mit ADVATE 500 I.E Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt .
T-1640	1 vial with 500 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-1640	-0.16297370195388794	1 vial of ADVATE 500 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product .
D-1640	-0.16297370195388794	1 vial of ADVATE 500 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product .
P-1640	-0.1254 -0.0588 -0.0982 -0.4342 -0.1106 -0.1460 -0.0831 -0.1028 -0.1002 -0.0861 -0.1885 -0.2101 -0.0796 -0.1524 -0.2152 -0.1118 -0.0777 -0.1399 -0.1310 -0.0774 -0.0833 -0.2334 -0.1796 -0.0904 -0.3936 -0.1251 -0.1081 -0.1410 -0.1129 -0.1351 -0.1755 -0.1406 -0.1325 -0.4711 -0.1715 -0.2915 -0.0889 -0.1051 -0.2099 -0.1846 -0.3915 -0.1597 -0.1537
S-212	Die mittleren BMD-Zunahmen betrugen 2,3 % bzw. 2,9 % am Femurhals und 2,9 % bzw. 3,1 % an der gesamten Hüfte in der Gruppe mit 70 mg einmal wöchentlich bzw. in der mit 10 mg täglich . Die zwei
T-212	The mean BMD increases were 2.3 % and 2.9 % at the femoral neck and 2.9 % and 3.1 % at the total hip in the 70 mg once weekly and 10 mg daily groups , respectively .
H-212	-0.30944085121154785	Mean BMD increases were 2.3 % and 2.9 % for the femoral neck and 2.9 % and 3.1 % for the entire hip , respectively , in the 70 mg weekly and 10 mg daily groups .
D-212	-0.30944085121154785	Mean BMD increases were 2.3 % and 2.9 % for the femoral neck and 2.9 % and 3.1 % for the entire hip , respectively , in the 70 mg weekly and 10 mg daily groups .
P-212	-0.3166 -0.1116 -1.1411 -0.1515 -0.1938 -0.1371 -0.1066 -0.1236 -0.0942 -0.1355 -0.1242 -0.1258 -0.1063 -1.2002 -0.1261 -0.0730 -0.7958 -0.0919 -0.4170 -0.1449 -0.1155 -0.1035 -0.1288 -0.0645 -0.1477 -0.1053 -0.1557 -1.3466 -1.3438 -0.1237 -0.2222 -0.1250 -0.1830 -0.1992 -0.1315 -0.2427 -0.0363 -0.3115 -0.1846 -0.1432 -0.0556 -0.2721 -2.1132 -0.2071 -0.1458
S-1782	Wenn plötzliche , schwere ( anaphylaktische ) Nebenwirkungen auftreten , muss die Injektion sofort abgebrochen werden.Sie müssen sofort Kontakt mit Ihrem Arzt aufnehmen , wenn Sieeins der folgenden Frühsymptome für allergische ( überempfindliche ) Reaktionen haben :
T-1782	Wenn plötzliche , schwere ( anaphylaktische ) Nebenwirkungen auftreten , muss die Injektion sofort abgebrochen werden.Sie müssen sofort Kontakt mit Ihrem Arzt aufnehmen , wenn Sieeins der folgenden Frühsymptome für allergische ( überempfindliche ) Reaktionen haben : You must contact your doctor immediately if you have any of the following early symptoms of allergic ( hypersensitivity ) reactions :
H-1782	-0.22000521421432495	If sudden , severe ( anaphylactic ) side effects occur , the injection must be discontinued immediately . You must contact your doctor immediately if you have any of the following early symptoms of allergic ( hypersensitive ) reactions :
D-1782	-0.22000521421432495	If sudden , severe ( anaphylactic ) side effects occur , the injection must be discontinued immediately . You must contact your doctor immediately if you have any of the following early symptoms of allergic ( hypersensitive ) reactions :
P-1782	-0.2314 -0.2934 -0.1869 -0.1320 -0.1489 -0.1111 -0.0921 -0.0682 -0.1074 -0.0812 -0.1708 -1.0084 -0.1159 -0.2045 -0.2394 -0.5753 -0.0676 -0.1375 -0.6817 -0.1597 -0.8436 -0.0844 -0.2925 -0.1597 -0.3689 -0.7903 -0.0620 -0.1387 -0.1029 -0.3259 -0.0975 -0.1516 -0.1289 -0.2808 -0.1576 -0.1417 -0.0920 -0.2783 -0.1680 -0.1951 -0.1731 -0.0576 -0.1569 -0.0612 -0.1225 -0.1378 -0.2882 -0.0624 -0.1175 -0.1492
S-445	21 Vitamin D3 wird in der Leber rasch zu 25-Hydroxyvitamin D3 hydroxyliert und dann in der Niere zu 1,25-Dihydroxyvitamin D3 , der biologisch aktiven Form , metabolisiert .
T-445	Biotransformation Vitamin D3 is rapidly metabolized by hydroxylation in the liver to 25-hydroxyvitamin D3 , and subsequently metabolized in the kidney to 1,25-dihydroxyvitamin D3 , which represents the biologically active form .
H-445	-0.2543990910053253	21 Vitamin D3 is rapidly hydroxylated by the liver to 25-hydroxyvitamin D3 and then metabolised by the kidney to 1,25 -dihydroxyvitamin D3 , the biologically active form .
D-445	-0.2543990910053253	21 Vitamin D3 is rapidly hydroxylated by the liver to 25-hydroxyvitamin D3 and then metabolised by the kidney to 1,25 -dihydroxyvitamin D3 , the biologically active form .
P-445	-1.2605 -0.4238 -0.0808 -0.1219 -0.1381 -0.1752 -0.1223 -0.0678 -0.1477 -0.1749 -0.0214 -0.9789 -0.1224 -0.0597 -0.4255 -0.8051 -0.1172 -0.0530 -0.2126 -0.0971 -0.1271 -0.0970 -0.1247 -0.1295 -1.0063 -0.3644 -0.1662 -0.0428 -0.1122 -0.1556 -0.1184 -0.2480 -0.2768 -0.2120 -0.2027 -0.5884 -0.7970 -0.1487 -0.0480 -0.1093 -0.1050 -0.0950 -0.1227 -0.1332 -0.1253 -0.1769 -1.0964 -0.0945 -0.1933 -0.1081 -0.0641 -0.4153 -0.1691 -0.1577
S-396	Die Wirkung der niedrigeren Dosis von ADROVANCE ( 70 mg Alendronat<unk> 2.800 I.E. Vitamin D3 ) mit zusätzlicher Gabe von 2.800 I.E. Vitamin D3 , was insgesamt 5.600 I.E.
T-396	The effect of the lower dose of ADROVANCE ( alendronate 70 mg/ vitamin D3 2800 IU ) plus an additional 2800 IU Vitamin D3 for a total of 5600 IU ( the amount of vitamin D3 in the higher dose of ADROVANCE ) once weekly was demonstrated in a 24-week , extension study that enrolled 619 osteoporotic post-menopausal women .
H-396	-0.26637229323387146	The effect of the lower dose of ADROVANCE ( 70 mg alendronat/ 2,800 IU of vitamin D3 ) with an additional 2,800 IU of vitamin D3 , totaling 5,600 IU
D-396	-0.26637229323387146	The effect of the lower dose of ADROVANCE ( 70 mg alendronat/ 2,800 IU of vitamin D3 ) with an additional 2,800 IU of vitamin D3 , totaling 5,600 IU
P-396	-0.2272 -0.2533 -0.1514 -0.3123 -0.1297 -0.0418 -0.1505 -0.0520 -0.0730 -0.1269 -0.0998 -0.1247 -0.1373 -0.1370 -0.0367 -0.1863 -0.1205 -0.1233 -0.1360 -0.4667 -0.3818 -0.2717 -0.0948 -0.0939 -0.1099 -0.5559 -0.1895 -0.1543 -0.1232 -0.1346 -0.1439 -0.2141 -0.2687 -0.4330 -0.5750 -0.1102 -0.1012 -0.1200 -0.1727 -0.1557 -0.1153 -0.1254 -0.1389 -1.6741 -1.9512 -0.6342 -0.3057 -0.0537 -0.1076 -0.1001 -0.8885
S-1507	11 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-1507	11 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-1507	-0.2416502982378006	11 newborns ( aged 0 1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 12 years ) , adolescents ( aged 12 16 years ) , adults ( over 16 years )
D-1507	-0.2416502982378006	11 newborns ( aged 0 1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 12 years ) , adolescents ( aged 12 16 years ) , adults ( over 16 years )
P-1507	-0.4407 -0.3342 -0.7369 -0.1314 -0.1570 -1.8651 -0.1321 -0.7471 -0.1144 -0.1316 -0.1551 -0.7767 -0.2537 -0.1513 -0.1871 -0.1361 -0.1061 -0.5127 -0.1382 -0.1011 -0.1197 -0.1513 -0.1988 -0.1501 -0.2813 -0.1410 -0.1809 -0.1252 -0.1172 -0.1510 -0.1879 -0.0544 -0.0439 -0.1502 -0.3712 -0.0927 -0.1304 -0.1287 -0.1225 -0.1544 -0.1649 -0.1445 -0.1874 -0.1325 -0.1026 -0.1261 -0.1379
S-1154	7 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-1154	7 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-1154	-0.24444018304347992	7 newborns ( aged 0 1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 12 years ) , adolescents ( aged 12 16 years ) , adults ( over 16 years )
D-1154	-0.24444018304347992	7 newborns ( aged 0 1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 12 years ) , adolescents ( aged 12 16 years ) , adults ( over 16 years )
P-1154	-0.2128 -0.3483 -0.7765 -0.1279 -0.1570 -2.2718 -0.1301 -0.6699 -0.1147 -0.1313 -0.1540 -0.7513 -0.2481 -0.1498 -0.1963 -0.1379 -0.1072 -0.5112 -0.1383 -0.1015 -0.1207 -0.1516 -0.2031 -0.1499 -0.2820 -0.1409 -0.1841 -0.1234 -0.1176 -0.1510 -0.1927 -0.0540 -0.0449 -0.1498 -0.3680 -0.0924 -0.1277 -0.1295 -0.1213 -0.1535 -0.1645 -0.1446 -0.1867 -0.1318 -0.1029 -0.1251 -0.1392
S-740	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-740	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-740	-0.2743137776851654	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
D-740	-0.2743137776851654	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
P-740	-0.6720 -0.2984 -0.2558 -0.0981 -0.1686 -0.1690 -1.0980 -1.0131 -0.1374 -0.1391 -0.0307 -0.1334 -0.0824 -0.1940 -0.4752 -0.1300 -0.2765 -0.1251 -0.5392 -0.1858 -0.1557 -0.0992 -0.0833 -0.1650 -0.3752 -0.1337 -0.1621 -0.1368 -0.0653 -0.4321 -0.0531 -0.7314 -0.4302 -0.9332 -0.1906 -1.4916 -0.0824 -0.1263 -0.1489 -0.0971 -0.0901 -0.1593 -0.1037 -0.1296 -0.1667 -0.1428 -0.0413 -0.1379 -0.1553
S-1330	9 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-1330	9 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-1330	-0.247244194149971	9 newborns ( aged 0 1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 12 years ) , adolescents ( aged 12 16 years ) , adults ( over 16 years )
D-1330	-0.247244194149971	9 newborns ( aged 0 1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 12 years ) , adolescents ( aged 12 16 years ) , adults ( over 16 years )
P-1330	-0.4243 -0.3547 -0.7362 -0.1308 -0.1561 -2.2934 -0.1211 -0.6666 -0.1146 -0.1318 -0.1545 -0.7074 -0.2478 -0.1490 -0.1935 -0.1391 -0.1064 -0.5022 -0.1386 -0.1014 -0.1201 -0.1512 -0.2038 -0.1490 -0.2840 -0.1420 -0.1838 -0.1275 -0.1172 -0.1516 -0.1858 -0.0552 -0.0442 -0.1498 -0.3650 -0.0924 -0.1271 -0.1303 -0.1221 -0.1539 -0.1649 -0.1433 -0.1845 -0.1332 -0.1037 -0.1268 -0.1386
S-1092	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-1092	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-1092	-0.2743137776851654	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
D-1092	-0.2743137776851654	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
P-1092	-0.6720 -0.2984 -0.2558 -0.0981 -0.1686 -0.1690 -1.0980 -1.0131 -0.1374 -0.1391 -0.0307 -0.1334 -0.0824 -0.1940 -0.4752 -0.1300 -0.2765 -0.1251 -0.5392 -0.1858 -0.1557 -0.0992 -0.0833 -0.1650 -0.3752 -0.1337 -0.1621 -0.1368 -0.0653 -0.4321 -0.0531 -0.7314 -0.4302 -0.9332 -0.1906 -1.4916 -0.0824 -0.1263 -0.1489 -0.0971 -0.0901 -0.1593 -0.1037 -0.1296 -0.1667 -0.1428 -0.0413 -0.1379 -0.1553
S-978	5 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-978	5 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-978	-0.2423657327890396	5 newborns ( aged 0 1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 12 years ) , adolescents ( aged 12 16 years ) , adults ( over 16 years )
D-978	-0.2423657327890396	5 newborns ( aged 0 1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 12 years ) , adolescents ( aged 12 16 years ) , adults ( over 16 years )
P-978	-0.3104 -0.2925 -0.7737 -0.1264 -0.1555 -2.1319 -0.1412 -0.6683 -0.1129 -0.1315 -0.1515 -0.7435 -0.2455 -0.1494 -0.1853 -0.1378 -0.1052 -0.4983 -0.1385 -0.1004 -0.1206 -0.1519 -0.2069 -0.1496 -0.2971 -0.1436 -0.1861 -0.1225 -0.1180 -0.1515 -0.1993 -0.0534 -0.0435 -0.1502 -0.3700 -0.0931 -0.1304 -0.1302 -0.1210 -0.1539 -0.1627 -0.1438 -0.1910 -0.1322 -0.1038 -0.1263 -0.1389
S-802	3 Neugeborene ( im Alter von 0-1 Monat ) , Kleinkinder ( im Alter von 1 Monat - 2 Jahren ) , Kinder ( im Alter von 2-12 Jahren ) , Jugendliche ( im Alter von 12-16 Jahren ) , Erwachsene ( über 16 Jahre )
T-802	3 Neonates ( age 0 1 month ) , infants ( age 1 month 2 years ) , children ( age 2 - 12 years ) , adolescents ( age 12 - 16 years ) and adults ( age over 16 years )
H-802	-0.2423291653394699	3 newborns ( aged 0 1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 12 years ) , adolescents ( aged 12 16 years ) , adults ( over 16 years )
D-802	-0.2423291653394699	3 newborns ( aged 0 1 month ) , infants ( aged 1 month - 2 years ) , children ( aged 2 12 years ) , adolescents ( aged 12 16 years ) , adults ( over 16 years )
P-802	-0.1300 -0.2883 -0.7287 -0.1254 -0.1554 -2.3428 -0.1377 -0.6641 -0.1146 -0.1311 -0.1521 -0.7243 -0.2653 -0.1499 -0.1932 -0.1383 -0.1069 -0.4935 -0.1380 -0.1015 -0.1206 -0.1527 -0.2115 -0.1503 -0.2951 -0.1423 -0.1856 -0.1290 -0.1181 -0.1527 -0.1973 -0.0529 -0.0442 -0.1502 -0.3750 -0.0931 -0.1287 -0.1292 -0.1221 -0.1551 -0.1687 -0.1438 -0.1871 -0.1327 -0.1037 -0.1265 -0.1407
S-1865	Das p53-Protein , das aus dem nicht defekten im menschlichen Körper vorhandenen p53-Gen gebildet wird , trägt normalerweise zur Wiederherstellung beschädigter DNA und zum Abtöten der Zellen bei , wenn die DNA nicht wiederhergestellt werden kann .
T-1865	The p53 protein , which is produced from the non-defective p53 gene present in the human body , normally contributes to the repair of damaged DNA and causes cell death when the DNA cannot be repaired .
H-1865	-0.4635895788669586	The p53 protein , which is made up of the non-defective p53 gene present in the human body , normally contributes to the recovery of damaged DNA and to the killing of cells when DNA cannot be recovered .
D-1865	-0.4635895788669586	The p53 protein , which is made up of the non-defective p53 gene present in the human body , normally contributes to the recovery of damaged DNA and to the killing of cells when DNA cannot be recovered .
P-1865	-1.3018 -0.1524 -0.2132 -0.0980 -0.2333 -1.0841 -0.2172 -1.4614 -0.1621 -0.1499 -0.2830 -1.9608 -0.4320 -0.4373 -0.1425 -0.1612 -0.0949 -0.1284 -0.6237 -0.1449 -0.1295 -0.1445 -0.1856 -0.1474 -1.9788 -0.2211 -0.0738 -0.1948 -0.6616 -1.3762 -0.1606 -1.0414 -0.0356 -0.1498 -0.9239 -0.4708 -1.9408 -0.1510 -0.1072 -0.9123 -0.1415 -0.0323 -0.1811 -0.1870 -0.1409 -0.1538
S-1674	1 Durchstechflasche mit ADVATE 1500 I.E. Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt
T-1674	1 vial with 1500 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-1674	-0.1927177608013153	1 vial of ADVATE 1500 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
D-1674	-0.1927177608013153	1 vial of ADVATE 1500 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
P-1674	-0.1283 -0.0642 -0.0931 -0.5135 -0.0853 -0.1493 -0.0834 -0.1004 -0.2631 -0.0894 -0.1066 -1.2112 -0.0813 -0.1554 -0.2115 -0.1167 -0.0813 -0.1392 -0.1319 -0.0697 -0.0777 -0.1988 -0.1777 -0.0906 -0.3659 -0.1270 -0.1090 -0.1446 -0.1137 -0.1333 -0.1776 -0.1414 -0.1341 -0.4203 -0.1680 -0.2932 -0.0869 -0.1060 -0.2942 -0.2100 -0.4898 -0.1593
S-1656	1 Durchstechflasche mit ADVATE 1000 I.E Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt
T-1656	1 vial with 1000 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-1656	-0.16402094066143036	1 vial of ADVATE 1000 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
D-1656	-0.16402094066143036	1 vial of ADVATE 1000 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
P-1656	-0.1254 -0.0628 -0.0944 -0.4191 -0.1028 -0.1481 -0.0829 -0.0985 -0.0925 -0.0831 -0.1950 -0.2687 -0.0796 -0.1552 -0.2186 -0.1121 -0.0776 -0.1395 -0.1315 -0.0684 -0.0778 -0.1912 -0.1751 -0.0907 -0.3687 -0.1257 -0.1042 -0.1457 -0.1127 -0.1350 -0.1830 -0.1416 -0.1341 -0.4212 -0.1705 -0.2894 -0.0880 -0.1069 -0.1976 -0.2279 -0.4868 -0.1591
S-916	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-916	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-916	-0.2743137776851654	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
D-916	-0.2743137776851654	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
P-916	-0.6720 -0.2984 -0.2558 -0.0981 -0.1686 -0.1690 -1.0980 -1.0131 -0.1374 -0.1391 -0.0307 -0.1334 -0.0824 -0.1940 -0.4752 -0.1300 -0.2765 -0.1251 -0.5392 -0.1858 -0.1557 -0.0992 -0.0833 -0.1650 -0.3752 -0.1337 -0.1621 -0.1368 -0.0653 -0.4321 -0.0531 -0.7314 -0.4302 -0.9332 -0.1906 -1.4916 -0.0824 -0.1263 -0.1489 -0.0971 -0.0901 -0.1593 -0.1037 -0.1296 -0.1667 -0.1428 -0.0413 -0.1379 -0.1553
S-1624	1 Durchstechflasche mit ADVATE 250 I.E. Octocog alfa , 1 Durchstechflasche mit 5 ml sterilisiertem Wasser für Injektionszwecke , 1 BAXJECT II-Medizinprodukt
T-1624	1 vial with 250 IU octocog alfa , 1 vial with 5 ml sterilised water for injections , 1 BAXJECT II device .
H-1624	-0.18303538858890533	1 vial of ADVATE 250 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
D-1624	-0.18303538858890533	1 vial of ADVATE 250 IU Octocog alfa , 1 vial of 5 ml sterilised water for injections , 1 BAXJECT II medical product
P-1624	-0.1279 -0.0669 -0.0939 -0.5651 -0.0850 -0.1472 -0.0839 -0.1019 -0.0987 -0.0904 -0.1066 -0.8950 -0.0816 -0.1547 -0.2106 -0.1170 -0.0805 -0.1391 -0.1317 -0.0721 -0.0774 -0.1972 -0.1693 -0.0899 -0.3643 -0.1248 -0.1112 -0.1419 -0.1137 -0.1351 -0.1751 -0.1405 -0.1335 -0.4172 -0.1692 -0.2934 -0.0871 -0.1069 -0.3244 -0.2122 -0.4951 -0.1583
S-1691	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-1691	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-1691	-0.14920315146446228	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH
D-1691	-0.14920315146446228	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH
P-1691	-0.1154 -0.0358 -0.0303 -0.1005 -0.0399 -0.0325 -0.0295 -0.0237 -0.0410 -0.0244 -0.0329 -0.0885 -0.1202 -0.0337 -0.0548 -0.1143 -0.0899 -0.1390 -0.0894 -0.0373 -0.1320 -2.4569 -0.0275 -0.0718 -0.1926 -0.0210 -0.0169 -0.0306 -0.1132 -0.0137 -0.1133 -0.0505 -0.0514 -0.0504 -0.0565 -0.0285 -0.8210
S-1658	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-1658	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-1658	-0.14920315146446228	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH
D-1658	-0.14920315146446228	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH
P-1658	-0.1154 -0.0358 -0.0303 -0.1005 -0.0399 -0.0325 -0.0295 -0.0237 -0.0410 -0.0244 -0.0329 -0.0885 -0.1202 -0.0337 -0.0548 -0.1143 -0.0899 -0.1390 -0.0894 -0.0373 -0.1320 -2.4569 -0.0275 -0.0718 -0.1926 -0.0210 -0.0169 -0.0306 -0.1132 -0.0137 -0.1133 -0.0505 -0.0514 -0.0504 -0.0565 -0.0285 -0.8210
S-355	Hautausschlag , Pruritus , Erythem . Selten : Ausschlag mit Photosensitivität . Sehr selten : schwere Hautreaktionen einschließlich Stevens-Johnson- Syndrom und toxische epidermale Nekrolyse .
T-355	Uncommon : rash , pruritus , erythema Rare : rash with photosensitivity Very rare : severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
H-355	-0.2398781031370163	rash , pruritus , erythema . Rare : rash with photosensitivity . Very rare : severe skin reactions including Stevenson Syndrome and toxic epidermal necrolysis .
D-355	-0.2398781031370163	rash , pruritus , erythema . Rare : rash with photosensitivity . Very rare : severe skin reactions including Stevenson Syndrome and toxic epidermal necrolysis .
P-355	-0.1063 -0.0752 -0.1479 -0.1133 -0.0491 -0.0335 -0.1138 -0.1517 -0.0863 -0.1347 -0.1452 -0.1392 -0.1629 -0.1389 -0.1433 -0.1026 -0.0471 -0.1355 -0.2924 -0.1556 -0.1443 -0.2164 -0.0688 -0.1369 -0.1040 -0.0826 -0.1396 -0.1458 -0.0823 -0.1264 -0.0742 -0.0684 -0.2851 -1.3023 -1.7179 -2.1122 -0.0361 -0.1365 -0.1183 -0.1211 -0.1352 -0.1851 -0.2369 -0.4433 -0.5331 -0.0948 -0.1329 -0.1436 -0.1553
S-167	Hautausschlag , Pruritus , Erythem . Selten : Ausschlag mit Photosensitivität . Sehr selten : schwere Hautreaktionen einschließlich Stevens-Johnson- Syndrom und toxische epidermale Nekrolyse .
T-167	Uncommon : rash , pruritus , erythema Rare : rash with photosensitivity Very rare : severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis
H-167	-0.2398781031370163	rash , pruritus , erythema . Rare : rash with photosensitivity . Very rare : severe skin reactions including Stevenson Syndrome and toxic epidermal necrolysis .
D-167	-0.2398781031370163	rash , pruritus , erythema . Rare : rash with photosensitivity . Very rare : severe skin reactions including Stevenson Syndrome and toxic epidermal necrolysis .
P-167	-0.1063 -0.0752 -0.1479 -0.1133 -0.0491 -0.0335 -0.1138 -0.1517 -0.0863 -0.1347 -0.1452 -0.1392 -0.1629 -0.1389 -0.1433 -0.1026 -0.0471 -0.1355 -0.2924 -0.1556 -0.1443 -0.2164 -0.0688 -0.1369 -0.1040 -0.0826 -0.1396 -0.1458 -0.0823 -0.1264 -0.0742 -0.0684 -0.2851 -1.3023 -1.7179 -2.1122 -0.0361 -0.1365 -0.1183 -0.1211 -0.1352 -0.1851 -0.2369 -0.4433 -0.5331 -0.0948 -0.1329 -0.1436 -0.1553
S-1707	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-1707	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-1707	-0.14920315146446228	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH
D-1707	-0.14920315146446228	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH
P-1707	-0.1154 -0.0358 -0.0303 -0.1005 -0.0399 -0.0325 -0.0295 -0.0237 -0.0410 -0.0244 -0.0329 -0.0885 -0.1202 -0.0337 -0.0548 -0.1143 -0.0899 -0.1390 -0.0894 -0.0373 -0.1320 -2.4569 -0.0275 -0.0718 -0.1926 -0.0210 -0.0169 -0.0306 -0.1132 -0.0137 -0.1133 -0.0505 -0.0514 -0.0504 -0.0565 -0.0285 -0.8210
S-1268	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-1268	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-1268	-0.2743137776851654	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
D-1268	-0.2743137776851654	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
P-1268	-0.6720 -0.2984 -0.2558 -0.0981 -0.1686 -0.1690 -1.0980 -1.0131 -0.1374 -0.1391 -0.0307 -0.1334 -0.0824 -0.1940 -0.4752 -0.1300 -0.2765 -0.1251 -0.5392 -0.1858 -0.1557 -0.0992 -0.0833 -0.1650 -0.3752 -0.1337 -0.1621 -0.1368 -0.0653 -0.4321 -0.0531 -0.7314 -0.4302 -0.9332 -0.1906 -1.4916 -0.0824 -0.1263 -0.1489 -0.0971 -0.0901 -0.1593 -0.1037 -0.1296 -0.1667 -0.1428 -0.0413 -0.1379 -0.1553
S-1675	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-1675	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-1675	-0.14920315146446228	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH
D-1675	-0.14920315146446228	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH
P-1675	-0.1154 -0.0358 -0.0303 -0.1005 -0.0399 -0.0325 -0.0295 -0.0237 -0.0410 -0.0244 -0.0329 -0.0885 -0.1202 -0.0337 -0.0548 -0.1143 -0.0899 -0.1390 -0.0894 -0.0373 -0.1320 -2.4569 -0.0275 -0.0718 -0.1926 -0.0210 -0.0169 -0.0306 -0.1132 -0.0137 -0.1133 -0.0505 -0.0514 -0.0504 -0.0565 -0.0285 -0.8210
S-1444	Die Berechnung der erforderlichen Faktor VIII Dosis basiert auf dem empirischen Befund , dass 1 I.E. Faktor VIII pro kg Körpergewicht die Faktor VIII-Aktivität im Plasma um 2 I.E.<unk> dl erhöht .
T-1444	The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor VIII per kg body weight raises the plasma factor VIII activity by 2 IU/ dl .
H-1444	-0.2743137776851654	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
D-1444	-0.2743137776851654	The calculation of the required Factor VIII dose is based on empirical evidence that 1 IU of Factor VIII per kg bodyweight increases Factor VIII activity in plasma by 2 IU/ dl .
P-1444	-0.6720 -0.2984 -0.2558 -0.0981 -0.1686 -0.1690 -1.0980 -1.0131 -0.1374 -0.1391 -0.0307 -0.1334 -0.0824 -0.1940 -0.4752 -0.1300 -0.2765 -0.1251 -0.5392 -0.1858 -0.1557 -0.0992 -0.0833 -0.1650 -0.3752 -0.1337 -0.1621 -0.1368 -0.0653 -0.4321 -0.0531 -0.7314 -0.4302 -0.9332 -0.1906 -1.4916 -0.0824 -0.1263 -0.1489 -0.0971 -0.0901 -0.1593 -0.1037 -0.1296 -0.1667 -0.1428 -0.0413 -0.1379 -0.1553
S-1641	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-1641	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-1641	-0.14920315146446228	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH
D-1641	-0.14920315146446228	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH
P-1641	-0.1154 -0.0358 -0.0303 -0.1005 -0.0399 -0.0325 -0.0295 -0.0237 -0.0410 -0.0244 -0.0329 -0.0885 -0.1202 -0.0337 -0.0548 -0.1143 -0.0899 -0.1390 -0.0894 -0.0373 -0.1320 -2.4569 -0.0275 -0.0718 -0.1926 -0.0210 -0.0169 -0.0306 -0.1132 -0.0137 -0.1133 -0.0505 -0.0514 -0.0504 -0.0565 -0.0285 -0.8210
S-1625	WARNHINWEIS , DASS DAS ARZNEIMITTEL FÜR KINDER UNERREICHBAR UND NICHT SICHTBAR AUFZUBEWAHREN IST
T-1625	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
H-1625	-0.14920315146446228	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH
D-1625	-0.14920315146446228	SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH
P-1625	-0.1154 -0.0358 -0.0303 -0.1005 -0.0399 -0.0325 -0.0295 -0.0237 -0.0410 -0.0244 -0.0329 -0.0885 -0.1202 -0.0337 -0.0548 -0.1143 -0.0899 -0.1390 -0.0894 -0.0373 -0.1320 -2.4569 -0.0275 -0.0718 -0.1926 -0.0210 -0.0169 -0.0306 -0.1132 -0.0137 -0.1133 -0.0505 -0.0514 -0.0504 -0.0565 -0.0285 -0.8210
S-1615	BEDINGUNGEN ODER EINSCHRÄNKUNGEN BEZÜGLICH DER SICHEREN UND WIRKSAMEN ANWENDUNG DES ARZNEIMITTELS
T-1615	CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
H-1615	-0.12033656239509583	CONDITIONS OR RESTRICTIONS REGARDING THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
D-1615	-0.12033656239509583	CONDITIONS OR RESTRICTIONS REGARDING THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
P-1615	-0.0552 -0.0763 -0.0144 -0.0277 -0.0484 -0.1506 -0.1761 -0.1269 -0.1508 -0.0304 -0.0212 -0.0121 -0.0187 -0.0461 -0.1138 -0.6887 -0.0950 -0.0754 -0.0862 -0.0326 -0.5615 -0.2248 -0.0236 -0.0898 -0.0800 -0.1382 -0.0176 -0.0115 -0.0824 -0.0129 -0.1267 -0.0630 -0.0752 -0.7346 -0.1193 -0.1465 -0.0451 -0.0722 -0.0364 -0.0354 -0.0946 -0.3013 -0.0989 -0.0889 -0.0350 -0.1103 -0.1836
S-1464	58 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-1464	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-1464	-0.35444632172584534	58 Prophylaxis Doses between 20 and 40 IU of factor VIII per kg bodyweight should be administered 2-3 days apart to prevent long term bleeding in patients with severe haemophilia A
D-1464	-0.35444632172584534	58 Prophylaxis Doses between 20 and 40 IU of factor VIII per kg bodyweight should be administered 2-3 days apart to prevent long term bleeding in patients with severe haemophilia A
P-1464	-0.6086 -0.9204 -0.0676 -0.1346 -0.0750 -0.0890 -1.9430 -0.0479 -0.8568 -0.1189 -0.1911 -0.1041 -0.1016 -0.0814 -0.1436 -0.0477 -0.1440 -0.1401 -0.1308 -0.0625 -0.7802 -0.0573 -0.5892 -0.2093 -0.4754 -0.0888 -0.2509 -0.1282 -0.1557 -0.1240 -0.1377 -0.3588 -1.8327 -0.4840 -1.1307 -1.0128 -0.2973 -0.1458 -0.9537 -0.1544 -0.0889 -0.2377 -0.1029 -0.1797 -0.2228 -0.1351 -0.3163
S-1112	36 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-1112	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-1112	-0.36463800072669983	36 prophylaxis Doses between 20 and 40 IU of factor VIII per kg bodyweight should be administered 2-3 days apart to prevent long term bleeding in patients with severe haemophilia A
D-1112	-0.36463800072669983	36 prophylaxis Doses between 20 and 40 IU of factor VIII per kg bodyweight should be administered 2-3 days apart to prevent long term bleeding in patients with severe haemophilia A
P-1112	-0.8218 -1.0807 -0.0629 -0.1378 -0.0883 -0.0647 -1.7792 -0.0448 -1.0476 -0.1191 -0.1894 -0.1050 -0.0999 -0.0840 -0.1446 -0.0472 -0.1448 -0.1442 -0.1298 -0.0613 -0.7962 -0.0580 -0.6492 -0.2112 -0.4912 -0.0878 -0.2480 -0.1250 -0.1613 -0.1233 -0.1409 -0.3650 -1.7838 -0.5020 -1.0874 -1.0333 -0.2962 -0.1468 -0.9949 -0.1546 -0.0872 -0.2344 -0.1008 -0.1877 -0.2212 -0.1331 -0.3205
S-586	3 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-586	3 Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-586	-0.3594084680080414	3 Prophylaxis Doses between 20 and 40 IU of factor VIII per kg bodyweight should be administered 2-3 days apart to prevent long term bleeding in patients with severe haemophilia A
D-586	-0.3594084680080414	3 Prophylaxis Doses between 20 and 40 IU of factor VIII per kg bodyweight should be administered 2-3 days apart to prevent long term bleeding in patients with severe haemophilia A
P-586	-0.5740 -0.7058 -0.0688 -0.1374 -0.0774 -0.0723 -2.3044 -0.0488 -0.8439 -0.1189 -0.2044 -0.1055 -0.1003 -0.0845 -0.1438 -0.0507 -0.1434 -0.1483 -0.1330 -0.0630 -0.7688 -0.0571 -0.4639 -0.2109 -0.5090 -0.0887 -0.2660 -0.1412 -0.1389 -0.1220 -0.1452 -0.3574 -1.7710 -0.5128 -1.1395 -1.0466 -0.3052 -0.1462 -1.0196 -0.1548 -0.0883 -0.2390 -0.0981 -0.1858 -0.2209 -0.1356 -0.4313
S-1288	47 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-1288	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-1288	-0.34976205229759216	47 prophylaxis Doses between 20 and 40 IU of factor VIII per kg bodyweight should be administered 2-3 days apart to prevent long term bleeding in patients with severe haemophilia A
D-1288	-0.34976205229759216	47 prophylaxis Doses between 20 and 40 IU of factor VIII per kg bodyweight should be administered 2-3 days apart to prevent long term bleeding in patients with severe haemophilia A
P-1288	-0.0827 -1.1706 -0.0628 -0.1367 -0.0872 -0.0630 -1.7679 -0.0470 -1.0176 -0.1190 -0.1944 -0.1059 -0.1020 -0.0821 -0.1438 -0.0476 -0.1449 -0.1421 -0.1311 -0.0631 -0.7711 -0.0587 -0.6400 -0.2119 -0.4884 -0.0884 -0.2596 -0.1220 -0.1597 -0.1247 -0.1428 -0.3573 -1.7547 -0.5022 -1.0877 -1.0324 -0.2938 -0.1458 -1.0067 -0.1550 -0.0878 -0.2382 -0.1012 -0.1844 -0.2224 -0.1337 -0.3568
S-760	14 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-760	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-760	-0.3794960379600525	14 Prophylaxis Doses between 20 and 40 IU of factor VIII per kg bodyweight should be administered 2-3 days apart to prevent long term bleeding in patients with severe haemophilia A
D-760	-0.3794960379600525	14 Prophylaxis Doses between 20 and 40 IU of factor VIII per kg bodyweight should be administered 2-3 days apart to prevent long term bleeding in patients with severe haemophilia A
P-760	-1.5941 -0.8028 -0.0694 -0.1362 -0.0768 -0.0924 -2.0808 -0.0477 -0.8649 -0.1184 -0.1988 -0.1044 -0.1005 -0.0841 -0.1434 -0.0500 -0.1441 -0.1437 -0.1319 -0.0621 -0.7840 -0.0565 -0.5504 -0.2103 -0.4931 -0.0892 -0.2493 -0.1353 -0.1590 -0.1234 -0.1397 -0.3534 -1.8096 -0.4849 -1.1433 -1.0213 -0.3012 -0.1477 -1.0186 -0.1544 -0.0883 -0.2416 -0.1014 -0.1866 -0.2193 -0.1353 -0.3927
S-936	25 Prophylaxe Zur Langzeitprophylaxe von Blutungen bei Patienten mit schwerer Hämophilie A sollen Dosen zwischen 20 und 40 I.E. von Faktor VIII pro kg Körpergewicht im Abstand von 2-3 Tagen gegeben werden .
T-936	Prophylaxis For long-term prophylaxis against bleeding in patients with severe haemophilia A , the usual doses are 20 to 40 IU of factor VIIIper kg body weight at intervals of 2 to 3 days.
H-936	-0.38626959919929504	25 Prophylaxis Doses between 20 and 40 IU of factor VIII per kg bodyweight should be administered 2-3 days apart to prevent long term bleeding in patients with severe haemophilia A
D-936	-0.38626959919929504	25 Prophylaxis Doses between 20 and 40 IU of factor VIII per kg bodyweight should be administered 2-3 days apart to prevent long term bleeding in patients with severe haemophilia A
P-936	-1.8239 -0.5690 -0.0699 -0.1340 -0.0778 -0.0923 -2.3836 -0.0486 -0.8797 -0.1197 -0.2003 -0.1039 -0.1009 -0.0818 -0.1449 -0.0487 -0.1437 -0.1439 -0.1327 -0.0628 -0.8435 -0.0563 -0.5969 -0.2111 -0.4852 -0.0886 -0.2518 -0.1388 -0.1562 -0.1258 -0.1303 -0.3711 -1.8004 -0.4824 -1.1128 -1.0206 -0.2982 -0.1454 -1.0149 -0.1550 -0.0881 -0.2378 -0.1035 -0.1875 -0.2180 -0.1362 -0.3365
S-71	Das Unternehmen führte außerdem eine Studie mit 35 Männern und 682 postmenopausalen Frauen mit Osteoporose durch , um die Wirksamkeit von ADROVANCE in Bezug auf die Steigerung des Vitamin-D-Spiegels nachzuweisen .
T-71	The company also carried out a study in 35 men and 682 post-menopausal women with osteoporosis to show ADROVANCE s effectiveness in increasing vitamin D levels .
H-71	-0.29348284006118774	The company also conducted a trial in 35 men and 682 post-menopausal women with osteoporosis to demonstrate ADROVANCE &apos;s efficacy in increasing vitamin D levels .
D-71	-0.29348284006118774	The company also conducted a trial in 35 men and 682 post-menopausal women with osteoporosis to demonstrate ADROVANCE &apos;s efficacy in increasing vitamin D levels .
P-71	-0.3696 -0.2013 -0.1264 -0.5773 -0.1239 -0.9605 -0.2857 -0.0677 -0.1753 -0.1287 -0.1051 -0.0851 -0.1394 -0.1813 -0.0383 -0.1076 -0.0298 -0.1284 -0.0927 -0.1223 -0.1298 -0.0721 -0.1114 -0.1270 -0.1095 -0.0952 -0.1898 -0.5236 -0.3248 -0.0877 -0.1172 -0.1107 -0.1186 -3.1552 -0.5298 -0.0476 -0.0883 -0.1623 -0.6935 -1.5854 -0.0673 -0.0757 -0.3352 -0.1468 -0.1561
S-826	18 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-826	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-826	-0.28550004959106445	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reactions ( frequency unknown ) have been reported in ADVATE .
D-826	-0.28550004959106445	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reactions ( frequency unknown ) have been reported in ADVATE .
P-826	-0.9899 -0.6517 -0.1415 -0.1418 -0.0763 -0.0892 -0.1178 -0.1473 -0.1385 -2.5563 -0.0516 -0.0413 -0.0474 -0.0425 -0.1291 -0.5248 -0.0449 -0.0886 -0.1813 -0.6170 -0.0606 -0.1553 -0.1026 -0.0636 -0.0863 -0.0987 -0.1703 -0.1468 -0.0924 -0.0652 -0.0969 -0.3835 -0.3873 -1.0758 -0.4542 -0.0466 -0.1494 -0.4959 -0.0635 -0.6683 -0.1498 -0.5294 -0.1866 -0.1220 -1.1425 -0.1032 -0.1359 -0.0764 -0.1037 -0.1743 -0.1544
S-1920	Wenn nur die Schwellung der Nasenschleimhaut betrachtet wurde , zeigten die Patienten unter Aerinaze eine Linderung der Symptome um 37,4 % gegenüber 26,7 % bei den Patienten , die Desloratadin allein einnahmen .
T-1920	When looking at nasal congestion , patients taking Aerinaze had a reduction in symptoms of 37.4 % , compared with 26.7 % in those taking desloratadine alone .
H-1920	-0.4519292116165161	When only nasal swelling was considered , patients on Aerinaze experienced a 37.4 % relief compared to 26.7 % for those taking desloratadine alone .
D-1920	-0.4519292116165161	When only nasal swelling was considered , patients on Aerinaze experienced a 37.4 % relief compared to 26.7 % for those taking desloratadine alone .
P-1920	-1.3787 -2.0544 -0.0800 -0.0211 -0.2126 -0.0491 -0.1183 -0.2159 -0.9650 -0.1691 -1.4702 -0.5191 -0.1771 -0.1210 -0.1116 -0.1478 -0.1076 -1.5787 -0.7990 -0.3186 -0.1052 -0.1228 -0.1248 -1.9764 -1.1301 -0.4539 -0.1149 -0.1365 -0.1085 -0.1617 -0.4559 -0.1325 -0.3047 -0.0627 -0.1067 -0.3464 -1.1955 -0.1270 -0.1356 -0.1604
S-1531	62 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-1531	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-1531	-0.27041056752204895	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reactions ( frequency unknown ) have been reported in ADVATE .
D-1531	-0.27041056752204895	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reactions ( frequency unknown ) have been reported in ADVATE .
P-1531	-0.2934 -0.5818 -0.1406 -0.1459 -0.0770 -0.0888 -0.1157 -0.1462 -0.1397 -2.5200 -0.0537 -0.0416 -0.0478 -0.0430 -0.1296 -0.5179 -0.0435 -0.0894 -0.1797 -0.6092 -0.0611 -0.1547 -0.1029 -0.0639 -0.0870 -0.0991 -0.1701 -0.1461 -0.0928 -0.0660 -0.0982 -0.3848 -0.3737 -1.0665 -0.4422 -0.0472 -0.1512 -0.4880 -0.0633 -0.7331 -0.1495 -0.5192 -0.1838 -0.1215 -1.1725 -0.1045 -0.1345 -0.0775 -0.1039 -0.1746 -0.1531
S-408	Die mittleren BMD-Zunahmen betrugen 2,3 % bzw. 2,9 % am Femurhals und 2,9 % bzw. 3,1 % an der gesamten Hüfte in der Gruppe mit 70 mg einmal wöchentlich bzw. in der mit 10 mg täglich .
T-408	The mean BMD increases were 2.3 % and 2.9 % at the femoral neck and 2.9 % and 3.1 % at the total hip in the 70 mg once weekly and 10 mg daily groups , respectively .
H-408	-0.3013022840023041	Mean BMD increases were 2.3 % and 2.9 % for the femoral neck and 2.9 % and 3.1 % for the total hip , respectively , in the 70 mg weekly and 10 mg daily groups .
D-408	-0.3013022840023041	Mean BMD increases were 2.3 % and 2.9 % for the femoral neck and 2.9 % and 3.1 % for the total hip , respectively , in the 70 mg weekly and 10 mg daily groups .
P-408	-0.2956 -0.1129 -1.1025 -0.1438 -0.1857 -0.1323 -0.1050 -0.1230 -0.0951 -0.1332 -0.1231 -0.1275 -0.1103 -0.9073 -0.1266 -0.0730 -0.9030 -0.1038 -0.3679 -0.1429 -0.1163 -0.1046 -0.1286 -0.0637 -0.1491 -0.1082 -0.1438 -1.3002 -1.1720 -0.1134 -0.6251 -0.1407 -0.2168 -0.2181 -0.1310 -0.2407 -0.0371 -0.4075 -0.2031 -0.1378 -0.0521 -0.2242 -1.7780 -0.1830 -0.1487
S-1741	Dann besteht nämlich ein erhöhtes Risiko , dass dies abermals auftritt . Inhibitoren sind neutralisierende Antikörper gegen Faktor VIII , die die Wirksamkeit von ADVATE , Blutungen zu verhindern oder zu kontrollieren , vermindern .
T-1741	Inhibitors are blocking antibodies against factor VIII that reduce the efficacy of ADVATE to prevent or control bleeding .
H-1741	-0.5105080008506775	These inhibitors are neutralising antibodies to factor VIII that reduce the effectiveness of ADVATE in preventing or controlling haemorrhage .
D-1741	-0.5105080008506775	These inhibitors are neutralising antibodies to factor VIII that reduce the effectiveness of ADVATE in preventing or controlling haemorrhage .
P-1741	-3.4914 -0.8926 -0.0127 -0.0556 -0.1435 -0.1104 -0.1268 -1.1422 -0.1697 -0.1029 -0.2309 -0.7651 -0.1476 -0.1274 -0.4371 -0.6482 -1.3640 -0.8481 -0.0671 -0.1604 -0.0901 -0.1364 -0.0699 -0.0940 -0.9497 -0.0466 -0.2152 -0.4948 -1.7261 -0.5012 -0.0258 -0.2983 -0.2106 -1.4549
S-652	7 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-652	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-652	-0.2744632959365845	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reactions ( frequency unknown ) have been reported in ADVATE .
D-652	-0.2744632959365845	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reactions ( frequency unknown ) have been reported in ADVATE .
P-652	-0.4950 -0.6482 -0.1418 -0.1457 -0.0766 -0.0889 -0.1167 -0.1440 -0.1383 -2.4148 -0.0519 -0.0418 -0.0472 -0.0430 -0.1308 -0.5046 -0.0458 -0.0895 -0.1873 -0.6343 -0.0619 -0.1562 -0.1020 -0.0642 -0.0874 -0.0995 -0.1705 -0.1459 -0.0926 -0.0657 -0.0980 -0.3887 -0.3894 -1.0822 -0.4452 -0.0475 -0.1506 -0.4917 -0.0632 -0.6855 -0.1510 -0.5426 -0.1886 -0.1220 -1.1653 -0.1074 -0.1368 -0.0768 -0.1047 -0.1742 -0.1541
S-1002	29 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-1002	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-1002	-0.27383166551589966	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reactions ( frequency unknown ) have been reported in ADVATE .
D-1002	-0.27383166551589966	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reactions ( frequency unknown ) have been reported in ADVATE .
P-1002	-0.4913 -0.6543 -0.1411 -0.1421 -0.0774 -0.0888 -0.1156 -0.1458 -0.1386 -2.4977 -0.0519 -0.0410 -0.0482 -0.0428 -0.1287 -0.4865 -0.0445 -0.0884 -0.1810 -0.6092 -0.0604 -0.1548 -0.1018 -0.0643 -0.0869 -0.0992 -0.1710 -0.1426 -0.0924 -0.0659 -0.0978 -0.3672 -0.3998 -1.0815 -0.4270 -0.0471 -0.1490 -0.4607 -0.0638 -0.7351 -0.1492 -0.5174 -0.1880 -0.1204 -1.1596 -0.1015 -0.1359 -0.0764 -0.1038 -0.1753 -0.1547
S-1178	40 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-1178	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-1178	-0.2754068374633789	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reactions ( frequency unknown ) have been reported in ADVATE .
D-1178	-0.2754068374633789	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reactions ( frequency unknown ) have been reported in ADVATE .
P-1178	-0.4661 -0.5757 -0.1414 -0.1457 -0.0773 -0.0887 -0.1168 -0.1395 -0.1385 -2.5149 -0.0521 -0.0415 -0.0471 -0.0435 -0.1293 -0.5046 -0.0448 -0.0881 -0.1792 -0.6263 -0.0600 -0.1572 -0.1021 -0.0638 -0.0869 -0.0966 -0.1696 -0.1471 -0.0921 -0.0654 -0.0981 -0.3976 -0.3617 -1.0744 -0.4579 -0.0479 -0.1510 -0.4975 -0.0630 -0.7016 -0.1512 -0.5038 -0.1860 -0.1205 -1.2754 -0.1054 -0.1350 -0.0758 -0.1041 -0.1815 -0.1543
S-1354	51 Wie bei anderen intravenösen Produkten wurde bei ADVATE über Überempfindlichkeitreaktionen vom allergischen Typ , inklusive anaphylaktischer / anaphylaktoider Reaktionen ( Häufigkeit nicht bekannt ) berichtet .
T-1354	As with other intravenous products , allergic type hypersensitivity reactions , including anaphylaxis/ anaphylactoid reactions , have been reported with ADVATE ( frequency not known ) .
H-1354	-0.2750621438026428	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reactions ( frequency unknown ) have been reported in ADVATE .
D-1354	-0.2750621438026428	As for other intravenous products , hypersensitivity reactions of the allergic type , including anaphylactic / anaphylactoid reactions ( frequency unknown ) have been reported in ADVATE .
P-1354	-0.3324 -0.6184 -0.1432 -0.1454 -0.0774 -0.0889 -0.1162 -0.1458 -0.1382 -2.6712 -0.0536 -0.0414 -0.0463 -0.0421 -0.1273 -0.5228 -0.0440 -0.0897 -0.1811 -0.6099 -0.0601 -0.1543 -0.1022 -0.0640 -0.0858 -0.1014 -0.1723 -0.1455 -0.0922 -0.0661 -0.0967 -0.3704 -0.4164 -1.1067 -0.4698 -0.0469 -0.1505 -0.5025 -0.0636 -0.6997 -0.1498 -0.5196 -0.1886 -0.1193 -1.1003 -0.1039 -0.1335 -0.0766 -0.1035 -0.1781 -0.1527
S-54	ADROVANCE wird zur Behandlung von Osteoporose ( einer Erkrankung , bei der die Knochen brüchig werden ) bei Frauen nach der Menopause eingesetzt , bei denen ein Risiko für einen geringen Vitamin-D-Spiegel besteht .
T-54	ADROVANCE is used to treat osteoporosis ( a disease that makes bones fragile ) in post-menopausal women at risk of low vitamin D levels .
H-54	-0.273491770029068	ADROVANCE is used to treat osteoporosis ( a condition in which bones become fragile ) in post-menopausal women who are at risk for low vitamin D levels .
D-54	-0.273491770029068	ADROVANCE is used to treat osteoporosis ( a condition in which bones become fragile ) in post-menopausal women who are at risk for low vitamin D levels .
P-54	-0.0652 -0.0735 -0.1242 -0.1084 -0.1430 -0.1289 -0.0745 -0.1566 -0.1022 -0.1237 -0.0716 -0.1028 -0.1339 -0.0996 -0.0861 -0.1402 -0.2751 -1.0017 -1.0237 -0.2079 -0.5861 -0.3753 -0.4969 -0.0985 -0.1286 -0.1650 -0.0713 -0.1950 -0.0461 -0.0974 -0.0840 -0.1332 -0.1415 -1.0853 -0.2328 -0.0128 -0.0704 -0.9739 -0.2326 -2.1280 -0.0905 -0.0967 -0.2060 -0.1600 -0.1561
S-133	Andere Erkrankungen , die den Mineralstoffwechsel beeinträchtigen ( wie Vitamin-D-Mangel und Hypoparathyreoidismus ) , sollten vor Beginn der Therapie mit ADROVANCE ebenfalls adäquat behandelt werden .
T-133	Other disorders affecting mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be effectively treated before starting ADROVANCE .
H-133	-0.26600709557533264	Other disorders that affect mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be adequately treated before starting therapy with ADROVANCE .
D-133	-0.26600709557533264	Other disorders that affect mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be adequately treated before starting therapy with ADROVANCE .
P-133	-0.2352 -0.8798 -0.0897 -0.5352 -1.4508 -0.1374 -0.0777 -0.0481 -0.0848 -0.1153 -0.1597 -0.2168 -0.1619 -0.1252 -0.0576 -0.1264 -0.0465 -0.0246 -0.3581 -0.1351 -0.1348 -0.0712 -0.1317 -0.1804 -0.1105 -0.1248 -0.2558 -0.0861 -0.0842 -0.1041 -0.1288 -0.2890 -0.0769 -0.1698 -0.0701 -0.0607 -0.5378 -1.0908 -1.4407 -1.5610 -0.1774 -0.0751 -0.0841 -0.1207 -0.1041 -0.1309 -0.1476 -0.1534
S-260	Alendronat Nicht-klinische Daten auf Grundlage konventioneller Studien zur Sicherheitspharmakologie , zur chronischen Toxizität , zur Genotoxizität und zum kanzerogenen Potenzial lassen keine besonderen Gefahren für den Menschen erkennen .
T-260	Alendronate Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology , repeated dose toxicity , genotoxicity and carcinogenic potential .
H-260	-0.41788843274116516	Alendronate Non-clinical data based on conventional trials in safety pharmacology , chronic toxicity , genotoxicity and carcinogenic potential do not reveal any specific risks to humans .
D-260	-0.41788843274116516	Alendronate Non-clinical data based on conventional trials in safety pharmacology , chronic toxicity , genotoxicity and carcinogenic potential do not reveal any specific risks to humans .
P-260	-0.4569 -0.1477 -0.0945 -0.0589 -1.3051 -0.4506 -0.0193 -0.1996 -0.6475 -0.1701 -0.2015 -2.7080 -0.2122 -0.4532 -0.0598 -0.0583 -0.1422 -0.0629 -0.0670 -0.0862 -0.1603 -0.1697 -0.0179 -0.0534 -0.1165 -0.0671 -0.1076 -0.1664 -1.2189 -0.0433 -0.1130 -0.0797 -0.0915 -0.0485 -1.6004 -0.1259 -1.5703 -0.4431 -1.2616 -2.3784 -0.3173 -0.3044 -0.1701 -0.1599
S-456	Alendronat Nicht-klinische Daten auf Grundlage konventioneller Studien zur Sicherheitspharmakologie , zur chronischen Toxizität , zur Genotoxizität und zum kanzerogenen Potenzial lassen keine besonderen Gefahren für den Menschen erkennen .
T-456	Alendronate Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology , repeated dose toxicity , genotoxicity and carcinogenic potential .
H-456	-0.41788843274116516	Alendronate Non-clinical data based on conventional trials in safety pharmacology , chronic toxicity , genotoxicity and carcinogenic potential do not reveal any specific risks to humans .
D-456	-0.41788843274116516	Alendronate Non-clinical data based on conventional trials in safety pharmacology , chronic toxicity , genotoxicity and carcinogenic potential do not reveal any specific risks to humans .
P-456	-0.4569 -0.1477 -0.0945 -0.0589 -1.3051 -0.4506 -0.0193 -0.1996 -0.6475 -0.1701 -0.2015 -2.7080 -0.2122 -0.4532 -0.0598 -0.0583 -0.1422 -0.0629 -0.0670 -0.0862 -0.1603 -0.1697 -0.0179 -0.0534 -0.1165 -0.0671 -0.1076 -0.1664 -1.2189 -0.0433 -0.1130 -0.0797 -0.0915 -0.0485 -1.6004 -0.1259 -1.5703 -0.4431 -1.2616 -2.3784 -0.3173 -0.3044 -0.1701 -0.1599
S-468	INHABER DER HERSTELLUNGSERLAUBNIS , DER ( DIE ) FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST ( SIND )
T-468	MANUFACTURING AUTHORISATION HOLDER<<unk>> S ) RESPONSIBLE FOR BATCH RELEASE
H-468	-0.23789578676223755	MANUFACTURING AUTHORISATION HOLDER ( s ) RESPONSIBLE FOR BATCH RELEASE ( IS )
D-468	-0.23789578676223755	MANUFACTURING AUTHORISATION HOLDER ( s ) RESPONSIBLE FOR BATCH RELEASE ( IS )
P-468	-0.7386 -0.0140 -0.0693 -0.0300 -0.0167 -0.0525 -0.0329 -0.0400 -0.0207 -0.0208 -0.0547 -0.0175 -0.0121 -0.0675 -0.0861 -0.0587 -0.7152 -0.1103 -1.7173 -0.1261 -0.1566 -0.0526 -0.0445 -0.0892 -0.0202 -0.0857 -0.0757 -0.0749 -0.0419 -0.0571 -0.1160 -0.2912 -0.0265 -0.0634 -0.1004 -0.2632 -3.4303 -0.1208 -0.1665
S-401	19 Vitamin-D-Mangel war 0,3 % in der 2.800-I.E.-Vitamin-D3-Gruppe vs . 0 % in der 5.600-I.E.-Vitamin- D3-Gruppe .
T-401	The percentage of patients with vitamin D deficiency was 0.3 % in the Vitamin D3 2800 group vs. zero in the Vitamin D3 5600 group .
H-401	-0.1965910941362381	19 vitamin D deficiency was 0.3 % in the 2,800 IU vitamin D3 group vs. 0 % in the 5,600 IU vitamin D3 group .
D-401	-0.1965910941362381	19 vitamin D deficiency was 0.3 % in the 2,800 IU vitamin D3 group vs. 0 % in the 5,600 IU vitamin D3 group .
P-401	-0.2541 -1.4892 -0.0618 -0.0921 -0.0304 -0.0211 -0.2327 -0.0885 -0.0765 -0.1272 -0.1219 -0.1655 -0.1635 -0.4160 -0.1141 -0.0964 -0.2129 -0.4280 -0.1141 -0.2447 -0.1266 -0.1902 -0.2111 -0.0982 -0.1144 -0.1403 -0.1464 -0.3296 -0.0383 -0.1058 -0.3466 -0.2765 -0.1448 -0.1595 -0.1106 -0.0893 -0.1377 -0.1540
S-321	Andere Erkrankungen , die den Mineralstoffwechsel beeinträchtigen ( wie Vitamin-D-Mangel und Hypoparathyreoidismus ) , sollten vor Beginn der Therapie mit ADROVANCE ebenfalls adäquat behandelt werden .
T-321	Other disorders affecting mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be effectively treated before starting ADROVANCE .
H-321	-0.26600709557533264	Other disorders that affect mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be adequately treated before starting therapy with ADROVANCE .
D-321	-0.26600709557533264	Other disorders that affect mineral metabolism ( such as vitamin D deficiency and hypoparathyroidism ) should also be adequately treated before starting therapy with ADROVANCE .
P-321	-0.2352 -0.8798 -0.0897 -0.5352 -1.4508 -0.1374 -0.0777 -0.0481 -0.0848 -0.1153 -0.1597 -0.2168 -0.1619 -0.1252 -0.0576 -0.1264 -0.0465 -0.0246 -0.3581 -0.1351 -0.1348 -0.0712 -0.1317 -0.1804 -0.1105 -0.1248 -0.2558 -0.0861 -0.0842 -0.1041 -0.1288 -0.2890 -0.0769 -0.1698 -0.0701 -0.0607 -0.5378 -1.0908 -1.4407 -1.5610 -0.1774 -0.0751 -0.0841 -0.1207 -0.1041 -0.1309 -0.1476 -0.1534
S-1358	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-1358	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-1358	-0.23274360597133636	ADVATE contains recombinant blood coagulation factor VIII ( Octocog alfa ) , a glycoprotein equivalent to that found in human plasma .
D-1358	-0.23274360597133636	ADVATE contains recombinant blood coagulation factor VIII ( Octocog alfa ) , a glycoprotein equivalent to that found in human plasma .
P-1358	-0.0637 -0.1497 -0.0781 -0.1081 -0.0600 -0.1424 -0.1115 -0.0979 -0.1395 -0.1611 -1.1382 -0.0908 -0.5248 -0.0474 -0.1353 -0.1194 -0.1286 -0.9586 -0.0807 -0.1423 -0.2079 -0.1312 -0.0704 -0.1349 -0.1474 -0.1922 -0.1733 -0.1254 -0.0954 -0.0293 -0.1153 -0.1309 -0.1530 -1.0958 -1.4446 -0.1508 -0.2245 -0.0827 -0.1299 -0.1574 -0.1513 -0.1534
S-1535	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-1535	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-1535	-0.23274360597133636	ADVATE contains recombinant blood coagulation factor VIII ( Octocog alfa ) , a glycoprotein equivalent to that found in human plasma .
D-1535	-0.23274360597133636	ADVATE contains recombinant blood coagulation factor VIII ( Octocog alfa ) , a glycoprotein equivalent to that found in human plasma .
P-1535	-0.0637 -0.1497 -0.0781 -0.1081 -0.0600 -0.1424 -0.1115 -0.0979 -0.1395 -0.1611 -1.1382 -0.0908 -0.5248 -0.0474 -0.1353 -0.1194 -0.1286 -0.9586 -0.0807 -0.1423 -0.2079 -0.1312 -0.0704 -0.1349 -0.1474 -0.1922 -0.1733 -0.1254 -0.0954 -0.0293 -0.1153 -0.1309 -0.1530 -1.0958 -1.4446 -0.1508 -0.2245 -0.0827 -0.1299 -0.1574 -0.1513 -0.1534
S-1006	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-1006	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-1006	-0.23274360597133636	ADVATE contains recombinant blood coagulation factor VIII ( Octocog alfa ) , a glycoprotein equivalent to that found in human plasma .
D-1006	-0.23274360597133636	ADVATE contains recombinant blood coagulation factor VIII ( Octocog alfa ) , a glycoprotein equivalent to that found in human plasma .
P-1006	-0.0637 -0.1497 -0.0781 -0.1081 -0.0600 -0.1424 -0.1115 -0.0979 -0.1395 -0.1611 -1.1382 -0.0908 -0.5248 -0.0474 -0.1353 -0.1194 -0.1286 -0.9586 -0.0807 -0.1423 -0.2079 -0.1312 -0.0704 -0.1349 -0.1474 -0.1922 -0.1733 -0.1254 -0.0954 -0.0293 -0.1153 -0.1309 -0.1530 -1.0958 -1.4446 -0.1508 -0.2245 -0.0827 -0.1299 -0.1574 -0.1513 -0.1534
S-1182	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-1182	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-1182	-0.23274360597133636	ADVATE contains recombinant blood coagulation factor VIII ( Octocog alfa ) , a glycoprotein equivalent to that found in human plasma .
D-1182	-0.23274360597133636	ADVATE contains recombinant blood coagulation factor VIII ( Octocog alfa ) , a glycoprotein equivalent to that found in human plasma .
P-1182	-0.0637 -0.1497 -0.0781 -0.1081 -0.0600 -0.1424 -0.1115 -0.0979 -0.1395 -0.1611 -1.1382 -0.0908 -0.5248 -0.0474 -0.1353 -0.1194 -0.1286 -0.9586 -0.0807 -0.1423 -0.2079 -0.1312 -0.0704 -0.1349 -0.1474 -0.1922 -0.1733 -0.1254 -0.0954 -0.0293 -0.1153 -0.1309 -0.1530 -1.0958 -1.4446 -0.1508 -0.2245 -0.0827 -0.1299 -0.1574 -0.1513 -0.1534
S-1831	Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira , Edifício 10 P-2710-089 Sintra Tel : <unk> 351 21 925 25 00
T-1831	Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira , Edifício 10 P-2710-089 Sintra Tel : <<unk>> 351 21 925 25 00
H-1831	-0.1499696969985962	Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira , Edifício 10 P-2710 -089 Sintra Tel : <unk> 351 21 925 25 00
D-1831	-0.1499696969985962	Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira , Edifício 10 P-2710 -089 Sintra Tel : <unk> 351 21 925 25 00
P-1831	-0.0463 -0.2289 -0.1902 -0.1319 -0.1691 -0.0795 -0.1289 -0.3340 -0.0777 -0.0686 -0.0182 -0.1259 -0.2683 -0.1209 -0.0893 -0.0828 -0.1851 -0.0708 -0.0925 -0.1064 -0.3315 -0.0691 -0.1086 -0.1261 -0.1774 -0.1432 -0.0786 -0.1557 -0.4328 -0.1044 -0.0577 -0.1713 -0.1543 -0.1049 -0.1163 -0.0812 -0.5826 -0.5087 -0.0965 -0.1109 -0.0781 -0.1879 -0.0580 -0.1392 -0.0347 -0.1194 -0.0818 -0.1091 -0.1268 -0.1100 -0.1293 -0.2956 -0.1512
S-830	ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-830	ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-830	-0.23274360597133636	ADVATE contains recombinant blood coagulation factor VIII ( Octocog alfa ) , a glycoprotein equivalent to that found in human plasma .
D-830	-0.23274360597133636	ADVATE contains recombinant blood coagulation factor VIII ( Octocog alfa ) , a glycoprotein equivalent to that found in human plasma .
P-830	-0.0637 -0.1497 -0.0781 -0.1081 -0.0600 -0.1424 -0.1115 -0.0979 -0.1395 -0.1611 -1.1382 -0.0908 -0.5248 -0.0474 -0.1353 -0.1194 -0.1286 -0.9586 -0.0807 -0.1423 -0.2079 -0.1312 -0.0704 -0.1349 -0.1474 -0.1922 -0.1733 -0.1254 -0.0954 -0.0293 -0.1153 -0.1309 -0.1530 -1.0958 -1.4446 -0.1508 -0.2245 -0.0827 -0.1299 -0.1574 -0.1513 -0.1534
S-1815	België<unk> Belgique<unk> Belgien Baxter Belgium SPRL Bd. de la Plaine<unk> Pleinlaan 5 B-1050 Brussel<unk> Bruxelles<unk> Brüssel Tél<unk> Tel : <unk> 32 2 650 1711
T-1815	België/ Belgique/ Belgien Baxter Belgium SPRL Bd . de la Plaine/ Pleinlaan 5 B-1050 Brussel/ Bruxelles/ Brüssel Tél/ Tel : <<unk>> 32 2 650 1711
H-1815	-0.17785705626010895	België/ Belgique/ Belgien Baxter Belgium SPRL Bd. de la Plaine/ Pleinlaan 5 B-1050 Brussel/ Bruxelles/ Brüssel Tél/ Tel : <unk> 32 2 650 1711
D-1815	-0.17785705626010895	België/ Belgique/ Belgien Baxter Belgium SPRL Bd. de la Plaine/ Pleinlaan 5 B-1050 Brussel/ Bruxelles/ Brüssel Tél/ Tel : <unk> 32 2 650 1711
P-1815	-0.0305 -0.0175 -0.1016 -0.0285 -0.1124 -0.1232 -0.1324 -0.0282 -0.2229 -0.1463 -0.1456 -0.1944 -0.0842 -0.1252 -0.1236 -0.1361 -0.0470 -0.1241 -0.1993 -0.1498 -0.0363 -0.1007 -0.3286 -0.0829 -0.1032 -0.1236 -0.1126 -0.1205 -0.1361 -0.2397 -0.1336 -0.5738 -0.1337 -0.1713 -0.3610 -0.1357 -0.1019 -0.1947 -0.1210 -2.1169 -0.1403 -0.0803 -0.1326 -0.1524 -0.0604 -0.1394 -0.0446 -0.0986 -0.1341 -0.3669 -0.1110 -0.1060 -0.1592
S-651	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-651	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-651	-0.3540579378604889	Sporadic occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes was reported in four patients during multiple repeated product exposures during the study .
D-651	-0.3540579378604889	Sporadic occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes was reported in four patients during multiple repeated product exposures during the study .
P-651	-1.7784 -0.0215 -0.1093 -1.3030 -0.0320 -0.3492 -0.1276 -0.1353 -0.0895 -0.0484 -0.0893 -0.1513 -0.0947 -0.0333 -0.0324 -0.1184 -0.1577 -0.0994 -0.0591 -0.2029 -0.1523 -1.4066 -0.1605 -0.0860 -0.1612 -0.1348 -1.4497 -0.0948 -0.2459 -0.1467 -0.1321 -0.0645 -0.1268 -1.8286 -0.1531 -0.1316 -0.1089 -0.0444 -0.5593 -0.8510 -1.3301 -0.0774 -0.7877 -0.0973 -0.0930 -0.9721 -0.1713 -0.8080 -0.1425 -0.1520
S-1177	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-1177	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-1177	-0.3540579378604889	Sporadic occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes was reported in four patients during multiple repeated product exposures during the study .
D-1177	-0.3540579378604889	Sporadic occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes was reported in four patients during multiple repeated product exposures during the study .
P-1177	-1.7784 -0.0215 -0.1093 -1.3030 -0.0320 -0.3492 -0.1276 -0.1353 -0.0895 -0.0484 -0.0893 -0.1513 -0.0947 -0.0333 -0.0324 -0.1184 -0.1577 -0.0994 -0.0591 -0.2029 -0.1523 -1.4066 -0.1605 -0.0860 -0.1612 -0.1348 -1.4497 -0.0948 -0.2459 -0.1467 -0.1321 -0.0645 -0.1268 -1.8286 -0.1531 -0.1316 -0.1089 -0.0444 -0.5593 -0.8510 -1.3301 -0.0774 -0.7877 -0.0973 -0.0930 -0.9721 -0.1713 -0.8080 -0.1425 -0.1520
S-825	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-825	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-825	-0.3540579378604889	Sporadic occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes was reported in four patients during multiple repeated product exposures during the study .
D-825	-0.3540579378604889	Sporadic occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes was reported in four patients during multiple repeated product exposures during the study .
P-825	-1.7784 -0.0215 -0.1093 -1.3030 -0.0320 -0.3492 -0.1276 -0.1353 -0.0895 -0.0484 -0.0893 -0.1513 -0.0947 -0.0333 -0.0324 -0.1184 -0.1577 -0.0994 -0.0591 -0.2029 -0.1523 -1.4066 -0.1605 -0.0860 -0.1612 -0.1348 -1.4497 -0.0948 -0.2459 -0.1467 -0.1321 -0.0645 -0.1268 -1.8286 -0.1531 -0.1316 -0.1089 -0.0444 -0.5593 -0.8510 -1.3301 -0.0774 -0.7877 -0.0973 -0.0930 -0.9721 -0.1713 -0.8080 -0.1425 -0.1520
S-1001	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-1001	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-1001	-0.3540579378604889	Sporadic occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes was reported in four patients during multiple repeated product exposures during the study .
D-1001	-0.3540579378604889	Sporadic occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes was reported in four patients during multiple repeated product exposures during the study .
P-1001	-1.7784 -0.0215 -0.1093 -1.3030 -0.0320 -0.3492 -0.1276 -0.1353 -0.0895 -0.0484 -0.0893 -0.1513 -0.0947 -0.0333 -0.0324 -0.1184 -0.1577 -0.0994 -0.0591 -0.2029 -0.1523 -1.4066 -0.1605 -0.0860 -0.1612 -0.1348 -1.4497 -0.0948 -0.2459 -0.1467 -0.1321 -0.0645 -0.1268 -1.8286 -0.1531 -0.1316 -0.1089 -0.0444 -0.5593 -0.8510 -1.3301 -0.0774 -0.7877 -0.0973 -0.0930 -0.9721 -0.1713 -0.8080 -0.1425 -0.1520
S-424	Der Alendronatbestandteil der ADROVANCE Kombinationstablette ( 70 mg<unk> 5.600 I.E. ) und einer Tablette mit 70 mg Alendronat sind bioäquivalent .
T-424	The alendronate component in the ADROVANCE ( 70mg/ 5600 IU ) combination tablet is bioequivalent to the alendronate 70 mg tablet .
H-424	-0.22961048781871796	The alendronate component of the ADROVANCE combination tablet ( 70 mg/ 5,600 IU ) and a tablet of 70 mg alendronate are bioequivalent .
D-424	-0.22961048781871796	The alendronate component of the ADROVANCE combination tablet ( 70 mg/ 5,600 IU ) and a tablet of 70 mg alendronate are bioequivalent .
P-424	-0.1757 -0.1509 -0.1508 -0.1494 -0.6548 -0.2820 -2.4768 -0.1018 -0.1594 -0.1368 -0.1064 -0.0797 -0.1141 -0.1089 -0.1337 -0.1302 -0.2447 -0.1450 -0.1355 -0.1200 -0.1634 -0.1307 -0.1295 -0.4167 -0.0839 -0.1117 -0.0864 -0.1262 -0.1511 -0.3249 -0.6196 -0.0987 -0.5788 -0.1139 -0.0394 -0.1912 -0.1719 -0.1142 -0.0661 -0.2200 -0.0600 -0.0514 -0.1445 -0.1520
S-1530	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-1530	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-1530	-0.3540579378604889	Sporadic occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes was reported in four patients during multiple repeated product exposures during the study .
D-1530	-0.3540579378604889	Sporadic occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes was reported in four patients during multiple repeated product exposures during the study .
P-1530	-1.7784 -0.0215 -0.1093 -1.3030 -0.0320 -0.3492 -0.1276 -0.1353 -0.0895 -0.0484 -0.0893 -0.1513 -0.0947 -0.0333 -0.0324 -0.1184 -0.1577 -0.0994 -0.0591 -0.2029 -0.1523 -1.4066 -0.1605 -0.0860 -0.1612 -0.1348 -1.4497 -0.0948 -0.2459 -0.1467 -0.1321 -0.0645 -0.1268 -1.8286 -0.1531 -0.1316 -0.1089 -0.0444 -0.5593 -0.8510 -1.3301 -0.0774 -0.7877 -0.0973 -0.0930 -0.9721 -0.1713 -0.8080 -0.1425 -0.1520
S-228	Der Alendronatbestandteil der ADROVANCE Kombinationstablette ( 70 mg<unk> 2.800 I.E. ) und der Tablette mit 70 mg Alendronat sind bioäquivalent .
T-228	The alendronate component in the ADROVANCE ( 70 mg/ 2800 IU ) combination tablet is bioequivalent to the alendronate 70 mg tablet .
H-228	-0.2317090630531311	The alendronate component of the ADROVANCE combination tablet ( 70 mg/ 2,800 IU ) and the 70 mg alendronate tablet are bioequivalent .
D-228	-0.2317090630531311	The alendronate component of the ADROVANCE combination tablet ( 70 mg/ 2,800 IU ) and the 70 mg alendronate tablet are bioequivalent .
P-228	-0.1675 -0.1469 -0.1535 -0.1511 -0.5167 -0.2780 -2.5018 -0.1026 -0.1621 -0.1350 -0.1054 -0.0796 -0.1138 -0.1086 -0.1315 -0.1386 -0.2850 -0.1433 -0.1340 -0.1164 -0.1726 -0.1334 -0.1280 -0.2121 -0.1125 -0.1156 -0.0823 -0.1248 -0.1296 -1.1486 -0.3250 -0.0425 -0.1895 -0.1684 -0.1146 -0.0638 -0.2066 -0.1164 -0.2838 -0.0638 -0.0632 -0.1433 -0.1519
S-309	Es stehen keine Daten zur Verfügung , die Hinweise geben , ob das Absetzen einer Bisphosphonattherapie bei Patienten , die einen kieferchirurgischen Eingriff benötigen , das Risiko einer Osteonekrose des Kiefers vermindert .
T-309	For patients requiring dental procedures , there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw .
H-309	-0.35579144954681396	Data are not available to show whether discontinuation of bisphosphonate therapy in patients in need of maxillofacial surgery decreases the risk of osteonecrosis of the jaw .
D-309	-0.35579144954681396	Data are not available to show whether discontinuation of bisphosphonate therapy in patients in need of maxillofacial surgery decreases the risk of osteonecrosis of the jaw .
P-309	-1.4693 -0.1760 -0.5131 -0.2912 -0.1607 -2.8608 -0.1388 -0.1047 -0.0128 -0.1133 -0.1514 -0.1055 -0.0292 -0.0330 -0.5970 -0.5238 -0.1150 -0.8085 -0.2297 -1.9077 -0.1844 -0.1521 -0.8669 -0.1901 -0.3394 -0.3154 -0.0539 -0.0460 -1.2635 -0.0559 -0.1383 -0.0936 -0.1453 -0.6397 -0.0768 -0.1262 -0.1087 -0.0094 -0.1167 -0.1520 -0.1143 -0.0618 -0.1224 -0.1373 -0.1588
S-121	Es stehen keine Daten zur Verfügung , die Hinweise geben , ob das Absetzen einer Bisphosphonattherapie bei Patienten , die einen kieferchirurgischen Eingriff benötigen , das Risiko einer Osteonekrose des Kiefers vermindert .
T-121	For patients requiring dental procedures , there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw .
H-121	-0.35579144954681396	Data are not available to show whether discontinuation of bisphosphonate therapy in patients in need of maxillofacial surgery decreases the risk of osteonecrosis of the jaw .
D-121	-0.35579144954681396	Data are not available to show whether discontinuation of bisphosphonate therapy in patients in need of maxillofacial surgery decreases the risk of osteonecrosis of the jaw .
P-121	-1.4693 -0.1760 -0.5131 -0.2912 -0.1607 -2.8608 -0.1388 -0.1047 -0.0128 -0.1133 -0.1514 -0.1055 -0.0292 -0.0330 -0.5970 -0.5238 -0.1150 -0.8085 -0.2297 -1.9077 -0.1844 -0.1521 -0.8669 -0.1901 -0.3394 -0.3154 -0.0539 -0.0460 -1.2635 -0.0559 -0.1383 -0.0936 -0.1453 -0.6397 -0.0768 -0.1262 -0.1087 -0.0094 -0.1167 -0.1520 -0.1143 -0.0618 -0.1224 -0.1373 -0.1588
S-457	Studien an Ratten zeigten , dass die Gabe von Alendronat an trächtige Ratten mit dem Auftreten von Dystokie bei den Muttertieren einherging , die auf eine Hypocalcämie zurückzuführen war .
T-457	Studies in rats have shown that treatment with alendronate during pregnancy was associated with dystocia in dams during parturition which was related to hypocalcaemia .
H-457	-0.517478883266449	Studies in rats showed that administration of alendronate to pregnant rats was associated with the occurrence of dystokia in their mothers due to hypocalcaemia .
D-457	-0.517478883266449	Studies in rats showed that administration of alendronate to pregnant rats was associated with the occurrence of dystokia in their mothers due to hypocalcaemia .
P-457	-0.8061 -0.1301 -0.0694 -2.1688 -0.1195 -1.9979 -0.1529 -0.1606 -0.1504 -0.1199 -0.0739 -0.1620 -0.0775 -0.1039 -0.2971 -0.5173 -0.1351 -0.7936 -1.7720 -0.0434 -0.0728 -0.1180 -0.1639 -1.0854 -3.6443 -0.4487 -0.1201 -0.1541 -1.0128 -1.4946 -1.1887 -0.1504 -0.0353 -0.0874 -0.0692 -0.0577 -0.1290 -0.1418 -0.1562
S-261	Studien an Ratten zeigten , dass die Gabe von Alendronat an trächtige Ratten mit dem Auftreten von Dystokie bei den Muttertieren einherging , die auf eine Hypocalcämie zurückzuführen war .
T-261	Studies in rats have shown that treatment with alendronate during pregnancy was associated with dystocia in dams during parturition which was related to hypocalcaemia .
H-261	-0.517478883266449	Studies in rats showed that administration of alendronate to pregnant rats was associated with the occurrence of dystokia in their mothers due to hypocalcaemia .
D-261	-0.517478883266449	Studies in rats showed that administration of alendronate to pregnant rats was associated with the occurrence of dystokia in their mothers due to hypocalcaemia .
P-261	-0.8061 -0.1301 -0.0694 -2.1688 -0.1195 -1.9979 -0.1529 -0.1606 -0.1504 -0.1199 -0.0739 -0.1620 -0.0775 -0.1039 -0.2971 -0.5173 -0.1351 -0.7936 -1.7720 -0.0434 -0.0728 -0.1180 -0.1639 -1.0854 -3.6443 -0.4487 -0.1201 -0.1541 -1.0128 -1.4946 -1.1887 -0.1504 -0.0353 -0.0874 -0.0692 -0.0577 -0.1290 -0.1418 -0.1562
S-467	INHABER DER HERSTELLUNGSERLAUBNIS , DER ( DIE ) FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST ( SIND
T-467	MANUFACTURING AUTHORISATION HOLDER<<unk>> S ) RESPONSIBLE FOR BATCH RELEASE
H-467	-0.21890690922737122	MANUFACTURING AUTHORISATION HOLDER ( s ) RESPONSIBLE FOR BATCH RELEASE (
D-467	-0.21890690922737122	MANUFACTURING AUTHORISATION HOLDER ( s ) RESPONSIBLE FOR BATCH RELEASE (
P-467	-0.6931 -0.0144 -0.0691 -0.0298 -0.0170 -0.0505 -0.0329 -0.0384 -0.0201 -0.0208 -0.0527 -0.0170 -0.0111 -0.0683 -0.0844 -0.0587 -0.7749 -0.1122 -1.4850 -0.1276 -0.1555 -0.0548 -0.0445 -0.0912 -0.0195 -0.0850 -0.0702 -0.0737 -0.0408 -0.0514 -0.1085 -0.2273 -0.0268 -0.0720 -0.1029 -0.1589 -2.9385
S-1401	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-1401	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-1401	-0.3685038685798645	When the product is in a refrigerator , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
D-1401	-0.3685038685798645	When the product is in a refrigerator , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
P-1401	-1.4820 -1.0306 -0.0925 -0.0971 -2.1958 -0.2848 -0.1115 -0.0709 -0.0773 -0.1155 -0.1520 -0.7778 -0.2488 -0.0345 -0.1745 -1.1283 -0.1271 -0.1521 -0.0739 -0.0845 -0.0846 -0.1454 -0.2064 -0.5960 -0.1483 -0.1516 -0.2642 -0.0441 -0.0777 -0.1026 -0.1132 -0.8393 -0.4961 -2.0560 -0.2017 -0.0980 -0.1612 -0.1220 -0.1427 -0.1203 -0.3414 -0.4526 -1.2396 -0.1557 -0.1598 -0.1350 -0.1526
S-1353	Bei vier Patienten wurde vereinzelt über das Auftreten von Urtikaria , Pruritus , Hautausschlag und erhöhte Anzahl eosinophiler Granulozyten bei mehreren wiederholten Produktexpositionen im Rahmen der Studie berichtet .
T-1353	Four of these patients reported isolated events of urticaria , pruritus , rash , and slightly elevated eosinophil counts amongst numerous repeated exposures to the study product .
H-1353	-0.3540579378604889	Sporadic occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes was reported in four patients during multiple repeated product exposures during the study .
D-1353	-0.3540579378604889	Sporadic occurrence of urticaria , pruritus , rash and increased number of eosinophilic granulocytes was reported in four patients during multiple repeated product exposures during the study .
P-1353	-1.7784 -0.0215 -0.1093 -1.3030 -0.0320 -0.3492 -0.1276 -0.1353 -0.0895 -0.0484 -0.0893 -0.1513 -0.0947 -0.0333 -0.0324 -0.1184 -0.1577 -0.0994 -0.0591 -0.2029 -0.1523 -1.4066 -0.1605 -0.0860 -0.1612 -0.1348 -1.4497 -0.0948 -0.2459 -0.1467 -0.1321 -0.0645 -0.1268 -1.8286 -0.1531 -0.1316 -0.1089 -0.0444 -0.5593 -0.8510 -1.3301 -0.0774 -0.7877 -0.0973 -0.0930 -0.9721 -0.1713 -0.8080 -0.1425 -0.1520
S-399	Der Anteil an Patientinnen mit Vitamin-D-Insuffizienz betrug während der 24-wöchigen Verlängerungsstudie 5,4 % in der 2.800-I.E.- Vitamin-D3-Gruppe vs .
T-399	The percentage of patients with vitamin D insufficiency was 5.4 % in the Vitamin D3 2800 group vs.
H-399	-0.39019957184791565	The proportion of patients with vitamin D deficiency during the 24 week extension trial was 5.4 % in the 2,800 IU vitamin D3 group vs.
D-399	-0.39019957184791565	The proportion of patients with vitamin D deficiency during the 24 week extension trial was 5.4 % in the 2,800 IU vitamin D3 group vs.
P-399	-0.3435 -1.1918 -0.1868 -1.4287 -0.1724 -0.5539 -0.0815 -0.2070 -1.8774 -0.0436 -0.1847 -0.4178 -0.1330 -0.5147 -0.3429 -0.9262 -1.3125 -0.1197 -0.0739 -0.1263 -0.1239 -0.2848 -0.1301 -0.3694 -0.1014 -0.0920 -0.3344 -0.2853 -0.0955 -0.2143 -0.1249 -0.2644 -0.3033 -0.3048
S-873	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-873	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-873	-0.3685038685798645	When the product is in a refrigerator , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
D-873	-0.3685038685798645	When the product is in a refrigerator , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
P-873	-1.4820 -1.0306 -0.0925 -0.0971 -2.1958 -0.2848 -0.1115 -0.0709 -0.0773 -0.1155 -0.1520 -0.7778 -0.2488 -0.0345 -0.1745 -1.1283 -0.1271 -0.1521 -0.0739 -0.0845 -0.0846 -0.1454 -0.2064 -0.5960 -0.1483 -0.1516 -0.2642 -0.0441 -0.0777 -0.1026 -0.1132 -0.8393 -0.4961 -2.0560 -0.2017 -0.0980 -0.1612 -0.1220 -0.1427 -0.1203 -0.3414 -0.4526 -1.2396 -0.1557 -0.1598 -0.1350 -0.1526
S-1291	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-1291	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-1291	-0.3895978033542633	If the expected Factor VIII-plasma activities are not achieved , or if bleeding is not controlled at an appropriate dose , a test must be performed to detect an inhibitor if necessary .
D-1291	-0.3895978033542633	If the expected Factor VIII-plasma activities are not achieved , or if bleeding is not controlled at an appropriate dose , a test must be performed to detect an inhibitor if necessary .
P-1291	-0.2175 -0.2857 -0.3107 -1.3139 -0.5222 -0.1312 -1.2868 -0.3382 -0.5236 -0.0666 -0.0905 -0.7400 -0.1761 -0.2219 -0.0988 -0.4901 -0.1405 -0.0453 -1.5411 -0.1425 -0.2754 -0.2646 -0.1304 -0.3008 -0.7939 -0.3617 -0.1031 -0.1498 -0.2202 -0.1226 -1.5924 -0.1672 -0.7293 -0.1847 -0.5792 -0.0956 -0.2824 -0.0973 -0.0252 -0.0708 -0.1473 -1.5581 -0.2944 -0.1494 -0.1529
S-1578	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-1578	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-1578	-0.3685038685798645	When the product is in a refrigerator , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
D-1578	-0.3685038685798645	When the product is in a refrigerator , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
P-1578	-1.4820 -1.0306 -0.0925 -0.0971 -2.1958 -0.2848 -0.1115 -0.0709 -0.0773 -0.1155 -0.1520 -0.7778 -0.2488 -0.0345 -0.1745 -1.1283 -0.1271 -0.1521 -0.0739 -0.0845 -0.0846 -0.1454 -0.2064 -0.5960 -0.1483 -0.1516 -0.2642 -0.0441 -0.0777 -0.1026 -0.1132 -0.8393 -0.4961 -2.0560 -0.2017 -0.0980 -0.1612 -0.1220 -0.1427 -0.1203 -0.3414 -0.4526 -1.2396 -0.1557 -0.1598 -0.1350 -0.1526
S-1225	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-1225	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-1225	-0.3685038685798645	When the product is in a refrigerator , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
D-1225	-0.3685038685798645	When the product is in a refrigerator , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
P-1225	-1.4820 -1.0306 -0.0925 -0.0971 -2.1958 -0.2848 -0.1115 -0.0709 -0.0773 -0.1155 -0.1520 -0.7778 -0.2488 -0.0345 -0.1745 -1.1283 -0.1271 -0.1521 -0.0739 -0.0845 -0.0846 -0.1454 -0.2064 -0.5960 -0.1483 -0.1516 -0.2642 -0.0441 -0.0777 -0.1026 -0.1132 -0.8393 -0.4961 -2.0560 -0.2017 -0.0980 -0.1612 -0.1220 -0.1427 -0.1203 -0.3414 -0.4526 -1.2396 -0.1557 -0.1598 -0.1350 -0.1526
S-1467	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-1467	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-1467	-0.3895978033542633	If the expected Factor VIII-plasma activities are not achieved , or if bleeding is not controlled at an appropriate dose , a test must be performed to detect an inhibitor if necessary .
D-1467	-0.3895978033542633	If the expected Factor VIII-plasma activities are not achieved , or if bleeding is not controlled at an appropriate dose , a test must be performed to detect an inhibitor if necessary .
P-1467	-0.2175 -0.2857 -0.3107 -1.3139 -0.5222 -0.1312 -1.2868 -0.3382 -0.5236 -0.0666 -0.0905 -0.7400 -0.1761 -0.2219 -0.0988 -0.4901 -0.1405 -0.0453 -1.5411 -0.1425 -0.2754 -0.2646 -0.1304 -0.3008 -0.7939 -0.3617 -0.1031 -0.1498 -0.2202 -0.1226 -1.5924 -0.1672 -0.7293 -0.1847 -0.5792 -0.0956 -0.2824 -0.0973 -0.0252 -0.0708 -0.1473 -1.5581 -0.2944 -0.1494 -0.1529
S-1049	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-1049	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-1049	-0.3685038685798645	When the product is in a refrigerator , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
D-1049	-0.3685038685798645	When the product is in a refrigerator , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
P-1049	-1.4820 -1.0306 -0.0925 -0.0971 -2.1958 -0.2848 -0.1115 -0.0709 -0.0773 -0.1155 -0.1520 -0.7778 -0.2488 -0.0345 -0.1745 -1.1283 -0.1271 -0.1521 -0.0739 -0.0845 -0.0846 -0.1454 -0.2064 -0.5960 -0.1483 -0.1516 -0.2642 -0.0441 -0.0777 -0.1026 -0.1132 -0.8393 -0.4961 -2.0560 -0.2017 -0.0980 -0.1612 -0.1220 -0.1427 -0.1203 -0.3414 -0.4526 -1.2396 -0.1557 -0.1598 -0.1350 -0.1526
S-13	Während der ersten Behandlungsmonate können immer noch Gichtanfälle auftreten ; deshalb wird empfohlen , dass die Patienten mindestens während der ersten sechs Monate unter Behandlung mit Adenuric noch weitere Arzneimittel zur Verhütung von Gichtanfällen einnehmen .
T-13	Attacks of gout can still occur during the first few months of treatment , so it is recommended that patients take other medicines to prevent attacks of gout for at least the first six months of treatment with Adenuric .
H-13	-0.3926462233066559	Attacks of gout may still occur during the first months of treatment ; it is therefore recommended that patients take other medicines to prevent gout attacks during at least the first six months of treatment with Adenuric .
D-13	-0.3926462233066559	Attacks of gout may still occur during the first months of treatment ; it is therefore recommended that patients take other medicines to prevent gout attacks during at least the first six months of treatment with Adenuric .
P-13	-0.7945 -0.3545 -0.5398 -0.1209 -0.5154 -1.0861 -0.2386 -0.0679 -0.0992 -0.1300 -0.1287 -1.5429 -0.1422 -0.4411 -0.7642 -0.7719 -0.1228 -0.6416 -0.0666 -0.1351 -0.6031 -0.3680 -2.2544 -0.1634 -0.9029 -0.1323 -0.1583 -0.7870 -0.3609 -0.9632 -0.6113 -0.1467 -0.1061 -0.1339 -0.1512 -0.1092 -0.1378 -0.2617 -0.0656 -0.1306 -0.1213 -0.1914 -0.0844 -0.1153 -0.1450 -0.1525
S-697	Wenn das Produkt noch im Kühlschrank gelagert wird , beide Durchstechflaschen mit ADVATE Pulver und Lösungsmittel aus dem Kühlschrank entnehmen und auf Raumtemperatur ( zwischen 15 und 25<unk> C ) aufwärmen lassen .
T-697	If the product is still stored in a refrigerator , take both the ADVATE powder and solvent vials from the refrigerator and let them reach room temperature ( between 15<<unk>> C and 25<<unk>> C ) .
H-697	-0.3685038685798645	When the product is in a refrigerator , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
D-697	-0.3685038685798645	When the product is in a refrigerator , remove both vials of ADVATE powder and solvent from the refrigerator and allow to heat to room temperature ( between 15 and 25<unk> C ) .
P-697	-1.4820 -1.0306 -0.0925 -0.0971 -2.1958 -0.2848 -0.1115 -0.0709 -0.0773 -0.1155 -0.1520 -0.7778 -0.2488 -0.0345 -0.1745 -1.1283 -0.1271 -0.1521 -0.0739 -0.0845 -0.0846 -0.1454 -0.2064 -0.5960 -0.1483 -0.1516 -0.2642 -0.0441 -0.0777 -0.1026 -0.1132 -0.8393 -0.4961 -2.0560 -0.2017 -0.0980 -0.1612 -0.1220 -0.1427 -0.1203 -0.3414 -0.4526 -1.2396 -0.1557 -0.1598 -0.1350 -0.1526
S-1990	Da sich Reproduktionsstudien an Tieren nicht immer auf den Menschen übertragen lassen und auf Grund der vasokonstriktorischen Eigenschaften von Pseudoephedrin sollte Aerinaze in der Schwangerschaft nicht angewendet werden .
T-1990	4 Because animal reproduction studies are not always predictive of human response , and due to the vasoconstrictive properties of pseudoephedrine , Aerinaze should not be used during pregnancy .
H-1990	-0.41088029742240906	Since reproduction studies in animals cannot always be transmitted to humans , and due to the vasoconstrictory characteristics of pseudoephedrine , Aerinaze should not be used in pregnancy .
D-1990	-0.41088029742240906	Since reproduction studies in animals cannot always be transmitted to humans , and due to the vasoconstrictory characteristics of pseudoephedrine , Aerinaze should not be used in pregnancy .
P-1990	-2.7953 -0.2144 -0.3763 -0.1222 -0.1344 -0.0832 -0.4663 -0.0933 -0.1524 -3.1178 -0.5842 -0.1774 -0.9368 -1.0601 -0.1555 -0.5234 -0.1458 -0.4214 -0.0757 -0.1711 -0.1445 -0.3854 -0.0777 -1.6458 -0.9746 -1.3555 -0.1151 -0.1521 -0.1094 -0.6949 -0.1768 -0.0639 -0.1439 -0.1276 -0.1162 -0.2174 -0.1974 -0.1118 -0.1141 -0.1659 -0.1210 -0.1750 -0.1336 -0.1199 -0.1225 -0.1538 -0.1173 -0.1371 -0.1562
S-1115	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-1115	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-1115	-0.3895978033542633	If the expected Factor VIII-plasma activities are not achieved , or if bleeding is not controlled at an appropriate dose , a test must be performed to detect an inhibitor if necessary .
D-1115	-0.3895978033542633	If the expected Factor VIII-plasma activities are not achieved , or if bleeding is not controlled at an appropriate dose , a test must be performed to detect an inhibitor if necessary .
P-1115	-0.2175 -0.2857 -0.3107 -1.3139 -0.5222 -0.1312 -1.2868 -0.3382 -0.5236 -0.0666 -0.0905 -0.7400 -0.1761 -0.2219 -0.0988 -0.4901 -0.1405 -0.0453 -1.5411 -0.1425 -0.2754 -0.2646 -0.1304 -0.3008 -0.7939 -0.3617 -0.1031 -0.1498 -0.2202 -0.1226 -1.5924 -0.1672 -0.7293 -0.1847 -0.5792 -0.0956 -0.2824 -0.0973 -0.0252 -0.0708 -0.1473 -1.5581 -0.2944 -0.1494 -0.1529
S-939	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-939	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-939	-0.3895978033542633	If the expected Factor VIII-plasma activities are not achieved , or if bleeding is not controlled at an appropriate dose , a test must be performed to detect an inhibitor if necessary .
D-939	-0.3895978033542633	If the expected Factor VIII-plasma activities are not achieved , or if bleeding is not controlled at an appropriate dose , a test must be performed to detect an inhibitor if necessary .
P-939	-0.2175 -0.2857 -0.3107 -1.3139 -0.5222 -0.1312 -1.2868 -0.3382 -0.5236 -0.0666 -0.0905 -0.7400 -0.1761 -0.2219 -0.0988 -0.4901 -0.1405 -0.0453 -1.5411 -0.1425 -0.2754 -0.2646 -0.1304 -0.3008 -0.7939 -0.3617 -0.1031 -0.1498 -0.2202 -0.1226 -1.5924 -0.1672 -0.7293 -0.1847 -0.5792 -0.0956 -0.2824 -0.0973 -0.0252 -0.0708 -0.1473 -1.5581 -0.2944 -0.1494 -0.1529
S-763	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-763	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-763	-0.3895978033542633	If the expected Factor VIII-plasma activities are not achieved , or if bleeding is not controlled at an appropriate dose , a test must be performed to detect an inhibitor if necessary .
D-763	-0.3895978033542633	If the expected Factor VIII-plasma activities are not achieved , or if bleeding is not controlled at an appropriate dose , a test must be performed to detect an inhibitor if necessary .
P-763	-0.2175 -0.2857 -0.3107 -1.3139 -0.5222 -0.1312 -1.2868 -0.3382 -0.5236 -0.0666 -0.0905 -0.7400 -0.1761 -0.2219 -0.0988 -0.4901 -0.1405 -0.0453 -1.5411 -0.1425 -0.2754 -0.2646 -0.1304 -0.3008 -0.7939 -0.3617 -0.1031 -0.1498 -0.2202 -0.1226 -1.5924 -0.1672 -0.7293 -0.1847 -0.5792 -0.0956 -0.2824 -0.0973 -0.0252 -0.0708 -0.1473 -1.5581 -0.2944 -0.1494 -0.1529
S-589	Falls die erwarteten Faktor VIII-Plasmaaktivitäten nicht erreicht werden oder wenn die Blutung mit einer angemessenen Dosis nicht beherrscht wird , muss ein Test durchgeführt werden , um ggf. einen Inhibitor nachzuweisen .
T-589	If the expected factor VIII plasma activity levels are not attained , or if bleeding is not controlled with an appropriate dose , an assay should be performed to determine if a factor VIII inhibitor is present .
H-589	-0.3895978033542633	If the expected Factor VIII-plasma activities are not achieved , or if bleeding is not controlled at an appropriate dose , a test must be performed to detect an inhibitor if necessary .
D-589	-0.3895978033542633	If the expected Factor VIII-plasma activities are not achieved , or if bleeding is not controlled at an appropriate dose , a test must be performed to detect an inhibitor if necessary .
P-589	-0.2175 -0.2857 -0.3107 -1.3139 -0.5222 -0.1312 -1.2868 -0.3382 -0.5236 -0.0666 -0.0905 -0.7400 -0.1761 -0.2219 -0.0988 -0.4901 -0.1405 -0.0453 -1.5411 -0.1425 -0.2754 -0.2646 -0.1304 -0.3008 -0.7939 -0.3617 -0.1031 -0.1498 -0.2202 -0.1226 -1.5924 -0.1672 -0.7293 -0.1847 -0.5792 -0.0956 -0.2824 -0.0973 -0.0252 -0.0708 -0.1473 -1.5581 -0.2944 -0.1494 -0.1529
S-842	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-842	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-842	-0.2391865849494934	Summary of ADVATE pharmacokinetic parameters for 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-842	-0.2391865849494934	Summary of ADVATE pharmacokinetic parameters for 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-842	-0.8873 -0.0641 -0.1614 -0.5029 -0.1468 -0.0771 -0.0832 -1.2772 -0.1227 -0.0776 -0.1155 -0.1670 -0.0580 -0.1173 -1.0135 -0.1642 -0.5546 -0.1447 -0.0772 -0.2517 -0.0733 -0.3151 -0.1034 -0.1529 -0.1820 -0.1464 -0.1337 -0.3557 -0.1590 -0.1097 -0.1194 -0.1483 -0.1201 -0.1282 -0.1281 -0.2034 -1.2381 -0.1704 -0.1184 -0.1355 -0.1157 -0.1175 -0.0704 -0.0970 -0.1378 -0.1589
S-1194	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-1194	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-1194	-0.2391865849494934	Summary of ADVATE pharmacokinetic parameters for 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-1194	-0.2391865849494934	Summary of ADVATE pharmacokinetic parameters for 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-1194	-0.8873 -0.0641 -0.1614 -0.5029 -0.1468 -0.0771 -0.0832 -1.2772 -0.1227 -0.0776 -0.1155 -0.1670 -0.0580 -0.1173 -1.0135 -0.1642 -0.5546 -0.1447 -0.0772 -0.2517 -0.0733 -0.3151 -0.1034 -0.1529 -0.1820 -0.1464 -0.1337 -0.3557 -0.1590 -0.1097 -0.1194 -0.1483 -0.1201 -0.1282 -0.1281 -0.2034 -1.2381 -0.1704 -0.1184 -0.1355 -0.1157 -0.1175 -0.0704 -0.0970 -0.1378 -0.1589
S-84	Jede Tablette enthält 70 mg Alendronsäure als Natriumalendronat 3 H2O und 70 Mikrogramm ( 2.800 I.E. ) Colecalciferol ( Vitamin D3 ) .
T-84	Each tablet contains 70 mg alendronic acid as alendronate sodium trihydrate , and 70 micrograms ( 2800 IU ) colecalciferol ( vitamin D3 ) .
H-84	-0.14092998206615448	Each tablet contains 70 mg alendronic acid as sodium alendronate 3 H2O and 70 micrograms ( 2,800 IU ) of colecalciferol ( vitamin D3 ) .
D-84	-0.14092998206615448	Each tablet contains 70 mg alendronic acid as sodium alendronate 3 H2O and 70 micrograms ( 2,800 IU ) of colecalciferol ( vitamin D3 ) .
P-84	-0.0414 -0.1124 -0.0954 -0.0497 -0.1320 -0.0539 -0.4647 -0.1404 -0.1350 -0.1158 -0.1012 -0.1614 -0.1169 -0.0405 -0.1696 -0.1685 -0.1544 -0.1206 -0.1570 -0.1060 -0.1047 -0.2013 -0.1508 -0.1059 -0.1050 -0.0479 -0.1482 -0.3106 -0.1238 -0.1027 -0.1057 -0.1323 -0.3719 -0.1375 -0.1473 -0.2121 -0.1031 -0.1027 -0.1741 -0.1369 -0.1741 -0.1076 -0.1162 -0.1281 -0.1370 -0.1480 -0.1515
S-1018	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-1018	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-1018	-0.2391865849494934	Summary of ADVATE pharmacokinetic parameters for 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-1018	-0.2391865849494934	Summary of ADVATE pharmacokinetic parameters for 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-1018	-0.8873 -0.0641 -0.1614 -0.5029 -0.1468 -0.0771 -0.0832 -1.2772 -0.1227 -0.0776 -0.1155 -0.1670 -0.0580 -0.1173 -1.0135 -0.1642 -0.5546 -0.1447 -0.0772 -0.2517 -0.0733 -0.3151 -0.1034 -0.1529 -0.1820 -0.1464 -0.1337 -0.3557 -0.1590 -0.1097 -0.1194 -0.1483 -0.1201 -0.1282 -0.1281 -0.2034 -1.2381 -0.1704 -0.1184 -0.1355 -0.1157 -0.1175 -0.0704 -0.0970 -0.1378 -0.1589
S-434	Nach intravenöser Gabe einer einzelnen Dosis von 10 mg betrug die renale Clearance von Alendronat 71 ml<unk> min und die systemische Clearance überschritt nicht 200 ml<unk> min .
T-434	Following a single 10 mg intravenous dose , the renal clearance of alendronate was 71 ml/ min , and systemic clearance did not exceed 200 ml/ min .
H-434	-0.21673999726772308	After the intravenous single dose of 10 mg , the renal clearance of alendronate was 71 ml/ min and the systemic clearance did not exceed 200 ml/ min .
D-434	-0.21673999726772308	After the intravenous single dose of 10 mg , the renal clearance of alendronate was 71 ml/ min and the systemic clearance did not exceed 200 ml/ min .
P-434	-0.9043 -0.4932 -0.5663 -0.0866 -0.0825 -0.1279 -1.4488 -0.0777 -0.1510 -0.1615 -0.0402 -0.2990 -0.4735 -0.0863 -0.1164 -0.0234 -0.1249 -0.1700 -0.1835 -0.1504 -0.0945 -0.0404 -0.1414 -0.0948 -0.1425 -0.1828 -0.1408 -0.2614 -0.1632 -1.1974 -0.0518 -0.0726 -0.0965 -0.0393 -0.1009 -0.0889 -0.1240 -0.0222 -0.0712 -0.1002 -0.1483 -0.1676 -0.1359 -0.2339 -0.1402 -0.1501
S-1370	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-1370	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-1370	-0.2391865849494934	Summary of ADVATE pharmacokinetic parameters for 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-1370	-0.2391865849494934	Summary of ADVATE pharmacokinetic parameters for 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-1370	-0.8873 -0.0641 -0.1614 -0.5029 -0.1468 -0.0771 -0.0832 -1.2772 -0.1227 -0.0776 -0.1155 -0.1670 -0.0580 -0.1173 -1.0135 -0.1642 -0.5546 -0.1447 -0.0772 -0.2517 -0.0733 -0.3151 -0.1034 -0.1529 -0.1820 -0.1464 -0.1337 -0.3557 -0.1590 -0.1097 -0.1194 -0.1483 -0.1201 -0.1282 -0.1281 -0.2034 -1.2381 -0.1704 -0.1184 -0.1355 -0.1157 -0.1175 -0.0704 -0.0970 -0.1378 -0.1589
S-1547	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-1547	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) Interquartile PK Parameter
H-1547	-0.2391865849494934	Summary of ADVATE pharmacokinetic parameters for 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-1547	-0.2391865849494934	Summary of ADVATE pharmacokinetic parameters for 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-1547	-0.8873 -0.0641 -0.1614 -0.5029 -0.1468 -0.0771 -0.0832 -1.2772 -0.1227 -0.0776 -0.1155 -0.1670 -0.0580 -0.1173 -1.0135 -0.1642 -0.5546 -0.1447 -0.0772 -0.2517 -0.0733 -0.3151 -0.1034 -0.1529 -0.1820 -0.1464 -0.1337 -0.3557 -0.1590 -0.1097 -0.1194 -0.1483 -0.1201 -0.1282 -0.1281 -0.2034 -1.2381 -0.1704 -0.1184 -0.1355 -0.1157 -0.1175 -0.0704 -0.0970 -0.1378 -0.1589
S-241	Alendronat wird bei Ratten nicht über das saure oder basische Transportsystem der Nieren ausgeschieden und daher wird nicht angenommen , dass es beim Menschen die Ausscheidung anderer Arzneimittel durch diese Transportsysteme beeinflusst .
T-241	Alendronate is not excreted through the acidic or basic transport systems of the kidney in rats , and thus it is not anticipated to interfere with the excretion of other medicinal products by those systems in humans .
H-241	-0.35866090655326843	Alendronate in rats is not excreted via the acidic or alkaline transport system of the kidneys and is therefore not thought to affect the excretion of other medicinal products through these transport systems in humans .
D-241	-0.35866090655326843	Alendronate in rats is not excreted via the acidic or alkaline transport system of the kidneys and is therefore not thought to affect the excretion of other medicinal products through these transport systems in humans .
P-241	-0.1596 -0.1689 -0.0973 -0.0336 -1.7685 -0.0671 -0.1504 -0.1730 -0.3411 -0.0113 -0.1010 -0.4066 -0.1771 -0.7443 -0.0296 -0.1951 -0.6960 -0.1055 -0.0875 -1.9865 -0.1813 -0.9869 -0.1342 -0.2901 -0.4519 -0.0744 -0.1964 -0.9278 -0.7620 -0.1494 -0.6879 -0.1410 -0.4675 -0.2718 -0.0979 -0.0146 -0.1290 -0.2797 -0.1250 -0.1700 -0.0490 -0.1039 -2.0699 -0.1902 -0.3538 -0.2815 -0.1681 -0.3700 -0.1570 -0.1508
S-437	Alendronat wird bei Ratten nicht über das saure oder basische Transportsystem der Nieren ausgeschieden und daher wird nicht angenommen , dass es beim Menschen die Ausscheidung anderer Arzneimittel durch diese Transportsysteme beeinflusst .
T-437	Alendronate is not excreted through the acidic or basic transport systems of the kidney in rats , and thus it is not anticipated to interfere with the excretion of other medicinal products by those systems in humans .
H-437	-0.35866090655326843	Alendronate in rats is not excreted via the acidic or alkaline transport system of the kidneys and is therefore not thought to affect the excretion of other medicinal products through these transport systems in humans .
D-437	-0.35866090655326843	Alendronate in rats is not excreted via the acidic or alkaline transport system of the kidneys and is therefore not thought to affect the excretion of other medicinal products through these transport systems in humans .
P-437	-0.1596 -0.1689 -0.0973 -0.0336 -1.7685 -0.0671 -0.1504 -0.1730 -0.3411 -0.0113 -0.1010 -0.4066 -0.1771 -0.7443 -0.0296 -0.1951 -0.6960 -0.1055 -0.0875 -1.9865 -0.1813 -0.9869 -0.1342 -0.2901 -0.4519 -0.0744 -0.1964 -0.9278 -0.7620 -0.1494 -0.6879 -0.1410 -0.4675 -0.2718 -0.0979 -0.0146 -0.1290 -0.2797 -0.1250 -0.1700 -0.0490 -0.1039 -2.0699 -0.1902 -0.3538 -0.2815 -0.1681 -0.3700 -0.1570 -0.1508
S-667	Tabelle 3 Zusammenfassung der Pharmakokinetischen Parameter von ADVATE bei 100 Patienten mit schwerer bis mäßiger Hämophilie A ( Faktor VIII <unk> 2 % ) PK-Parameter ( Pharmakokinetik )
T-667	Table 3 Summary of pharmacokinetic parameters for ADVATE in 100 patients with severe to moderately severe haemophilia A ( factor VIII 2 % ) PK Parameter AUC0- ( IU h/ dl ) t1/ 2 ( h ) Adjusted Recovery
H-667	-0.2391865849494934	Summary of ADVATE pharmacokinetic parameters for 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
D-667	-0.2391865849494934	Summary of ADVATE pharmacokinetic parameters for 100 patients with severe to moderate haemophilia A ( factor VIII <unk> 2 % ) PK parameters ( pharmacokinetics )
P-667	-0.8873 -0.0641 -0.1614 -0.5029 -0.1468 -0.0771 -0.0832 -1.2772 -0.1227 -0.0776 -0.1155 -0.1670 -0.0580 -0.1173 -1.0135 -0.1642 -0.5546 -0.1447 -0.0772 -0.2517 -0.0733 -0.3151 -0.1034 -0.1529 -0.1820 -0.1464 -0.1337 -0.3557 -0.1590 -0.1097 -0.1194 -0.1483 -0.1201 -0.1282 -0.1281 -0.2034 -1.2381 -0.1704 -0.1184 -0.1355 -0.1157 -0.1175 -0.0704 -0.0970 -0.1378 -0.1589
S-271	Jede Tablette enthält 70 mg Alendronsäure als Natriumalendronat 3 H2O und 140 Mikrogramm ( 5.600 I.E. ) Colecalciferol ( Vitamin D3 ) .
T-271	Each tablet contains 70 mg alendronic acid as alendronate sodium trihydrate and 140 micrograms ( 5600 IU ) colecalciferol ( vitamin D3 ) .
H-271	-0.14125211536884308	Each tablet contains 70 mg alendronic acid as sodium alendronate 3 H2O and 140 micrograms ( 5,600 IU ) of colecalciferol ( vitamin D3 ) .
D-271	-0.14125211536884308	Each tablet contains 70 mg alendronic acid as sodium alendronate 3 H2O and 140 micrograms ( 5,600 IU ) of colecalciferol ( vitamin D3 ) .
P-271	-0.0415 -0.1117 -0.0946 -0.0488 -0.1336 -0.0536 -0.4739 -0.1422 -0.1364 -0.1155 -0.0997 -0.1575 -0.1126 -0.0409 -0.1687 -0.1699 -0.1555 -0.1221 -0.1551 -0.1079 -0.1055 -0.1940 -0.1493 -0.1483 -0.1298 -0.0432 -0.1469 -0.3765 -0.0757 -0.0998 -0.0971 -0.1320 -0.3332 -0.1361 -0.1466 -0.2083 -0.1021 -0.1025 -0.1698 -0.1365 -0.1751 -0.1087 -0.1160 -0.1278 -0.1379 -0.1482 -0.1504
S-1612	BEDINGUNGEN ODER EINSCHRÄNKUNGEN FÜR DIE ABGABE UND DEN GEBRAUCH , DIE DEM INHABER DER GENEHMIGUNG FÜR DAS INVERKEHRBRINGEN AUFERLEGT WERDEN
T-1612	CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON THE MARKETING AUTHORISATION HOLDER
H-1612	-0.156951904296875	CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE DERIVED FROM THE MARKETING AUTHORISATION
D-1612	-0.156951904296875	CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE DERIVED FROM THE MARKETING AUTHORISATION
P-1612	-0.0666 -0.0801 -0.0138 -0.0295 -0.0462 -0.1382 -0.1767 -0.1268 -0.1214 -0.0421 -0.0244 -0.0126 -0.0230 -0.0392 -0.0948 -0.2522 -0.1728 -0.0256 -0.0548 -0.0324 -0.0541 -0.0490 -0.0163 -0.1348 -0.1094 -0.0561 -0.1152 -3.4472 -0.1130 -0.0113 -0.0594 -0.3117 -0.0120 -0.0550 -0.1748 -0.3481 -0.0488 -0.0335 -0.0776 -0.0210 -0.0253 -0.0605 -0.0063 -0.0017 -0.0973 -0.2073
S-1607	68 A. HERSTELLER DES WIRKSTOFFS BIOLOGISCHEN URSPRUNGS UND INHABER DER HERSTELLUNGSERLAUBNIS , DER FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST
T-1607	62 A MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
H-1607	-0.25547340512275696	A MANUFACTURER OF THE EFFECTIVE BIOLOGICAL Origin AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
D-1607	-0.25547340512275696	A MANUFACTURER OF THE EFFECTIVE BIOLOGICAL Origin AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
P-1607	-1.7782 -0.2963 -0.0146 -0.0843 -0.0289 -0.0087 -0.1215 -0.0327 -0.5914 -0.0913 -0.1034 -0.2696 -0.6725 -0.0514 -0.2955 -0.6445 -0.1652 -0.0538 -0.2980 -0.1883 -0.0620 -0.1319 -0.1086 -0.5825 -0.1959 -3.6330 -0.1091 -0.1425 -0.4214 -0.0102 -0.1117 -0.0280 -0.0153 -0.0408 -0.0654 -0.0927 -0.1124 -0.0192 -0.0730 -0.0100 -0.0062 -0.0670 -1.0932 -0.0367 -0.3583 -0.2988 -0.0700 -0.0445 -0.1371 -0.0388 -0.1040 -0.0500 -0.0829 -0.0442 -0.1540 -0.0961 -0.8435 -0.0450 -0.0355 -0.0775 -0.1451
S-1500	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-1500	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-1500	-0.2608243525028229	The ADRs that occurred in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of whom occurred in previously untreated patients at higher risk of forming inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-1500	-0.2608243525028229	The ADRs that occurred in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of whom occurred in previously untreated patients at higher risk of forming inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-1500	-0.2245 -0.1737 -0.0903 -0.1152 -1.4482 -0.0702 -0.1560 -0.1730 -1.2328 -0.4961 -0.1517 -0.0608 -0.1583 -0.4893 -0.1568 -0.1196 -0.0894 -0.0200 -0.0632 -0.1239 -0.1282 -0.1669 -0.0995 -0.1379 -0.1541 -0.2749 -0.2087 -0.9231 -0.1024 -0.1220 -0.0417 -0.1371 -0.0266 -0.1009 -0.7501 -1.1367 -0.0641 -1.5872 -1.6599 -0.1351 -0.0316 -0.0486 -0.1237 -0.2011 -0.0966 -0.0241 -0.0830 -0.1316 -0.1448 -0.0779 -0.1386 -0.1514 -0.1851 -0.0688 -0.1373 -0.0960 -0.0617 -0.0818 -0.1313 -0.2725 -0.0782 -0.5948 -0.1280 -0.1446 -0.1508
S-176	Laborwerte In klinischen Studien wurden asymptomatische , leichte und vorübergehende Abnahmen des Serum- Calciums und -Phosphats bei ca. 18 % beziehungsweise 10 % der Patienten beobachtet , die Alendronat 10 mg<unk> Tag einnahmen , gegenüber ca. 12 % und 3 % derjenigen , die Plazebo einnahmen .
T-176	Laboratory test findings In clinical studies , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % , respectively , of patients taking alendronate 10 mg/ day versus approximately 12 % and 3 % of those taking placebo .
H-176	-0.25514766573905945	Laboratory scores In clinical trials , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % of patients taking alendronate 10 mg/ day , compared to approximately 12 % and 3 % of those taking placebo , respectively .
D-176	-0.25514766573905945	Laboratory scores In clinical trials , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % of patients taking alendronate 10 mg/ day , compared to approximately 12 % and 3 % of those taking placebo , respectively .
P-176	-0.4955 -0.1245 -0.4320 -0.1580 -0.0555 -0.0921 -0.2187 -0.0823 -0.0575 -0.0887 -0.1102 -0.1551 -0.7927 -0.9933 -0.4951 -0.0746 -0.1244 -0.1252 -0.0954 -0.1691 -0.0442 -0.1127 -0.1091 -0.0711 -0.1104 -0.1385 -0.0556 -0.0640 -0.0971 -0.5153 -0.1542 -0.1491 -0.3937 -0.1140 -0.1281 -0.1268 -0.1520 -0.1285 -0.3814 -1.2002 -1.2274 -0.2705 -0.1662 -0.1027 -0.0822 -0.1592 -0.1995 -0.1119 -0.1174 -0.1490 -0.1147 -1.0070 -0.6230 -0.1452 -0.1144 -0.1453 -0.1232 -0.1307 -0.1314 -0.3164 -0.2217 -0.3852 -0.0265 -0.1412 -0.1409 -0.1294 -1.7870 -0.1250 -0.1312 -0.1487
S-972	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-972	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-972	-0.2608243525028229	The ADRs that occurred in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of whom occurred in previously untreated patients at higher risk of forming inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-972	-0.2608243525028229	The ADRs that occurred in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of whom occurred in previously untreated patients at higher risk of forming inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-972	-0.2245 -0.1737 -0.0903 -0.1152 -1.4482 -0.0702 -0.1560 -0.1730 -1.2328 -0.4961 -0.1517 -0.0608 -0.1583 -0.4893 -0.1568 -0.1196 -0.0894 -0.0200 -0.0632 -0.1239 -0.1282 -0.1669 -0.0995 -0.1379 -0.1541 -0.2749 -0.2087 -0.9231 -0.1024 -0.1220 -0.0417 -0.1371 -0.0266 -0.1009 -0.7501 -1.1367 -0.0641 -1.5872 -1.6599 -0.1351 -0.0316 -0.0486 -0.1237 -0.2011 -0.0966 -0.0241 -0.0830 -0.1316 -0.1448 -0.0779 -0.1386 -0.1514 -0.1851 -0.0688 -0.1373 -0.0960 -0.0617 -0.0818 -0.1313 -0.2725 -0.0782 -0.5948 -0.1280 -0.1446 -0.1508
S-1148	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-1148	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-1148	-0.2608243525028229	The ADRs that occurred in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of whom occurred in previously untreated patients at higher risk of forming inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-1148	-0.2608243525028229	The ADRs that occurred in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of whom occurred in previously untreated patients at higher risk of forming inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-1148	-0.2245 -0.1737 -0.0903 -0.1152 -1.4482 -0.0702 -0.1560 -0.1730 -1.2328 -0.4961 -0.1517 -0.0608 -0.1583 -0.4893 -0.1568 -0.1196 -0.0894 -0.0200 -0.0632 -0.1239 -0.1282 -0.1669 -0.0995 -0.1379 -0.1541 -0.2749 -0.2087 -0.9231 -0.1024 -0.1220 -0.0417 -0.1371 -0.0266 -0.1009 -0.7501 -1.1367 -0.0641 -1.5872 -1.6599 -0.1351 -0.0316 -0.0486 -0.1237 -0.2011 -0.0966 -0.0241 -0.0830 -0.1316 -0.1448 -0.0779 -0.1386 -0.1514 -0.1851 -0.0688 -0.1373 -0.0960 -0.0617 -0.0818 -0.1313 -0.2725 -0.0782 -0.5948 -0.1280 -0.1446 -0.1508
S-622	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-622	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-622	-0.2608243525028229	The ADRs that occurred in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of whom occurred in previously untreated patients at higher risk of forming inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-622	-0.2608243525028229	The ADRs that occurred in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of whom occurred in previously untreated patients at higher risk of forming inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-622	-0.2245 -0.1737 -0.0903 -0.1152 -1.4482 -0.0702 -0.1560 -0.1730 -1.2328 -0.4961 -0.1517 -0.0608 -0.1583 -0.4893 -0.1568 -0.1196 -0.0894 -0.0200 -0.0632 -0.1239 -0.1282 -0.1669 -0.0995 -0.1379 -0.1541 -0.2749 -0.2087 -0.9231 -0.1024 -0.1220 -0.0417 -0.1371 -0.0266 -0.1009 -0.7501 -1.1367 -0.0641 -1.5872 -1.6599 -0.1351 -0.0316 -0.0486 -0.1237 -0.2011 -0.0966 -0.0241 -0.0830 -0.1316 -0.1448 -0.0779 -0.1386 -0.1514 -0.1851 -0.0688 -0.1373 -0.0960 -0.0617 -0.0818 -0.1313 -0.2725 -0.0782 -0.5948 -0.1280 -0.1446 -0.1508
S-1324	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-1324	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-1324	-0.2608243525028229	The ADRs that occurred in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of whom occurred in previously untreated patients at higher risk of forming inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-1324	-0.2608243525028229	The ADRs that occurred in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of whom occurred in previously untreated patients at higher risk of forming inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-1324	-0.2245 -0.1737 -0.0903 -0.1152 -1.4482 -0.0702 -0.1560 -0.1730 -1.2328 -0.4961 -0.1517 -0.0608 -0.1583 -0.4893 -0.1568 -0.1196 -0.0894 -0.0200 -0.0632 -0.1239 -0.1282 -0.1669 -0.0995 -0.1379 -0.1541 -0.2749 -0.2087 -0.9231 -0.1024 -0.1220 -0.0417 -0.1371 -0.0266 -0.1009 -0.7501 -1.1367 -0.0641 -1.5872 -1.6599 -0.1351 -0.0316 -0.0486 -0.1237 -0.2011 -0.0966 -0.0241 -0.0830 -0.1316 -0.1448 -0.0779 -0.1386 -0.1514 -0.1851 -0.0688 -0.1373 -0.0960 -0.0617 -0.0818 -0.1313 -0.2725 -0.0782 -0.5948 -0.1280 -0.1446 -0.1508
S-109	Ösophageale Reaktionen , wie Ösophagitis , ösophageale Ulzera und ösophageale Erosionen , selten gefolgt von ösophagealen Strikturen , wurden bei Patienten unter der Einnahme von Alendronat berichtet ( teilweise waren diese schwerwiegend und erforderten eine Krankenhauseinweisung ) .
T-109	Oesophageal reactions ( sometimes severe and requiring hospitalisation ) , such as oesophagitis , oesophageal ulcers and oesophageal erosions , rarely followed by oesophageal stricture , have been reported in patients receiving alendronate .
H-109	-0.2999609410762787	Oesophageal reactions , such as oesophagitis , oesophageal ulcers and oesophageal erosions , rarely followed by oesophageal stricture , have been reported in patients taking alendronate ( some of them severe and required hospitalization ) .
D-109	-0.2999609410762787	Oesophageal reactions , such as oesophagitis , oesophageal ulcers and oesophageal erosions , rarely followed by oesophageal stricture , have been reported in patients taking alendronate ( some of them severe and required hospitalization ) .
P-109	-0.2015 -0.0805 -1.2650 -0.0551 -0.1135 -0.1695 -0.0950 -0.0688 -0.5269 -0.1790 -0.1670 -0.5993 -0.0696 -0.0800 -0.0800 -0.1138 -0.0643 -0.1508 -0.9187 -0.0589 -0.4004 -0.0511 -0.1069 -0.1697 -0.1351 -0.2160 -0.1849 -0.2183 -0.5860 -0.0611 -0.1675 -0.0467 -0.0958 -0.1677 -0.1183 -0.8442 -0.1272 -0.6602 -0.1692 -0.1461 -0.4059 -0.0841 -0.1871 -0.0521 -0.1093 -0.1565 -0.9330 -1.0121 -0.1818 -0.1945 -0.1760 -0.1218 -0.2113 -0.1475 -0.2513 -0.2308 -0.1416 -0.1183 -0.0775 -0.1272 -1.2978 -0.3799 -0.4774 -0.2057 -0.1980 -1.8403 -0.9840 -0.7228 -0.4164 -0.1329 -0.1424 -0.1496
S-297	Ösophageale Reaktionen , wie Ösophagitis , ösophageale Ulzera und ösophageale Erosionen , selten gefolgt von ösophagealen Strikturen , wurden bei Patienten unter der Einnahme von Alendronat berichtet ( teilweise waren diese schwerwiegend und erforderten eine Krankenhauseinweisung ) .
T-297	Oesophageal reactions ( sometimes severe and requiring hospitalisation ) , such as oesophagitis , oesophageal ulcers and oesophageal erosions , rarely followed by oesophageal stricture , have been reported in patients receiving alendronate .
H-297	-0.2999609410762787	Oesophageal reactions , such as oesophagitis , oesophageal ulcers and oesophageal erosions , rarely followed by oesophageal stricture , have been reported in patients taking alendronate ( some of them severe and required hospitalization ) .
D-297	-0.2999609410762787	Oesophageal reactions , such as oesophagitis , oesophageal ulcers and oesophageal erosions , rarely followed by oesophageal stricture , have been reported in patients taking alendronate ( some of them severe and required hospitalization ) .
P-297	-0.2015 -0.0805 -1.2650 -0.0551 -0.1135 -0.1695 -0.0950 -0.0688 -0.5269 -0.1790 -0.1670 -0.5993 -0.0696 -0.0800 -0.0800 -0.1138 -0.0643 -0.1508 -0.9187 -0.0589 -0.4004 -0.0511 -0.1069 -0.1697 -0.1351 -0.2160 -0.1849 -0.2183 -0.5860 -0.0611 -0.1675 -0.0467 -0.0958 -0.1677 -0.1183 -0.8442 -0.1272 -0.6602 -0.1692 -0.1461 -0.4059 -0.0841 -0.1871 -0.0521 -0.1093 -0.1565 -0.9330 -1.0121 -0.1818 -0.1945 -0.1760 -0.1218 -0.2113 -0.1475 -0.2513 -0.2308 -0.1416 -0.1183 -0.0775 -0.1272 -1.2978 -0.3799 -0.4774 -0.2057 -0.1980 -1.8403 -0.9840 -0.7228 -0.4164 -0.1329 -0.1424 -0.1496
S-364	Laborwerte In klinischen Studien wurden asymptomatische , leichte und vorübergehende Abnahmen des Serum- Calciums und -Phosphats bei ca. 18 % beziehungsweise 10 % der Patienten beobachtet , die Alendronat 10 mg<unk> Tag einnahmen , gegenüber ca. 12 % und 3 % derjenigen , die Plazebo einnahmen .
T-364	Laboratory test findings In clinical studies , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % , respectively , of patients taking alendronate 10 mg/ day versus approximately 12 % and 3 % of those taking placebo .
H-364	-0.25514766573905945	Laboratory scores In clinical trials , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % of patients taking alendronate 10 mg/ day , compared to approximately 12 % and 3 % of those taking placebo , respectively .
D-364	-0.25514766573905945	Laboratory scores In clinical trials , asymptomatic , mild and transient decreases in serum calcium and phosphate were observed in approximately 18 % and 10 % of patients taking alendronate 10 mg/ day , compared to approximately 12 % and 3 % of those taking placebo , respectively .
P-364	-0.4955 -0.1245 -0.4320 -0.1580 -0.0555 -0.0921 -0.2187 -0.0823 -0.0575 -0.0887 -0.1102 -0.1551 -0.7927 -0.9933 -0.4951 -0.0746 -0.1244 -0.1252 -0.0954 -0.1691 -0.0442 -0.1127 -0.1091 -0.0711 -0.1104 -0.1385 -0.0556 -0.0640 -0.0971 -0.5153 -0.1542 -0.1491 -0.3937 -0.1140 -0.1281 -0.1268 -0.1520 -0.1285 -0.3814 -1.2002 -1.2274 -0.2705 -0.1662 -0.1027 -0.0822 -0.1592 -0.1995 -0.1119 -0.1174 -0.1490 -0.1147 -1.0070 -0.6230 -0.1452 -0.1144 -0.1453 -0.1232 -0.1307 -0.1314 -0.3164 -0.2217 -0.3852 -0.0265 -0.1412 -0.1409 -0.1294 -1.7870 -0.1250 -0.1312 -0.1487
S-796	Die bei der größten Zahl der Patienten auftretenden ADRs waren Inhibitoren gegen Faktor VIII ( 5 Patienten ) , die alle bei zuvor unbehandelten Patienten auftraten , die ein höheres Risiko zur Bildung von Inhibitoren aufweisen , Kopfschmerzen ( 5 Patienten ) , Fieber und Schwindel ( jeweils 3 Patienten ) .
T-796	The ADRs that occurred in the highest number of patients were development of factor VIII inhibitors ( 5 patients ) , all occurring in previously untreated patients who had elevated risk of inhibitor development , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
H-796	-0.2608243525028229	The ADRs that occurred in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of whom occurred in previously untreated patients at higher risk of forming inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
D-796	-0.2608243525028229	The ADRs that occurred in the largest number of patients were factor VIII inhibitors ( 5 patients ) , all of whom occurred in previously untreated patients at higher risk of forming inhibitors , headache ( 5 patients ) , fever and dizziness ( 3 patients each ) .
P-796	-0.2245 -0.1737 -0.0903 -0.1152 -1.4482 -0.0702 -0.1560 -0.1730 -1.2328 -0.4961 -0.1517 -0.0608 -0.1583 -0.4893 -0.1568 -0.1196 -0.0894 -0.0200 -0.0632 -0.1239 -0.1282 -0.1669 -0.0995 -0.1379 -0.1541 -0.2749 -0.2087 -0.9231 -0.1024 -0.1220 -0.0417 -0.1371 -0.0266 -0.1009 -0.7501 -1.1367 -0.0641 -1.5872 -1.6599 -0.1351 -0.0316 -0.0486 -0.1237 -0.2011 -0.0966 -0.0241 -0.0830 -0.1316 -0.1448 -0.0779 -0.1386 -0.1514 -0.1851 -0.0688 -0.1373 -0.0960 -0.0617 -0.0818 -0.1313 -0.2725 -0.0782 -0.5948 -0.1280 -0.1446 -0.1508
S-1024	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1024	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-1024	-0.21227702498435974	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl / kg h ) MRI ( h ) VSS ( dl / kg ) * Geometric means
D-1024	-0.21227702498435974	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl / kg h ) MRI ( h ) VSS ( dl / kg ) * Geometric means
P-1024	-0.0524 -0.2586 -0.2968 -0.1503 -0.1368 -0.8679 -0.1865 -0.1357 -0.0514 -0.1255 -0.1925 -0.0796 -0.0824 -0.1777 -0.1348 -0.3687 -0.1225 -0.2219 -0.1433 -0.0687 -0.1326 -0.1724 -0.1522 -0.1333 -0.2799 -0.1779 -0.1671 -0.1769 -0.1428 -0.1095 -0.2518 -0.1281 -0.1220 -0.0800 -0.1355 -0.1545 -0.1382 -0.1319 -0.0420 -0.1217 -0.4939 -0.3473 -0.1074 -0.1339 -1.7859 -0.1488 -0.0891 -0.4784 -0.1265 -0.0752 -0.1549 -0.1409 -0.4089 -0.1289 -0.1197 -0.0471 -0.1421 -0.5773 -0.1328 -0.0592 -0.1275 -0.0722 -0.4676 -0.0549 -0.0957 -0.7373 -0.1653
S-1200	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1200	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-1200	-0.21227702498435974	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl / kg h ) MRI ( h ) VSS ( dl / kg ) * Geometric means
D-1200	-0.21227702498435974	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl / kg h ) MRI ( h ) VSS ( dl / kg ) * Geometric means
P-1200	-0.0524 -0.2586 -0.2968 -0.1503 -0.1368 -0.8679 -0.1865 -0.1357 -0.0514 -0.1255 -0.1925 -0.0796 -0.0824 -0.1777 -0.1348 -0.3687 -0.1225 -0.2219 -0.1433 -0.0687 -0.1326 -0.1724 -0.1522 -0.1333 -0.2799 -0.1779 -0.1671 -0.1769 -0.1428 -0.1095 -0.2518 -0.1281 -0.1220 -0.0800 -0.1355 -0.1545 -0.1382 -0.1319 -0.0420 -0.1217 -0.4939 -0.3473 -0.1074 -0.1339 -1.7859 -0.1488 -0.0891 -0.4784 -0.1265 -0.0752 -0.1549 -0.1409 -0.4089 -0.1289 -0.1197 -0.0471 -0.1421 -0.5773 -0.1328 -0.0592 -0.1275 -0.0722 -0.4676 -0.0549 -0.0957 -0.7373 -0.1653
S-1376	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1376	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-1376	-0.21227702498435974	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl / kg h ) MRI ( h ) VSS ( dl / kg ) * Geometric means
D-1376	-0.21227702498435974	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl / kg h ) MRI ( h ) VSS ( dl / kg ) * Geometric means
P-1376	-0.0524 -0.2586 -0.2968 -0.1503 -0.1368 -0.8679 -0.1865 -0.1357 -0.0514 -0.1255 -0.1925 -0.0796 -0.0824 -0.1777 -0.1348 -0.3687 -0.1225 -0.2219 -0.1433 -0.0687 -0.1326 -0.1724 -0.1522 -0.1333 -0.2799 -0.1779 -0.1671 -0.1769 -0.1428 -0.1095 -0.2518 -0.1281 -0.1220 -0.0800 -0.1355 -0.1545 -0.1382 -0.1319 -0.0420 -0.1217 -0.4939 -0.3473 -0.1074 -0.1339 -1.7859 -0.1488 -0.0891 -0.4784 -0.1265 -0.0752 -0.1549 -0.1409 -0.4089 -0.1289 -0.1197 -0.0471 -0.1421 -0.5773 -0.1328 -0.0592 -0.1275 -0.0722 -0.4676 -0.0549 -0.0957 -0.7373 -0.1653
S-848	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-848	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-848	-0.21227702498435974	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl / kg h ) MRI ( h ) VSS ( dl / kg ) * Geometric means
D-848	-0.21227702498435974	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl / kg h ) MRI ( h ) VSS ( dl / kg ) * Geometric means
P-848	-0.0524 -0.2586 -0.2968 -0.1503 -0.1368 -0.8679 -0.1865 -0.1357 -0.0514 -0.1255 -0.1925 -0.0796 -0.0824 -0.1777 -0.1348 -0.3687 -0.1225 -0.2219 -0.1433 -0.0687 -0.1326 -0.1724 -0.1522 -0.1333 -0.2799 -0.1779 -0.1671 -0.1769 -0.1428 -0.1095 -0.2518 -0.1281 -0.1220 -0.0800 -0.1355 -0.1545 -0.1382 -0.1319 -0.0420 -0.1217 -0.4939 -0.3473 -0.1074 -0.1339 -1.7859 -0.1488 -0.0891 -0.4784 -0.1265 -0.0752 -0.1549 -0.1409 -0.4089 -0.1289 -0.1197 -0.0471 -0.1421 -0.5773 -0.1328 -0.0592 -0.1275 -0.0722 -0.4676 -0.0549 -0.0957 -0.7373 -0.1653
S-672	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-672	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-672	-0.21227702498435974	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl / kg h ) MRI ( h ) VSS ( dl / kg ) * Geometric means
D-672	-0.21227702498435974	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl / kg h ) MRI ( h ) VSS ( dl / kg ) * Geometric means
P-672	-0.0524 -0.2586 -0.2968 -0.1503 -0.1368 -0.8679 -0.1865 -0.1357 -0.0514 -0.1255 -0.1925 -0.0796 -0.0824 -0.1777 -0.1348 -0.3687 -0.1225 -0.2219 -0.1433 -0.0687 -0.1326 -0.1724 -0.1522 -0.1333 -0.2799 -0.1779 -0.1671 -0.1769 -0.1428 -0.1095 -0.2518 -0.1281 -0.1220 -0.0800 -0.1355 -0.1545 -0.1382 -0.1319 -0.0420 -0.1217 -0.4939 -0.3473 -0.1074 -0.1339 -1.7859 -0.1488 -0.0891 -0.4784 -0.1265 -0.0752 -0.1549 -0.1409 -0.4089 -0.1289 -0.1197 -0.0471 -0.1421 -0.5773 -0.1328 -0.0592 -0.1275 -0.0722 -0.4676 -0.0549 -0.0957 -0.7373 -0.1653
S-1553	AUC0- ( I.E. h<unk> dl ) t 1<unk> 2 ( h ) Recovery ( I.E.<unk> dL<unk> I.E.<unk> kg ) Cmax ( I.E.<unk> dl ) Clearance ( dl<unk> kg h ) MRT ( h ) VSS ( dl<unk> kg ) * Geometrisches Mittel
T-1553	( IU/ dl/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl/ kg h ) MRT ( h ) VSS ( dl/ kg ) * Geometric Mean
H-1553	-0.21227702498435974	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl / kg h ) MRI ( h ) VSS ( dl / kg ) * Geometric means
D-1553	-0.21227702498435974	AUC0 ( IU h/ dl ) t 1/ 2 ( h ) Recovery ( IU/ dL/ IU/ kg ) Cmax ( IU/ dl ) Clearance ( dl / kg h ) MRI ( h ) VSS ( dl / kg ) * Geometric means
P-1553	-0.0524 -0.2586 -0.2968 -0.1503 -0.1368 -0.8679 -0.1865 -0.1357 -0.0514 -0.1255 -0.1925 -0.0796 -0.0824 -0.1777 -0.1348 -0.3687 -0.1225 -0.2219 -0.1433 -0.0687 -0.1326 -0.1724 -0.1522 -0.1333 -0.2799 -0.1779 -0.1671 -0.1769 -0.1428 -0.1095 -0.2518 -0.1281 -0.1220 -0.0800 -0.1355 -0.1545 -0.1382 -0.1319 -0.0420 -0.1217 -0.4939 -0.3473 -0.1074 -0.1339 -1.7859 -0.1488 -0.0891 -0.4784 -0.1265 -0.0752 -0.1549 -0.1409 -0.4089 -0.1289 -0.1197 -0.0471 -0.1421 -0.5773 -0.1328 -0.0592 -0.1275 -0.0722 -0.4676 -0.0549 -0.0957 -0.7373 -0.1653
S-381	Die Hauptwirkung von 1,25-Dihydroxyvitamin D3 ist die Erhöhung der intestinalen Resorption von Calcium und Phosphat sowie die Regulierung von Serum-Calcium , der renalen Ausscheidung von Calcium und von Phosphat , der Knochenbildung und Knochenresorption .
T-381	The principal action of 1,25-dihydroxyvitamin D3 is to increase intestinal absorption of both calcium and phosphate as well as regulate serum calcium , renal calcium and phosphate excretion , bone formation and bone resorption .
H-381	-0.20222626626491547	The main effect of 1,25 dihydroxyvitamin D3 is to increase the intestinal absorption of calcium and phosphate and to regulate serum calcium , renal excretion of calcium and phosphate , bone formation and bone resorption .
D-381	-0.20222626626491547	The main effect of 1,25 dihydroxyvitamin D3 is to increase the intestinal absorption of calcium and phosphate and to regulate serum calcium , renal excretion of calcium and phosphate , bone formation and bone resorption .
P-381	-0.2495 -0.2817 -0.1041 -0.1599 -0.2968 -0.3551 -1.4090 -0.0583 -0.1306 -0.0860 -0.1236 -0.1657 -0.1338 -0.1377 -0.1501 -0.1424 -0.0828 -0.7630 -0.0632 -0.0913 -0.0721 -0.1075 -0.0868 -0.1502 -0.0902 -0.0811 -0.1263 -0.1300 -0.0681 -0.0698 -0.0901 -0.9369 -0.2295 -1.1993 -0.0919 -0.0562 -0.1188 -0.1015 -0.0690 -0.1185 -0.1880 -0.4514 -0.0949 -0.2809 -0.0259 -0.1479 -0.1451 -0.0962 -0.0838 -0.1351 -0.1359 -0.0696 -0.0646 -0.0915 -0.1512 -0.2720 -0.1543 -0.1308 -0.1528 -0.5251 -0.2081 -0.0668 -0.1382 -0.1538
S-410	Die Wirkungen von Alendronat auf Knochenmasse und Frakturinzidenz bei postmenopausalen Frauen wurden in zwei Phase-III-Studien von identischem Design ( n<unk> 944 ) sowie in der Fraktur-Interventions- Studie ( FIT : n<unk> 6.459 ) untersucht .
T-410	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were examined in two initial efficacy studies of identical design ( n<<unk>> 994 ) as well as in the Fracture Intervention Trial ( FIT : n<<unk>> 6,459 ) .
H-410	-0.2762279212474823	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were investigated in two phase III studies of identical design ( n/ 944 ) and in the Fracture Intervention Study ( FIT : n/ 6,459 ) .
D-410	-0.2762279212474823	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were investigated in two phase III studies of identical design ( n/ 944 ) and in the Fracture Intervention Study ( FIT : n/ 6,459 ) .
P-410	-2.0436 -0.6930 -0.1608 -0.1660 -0.1695 -0.1064 -0.0376 -0.1372 -0.0695 -0.0862 -0.1356 -0.1812 -0.0374 -0.0920 -0.0834 -0.1630 -0.1267 -0.1864 -0.0344 -0.1106 -0.0267 -0.1334 -0.0825 -0.3840 -0.6349 -0.1404 -0.2017 -0.2123 -1.5791 -0.1885 -0.9437 -0.6775 -0.1574 -0.3894 -0.1351 -0.1916 -0.1287 -0.1784 -0.8818 -0.1149 -0.1090 -0.1385 -0.1741 -0.2040 -0.4370 -0.2239 -0.2682 -0.2069 -0.0477 -1.1424 -0.1490 -0.1265 -0.1155 -0.0853 -0.1462 -0.1564 -0.2367 -0.6164 -0.1021 -0.1076 -0.1259 -0.1316 -0.1491
S-325	Jedoch wurden selten Fälle symptomatischer Hypocalcämie berichtet , manche auch 15 schwer , die oft bei Patienten mit entsprechenden prädisponierenden Faktoren auftraten ( z. B. Hypoparathyreoidismus , Vitamin-D-Mangel und Calcium-Malabsorption ) ( siehe Abschnitt 4.8 ) .
T-325	However , there have been rare reports of symptomatic hypocalcaemia , which have occasionally been severe and often occurred in patients with predisposing conditions ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
H-325	-0.20123165845870972	However , rare cases of symptomatic hypocalcaemia , some severe even 15 , have been reported and frequently occurred in patients with corresponding predisposing factors ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
D-325	-0.20123165845870972	However , rare cases of symptomatic hypocalcaemia , some severe even 15 , have been reported and frequently occurred in patients with corresponding predisposing factors ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
P-325	-0.0998 -0.1396 -0.6710 -0.1011 -0.1447 -0.0338 -0.0763 -0.1348 -0.0198 -0.0992 -0.1080 -0.0938 -0.1321 -0.2659 -0.2981 -0.1763 -0.8071 -0.1501 -0.2686 -0.7830 -0.2463 -0.0621 -0.7579 -1.8545 -0.0855 -0.1377 -0.1802 -0.2196 -0.3254 -0.1124 -0.2867 -0.2238 -0.2834 -0.2019 -0.1414 -0.1079 -0.0902 -0.0787 -0.2273 -0.1030 -0.1175 -0.1606 -0.1156 -0.1158 -0.3602 -0.1153 -0.0806 -0.1061 -0.1544 -0.1196 -0.0575 -0.1489 -0.0562 -0.0240 -0.1670 -0.1615 -0.1158 -0.0842 -0.1355 -0.0699 -0.0530 -0.0781 -0.1385 -0.1347 -0.3252 -0.0948 -0.1146 -0.1232 -0.1343 -0.1477 -0.1484
S-193	Die Hauptwirkung von 1,25-Dihydroxyvitamin D3 ist die Erhöhung der intestinalen Resorption von Calcium und Phosphat sowie die Regulierung von Serum-Calcium , der renalen Ausscheidung von Calcium und von Phosphat , der Knochenbildung und Knochenresorption .
T-193	The principal action of 1,25-dihydroxyvitamin D3 is to increase intestinal absorption of both calcium and phosphate as well as regulate serum calcium , renal calcium and phosphate excretion , bone formation and bone resorption .
H-193	-0.20222626626491547	The main effect of 1,25 dihydroxyvitamin D3 is to increase the intestinal absorption of calcium and phosphate and to regulate serum calcium , renal excretion of calcium and phosphate , bone formation and bone resorption .
D-193	-0.20222626626491547	The main effect of 1,25 dihydroxyvitamin D3 is to increase the intestinal absorption of calcium and phosphate and to regulate serum calcium , renal excretion of calcium and phosphate , bone formation and bone resorption .
P-193	-0.2495 -0.2817 -0.1041 -0.1599 -0.2968 -0.3551 -1.4090 -0.0583 -0.1306 -0.0860 -0.1236 -0.1657 -0.1338 -0.1377 -0.1501 -0.1424 -0.0828 -0.7630 -0.0632 -0.0913 -0.0721 -0.1075 -0.0868 -0.1502 -0.0902 -0.0811 -0.1263 -0.1300 -0.0681 -0.0698 -0.0901 -0.9369 -0.2295 -1.1993 -0.0919 -0.0562 -0.1188 -0.1015 -0.0690 -0.1185 -0.1880 -0.4514 -0.0949 -0.2809 -0.0259 -0.1479 -0.1451 -0.0962 -0.0838 -0.1351 -0.1359 -0.0696 -0.0646 -0.0915 -0.1512 -0.2720 -0.1543 -0.1308 -0.1528 -0.5251 -0.2081 -0.0668 -0.1382 -0.1538
S-1606	HERSTELLER DES WIRKSTOFFS BIOLOGISCHEN URSPRUNGS UND INHABER DER HERSTELLUNGSERLAUBNIS , DER FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST
T-1606	MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
H-1606	-0.30902767181396484	MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE
D-1606	-0.30902767181396484	MANUFACTURING AUTHORISATION HOLDERS RESPONSIBLE FOR BATCH RELEASE
P-1606	-0.7670 -0.0176 -0.0753 -0.0206 -0.0049 -0.1009 -0.0243 -2.3657 -1.5460 -0.0301 -0.0597 -0.0079 -0.0109 -0.0817 -1.2223 -0.0359 -1.6707 -0.0190 -0.1969 -0.4737 -0.2005 -0.0540 -0.1227 -0.0666 -0.1285 -0.0834 -0.0861 -0.0411 -0.1204 -0.1118 -0.2917 -0.0271 -0.0406 -0.0892 -0.6214
S-8	Adenuric wird bei Patienten angewendet , die bereits Anzeichen von Kristallablagerungen aufweisen , einschließlich Arthritis ( Schmerzen und Entzündung in den Gelenken ) oder Gichtknoten ( Steine d. h. größere Uratkristallablagerungen , die zu Gelenk- und Knochenschädigungen führen können ) .
T-8	Adenuric is used in patients who already have signs of a build-up of crystals , including arthritis ( pain and inflammation in the joints ) or tophi ( stones , larger deposits of urate crystals that can cause joint and bone damage ) .
H-8	-0.36466357111930847	Adenuric is used in patients who already show signs of crystal deposition , including arthritis ( pain and inflammation in the joints ) or rheumatoid nodes ( stones i. e. larger urine crystal deposition that may cause joint and bone damage ) .
D-8	-0.36466357111930847	Adenuric is used in patients who already show signs of crystal deposition , including arthritis ( pain and inflammation in the joints ) or rheumatoid nodes ( stones i. e. larger urine crystal deposition that may cause joint and bone damage ) .
P-8	-0.1057 -0.1576 -0.0685 -0.1191 -0.1457 -0.6643 -1.2541 -0.1986 -0.1706 -0.6384 -0.7509 -0.1665 -0.1535 -0.7068 -0.4237 -0.4167 -0.1082 -0.1856 -0.1576 -0.1444 -0.0938 -0.0820 -0.1316 -0.4902 -0.1273 -0.1388 -0.0805 -0.1186 -0.2260 -0.2333 -0.0937 -0.0630 -0.1353 -0.2693 -0.6699 -0.5267 -0.3003 -0.2493 -0.4663 -0.6500 -0.4873 -0.1413 -0.5328 -0.5333 -0.1508 -0.1032 -0.1213 -0.6061 -1.3096 -0.3573 -0.3249 -0.3442 -0.9696 -0.4985 -1.0308 -0.3822 -1.2699 -1.2944 -0.1854 -0.0899 -0.2866 -0.1334 -0.1532 -0.1500
S-214	Die Wirkungen von Alendronat auf Knochenmasse und Frakturinzidenz bei postmenopausalen Frauen wurden in zwei Phase-III-Studien von identischem Design ( n<unk> 944 ) sowie in der Fraktur-Interventions- Studie ( FIT : n<unk> 6.459 ) untersucht .
T-214	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were examined in two initial efficacy studies of identical design ( n<<unk>> 994 ) as well as in the Fracture Intervention Trial ( FIT : n<<unk>> 6,459 ) .
H-214	-0.2762279212474823	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were investigated in two phase III studies of identical design ( n/ 944 ) and in the Fracture Intervention Study ( FIT : n/ 6,459 ) .
D-214	-0.2762279212474823	The effects of alendronate on bone mass and fracture incidence in post-menopausal women were investigated in two phase III studies of identical design ( n/ 944 ) and in the Fracture Intervention Study ( FIT : n/ 6,459 ) .
P-214	-2.0436 -0.6930 -0.1608 -0.1660 -0.1695 -0.1064 -0.0376 -0.1372 -0.0695 -0.0862 -0.1356 -0.1812 -0.0374 -0.0920 -0.0834 -0.1630 -0.1267 -0.1864 -0.0344 -0.1106 -0.0267 -0.1334 -0.0825 -0.3840 -0.6349 -0.1404 -0.2017 -0.2123 -1.5791 -0.1885 -0.9437 -0.6775 -0.1574 -0.3894 -0.1351 -0.1916 -0.1287 -0.1784 -0.8818 -0.1149 -0.1090 -0.1385 -0.1741 -0.2040 -0.4370 -0.2239 -0.2682 -0.2069 -0.0477 -1.1424 -0.1490 -0.1265 -0.1155 -0.0853 -0.1462 -0.1564 -0.2367 -0.6164 -0.1021 -0.1076 -0.1259 -0.1316 -0.1491
S-1964	Bei der Behandlung von folgenden Patientengruppen wird zur Vorsicht geraten : Patienten unter Digitalis Patienten mit Herzrhythmusstörungen Patienten mit Hypertonie Patienten mit einem Myokardinfarkt in der Anamnese , Diabetes mellitus , Blasenhalsobstruktion oder Bronchospasmus in der Anamnese .
T-1964	Caution should be exercised in the following patient groups : Patients receiving digitalis Patients with cardiac arrhythmias Patients with hypertension Patients with a history of myocardial infarction , diabetes mellitus , bladder neck obstruction , or positive anamnesis of bronchospasm .
H-1964	-0.30620595812797546	Caution should be exercised when treating the following populations : Digitalis patients with cardiac dysrhythmia Patients with hypertension Patients with a history of myocardial infarction , diabetes mellitus , bladder obstruction or bronchospasm .
D-1964	-0.30620595812797546	Caution should be exercised when treating the following populations : Digitalis patients with cardiac dysrhythmia Patients with hypertension Patients with a history of myocardial infarction , diabetes mellitus , bladder obstruction or bronchospasm .
P-1964	-0.3598 -0.0508 -1.6290 -0.2381 -0.5423 -0.1025 -0.2924 -0.2999 -0.2916 -0.1006 -0.8183 -0.0878 -0.1372 -2.7108 -0.1555 -0.1462 -0.1952 -0.2605 -0.0331 -0.1206 -0.0289 -0.0559 -0.5308 -0.0919 -0.1405 -0.0209 -0.0271 -0.2796 -0.0967 -0.1503 -0.1310 -0.5091 -0.1481 -0.1332 -0.0473 -0.0191 -0.0944 -0.0640 -0.0497 -0.0504 -0.1414 -0.0463 -0.0822 -0.1185 -0.0521 -0.1583 -0.4664 -0.6169 -1.6672 -0.0649 -0.1703 -1.9743 -0.1346 -0.1283 -0.0339 -0.1771 -0.3222 -0.1642
S-404	Studien mit Alendronat Die therapeutische Gleichwertigkeit von Alendronat einmal wöchentlich 70 mg ( n<unk> 519 ) und Alendronat 10 mg täglich ( n<unk> 370 ) wurde in einer Ein-Jahres-Multicenter-Studie an postmenopausalen Frauen mit Osteoporose nachgewiesen .
T-404	Alendronate studies The therapeutic equivalence of alendronate once weekly 70 mg ( n<<unk>> 519 ) and alendronate 10 mg daily ( n<<unk>> 370 ) was demonstrated in a one-year multicentre study of post-menopausal women with osteoporosis .
H-404	-0.26454219222068787	trials of alendronate The therapeutic equivalence of alendronate given weekly 70 mg ( n/ 519 ) and alendronate 10 mg daily ( n/ 370 ) was demonstrated in a one-year multicenter trial in post-menopausal women with osteoporosis .
D-404	-0.26454219222068787	trials of alendronate The therapeutic equivalence of alendronate given weekly 70 mg ( n/ 519 ) and alendronate 10 mg daily ( n/ 370 ) was demonstrated in a one-year multicenter trial in post-menopausal women with osteoporosis .
P-404	-1.1122 -0.3048 -0.2062 -0.1618 -0.0994 -0.0637 -0.4880 -0.2109 -0.1500 -0.3307 -0.1095 -0.3174 -0.1583 -0.2169 -0.1646 -0.0818 -0.0581 -1.6155 -0.0606 -0.7906 -0.0466 -0.1411 -0.1901 -0.5264 -0.1061 -0.1320 -0.1329 -0.2050 -0.3031 -0.1583 -0.0800 -0.0334 -0.1871 -0.0327 -0.3162 -0.1377 -0.1519 -0.1540 -0.0425 -0.1302 -0.9648 -0.7236 -0.1205 -0.1365 -0.2139 -0.3722 -0.0628 -0.3600 -0.0802 -2.2292 -0.7598 -0.1623 -0.0975 -0.2739 -0.0493 -0.1119 -0.0285 -0.1347 -0.0985 -0.1276 -0.1360 -0.0728 -0.1033 -0.1462 -0.1128 -0.0908 -0.1622 -0.1487
S-137	Jedoch wurden selten Fälle symptomatischer Hypocalcämie berichtet , manche auch schwer , die oft bei Patienten mit entsprechenden prädisponierenden Faktoren auftraten ( z. B. Hypoparathyreoidismus , Vitamin-D-Mangel und Calcium-Malabsorption ) ( siehe Abschnitt 4.8 ) .
T-137	However , there have been rare reports of symptomatic hypocalcaemia , which have occasionally been severe and often occurred in patients with predisposing conditions ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
H-137	-0.20050324499607086	However , rare cases of symptomatic hypocalcaemia , some severe , have been reported and often occurred in patients with corresponding predisposing factors ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
D-137	-0.20050324499607086	However , rare cases of symptomatic hypocalcaemia , some severe , have been reported and often occurred in patients with corresponding predisposing factors ( e. g. hypoparathyroidism , vitamin D deficiency and calcium malabsorption ) ( see section 4.8 ) .
P-137	-0.0991 -0.1432 -1.2633 -0.1165 -0.1526 -0.0313 -0.0750 -0.1319 -0.0347 -0.0968 -0.1030 -0.0907 -0.1331 -0.1973 -0.3675 -0.0181 -0.3548 -0.8072 -0.2467 -0.0640 -0.5617 -1.7956 -0.1693 -0.1390 -0.1855 -0.2256 -0.4283 -0.1106 -0.3003 -0.2900 -0.2442 -0.2166 -0.1408 -0.1064 -0.0909 -0.0799 -0.2115 -0.1036 -0.1242 -0.1623 -0.1102 -0.1147 -0.3174 -0.1103 -0.0729 -0.1076 -0.1535 -0.1179 -0.0556 -0.1381 -0.0549 -0.0236 -0.1883 -0.1721 -0.1109 -0.0826 -0.1351 -0.0699 -0.0548 -0.0792 -0.1378 -0.1304 -0.3185 -0.0996 -0.1150 -0.1223 -0.1330 -0.1457 -0.1498
S-208	Studien mit Alendronat Die therapeutische Gleichwertigkeit von Alendronat einmal wöchentlich 70 mg ( n<unk> 519 ) und Alendronat 10 mg täglich ( n<unk> 370 ) wurde in einer Ein-Jahres-Multicenter-Studie an postmenopausalen Frauen mit Osteoporose nachgewiesen .
T-208	Alendronate studies The therapeutic equivalence of alendronate once weekly 70 mg ( n<<unk>> 519 ) and alendronate 10 mg daily ( n<<unk>> 370 ) was demonstrated in a one-year multicentre study of post-menopausal women with osteoporosis .
H-208	-0.26454219222068787	trials of alendronate The therapeutic equivalence of alendronate given weekly 70 mg ( n/ 519 ) and alendronate 10 mg daily ( n/ 370 ) was demonstrated in a one-year multicenter trial in post-menopausal women with osteoporosis .
D-208	-0.26454219222068787	trials of alendronate The therapeutic equivalence of alendronate given weekly 70 mg ( n/ 519 ) and alendronate 10 mg daily ( n/ 370 ) was demonstrated in a one-year multicenter trial in post-menopausal women with osteoporosis .
P-208	-1.1122 -0.3048 -0.2062 -0.1618 -0.0994 -0.0637 -0.4880 -0.2109 -0.1500 -0.3307 -0.1095 -0.3174 -0.1583 -0.2169 -0.1646 -0.0818 -0.0581 -1.6155 -0.0606 -0.7906 -0.0466 -0.1411 -0.1901 -0.5264 -0.1061 -0.1320 -0.1329 -0.2050 -0.3031 -0.1583 -0.0800 -0.0334 -0.1871 -0.0327 -0.3162 -0.1377 -0.1519 -0.1540 -0.0425 -0.1302 -0.9648 -0.7236 -0.1205 -0.1365 -0.2139 -0.3722 -0.0628 -0.3600 -0.0802 -2.2292 -0.7598 -0.1623 -0.0975 -0.2739 -0.0493 -0.1119 -0.0285 -0.1347 -0.0985 -0.1276 -0.1360 -0.0728 -0.1033 -0.1462 -0.1128 -0.0908 -0.1622 -0.1487
S-40	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass Adenuric bei der Senkung des Harnsäurespiegels im Blut wirksamer war als Allopurinol , dafür aber auch ein höheres Risiko von Nebenwirkungen im Zusammenhang mit dem Herzen und den Blutgefäßen bergen könnte .
T-40	The Committee for Medicinal Products for Human Use ( CHMP ) concluded that Adenuric was more effective than allopurinol at lowering blood uric acid levels , but that it could carry a greater risk of side effects affecting the heart and blood vessels .
H-40	-0.3990956246852875	The Committee for Medicinal products for Human Use ( CHMP ) concluded that while Adenuric was more effective at lowering uric acid levels in the blood than allopurinol , it may also pose a higher risk of heart and blood vessel related side effects .
D-40	-0.3990956246852875	The Committee for Medicinal products for Human Use ( CHMP ) concluded that while Adenuric was more effective at lowering uric acid levels in the blood than allopurinol , it may also pose a higher risk of heart and blood vessel related side effects .
P-40	-0.2055 -0.0779 -0.1470 -0.1061 -0.0716 -0.6971 -0.1362 -1.4966 -0.1916 -0.1336 -0.0962 -0.0575 -0.1275 -1.0431 -0.1279 -1.5275 -0.4524 -0.1874 -0.0638 -0.1059 -0.2440 -0.1402 -0.1922 -1.5343 -0.3130 -0.0825 -0.2469 -0.0797 -0.1285 -0.3515 -0.1192 -0.1224 -0.0400 -0.1532 -0.4594 -0.1397 -0.1353 -0.1655 -0.3832 -0.1342 -1.4599 -0.0627 -2.6172 -0.2223 -0.6050 -0.0864 -0.2609 -0.3443 -0.1966 -1.1177 -0.5192 -0.6901 -1.4763 -0.1466 -0.1762 -0.1510
S-411	In den Phase-III-Studien betrugen die mittleren Anstiege der BMD mit Alendronat 10 mg<unk> Tag im Verhältnis zu Plazebo nach 3 Jahren 8,8 % an der Wirbelsäule , 5,9 % am Femurhals und 7,8 % am Trochanter .
T-411	In the initial efficacy studies , the mean BMD increases with alendronate 10 mg/ day relative to placebo at three years were 8.8 % , 5.9 % and 7.8 % at the spine , femoral neck and trochanter , respectively .
H-411	-0.2986171841621399	In the phase IIIs , mean increases in BMD with alendronate 10 mg/ day versus placebo at 3 years were 8.8 % in the spine , 5.9 % in the femoral neck and 7.8 % in the trochanter .
D-411	-0.2986171841621399	In the phase IIIs , mean increases in BMD with alendronate 10 mg/ day versus placebo at 3 years were 8.8 % in the spine , 5.9 % in the femoral neck and 7.8 % in the trochanter .
P-411	-0.2490 -0.9701 -0.9135 -0.6427 -0.1222 -0.8087 -0.6651 -0.1890 -1.0094 -0.2214 -0.1326 -0.1103 -0.1489 -0.2687 -0.1610 -0.1602 -0.1028 -0.0494 -0.7527 -0.1849 -0.1243 -0.1289 -0.1364 -1.3792 -0.0685 -0.1453 -0.1100 -0.1204 -0.6627 -0.5024 -0.1050 -0.1450 -0.0547 -0.1156 -0.1107 -0.7110 -0.1479 -0.1098 -0.1037 -0.1465 -0.0749 -0.1257 -0.0986 -0.1570 -0.1242 -0.0918 -1.4637 -0.0993 -0.9340 -0.0768 -0.1160 -0.1060 -0.2323 -0.1227 -0.0822 -0.2702 -0.1539 -0.1482 -0.1501
S-1616	Pharmakovigilanz-System Der Zulassungsinhaber muss sicherstellen , dass ein Pharmakovigilanz-System , wie im Abschnitt 1.1 des Kapitels 1.8.1 der Arzneimittelzulassung beschrieben , eingerichtet wurde und dass dieses System während des gesamten Zeitraumes , in dem sich das Produkt auf dem Markt befindet , in Kraft bleibt .
T-1616	Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance , as described in version 1.1 presented in Module 1.8.1 . of the Marketing Authorisation , is in place and functioning before and whilst the product is on the market .
H-1616	-0.38734573125839233	Pharmacovigilance System The marketing authorisation holder must ensure that a pharmacovigilance system is in place as described in section 1.1 of section 1.8.1 of the marketing authorisation and that this system remains in place for the entire period during which the product is on the market .
D-1616	-0.38734573125839233	Pharmacovigilance System The marketing authorisation holder must ensure that a pharmacovigilance system is in place as described in section 1.1 of section 1.8.1 of the marketing authorisation and that this system remains in place for the entire period during which the product is on the market .
P-1616	-1.2749 -0.3091 -0.1791 -0.1628 -0.1243 -0.2624 -0.1866 -1.0146 -0.2515 -2.1802 -0.0223 -0.0660 -0.1412 -0.2570 -0.0558 -0.1282 -0.1485 -0.1890 -0.1409 -0.1378 -0.2850 -0.1962 -0.2250 -1.8943 -0.4736 -0.2573 -0.3270 -0.1718 -0.1300 -0.1898 -0.0709 -0.2706 -1.4609 -0.1342 -0.1086 -0.1476 -0.2165 -0.1487 -1.2392 -0.0195 -0.0917 -0.3008 -0.1222 -0.6926 -0.2473 -0.6636 -0.2116 -0.7590 -0.8138 -0.1877 -0.5063 -0.4438 -1.5315 -0.2634 -0.1965 -0.1223 -0.1372 -0.6217 -0.1400 -0.4504 -0.1605 -0.1525
S-51	ADROVANCE ist eine weiße Tablette in Kapselform , die zwei arzneilich wirksame Bestandteile enthält : Natriumalendronat 3 H2O ( 70 mg ) und Colecalciferol ( Vitamin D3 , 70 Mikrogramm entsprechend 2800 internationalen Einheiten I.E . ) .
T-51	ADROVANCE is a white capsule-shaped tablet containing two active substances : alendronate sodium trihydrate ( 70 mg ) and colecalciferol ( vitamin D3 , 70 micrograms equivalent to 2,800 international units ) .
H-51	-0.1841331571340561	ADROVANCE is a white capsule tablet containing two active ingredients : sodium alendronate 3 H2O ( 70 mg ) and colecalciferol ( vitamin D3 , 70 micrograms equivalent to 2800 international units IU ) .
D-51	-0.1841331571340561	ADROVANCE is a white capsule tablet containing two active ingredients : sodium alendronate 3 H2O ( 70 mg ) and colecalciferol ( vitamin D3 , 70 micrograms equivalent to 2800 international units IU ) .
P-51	-0.0848 -0.0734 -0.1226 -0.1001 -0.1195 -0.1156 -0.1308 -0.2280 -1.7890 -0.1415 -0.2062 -0.2067 -0.1284 -0.1868 -0.2505 -0.1358 -0.5603 -0.1628 -0.1017 -0.0614 -0.1809 -0.1871 -0.1421 -0.0880 -0.1871 -0.0991 -0.1150 -0.1873 -0.1371 -0.1438 -0.0408 -0.1364 -0.1504 -0.1625 -0.1725 -0.1946 -0.1141 -0.1059 -0.1512 -0.1381 -0.1556 -0.1035 -0.1219 -0.1372 -0.3351 -0.1073 -0.0657 -0.0378 -0.5014 -0.1377 -0.1874 -0.1129 -0.1407 -0.2619 -0.1778 -0.1076 -0.1325 -0.1483 -0.1516
S-1924	Aerinaze darf bei Patienten , die möglicherweise überempfindlich ( allergisch ) gegen Desloratadin , Pseudoephedrin oder einen der anderen Bestandteile , gegen adrenerge Wirkstoffe oder Loratadin ( ein anderes Arzneimittel zur Behandlung von Allergien ) sind , nicht angewendet werden .
T-1924	Aerinaze should not be used in people who may be hypersensitive ( allergic ) to desloratadine , pseudoephedrine or any of the other ingredients , to adrenergic agents or to loratadine ( another medicine used to treat allergies ) .
H-1924	-0.26448529958724976	Do not use Aerinaze in patients who may be hypersensitive ( allergic ) to desloratadine , pseudoephedrine or to any of the ingredients , to adrenergic agents or loratadine ( another allergic medicinal product ) .
D-1924	-0.26448529958724976	Do not use Aerinaze in patients who may be hypersensitive ( allergic ) to desloratadine , pseudoephedrine or to any of the ingredients , to adrenergic agents or loratadine ( another allergic medicinal product ) .
P-1924	-1.7438 -0.1300 -0.1170 -0.1524 -0.1407 -0.1167 -0.1744 -0.1211 -0.2888 -0.6167 -0.1797 -0.1739 -0.1616 -0.1090 -0.0593 -0.1662 -0.0883 -0.0296 -0.1598 -0.1538 -0.7475 -0.0724 -0.1129 -0.3826 -0.7591 -0.1472 -0.0939 -0.4238 -0.1526 -0.0662 -0.1131 -0.1236 -0.1493 -0.1525 -0.1852 -0.1362 -0.1518 -0.1786 -1.0706 -0.1495 -0.9890 -0.1445 -0.0702 -0.1285 -0.0852 -0.0676 -0.1683 -0.3794 -0.1094 -0.4002 -0.8053 -0.1850 -0.0850 -1.0780 -0.1685 -0.4054 -0.0831 -0.0546 -0.1595 -0.1578 -0.1575
S-142	Patienten mit der seltenen hereditären Fructose-Intoleranz , Galactose-Intoleranz , Lactase-Mangel , Glucose-Galactose-Malabsorption oder Sucrase-Isomaltase-Insuffizienz sollten dieses Arzneimittel nicht einnehmen .
T-142	Patients with rare hereditary problems of fructose intolerance , galactose intolerance , the Lapp lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product .
H-142	-0.16445806622505188	Patients with rare hereditary fructose intolerance , galactose intolerance , lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine .
D-142	-0.16445806622505188	Patients with rare hereditary fructose intolerance , galactose intolerance , lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine .
P-142	-0.1971 -0.0910 -0.1570 -0.4168 -0.0752 -0.1028 -0.0677 -0.1317 -0.1049 -0.0428 -0.0280 -0.0684 -0.1823 -0.1515 -0.2385 -0.1466 -0.0366 -0.0813 -0.0554 -0.1338 -0.1554 -0.1701 -0.0480 -0.0794 -0.0423 -0.0356 -0.1106 -0.1584 -0.0337 -0.2361 -0.2632 -0.1051 -0.0898 -0.1140 -0.0625 -0.0423 -0.0561 -0.0792 -0.2172 -0.3123 -0.2044 -0.4627 -0.4308 -0.0691 -0.0765 -0.0462 -0.0788 -1.0635 -0.1804 -0.0771 -0.0947 -0.1072 -0.1520 -0.1329 -0.1278 -1.0050 -0.1569 -0.1521
S-330	Patienten mit der seltenen hereditären Fructose-Intoleranz , Galactose-Intoleranz , Lactase-Mangel , Glucose-Galactose-Malabsorption oder Sucrase-Isomaltase-Insuffizienz sollten dieses Arzneimittel nicht einnehmen .
T-330	Patients with rare hereditary problems of fructose intolerance , galactose intolerance , the Lapp lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product .
H-330	-0.16445806622505188	Patients with rare hereditary fructose intolerance , galactose intolerance , lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine .
D-330	-0.16445806622505188	Patients with rare hereditary fructose intolerance , galactose intolerance , lactase deficiency , glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine .
P-330	-0.1971 -0.0910 -0.1570 -0.4168 -0.0752 -0.1028 -0.0677 -0.1317 -0.1049 -0.0428 -0.0280 -0.0684 -0.1823 -0.1515 -0.2385 -0.1466 -0.0366 -0.0813 -0.0554 -0.1338 -0.1554 -0.1701 -0.0480 -0.0794 -0.0423 -0.0356 -0.1106 -0.1584 -0.0337 -0.2361 -0.2632 -0.1051 -0.0898 -0.1140 -0.0625 -0.0423 -0.0561 -0.0792 -0.2172 -0.3123 -0.2044 -0.4627 -0.4308 -0.0691 -0.0765 -0.0462 -0.0788 -1.0635 -0.1804 -0.0771 -0.0947 -0.1072 -0.1520 -0.1329 -0.1278 -1.0050 -0.1569 -0.1521
S-215	In den Phase-III-Studien betrugen die mittleren Anstiege der BMD mit Alendronat 10 mg<unk> Tag im Verhältnis zu Plazebo nach 3 Jahren 8,8 % an der Wirbelsäule , 5,9 % am Femurhals und 7,8 % am Trochanter .
T-215	In the initial efficacy studies , the mean BMD increases with alendronate 10 mg/ day relative to placebo at three years were 8.8 % , 5.9 % and 7.8 % at the spine , femoral neck and trochanter , respectively .
H-215	-0.2986171841621399	In the phase IIIs , mean increases in BMD with alendronate 10 mg/ day versus placebo at 3 years were 8.8 % in the spine , 5.9 % in the femoral neck and 7.8 % in the trochanter .
D-215	-0.2986171841621399	In the phase IIIs , mean increases in BMD with alendronate 10 mg/ day versus placebo at 3 years were 8.8 % in the spine , 5.9 % in the femoral neck and 7.8 % in the trochanter .
P-215	-0.2490 -0.9701 -0.9135 -0.6427 -0.1222 -0.8087 -0.6651 -0.1890 -1.0094 -0.2214 -0.1326 -0.1103 -0.1489 -0.2687 -0.1610 -0.1602 -0.1028 -0.0494 -0.7527 -0.1849 -0.1243 -0.1289 -0.1364 -1.3792 -0.0685 -0.1453 -0.1100 -0.1204 -0.6627 -0.5024 -0.1050 -0.1450 -0.0547 -0.1156 -0.1107 -0.7110 -0.1479 -0.1098 -0.1037 -0.1465 -0.0749 -0.1257 -0.0986 -0.1570 -0.1242 -0.0918 -1.4637 -0.0993 -0.9340 -0.0768 -0.1160 -0.1060 -0.2323 -0.1227 -0.0822 -0.2702 -0.1539 -0.1482 -0.1501
S-810	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-810	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-810	-0.3775849938392639	a ) The percentage of patients was calculated based on the sum of individual patients ( 234 ) . b ) The unexpected decrease in blood coagulation factor VIII occurred post-operatively ( 10th - 14th post-surgery day ) in a continuous ADVATE infusion patient .
D-810	-0.3775849938392639	a ) The percentage of patients was calculated based on the sum of individual patients ( 234 ) . b ) The unexpected decrease in blood coagulation factor VIII occurred post-operatively ( 10th - 14th post-surgery day ) in a continuous ADVATE infusion patient .
P-810	-0.0978 -0.1302 -0.3440 -0.4105 -0.3567 -0.1371 -0.1276 -0.1523 -0.1343 -2.0343 -0.1921 -0.1663 -1.0312 -0.2046 -1.0515 -0.0978 -0.1378 -0.1106 -0.0711 -0.1415 -0.2465 -0.1263 -0.1280 -0.2557 -0.4438 -0.9031 -0.1248 -0.1216 -0.1505 -1.2677 -0.1332 -0.2345 -0.0572 -0.2724 -0.2869 -1.2554 -0.1791 -0.4797 -0.4391 -0.8224 -0.7391 -0.1197 -1.6940 -0.8995 -0.3848 -0.5846 -0.1239 -1.3880 -0.2773 -0.1243 -0.1508 -0.1726 -0.2312 -0.1376 -0.7684 -0.1452 -0.1033 -0.1739 -0.0866 -0.0625 -0.0468 -0.1671 -0.1496
S-986	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-986	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-986	-0.3775849938392639	a ) The percentage of patients was calculated based on the sum of individual patients ( 234 ) . b ) The unexpected decrease in blood coagulation factor VIII occurred post-operatively ( 10th - 14th post-surgery day ) in a continuous ADVATE infusion patient .
D-986	-0.3775849938392639	a ) The percentage of patients was calculated based on the sum of individual patients ( 234 ) . b ) The unexpected decrease in blood coagulation factor VIII occurred post-operatively ( 10th - 14th post-surgery day ) in a continuous ADVATE infusion patient .
P-986	-0.0978 -0.1302 -0.3440 -0.4105 -0.3567 -0.1371 -0.1276 -0.1523 -0.1343 -2.0343 -0.1921 -0.1663 -1.0312 -0.2046 -1.0515 -0.0978 -0.1378 -0.1106 -0.0711 -0.1415 -0.2465 -0.1263 -0.1280 -0.2557 -0.4438 -0.9031 -0.1248 -0.1216 -0.1505 -1.2677 -0.1332 -0.2345 -0.0572 -0.2724 -0.2869 -1.2554 -0.1791 -0.4797 -0.4391 -0.8224 -0.7391 -0.1197 -1.6940 -0.8995 -0.3848 -0.5846 -0.1239 -1.3880 -0.2773 -0.1243 -0.1508 -0.1726 -0.2312 -0.1376 -0.7684 -0.1452 -0.1033 -0.1739 -0.0866 -0.0625 -0.0468 -0.1671 -0.1496
S-1338	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-1338	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-1338	-0.3775849938392639	a ) The percentage of patients was calculated based on the sum of individual patients ( 234 ) . b ) The unexpected decrease in blood coagulation factor VIII occurred post-operatively ( 10th - 14th post-surgery day ) in a continuous ADVATE infusion patient .
D-1338	-0.3775849938392639	a ) The percentage of patients was calculated based on the sum of individual patients ( 234 ) . b ) The unexpected decrease in blood coagulation factor VIII occurred post-operatively ( 10th - 14th post-surgery day ) in a continuous ADVATE infusion patient .
P-1338	-0.0978 -0.1302 -0.3440 -0.4105 -0.3567 -0.1371 -0.1276 -0.1523 -0.1343 -2.0343 -0.1921 -0.1663 -1.0312 -0.2046 -1.0515 -0.0978 -0.1378 -0.1106 -0.0711 -0.1415 -0.2465 -0.1263 -0.1280 -0.2557 -0.4438 -0.9031 -0.1248 -0.1216 -0.1505 -1.2677 -0.1332 -0.2345 -0.0572 -0.2724 -0.2869 -1.2554 -0.1791 -0.4797 -0.4391 -0.8224 -0.7391 -0.1197 -1.6940 -0.8995 -0.3848 -0.5846 -0.1239 -1.3880 -0.2773 -0.1243 -0.1508 -0.1726 -0.2312 -0.1376 -0.7684 -0.1452 -0.1033 -0.1739 -0.0866 -0.0625 -0.0468 -0.1671 -0.1496
S-636	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-636	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-636	-0.3775849938392639	a ) The percentage of patients was calculated based on the sum of individual patients ( 234 ) . b ) The unexpected decrease in blood coagulation factor VIII occurred post-operatively ( 10th - 14th post-surgery day ) in a continuous ADVATE infusion patient .
D-636	-0.3775849938392639	a ) The percentage of patients was calculated based on the sum of individual patients ( 234 ) . b ) The unexpected decrease in blood coagulation factor VIII occurred post-operatively ( 10th - 14th post-surgery day ) in a continuous ADVATE infusion patient .
P-636	-0.0978 -0.1302 -0.3440 -0.4105 -0.3567 -0.1371 -0.1276 -0.1523 -0.1343 -2.0343 -0.1921 -0.1663 -1.0312 -0.2046 -1.0515 -0.0978 -0.1378 -0.1106 -0.0711 -0.1415 -0.2465 -0.1263 -0.1280 -0.2557 -0.4438 -0.9031 -0.1248 -0.1216 -0.1505 -1.2677 -0.1332 -0.2345 -0.0572 -0.2724 -0.2869 -1.2554 -0.1791 -0.4797 -0.4391 -0.8224 -0.7391 -0.1197 -1.6940 -0.8995 -0.3848 -0.5846 -0.1239 -1.3880 -0.2773 -0.1243 -0.1508 -0.1726 -0.2312 -0.1376 -0.7684 -0.1452 -0.1033 -0.1739 -0.0866 -0.0625 -0.0468 -0.1671 -0.1496
S-385	In schweren Fällen kann ein Mangel zu sekundärem Hyperparathyreoidismus , Hypophosphatämie , Schwäche der proximalen Muskulatur und Osteomalazie und so zu einem weiter erhöhten Risiko für Stürze und Knochenbrüche bei osteoporotischen Personen führen .
T-385	In severe cases , deficiency results in secondary hyperparathyroidism , hypophosphataemia , proximal muscle weakness and osteomalacia , further increasing the risk of falls and fractures in osteoporotic individuals .
H-385	-0.22056950628757477	In severe cases , deficiency may lead to secondary hyperparathyroidism , hypophosphataemia , proximal muscle weakness and osteomalacia , further increasing the risk of falls and fractures in osteoporotic subjects .
D-385	-0.22056950628757477	In severe cases , deficiency may lead to secondary hyperparathyroidism , hypophosphataemia , proximal muscle weakness and osteomalacia , further increasing the risk of falls and fractures in osteoporotic subjects .
P-385	-0.1661 -0.2086 -0.0739 -0.3145 -0.2069 -0.0499 -0.2015 -0.3440 -0.1813 -0.1485 -0.0663 -0.0398 -0.1402 -0.0903 -0.1208 -0.2822 -0.1231 -0.0849 -0.0949 -0.1415 -0.2049 -0.0479 -0.1707 -0.1135 -0.2927 -0.2990 -0.0910 -0.1310 -0.1431 -0.3743 -0.0635 -0.1252 -0.1745 -0.0349 -0.2846 -0.1237 -0.0803 -0.0947 -0.1368 -0.1547 -0.1102 -0.1425 -1.9916 -0.1251 -0.2216 -0.1741 -0.2023 -0.1673 -0.1317 -0.8346 -0.0475 -0.1898 -0.1239 -0.0668 -0.0949 -0.1467 -1.5243 -0.4203 -0.1438 -0.1549
S-197	In schweren Fällen kann ein Mangel zu sekundärem Hyperparathyreoidismus , Hypophosphatämie , Schwäche der proximalen Muskulatur und Osteomalazie und so zu einem weiter erhöhten Risiko für Stürze und Knochenbrüche bei osteoporotischen Personen führen .
T-197	In severe cases , deficiency results in secondary hyperparathyroidism , hypophosphataemia , proximal muscle weakness and osteomalacia , further increasing the risk of falls and fractures in osteoporotic individuals .
H-197	-0.22056950628757477	In severe cases , deficiency may lead to secondary hyperparathyroidism , hypophosphataemia , proximal muscle weakness and osteomalacia , further increasing the risk of falls and fractures in osteoporotic subjects .
D-197	-0.22056950628757477	In severe cases , deficiency may lead to secondary hyperparathyroidism , hypophosphataemia , proximal muscle weakness and osteomalacia , further increasing the risk of falls and fractures in osteoporotic subjects .
P-197	-0.1661 -0.2086 -0.0739 -0.3145 -0.2069 -0.0499 -0.2015 -0.3440 -0.1813 -0.1485 -0.0663 -0.0398 -0.1402 -0.0903 -0.1208 -0.2822 -0.1231 -0.0849 -0.0949 -0.1415 -0.2049 -0.0479 -0.1707 -0.1135 -0.2927 -0.2990 -0.0910 -0.1310 -0.1431 -0.3743 -0.0635 -0.1252 -0.1745 -0.0349 -0.2846 -0.1237 -0.0803 -0.0947 -0.1368 -0.1547 -0.1102 -0.1425 -1.9916 -0.1251 -0.2216 -0.1741 -0.2023 -0.1673 -0.1317 -0.8346 -0.0475 -0.1898 -0.1239 -0.0668 -0.0949 -0.1467 -1.5243 -0.4203 -0.1438 -0.1549
S-1162	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-1162	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-1162	-0.3775849938392639	a ) The percentage of patients was calculated based on the sum of individual patients ( 234 ) . b ) The unexpected decrease in blood coagulation factor VIII occurred post-operatively ( 10th - 14th post-surgery day ) in a continuous ADVATE infusion patient .
D-1162	-0.3775849938392639	a ) The percentage of patients was calculated based on the sum of individual patients ( 234 ) . b ) The unexpected decrease in blood coagulation factor VIII occurred post-operatively ( 10th - 14th post-surgery day ) in a continuous ADVATE infusion patient .
P-1162	-0.0978 -0.1302 -0.3440 -0.4105 -0.3567 -0.1371 -0.1276 -0.1523 -0.1343 -2.0343 -0.1921 -0.1663 -1.0312 -0.2046 -1.0515 -0.0978 -0.1378 -0.1106 -0.0711 -0.1415 -0.2465 -0.1263 -0.1280 -0.2557 -0.4438 -0.9031 -0.1248 -0.1216 -0.1505 -1.2677 -0.1332 -0.2345 -0.0572 -0.2724 -0.2869 -1.2554 -0.1791 -0.4797 -0.4391 -0.8224 -0.7391 -0.1197 -1.6940 -0.8995 -0.3848 -0.5846 -0.1239 -1.3880 -0.2773 -0.1243 -0.1508 -0.1726 -0.2312 -0.1376 -0.7684 -0.1452 -0.1033 -0.1739 -0.0866 -0.0625 -0.0468 -0.1671 -0.1496
S-389	Die Patienten erhielten ADROVANCE in der niedrigeren Stärke ( 70 mg<unk> 2.800 I.E. ) ( n<unk> 350 ) oder FOSAMAX ( Alendronat ) 70 mg einmal wöchentlich ( n<unk> 332 ) ; weitere Vitamin-D-Ergänzungsmittel waren untersagt .
T-389	Patients received the lower strength ( 70 mg/ 2800 IU ) of ADROVANCE ( n<<unk>> 350 ) or FOSAMAX ( alendronate ) 70 mg ( n<<unk>> 332 ) once a week ; additional vitamin
H-389	-0.2670815885066986	Patients were receiving lower strength ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 350 ) or FOSAMAX ( alendronate ) 70 mg once a week ( n/ 332 ) ; further vitamin D supplements were prohibited .
D-389	-0.2670815885066986	Patients were receiving lower strength ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 350 ) or FOSAMAX ( alendronate ) 70 mg once a week ( n/ 332 ) ; further vitamin D supplements were prohibited .
P-389	-0.3514 -0.0937 -1.0548 -0.1778 -0.2788 -1.3592 -0.7396 -0.0599 -0.1244 -0.1100 -0.1006 -0.1268 -0.1322 -0.1497 -0.1381 -0.1210 -0.1923 -0.1003 -0.1066 -0.0954 -0.1230 -0.1528 -0.2060 -0.1358 -0.5559 -0.1278 -0.1538 -0.1641 -0.0787 -0.1137 -0.1504 -0.0988 -0.1373 -0.1618 -0.1452 -0.1115 -0.0380 -0.1363 -0.2884 -0.0384 -0.4414 -0.3148 -0.0845 -0.1337 -0.1653 -0.1289 -0.1488 -0.1172 -0.1331 -0.5340 -1.9823 -0.1923 -0.1201 -0.1353 -0.0565 -0.2237 -0.1161 -2.1965 -0.0452 -0.1414 -0.1512
S-1515	a ) Der Prozentsatz der Patienten wurde anhand der Summe der einzelnen Patienten ( 234 ) berechnet. b ) Der unerwartete Abfall des Blutgerinnungsfaktor VIII-Spiegels trat postoperativ ( 10 . - 14. postoperativer Tag ) bei einem Patienten unter kontinuierlicher ADVATE-Infusion auf .
T-1515	a ) Percent of patients calculated based on total number of unique patients ( 234 ) . b ) The unexpected decrease in coagulation factor VIII levels occurred in one patient during continuous infusion of ADVATE following surgery ( postoperative days 10-14 ) .
H-1515	-0.3775849938392639	a ) The percentage of patients was calculated based on the sum of individual patients ( 234 ) . b ) The unexpected decrease in blood coagulation factor VIII occurred post-operatively ( 10th - 14th post-surgery day ) in a continuous ADVATE infusion patient .
D-1515	-0.3775849938392639	a ) The percentage of patients was calculated based on the sum of individual patients ( 234 ) . b ) The unexpected decrease in blood coagulation factor VIII occurred post-operatively ( 10th - 14th post-surgery day ) in a continuous ADVATE infusion patient .
P-1515	-0.0978 -0.1302 -0.3440 -0.4105 -0.3567 -0.1371 -0.1276 -0.1523 -0.1343 -2.0343 -0.1921 -0.1663 -1.0312 -0.2046 -1.0515 -0.0978 -0.1378 -0.1106 -0.0711 -0.1415 -0.2465 -0.1263 -0.1280 -0.2557 -0.4438 -0.9031 -0.1248 -0.1216 -0.1505 -1.2677 -0.1332 -0.2345 -0.0572 -0.2724 -0.2869 -1.2554 -0.1791 -0.4797 -0.4391 -0.8224 -0.7391 -0.1197 -1.6940 -0.8995 -0.3848 -0.5846 -0.1239 -1.3880 -0.2773 -0.1243 -0.1508 -0.1726 -0.2312 -0.1376 -0.7684 -0.1452 -0.1033 -0.1739 -0.0866 -0.0625 -0.0468 -0.1671 -0.1496
S-642	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-642	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-642	-0.29398465156555176	In addition , no FVIII inhibitor has been detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
D-642	-0.29398465156555176	In addition , no FVIII inhibitor has been detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
P-642	-1.6063 -0.1006 -0.1470 -1.8081 -0.1473 -0.1346 -0.1591 -0.5725 -0.1226 -0.0278 -0.0798 -0.1619 -0.8017 -0.1802 -0.5065 -0.0987 -0.1680 -0.2076 -0.1723 -0.1891 -0.1067 -0.1056 -0.0305 -0.0493 -0.1151 -0.0930 -2.1476 -0.1371 -0.2125 -0.0898 -0.2864 -0.0977 -1.0868 -0.4505 -0.3446 -0.1646 -0.2241 -0.1535 -0.2698 -0.1674 -0.1539 -0.2479 -0.1154 -0.1364 -0.1490 -0.1624 -0.1385 -0.1167 -0.1451 -0.1361 -0.5286 -0.6465 -0.1036 -0.1693 -0.3719 -0.4114 -0.2414 -0.3416 -0.3846 -0.1039 -0.1513 -0.1576 -0.1051 -0.1509 -0.1600 -0.1494
S-816	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-816	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-816	-0.29398465156555176	In addition , no FVIII inhibitor has been detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
D-816	-0.29398465156555176	In addition , no FVIII inhibitor has been detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
P-816	-1.6063 -0.1006 -0.1470 -1.8081 -0.1473 -0.1346 -0.1591 -0.5725 -0.1226 -0.0278 -0.0798 -0.1619 -0.8017 -0.1802 -0.5065 -0.0987 -0.1680 -0.2076 -0.1723 -0.1891 -0.1067 -0.1056 -0.0305 -0.0493 -0.1151 -0.0930 -2.1476 -0.1371 -0.2125 -0.0898 -0.2864 -0.0977 -1.0868 -0.4505 -0.3446 -0.1646 -0.2241 -0.1535 -0.2698 -0.1674 -0.1539 -0.2479 -0.1154 -0.1364 -0.1490 -0.1624 -0.1385 -0.1167 -0.1451 -0.1361 -0.5286 -0.6465 -0.1036 -0.1693 -0.3719 -0.4114 -0.2414 -0.3416 -0.3846 -0.1039 -0.1513 -0.1576 -0.1051 -0.1509 -0.1600 -0.1494
S-992	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-992	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-992	-0.29398465156555176	In addition , no FVIII inhibitor has been detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
D-992	-0.29398465156555176	In addition , no FVIII inhibitor has been detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
P-992	-1.6063 -0.1006 -0.1470 -1.8081 -0.1473 -0.1346 -0.1591 -0.5725 -0.1226 -0.0278 -0.0798 -0.1619 -0.8017 -0.1802 -0.5065 -0.0987 -0.1680 -0.2076 -0.1723 -0.1891 -0.1067 -0.1056 -0.0305 -0.0493 -0.1151 -0.0930 -2.1476 -0.1371 -0.2125 -0.0898 -0.2864 -0.0977 -1.0868 -0.4505 -0.3446 -0.1646 -0.2241 -0.1535 -0.2698 -0.1674 -0.1539 -0.2479 -0.1154 -0.1364 -0.1490 -0.1624 -0.1385 -0.1167 -0.1451 -0.1361 -0.5286 -0.6465 -0.1036 -0.1693 -0.3719 -0.4114 -0.2414 -0.3416 -0.3846 -0.1039 -0.1513 -0.1576 -0.1051 -0.1509 -0.1600 -0.1494
S-1168	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-1168	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-1168	-0.29398465156555176	In addition , no FVIII inhibitor has been detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
D-1168	-0.29398465156555176	In addition , no FVIII inhibitor has been detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
P-1168	-1.6063 -0.1006 -0.1470 -1.8081 -0.1473 -0.1346 -0.1591 -0.5725 -0.1226 -0.0278 -0.0798 -0.1619 -0.8017 -0.1802 -0.5065 -0.0987 -0.1680 -0.2076 -0.1723 -0.1891 -0.1067 -0.1056 -0.0305 -0.0493 -0.1151 -0.0930 -2.1476 -0.1371 -0.2125 -0.0898 -0.2864 -0.0977 -1.0868 -0.4505 -0.3446 -0.1646 -0.2241 -0.1535 -0.2698 -0.1674 -0.1539 -0.2479 -0.1154 -0.1364 -0.1490 -0.1624 -0.1385 -0.1167 -0.1451 -0.1361 -0.5286 -0.6465 -0.1036 -0.1693 -0.3719 -0.4114 -0.2414 -0.3416 -0.3846 -0.1039 -0.1513 -0.1576 -0.1051 -0.1509 -0.1600 -0.1494
S-1344	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-1344	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-1344	-0.29398465156555176	In addition , no FVIII inhibitor has been detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
D-1344	-0.29398465156555176	In addition , no FVIII inhibitor has been detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
P-1344	-1.6063 -0.1006 -0.1470 -1.8081 -0.1473 -0.1346 -0.1591 -0.5725 -0.1226 -0.0278 -0.0798 -0.1619 -0.8017 -0.1802 -0.5065 -0.0987 -0.1680 -0.2076 -0.1723 -0.1891 -0.1067 -0.1056 -0.0305 -0.0493 -0.1151 -0.0930 -2.1476 -0.1371 -0.2125 -0.0898 -0.2864 -0.0977 -1.0868 -0.4505 -0.3446 -0.1646 -0.2241 -0.1535 -0.2698 -0.1674 -0.1539 -0.2479 -0.1154 -0.1364 -0.1490 -0.1624 -0.1385 -0.1167 -0.1451 -0.1361 -0.5286 -0.6465 -0.1036 -0.1693 -0.3719 -0.4114 -0.2414 -0.3416 -0.3846 -0.1039 -0.1513 -0.1576 -0.1051 -0.1509 -0.1600 -0.1494
S-1521	Darüber hinaus wurde bei keinem der 53 pädiatrischen Patienten mit einem Alter von unter 6 Jahren und diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) nach vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 50 Tage ) ein FVIII-Inhibitor festgestellt .
T-1521	Also , in 53 paediatric patients under the age of 6 , also diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 50 days , no FVIII inhibitor was detected .
H-1521	-0.29398465156555176	In addition , no FVIII inhibitor has been detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
D-1521	-0.29398465156555176	In addition , no FVIII inhibitor has been detected in any of the 53 paediatric patients less than 6 years of age and diagnosed with severe to moderate haemophilia A ( FVIII 2 % ) after prior exposure to factor VIII concentrates ( 50 days ) .
P-1521	-1.6063 -0.1006 -0.1470 -1.8081 -0.1473 -0.1346 -0.1591 -0.5725 -0.1226 -0.0278 -0.0798 -0.1619 -0.8017 -0.1802 -0.5065 -0.0987 -0.1680 -0.2076 -0.1723 -0.1891 -0.1067 -0.1056 -0.0305 -0.0493 -0.1151 -0.0930 -2.1476 -0.1371 -0.2125 -0.0898 -0.2864 -0.0977 -1.0868 -0.4505 -0.3446 -0.1646 -0.2241 -0.1535 -0.2698 -0.1674 -0.1539 -0.2479 -0.1154 -0.1364 -0.1490 -0.1624 -0.1385 -0.1167 -0.1451 -0.1361 -0.5286 -0.6465 -0.1036 -0.1693 -0.3719 -0.4114 -0.2414 -0.3416 -0.3846 -0.1039 -0.1513 -0.1576 -0.1051 -0.1509 -0.1600 -0.1494
S-1961	Die Patienten müssen darüber informiert werden , dass die Behandlung bei Auftreten einer Hypertonie oder einer Tachykardie oder von Palpitationen , Herzrhythmusstörungen , Übelkeit oder etwaigen sonstigen neurologischen Symptomen ( wie Kopfschmerzen oder einer Verstärkung der Kopfschmerzen ) abgesetzt werden muss .
T-1961	Patients should be informed that the treatment should be discontinued in case of hypertension , tachycardia , palpitations or cardiac arrhythmias , nausea or any other neurological sign ( such as headache or increased headache ) .
H-1961	-0.2839507460594177	Patients should be advised that treatment should be discontinued if hypertension or tachycardia occur or if palpitations , cardiac dysrhythmia , nausea or any other neurological symptoms ( such as headache or headache aggravation ) occur .
D-1961	-0.2839507460594177	Patients should be advised that treatment should be discontinued if hypertension or tachycardia occur or if palpitations , cardiac dysrhythmia , nausea or any other neurological symptoms ( such as headache or headache aggravation ) occur .
P-1961	-0.1064 -0.0933 -1.3537 -0.1652 -0.7429 -0.1942 -1.5714 -0.7741 -0.1268 -0.2449 -0.0553 -0.3316 -0.0488 -0.0196 -0.1157 -0.0643 -0.0828 -0.1311 -0.1288 -0.0309 -1.3449 -0.9975 -0.0912 -0.6311 -0.1612 -0.3779 -0.1448 -0.1744 -0.0198 -0.0719 -0.0170 -0.0540 -0.1608 -0.0217 -0.0308 -0.1285 -0.3487 -0.2877 -0.0510 -0.1983 -0.1361 -0.1741 -0.1841 -0.1682 -0.0806 -0.0360 -0.1306 -0.1180 -1.6841 -0.0219 -0.0647 -1.0236 -0.0570 -0.0563 -0.1435 -0.3907 -0.1528 -0.1520
S-1857	Li-Fraumeni-Krebs ist eine Art von Krebs , der bei Patienten mit Li- Fraumeni-Syndrom auftritt , bei dem das so genannte p53-Gen aufgrund einer Mutation defekt ist . Bei Menschen , die diese Mutation aufweisen , besteht eine höhere Wahrscheinlichkeit , an Krebs zu erkranken .
T-1857	Li-Fraumeni cancer is a type of cancer that occurs in patients with Li-Fraumeni syndrome , a condition where a gene called p53 is defective because of a mutation .
H-1857	-0.5504312515258789	Li-Fraumeni Cancer is a type of cancer that affects patients with Li-Fraumeni Syndrome who have a mutation defective gene called p53 and are more likely to get cancer if they have this mutation .
D-1857	-0.5504312515258789	Li-Fraumeni Cancer is a type of cancer that affects patients with Li-Fraumeni Syndrome who have a mutation defective gene called p53 and are more likely to get cancer if they have this mutation .
P-1857	-1.0533 -0.4156 -0.3426 -0.0378 -0.2483 -0.7552 -0.1310 -0.1523 -0.1015 -0.1432 -0.0587 -0.1363 -1.2575 -0.4555 -0.1711 -3.4843 -0.6760 -0.4140 -0.0480 -0.3447 -0.9943 -0.0439 -0.5398 -0.2589 -0.1534 -0.9078 -0.3643 -2.2856 -0.9785 -1.0141 -0.3025 -0.1387 -0.1389 -2.2519 -0.5864 -0.3234 -0.1979 -0.1595 -1.6822 -0.0810 -0.3554 -0.0935 -0.3054 -0.8087 -0.5288 -0.1617 -0.1522 -0.1847
S-201	Die Patienten erhielten ADROVANCE in der niedrigeren Stärke ( 70 mg <unk> 2.800 I.E. ) ( n<unk> 350 ) oder FOSAMAX ( Alendronat ) 70 mg einmal wöchentlich ( n<unk> 332 ) ; weitere Vitamin-D-Ergänzungsmittel waren untersagt .
T-201	Patients received the lower strength ( 70 mg/ 2800 IU ) of ADROVANCE ( n<<unk>> 350 ) or FOSAMAX ( alendronate ) 70 mg ( n<<unk>> 332 ) once a week ; additional vitamin D supplements
H-201	-0.27949440479278564	Patients were receiving lower strength ADROVANCE ( 70 mg / 2,800 IU ) ( n/ 350 ) or FOSAMAX ( alendronate ) 70 mg once a week ( n/ 332 ) ; further vitamin D supplements were prohibited .
D-201	-0.27949440479278564	Patients were receiving lower strength ADROVANCE ( 70 mg / 2,800 IU ) ( n/ 350 ) or FOSAMAX ( alendronate ) 70 mg once a week ( n/ 332 ) ; further vitamin D supplements were prohibited .
P-201	-0.3538 -0.0945 -1.1836 -0.1886 -0.2589 -1.5147 -0.4673 -0.0631 -0.1236 -0.1083 -0.1025 -0.1240 -0.1263 -0.0483 -0.6632 -0.1771 -0.0962 -0.1046 -0.0862 -0.1260 -0.1597 -0.2011 -0.2558 -0.5415 -0.1278 -0.1527 -0.1684 -0.0751 -0.1108 -0.1555 -0.1022 -0.1399 -0.1747 -0.1448 -0.1248 -0.0408 -0.1383 -0.2536 -0.0412 -0.4864 -0.3048 -0.0839 -0.1332 -0.1690 -0.1388 -0.1589 -0.1175 -0.1335 -0.6240 -1.9518 -0.1902 -0.1069 -0.1154 -0.0591 -0.2205 -0.1175 -2.1982 -0.0449 -0.1438 -0.1521
S-1898	Aerinaze wird zur Behandlung der Symptome der saisonalen allergischen Rhinitis ( Heuschnupfen , durch eine Allergie gegen Pollen hervorgerufene Entzündung der Nasenwege ) bei Patienten mit Nasenschleimhautschwellung ( verstopfter Nase ) angewendet .
T-1898	Aerinaze is used to treat the symptoms of seasonal allergic rhinitis ( hayfever , inflammation of the nasal passages caused by an allergy to pollen ) in patients who have nasal congestion ( a blocked nose ) .
H-1898	-0.30155467987060547	Aerinaze is used to treat symptoms of seasonal allergic rhinitis ( hayfever , nasal inflammation induced by allergy to pollen ) in patients with nasal swelling ( nasal congestion ) .
D-1898	-0.30155467987060547	Aerinaze is used to treat symptoms of seasonal allergic rhinitis ( hayfever , nasal inflammation induced by allergy to pollen ) in patients with nasal swelling ( nasal congestion ) .
P-1898	-0.1397 -0.1425 -0.1234 -0.1700 -0.1114 -0.1199 -0.0625 -0.1350 -0.1264 -0.4465 -0.1456 -0.7324 -0.1511 -0.0683 -0.0903 -0.1347 -0.0792 -0.1042 -0.0790 -0.1205 -0.1041 -0.8000 -0.1841 -0.1250 -0.1499 -0.1365 -0.0299 -0.2052 -3.2220 -0.0624 -0.1181 -1.3306 -0.1591 -0.1522 -1.2387 -0.2100 -0.1614 -0.1521 -0.0948 -0.3141 -0.1216 -0.1698 -0.9385 -0.1357 -0.0331 -0.0256 -0.1712 -0.1494 -0.1156 -0.1210 -0.5707 -0.0295 -0.1530 -1.0350 -1.2067 -0.1408 -0.1388 -0.1509 -0.1519
S-306	Eine zahnärztliche Untersuchung mit geeigneten Präventionsmaßnahmen sollte einer Behandlung mit Bisphosphonaten vorangehen , wenn die Patienten entsprechende Risikofaktoren aufweisen ( z. B. Krebs , Chemotherapie , Strahlentherapie , Kortikosteroide , schlechte Mundhygiene , Parodontitis ) .
T-306	A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontal disease ) .
H-306	-0.2568868398666382	A dental examination with appropriate preventive measures should precede treatment with bisphosphonates if patients exhibit corresponding risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontitis ) .
D-306	-0.2568868398666382	A dental examination with appropriate preventive measures should precede treatment with bisphosphonates if patients exhibit corresponding risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontitis ) .
P-306	-1.6469 -0.2372 -1.6966 -0.2604 -0.2262 -0.1913 -0.4781 -0.3171 -0.6150 -0.1427 -0.7394 -0.6019 -0.2726 -0.1512 -0.1195 -0.0300 -0.0695 -0.1473 -0.0646 -0.4679 -0.6281 -0.7563 -0.0501 -0.6431 -0.1048 -0.0547 -0.0448 -0.1499 -0.2142 -0.0946 -0.0715 -0.0873 -0.1521 -0.1065 -0.0467 -0.0678 -0.1517 -0.3392 -0.0762 -0.1499 -0.1874 -0.1034 -0.0831 -0.1158 -0.1580 -0.0640 -0.1462 -0.2824 -0.1980 -0.0686 -0.2481 -0.1606 -0.0661 -0.0917 -0.2071 -0.0711 -0.1338 -0.1566 -0.1494
S-1985	4 leistungsmindernde Wirkung von Alkohol jedoch nicht verstärkt . Bei den Ergebnissen des psychomotorischen Tests konnten keine signifikanten Unterschiede zwischen den mit Desloratadin und den mit Placebo behandelten Patienten festgestellt werden , unabhängig davon , ob Desloratadin alleine oder mit Alkohol eingenommen wurde .
T-1985	No significant differences were found in the psychomotor test results between desloratadine and placebo groups , whether administered alone or with alcohol .
H-1985	-0.4937911927700043	no significant differences could be detected between patients treated with desloratadine and those treated with placebo , whether desloratadine was administered alone or with alcohol .
D-1985	-0.4937911927700043	no significant differences could be detected between patients treated with desloratadine and those treated with placebo , whether desloratadine was administered alone or with alcohol .
P-1985	-4.3672 -0.1918 -0.1261 -1.1333 -0.1426 -0.5289 -0.0895 -0.3589 -0.7629 -0.8976 -0.1504 -0.6211 -0.0653 -0.0950 -0.3815 -1.5483 -0.1491 -1.6129 -0.3768 -0.1375 -0.0265 -0.1302 -0.1076 -0.1426 -0.3042 -0.6176 -0.3813 -0.0804 -0.1051 -0.2033 -0.8164 -0.2470 -1.5065 -0.0741 -0.1659 -0.1223 -0.2177 -0.0935 -0.3689 -0.3039
S-1980	Andere Wirkstoffe mit gefäßverengender Wirkung , die oral oder nasal als abschwellende Rhinologika angewendet werden ( Phenylpropanolamin , Phenylephrin , Ephedrin , Oxymetazolin , Naphazolin etc . ) :
T-1980	Other vasoconstrictors used as nasal decongestant , by oral or nasal route ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazoline , naphazoline ) : risk of vasoconstriction .
H-1980	-0.3515830338001251	Other vasoconstricting agents used orally or nasally as decongestant rhinologic agents ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazoline , naphazolin , etc. ) :
D-1980	-0.3515830338001251	Other vasoconstricting agents used orally or nasally as decongestant rhinologic agents ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazoline , naphazolin , etc. ) :
P-1980	-0.5752 -0.3391 -0.0175 -0.4155 -0.1312 -0.3254 -0.6460 -0.0771 -0.4911 -0.2574 -0.1201 -0.1751 -0.0935 -0.1362 -0.1901 -0.1464 -0.3226 -0.4610 -0.2631 -0.6374 -0.2419 -0.0952 -0.8202 -1.7711 -0.1416 -0.1299 -0.0981 -0.3049 -0.1135 -0.1412 -0.0802 -0.0781 -0.1481 -0.1396 -0.1626 -0.0577 -0.1017 -0.0444 -0.2343 -0.1503 -0.1170 -0.1292 -0.1110 -0.1280 -0.1486 -0.9106 -0.0655 -0.0855 -0.0474 -3.7208 -0.1521 -0.1480 -0.5870 -0.1055 -0.1421 -2.3300 -0.1674 -0.4777 -0.7494 -0.2892 -0.1439 -0.1665
S-118	Eine zahnärztliche Untersuchung mit geeigneten Präventionsmaßnahmen sollte einer Behandlung mit Bisphosphonaten vorangehen , wenn die Patienten entsprechende Risikofaktoren aufweisen ( z. B. Krebs , Chemotherapie , Strahlentherapie , Kortikosteroide , schlechte Mundhygiene , Parodontitis ) .
T-118	A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontal disease ) .
H-118	-0.2568868398666382	A dental examination with appropriate preventive measures should precede treatment with bisphosphonates if patients exhibit corresponding risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontitis ) .
D-118	-0.2568868398666382	A dental examination with appropriate preventive measures should precede treatment with bisphosphonates if patients exhibit corresponding risk factors ( e. g. cancer , chemotherapy , radiotherapy , corticosteroids , poor oral hygiene , periodontitis ) .
P-118	-1.6469 -0.2372 -1.6966 -0.2604 -0.2262 -0.1913 -0.4781 -0.3171 -0.6150 -0.1427 -0.7394 -0.6019 -0.2726 -0.1512 -0.1195 -0.0300 -0.0695 -0.1473 -0.0646 -0.4679 -0.6281 -0.7563 -0.0501 -0.6431 -0.1048 -0.0547 -0.0448 -0.1499 -0.2142 -0.0946 -0.0715 -0.0873 -0.1521 -0.1065 -0.0467 -0.0678 -0.1517 -0.3392 -0.0762 -0.1499 -0.1874 -0.1034 -0.0831 -0.1158 -0.1580 -0.0640 -0.1462 -0.2824 -0.1980 -0.0686 -0.2481 -0.1606 -0.0661 -0.0917 -0.2071 -0.0711 -0.1338 -0.1566 -0.1494
S-303	Osteonekrose des Kiefers , üblicherweise im Zusammenhang mit einer Zahnextraktion und<unk> oder einer lokalen Infektion ( einschließlich Osteomyelitis ) , wurde bei Krebspatienten berichtet , deren Therapieregime vorwiegend intravenös verabreichte Bisphosphonate enthält .
T-303	Osteonecrosis of the jaw , generally associated with tooth extraction and/ or local infection ( including osteomyelitis ) has been reported in patients with cancer who are receiving treatment regimens including primarily intravenously administered bisphosphonates .
H-303	-0.20502866804599762	jaw osteonecrosis , usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) , has been reported in cancer patients whose regimens predominantly contain intravenously administered bisphosphonates .
D-303	-0.20502866804599762	jaw osteonecrosis , usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) , has been reported in cancer patients whose regimens predominantly contain intravenously administered bisphosphonates .
P-303	-0.8190 -0.2621 -0.1267 -0.0652 -0.1290 -0.0792 -0.0473 -0.0808 -0.1384 -0.2979 -0.6852 -0.1821 -0.0751 -0.0494 -0.2700 -0.2044 -0.0546 -0.1528 -0.1497 -0.3764 -0.0604 -0.1596 -0.0827 -0.1201 -0.0729 -0.1243 -0.1615 -0.0780 -0.0578 -0.1345 -0.3808 -0.2898 -0.2005 -0.1144 -0.1429 -0.0512 -0.1247 -0.0909 -0.4494 -0.1639 -2.0551 -0.0459 -0.0697 -0.5920 -0.2313 -0.0734 -0.1111 -0.4563 -0.0443 -0.0878 -0.1256 -0.0335 -0.0764 -0.0561 -0.0375 -0.1367 -0.1481
S-366	Alendronat Infolge einer oralen Überdosis können Hypocalcämie , Hypophosphatämie und Nebenwirkungen im oberen Gastrointestinaltrakt wie Magenverstimmung , Sodbrennen , Ösophagitis , Gastritis oder Ulzera auftreten .
T-366	Alendronate Hypocalcaemia , hypophosphataemia and upper gastrointestinal adverse reactions , such as upset stomach , heartburn , oesophagitis , gastritis , or ulcer , may result from oral overdose .
H-366	-0.25159695744514465	Oral overdose may result in hypocalcaemia , hypophosphataemia and upper gastrointestinal effects such as upset stomach , heartburn , oesophagitis , gastritis or ulcers .
D-366	-0.25159695744514465	Oral overdose may result in hypocalcaemia , hypophosphataemia and upper gastrointestinal effects such as upset stomach , heartburn , oesophagitis , gastritis or ulcers .
P-366	-1.3601 -0.0252 -0.2601 -0.0333 -0.2845 -1.3711 -0.1439 -0.0251 -0.0793 -0.0514 -0.0360 -0.1326 -0.1419 -0.2401 -0.0509 -0.2253 -0.1163 -0.2167 -0.5282 -0.0791 -0.1393 -0.2654 -0.3087 -0.1289 -0.0816 -0.2902 -0.0781 -0.0486 -2.1421 -0.2019 -0.1605 -0.5968 -0.1333 -0.1492 -0.0341 -0.0585 -0.1513 -0.5787 -0.0764 -0.0630 -0.0832 -0.1165 -0.0876 -0.1531 -0.1895 -0.0667 -0.0576 -0.2496 -0.1727 -0.5573 -0.1871 -0.1660 -0.1603
S-178	Alendronat Infolge einer oralen Überdosis können Hypocalcämie , Hypophosphatämie und Nebenwirkungen im oberen Gastrointestinaltrakt wie Magenverstimmung , Sodbrennen , Ösophagitis , Gastritis oder Ulzera auftreten .
T-178	Alendronate Hypocalcaemia , hypophosphataemia and upper gastrointestinal adverse reactions , such as upset stomach , heartburn , oesophagitis , gastritis , or ulcer , may result from oral overdose .
H-178	-0.25159695744514465	Oral overdose may result in hypocalcaemia , hypophosphataemia and upper gastrointestinal effects such as upset stomach , heartburn , oesophagitis , gastritis or ulcers .
D-178	-0.25159695744514465	Oral overdose may result in hypocalcaemia , hypophosphataemia and upper gastrointestinal effects such as upset stomach , heartburn , oesophagitis , gastritis or ulcers .
P-178	-1.3601 -0.0252 -0.2601 -0.0333 -0.2845 -1.3711 -0.1439 -0.0251 -0.0793 -0.0514 -0.0360 -0.1326 -0.1419 -0.2401 -0.0509 -0.2253 -0.1163 -0.2167 -0.5282 -0.0791 -0.1393 -0.2654 -0.3087 -0.1289 -0.0816 -0.2902 -0.0781 -0.0486 -2.1421 -0.2019 -0.1605 -0.5968 -0.1333 -0.1492 -0.0341 -0.0585 -0.1513 -0.5787 -0.0764 -0.0630 -0.0832 -0.1165 -0.0876 -0.1531 -0.1895 -0.0667 -0.0576 -0.2496 -0.1727 -0.5573 -0.1871 -0.1660 -0.1603
S-1458	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-1458	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-1458	-0.25870993733406067	injection every 8-24 hours ( 6-24 hours for patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
D-1458	-0.25870993733406067	injection every 8-24 hours ( 6-24 hours for patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
P-1458	-0.3722 -0.1141 -0.1926 -0.2567 -0.1301 -0.1349 -0.1400 -0.1543 -0.1421 -0.1135 -0.1592 -0.1645 -0.7616 -0.1754 -0.6425 -0.2604 -0.0961 -0.3067 -0.1037 -0.1405 -0.1338 -1.5739 -0.2444 -0.5494 -0.0641 -0.2849 -0.2286 -0.2012 -0.2342 -0.1185 -0.1456 -0.1274 -0.4867 -0.2593 -0.2155 -0.0233 -0.1132 -0.3789 -0.2808 -1.5538 -0.2518 -0.1462 -0.3907 -0.1462 -0.1026 -0.1481 -0.1380 -0.1490 -0.1134 -0.1415 -0.0434 -0.1270 -0.1432 -0.1507
S-115	Osteonekrose des Kiefers , üblicherweise im Zusammenhang mit einer Zahnextraktion und<unk> oder einer lokalen Infektion ( einschließlich Osteomyelitis ) , wurde bei Krebspatienten berichtet , deren Therapieregime vorwiegend intravenös verabreichte Bisphosphonate enthält .
T-115	Osteonecrosis of the jaw , generally associated with tooth extraction and/ or local infection ( including osteomyelitis ) has been reported in patients with cancer who are receiving treatment regimens including primarily intravenously administered bisphosphonates .
H-115	-0.20502866804599762	jaw osteonecrosis , usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) , has been reported in cancer patients whose regimens predominantly contain intravenously administered bisphosphonates .
D-115	-0.20502866804599762	jaw osteonecrosis , usually associated with tooth extraction and/ or local infection ( including osteomyelitis ) , has been reported in cancer patients whose regimens predominantly contain intravenously administered bisphosphonates .
P-115	-0.8190 -0.2621 -0.1267 -0.0652 -0.1290 -0.0792 -0.0473 -0.0808 -0.1384 -0.2979 -0.6852 -0.1821 -0.0751 -0.0494 -0.2700 -0.2044 -0.0546 -0.1528 -0.1497 -0.3764 -0.0604 -0.1596 -0.0827 -0.1201 -0.0729 -0.1243 -0.1615 -0.0780 -0.0578 -0.1345 -0.3808 -0.2898 -0.2005 -0.1144 -0.1429 -0.0512 -0.1247 -0.0909 -0.4494 -0.1639 -2.0551 -0.0459 -0.0697 -0.5920 -0.2313 -0.0734 -0.1111 -0.4563 -0.0443 -0.0878 -0.1256 -0.0335 -0.0764 -0.0561 -0.0375 -0.1367 -0.1481
S-1487	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-1487	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-1487	-0.3662869334220886	In previously treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titer ) inhibitors has been observed after transfer from one recombinant factor VIII product to another .
D-1487	-0.3662869334220886	In previously treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titer ) inhibitors has been observed after transfer from one recombinant factor VIII product to another .
P-1487	-0.2552 -0.9489 -0.0880 -0.1156 -0.1356 -0.1005 -0.1854 -0.2662 -0.1357 -1.3776 -0.4832 -0.1367 -0.1045 -0.9923 -0.2258 -0.0791 -0.1551 -0.3351 -0.5698 -0.1436 -0.1004 -0.0396 -0.0924 -0.3395 -0.4052 -0.1615 -0.8078 -0.0558 -0.0423 -0.1209 -0.1430 -0.1814 -1.2682 -1.4353 -0.1682 -1.5889 -0.1706 -0.1308 -0.0293 -0.0889 -0.1149 -0.7787 -0.3156 -0.1647 -0.3082 -2.4453 -0.1600 -0.2981 -0.1192 -0.0840 -0.0697 -0.1316 -0.1965 -0.3444 -0.4697 -1.2933 -0.0655 -0.1930 -0.2886 -0.1473 -0.1512
S-1790	In Verbindung mit Operationen Katheterinfektionen , geringere Anzahl der roten Blutkörperchen , Anschwellen von Gliedmaßen und Gelenken , verlängerte Blutung nach der Entfernung einer Drainage , verminderter Faktor-VIII-Spiegel und postoperative Hämatome .
T-1790	Related to surgery catheter-related infection , decreased red cell blood count , swelling of limbs and joints , prolonged bleeding after drain removal , decreased Factor VIII level and post-operative bruise .
H-1790	-0.3636458218097687	Concomitant with surgery , catheter infections , lower red blood cell count , swelling of limbs and joints , prolonged bleeding after removal of drainage , decreased factor VIII levels and post-surgery haematomas .
D-1790	-0.3636458218097687	Concomitant with surgery , catheter infections , lower red blood cell count , swelling of limbs and joints , prolonged bleeding after removal of drainage , decreased factor VIII levels and post-surgery haematomas .
P-1790	-0.4615 -1.4496 -0.0351 -0.2448 -2.0896 -0.6264 -1.0925 -0.1285 -0.0747 -0.3847 -1.1642 -0.0460 -0.1365 -1.7615 -0.2080 -0.2083 -0.0621 -0.0234 -0.1436 -0.1867 -0.0858 -0.1551 -0.1679 -0.0473 -0.1348 -0.1383 -0.1493 -0.0610 -0.1457 -0.1900 -0.1113 -0.0733 -0.5651 -0.1312 -0.3867 -1.2761 -0.1800 -0.2024 -0.1873 -0.1357 -0.1426 -0.0725 -0.0786 -0.1435 -0.5237 -0.1815 -1.6253 -1.0052 -0.1522 -0.0754 -0.4270 -0.8738 -0.1693 -0.0725 -0.0541 -0.3924 -0.1006 -0.1619 -0.1510
S-783	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-783	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-783	-0.3662869334220886	In previously treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titer ) inhibitors has been observed after transfer from one recombinant factor VIII product to another .
D-783	-0.3662869334220886	In previously treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titer ) inhibitors has been observed after transfer from one recombinant factor VIII product to another .
P-783	-0.2552 -0.9489 -0.0880 -0.1156 -0.1356 -0.1005 -0.1854 -0.2662 -0.1357 -1.3776 -0.4832 -0.1367 -0.1045 -0.9923 -0.2258 -0.0791 -0.1551 -0.3351 -0.5698 -0.1436 -0.1004 -0.0396 -0.0924 -0.3395 -0.4052 -0.1615 -0.8078 -0.0558 -0.0423 -0.1209 -0.1430 -0.1814 -1.2682 -1.4353 -0.1682 -1.5889 -0.1706 -0.1308 -0.0293 -0.0889 -0.1149 -0.7787 -0.3156 -0.1647 -0.3082 -2.4453 -0.1600 -0.2981 -0.1192 -0.0840 -0.0697 -0.1316 -0.1965 -0.3444 -0.4697 -1.2933 -0.0655 -0.1930 -0.2886 -0.1473 -0.1512
S-959	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-959	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-959	-0.3662869334220886	In previously treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titer ) inhibitors has been observed after transfer from one recombinant factor VIII product to another .
D-959	-0.3662869334220886	In previously treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titer ) inhibitors has been observed after transfer from one recombinant factor VIII product to another .
P-959	-0.2552 -0.9489 -0.0880 -0.1156 -0.1356 -0.1005 -0.1854 -0.2662 -0.1357 -1.3776 -0.4832 -0.1367 -0.1045 -0.9923 -0.2258 -0.0791 -0.1551 -0.3351 -0.5698 -0.1436 -0.1004 -0.0396 -0.0924 -0.3395 -0.4052 -0.1615 -0.8078 -0.0558 -0.0423 -0.1209 -0.1430 -0.1814 -1.2682 -1.4353 -0.1682 -1.5889 -0.1706 -0.1308 -0.0293 -0.0889 -0.1149 -0.7787 -0.3156 -0.1647 -0.3082 -2.4453 -0.1600 -0.2981 -0.1192 -0.0840 -0.0697 -0.1316 -0.1965 -0.3444 -0.4697 -1.2933 -0.0655 -0.1930 -0.2886 -0.1473 -0.1512
S-1135	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-1135	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-1135	-0.3662869334220886	In previously treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titer ) inhibitors has been observed after transfer from one recombinant factor VIII product to another .
D-1135	-0.3662869334220886	In previously treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titer ) inhibitors has been observed after transfer from one recombinant factor VIII product to another .
P-1135	-0.2552 -0.9489 -0.0880 -0.1156 -0.1356 -0.1005 -0.1854 -0.2662 -0.1357 -1.3776 -0.4832 -0.1367 -0.1045 -0.9923 -0.2258 -0.0791 -0.1551 -0.3351 -0.5698 -0.1436 -0.1004 -0.0396 -0.0924 -0.3395 -0.4052 -0.1615 -0.8078 -0.0558 -0.0423 -0.1209 -0.1430 -0.1814 -1.2682 -1.4353 -0.1682 -1.5889 -0.1706 -0.1308 -0.0293 -0.0889 -0.1149 -0.7787 -0.3156 -0.1647 -0.3082 -2.4453 -0.1600 -0.2981 -0.1192 -0.0840 -0.0697 -0.1316 -0.1965 -0.3444 -0.4697 -1.2933 -0.0655 -0.1930 -0.2886 -0.1473 -0.1512
S-1282	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-1282	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-1282	-0.25870993733406067	injection every 8-24 hours ( 6-24 hours for patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
D-1282	-0.25870993733406067	injection every 8-24 hours ( 6-24 hours for patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
P-1282	-0.3722 -0.1141 -0.1926 -0.2567 -0.1301 -0.1349 -0.1400 -0.1543 -0.1421 -0.1135 -0.1592 -0.1645 -0.7616 -0.1754 -0.6425 -0.2604 -0.0961 -0.3067 -0.1037 -0.1405 -0.1338 -1.5739 -0.2444 -0.5494 -0.0641 -0.2849 -0.2286 -0.2012 -0.2342 -0.1185 -0.1456 -0.1274 -0.4867 -0.2593 -0.2155 -0.0233 -0.1132 -0.3789 -0.2808 -1.5538 -0.2518 -0.1462 -0.3907 -0.1462 -0.1026 -0.1481 -0.1380 -0.1490 -0.1134 -0.1415 -0.0434 -0.1270 -0.1432 -0.1507
S-609	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-609	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-609	-0.3662869334220886	In previously treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titer ) inhibitors has been observed after transfer from one recombinant factor VIII product to another .
D-609	-0.3662869334220886	In previously treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titer ) inhibitors has been observed after transfer from one recombinant factor VIII product to another .
P-609	-0.2552 -0.9489 -0.0880 -0.1156 -0.1356 -0.1005 -0.1854 -0.2662 -0.1357 -1.3776 -0.4832 -0.1367 -0.1045 -0.9923 -0.2258 -0.0791 -0.1551 -0.3351 -0.5698 -0.1436 -0.1004 -0.0396 -0.0924 -0.3395 -0.4052 -0.1615 -0.8078 -0.0558 -0.0423 -0.1209 -0.1430 -0.1814 -1.2682 -1.4353 -0.1682 -1.5889 -0.1706 -0.1308 -0.0293 -0.0889 -0.1149 -0.7787 -0.3156 -0.1647 -0.3082 -2.4453 -0.1600 -0.2981 -0.1192 -0.0840 -0.0697 -0.1316 -0.1965 -0.3444 -0.4697 -1.2933 -0.0655 -0.1930 -0.2886 -0.1473 -0.1512
S-1311	Bei vorbehandelten Patienten ( PTPs ) mit mehr als 100 Expositionstagen und anamnestisch bekannter Inhibitorentwicklung wurde , nach Umstellung von einem rekombinanten Faktor VIII-Produkt auf ein anderes , das Wiederauftreten von ( niedrigtitrigen ) Inhibitoren beobachtet .
T-1311	Cases of recurrent inhibitor ( low titre ) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a history of inhibitor development .
H-1311	-0.3662869334220886	In previously treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titer ) inhibitors has been observed after transfer from one recombinant factor VIII product to another .
D-1311	-0.3662869334220886	In previously treated patients ( PTPs ) with more than 100 days of exposure and a history of inhibitor development , recurrence of ( low-titer ) inhibitors has been observed after transfer from one recombinant factor VIII product to another .
P-1311	-0.2552 -0.9489 -0.0880 -0.1156 -0.1356 -0.1005 -0.1854 -0.2662 -0.1357 -1.3776 -0.4832 -0.1367 -0.1045 -0.9923 -0.2258 -0.0791 -0.1551 -0.3351 -0.5698 -0.1436 -0.1004 -0.0396 -0.0924 -0.3395 -0.4052 -0.1615 -0.8078 -0.0558 -0.0423 -0.1209 -0.1430 -0.1814 -1.2682 -1.4353 -0.1682 -1.5889 -0.1706 -0.1308 -0.0293 -0.0889 -0.1149 -0.7787 -0.3156 -0.1647 -0.3082 -2.4453 -0.1600 -0.2981 -0.1192 -0.0840 -0.0697 -0.1316 -0.1965 -0.3444 -0.4697 -1.2933 -0.0655 -0.1930 -0.2886 -0.1473 -0.1512
S-580	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-580	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-580	-0.25870993733406067	injection every 8-24 hours ( 6-24 hours for patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
D-580	-0.25870993733406067	injection every 8-24 hours ( 6-24 hours for patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
P-580	-0.3722 -0.1141 -0.1926 -0.2567 -0.1301 -0.1349 -0.1400 -0.1543 -0.1421 -0.1135 -0.1592 -0.1645 -0.7616 -0.1754 -0.6425 -0.2604 -0.0961 -0.3067 -0.1037 -0.1405 -0.1338 -1.5739 -0.2444 -0.5494 -0.0641 -0.2849 -0.2286 -0.2012 -0.2342 -0.1185 -0.1456 -0.1274 -0.4867 -0.2593 -0.2155 -0.0233 -0.1132 -0.3789 -0.2808 -1.5538 -0.2518 -0.1462 -0.3907 -0.1462 -0.1026 -0.1481 -0.1380 -0.1490 -0.1134 -0.1415 -0.0434 -0.1270 -0.1432 -0.1507
S-754	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-754	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-754	-0.25870993733406067	injection every 8-24 hours ( 6-24 hours for patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
D-754	-0.25870993733406067	injection every 8-24 hours ( 6-24 hours for patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
P-754	-0.3722 -0.1141 -0.1926 -0.2567 -0.1301 -0.1349 -0.1400 -0.1543 -0.1421 -0.1135 -0.1592 -0.1645 -0.7616 -0.1754 -0.6425 -0.2604 -0.0961 -0.3067 -0.1037 -0.1405 -0.1338 -1.5739 -0.2444 -0.5494 -0.0641 -0.2849 -0.2286 -0.2012 -0.2342 -0.1185 -0.1456 -0.1274 -0.4867 -0.2593 -0.2155 -0.0233 -0.1132 -0.3789 -0.2808 -1.5538 -0.2518 -0.1462 -0.3907 -0.1462 -0.1026 -0.1481 -0.1380 -0.1490 -0.1134 -0.1415 -0.0434 -0.1270 -0.1432 -0.1507
S-930	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-930	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-930	-0.25870993733406067	injection every 8-24 hours ( 6-24 hours for patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
D-930	-0.25870993733406067	injection every 8-24 hours ( 6-24 hours for patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
P-930	-0.3722 -0.1141 -0.1926 -0.2567 -0.1301 -0.1349 -0.1400 -0.1543 -0.1421 -0.1135 -0.1592 -0.1645 -0.7616 -0.1754 -0.6425 -0.2604 -0.0961 -0.3067 -0.1037 -0.1405 -0.1338 -1.5739 -0.2444 -0.5494 -0.0641 -0.2849 -0.2286 -0.2012 -0.2342 -0.1185 -0.1456 -0.1274 -0.4867 -0.2593 -0.2155 -0.0233 -0.1132 -0.3789 -0.2808 -1.5538 -0.2518 -0.1462 -0.3907 -0.1462 -0.1026 -0.1481 -0.1380 -0.1490 -0.1134 -0.1415 -0.0434 -0.1270 -0.1432 -0.1507
S-1106	Injektion alle 8-24 Stunden ( 6-24 Stunden bei Patienten unter 6 Jahren ) bis zu angemessener Wundheilung wiederholen , dann Therapie für noch mind. 7 Tage fortsetzen , um eine Faktor VIII-Aktivität von 30-60 % ( I.E.<unk> dl ) aufrechtzuerhalten .
T-1106	Repeat injections every 8 to 24 hours ( 6 to 24 hours for patients under the age of 6 ) until adequate wound healing , then continue therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60 % ( IU/ dl ) .
H-1106	-0.25870993733406067	injection every 8-24 hours ( 6-24 hours for patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
D-1106	-0.25870993733406067	injection every 8-24 hours ( 6-24 hours for patients under 6 years of age ) until appropriate wound healing , then continue therapy for at least 7 days to maintain factor VIII activity of 30-60 % ( IU/ dl ) .
P-1106	-0.3722 -0.1141 -0.1926 -0.2567 -0.1301 -0.1349 -0.1400 -0.1543 -0.1421 -0.1135 -0.1592 -0.1645 -0.7616 -0.1754 -0.6425 -0.2604 -0.0961 -0.3067 -0.1037 -0.1405 -0.1338 -1.5739 -0.2444 -0.5494 -0.0641 -0.2849 -0.2286 -0.2012 -0.2342 -0.1185 -0.1456 -0.1274 -0.4867 -0.2593 -0.2155 -0.0233 -0.1132 -0.3789 -0.2808 -1.5538 -0.2518 -0.1462 -0.3907 -0.1462 -0.1026 -0.1481 -0.1380 -0.1490 -0.1134 -0.1415 -0.0434 -0.1270 -0.1432 -0.1507
S-413	In der mit Alendronat behandelten Gruppe wurde im Vergleich zur Plazebo-Gruppe eine Reduktion um 48 % ( Alendronat 3,2 % gegenüber Plazebo 6,2 % ) bei dem Anteil von Patientinnen , die eine oder mehrere Wirbelfrakturen erlitten , erreicht .
T-413	There was a 48 % reduction ( alendronate 3.2 % vs placebo 6.2 % ) in the proportion of patients treated with alendronate experiencing one or more vertebral fractures relative to those treated with placebo .
H-413	-0.2361450344324112	In the alendronate treated group , a 48 % reduction ( alendronate 3.2 % vs. placebo 6.2 % ) was achieved in the proportion of patients who sustained one or more vertebral fractures .
D-413	-0.2361450344324112	In the alendronate treated group , a 48 % reduction ( alendronate 3.2 % vs. placebo 6.2 % ) was achieved in the proportion of patients who sustained one or more vertebral fractures .
P-413	-0.6230 -0.2088 -0.3273 -0.1973 -0.1392 -0.0602 -0.1447 -0.1678 -0.4301 -0.2278 -0.0746 -0.1113 -0.3202 -0.2841 -0.1994 -0.1610 -0.1313 -0.0338 -0.0897 -0.1496 -0.0788 -1.0598 -0.0920 -0.1620 -0.1821 -0.1221 -0.1274 -0.1597 -0.1230 -0.1295 -0.2098 -0.2002 -1.2228 -0.1730 -0.1987 -0.1769 -0.1986 -0.1970 -1.0700 -0.1243 -0.1663 -0.1497 -0.0687 -0.1478 -0.0469 -0.1403 -0.1203 -0.0638 -0.6626 -0.1524
S-821	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-821	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-821	-0.3843049108982086	3 of the 182 treated patients who tested for antibodies to CHO-cell protein exhibited a statistically significant uptrend in titers in linear regression analysis . 4 of these patients had sustained peaks or transient spikes .
D-821	-0.3843049108982086	3 of the 182 treated patients who tested for antibodies to CHO-cell protein exhibited a statistically significant uptrend in titers in linear regression analysis . 4 of these patients had sustained peaks or transient spikes .
P-821	-3.0836 -0.3796 -0.1984 -0.1107 -0.1558 -0.0646 -0.1395 -0.9715 -0.6780 -0.1897 -0.0345 -0.1224 -0.1606 -0.4235 -1.3191 -0.3948 -0.1256 -0.0882 -1.1926 -0.0663 -1.6618 -0.1195 -0.0892 -0.0574 -0.1862 -0.2225 -1.8357 -0.1996 -0.0826 -0.4205 -0.3265 -0.1386 -0.1249 -0.0229 -0.1075 -0.1203 -0.1467 -0.2749 -0.2162 -0.1779 -0.1314 -0.1006 -0.8984 -0.1821 -0.7806 -0.0718 -0.1204 -0.4804 -0.0717 -0.0841 -1.2579 -0.1186 -0.1103 -0.1447 -0.1538
S-225	Resorption Bezogen auf eine intravenöse Referenzdosis betrug die mittlere orale Bioverfügbarkeit von Alendronat bei Frauen 0,64 % für Dosen zwischen 5 und 70 mg nach nächtlichem Fasten und zwei Stunden vor Aufnahme eines standardisierten Frühstücks .
T-225	Absorption Relative to an intravenous reference dose , the oral mean bioavailability of alendronate in women was 0.64 % for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardised breakfast .
H-225	-0.3281944990158081	Absorption Based on a reference intravenous dose , the mean oral bioavailability of alendronate in women was 0.64 % for doses between 5 and 70 mg after nocturnal fasting and two hours prior to eating a standardized breakfast .
D-225	-0.3281944990158081	Absorption Based on a reference intravenous dose , the mean oral bioavailability of alendronate in women was 0.64 % for doses between 5 and 70 mg after nocturnal fasting and two hours prior to eating a standardized breakfast .
P-225	-0.2632 -0.1331 -0.1180 -3.2480 -0.1709 -0.8666 -0.2868 -0.0558 -0.0861 -0.0997 -0.1238 -0.0614 -0.1621 -0.1563 -0.1468 -0.2520 -0.0804 -0.0788 -0.1505 -0.1694 -0.1661 -0.1414 -0.0455 -0.4128 -0.1589 -0.1512 -0.0999 -0.0964 -0.1350 -0.1755 -0.1166 -0.0472 -0.3651 -0.1198 -0.1794 -0.1453 -0.0678 -0.5609 -1.3500 -0.1436 -0.0188 -0.2662 -0.0239 -0.6887 -0.1368 -0.3967 -0.1015 -1.0899 -0.1315 -2.0847 -0.2964 -0.4235 -0.6614 -0.6063 -0.0984 -0.1448 -0.1494
S-217	In der mit Alendronat behandelten Gruppe wurde im Vergleich zur Plazebo-Gruppe eine Reduktion um 48 % ( Alendronat 3,2 % gegenüber Plazebo 6,2 % ) bei dem Anteil von Patientinnen , die eine oder mehrere Wirbelfrakturen erlitten , erreicht .
T-217	There was a 48 % reduction ( alendronate 3.2 % vs placebo 6.2 % ) in the proportion of patients treated with alendronate experiencing one or more vertebral fractures relative to those treated with placebo .
H-217	-0.2361450344324112	In the alendronate treated group , a 48 % reduction ( alendronate 3.2 % vs. placebo 6.2 % ) was achieved in the proportion of patients who sustained one or more vertebral fractures .
D-217	-0.2361450344324112	In the alendronate treated group , a 48 % reduction ( alendronate 3.2 % vs. placebo 6.2 % ) was achieved in the proportion of patients who sustained one or more vertebral fractures .
P-217	-0.6230 -0.2088 -0.3273 -0.1973 -0.1392 -0.0602 -0.1447 -0.1678 -0.4301 -0.2278 -0.0746 -0.1113 -0.3202 -0.2841 -0.1994 -0.1610 -0.1313 -0.0338 -0.0897 -0.1496 -0.0788 -1.0598 -0.0920 -0.1620 -0.1821 -0.1221 -0.1274 -0.1597 -0.1230 -0.1295 -0.2098 -0.2002 -1.2228 -0.1730 -0.1987 -0.1769 -0.1986 -0.1970 -1.0700 -0.1243 -0.1663 -0.1497 -0.0687 -0.1478 -0.0469 -0.1403 -0.1203 -0.0638 -0.6626 -0.1524
S-647	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-647	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-647	-0.3843049108982086	3 of the 182 treated patients who tested for antibodies to CHO-cell protein exhibited a statistically significant uptrend in titers in linear regression analysis . 4 of these patients had sustained peaks or transient spikes .
D-647	-0.3843049108982086	3 of the 182 treated patients who tested for antibodies to CHO-cell protein exhibited a statistically significant uptrend in titers in linear regression analysis . 4 of these patients had sustained peaks or transient spikes .
P-647	-3.0836 -0.3796 -0.1984 -0.1107 -0.1558 -0.0646 -0.1395 -0.9715 -0.6780 -0.1897 -0.0345 -0.1224 -0.1606 -0.4235 -1.3191 -0.3948 -0.1256 -0.0882 -1.1926 -0.0663 -1.6618 -0.1195 -0.0892 -0.0574 -0.1862 -0.2225 -1.8357 -0.1996 -0.0826 -0.4205 -0.3265 -0.1386 -0.1249 -0.0229 -0.1075 -0.1203 -0.1467 -0.2749 -0.2162 -0.1779 -0.1314 -0.1006 -0.8984 -0.1821 -0.7806 -0.0718 -0.1204 -0.4804 -0.0717 -0.0841 -1.2579 -0.1186 -0.1103 -0.1447 -0.1538
S-1349	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-1349	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-1349	-0.3843049108982086	3 of the 182 treated patients who tested for antibodies to CHO-cell protein exhibited a statistically significant uptrend in titers in linear regression analysis . 4 of these patients had sustained peaks or transient spikes .
D-1349	-0.3843049108982086	3 of the 182 treated patients who tested for antibodies to CHO-cell protein exhibited a statistically significant uptrend in titers in linear regression analysis . 4 of these patients had sustained peaks or transient spikes .
P-1349	-3.0836 -0.3796 -0.1984 -0.1107 -0.1558 -0.0646 -0.1395 -0.9715 -0.6780 -0.1897 -0.0345 -0.1224 -0.1606 -0.4235 -1.3191 -0.3948 -0.1256 -0.0882 -1.1926 -0.0663 -1.6618 -0.1195 -0.0892 -0.0574 -0.1862 -0.2225 -1.8357 -0.1996 -0.0826 -0.4205 -0.3265 -0.1386 -0.1249 -0.0229 -0.1075 -0.1203 -0.1467 -0.2749 -0.2162 -0.1779 -0.1314 -0.1006 -0.8984 -0.1821 -0.7806 -0.0718 -0.1204 -0.4804 -0.0717 -0.0841 -1.2579 -0.1186 -0.1103 -0.1447 -0.1538
S-997	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-997	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-997	-0.3843049108982086	3 of the 182 treated patients who tested for antibodies to CHO-cell protein exhibited a statistically significant uptrend in titers in linear regression analysis . 4 of these patients had sustained peaks or transient spikes .
D-997	-0.3843049108982086	3 of the 182 treated patients who tested for antibodies to CHO-cell protein exhibited a statistically significant uptrend in titers in linear regression analysis . 4 of these patients had sustained peaks or transient spikes .
P-997	-3.0836 -0.3796 -0.1984 -0.1107 -0.1558 -0.0646 -0.1395 -0.9715 -0.6780 -0.1897 -0.0345 -0.1224 -0.1606 -0.4235 -1.3191 -0.3948 -0.1256 -0.0882 -1.1926 -0.0663 -1.6618 -0.1195 -0.0892 -0.0574 -0.1862 -0.2225 -1.8357 -0.1996 -0.0826 -0.4205 -0.3265 -0.1386 -0.1249 -0.0229 -0.1075 -0.1203 -0.1467 -0.2749 -0.2162 -0.1779 -0.1314 -0.1006 -0.8984 -0.1821 -0.7806 -0.0718 -0.1204 -0.4804 -0.0717 -0.0841 -1.2579 -0.1186 -0.1103 -0.1447 -0.1538
S-421	Resorption Bezogen auf eine intravenöse Referenzdosis betrug die mittlere orale Bioverfügbarkeit von Alendronat bei Frauen 0,64 % für Dosen zwischen 5 und 70 mg nach nächtlichem Fasten und zwei Stunden vor Aufnahme eines standardisierten Frühstücks .
T-421	Absorption Relative to an intravenous reference dose , the oral mean bioavailability of alendronate in women was 0.64 % for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardised breakfast .
H-421	-0.3281944990158081	Absorption Based on a reference intravenous dose , the mean oral bioavailability of alendronate in women was 0.64 % for doses between 5 and 70 mg after nocturnal fasting and two hours prior to eating a standardized breakfast .
D-421	-0.3281944990158081	Absorption Based on a reference intravenous dose , the mean oral bioavailability of alendronate in women was 0.64 % for doses between 5 and 70 mg after nocturnal fasting and two hours prior to eating a standardized breakfast .
P-421	-0.2632 -0.1331 -0.1180 -3.2480 -0.1709 -0.8666 -0.2868 -0.0558 -0.0861 -0.0997 -0.1238 -0.0614 -0.1621 -0.1563 -0.1468 -0.2520 -0.0804 -0.0788 -0.1505 -0.1694 -0.1661 -0.1414 -0.0455 -0.4128 -0.1589 -0.1512 -0.0999 -0.0964 -0.1350 -0.1755 -0.1166 -0.0472 -0.3651 -0.1198 -0.1794 -0.1453 -0.0678 -0.5609 -1.3500 -0.1436 -0.0188 -0.2662 -0.0239 -0.6887 -0.1368 -0.3967 -0.1015 -1.0899 -0.1315 -2.0847 -0.2964 -0.4235 -0.6614 -0.6063 -0.0984 -0.1448 -0.1494
S-1526	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-1526	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-1526	-0.3843049108982086	3 of the 182 treated patients who tested for antibodies to CHO-cell protein exhibited a statistically significant uptrend in titers in linear regression analysis . 4 of these patients had sustained peaks or transient spikes .
D-1526	-0.3843049108982086	3 of the 182 treated patients who tested for antibodies to CHO-cell protein exhibited a statistically significant uptrend in titers in linear regression analysis . 4 of these patients had sustained peaks or transient spikes .
P-1526	-3.0836 -0.3796 -0.1984 -0.1107 -0.1558 -0.0646 -0.1395 -0.9715 -0.6780 -0.1897 -0.0345 -0.1224 -0.1606 -0.4235 -1.3191 -0.3948 -0.1256 -0.0882 -1.1926 -0.0663 -1.6618 -0.1195 -0.0892 -0.0574 -0.1862 -0.2225 -1.8357 -0.1996 -0.0826 -0.4205 -0.3265 -0.1386 -0.1249 -0.0229 -0.1075 -0.1203 -0.1467 -0.2749 -0.2162 -0.1779 -0.1314 -0.1006 -0.8984 -0.1821 -0.7806 -0.0718 -0.1204 -0.4804 -0.0717 -0.0841 -1.2579 -0.1186 -0.1103 -0.1447 -0.1538
S-41	Der Ausschuss gelangte zu dem Schluss , dass die Vorteile von Adenuric bei der Behandlung der chronischen Hyperurikämie , wenn bereits Uratablagerungen auftraten , gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Adenuric zu erteilen .
T-41	Der Ausschuss gelangte zu dem Schluss , dass die Vorteile von Adenuric bei der Behandlung der chronischen Hyperurikämie , wenn bereits Uratablagerungen auftraten , gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Adenuric zu erteilen . The Committee recommended that Adenuric be given marketing authorisation .
H-41	-0.37764447927474976	The Committee concluded that the benefits of Adenuric in treating chronic hyperuricaemia when urine deposition has occurred outweigh the risks and recommended that Adenuric be authorised to be marketed .
D-41	-0.37764447927474976	The Committee concluded that the benefits of Adenuric in treating chronic hyperuricaemia when urine deposition has occurred outweigh the risks and recommended that Adenuric be authorised to be marketed .
P-41	-0.4496 -0.2515 -0.5836 -0.1444 -0.6687 -0.6521 -0.3599 -0.1757 -0.2355 -0.0998 -0.1115 -0.3027 -0.7651 -0.1043 -0.0791 -0.0816 -0.3970 -0.0327 -0.1353 -0.5816 -0.9918 -0.4801 -1.8657 -0.0993 -0.5450 -0.1188 -0.6186 -0.4579 -0.1405 -0.2501 -0.2085 -0.0852 -0.3684 -2.3353 -0.2340 -0.1015 -0.0972 -0.0669 -0.8004 -0.1135 -0.2363 -0.2875 -0.2833 -0.0731 -0.1479 -0.1529
S-1173	Von den 182 behandelten , auf Antikörper gegen CHO-Zellprotein getesteten Patienten zeigten 3 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 4 dieser Patienten wiesen anhaltende Peaks oder vorübergehende Spitzen auf .
T-1173	Of the 182 treated patients who were assessed for antibodies to Chinese hamster ovary ( CHO ) cell protein , 3 showed a statistically significant upward trend in titres by linear regression analysis and 4 displayed sustained peaks or transient spikes .
H-1173	-0.3843049108982086	3 of the 182 treated patients who tested for antibodies to CHO-cell protein exhibited a statistically significant uptrend in titers in linear regression analysis . 4 of these patients had sustained peaks or transient spikes .
D-1173	-0.3843049108982086	3 of the 182 treated patients who tested for antibodies to CHO-cell protein exhibited a statistically significant uptrend in titers in linear regression analysis . 4 of these patients had sustained peaks or transient spikes .
P-1173	-3.0836 -0.3796 -0.1984 -0.1107 -0.1558 -0.0646 -0.1395 -0.9715 -0.6780 -0.1897 -0.0345 -0.1224 -0.1606 -0.4235 -1.3191 -0.3948 -0.1256 -0.0882 -1.1926 -0.0663 -1.6618 -0.1195 -0.0892 -0.0574 -0.1862 -0.2225 -1.8357 -0.1996 -0.0826 -0.4205 -0.3265 -0.1386 -0.1249 -0.0229 -0.1075 -0.1203 -0.1467 -0.2749 -0.2162 -0.1779 -0.1314 -0.1006 -0.8984 -0.1821 -0.7806 -0.0718 -0.1204 -0.4804 -0.0717 -0.0841 -1.2579 -0.1186 -0.1103 -0.1447 -0.1538
S-1527	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-1527	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-1527	-0.40486055612564087	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise no signs or symptoms suggesting allergic reaction or hypersensitivity occurred .
D-1527	-0.40486055612564087	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise no signs or symptoms suggesting allergic reaction or hypersensitivity occurred .
P-1527	-1.7472 -0.0569 -1.7118 -0.0621 -0.1250 -0.1556 -0.0882 -0.0910 -0.0642 -0.1722 -0.1506 -1.3770 -0.1440 -0.3953 -0.0653 -0.0238 -0.1784 -0.0870 -0.2293 -0.1533 -0.3029 -0.4821 -0.1041 -0.3240 -1.1634 -0.4530 -0.1980 -0.5277 -0.1186 -0.2087 -1.1259 -0.3982 -0.1253 -0.1115 -2.7399 -0.4202 -0.0611 -0.1722 -0.1079 -0.0617 -0.0572 -0.0437 -1.5227 -0.1494 -0.1609
S-823	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-823	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-823	-0.3574082851409912	Of the 182 treated subjects who tested for antibodies to murine IgG , 10 exhibited a statistically significant uptrend in titers in linear regression analysis . 2 of the patients had a sustained peak or transient peak .
D-823	-0.3574082851409912	Of the 182 treated subjects who tested for antibodies to murine IgG , 10 exhibited a statistically significant uptrend in titers in linear regression analysis . 2 of the patients had a sustained peak or transient peak .
P-823	-2.3642 -0.1823 -0.0987 -0.1545 -0.0469 -0.5791 -0.7373 -0.3819 -0.2181 -0.0343 -0.1475 -0.1555 -0.0307 -0.2729 -0.1209 -0.1947 -0.1293 -0.1651 -2.3525 -0.0710 -1.5034 -0.1265 -0.0787 -0.0581 -0.1900 -0.2128 -2.0421 -0.2112 -0.0847 -0.5078 -0.2589 -0.1631 -0.1310 -0.0263 -0.1229 -0.1212 -0.1299 -0.2609 -0.1626 -0.2296 -0.2477 -0.0856 -0.8590 -0.4109 -0.1336 -0.0237 -0.1646 -1.3765 -0.0682 -0.1066 -0.0788 -0.1685 -0.1595
S-649	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-649	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-649	-0.3574082851409912	Of the 182 treated subjects who tested for antibodies to murine IgG , 10 exhibited a statistically significant uptrend in titers in linear regression analysis . 2 of the patients had a sustained peak or transient peak .
D-649	-0.3574082851409912	Of the 182 treated subjects who tested for antibodies to murine IgG , 10 exhibited a statistically significant uptrend in titers in linear regression analysis . 2 of the patients had a sustained peak or transient peak .
P-649	-2.3642 -0.1823 -0.0987 -0.1545 -0.0469 -0.5791 -0.7373 -0.3819 -0.2181 -0.0343 -0.1475 -0.1555 -0.0307 -0.2729 -0.1209 -0.1947 -0.1293 -0.1651 -2.3525 -0.0710 -1.5034 -0.1265 -0.0787 -0.0581 -0.1900 -0.2128 -2.0421 -0.2112 -0.0847 -0.5078 -0.2589 -0.1631 -0.1310 -0.0263 -0.1229 -0.1212 -0.1299 -0.2609 -0.1626 -0.2296 -0.2477 -0.0856 -0.8590 -0.4109 -0.1336 -0.0237 -0.1646 -1.3765 -0.0682 -0.1066 -0.0788 -0.1685 -0.1595
S-998	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-998	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-998	-0.40486055612564087	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise no signs or symptoms suggesting allergic reaction or hypersensitivity occurred .
D-998	-0.40486055612564087	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise no signs or symptoms suggesting allergic reaction or hypersensitivity occurred .
P-998	-1.7472 -0.0569 -1.7118 -0.0621 -0.1250 -0.1556 -0.0882 -0.0910 -0.0642 -0.1722 -0.1506 -1.3770 -0.1440 -0.3953 -0.0653 -0.0238 -0.1784 -0.0870 -0.2293 -0.1533 -0.3029 -0.4821 -0.1041 -0.3240 -1.1634 -0.4530 -0.1980 -0.5277 -0.1186 -0.2087 -1.1259 -0.3982 -0.1253 -0.1115 -2.7399 -0.4202 -0.0611 -0.1722 -0.1079 -0.0617 -0.0572 -0.0437 -1.5227 -0.1494 -0.1609
S-1350	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-1350	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-1350	-0.40486055612564087	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise no signs or symptoms suggesting allergic reaction or hypersensitivity occurred .
D-1350	-0.40486055612564087	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise no signs or symptoms suggesting allergic reaction or hypersensitivity occurred .
P-1350	-1.7472 -0.0569 -1.7118 -0.0621 -0.1250 -0.1556 -0.0882 -0.0910 -0.0642 -0.1722 -0.1506 -1.3770 -0.1440 -0.3953 -0.0653 -0.0238 -0.1784 -0.0870 -0.2293 -0.1533 -0.3029 -0.4821 -0.1041 -0.3240 -1.1634 -0.4530 -0.1980 -0.5277 -0.1186 -0.2087 -1.1259 -0.3982 -0.1253 -0.1115 -2.7399 -0.4202 -0.0611 -0.1722 -0.1079 -0.0617 -0.0572 -0.0437 -1.5227 -0.1494 -0.1609
S-1174	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-1174	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-1174	-0.40486055612564087	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise no signs or symptoms suggesting allergic reaction or hypersensitivity occurred .
D-1174	-0.40486055612564087	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise no signs or symptoms suggesting allergic reaction or hypersensitivity occurred .
P-1174	-1.7472 -0.0569 -1.7118 -0.0621 -0.1250 -0.1556 -0.0882 -0.0910 -0.0642 -0.1722 -0.1506 -1.3770 -0.1440 -0.3953 -0.0653 -0.0238 -0.1784 -0.0870 -0.2293 -0.1533 -0.3029 -0.4821 -0.1041 -0.3240 -1.1634 -0.4530 -0.1980 -0.5277 -0.1186 -0.2087 -1.1259 -0.3982 -0.1253 -0.1115 -2.7399 -0.4202 -0.0611 -0.1722 -0.1079 -0.0617 -0.0572 -0.0437 -1.5227 -0.1494 -0.1609
S-822	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-822	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-822	-0.40486055612564087	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise no signs or symptoms suggesting allergic reaction or hypersensitivity occurred .
D-822	-0.40486055612564087	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise no signs or symptoms suggesting allergic reaction or hypersensitivity occurred .
P-822	-1.7472 -0.0569 -1.7118 -0.0621 -0.1250 -0.1556 -0.0882 -0.0910 -0.0642 -0.1722 -0.1506 -1.3770 -0.1440 -0.3953 -0.0653 -0.0238 -0.1784 -0.0870 -0.2293 -0.1533 -0.3029 -0.4821 -0.1041 -0.3240 -1.1634 -0.4530 -0.1980 -0.5277 -0.1186 -0.2087 -1.1259 -0.3982 -0.1253 -0.1115 -2.7399 -0.4202 -0.0611 -0.1722 -0.1079 -0.0617 -0.0572 -0.0437 -1.5227 -0.1494 -0.1609
S-999	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-999	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-999	-0.3574082851409912	Of the 182 treated subjects who tested for antibodies to murine IgG , 10 exhibited a statistically significant uptrend in titers in linear regression analysis . 2 of the patients had a sustained peak or transient peak .
D-999	-0.3574082851409912	Of the 182 treated subjects who tested for antibodies to murine IgG , 10 exhibited a statistically significant uptrend in titers in linear regression analysis . 2 of the patients had a sustained peak or transient peak .
P-999	-2.3642 -0.1823 -0.0987 -0.1545 -0.0469 -0.5791 -0.7373 -0.3819 -0.2181 -0.0343 -0.1475 -0.1555 -0.0307 -0.2729 -0.1209 -0.1947 -0.1293 -0.1651 -2.3525 -0.0710 -1.5034 -0.1265 -0.0787 -0.0581 -0.1900 -0.2128 -2.0421 -0.2112 -0.0847 -0.5078 -0.2589 -0.1631 -0.1310 -0.0263 -0.1229 -0.1212 -0.1299 -0.2609 -0.1626 -0.2296 -0.2477 -0.0856 -0.8590 -0.4109 -0.1336 -0.0237 -0.1646 -1.3765 -0.0682 -0.1066 -0.0788 -0.1685 -0.1595
S-648	Ein Patient zeigte sowohl einen statistisch signifikanten Aufwärtstrend als auch einen anhaltenden Peak des Antikörperspiegels gegen Anti-CHO-Zellproteins , ansonsten traten jedoch keinerlei Anzeichen oder Symptome auf , die auf eine allergische Reaktion oder eine Überempfindlichkeit hinwiesen .
T-648	One patient had both a statistically significant upward trend and displayed a sustained peak in anti-CHO protein antibody level , but no other signs or symptoms indicative of an allergic or hypersensitivity response .
H-648	-0.40486055612564087	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise no signs or symptoms suggesting allergic reaction or hypersensitivity occurred .
D-648	-0.40486055612564087	One patient exhibited both a statistically significant uptrend and a sustained peak in antibody levels to anti-CHO cell protein , but otherwise no signs or symptoms suggesting allergic reaction or hypersensitivity occurred .
P-648	-1.7472 -0.0569 -1.7118 -0.0621 -0.1250 -0.1556 -0.0882 -0.0910 -0.0642 -0.1722 -0.1506 -1.3770 -0.1440 -0.3953 -0.0653 -0.0238 -0.1784 -0.0870 -0.2293 -0.1533 -0.3029 -0.4821 -0.1041 -0.3240 -1.1634 -0.4530 -0.1980 -0.5277 -0.1186 -0.2087 -1.1259 -0.3982 -0.1253 -0.1115 -2.7399 -0.4202 -0.0611 -0.1722 -0.1079 -0.0617 -0.0572 -0.0437 -1.5227 -0.1494 -0.1609
S-1175	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-1175	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-1175	-0.3574082851409912	Of the 182 treated subjects who tested for antibodies to murine IgG , 10 exhibited a statistically significant uptrend in titers in linear regression analysis . 2 of the patients had a sustained peak or transient peak .
D-1175	-0.3574082851409912	Of the 182 treated subjects who tested for antibodies to murine IgG , 10 exhibited a statistically significant uptrend in titers in linear regression analysis . 2 of the patients had a sustained peak or transient peak .
P-1175	-2.3642 -0.1823 -0.0987 -0.1545 -0.0469 -0.5791 -0.7373 -0.3819 -0.2181 -0.0343 -0.1475 -0.1555 -0.0307 -0.2729 -0.1209 -0.1947 -0.1293 -0.1651 -2.3525 -0.0710 -1.5034 -0.1265 -0.0787 -0.0581 -0.1900 -0.2128 -2.0421 -0.2112 -0.0847 -0.5078 -0.2589 -0.1631 -0.1310 -0.0263 -0.1229 -0.1212 -0.1299 -0.2609 -0.1626 -0.2296 -0.2477 -0.0856 -0.8590 -0.4109 -0.1336 -0.0237 -0.1646 -1.3765 -0.0682 -0.1066 -0.0788 -0.1685 -0.1595
S-1528	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-1528	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-1528	-0.3574082851409912	Of the 182 treated subjects who tested for antibodies to murine IgG , 10 exhibited a statistically significant uptrend in titers in linear regression analysis . 2 of the patients had a sustained peak or transient peak .
D-1528	-0.3574082851409912	Of the 182 treated subjects who tested for antibodies to murine IgG , 10 exhibited a statistically significant uptrend in titers in linear regression analysis . 2 of the patients had a sustained peak or transient peak .
P-1528	-2.3642 -0.1823 -0.0987 -0.1545 -0.0469 -0.5791 -0.7373 -0.3819 -0.2181 -0.0343 -0.1475 -0.1555 -0.0307 -0.2729 -0.1209 -0.1947 -0.1293 -0.1651 -2.3525 -0.0710 -1.5034 -0.1265 -0.0787 -0.0581 -0.1900 -0.2128 -2.0421 -0.2112 -0.0847 -0.5078 -0.2589 -0.1631 -0.1310 -0.0263 -0.1229 -0.1212 -0.1299 -0.2609 -0.1626 -0.2296 -0.2477 -0.0856 -0.8590 -0.4109 -0.1336 -0.0237 -0.1646 -1.3765 -0.0682 -0.1066 -0.0788 -0.1685 -0.1595
S-1351	Von den 182 behandelten , auf Antikörper gegen murines IgG getesteten Personen zeigten 10 in der linearen Regressionsanalyse einen statistisch signifikanten Aufwärtstrend der Titer . 2 der Patienten wiesen einen anhaltenden Peak oder eine vorübergehende Spitze auf .
T-1351	Of the 182 treated patients who were assessed for antibodies to murine IgG , 10 showed a statistically significant upward trend by linear regression analysis and 2 displayed a sustained peak or transient spike .
H-1351	-0.3574082851409912	Of the 182 treated subjects who tested for antibodies to murine IgG , 10 exhibited a statistically significant uptrend in titers in linear regression analysis . 2 of the patients had a sustained peak or transient peak .
D-1351	-0.3574082851409912	Of the 182 treated subjects who tested for antibodies to murine IgG , 10 exhibited a statistically significant uptrend in titers in linear regression analysis . 2 of the patients had a sustained peak or transient peak .
P-1351	-2.3642 -0.1823 -0.0987 -0.1545 -0.0469 -0.5791 -0.7373 -0.3819 -0.2181 -0.0343 -0.1475 -0.1555 -0.0307 -0.2729 -0.1209 -0.1947 -0.1293 -0.1651 -2.3525 -0.0710 -1.5034 -0.1265 -0.0787 -0.0581 -0.1900 -0.2128 -2.0421 -0.2112 -0.0847 -0.5078 -0.2589 -0.1631 -0.1310 -0.0263 -0.1229 -0.1212 -0.1299 -0.2609 -0.1626 -0.2296 -0.2477 -0.0856 -0.8590 -0.4109 -0.1336 -0.0237 -0.1646 -1.3765 -0.0682 -0.1066 -0.0788 -0.1685 -0.1595
S-237	Ausscheidung Nach intravenöser Gabe einer einzelnen Dosis von 14C-Alendronat wurden etwa 50 % der radioaktiv markierten Substanz innerhalb von 72 Stunden mit dem Urin ausgeschieden und wenig oder keine Radioaktivität wurde in den Fäzes wiedergefunden .
T-237	Elimination Following a single intravenous dose of <<unk>> 14C<<unk>> alendronate , approximately 50 % of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
H-237	-0.19067087769508362	Excretion After intravenous administration of a single dose of 14C-alendronate , approximately 50 % of the radiolabelled substance was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
D-237	-0.19067087769508362	Excretion After intravenous administration of a single dose of 14C-alendronate , approximately 50 % of the radiolabelled substance was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
P-237	-0.4111 -0.0790 -0.1841 -0.8049 -0.8861 -0.0837 -0.0765 -0.1324 -0.1789 -0.1836 -0.1267 -0.2605 -0.0516 -0.1527 -0.1416 -0.2956 -0.1717 -0.1173 -0.1446 -0.1044 -0.0443 -0.1585 -0.4254 -0.1318 -0.1069 -0.1566 -0.1965 -0.4130 -0.0211 -0.0206 -0.0669 -0.1479 -0.5687 -0.1038 -0.0110 -0.0998 -0.3369 -0.1303 -0.0549 -0.0843 -0.3064 -0.1019 -0.1167 -0.1780 -0.1817 -0.3791 -0.2008 -0.3173 -0.0824 -0.1512 -0.1474 -0.1740 -0.1318 -0.3009 -0.0208 -0.1115 -0.1389 -0.1520
S-1919	Bei Betrachtung aller Heuschnupfensymptome außer der Verstopfung der Nase berichteten die Patienten , die Aerinaze einnahmen , über eine Abnahme der Symptome um 46,0 % , verglichen mit 35,9 % bei den Patienten , die Pseudoephedrin allein einnahmen .
T-1919	When looking at all hayfever symptoms except for nasal congestion , patients taking Aerinaze reported a reduction in symptoms of 46.0 % , compared with 35.9 % in those taking pseudoephedrine alone .
H-1919	-0.3288280665874481	When looking at all hayfever symptoms except nose constipation , patients taking Aerinaze reported a 46.0 % decrease in symptoms compared to 35.9 % for pseudoephedrine alone .
D-1919	-0.3288280665874481	When looking at all hayfever symptoms except nose constipation , patients taking Aerinaze reported a 46.0 % decrease in symptoms compared to 35.9 % for pseudoephedrine alone .
P-1919	-0.7550 -2.3763 -0.2127 -0.1542 -1.2588 -0.9131 -0.1679 -0.1740 -0.1036 -0.8046 -1.4347 -0.2867 -0.3145 -0.0754 -0.1326 -0.1544 -0.5836 -0.2471 -0.1726 -0.1067 -0.1137 -0.1597 -0.1078 -0.0350 -0.1242 -0.2264 -0.1517 -0.1271 -0.1248 -0.5060 -0.1417 -0.2269 -0.2295 -0.7302 -0.4229 -0.1665 -0.0806 -0.1243 -0.1029 -0.1661 -0.4230 -0.5226 -0.1357 -0.0928 -0.1122 -0.1284 -0.1270 -0.1026 -0.1430 -0.1576
S-177	Dennoch traten Abnahmen des Serum-Calciums bis <unk> 8,0 mg<unk> dl ( 2,0 mmol<unk> l ) und des Serum- Phosphats bis 2,0 mg<unk> dl ( 0,65 mmol<unk> l ) in beiden Behandlungsgruppen mit ähnlicher Häufigkeit auf .
T-177	However , the incidences of decreases in serum calcium to <<unk>> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) were similar in both treatment groups .
H-177	-0.1831735521554947	However , decreases in serum calcium to <unk> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) occurred with a similar frequency in both treatment groups .
D-177	-0.1831735521554947	However , decreases in serum calcium to <unk> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) occurred with a similar frequency in both treatment groups .
P-177	-1.1741 -0.1632 -0.9027 -0.1177 -0.1684 -0.0517 -0.1119 -0.1171 -0.0953 -0.1050 -0.1607 -0.0188 -0.1289 -0.1242 -0.1543 -0.1780 -0.1575 -0.0890 -0.1354 -0.0294 -0.0630 -0.0903 -0.1355 -0.0873 -0.1274 -0.1465 -0.1576 -0.1022 -0.0867 -0.0622 -0.0833 -0.1285 -0.0221 -0.1459 -0.1285 -0.1385 -0.0419 -0.1386 -0.0562 -0.1044 -0.1039 -0.0848 -0.1337 -0.1023 -0.1229 -0.6043 -0.4267 -0.2015 -0.1841 -0.7282 -0.1122 -0.1446 -0.1316 -0.2063 -0.6370 -0.1383 -0.1490
S-365	Dennoch traten Abnahmen des Serum-Calciums bis <unk> 8,0 mg<unk> dl ( 2,0 mmol<unk> l ) und des Serum- Phosphats bis 2,0 mg<unk> dl ( 0,65 mmol<unk> l ) in beiden Behandlungsgruppen mit ähnlicher Häufigkeit auf .
T-365	However , the incidences of decreases in serum calcium to <<unk>> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) were similar in both treatment groups .
H-365	-0.1831735521554947	However , decreases in serum calcium to <unk> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) occurred with a similar frequency in both treatment groups .
D-365	-0.1831735521554947	However , decreases in serum calcium to <unk> 8.0 mg/ dl ( 2.0 mmol/ l ) and serum phosphate to 2.0 mg/ dl ( 0.65 mmol/ l ) occurred with a similar frequency in both treatment groups .
P-365	-1.1741 -0.1632 -0.9027 -0.1177 -0.1684 -0.0517 -0.1119 -0.1171 -0.0953 -0.1050 -0.1607 -0.0188 -0.1289 -0.1242 -0.1543 -0.1780 -0.1575 -0.0890 -0.1354 -0.0294 -0.0630 -0.0903 -0.1355 -0.0873 -0.1274 -0.1465 -0.1576 -0.1022 -0.0867 -0.0622 -0.0833 -0.1285 -0.0221 -0.1459 -0.1285 -0.1385 -0.0419 -0.1386 -0.0562 -0.1044 -0.1039 -0.0848 -0.1337 -0.1023 -0.1229 -0.6043 -0.4267 -0.2015 -0.1841 -0.7282 -0.1122 -0.1446 -0.1316 -0.2063 -0.6370 -0.1383 -0.1490
S-433	Ausscheidung Nach intravenöser Gabe einer einzelnen Dosis von 14C-Alendronat wurden etwa 50 % der radioaktiv markierten Substanz innerhalb von 72 Stunden mit dem Urin ausgeschieden und wenig oder keine Radioaktivität wurde in den Fäzes wiedergefunden .
T-433	Elimination Following a single intravenous dose of <<unk>> 14C<<unk>> alendronate , approximately 50 % of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
H-433	-0.19067087769508362	Excretion After intravenous administration of a single dose of 14C-alendronate , approximately 50 % of the radiolabelled substance was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
D-433	-0.19067087769508362	Excretion After intravenous administration of a single dose of 14C-alendronate , approximately 50 % of the radiolabelled substance was excreted in the urine within 72 hours and little or no radioactivity was recovered in the faeces .
P-433	-0.4111 -0.0790 -0.1841 -0.8049 -0.8861 -0.0837 -0.0765 -0.1324 -0.1789 -0.1836 -0.1267 -0.2605 -0.0516 -0.1527 -0.1416 -0.2956 -0.1717 -0.1173 -0.1446 -0.1044 -0.0443 -0.1585 -0.4254 -0.1318 -0.1069 -0.1566 -0.1965 -0.4130 -0.0211 -0.0206 -0.0669 -0.1479 -0.5687 -0.1038 -0.0110 -0.0998 -0.3369 -0.1303 -0.0549 -0.0843 -0.3064 -0.1019 -0.1167 -0.1780 -0.1817 -0.3791 -0.2008 -0.3173 -0.0824 -0.1512 -0.1474 -0.1740 -0.1318 -0.3009 -0.0208 -0.1115 -0.1389 -0.1520
S-1987	Desloratadin hemmt in-vivo CYP3A4 nicht , und in-vitro-Studien haben gezeigt , dass das Arzneimittel CYP2D6 nicht hemmt und weder ein Substrat noch ein Inhibitor des P-Glykoproteins ist .
T-1987	Desloratadine does not inhibit CYP3A4 in vivo , and in vitro studies have shown that the medicinal product does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein .
H-1987	-0.22757326066493988	Desloratadine does not inhibit CYP3A4 in vivo , and in vitro studies have shown that the medicine does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein .
D-1987	-0.22757326066493988	Desloratadine does not inhibit CYP3A4 in vivo , and in vitro studies have shown that the medicine does not inhibit CYP2D6 and is neither a substrate nor an inhibitor of P-glycoprotein .
P-1987	-0.3712 -0.0429 -0.1055 -0.5330 -0.3299 -0.3207 -0.1246 -0.1702 -0.1168 -0.0408 -0.7344 -0.1065 -0.1173 -0.1244 -0.0557 -0.2915 -0.3161 -0.0501 -0.7986 -0.1338 -0.2782 -0.1066 -0.0676 -0.3447 -0.1840 -0.2866 -0.1167 -0.7809 -1.4080 -0.1777 -0.1292 -0.3096 -0.1572 -0.0476 -0.1314 -0.1095 -0.1182 -0.1086 -0.1287 -0.1281 -0.1625 -0.1063 -0.7889 -0.1350 -0.0855 -0.0619 -0.2082 -0.0845 -0.6642 -0.1151 -0.0522 -0.0472 -0.1405 -0.1606 -0.4074 -0.3154 -0.1704 -0.0920 -0.0631 -0.0462 -0.1330 -0.1393 -0.1545
S-231	Bei gesunden Probanden führte die Gabe von oralem Prednison ( 20 mg dreimal täglich über fünf Tage ) zu keiner klinisch bedeutsamen Veränderung der oralen Bioverfügbarkeit von Alendronat ( Anstieg im Mittel im Bereich von 20 % bis 44 % ) .
T-231	In healthy subjects , oral prednisone ( 20 mg three times daily for five days ) did not produce a clinically meaningful change in oral bioavailability of alendronate ( a mean increase ranging from 20 % to 44 % ) .
H-231	-0.2993531823158264	In healthy subjects , oral prednisone ( 20 mg 3 times daily for five days ) did not lead to any clinically important change in oral bioavailability of alendronate ( mean increase in the 20 % to 44 % range ) .
D-231	-0.2993531823158264	In healthy subjects , oral prednisone ( 20 mg 3 times daily for five days ) did not lead to any clinically important change in oral bioavailability of alendronate ( mean increase in the 20 % to 44 % range ) .
P-231	-0.1946 -0.1183 -0.0858 -0.2965 -0.4189 -0.1411 -0.1460 -0.5657 -0.1764 -0.4082 -0.1346 -0.0408 -0.2515 -0.0872 -1.8826 -0.1950 -0.2346 -0.1370 -0.1526 -0.1919 -0.1481 -2.3086 -0.1510 -0.8847 -0.0319 -0.0799 -0.1970 -0.1236 -0.1320 -0.4799 -0.0939 -0.0698 -0.1675 -0.1995 -0.1480 -0.1213 -0.0361 -0.1354 -1.2841 -0.1295 -0.2556 -0.1539 -0.5834 -0.1388 -0.1944 -0.0957 -0.1365 -0.4935 -0.1393 -0.1452 -0.1494
S-1849	Hinweise zur Herstellung der Lösung Nicht nach dem auf Durchstechflaschen und Umkarton angegebenen Haltbarkeitsdatum verwenden . Den BAXJECT II nicht verwenden , wenn seine sterile Barriere durchbrochen , seine Verpackung beschädigt ist oder Zeichen einer Manipulation aufweist , wie in dem Symbol
T-1849	Instructions for reconstitution Do not use after the expiry date stated on the labels and carton . Do not use if the BAXJECT II device , its sterile barrier system or its packaging is damaged or
H-1849	-0.4416966438293457	Method of preparation Do not use after the expiry date specified on the vials and outer carton . Do not use BAXJECT II if its sterile barrier is broken , its packaging is damaged or exhibits signs of manipulation , such as the
D-1849	-0.4416966438293457	Method of preparation Do not use after the expiry date specified on the vials and outer carton . Do not use BAXJECT II if its sterile barrier is broken , its packaging is damaged or exhibits signs of manipulation , such as the
P-1849	-0.9124 -0.0122 -0.0179 -0.2091 -2.2366 -0.2763 -0.2176 -0.0644 -0.4191 -0.2002 -0.7898 -0.1014 -0.0894 -2.9971 -0.0686 -0.5436 -0.3894 -0.1873 -1.0787 -0.1226 -0.6792 -0.1304 -0.0770 -0.0888 -0.2122 -0.0324 -0.1476 -0.1047 -0.6523 -0.1859 -0.3105 -0.0752 -0.1082 -0.1128 -0.3608 -0.1120 -0.2855 -0.0532 -0.1692 -0.8848 -0.7998 -0.1523 -0.0841 -0.4288 -0.1768 -0.9483 -0.3877 -0.1443 -1.9550 -0.8050 -1.3998 -0.1406 -0.4693 -0.0676 -0.2668 -1.1256 -0.1412 -0.6190 -0.2319
S-427	Bei gesunden Probanden führte die Gabe von oralem Prednison ( 20 mg dreimal täglich über fünf Tage ) zu keiner klinisch bedeutsamen Veränderung der oralen Bioverfügbarkeit von Alendronat ( Anstieg im Mittel im Bereich von 20 % bis 44 % ) .
T-427	In healthy subjects , oral prednisone ( 20 mg three times daily for five days ) did not produce a clinically meaningful change in oral bioavailability of alendronate ( a mean increase ranging from 20 % to 44 % ) .
H-427	-0.2993531823158264	In healthy subjects , oral prednisone ( 20 mg 3 times daily for five days ) did not lead to any clinically important change in oral bioavailability of alendronate ( mean increase in the 20 % to 44 % range ) .
D-427	-0.2993531823158264	In healthy subjects , oral prednisone ( 20 mg 3 times daily for five days ) did not lead to any clinically important change in oral bioavailability of alendronate ( mean increase in the 20 % to 44 % range ) .
P-427	-0.1946 -0.1183 -0.0858 -0.2965 -0.4189 -0.1411 -0.1460 -0.5657 -0.1764 -0.4082 -0.1346 -0.0408 -0.2515 -0.0872 -1.8826 -0.1950 -0.2346 -0.1370 -0.1526 -0.1919 -0.1481 -2.3086 -0.1510 -0.8847 -0.0319 -0.0799 -0.1970 -0.1236 -0.1320 -0.4799 -0.0939 -0.0698 -0.1675 -0.1995 -0.1480 -0.1213 -0.0361 -0.1354 -1.2841 -0.1295 -0.2556 -0.1539 -0.5834 -0.1388 -0.1944 -0.0957 -0.1365 -0.4935 -0.1393 -0.1452 -0.1494
S-778	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-778	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-778	-0.2891644537448883	These inhibitors are always anti-procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by a modified Bethesda assay .
D-778	-0.2891644537448883	These inhibitors are always anti-procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by a modified Bethesda assay .
P-778	-0.3923 -0.1385 -0.0249 -0.0749 -0.1492 -0.1148 -1.2478 -1.3654 -0.3244 -0.0617 -0.2921 -0.0933 -0.1786 -0.9195 -0.2218 -0.1632 -0.2718 -0.1442 -0.1423 -0.7564 -0.1988 -0.3038 -0.3112 -0.0629 -0.0709 -0.1436 -0.5833 -0.1025 -0.1264 -0.2667 -0.0811 -0.1278 -0.6546 -0.1450 -1.5303 -0.1551 -0.1340 -0.1101 -0.1084 -0.9430 -0.0913 -0.0680 -0.1480 -0.3603 -0.2898 -0.0454 -0.0858 -0.2590 -0.0734 -0.1262 -0.3740 -0.1687 -0.1384 -0.1495
S-1130	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-1130	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-1130	-0.2891644537448883	These inhibitors are always anti-procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by a modified Bethesda assay .
D-1130	-0.2891644537448883	These inhibitors are always anti-procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by a modified Bethesda assay .
P-1130	-0.3923 -0.1385 -0.0249 -0.0749 -0.1492 -0.1148 -1.2478 -1.3654 -0.3244 -0.0617 -0.2921 -0.0933 -0.1786 -0.9195 -0.2218 -0.1632 -0.2718 -0.1442 -0.1423 -0.7564 -0.1988 -0.3038 -0.3112 -0.0629 -0.0709 -0.1436 -0.5833 -0.1025 -0.1264 -0.2667 -0.0811 -0.1278 -0.6546 -0.1450 -1.5303 -0.1551 -0.1340 -0.1101 -0.1084 -0.9430 -0.0913 -0.0680 -0.1480 -0.3603 -0.2898 -0.0454 -0.0858 -0.2590 -0.0734 -0.1262 -0.3740 -0.1687 -0.1384 -0.1495
S-604	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-604	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-604	-0.2891644537448883	These inhibitors are always anti-procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by a modified Bethesda assay .
D-604	-0.2891644537448883	These inhibitors are always anti-procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by a modified Bethesda assay .
P-604	-0.3923 -0.1385 -0.0249 -0.0749 -0.1492 -0.1148 -1.2478 -1.3654 -0.3244 -0.0617 -0.2921 -0.0933 -0.1786 -0.9195 -0.2218 -0.1632 -0.2718 -0.1442 -0.1423 -0.7564 -0.1988 -0.3038 -0.3112 -0.0629 -0.0709 -0.1436 -0.5833 -0.1025 -0.1264 -0.2667 -0.0811 -0.1278 -0.6546 -0.1450 -1.5303 -0.1551 -0.1340 -0.1101 -0.1084 -0.9430 -0.0913 -0.0680 -0.1480 -0.3603 -0.2898 -0.0454 -0.0858 -0.2590 -0.0734 -0.1262 -0.3740 -0.1687 -0.1384 -0.1495
S-531	Reproduction is authorised provided the source is acknowledged . Wie wurde Advate untersucht ? Advate ist einem anderen in der Europäischen Union zugelassenen Arzneimittel namens Recombinate , ähnlich , wird jedoch anders hergestellt , sodass das Arzneimittel keine Proteine humanen bzw. tierischen Ursprungs enthält .
T-531	Reproduction is authorised provided the source is acknowledged . of bleeding episodes and rated Advate s effectiveness in stopping bleeding on a scale from none to excellent in 107 patients , all of whom received Advate .
H-531	-0.41588208079338074	Reproduction is authorised provided the source is recognised . How has Advate been investigated ? Advate is similar to another medicinal product authorised in the European Union called Recombinate but manufactured in a different way and does not contain human or animal source proteins .
D-531	-0.41588208079338074	Reproduction is authorised provided the source is recognised . How has Advate been investigated ? Advate is similar to another medicinal product authorised in the European Union called Recombinate but manufactured in a different way and does not contain human or animal source proteins .
P-531	-0.1779 -0.4500 -0.1160 -0.3920 -0.0997 -0.1327 -0.1473 -0.0472 -0.1088 -1.9690 -0.5822 -0.2395 -0.9572 -0.6725 -0.0920 -0.0947 -1.6925 -0.7705 -1.0360 -0.1032 -0.1220 -0.1548 -0.1504 -0.1156 -0.7656 -0.0460 -0.0797 -1.1433 -0.1486 -0.2281 -0.1386 -0.2130 -0.2003 -0.1315 -0.1836 -0.1121 -0.0758 -0.1073 -0.9167 -1.2100 -0.1990 -0.7747 -0.1621 -0.3330 -0.7202 -0.4828 -1.2643 -0.1244 -0.2293 -1.1930 -0.4346 -0.0620 -1.0875 -0.1251 -0.0475 -0.1873 -0.1543
S-954	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-954	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-954	-0.2891644537448883	These inhibitors are always anti-procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by a modified Bethesda assay .
D-954	-0.2891644537448883	These inhibitors are always anti-procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by a modified Bethesda assay .
P-954	-0.3923 -0.1385 -0.0249 -0.0749 -0.1492 -0.1148 -1.2478 -1.3654 -0.3244 -0.0617 -0.2921 -0.0933 -0.1786 -0.9195 -0.2218 -0.1632 -0.2718 -0.1442 -0.1423 -0.7564 -0.1988 -0.3038 -0.3112 -0.0629 -0.0709 -0.1436 -0.5833 -0.1025 -0.1264 -0.2667 -0.0811 -0.1278 -0.6546 -0.1450 -1.5303 -0.1551 -0.1340 -0.1101 -0.1084 -0.9430 -0.0913 -0.0680 -0.1480 -0.3603 -0.2898 -0.0454 -0.0858 -0.2590 -0.0734 -0.1262 -0.3740 -0.1687 -0.1384 -0.1495
S-182	Colecalciferol Bei Langzeittherapie allgemein gesunder Erwachsener wurde für Dosierungen von weniger als 10.000 I.E.<unk> Tag keine Vitamin-D-Toxizität dokumentiert . In einer klinischen Studie bei gesunden Erwachsenen war eine tägliche Dosis von 4.000 I.E.
T-182	Colecalciferol Vitamin D toxicity has not been documented during chronic therapy in generally healthy adults at a dose less than 10,000 IU/ day .
H-182	-0.32946428656578064	Colecalciferol No vitamin D toxicity has been documented for doses less than 10,000 IU/ day In a clinical trial in healthy adults , a daily dose of 4,000 IU
D-182	-0.32946428656578064	Colecalciferol No vitamin D toxicity has been documented for doses less than 10,000 IU/ day In a clinical trial in healthy adults , a daily dose of 4,000 IU
P-182	-0.1480 -0.1108 -0.1892 -0.1312 -0.1281 -0.1963 -0.9815 -0.1837 -0.0711 -0.1037 -0.0532 -0.1001 -0.0906 -0.9998 -0.1385 -0.7792 -0.2733 -0.3538 -0.0627 -1.1645 -0.1459 -0.3560 -0.1270 -0.5996 -0.1461 -0.1454 -1.3193 -0.1742 -0.0869 -0.1056 -0.1525 -0.1657 -0.2786 -0.7520 -0.1452 -0.0760 -0.0696 -0.1462 -0.8825 -0.1331 -0.4650 -1.1058
S-1306	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-1306	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-1306	-0.2891644537448883	These inhibitors are always anti-procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by a modified Bethesda assay .
D-1306	-0.2891644537448883	These inhibitors are always anti-procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by a modified Bethesda assay .
P-1306	-0.3923 -0.1385 -0.0249 -0.0749 -0.1492 -0.1148 -1.2478 -1.3654 -0.3244 -0.0617 -0.2921 -0.0933 -0.1786 -0.9195 -0.2218 -0.1632 -0.2718 -0.1442 -0.1423 -0.7564 -0.1988 -0.3038 -0.3112 -0.0629 -0.0709 -0.1436 -0.5833 -0.1025 -0.1264 -0.2667 -0.0811 -0.1278 -0.6546 -0.1450 -1.5303 -0.1551 -0.1340 -0.1101 -0.1084 -0.9430 -0.0913 -0.0680 -0.1480 -0.3603 -0.2898 -0.0454 -0.0858 -0.2590 -0.0734 -0.1262 -0.3740 -0.1687 -0.1384 -0.1495
S-1482	Diese Inhibitoren sind stets gegen die prokoagulatorische Aktivität von Faktor VIII gerichtete IgG Immunglobuline , die in Bethesda Einheiten ( B.E. ) pro ml Plasma mittels modifiziertem Bethesda Assay quantifiziert werden .
T-1482	These inhibitors are usually IgGs directed against the factor VIII procoagulant activity , which are quantified in Bethesda Units ( BU ) per ml of plasma using the modified Bethesda assay .
H-1482	-0.2891644537448883	These inhibitors are always anti-procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by a modified Bethesda assay .
D-1482	-0.2891644537448883	These inhibitors are always anti-procoagulatory activity of factor VIII IgG immunoglobulins quantified in Bethesda units ( BU ) per ml of plasma by a modified Bethesda assay .
P-1482	-0.3923 -0.1385 -0.0249 -0.0749 -0.1492 -0.1148 -1.2478 -1.3654 -0.3244 -0.0617 -0.2921 -0.0933 -0.1786 -0.9195 -0.2218 -0.1632 -0.2718 -0.1442 -0.1423 -0.7564 -0.1988 -0.3038 -0.3112 -0.0629 -0.0709 -0.1436 -0.5833 -0.1025 -0.1264 -0.2667 -0.0811 -0.1278 -0.6546 -0.1450 -1.5303 -0.1551 -0.1340 -0.1101 -0.1084 -0.9430 -0.0913 -0.0680 -0.1480 -0.3603 -0.2898 -0.0454 -0.0858 -0.2590 -0.0734 -0.1262 -0.3740 -0.1687 -0.1384 -0.1495
S-48	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen .
T-48	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
H-48	-0.30296507477760315	This document is a summary of the European Public Evaluation Report ( EPAR ) , which explains how the Committee for Medicinal products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
D-48	-0.30296507477760315	This document is a summary of the European Public Evaluation Report ( EPAR ) , which explains how the Committee for Medicinal products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
P-48	-0.1404 -0.3961 -0.2254 -0.2436 -0.4813 -0.0910 -0.1684 -0.1442 -0.2319 -0.3530 -1.0552 -0.2503 -0.1486 -0.1509 -0.0767 -0.0378 -0.1345 -1.4190 -0.3954 -0.4040 -0.0757 -0.1556 -0.0891 -0.1408 -0.1268 -0.0725 -0.5899 -0.1301 -0.6615 -0.1785 -0.1385 -0.1180 -0.0557 -0.1345 -0.2030 -0.5322 -0.0764 -0.3425 -0.7826 -0.7988 -0.1273 -0.2634 -0.1089 -0.1578 -1.1499 -0.1267 -0.6404 -0.1942 -0.2256 -0.1690 -0.3472 -0.6007 -0.1484 -0.1503
S-1893	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen .
T-1893	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
H-1893	-0.30296507477760315	This document is a summary of the European Public Evaluation Report ( EPAR ) , which explains how the Committee for Medicinal products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
D-1893	-0.30296507477760315	This document is a summary of the European Public Evaluation Report ( EPAR ) , which explains how the Committee for Medicinal products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
P-1893	-0.1404 -0.3961 -0.2254 -0.2436 -0.4813 -0.0910 -0.1684 -0.1442 -0.2319 -0.3530 -1.0552 -0.2503 -0.1486 -0.1509 -0.0767 -0.0378 -0.1345 -1.4190 -0.3954 -0.4040 -0.0757 -0.1556 -0.0891 -0.1408 -0.1268 -0.0725 -0.5899 -0.1301 -0.6615 -0.1785 -0.1385 -0.1180 -0.0557 -0.1345 -0.2030 -0.5322 -0.0764 -0.3425 -0.7826 -0.7988 -0.1273 -0.2634 -0.1089 -0.1578 -1.1499 -0.1267 -0.6404 -0.1942 -0.2256 -0.1690 -0.3472 -0.6007 -0.1484 -0.1503
S-0	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen .
T-0	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
H-0	-0.30296507477760315	This document is a summary of the European Public Evaluation Report ( EPAR ) , which explains how the Committee for Medicinal products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
D-0	-0.30296507477760315	This document is a summary of the European Public Evaluation Report ( EPAR ) , which explains how the Committee for Medicinal products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
P-0	-0.1404 -0.3961 -0.2254 -0.2436 -0.4813 -0.0910 -0.1684 -0.1442 -0.2319 -0.3530 -1.0552 -0.2503 -0.1486 -0.1509 -0.0767 -0.0378 -0.1345 -1.4190 -0.3954 -0.4040 -0.0757 -0.1556 -0.0891 -0.1408 -0.1268 -0.0725 -0.5899 -0.1301 -0.6615 -0.1785 -0.1385 -0.1180 -0.0557 -0.1345 -0.2030 -0.5322 -0.0764 -0.3425 -0.7826 -0.7988 -0.1273 -0.2634 -0.1089 -0.1578 -1.1499 -0.1267 -0.6404 -0.1942 -0.2256 -0.1690 -0.3472 -0.6007 -0.1484 -0.1503
S-509	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen .
T-509	Das vorliegende Dokument ist eine Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts ( EPAR ) , in dem erläutert wird , wie der Ausschuss für Humanarzneimittel ( CHMP ) die durchgeführten Studien beurteilt hat , um zu Empfehlungen bezüglich der Anwendung des Arzneimittels zu gelangen . It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the studies performed , to reach their recommendations on how to use the medicine .
H-509	-0.30296507477760315	This document is a summary of the European Public Evaluation Report ( EPAR ) , which explains how the Committee for Medicinal products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
D-509	-0.30296507477760315	This document is a summary of the European Public Evaluation Report ( EPAR ) , which explains how the Committee for Medicinal products for Human Use ( CHMP ) has assessed the studies carried out in order to make recommendations on the use of the product .
P-509	-0.1404 -0.3961 -0.2254 -0.2436 -0.4813 -0.0910 -0.1684 -0.1442 -0.2319 -0.3530 -1.0552 -0.2503 -0.1486 -0.1509 -0.0767 -0.0378 -0.1345 -1.4190 -0.3954 -0.4040 -0.0757 -0.1556 -0.0891 -0.1408 -0.1268 -0.0725 -0.5899 -0.1301 -0.6615 -0.1785 -0.1385 -0.1180 -0.0557 -0.1345 -0.2030 -0.5322 -0.0764 -0.3425 -0.7826 -0.7988 -0.1273 -0.2634 -0.1089 -0.1578 -1.1499 -0.1267 -0.6404 -0.1942 -0.2256 -0.1690 -0.3472 -0.6007 -0.1484 -0.1503
S-370	Colecalciferol Bei Langzeittherapie allgemein gesunder Erwachsener wurde für Dosierungen von weniger als 10.000 I.E.<unk> Tag keine Vitamin-D-Toxizität dokumentiert . In einer klinischen Studie bei gesunden Erwachsenen war eine tägliche Dosis von 4.000 I.E.
T-370	Colecalciferol Vitamin D toxicity has not been documented during chronic therapy in generally healthy adults at a dose less than 10,000 IU/ day .
H-370	-0.32946428656578064	Colecalciferol No vitamin D toxicity has been documented for doses less than 10,000 IU/ day In a clinical trial in healthy adults , a daily dose of 4,000 IU
D-370	-0.32946428656578064	Colecalciferol No vitamin D toxicity has been documented for doses less than 10,000 IU/ day In a clinical trial in healthy adults , a daily dose of 4,000 IU
P-370	-0.1480 -0.1108 -0.1892 -0.1312 -0.1281 -0.1963 -0.9815 -0.1837 -0.0711 -0.1037 -0.0532 -0.1001 -0.0906 -0.9998 -0.1385 -0.7792 -0.2733 -0.3538 -0.0627 -1.1645 -0.1459 -0.3560 -0.1270 -0.5996 -0.1461 -0.1454 -1.3193 -0.1742 -0.0869 -0.1056 -0.1525 -0.1657 -0.2786 -0.7520 -0.1452 -0.0760 -0.0696 -0.1462 -0.8825 -0.1331 -0.4650 -1.1058
S-75	Nach einer 15-wöchigen Behandlung war der Anteil der Patienten mit niedrigem Vitamin-D-Spiegel bei den Patienten , die mit ADROVANCE behandelt worden waren , geringer ( 11 % ) als bei denjenigen , die ausschließlich Alendronat einnahmen ( 32 % ) .
T-75	After 15 weeks of treatment , the proportion of patients with low vitamin D levels was lower among the patients treated with ADROVANCE ( 11 % ) than those taking alendronate only ( 32 % ) .
H-75	-0.39864876866340637	Following 15 weeks of treatment , the proportion of patients with low vitamin D levels was lower ( 11 % ) in those treated with ADROVANCE than in those taking alendronate alone ( 32 % ) .
D-75	-0.39864876866340637	Following 15 weeks of treatment , the proportion of patients with low vitamin D levels was lower ( 11 % ) in those treated with ADROVANCE than in those taking alendronate alone ( 32 % ) .
P-75	-0.7372 -1.0788 -0.1820 -0.1992 -0.3334 -0.1584 -2.6050 -0.2598 -0.1825 -0.4854 -0.5826 -0.2167 -1.3450 -0.0763 -0.0830 -0.4064 -0.4744 -0.9245 -0.6387 -0.1115 -0.1505 -0.1330 -0.4626 -0.6218 -0.3788 -0.1554 -0.0756 -0.0867 -0.1182 -0.0998 -0.0991 -0.3147 -0.2404 -0.0439 -1.4514 -0.5809 -0.1463 -0.1311 -0.0877 -1.0587 -0.1236 -0.1187 -0.1271 -0.1298 -0.1689 -0.1521
S-1619	wenn neue Informationen vorliegen , die Einfluss auf die gültigen Sicherheitshinweise , den Pharmakovigilanz-Plan oder die Maßnahmen zur Risiko-Minimierung haben könnten innerhalb von 60 Tagen nach einem wichtigen Ereignis ( hinsichtlich der Pharmakovigilanz oder hinsichtlich einer Maßnahme zur Risiko-Minimierung )
T-1619	In addition , an updated RMP should be submitted When new information is received that may impact on the current Safety Specification , Pharmacovigilance Plan or risk minimisation activities Within 60 days of an important ( pharmacovigilance or risk minimisation ) milestone being reached At the request of the EMEA
H-1619	-0.5281129479408264	if new information is received that could affect valid safety warnings , the pharmacovigilance plan or risk minimisation measures , within 60 days following a major event ( in pharmacovigilance or in risk minimisation measures )
D-1619	-0.5281129479408264	if new information is received that could affect valid safety warnings , the pharmacovigilance plan or risk minimisation measures , within 60 days following a major event ( in pharmacovigilance or in risk minimisation measures )
P-1619	-2.1199 -0.3596 -0.0952 -0.9640 -0.6083 -0.2907 -1.1748 -0.5488 -1.7592 -0.0499 -0.4916 -1.3536 -0.1596 -0.1423 -0.2214 -0.1138 -0.1793 -0.2281 -0.2022 -0.1821 -0.2269 -0.2208 -0.4623 -0.1945 -0.1092 -0.3115 -1.5889 -0.1834 -0.1302 -0.1202 -1.4354 -0.8877 -0.5291 -0.3197 -0.1311 -0.5971 -1.1135 -0.1347 -0.2321 -0.2289 -0.1341 -0.1908 -0.9597 -0.8382 -0.2146 -0.0479 -0.1195 -3.1566 -0.1787 -0.1636
S-466	EU<unk> 1<unk> 06<unk> 364<unk> 006 2 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 007 4 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 008 12 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 009 40 Tabletten
T-466	EU/ 1/ 06/ 364/ 006 2 tablets EU/ 1/ 06/ 364/ 007 4 tablets EU/ 1/ 06/ 364/ 008 12 tablets EU/ 1/ 06/ 364/ 009 40 tablets
H-466	-0.265386164188385	06/ 364/ 006 2 tablets EU/ 1/ 364/ 007 4 tablets EU/ 1/ 364/ 008 12 tablets EU/ 1/ 364/ 009 40 tablets EU/ 1/ 364/ 006
D-466	-0.265386164188385	06/ 364/ 006 2 tablets EU/ 1/ 364/ 007 4 tablets EU/ 1/ 364/ 008 12 tablets EU/ 1/ 364/ 009 40 tablets EU/ 1/ 364/ 006
P-466	-0.7931 -0.1323 -0.1286 -0.1067 -0.1034 -0.0976 -0.6264 -0.1450 -0.1466 -0.1045 -0.2758 -0.0989 -1.3636 -0.0862 -0.2051 -0.0985 -0.1172 -0.0784 -0.3375 -0.1303 -0.1218 -0.1003 -0.0764 -0.1154 -0.2480 -0.0910 -0.4133 -0.0899 -0.1225 -0.0774 -0.2360 -0.0844 -0.1184 -0.0888 -0.0775 -0.1108 -0.3716 -0.0809 -0.6881 -0.0891 -0.1213 -0.0694 -0.1598 -0.0821 -0.0846 -0.1016 -0.2472 -0.1116 -1.2178 -0.0928 -0.3854 -0.0850 -0.1126 -0.0773 -2.0489 -1.2872
S-1884	Aufgrund der geprüften Daten und Antworten des Unternehmens auf die Liste von Fragen des CHMP bestanden seitens des CHMP zum Zeitpunkt der Rücknahme gewisse Bedenken . Der Ausschuss war der vorläufigen Ansicht , dass Advexin zur Behandlung von Li-Fraumeni-Krebs nicht hätte zugelassen werden können .
T-1884	Based on the review of the data and the company s response to the CHMP list of questions , at the time of the withdrawal , the CHMP had some concerns and was of the provisional opinion that Advexin could not have been approved for the treatment of Li-Fraumeni cancer .
H-1884	-0.47298693656921387	Based on the data reviewed and the company &apos;s response to the CHMP list of questions , there were some concerns on the part of CHMP at the time of withdrawal and the Committee took the preliminary view that Advexin could not have been approved for the treatment of Li-Fraumeni cancer .
D-1884	-0.47298693656921387	Based on the data reviewed and the company &apos;s response to the CHMP list of questions , there were some concerns on the part of CHMP at the time of withdrawal and the Committee took the preliminary view that Advexin could not have been approved for the treatment of Li-Fraumeni cancer .
P-1884	-1.6328 -0.1919 -0.9481 -0.6059 -0.2759 -0.1527 -0.5578 -0.6732 -1.8198 -1.0794 -0.1511 -0.3336 -0.4587 -0.0311 -1.4576 -0.1809 -0.6928 -0.1597 -0.5637 -0.2053 -0.4733 -0.6803 -0.6858 -0.1786 -0.5029 -0.1474 -0.3876 -0.0406 -0.1285 -0.1523 -0.1893 -0.1596 -1.0095 -0.4363 -0.2001 -0.2863 -3.7364 -0.1434 -0.3453 -0.3456 -0.0968 -0.5085 -0.1716 -0.1406 -0.5333 -0.1441 -0.4068 -0.0570 -0.6867 -0.8241 -0.1859 -0.0923 -0.1437 -0.7007 -0.2611 -0.3793 -0.0554 -0.3172 -0.4489 -0.1451 -0.1517
S-249	Biotransformation Vitamin D3 wird in der Leber rasch zu 25-Hydroxyvitamin D3 hydroxyliert und dann in der Niere zu 1,25-Dihydroxyvitamin D3 , der biologisch aktiven Form , metabolisiert .
T-249	Biotransformation Vitamin D3 is rapidly metabolized by hydroxylation in the liver to 25-hydroxyvitamin D3 , and subsequently metabolized in the kidney to 1,25-dihydroxyvitamin D3 , which represents the biologically active form .
H-249	-0.24388487637043	biotransformation Vitamin D3 is rapidly hydroxylated by the liver to 25-hydroxyvitamin D3 and then metabolised by the kidney to 1,25 -dihydroxyvitamin D3 , the biologically active form .
D-249	-0.24388487637043	biotransformation Vitamin D3 is rapidly hydroxylated by the liver to 25-hydroxyvitamin D3 and then metabolised by the kidney to 1,25 -dihydroxyvitamin D3 , the biologically active form .
P-249	-0.8362 -0.0852 -0.0579 -0.1214 -0.0421 -0.6589 -0.0896 -0.1240 -0.1276 -0.1736 -0.1285 -0.0585 -0.1447 -0.1656 -0.0279 -1.3493 -0.1252 -0.0581 -0.3659 -0.9033 -0.1158 -0.0547 -0.1181 -0.1025 -0.1226 -0.1190 -0.1208 -0.1274 -0.7382 -0.3361 -0.1609 -0.0392 -0.1093 -0.1445 -0.1188 -0.2376 -0.2471 -0.1991 -0.5358 -0.6793 -0.6560 -0.1410 -0.0496 -0.1242 -0.1065 -0.0860 -0.1381 -0.1318 -0.1238 -0.1763 -1.0849 -0.0840 -0.2338 -0.1204 -0.0634 -0.4320 -0.1658 -0.1574
S-1767	Patienten , die Faktor-VIII-Inhibitoren entwickeln Wenn die erwarteten FaktorVIII-Spiegel in Ihrem Plasma mit ADVATE nicht erreicht werden oder die Blutung nicht beherrscht werden kann , könnte dies an der Entwicklung von Faktor VIII-
T-1767	93 Patients developing Factor VIII inhibitors If your plasma Factor VIII fails to reach expected levels with ADVATE , or if bleeding is not adequately controlled , it could be due to the development of Factor VIII inhibitors .
H-1767	-0.5378385186195374	Patients developing factor VIII inhibitors If the expected levels of factor VIII in your plasma cannot be achieved or the bleeding cannot be controlled , then factor VIII may be involved in
D-1767	-0.5378385186195374	Patients developing factor VIII inhibitors If the expected levels of factor VIII in your plasma cannot be achieved or the bleeding cannot be controlled , then factor VIII may be involved in
P-1767	-0.1148 -0.0999 -0.9574 -0.2779 -0.5262 -0.2633 -1.5187 -0.0943 -0.0365 -0.0902 -0.1199 -0.2649 -1.3248 -0.9920 -0.9185 -0.5750 -0.0928 -0.3076 -0.7865 -0.6812 -0.1550 -0.1636 -0.1025 -0.0501 -0.1152 -0.2412 -0.1217 -0.8183 -0.2299 -2.1000 -1.3465 -0.2399 -0.1143 -0.1540 -0.1303 -0.1661 -1.1187 -1.2994 -0.3743 -1.3108 -0.3919 -1.2053 -0.3556 -0.3723 -0.6280 -1.3932
S-398	Die Patientinnen der 2.800-I.E.-Vitamin-D3-Gruppe erhielten ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( n<unk> 299 ) und die Patientinnen der 5.600-I.E.-Vitamin-D3-Gruppe erhielten ADROVANCE ( 70 mg<unk> 2.800 I.E. ) sowie zusätzlich 2.800 I.E. Vitamin D3 ( n<unk> 309 ) einmal wöchentlich ; weitere Vitamin-D- Ergänzungsmittel waren erlaubt . Nach 24-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher in der 5.600-I.E.-Vitamin-D3-Gruppe ( 69 nmol<unk> l <unk> 27,6 ng<unk> ml <unk> ) als in der 2.800-I.E.-Vitamin-D3-Gruppe ( 64 nmol<unk> l <unk> 25,5 ng<unk> ml <unk> ) .
T-398	After 24-weeks of treatment , the mean serum 25- hydroxyvitamin D levels were significantly higher in the Vitamin D3 5600 group ( 69 nmol/ l <<unk>> 27.6 ng/ ml <<unk>> ) than in the Vitamin D3 2800 group ( 64 nmol/ l <<unk>> 25.5 ng/ ml <<unk>> ) .
H-398	-0.23916594684123993	2,800 IU of vitamin D3 group received ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 299 ) , and 5,600 IU of vitamin D3 group received ADROVANCE ( 70 mg/ 2,800 IU ) , and an additional 2,800 IU of vitamin D3 ( n/ 309 ) once a week ; additional vitamin D supplements were allowed ; after 24 weeks of treatment , mean serum levels of 25 hydroxyvitamin D were significantly higher in the 5,600 IU of vitamin D3 ( 69 nmol/ l / 27.6 ng/ ml <unk> ) than in the 2,800 IU of vitamin D3 group ( 64 nmol/ l / 25.5 ng/ ml <unk> ) .
D-398	-0.23916594684123993	2,800 IU of vitamin D3 group received ADROVANCE ( 70 mg/ 2,800 IU ) ( n/ 299 ) , and 5,600 IU of vitamin D3 group received ADROVANCE ( 70 mg/ 2,800 IU ) , and an additional 2,800 IU of vitamin D3 ( n/ 309 ) once a week ; additional vitamin D supplements were allowed ; after 24 weeks of treatment , mean serum levels of 25 hydroxyvitamin D were significantly higher in the 5,600 IU of vitamin D3 ( 69 nmol/ l / 27.6 ng/ ml <unk> ) than in the 2,800 IU of vitamin D3 group ( 64 nmol/ l / 25.5 ng/ ml <unk> ) .
P-398	-0.8923 -0.1273 -0.0980 -0.3447 -0.3637 -0.2828 -0.1252 -0.1549 -0.1229 -1.2786 -0.6937 -0.0680 -0.0588 -0.1170 -0.1015 -0.1065 -0.1427 -0.1218 -0.1813 -0.1626 -0.1274 -0.1285 -0.1052 -0.1078 -0.1677 -0.1315 -0.1481 -0.1904 -0.0987 -0.1140 -0.0485 -0.1308 -0.4916 -0.4123 -0.5934 -0.0513 -0.1231 -0.2966 -0.1926 -0.2510 -0.1444 -0.1485 -0.1389 -0.1877 -0.7211 -0.0590 -0.0544 -0.1196 -0.1167 -0.0980 -0.1370 -0.1189 -0.1526 -0.1808 -0.1206 -0.0972 -0.1188 -0.1132 -0.1732 -0.1277 -0.8893 -1.5563 -0.3039 -0.1602 -0.2174 -0.1131 -0.1097 -0.1939 -0.1640 -0.1356 -0.1349 -0.1214 -0.1364 -0.1547 -0.1846 -0.1186 -0.1030 -0.1154 -0.1372 -0.1048 -0.2030 -0.0991 -0.2375 -0.6841 -0.1552 -0.1267 -0.1801 -0.0609 -0.2467 -0.1657 -1.1987 -0.6756 -1.3886 -0.3288 -0.1328 -0.1600 -0.0857 -0.1944 -0.1854 -0.7872 -0.1366 -0.0431 -0.1822 -0.3584 -0.8526 -0.1286 -0.1294 -0.0953 -0.1438 -0.0978 -0.2331 -0.1271 -0.0542 -0.1545 -0.1356 -0.3972 -0.0672 -0.1342 -0.1711 -0.7769 -0.1653 -0.1810 -0.1345 -0.1042 -0.1504 -0.0956 -0.1216 -0.3311 -0.1189 -0.7095 -0.6153 -0.3573 -0.1385 -0.1221 -0.1285 -0.1171 -0.0562 -0.1410 -0.1342 -0.2154 -0.1996 -0.1286 -0.2561 -0.0728 -0.1996 -0.5029 -0.2897 -0.3040 -0.1982 -0.2334 -0.1158 -1.0256 -0.1471 -0.0563 -0.1231 -0.4457 -0.1330 -0.3292 -0.9851 -0.0242 -0.1017 -0.1425 -0.1503 -0.1076 -0.0592 -0.0873 -0.1209 -0.1383 -0.1510
S-1953	- Harnverhalt , - Herz-Kreislauf-Erkrankungen wie ischämische Herzerkrankung , Tachyarrhythmie und schwere Hypertonie , - Hyperthyreose , - einem hämorrhagischen Schlaganfall in der Anamnese oder Risikofaktoren , die das Risiko für das Auftreten eines hämorrhagischen Schlaganfalls erhöhen können . Dies ist auf die alphamimetische Aktivität bei kombinierter Anwendung von Pseudoephedrin mit anderen Vasokonstriktoren wie Bromocripitin , Pergolid , Lisurid , Cabergolin , Ergotamin , Dihydroergotamin oder anderen Dekongestiva , die peroral oder nasal als abschwellendes Rhinologikum angewendet werden ( Phenylpropanolamin , Phenylephrin , Ephedrin , Oxymetazolin , Naphazolin etc. ) zurückzuführen .
T-1953	This is due to the alpha-mimetic activity of pseudoephedrine in combination with other vasoconstrictors such as bromocripitine , pergolide , lisuride , cabergoline , ergotamine , dihydroergotamine or any other decongestant medicinal product used as a nasal decongestant , either by oral route or by nasal route ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazoline , naphazoline ) .
H-1953	-0.33100929856300354	Cardiovascular disorders such as ischaemic heart disease , tachyarrhythmia and severe hypertension , hyperthyroidism , a history of haemorrhagic stroke or risk factors that may increase the risk of having a haemorrhagic stroke . This is due to alphamimetic activity associated with combined use of pseudoephedrine with other vasoconstrictors such as bromocripitin , pergolide , lisuride , cabergolin , ergotamine , dihydroergotamine or other decongestants used perorally or nasally as a decongestant ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazolin , naphazolin , etc . ) .
D-1953	-0.33100929856300354	Cardiovascular disorders such as ischaemic heart disease , tachyarrhythmia and severe hypertension , hyperthyroidism , a history of haemorrhagic stroke or risk factors that may increase the risk of having a haemorrhagic stroke . This is due to alphamimetic activity associated with combined use of pseudoephedrine with other vasoconstrictors such as bromocripitin , pergolide , lisuride , cabergolin , ergotamine , dihydroergotamine or other decongestants used perorally or nasally as a decongestant ( phenylpropanolamine , phenylephrine , ephedrine , oxymetazolin , naphazolin , etc . ) .
P-1953	-0.5734 -0.0676 -0.1156 -0.0962 -0.3892 -0.1001 -0.2581 -0.1635 -0.1092 -0.0257 -0.0489 -0.0788 -0.3298 -0.1055 -0.1502 -0.0964 -0.1149 -0.1330 -0.0291 -0.0543 -0.3535 -0.1418 -0.0597 -0.0221 -0.0246 -0.1482 -0.0665 -0.1384 -0.1297 -0.0913 -0.2518 -0.0296 -0.0830 -0.1383 -2.6753 -0.9242 -0.1374 -0.4204 -0.7276 -0.0649 -0.4378 -0.1160 -0.1186 -0.5295 -0.0789 -0.0536 -0.9409 -0.3283 -0.0664 -0.1500 -0.1887 -0.7498 -2.5076 -0.1498 -0.6108 -1.1361 -0.3211 -0.1148 -0.3596 -0.1706 -0.0998 -1.1088 -0.1824 -0.1452 -0.3755 -0.1545 -0.0910 -0.0777 -0.2319 -0.0833 -0.1407 -0.2242 -2.0210 -0.1584 -1.6116 -0.1587 -0.1530 -0.2799 -0.5825 -0.1910 -0.0422 -0.1546 -0.1263 -0.1637 -0.2151 -0.1144 -0.1117 -0.1065 -0.1443 -0.5003 -0.2249 -0.5135 -0.2448 -0.1567 -0.0662 -0.1139 -0.0550 -0.2379 -0.2989 -0.1534 -0.2581 -0.1735 -0.1126 -0.2990 -0.1580 -0.6903 -0.4188 -1.0014 -0.1628 -0.2192 -0.1832 -2.2333 -0.1416 -0.1573 -1.0511 -0.0998 -0.0866 -0.1521 -0.1672 -0.0489 -0.2235 -0.0774 -0.0928 -0.1922 -0.1306 -0.1134 -0.1525 -0.7549 -1.1649 -0.7415 -0.1255 -1.0224 -0.0820 -0.1622 -0.0810 -0.1099 -0.2727 -0.1623 -0.6394 -0.2411 -0.7750 -3.0851 -0.2294 -1.1290 -0.0749 -0.1577 -0.0556 -0.1011 -0.0547 -0.0606 -0.1497 -0.1115 -0.1281 -0.0637 -0.0905 -0.1271 -0.2730 -0.1533 -0.1651 -0.1638 -0.3728 -0.1631 -0.1501 -0.5479 -0.0390 -0.0718 -0.0404 -2.1318 -0.1274 -0.1530 -0.1346 -1.3274 -0.1034 -0.1593 -0.4892 -0.1259 -0.3931 -0.7415 -0.1933 -0.1291 -0.3784 -0.1531
S-394	In dieser Studie stiegen nach 15 Wochen die mittleren Serumwerte von 25-Hydroxyvitamin D bei Patienten mit Vitamin-D-Insuffizienz bei Studienbeginn ( 25-Hydroxyvitamin D 22,5 bis 37,5 nmol<unk> l <unk> 9 - <unk> 15 ng<unk> ml <unk> ) von 30 nmol<unk> l ( 12,1 ng<unk> ml ) auf 40 nmol<unk> l ( 15,9 ng<unk> ml ) in der Gruppe unter ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( n<unk> 75 ) und sanken von 30 nmol<unk> l ( 12,0 ng<unk> ml ) bei Studienbeginn auf 26 nmol<unk> l ( 10,4 ng<unk> ml ) in der Gruppe unter Alendronat allein ( n<unk> 70 ) .
T-394	In this study , mean 25- hydroxyvitamin D levels in patients with vitamin D insufficiency at baseline ( 25- hydroxyvitamin D , 22.5 to 37.5 nmol/ l <<unk>> 9 to <<unk>> 15 ng/ ml <<unk>> ) increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) at week 15 in the ADROVANCE ( 70 mg/ 2800 IU ) group ( n<<unk>> 75 ) and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at baseline to 26 nmol/ l ( 10.4 ng/ ml ) at week 15 in the alendronate-only group ( n<<unk>> 70 ) .
H-394	-0.2227148711681366	In this trial , at 15 weeks , mean serum levels of 25-hydroxyvitamin D in patients with vitamin D deficiency at the start of the trial ( 25-hydroxyvitamin D 22.5 to 37.5 nmol/ l / 9 - <unk> 15 ng/ ml <unk> ) increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( n<unk> 75 ) group and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at the start of the trial to 26 nmol/ l ( 10.4 ng/ ml ) in the alendronate alone group ( n<unk> 70 ) .
D-394	-0.2227148711681366	In this trial , at 15 weeks , mean serum levels of 25-hydroxyvitamin D in patients with vitamin D deficiency at the start of the trial ( 25-hydroxyvitamin D 22.5 to 37.5 nmol/ l / 9 - <unk> 15 ng/ ml <unk> ) increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( n<unk> 75 ) group and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at the start of the trial to 26 nmol/ l ( 10.4 ng/ ml ) in the alendronate alone group ( n<unk> 70 ) .
P-394	-0.5663 -0.1059 -1.2618 -0.3156 -1.0804 -0.2152 -0.1126 -1.4053 -0.1287 -0.1962 -0.1384 -0.9244 -0.2183 -0.7030 -0.1537 -0.0788 -0.1190 -0.1252 -0.1102 -0.1179 -0.1153 -0.1951 -0.7702 -0.2352 -0.5283 -0.0898 -0.1600 -1.9802 -0.0345 -0.1356 -0.2084 -0.1664 -0.6493 -0.2619 -0.1353 -0.7265 -0.1264 -0.5698 -0.0908 -0.0499 -0.0967 -0.1409 -0.0816 -0.1630 -0.1029 -0.0381 -0.1003 -0.6971 -0.1013 -0.0656 -0.1474 -0.2897 -0.1309 -0.1316 -0.6931 -0.1183 -0.7640 -0.1188 -0.1508 -0.1108 -0.1530 -0.1313 -0.0795 -0.1369 -0.1288 -0.5194 -0.1665 -0.1590 -0.1739 -0.2440 -0.1389 -0.1251 -0.1462 -0.1109 -0.1482 -0.1595 -0.1299 -0.1292 -0.0858 -0.1299 -0.1588 -0.0740 -0.1889 -0.2448 -0.1333 -0.1378 -0.1394 -0.0477 -0.1087 -0.1533 -0.1298 -0.1206 -0.0843 -0.1272 -0.1221 -0.1351 -0.0984 -0.0727 -0.1129 -0.1030 -0.1102 -0.1534 -0.1317 -0.1401 -0.1537 -0.1229 -0.1714 -0.1344 -0.1023 -0.0958 -0.1287 -0.1567 -0.1541 -0.8245 -0.0852 -0.1301 -0.2364 -0.5352 -0.3049 -0.1123 -0.1788 -0.1425 -0.1790 -0.2110 -0.1305 -0.1382 -0.1456 -0.1044 -0.1027 -0.1357 -0.1148 -0.1269 -0.0765 -0.1420 -0.1342 -0.1377 -0.4078 -0.1750 -0.1350 -0.3293 -0.1543 -0.2645 -0.1664 -0.2545 -0.1229 -0.1223 -0.1375 -0.1048 -0.1068 -0.1141 -0.1104 -0.1222 -0.0845 -0.1359 -0.1392 -0.1406 -0.7385 -0.1198 -0.0949 -0.0994 -0.4248 -0.4089 -0.1465 -0.1408 -0.2320 -0.0698 -0.1279 -0.1372 -0.1484
S-206	In dieser Studie stiegen nach 15 Wochen die mittleren Serumwerte von 25-Hydroxyvitamin D bei Patienten mit Vitamin-D-Insuffizienz bei Studienbeginn ( 25-Hydroxyvitamin D 22,5 bis 37,5 nmol<unk> l <unk> 9 - <unk> 15 ng<unk> ml <unk> ) von 30 nmol<unk> l ( 12,1 ng<unk> ml ) auf 40 nmol<unk> l ( 15,9 ng<unk> ml ) in der Gruppe unter ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( n<unk> 75 ) und sanken von 30 nmol<unk> l ( 12,0 ng<unk> ml ) bei Studienbeginn auf 26 nmol<unk> l ( 10,4 ng<unk> ml ) in der Gruppe unter Alendronat allein ( n<unk> 70 ) .
T-206	In this study , mean 25-hydroxyvitamin D levels in patients with vitamin D insufficiency at baseline ( 25- hydroxyvitamin D , 22.5 to 37.5 nmol/ l <<unk>> 9 to <<unk>> 15 ng/ ml <<unk>> ) increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) at week 15 in the ADROVANCE ( 70 mg/ 2800 IU ) group ( n<<unk>> 75 ) and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at baseline to 26 nmol/ l ( 10.4 ng/ ml ) at week 15 in the alendronate-only group ( n<<unk>> 70 ) .
H-206	-0.2227148711681366	In this trial , at 15 weeks , mean serum levels of 25-hydroxyvitamin D in patients with vitamin D deficiency at the start of the trial ( 25-hydroxyvitamin D 22.5 to 37.5 nmol/ l / 9 - <unk> 15 ng/ ml <unk> ) increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( n<unk> 75 ) group and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at the start of the trial to 26 nmol/ l ( 10.4 ng/ ml ) in the alendronate alone group ( n<unk> 70 ) .
D-206	-0.2227148711681366	In this trial , at 15 weeks , mean serum levels of 25-hydroxyvitamin D in patients with vitamin D deficiency at the start of the trial ( 25-hydroxyvitamin D 22.5 to 37.5 nmol/ l / 9 - <unk> 15 ng/ ml <unk> ) increased from 30 nmol/ l ( 12.1 ng/ ml ) to 40 nmol/ l ( 15.9 ng/ ml ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( n<unk> 75 ) group and decreased from 30 nmol/ l ( 12.0 ng/ ml ) at the start of the trial to 26 nmol/ l ( 10.4 ng/ ml ) in the alendronate alone group ( n<unk> 70 ) .
P-206	-0.5663 -0.1059 -1.2618 -0.3156 -1.0804 -0.2152 -0.1126 -1.4053 -0.1287 -0.1962 -0.1384 -0.9244 -0.2183 -0.7030 -0.1537 -0.0788 -0.1190 -0.1252 -0.1102 -0.1179 -0.1153 -0.1951 -0.7702 -0.2352 -0.5283 -0.0898 -0.1600 -1.9802 -0.0345 -0.1356 -0.2084 -0.1664 -0.6493 -0.2619 -0.1353 -0.7265 -0.1264 -0.5698 -0.0908 -0.0499 -0.0967 -0.1409 -0.0816 -0.1630 -0.1029 -0.0381 -0.1003 -0.6971 -0.1013 -0.0656 -0.1474 -0.2897 -0.1309 -0.1316 -0.6931 -0.1183 -0.7640 -0.1188 -0.1508 -0.1108 -0.1530 -0.1313 -0.0795 -0.1369 -0.1288 -0.5194 -0.1665 -0.1590 -0.1739 -0.2440 -0.1389 -0.1251 -0.1462 -0.1109 -0.1482 -0.1595 -0.1299 -0.1292 -0.0858 -0.1299 -0.1588 -0.0740 -0.1889 -0.2448 -0.1333 -0.1378 -0.1394 -0.0477 -0.1087 -0.1533 -0.1298 -0.1206 -0.0843 -0.1272 -0.1221 -0.1351 -0.0984 -0.0727 -0.1129 -0.1030 -0.1102 -0.1534 -0.1317 -0.1401 -0.1537 -0.1229 -0.1714 -0.1344 -0.1023 -0.0958 -0.1287 -0.1567 -0.1541 -0.8245 -0.0852 -0.1301 -0.2364 -0.5352 -0.3049 -0.1123 -0.1788 -0.1425 -0.1790 -0.2110 -0.1305 -0.1382 -0.1456 -0.1044 -0.1027 -0.1357 -0.1148 -0.1269 -0.0765 -0.1420 -0.1342 -0.1377 -0.4078 -0.1750 -0.1350 -0.3293 -0.1543 -0.2645 -0.1664 -0.2545 -0.1229 -0.1223 -0.1375 -0.1048 -0.1068 -0.1141 -0.1104 -0.1222 -0.0845 -0.1359 -0.1392 -0.1406 -0.7385 -0.1198 -0.0949 -0.0994 -0.4248 -0.4089 -0.1465 -0.1408 -0.2320 -0.0698 -0.1279 -0.1372 -0.1484
S-354	Uveitis , Skleritis , Episkleritis . Häufig : Bauchschmerzen , Dyspepsie , Verstopfung , Durchfall , Flatulenz , ösophageales Ulkus* , Dysphagie* , aufgetriebenes Abdomen , saures Aufstoßen . Gelegentlich : Übelkeit , Erbrechen , Gastritis , Ösophagitis* , ösophageale Erosionen* , Meläna . Selten : Ösophagusstriktur* , oropharyngeale Ulzerationen* , Perforationen , Ulzera und Blutungen im oberen Gastrointestinaltrakt ( siehe Abschnitt 4.4<unk> . * Siehe Abschnitte 4.2 und 4.4 .
T-354	Rare : uveitis , scleritis , episcleritis Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcer* , dysphagia* , abdominal distension , acid regurgitation Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosions* , melena Rare : oesophageal stricture* , oropharyngeal ulceration* , upper gastrointestinal PUBs ( perforation , ulcers , bleeding<<unk>> <<unk>> see section 4.4 ) . <<unk>> See sections 4.2 and 4.4
H-354	-0.2857204079627991	Uveitis , scleritis , episcleritis . Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcers * , dysphagy* , distended abdomen , acid belching . Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosions* , melena . Rare : oesophagus stricture * , oropharyngeal ulceration* , perforations , ulcers and upper gastrointestinal haemorrhage ( see section 4.4<unk> . * See sections 4.2 and 4.4 .
D-354	-0.2857204079627991	Uveitis , scleritis , episcleritis . Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcers * , dysphagy* , distended abdomen , acid belching . Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosions* , melena . Rare : oesophagus stricture * , oropharyngeal ulceration* , perforations , ulcers and upper gastrointestinal haemorrhage ( see section 4.4<unk> . * See sections 4.2 and 4.4 .
P-354	-0.2401 -0.0627 -0.0569 -0.1507 -0.1887 -2.3886 -0.0665 -0.0715 -0.1456 -0.0531 -0.2089 -0.0643 -0.0971 -0.1646 -0.0219 -0.1262 -0.1441 -0.1183 -0.0158 -0.0868 -0.0822 -0.1449 -0.0415 -0.1164 -0.0783 -0.0724 -0.1416 -0.0918 -0.0599 -0.0658 -0.1290 -0.1434 -0.1340 -0.0359 -0.0502 -0.0644 -0.1433 -0.1672 -0.0672 -0.1589 -0.1417 -0.5839 -0.1027 -0.2452 -0.0474 -0.0655 -0.1645 -0.1422 -2.1086 -2.6549 -0.6671 -0.1439 -0.0393 -0.0235 -0.1233 -1.8682 -0.2355 -0.1436 -3.2934 -0.2838 -0.1280 -0.1806 -0.0591 -0.4855 -0.1406 -0.2888 -2.4135 -0.1399 -0.1581 -0.1350 -0.0726 -0.1417 -0.0339 -0.0400 -0.1430 -0.0536 -0.0583 -0.1054 -0.1398 -0.0767 -0.0564 -0.0783 -0.1441 -0.4383 -0.1679 -0.0801 -0.0780 -0.1087 -0.4462 -0.1994 -0.1494 -0.6300 -0.1116 -0.3026 -0.0410 -0.0587 -0.1590 -0.1586 -0.3605 -1.0058 -0.0808 -0.1418 -0.1580 -3.3822 -0.3309 -0.1246 -0.1121 -0.1542 -0.3258 -0.0971 -0.2799 -0.0646 -0.2148 -0.3357 -0.6241 -0.1507 -0.1472 -0.1573 -0.1072 -0.1718 -0.1792 -0.0841 -0.1501 -0.0744 -0.2472 -1.1311 -0.1736 -0.1517 -0.0333 -0.1351 -0.3831 -0.1465 -0.2036 -0.1365 -0.1158 -0.2518 -0.5213 -0.3699 -0.1417 -0.0932 -0.0561 -0.0242 -1.2726 -0.3336 -0.0179 -0.1353 -0.1439 -0.3705 -0.0716 -0.1400 -1.3650 -0.0598 -0.2301 -0.0575 -0.0723 -0.0540 -0.1256 -0.1596 -0.1307 -0.1200 -0.1253 -0.1562 -0.1588
S-166	Uveitis , Skleritis , Episkleritis . Häufig : Bauchschmerzen , Dyspepsie , Verstopfung , Durchfall , Flatulenz , ösophageales Ulkus* , Dysphagie* , aufgetriebenes Abdomen , saures Aufstoßen . Gelegentlich : Übelkeit , Erbrechen , Gastritis , Ösophagitis* , ösophageale Erosionen* , Meläna . Selten : Ösophagusstriktur* , oropharyngeale Ulzerationen* , Perforationen , Ulzera und Blutungen im oberen Gastrointestinaltrakt ( siehe Abschnitt 4.4<unk> . * Siehe Abschnitte 4.2 und 4.4 .
T-166	Rare : uveitis , scleritis , episcleritis Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcer* , dysphagia* , abdominal distension , acid regurgitation Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosions* , melena Rare : oesophageal stricture* , oropharyngeal ulceration* , upper gastrointestinal PUBs ( perforation , ulcers , bleeding<<unk>> <<unk>> see section 4.4 ) . <<unk>> See sections 4.2 and 4.4
H-166	-0.2857204079627991	Uveitis , scleritis , episcleritis . Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcers * , dysphagy* , distended abdomen , acid belching . Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosions* , melena . Rare : oesophagus stricture * , oropharyngeal ulceration* , perforations , ulcers and upper gastrointestinal haemorrhage ( see section 4.4<unk> . * See sections 4.2 and 4.4 .
D-166	-0.2857204079627991	Uveitis , scleritis , episcleritis . Common : abdominal pain , dyspepsia , constipation , diarrhoea , flatulence , oesophageal ulcers * , dysphagy* , distended abdomen , acid belching . Uncommon : nausea , vomiting , gastritis , oesophagitis* , oesophageal erosions* , melena . Rare : oesophagus stricture * , oropharyngeal ulceration* , perforations , ulcers and upper gastrointestinal haemorrhage ( see section 4.4<unk> . * See sections 4.2 and 4.4 .
P-166	-0.2401 -0.0627 -0.0569 -0.1507 -0.1887 -2.3886 -0.0665 -0.0715 -0.1456 -0.0531 -0.2089 -0.0643 -0.0971 -0.1646 -0.0219 -0.1262 -0.1441 -0.1183 -0.0158 -0.0868 -0.0822 -0.1449 -0.0415 -0.1164 -0.0783 -0.0724 -0.1416 -0.0918 -0.0599 -0.0658 -0.1290 -0.1434 -0.1340 -0.0359 -0.0502 -0.0644 -0.1433 -0.1672 -0.0672 -0.1589 -0.1417 -0.5839 -0.1027 -0.2452 -0.0474 -0.0655 -0.1645 -0.1422 -2.1086 -2.6549 -0.6671 -0.1439 -0.0393 -0.0235 -0.1233 -1.8682 -0.2355 -0.1436 -3.2934 -0.2838 -0.1280 -0.1806 -0.0591 -0.4855 -0.1406 -0.2888 -2.4135 -0.1399 -0.1581 -0.1350 -0.0726 -0.1417 -0.0339 -0.0400 -0.1430 -0.0536 -0.0583 -0.1054 -0.1398 -0.0767 -0.0564 -0.0783 -0.1441 -0.4383 -0.1679 -0.0801 -0.0780 -0.1087 -0.4462 -0.1994 -0.1494 -0.6300 -0.1116 -0.3026 -0.0410 -0.0587 -0.1590 -0.1586 -0.3605 -1.0058 -0.0808 -0.1418 -0.1580 -3.3822 -0.3309 -0.1246 -0.1121 -0.1542 -0.3258 -0.0971 -0.2799 -0.0646 -0.2148 -0.3357 -0.6241 -0.1507 -0.1472 -0.1573 -0.1072 -0.1718 -0.1792 -0.0841 -0.1501 -0.0744 -0.2472 -1.1311 -0.1736 -0.1517 -0.0333 -0.1351 -0.3831 -0.1465 -0.2036 -0.1365 -0.1158 -0.2518 -0.5213 -0.3699 -0.1417 -0.0932 -0.0561 -0.0242 -1.2726 -0.3336 -0.0179 -0.1353 -0.1439 -0.3705 -0.0716 -0.1400 -1.3650 -0.0598 -0.2301 -0.0575 -0.0723 -0.0540 -0.1256 -0.1596 -0.1307 -0.1200 -0.1253 -0.1562 -0.1588
S-69	Es hemmt die Aktivität der Osteoklasten , das sind Zellen , die am Abbau des Knochengewebes beteiligt sind . Indem es die Aktivität dieser Zellen blockiert , verlangsamt Alendronat den Knochenverlust . Vitamin D3 ist ein Nährstoff , der in manchen Lebensmitteln enthalten ist , aber auch bei Bestrahlung mit natürlichem Sonnenlicht in der Haut hergestellt wird . Vitamin D3 wird , genauso wie andere Formen des Vitamins D , für die Calciumaufnahme und die normale Knochenbildung benötigt . Da Patientinnen mit Osteoporose möglicherweise nicht genügend Vitamin D3 durch Sonnenbestrahlung bilden , ist das Vitamin in ADROVANCE enthalten .
T-69	Since patients with osteoporosis may not get enough vitamin D3 through exposure to sunlight , it is included in ADROVANCE .
H-69	-0.3546449542045593	It inhibits the activity of osteoclasts , cells involved in bone tissue breakdown . By blocking the activity of these cells , alendronate slows bone loss . Vitamin D3 is a nutrient found in some foods but also produced in the skin when exposed to natural sunlight . Vitamin D3 , like other forms of vitamin D , is necessary for calcium uptake and normal bone formation . As osteoporosis patients may not produce enough vitamin D3 from exposure to the sun , this vitamin is included in ADROVANCE .
D-69	-0.3546449542045593	It inhibits the activity of osteoclasts , cells involved in bone tissue breakdown . By blocking the activity of these cells , alendronate slows bone loss . Vitamin D3 is a nutrient found in some foods but also produced in the skin when exposed to natural sunlight . Vitamin D3 , like other forms of vitamin D , is necessary for calcium uptake and normal bone formation . As osteoporosis patients may not produce enough vitamin D3 from exposure to the sun , this vitamin is included in ADROVANCE .
P-69	-1.7925 -0.5632 -0.2291 -0.3623 -0.4984 -0.2200 -0.1524 -1.1875 -0.0799 -0.1656 -0.0391 -0.1141 -0.1628 -1.0801 -0.5282 -0.1255 -1.1326 -0.8328 -0.6568 -0.4071 -0.3279 -0.0827 -0.4002 -0.2648 -0.1534 -0.1450 -0.1500 -0.1539 -0.1456 -0.1397 -0.1229 -0.0584 -0.1678 -0.2147 -0.1384 -0.0884 -0.1749 -0.7534 -0.1077 -0.1344 -0.1338 -0.1943 -0.1318 -0.1714 -0.0900 -0.8687 -0.1780 -0.2201 -0.6648 -0.2727 -0.6010 -0.3684 -0.8307 -0.1239 -0.1080 -0.8939 -0.1003 -0.1420 -0.2056 -0.3566 -0.1655 -0.1351 -0.6154 -0.0885 -0.1328 -0.1310 -1.5570 -0.9341 -0.0811 -0.2270 -0.1549 -0.0916 -0.0757 -0.1127 -0.1785 -0.1049 -1.8573 -0.1387 -0.0596 -0.0554 -0.1183 -0.4941 -0.0234 -0.1425 -0.2357 -0.2306 -0.2016 -0.1995 -1.2141 -0.9075 -0.0625 -0.0937 -0.1336 -0.1545 -0.0965 -0.0747 -0.2754 -0.1581 -0.4400 -0.8420 -0.2259 -0.0918 -0.1216 -0.1224 -0.2576 -2.9693 -0.1523 -0.2054 -0.0828 -0.1550 -2.4287 -0.0775 -0.1119 -0.2033 -0.9548 -0.1177 -0.0821 -0.0703 -0.1142 -0.0815 -0.0761 -0.5362 -0.4774
S-1912	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu <unk> EMEA 2007 Reproduction and<unk> or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Aerinaze Tabletten bestehen aus zwei Schichten , von denen eine Desloratadin und die andere Pseudoephedrin enthält . Desloratadin wird sofort nach der Einnahme aus seiner Schicht freigesetzt , während Pseudoephedrin langsam über 12 Stunden hinweg freigesetzt wird . Daher muss die Tablette nur zweimal täglich eingenommen werden .
T-1912	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu <<unk>> EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Desloratadine has been available in the European Union ( EU ) since 2001 , and pseudoephedrine is widely used in medicines that have been available over-the-counter for many years .
H-1912	-0.319344162940979	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail/ emea.europa.eu http/ <unk> <unk> <unk> <unk> <unk> www.emea <unk> EMEA 2007 Reproduction and/ or distribution of this document is authorised for noncommercial purposes only provided the EMEA is recognised Aerinaze tablets consist of two layers , one containing desloratadine and the other pseudoephedrine . Desloratadine is released from its layer immediately after administration , while pseudoephedrine is slowly released for 12 hours . Therefore , the tablet has to be taken only twice daily .
D-1912	-0.319344162940979	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail/ emea.europa.eu http/ <unk> <unk> <unk> <unk> <unk> www.emea <unk> EMEA 2007 Reproduction and/ or distribution of this document is authorised for noncommercial purposes only provided the EMEA is recognised Aerinaze tablets consist of two layers , one containing desloratadine and the other pseudoephedrine . Desloratadine is released from its layer immediately after administration , while pseudoephedrine is slowly released for 12 hours . Therefore , the tablet has to be taken only twice daily .
P-1912	-0.2071 -0.0687 -0.0683 -0.1159 -0.1353 -0.0622 -0.1039 -0.0445 -0.1168 -0.5570 -0.1359 -0.0772 -0.0594 -0.1212 -0.1292 -0.0626 -0.1062 -0.0358 -0.1149 -0.1013 -0.4103 -0.4930 -0.1464 -0.4419 -0.4425 -0.1159 -2.3189 -0.1530 -0.3269 -0.1104 -0.2889 -0.1535 -0.1262 -0.1466 -0.5321 -0.5289 -0.6508 -0.7765 -3.1837 -0.0304 -0.8797 -0.7443 -1.0926 -0.0718 -0.1546 -0.2011 -0.1952 -0.4197 -0.0295 -0.0984 -0.1201 -0.1618 -0.1577 -0.1388 -0.1570 -0.1249 -0.6976 -0.1278 -0.1154 -1.4462 -0.5559 -0.3265 -0.1039 -0.1844 -0.1454 -0.0972 -0.1024 -0.0944 -0.1347 -1.3189 -0.1550 -0.1359 -0.1276 -0.1528 -0.1126 -0.1153 -0.1085 -0.2813 -0.1549 -0.1606 -0.1849 -0.5014 -0.1487 -0.1874 -0.1393 -0.1751 -0.6638 -0.0739 -0.1182 -0.4351 -0.3061 -0.1492 -0.1475 -0.0851 -0.3127 -0.6902 -0.2192 -0.0427 -0.1430 -0.1462 -0.2831 -0.2990 -0.2643 -0.0759 -0.1130 -0.4169 -0.2837 -0.1324 -0.5668 -0.1607 -0.4931 -0.6197 -0.2489 -0.3875 -1.1576 -0.5220 -0.7092 -0.1121 -0.3776 -0.2227 -0.0497 -0.1249 -0.1017 -0.1579 -0.1198 -0.6811 -0.7251 -0.5791 -0.2033 -0.1149 -0.6380 -1.0011 -0.0868 -0.2756 -0.2090 -0.1034 -0.1350 -1.4506 -0.2778 -0.2466 -0.3357 -0.2172 -0.3770 -0.2853 -0.1552 -0.1541
S-532	Aus diesem Grund wurde Advate in einer Hauptstudie an 111 Patienten , die an Hämophilie A leiden , mit Recombinate verglichen , um zu zeigen , dass beide Arzneimittel äquivalent sind . In der Studie wurde bei 107 Patienten , die alle Advate erhielten , zudem die Anzahl der Blutungsepisoden untersucht und die Wirksamkeit von Advate bei der Blutstillung auf einer Skala von unwirksam bis ausgezeichnet bewertet . In drei zusätzlichen Studien an Patienten mit schwerer bis mittelschwerer Hämophilie A , darunter eine Studie mit 53 Kindern unter sechs Jahren , wurde die Anwendung des Arzneimittels zur Vorbeugung von Blutungen sowie bei chirurgischen Eingriffen untersucht .
T-532	Three additional studies looked at the use of the medicine in the prevention of bleeding and in surgery in patients with severe or moderately severe haemophilia A , including one study in 53 children under the age of six years .
H-532	-0.3999521732330322	Therefore , in a main study of 111 patients with haemophilia A , Advate was compared to Recombinate to show that both medicinal products are equivalent . In addition , in 107 patients who received all of Advate , the number of bleeding episodes and the efficacy of Advate in haemostasis was evaluated on a scale from ineffective to excellent . Three additional trials in patients with severe to moderate haemophilia A , including a trial of 53 children under six years of age , investigated the use of the blood prevention and surgery medicinal product .
D-532	-0.3999521732330322	Therefore , in a main study of 111 patients with haemophilia A , Advate was compared to Recombinate to show that both medicinal products are equivalent . In addition , in 107 patients who received all of Advate , the number of bleeding episodes and the efficacy of Advate in haemostasis was evaluated on a scale from ineffective to excellent . Three additional trials in patients with severe to moderate haemophilia A , including a trial of 53 children under six years of age , investigated the use of the blood prevention and surgery medicinal product .
P-532	-0.8907 -0.1007 -0.1468 -0.6415 -0.3507 -0.4721 -0.8431 -1.0580 -0.1320 -0.4054 -1.0126 -0.2357 -0.0624 -0.1297 -0.2184 -0.1292 -0.1337 -0.3518 -0.1097 -0.1495 -0.0995 -0.3739 -0.1064 -0.1048 -0.0676 -0.1071 -0.1739 -0.5616 -0.3006 -0.1601 -0.4543 -0.3848 -0.0810 -0.1640 -0.1077 -0.1957 -1.3834 -0.0732 -0.1532 -0.9470 -0.1905 -0.1190 -0.0968 -0.5141 -0.8660 -0.6575 -0.5494 -1.0099 -0.1600 -0.2833 -0.2064 -0.5720 -0.1484 -1.4861 -0.2194 -0.0095 -0.2914 -1.5647 -2.0368 -0.0492 -0.1125 -0.1817 -0.2550 -0.1040 -0.1565 -1.2531 -0.0912 -0.1980 -0.2580 -1.2408 -1.2953 -0.1405 -0.1476 -0.1380 -0.0515 -0.9729 -0.5831 -0.2698 -0.1384 -0.2447 -0.1605 -1.1193 -0.1535 -0.9683 -0.2069 -0.2020 -0.1350 -0.0997 -0.3257 -0.1958 -0.1530 -0.0987 -0.1024 -0.2360 -0.1144 -0.2094 -0.0808 -0.1771 -0.4730 -0.9464 -0.0966 -0.2901 -0.2539 -0.5617 -0.1238 -0.2337 -0.0972 -0.1496 -0.8384 -0.1759 -0.0915 -0.1490 -0.2362 -3.7169 -0.9451 -0.1825 -0.2402 -0.0997 -1.5244 -0.1012 -0.0650 -0.2770 -0.1498
S-388	Studien mit ADROVANCE Die Wirkung der niedrigeren Dosis von ADROVANCE ( 70 mg Alendronat<unk> 2.800 I.E. Vitamin D3 ) auf den Vitamin-D-Status wurde in einer 15-wöchigen , multinationalen Studie an 682 postmenopausalen Frauen mit Osteoporose gezeigt ( mittlerer Serum-Ausgangswert von 25-Hydroxyvitamin D : 56 nmol<unk> l <unk> 22,3 ng<unk> ml <unk> ; Bereich : 22,5-225 nmol<unk> l <unk> 9-90 ng<unk> ml <unk> ) .
T-388	ADROVANCE studies The effect of the lower dose of ADROVANCE ( alendronate 70 mg/ vitamin D3 2800 IU ) on vitamin D status was demonstrated in a 15-week , multinational study that enrolled 682 osteoporotic post- menopausal women ( serum 25-hydroxyvitamin D at baseline : mean , 56 nmol/ l <<unk>> 22.3 ng/ ml <<unk>> ; range , 22.5-225 nmol/ l <<unk>> 9-90 ng/ ml <<unk>> ) .
H-388	-0.21896915137767792	trials with ADROVANCE The effect of the lower dose of ADROVANCE ( 70 mg alendronate/ 2,800 IU of vitamin D3 ) on vitamin D status was demonstrated in a 15 week , multinational trial in 682 post-menopausal women with osteoporosis ( mean serum baseline of 25 -hydroxyvitamin D : 56 nmol/ l <unk> 22.3 ng/ ml <unk> ; range : 22.5 -225 nmol/ l <unk> 9 -90 ng/ ml <unk> ) .
D-388	-0.21896915137767792	trials with ADROVANCE The effect of the lower dose of ADROVANCE ( 70 mg alendronate/ 2,800 IU of vitamin D3 ) on vitamin D status was demonstrated in a 15 week , multinational trial in 682 post-menopausal women with osteoporosis ( mean serum baseline of 25 -hydroxyvitamin D : 56 nmol/ l <unk> 22.3 ng/ ml <unk> ; range : 22.5 -225 nmol/ l <unk> 9 -90 ng/ ml <unk> ) .
P-388	-1.2412 -0.9012 -0.0886 -0.0721 -0.1262 -0.1142 -0.1315 -0.1404 -0.1999 -0.1924 -0.2512 -0.1145 -0.0349 -0.1457 -0.0478 -0.0661 -0.1168 -0.1069 -0.1349 -0.1400 -0.1389 -0.0305 -0.2456 -0.1153 -0.1067 -0.1312 -1.2826 -0.4888 -0.1993 -0.0899 -0.0894 -0.1253 -0.4177 -0.1606 -0.1086 -0.1142 -0.1326 -0.1324 -0.1681 -0.2291 -0.1215 -0.2035 -0.0315 -0.2054 -0.1302 -0.1224 -0.1248 -0.6757 -0.8784 -0.2546 -0.1173 -0.0942 -0.1376 -0.4781 -0.2073 -0.1285 -0.0750 -0.0928 -0.2964 -0.0459 -0.1223 -0.0278 -0.1286 -0.1160 -0.1376 -0.1285 -0.0713 -0.1111 -0.1404 -0.1331 -0.1242 -0.1279 -0.2003 -0.5337 -0.1561 -0.1665 -0.0386 -0.1617 -0.5384 -1.8658 -0.0538 -0.1189 -0.1301 -0.0946 -0.1303 -0.0929 -0.1669 -0.0896 -0.1357 -0.2629 -0.1270 -0.1978 -0.7339 -0.0522 -0.1165 -0.1178 -0.1648 -0.1148 -0.0782 -0.3160 -0.1147 -0.1895 -0.7696 -0.0796 -0.5745 -0.5355 -0.1170 -0.1128 -0.1432 -0.1725 -0.1224 -0.1276 -0.0282 -1.0305 -0.4188 -0.0940 -0.1471 -0.1243 -0.1165 -0.0722 -0.0289 -0.1216 -0.1436 -0.1483
S-296	Aufgrund der möglichen Verschlechterung der zugrunde liegenden Erkrankung sollte Alendronat bei Patienten mit aktiven gastrointestinalen Erkrankungen , wie Dysphagie , Erkrankungen des Ösophagus , Gastritis , Duodenitis , Ulzera , oder mit kürzlich aufgetretenen ( innerhalb des letzten Jahres ) , schweren gastrointestinalen Erkrankungen , wie z. B. peptisches Ulkus , aktive gastrointestinale Blutungen oder chirurgische Eingriffe im oberen Gastrointestinaltrakt außer Pyloroplastik , nur unter besonderer Vorsicht gegeben werden ( siehe Abschnitt 4.3 ) .
T-296	Because there is a potential for worsening of the underlying disease , caution should be used when alendronate is given to patients with active upper gastrointestinal problems , such as dysphagia , oesophageal disease , gastritis , duodenitis , ulcers , or with a recent history ( within the previous year ) of major gastrointestinal disease such as peptic ulcer , or active gastrointestinal bleeding , or surgery of the upper gastrointestinal tract other than pyloroplasty ( see section 4.3 ) .
H-296	-0.2742711007595062	Due to the possible worsening of the underlying condition , special care should be taken with alendronate in patients with active gastro-intestinal disorders , such as dysphagia , esophagus disorders , gastritis , duodenitis , ulcers , or with recent ( within the last year ) severe gastro-intestinal disorders , such as peptic ulcer , active gastro-intestinal haemorrhage or upper gastro-intestinal surgery except for pyloroplasty ( see section 4.3 ) .
D-296	-0.2742711007595062	Due to the possible worsening of the underlying condition , special care should be taken with alendronate in patients with active gastro-intestinal disorders , such as dysphagia , esophagus disorders , gastritis , duodenitis , ulcers , or with recent ( within the last year ) severe gastro-intestinal disorders , such as peptic ulcer , active gastro-intestinal haemorrhage or upper gastro-intestinal surgery except for pyloroplasty ( see section 4.3 ) .
P-296	-0.1915 -0.0770 -0.1364 -0.6238 -1.4501 -0.2907 -0.0468 -0.1563 -0.1462 -0.9557 -0.0704 -0.8068 -0.1629 -1.2197 -0.6716 -0.1679 -0.2173 -1.8343 -0.1301 -0.3473 -0.1517 -0.0987 -0.0451 -0.3218 -0.2062 -0.1759 -0.0482 -0.0311 -0.0896 -0.9254 -0.0400 -0.0870 -0.0592 -0.4642 -0.0958 -1.3915 -0.1217 -0.1582 -0.0548 -0.0360 -0.1390 -0.1040 -0.1435 -1.2192 -0.3586 -0.0870 -0.1988 -0.2379 -0.1038 -0.1418 -0.2134 -0.0946 -0.0527 -0.1494 -0.0621 -0.1380 -0.1130 -0.1052 -0.0584 -0.1452 -0.1772 -0.7052 -0.1865 -0.1481 -0.2189 -0.2638 -0.1095 -0.2024 -0.2743 -0.2619 -1.1958 -0.1087 -0.1349 -1.1409 -0.0535 -0.0984 -0.2348 -0.0388 -0.0741 -0.0448 -0.3472 -0.0822 -0.2368 -0.1675 -0.1552 -0.3018 -0.0819 -0.1124 -0.1191 -0.3800 -0.1581 -0.0768 -0.1042 -0.1097 -0.3950 -0.0640 -0.0594 -0.0480 -1.2836 -0.1186 -0.0151 -0.3810 -0.2946 -0.3678 -0.2794 -0.0839 -0.2969 -0.1929 -0.0567 -0.0403 -0.4492 -0.8959 -0.2837 -0.0853 -0.0862 -0.1017 -0.1953 -0.5311 -0.2091 -0.3321 -0.0895 -0.1161 -0.1166 -0.1319 -0.5316 -0.1495
S-108	Aufgrund der möglichen Verschlechterung der zugrunde liegenden Erkrankung sollte Alendronat bei Patienten mit aktiven gastrointestinalen Erkrankungen , wie Dysphagie , Erkrankungen des Ösophagus , Gastritis , Duodenitis , Ulzera , oder mit kürzlich aufgetretenen ( innerhalb des letzten Jahres ) , schweren gastrointestinalen Erkrankungen , wie z. B. peptisches Ulkus , aktive gastrointestinale Blutungen oder chirurgische Eingriffe im oberen Gastrointestinaltrakt außer Pyloroplastik , nur unter besonderer Vorsicht gegeben werden ( siehe Abschnitt 4.3 ) .
T-108	Because there is a potential for worsening of the underlying disease , caution should be used when alendronate is given to patients with active upper gastrointestinal problems , such as dysphagia , oesophageal disease , gastritis , duodenitis , ulcers , or with a recent history ( within the previous year ) of major gastrointestinal disease such as peptic ulcer , or active gastrointestinal bleeding , or surgery of the upper gastrointestinal tract other than pyloroplasty ( see section 4.3 ) .
H-108	-0.2742711007595062	Due to the possible worsening of the underlying condition , special care should be taken with alendronate in patients with active gastro-intestinal disorders , such as dysphagia , esophagus disorders , gastritis , duodenitis , ulcers , or with recent ( within the last year ) severe gastro-intestinal disorders , such as peptic ulcer , active gastro-intestinal haemorrhage or upper gastro-intestinal surgery except for pyloroplasty ( see section 4.3 ) .
D-108	-0.2742711007595062	Due to the possible worsening of the underlying condition , special care should be taken with alendronate in patients with active gastro-intestinal disorders , such as dysphagia , esophagus disorders , gastritis , duodenitis , ulcers , or with recent ( within the last year ) severe gastro-intestinal disorders , such as peptic ulcer , active gastro-intestinal haemorrhage or upper gastro-intestinal surgery except for pyloroplasty ( see section 4.3 ) .
P-108	-0.1915 -0.0770 -0.1364 -0.6238 -1.4501 -0.2907 -0.0468 -0.1563 -0.1462 -0.9557 -0.0704 -0.8068 -0.1629 -1.2197 -0.6716 -0.1679 -0.2173 -1.8343 -0.1301 -0.3473 -0.1517 -0.0987 -0.0451 -0.3218 -0.2062 -0.1759 -0.0482 -0.0311 -0.0896 -0.9254 -0.0400 -0.0870 -0.0592 -0.4642 -0.0958 -1.3915 -0.1217 -0.1582 -0.0548 -0.0360 -0.1390 -0.1040 -0.1435 -1.2192 -0.3586 -0.0870 -0.1988 -0.2379 -0.1038 -0.1418 -0.2134 -0.0946 -0.0527 -0.1494 -0.0621 -0.1380 -0.1130 -0.1052 -0.0584 -0.1452 -0.1772 -0.7052 -0.1865 -0.1481 -0.2189 -0.2638 -0.1095 -0.2024 -0.2743 -0.2619 -1.1958 -0.1087 -0.1349 -1.1409 -0.0535 -0.0984 -0.2348 -0.0388 -0.0741 -0.0448 -0.3472 -0.0822 -0.2368 -0.1675 -0.1552 -0.3018 -0.0819 -0.1124 -0.1191 -0.3800 -0.1581 -0.0768 -0.1042 -0.1097 -0.3950 -0.0640 -0.0594 -0.0480 -1.2836 -0.1186 -0.0151 -0.3810 -0.2946 -0.3678 -0.2794 -0.0839 -0.2969 -0.1929 -0.0567 -0.0403 -0.4492 -0.8959 -0.2837 -0.0853 -0.0862 -0.1017 -0.1953 -0.5311 -0.2091 -0.3321 -0.0895 -0.1161 -0.1166 -0.1319 -0.5316 -0.1495
S-67	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<unk> emea.europa.eu http<unk> <unk> <unk> www.emea.europa.eu <unk> EMEA 2007 Reproduction and<unk> or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Menopause ) auf , wenn der Spiegel des weiblichen Hormons Östrogen sinkt , denn das Hormon Östrogen unterstützt die Knochengesundheit . Die arzneilich wirksamen Bestandteile in ADROVANCE sind Alendronat und Vitamin D3 .
T-67	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail<<unk>> emea . europa . eu http : / <<unk>> www . emea . europa . eu <<unk>> EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged Vitamin D3 is a nutrient that is found in some foods , but is also made in the skin through exposure to natural sunlight .
H-67	-0.3500111401081085	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail/ emea.europa.eu http/ <unk> <unk> <unk> www.emea <unk> EMEA 2007 Reproduction and/ or distribution of this document is authorised for noncommercial purposes only provided the EMEA is recognised menopause ) when levels of the female hormone oestrogen fall because the hormone oestrogen supports bone health .
D-67	-0.3500111401081085	( 44-20 ) 74 18 84 00 Fax ( 44-20 ) 74 18 84 16 E-mail : mail/ emea.europa.eu http/ <unk> <unk> <unk> www.emea <unk> EMEA 2007 Reproduction and/ or distribution of this document is authorised for noncommercial purposes only provided the EMEA is recognised menopause ) when levels of the female hormone oestrogen fall because the hormone oestrogen supports bone health .
P-67	-0.2420 -0.0672 -0.0762 -0.1197 -0.1348 -0.0635 -0.1091 -0.0465 -0.1178 -0.5357 -0.1370 -0.0770 -0.0625 -0.1232 -0.1307 -0.0614 -0.1094 -0.0371 -0.1192 -0.1069 -0.4882 -0.5503 -0.1445 -0.5139 -0.3796 -0.1448 -3.2246 -0.1756 -0.3307 -0.1034 -0.3153 -0.1591 -0.1181 -0.2652 -0.7521 -0.7382 -2.7100 -0.0363 -0.7520 -1.0840 -0.4015 -0.0766 -0.1066 -0.1724 -0.1581 -0.3424 -0.0821 -0.1236 -0.1217 -0.1411 -0.1573 -0.1300 -0.1639 -0.1388 -0.7427 -0.1295 -0.1113 -1.3960 -0.7909 -0.4134 -0.1133 -0.1742 -0.1439 -0.0959 -0.1556 -0.0966 -0.1108 -1.5690 -0.3593 -0.1265 -0.0587 -0.1287 -0.1981 -0.1956 -0.1443 -0.1356 -0.0955 -0.1191 -0.0658 -0.6320 -0.1728 -0.0712 -0.0436 -1.0267 -0.7536 -0.7261 -0.1164 -0.0649 -0.1456 -0.1459 -0.0734 -0.0471 -0.8967 -0.0722 -1.5101 -0.1893 -1.8144
S-200	Studien mit ADROVANCE Die Wirkung von ADROVANCE ( 70 mg Alendronat<unk> 2.800 I.E. Vitamin D3 ) auf den Vitamin-D- Status wurde in einer 15-wöchigen , multinationalen Studie an 682 postmenopausalen Frauen mit Osteoporose gezeigt ( mittlerer Serum-Ausgangswert von 25-Hydroxyvitamin D : 56 nmol<unk> l <unk> 22,3 ng<unk> ml <unk> ; Bereich : 22,5-225 nmol<unk> l <unk> 9-90 ng<unk> ml <unk> ) .
T-200	ADROVANCE studies The effect of ADROVANCE ( alendronate 70 mg/ vitamin D3 2800 IU ) on vitamin D status was demonstrated in a 15-week , multinational study that enrolled 682 osteoporotic post-menopausal women ( serum 25-hydroxyvitamin D at baseline : mean , 56 nmol/ l <<unk>> 22.3 ng/ ml <<unk>> ; range , 22.5- 225 nmol/ l <<unk>> 9-90 ng/ ml <<unk>> ) .
H-200	-0.27239760756492615	trials with ADROVANCE ADROVANCE ( 70 mg alendronat/ 2,800 IU of vitamin D3 ) effect on vitamin D status was demonstrated in a 15 week , multinational trial in 682 post-menopausal women with osteoporosis ( mean serum baseline of 25-hydroxyvitamin D : 56 nmol/ l / 22.3 ng/ ml <unk> ; range : 22.5 -225 nmol/ l <unk> 9-90 ng/ ml <unk> ) .
D-200	-0.27239760756492615	trials with ADROVANCE ADROVANCE ( 70 mg alendronat/ 2,800 IU of vitamin D3 ) effect on vitamin D status was demonstrated in a 15 week , multinational trial in 682 post-menopausal women with osteoporosis ( mean serum baseline of 25-hydroxyvitamin D : 56 nmol/ l / 22.3 ng/ ml <unk> ; range : 22.5 -225 nmol/ l <unk> 9-90 ng/ ml <unk> ) .
P-200	-1.4416 -0.7333 -0.0842 -0.0707 -0.1266 -0.1110 -0.1230 -0.4838 -0.0638 -0.1166 -0.1097 -0.1234 -0.1557 -0.1314 -0.0302 -0.1638 -0.0990 -0.1150 -0.1336 -0.9206 -1.0412 -0.1831 -0.0830 -0.0884 -0.1285 -0.7979 -0.1560 -0.1266 -0.1210 -0.1297 -0.1369 -3.7606 -0.1238 -0.2500 -0.1345 -0.1432 -0.0345 -0.2218 -0.1211 -0.1213 -0.1253 -0.6218 -0.9661 -0.3353 -0.1044 -0.0823 -0.1512 -0.4420 -0.2233 -0.1261 -0.0795 -0.0983 -0.2743 -0.0381 -0.1165 -0.0317 -0.1352 -0.1101 -0.1340 -0.1214 -0.0736 -0.1171 -0.1440 -0.1376 -0.1158 -0.1274 -0.2029 -0.6690 -0.1560 -0.1952 -0.0342 -0.2058 -1.4955 -0.1474 -0.0463 -0.1090 -0.1273 -0.0888 -0.1318 -0.0920 -0.1631 -0.0980 -0.1302 -0.3650 -0.1269 -0.2125 -1.5463 -0.0784 -0.1287 -0.1092 -0.1606 -0.1060 -0.0684 -0.8072 -0.1019 -0.1717 -0.5133 -0.0956 -0.7990 -1.0678 -0.1123 -0.1135 -0.1437 -0.1957 -0.1249 -0.1485 -0.1419 -1.2843 -0.0712 -0.0833 -0.1269 -0.1239 -0.1139 -0.0651 -0.0475 -0.1230 -0.1503 -0.1491
S-77	Die häufigsten Nebenwirkungen ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Kopfschmerzen , Schmerzen des Bewegungsapparats ( Muskeln , Knochen oder Gelenke ) und Symptome des Verdauungsapparats wie Bauchschmerzen , Dyspepsie ( Verdauungsstörungen ) , Verstopfung , Diarrhoe ( Durchfall ) , Flatulenz ( Blähungen ) , Geschwüre ( Ulcera ) der Speiseröhre , Dysphagie ( Schluckbeschwerden ) , aufgetriebenes Abdomen ( geblähter Bauch ) sowie saures Aufstoßen .
T-77	The most common side effects ( seen in between 1 and 10 patients in 100 ) are headache , musculoskeletal ( bone , muscle or joint ) pain and gastro-intestinal symptoms such as abdominal ( tummy ) pain , dyspepsia ( indigestion ) , constipation , diarrhoea , flatulence ( wind ) , oesophageal ( gullet ) ulcers , dysphagia ( difficulty swallowing ) , abdominal distension ( swollen tummy ) and acid regurgitation .
H-77	-0.2578139305114746	The most frequent adverse reactions ( observed in 1 to 10 in 100 patients ) are headache , musculoskeletal pain ( muscles , bones or joints ) and digestive system symptoms such as abdominal pain , dyspepsia ( indigestion ) , constipation , diarrhoea ( diarrhoea ) , flatulence ( flatulence ) , ulcers ( oesophagus ) , dysphagia ( difficulty swallowing ) , bloated abdomen ( bloated abdomen ) and acid belching .
D-77	-0.2578139305114746	The most frequent adverse reactions ( observed in 1 to 10 in 100 patients ) are headache , musculoskeletal pain ( muscles , bones or joints ) and digestive system symptoms such as abdominal pain , dyspepsia ( indigestion ) , constipation , diarrhoea ( diarrhoea ) , flatulence ( flatulence ) , ulcers ( oesophagus ) , dysphagia ( difficulty swallowing ) , bloated abdomen ( bloated abdomen ) and acid belching .
P-77	-0.1956 -0.1416 -1.1584 -0.2344 -0.0489 -0.1404 -0.0401 -0.1393 -0.1935 -0.1462 -0.1655 -0.1400 -0.1399 -2.1519 -0.2353 -0.0918 -0.1366 -0.2142 -0.2112 -0.0338 -0.1230 -0.1566 -0.5328 -0.2189 -0.0848 -0.2084 -0.1914 -0.1274 -0.1651 -0.1295 -0.2586 -0.1531 -0.7469 -0.1675 -0.0570 -0.0336 -0.1272 -0.3600 -0.3259 -0.1476 -0.0465 -1.4712 -0.0906 -0.3036 -0.1759 -0.1292 -0.0310 -0.0590 -0.0946 -0.1414 -0.0521 -0.1303 -0.1047 -0.0976 -0.1641 -0.8522 -0.0719 -0.1818 -0.1324 -0.1451 -0.0945 -0.0771 -0.0590 -0.1404 -0.1531 -0.1215 -0.0765 -0.1121 -0.0613 -0.1840 -0.1972 -0.1866 -0.0530 -0.0454 -0.1374 -0.1443 -0.0596 -0.0218 -0.1391 -0.1599 -0.0538 -0.0327 -0.1061 -0.1472 -0.1443 -0.0770 -0.7667 -0.1498 -0.1380 -0.5225 -0.0470 -1.0075 -0.0361 -0.1354 -0.2470 -0.1440 -0.0319 -0.0333 -0.1437 -0.1113 -0.1398 -1.0992 -0.0560 -0.0796 -0.1664 -0.1485 -2.5239 -0.0722 -0.1275 -0.0682 -0.3120 -0.1520 -1.4183 -0.0908 -0.3830 -0.0396 -0.2934 -0.1256 -0.3454 -0.2448 -2.4197 -0.3235 -0.1421 -0.1493
S-1926	Aerinaze darf auch nicht bei Patienten angewendet werden , die an einem Engwinkelglaukom ( erhöhtem Augeninnendruck ) , Harnverhaltung ( erschwertem Wasserlassen ) , Herz- oder Gefäßerkrankungen einschließlich Hypertonie ( Bluthochdruck ) , Hyperthyreose ( Überfunktion der Schilddrüse ) leiden oder bereits einen hämorrhagischen Schlaganfall ( durch eine Gehirnblutung verursachten Schlaganfall ) hatten oder ein Risiko für einen hämorrhagischen Schlaganfall haben .
T-1926	Aerinaze should also not be taken by people who have narrow- angle glaucoma ( increased pressure inside the eye ) , urinary retention ( difficulty in passing urine ) , heart or blood vessel diseases including hypertension ( high blood pressure ) , hyperthyroidism ( an overactive thyroid gland ) , or a history or risk of haemorrhagic stroke ( stroke caused by bleeding within the brain ) .
H-1926	-0.34750258922576904	Nor should Aerinaze be used in patients with narrow angle glaucoma ( increased intraocular pressure ) , urinary retention ( difficult urination ) , cardiovascular disorders including hypertension ( hypertension ) , hyperthyroidism ( thyroid hypersecretion ) , or who have had a haemorrhagic stroke ( stroke caused by cerebral haemorrhage ) or are at risk of a haemorrhagic stroke .
D-1926	-0.34750258922576904	Nor should Aerinaze be used in patients with narrow angle glaucoma ( increased intraocular pressure ) , urinary retention ( difficult urination ) , cardiovascular disorders including hypertension ( hypertension ) , hyperthyroidism ( thyroid hypersecretion ) , or who have had a haemorrhagic stroke ( stroke caused by cerebral haemorrhage ) or are at risk of a haemorrhagic stroke .
P-1926	-0.7531 -0.7764 -0.2377 -0.1435 -0.1191 -0.1844 -0.1149 -0.1706 -0.1774 -0.2763 -0.4430 -1.3057 -1.2674 -1.6918 -1.3018 -0.2348 -0.1330 -0.1343 -0.3919 -0.2733 -0.2095 -0.7603 -0.2259 -0.1016 -0.1383 -0.1475 -0.4226 -1.0201 -0.0791 -0.1305 -0.1371 -1.5581 -0.0998 -0.0704 -0.1425 -0.1501 -0.2129 -0.1296 -0.0876 -0.0773 -0.8201 -0.0836 -0.1715 -0.0154 -0.0294 -0.1548 -0.9294 -0.2306 -0.1340 -0.1495 -0.0447 -0.1427 -0.1212 -0.2400 -0.5648 -0.0663 -0.0957 -0.1395 -1.2050 -0.0835 -0.0593 -0.1143 -0.1015 -2.4923 -0.1147 -0.1274 -0.2246 -0.2188 -1.2387 -0.1610 -0.1342 -0.1543 -0.7892 -0.8791 -0.0987 -0.2355 -0.0887 -0.0673 -0.1232 -0.2302 -0.8795 -0.1484 -0.2671 -0.0612 -0.0503 -0.1518 -0.1857 -0.0459 -0.6411 -0.1310 -0.2084 -0.5795 -0.0241 -0.0589 -0.3636 -0.8122 -0.4467 -0.9509 -0.0864 -0.3834 -0.1285 -0.0639 -0.2046 -0.1607
S-1922	Die häufigsten Nebenwirkungen von Aerinaze ( beobachtet bei 1 bis 10 von 100 Patienten ) sind Tachykardie ( Herzjagen ) , Mundtrockenheit , Schwindel , psychomotorische Hyperaktivität ( Ruhelosigkeit ) , Pharyngitis ( Rachenentzündung ) , Anorexie ( Appetitlosigkeit ) , Verstopfung , Kopfschmerzen , Müdigkeit , Insomnie ( Schlaflosigkeit ) , Somnolenz ( Schläfrigkeit ) , Schlafstörungen und Nervosität .
T-1922	The most common side effects with Aerinaze ( seen in between 1 and 10 patients in 100 ) are tachycardia ( fast heart rate ) , dry mouth , dizziness , psychomotor hyperactivity ( restlessness ) , pharyngitis ( sore throat ) , anorexia ( loss of appetite ) , constipation , headache , fatigue ( tiredness ) , insomnia ( difficulty sleeping ) , somnolence ( sleepiness ) , sleep disorders and nervousness .
H-1922	-0.239792138338089	The most frequent adverse reactions with Aerinaze ( observed in 1 to 10 in 100 patients ) are tachycardia ( racing ) , dry mouth , dizziness , psychomotor hyperactivity ( restlessness ) , pharyngitis ( pharyngitis ) , anorexia ( anorexia ) , constipation , headache , tiredness , insomnia , somnolence ( somnolence ) , trouble sleeping and nervousness .
D-1922	-0.239792138338089	The most frequent adverse reactions with Aerinaze ( observed in 1 to 10 in 100 patients ) are tachycardia ( racing ) , dry mouth , dizziness , psychomotor hyperactivity ( restlessness ) , pharyngitis ( pharyngitis ) , anorexia ( anorexia ) , constipation , headache , tiredness , insomnia , somnolence ( somnolence ) , trouble sleeping and nervousness .
P-1922	-0.2354 -0.1689 -1.2071 -0.4321 -0.0620 -0.0947 -0.0402 -1.3949 -0.1559 -0.1327 -0.1190 -0.1637 -0.1139 -0.1439 -0.2001 -0.1415 -0.1539 -0.1322 -0.1439 -2.2301 -0.1935 -0.0956 -0.1367 -0.2017 -0.0417 -0.0809 -0.1467 -0.1032 -0.0305 -0.1440 -3.5049 -0.4828 -0.1618 -0.1979 -0.0515 -0.1507 -0.2065 -0.0446 -0.0640 -0.1418 -0.2441 -0.0975 -0.2394 -0.4766 -0.0413 -0.1168 -0.1304 -0.0524 -0.0512 -0.1026 -0.1265 -0.1468 -0.4358 -0.0551 -0.0882 -0.1386 -0.0712 -0.4077 -0.1552 -0.0436 -0.0362 -1.8731 -0.3460 -0.1287 -0.1463 -0.1214 -0.1176 -0.0874 -0.0803 -0.1445 -1.5209 -0.0623 -0.0403 -0.0557 -0.1272 -0.1463 -0.0923 -0.0651 -0.0829 -0.1267 -0.1404 -0.1389 -0.0210 -0.1299 -0.1434 -0.0989 -0.0469 -0.0760 -0.1520 -0.2106 -0.0543 -0.0545 -0.6413 -0.0692 -0.0968 -0.0330 -0.1158 -0.1749 -0.0516 -0.0513 -0.0512 -0.0826 -0.1258 -0.1456 -0.8866 -0.0215 -0.1417 -0.0249 -0.0703 -0.1453 -0.1513
S-420	In dieser Studie wurde in der Analyse der Subgruppe mit osteoporotischen Frauen ( 37 % der Gesamtzahl , die nach der o. g. Definition an Osteoporose litten ) ein signifikanter Unterschied in der Inzidenz von Hüftfrakturen ( Alendronat 1,0 % gegenüber Plazebo 2,2 % ; Reduktion um 56 % ) und in der Inzidenz von mindestens einer Wirbelfraktur ( 2,9 % gegenüber 5,8 % ; Reduktion um 50 % ) beobachtet .
T-420	In dieser Studie wurde in der Analyse der Subgruppe mit osteoporotischen Frauen ( 37 % der Gesamtzahl , die nach der o. g. Definition an Osteoporose litten ) ein signifikanter Unterschied in der Inzidenz von Hüftfrakturen ( Alendronat 1,0 % gegenüber Plazebo 2,2 % ; Reduktion um 56 % ) und in der Inzidenz von mindestens einer Wirbelfraktur ( 2,9 % gegenüber 5,8 % ; Reduktion um 50 % ) beobachtet . 5.8 % , a reduction of 50 % ) .
H-420	-0.27497145533561707	In this study , a significant difference in the incidence of hip fractures ( alendronate 1.0 % vs. placebo 2.2 % ; reduction of 56 % ) and in the incidence of at least one vertebral fracture ( 2.9 % vs. 5.8 % ; reduction of 50 % ) was observed in analysis of the subgroup of osteoporotic women ( 37 % of the total number who suffered from osteoporosis according to the above definition ) .
D-420	-0.27497145533561707	In this study , a significant difference in the incidence of hip fractures ( alendronate 1.0 % vs. placebo 2.2 % ; reduction of 56 % ) and in the incidence of at least one vertebral fracture ( 2.9 % vs. 5.8 % ; reduction of 50 % ) was observed in analysis of the subgroup of osteoporotic women ( 37 % of the total number who suffered from osteoporosis according to the above definition ) .
P-420	-0.2682 -0.1439 -0.1840 -0.1596 -3.1263 -0.1612 -0.1549 -0.1725 -0.4158 -0.0883 -0.0625 -0.1509 -0.0603 -0.6599 -0.0916 -0.1340 -0.2148 -0.1290 -0.1351 -0.0569 -0.1451 -0.1106 -0.1045 -0.9930 -0.0537 -0.1593 -0.1669 -0.1262 -0.2060 -0.1404 -0.1070 -0.1385 -0.1559 -1.5585 -0.0882 -0.1246 -0.1428 -0.1674 -1.1020 -0.1334 -0.0521 -0.0697 -0.1491 -0.2006 -0.1249 -0.1782 -0.0822 -0.0685 -0.0420 -0.1553 -0.0626 -0.0962 -0.1363 -0.1153 -0.1253 -0.1183 -0.1472 -0.1000 -0.1144 -0.1285 -0.1343 -0.1209 -0.2218 -0.1160 -0.1221 -0.1412 -0.1873 -0.3857 -0.1408 -2.0293 -0.1960 -0.2270 -0.1646 -0.4251 -0.5511 -0.0973 -0.0707 -0.1177 -0.1492 -1.2543 -0.1372 -0.1368 -0.1202 -0.1151 -0.1974 -0.1940 -0.1110 -0.1779 -0.5565 -1.3936 -0.1911 -0.1040 -0.0736 -0.1272 -0.1308 -0.1104 -0.0816 -0.8817 -0.1396 -0.1407 -0.4475 -0.4112 -0.9850 -0.1485 -0.1468
S-224	In dieser Studie wurde in der Analyse der Subgruppe mit osteoporotischen Frauen ( 37 % der Gesamtzahl , die nach der o. g. Definition an Osteoporose litten ) ein signifikanter Unterschied in der Inzidenz von Hüftfrakturen ( Alendronat 1,0 % gegenüber Plazebo 2,2 % ; Reduktion um 56 % ) und in der Inzidenz von mindestens einer Wirbelfraktur ( 2,9 % gegenüber 5,8 % ; Reduktion um 50 % ) beobachtet .
T-224	In dieser Studie wurde in der Analyse der Subgruppe mit osteoporotischen Frauen ( 37 % der Gesamtzahl , die nach der o. g. Definition an Osteoporose litten ) ein signifikanter Unterschied in der Inzidenz von Hüftfrakturen ( Alendronat 1,0 % gegenüber Plazebo 2,2 % ; Reduktion um 56 % ) und in der Inzidenz von mindestens einer Wirbelfraktur ( 2,9 % gegenüber 5,8 % ; Reduktion um 50 % ) beobachtet . 5.8 % , a reduction of 50 % ) .
H-224	-0.27497145533561707	In this study , a significant difference in the incidence of hip fractures ( alendronate 1.0 % vs. placebo 2.2 % ; reduction of 56 % ) and in the incidence of at least one vertebral fracture ( 2.9 % vs. 5.8 % ; reduction of 50 % ) was observed in analysis of the subgroup of osteoporotic women ( 37 % of the total number who suffered from osteoporosis according to the above definition ) .
D-224	-0.27497145533561707	In this study , a significant difference in the incidence of hip fractures ( alendronate 1.0 % vs. placebo 2.2 % ; reduction of 56 % ) and in the incidence of at least one vertebral fracture ( 2.9 % vs. 5.8 % ; reduction of 50 % ) was observed in analysis of the subgroup of osteoporotic women ( 37 % of the total number who suffered from osteoporosis according to the above definition ) .
P-224	-0.2682 -0.1439 -0.1840 -0.1596 -3.1263 -0.1612 -0.1549 -0.1725 -0.4158 -0.0883 -0.0625 -0.1509 -0.0603 -0.6599 -0.0916 -0.1340 -0.2148 -0.1290 -0.1351 -0.0569 -0.1451 -0.1106 -0.1045 -0.9930 -0.0537 -0.1593 -0.1669 -0.1262 -0.2060 -0.1404 -0.1070 -0.1385 -0.1559 -1.5585 -0.0882 -0.1246 -0.1428 -0.1674 -1.1020 -0.1334 -0.0521 -0.0697 -0.1491 -0.2006 -0.1249 -0.1782 -0.0822 -0.0685 -0.0420 -0.1553 -0.0626 -0.0962 -0.1363 -0.1153 -0.1253 -0.1183 -0.1472 -0.1000 -0.1144 -0.1285 -0.1343 -0.1209 -0.2218 -0.1160 -0.1221 -0.1412 -0.1873 -0.3857 -0.1408 -2.0293 -0.1960 -0.2270 -0.1646 -0.4251 -0.5511 -0.0973 -0.0707 -0.1177 -0.1492 -1.2543 -0.1372 -0.1368 -0.1202 -0.1151 -0.1974 -0.1940 -0.1110 -0.1779 -0.5565 -1.3936 -0.1911 -0.1040 -0.0736 -0.1272 -0.1308 -0.1104 -0.0816 -0.8817 -0.1396 -0.1407 -0.4475 -0.4112 -0.9850 -0.1485 -0.1468
S-265	Mikrokristalline Cellulose ( E 460 ) Lactose Mittelkettige Triglyceride Gelatine Croscarmellose-Natrium Sucrose Hochdisperses Siliciumdioxid Magnesiumstearat ( Ph.Eur. ) ( E 572 ) Butylhydroxytoluol ( Ph.Eur. ) ( E 321 ) Stärke , modifiziert ( Mais ) Aluminiumnatriumsilicat ( E 554 )
T-265	Microcrystalline cellulose ( E460 ) Lactose anhydrous Medium chain triglycerides Gelatin Croscarmellose sodium Sucrose Colloidal silicon dioxide Magnesium stearate ( E572 ) Butyl hydroxytoluene ( E321 ) Modified starch ( maize ) Sodium aluminium silicate ( E554 )
H-265	-0.2293989658355713	Microcrystalline cellulose ( E 460 ) Lactose Medium chain triglycerides Gelatine Croscarmellose sodium Sucrose High dispersible silicon dioxide Magnesium stearate ( Ph.Eur. ) ( E572 ) Butylated hydroxytoluene ( Ph.Eur. ) ( E321 ) Starch modified ( maize ) Aluminium sodium silicate ( E554 )
D-265	-0.2293989658355713	Microcrystalline cellulose ( E 460 ) Lactose Medium chain triglycerides Gelatine Croscarmellose sodium Sucrose High dispersible silicon dioxide Magnesium stearate ( Ph.Eur. ) ( E572 ) Butylated hydroxytoluene ( Ph.Eur. ) ( E321 ) Starch modified ( maize ) Aluminium sodium silicate ( E554 )
P-265	-0.0659 -0.1014 -0.0444 -0.0430 -0.0683 -0.0998 -0.0595 -0.0793 -0.0493 -0.1424 -0.5417 -0.1134 -0.1279 -0.1293 -0.0957 -0.0758 -0.0319 -0.2513 -0.1301 -0.8065 -0.4536 -0.0496 -0.2130 -0.0661 -0.1073 -0.2620 -0.6151 -0.0876 -0.0395 -0.1240 -0.0964 -0.0647 -0.0604 -0.0969 -0.0694 -0.1076 -0.1036 -0.0484 -3.0682 -0.0317 -0.1337 -0.9536 -0.4043 -0.0652 -0.1293 -0.1165 -0.0395 -0.2977 -0.1278 -0.0754 -0.1191 -0.0156 -0.1587 -0.0679 -0.1561 -0.4358 -0.6837 -1.0462 -0.1135 -0.1342 -0.1478 -1.4122 -0.0985 -0.1205 -0.1301 -0.0100 -0.3404 -0.1145 -0.0305 -0.1207 -0.1406 -0.1307 -0.0834 -0.1109 -0.0770 -0.1541 -0.3263 -0.6635 -0.6722 -0.1057 -0.1279 -0.1392 -0.6761 -0.1109 -0.1098 -0.1283 -0.3619 -0.1658 -1.0552 -0.0773 -0.1552 -0.2914 -0.0437 -0.0666 -0.1339 -0.3159 -0.0627 -0.0584 -0.0699 -0.1048 -0.0753 -0.1279 -0.1348 -0.5637 -0.1225 -0.0756 -0.1335 -0.2018
S-461	Mikrokristalline Cellulose ( E 460 ) Lactose Mittelkettige Triglyceride Gelatine Croscarmellose-Natrium Sucrose Hochdisperses Siliciumdioxid Magnesiumstearat ( Ph.Eur. ) ( E 572 ) Butylhydroxytoluol ( Ph.Eur. ) ( E 321 ) Stärke , modifiziert ( Mais ) Aluminiumnatriumsilicat ( E 554 )
T-461	Microcrystalline cellulose ( E460 ) Lactose anhydrous Medium chain triglycerides Gelatin Croscarmellose sodium Sucrose Colloidal silicon dioxide Magnesium stearate ( E572 ) Butyl hydroxytoluene ( E321 ) Modified starch ( maize ) Sodium aluminium silicate ( E554 )
H-461	-0.2293989658355713	Microcrystalline cellulose ( E 460 ) Lactose Medium chain triglycerides Gelatine Croscarmellose sodium Sucrose High dispersible silicon dioxide Magnesium stearate ( Ph.Eur. ) ( E572 ) Butylated hydroxytoluene ( Ph.Eur. ) ( E321 ) Starch modified ( maize ) Aluminium sodium silicate ( E554 )
D-461	-0.2293989658355713	Microcrystalline cellulose ( E 460 ) Lactose Medium chain triglycerides Gelatine Croscarmellose sodium Sucrose High dispersible silicon dioxide Magnesium stearate ( Ph.Eur. ) ( E572 ) Butylated hydroxytoluene ( Ph.Eur. ) ( E321 ) Starch modified ( maize ) Aluminium sodium silicate ( E554 )
P-461	-0.0659 -0.1014 -0.0444 -0.0430 -0.0683 -0.0998 -0.0595 -0.0793 -0.0493 -0.1424 -0.5417 -0.1134 -0.1279 -0.1293 -0.0957 -0.0758 -0.0319 -0.2513 -0.1301 -0.8065 -0.4536 -0.0496 -0.2130 -0.0661 -0.1073 -0.2620 -0.6151 -0.0876 -0.0395 -0.1240 -0.0964 -0.0647 -0.0604 -0.0969 -0.0694 -0.1076 -0.1036 -0.0484 -3.0682 -0.0317 -0.1337 -0.9536 -0.4043 -0.0652 -0.1293 -0.1165 -0.0395 -0.2977 -0.1278 -0.0754 -0.1191 -0.0156 -0.1587 -0.0679 -0.1561 -0.4358 -0.6837 -1.0462 -0.1135 -0.1342 -0.1478 -1.4122 -0.0985 -0.1205 -0.1301 -0.0100 -0.3404 -0.1145 -0.0305 -0.1207 -0.1406 -0.1307 -0.0834 -0.1109 -0.0770 -0.1541 -0.3263 -0.6635 -0.6722 -0.1057 -0.1279 -0.1392 -0.6761 -0.1109 -0.1098 -0.1283 -0.3619 -0.1658 -1.0552 -0.0773 -0.1552 -0.2914 -0.0437 -0.0666 -0.1339 -0.3159 -0.0627 -0.0584 -0.0699 -0.1048 -0.0753 -0.1279 -0.1348 -0.5637 -0.1225 -0.0756 -0.1335 -0.2018
S-438	Resorption Bei gesunden erwachsenen Probanden ( Frauen und Männer ) betrug nach der Gabe von ADROVANCE ( 70 mg<unk> 5.600 I.E. ) nach nächtlichem Fasten und zwei Stunden vor Aufnahme einer Mahlzeit die mittlere Fläche unter der Serum-Konzentration-Zeit-Kurve ( AUC0-80 h ) für Vitamin D3 490,2 ng h<unk> ml ( ohne Berücksichtigung endogener Vitamin-D3-Spiegel ) .
T-438	Absorption In healthy adult subjects ( males and females ) , following administration of ADROVANCE 70 mg/ 5600 IU after an overnight fast and two hours before a meal , the mean area under the serum- concentration-time curve ( AUC0-80 hrs ) for vitamin D3 ( unadjusted for endogenous vitamin D3 levels ) was 490.2 ng hr/ ml .
H-438	-0.2556586265563965	Absorption In healthy adult subjects ( women and men ) after ADROVANCE ( 70 mg/ 5,600 IU ) was administered after nocturnal fasting and two hours before meal , the mean surface area below the serum concentration time curve ( AUC0-80 h ) for vitamin D3 was 490.2 ng h/ ml ( excluding endogenous vitamin D3 levels ) .
D-438	-0.2556586265563965	Absorption In healthy adult subjects ( women and men ) after ADROVANCE ( 70 mg/ 5,600 IU ) was administered after nocturnal fasting and two hours before meal , the mean surface area below the serum concentration time curve ( AUC0-80 h ) for vitamin D3 was 490.2 ng h/ ml ( excluding endogenous vitamin D3 levels ) .
P-438	-0.6307 -0.0562 -0.1139 -0.2348 -0.1667 -0.0697 -0.0690 -0.1363 -0.6756 -0.1573 -0.1099 -0.1303 -0.7228 -0.6290 -0.0740 -0.1194 -0.0929 -0.1001 -0.1408 -0.1163 -0.1601 -0.1240 -0.1220 -0.5175 -0.0903 -0.1126 -0.0624 -0.1348 -0.6241 -0.1622 -0.0768 -1.3807 -1.2258 -0.1435 -0.0256 -0.2487 -0.0210 -0.4950 -0.1521 -0.2641 -0.0963 -0.3704 -0.9703 -0.4163 -0.1293 -0.0778 -0.7035 -0.3137 -1.0325 -0.1289 -0.2835 -0.1153 -0.1228 -0.1888 -1.2376 -0.0937 -0.1218 -0.0775 -0.1461 -0.8851 -0.1247 -0.1347 -0.3993 -0.1293 -0.1326 -0.1937 -0.0977 -0.1246 -0.1254 -0.0990 -0.0306 -0.0594 -0.1407 -0.1184 -0.3022 -0.1734 -0.1177 -0.0730 -0.1221 -0.9424 -0.2081 -0.2012 -0.1488 -0.0428 -0.2366 -0.1318 -0.1221 -0.1225 -0.0442 -0.1349 -0.1387 -0.1480
S-242	Resorption Bei gesunden erwachsenen Probanden ( Frauen und Männer ) betrug nach der Gabe von ADROVANCE nach nächtlichem Fasten und zwei Stunden vor Aufnahme einer Mahlzeit die mittlere Fläche unter der Serum-Konzentration-Zeit-Kurve ( AUC0-120 h ) für Vitamin D3 296,4 ng h<unk> ml ( ohne Berücksichtigung endogener Vitamin-D3-Spiegel ) .
T-242	Absorption In healthy adult subjects ( males and females ) , following administration of ADROVANCE after an overnight fast and two hours before a meal , the mean area under the serum-concentration-time curve ( AUC0-120 hrs ) for vitamin D3 ( unadjusted for endogenous vitamin D3 levels ) was 296.4 ng hr/ ml .
H-242	-0.28316810727119446	Absorption In healthy adult subjects ( women and men ) after ADROVANCE was administered after nocturnal fasting and two hours before meal , the mean surface area below the serum concentration time curve ( AUC0-120 h ) for vitamin D3 was 296.4 ng h/ ml ( excluding endogenous vitamin D3 levels ) .
D-242	-0.28316810727119446	Absorption In healthy adult subjects ( women and men ) after ADROVANCE was administered after nocturnal fasting and two hours before meal , the mean surface area below the serum concentration time curve ( AUC0-120 h ) for vitamin D3 was 296.4 ng h/ ml ( excluding endogenous vitamin D3 levels ) .
P-242	-0.5922 -0.0561 -0.1159 -0.2335 -0.1608 -0.0705 -0.0741 -0.1364 -0.5645 -0.1595 -0.1103 -0.1319 -0.5049 -1.0838 -0.0875 -0.1215 -0.0984 -0.0986 -1.2917 -0.2010 -0.0831 -0.5100 -1.3285 -0.1632 -0.0300 -0.2807 -0.0154 -0.4978 -0.1431 -0.2648 -0.0943 -0.4252 -1.6771 -0.7456 -0.1303 -0.0624 -0.4825 -0.2634 -1.0496 -0.1375 -0.6902 -0.1127 -0.1281 -0.1683 -1.5054 -0.0964 -0.1222 -0.0678 -0.1387 -0.4071 -0.0944 -0.0837 -0.4660 -0.1313 -0.1358 -0.1563 -0.0876 -0.1302 -0.1325 -0.1092 -0.2697 -0.0964 -0.1279 -0.1299 -0.2650 -0.1803 -0.1135 -0.0690 -0.1240 -1.0072 -0.2182 -0.1650 -0.1068 -0.0397 -0.2239 -0.1241 -0.1123 -0.1267 -0.0519 -0.1387 -0.1403 -0.1475
S-96	ADROVANCE soll nach dem Aufstehen des Tages nur mit einem vollen Glas Wasser ( mindestens 200 ml ) geschluckt werden . Die Patienten sollen die Tablette nicht kauen oder die Tablette im Mund zergehen lassen , da ein Risiko für oropharyngeale Ulzera besteht . Die Patienten sollen sich nicht vor der ersten Nahrungsaufnahme des Tages , die frühestens 30 Minuten nach Einnahme der Tablette erfolgen soll , hinlegen .
T-96	ADROVANCE should only be swallowed after getting up for the day with a full glass of water ( not less than 200ml or 7fl . oz . ) .
H-96	-0.33990761637687683	ADROVANCE should only be swallowed with a full glass of water ( at least 200 ml ) after getting up . Patients should not chew the tablet or allow the tablet to melt in the mouth as there is a risk for oropharyngeal ulcers . Patients should not lie down before the first food intake of the day , which should not be until 30 minutes after taking the tablet at the earliest .
D-96	-0.33990761637687683	ADROVANCE should only be swallowed with a full glass of water ( at least 200 ml ) after getting up . Patients should not chew the tablet or allow the tablet to melt in the mouth as there is a risk for oropharyngeal ulcers . Patients should not lie down before the first food intake of the day , which should not be until 30 minutes after taking the tablet at the earliest .
P-96	-0.2013 -0.0679 -0.1253 -0.1048 -0.1133 -0.3723 -1.0501 -0.1395 -0.3238 -0.2068 -0.0548 -0.4281 -0.1460 -0.0681 -0.0450 -0.1702 -0.1299 -0.1458 -0.2600 -0.1330 -0.0954 -0.0790 -0.1367 -0.6100 -2.3524 -0.1558 -0.7746 -0.2976 -0.0914 -0.1399 -0.1801 -0.0419 -0.1190 -1.1036 -0.1129 -0.1164 -0.1544 -1.0768 -0.6460 -0.1193 -0.0897 -0.1790 -1.0911 -0.3384 -0.4293 -0.8381 -0.0839 -0.9704 -0.1507 -0.1215 -0.5763 -0.0735 -0.6399 -0.1779 -0.1025 -0.2584 -0.1292 -0.0986 -0.1301 -0.2603 -0.5506 -0.1810 -0.2344 -0.2613 -0.0910 -0.1031 -0.1722 -0.3317 -0.0687 -0.4090 -0.5363 -0.0993 -0.2077 -0.3124 -0.2116 -0.1512 -0.1394 -0.0949 -0.1556 -0.3594 -1.5776 -0.3087 -0.7646 -3.1655 -0.1067 -0.1290 -0.2241 -0.2523 -0.1582 -0.0808 -0.1528 -0.9862 -0.1370 -0.2005 -0.3154 -0.1616 -0.1516
S-655	Der Faktor-VIII<unk> von-Willebrand-Faktor-Komplex besteht aus zwei Proteinen ( Faktor VIII und von- Willebrand-Faktor ) mit unterschiedlichen , physiologischen Funktionen . ADVATE enthält rekombinanten Blutgerinnungsfaktor VIII ( Octocog alfa ) , ein Glykoprotein , das äquivalent zum Glykoprotein ist , das im menschlichen Plasma auftritt .
T-655	The factor VIII/ von Willebrand Factor complex consists of two molecules ( factor VIII and von Willebrand factor ) with different physiological functions . ADVATE contains recombinant coagulation factor VIII ( octocog alfa ) , a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma .
H-655	-0.26248371601104736	The factor VIII/ von Willebrand factor complex consists of two proteins ( Factor VIII and von Willebrand Factor ) with differing physiological functions . ADVATE contains recombinant blood coagulation factor VIII ( Octocog alfa ) , a glycoprotein equivalent to glycoprotein found in human plasma .
D-655	-0.26248371601104736	The factor VIII/ von Willebrand factor complex consists of two proteins ( Factor VIII and von Willebrand Factor ) with differing physiological functions . ADVATE contains recombinant blood coagulation factor VIII ( Octocog alfa ) , a glycoprotein equivalent to glycoprotein found in human plasma .
P-655	-0.3305 -0.5405 -0.2504 -0.1404 -0.5323 -0.1136 -1.3755 -0.6452 -0.1183 -0.1506 -0.3846 -0.2840 -0.0981 -0.1006 -0.1598 -0.2012 -0.0696 -0.0732 -0.1405 -1.2876 -0.1444 -0.1412 -0.1565 -0.5388 -0.1215 -0.1147 -0.1695 -0.5437 -0.1334 -0.2098 -1.7934 -0.3176 -0.0313 -0.1208 -0.3112 -0.1442 -0.0467 -0.1430 -0.0690 -0.1165 -0.0542 -0.1361 -0.1198 -0.0837 -0.1288 -0.1256 -1.2193 -0.1085 -0.2748 -0.0437 -0.1451 -0.1258 -0.1298 -0.4852 -0.0738 -0.1446 -0.1996 -0.1278 -0.0632 -0.1349 -0.1462 -0.1592 -0.1332 -0.1018 -0.0807 -0.0344 -0.1363 -0.1577 -0.1497 -1.4256 -0.1027 -0.0749 -0.0299 -0.1404 -1.3763 -0.1500 -0.1942 -0.0814 -0.1016 -0.1528 -0.1544 -0.1525
S-283	ADROVANCE soll nach dem Aufstehen des Tages nur mit einem vollen Glas Wasser ( mindestens 200 ml ) geschluckt werden . Die Patienten sollen die Tablette nicht kauen oder die Tablette im Mund zergehen lassen , da ein Risiko für oropharyngeale Ulzera besteht . Die Patienten sollen sich nicht vor der ersten Nahrungsaufnahme des Tages , die frühestens 30 Minuten nach Einnahme der Tablette erfolgen soll , hinlegen .
T-283	ADROVANCE should only be swallowed after getting up for the day with a full glass of water ( not less than 200ml or 7fl . oz . ) .
H-283	-0.33990761637687683	ADROVANCE should only be swallowed with a full glass of water ( at least 200 ml ) after getting up . Patients should not chew the tablet or allow the tablet to melt in the mouth as there is a risk for oropharyngeal ulcers . Patients should not lie down before the first food intake of the day , which should not be until 30 minutes after taking the tablet at the earliest .
D-283	-0.33990761637687683	ADROVANCE should only be swallowed with a full glass of water ( at least 200 ml ) after getting up . Patients should not chew the tablet or allow the tablet to melt in the mouth as there is a risk for oropharyngeal ulcers . Patients should not lie down before the first food intake of the day , which should not be until 30 minutes after taking the tablet at the earliest .
P-283	-0.2013 -0.0679 -0.1253 -0.1048 -0.1133 -0.3723 -1.0501 -0.1395 -0.3238 -0.2068 -0.0548 -0.4281 -0.1460 -0.0681 -0.0450 -0.1702 -0.1299 -0.1458 -0.2600 -0.1330 -0.0954 -0.0790 -0.1367 -0.6100 -2.3524 -0.1558 -0.7746 -0.2976 -0.0914 -0.1399 -0.1801 -0.0419 -0.1190 -1.1036 -0.1129 -0.1164 -0.1544 -1.0768 -0.6460 -0.1193 -0.0897 -0.1790 -1.0911 -0.3384 -0.4293 -0.8381 -0.0839 -0.9704 -0.1507 -0.1215 -0.5763 -0.0735 -0.6399 -0.1779 -0.1025 -0.2584 -0.1292 -0.0986 -0.1301 -0.2603 -0.5506 -0.1810 -0.2344 -0.2613 -0.0910 -0.1031 -0.1722 -0.3317 -0.0687 -0.4090 -0.5363 -0.0993 -0.2077 -0.3124 -0.2116 -0.1512 -0.1394 -0.0949 -0.1556 -0.3594 -1.5776 -0.3087 -0.7646 -3.1655 -0.1067 -0.1290 -0.2241 -0.2523 -0.1582 -0.0808 -0.1528 -0.9862 -0.1370 -0.2005 -0.3154 -0.1616 -0.1516
S-1617	Risiko-Management-Plan Der Zulassungsinhaber verpflichtet sich , alle Studien und Pharmakovigilanz-Aktivitäten durchzuführen , die detailliert im Pharmakovigilanz-Plan beschrieben sind . Dieser Pharmakovigilanz- Plan wurde mit der Version 3.0 des Risiko-Management-Plans ( RMP ) festgelegt . Der RMP wurde mit dem CHMP abgestimmt und ist im Kapitel 1.8.2 der Arzneimittelzulassung enthalten .
T-1617	Risk Management Plan The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan , as agreed in version 3.0 of the Risk Management Plan ( RMP ) presented in Module 1.8.2 . of the Marketing Authorisation and any subsequent updates of the RMP agreed by the CHMP .
H-1617	-0.365217924118042	The Authorisation Holder undertakes to carry out all trials and pharmacovigilance activities detailed in the Pharmacovigilance Plan . This pharmacovigilance plan was established in version 3.0 of the Risk Management Plan ( RMP ) and has been agreed with the CHMP and is included in section 1.8.2 of the Marketing Authorisation .
D-1617	-0.365217924118042	The Authorisation Holder undertakes to carry out all trials and pharmacovigilance activities detailed in the Pharmacovigilance Plan . This pharmacovigilance plan was established in version 3.0 of the Risk Management Plan ( RMP ) and has been agreed with the CHMP and is included in section 1.8.2 of the Marketing Authorisation .
P-1617	-1.9364 -0.7110 -0.0821 -0.0461 -0.0049 -0.1120 -0.7536 -0.4305 -0.1441 -1.5019 -0.1366 -0.2138 -1.0286 -0.1256 -0.1144 -0.1110 -0.1696 -0.2564 -0.2660 -0.1860 -0.2964 -0.1067 -0.1405 -1.0369 -0.2429 -0.1649 -0.1366 -0.1657 -0.2453 -0.2407 -0.8018 -0.7412 -0.1489 -0.1108 -0.1450 -0.2122 -0.3099 -0.2386 -0.3744 -1.1721 -1.5691 -0.2150 -1.6999 -0.1369 -0.1107 -0.1628 -0.1343 -0.1967 -0.1018 -0.1522 -0.3749 -0.1376 -0.1390 -0.0951 -0.1294 -0.3680 -0.8444 -0.1398 -1.4190 -0.1693 -0.2534 -0.1394 -0.0407 -0.1139 -0.1421 -1.0765 -0.1097 -1.8742 -0.1634 -0.1090 -0.1446 -0.1476 -0.1612 -0.1376 -0.0670 -0.0513 -0.0327 -0.2755 -0.1547
S-298	Der Arzt soll deshalb aufmerksam auf alle Anzeichen und Symptome achten , die auf mögliche ösophageale Reaktionen hinweisen , und die Patienten sollen darauf hingewiesen werden , beim Auftreten von Symptomen ösophagealer Irritation wie Dysphagie , Schmerzen beim Schlucken oder retrosternale Schmerzen oder neues oder sich verschlimmerndes Sodbrennen das Arzneimittel abzusetzen und ärztliche Beratung einzuholen ( siehe Abschnitt 4.8 ) .
T-298	Physicians should therefore be alert to any signs or symptoms signalling a possible oesophageal reaction and patients should be instructed to discontinue alendronate and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia , pain on swallowing or retrosternal pain or new or worsening heartburn ( see section 4.8 ) .
H-298	-0.39008378982543945	The physician should therefore be alert to all signs and symptoms that indicate possible oesophageal reactions and patients should be advised to discontinue the medicinal product and seek medical advice if symptoms of oesophageal irritation occur , such as dysphagia , swallowing pain or retrostar pain or new or worsening heartburn ( see section 4.8 ) .
D-298	-0.39008378982543945	The physician should therefore be alert to all signs and symptoms that indicate possible oesophageal reactions and patients should be advised to discontinue the medicinal product and seek medical advice if symptoms of oesophageal irritation occur , such as dysphagia , swallowing pain or retrostar pain or new or worsening heartburn ( see section 4.8 ) .
P-298	-0.2103 -0.4010 -0.2440 -0.1612 -0.1908 -1.2036 -0.4816 -0.2326 -0.5670 -0.1257 -0.1307 -0.1001 -2.3884 -1.3060 -0.0952 -0.6642 -0.0579 -0.1610 -0.0571 -0.0863 -0.1466 -0.7618 -0.0945 -0.2369 -0.4553 -0.1619 -0.1463 -0.4405 -0.3576 -0.9490 -0.1062 -1.7949 -1.5621 -0.0706 -0.0243 -0.3332 -0.1402 -0.4365 -0.0606 -0.3841 -2.5181 -0.1670 -0.4949 -0.1051 -0.1538 -0.0635 -0.0882 -0.1816 -0.0379 -0.1337 -0.7616 -1.2734 -0.1157 -0.1589 -0.0727 -0.0349 -0.1239 -0.1012 -0.1687 -0.7188 -0.2862 -0.2511 -0.1245 -0.1828 -0.0863 -3.5704 -0.0559 -0.1608 -0.3019 -0.1380 -0.6172 -0.0464 -0.1565 -0.0236 -0.0737 -0.2006 -0.3382 -0.0954 -0.1076 -0.1296 -0.1326 -0.1457 -0.1506
S-814	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 4 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-814	During clinical trials with ADVATE in 145 paediatric and adult patients 4 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-814	-0.29145097732543945	In clinical trials of ADVATE in 145 adult and paediatric patients 4 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitor titer ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-814	-0.29145097732543945	In clinical trials of ADVATE in 145 adult and paediatric patients 4 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitor titer ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-814	-0.1584 -0.2010 -0.0280 -0.3460 -0.0889 -0.1444 -0.0783 -0.0962 -0.1555 -0.0846 -0.1188 -0.5024 -0.5799 -0.1609 -0.0387 -0.0196 -0.1103 -0.0635 -0.9012 -0.1767 -1.4904 -0.2029 -0.2688 -0.1396 -0.2941 -0.1529 -0.1576 -0.2353 -0.1162 -0.1320 -0.1463 -0.1435 -0.1355 -0.1198 -0.1240 -0.1309 -0.2798 -0.5272 -0.0903 -0.1784 -0.2484 -0.6244 -0.3332 -0.5817 -0.5709 -0.1142 -0.1417 -0.0934 -0.1066 -0.1401 -0.2015 -0.2590 -0.1918 -0.0407 -1.4276 -0.0613 -1.5496 -0.1847 -0.0964 -0.1012 -0.0969 -1.3861 -0.1088 -0.6783 -0.1784 -0.1206 -0.1303 -0.9795 -0.5075 -0.2684 -1.1946 -0.0610 -0.0774 -0.2650 -0.0711 -0.2249 -0.9316 -0.1782 -0.5660 -0.4356 -0.3808 -0.1670 -0.0686 -0.2282 -0.0609 -0.1335 -0.0758 -0.1018 -0.2188 -0.1477
S-110	Der Arzt soll deshalb aufmerksam auf alle Anzeichen und Symptome achten , die auf mögliche ösophageale Reaktionen hinweisen , und die Patienten sollen darauf hingewiesen werden , beim Auftreten von Symptomen ösophagealer Irritation wie Dysphagie , Schmerzen beim Schlucken oder retrosternale Schmerzen oder neues oder sich verschlimmerndes Sodbrennen das Arzneimittel abzusetzen und ärztliche Beratung einzuholen ( siehe Abschnitt 4.8 ) .
T-110	Physicians should therefore be alert to any signs or symptoms signalling a possible oesophageal reaction and patients should be instructed to discontinue alendronate and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia , pain on swallowing or retrosternal pain or new or worsening heartburn ( see section 4.8 ) .
H-110	-0.39008378982543945	The physician should therefore be alert to all signs and symptoms that indicate possible oesophageal reactions and patients should be advised to discontinue the medicinal product and seek medical advice if symptoms of oesophageal irritation occur , such as dysphagia , swallowing pain or retrostar pain or new or worsening heartburn ( see section 4.8 ) .
D-110	-0.39008378982543945	The physician should therefore be alert to all signs and symptoms that indicate possible oesophageal reactions and patients should be advised to discontinue the medicinal product and seek medical advice if symptoms of oesophageal irritation occur , such as dysphagia , swallowing pain or retrostar pain or new or worsening heartburn ( see section 4.8 ) .
P-110	-0.2103 -0.4010 -0.2440 -0.1612 -0.1908 -1.2036 -0.4816 -0.2326 -0.5670 -0.1257 -0.1307 -0.1001 -2.3884 -1.3060 -0.0952 -0.6642 -0.0579 -0.1610 -0.0571 -0.0863 -0.1466 -0.7618 -0.0945 -0.2369 -0.4553 -0.1619 -0.1463 -0.4405 -0.3576 -0.9490 -0.1062 -1.7949 -1.5621 -0.0706 -0.0243 -0.3332 -0.1402 -0.4365 -0.0606 -0.3841 -2.5181 -0.1670 -0.4949 -0.1051 -0.1538 -0.0635 -0.0882 -0.1816 -0.0379 -0.1337 -0.7616 -1.2734 -0.1157 -0.1589 -0.0727 -0.0349 -0.1239 -0.1012 -0.1687 -0.7188 -0.2862 -0.2511 -0.1245 -0.1828 -0.0863 -3.5704 -0.0559 -0.1608 -0.3019 -0.1380 -0.6172 -0.0464 -0.1565 -0.0236 -0.0737 -0.2006 -0.3382 -0.0954 -0.1076 -0.1296 -0.1326 -0.1457 -0.1506
S-640	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 2 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-640	During clinical trials with ADVATE in 145 paediatric and adult patients 2 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-640	-0.28445103764533997	In clinical trials of ADVATE in 145 adult and paediatric patients 2 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitor titer ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-640	-0.28445103764533997	In clinical trials of ADVATE in 145 adult and paediatric patients 2 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitor titer ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-640	-0.1548 -0.1996 -0.0286 -0.3435 -0.0883 -0.1443 -0.0781 -0.0961 -0.1516 -0.0845 -0.1209 -0.5733 -0.3998 -0.1629 -0.0392 -0.0204 -0.1061 -0.1346 -0.3542 -0.2909 -1.4516 -0.2017 -0.2550 -0.1371 -0.2949 -0.1497 -0.1579 -0.2361 -0.1140 -0.1333 -0.1470 -0.1438 -0.1370 -0.1232 -0.1254 -0.1314 -0.2735 -0.5489 -0.0961 -0.1760 -0.2429 -0.6214 -0.3355 -0.5808 -0.5732 -0.1133 -0.1451 -0.0953 -0.1066 -0.1403 -0.2018 -0.2568 -0.1904 -0.0419 -1.4133 -0.0608 -1.5166 -0.1842 -0.0964 -0.1004 -0.0969 -1.3761 -0.1079 -0.6801 -0.1789 -0.1194 -0.1295 -0.9979 -0.4962 -0.2718 -1.1272 -0.0616 -0.0768 -0.2643 -0.0706 -0.2266 -0.9234 -0.1759 -0.5583 -0.4409 -0.3905 -0.1662 -0.0697 -0.2295 -0.0616 -0.1327 -0.0758 -0.1018 -0.2221 -0.1478
S-267	Etui mit versiegelten Aluminium<unk> Aluminium-Blisterpackungen in Umkartons zu 2 ( 1 Etui mit 2 Tabletten ) , 4 ( 1 Etui mit 4 Tabletten ) , 6 ( 3 Etuis mit 2 Tabletten ) , 12 ( 3 Etuis mit 4 Tabletten ) oder 40 ( 10 Etuis mit 4 Tabletten ) Tabletten .
T-267	Wallet with sealed aluminium/ aluminium blisters , in cartons containing 2 ( 1 wallet x 2 tablets ) , 4 ( 1 wallet x 4 tablets ) , 6 ( 3 wallets x 2 tablets ) , 12 ( 3 wallets x 4 tablets ) or 40 ( 10 wallets x 4 tablets ) tablets .
H-267	-0.2110287994146347	Aluminium sealed blister case in outer cartons of 2 ( 1 case of 2 tablets ) , 4 ( 1 case of 4 tablets ) , 6 ( 3 cases of 2 tablets ) , 12 ( 3 cases of 4 tablets ) or 40 ( 10 cases of 4 tablets ) tablets .
D-267	-0.2110287994146347	Aluminium sealed blister case in outer cartons of 2 ( 1 case of 2 tablets ) , 4 ( 1 case of 4 tablets ) , 6 ( 3 cases of 2 tablets ) , 12 ( 3 cases of 4 tablets ) or 40 ( 10 cases of 4 tablets ) tablets .
P-267	-0.6866 -0.1784 -0.2134 -0.2855 -0.1972 -0.8996 -0.1365 -0.4695 -0.1288 -1.1086 -0.2286 -0.1626 -0.1175 -0.1292 -0.1377 -1.0841 -0.5115 -0.1141 -0.0663 -0.1310 -0.1416 -0.1473 -0.1416 -0.1333 -0.1408 -0.4367 -0.1619 -0.1443 -0.0523 -0.1270 -0.1338 -0.1461 -0.1449 -0.1319 -0.1017 -0.3759 -0.2044 -0.1107 -0.0547 -0.1164 -0.1311 -0.1486 -0.1026 -0.1352 -0.0975 -0.3872 -0.1784 -0.1220 -0.0497 -0.1370 -0.1230 -0.1607 -0.1015 -0.1352 -0.1356 -0.3413 -0.1837 -0.1284 -0.0491 -0.1163 -0.1279 -0.0700 -0.1244 -0.1341 -0.1627
S-990	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 6 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-990	During clinical trials with ADVATE in 145 paediatric and adult patients 6 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-990	-0.2902676463127136	In clinical trials of ADVATE in 145 paediatric and adult patients 6 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitor titer ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-990	-0.2902676463127136	In clinical trials of ADVATE in 145 paediatric and adult patients 6 with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitor titer ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-990	-0.1577 -0.1892 -0.0284 -0.3463 -0.0870 -0.1443 -0.0789 -0.0962 -0.1549 -0.0904 -0.1174 -1.7731 -0.0147 -0.0143 -0.1087 -0.1481 -0.0708 -0.0232 -0.4645 -0.1574 -1.5015 -0.2019 -0.2420 -0.1399 -0.2654 -0.1505 -0.1572 -0.2412 -0.1164 -0.1321 -0.1434 -0.1443 -0.1365 -0.1191 -0.1252 -0.1316 -0.2585 -0.4942 -0.1030 -0.1758 -0.2549 -0.6336 -0.3402 -0.5749 -0.5663 -0.1140 -0.1445 -0.0953 -0.1077 -0.1410 -0.1969 -0.2546 -0.1908 -0.0403 -1.4355 -0.0609 -1.4865 -0.1847 -0.0967 -0.1017 -0.0971 -1.3520 -0.1081 -0.6782 -0.1776 -0.1195 -0.1291 -1.0125 -0.4981 -0.2660 -1.0567 -0.0604 -0.0764 -0.2642 -0.0707 -0.2278 -0.9178 -0.1783 -0.5510 -0.4439 -0.3587 -0.1665 -0.0685 -0.2371 -0.0620 -0.1338 -0.0760 -0.1020 -0.2210 -0.1474
S-1166	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 8 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-1166	During clinical trials with ADVATE in 145 paediatric and adult patients 8 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-1166	-0.2873311936855316	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitor titer ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-1166	-0.2873311936855316	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitor titer ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-1166	-0.1579 -0.1989 -0.0274 -0.3433 -0.0887 -0.1443 -0.0782 -0.0964 -0.1553 -0.0930 -0.1191 -0.4885 -0.5189 -0.1513 -0.0313 -0.0199 -0.1110 -0.0604 -0.4703 -1.5553 -0.1754 -0.2666 -0.1327 -0.2723 -0.1576 -0.1659 -0.2325 -0.1191 -0.1293 -0.1454 -0.1447 -0.1364 -0.1165 -0.1285 -0.1304 -0.2802 -0.5749 -0.0959 -0.1847 -0.2734 -0.6314 -0.3516 -0.5697 -0.6075 -0.1125 -0.1372 -0.0948 -0.1069 -0.1404 -0.1947 -0.2853 -0.1812 -0.0400 -1.4886 -0.0614 -1.5084 -0.1825 -0.0974 -0.0996 -0.0974 -1.2605 -0.1076 -0.6703 -0.1818 -0.1186 -0.1296 -0.9978 -0.4959 -0.2705 -1.1335 -0.0619 -0.0777 -0.2640 -0.0715 -0.2266 -0.9709 -0.1857 -0.5804 -0.4106 -0.3897 -0.1666 -0.0687 -0.2302 -0.0618 -0.1334 -0.0759 -0.1015 -0.2229 -0.1465
S-1342	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 10 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-1342	During clinical trials with ADVATE in 145 paediatric and adult patients 10 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-1342	-0.2794305682182312	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitor titer ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-1342	-0.2794305682182312	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitor titer ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-1342	-0.1556 -0.2134 -0.0285 -0.3693 -0.0918 -0.1443 -0.0782 -0.0961 -0.1542 -0.0908 -0.1168 -0.2672 -0.5890 -0.1564 -0.0288 -0.0187 -0.1121 -0.0535 -0.4282 -1.0606 -0.1785 -0.2686 -0.1344 -0.2817 -0.1572 -0.1631 -0.2324 -0.1200 -0.1301 -0.1442 -0.1448 -0.1355 -0.1163 -0.1292 -0.1310 -0.2753 -0.5804 -0.0983 -0.1860 -0.2887 -0.6134 -0.3469 -0.5673 -0.6046 -0.1117 -0.1386 -0.0931 -0.1070 -0.1397 -0.1953 -0.2882 -0.1840 -0.0394 -1.4707 -0.0609 -1.5008 -0.1835 -0.0981 -0.0990 -0.0988 -1.2332 -0.1087 -0.6745 -0.1801 -0.1188 -0.1281 -1.0046 -0.4996 -0.2674 -1.1544 -0.0615 -0.0771 -0.2610 -0.0715 -0.2237 -0.9670 -0.1858 -0.5627 -0.4093 -0.3875 -0.1675 -0.0696 -0.2286 -0.0606 -0.1326 -0.0759 -0.1015 -0.2187 -0.1474
S-1519	Bei klinischen Studien mit ADVATE an 145 Kindern und Erwachsenen 12 mit diagnostizierter schwerer bis mittelschwerer Hämophilie A ( FVIII 2 % ) und vorheriger Exposition gegenüber Faktor VIII- Konzentraten ( 150 Tage ) zeigte nur ein Patient nach 26 Expositionstagen mit ADVATE einen niedrigen Inhibitortiter ( 2,4 B.E. im modifizierten Bethesda-Ansatz ) .
T-1519	During clinical trials with ADVATE in 145 paediatric and adult patients 12 diagnosed with severe to moderately severe haemophilia A ( FVIII 2 % ) , with previous exposure to factor VIII concentrates 150 days , one patient developed a low-titre inhibitor ( 2.4 BU in the modified Bethesda assay ) after 26 exposure days to ADVATE .
H-1519	-0.29647180438041687	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitor titer ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
D-1519	-0.29647180438041687	In clinical trials of ADVATE in 145 adult and paediatric patients with diagnosed severe to moderate haemophilia A ( FVIII 2 % ) and previous exposure to factor VIII concentrates ( 150 days ) , only one patient exhibited a low inhibitor titer ( 2.4 BU in the modified Bethesda approach ) after 26 days of exposure to ADVATE .
P-1519	-0.1595 -0.1799 -0.0274 -0.3740 -0.0956 -0.1444 -0.0783 -0.0957 -0.1579 -0.0956 -0.1193 -0.2649 -0.8484 -0.1573 -0.0295 -0.0169 -0.1128 -0.0765 -1.4185 -1.3735 -0.1795 -0.2637 -0.1374 -0.2744 -0.1613 -0.1648 -0.2321 -0.1223 -0.1296 -0.1455 -0.1444 -0.1355 -0.1152 -0.1285 -0.1304 -0.2855 -0.5661 -0.1037 -0.1880 -0.2875 -0.6277 -0.3456 -0.5681 -0.6084 -0.1124 -0.1383 -0.0941 -0.1081 -0.1399 -0.1924 -0.2868 -0.1858 -0.0410 -1.4260 -0.0611 -1.4746 -0.1842 -0.0975 -0.0991 -0.0982 -1.2400 -0.1070 -0.6661 -0.1800 -0.1179 -0.1292 -1.0007 -0.4991 -0.2688 -1.1120 -0.0615 -0.0778 -0.2647 -0.0720 -0.2279 -0.9722 -0.1843 -0.5785 -0.4058 -0.4006 -0.1671 -0.0706 -0.2272 -0.0602 -0.1333 -0.0765 -0.1015 -0.2253 -0.1475
S-1256	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-1256	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-1256	-0.4177282750606537	* Activity ( International Units ) is determined by the chromogenic assay against an internal standard related to the WHO standard and its specific activity is approximately 4,000-10,000 IU/ mg protein . <unk> Human blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
D-1256	-0.4177282750606537	* Activity ( International Units ) is determined by the chromogenic assay against an internal standard related to the WHO standard and its specific activity is approximately 4,000-10,000 IU/ mg protein . <unk> Human blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
P-1256	-3.0263 -0.8905 -0.0917 -0.1322 -1.2293 -0.0636 -0.1097 -0.1297 -0.1258 -0.2134 -0.8092 -0.9675 -0.0452 -0.1097 -0.1622 -0.2898 -0.0638 -0.1091 -0.1474 -0.5186 -0.3159 -1.8691 -0.4261 -2.1960 -0.1402 -0.6793 -0.1320 -1.8987 -0.6348 -0.4181 -0.4008 -0.3735 -0.1836 -0.1705 -0.0664 -1.3499 -0.0734 -0.0695 -0.6995 -0.4688 -0.1316 -0.1078 -0.1585 -0.0544 -0.3280 -0.9517 -0.4787 -1.4846 -0.3483 -0.7867 -0.0266 -0.0889 -0.0968 -0.1282 -0.1213 -0.4922 -0.4991 -0.1084 -0.0990 -0.0768 -0.1222 -0.0384 -0.0799 -0.1482 -1.8274 -0.1958 -0.1606 -0.1084 -0.2742 -0.1533 -0.1188 -0.4153 -0.1076 -0.1399 -0.1293 -0.1856 -0.1270 -0.1496 -0.1511
S-904	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-904	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-904	-0.4177282750606537	* Activity ( International Units ) is determined by the chromogenic assay against an internal standard related to the WHO standard and its specific activity is approximately 4,000-10,000 IU/ mg protein . <unk> Human blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
D-904	-0.4177282750606537	* Activity ( International Units ) is determined by the chromogenic assay against an internal standard related to the WHO standard and its specific activity is approximately 4,000-10,000 IU/ mg protein . <unk> Human blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
P-904	-3.0263 -0.8905 -0.0917 -0.1322 -1.2293 -0.0636 -0.1097 -0.1297 -0.1258 -0.2134 -0.8092 -0.9675 -0.0452 -0.1097 -0.1622 -0.2898 -0.0638 -0.1091 -0.1474 -0.5186 -0.3159 -1.8691 -0.4261 -2.1960 -0.1402 -0.6793 -0.1320 -1.8987 -0.6348 -0.4181 -0.4008 -0.3735 -0.1836 -0.1705 -0.0664 -1.3499 -0.0734 -0.0695 -0.6995 -0.4688 -0.1316 -0.1078 -0.1585 -0.0544 -0.3280 -0.9517 -0.4787 -1.4846 -0.3483 -0.7867 -0.0266 -0.0889 -0.0968 -0.1282 -0.1213 -0.4922 -0.4991 -0.1084 -0.0990 -0.0768 -0.1222 -0.0384 -0.0799 -0.1482 -1.8274 -0.1958 -0.1606 -0.1084 -0.2742 -0.1533 -0.1188 -0.4153 -0.1076 -0.1399 -0.1293 -0.1856 -0.1270 -0.1496 -0.1511
S-1432	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-1432	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-1432	-0.4177282750606537	* Activity ( International Units ) is determined by the chromogenic assay against an internal standard related to the WHO standard and its specific activity is approximately 4,000-10,000 IU/ mg protein . <unk> Human blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
D-1432	-0.4177282750606537	* Activity ( International Units ) is determined by the chromogenic assay against an internal standard related to the WHO standard and its specific activity is approximately 4,000-10,000 IU/ mg protein . <unk> Human blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
P-1432	-3.0263 -0.8905 -0.0917 -0.1322 -1.2293 -0.0636 -0.1097 -0.1297 -0.1258 -0.2134 -0.8092 -0.9675 -0.0452 -0.1097 -0.1622 -0.2898 -0.0638 -0.1091 -0.1474 -0.5186 -0.3159 -1.8691 -0.4261 -2.1960 -0.1402 -0.6793 -0.1320 -1.8987 -0.6348 -0.4181 -0.4008 -0.3735 -0.1836 -0.1705 -0.0664 -1.3499 -0.0734 -0.0695 -0.6995 -0.4688 -0.1316 -0.1078 -0.1585 -0.0544 -0.3280 -0.9517 -0.4787 -1.4846 -0.3483 -0.7867 -0.0266 -0.0889 -0.0968 -0.1282 -0.1213 -0.4922 -0.4991 -0.1084 -0.0990 -0.0768 -0.1222 -0.0384 -0.0799 -0.1482 -1.8274 -0.1958 -0.1606 -0.1084 -0.2742 -0.1533 -0.1188 -0.4153 -0.1076 -0.1399 -0.1293 -0.1856 -0.1270 -0.1496 -0.1511
S-1080	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-1080	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-1080	-0.4177282750606537	* Activity ( International Units ) is determined by the chromogenic assay against an internal standard related to the WHO standard and its specific activity is approximately 4,000-10,000 IU/ mg protein . <unk> Human blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
D-1080	-0.4177282750606537	* Activity ( International Units ) is determined by the chromogenic assay against an internal standard related to the WHO standard and its specific activity is approximately 4,000-10,000 IU/ mg protein . <unk> Human blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
P-1080	-3.0263 -0.8905 -0.0917 -0.1322 -1.2293 -0.0636 -0.1097 -0.1297 -0.1258 -0.2134 -0.8092 -0.9675 -0.0452 -0.1097 -0.1622 -0.2898 -0.0638 -0.1091 -0.1474 -0.5186 -0.3159 -1.8691 -0.4261 -2.1960 -0.1402 -0.6793 -0.1320 -1.8987 -0.6348 -0.4181 -0.4008 -0.3735 -0.1836 -0.1705 -0.0664 -1.3499 -0.0734 -0.0695 -0.6995 -0.4688 -0.1316 -0.1078 -0.1585 -0.0544 -0.3280 -0.9517 -0.4787 -1.4846 -0.3483 -0.7867 -0.0266 -0.0889 -0.0968 -0.1282 -0.1213 -0.4922 -0.4991 -0.1084 -0.0990 -0.0768 -0.1222 -0.0384 -0.0799 -0.1482 -1.8274 -0.1958 -0.1606 -0.1084 -0.2742 -0.1533 -0.1188 -0.4153 -0.1076 -0.1399 -0.1293 -0.1856 -0.1270 -0.1496 -0.1511
S-728	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-728	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-728	-0.4177282750606537	* Activity ( International Units ) is determined by the chromogenic assay against an internal standard related to the WHO standard and its specific activity is approximately 4,000-10,000 IU/ mg protein . <unk> Human blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
D-728	-0.4177282750606537	* Activity ( International Units ) is determined by the chromogenic assay against an internal standard related to the WHO standard and its specific activity is approximately 4,000-10,000 IU/ mg protein . <unk> Human blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
P-728	-3.0263 -0.8905 -0.0917 -0.1322 -1.2293 -0.0636 -0.1097 -0.1297 -0.1258 -0.2134 -0.8092 -0.9675 -0.0452 -0.1097 -0.1622 -0.2898 -0.0638 -0.1091 -0.1474 -0.5186 -0.3159 -1.8691 -0.4261 -2.1960 -0.1402 -0.6793 -0.1320 -1.8987 -0.6348 -0.4181 -0.4008 -0.3735 -0.1836 -0.1705 -0.0664 -1.3499 -0.0734 -0.0695 -0.6995 -0.4688 -0.1316 -0.1078 -0.1585 -0.0544 -0.3280 -0.9517 -0.4787 -1.4846 -0.3483 -0.7867 -0.0266 -0.0889 -0.0968 -0.1282 -0.1213 -0.4922 -0.4991 -0.1084 -0.0990 -0.0768 -0.1222 -0.0384 -0.0799 -0.1482 -1.8274 -0.1958 -0.1606 -0.1084 -0.2742 -0.1533 -0.1188 -0.4153 -0.1076 -0.1399 -0.1293 -0.1856 -0.1270 -0.1496 -0.1511
S-553	<unk> Die Aktivität ( Internationale Einheiten ) wird unter Verwendung des chromogenen Assays gegen einen hausinternen Standard , der sich auf den WHO-Standard bezieht , bestimmt . Die spezifische Aktivität beträgt ca. 4.000-10.000 I.E.<unk> mg Protein. <unk> <unk> Blutgerinnungsfaktor VIII vom Menschen , hergestellt mittels rekombinanter DNS-Technologie in Ovarialzellen des chinesischen Hamsters ( CHO ) .
T-553	The specific activity is approximately 4,000- 10,000 IU/ mg protein . <<unk>> * Human coagulation factor VIII produced by recombinant DNA technology in Chinese hamster ovary ( CHO ) cells .
H-553	-0.4177282750606537	* Activity ( International Units ) is determined by the chromogenic assay against an internal standard related to the WHO standard and its specific activity is approximately 4,000-10,000 IU/ mg protein . <unk> Human blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
D-553	-0.4177282750606537	* Activity ( International Units ) is determined by the chromogenic assay against an internal standard related to the WHO standard and its specific activity is approximately 4,000-10,000 IU/ mg protein . <unk> Human blood clotting factor VIII produced by recombinant DNA technology in ovarian cells of the Chinese hamster ( CHO ) .
P-553	-3.0263 -0.8905 -0.0917 -0.1322 -1.2293 -0.0636 -0.1097 -0.1297 -0.1258 -0.2134 -0.8092 -0.9675 -0.0452 -0.1097 -0.1622 -0.2898 -0.0638 -0.1091 -0.1474 -0.5186 -0.3159 -1.8691 -0.4261 -2.1960 -0.1402 -0.6793 -0.1320 -1.8987 -0.6348 -0.4181 -0.4008 -0.3735 -0.1836 -0.1705 -0.0664 -1.3499 -0.0734 -0.0695 -0.6995 -0.4688 -0.1316 -0.1078 -0.1585 -0.0544 -0.3280 -0.9517 -0.4787 -1.4846 -0.3483 -0.7867 -0.0266 -0.0889 -0.0968 -0.1282 -0.1213 -0.4922 -0.4991 -0.1084 -0.0990 -0.0768 -0.1222 -0.0384 -0.0799 -0.1482 -1.8274 -0.1958 -0.1606 -0.1084 -0.2742 -0.1533 -0.1188 -0.4153 -0.1076 -0.1399 -0.1293 -0.1856 -0.1270 -0.1496 -0.1511
S-390	Nach 15-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher ( 26 % ) in der Gruppe unter ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( 56 nmol<unk> l <unk> 23 ng<unk> ml <unk> ) als in der Gruppe unter Alendronat allein ( 46 nmol<unk> l <unk> 18,2 ng<unk> ml <unk> ) .
T-390	Nach 15-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher ( 26 % ) in der Gruppe unter ADROVANCE ( 70 mg<<unk>> 2.800 I.E. ) ( 56 nmol<<unk>> l <<unk>> 23 ng<<unk>> ml <<unk>> ) als in der Gruppe unter Alendronat allein ( 46 nmol<<unk>> l <<unk>> 18,2 ng<<unk>> ml <<unk>> ) . After 15 weeks of treatment , the mean serum 25-hydroxyvitamin D levels were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2800 IU ) group ( 56 nmol/ l <<unk>> 23 ng/ ml <<unk>> ) than in the alendronate-only group ( 46 nmol/ l <<unk>> 18.2 ng/ ml <<unk>> ) .
H-390	-0.19906611740589142	After 15 weeks of treatment , mean levels of 25-hydroxyvitamin D were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( 56 nmol/ l <unk> 23 ng/ ml <unk> ) group than in the alendronate group alone ( 46 nmol/ l <unk> 18.2 ng/ ml <unk> ) .
D-390	-0.19906611740589142	After 15 weeks of treatment , mean levels of 25-hydroxyvitamin D were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( 56 nmol/ l <unk> 23 ng/ ml <unk> ) group than in the alendronate group alone ( 46 nmol/ l <unk> 18.2 ng/ ml <unk> ) .
P-390	-1.3215 -0.2603 -0.1402 -0.1632 -0.0953 -0.1732 -0.1483 -1.1767 -0.1520 -0.4161 -0.1438 -0.0662 -0.1103 -0.1143 -0.1149 -0.1021 -0.1136 -0.1577 -0.1542 -0.0775 -0.1338 -0.3827 -0.1536 -0.1297 -0.1443 -0.1421 -0.0664 -0.0756 -0.1251 -0.1102 -0.1062 -0.3284 -0.1346 -0.1985 -0.1582 -0.1290 -0.1782 -0.1028 -0.1077 -0.0719 -0.1335 -0.1969 -0.0872 -0.1612 -0.2356 -0.1337 -0.2676 -0.9076 -0.0928 -0.1406 -0.1214 -0.1361 -0.0619 -0.0603 -0.1204 -0.2206 -0.2540 -0.2357 -0.5315 -0.3429 -0.1349 -0.0914 -0.0491 -1.1654 -0.1681 -0.1251 -0.0750 -0.1834 -0.2677 -0.1366 -0.1873 -0.0566 -0.0392 -0.1419 -0.1410 -0.1102 -0.1250 -0.0639 -0.0205 -0.1259 -0.1422 -0.1510
S-202	Nach 15-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher ( 26 % ) in der Gruppe unter ADROVANCE ( 70 mg<unk> 2.800 I.E. ) ( 56 nmol<unk> l <unk> 23 ng<unk> ml <unk> ) als in der Gruppe unter Alendronat allein ( 46 nmol<unk> l <unk> 18,2 ng<unk> ml <unk> ) .
T-202	Nach 15-wöchiger Behandlung waren die mittleren Serumspiegel von 25-Hydroxyvitamin D signifikant höher ( 26 % ) in der Gruppe unter ADROVANCE ( 70 mg<<unk>> 2.800 I.E. ) ( 56 nmol<<unk>> l <<unk>> 23 ng<<unk>> ml <<unk>> ) als in der Gruppe unter Alendronat allein ( 46 nmol<<unk>> l <<unk>> 18,2 ng<<unk>> ml <<unk>> ) . After 15 weeks of treatment , the mean serum 25-hydroxyvitamin D levels were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2800 IU ) group ( 56 nmol/ l <<unk>> 23 ng/ ml <<unk>> ) than in the alendronate-only group ( 46 nmol/ l <<unk>> 18.2 ng/ ml <<unk>> ) .
H-202	-0.19906611740589142	After 15 weeks of treatment , mean levels of 25-hydroxyvitamin D were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( 56 nmol/ l <unk> 23 ng/ ml <unk> ) group than in the alendronate group alone ( 46 nmol/ l <unk> 18.2 ng/ ml <unk> ) .
D-202	-0.19906611740589142	After 15 weeks of treatment , mean levels of 25-hydroxyvitamin D were significantly higher ( 26 % ) in the ADROVANCE ( 70 mg/ 2,800 IU ) ( 56 nmol/ l <unk> 23 ng/ ml <unk> ) group than in the alendronate group alone ( 46 nmol/ l <unk> 18.2 ng/ ml <unk> ) .
P-202	-1.3215 -0.2603 -0.1402 -0.1632 -0.0953 -0.1732 -0.1483 -1.1767 -0.1520 -0.4161 -0.1438 -0.0662 -0.1103 -0.1143 -0.1149 -0.1021 -0.1136 -0.1577 -0.1542 -0.0775 -0.1338 -0.3827 -0.1536 -0.1297 -0.1443 -0.1421 -0.0664 -0.0756 -0.1251 -0.1102 -0.1062 -0.3284 -0.1346 -0.1985 -0.1582 -0.1290 -0.1782 -0.1028 -0.1077 -0.0719 -0.1335 -0.1969 -0.0872 -0.1612 -0.2356 -0.1337 -0.2676 -0.9076 -0.0928 -0.1406 -0.1214 -0.1361 -0.0619 -0.0603 -0.1204 -0.2206 -0.2540 -0.2357 -0.5315 -0.3429 -0.1349 -0.0914 -0.0491 -1.1654 -0.1681 -0.1251 -0.0750 -0.1834 -0.2677 -0.1366 -0.1873 -0.0566 -0.0392 -0.1419 -0.1410 -0.1102 -0.1250 -0.0639 -0.0205 -0.1259 -0.1422 -0.1510
S-1788	Gelegentliche Nebenwirkungen Juckreiz , verstärktes Schwitzen , ungewöhnliches Geschmacksempfinden , Hitzewallungen , Migräne , Gedächtnisstörungen , Schüttelfrost , Durchfall , Übelkeit , Erbrechen , Kurzatmigkeit , rauher Hals , Entzündungen der Lymphgefäße , Blässe , Augenentzündungen , Hautausschläge , extremes Schwitzen ,
T-1788	Uncommon side effects
H-1788	-0.34755271673202515	Uncommon side effects Itching , increased sweating , unusual taste sensation , hot flashes , migraine , memory disturbance , chills , diarrhoea , nausea , vomiting , shortness of breath , rough neck , inflammation of the lymphatic vessels , pallor , eye inflammation , rash , extreme sweating ,
D-1788	-0.34755271673202515	Uncommon side effects Itching , increased sweating , unusual taste sensation , hot flashes , migraine , memory disturbance , chills , diarrhoea , nausea , vomiting , shortness of breath , rough neck , inflammation of the lymphatic vessels , pallor , eye inflammation , rash , extreme sweating ,
P-1788	-0.3656 -0.1275 -0.9643 -0.1438 -2.2093 -0.1251 -0.1491 -0.1485 -1.1253 -0.1813 -0.1374 -0.1414 -0.0453 -0.6782 -0.0591 -0.1253 -0.1395 -1.2575 -1.2952 -0.3297 -0.1425 -0.0963 -0.0277 -0.5796 -0.1316 -1.6207 -2.0954 -0.1669 -0.1272 -0.1406 -0.2592 -0.0255 -0.1392 -0.1351 -0.0532 -0.0721 -0.0268 -0.1455 -0.0657 -0.0376 -0.1458 -0.0687 -0.0649 -0.0980 -0.1429 -0.0419 -0.1383 -0.1454 -0.0770 -0.1440 -0.8180 -0.9884 -0.1515 -1.1537 -0.0544 -0.1228 -0.1520 -0.5795 -0.3053 -1.2473 -0.2649 -0.5145 -0.0830 -0.1436 -0.4340 -0.2931 -0.7112 -0.1424 -0.2643 -0.1492 -0.0354 -0.1374 -0.1457 -0.2553 -1.2228 -0.1437 -0.1952 -0.1132 -0.1225 -0.1511 -0.1523
S-391	ADROVANCE ( 70 mg<unk> 2.800 I.E. ) senkte signifikant nach 15 Wochen den Anteil an Patienten mit Vitamin-D-Insuffizienz ( Serumwert von 25-Hydroxyvitamin D <unk> 37,5 nmol<unk> l <unk> <unk> 15 ng<unk> ml <unk> ) um 62,5 % im Vergleich zu Alendronat allein ( 12 % vs .
T-391	The percentage of patients with vitamin D insufficiency ( serum 25-hydroxyvitamin D <<unk>> 37.5 nmol/ l <<unk>> <<unk>> 15 ng/ ml <<unk>> ) was significantly reduced by 62.5 % with ADROVANCE ( 70 mg/ 2800 IU ) vs. alendronate-only ( 12 % vs.
H-391	-0.2204708606004715	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 37.5 nmol/ l <unk> 15 ng/ ml <unk> ) by 62.5 % compared to alendronate alone ( 12 % vs.
D-391	-0.2204708606004715	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 37.5 nmol/ l <unk> 15 ng/ ml <unk> ) by 62.5 % compared to alendronate alone ( 12 % vs.
P-391	-0.0865 -0.0768 -0.1231 -0.1100 -0.1264 -0.1468 -0.1064 -0.1510 -0.1295 -0.1221 -0.1775 -0.1003 -0.1023 -0.0788 -0.1355 -0.3030 -0.2689 -0.1266 -0.3050 -0.8178 -0.2215 -0.1136 -0.1823 -0.4155 -0.0797 -0.1514 -1.3050 -0.0332 -0.1833 -0.1964 -0.2037 -0.1487 -1.6550 -0.9641 -0.1061 -0.0540 -0.1181 -0.1202 -0.0889 -0.1058 -0.0965 -1.0099 -0.0948 -0.0745 -0.1383 -0.1619 -0.1418 -0.1998 -0.0891 -0.1518 -0.1254 -0.1275 -0.1324 -0.0745 -0.0341 -0.1265 -0.7335 -0.1079 -0.0693 -0.1272 -0.3367 -0.2782 -0.1858 -0.1502 -0.1128 -0.0481 -0.0839 -0.1246 -0.1055 -0.1170 -0.3209 -0.1527
S-203	ADROVANCE ( 70 mg<unk> 2.800 I.E. ) senkte signifikant nach 15 Wochen den Anteil an Patienten mit Vitamin-D-Insuffizienz ( Serumwert von 25-Hydroxyvitamin D <unk> 37,5 nmol<unk> l <unk> <unk> 15 ng<unk> ml <unk> ) um 62,5 % im Vergleich zu Alendronat allein ( 12 % vs .
T-203	The percentage of patients with vitamin D insufficiency ( serum 25-hydroxyvitamin D <<unk>> 37.5 nmol/ l <<unk>> <<unk>> 15 ng/ ml <<unk>> ) was significantly reduced by 62.5 % with ADROVANCE ( 70 mg/ 2800 IU ) vs. alendronate-only ( 12 % vs.
H-203	-0.2204708606004715	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 37.5 nmol/ l <unk> 15 ng/ ml <unk> ) by 62.5 % compared to alendronate alone ( 12 % vs.
D-203	-0.2204708606004715	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 37.5 nmol/ l <unk> 15 ng/ ml <unk> ) by 62.5 % compared to alendronate alone ( 12 % vs.
P-203	-0.0865 -0.0768 -0.1231 -0.1100 -0.1264 -0.1468 -0.1064 -0.1510 -0.1295 -0.1221 -0.1775 -0.1003 -0.1023 -0.0788 -0.1355 -0.3030 -0.2689 -0.1266 -0.3050 -0.8178 -0.2215 -0.1136 -0.1823 -0.4155 -0.0797 -0.1514 -1.3050 -0.0332 -0.1833 -0.1964 -0.2037 -0.1487 -1.6550 -0.9641 -0.1061 -0.0540 -0.1181 -0.1202 -0.0889 -0.1058 -0.0965 -1.0099 -0.0948 -0.0745 -0.1383 -0.1619 -0.1418 -0.1998 -0.0891 -0.1518 -0.1254 -0.1275 -0.1324 -0.0745 -0.0341 -0.1265 -0.7335 -0.1079 -0.0693 -0.1272 -0.3367 -0.2782 -0.1858 -0.1502 -0.1128 -0.0481 -0.0839 -0.1246 -0.1055 -0.1170 -0.3209 -0.1527
S-974	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-974	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-974	-0.3374551832675934	Frequency categories are defined by the following criteria : Very common ( 1/ 10 ) , common ( 1/ 100 to 1/ 10 ) , uncommon ( 1/ 1,000 to 1/ 100 ) , rare ( 1/ 10,000 to 1/ 1,000 ) , very rare <unk> 1/ 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
D-974	-0.3374551832675934	Frequency categories are defined by the following criteria : Very common ( 1/ 10 ) , common ( 1/ 100 to 1/ 10 ) , uncommon ( 1/ 1,000 to 1/ 100 ) , rare ( 1/ 10,000 to 1/ 1,000 ) , very rare <unk> 1/ 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
P-974	-0.4728 -0.0670 -0.1130 -1.1427 -0.1562 -0.1444 -0.8805 -0.4892 -0.0775 -0.2729 -0.1395 -0.1471 -0.3719 -0.1414 -0.1095 -0.2929 -0.5304 -0.1461 -0.1437 -0.5291 -0.1385 -0.0867 -0.1209 -0.1775 -0.2466 -0.6571 -0.1095 -0.1781 -0.1242 -0.1463 -3.4902 -0.0150 -0.1337 -0.0882 -0.1069 -1.5885 -0.1388 -0.5547 -0.1103 -0.1907 -0.1234 -0.1507 -0.0325 -0.1353 -0.1140 -0.0925 -0.8526 -0.1333 -0.7482 -0.1053 -0.5227 -0.1240 -0.1510 -0.1342 -0.0556 -0.3848 -2.0305 -0.1161 -0.7886 -0.1203 -0.1509 -0.7373 -0.1253 -0.1923 -0.0803 -0.1858 -0.1497 -0.6538 -0.3345 -0.2220 -0.1505 -0.1939 -0.1391 -0.1571 -0.1507
S-1502	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-1502	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-1502	-0.3374551832675934	Frequency categories are defined by the following criteria : Very common ( 1/ 10 ) , common ( 1/ 100 to 1/ 10 ) , uncommon ( 1/ 1,000 to 1/ 100 ) , rare ( 1/ 10,000 to 1/ 1,000 ) , very rare <unk> 1/ 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
D-1502	-0.3374551832675934	Frequency categories are defined by the following criteria : Very common ( 1/ 10 ) , common ( 1/ 100 to 1/ 10 ) , uncommon ( 1/ 1,000 to 1/ 100 ) , rare ( 1/ 10,000 to 1/ 1,000 ) , very rare <unk> 1/ 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
P-1502	-0.4728 -0.0670 -0.1130 -1.1427 -0.1562 -0.1444 -0.8805 -0.4892 -0.0775 -0.2729 -0.1395 -0.1471 -0.3719 -0.1414 -0.1095 -0.2929 -0.5304 -0.1461 -0.1437 -0.5291 -0.1385 -0.0867 -0.1209 -0.1775 -0.2466 -0.6571 -0.1095 -0.1781 -0.1242 -0.1463 -3.4902 -0.0150 -0.1337 -0.0882 -0.1069 -1.5885 -0.1388 -0.5547 -0.1103 -0.1907 -0.1234 -0.1507 -0.0325 -0.1353 -0.1140 -0.0925 -0.8526 -0.1333 -0.7482 -0.1053 -0.5227 -0.1240 -0.1510 -0.1342 -0.0556 -0.3848 -2.0305 -0.1161 -0.7886 -0.1203 -0.1509 -0.7373 -0.1253 -0.1923 -0.0803 -0.1858 -0.1497 -0.6538 -0.3345 -0.2220 -0.1505 -0.1939 -0.1391 -0.1571 -0.1507
S-624	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-624	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-624	-0.3374551832675934	Frequency categories are defined by the following criteria : Very common ( 1/ 10 ) , common ( 1/ 100 to 1/ 10 ) , uncommon ( 1/ 1,000 to 1/ 100 ) , rare ( 1/ 10,000 to 1/ 1,000 ) , very rare <unk> 1/ 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
D-624	-0.3374551832675934	Frequency categories are defined by the following criteria : Very common ( 1/ 10 ) , common ( 1/ 100 to 1/ 10 ) , uncommon ( 1/ 1,000 to 1/ 100 ) , rare ( 1/ 10,000 to 1/ 1,000 ) , very rare <unk> 1/ 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
P-624	-0.4728 -0.0670 -0.1130 -1.1427 -0.1562 -0.1444 -0.8805 -0.4892 -0.0775 -0.2729 -0.1395 -0.1471 -0.3719 -0.1414 -0.1095 -0.2929 -0.5304 -0.1461 -0.1437 -0.5291 -0.1385 -0.0867 -0.1209 -0.1775 -0.2466 -0.6571 -0.1095 -0.1781 -0.1242 -0.1463 -3.4902 -0.0150 -0.1337 -0.0882 -0.1069 -1.5885 -0.1388 -0.5547 -0.1103 -0.1907 -0.1234 -0.1507 -0.0325 -0.1353 -0.1140 -0.0925 -0.8526 -0.1333 -0.7482 -0.1053 -0.5227 -0.1240 -0.1510 -0.1342 -0.0556 -0.3848 -2.0305 -0.1161 -0.7886 -0.1203 -0.1509 -0.7373 -0.1253 -0.1923 -0.0803 -0.1858 -0.1497 -0.6538 -0.3345 -0.2220 -0.1505 -0.1939 -0.1391 -0.1571 -0.1507
S-798	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-798	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-798	-0.3374551832675934	Frequency categories are defined by the following criteria : Very common ( 1/ 10 ) , common ( 1/ 100 to 1/ 10 ) , uncommon ( 1/ 1,000 to 1/ 100 ) , rare ( 1/ 10,000 to 1/ 1,000 ) , very rare <unk> 1/ 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
D-798	-0.3374551832675934	Frequency categories are defined by the following criteria : Very common ( 1/ 10 ) , common ( 1/ 100 to 1/ 10 ) , uncommon ( 1/ 1,000 to 1/ 100 ) , rare ( 1/ 10,000 to 1/ 1,000 ) , very rare <unk> 1/ 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
P-798	-0.4728 -0.0670 -0.1130 -1.1427 -0.1562 -0.1444 -0.8805 -0.4892 -0.0775 -0.2729 -0.1395 -0.1471 -0.3719 -0.1414 -0.1095 -0.2929 -0.5304 -0.1461 -0.1437 -0.5291 -0.1385 -0.0867 -0.1209 -0.1775 -0.2466 -0.6571 -0.1095 -0.1781 -0.1242 -0.1463 -3.4902 -0.0150 -0.1337 -0.0882 -0.1069 -1.5885 -0.1388 -0.5547 -0.1103 -0.1907 -0.1234 -0.1507 -0.0325 -0.1353 -0.1140 -0.0925 -0.8526 -0.1333 -0.7482 -0.1053 -0.5227 -0.1240 -0.1510 -0.1342 -0.0556 -0.3848 -2.0305 -0.1161 -0.7886 -0.1203 -0.1509 -0.7373 -0.1253 -0.1923 -0.0803 -0.1858 -0.1497 -0.6538 -0.3345 -0.2220 -0.1505 -0.1939 -0.1391 -0.1571 -0.1507
S-1150	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-1150	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-1150	-0.3374551832675934	Frequency categories are defined by the following criteria : Very common ( 1/ 10 ) , common ( 1/ 100 to 1/ 10 ) , uncommon ( 1/ 1,000 to 1/ 100 ) , rare ( 1/ 10,000 to 1/ 1,000 ) , very rare <unk> 1/ 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
D-1150	-0.3374551832675934	Frequency categories are defined by the following criteria : Very common ( 1/ 10 ) , common ( 1/ 100 to 1/ 10 ) , uncommon ( 1/ 1,000 to 1/ 100 ) , rare ( 1/ 10,000 to 1/ 1,000 ) , very rare <unk> 1/ 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
P-1150	-0.4728 -0.0670 -0.1130 -1.1427 -0.1562 -0.1444 -0.8805 -0.4892 -0.0775 -0.2729 -0.1395 -0.1471 -0.3719 -0.1414 -0.1095 -0.2929 -0.5304 -0.1461 -0.1437 -0.5291 -0.1385 -0.0867 -0.1209 -0.1775 -0.2466 -0.6571 -0.1095 -0.1781 -0.1242 -0.1463 -3.4902 -0.0150 -0.1337 -0.0882 -0.1069 -1.5885 -0.1388 -0.5547 -0.1103 -0.1907 -0.1234 -0.1507 -0.0325 -0.1353 -0.1140 -0.0925 -0.8526 -0.1333 -0.7482 -0.1053 -0.5227 -0.1240 -0.1510 -0.1342 -0.0556 -0.3848 -2.0305 -0.1161 -0.7886 -0.1203 -0.1509 -0.7373 -0.1253 -0.1923 -0.0803 -0.1858 -0.1497 -0.6538 -0.3345 -0.2220 -0.1505 -0.1939 -0.1391 -0.1571 -0.1507
S-1126	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-1126	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-1126	-0.23533761501312256	Patients should be alert to immediate type of hypersensitivity reaction , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. chest tightness , wheezing ) .
D-1126	-0.23533761501312256	Patients should be alert to immediate type of hypersensitivity reaction , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. chest tightness , wheezing ) .
P-1126	-1.1148 -0.0915 -0.1554 -0.1787 -0.2417 -0.1653 -1.6244 -0.6968 -1.1611 -0.0827 -0.0530 -0.0304 -0.1309 -0.6702 -0.1241 -0.1572 -0.1525 -0.0453 -0.1409 -0.0996 -0.0712 -0.1418 -0.1013 -0.2306 -0.0783 -0.0600 -0.1025 -0.1462 -0.1352 -0.0855 -0.0099 -0.0675 -0.0748 -0.1455 -0.0816 -0.0433 -0.0665 -0.0422 -0.1354 -0.1491 -0.1038 -0.0538 -0.1403 -0.0690 -0.0716 -0.1164 -0.0962 -0.1041 -0.1375 -0.1476 -0.1322 -0.1552 -0.1179 -0.0730 -0.0725 -0.0603 -0.1104 -1.5799 -0.1226 -0.1475 -0.0822 -0.1175 -0.0428 -0.4014 -0.1031 -1.1312 -0.0976 -0.1471 -1.5988 -0.0096 -0.5504 -0.1359 -0.1510 -0.1497
S-600	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-600	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-600	-0.23533761501312256	Patients should be alert to immediate type of hypersensitivity reaction , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. chest tightness , wheezing ) .
D-600	-0.23533761501312256	Patients should be alert to immediate type of hypersensitivity reaction , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. chest tightness , wheezing ) .
P-600	-1.1148 -0.0915 -0.1554 -0.1787 -0.2417 -0.1653 -1.6244 -0.6968 -1.1611 -0.0827 -0.0530 -0.0304 -0.1309 -0.6702 -0.1241 -0.1572 -0.1525 -0.0453 -0.1409 -0.0996 -0.0712 -0.1418 -0.1013 -0.2306 -0.0783 -0.0600 -0.1025 -0.1462 -0.1352 -0.0855 -0.0099 -0.0675 -0.0748 -0.1455 -0.0816 -0.0433 -0.0665 -0.0422 -0.1354 -0.1491 -0.1038 -0.0538 -0.1403 -0.0690 -0.0716 -0.1164 -0.0962 -0.1041 -0.1375 -0.1476 -0.1322 -0.1552 -0.1179 -0.0730 -0.0725 -0.0603 -0.1104 -1.5799 -0.1226 -0.1475 -0.0822 -0.1175 -0.0428 -0.4014 -0.1031 -1.1312 -0.0976 -0.1471 -1.5988 -0.0096 -0.5504 -0.1359 -0.1510 -0.1497
S-1326	Die Häufigkeitskategorien sind nach folgenden Kriterien definiert : Sehr häufig ( 1<unk> 10 ) , häufig ( 1<unk> 100 bis <unk> 1<unk> 10 ) , gelegentlich ( 1<unk> 1.000 bis <unk> 1<unk> 100 ) , selten ( 1<unk> 10.000 bis <unk> 1<unk> 1.000 ) , sehr selten <unk> 1<unk> 10.000 ) , nicht bekannt ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-1326	Frequency categories are defined according to the following convention : very common ( 1/ 10 ) , common ( 1/ 100 to <<unk>> 1/ 10 ) , uncommon ( 1/ 1,000 to <<unk>> 1/ 100 ) , rare ( 1/ 10,000 to <<unk>> 1/ 1,000 ) , very rare ( <<unk>> 1/ 10,000 ) , not known ( cannot be calculated from the available data ) .
H-1326	-0.3374551832675934	Frequency categories are defined by the following criteria : Very common ( 1/ 10 ) , common ( 1/ 100 to 1/ 10 ) , uncommon ( 1/ 1,000 to 1/ 100 ) , rare ( 1/ 10,000 to 1/ 1,000 ) , very rare <unk> 1/ 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
D-1326	-0.3374551832675934	Frequency categories are defined by the following criteria : Very common ( 1/ 10 ) , common ( 1/ 100 to 1/ 10 ) , uncommon ( 1/ 1,000 to 1/ 100 ) , rare ( 1/ 10,000 to 1/ 1,000 ) , very rare <unk> 1/ 10,000 ) , unknown ( frequency cannot be estimated based on available data ) .
P-1326	-0.4728 -0.0670 -0.1130 -1.1427 -0.1562 -0.1444 -0.8805 -0.4892 -0.0775 -0.2729 -0.1395 -0.1471 -0.3719 -0.1414 -0.1095 -0.2929 -0.5304 -0.1461 -0.1437 -0.5291 -0.1385 -0.0867 -0.1209 -0.1775 -0.2466 -0.6571 -0.1095 -0.1781 -0.1242 -0.1463 -3.4902 -0.0150 -0.1337 -0.0882 -0.1069 -1.5885 -0.1388 -0.5547 -0.1103 -0.1907 -0.1234 -0.1507 -0.0325 -0.1353 -0.1140 -0.0925 -0.8526 -0.1333 -0.7482 -0.1053 -0.5227 -0.1240 -0.1510 -0.1342 -0.0556 -0.3848 -2.0305 -0.1161 -0.7886 -0.1203 -0.1509 -0.7373 -0.1253 -0.1923 -0.0803 -0.1858 -0.1497 -0.6538 -0.3345 -0.2220 -0.1505 -0.1939 -0.1391 -0.1571 -0.1507
S-774	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-774	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-774	-0.23533761501312256	Patients should be alert to immediate type of hypersensitivity reaction , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. chest tightness , wheezing ) .
D-774	-0.23533761501312256	Patients should be alert to immediate type of hypersensitivity reaction , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. chest tightness , wheezing ) .
P-774	-1.1148 -0.0915 -0.1554 -0.1787 -0.2417 -0.1653 -1.6244 -0.6968 -1.1611 -0.0827 -0.0530 -0.0304 -0.1309 -0.6702 -0.1241 -0.1572 -0.1525 -0.0453 -0.1409 -0.0996 -0.0712 -0.1418 -0.1013 -0.2306 -0.0783 -0.0600 -0.1025 -0.1462 -0.1352 -0.0855 -0.0099 -0.0675 -0.0748 -0.1455 -0.0816 -0.0433 -0.0665 -0.0422 -0.1354 -0.1491 -0.1038 -0.0538 -0.1403 -0.0690 -0.0716 -0.1164 -0.0962 -0.1041 -0.1375 -0.1476 -0.1322 -0.1552 -0.1179 -0.0730 -0.0725 -0.0603 -0.1104 -1.5799 -0.1226 -0.1475 -0.0822 -0.1175 -0.0428 -0.4014 -0.1031 -1.1312 -0.0976 -0.1471 -1.5988 -0.0096 -0.5504 -0.1359 -0.1510 -0.1497
S-950	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-950	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-950	-0.23533761501312256	Patients should be alert to immediate type of hypersensitivity reaction , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. chest tightness , wheezing ) .
D-950	-0.23533761501312256	Patients should be alert to immediate type of hypersensitivity reaction , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. chest tightness , wheezing ) .
P-950	-1.1148 -0.0915 -0.1554 -0.1787 -0.2417 -0.1653 -1.6244 -0.6968 -1.1611 -0.0827 -0.0530 -0.0304 -0.1309 -0.6702 -0.1241 -0.1572 -0.1525 -0.0453 -0.1409 -0.0996 -0.0712 -0.1418 -0.1013 -0.2306 -0.0783 -0.0600 -0.1025 -0.1462 -0.1352 -0.0855 -0.0099 -0.0675 -0.0748 -0.1455 -0.0816 -0.0433 -0.0665 -0.0422 -0.1354 -0.1491 -0.1038 -0.0538 -0.1403 -0.0690 -0.0716 -0.1164 -0.0962 -0.1041 -0.1375 -0.1476 -0.1322 -0.1552 -0.1179 -0.0730 -0.0725 -0.0603 -0.1104 -1.5799 -0.1226 -0.1475 -0.0822 -0.1175 -0.0428 -0.4014 -0.1031 -1.1312 -0.0976 -0.1471 -1.5988 -0.0096 -0.5504 -0.1359 -0.1510 -0.1497
S-1302	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-1302	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-1302	-0.23533761501312256	Patients should be alert to immediate type of hypersensitivity reaction , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. chest tightness , wheezing ) .
D-1302	-0.23533761501312256	Patients should be alert to immediate type of hypersensitivity reaction , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. chest tightness , wheezing ) .
P-1302	-1.1148 -0.0915 -0.1554 -0.1787 -0.2417 -0.1653 -1.6244 -0.6968 -1.1611 -0.0827 -0.0530 -0.0304 -0.1309 -0.6702 -0.1241 -0.1572 -0.1525 -0.0453 -0.1409 -0.0996 -0.0712 -0.1418 -0.1013 -0.2306 -0.0783 -0.0600 -0.1025 -0.1462 -0.1352 -0.0855 -0.0099 -0.0675 -0.0748 -0.1455 -0.0816 -0.0433 -0.0665 -0.0422 -0.1354 -0.1491 -0.1038 -0.0538 -0.1403 -0.0690 -0.0716 -0.1164 -0.0962 -0.1041 -0.1375 -0.1476 -0.1322 -0.1552 -0.1179 -0.0730 -0.0725 -0.0603 -0.1104 -1.5799 -0.1226 -0.1475 -0.0822 -0.1175 -0.0428 -0.4014 -0.1031 -1.1312 -0.0976 -0.1471 -1.5988 -0.0096 -0.5504 -0.1359 -0.1510 -0.1497
S-1478	Die Patienten sollen über die Anzeichen einer Überempfindlichkeitsreaktion vom Soforttyp , wie Ausschlag , Juckreiz , generalisierte Urtikaria , Angioödem , Hypotonie ( z.B . Schwindel oder Synkope ) , Schock und akute respiratorische Beschwerden ( z.B . Engegefühl in der Brust , Keuchatmung ) aufgeklärt sein .
T-1478	Patients should be informed of the signs of immediate-type hypersensitivity reactions including hives , pruritus , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory distress ( e. g. tightness in the chest , wheezing ) .
H-1478	-0.23533761501312256	Patients should be alert to immediate type of hypersensitivity reaction , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. chest tightness , wheezing ) .
D-1478	-0.23533761501312256	Patients should be alert to immediate type of hypersensitivity reaction , such as rash , itching , generalised urticaria , angioedema , hypotension ( e. g. dizziness or syncope ) , shock and acute respiratory discomfort ( e. g. chest tightness , wheezing ) .
P-1478	-1.1148 -0.0915 -0.1554 -0.1787 -0.2417 -0.1653 -1.6244 -0.6968 -1.1611 -0.0827 -0.0530 -0.0304 -0.1309 -0.6702 -0.1241 -0.1572 -0.1525 -0.0453 -0.1409 -0.0996 -0.0712 -0.1418 -0.1013 -0.2306 -0.0783 -0.0600 -0.1025 -0.1462 -0.1352 -0.0855 -0.0099 -0.0675 -0.0748 -0.1455 -0.0816 -0.0433 -0.0665 -0.0422 -0.1354 -0.1491 -0.1038 -0.0538 -0.1403 -0.0690 -0.0716 -0.1164 -0.0962 -0.1041 -0.1375 -0.1476 -0.1322 -0.1552 -0.1179 -0.0730 -0.0725 -0.0603 -0.1104 -1.5799 -0.1226 -0.1475 -0.0822 -0.1175 -0.0428 -0.4014 -0.1031 -1.1312 -0.0976 -0.1471 -1.5988 -0.0096 -0.5504 -0.1359 -0.1510 -0.1497
S-393	ADROVANCE ( 70 mg<unk> 2.800 I.E. ) senkte signifikant den Anteil an Patienten mit Vitamin-D-Mangel ( Serumwert von 25-Hydroxyvitamin D <unk> 22,5 nmol<unk> l <unk> <unk> 9 ng<unk> ml <unk> ) um 92 % im Vergleich zu Alendronat allein ( 1 % vs . 13 % ) .
T-393	The percentage of patients with vitamin D deficiency ( serum 25- hydroxyvitamin D <<unk>> 22.5 nmol/ l <<unk>> <<unk>> 9 ng/ ml <<unk>> ) was significantly reduced by 92 % with ADROVANCE ( 70 mg/ 2800 IU ) vs. alendronate-only ( 1 % vs 13 % , respectively ) .
H-393	-0.19342388212680817	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 22.5 nmol/ l <unk> 9 ng/ ml <unk> ) by 92 % compared to alendronate alone ( 1 % vs. 13 % ) .
D-393	-0.19342388212680817	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 22.5 nmol/ l <unk> 9 ng/ ml <unk> ) by 92 % compared to alendronate alone ( 1 % vs. 13 % ) .
P-393	-0.0803 -0.0752 -0.1244 -0.1120 -0.1245 -0.1465 -0.1043 -0.1486 -0.1386 -0.1249 -0.1674 -0.1016 -0.1029 -0.0746 -0.1283 -0.1673 -0.8739 -0.1439 -0.1666 -0.6538 -0.2252 -0.1434 -0.2078 -0.3145 -0.0673 -0.1322 -0.0206 -0.0529 -0.2284 -0.1240 -0.1032 -0.1290 -1.6366 -1.0297 -0.1050 -0.0529 -0.1144 -0.1350 -0.0963 -0.1027 -0.0972 -0.2960 -0.0262 -0.1021 -0.1332 -0.1818 -0.1420 -0.2208 -0.5618 -0.1183 -0.1329 -0.1217 -0.1372 -0.0690 -0.0384 -0.1312 -0.1671 -0.1914 -0.1372 -0.2975 -0.2920 -0.2084 -0.1546 -0.1062 -0.0480 -0.1024 -0.1276 -0.1445 -0.1375 -0.4461 -0.1191 -0.1233 -0.1265 -0.1387 -0.1478
S-205	ADROVANCE ( 70 mg<unk> 2.800 I.E. ) senkte signifikant den Anteil an Patienten mit Vitamin-D-Mangel ( Serumwert von 25-Hydroxyvitamin D <unk> 22,5 nmol<unk> l <unk> <unk> 9 ng<unk> ml <unk> ) um 92 % im Vergleich zu Alendronat allein ( 1 % vs . 13 % ) .
T-205	The percentage of patients with vitamin D deficiency ( serum 25-hydroxyvitamin D <<unk>> 22.5 nmol/ l <<unk>> <<unk>> 9 ng/ ml <<unk>> ) was significantly reduced by 92 % with ADROVANCE ( 70 mg/ 2800 IU ) vs. alendronate-only ( 1 % vs 13 % , respectively ) .
H-205	-0.19342388212680817	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 22.5 nmol/ l <unk> 9 ng/ ml <unk> ) by 92 % compared to alendronate alone ( 1 % vs. 13 % ) .
D-205	-0.19342388212680817	ADROVANCE ( 70 mg/ 2,800 IU ) significantly decreased the proportion of patients with vitamin D deficiency ( serum of 25-hydroxyvitamin D <unk> 22.5 nmol/ l <unk> 9 ng/ ml <unk> ) by 92 % compared to alendronate alone ( 1 % vs. 13 % ) .
P-205	-0.0803 -0.0752 -0.1244 -0.1120 -0.1245 -0.1465 -0.1043 -0.1486 -0.1386 -0.1249 -0.1674 -0.1016 -0.1029 -0.0746 -0.1283 -0.1673 -0.8739 -0.1439 -0.1666 -0.6538 -0.2252 -0.1434 -0.2078 -0.3145 -0.0673 -0.1322 -0.0206 -0.0529 -0.2284 -0.1240 -0.1032 -0.1290 -1.6366 -1.0297 -0.1050 -0.0529 -0.1144 -0.1350 -0.0963 -0.1027 -0.0972 -0.2960 -0.0262 -0.1021 -0.1332 -0.1818 -0.1420 -0.2208 -0.5618 -0.1183 -0.1329 -0.1217 -0.1372 -0.0690 -0.0384 -0.1312 -0.1671 -0.1914 -0.1372 -0.2975 -0.2920 -0.2084 -0.1546 -0.1062 -0.0480 -0.1024 -0.1276 -0.1445 -0.1375 -0.4461 -0.1191 -0.1233 -0.1265 -0.1387 -0.1478
S-1927	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Aerinaze bei der symptomatischen Behandlung der saisonalen allergischen Rhinitis mit Nasenschleimhautschwellung gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Aerinaze zu erteilen .
T-1927	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Aerinaze bei der symptomatischen Behandlung der saisonalen allergischen Rhinitis mit Nasenschleimhautschwellung gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Aerinaze zu erteilen . The Committee recommended that Aerinaze be given marketing authorisation .
H-1927	-0.27877378463745117	The Committee for Medicinal products for Human Use ( CHMP ) concluded that the benefits of Aerinaze in treating seasonal allergic rhinitis with nasal swelling outweigh the risks and recommended that Aerinaze be authorised to be marketed .
D-1927	-0.27877378463745117	The Committee for Medicinal products for Human Use ( CHMP ) concluded that the benefits of Aerinaze in treating seasonal allergic rhinitis with nasal swelling outweigh the risks and recommended that Aerinaze be authorised to be marketed .
P-1927	-0.1824 -0.0729 -0.1571 -0.0810 -0.0852 -0.7467 -0.1354 -1.1217 -0.2209 -0.1332 -0.0826 -0.0554 -0.1288 -0.8800 -0.1578 -0.4722 -0.2386 -0.3239 -0.1691 -0.1348 -0.1302 -0.1684 -0.1208 -1.3543 -0.2327 -1.2834 -0.1322 -0.1011 -0.0632 -0.0416 -0.0695 -0.1052 -0.0729 -0.1521 -0.0732 -0.0197 -0.1980 -0.0352 -0.1118 -0.4333 -0.2870 -0.1393 -0.2248 -0.1914 -0.0665 -0.4054 -2.1230 -0.1181 -0.1231 -0.1643 -0.1158 -0.0791 -0.9453 -0.1185 -0.2288 -0.2835 -0.2595 -0.0732 -0.1505 -0.1508
S-463	Etui mit versiegelten Aluminium<unk> Aluminium-Blisterpackungen in Umkartons zu 2 ( 1 Etui mit 2 Tabletten ) , 4 ( 1 Etui mit 4 Tabletten ) , 12 ( 3 Etuis mit 4 Tabletten ) oder 40 ( 10 Etuis mit 4 Tabletten ) Tabletten .
T-463	Wallet with sealed aluminium/ aluminium blisters , in cartons containing 2 ( 1 wallet x 2 tablets ) , 4 ( 1 wallet x 4 tablets ) , 12 ( 3 wallets x 4 tablets ) or 40 ( 10 wallets x 4 tablets ) tablets .
H-463	-0.22627004981040955	Aluminium sealed blister case in outer cartons of 2 ( 1 case of 2 tablets ) , 4 ( 1 case of 4 tablets ) , 12 ( 3 cases of 4 tablets ) or 40 ( 10 cases of 4 tablets ) tablets .
D-463	-0.22627004981040955	Aluminium sealed blister case in outer cartons of 2 ( 1 case of 2 tablets ) , 4 ( 1 case of 4 tablets ) , 12 ( 3 cases of 4 tablets ) or 40 ( 10 cases of 4 tablets ) tablets .
P-463	-0.7937 -0.1765 -0.3009 -0.3517 -0.2085 -0.7917 -0.1379 -0.3826 -0.1235 -0.9961 -0.2297 -0.1614 -0.1166 -0.1296 -0.1376 -1.1137 -0.5946 -0.1128 -0.0672 -0.1328 -0.1468 -0.1475 -0.1456 -0.1329 -0.1259 -0.4866 -0.1593 -0.1616 -0.0500 -0.1198 -0.1292 -0.1506 -0.1062 -0.1300 -0.1008 -0.3246 -0.1747 -0.1453 -0.0484 -0.1052 -0.1230 -0.1751 -0.0984 -0.1401 -0.1483 -0.5178 -0.1744 -0.1302 -0.0484 -0.1182 -0.1283 -0.0764 -0.1205 -0.1320 -0.1636
S-1679	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-1679	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-1679	-0.15004032850265503	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
D-1679	-0.15004032850265503	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
P-1679	-0.0310 -0.0378 -0.0411 -0.0798 -0.1268 -0.0135 -0.0020 -0.0160 -0.0240 -0.0731 -0.0190 -0.0765 -0.0329 -0.0192 -0.0185 -0.1006 -0.0698 -0.0838 -0.7672 -0.0032 -0.0586 -0.0772 -0.0498 -0.0512 -0.0492 -0.0815 -0.0398 -0.0587 -0.0600 -0.0366 -0.0518 -0.7584 -0.0614 -0.2084 -0.0215 -0.0068 -0.0564 -0.0459 -0.0134 -0.2910 -0.1554 -0.1233 -0.1647 -2.4453
S-1662	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-1662	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-1662	-0.15004032850265503	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
D-1662	-0.15004032850265503	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
P-1662	-0.0310 -0.0378 -0.0411 -0.0798 -0.1268 -0.0135 -0.0020 -0.0160 -0.0240 -0.0731 -0.0190 -0.0765 -0.0329 -0.0192 -0.0185 -0.1006 -0.0698 -0.0838 -0.7672 -0.0032 -0.0586 -0.0772 -0.0498 -0.0512 -0.0492 -0.0815 -0.0398 -0.0587 -0.0600 -0.0366 -0.0518 -0.7584 -0.0614 -0.2084 -0.0215 -0.0068 -0.0564 -0.0459 -0.0134 -0.2910 -0.1554 -0.1233 -0.1647 -2.4453
S-1629	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-1629	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-1629	-0.15004032850265503	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
D-1629	-0.15004032850265503	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
P-1629	-0.0310 -0.0378 -0.0411 -0.0798 -0.1268 -0.0135 -0.0020 -0.0160 -0.0240 -0.0731 -0.0190 -0.0765 -0.0329 -0.0192 -0.0185 -0.1006 -0.0698 -0.0838 -0.7672 -0.0032 -0.0586 -0.0772 -0.0498 -0.0512 -0.0492 -0.0815 -0.0398 -0.0587 -0.0600 -0.0366 -0.0518 -0.7584 -0.0614 -0.2084 -0.0215 -0.0068 -0.0564 -0.0459 -0.0134 -0.2910 -0.1554 -0.1233 -0.1647 -2.4453
S-1695	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-1695	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-1695	-0.15004032850265503	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
D-1695	-0.15004032850265503	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
P-1695	-0.0310 -0.0378 -0.0411 -0.0798 -0.1268 -0.0135 -0.0020 -0.0160 -0.0240 -0.0731 -0.0190 -0.0765 -0.0329 -0.0192 -0.0185 -0.1006 -0.0698 -0.0838 -0.7672 -0.0032 -0.0586 -0.0772 -0.0498 -0.0512 -0.0492 -0.0815 -0.0398 -0.0587 -0.0600 -0.0366 -0.0518 -0.7584 -0.0614 -0.2084 -0.0215 -0.0068 -0.0564 -0.0459 -0.0134 -0.2910 -0.1554 -0.1233 -0.1647 -2.4453
S-1711	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-1711	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-1711	-0.15004032850265503	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
D-1711	-0.15004032850265503	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
P-1711	-0.0310 -0.0378 -0.0411 -0.0798 -0.1268 -0.0135 -0.0020 -0.0160 -0.0240 -0.0731 -0.0190 -0.0765 -0.0329 -0.0192 -0.0185 -0.1006 -0.0698 -0.0838 -0.7672 -0.0032 -0.0586 -0.0772 -0.0498 -0.0512 -0.0492 -0.0815 -0.0398 -0.0587 -0.0600 -0.0366 -0.0518 -0.7584 -0.0614 -0.2084 -0.0215 -0.0068 -0.0564 -0.0459 -0.0134 -0.2910 -0.1554 -0.1233 -0.1647 -2.4453
S-81	Der Ausschuss für Humanarzneimittel ( CHMP ) entschied , dass die Vorteile von ADROVANCE bei der Behandlung von Osteoporose bei postmenopausalen Patientinnen mit Risiko eines Vitamin-D- Mangels gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von ADROVANCE zu erteilen .
T-81	Der Ausschuss für Humanarzneimittel ( CHMP ) entschied , dass die Vorteile von ADROVANCE bei der Behandlung von Osteoporose bei postmenopausalen Patientinnen mit Risiko eines Vitamin-D- Mangels gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von ADROVANCE zu erteilen . The Committee recommended that ADROVANCE be given marketing authorisation .
H-81	-0.23044610023498535	The Committee for Medicinal products for Human Use ( CHMP ) decided that the benefits of ADROVANCE in the treatment of osteoporosis in post-menopausal patients at risk of vitamin D deficiency outweigh the risks and recommended that ADROVANCE be authorised to be marketed .
D-81	-0.23044610023498535	The Committee for Medicinal products for Human Use ( CHMP ) decided that the benefits of ADROVANCE in the treatment of osteoporosis in post-menopausal patients at risk of vitamin D deficiency outweigh the risks and recommended that ADROVANCE be authorised to be marketed .
P-81	-0.2090 -0.0674 -0.1571 -0.0616 -0.0943 -0.7493 -0.1409 -1.1271 -0.2084 -0.1310 -0.0818 -0.0526 -0.1286 -0.5607 -0.1330 -0.4767 -0.3273 -0.1941 -0.0717 -0.0804 -0.1208 -0.1098 -0.1286 -0.2889 -0.8916 -0.1463 -0.1457 -0.1458 -0.0676 -0.1011 -0.1356 -0.0984 -0.1130 -0.1469 -0.1194 -0.1653 -0.0385 -0.1184 -0.0371 -0.1455 -0.3460 -0.0531 -0.0843 -0.1785 -0.1953 -0.0379 -0.1234 -0.0450 -0.0394 -0.2050 -0.5422 -0.3617 -0.1430 -0.2565 -0.2600 -0.0656 -0.3462 -1.8875 -0.0642 -0.1124 -0.1067 -0.1109 -0.0758 -1.0019 -0.1155 -0.3451 -0.3273 -0.2588 -0.0658 -0.1393 -0.1499
S-1645	GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG VON NICHT VERWENDETEN ARZNEIMITTELN ODER DAVON STAMMENDEN ABFALLMATERIALIEN
T-1645	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS , IF APPROPRIATE
H-1645	-0.15004032850265503	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
D-1645	-0.15004032850265503	SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
P-1645	-0.0310 -0.0378 -0.0411 -0.0798 -0.1268 -0.0135 -0.0020 -0.0160 -0.0240 -0.0731 -0.0190 -0.0765 -0.0329 -0.0192 -0.0185 -0.1006 -0.0698 -0.0838 -0.7672 -0.0032 -0.0586 -0.0772 -0.0498 -0.0512 -0.0492 -0.0815 -0.0398 -0.0587 -0.0600 -0.0366 -0.0518 -0.7584 -0.0614 -0.2084 -0.0215 -0.0068 -0.0564 -0.0459 -0.0134 -0.2910 -0.1554 -0.1233 -0.1647 -2.4453
S-23	Harnsäurespiegel im Blut senken und auf einem niedrigeren Niveau halten , so dass sich keine Kristalle mehr bilden können . Dadurch können die Symptome der Gicht gelindert werden . Wenn der Harnsäurespiegel lange genug auf niedrigem Niveau gehalten wird , können unter Umständen sogar bereits vorhandene Gichtknoten kleiner werden . Wie wurde Adenuric untersucht ?
T-23	How has Adenuric been studied ?
H-23	-0.46470677852630615	lower uric acid levels in the blood and maintain them at a lower level so that crystals cannot form and thus relieve the symptoms of gout . If uric acid levels are kept low enough , even existing rheumatoid nodes may become smaller . How has Adenuric been studied ?
D-23	-0.46470677852630615	lower uric acid levels in the blood and maintain them at a lower level so that crystals cannot form and thus relieve the symptoms of gout . If uric acid levels are kept low enough , even existing rheumatoid nodes may become smaller . How has Adenuric been studied ?
P-23	-0.7385 -1.4220 -0.0737 -0.1406 -0.1627 -0.1418 -0.1480 -0.0458 -0.1344 -1.1407 -0.3101 -0.1776 -0.3102 -0.1641 -0.0294 -0.7670 -0.2116 -0.3519 -0.0320 -0.1810 -0.3789 -1.2482 -0.5129 -1.1970 -0.9469 -0.1178 -1.7203 -0.0329 -0.1346 -0.0530 -0.3913 -0.1619 -0.1362 -0.7212 -0.0660 -0.0979 -0.1779 -0.3111 -1.3764 -0.8151 -0.9296 -0.2883 -1.8933 -0.1978 -1.5730 -1.0899 -0.2029 -0.5564 -0.7729 -0.5028 -0.1362 -0.1376 -0.4673 -0.1140 -0.1732 -0.7372 -1.2778 -0.0849 -0.2071 -0.0709 -0.1141 -0.0656 -0.5312 -0.6359 -0.1656
S-544	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Advate bei der Behandlung und Propyhlaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Mangel an Faktor VIII ) gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Advate zu erteilen .
T-544	Der Ausschuss für Humanarzneimittel ( CHMP ) gelangte zu dem Schluss , dass die Vorteile von Advate bei der Behandlung und Propyhlaxe von Blutungen bei Patienten mit Hämophilie A ( angeborener Mangel an Faktor VIII ) gegenüber den Risiken überwiegen , und empfahl , die Genehmigung für das Inverkehrbringen von Advate zu erteilen . The Committee recommended that Advate be given marketing authorisation .
H-544	-0.3610582947731018	The Committee for Medicinal products for Human Use ( CHMP ) concluded that the benefits of Advate in the treatment and propyhlaxis of bleeding in patients with haemophilia A ( congenital deficiency in factor VIII ) outweigh the risks and recommended that marketing authorisation for Advate be granted .
D-544	-0.3610582947731018	The Committee for Medicinal products for Human Use ( CHMP ) concluded that the benefits of Advate in the treatment and propyhlaxis of bleeding in patients with haemophilia A ( congenital deficiency in factor VIII ) outweigh the risks and recommended that marketing authorisation for Advate be granted .
P-544	-0.2018 -0.0659 -0.1486 -0.0657 -0.0703 -0.5898 -0.1368 -1.2802 -0.1759 -0.1367 -0.0880 -0.0542 -0.1283 -0.9295 -0.1543 -0.6189 -0.3192 -0.2495 -0.5323 -0.0895 -0.2374 -1.6378 -0.2108 -0.1183 -0.1170 -0.1612 -0.1281 -0.1173 -0.2940 -0.1450 -1.5224 -0.1897 -0.1775 -0.1229 -0.1246 -0.1088 -0.0664 -0.1859 -0.2126 -0.1164 -0.1451 -1.0406 -0.5328 -0.3414 -0.7961 -0.0809 -0.1171 -0.4589 -0.9575 -0.1386 -0.1156 -0.1297 -0.4970 -0.4278 -0.1376 -0.2233 -0.2437 -0.0710 -0.4693 -2.5334 -0.3721 -0.0514 -0.6235 -0.7479 -0.0845 -0.3965 -0.8526 -0.1487 -0.1490
S-26	In der ersten Studie , an der 1 072 Patienten teilnahmen , wurde die Wirksamkeit dreier verschiedener Adenuric-Dosierungen ( einmal täglich 80 , 120 und 240 mg ) mit der eines Placebo ( Scheinmedikaments ) und von Allopurinol ( einem anderen Arzneimittel zur Behandlung der Hyperurikämie ) verglichen .
T-26	The first study , carried out in 1,072 patients , compared the effectiveness of three doses of Adenuric ( 80 , 120 and 240 mg once a day ) with that of placebo ( a dummy treatment ) and of allopurinol ( another medicine used to treat hyperuricaemia ) .
H-26	-0.3616701364517212	The first trial , in which 1,072 patients participated , compared the efficacy of three different doses of adenuric ( 80 , 120 and 240 mg once a day ) to that of placebo ( apparent ) and allopurinol ( another medicinal product used to treat hyperuricaemia ) .
D-26	-0.3616701364517212	The first trial , in which 1,072 patients participated , compared the efficacy of three different doses of adenuric ( 80 , 120 and 240 mg once a day ) to that of placebo ( apparent ) and allopurinol ( another medicinal product used to treat hyperuricaemia ) .
P-26	-0.4778 -0.0902 -0.6801 -0.4263 -1.9070 -0.4941 -0.1116 -0.0838 -0.1707 -0.0936 -0.1767 -0.1187 -0.1452 -0.0704 -0.1427 -0.6633 -0.0560 -0.0990 -0.1698 -0.1677 -1.2796 -1.4716 -0.0647 -0.2113 -0.1586 -0.0885 -0.1631 -0.1454 -0.3682 -0.1494 -0.0593 -0.2500 -0.1347 -0.0567 -0.7049 -0.9149 -0.0727 -0.1403 -1.6057 -0.4326 -0.1816 -0.0460 -0.1501 -0.1176 -0.1308 -0.1586 -4.3509 -1.2175 -0.1418 -0.3175 -0.1551 -0.1398 -0.1014 -0.3125 -0.0663 -0.6571 -0.0630 -0.0768 -0.2238 -0.3630 -0.0693 -0.0466 -0.0788 -0.2965 -0.0393 -0.1336 -0.1969 -0.1578 -0.1484
S-1876	Wirksamkeit des Arzneimittels wurde mithilfe von Scans bewertet , wobei untersucht wurde , wie die Tumore auf die Behandlung ansprachen . Das Unternehmen legte ferner Ergebnisse mehrerer kleiner Studien vor , in denen die Wirkungen eines Dosisbereichs von Advexin bei verschiedenen Krebsarten untersucht wurden . In welchem Stadium der Beurteilung befand sich der Antrag zum Zeitpunkt der Rücknahme ?
T-1876	How far into the evaluation was the application when it was withdrawn ?
H-1876	-0.5346311330795288	efficacy was assessed by scans looking at how tumours responded to treatment and presented results of several small studies looking at the effects of a dose range of Advexin in various cancer types . At what stage in the assessment was the withdrawal request at ?
D-1876	-0.5346311330795288	efficacy was assessed by scans looking at how tumours responded to treatment and presented results of several small studies looking at the effects of a dose range of Advexin in various cancer types . At what stage in the assessment was the withdrawal request at ?
P-1876	-1.7831 -0.0489 -0.0845 -1.1474 -0.8764 -0.1137 -0.6272 -0.1529 -0.2682 -1.2443 -0.1232 -0.0699 -0.7181 -0.1369 -0.0398 -0.1320 -0.1082 -1.3683 -1.8316 -0.3384 -0.9903 -0.1571 -0.2051 -0.8866 -1.1353 -0.1079 -0.4387 -0.2222 -0.2052 -0.1380 -0.0941 -0.1440 -0.1750 -0.8636 -0.2012 -0.1346 -1.1687 -1.1515 -1.2493 -0.0596 -0.2263 -0.2977 -0.0673 -0.2607 -1.6063 -0.6409 -0.8117 -0.3891 -0.1887 -1.4414 -0.8436 -0.3884 -0.5785 -0.1883
S-106	Überempfindlichkeit gegen einen der arzneilich wirksamen Bestandteile oder der sonstigen Bestandteile . Erkrankungen des Ösophagus und andere Faktoren , welche die ösophageale Entleerung verzögern , wie Strikturen oder Achalasie . Unfähigkeit , für mindestens 30 Minuten aufrecht zu stehen oder zu sitzen . Hypocalcämie .
T-106	Inability to stand or sit upright for at least 30 minutes .
H-106	-0.30112454295158386	Hypersensitivity to any of the active ingredients or excipients . Oesophageal disorders and other factors that delay esophageal emptying , such as stricture or achalasia . inability to stand or sit upright for at least 30 minutes . Hypocalcaemia .
D-106	-0.30112454295158386	Hypersensitivity to any of the active ingredients or excipients . Oesophageal disorders and other factors that delay esophageal emptying , such as stricture or achalasia . inability to stand or sit upright for at least 30 minutes . Hypocalcaemia .
P-106	-0.1231 -0.0360 -0.0592 -0.0539 -0.1460 -0.2265 -0.3608 -0.1558 -0.4507 -0.0988 -0.0995 -0.6196 -0.0361 -0.0527 -0.0798 -0.2023 -0.1870 -0.0597 -0.8652 -0.0257 -0.0478 -0.1732 -0.1670 -0.0916 -0.1429 -0.1123 -0.0541 -1.6909 -0.3033 -1.2530 -0.1635 -0.0425 -0.0936 -0.1582 -1.1217 -0.1361 -0.1873 -0.1662 -0.2108 -0.1619 -1.4758 -0.5151 -0.1392 -0.0893 -0.1536 -0.3588 -0.3588 -0.1405 -0.9823 -0.1798 -0.6386 -0.6909 -0.3196 -1.3203 -0.2375 -0.0936 -0.1844 -0.0975 -0.1007 -0.1375 -0.1285 -0.1363 -1.4536 -0.0472 -0.0561 -0.1216 -0.0521 -0.1311 -0.1482 -0.1738
S-138	Colecalciferol Vitamin D3 kann das Ausmaß einer Hypercalcämie und<unk> oder Hypercalciurie verstärken , wenn es an Patienten mit Krankheiten , die mit einer unkontrollierten Überproduktion von Calcitriol in Verbindung stehen , gegeben wird ( z. B. Leukämie , Lymphom , Sarkoidose ) .
T-138	Colecalciferol Vitamin D3 may increase the magnitude of hypercalcaemia and/ or hypercalciuria when administered to patients with disease associated with unregulated overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
H-138	-0.2702995538711548	Colecalciferol vitamin D3 may increase the extent of hypercalcaemia and/ or hypercalciuria when administered to patients with illnesses associated with uncontrolled overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
D-138	-0.2702995538711548	Colecalciferol vitamin D3 may increase the extent of hypercalcaemia and/ or hypercalciuria when administered to patients with illnesses associated with uncontrolled overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
P-138	-0.2932 -0.1134 -0.2230 -0.1204 -0.1545 -0.1310 -1.2379 -0.1195 -0.1245 -0.1367 -0.1273 -0.5614 -0.1330 -2.2349 -0.1934 -0.0333 -0.1088 -0.0400 -0.0729 -0.2227 -0.0315 -0.1208 -0.1201 -0.0256 -0.1188 -0.1267 -0.0586 -0.1466 -0.1928 -0.8233 -0.0834 -0.2300 -0.2124 -0.1974 -1.1342 -0.0517 -0.4993 -0.1444 -0.1729 -0.2847 -0.9243 -0.2994 -0.1613 -0.2279 -0.1416 -0.1545 -0.2263 -0.1379 -0.0931 -0.0948 -0.0734 -0.0457 -1.9645 -0.0207 -0.1496 -0.1526 -0.1104 -0.3043 -0.1553 -0.3497 -0.3476 -0.1074 -0.1758 -0.0908 -0.1540 -0.1388 -0.1519
S-326	Colecalciferol Vitamin D3 kann das Ausmaß einer Hypercalcämie und<unk> oder Hypercalciurie verstärken , wenn es an Patienten mit Krankheiten , die mit einer unkontrollierten Überproduktion von Calcitriol in Verbindung stehen , gegeben wird ( z. B. Leukämie , Lymphom , Sarkoidose ) .
T-326	Colecalciferol Vitamin D3 may increase the magnitude of hypercalcaemia and/ or hypercalciuria when administered to patients with disease associated with unregulated overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
H-326	-0.2702995538711548	Colecalciferol vitamin D3 may increase the extent of hypercalcaemia and/ or hypercalciuria when administered to patients with illnesses associated with uncontrolled overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
D-326	-0.2702995538711548	Colecalciferol vitamin D3 may increase the extent of hypercalcaemia and/ or hypercalciuria when administered to patients with illnesses associated with uncontrolled overproduction of calcitriol ( e. g. leukaemia , lymphoma , sarcoidosis ) .
P-326	-0.2932 -0.1134 -0.2230 -0.1204 -0.1545 -0.1310 -1.2379 -0.1195 -0.1245 -0.1367 -0.1273 -0.5614 -0.1330 -2.2349 -0.1934 -0.0333 -0.1088 -0.0400 -0.0729 -0.2227 -0.0315 -0.1208 -0.1201 -0.0256 -0.1188 -0.1267 -0.0586 -0.1466 -0.1928 -0.8233 -0.0834 -0.2300 -0.2124 -0.1974 -1.1342 -0.0517 -0.4993 -0.1444 -0.1729 -0.2847 -0.9243 -0.2994 -0.1613 -0.2279 -0.1416 -0.1545 -0.2263 -0.1379 -0.0931 -0.0948 -0.0734 -0.0457 -1.9645 -0.0207 -0.1496 -0.1526 -0.1104 -0.3043 -0.1553 -0.3497 -0.3476 -0.1074 -0.1758 -0.0908 -0.1540 -0.1388 -0.1519
S-1786	Sehr häufig : es sind mehr als 1 von 10 Patienten betroffen Häufig : betrifft zwischen 1 und 10 von 100 Patienten Gelegentlich : betrifft zwischen 1 und 10 von 1.000 Patienten Selten : betrifft zwischen 1 und 10 von 10.000 Patienten Sehr selten : betrifft weniger als 1 von 10.000 Patienten Nicht bekannt : ( Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar ) .
T-1786	Side effects may occur with certain frequencies , which are defined as follows : very common : affects more than 1 user in 10 common : affects 1 to 10 users in 100 uncommon : affects 1 to 10 users in 1,000 rare : affects 1 to 10 users in 10,000 very rare : affects less than 1 user in 10,000 not known : frequency cannot be estimated from the available data .
H-1786	-0.25518083572387695	Very common : affecting more than 1 in 10 patients Common : affects between 1 and 10 in 100 patients Uncommon : affects between 1 and 10 in 1,000 patients Rare : affects between 1 and 10 in 10,000 patients Very rare : affects less than 1 in 10,000 patients Unknown : ( frequency cannot be estimated based on available data ) .
D-1786	-0.25518083572387695	Very common : affecting more than 1 in 10 patients Common : affects between 1 and 10 in 100 patients Uncommon : affects between 1 and 10 in 1,000 patients Rare : affects between 1 and 10 in 10,000 patients Very rare : affects less than 1 in 10,000 patients Unknown : ( frequency cannot be estimated based on available data ) .
P-1786	-0.2608 -0.3223 -0.1368 -1.4326 -0.2056 -0.1375 -0.1436 -0.5554 -0.1538 -0.4129 -0.0588 -0.1377 -0.1480 -0.4049 -0.3349 -0.1469 -0.2441 -0.1514 -0.2491 -0.1419 -0.2483 -0.1788 -0.0708 -0.1427 -0.2935 -0.1384 -0.1282 -0.2168 -0.1785 -0.2109 -0.1080 -0.1949 -0.1494 -0.1447 -0.1445 -0.3778 -0.1784 -0.1254 -0.4310 -0.1557 -0.1529 -0.7725 -0.0998 -0.1209 -0.0330 -0.1490 -0.2732 -0.2283 -0.1590 -0.1340 -0.1900 -0.5672 -0.3413 -0.7334 -0.0423 -0.1565 -0.1516 -0.4145 -0.0914 -0.6863 -0.1549 -0.8708 -0.4696 -0.2048 -0.1432 -0.1742 -0.1474 -0.1977 -0.1516
S-294	Überempfindlichkeit gegen einen der arzneilich wirksamen Bestandteile oder der sonstigen Bestandteile . Erkrankungen des Ösophagus und andere Faktoren , welche die ösophageale Entleerung verzögern , wie Strikturen oder Achalasie . Unfähigkeit , für mindestens 30 Minuten aufrecht zu stehen oder zu sitzen . Hypocalcämie .
T-294	Inability to stand or sit upright for at least 30 minutes .
H-294	-0.30112454295158386	Hypersensitivity to any of the active ingredients or excipients . Oesophageal disorders and other factors that delay esophageal emptying , such as stricture or achalasia . inability to stand or sit upright for at least 30 minutes . Hypocalcaemia .
D-294	-0.30112454295158386	Hypersensitivity to any of the active ingredients or excipients . Oesophageal disorders and other factors that delay esophageal emptying , such as stricture or achalasia . inability to stand or sit upright for at least 30 minutes . Hypocalcaemia .
P-294	-0.1231 -0.0360 -0.0592 -0.0539 -0.1460 -0.2265 -0.3608 -0.1558 -0.4507 -0.0988 -0.0995 -0.6196 -0.0361 -0.0527 -0.0798 -0.2023 -0.1870 -0.0597 -0.8652 -0.0257 -0.0478 -0.1732 -0.1670 -0.0916 -0.1429 -0.1123 -0.0541 -1.6909 -0.3033 -1.2530 -0.1635 -0.0425 -0.0936 -0.1582 -1.1217 -0.1361 -0.1873 -0.1662 -0.2108 -0.1619 -1.4758 -0.5151 -0.1392 -0.0893 -0.1536 -0.3588 -0.3588 -0.1405 -0.9823 -0.1798 -0.6386 -0.6909 -0.3196 -1.3203 -0.2375 -0.0936 -0.1844 -0.0975 -0.1007 -0.1375 -0.1285 -0.1363 -1.4536 -0.0472 -0.0561 -0.1216 -0.0521 -0.1311 -0.1482 -0.1738
S-270	EU<unk> 1<unk> 06<unk> 364<unk> 001 2 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 002 4 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 003 6 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 004 12 Tabletten EU<unk> 1<unk> 06<unk> 364<unk> 005 40 Tabletten
T-270	EU/ 1/ 06/ 364/ 001 2 tablets EU/ 1/ 06/ 364/ 002 4 tablets EU/ 1/ 06/ 364/ 003 6 tablets EU/ 1/ 06/ 364/ 004 12 tablets EU/ 1/ 06/ 364/ 005 40 tablets
H-270	-0.32709991931915283	06/ 364/ 002 tablets EU/ 06/ 364/ 004 tablets EU/ 06/ 364/ 003 6 tablets EU/ 06/ 364/ 004 12 tablets EU/ 06/ 364/ 005 40 tablets EU/
D-270	-0.32709991931915283	06/ 364/ 002 tablets EU/ 06/ 364/ 004 tablets EU/ 06/ 364/ 003 6 tablets EU/ 06/ 364/ 004 12 tablets EU/ 06/ 364/ 005 40 tablets EU/
P-270	-0.8169 -0.2111 -0.1514 -0.1071 -0.1019 -0.1078 -2.9068 -0.1275 -0.1148 -0.2244 -0.0944 -1.5214 -0.1487 -0.1026 -0.1081 -0.1177 -0.0963 -0.9386 -0.4658 -0.1067 -0.1069 -0.1146 -0.8900 -0.1579 -0.1057 -0.1085 -0.1172 -0.0907 -1.5229 -0.1184 -0.0874 -0.0923 -0.0779 -0.1188 -1.0019 -0.1779 -0.0935 -0.1127 -0.1222 -0.0891 -0.1856 -0.0928 -0.1255 -0.0809 -0.0935 -0.1154 -0.9150 -0.2031 -0.0886 -0.1129 -0.1174 -0.0791 -0.2475 -0.0849 -0.0854 -0.0988 -0.2685 -0.1193 -2.3080
S-33	In der ersten Studie hatten 48 % ( 126 von 262 ) der Patienten , die Adenuric in einer Dosis von einmal täglich 80 mg einnahmen , und 65 % ( 175 von 269 ) der Patienten , die einmal täglich 120 mg einnahmen , bei den letzten drei Messungen einen Harnsäurespiegel im Blut von unter 6 mg<unk> dl .
T-33	In the first study , 48 % of the patients taking 80 mg Adenuric once a day ( 126 out of 262 ) and 65 % of the patients taking 120 mg once a day ( 175 out of 269 ) had levels of uric acid below 6 mg/ dl in the final three measurements .
H-33	-0.3098098337650299	In the first trial , 48 % ( 126 out of 262 ) of the patients taking 80 mg of adenuric at once daily dose and 65 % ( 175 out of 269 ) of the patients taking 120 mg once daily had uric acid levels in their blood below 6 mg/ dl at the last three measurements .
D-33	-0.3098098337650299	In the first trial , 48 % ( 126 out of 262 ) of the patients taking 80 mg of adenuric at once daily dose and 65 % ( 175 out of 269 ) of the patients taking 120 mg once daily had uric acid levels in their blood below 6 mg/ dl at the last three measurements .
P-33	-0.2038 -0.1363 -0.1104 -0.6323 -0.2301 -0.1363 -0.1135 -0.1430 -0.0891 -0.1334 -0.2618 -0.1551 -0.0561 -0.1679 -0.1545 -0.1629 -1.2494 -0.0926 -1.5825 -0.8893 -0.0590 -0.9777 -0.6334 -0.0589 -0.1083 -1.1459 -0.3948 -0.1396 -0.3785 -0.2230 -0.0808 -0.0850 -0.1381 -0.0662 -0.2113 -0.1535 -0.0558 -0.1246 -0.1459 -0.1537 -0.1963 -0.0773 -0.5308 -0.0434 -0.0572 -0.3069 -0.1370 -0.0332 -0.7749 -0.0785 -0.0973 -0.1820 -0.2805 -0.9166 -0.0645 -0.9500 -0.1381 -0.2340 -0.1271 -0.1420 -0.0553 -0.7419 -0.4103 -0.2630 -0.1188 -1.3943 -0.0973 -0.9158 -0.1405 -0.1476
2021-02-15 20:26:15 | INFO | fairseq_cli.generate | NOTE: hypothesis and token scores are output in base 2
2021-02-15 20:26:15 | INFO | fairseq_cli.generate | Translated 2001 sentences (61230 tokens) in 18.9s (105.77 sentences/s, 3236.54 tokens/s)
2021-02-15 20:26:15 | WARNING | root | That's 100 lines that end in a tokenized period ('.')
2021-02-15 20:26:15 | WARNING | root | It looks like you forgot to detokenize your test data, which may hurt your score.
2021-02-15 20:26:15 | WARNING | root | If you insist your data is detokenized, or don't care, you can suppress this message with '--force'.
Generate test with beam=5: BLEU = 41.52 73.8/52.7/39.6/30.0 (BP = 0.895 ratio = 0.900 hyp_len = 41612 ref_len = 46222)
